<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7171471\results\search\disease\results.xml">
   <result pre="subtypes circulation among hospitalized patients in Laleh hospital during two" exact="influenza" post="seasonal (2016-2017 and 2017-2018) using a multiplex Real Time-Polymerase"/>
   <result pre="was to apply the above technology for the diagnosis of" exact="influenza" post="infections and at the same time to differentiate between"/>
   <result pre="female, respectively. 219 out of 540 (40.5%) were positive for" exact="influenza" post="infection including flu A (n=97, 44.3%), flu A (H1N1)"/>
   <result pre="0.016). Application of multiplex real time PCR could facilitate the" exact="influenza" post="diagnosis in a short period of time, benefiting patients"/>
   <result pre="based on the immunological and biological properties, three types of" exact="influenza" post="viruses including A, B, and C have been recognized.1,2"/>
   <result pre="recognized.1,2 Due to their fatal potential and highly contagious nature," exact="influenza" post="viruses have more predominant effects on communities rather than"/>
   <result pre="to the presence of effective antivirals against different types of" exact="influenza" post="viruses, rapid laboratory diagnosis may result in less antibiotic"/>
   <result pre="the routine diagnosis and epidemiological detection of respiratory infections including" exact="influenza" post="in many centers with reasonable specificity and sensitivity.7-9 On"/>
   <result pre="were to apply the above technology for the diagnosis of" exact="influenza" post="infections and at the same time to differentiate between"/>
   <result pre="for acute exacerbations of pre-existing chronic medical conditions (e.g. chronic" exact="lung disease," post="asthma, cardiovascular disease, stroke or diabetes). According to guidelines"/>
   <result pre="of pre-existing chronic medical conditions (e.g. chronic lung disease, asthma," exact="cardiovascular disease," post="stroke or diabetes). According to guidelines in Laleh hospital,"/>
   <result pre="chronic medical conditions (e.g. chronic lung disease, asthma, cardiovascular disease," exact="stroke" post="or diabetes). According to guidelines in Laleh hospital, all"/>
   <result pre="to manufacturer’s instructions. This kit could differentiate between the pandemic" exact="influenza" post="A (H1N1)pdm strain and other (untyped) influenza A strains;"/>
   <result pre="between the pandemic influenza A (H1N1)pdm strain and other (untyped)" exact="influenza" post="A strains; the results were classified as and flu"/>
   <result pre="A (H1N1) if a sample was positive for to both" exact="influenza" post="A and H1, and flu A if a sample"/>
   <result pre="H1, and flu A if a sample was positive to" exact="influenza" post="A and negative to H1. If a positive laboratory"/>
   <result pre="hundred and nineteen out of 540 (40.5%) were positive for" exact="influenza" post="infection including flu A (n= 97, 44.3%), flu A"/>
   <result pre="1B). In the two year period, the peaks of seasonal" exact="influenza" post="occurred in January, December, February and March in the"/>
   <result pre="from January 2017 to March 2018, and was the unique" exact="influenza" post="type detected in March 2018 (Figure 1D). The 540"/>
   <result pre="(P=0.744) (Table 1). Histories of heart and pulmonary disorders, hypertension," exact="diabetes mellitus" post="and smoking were found in different proportions of patients,"/>
   <result pre="(Table 1). Discussion and Conclusions Early and rapid detection of" exact="influenza" post="viruses is crucial in controlling the severity and spread"/>
   <result pre="existence of neuraminidase inhibitors as therapeutic option. Nevertheless, differentiation between" exact="influenza" post="subtypes is of clinical importance because flu A infection"/>
   <result pre="to acute respiratory symptoms were infected by different types of" exact="influenza" post="virus. Similar to our finding, others reported influenza prevalence"/>
   <result pre="types of influenza virus. Similar to our finding, others reported" exact="influenza" post="prevalence between 34.5% and 52.2% circulating in Iran.10-13 Contrary"/>
   <result pre="from January 2017 to March 2018 which was the unique" exact="influenza" post="type detected in March 2018. Yet, no data reported"/>
   <result pre="to be the exclusive type during spring. Circulation of different" exact="influenza" post="types seemed to be seasonal which might be correlated"/>
   <result pre="flu A, flu B and flu A (H1N1) during the" exact="influenza" post="seasons 2016-2017 and 2017-2018. A) Overall frequency of Flu"/>
   <result pre="2017-2018. A) Overall frequency of Flu types in the two" exact="influenza" post="seasons. B) Montly distribution of fluA, fluB and flu"/>
   <result pre="Other studies have evaluated distribution of types and subtypes of" exact="influenza" post="viruses in patients. Horthongkham et al. reported 3.1% for"/>
   <result pre="and flu B (28.5%) had the highest rates for 2017-2018" exact="influenza" post="seasonality. 9 Among general and specific respiratory illness symptoms,"/>
   <result pre="discharge.10-13 A majority of flu-positive patients had either pulmonary or" exact="heart disease" post="backgrounds, in line with their ages. Most often older"/>
   <result pre="cardiac, and metabolic or other disease have a more complicated" exact="influenza" post="illness with subsequent secondary bacterial infections.2,14-16 Different specimen types"/>
   <result pre="infections.2,14-16 Different specimen types have been proposed by different for" exact="influenza" post="virus detection. Flocked nasal and/or throat swabs or gargling"/>
   <result pre="to sputum (5%) samples. This finding suggests that the molecular" exact="influenza" post="tests show different sensitivity depending on the specimen types,"/>
   <result pre="40% of patients admitted to Laleh hospital were infected by" exact="influenza" post="virus. Influenza diagnosis was not achieved in up to"/>
   <result pre="his critical data and statistical analysis. References References 1.Rack-HochALLaniadoGHubnerJ.Comparison of" exact="influenza" post="and RSV diagnostic from nasopharyngeal swabs by rapid fluorescent"/>
   <result pre="in a German university children’s hospital. Infection2017;45:529-32.28290129 2.PapastergiouJFolkinsCLiWYoungL.Community pharmacy rapid" exact="influenza" post="A and B screening: A novel approach to expedite"/>
   <result pre="among the hospitalized young children with acute respiratory infection. Is" exact="influenza" post="A co infected with respiratory syncytial virus?Caspian J Intern"/>
   <result pre="Jundishapur J Microbiol2017;10. 7.HorthongkhamNAthipanyasilpNPattamaAet al.Epidemiological, clinical and virological characteristics of" exact="influenza" post="b virus from patients at the hospital tertiary care"/>
   <result pre="units in bangkok during 2011-2014. PloS One2016;11:e0158244.27387488 8.CohenALHellfersceeOPretoriusMet al.Epidemiology of" exact="influenza" post="virus types and subtypes in South Africa, 2009–2012. Emerg"/>
   <result pre="and outcomes of a cohort hospitalized for pandemic and seasonal" exact="influenza" post="in Germany based on nationwide inpatient data. PloS One2017;12:e0180920.28708896"/>
   <result pre="patient outcomes. Arch pathol lab med2015;139:636-41.25152311 14.YangJJitMZhengYet al.The impact of" exact="influenza" post="on the health related quality of life in China:"/>
   <result pre="EQ-5D survey. BMC Infect Dis2017;17:686.29037172 15.MenonNPerez-VelezCMWheelerJAet al.Extracorporeal membrane oxygenation in" exact="acute respiratory distress syndrome" post="due to influenza A (H1N1)pdm09 pneumonia. A singlecenter experience"/>
   <result pre="al.Extracorporeal membrane oxygenation in acute respiratory distress syndrome due to" exact="influenza" post="A (H1N1)pdm09 pneumonia. A singlecenter experience during the 2013-2014"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7172155\results\search\disease\results.xml">
   <result pre="7172155S0147-9571(19)30049-9 doi: 10.1016/j.cimid.2019.03.004 : Article Etiology and characteristics of community-acquired" exact="pneumonia" post="in an influenza epidemic period LinChun369168231@qq.comb1ChenHuanzhu13592849398@163.comac1HePingphe@stu.edu.cnaLiYazhen742795693@qq.comaKeChangwenkecw1965@aliyun.comaJiaoXiaoyangxyjiao@stu.edu.cna�?�[a], [b], [c], �?�Corresponding"/>
   <result pre=": Article Etiology and characteristics of community-acquired pneumonia in an" exact="influenza" post="epidemic period LinChun369168231@qq.comb1ChenHuanzhu13592849398@163.comac1HePingphe@stu.edu.cnaLiYazhen742795693@qq.comaKeChangwenkecw1965@aliyun.comaJiaoXiaoyangxyjiao@stu.edu.cna�?�[a], [b], [c], �?�Corresponding author at: 22"/>
   <result pre="have high positive rate. Abstract Purpose The etiology of community-acquired" exact="pneumonia" post="(CAP) in hospital patients is often ambiguous due to"/>
   <result pre="baumannii and klebsiella pneumoniae, whereas the most common virus was" exact="influenza" post="A. Conclusions Non-influenza respiratory microorganisms frequently co-circulated during the"/>
   <result pre="the etiologic agent is crucial for patient’s therapy. Keywords Community-acquired" exact="pneumonia" post="Influenza Respiratory virus bacterial/Yeast infection Co-infections 1 Introduction Community-acquired"/>
   <result pre="pneumonia Influenza Respiratory virus bacterial/Yeast infection Co-infections 1 Introduction Community-acquired" exact="pneumonia" post="(CAP) is a common disease and a significant cause"/>
   <result pre="cases of viral CAP occur every year, the incidence of" exact="viral pneumonia" post="still has been underestimated. In hospital, bacteria remain the"/>
   <result pre="of viral CAP occur every year, the incidence of viral" exact="pneumonia" post="still has been underestimated. In hospital, bacteria remain the"/>
   <result pre="mortality cases worldwide each year [4]. IVI can cause primary" exact="viral pneumonia," post="which may progress to a potentially fatal outcome [5]."/>
   <result pre="suppress host immune defenses, leading to bacterial complications [7]. Secondary" exact="bacterial pneumonia" post="is a frequent cause of excess mortality during influenza"/>
   <result pre="host immune defenses, leading to bacterial complications [7]. Secondary bacterial" exact="pneumonia" post="is a frequent cause of excess mortality during influenza"/>
   <result pre="bacterial pneumonia is a frequent cause of excess mortality during" exact="influenza" post="epidemics, but the epidemiology remains unclear [8]. Hospital admissions"/>
   <result pre="the epidemiology remains unclear [8]. Hospital admissions during the 2009" exact="influenza" post="epidemic season showed a moderate to strong association between"/>
   <result pre="influenza epidemic season showed a moderate to strong association between" exact="influenza" post="and bacterial pneumonia, whereas the interaction is modest or"/>
   <result pre="season showed a moderate to strong association between influenza and" exact="bacterial pneumonia," post="whereas the interaction is modest or non-existent during non-epidemic"/>
   <result pre="and staphylococcus aureus, often interact with respiratory viruses (esp. the" exact="influenza" post="virus), and shape the outcome of respiratory infection [10]."/>
   <result pre="subsequent bacterial infection [8,11,12]. In vitro studies have shown that" exact="influenza" post="infection enhanced susceptibility to pneumococcal pneumonia by about 100-fold"/>
   <result pre="studies have shown that influenza infection enhanced susceptibility to pneumococcal" exact="pneumonia" post="by about 100-fold in a week, but the interaction"/>
   <result pre="by about 100-fold in a week, but the interaction between" exact="influenza" post="and bacteria is not limited in pneumococcal pneumonia [13]."/>
   <result pre="interaction between influenza and bacteria is not limited in pneumococcal" exact="pneumonia" post="[13]. In the hospital, viral testing among patients with"/>
   <result pre="and clinical presentation of CAP caused by viruses other than" exact="influenza" post="during an influenza epidemic season were limited [[15], [16],"/>
   <result pre="of CAP caused by viruses other than influenza during an" exact="influenza" post="epidemic season were limited [[15], [16], [17]]. In this"/>
   <result pre="be new and without other obvious causes [18]. Patients with" exact="cystic fibrosis" post="or HIV infection were excluded from our study. 2.2"/>
   <result pre="were included in each analytical procedure. Fourteen respiratory viruses including" exact="influenza" post="A, influenza B, parainfluenza viruses 1–3 (PIV1-3), respiratory syncytial"/>
   <result pre="in each analytical procedure. Fourteen respiratory viruses including influenza A," exact="influenza" post="B, parainfluenza viruses 1–3 (PIV1-3), respiratory syncytial virus (RSV),"/>
   <result pre="of COPD, 3 cases of tuberculosis, 3 cases of pulmonary" exact="heart disease," post="and 4 cases of emphysema. A total of 106"/>
   <result pre="at least 1 underlying disease, including high blood pressure, diabetes," exact="heart disease," post="epilepsy, tumors and hepatitis. After admission, broad-spectrum antibiotics were"/>
   <result pre="17 8.72% Virus+ Yeast 8 4.10% Unidentified 72 36.92% Associated" exact="lung disease" post="COPD 6 3.08% Tuberculosis 3 1.54% Emphysema 4 2.05%"/>
   <result pre="COPD 6 3.08% Tuberculosis 3 1.54% Emphysema 4 2.05% Pulmonary" exact="heart disease" post="3 1.54% Asthma 2 1.03% Bronchiectasis 1 0.51% Bronchitis"/>
   <result pre="after healing Death 9 4.62% Alive 186 95.38% Abbreviations: COPD," exact="chronic obstructive pulmonary disease." post="3.2 Pathogen detection in patients with CAP A single-bacterial"/>
   <result pre="was identified in 57/195 (29.23%) of the patients. Influenza A," exact="influenza" post="B, PIV3 and RSV were the most common viruses"/>
   <result pre="with non-influenza viruses were more frequent than bacterial /Yeast and" exact="influenza" post="co-infections (Table 5). 3.3 Clinical presentation in relation to"/>
   <result pre="Clinical presentation in relation to etiological findings Fever, cough, and" exact="shortness" post="of breath were the most common clinical signs observed"/>
   <result pre="these patients, pharyngeal discomfort was only found in the pure" exact="influenza" post="group. Bacterium / Yeast co-infected with non-influenza viruses were"/>
   <result pre="with non-influenza viruses were more common than bacterium/ Yeast and" exact="influenza" post="co-infections. WBC counts in the non-influenza groups were significantly"/>
   <result pre="in the non-influenza groups were significantly higher than in the" exact="influenza" post="groups, and the highest WBC counts were observed in"/>
   <result pre="The number of bacterial infections and viral infections in the" exact="influenza" post="seasons and non-flu seasons in 2016. [alt-text] Table 4"/>
   <result pre="The status of bacterial infections and viral infections in the" exact="influenza" post="season and non-flu seasons In the flu season, the"/>
   <result pre="maltophilia, E. cloacae, K. ornithinolytica, S. marcescens, S. haemolyticus, S." exact="pneumonia" post="were not detected in the non-flu season. The emergence"/>
   <result pre="were not detected in the non-flu season. The emergence of" exact="influenza" post="viruses (Flu A and Flu B) was more common"/>
   <result pre="like MPV and 229E were smaller than flu in the" exact="influenza" post="season (Table 4). 4 Discussion Pathogen-directed therapy avoids unnecessary"/>
   <result pre="of empirical antimicrobial treatment [28]. Even there was a severe" exact="influenza" post="outbreak during our study, other respiratory viral infections were"/>
   <result pre="during our study, other respiratory viral infections were more than" exact="influenza" post="infection (63.16% vs. 36.84%). In all pathogens that cause"/>
   <result pre="pseudomallei (29%), S. pneumoniae (20%), K. pneumoniae (19%) and H." exact="influenza" post="(11%), respectively [33]. Although A. baumannii is an important"/>
   <result pre="popularity in this area. Most community-acquired cases of A. baumannii" exact="pneumonia" post="are from tropical or subtropical countries in the Asia-Pacific"/>
   <result pre="its mortality is 10 times higher than hospital-acquired A. baumannii" exact="pneumonia" post="[33,34]. In another aspect, most of our patients had"/>
   <result pre="baumannii infection [34]. Moreover, the mortality of carbapenem-resistant A. baumannii" exact="pneumonia" post="patients is higher than that of carbapenem-sensitive A. baumannii"/>
   <result pre="pneumonia patients is higher than that of carbapenem-sensitive A. baumannii" exact="pneumonia" post="patients [35,36]. S. pneumoniae and H. influenza, as co-pathogens,"/>
   <result pre="viruses usually followed seasonal patterns of activity [39], and epidemic" exact="influenza" post="was noted in our studied area, which was active"/>
   <result pre="study period, and there was a high detecting rate of" exact="influenza" post="A/influenza B was from January to May. During an"/>
   <result pre="influenza A/influenza B was from January to May. During an" exact="influenza" post="epidemic season, a high percentage of samples from CAP"/>
   <result pre="infections were very common [40]. The respiratory virus other than" exact="influenza" post="accounted for 63.16% viral CAP in our study, revealing"/>
   <result pre="can be co-circulating even during the highest epidemic peaks of" exact="influenza" post="that showed a seasonal distribution. Bacterial or fungal infections"/>
   <result pre="showed a seasonal distribution. Bacterial or fungal infections secondary to" exact="influenza" post="viral infections were common [41], though we could not"/>
   <result pre="viral infection. As the clinical signs and symptoms overlapped between" exact="influenza" post="and non-influenza viruses, pathogen-directed therapy is difficult if only"/>
   <result pre="interest. References References 1SpindlerC.StralinK.ErikssonL.Swedish guidelines on the management of community-acquired" exact="pneumonia" post="in immunocompetent adults—Swedish Society of Infectious Diseases 2012Scand. J."/>
   <result pre="for detection of respiratory viruses in pediatric patients at a" exact="cancer" post="hospitalJ. Clin. Microbiol.5020122282228822518855 4WHOInfluenza (seasonal) Fact Sheet No 211."/>
   <result pre="acute lung injury and repair in a murine model of" exact="influenza" post="pneumoniaSci. Rep.620162607627188343 6NorowitzY.M.KohlhoffS.Smith-NorowitzT.A.Relationship of influenza virus infection to associated"/>
   <result pre="in a murine model of influenza pneumoniaSci. Rep.620162607627188343 6NorowitzY.M.KohlhoffS.Smith-NorowitzT.A.Relationship of" exact="influenza" post="virus infection to associated infections in children who present"/>
   <result pre="who present with influenza-like symptomsBMC Infect. Dis.16201630427317396 7TaubenbergerJ.K.MorensD.M.The pathology of" exact="influenza" post="virus infectionsAnnu. Rev. Pathol.3200849952218039138 8McCullersJ.A.Do specific virus-bacteria pairings drive"/>
   <result pre="viral illness: a comprehensive evaluationJ. Infect. Dis.208201343244123661797 11McCullersJ.A.The co-pathogenesis of" exact="influenza" post="viruses with bacteria in the lungNat. Rev. Microbiol.12201425226224590244 12van"/>
   <result pre="the lungNat. Rev. Microbiol.12201425226224590244 12van der SluijsK.F.van der PollT.LutterR.Bench-to-bedside review:" exact="bacterial pneumonia" post="with influenza - pathogenesis and clinical implicationsCrit Care14201021920459593 13ShresthaS.FoxmanB.WeinbergerD.M.Identifying"/>
   <result pre="lungNat. Rev. Microbiol.12201425226224590244 12van der SluijsK.F.van der PollT.LutterR.Bench-to-bedside review: bacterial" exact="pneumonia" post="with influenza - pathogenesis and clinical implicationsCrit Care14201021920459593 13ShresthaS.FoxmanB.WeinbergerD.M.Identifying"/>
   <result pre="Microbiol.12201425226224590244 12van der SluijsK.F.van der PollT.LutterR.Bench-to-bedside review: bacterial pneumonia with" exact="influenza" post="- pathogenesis and clinical implicationsCrit Care14201021920459593 13ShresthaS.FoxmanB.WeinbergerD.M.Identifying the interaction"/>
   <result pre="- pathogenesis and clinical implicationsCrit Care14201021920459593 13ShresthaS.FoxmanB.WeinbergerD.M.Identifying the interaction between" exact="influenza" post="and pneumococcal pneumonia using incidence dataSci. Transl. Med.52013191ra84 14JuX.FangQ.ZhangJ.Viral"/>
   <result pre="clinical implicationsCrit Care14201021920459593 13ShresthaS.FoxmanB.WeinbergerD.M.Identifying the interaction between influenza and pneumococcal" exact="pneumonia" post="using incidence dataSci. Transl. Med.52013191ra84 14JuX.FangQ.ZhangJ.Viral etiology of influenza-like"/>
   <result pre="22CherianT.MulhollandE.K.CarlinJ.B.Standardized interpretation of paediatric chest radiographs for the diagnosis of" exact="pneumonia" post="in epidemiological studiesBull. World Health Organ.83200535335915976876 23MandellL.A.WunderinkR.G.AnzuetoA.Infectious Diseases Society"/>
   <result pre="America/American Thoracic Society consensus guidelines on the management of community-acquired" exact="pneumonia" post="in adultsClin. Infect. Dis.44Suppl 22007S277217278083 24BartlettJ.G.Diagnostic tests for agents"/>
   <result pre="agents of community-acquired pneumoniaClin. Infect. Dis.52Suppl 42011S29630421460288 25PirroneM.PinciroliR.BerraL.Microbiome, biofilms, and" exact="pneumonia" post="in the ICUCurr. Opin. Infect. Dis.29201616016626855081 26JohanssonN.KalinM.Tiveljung-LindellA.Etiology of community-acquired"/>
   <result pre="increased microbiological yield with new diagnostic methodsClin. Infect. Dis.50201020220920014950 27LuchsingerV.RuizM.ZuninoE.Community-acquired" exact="pneumonia" post="in Chile: the clinical relevance in the detection of"/>
   <result pre="the detection of viruses and atypical bacteriaThorax6820131000100623783373 28HolterJ.C.MullerF.BjorangO.Etiology of community-acquired" exact="pneumonia" post="and diagnostic yields of microbiological methods: a 3-year prospective"/>
   <result pre="in lung tissue specimens from fatal cases of 2009 pandemic" exact="influenza" post="A (H1N1) - United States, May–August 2009MMWR Morb. Mortal."/>
   <result pre="May–August 2009MMWR Morb. Mortal. Wkly. Rep.5820091071107419798021 30JokinenC.HeiskanenL.JuvonenH.Microbial etiology of community-acquired" exact="pneumonia" post="in the adult population of 4 municipalities in eastern"/>
   <result pre="care C. BTS guidelines for the management of community acquired" exact="pneumonia" post="in adultsThorax56Suppl 42001IV16411713364 32RhedinS.LindstrandA.HjelmgrenA.Respiratory viruses associated with community-acquired pneumonia"/>
   <result pre="acquired pneumonia in adultsThorax56Suppl 42001IV16411713364 32RhedinS.LindstrandA.HjelmgrenA.Respiratory viruses associated with community-acquired" exact="pneumonia" post="in children: matched case-control studyThorax70201584785326077969 33BachoumasK.LebertC.LacheradeJ.C.Community-acquired Acinetobacter baumannii pneumoniaMed."/>
   <result pre="British thoracic society guidelines for the management of community acquired" exact="pneumonia" post="in childhoodThorax57Suppl 12002i12411994552 39RuuskanenO.LahtiE.JenningsL.C.Viral pneumoniaLancet37720111264127521435708 40MengelleC.MansuyJ.M.PierreA.The use of a"/>
   <result pre="an emergency unitJ. Clin. Virol.61201441141725223920 41RiceT.W.RubinsonL.UyekiT.M.Critical illness from 2009 pandemic" exact="influenza" post="A virus and bacterial coinfection in the United StatesCrit."/>
   <result pre="in the United StatesCrit. Care Med.4020121487149822511131 42ChienY.S.SuC.P.TsaiH.T.Predictors and outcomes of" exact="respiratory failure" post="among hospitalized pneumonia patients with 2009 H1N1 influenza in"/>
   <result pre="Care Med.4020121487149822511131 42ChienY.S.SuC.P.TsaiH.T.Predictors and outcomes of respiratory failure among hospitalized" exact="pneumonia" post="patients with 2009 H1N1 influenza in TaiwanJ. Infect.60201016817420036689 43BagshawS.M.EgiM.GeorgeC.Early"/>
   <result pre="of respiratory failure among hospitalized pneumonia patients with 2009 H1N1" exact="influenza" post="in TaiwanJ. Infect.60201016817420036689 43BagshawS.M.EgiM.GeorgeC.Early blood glucose control and mortality"/>
   <result pre="ill patients in AustraliaCrit. Care Med.37200946347019114915 44CunhaB.A.IrshadN.ConnollyJ.J.Adult human metapneumonovirus (hMPV)" exact="pneumonia" post="mimicking Legionnaire’s diseaseHeart Lung45201627027226988110 45DavenportE.E.BurnhamK.L.RadhakrishnanJ.Genomic landscape of the individual"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7173238\results\search\disease\results.xml">
   <result pre="multi-target activity against viral infections of great medical importance (e.g.," exact="herpes simplex" post="virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus"/>
   <result pre="virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV) and hepatitis C virus (HCV)) and/or"/>
   <result pre="(VZV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and" exact="hepatitis" post="C virus (HCV)) and/or that are known antineoplastic agents"/>
   <result pre="Experimental development Acyclovir Acyclic guanosine analogue HSV, VZV (1982) Breast" exact="cancer" post="(Shaimerdenova et al., 2017)EBV (Pagano et al., 2018) Azacitidine"/>
   <result pre="al., 2018) Gemcitabine Cytidine analogue Various carcinomas (1995): non-small cell" exact="lung cancer," post="pancreatic cancer, bladder cancer breast cancer ovarian cancer HIV-1"/>
   <result pre="Gemcitabine Cytidine analogue Various carcinomas (1995): non-small cell lung cancer," exact="pancreatic cancer," post="bladder cancer breast cancer ovarian cancer HIV-1 (Rawson et"/>
   <result pre="analogue Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer," exact="bladder cancer" post="breast cancer ovarian cancer HIV-1 (Rawson et al. (2013);"/>
   <result pre="Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder" exact="cancer" post="breast cancer ovarian cancer HIV-1 (Rawson et al. (2013);"/>
   <result pre="carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder cancer" exact="breast cancer" post="ovarian cancer HIV-1 (Rawson et al. (2013); Clouser et"/>
   <result pre="(1995): non-small cell lung cancer, pancreatic cancer, bladder cancer breast" exact="cancer" post="ovarian cancer HIV-1 (Rawson et al. (2013); Clouser et"/>
   <result pre="non-small cell lung cancer, pancreatic cancer, bladder cancer breast cancer" exact="ovarian cancer" post="HIV-1 (Rawson et al. (2013); Clouser et al. (2010);"/>
   <result pre="cell lung cancer, pancreatic cancer, bladder cancer breast cancer ovarian" exact="cancer" post="HIV-1 (Rawson et al. (2013); Clouser et al. (2010);"/>
   <result pre="in combination with inarigivir) Trifluridine Thymidine analogue HSV (1980) Metastatic" exact="colorectal cancer" post="(2015) in combination with tipiracil Mycoplasma pneumonia (Sun and"/>
   <result pre="combination with inarigivir) Trifluridine Thymidine analogue HSV (1980) Metastatic colorectal" exact="cancer" post="(2015) in combination with tipiracil Mycoplasma pneumonia (Sun and"/>
   <result pre="(1980) Metastatic colorectal cancer (2015) in combination with tipiracil Mycoplasma" exact="pneumonia" post="(Sun and Wang, 2013) Valaciclovir Acyclic guanosine analogue HSV,"/>
   <result pre="humans worldwide (Leoni et al., 2018). According to the WHO," exact="viral hepatitis" post="caused 1.34 million deaths in 2015, a number that"/>
   <result pre="worldwide (Leoni et al., 2018). According to the WHO, viral" exact="hepatitis" post="caused 1.34 million deaths in 2015, a number that"/>
   <result pre="is comparable to the number of annual deaths caused by" exact="tuberculosis" post="and that is even higher than those attributed to"/>
   <result pre="is even higher than those attributed to HIV. A global" exact="hepatitis" post="report concluded that mortality from HIV, tuberculosis, and malaria"/>
   <result pre="global hepatitis report concluded that mortality from HIV, tuberculosis, and" exact="malaria" post="is now declining, while mortality from viral hepatitis has"/>
   <result pre="HIV, tuberculosis, and malaria is now declining, while mortality from" exact="viral hepatitis" post="has been increasing over time (World Health Organization, 2017)."/>
   <result pre="tuberculosis, and malaria is now declining, while mortality from viral" exact="hepatitis" post="has been increasing over time (World Health Organization, 2017)."/>
   <result pre="These individuals are at risk of developing severe complications, including" exact="cirrhosis" post="and hepatocellular carcinoma. In 2015, hepatitis B resulted in"/>
   <result pre="are at risk of developing severe complications, including cirrhosis and" exact="hepatocellular carcinoma." post="In 2015, hepatitis B resulted in 887,000 deaths, mostly"/>
   <result pre="developing severe complications, including cirrhosis and hepatocellular carcinoma. In 2015," exact="hepatitis" post="B resulted in 887,000 deaths, mostly due to complications."/>
   <result pre="and mortality among those living with HIV and coinfected with" exact="viral hepatitis." post="People with these conditions should be prioritized for diagnosis"/>
   <result pre="HBV infections. Telbivudine (L-thymidine) is used in the treatment of" exact="hepatitis" post="B infection. Clinical trials have shown that this drug"/>
   <result pre="endothelial-protective effects on B19V-infected endothelial cells and improves the chronic" exact="myocarditis" post="associated with B19V transcriptional activity (Van Linthout et al.,"/>
   <result pre="approved by the FDA in 2013 for use against chronic" exact="hepatitis" post="C infection. Sofosbuvir was the first drug that demonstrated"/>
   <result pre="(NCT03312023). It has been observed that patients who had both" exact="hepatitis" post="B and hepatitis C and who were treated for"/>
   <result pre="been observed that patients who had both hepatitis B and" exact="hepatitis" post="C and who were treated for hepatitis C for"/>
   <result pre="hepatitis B and hepatitis C and who were treated for" exact="hepatitis" post="C for 12 weeks with a combination of ledipasvir/sofosbuvir"/>
   <result pre="for 12 weeks with a combination of ledipasvir/sofosbuvir had decreased" exact="hepatitis" post="B surface antigen levels. This finding was the basis"/>
   <result pre="a similar decrease could be observed in mono-infected individuals with" exact="hepatitis" post="B. Sofosbuvir was also recently shown to protect against"/>
   <result pre="flaviviruses, such as dengue virus (DENV) (Xu et al., 2017)," exact="yellow fever" post="virus (YFV) (De Freitas et al., 2019), and chikungunya"/>
   <result pre="yellow fever virus (YFV) (De Freitas et al., 2019), and" exact="chikungunya" post="virus (CHIKV) (Ferreira et al., 2019). 3 Multi-target nucleos(t)ide-based"/>
   <result pre="in DMSO is available for the treatment of herpes labialis," exact="herpes genitalis" post="and herpes zoster (Aoki, 2015). Fig. 4 Nucleoside-based marketed"/>
   <result pre="available for the treatment of herpes labialis, herpes genitalis and" exact="herpes zoster" post="(Aoki, 2015). Fig. 4 Nucleoside-based marketed drugs against various"/>
   <result pre="brivudine, famciclovir and valaciclovir treatment in immunocompetent adult patients with" exact="herpes zoster" post="indicate that brivudine may be the first choice in"/>
   <result pre="brivudine may be the first choice in cases of severe" exact="herpes zoster" post="because of its ability to promptly control pain and"/>
   <result pre="been evaluated for their cytotoxic activity against a panel of" exact="cancer" post="cell lines. Compared to parent nucleoside, such as idoxuridine"/>
   <result pre="monophosphate, it inhibits thymidylate synthetase, which is elevated in different" exact="cancer" post="cell lines. After further phosphorylation, the corresponding triphosphate competitively"/>
   <result pre="European Union for the treatment of adult patients with metastatic" exact="colorectal cancer" post="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin"/>
   <result pre="Union for the treatment of adult patients with metastatic colorectal" exact="cancer" post="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin"/>
   <result pre="efficacy of trifluridine-tipiracil during the treatment of patients with metastatic" exact="colorectal cancer" post="(NCT03306394). Trifluridine was also tested as an antibacterial agent."/>
   <result pre="of trifluridine-tipiracil during the treatment of patients with metastatic colorectal" exact="cancer" post="(NCT03306394). Trifluridine was also tested as an antibacterial agent."/>
   <result pre="2017, studies conducted to determine the effect of acyclovir on" exact="breast cancer" post="MCF-7 cells were described (Shaimerdenova et al., 2017). The obtained"/>
   <result pre="studies conducted to determine the effect of acyclovir on breast" exact="cancer" post="MCF-7 cells were described (Shaimerdenova et al., 2017). The obtained"/>
   <result pre="The obtained results demonstrate the suppressive effect of acyclovir on" exact="breast cancer" post="cells. Acyclovir treatment decreases the proliferation rate as well"/>
   <result pre="obtained results demonstrate the suppressive effect of acyclovir on breast" exact="cancer" post="cells. Acyclovir treatment decreases the proliferation rate as well"/>
   <result pre="inhibits the colony formation ability and cell invasion capacity of" exact="cancer" post="cells. These results demonstrate the possibility of partial suppression"/>
   <result pre="of cancer cells. These results demonstrate the possibility of partial" exact="suppression" post="of cancer cell proliferation using this antiviral agent. However,"/>
   <result pre="cells. These results demonstrate the possibility of partial suppression of" exact="cancer" post="cell proliferation using this antiviral agent. However, further research"/>
   <result pre="would be a cytotoxic agent when properly delivered to the" exact="cancer" post="cells. To facilitate the targeted delivery of phosphorylated acyclovir"/>
   <result pre="penciclovir probably distorts the DNA conformation and then induces the" exact="suppression" post="of further DNA elongation (Piret and Boivin, 2011). Penciclovir"/>
   <result pre="EBV-infectious mononucleosis (NCT00575185) as well as for the treatment of" exact="herpes zoster" post="(NCT00831103). Cyclopropavir (MBX-400) is another extensively investigated compound. It"/>
   <result pre="a phase 2 clinical trial in comparison with valaciclovir for" exact="herpes zoster" post="(NCT00900783) and in a phase 3 clinical trial in"/>
   <result pre="including leukaemias, lymphomas, and pancreatic, breast, bladder, ovarian, colon or" exact="kidney cancer." post="By mimicking the physiological role of their natural counterparts,"/>
   <result pre="floxuridine in 1970), which have had important roles in several" exact="cancer" post="treatments (Parker, 2009). Some of the cytotoxic nucleoside analogues"/>
   <result pre="bacteria were lower than those used for the treatment of" exact="cancer" post="patients, which can reduce the problem of toxicity (Jordheim"/>
   <result pre="for the treatment of locally advanced or metastatic non-small cell" exact="lung cancer," post="and Gemzar in combination with paclitaxel was approved as"/>
   <result pre="was approved as the first-line therapy for women battling metastatic" exact="breast cancer." post="Gemzar demonstrates dose-dependent synergistic activity with cisplatin. In the"/>
   <result pre="dose-dependent synergistic activity with cisplatin. In the treatment of advanced" exact="ovarian cancer" post="(at least 6 months after completion of platinum-based therapy),"/>
   <result pre="synergistic activity with cisplatin. In the treatment of advanced ovarian" exact="cancer" post="(at least 6 months after completion of platinum-based therapy),"/>
   <result pre="study showed that co-treatment with gemcitabine and zidovudine re-sensitized gemcitabine-resistant" exact="pancreatic cancer" post="by inhibiting the key signalling pathway, Akt-GSK3β-Snail1, in the"/>
   <result pre="showed that co-treatment with gemcitabine and zidovudine re-sensitized gemcitabine-resistant pancreatic" exact="cancer" post="by inhibiting the key signalling pathway, Akt-GSK3β-Snail1, in the"/>
   <result pre="brivudine with gemcitabine or cisplatin enhanced their efficacy as a" exact="pancreatic cancer" post="therapy (Heinrich et al., 2011). Recently (2018), the FDA"/>
   <result pre="with gemcitabine or cisplatin enhanced their efficacy as a pancreatic" exact="cancer" post="therapy (Heinrich et al., 2011). Recently (2018), the FDA"/>
   <result pre="FDA in 2004 for the treatment of all subtypes of" exact="myelodysplastic syndrome" post="(MDS). To date, azacytidine has also been approved for"/>
   <result pre="FDA in 2006 for the treatment of multiple types of" exact="myelodysplastic syndrome." post="It promotes cytotoxic DNA hypomethylation and cell death in"/>
   <result pre="et al., 2017). Additionally, it was shown that in muscle-invasive" exact="bladder cancer" post="cells, decitabine treatment (at low non-cytotoxic doses) restored NOTCH1"/>
   <result pre="al., 2017). Additionally, it was shown that in muscle-invasive bladder" exact="cancer" post="cells, decitabine treatment (at low non-cytotoxic doses) restored NOTCH1"/>
   <result pre="and decitabine at concentrations much lower than those used in" exact="cancer" post="treatment synergistically lowered HIV-1 infectivity by 73% and significantly"/>
   <result pre="inhibitor from an HSP90 inhibitor as a selective inhibitor of" exact="hepatitis" post="C virusPLoS One72012e3028610.1371/journal.pone.0030286 BöslK.IanevskiA.ThanT.T.AndersenP.I.KuivanenS.TepporM.ZusinaiteE.DumpisU.VitkauskieneA.CoxR.J.Kallio-KokkoH.BergqvistA.TensonT.OksenychV.BjøråsM.AnthonsenM.W.ShumD.KaarbøM.VapalahtiO.WindischM.P.Superti-FurgaG.SnijderB.KainovD.KandasamyR.K.Critical nodes of virus-host interaction revealed"/>
   <result pre="vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072 DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.KuivanenS.VapalahtiO.KanteleA.TynellJ.JulkunenI.Kallio-KokkoH.PaavilainenH.HukkanenV.ElliottR.M.De BrabanderJ.K.SaelensX.KainovD.E.Obatoclax, saliphenylhalamide, and gemcitabine inhibit" exact="influenza" post="A virus infectionJ. Biol. Chem.2872012353243533210.1074/jbc.M112.39214222910914 DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity of 5-azacytidine"/>
   <result pre="DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive" exact="myelodysplastic syndrome" post="with autoimmune manifestationsVirol. J.92012110.1186/1743-422X-9-122214262 DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs"/>
   <result pre="Faria NetoH.C.BoechatN.RehenS.K.BrüningK.BozzaF.A.BozzaP.T.SouzaT.M.L.Beyond members of the Flaviviridae family, sofosbuvir also inhibits" exact="chikungunya" post="virus replicationAntimicrob. Agents Chemother.63201910.1128/AAC.01389-18e01389-18 FlorescuD.F.PergamS.A.NeelyM.N.QiuF.JohnstonC.WayS.S.SandeJ.LewinsohnD.A.Guzman-CottrillJ.A.GrahamM.L.PapanicolaouG.KurtzbergJ.RigdonJ.PainterW.Mommeja-MarinH.LanierR.AndersonM.van der HorstC.Safety and efficacy"/>
   <result pre="shock protein HSP27 (HSPB1) and enhances survival in animals and" exact="pancreatic cancer" post="patientsJ. Cancer Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the"/>
   <result pre="protein HSP27 (HSPB1) and enhances survival in animals and pancreatic" exact="cancer" post="patientsJ. Cancer Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the"/>
   <result pre="JordheimL.P.DurantelD.ZoulimF.DumontetC.Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseasesNat. Rev. Drug Discov.12201344746410.1038/nrd401023722347 JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.Van WettereA.LeeY.M.SheridanW.P.MorreyJ.D.BabuY.S.Efficacy of"/>
   <result pre="differentially affect cellular signaling, transcription and metabolismAntivir. Res.139201711712810.1016/j.antiviral.2016.12.02228049006 LahmerT.HoffmannD.HeemannU.KüchleC.FrankH.Epstein-Barr virus" exact="encephalitis" post="after kidney transplantation and successful treatment with brivudineTranspl. Int.232010e24e2510.1111/j.1432-2277.2009.01045.x20070626"/>
   <result pre="and subtype profiling of PSI-7977 as a nucleotide inhibitor of" exact="hepatitis" post="C virusAntimicrob. Agents Chemother.5620123359336810.1128/aac.00054-1222430955 LaskinO.L.Acyclovir: pharmacology and clinical experienceArch."/>
   <result pre="virusAntimicrob. Agents Chemother.27198597197310.1128/AAC.27.6.9712992367 LittlerE.ZhouX.-X.Deoxyribonucleic acid viruses: antivirals for herpesviruses and" exact="hepatitis" post="B virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management"/>
   <result pre="virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management of chronic" exact="hepatitis" post="B virus infectionExpert Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates"/>
   <result pre="Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates of prevalent and incident" exact="herpes simplex" post="virus type 1 infections in 2012PLoS One10201511710.1371/journal.pone.0140765 LuberA.D.FlahertyJ.F.Famciclovir for"/>
   <result pre="of varicella zoster virusJ. Antimicrob. Chemother.6020071316133010.1093/jac/dkm37617956908 Menéndez-AriasL.�?lvarezM.PachecoB.Nucleoside/nucleotide analog inhibitors of" exact="hepatitis" post="B virus polymerase: mechanism of action and resistanceCurr. Opin."/>
   <result pre="liquid chromatographyJ. Virol. Methods161200922323010.1016/j.jviromet.2009.06.01619559728 NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant" exact="pancreatic cancer" post="cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell"/>
   <result pre="chromatographyJ. Virol. Methods161200922323010.1016/j.jviromet.2009.06.01619559728 NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic" exact="cancer" post="cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell"/>
   <result pre="in the treatment of cancerChem. Rev.10920092880289310.1021/cr900028pEnzymology19476376 PaulyM.D.LauringA.S.Effective lethal mutagenesis of" exact="influenza" post="virus by three nucleoside analogsJ. Virol.8920153584359710.1128/jvi.03483-1425589650 PiretJ.BoivinG.Resistance of herpes"/>
   <result pre="of influenza virus by three nucleoside analogsJ. Virol.8920153584359710.1128/jvi.03483-1425589650 PiretJ.BoivinG.Resistance of" exact="herpes simplex" post="viruses to nucleoside analogues: mechanisms, prevalence, and managementAntimicrob. Agents"/>
   <result pre="of thymidineBBA - Biochim. Biophys. Acta32195929529610.1016/0006-3002(59)90597-913628760 QuenelleD.C.LampertB.CollinsD.J.RiceT.L.PainterG.R.KernE.R.Efficacy of CMX001 against" exact="herpes simplex" post="virus infections in mice and correlations with drug distribution"/>
   <result pre="reductaseBioorg. Med. Chem.2420162410242210.1016/j.bmc.2016.03.05227117260 RehermannB.BertolettiA.Immunological aspects of antiviral therapy of chronic" exact="hepatitis" post="B virus and hepatitis C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update"/>
   <result pre="aspects of antiviral therapy of chronic hepatitis B virus and" exact="hepatitis" post="C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update on the treatment options"/>
   <result pre="the nucleoside scaffoldAntivir. Res.1542018668610.1016/j.antiviral.2018.04.00429649496 ShaimerdenovaM.KarapinaO.MektepbayevaD.AlibekK.AkilbekovaD.The effects of antiviral treatment on" exact="breast cancer" post="cell lineInfect. Agents Cancer12201711010.1186/s13027-017-0128-728053656 ShinH.J.KimC.ChoS.Gemcitabine and nucleos(t)ide synthesis inhibitors"/>
   <result pre="nucleoside scaffoldAntivir. Res.1542018668610.1016/j.antiviral.2018.04.00429649496 ShaimerdenovaM.KarapinaO.MektepbayevaD.AlibekK.AkilbekovaD.The effects of antiviral treatment on breast" exact="cancer" post="cell lineInfect. Agents Cancer12201711010.1186/s13027-017-0128-728053656 ShinH.J.KimC.ChoS.Gemcitabine and nucleos(t)ide synthesis inhibitors"/>
   <result pre="luoro-2′-β- C -methyluridine Nucleotide Prodrug (PSI-7977) for the treatment of" exact="hepatitis" post="C virusJ. Med. Chem.5320107202721810.1021/jm100863x20845908 SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD. eunChoS.ChangS.Y.YoonB. IlSeongJ.KoH.J.Antiviral activity of"/>
   <result pre="analogsBMC Microbiol.13201318410.1186/1471-2180-13-18423919755 ThackrayA.M.FieldH.J.Famciclovir and valaciclovir differ in the prevention of" exact="herpes simplex" post="virus type 1 latency in mice: a quantitative studyAntimicrob."/>
   <result pre="placebo- controlled trialAnn. Intern. Med.1231995899610.7326/0003-4819-123-2-199507150-000027778840 Van LinthoutS.ElsanhouryA.KleinO.SosnowskiM.MitevaK.LassnerD.Abou-El-EneinM.PieskeB.KühlU.TschöpeC.Telbivudine in chronic lymphocytic" exact="myocarditis" post="and human parvovirus B19 transcriptional activityESC Hear. Fail.5201881882910.1002/ehf2.12341 VatnerS.F.ParkM.YanL.LeeG.J.LaiL.IwatsuboK.IshikawaY.PessinJ.VatnerD.E.Adenylyl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7173702\results\search\disease\results.xml">
   <result pre="and creation of adaptations, all for non-commercial purposes. Abstract During" exact="influenza" post="infection, hemagglutinins (HAs) on the viral surface bind to"/>
   <result pre="host cell’s surface. While all HAs bind sialic acids, human" exact="influenza" post="targets terminal α2,6 sialic acids and avian influenza targets"/>
   <result pre="sialic acids, human influenza targets terminal α2,6 sialic acids and" exact="avian influenza" post="targets α2,3 sialic acids. For interspecies transmission (zoonosis), HA"/>
   <result pre="acids, human influenza targets terminal α2,6 sialic acids and avian" exact="influenza" post="targets α2,3 sialic acids. For interspecies transmission (zoonosis), HA"/>
   <result pre="binding analyzed against a panel of HAs derived from pathogenic" exact="influenza" post="strains including low pathogenic avian strains. This showed significant"/>
   <result pre="disease and zoonosis transmission. Introduction Worldwide, annual epidemics of seasonal" exact="influenza" post="are estimated to result in 3–5 million cases of"/>
   <result pre="annually are associated with respiratory diseases from seasonal influenza.1 While" exact="influenza" post="A and B viruses cause seasonal epidemics, only A"/>
   <result pre="(NA)—for example, the H1N1 strain pandemic in 2009.2 During infection," exact="influenza" post="virus particles display trimeric HAs that bind to sialosides"/>
   <result pre="surface of their host cells to facilitate internalization. While all" exact="influenza" post="strains bind sialosides, human strains preferentially bind to terminal"/>
   <result pre="human strains preferentially bind to terminal α2,6 sialic acids, whereas" exact="avian influenza" post="viruses show preference for α2,3 sialic acids.3,4 Zoonosis (interspecies"/>
   <result pre="strains preferentially bind to terminal α2,6 sialic acids, whereas avian" exact="influenza" post="viruses show preference for α2,3 sialic acids.3,4 Zoonosis (interspecies"/>
   <result pre="HA, enabling a switch from α2,3 to α2,6. This allows" exact="avian influenza" post="to infect humans, and often occurs in porcine (pig)"/>
   <result pre="enabling a switch from α2,3 to α2,6. This allows avian" exact="influenza" post="to infect humans, and often occurs in porcine (pig)"/>
   <result pre="Humans can be infected with avian, porcine, and other zoonotic" exact="influenza" post="viruses including avian influenza subtypes; H5N1, H7N9, and H9N2"/>
   <result pre="infected with avian, porcine, and other zoonotic influenza viruses including" exact="avian influenza" post="subtypes; H5N1, H7N9, and H9N2 and swine flu virus"/>
   <result pre="with avian, porcine, and other zoonotic influenza viruses including avian" exact="influenza" post="subtypes; H5N1, H7N9, and H9N2 and swine flu virus"/>
   <result pre="N-acetyl) play a significant role in species-dependent binding9 and that" exact="influenza" post="can bind phosphorylated, non-sialylated glycans determined against an array"/>
   <result pre="Whitesides and co-workers synthesized sialic acid containing glycopolymeric inhibitors of" exact="influenza" post="virus X-31 via a poly(N-acrylyloxy succinimide) reactive scaffold. Using"/>
   <result pre="and 2,6-sialyllactose-functional glycopolymers that were able to recognize two different" exact="influenza" post="strains. They found that 2,6-sialyllactose-functional glycopolymers inhibited hemagglutination caused"/>
   <result pre="used for the discrimination of human (H3N2) and avian (H5N1)" exact="influenza" post="using PEGylated gold particles presenting trivalent α2,6 sialic acid"/>
   <result pre="a multivalent nanoparticle platform to dissect the binding trends of" exact="influenza" post="HAs toward multivalent sialic acid isomers. A library-oriented screen"/>
   <result pre="obtained through BEI resources, NIAID, NIH: H1 HA protein from" exact="influenza" post="virus, A/California/07/2009 (H1N1)pdm09, recombinant from baculovirus, NR-44074, H2 HA"/>
   <result pre="A/California/07/2009 (H1N1)pdm09, recombinant from baculovirus, NR-44074, H2 HA protein from" exact="influenza" post="virus, A/Singapore/1/1957 (H2N2), recombinant from baculovirus, NR-2668, H3 HA"/>
   <result pre="A/Singapore/1/1957 (H2N2), recombinant from baculovirus, NR-2668, H3 HA protein from" exact="influenza" post="virus, A/Uruguay/716/2007 (H3N2), recombinant from baculovirus, NR-15168, H4 HA"/>
   <result pre="A/Uruguay/716/2007 (H3N2), recombinant from baculovirus, NR-15168, H4 HA protein from" exact="influenza" post="virus, A/mallard/Alberta/455/2015 (H4N6), recombinant from baculovirus, NR-51128, H5 HA"/>
   <result pre="A/mallard/Alberta/455/2015 (H4N6), recombinant from baculovirus, NR-51128, H5 HA protein from" exact="influenza" post="virus, A/duck/Hunan/795/2002 (H5N1), recombinant from baculovirus, NR-43739, H7 HA"/>
   <result pre="A/duck/Hunan/795/2002 (H5N1), recombinant from baculovirus, NR-43739, H7 HA protein from" exact="influenza" post="virus, A/Canada/rv444/2004 (H7N3), recombinant from baculovirus, NR-43740, H9 HA"/>
   <result pre="A/Canada/rv444/2004 (H7N3), recombinant from baculovirus, NR-43740, H9 HA protein from" exact="influenza" post="virus, A/Hong Kong/33982/2009 (H9N2), recombinant from baculovirus, NR-41792 and"/>
   <result pre="NR-41792 and H10 HA protein with C-terminal histidine tag from" exact="influenza" post="virus, A/harbor seal/Germany/1/2014 (H10N7), recombinant from baculovirus, NR-50172. Clear"/>
   <result pre="investigated the mammalian transmissibility of many avian and other zoonotic" exact="influenza" post="strains including H7N9,49 H9N2,50 and H10N852 by looking at"/>
   <result pre="the affinity of sialic acid isomers against a panel of" exact="influenza" post="A HAs to map their affinity. This allows for"/>
   <result pre="were then interrogated for their binding against a panel of" exact="influenza" post="A HAs including three mammalian strains, four avian strains,"/>
   <result pre="including three mammalian strains, four avian strains, and a zoonotic" exact="influenza" post="strain. As expected, 2,3-sialyllactosamine had strong affinity toward avian"/>
   <result pre="obtained through BEI Resources, NIAID, NIH: H1 HA protein from" exact="influenza" post="virus, A/California/07/2009 (H1N1)pdm09, recombinant from baculovirus, NR-44074, H2 HA"/>
   <result pre="A/California/07/2009 (H1N1)pdm09, recombinant from baculovirus, NR-44074, H2 HA protein from" exact="influenza" post="virus, A/Singapore/1/1957 (H2N2), recombinant from baculovirus, NR-2668, H3 HA"/>
   <result pre="A/Singapore/1/1957 (H2N2), recombinant from baculovirus, NR-2668, H3 HA protein from" exact="influenza" post="virus, A/Uruguay/716/2007 (H3N2), recombinant from baculovirus, NR-15168, H4 HA"/>
   <result pre="A/Uruguay/716/2007 (H3N2), recombinant from baculovirus, NR-15168, H4 HA protein from" exact="influenza" post="virus, A/mallard/Alberta/455/2015 (H4N6), recombinant from baculovirus, NR-51128, H5 HA"/>
   <result pre="A/mallard/Alberta/455/2015 (H4N6), recombinant from baculovirus, NR-51128, H5 HA protein from" exact="influenza" post="virus, A/duck/Hunan/795/2002 (H5N1), recombinant from baculovirus, NR-43739, H7 HA"/>
   <result pre="A/duck/Hunan/795/2002 (H5N1), recombinant from baculovirus, NR-43739, H7 HA protein from" exact="influenza" post="virus, A/Canada/rv444/2004 (H7N3), recombinant from baculovirus, NR-43740, H9 HA"/>
   <result pre="A/Canada/rv444/2004 (H7N3), recombinant from baculovirus, NR-43740, H9 HA protein from" exact="influenza" post="virus, A/Hong Kong/33982/2009 (H9N2), recombinant from baculovirus, NR-41792 and"/>
   <result pre="NR-41792 and H10 HA protein with C-terminal histidine tag from" exact="influenza" post="virus, A/harbor seal/Germany/1/2014 (H10N7), recombinant from baculovirus, NR-50172. References"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7173783\results\search\disease\results.xml">
   <result pre="Health : Preventive Medicine: Vaccination and Immunization Stochastic modeling of" exact="influenza" post="spread dynamics with recurrences Stochastic modeling of influenza spread"/>
   <result pre="modeling of influenza spread dynamics with recurrences Stochastic modeling of" exact="influenza" post="spread dynamics with recurrences http://orcid.org/0000-0001-5848-0164WhitmanJohnData curationFormal analysisInvestigationSoftwareVisualizationWriting – original"/>
   <result pre="of a study of a simple, stochastic, agent-based model of" exact="influenza" post="A infection, simulating its dynamics over the course of"/>
   <result pre="have added to their enormous negative impact. The control of" exact="influenza" post="A virus, a major international health concern [3] poses"/>
   <result pre="and 11%, depending on the season [4]. The problem of" exact="influenza" post="spread and proliferation spans length scales from the sub-cellular"/>
   <result pre="simulations of a stochastic agent-based model of the spread of" exact="influenza" post="A over the course of a season and an"/>
   <result pre="conducted one of the earliest studies of spatial-temporal model of" exact="influenza" post="and applied it to spread in the Soviet Union"/>
   <result pre="metapopulation models and agent-based models to investigate the epidemiology of" exact="influenza" post="and other infectious diseases. Watts et al. [14] introduce"/>
   <result pre="Model (IBM) and address the ecology, epidemiology, and evolution of" exact="influenza" post="A viruses. Longini et al. studied a stochastic influenza"/>
   <result pre="of influenza A viruses. Longini et al. studied a stochastic" exact="influenza" post="simulation model for rural Southeast Asia and determined the"/>
   <result pre="the effectiveness of targeted antiviral strategies for containing an emerging" exact="influenza" post="strain at the source as a function of the"/>
   <result pre="and numerical simulations to show that recurrences can occur in" exact="measles" post="epidemics on the scale of years when immigration is"/>
   <result pre="model. Emphasis is on the behavior of the spread of" exact="influenza" post="infection during the course of one flu season, and"/>
   <result pre="as the city of Columbus, Ohio [23, 24], the 2018–19" exact="influenza" post="season had two waves of influenza A activity of"/>
   <result pre="[23, 24], the 2018–19 influenza season had two waves of" exact="influenza" post="A activity of similar magnitude: A(H1N1), a pandemic strain"/>
   <result pre="and methods In early, seminal work in the context of" exact="measles" post="epidemics, Bartlett showed the existence of a critical population"/>
   <result pre="compared to the interval of 70 weeks or more for" exact="measles" post="[27]) and study the agent-based model described in detail"/>
   <result pre="it is known from data for the pathogenesis of the" exact="influenza" post="virus that there is an incubation period corresponding to"/>
   <result pre="with rate parameters chosen to reflect the known features of" exact="influenza" post="A dynamics. The primary quantity of interest is the"/>
   <result pre="time step of 1 day, which is appropriate for describing" exact="influenza" post="infection in a group of individuals in a single"/>
   <result pre="single season. We simulate for a time of one season:" exact="influenza" post="strains mutate on the time scale of a year"/>
   <result pre="mutate on the time scale of a year [29], particular" exact="influenza" post="strains tend to dominate in each season, and which"/>
   <result pre="addition, it is common for municipalities to collect data on" exact="influenza" post="infections for this time period, as is the case"/>
   <result pre="day because available immunological data which details the course of" exact="influenza" post="infection for individuals is on the scale of days"/>
   <result pre="Longini et al. [20] utilized a hierarchical population to model" exact="influenza" post="spread through close groups (families, schools, workplaces) and casual"/>
   <result pre="also define a many tiered population structure in which recurrent" exact="influenza" post="infections are shown to occur. The closely connected contexts"/>
   <result pre="increase in the immune profile of the population is a" exact="suppression" post="of (a) the initial spread of the disease, seen"/>
   <result pre="taken over 10,000 individual realizations. Thus, there is a stochastic" exact="suppression" post="of the spread; such extinctions are known to occur"/>
   <result pre="we investigate a scenario within our model in which the" exact="influenza" post="vaccine is effective against the pandemic virus that spreads"/>
   <result pre="infected people with either the seasonal or pandemic strain of" exact="influenza" post="in a season. In the left figure, half of"/>
   <result pre="a numerical simulation study of a simple agent-based model of" exact="influenza" post="spread. We have investigated the effect of the topology"/>
   <result pre="people infected with pandemic flu increases. However, we observe the" exact="suppression" post="of infection recurrences in the seasonal strain for lower"/>
   <result pre="and future. International Journal of Epidemiology. 2003;32(5):684–686. 10.1093/ije/dyg28214559728 2FonkwoPN. Pricing" exact="infectious disease." post="EMBO reports. 2008;9(S1):S13–S17. 10.1038/embor.2008.11018578017 3IulianoAD, RoguskiKM, ChangHH, MuscatelloDJ, PalekarR,"/>
   <result pre="KronemanM, WiegersT, El Guerche-SéblainC, PagetJ. Clinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype, and lineage: A systematic"/>
   <result pre="PetersTR, SnivelyBM, PoehlingKA, ZhouX. Multi-scale modeling for the transmission of" exact="influenza" post="and the evaluation of interventions toward it. Scientific Reports."/>
   <result pre="–. 10.1038/srep0898025757402 18FoxSJ, MillerJC, MeyersLA. Seasonality in risk of pandemic" exact="influenza" post="emergence. PLOS Computational Biology. 2017;13(10):1–23. 10.1371/journal.pcbi.1005749 19RocheB, DrakeJM, RohaniP."/>
   <result pre="RosenfeldR, GhedinE, MochanE, BrownST, et al.A large-scale immuno-epidemiological simulation of" exact="influenza" post="A epidemics. BMC Public Health. 2014;14(1):101910.1186/1471-2458-14-101925266818 31WoodhouseDE, RothenbergRB, PotteratJJ,"/>
   <result pre="Language Documentation. 2019;. 41MurilloLN, MurilloMS, PerelsonAS. Towards multiscale modeling of" exact="influenza" post="infection. Journal of Theoretical Biology. 2013;332:267—290. 10.1016/j.jtbi.2013.03.02423608630 42SmithH. An"/>
   <result pre="Isotropic Noise. Oikos. 1998;83(2):353–358. 10.2307/3546849 47CaravagnaG, d’OnofrioA, MilazzoP, BarbutiR. Tumour" exact="suppression" post="by immune system through stochastic oscillations. Journal of Theoretical"/>
   <result pre="SmithG, Ruf-zamojskiF, Martinez-RomeroC, FribourgM, CarbajalEA, et al.Innate immune response to" exact="influenza" post="virus at single-cell resolution in human epithelial cells revealed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7173960\results\search\disease\results.xml">
   <result pre="development of bunyavirus antiviral therapies. bunyavirus therapy single-domain antibody vhh" exact="rift valley fever" post="virus schmallenberg virus Research organism Virus Funding http://dx.doi.org/10.13039/501100010767Innovative Medicines"/>
   <result pre="severe flu-like symptoms, however a minority of patients may develop" exact="encephalitis" post="or hemorrhagic fever. In addition to members of the"/>
   <result pre="RVFV, Crimean-Congo hemorrhagic fever virus (CCHFV) and severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV), on the Blueprint list of viruses"/>
   <result pre="assembly strategy may also facilitate the development of biotherapeutics targeting" exact="cancer" post="and toxins. Interestingly, a related approach primarily based on"/>
   <result pre="is expected to provide novel opportunities for the development of" exact="cancer" post="and toxin biotherapeutics. Materials and methods Key resources table"/>
   <result pre="the RVFV VLP antigen, this llama was also immunized with" exact="influenza" post="antigens for a different study (Harmsen et al., 2013)."/>
   <result pre="llama Single-Domain antibody fragments binding all nine neuraminidase subtypes of" exact="influenza" post="A virusAntibodies216819210.3390/antib2020168 HarmsenMMDe HaardHJ2007aProperties, production, and applications of camelid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7175453\results\search\disease\results.xml">
   <result pre="how a pandemic may occur by looking into the past" exact="influenza" post="pandemic events. We discuss interpretations of the experimental evidences"/>
   <result pre="suggest what should be assessed to prevent global catastrophes from" exact="influenza" post="virus, Middle East respiratory syndrome coronavirus, dengue and Zika"/>
   <result pre="National Research Foundation KoreaNRF-2017R1A2B2003773ParkMan-Seong Introduction Of the four types of" exact="influenza" post="viruses, influenza A virus (IAV) and influenza B virus"/>
   <result pre="Foundation KoreaNRF-2017R1A2B2003773ParkMan-Seong Introduction Of the four types of influenza viruses," exact="influenza" post="A virus (IAV) and influenza B virus (IBV) cause"/>
   <result pre="four types of influenza viruses, influenza A virus (IAV) and" exact="influenza" post="B virus (IBV) cause major respiratory diseases to humans"/>
   <result pre="‘influenza-like illness’ and outcomes [11–14]. There have been four major" exact="influenza" post="pandemics since 1918 with some glimpses of pandemic-like events"/>
   <result pre="some glimpses of pandemic-like events in history [15–17]. The H1N1" exact="influenza" post="pandemic of 1918 (pdm1918) is estimated to have caused"/>
   <result pre="devastating one pandemic outbreak can be. It is believed that" exact="influenza" post="pandemics can be occurred by antigenic shift, which generally"/>
   <result pre="of IAVs, which are the descendants of 2009 and 1968" exact="influenza" post="pandemics, respectively, and the Victoria and Yamagata lineages of"/>
   <result pre="other subtypes of avian HA and NA isolated from human" exact="influenza" post="cases sporadically [24, 25]. Given their pandemic potential, we"/>
   <result pre="detail by comparing with the viruses that had caused past" exact="influenza" post="pandemics. Recently, Middle East respiratory syndrome coronavirus (MERS-CoV) is"/>
   <result pre="M and the N protein [31]. Similarity of MERS-CoV with" exact="influenza" post="viruses is not in its genome organization but probably"/>
   <result pre="and the mode of respiratory transmission [32–34]. In addition to" exact="influenza" post="viruses and MERS-CoVs, arthropod-borne viruses, such as dengue and"/>
   <result pre="into the past pandemic events. Main text Zoonotic origins of" exact="influenza" post="pandemics IAVs have eight segmented genomes of single-stranded, negative-sense"/>
   <result pre="1 (NS1), and nonstructural 2 (NS2/NEP) [1]. Studying the past" exact="influenza" post="pandemics helps us to understand the mechanisms of such"/>
   <result pre="H3N2 subtypes have been identified as the causes of human" exact="influenza" post="pandemics. Of these, the H1N1 subtype caused the 1918"/>
   <result pre="the 1918 and 2009 pandemics and the ‘abortive pandemic’-like swine" exact="influenza" post="epidemic in 1976, which hundreds of soldiers at Fort"/>
   <result pre="transmitting to humans remains unanswered [16]. Fig. 1 Timeline of" exact="influenza" post="pandemics. Each pandemic event is marked by a bold"/>
   <result pre="humans to be pandemic viruses [69]. Ingredients and recipe of" exact="influenza" post="pandemics From the examples of the past influenza pandemics"/>
   <result pre="recipe of influenza pandemics From the examples of the past" exact="influenza" post="pandemics discussed so far, the recipe of a pandemic"/>
   <result pre="of a pandemic may be drawn up. The ingredients of" exact="influenza" post="pandemics appear to be (1) non-human animal reservoir(s) that"/>
   <result pre="with a new antigenic flavor. We have seen that the" exact="influenza" post="pandemics came about with these ingredients and the human"/>
   <result pre="its pandemic potential. Fig. 2 The ingredients and recipe of" exact="influenza" post="virus pandemic. The workings of the five ingredients of"/>
   <result pre="and between humans [34]. Unlike other human virus, such as" exact="measles" post="[91], MERS-CoV might evolve constantly in the dromedary camels"/>
   <result pre="by antigenically ‘drifted’ strains might follow the pattern of seasonal" exact="influenza" post="viruses until antigenically shifted (recombined) MERS-CoV strains hit humans"/>
   <result pre="animal models can be translated to humans. Animal models of" exact="influenza" post="viruses Non-reservoir animals used for influenza virus infection experiments"/>
   <result pre="humans. Animal models of influenza viruses Non-reservoir animals used for" exact="influenza" post="virus infection experiments include ferrets, mice, guinea pigs, Syrian"/>
   <result pre="non-human primates [102–109]. Historically, the discovery of the first human" exact="influenza" post="virus was made by infecting ferrets with throat washings"/>
   <result pre="virus was made by infecting ferrets with throat washings of" exact="influenza" post="patients [110]. Ferrets could also be readily infected with"/>
   <result pre="patients [110]. Ferrets could also be readily infected with swine" exact="influenza" post="virus. The different species of guinea pigs, mice, rabbits,"/>
   <result pre="these asymptomatic animals have become useful for special purposes of" exact="influenza" post="virus infection experiments now because virus detection and titration"/>
   <result pre="cost- and space-wise. In the case of mice, human infecting" exact="influenza" post="viruses do not usually infect mice well, which is"/>
   <result pre="awaits further reports of the use of animal models in" exact="influenza" post="virus research. Nonhuman primates (NHPs) are genetically closest to"/>
   <result pre="in search of appropriate animal models. In the case of" exact="influenza" post="virus research, among the frequently used animal models, ferrets"/>
   <result pre="model other than NHPs [127]. Table 1 Animal models for" exact="influenza" post="virus Animal model Model for References Pathogenicity Transmission Antiviral"/>
   <result pre="express both α-2,3 and α-2,6 SAs and support replication of" exact="influenza" post="viruses ubiquitously due to the lack of the Mx"/>
   <result pre="cells for MERS-CoV infection may function like MDCK cells for" exact="influenza" post="viruses. Growth of MERS-CoVs in Vero cells may indicate"/>
   <result pre="aerosol transmitting IAV but can be infected with aerosolized live-attenuated" exact="influenza" post="vaccine virus using a nebulizer [195]. Since it has"/>
   <result pre="required to be a pandemic virus by analyzing the past" exact="influenza" post="pandemics. The uniqueness of the past influenza pandemics is"/>
   <result pre="analyzing the past influenza pandemics. The uniqueness of the past" exact="influenza" post="pandemics is in that the three pools of reservoirs"/>
   <result pre="to bring about pandemics recurrently. Moreover, the ingredients of the" exact="influenza" post="pandemics and the modes of transmission may apply to"/>
   <result pre="the translational purposes and insights of the pandemic potential of" exact="influenza" post="and other RNA viruses. Publisher’s Note Springer Nature remains"/>
   <result pre="a narrative literature review. Viruses. 2019;11(6):10.3390/v11060561. 3.CiminskiKThamamongoodTZimmerGSchwemmleMNovel insights into bat" exact="influenza" post="A virusesJ Gen Virol201798102393240010.1099/jgv.0.00092728906230 4.WuYWuYTefsenBShiYGaoGFBat-derived influenza-like viruses H17N10 and"/>
   <result pre="Williams &amp;amp; Wilkins 6.RotaPAWallisTRHarmonMWRotaJSKendalAPNeromeKCocirculation of two distinct evolutionary lineages of" exact="influenza" post="type B virus since 1983Virology19901751596810.1016/0042-6822(90)90186-U2309452 7.BodewesRMorickDde MutsertGOsingaNBestebroerTvan der VlietSet"/>
   <result pre="type B virus since 1983Virology19901751596810.1016/0042-6822(90)90186-U2309452 7.BodewesRMorickDde MutsertGOsingaNBestebroerTvan der VlietSet al.Recurring" exact="influenza" post="B virus infections in sealsEmerg Infect Dis201319351151210.3201/eid1903.12096523750359 8.OsterhausADRimmelzwaanGFMartinaBEBestebroerTMFouchierRAInfluenza B"/>
   <result pre="in sealsScience200028854681051105310.1126/science.288.5468.105110807575 9.RanZShenHLangYKolbEATuranNZhuLet al.Domestic pigs are susceptible to infection with" exact="influenza" post="B virusesJ Virol20158994818482610.1128/JVI.00059-1525673727 10.TakatsyGFarkasERomvaryJSusceptibility of the domestic pig to"/>
   <result pre="influenza B virusesJ Virol20158994818482610.1128/JVI.00059-1525673727 10.TakatsyGFarkasERomvaryJSusceptibility of the domestic pig to" exact="influenza" post="B virusNature1969222518918418510.1038/222184a04304929 11.IrvingSAPatelDCKiekeBADonahueJGVandermauseMFShayDKet al.Comparison of clinical features and outcomes"/>
   <result pre="11.IrvingSAPatelDCKiekeBADonahueJGVandermauseMFShayDKet al.Comparison of clinical features and outcomes of medically attended" exact="influenza" post="A and influenza B in a defined population over"/>
   <result pre="clinical features and outcomes of medically attended influenza A and" exact="influenza" post="B in a defined population over four seasons: 2004-2005"/>
   <result pre="Respi Viruses201261374310.1111/j.1750-2659.2011.00263.x 12.WangYFanGHorbyPHaydenFLiQWuQZouXLiHZhanQWangCet al.Comparative outcomes of adults hospitalized with seasonal" exact="influenza" post="A or B virus infection: application of the 7-category"/>
   <result pre="Dis201963ofz05310.1093/ofid/ofz05330895200 13.SuSChavesSSPerezAD'MelloTKirleyPDYousey-HindesKet al.Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="A and B virus infectionClin Infect Dis201459225225510.1093/cid/ciu26924748521 14.Tran D,"/>
   <result pre="Bettinger JA, Halperin SA, Scheifele DW, et al. Hospitalization for" exact="influenza" post="A versus B. Pediatrics. 2016;138(3):e20154643. 15.KilbourneEDInfluenza pandemics of the"/>
   <result pre="15.KilbourneEDInfluenza pandemics of the 20th centuryEmerg Infect Dis200612191410.3201/eid1201.05125416494710 16.NeumannGKawaokaYThe first" exact="influenza" post="pandemic of the new millenniumInfluenza Other Respi Viruses20115315716610.1111/j.1750-2659.2011.00231.x 17.MorensDMTaubenbergerJKHistorical"/>
   <result pre="of the new millenniumInfluenza Other Respi Viruses20115315716610.1111/j.1750-2659.2011.00231.x 17.MorensDMTaubenbergerJKHistorical thoughts on" exact="influenza" post="viral ecosystems, or behold a pale horse, dead dogs,"/>
   <result pre="Other Respi Viruses20104632733710.1111/j.1750-2659.2010.00148.x 18.NeumannGNodaTKawaokaYEmergence and pandemic potential of swine-origin H1N1" exact="influenza" post="virusNature2009459724993193910.1038/nature0815719525932 19.LigonBLAvian influenza virus H5N1: a review of its"/>
   <result pre="18.NeumannGNodaTKawaokaYEmergence and pandemic potential of swine-origin H1N1 influenza virusNature2009459724993193910.1038/nature0815719525932 19.LigonBLAvian" exact="influenza" post="virus H5N1: a review of its history and information"/>
   <result pre="potential to cause the next pandemicSemin Pediatr Infect Dis200516432633510.1053/j.spid.2005.07.00216210112 20.FauciASPandemic" exact="influenza" post="threat and preparednessEmerg Infect Dis2006121737710.3201/eid1201.05098316494721 21.de Vries RD, Herfst"/>
   <result pre="Infect Dis2006121737710.3201/eid1201.05098316494721 21.de Vries RD, Herfst S, Richard M. Avian" exact="influenza" post="A virus pandemic preparedness and vaccine development. Vaccines (Basel)."/>
   <result pre="22.Sutton TC. The pandemic threat of emerging H5 and H7" exact="avian influenza" post="viruses. Viruses. 2018;10(9):10.3390/v10090461. 23.KimJILeeIParkSLeeSHwangMWBaeJYet al.Phylogenetic analysis of a swine"/>
   <result pre="TC. The pandemic threat of emerging H5 and H7 avian" exact="influenza" post="viruses. Viruses. 2018;10(9):10.3390/v10090461. 23.KimJILeeIParkSLeeSHwangMWBaeJYet al.Phylogenetic analysis of a swine"/>
   <result pre="influenza viruses. Viruses. 2018;10(9):10.3390/v10090461. 23.KimJILeeIParkSLeeSHwangMWBaeJYet al.Phylogenetic analysis of a swine" exact="influenza" post="A(H3N2) virus isolated in Korea in 2012PLoS One201492e8878210.1371/journal.pone.008878224523938 24.AlexanderDJBrownIHRecent"/>
   <result pre="isolated in Korea in 2012PLoS One201492e8878210.1371/journal.pone.008878224523938 24.AlexanderDJBrownIHRecent zoonoses caused by" exact="influenza" post="A virusesRev Sci Tech200019119722510.20506/rst.19.1.122011189716 25.Mostafa A, Abdelwhab EM, Mettenleiter"/>
   <result pre="A, Abdelwhab EM, Mettenleiter TC, Pleschka S. Zoonotic potential of" exact="influenza" post="A viruses: a comprehensive overview. Viruses. 2018;10(9):10.3390/v10090497. 26.YongCYOngHKYeapSKHoKLTanWSRecent advances"/>
   <result pre="28.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med2012367191814182010.1056/NEJMoa121172123075143 29.RajVSOsterhausADFouchierRAHaagmansBLMERS: emergence of"/>
   <result pre="al. Genomic characterization of a newly discovered coronavirus associated with" exact="acute respiratory distress syndrome" post="in humans. MBio. 2012;3(6):10.1128/mBio.00473-12. 32.PeckKMBurchCLHeiseMTBaricRSCoronavirus host range expansion and"/>
   <result pre="a prospective observational studyLancet Infect Dis201717111200120810.1016/S1473-3099(17)30444-928838639 39.CasaleTBTengMNMoranoJPUnnaschTLockwoodCJZika virus: an emerging" exact="infectious disease" post="with serious perinatal and neurologic complicationsJ Allergy Clin Immunol2018141248249010.1016/j.jaci.2017.11.02929273403"/>
   <result pre="with serious perinatal and neurologic complicationsJ Allergy Clin Immunol2018141248249010.1016/j.jaci.2017.11.02929273403 40.IskanderJStrikasRAGensheimerKFCoxNJReddSCPandemic" exact="influenza" post="planning, United States, 1978-2008Emerg Infect Dis201319687988510.3201/eid1906.12147823731839 41.GaydosJCTopFHJrHodderRARussellPKSwine influenza A"/>
   <result pre="Immunol2018141248249010.1016/j.jaci.2017.11.02929273403 40.IskanderJStrikasRAGensheimerKFCoxNJReddSCPandemic influenza planning, United States, 1978-2008Emerg Infect Dis201319687988510.3201/eid1906.12147823731839 41.GaydosJCTopFHJrHodderRARussellPKSwine" exact="influenza" post="A outbreak, fort dix, New Jersey, 1976Emerg Infect Dis2006121232810.3201/eid1201.05096516494712"/>
   <result pre="outbreak, fort dix, New Jersey, 1976Emerg Infect Dis2006121232810.3201/eid1201.05096516494712 42.Brockwell-StaatsCWebsterRGWebbyRJDiversity of" exact="influenza" post="viruses in swine and the emergence of a novel"/>
   <result pre="in swine and the emergence of a novel human pandemic" exact="influenza" post="A(H1N1)Influenza Other Respi Viruses20093520721310.1111/j.1750-2659.2009.00096.x 43.ZhuHWebbyRLamTTSmithDKPeirisJSGuanYHistory of swine influenza viruses"/>
   <result pre="human pandemic influenza A(H1N1)Influenza Other Respi Viruses20093520721310.1111/j.1750-2659.2009.00096.x 43.ZhuHWebbyRLamTTSmithDKPeirisJSGuanYHistory of swine" exact="influenza" post="viruses in AsiaCurr Top Microbiol Immunol2013370576821948002 44.ZellRScholtissekCLudwigSGenetics, evolution, and"/>
   <result pre="Immunol2013370576821948002 44.ZellRScholtissekCLudwigSGenetics, evolution, and the zoonotic capacity of European swine" exact="influenza" post="virusesCurr Top Microbiol Immunol2013370295523011571 45.Pulit-Penaloza JA, Belser JA, Tumpey"/>
   <result pre="of a pandemic? Mammalian pathogenicity and transmissibility of H1 variant" exact="influenza" post="viruses from the swine reservoir. Trop Med Infect Dis."/>
   <result pre="Dis. 2019;4(1):10.3390/tropicalmed4010041. 46.TaubenbergerJKThe origin and virulence of the 1918 &quot;Spanish&quot;" exact="influenza" post="virusProc Am Philos Soc200615018611217526158 47.TumpeyTMMainesTRVan HoevenNGlaserLSolorzanoAPappasCet al.A two-amino acid"/>
   <result pre="al.A two-amino acid change in the hemagglutinin of the 1918" exact="influenza" post="virus abolishes transmissionScience2007315581265565910.1126/science.113621217272724 48.ZhuHWangDKelvinDJLiLZhengZYoonSWet al.Infectivity, transmission, and pathology of"/>
   <result pre="abolishes transmissionScience2007315581265565910.1126/science.113621217272724 48.ZhuHWangDKelvinDJLiLZhengZYoonSWet al.Infectivity, transmission, and pathology of human-isolated H7N9" exact="influenza" post="virus in ferrets and pigsScience2013341614218318610.1126/science.123984423704376 49.ZaraketHBridgesOADuanSBaranovichTYoonSWReedMLet al.Increased acid stability"/>
   <result pre="49.ZaraketHBridgesOADuanSBaranovichTYoonSWReedMLet al.Increased acid stability of the hemagglutinin protein enhances H5N1" exact="influenza" post="virus growth in the upper respiratory tract but is"/>
   <result pre="tract but is insufficient for transmission in ferretsJ Virol201387179911992210.1128/JVI.01175-1323824818 50.FanningTGSlemonsRDReidAHJanczewskiTADeanJTaubenbergerJK1917" exact="avian influenza" post="virus sequences suggest that the 1918 pandemic virus did"/>
   <result pre="but is insufficient for transmission in ferretsJ Virol201387179911992210.1128/JVI.01175-1323824818 50.FanningTGSlemonsRDReidAHJanczewskiTADeanJTaubenbergerJK1917 avian" exact="influenza" post="virus sequences suggest that the 1918 pandemic virus did"/>
   <result pre="birdsJ Virol200276157860786210.1128/JVI.76.15.7860-7862.200212097598 51.GlaserLStevensJZamarinDWilsonIAGarcia-SastreATumpeyTMet al.A single amino acid substitution in 1918" exact="influenza" post="virus hemagglutinin changes receptor binding specificityJ Virol20057917115331153610.1128/JVI.79.17.11533-11536.200516103207 52.WorobeyMHanGZRambautAGenesis and"/>
   <result pre="specificityJ Virol20057917115331153610.1128/JVI.79.17.11533-11536.200516103207 52.WorobeyMHanGZRambautAGenesis and pathogenesis of the 1918 pandemic H1N1" exact="influenza" post="A virusProc Natl Acad Sci U S A2014111228107811210.1073/pnas.132419711124778238 53.ParrishCRKawaokaYThe"/>
   <result pre="the acquisition of new host ranges by canine parvovirus and" exact="influenza" post="A virusesAnnu Rev Microbiol20055955358610.1146/annurev.micro.59.030804.12105916153179 54.WebsterRGBeanWJGormanOTChambersTMKawaokaYEvolution and ecology of influenza"/>
   <result pre="and influenza A virusesAnnu Rev Microbiol20055955358610.1146/annurev.micro.59.030804.12105916153179 54.WebsterRGBeanWJGormanOTChambersTMKawaokaYEvolution and ecology of" exact="influenza" post="A virusesMicrobiol Rev199256115217910.1128/MMBR.56.1.152-179.19921579108 55.RogersGNPaulsonJCReceptor determinants of human and animal"/>
   <result pre="influenza A virusesMicrobiol Rev199256115217910.1128/MMBR.56.1.152-179.19921579108 55.RogersGNPaulsonJCReceptor determinants of human and animal" exact="influenza" post="virus isolates: differences in receptor specificity of the H3"/>
   <result pre="based on species of originVirology1983127236137310.1016/0042-6822(83)90150-26868370 56.LongJSMistryBHaslamSMBarclayWSHost and viral determinants of" exact="influenza" post="A virus species specificityNat Rev Microbiol2019172678110.1038/s41579-018-0115-z30487536 57.CostaTChavesAJValleRDarjiAvan RielDKuikenTet al.Distribution"/>
   <result pre="virus species specificityNat Rev Microbiol2019172678110.1038/s41579-018-0115-z30487536 57.CostaTChavesAJValleRDarjiAvan RielDKuikenTet al.Distribution patterns of" exact="influenza" post="virus receptors and viral attachment patterns in the respiratory"/>
   <result pre="intestinal tracts of seven avian speciesVet Res2012432810.1186/1297-9716-43-2822489675 58.VanDalenKKFranklinABMooersNLSullivanHJShrinerSAShedding light on" exact="avian influenza" post="H4N6 infection in mallards: modes of transmission and implications"/>
   <result pre="tracts of seven avian speciesVet Res2012432810.1186/1297-9716-43-2822489675 58.VanDalenKKFranklinABMooersNLSullivanHJShrinerSAShedding light on avian" exact="influenza" post="H4N6 infection in mallards: modes of transmission and implications"/>
   <result pre="J2012913310.1186/1743-422X-9-13322824586 60.ItoTCouceiroJNKelmSBaumLGKraussSCastrucciMRet al.Molecular basis for the generation in pigs of" exact="influenza" post="A viruses with pandemic potentialJ Virol19987297367737310.1128/JVI.72.9.7367-7373.19989696833 61.ShinyaKEbinaMYamadaSOnoMKasaiNKawaokaYAvian flu: influenza"/>
   <result pre="of influenza A viruses with pandemic potentialJ Virol19987297367737310.1128/JVI.72.9.7367-7373.19989696833 61.ShinyaKEbinaMYamadaSOnoMKasaiNKawaokaYAvian flu:" exact="influenza" post="virus receptors in the human airwayNature2006440708343543610.1038/440435a16554799 62.KumlinUOlofssonSDimockKArnbergNSialic acid tissue"/>
   <result pre="receptors in the human airwayNature2006440708343543610.1038/440435a16554799 62.KumlinUOlofssonSDimockKArnbergNSialic acid tissue distribution and" exact="influenza" post="virus tropismInfluenza Other Respi Viruses20082514715410.1111/j.1750-2659.2008.00051.x 63.de GraafMFouchierRARole of receptor"/>
   <result pre="Other Respi Viruses20082514715410.1111/j.1750-2659.2008.00051.x 63.de GraafMFouchierRARole of receptor binding specificity in" exact="influenza" post="A virus transmission and pathogenesisEMBO J201433882384110.1002/embj.20138744224668228 64.NichollsJMBourneAJChenHGuanYPeirisJSSialic acid receptor"/>
   <result pre="for widespread distribution of potential binding sites for human and" exact="avian influenza" post="virusesRespir Res200787310.1186/1465-9921-8-7317961210 65.NelliRKKuchipudiSVWhiteGAPerezBBDunhamSPChangKCComparative distribution of human and avian type"/>
   <result pre="widespread distribution of potential binding sites for human and avian" exact="influenza" post="virusesRespir Res200787310.1186/1465-9921-8-7317961210 65.NelliRKKuchipudiSVWhiteGAPerezBBDunhamSPChangKCComparative distribution of human and avian type"/>
   <result pre="Res200787310.1186/1465-9921-8-7317961210 65.NelliRKKuchipudiSVWhiteGAPerezBBDunhamSPChangKCComparative distribution of human and avian type sialic acid" exact="influenza" post="receptors in the pigBMC Vet Res20106410.1186/1746-6148-6-420105300 66.TrebbienRLarsenLEViuffBMDistribution of sialic"/>
   <result pre="the pigBMC Vet Res20106410.1186/1746-6148-6-420105300 66.TrebbienRLarsenLEViuffBMDistribution of sialic acid receptors and" exact="influenza" post="A virus of avian and swine origin in experimentally"/>
   <result pre="al.Tissue tropisms opt for transmissible reassortants during avian and swine" exact="influenza" post="A virus co-infection in swinePLoS Pathog20181412e100741710.1371/journal.ppat.100741730507946 68.BowmanASNoltingJMWorkmanJDCooperMFisherAEMarshBet al.The inability"/>
   <result pre="swinePLoS Pathog20181412e100741710.1371/journal.ppat.100741730507946 68.BowmanASNoltingJMWorkmanJDCooperMFisherAEMarshBet al.The inability to screen exhibition swine for" exact="influenza" post="A virus using body temperatureZoonoses Public Health2016631343910.1111/zph.1220125884907 69.WeingartlHMAlbrechtRALagerKMBabiukSMarszalPNeufeldJet al.Experimental"/>
   <result pre="69.WeingartlHMAlbrechtRALagerKMBabiukSMarszalPNeufeldJet al.Experimental infection of pigs with the human 1918 pandemic" exact="influenza" post="virusJ Virol20098394287429610.1128/JVI.02399-0819224986 70.KaplanBSTorchettiMKLagerKMWebbyRJVincentALAbsence of clinical disease and contact transmission"/>
   <result pre="North America in experimentally infected pigsInfluenza Other Respi Viruses201711546447010.1111/irv.12463 71.DowdleWRHattwickMASwine" exact="influenza" post="virus infections in humansJ Infect Dis1977136SupplS386S38910.1093/infdis/136.Supplement_3.S386342616 72.Pulit-PenalozaJABelserJATumpeyTMMainesTRMammalian pathogenicity and"/>
   <result pre="72.Pulit-PenalozaJABelserJATumpeyTMMainesTRMammalian pathogenicity and transmissibility of a reassortant Eurasian avian-like A(H1N1v)" exact="influenza" post="virus associated with human infection in China (2015)Virology2019537313510.1016/j.virol.2019.08.00831430632 73.ShindeVBridgesCBUyekiTMShuBBalishAXuXet"/>
   <result pre="associated with human infection in China (2015)Virology2019537313510.1016/j.virol.2019.08.00831430632 73.ShindeVBridgesCBUyekiTMShuBBalishAXuXet al.Triple-reassortant swine" exact="influenza" post="A (H1) in humans in the United States, 2005-2009N"/>
   <result pre="the United States, 2005-2009N Engl J Med2009360252616262510.1056/NEJMoa090381219423871 74.TerebuhPOlsenCWWrightJKlimovAKarasinAToddKet al.Transmission of" exact="influenza" post="A viruses between pigs and people, Iowa, 2002-2004Influenza Other"/>
   <result pre="Michigan and Ohio, USA, 2016Emerg Infect Dis20172391551155510.3201/eid2309.17084728820376 76.SchickerRSRossowJEckelSFisherNBidolSTathamLet al.Outbreak of" exact="influenza" post="A(H3N2) variant virus infections among persons attending agricultural fairs"/>
   <result pre="Morb Mortal Wkly Rep201665421157116010.15585/mmwr.mm6542a127787493 77.NelsonMIStrattonJKillianMLJanas-MartindaleAVincentALContinual reintroduction of human pandemic H1N1" exact="influenza" post="A viruses into swine in the United States, 2009"/>
   <result pre="States, 2009 to 2014J Virol201589126218622610.1128/JVI.00459-1525833052 78.HerfstSSchrauwenEJLinsterMChutinimitkulSde WitEMunsterVJet al.Airborne transmission of" exact="influenza" post="A/H5N1 virus between ferretsScience201233660881534154110.1126/science.121336222723413 79.LipatovASKwonYKSarmentoLVLagerKMSpackmanESuarezDLet al.Domestic pigs have low"/>
   <result pre="79.LipatovASKwonYKSarmentoLVLagerKMSpackmanESuarezDLet al.Domestic pigs have low susceptibility to H5N1 highly pathogenic" exact="avian influenza" post="virusesPLoS Pathog200847e100010210.1371/journal.ppat.100010218617994 80.GaoRCaoBHuYFengZWangDHuWet al.Human infection with a novel avian-origin"/>
   <result pre="al.Domestic pigs have low susceptibility to H5N1 highly pathogenic avian" exact="influenza" post="virusesPLoS Pathog200847e100010210.1371/journal.ppat.100010218617994 80.GaoRCaoBHuYFengZWangDHuWet al.Human infection with a novel avian-origin"/>
   <result pre="influenza virusesPLoS Pathog200847e100010210.1371/journal.ppat.100010218617994 80.GaoRCaoBHuYFengZWangDHuWet al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virusN Engl J Med2013368201888189710.1056/NEJMoa130445923577628 81.QiXQianYHBaoCJGuoXLCuiLBTangFYet al.Probable person"/>
   <result pre="J Med2013368201888189710.1056/NEJMoa130445923577628 81.QiXQianYHBaoCJGuoXLCuiLBTangFYet al.Probable person to person transmission of novel" exact="avian influenza" post="A (H7N9) virus in eastern China, 2013: epidemiological investigationBMJ2013347f475210.1136/bmj.f475223920350"/>
   <result pre="Med2013368201888189710.1056/NEJMoa130445923577628 81.QiXQianYHBaoCJGuoXLCuiLBTangFYet al.Probable person to person transmission of novel avian" exact="influenza" post="A (H7N9) virus in eastern China, 2013: epidemiological investigationBMJ2013347f475210.1136/bmj.f475223920350"/>
   <result pre="Liu L, Gu K, et al. Limited human-to-human transmission of" exact="avian influenza" post="A(H7N9) virus, Shanghai, China, march to April 2013. Euro"/>
   <result pre="L, Gu K, et al. Limited human-to-human transmission of avian" exact="influenza" post="A(H7N9) virus, Shanghai, China, march to April 2013. Euro"/>
   <result pre="et al. Clusters of human infection and human-to-human transmission of" exact="avian influenza" post="A(H7N9) virus, 2013-2017. Emerg Infect Dis. 2018;24(2):397-400. 84.WidagdoWBegemanLSchipperDRunPRVCunninghamAAKleyNet al.Tissue"/>
   <result pre="al. Clusters of human infection and human-to-human transmission of avian" exact="influenza" post="A(H7N9) virus, 2013-2017. Emerg Infect Dis. 2018;24(2):397-400. 84.WidagdoWBegemanLSchipperDRunPRVCunninghamAAKleyNet al.Tissue"/>
   <result pre="coronavirus (MERS-CoV) origin and animal reservoirVirol J2016138710.1186/s12985-016-0544-027255185 91.MossWJStrebelPBiological feasibility of" exact="measles" post="eradicationJ Infect Dis2011204Suppl 1S47S5310.1093/infdis/jir06521666201 92.ChuDKWHuiKPYPereraRMiguelENiemeyerDZhaoJet al.MERS coronaviruses from camels"/>
   <result pre="Korea has been shaped by recombinationSci Rep201661882510.1038/srep1882526732651 96.NelsonMIVincentALReverse zoonosis of" exact="influenza" post="to swine: new perspectives on the human-animal interfaceTrends Microbiol201523314215310.1016/j.tim.2014.12.00225564096"/>
   <result pre="to the understanding of the host range and virulence of" exact="influenza" post="A virusesMicrobes Infect201113550251510.1016/j.micinf.2011.01.01421276869 103.BouvierNMAnimal models for influenza virus transmission"/>
   <result pre="and virulence of influenza A virusesMicrobes Infect201113550251510.1016/j.micinf.2011.01.01421276869 103.BouvierNMAnimal models for" exact="influenza" post="virus transmission studies: a historical perspectiveCurr Opin Virol20151310110810.1016/j.coviro.2015.06.00226126082 104.BouvierNMLowenACAnimal"/>
   <result pre="transmission studies: a historical perspectiveCurr Opin Virol20151310110810.1016/j.coviro.2015.06.00226126082 104.BouvierNMLowenACAnimal models for" exact="influenza" post="virus pathogenesis and transmissionViruses2010281530156310.3390/v2080153021442033 105.KwonYKLipatovASSwayneDEBronchointerstitial pneumonia in Guinea pigs"/>
   <result pre="Virol20151310110810.1016/j.coviro.2015.06.00226126082 104.BouvierNMLowenACAnimal models for influenza virus pathogenesis and transmissionViruses2010281530156310.3390/v2080153021442033 105.KwonYKLipatovASSwayneDEBronchointerstitial" exact="pneumonia" post="in Guinea pigs following inoculation with H5N1 high pathogenicity"/>
   <result pre="pneumonia in Guinea pigs following inoculation with H5N1 high pathogenicity" exact="avian influenza" post="virusVet Pathol200946113814110.1354/vp.46-1-13819112127 106.Van HoevenNBelserJASzretterKJZengHStaeheliPSwayneDEet al.Pathogenesis of 1918 pandemic and"/>
   <result pre="in Guinea pigs following inoculation with H5N1 high pathogenicity avian" exact="influenza" post="virusVet Pathol200946113814110.1354/vp.46-1-13819112127 106.Van HoevenNBelserJASzretterKJZengHStaeheliPSwayneDEet al.Pathogenesis of 1918 pandemic and"/>
   <result pre="virusVet Pathol200946113814110.1354/vp.46-1-13819112127 106.Van HoevenNBelserJASzretterKJZengHStaeheliPSwayneDEet al.Pathogenesis of 1918 pandemic and H5N1" exact="influenza" post="virus infections in a Guinea pig model: antiviral potential"/>
   <result pre="Virol20098372851286110.1128/JVI.02174-0819144714 107.LowenACMubarekaSTumpeyTMGarcia-SastreAPalesePThe Guinea pig as a transmission model for human" exact="influenza" post="virusesProc Natl Acad Sci U S A2006103269988999210.1073/pnas.060415710316785447 108.Iwatsuki-Horimoto K,"/>
   <result pre="hamster as an animal model for the study of human" exact="influenza" post="virus infection. J Virol. 2018;92(4):10.1128/JVI.01693-17. 109.van der LaanJWHerbertsCLambkin-WilliamsRBoyersAMannAJOxfordJAnimal models"/>
   <result pre="virus infection. J Virol. 2018;92(4):10.1128/JVI.01693-17. 109.van der LaanJWHerbertsCLambkin-WilliamsRBoyersAMannAJOxfordJAnimal models in" exact="influenza" post="vaccine testingExpert Rev Vaccines20087678379310.1586/14760584.7.6.78318665776 110.Smith WA, CH, Laidlaw PP."/>
   <result pre="Vaccines20087678379310.1586/14760584.7.6.78318665776 110.Smith WA, CH, Laidlaw PP. A virus obtained from" exact="influenza" post="patients. Lancet. 1933;222(5732):66–8. 111.PicaNChouYYBouvierNMPalesePTransmission of influenza B viruses in"/>
   <result pre="A virus obtained from influenza patients. Lancet. 1933;222(5732):66–8. 111.PicaNChouYYBouvierNMPalesePTransmission of" exact="influenza" post="B viruses in the Guinea pigJ Virol20128684279428710.1128/JVI.06645-1122301149 112.LowenACBouvierNMSteelJTransmission in"/>
   <result pre="use of nonhuman primates in research on seasonal, pandemic and" exact="avian influenza," post="1893–2014Antiviral Res2015117759810.1016/j.antiviral.2015.02.01125746173 114.RimmelzwaanGFKuikenTvan AmerongenGBestebroerTMFouchierRAOsterhausADPathogenesis of influenza A (H5N1) virus"/>
   <result pre="seasonal, pandemic and avian influenza, 1893–2014Antiviral Res2015117759810.1016/j.antiviral.2015.02.01125746173 114.RimmelzwaanGFKuikenTvan AmerongenGBestebroerTMFouchierRAOsterhausADPathogenesis of" exact="influenza" post="A (H5N1) virus infection in a primate modelJ Virol200175146687669110.1128/JVI.75.14.6687-6691.200111413336"/>
   <result pre="disease in cebus monkeys after intratracheal or intranasal infection with" exact="influenza" post="A/Victoria/3/75 or influenza A/New Jersey/76 virusInfect Immun197821120120510.1128/IAI.21.1.201-205.1978101457 116.MatsuokaYSuguitanAJrOrandleMPaskelMBoonnakKGardnerDJet al.African"/>
   <result pre="monkeys after intratracheal or intranasal infection with influenza A/Victoria/3/75 or" exact="influenza" post="A/New Jersey/76 virusInfect Immun197821120120510.1128/IAI.21.1.201-205.1978101457 116.MatsuokaYSuguitanAJrOrandleMPaskelMBoonnakKGardnerDJet al.African green monkeys recapitulate"/>
   <result pre="recapitulate the clinical experience with replication of live attenuated pandemic" exact="influenza" post="virus vaccine candidatesJ Virol201488148139815210.1128/JVI.00425-1424807726 117.BoonnakKPaskelMMatsuokaYVogelLSubbaraoKEvaluation of replication, immunogenicity and"/>
   <result pre="and protective efficacy of a live attenuated cold-adapted pandemic H1N1" exact="influenza" post="virus vaccine in non-human primatesVaccine201230385603561010.1016/j.vaccine.2012.06.08822789506 118.KitanoMItohYKodamaMIshigakiHNakayamaMNagataTet al.Establishment of a"/>
   <result pre="non-human primatesVaccine201230385603561010.1016/j.vaccine.2012.06.08822789506 118.KitanoMItohYKodamaMIshigakiHNakayamaMNagataTet al.Establishment of a cynomolgus macaque model of" exact="influenza" post="B virus infectionVirology2010407217818410.1016/j.virol.2010.08.00620822788 119.Bae JY, Lee I, Kim JI,"/>
   <result pre="acid in the polymerase acidic protein determines the pathogenicity of" exact="influenza" post="B viruses. J Virol. 2018;92(13):10.1128/JVI.00259-18. 120.ParkSIl KimJLeeIBaeJYYooKNamMet al.Adaptive mutations"/>
   <result pre="of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of" exact="influenza" post="A virusesSci Rep2017711092810.1038/s41598-017-11348-028883554 121.IbricevicAPekoszAWalterMJNewbyCBattaileJTBrownEGet al.Influenza virus receptor specificity and"/>
   <result pre="human airway epithelial cellsJ Virol200680157469748010.1128/JVI.02677-0516840327 122.BelserJAGustinKMPearceMBMainesTRZengHPappasCet al.Pathogenesis and transmission of" exact="avian influenza" post="A (H7N9) virus in ferrets and miceNature2013501746855655910.1038/nature1239123842497 123.KimJIParkSLeeSLeeIHeoJHwangMWet al.DBA/2"/>
   <result pre="airway epithelial cellsJ Virol200680157469748010.1128/JVI.02677-0516840327 122.BelserJAGustinKMPearceMBMainesTRZengHPappasCet al.Pathogenesis and transmission of avian" exact="influenza" post="A (H7N9) virus in ferrets and miceNature2013501746855655910.1038/nature1239123842497 123.KimJIParkSLeeSLeeIHeoJHwangMWet al.DBA/2"/>
   <result pre="disease following infection with a broad, but limited, range of" exact="influenza" post="A and B virusesJ Virol20118523128251282910.1128/JVI.05930-1121917963 125.LutzRJDedrickRLTueyDSipesIGAndersonMWMatthewsHBComparison of the pharmacokinetics"/>
   <result pre="MERS coronavirusVirology2015479–48024725810.1016/j.virol.2015.02.03025791336 127.BelserJAKatzJMTumpeyTMThe ferret as a model organism to study" exact="influenza" post="A virus infectionDis Model Mech20114557557910.1242/dmm.00782321810904 128.van DoremalenNMiazgowiczKLMilne-PriceSBushmakerTRobertsonSScottDet al.Host species"/>
   <result pre="rhesus macaquesFront Immunol2018920510.3389/fimmu.2018.0020529483914 147.FalzaranoDde WitEFeldmannFRasmussenALOkumuraAPengXet al.Infection with MERS-CoV causes lethal" exact="pneumonia" post="in the common marmosetPLoS Pathog2014108e100425010.1371/journal.ppat.100425025144235 148.YuPXuYDengWBaoLHuangLXuYet al.Comparative pathology of"/>
   <result pre="Virol20169094838484210.1128/JVI.02994-1526889022 154.SubbaraoEKLondonWMurphyBRA single amino acid in the PB2 gene of" exact="influenza" post="A virus is a determinant of host rangeJ Virol19936741761176410.1128/JVI.67.4.1761-1764.19938445709"/>
   <result pre="a determinant of host rangeJ Virol19936741761176410.1128/JVI.67.4.1761-1764.19938445709 155.KomadinaNMcVernonJHallRLederKA historical perspective of" exact="influenza" post="A(H1N2) virusEmerg Infect Dis201420161210.3201/eid2001.12184824377419 156.BusseyKABousseTLDesmetEAKimBTakimotoTPB2 residue 271 plays a"/>
   <result pre="271 plays a key role in enhanced polymerase activity of" exact="influenza" post="A viruses in mammalian host cellsJ Virol20108494395440610.1128/JVI.02642-0920181719 157.HattaMHattaYKimJHWatanabeSShinyaKNguyenTet al.Growth"/>
   <result pre="viruses in mammalian host cellsJ Virol20108494395440610.1128/JVI.02642-0920181719 157.HattaMHattaYKimJHWatanabeSShinyaKNguyenTet al.Growth of H5N1" exact="influenza" post="A viruses in the upper respiratory tracts of micePLoS"/>
   <result pre="upper respiratory tracts of micePLoS Pathog20073101374137910.1371/journal.ppat.003013317922570 158.WatanabeTKisoMFukuyamaSNakajimaNImaiMYamadaSet al.Characterization of H7N9" exact="influenza" post="A viruses isolated from humansNature2013501746855155510.1038/nature1239223842494 159.StraySJCummingsRDAirGMInfluenza virus infection of"/>
   <result pre="E627K substitution in a fatal human case of highly pathogenic" exact="avian influenza" post="virus A(H7N7) infection as determined by Illumina ultra-deep sequencingJ"/>
   <result pre="substitution in a fatal human case of highly pathogenic avian" exact="influenza" post="virus A(H7N7) infection as determined by Illumina ultra-deep sequencingJ"/>
   <result pre="sequencingJ Virol20148831694170210.1128/JVI.02044-1324257603 161.OctavianiCPGotoHKawaokaYReassortment between seasonal H1N1 and pandemic (H1N1) 2009" exact="influenza" post="viruses is restricted by limited compatibility among polymerase subunitsJ"/>
   <result pre="subunitsJ Virol201185168449845210.1128/JVI.05054-1121680507 162.LiCHattaMNidomCAMuramotoYWatanabeSNeumannGet al.Reassortment between avian H5N1 and human H3N2" exact="influenza" post="viruses creates hybrid viruses with substantial virulenceProc Natl Acad"/>
   <result pre="of reassortants derived from contemporary avian H5N1 and human H3N2" exact="influenza" post="A virusesPLoS Pathog200845e100007210.1371/journal.ppat.100007218497857 164.SongMSPascuaPNLeeJHBaekYHParkKJKwonHIet al.Virulence and genetic compatibility of"/>
   <result pre="of polymerase reassortant viruses derived from the pandemic (H1N1) 2009" exact="influenza" post="virus and circulating influenza A virusesJ Virol201185136275628610.1128/JVI.02125-1021507962 165.FodorEDevenishLEngelhardtOGPalesePBrownleeGGGarcia-SastreARescue of"/>
   <result pre="derived from the pandemic (H1N1) 2009 influenza virus and circulating" exact="influenza" post="A virusesJ Virol201185136275628610.1128/JVI.02125-1021507962 165.FodorEDevenishLEngelhardtOGPalesePBrownleeGGGarcia-SastreARescue of influenza A virus from"/>
   <result pre="influenza virus and circulating influenza A virusesJ Virol201185136275628610.1128/JVI.02125-1021507962 165.FodorEDevenishLEngelhardtOGPalesePBrownleeGGGarcia-SastreARescue of" exact="influenza" post="A virus from recombinant DNAJ Virol199973119679968210.1128/JVI.73.11.9679-9682.199910516084 166.HoffmannENeumannGKawaokaYHobomGWebsterRGA DNA transfection"/>
   <result pre="recombinant DNAJ Virol199973119679968210.1128/JVI.73.11.9679-9682.199910516084 166.HoffmannENeumannGKawaokaYHobomGWebsterRGA DNA transfection system for generation of" exact="influenza" post="A virus from eight plasmidsProc Natl Acad Sci U"/>
   <result pre="kidney (Vero) cells provide an alternative host cell system for" exact="influenza" post="A and B virusesJ Virol19967085519552410.1128/JVI.70.8.5519-5524.19968764064 168.SeitzCFrensingTHoperDKochsGReichlUHigh yields of influenza"/>
   <result pre="for influenza A and B virusesJ Virol19967085519552410.1128/JVI.70.8.5519-5524.19968764064 168.SeitzCFrensingTHoperDKochsGReichlUHigh yields of" exact="influenza" post="A virus in Madin-Darby canine kidney cells are promoted"/>
   <result pre="Gen Virol201091Pt 71754176310.1099/vir.0.020370-020357039 169.KumariKGulatiSSmithDFGulatiUCummingsRDAirGMReceptor binding specificity of recent human H3N2" exact="influenza" post="virusesVirol J200744210.1186/1743-422X-4-4217490484 170.LiIWChanKHcollab: To KWWongSSHoPLLauSKet al.Differential susceptibility of different"/>
   <result pre="To KWWongSSHoPLLauSKet al.Differential susceptibility of different cell lines to swine-origin" exact="influenza" post="A H1N1, seasonal human influenza A H1N1, and avian"/>
   <result pre="different cell lines to swine-origin influenza A H1N1, seasonal human" exact="influenza" post="A H1N1, and avian influenza A H5N1 virusesJ Clin"/>
   <result pre="swine-origin influenza A H1N1, seasonal human influenza A H1N1, and" exact="avian influenza" post="A H5N1 virusesJ Clin Virol200946432533010.1016/j.jcv.2009.09.01319801200 171.KuikenTRiteauBFouchierRARimmelzwaanGFPathogenesis of influenza virus"/>
   <result pre="influenza A H1N1, seasonal human influenza A H1N1, and avian" exact="influenza" post="A H5N1 virusesJ Clin Virol200946432533010.1016/j.jcv.2009.09.01319801200 171.KuikenTRiteauBFouchierRARimmelzwaanGFPathogenesis of influenza virus"/>
   <result pre="and avian influenza A H5N1 virusesJ Clin Virol200946432533010.1016/j.jcv.2009.09.01319801200 171.KuikenTRiteauBFouchierRARimmelzwaanGFPathogenesis of" exact="influenza" post="virus infections: the good, the bad and the uglyCurr"/>
   <result pre="WitEMunsterVJSchrauwenEJet al.Introduction of virulence markers in PB2 of pandemic swine-origin" exact="influenza" post="virus does not result in enhanced virulence or transmissionJ"/>
   <result pre="transmissionJ Virol20108483752375810.1128/JVI.02634-0920130063 174.MainesTRJayaramanABelserJAWadfordDAPappasCZengHet al.Transmission and pathogenesis of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses in ferrets and miceScience2009325593948448710.1126/science.117723819574347 175.GartenRJDavisCTRussellCAShuBLindstromSBalishAet al.Antigenic and genetic"/>
   <result pre="miceScience2009325593948448710.1126/science.117723819574347 175.GartenRJDavisCTRussellCAShuBLindstromSBalishAet al.Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses circulating in humansScience2009325593719720110.1126/science.117622519465683 176.ItohYShinyaKKisoMWatanabeTSakodaYHattaMet al.In vitro and in"/>
   <result pre="al.In vitro and in vivo characterization of new swine-origin H1N1" exact="influenza" post="virusesNature200946072581021102510.1038/nature0826019672242 177.El-SheshenyRFeerozMMKraussSVogelPMcKenziePWebbyRJet al.Replication and pathogenic potential of influenza A"/>
   <result pre="swine-origin H1N1 influenza virusesNature200946072581021102510.1038/nature0826019672242 177.El-SheshenyRFeerozMMKraussSVogelPMcKenziePWebbyRJet al.Replication and pathogenic potential of" exact="influenza" post="A virus subtypes H3, H7, and H15 from free-range"/>
   <result pre="in mammalsEmerg Microbes Infect2018717010.1038/s41426-018-0072-729691394 178.UrakiRKisoMShinyaKGotoHTakanoRIwatsuki-HorimotoKet al.Virulence determinants of pandemic A(H1N1)2009" exact="influenza" post="virus in a mouse modelJ Virol20138742226223310.1128/JVI.01565-1223221570 179.PekoszANewbyCBosePSLutzASialic acid recognition"/>
   <result pre="modelJ Virol20138742226223310.1128/JVI.01565-1223221570 179.PekoszANewbyCBosePSLutzASialic acid recognition is a key determinant of" exact="influenza" post="A virus tropism in murine trachea epithelial cell culturesVirology20093861616710.1016/j.virol.2009.01.00519195676"/>
   <result pre="in murine trachea epithelial cell culturesVirology20093861616710.1016/j.virol.2009.01.00519195676 180.GlaserLConenelloGPaulsonJPalesePEffective replication of human" exact="influenza" post="viruses in mice lacking a major alpha2,6 sialyltransferaseVirus Res20071261–291810.1016/j.virusres.2007.01.01117313986"/>
   <result pre="functions as a receptor for attachment and infectious entry of" exact="influenza" post="A virusJ Virol201690120622110.1128/JVI.01447-1526468543 182.LondriganSLTurvilleSGTateMDDengYMBrooksAGReadingPCN-linked glycosylation facilitates sialic acid-independent attachment"/>
   <result pre="Virol201690120622110.1128/JVI.01447-1526468543 182.LondriganSLTurvilleSGTateMDDengYMBrooksAGReadingPCN-linked glycosylation facilitates sialic acid-independent attachment and entry of" exact="influenza" post="A viruses into cells expressing DC-SIGN or L-SIGNJ Virol20118562990300010.1128/JVI.01705-1021191006"/>
   <result pre="into cells expressing DC-SIGN or L-SIGNJ Virol20118562990300010.1128/JVI.01705-1021191006 183.NichollsJMChanRWRussellRJAirGMPeirisJSEvolving complexities of" exact="influenza" post="virus and its receptorsTrends Microbiol200816414915710.1016/j.tim.2008.01.00818375125 184.HughesMTMcGregorMSuzukiTSuzukiYKawaokaYAdaptation of influenza A"/>
   <result pre="complexities of influenza virus and its receptorsTrends Microbiol200816414915710.1016/j.tim.2008.01.00818375125 184.HughesMTMcGregorMSuzukiTSuzukiYKawaokaYAdaptation of" exact="influenza" post="A viruses to cells expressing low levels of sialic"/>
   <result pre="loss of neuraminidase activityJ Virol20017583766377010.1128/JVI.75.8.3766-3770.200111264365 185.IlyushinaNAKhalenkovAMSeilerJPForrestHLBovinNVMarjukiHet al.Adaptation of pandemic H1N1" exact="influenza" post="viruses in miceJ Virol201084178607861610.1128/JVI.00159-1020592084 186.StevensJBlixtOTumpeyTMTaubenbergerJKPaulsonJCWilsonIAStructure and receptor specificity of"/>
   <result pre="186.StevensJBlixtOTumpeyTMTaubenbergerJKPaulsonJCWilsonIAStructure and receptor specificity of the hemagglutinin from an H5N1" exact="influenza" post="virusScience2006312577240441010.1126/science.112451316543414 187.de VriesRPPengWGrantOCThompsonAJZhuXBouwmanKMet al.Three mutations switch H7N9 influenza to"/>
   <result pre="an H5N1 influenza virusScience2006312577240441010.1126/science.112451316543414 187.de VriesRPPengWGrantOCThompsonAJZhuXBouwmanKMet al.Three mutations switch H7N9" exact="influenza" post="to human-type receptor specificityPLoS Pathog2017136e100639010.1371/journal.ppat.100639028617868 188.LiuQZhouBMaWBawaBMaJWangWet al.Analysis of recombinant"/>
   <result pre="and immunogenicity in ferretsJ Virol201084104936494510.1128/JVI.02489-0920200248 190.ImaiMWatanabeTHattaMDasSCOzawaMShinyaKet al.Experimental adaptation of an" exact="influenza" post="H5 HA confers respiratory droplet transmission to a reassortant"/>
   <result pre="and neuraminidase activities accompanies the emergence of the 2009 H1N1" exact="influenza" post="pandemicJ Virol201286179221923210.1128/JVI.00697-1222718832 192.ParkSLeeIKimJIBaeJYYooKKimJet al.Effects of HA and NA glycosylation"/>
   <result pre="HA and NA glycosylation pattern changes on the transmission of" exact="avian influenza" post="A(H7N9) virus in Guinea pigsBiochem Biophys Res Commun2016479219219710.1016/j.bbrc.2016.09.02427613087 193.RajVSMouHSmitsSLDekkersDHMullerMADijkmanRet"/>
   <result pre="and NA glycosylation pattern changes on the transmission of avian" exact="influenza" post="A(H7N9) virus in Guinea pigsBiochem Biophys Res Commun2016479219219710.1016/j.bbrc.2016.09.02427613087 193.RajVSMouHSmitsSLDekkersDHMullerMADijkmanRet"/>
   <result pre="al.Aerosol vaccination induces robust protective immunity to homologous and heterologous" exact="influenza" post="infection in miceVaccine201129142568257510.1016/j.vaccine.2011.01.05921300100"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7175558\results\search\disease\results.xml">
   <result pre="doi: 10.1186/s40249-020-00655-w : Research Article Severity and outcomes of influenza-related" exact="pneumonia" post="in type A and B strains in China, 2013–2019"/>
   <result pre="Inconsistencies exist regarding the severity of illness caused by different" exact="influenza" post="strains. The aim of this study was to compare"/>
   <result pre="the clinical outcomes of hospitalized adults and adolescents with influenza-related" exact="pneumonia" post="(Flu-p) from type A and type B strains in"/>
   <result pre="Cox regression models were used to assess the effects of" exact="influenza" post="virus subtypes on clinical outcomes, and to explore the"/>
   <result pre="30-day mortality for Flu-p patients. Results In total, 963 laboratory-confirmed" exact="influenza" post="A-related pneumonia (FluA-p) and 386 influenza B-related pneumonia (FluB-p)"/>
   <result pre="for Flu-p patients. Results In total, 963 laboratory-confirmed influenza A-related" exact="pneumonia" post="(FluA-p) and 386 influenza B-related pneumonia (FluB-p) patients were"/>
   <result pre="In total, 963 laboratory-confirmed influenza A-related pneumonia (FluA-p) and 386" exact="influenza" post="B-related pneumonia (FluB-p) patients were included. Upon adjustment for"/>
   <result pre="963 laboratory-confirmed influenza A-related pneumonia (FluA-p) and 386 influenza B-related" exact="pneumonia" post="(FluB-p) patients were included. Upon adjustment for confounders, multivariate"/>
   <result pre="0.001) compared to FluB-p. Multivariate Cox regression models confirmed that" exact="influenza" post="A virus infection (hazard ratio: 2.637, 95% CI: 1.134–6.131,"/>
   <result pre="Clinical outcome Funding Beijing JishuitanHospitalZR-201921ChenLiang Background Influenza is a contagious" exact="respiratory disease" post="that is widespread across the globe. Despite advances in"/>
   <result pre="is widespread across the globe. Despite advances in medical technology," exact="influenza" post="causes considerable hospitalizations and mortality [1, 2]. It is"/>
   <result pre="is estimated that each year, 1 billion cases of symptomatic" exact="influenza" post="infection have occurred across the globe, including 3–5 million"/>
   <result pre="care unit (ICU) admissions and 12 000–79 000 deaths were associated with" exact="influenza" post="per year in the United States of America [4]."/>
   <result pre="the United States of America [4]. The disease burden of" exact="influenza" post="in Asia is similar to that of western countries"/>
   <result pre="or 0.6% of the global income [7]. For these reasons," exact="influenza" post="epidemics are regarded as the greatest threat to the"/>
   <result pre="cough. Kilbourne suggested that the disease features caused by different" exact="influenza" post="virus subtypes are clinically indistinguishable [8]. Several studies have"/>
   <result pre="examined the hypothesis that the severity of illness caused by" exact="influenza" post="is associated with causal virus types. For example, Mosnier"/>
   <result pre="found that the clinical symptoms and outcomes for patients with" exact="influenza" post="A and B infections were comparable [9, 10]. Studies"/>
   <result pre="comparable [9, 10]. Studies by Kaji and colleagues showed that" exact="influenza" post="A infection was more severe than influenza B [11]."/>
   <result pre="colleagues showed that influenza A infection was more severe than" exact="influenza" post="B [11]. The outcomes of different studies have been"/>
   <result pre="understand the differences of the severity and outcomes between specific" exact="influenza" post="virus types is of great significance to arrange rational"/>
   <result pre="other clinical decisions in the management of severe influenza. Influenza-related" exact="pneumonia" post="(Flu-p) is the major kind of severe influenza, which"/>
   <result pre="Study design Patient recruitment We screened hospitalized patients positive for" exact="influenza" post="virus RNA at the microbiology labs of five tertiary"/>
   <result pre="as follows: (i) Aged ≤ 14 years; (ii) not classified as community-onset" exact="pneumonia" post="(pneumonia onset ≥ 48 h post-admission and hospitalized within the last"/>
   <result pre="28 days [13]), as it was difficult to determine whether nosocomial" exact="pneumonia" post="occurred after the onset the influenza; (iii) it has"/>
   <result pre="that the clinical characteristics and outcomes of immunocompromised patients with" exact="influenza" post="differ to those of immunocompetent hosts. So, those who"/>
   <result pre="were excluded [14]. Disease and treatment definitions Patients with influenza-related" exact="pneumonia" post="were defined during the influenza season and manifested with"/>
   <result pre="treatment definitions Patients with influenza-related pneumonia were defined during the" exact="influenza" post="season and manifested with respiratory symptoms and were positive"/>
   <result pre="season and manifested with respiratory symptoms and were positive for" exact="influenza" post="virus by reverse-transcription polymerase chain reaction (RT-PCR), together with"/>
   <result pre="All probability tests were two-tailed. To evaluate the impact of" exact="influenza" post="virus subtypes on illness severity and clinical outcomes (invasive"/>
   <result pre="previously shown to be associated with the clinical outcomes of" exact="influenza" post="patients and served as confounders [15]. According to the"/>
   <result pre="Flu-p patients, variables with P-values &amp;lt; 0.1 in univariate analysis and" exact="influenza" post="virus type A were entered into the multivariate Cox"/>
   <result pre="USA). Results Screening process We screened 3190 patients that were" exact="influenza" post="RNA positive. A total of 693 laboratory-confirmed FluA-p patients"/>
   <result pre="patients hospitalized with Flu-p in China, 2013–2019. 3190 patients with" exact="influenza" post="RNA positive were screened. Totally, 693 laboratory-confirmed FluA-p patients"/>
   <result pre="More than 50% had at least one underlying disease, including" exact="cardiovascular disease" post="24.0% (259/1079), diabetes mellitus 11.8% (127/1079) and cerebrovascular disease"/>
   <result pre="at least one underlying disease, including cardiovascular disease 24.0% (259/1079)," exact="diabetes mellitus" post="11.8% (127/1079) and cerebrovascular disease 9.0% (97/1079). In total,"/>
   <result pre="hospitalization, whilst 23.1% (249/1079), 24.6% (265/1079) and 4.9% (53/1079) developed" exact="respiratory failure," post="heart failure and septic shock, respectively. In total, 17.9%"/>
   <result pre="were younger and predominantly male. In FluA-p patients, cerebrovascular disease," exact="diabetes mellitus" post="and smoking history were frequent, whilst cardiovascular disease was"/>
   <result pre="cerebrovascular disease, diabetes mellitus and smoking history were frequent, whilst" exact="cardiovascular disease" post="was less common. FluA-p patients more frequently showed axillary"/>
   <result pre="clinical outcomes of flu-p patients Univariate logistic analysis showed that" exact="influenza" post="A virus infection was associated with an increased risk"/>
   <result pre="in Flu-p patients (Table 3). Table 3 The impact of" exact="influenza" post="virus type A on the illness severity and outcomes"/>
   <result pre="corticosteroid use, and coinfections, multivariate logistic regression models revealed that" exact="influenza" post="A virus infection was associated with an increased risk"/>
   <result pre="patients (Table 3). The forrest plots of the impact of" exact="influenza" post="virus A on invasive ventilation, admittance to the ICU"/>
   <result pre="Fig. 2. Fig. 2 Forrest plot of the impact of" exact="influenza" post="virus type on the illness severity and outcomes of"/>
   <result pre="hospitalized with Flu-p in China, 2013–2019. Before adjusting for confounders," exact="influenza" post="A virus infection was associated with an increased risks"/>
   <result pre="did not correlate with 30-day mortality. After adjusting for confounders," exact="influenza" post="A virus infection was associated with an increased risks"/>
   <result pre="factors screened in the univariate analysis with P &amp;lt;  0.1 and" exact="influenza" post="A virus infection were added to the Cox regression"/>
   <result pre="model (Additional file 1). Multivariate Cox regression models confirmed that" exact="influenza" post="A virus infection (hazard ratio [HR]: 2.637, 95% CI:"/>
   <result pre="1.134–6.131, P = 0.024), age (HR: 1.055, 95% CI: 1.033–1.077, P &amp;lt;  0.001)," exact="cardiovascular disease" post="(HR: 7.683, 95% CI: 3.175–18.58, P &amp;lt;  0.001), smoking history"/>
   <result pre="than that of FluB-p patients after adjusting for confounders (age," exact="cardiovascular disease," post="chronic kidney disease, smoking history, confusion, lymphocytes &amp;lt; 0.8 × 109/L, hemoglobin"/>
   <result pre="of FluB-p patients after adjusting for confounders (age, cardiovascular disease," exact="chronic kidney disease," post="smoking history, confusion, lymphocytes &amp;lt; 0.8 × 109/L, hemoglobin &amp;lt; 100 g/L, BUN &amp;gt; 7 mmol/L,"/>
   <result pre="after adjusting for potential confounders, suggesting a direct impact of" exact="influenza" post="virus types on the characteristics and outcomes of influenza"/>
   <result pre="of influenza virus types on the characteristics and outcomes of" exact="influenza" post="related pneumonia. In this study, the 30-day mortality was"/>
   <result pre="patients with flu B infection. After adjustment for age, sex," exact="heart disease," post="malignancies and time from illness onset to antiviral treatment,"/>
   <result pre="Chaves and colleagues [21] performed a retrospective study using population-based" exact="influenza" post="hospitalization surveillance data. They found that A (H1N1) pdm09"/>
   <result pre="been elucidated, some mechanisms have been postulated. Hemagglutinin (HA) of" exact="influenza" post="B virus strains is heavily glycosylated [23]. Since glycosylated"/>
   <result pre="it is easily cleared from the lungs. HA of human" exact="influenza" post="B viruses also preferentially bind to α-2,6-linked sialic acids"/>
   <result pre="more prevalent in the lower respiratory tract [25]. Compared to" exact="influenza" post="A viruses, influenza B has lower receptor-binding affinity due"/>
   <result pre="the lower respiratory tract [25]. Compared to influenza A viruses," exact="influenza" post="B has lower receptor-binding affinity due to the presence"/>
   <result pre="The innate IFN response is also more rapidly initiated following" exact="influenza" post="B as opposed to influenza A virus infection. This"/>
   <result pre="also more rapidly initiated following influenza B as opposed to" exact="influenza" post="A virus infection. This leads to more rapid viral"/>
   <result pre="viral clearance and lower viral titers [27]. In vivo, both" exact="influenza" post="A and B viruses downregulate the surface expression of"/>
   <result pre="more pronounced reduction in surface MHC-I expression was observed in" exact="influenza" post="B patients, leading to milder immunologic reactions, followed by"/>
   <result pre="risk factor for death. They further confirmed that prior chronic" exact="respiratory disease" post="was associated with ICU admission in multivariate logistic regression"/>
   <result pre="admission in multivariate logistic regression models. The proportion of chronic" exact="respiratory disease" post="patients was significantly higher in flu A compared to"/>
   <result pre="the post-pandemic period was more related to poor outcomes (secondary" exact="bacterial pneumonia," post="ICU admission, and death) than influenza B viruses [33]."/>
   <result pre="poor outcomes (secondary bacterial pneumonia, ICU admission, and death) than" exact="influenza" post="B viruses [33]. To our knowledge, this is the"/>
   <result pre="hospital wards or ICUs) that focused on the association of" exact="influenza" post="viruses types with illness severity and clinical outcomes of"/>
   <result pre="types with illness severity and clinical outcomes of laboratory-confirmed influenza-related" exact="pneumonia" post="patients. Methods were taken to reduce selection bias and"/>
   <result pre="bias may have influenced the data. For example, during each" exact="influenza" post="season, patients with influenza-like illness (such as fever, sore"/>
   <result pre="(such as fever, sore throat or cough) were assessed through" exact="influenza" post="RNA tests by the subjective judgement of attending physicians"/>
   <result pre="our results. Thirdly, there is evidence of different severities of" exact="influenza" post="A virus subtypes [11, 32]. However, over 50% of"/>
   <result pre="of FluA-p are worse than FluB-p, highlighting the importance of" exact="influenza" post="virus strain testing in the management of severe influenza."/>
   <result pre="virus strain testing in the management of severe influenza. As" exact="influenza" post="A virus infection is a predictor for poor outcomes"/>
   <result pre="with FluA-p. Also, it suggests the priority of vaccination covered" exact="influenza" post="virus type A strains in certain populations is rational."/>
   <result pre="Abbreviations BUN Blood urea nitrogen CI Interval confidence Flu-p Influenza-related" exact="pneumonia" post="HR Hazard ratio ICU Intensive care unit IQR Interquartile"/>
   <result pre="authors declare no competing interests. References References 1.ThommesEWKruseMKohliMSharmaRNoorduynSGReview of seasonal" exact="influenza" post="in Canada: burden of disease and the cost-effectiveness of"/>
   <result pre="Canada: burden of disease and the cost-effectiveness of quadrivalent inactivated" exact="influenza" post="vaccinesHum Vaccin Immunother20171386787610.1080/21645515.2016.125153727858509 2.LozanoRNaghaviMForemanKLimSShibuyaKAboyansVet al.Global and regional mortality from"/>
   <result pre="burden of disease study 2010Lancet.20123802095212810.1016/S0140-6736(12)61728-023245604 3.LySArashiroTIengVTsuyuokaRParryAHorwoodPet al.Establishing seasonal and alert" exact="influenza" post="thresholds in Cambodia using the WHO method: implications for"/>
   <result pre="Cambodia using the WHO method: implications for effective utilization of" exact="influenza" post="surveillance in the tropics and subtropicsWestern Pac Surveill Response"/>
   <result pre="tropics and subtropicsWestern Pac Surveill Response J20178223210.5365/wpsar.2017.8.1.00228409056 4.ReedCChavesSSDaily KirleyPEmersonRAragonDHancockEBet al.Estimating" exact="influenza" post="disease burden from population-based surveillance data in the United"/>
   <result pre="9.MosnierACainiSDaviaudINauleauEBuiTTDebostEet al.Clinical characteristics are similar across type a and B" exact="influenza" post="virus infectionsPLoS One201510e013618610.1371/journal.pone.013618626325069 10.IrvingSAPatelDCKiekeBADonahueJGVandermauseMFShayDKet al.Comparison of clinical features and"/>
   <result pre="10.IrvingSAPatelDCKiekeBADonahueJGVandermauseMFShayDKet al.Comparison of clinical features and outcomes of medically attended" exact="influenza" post="a and influenza B in a defined population over"/>
   <result pre="clinical features and outcomes of medically attended influenza a and" exact="influenza" post="B in a defined population over four seasons: 2004-2005"/>
   <result pre="through 2007-2008Influenza Other Respir Viruses20126374310.1111/j.1750-2659.2011.00263.x21668663 11.KajiMWatanabeAAizawaHDifferences in clinical features between" exact="influenza" post="a H1N1, a H3N2, and B in adult patientsRespirology2003823123310.1046/j.1440-1843.2003.00457.x12753540"/>
   <result pre="adult patientsRespirology2003823123310.1046/j.1440-1843.2003.00457.x12753540 12.FuXZhouYWuJLiuXDingCHuangCet al.Clinical characteristics and outcomes during a severe" exact="influenza" post="season in China during 2017-2018BMC Infect Dis20191966810.1186/s12879-019-4181-231357951 13.ChenLZhouFLiHXingXHanXWangYet al.Disease"/>
   <result pre="characteristics and management of hospitalised adolescents and adults with community-acquired" exact="pneumonia" post="in China: a retrospective multicentre surveyBMJ Open20188e01870910.1136/bmjopen-2017-018709 14.KossyvakisAMentisAATryfinopoulouKPogkaVKalliaropoulosAet al.Antiviral"/>
   <result pre="a retrospective multicentre surveyBMJ Open20188e01870910.1136/bmjopen-2017-018709 14.KossyvakisAMentisAATryfinopoulouKPogkaVKalliaropoulosAet al.Antiviral susceptibility profile of" exact="influenza" post="a viruses; keep an eye on immunocompromised patients under"/>
   <result pre="inhibitors in reducing mortality in patients admitted to hospital with" exact="influenza" post="a H1N1pdm09 virus infection: a meta-analysis of individual participant"/>
   <result pre="a meta-analysis of individual participant dataLancet Respir Med2014239540410.1016/S2213-2600(14)70041-424815805 16.JainSSelfWHWunderinkRGFakhranSBalkRBramleyAMet al.Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. adultsN Engl J Med201537341542710.1056/NEJMoa150024526172429 17.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet"/>
   <result pre="among U.S. adultsN Engl J Med201537341542710.1056/NEJMoa150024526172429 17.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.The role of" exact="pneumonia" post="and secondary bacterial infection in fatal and serious outcomes"/>
   <result pre="secondary bacterial infection in fatal and serious outcomes of pandemic" exact="influenza" post="a(H1N1) pdm09BMC Infect Dis20181863710.1186/s12879-018-3548-030526505 18.LiuDXuJYuXTongFWallineJFuYet al.Clinical characteristics and prognosis"/>
   <result pre="a(H1N1) pdm09BMC Infect Dis20181863710.1186/s12879-018-3548-030526505 18.LiuDXuJYuXTongFWallineJFuYet al.Clinical characteristics and prognosis of" exact="influenza" post="B virus-related hospitalizations in northern China during the 2017-18"/>
   <result pre="influenza B virus-related hospitalizations in northern China during the 2017-18" exact="influenza" post="season: a multicenter case seriesBiomed Res Int20192019875656331828141 19.SohnCHRyooSMYoonJYSeoDWLimKSKimSHet al.Comparison"/>
   <result pre="clinical features and outcomes of hospitalized adult patients with novel" exact="influenza" post="a (H1N1) pneumonia and other pneumoniaAcad Emerg Med201320465310.1111/acem.1206223570478 20.WangYFanGHorbyPHaydenFLiQWuQet"/>
   <result pre="outcomes of hospitalized adult patients with novel influenza a (H1N1)" exact="pneumonia" post="and other pneumoniaAcad Emerg Med201320465310.1111/acem.1206223570478 20.WangYFanGHorbyPHaydenFLiQWuQet al.Comparative outcomes of"/>
   <result pre="Emerg Med201320465310.1111/acem.1206223570478 20.WangYFanGHorbyPHaydenFLiQWuQet al.Comparative outcomes of adults hospitalized with seasonal" exact="influenza" post="A or B virus infection: Application of the 7-category"/>
   <result pre="ordinal scaleOpen Forum Infect Dis20196ofz05330895200 21.ChavesSSAragonDBennettNCooperTD'MelloTFarleyMet al.Patients hospitalized with laboratory-confirmed" exact="influenza" post="during the 2010-2011 influenza season: exploring disease severity by"/>
   <result pre="Dis20196ofz05330895200 21.ChavesSSAragonDBennettNCooperTD'MelloTFarleyMet al.Patients hospitalized with laboratory-confirmed influenza during the 2010-2011" exact="influenza" post="season: exploring disease severity by virus type and subtypeJ"/>
   <result pre="al.Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and" exact="influenza" post="B infections depict distinct clinical pictures in ferretsPLoS One20116e2751210.1371/journal.pone.002751222110664"/>
   <result pre="pictures in ferretsPLoS One20116e2751210.1371/journal.pone.002751222110664 23.RogersGNPaulsonJCReceptor determinants of human and animal" exact="influenza" post="virus isolates: differences in receptor specificity of the H3"/>
   <result pre="based on species of originVirology198312736137310.1016/0042-6822(83)90150-26868370 24.KumlinUOlofssonSDimockKArnbergNSialic acid tissue distribution and" exact="influenza" post="virus tropismInfluenza Other Respir Viruses2008214715410.1111/j.1750-2659.2008.00051.x19453419 25.WaltherTKaramanskaRChanRWChanMCJiaNAirGet al.Glycomic analysis of"/>
   <result pre="al.Glycomic analysis of human respiratory tract tissues and correlation with" exact="influenza" post="virus infectionPLoS Pathog20139e100322310.1371/journal.ppat.100322323516363 26.MatrosovichMNGambaryanASTuzikovABByramovaNEMochalovaLVGolbraikhAAet al.Probing of the receptor-binding sites"/>
   <result pre="al.Probing of the receptor-binding sites of the H1 and H3" exact="influenza" post="a and influenza B virus hemagglutinins by synthetic and"/>
   <result pre="receptor-binding sites of the H1 and H3 influenza a and" exact="influenza" post="B virus hemagglutinins by synthetic and natural sialosidesVirology.199319611112110.1006/viro.1993.14598356788 27.ÖsterlundPStrengellMSarinLPPoranenMMFagerlundRMelénKet"/>
   <result pre="B virus hemagglutinins by synthetic and natural sialosidesVirology.199319611112110.1006/viro.1993.14598356788 27.ÖsterlundPStrengellMSarinLPPoranenMMFagerlundRMelénKet al.Incoming" exact="influenza" post="a virus evades early host recognition, while influenza B"/>
   <result pre="27.ÖsterlundPStrengellMSarinLPPoranenMMFagerlundRMelénKet al.Incoming influenza a virus evades early host recognition, while" exact="influenza" post="B virus induces interferon expression directly upon entryJ Virol201286111831119310.1128/JVI.01050-1222855501"/>
   <result pre="entryJ Virol201286111831119310.1128/JVI.01050-1222855501 28.KoutsakosMMcWilliamHEGAktepeTEFritzlarSIllingPTMifsudNAet al.Downregulation of MHC class I expression by" exact="influenza" post="a and B virusesFront Immunol201910115810.3389/fimmu.2019.0115831191533 29.LoubetPSamih-LenziNGaltierFVanhemsPLoulerguePDuvalXet al.Factors associated with"/>
   <result pre="29.LoubetPSamih-LenziNGaltierFVanhemsPLoulerguePDuvalXet al.Factors associated with poor outcomes among adults hospitalized for" exact="influenza" post="in France: a three-year prospective multicenter studyJ Clin Virol201679687310.1016/j.jcv.2016.04.00527105315"/>
   <result pre="Virol201679687310.1016/j.jcv.2016.04.00527105315 30.SuSChavesSSPerezAD'MelloTKirleyPDYousey-HindesKet al.Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="a and B virus infectionClin Infect Dis20145925225510.1093/cid/ciu26924748521 31.WieSHSoBHSongJYCheongHJSeoYBChoiSHet al.A"/>
   <result pre="the clinical and epidemiological characteristics of adult patients with laboratory-confirmed" exact="influenza" post="a or B during the 2011-2012 influenza season in"/>
   <result pre="patients with laboratory-confirmed influenza a or B during the 2011-2012" exact="influenza" post="season in Korea: a multi-center studyPLoS One20138e6268510.1371/journal.pone.006268523671624 32.IshiguroTTakayanagiNKanauchiTUozumiRKawateETakakuYet al.Clinical"/>
   <result pre="a multi-center studyPLoS One20138e6268510.1371/journal.pone.006268523671624 32.IshiguroTTakayanagiNKanauchiTUozumiRKawateETakakuYet al.Clinical and radiographic comparison of" exact="influenza" post="virus-associated pneumonia among three viral subtypesIntern Med20165573173710.2169/internalmedicine.55.522727041156 33.CainiSKronemanMWiegersTEl Guerche-SéblainCPagetJClinical"/>
   <result pre="studyPLoS One20138e6268510.1371/journal.pone.006268523671624 32.IshiguroTTakayanagiNKanauchiTUozumiRKawateETakakuYet al.Clinical and radiographic comparison of influenza virus-associated" exact="pneumonia" post="among three viral subtypesIntern Med20165573173710.2169/internalmedicine.55.522727041156 33.CainiSKronemanMWiegersTEl Guerche-SéblainCPagetJClinical characteristics and"/>
   <result pre="three viral subtypesIntern Med20165573173710.2169/internalmedicine.55.522727041156 33.CainiSKronemanMWiegersTEl Guerche-SéblainCPagetJClinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype, and lineage: a systematic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7176985\results\search\disease\results.xml">
   <result pre="for veterinary use (RVFV, bluetongue [34], African horsesickness [35], canine" exact="influenza" post="[36], and for human use [influenza [37] (US and"/>
   <result pre="It is relevant to note that FDA labeling of live" exact="influenza" post="vaccine (FluMist®), containing four genetically engineered influenza strains, does"/>
   <result pre="labeling of live influenza vaccine (FluMist®), containing four genetically engineered" exact="influenza" post="strains, does not contain precautions for reassortment. Table 2"/>
   <result pre="vaccine-associated paralytic polio caused by circulating recombinant strains Bovine viral" exact="diarrhea" post="Cows Pestivirus positive sense non-segmented ssRNA Recombination of LAV"/>
   <result pre="to virulent strain causing mucosal disease Sporadic mucosal disease Infectious" exact="laryngotracheitis" post="virus Chickens Herpesvirus double stranded linear DNA Recombination of"/>
   <result pre="reversion and reassortment. The benefit:risk ratio (cases of RVF illness," exact="retinitis" post="or death prevented per excess illness caused by a"/>
   <result pre="36Rodriguez L, Nogales A, Reilly EC, et al. A live-attenuated" exact="influenza" post="vaccine for H3N2 canine influenza virus. 2017; 504: 96–106."/>
   <result pre="EC, et al. A live-attenuated influenza vaccine for H3N2 canine" exact="influenza" post="virus. 2017; 504: 96–106. 37RodriguezL.Blanco-LoboP.ReillyE.C.Comparative Study of the Temperature"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7178760\results\search\disease\results.xml">
   <result pre="the data. Abstract Background Prophylactic vaccines are critical in preventing" exact="hand, foot, and mouth disease" post="(HFMD) primarily caused by human enterovirus 71 (EV71) infection."/>
   <result pre="Background Prophylactic vaccines are critical in preventing hand, foot, and" exact="mouth disease" post="(HFMD) primarily caused by human enterovirus 71 (EV71) infection."/>
   <result pre="http://dx.doi.org/10.13039/501100005150Chinese Academy of Medical Sciences 2016-I2M-2-006QinChuan Background Hand, foot, and" exact="mouth disease" post="(HFMD) is extremely contagious and prevalent among infants and"/>
   <result pre="to protect over 90% vaccinated children from EV71-related HFMD or" exact="herpangina" post="[10, 14, 15, 17]. The virus-like particles (VLPs), containing"/>
   <result pre="to animal experiments [18–22]. There’re also two inspiring examples, VLP-based" exact="hepatitis" post="B virus and human papillomavirus vaccines, which have been"/>
   <result pre="active immunization in neonates. Methods Virus and cell culture Human" exact="rhabdomyosarcoma" post="cells (RD) were cultured in Dulbecco’s modified Eagle’s medium"/>
   <result pre="addition to inactivated virus vaccine. Abbreviations HFMD Hand, foot, and" exact="mouth disease" post="EV71 Enterovirus 71 VLPs Virus-like particles BBB Blood-brain barrier"/>
   <result pre="71 and analysis of prevalent genotypesJ Med Virol20098131732410.1002/jmv.2137419107980 3.FowlkesALHonarmandSGlaserCYagiSet al.Enterovirus-associated" exact="encephalitis" post="in the California encephalitis project, 1998-2005J Infect Dis20081981685169110.1086/59298818959496 4.DiedrichSWeinbrechtASchreierESeroprevalence"/>
   <result pre="prevalent genotypesJ Med Virol20098131732410.1002/jmv.2137419107980 3.FowlkesALHonarmandSGlaserCYagiSet al.Enterovirus-associated encephalitis in the California" exact="encephalitis" post="project, 1998-2005J Infect Dis20081981685169110.1086/59298818959496 4.DiedrichSWeinbrechtASchreierESeroprevalence and molecular epidemiology of"/>
   <result pre="Anti-Infect Ther20141244745610.1586/14787210.2014.89566624579906 6.ChanLGParasharUDLyeMSet al.Deaths of children during an outbreak of" exact="hand, foot, and mouth disease" post="in Sarawak, Malaysia: clinical and pathological characteristics of the"/>
   <result pre="al.Deaths of children during an outbreak of hand, foot, and" exact="mouth disease" post="in Sarawak, Malaysia: clinical and pathological characteristics of the"/>
   <result pre="children: a further observationHum Vaccin Immunother.2018141517152310.1080/21645515.2018.144299729482422 13.XingWLiaoQViboudCet al.Hand, foot, and" exact="mouth disease" post="in China, 2008-12: an epidemiological studyLancet Infect Dis20141430831810.1016/S1473-3099(13)70342-624485991 14.ZhuFXuWXiaJet"/>
   <result pre="16.MaoQYWangYBianLet al.EV71 vaccine, a new tool to control outbreaks of" exact="hand, foot and mouth disease" post="(HFMD)Expert Rev Vaccines.20161559960610.1586/14760584.2016.113886226732723 17.ChenYJMengFYMaoQet al.Clinical evaluation for batch consistency"/>
   <result pre="a new tool to control outbreaks of hand, foot and" exact="mouth disease" post="(HFMD)Expert Rev Vaccines.20161559960610.1586/14760584.2016.113886226732723 17.ChenYJMengFYMaoQet al.Clinical evaluation for batch consistency"/>
   <result pre="in clinical developmentVaccine.201231588310.1016/j.vaccine.2012.10.08323142589 24.ZhangWDaiWZhangCet al.A virus-like particle-based tetravalent vaccine for" exact="hand, foot, and mouth disease" post="elicits broad and balanced protective immunityEmerg Microbes Infect201879429777102 25.KuZYeXHuangXet"/>
   <result pre="24.ZhangWDaiWZhangCet al.A virus-like particle-based tetravalent vaccine for hand, foot, and" exact="mouth disease" post="elicits broad and balanced protective immunityEmerg Microbes Infect201879429777102 25.KuZYeXHuangXet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7179685\results\search\disease\results.xml">
   <result pre="to the increased association of ZIKV infections with fetal abnormalities," exact="autoimmune disease," post="and neurological disorders. ZIKV has been relatively uninvestigated since"/>
   <result pre="infection rates, neurological pathologies such as Guillain-Barré syndrome, meningoencephalitis, and" exact="myelitis" post="in adults, and microcephaly in infants (Musso and Gubler,"/>
   <result pre="such as Guillain-Barré syndrome, meningoencephalitis, and myelitis in adults, and" exact="microcephaly" post="in infants (Musso and Gubler, 2016). By phylogenetic analysis,"/>
   <result pre="most alarming outcomes associated with ZIKV infection during pregnancy is" exact="microcephaly" post="(Petersen et al., 2016). While research is still ongoing"/>
   <result pre="the relationship, Asian lineage ZIKVs have been most associated with" exact="microcephaly" post="(Anfasa et al., 2017; Bhatnagar et al., 2017; Yuan"/>
   <result pre="as well as the brain of fetuses and infants with" exact="microcephaly" post="(Oliveira Melo et al., 2016; Mlakar et al., 2016)."/>
   <result pre="unable to support infection by multiple viruses such as HIV," exact="influenza" post="A virus, adenovirus, poliovirus and vaccinia virus (Sadat et"/>
   <result pre="viruses such as HIV, influenza A virus, adenovirus, poliovirus and" exact="vaccinia virus" post="(Sadat et al., 2014; Alonzi et al., 2017). Zika"/>
   <result pre="in ZIKV infection (Ma et al., 2018). In these studies," exact="hepatocellular carcinoma" post="cells with the knockout of α-glucosidases I or II"/>
   <result pre="developing brain cells and lead to ZIKV-induced damage such as" exact="microcephaly" post="(Limonta et al., 2018). A key pathogenicity factor in"/>
   <result pre="2016). Celgosivir has been considered in human clinical trials against" exact="hepatitis" post="C virus, HIV and dengue virus (Durantel, 2009; Sung"/>
   <result pre="(2007). Antiviral profiles of novel iminocyclitol compounds against bovine viral" exact="diarrhea" post="virus, west nile virus, dengue virus and hepatitis B"/>
   <result pre="bovine viral diarrhea virus, west nile virus, dengue virus and" exact="hepatitis" post="B Virus.Antivir. Chem. Chemother.1849–59. 10.1177/09563202070180010517354651 HaddowA. D.SchuhA. J.YasudaC. Y.KasperM."/>
   <result pre="genes for the normalization of RT-qpcr expression studies in human" exact="breast cancer" post="cell lines treated with and without transient transfection.PLoS One10:e0117058."/>
   <result pre="for the normalization of RT-qpcr expression studies in human breast" exact="cancer" post="cell lines treated with and without transient transfection.PLoS One10:e0117058."/>
   <result pre="Zika (PRVABC59) infection is associated with T cell Infiltration and" exact="neurodegeneration" post="in CNS of immunocompetent neonatal C57Bl/6 Mice.PLoS Pathog.12:e1006004. 10.1371/journal.ppat.100600427855206"/>
   <result pre="QuX.PanX.WeidnerJ.YuW.AlonziD.XuX.et al. (2011). Inhibitors of endoplasmic reticulum α-Glucosidases potently suppress" exact="hepatitis" post="C Virus virion assembly and release.Antimicrob. Agents Chemotherapy551036–1044. 10.1128/AAC.01319-1021173177"/>
   <result pre="interferon-stimulated genes in human bronchial epithelial (BEAS-2B) cells contributes to" exact="influenza" post="A virus resistance.PLoS One9:e109023. 10.1371/journal.pone.010902325313647 SheridanM. A.BalaramanV.SchustD. J.EzashiT.RobertsR. M.FranzA."/>
   <result pre="S. (2006). α-Glucosidase Inhibitors have a prolonged antiviral effect against" exact="hepatitis" post="B Virus through the sustained inhibition of the large"/>
   <result pre="endpoints of CELADEN: A randomized, placebo-controlled trial of celgosivir in" exact="dengue fever" post="patients.PLoS Negl. Trop. Dis.10:e0004851. 10.1371/journal.pntd.000485127509020 SwartwoutB.ZlotnickM.SaverA.McKennaC.BertkeA. (2017). Zika Virus"/>
   <result pre="castanospermine) against the pestivirus BVDV: implications for the treatment of" exact="hepatitis" post="C.Antivir. Chem. Chemother.15141–151. 10.1177/09563202040150030415266896 collab: WHO, (2016). Zika Virus,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7181926\results\search\disease\results.xml">
   <result pre="in 1947 from a caged sentinel rhesus monkey during a" exact="yellow fever" post="virus survey conducted in Zika forest of Uganda. The"/>
   <result pre="self-limiting symptoms that include macular or papular rash, fever, arthritis," exact="conjunctivitis" post="and headache) (8). In Martinique, estimates of truly asymptomatic"/>
   <result pre="fever or history of fever, and negative testing for HIV," exact="hepatitis" post="B and C, and syphilis. We excluded persons with"/>
   <result pre="the recent report of an association between ZIKV IgG and" exact="microcephaly" post="in Guinea-Bissau (32) suggests that comprehensive case-control studies of"/>
   <result pre="Université, Marseille, France. His research interests are arboviral diseases, malaria," exact="schistosomiasis" post="and tuberculosis. References References 1. WangA, ThurmondS, IslasL, HuiK,"/>
   <result pre="26. KouribaB, DiarraAB, DouyonI, DiabatéDT, KamissokoF, GuitteyeH, et al.P. falciparum" exact="malaria" post="prevalence among blood donors in Bamako, Mali.Transfus Clin Biol."/>
   <result pre="JadiR, KeelerC, ParrJB, MumbaD, et al.Seroepidemiology of dengue, Zika, and" exact="yellow fever" post="viruses among children in the Democratic Republic of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7181938\results\search\disease\results.xml">
   <result pre="Kong, China; email: bcowling@hku.hk ppub: 2020-5265967975 Abstract There were 3" exact="influenza" post="pandemics in the 20th century, and there has been"/>
   <result pre="health authorities regularly update their plans for mitigating the next" exact="influenza" post="pandemic in light of the latest available evidence on"/>
   <result pre="an improved characterization of the modes of person-to-person transmission. Keywords:" exact="influenza" post="pandemic influenza influenza virus viruses respiratory infections nonpharmaceutical measures"/>
   <result pre="characterization of the modes of person-to-person transmission. Keywords: influenza pandemic" exact="influenza" post="influenza virus viruses respiratory infections nonpharmaceutical measures nonhealthcare settings"/>
   <result pre="of the modes of person-to-person transmission. Keywords: influenza pandemic influenza" exact="influenza" post="virus viruses respiratory infections nonpharmaceutical measures nonhealthcare settings personal"/>
   <result pre="Influenza pandemics occur at irregular intervals when new strains of" exact="influenza" post="A virus spread in humans (1). Influenza pandemics cause"/>
   <result pre="and social impact that exceeds that of typical seasonal (interpandemic)" exact="influenza" post="epidemics. One of the characteristics of influenza pandemics is"/>
   <result pre="typical seasonal (interpandemic) influenza epidemics. One of the characteristics of" exact="influenza" post="pandemics is the high incidence of infections in all"/>
   <result pre="age groups because of the lack of population immunity. Although" exact="influenza" post="vaccines are the cornerstone of seasonal influenza control, specific"/>
   <result pre="population immunity. Although influenza vaccines are the cornerstone of seasonal" exact="influenza" post="control, specific vaccines for a novel pandemic strain are"/>
   <result pre="the next pandemic will rely largely on nonpharmaceutical interventions. Most" exact="influenza" post="virus infections cause mild and self-limiting disease; only a"/>
   <result pre="disease; only a small fraction of case-patients require hospitalization. Therefore," exact="influenza" post="virus infections spread mainly in the community. Influenza virus"/>
   <result pre="addition to standard precautions for healthcare personnel when interacting with" exact="influenza" post="patients and for all visitors during influenza seasons (4)."/>
   <result pre="when interacting with influenza patients and for all visitors during" exact="influenza" post="seasons (4). Outside healthcare settings, hand hygiene is recommended"/>
   <result pre="and medical face masks were a common sight during the" exact="influenza" post="pandemic in 2009. Hand hygiene has been proven to"/>
   <result pre="infectious diseases and might be considered a major component in" exact="influenza" post="pandemic plans, whether or not it has proven effectiveness"/>
   <result pre="pandemic plans, whether or not it has proven effectiveness against" exact="influenza" post="virus transmission, specifically because of its potential to reduce"/>
   <result pre="the effectiveness of these measures in reducing transmission of laboratory-confirmed" exact="influenza" post="in the community. We also discuss the implications of"/>
   <result pre="reviews to evaluate the effectiveness of personal protective measures on" exact="influenza" post="virus transmission, including hand hygiene, respiratory etiquette, and face"/>
   <result pre="identify randomized controlled trials (RCTs) of each measure for laboratory-confirmed" exact="influenza" post="outcomes for each of the measures because RCTs provide"/>
   <result pre="hand hygiene interventions do not have a substantial effect on" exact="influenza" post="transmission. Respiratory etiquette 0 NA We did not identify"/>
   <result pre="not identify research evaluating the effectiveness of respiratory etiquette on" exact="influenza" post="transmission. Face masks 10 RCT The evidence from RCTs"/>
   <result pre="by uninfected persons does not have a substantial effect on" exact="influenza" post="transmission. Surface and object cleaning 3 RCT, observational studies"/>
   <result pre="and object cleaning does not have a substantial effect on" exact="influenza" post="transmission. *NA, not available; RCT randomized controlled trial. †In these"/>
   <result pre="interventions and estimated the effect of these measures on laboratory-confirmed" exact="influenza" post="prevention by risk ratios (RRs). We used a fixed-effects"/>
   <result pre="the efficacy of hand hygiene interventions against transmission of laboratory-confirmed" exact="influenza" post="(8). We used this review as a starting point"/>
   <result pre="effect of hand hygiene combined with face masks on laboratory-confirmed" exact="influenza" post="was not statistically significant (RR 0.91, 95% CI 0.73–1.13;"/>
   <result pre="hand hygiene with or without face mask use on laboratory-confirmed" exact="influenza" post="from 10 randomized controlled trials with &amp;gt;11,000 participants. A)"/>
   <result pre="Egypt (18) reported that hand hygiene reduced the risk for" exact="influenza" post="by &amp;gt;50%. A pooled analysis of 2 studies in"/>
   <result pre="hygiene as an effective measure, experimental studies have reported that" exact="influenza" post="virus could survive on human hands for a short"/>
   <result pre="hands and contaminated surfaces (2,21). Some field studies reported that" exact="influenza" post="A(H1N1)pdm09 and influenza A(H3N2) virus RNA and viable influenza"/>
   <result pre="surfaces (2,21). Some field studies reported that influenza A(H1N1)pdm09 and" exact="influenza" post="A(H3N2) virus RNA and viable influenza virus could be"/>
   <result pre="that influenza A(H1N1)pdm09 and influenza A(H3N2) virus RNA and viable" exact="influenza" post="virus could be detected on the hands of persons"/>
   <result pre="could be detected on the hands of persons with laboratory-confirmed" exact="influenza" post="(22,23), supporting the potential of direct and indirect contact"/>
   <result pre="also demonstrated that hand hygiene could reduce or remove infectious" exact="influenza" post="virus from human hands (24,25). However, results from our"/>
   <result pre="protective measure in &amp;gt;50% of national preparedness plans for pandemic" exact="influenza" post="(5). Hand hygiene practice is commonly performed with soap"/>
   <result pre="effectiveness of respiratory etiquette in reducing the risk for laboratory-confirmed" exact="influenza" post="or ILI. One observational study reported a similar incidence"/>
   <result pre="Whether respiratory etiquette is an effective nonpharmaceutical intervention in preventing" exact="influenza" post="virus transmission remains questionable, and worthy of further research."/>
   <result pre="estimates of the effectiveness of face masks in reducing laboratory-confirmed" exact="influenza" post="virus infections in the community from literature published during"/>
   <result pre="2018. In pooled analysis, we found no significant reduction in" exact="influenza" post="transmission with the use of face masks (RR 0.78,"/>
   <result pre="and reported no major difference in the risk for laboratory-confirmed" exact="influenza" post="virus infection in the control or mask group (33)."/>
   <result pre="masks for primary protection by monitoring the incidence of laboratory-confirmed" exact="influenza" post="among student hall residents for 5 months (9,10). The"/>
   <result pre="5 months (9,10). The overall reduction in ILI or laboratory-confirmed" exact="influenza" post="cases in the face mask group was not significant"/>
   <result pre="the household studies reported a significant reduction in secondary laboratory-confirmed" exact="influenza" post="virus infections in the face mask group (11–13,15,17,34,35). Most"/>
   <result pre="mask use with or without enhanced hand hygiene on laboratory-confirmed" exact="influenza" post="from 10 randomized controlled trials with &amp;gt;6,500 participants. A)"/>
   <result pre="(36). There is limited evidence for their effectiveness in preventing" exact="influenza" post="virus transmission either when worn by the infected person"/>
   <result pre="from fine particles (37) and should provide better protection against" exact="influenza" post="virus exposures when properly worn because of higher filtration"/>
   <result pre="but this intervention was not significant in reducing detection of" exact="influenza" post="virus, and it had no major protective effect on"/>
   <result pre="with bleach was associated with a major increase in self-reported" exact="influenza" post="(40). Given that influenza virus can survive on some"/>
   <result pre="with a major increase in self-reported influenza (40). Given that" exact="influenza" post="virus can survive on some surfaces for prolonged periods"/>
   <result pre="that cleaning or disinfection procedures can effectively reduce or inactivate" exact="influenza" post="virus from surfaces and objects in experimental studies (44),"/>
   <result pre="a theoretical basis to believe that environmental cleaning could reduce" exact="influenza" post="transmission. As an illustration of this proposal, a modeling"/>
   <result pre="study estimated that cleaning of extensively touched surfaces could reduce" exact="influenza" post="A infection by 2% (45). However, most studies of"/>
   <result pre="influenza A infection by 2% (45). However, most studies of" exact="influenza" post="virus in the environment are based on detection of"/>
   <result pre="found no evidence that surface and object cleaning could reduce" exact="influenza" post="transmission, this measure does have an established impact on"/>
   <result pre="effect of personal protective measures or environmental measures in reducing" exact="influenza" post="transmission. Although these measures have mechanistic support based on"/>
   <result pre="measures have mechanistic support based on our knowledge of how" exact="influenza" post="is transmitted from person to person, randomized trials of"/>
   <result pre="evidence of a major effect of hand hygiene on laboratory-confirmed" exact="influenza" post="virus transmission (Figure 1). Nevertheless, hand hygiene might be"/>
   <result pre="transmission (Figure 1). Nevertheless, hand hygiene might be included in" exact="influenza" post="pandemic plans as part of general hygiene and infection"/>
   <result pre="evidence that surgical-type face masks are effective in reducing laboratory-confirmed" exact="influenza" post="transmission, either when worn by infected persons (source control)"/>
   <result pre="transmission of other infections and therefore have value in an" exact="influenza" post="pandemic when healthcare resources are stretched. It is essential"/>
   <result pre="impact of environmental factors, such as temperature and humidity, on" exact="influenza" post="transmission is also uncertain (47). These uncertainties over basic"/>
   <result pre="Further research on transmission modes and alternative interventions to reduce" exact="influenza" post="transmission would be valuable in improving pandemic preparedness. Finally,"/>
   <result pre="our review focused on nonpharmaceutical measures to be taken during" exact="influenza" post="pandemics, the findings could also apply to severe seasonal"/>
   <result pre="influenza pandemics, the findings could also apply to severe seasonal" exact="influenza" post="epidemics. Evidence from RCTs of hand hygiene or face"/>
   <result pre="Additional high-quality RCTs of efficacy of hand hygiene against laboratory-confirmed" exact="influenza" post="in other nonhealthcare settings, except households and university residential"/>
   <result pre="no evidence about the quantitative effectiveness of respiratory etiquette against" exact="influenza" post="virus. RCTs of interventions to demonstrate the effectiveness of"/>
   <result pre="interventions to demonstrate the effectiveness of respiratory etiquette in reducing" exact="influenza" post="transmission would be valuable. Face mask There are major"/>
   <result pre="Additional high-quality RCTs of efficacy of face masks against laboratory-confirmed" exact="influenza" post="would be valuable. Effectiveness of face masks or respirator"/>
   <result pre="valuable. Effectiveness of face masks or respirator use to prevent" exact="influenza" post="prevention in special subpopulation, such as immunocompromised persons, would"/>
   <result pre="object cleaning The effectiveness of different cleaning products in preventing" exact="influenza" post="transmission–in terms of cleaning frequency, cleaning dosage, cleaning time"/>
   <result pre="demonstrate the effectiveness of surface and object cleaning in reducing" exact="influenza" post="transmission would be valuable. Studies that can demonstrate the"/>
   <result pre="Studies that can demonstrate the reduction of environmental detection of" exact="influenza" post="virus through cleaning of surfaces and objects would also"/>
   <result pre="control trial. Appendix Additional information on nonpharmaceutical measures for pandemic" exact="influenza" post="in nonhealthcare settings—personal protective measures and environmental measures. LINK"/>
   <result pre="Fong MW, Ryu S, et al. Nonpharmaceutical measures for pandemic" exact="influenza" post="in nonhealthcare settings—personal protective and environmental measures. Emerg Infect"/>
   <result pre="Health Organization on the use of nonpharmaceutical interventions for pandemic" exact="influenza" post="in nonmedical settings. This study was supported by the"/>
   <result pre="Hong Kong, Hong Kong, China. Her primary research interests are" exact="influenza" post="epidemiology and the dynamics of person-to-person transmission. References References"/>
   <result pre="of person-to-person transmission. References References 1. UyekiTM, KatzJM, JerniganDB. Novel" exact="influenza" post="A viruses and pandemic threats.Lancet. 2017;389:2172–4. 10.1016/S0140-6736(17)31274-628589883 2. BeanB,"/>
   <result pre="10.1016/S0140-6736(17)31274-628589883 2. BeanB, MooreBM, SternerB, PetersonLR, GerdingDN, BalfourHHJr. Survival of" exact="influenza" post="viruses on environmental surfaces.J Infect Dis. 1982;146:47–51. 10.1093/infdis/146.1.476282993 3."/>
   <result pre="surfaces.J Infect Dis. 1982;146:47–51. 10.1093/infdis/146.1.476282993 3. TellierR. Aerosol transmission of" exact="influenza" post="A virus: a review of new studies.J R Soc"/>
   <result pre="5. collab: World Health Organization. Comparative analysis of national pandemic" exact="influenza" post="preparedness plans, 2011 [cited 2019 Jun 25]. https://www.who.int/influenza/resources/documents/comparative_analysis_php_2011_en.pdf 6."/>
   <result pre="10.1016/j.jclinepi.2010.04.02621195583 8. WongVW, CowlingBJ, AielloAE. Hand hygiene and risk of" exact="influenza" post="virus infections in the community: a systematic review and"/>
   <result pre="AielloAE, PerezV, CoulbornRM, DavisBM, UddinM, MontoAS. Facemasks, hand hygiene, and" exact="influenza" post="among young adults: a randomized intervention trial.PLoS One. 2012;7:e29744."/>
   <result pre="ChengCK, FungRO, WaiW, et al.Facemasks and hand hygiene to prevent" exact="influenza" post="transmission in households: a cluster randomized trial.Ann Intern Med."/>
   <result pre="findings of a randomized trial of non-pharmaceutical interventions to prevent" exact="influenza" post="transmission in households.PLoS One. 2008;3:e2101. 10.1371/journal.pone.000210118461182 13. LarsonEL, FerngYH,"/>
   <result pre="WangS, HaberM, MorseSS. Impact of non-pharmaceutical interventions on URIs and" exact="influenza" post="in crowded, urban households.Public Health Rep. 2010;125:178–91. 10.1177/00333549101250020620297744 14."/>
   <result pre="controlled trial of hand washing and face masks to reduce" exact="influenza" post="transmission in Bangkok, Thailand.Influenza Other Respir Viruses. 2011;5:256–67. 10.1111/j.1750-2659.2011.00205.x21651736"/>
   <result pre="StarkJH, VukotichC, MitrukaK, ThompsonW, et al.Reduction in the incidence of" exact="influenza" post="A but not influenza B associated with use of"/>
   <result pre="et al.Reduction in the incidence of influenza A but not" exact="influenza" post="B associated with use of hand sanitizer and cough"/>
   <result pre="role of facemasks and hand hygiene in the prevention of" exact="influenza" post="transmission in households: results from a cluster randomised trial;"/>
   <result pre="et al.Effects of hand hygiene campaigns on incidence of laboratory-confirmed" exact="influenza" post="and absenteeism in schoolchildren, Cairo, Egypt.Emerg Infect Dis. 2011;17:619–25."/>
   <result pre="AzmanAS, StarkJH, AlthouseBM, VukotichCJJr, StebbinsS, BurkeDS, et al.Household transmission of" exact="influenza" post="A and B in a school-based study of non-pharmaceutical"/>
   <result pre="SuntarattiwongP, SimmermanJM, JarmanRG, JohnsonK, OlsenSJ, et al.Increased hand washing reduces" exact="influenza" post="virus surface contamination in Bangkok households, 2009-2010.Influenza Other Respir"/>
   <result pre="10.1111/irv.1220424373290 21. MukherjeeDV, CohenB, BovinoME, DesaiS, WhittierS, LarsonEL. Survival of" exact="influenza" post="virus on hands and fomites in community and laboratory"/>
   <result pre="TorreA, Moreno-EspinosaS, LealPE, BourlonMT, Ruiz-PalaciosGM. Controlling the novel A (H1N1)" exact="influenza" post="virus: don’t touch your face!J Hosp Infect. 2009;73:280–1. 10.1016/j.jhin.2009.06.01719699011"/>
   <result pre="al.Influenza virus contamination of common household surfaces during the 2009" exact="influenza" post="A (H1N1) pandemic in Bangkok, Thailand: implications for contact"/>
   <result pre="soap and water and alcohol-based hand-rub preparations against live H1N1" exact="influenza" post="virus on the hands of human volunteers.Clin Infect Dis."/>
   <result pre="sanitizer delivery systems: efficacy of foam, gel, and wipes against" exact="influenza" post="A (H1N1) virus on hands.Am J Infect Control. 2012;40:806–9."/>
   <result pre="26. AielloAE, CoulbornRM, PerezV, LarsonEL. Effect of hand hygiene on" exact="infectious disease" post="risk in the community setting: a meta-analysis.Am J Public"/>
   <result pre="OxfordJ, BerezinEN, CourvalinP, DwyerDE, ExnerM, JanaLA, et al.The survival of" exact="influenza" post="A(H1N1)pdm09 virus on 4 household surfaces.Am J Infect Control."/>
   <result pre="disinfection.Appl Environ Microbiol. 2012;78:7769–75. 10.1128/AEM.02144-1222941071 45. ZhangN, LiY. Transmission of" exact="influenza" post="A in a student office based on realistic person-to-person"/>
   <result pre="LakdawalaSS. Mechanistic insights into the effect of humidity on airborne" exact="influenza" post="virus survival, transmission and incidence.J R Soc Interface. 2019;16:20180298."/>
   <result pre="UrbanMD, HammerlundMEM, LeeHB, et al.Humidity as a non-pharmaceutical intervention for" exact="influenza" post="A.PLoS One. 2018;13:e0204337. 10.1371/journal.pone.020433730252890 49. GaoX, WeiJ, CowlingBJ, LiY."/>
   <result pre="WeiJ, CowlingBJ, LiY. Potential impact of a ventilation intervention for" exact="influenza" post="in the context of a dense indoor contact network"/>
   <result pre="Environ. 2016;569-570:373–81. 10.1016/j.scitotenv.2016.06.17927351145 50. McDevittJJ, RudnickSN, RadonovichLJ. Aerosol susceptibility of" exact="influenza" post="virus to UV-C light.Appl Environ Microbiol. 2012;78:1666–9. 10.1128/AEM.06960-1122226954"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7182252\results\search\disease\results.xml">
   <result pre="hematopoietic cell transplant, immunocompromised, oncology, respiratory virus, solid organ transplant," exact="viral pneumonia" post="Epidemiology and risk factors The seasonality of respiratory virus"/>
   <result pre="cell transplant, immunocompromised, oncology, respiratory virus, solid organ transplant, viral" exact="pneumonia" post="Epidemiology and risk factors The seasonality of respiratory virus"/>
   <result pre="tends to be more predominant early in the season and" exact="influenza" post="B is often seen later in the season. Up-to-date"/>
   <result pre="influenza B is often seen later in the season. Up-to-date" exact="influenza" post="surveillance data for the United States are published on"/>
   <result pre="Parainfluenza viruses (PIVs) vary in seasonality by type. PIV-1 causes" exact="croup" post="epidemics in the autumn, generally every other year. PIV-2"/>
   <result pre="events), followed by RSV (22%), PIV (16%), HMPV (11%), and" exact="influenza" post="(10%). Lymphopenia was present in 22% of patients with"/>
   <result pre="for acquisition. Oncology patients. In a large cohort of pediatric" exact="cancer" post="patients with fever and neutropenia, at least one respiratory"/>
   <result pre="symptoms. Notable exceptions include a stronger association between RSV and" exact="bronchiolitis" post="in young infants, PIV and laryngotracheobronchitis, and HRVs and"/>
   <result pre="life-threatening disease.10 Recovery after assisted ventilation for RSV and HMPV" exact="pneumonia" post="occurs but remains uncommon despite advances in supportive care."/>
   <result pre="but remains uncommon despite advances in supportive care. The associated" exact="respiratory failure" post="in severely immunocompromised patients may result in multiorgan system"/>
   <result pre="and fatal infection attributed to HMPV has been reported in" exact="cancer" post="patients, and HMPV is a relatively common cause of"/>
   <result pre="pediatric HCT and SOT recipients, 22.1% of subjects presented with" exact="pneumonia" post="and 66.5% were hospitalized. Prior vaccination was associated with"/>
   <result pre="Prior vaccination was associated with decreased disease severity.18 Mortality after" exact="influenza" post="was 2.9% in adults and 0% in pediatric patients"/>
   <result pre="radiographs may be delayed or absent in patients with severe" exact="neutropenia" post="but may become apparent after immune reconstitution or on"/>
   <result pre="rare except in HMPV infections; fever was more common for" exact="influenza" post="and HMPV. Multivariate models indicated that onset within 60"/>
   <result pre="required some form of respiratory support. Oncology patients. Adults with" exact="leukemia" post="and profound chemotherapy-induced myelosuppression are also at risk of"/>
   <result pre="virus versus coinfection.4 Disease prophylaxis/prevention Influenza vaccination The mainstay of" exact="influenza" post="prevention in immunocompromised children is vaccination. Inactivated influenza vaccine"/>
   <result pre="mainstay of influenza prevention in immunocompromised children is vaccination. Inactivated" exact="influenza" post="vaccine (IIV) is recommended for all patients 6 months"/>
   <result pre="receiving intensive chemotherapy, such as induction or consolidation chemotherapy for" exact="acute leukemia," post="or those who have received anti–B-cell antibodies in the"/>
   <result pre="received anti–B-cell antibodies in the past 6 months.23 Live attenuated" exact="influenza" post="vaccine (LAIV) should not be used for immunosuppressed patients"/>
   <result pre="are ongoing to assess the immunogenicity and safety of high-dose" exact="influenza" post="vaccination in immunocompromised adults and children. Influenza vaccination is"/>
   <result pre="for 7 days after vaccination.24 HCT recipients. Immune responses to" exact="influenza" post="vaccination are likely more effective further out from HCT."/>
   <result pre="adult HCT recipients. SOT recipients. IDSA guidelines recommend against administering" exact="influenza" post="vaccine during intensified immunosuppression, including the first 2-month posttransplant"/>
   <result pre="receiving intensive chemotherapy, such as induction or consolidation chemotherapy for" exact="acute leukemia," post="or those who have received anti–B-cell antibodies in the"/>
   <result pre="in immunosuppressed patients who are in close contact with confirmed" exact="influenza" post="cases or during influenza outbreaks.27 In outbreak settings, HCT"/>
   <result pre="are in close contact with confirmed influenza cases or during" exact="influenza" post="outbreaks.27 In outbreak settings, HCT recipients should receive vaccine"/>
   <result pre="universally used and may be targeted to periods of high" exact="influenza" post="virus circulation.29 Antiviral resistance may emerge with widespread prophylaxis;"/>
   <result pre="guanosine nucleoside, has been licensed for the treatment of RSV" exact="respiratory disease" post="in children since 1986 and for the treatment of"/>
   <result pre="therapy with baloxavir if ≥ 12 years, or rimantadine (only" exact="influenza" post="A) and/or ribavirin •Consider IV peramivir if mechanically ventilated"/>
   <result pre="ribavirin can be considered in patients weighing more than 15kg;" exact="hemolytic anemia" post="is the most important side effect to consider, and"/>
   <result pre="can be considered in patients weighing more than 15kg; hemolytic" exact="anemia" post="is the most important side effect to consider, and"/>
   <result pre="confirmed in others. A small, nonrandomized unadjusted analysis in pediatric" exact="cancer" post="patients with RSV lower respiratory tract infection suggested a"/>
   <result pre="may decrease viral load and possibly reduce the risk of" exact="respiratory failure," post="although most data are based on retrospective uncontrolled data."/>
   <result pre="most data are based on retrospective uncontrolled data. Influenza. Early" exact="influenza" post="treatment is recommended for all immunocompromised individuals, although there"/>
   <result pre="oseltamivir and inhaled zanamivir has been demonstrated in patients with" exact="leukemia" post="or HCT recipients.18 Many mutations causing oseltamivir and peramivir"/>
   <result pre="tract infection. Baloxavir was recently approved for treatment of uncomplicated" exact="influenza" post="in adults and adolescents43; studies in younger children and"/>
   <result pre="studies in younger children and immunocompromised hosts are underway. Multidrug-resistant" exact="influenza" post="strains have been identified in immunocompromised patients. Triple-combination antiviral"/>
   <result pre="oseltamivir has been proposed to treat immunocompromised patients with severe" exact="influenza" post="A with resistance to oseltamivir. A randomized trial comparing"/>
   <result pre="clinical benefit.44 Parainfluenza. In a retrospective study of patients with" exact="leukemia" post="or HCT recipients with PIV infection, ribavirin had no"/>
   <result pre="studies of ribavirin and the known toxicities of therapy, including" exact="hemolytic anemia," post="limit its recommendation for HMPV. Currently, no approved antiviral"/>
   <result pre="trials in immunocompromised subjects are ongoing. Several studies of novel" exact="influenza" post="therapeutics are under investigation, including the NAIs IV zanamivir"/>
   <result pre="pediatric wards. Nosocomial RSV and PIV infections in adults with" exact="leukemia" post="and bone marrow transplants are associated with a high"/>
   <result pre="diagnosed with HMPV within 7 weeks in a tertiary care" exact="cancer" post="unit.7 Molecular subtyping revealed infection with genotype A2a virus,"/>
   <result pre="virus, implicating nosocomial transmission. Four patients (26.6%) died of HMPV-associated" exact="pneumonia" post="and consequent multiorgan failure. Nosocomial outbreaks characteristically occur from"/>
   <result pre="and severity of symptoms, should be considered. Donor transmission of" exact="influenza" post="is of particular concern in lung or small bowel"/>
   <result pre="in stem-cell transplant recipientsAnn Intern Med1445200634434916520475 11.WaghmareACampbellAPXieHRespiratory syncytial virus lower" exact="respiratory disease" post="in hematopoietic cell transplant recipients: viral RNA detection in"/>
   <result pre="malignancies and respiratory tract infectionsJ Infect Dis192620051061106516107960 14.WhimbeyECouchRBEnglundJARespiratory syncytial virus" exact="pneumonia" post="in hospitalized adult patients with leukemiaClin Infect Dis21219953763798562747 15.SeoSXieHKarronRAParainfluenza"/>
   <result pre="17.CollinsJPCampbellAPOpenoKClinical features and outcomes of immunocompromised children hospitalized with laboratory-confirmed" exact="influenza" post="in the United States, 2011-2015J Pediatric Infect Dis Soc2018doi:"/>
   <result pre="Infect Dis Soc2018doi: 10.1093/jpids/piy101 18.KumarDFerreiraVHBlumbergEA 5-year prospective multicenter evaluation of" exact="influenza" post="infection in transplant recipientsClin Infect Dis67920181322132929635437 19.WaghmareAXieHKuypersJHuman rhinovirus infections"/>
   <result pre="of the immunocompromised hostClin Infect Dis5832014e44e10024311479 24.GrohskopfLASojolowLZOlsenSJBreseeJSBroderKRKarronRAprevention and control of" exact="influenza" post="with vaccines: recommendations of the advisory committee on immunization"/>
   <result pre="of the advisory committee on immunization practices, United States, 2015-16" exact="influenza" post="seasonMMWR Morb Mortal Wkly Rep6430201581882526247435 25.HirzelCKumarDInfluenza vaccine strategies for"/>
   <result pre="J Transplant13suppl 4201321221923465014 29.IsonMGSzakalyPShapiraMYKrivanGNistADutkowskiREfficacy and safety of oral oseltamivir for" exact="influenza" post="prophylaxis in transplant recipientsAntivir Ther176201295596422728756 30.RalstonSLLieberthalASMeissnerHCClinical practice guideline: the"/>
   <result pre="cancerJ Pediatr Hematol Oncol3662014e376e38124327130 39.ChoiSMBoudreaultAAXieHEnglundJACoreyLBoeckhMDifferences in clinical outcomes after 2009" exact="influenza" post="A/H1N1 and seasonal influenza among hematopoietic cell transplant recipientsBlood1171920115050505621372154"/>
   <result pre="39.ChoiSMBoudreaultAAXieHEnglundJACoreyLBoeckhMDifferences in clinical outcomes after 2009 influenza A/H1N1 and seasonal" exact="influenza" post="among hematopoietic cell transplant recipientsBlood1171920115050505621372154 40.BoivinGDetection and management of"/>
   <result pre="cell transplant recipientsBlood1171920115050505621372154 40.BoivinGDetection and management of antiviral resistance for" exact="influenza" post="virusesInfluenza Other Respir Viruses7suppl 320131823 41.HernandezJEAdigaRArmstrongRClinical experience in adults"/>
   <result pre="in adults and children treated with intravenous peramivir for 2009" exact="influenza" post="A (H1N1) under an emergency IND program in the"/>
   <result pre="peramivir compared with oral oseltamivir for the treatment of seasonal" exact="influenza" post="in hospitalized adultsAntivir Ther185201365166123111657 43.HaydenFGSugayaNHirotsuNBaloxavir marboxil for uncomplicated influenza"/>
   <result pre="seasonal influenza in hospitalized adultsAntivir Ther185201365166123111657 43.HaydenFGSugayaNHirotsuNBaloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescentsN Engl J Med37910201891392330184455 44.BeigelJHBaoYBeelerJOseltamivir, amantadine,"/>
   <result pre="and outcomes of parainfluenza virus infections in 200 patients with" exact="leukemia" post="or recipients of hematopoietic stem cell transplantationBlood11912201227382745quiz 96922246027 46.ShahDPShahPKAzziJMChemalyRFParainfluenza"/>
   <result pre="prior to allogeneic hematopoietic cell transplantPediatr Transplant2282018e1330130338638 50.KumarDMorrisMIKottonCNGuidance on novel" exact="influenza" post="A/H1N1 in solid organ transplant recipientsAm J Transplant1012010182519958321"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7182292\results\search\disease\results.xml">
   <result pre="serum samples collected from patients presenting with clinical symptoms of" exact="dengue fever" post="and 152 mosquito pools. RESULTS: We detected the Asian"/>
   <result pre="during an outbreak. DENV-2 is the most frequent cause of" exact="dengue fever" post="epidemics worldwide and is usually associated with severe disease"/>
   <result pre="samples were collected from patients presenting with clinical symptoms of" exact="dengue fever" post="between February 2014 and December 2015. Furthermore, 778 mosquitoes"/>
   <result pre="Venezuela (1994), and Mexico (1995) epidemics, detected in cases of" exact="dengue hemorrhagic fever," post="were closely related to Asian II genotype strains from"/>
   <result pre="the Asian II genotype8. Interestingly, the Asian II genotype caused" exact="meningitis" post="in patients from Minas Gerais, in the southeast region"/>
   <result pre="in addition to the prevalent Asian/American genotype. Successive epidemics of" exact="dengue fever," post="with co-circulation of DENV-1, DENV-2, and DENV-4, have been"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7182600\results\search\disease\results.xml">
   <result pre="doi: 10.1111/irv.12713IRV12713 : Original Article: Original Articles Antigenic variants of" exact="influenza" post="B viruses isolated in Japan during the 2017�?2018 and"/>
   <result pre="B viruses isolated in Japan during the 2017�?2018 and 2018�?2019" exact="influenza" post="seasons KATO�?MIYASHITA et al. Kato�?MiyashitaSarihttps://orcid.org/0000-0003-0233-88171Sakai�?TagawaYuko1YamashitaMakoto1Iwatsuki�?HorimotoKiyokohttps://orcid.org/0000-0002-8266-020X1ItoMutsumi1TokitaAkifumi23HagiwaraHaruhisa34IzumidaNaomi35NishinoTamon36WadaNoriyuki37KogaMichikohttps://orcid.org/0000-0002-3122-97358AdachiEisukehttps://orcid.org/0000-0002-1623-873X9JubishiDaisuke110YotsuyanagiHiroshihttps://orcid.org/0000-0001-7882-52629KawaokaYoshihirohttps://orcid.org/0000-0001-5061-829611112yoshihiro.kawaoka@wisc.eduImaiMasakihttps://orcid.org/0000-0001-6988-19751mimai@ims.u-tokyo.ac.jp[1], Division of VirologyDepartment of"/>
   <result pre="cited.file:IRV-14-311.pdf Abstract Abstract Background Here, we genetically and antigenically analyzed" exact="influenza" post="B viruses (IBVs) isolated in Japan during the 2017�?2018"/>
   <result pre="viruses (IBVs) isolated in Japan during the 2017�?2018 and 2018�?2019" exact="influenza" post="seasons. Methods A total of 68 IBVs (61 B/Yamagata/16/88�?like"/>
   <result pre="and the variant with reduced NA inhibitor susceptibility. antigenicity hemagglutinin" exact="influenza" post="B virus Japan neuraminidase inhibitors Funding Leading Advanced Projects"/>
   <result pre="page-count: word-count: Kato�?MiyashitaS, Sakai�?TagawaY, YamashitaM, et al. Antigenic variants of" exact="influenza" post="B viruses isolated in Japan during the 2017�?2018 and"/>
   <result pre="B viruses isolated in Japan during the 2017�?2018 and 2018�?2019" exact="influenza" post="seasons. Influenza Other Respi Viruses. 2020;14:311–319. 10.1111/irv.12713 The peer"/>
   <result pre="available at https://publons.com/publon/10.1111/irv.12713 1 INTRODUCTION Influenza is an acute respiratory" exact="infectious disease" post="caused by influenza A and B viruses. Currently, two"/>
   <result pre="INTRODUCTION Influenza is an acute respiratory infectious disease caused by" exact="influenza" post="A and B viruses. Currently, two subtypes of influenza"/>
   <result pre="by influenza A and B viruses. Currently, two subtypes of" exact="influenza" post="A viruses (A/H1N1 and A/H3N2) and two lineages of"/>
   <result pre="influenza A viruses (A/H1N1 and A/H3N2) and two lineages of" exact="influenza" post="B viruses (B/Victoria/2/87�?like [B/Victoria]�? and B/Yamagata/16/88�?like [B/Yamagata]�?lineage) are cocirculating"/>
   <result pre="of adults and 20%�?30% of children are infected with seasonal" exact="influenza" post="viruses, causing 3�?5 million cases of severe illness,1 and"/>
   <result pre="and an estimated 290 000�?650 000 influenza�?related deaths.2 Therefore, seasonal" exact="influenza" post="is associated with significant morbidity and mortality worldwide. The"/>
   <result pre="influenza is associated with significant morbidity and mortality worldwide. The" exact="influenza" post="A and B viruses possess two surface glycoproteins, hemagglutinin"/>
   <result pre="to the emergence of drug�?resistant variants.5, 6 During the 2017�?2018" exact="influenza" post="season, influenza A/H1N1 2009 pandemic (A/H1N1pdm), A/H3N2, and B"/>
   <result pre="emergence of drug�?resistant variants.5, 6 During the 2017�?2018 influenza season," exact="influenza" post="A/H1N1 2009 pandemic (A/H1N1pdm), A/H3N2, and B viruses co�?circulated"/>
   <result pre="and B viruses co�?circulated in Japan.7 Notably, in Japan, the" exact="influenza" post="B epidemic of this season was larger than that"/>
   <result pre="Here, we examined the genetic and antigenic properties of the" exact="influenza" post="B viruses isolated in Japan during the winter season."/>
   <result pre="Japan during the winter season. In addition, we characterized the" exact="influenza" post="B viruses isolated in Japan during the 2018�?2019 season,"/>
   <result pre="viruses isolated in Japan during the 2018�?2019 season, even though" exact="influenza" post="B viruses circulated at a lower level in this"/>
   <result pre="the University of Tokyo (approval no. 26�?42�?0822). Samples that were" exact="influenza" post="B�?positive by real�?time RT�?PCR (see below) were used in"/>
   <result pre="the viral PB2, PB1, PA, and nucleoprotein proteins derived from" exact="influenza" post="B virus strain B/Yamagata/1/73, under the control of the"/>
   <result pre="Real�?time PCR was performed to determine the lineage of the" exact="influenza" post="B viruses in the clinical specimens. RNA was extracted"/>
   <result pre="with primers specific for the HA or NA genes of" exact="influenza" post="B virus. The PCR products were purified and directly"/>
   <result pre="2.7 Phylogenic analysis Nucleotide sequences of the HA genes of" exact="influenza" post="B viruses were aligned using mega version 7.0.26.13 The"/>
   <result pre="Health Protection Agency, London, UK.16 3 RESULTS 3.1 Detection of" exact="influenza" post="B viruses in Japan during the 2017�?2018 and 2018�?2019"/>
   <result pre="illness in Tokyo, Japan, and 108 were confirmed to be" exact="influenza" post="B virus�?positive by real�?time RT�?PCR using lineage�?specific primers/probes. Of"/>
   <result pre="B virus�?positive by real�?time RT�?PCR using lineage�?specific primers/probes. Of 97" exact="influenza" post="B virus�?positive samples collected during the 2017�?2018 season, 95"/>
   <result pre="with the National Institute of Infectious Diseases (NIID) report that" exact="influenza" post="B viruses of the B/Yamagata�? and B/Victoria�?lineages co�?circulated in"/>
   <result pre="during the winter season with the B/Yamagata�?lineage predominating.7 Of 11" exact="influenza" post="B virus�?positive samples collected during the 2018�?2019 season, two"/>
   <result pre="the B/Yamagata�?linage and nine were of the B/Victoria�?lineage. All 108" exact="influenza" post="B viruses were isolated from the clinical samples by"/>
   <result pre="inoculation to MDCK, AX4, or hCK cells. Of the 108" exact="influenza" post="B isolates, 68 (62 from the 2017�?2018 season and"/>
   <result pre="selected for further characterization. 3.2 Antigenic and genetic characterization of" exact="influenza" post="B viruses isolated in Japan during the 2017�?2018 and"/>
   <result pre="B/Brisbane/60/2008. To determine the HA gene clade of the 68" exact="influenza" post="B viruses isolated in Japan during the 2017�?2018 and"/>
   <result pre="Data (GISAID) EpiFlu database. Since the 2015�?2016 season, only quadrivalent" exact="influenza" post="vaccines containing two influenza A virus strains (A/H1N1pdm and"/>
   <result pre="Since the 2015�?2016 season, only quadrivalent influenza vaccines containing two" exact="influenza" post="A virus strains (A/H1N1pdm and A/H3N2) and two influenza"/>
   <result pre="two influenza A virus strains (A/H1N1pdm and A/H3N2) and two" exact="influenza" post="B virus strains (B/Yamagata�?lineage and B/Victoria�?lineage viruses) have been"/>
   <result pre="B/Victoria�?lineage viruses isolated in Japan during the 2017�?2018 and 2018�?2019" exact="influenza" post="seasons. The tree was built using the neighbor�?joining method"/>
   <result pre="deletion at positions 162�?164 in HA, respectively To elucidate whether" exact="influenza" post="B viruses isolated in Japan during the 2017�?2018 and"/>
   <result pre="B viruses isolated in Japan during the 2017�?2018 and 2018�?2019" exact="influenza" post="seasons were antigenically related to the vaccine strains used"/>
   <result pre="Sons, Ltd, 3.3 Antiviral susceptibility To monitor the susceptibility of" exact="influenza" post="B viruses to NA inhibitors in Japan during the"/>
   <result pre="mutations known to confer resistance to NA inhibitors in the" exact="influenza" post="B isolates, except for one B/Yamagata�?lineage isolate (B/Tokyo/UT�?AC032/2018) that"/>
   <result pre="the B/Victoria�?lineage viruses that were detected worldwide during the eight" exact="influenza" post="seasons that followed the 2009�?2010 season were antigenically closely"/>
   <result pre="virus with the two�?amino�?acid deletion for the 2019�?2020 northern hemisphere" exact="influenza" post="vaccine.18 Our antigenic analyses with post�?infection ferret sera showed"/>
   <result pre="the 2015�?2016 season.23 In this study, we also detected an" exact="influenza" post="B virus with the NA�?G407S mutation during the 2017�?2018"/>
   <result pre="it is unclear whether the patient had contact with an" exact="influenza" post="patient who was treated with NA inhibitors, it is"/>
   <result pre="to determine whether this NA�?G407S mutation affects the transmissibility of" exact="influenza" post="B viruses. This virological surveillance study may have been"/>
   <result pre="area in Japan and by the relatively small number of" exact="influenza" post="B isolates. Nevertheless, such monitoring of the most recent"/>
   <result pre="Initiative on Sharing Avian Influenza Data (GISAID) for sharing the" exact="influenza" post="virus sequence data used in this study. We also"/>
   <result pre="Lancet. 2018;391:1285�?1300.29248255 3HayAJ, GregoryV, DouglasAR, YiPL. The evolution of human" exact="influenza" post="viruses. Philos Trans R Soc B Biol Sci. 2001;356:1861�?1870."/>
   <result pre="antigenic drift. Vaccine. 2007;25:6852�?6862.17719149 5BurnhamAJ, BaranovichT, GovorkovaEA. Neuraminidase inhibitors for" exact="influenza" post="B virus infection: efficacy and resistance. Antiviral Res. 2013;100:520�?534.24013000"/>
   <result pre="α2,6�?linked sialic acid on MDCK cells improves isolation of human" exact="influenza" post="viruses and evaluation of their sensitivity to a neuraminidase"/>
   <result pre="cell line for the efficient isolation and propagation of human" exact="influenza" post="viruses. Nat Microbiol. 2019;4(8):1268�?1273.31036910 10NeumannG, WatanabeT, ItoH, et al."/>
   <result pre="Nat Microbiol. 2019;4(8):1268�?1273.31036910 10NeumannG, WatanabeT, ItoH, et al. Generation of" exact="influenza" post="A viruses entirely from cloned cDNAs. Proc Natl Acad"/>
   <result pre="copy number). Gene. 1991;108:193�?199.1660837 12ZhouB, LinX, WangW, et al. Universal" exact="influenza" post="B virus genomic amplification facilitates sequencing, diagnostics, and reverse"/>
   <result pre="2016;33:1870�?1874.27004904 14KisoM, Iwatsuki�?HorimotoK, YamayoshiS, et al. Emergence of oseltamivir�?resistant H7N9" exact="influenza" post="viruses in immunosuppressed cynomolgus macaques. J Infect Dis. 2017;216:582�?593.28931216"/>
   <result pre="Infect Dis. 2017;216:582�?593.28931216 15HatakeyamaS, SugayaN, ItoM, et al. Emergence of" exact="influenza" post="B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA."/>
   <result pre="2019. 19collab: WHO . WHO recommendations on the composition of" exact="influenza" post="virus vaccines. https://www.who.int/influenza/vaccines/virus/recommendations/en/. Accessed 3 June 2019. 20BlantonL, AlabiN,"/>
   <result pre="Accessed 3 June 2019. 20BlantonL, AlabiN, MustaquimD, et al. Update:" exact="influenza" post="activity in the United States during the 2016–17 season"/>
   <result pre="States during the 2016–17 season and composition of the 2017–18" exact="influenza" post="vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:668�?676.28662019 21collab: WHO"/>
   <result pre="Accessed 27 May 2019. 22collab: WHO . Recommended composition of" exact="influenza" post="virus vaccines for use in the 2019 southern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2019 southern hemisphere" exact="influenza" post="season. https://www.who.int/influenza/vaccines/virus/recommendations/201809_recommendation.pdf. Accessed 3 June 2019. 23GubarevaLV, BesselaarTG, DanielsRS,"/>
   <result pre="DanielsRS, et al. Global update on the susceptibility of human" exact="influenza" post="viruses to neuraminidase inhibitors, 2015–2016. Antiviral Res. 2017;146:12�?20.28802866"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7183126\results\search\disease\results.xml">
   <result pre="will exclude studies of patients with specific co-morbidities such as" exact="tuberculosis" post="or opportunistic infections. Primary outcomes will be &quot;the rate"/>
   <result pre="will first examine the therapeutic outcomes of DTG-use (e.g., viral" exact="suppression" post="and immunological response) and the rate of resistance to"/>
   <result pre="patients. Secondly, we will evaluate (a) the rate of viral" exact="suppression" post="according to clinical and biological parameters, (b) the effects"/>
   <result pre="will exclude studies of patients with specific co-morbidities such as" exact="tuberculosis" post="or opportunistic infections. Intervention DTG-based regimens will be our"/>
   <result pre="inhibitor-based regimens,�? and &quot;drug resistance according to viral subtypes/recombinants.�? Viral" exact="suppression" post="is defined as a plasma viral load less than"/>
   <result pre="and exclusion criteria) INSTI-based regimens Duration of INSTI-based regimens Viral" exact="suppression" post="Baseline viral load CD4-count following treatment INSTI drug resistance"/>
   <result pre="urban, rural), and study outcomes (i.e., the rate of viral" exact="suppression" post="and the level of drug resistance) using random intercept"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7183472\results\search\disease\results.xml">
   <result pre="Research Article Molecular and cellular evidence of natural Venezuelan equine" exact="encephalitis" post="virus infection in frugivorous bats in Colombia GuzmánCamilo1CalderónAlfonso2OviedoTeresa3MattarSalim4CastañedaJosé5RodriguezVirginia6Moraes FigueiredoLuiz"/>
   <result pre="article, unless otherwise stated. Abstract Background and Aim: Venezuelan equine" exact="encephalitis" post="virus (VEEV) is an alphavirus that causes encephalitis with"/>
   <result pre="Venezuelan equine encephalitis virus (VEEV) is an alphavirus that causes" exact="encephalitis" post="with a high impact on public health in Latin"/>
   <result pre="of this zoonosis. Alphavirus infections Chiroptera pathology Introduction Venezuelan equine" exact="encephalitis" post="virus (VEEV) is a positive-sense virus RNA of the"/>
   <result pre="the genus Alphavirus, within this same group are the equine" exact="encephalitis" post="viruses (EEV) of the East and West, Mayaro, Madariaga,"/>
   <result pre="and West, Mayaro, Madariaga, Mucambo, and Everglades [1,2]. Venezuelan equine" exact="encephalitis" post="is an emerging infectious disease in Latin America [3,4]."/>
   <result pre="Mucambo, and Everglades [1,2]. Venezuelan equine encephalitis is an emerging" exact="infectious disease" post="in Latin America [3,4]. There are several strains of"/>
   <result pre="the lyophilized vaccine prepared with the attenuated virus of equine" exact="encephalomyelitis" post="TC83 was used; molecular water grade as a negative"/>
   <result pre="registered in GenBank (Figure-1). Figure-1 Phylogeny of the Venezuelan equine" exact="encephalitis" post="virus detected in frugivorous bats. Figure-1 Shows phylogeny of"/>
   <result pre="lilium in the central nervous system, severe meningitis, and non-suppurative" exact="vasculitis" post="of the lymphocytic type, perivascular and perineuronal edema, diffuse"/>
   <result pre="changes in hepatocytes. The final diagnosis was a severe non-suppurative" exact="meningoencephalitis" post="of viral type and severe non-suppurative hepatitis of infectious"/>
   <result pre="a severe non-suppurative meningoencephalitis of viral type and severe non-suppurative" exact="hepatitis" post="of infectious viral type. Concerning the other specimen Artibeus"/>
   <result pre="mixed infiltrate with mononuclear predominance. In the liver, mild non-suppurative" exact="hepatitis" post="of the lymphocytic type was observed. Figure-2 Pathological lesions"/>
   <result pre="detected by Reverse transcription-polymerase chain reaction. (a and b) Non-suppurative" exact="myocarditis" post="staining with hematoxylin-eosin (100×). Perivascular edema, diffuse gliosis, satellitosis,"/>
   <result pre="satellitosis, neuronal death, demyelination. (c) Lymphocytic meningitis, non-suppurative viral type" exact="meningitis" post="(d). Immunohistochemical analysis Tissues of brain, spleen, and lung"/>
   <result pre="spleen, and lung. Figure-3 Controls and distribution of Venezuelan equine" exact="encephalitis" post="virus (VEEV) antigens. (a and b) Positive brain controls"/>
   <result pre="that bats of certain species are capable of transmitting the" exact="rabies" post="virus, but recent observations of outbreaks and epidemics of"/>
   <result pre="was found in the brain with neuronal necrosis and multifocal" exact="vasculitis" post="detected by histopathological diagnosis compatible with non-suppurative encephalitis of"/>
   <result pre="and multifocal vasculitis detected by histopathological diagnosis compatible with non-suppurative" exact="encephalitis" post="of viral type, these presumptive lesions of encephalitis were"/>
   <result pre="with non-suppurative encephalitis of viral type, these presumptive lesions of" exact="encephalitis" post="were confirmed by specific labeling of VEEV antigens. The"/>
   <result pre="generalists, such as St. Louis EEV, West Nile virus, Japanese" exact="encephalitis" post="virus, EEV, western EEV (WEEV), and VEEV. Immunohistochemical detection"/>
   <result pre="1ZacksM.APaesslerSEncephalitic AlphavirusesVet. Microbiol20101403-4281l28619775836 2GardnerS.NMcLoughlinKBeN.AAllenJWeaverS.CForresterNCharacterization of genetic variability of Venezuelan equine" exact="encephalitis" post="virusesPLoS One2016114e015260427054586 3AguilarP.VEstrada-FrancoJ.GNavarro-LopezRFerroCHaddowA.DWeaverS.CEndemic Venezuelan equine encephalitis in the Americas:Hidden"/>
   <result pre="variability of Venezuelan equine encephalitis virusesPLoS One2016114e015260427054586 3AguilarP.VEstrada-FrancoJ.GNavarro-LopezRFerroCHaddowA.DWeaverS.CEndemic Venezuelan equine" exact="encephalitis" post="in the Americas:Hidden under the dengue umbrellaFuture Virol20116672174021765860 4VittorA.YArmienBGonzalezPCarreraJ.PDominguezCValderramaAEpidemiology"/>
   <result pre="Americas:Hidden under the dengue umbrellaFuture Virol20116672174021765860 4VittorA.YArmienBGonzalezPCarreraJ.PDominguezCValderramaAEpidemiology of emergent Madariaga" exact="encephalitis" post="in a region with endemic Venezuelan equine encephalitis:Initial host"/>
   <result pre="Dis2016104e000455427101567 5WeaverS.CWinegarRMangerI.DForresterN.LAlphaviruses:Population genetics and determinants of emergenceAntiviral Res201294324225722522323 6ForresterN.LAugusteA.JGuerboisMRossiS.LLinDHariKVenezuelan equine" exact="encephalitis" post="virus strain COAN5506, complete genomeGenBank2016KR260736.1 7MedinaGGarzaroD.JBarriosMAugusteA.JWeaverS.CPujolF.HVenezuelan equine encephalitis virus"/>
   <result pre="6ForresterN.LAugusteA.JGuerboisMRossiS.LLinDHariKVenezuelan equine encephalitis virus strain COAN5506, complete genomeGenBank2016KR260736.1 7MedinaGGarzaroD.JBarriosMAugusteA.JWeaverS.CPujolF.HVenezuelan equine" exact="encephalitis" post="virus isolate AB66640 (VEEVIAB) nonstructural polyprotein precursor and structural"/>
   <result pre="genes, complete CDSAm. J. Trop. Med. Hy g2015931710 8CarraraAGonzalesMFerroCTamayoMAronsonJPaesslerSVenezuelan equine" exact="encephalitis" post="virus infection of spiny ratsEmerg. Infect. Dis200511566366915890116 9JohnsonK.MMartinD.HVenezuelan equine"/>
   <result pre="excellent descriptions of the first documentation of endemic Venezuelan equine" exact="encephalitis" post="(VEE), as well as studies of equine virulence and"/>
   <result pre="(melanoconion) taeniopus for equine-virulent subtype IE strains of Venezuelan equine" exact="encephalitis" post="virusAm. J. Trop. Med. Hyg20108261047105220519599 11DiazL.AFloresF.SQuagliaAContigianiM.SIntertwined arbovirus transmission activity:Reassessing"/>
   <result pre="the transmission cycle paradigmFront. Physiol2012349323335900 12CorreaG.PCalisherC.HBaerG.MEpidemic strain of Venezuelan equine" exact="encephalomyelitis" post="virus from a vampire bat captured in Oaxaca, Mexico,"/>
   <result pre="from a vampire bat captured in Oaxaca, Mexico, 1970Science197217540215465475008598 13SeymourCDickemanR.WMartinM.SVenezuelan" exact="encephalitis" post="virus infection in neotropical bats. I. Natural infection in"/>
   <result pre="Health2015621536024751420 15Sotomayor-BonillaJAbellaCChavesA�?lvarezPRico-ChávezOIbáñezSPotential sympatric vectors and mammalian hosts of Venezuelan equine" exact="encephalitis" post="virus in Southern MexicoJ. Wildl. Dis201753365766128384059 16ForresterN.LWertheimJ.ODuganV.GAugusteA.JLinDAdamsA.PWeaverS.CEvolution and spread"/>
   <result pre="Southern MexicoJ. Wildl. Dis201753365766128384059 16ForresterN.LWertheimJ.ODuganV.GAugusteA.JLinDAdamsA.PWeaverS.CEvolution and spread of Venezuelan equine" exact="encephalitis" post="complex Alphavirus in the AmericasPLoS Negl. Trop. Dis2017118e000569328771475 17LinaresOMamíferos"/>
   <result pre="regionsMem. Inst. Oswaldo Cruz20181131384429185594 23CharlesP.CWaltersEMargolisFJohnstonR.EMechanism of neuroinvasion of Venezuelan equine" exact="encephalitis" post="virus in the mouseVirology199520826626717747437 24DuganV.GHalpinmRGhedinEWesterEBeraJFedorovaNVenezuelan equine encephalitis virus strain"/>
   <result pre="of Venezuelan equine encephalitis virus in the mouseVirology199520826626717747437 24DuganV.GHalpinmRGhedinEWesterEBeraJFedorovaNVenezuelan equine" exact="encephalitis" post="virus strain VEEV/homo sapiens/GTM/69Z1/1969/IAB, complete genomeGenBank:KC344505.22016 25DuganV.GHalpinRGhedinEWesterEBeraJFedorovaNVenezuelan equine encephalitis"/>
   <result pre="equine encephalitis virus strain VEEV/homo sapiens/GTM/69Z1/1969/IAB, complete genomeGenBank:KC344505.22016 25DuganV.GHalpinRGhedinEWesterEBeraJFedorovaNVenezuelan equine" exact="encephalitis" post="virus strain VEEV/Equus ferus caballus/COL/CoAn5384/1967/IAB, complete genomeGenBank:KC344485.22012 26PlowrightR.KEbyPHudsonP.JSmithI.LWestcottDBrydenW.LEcological dynamics"/>
   <result pre="and pegivirusesProc. Natl. Acad. Sci. U.S.A2013110208194819923610427 31TongS.XLiYRivaillerPConrardyCCastilloD.AChenL.MA distinct lineage of" exact="influenza" post="A virus from batsProc. Natl. Acad. Sci. U.S.A2012109114269427422371588 32GuoW.PLinX.DWangWTianJ.HCongM.LZhangH.LPhylogeny"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7183730\results\search\disease\results.xml">
   <result pre="Flavivirus encompasses several worldwide-distributed arthropod-borne viruses including, dengue virus, Japanese" exact="encephalitis" post="virus, West Nile virus, yellow fever virus, Zika virus,"/>
   <result pre="viruses including, dengue virus, Japanese encephalitis virus, West Nile virus," exact="yellow fever" post="virus, Zika virus, and tick-borne encephalitis virus. Infection with"/>
   <result pre="virus, West Nile virus, yellow fever virus, Zika virus, and" exact="tick-borne encephalitis" post="virus. Infection with these viruses manifest with symptoms ranging"/>
   <result pre="West Nile virus, yellow fever virus, Zika virus, and tick-borne" exact="encephalitis" post="virus. Infection with these viruses manifest with symptoms ranging"/>
   <result pre="Aedes aegypti) was the mosquito responsible for the transmission of" exact="yellow fever," post="but he was unable to prove his hypothesis [1]."/>
   <result pre="two decades later, in 1901, Walter Reed’s research proved that" exact="yellow fever" post="was indeed transmitted by Aedes aegypti mosquitoes and caused"/>
   <result pre="with mosquito and tick-borne flaviviruses including dengue virus (DENV), Japanese" exact="encephalitis" post="virus (JEV), West Nile virus (WNV), YFV, Zika virus"/>
   <result pre="(JEV), West Nile virus (WNV), YFV, Zika virus (ZIKV), and" exact="tick-borne encephalitis" post="virus (TBEV). These viruses are of clinical importance as"/>
   <result pre="West Nile virus (WNV), YFV, Zika virus (ZIKV), and tick-borne" exact="encephalitis" post="virus (TBEV). These viruses are of clinical importance as"/>
   <result pre="with a variety of disease symptoms including hemorrhagic fever and" exact="encephalitis" post="[6]. DENV in particular is a significant human health"/>
   <result pre="year [7]. The severe manifestation of human DENV infection is" exact="dengue hemorrhagic fever" post="and dengue shock syndrome, which can be lethal, especially"/>
   <result pre="within the recipient cells and are considered potential biomarkers for" exact="cancer" post="and metabolic diseases [126–128]. Nevertheless, we lack understanding of"/>
   <result pre="virus hnRNP Heterogeneous nuclear ribonucleoprotein ILV Intraluminal vesicle JEV Japanese" exact="encephalitis" post="virus KUN Kunjin M Membrane miRNAs micro RNA MVB"/>
   <result pre="RNA SL Stem-loop TAM Tyro3, Axl, and Mer TBEV Tick-borne" exact="encephalitis" post="virus TDRD3 Tudor Domain Containing 3 TIM/TAM T-cell immunoglobulin"/>
   <result pre="3.ReedWCarrollJYellow fever : 100 years of discovery The etiology of" exact="yellow fever" post=": an additional noteJAMA Class200836813 4.BlitvichBJFirthAEInsect-specific flaviviruses: A systematic"/>
   <result pre="battlefield of dengue virusesFEMS Immunol Med Microbiol200853328729910.1111/j.1574-695X.2008.00420.x18522648 26.BredenbeekPJA stable full-length" exact="yellow fever" post="virus cDNA clone and the role of conserved RNA"/>
   <result pre="Klein P, Haneke K, et al. Flavivirus infection uncouples translation" exact="suppression" post="from cellular stress responses. MBio. 2017;8(1):e02150–16. Available from: 10.1128/mBio.02150-16."/>
   <result pre="stress responses. MBio. 2017;8(1):e02150–16. Available from: 10.1128/mBio.02150-16. 53.RiceCMLenchesEMEddySRShinSJSheetsRLStraussJHNucleotide sequence of" exact="yellow fever" post="virus: implications for flavivirus gene expression and evolutionScience1985229471572673310.1126/science.40237074023707 54.ChambersTJHahnCSGallerRRiceCMFlavivirus"/>
   <result pre="the Flavivirus RNA genome during pathogenesisFront Genet2018959510.3389/fgene.2018.0059530564270 59.StadlerKAllisonSLSchalichJHeinzFXProteolytic activation of" exact="tick-borne encephalitis" post="virus by furinJ Virol199771118475848110.1128/JVI.71.11.8475-8481.19979343204 60.WenglerGWenglerGCell-associated West Nile flavivirus is"/>
   <result pre="Flavivirus RNA genome during pathogenesisFront Genet2018959510.3389/fgene.2018.0059530564270 59.StadlerKAllisonSLSchalichJHeinzFXProteolytic activation of tick-borne" exact="encephalitis" post="virus by furinJ Virol199771118475848110.1128/JVI.71.11.8475-8481.19979343204 60.WenglerGWenglerGCell-associated West Nile flavivirus is"/>
   <result pre="complex and nonsense-mediated decay in flaviviral infectionNat Microbiol20194698599510.1038/s41564-019-0375-z30833725 71.KatohHOkamotoTFukuharaTKambaraHMoritaEMoriYet al.Japanese" exact="encephalitis" post="virus Core Protein inhibits stress granule formation through an"/>
   <result pre="viral propagationJ Virol201287148950210.1128/JVI.02186-1223097442 72.TsudaYMoriYAbeTYamashitaTOkamotoTIchimuraTet al.Nucleolar protein B23 interacts with Japanese" exact="encephalitis" post="virus core protein and participates in viral replicationMicrobiol Immunol200650322523410.1111/j.1348-0421.2006.tb03789.x16547420"/>
   <result pre="function of dengue virus NS2A ProteinJ Virol20138784609462210.1128/JVI.02424-1223408612 82.KummererBMRiceCMMutations in the" exact="yellow fever" post="virus nonstructural Protein NS2A selectively block production of infectious"/>
   <result pre="particlesJ Virol200276104773478410.1128/JVI.76.10.4773-4784.200211967294 83.VoßmannSWieselerJKerberRKümmererBMA basic cluster in the N terminus of" exact="yellow fever" post="virus NS2A contributes to infectious particle productionJ Virol20158994951496510.1128/JVI.03351-1425694595 84.LiuWJChenHBKhromykhAAMolecular"/>
   <result pre="91.ChangYSLiaoCLTsaoCHChenMCLiuCIChenLKet al.Membrane permeabilization by small hydrophobic nonstructural proteins of Japanese" exact="encephalitis" post="virusJ Virol19997386257626410.1128/JVI.73.8.6257-6264.199910400716 92.Urcuqui-inchimaSPatinCDıFJRecent developments in understanding dengue virus replicationAdv"/>
   <result pre="Microbiol.20111123410.1186/1471-2180-11-23422014111 101.Carpp LN, Galler R, Bonaldo MC. Interaction between the" exact="yellow fever" post="virus nonstructural protein NS3 and the host protein Alix"/>
   <result pre="immunodeficiency virus resistance to recipient cellsJ Virol200983251252110.1128/JVI.01658-0818987139 123.KalamvokiMDuTRoizmanBCells infected with" exact="herpes simplex" post="virus 1 export to uninfected cells exosomes containing STING,"/>
   <result pre="of viral infectionCurr Opin Microbiol201632778110.1016/j.mib.2016.05.00427232382 144.RamakrishnaiahVThumannCFofanaIHabersetzerFPanQDe RuiterPEet al.Exosome-mediated transmission of" exact="hepatitis" post="C virus between human hepatoma Huh7.5 cellsProc Natl Acad"/>
   <result pre="Hepatitis C virus RNA between permissive cellsJ Virol20158952956296110.1128/JVI.02721-1425505060 147.JoplingCYiMLancasterAModulation of" exact="hepatitis" post="C virus RNA abundance by a liver-specific MicroRNAScience (80-"/>
   <result pre="abundance by a liver-specific MicroRNAScience (80- )2005309September1577158110.1126/science.1113329 148.ShimakamiTYamaneDJangraRKKempfBJSpanielCBartonDJet al.Stabilization of" exact="hepatitis" post="C virus RNA by an Ago2-miR-122 complexProc Natl Acad"/>
   <result pre="3′ UTR structuresRNA Biol2011861173118610.4161/rna.8.6.1783621957497 154.AlbornozACarlettiTCorazzaGMarcelloAThe stress granule component TIA-1 binds" exact="tick-borne encephalitis" post="virus RNA and is recruited to Perinuclear sites of"/>
   <result pre="UTR structuresRNA Biol2011861173118610.4161/rna.8.6.1783621957497 154.AlbornozACarlettiTCorazzaGMarcelloAThe stress granule component TIA-1 binds tick-borne" exact="encephalitis" post="virus RNA and is recruited to Perinuclear sites of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7185310\results\search\disease\results.xml">
   <result pre="medium, provided the original author(s) and the source are cited.vim.2019.0167.pdf" exact="influenza" post="virus virus evolution universal vaccines immune specificity polyclonal responses"/>
   <result pre="(23). Currently, major efforts are underway to develop a universal" exact="influenza" post="virus vaccine that would provide broadly protective immunity for"/>
   <result pre="virus vaccine that would provide broadly protective immunity for all" exact="influenza" post="A viruses (IAVs). In this brief piece, we suggest"/>
   <result pre="brief piece, we suggest that the search for a universal" exact="influenza" post="virus vaccination strategy must consider the inclusion of multiple"/>
   <result pre="through the human population. Due to the antigenic evolution of" exact="influenza" post="viruses, influenza vaccine compositions are examined every year and"/>
   <result pre="human population. Due to the antigenic evolution of influenza viruses," exact="influenza" post="vaccine compositions are examined every year and adjusted as"/>
   <result pre="lethal IAV strains into the human population, have made improving" exact="influenza" post="vaccination a public health priority (27). Creating a universal"/>
   <result pre="influenza vaccination a public health priority (27). Creating a universal" exact="influenza" post="vaccine has long been a goal of influenza researchers."/>
   <result pre="a universal influenza vaccine has long been a goal of" exact="influenza" post="researchers. In the late 70s, CD8+ T cell responses"/>
   <result pre="researchers. In the late 70s, CD8+ T cell responses to" exact="influenza" post="were discovered to have broadly crossreactive specificities to peptides"/>
   <result pre="the population after infection or thanks to immunization with seasonal" exact="influenza" post="vaccines. A few years ago, it was found that"/>
   <result pre="Monoclonal antibodies and polyclonal sera have been shown to select" exact="influenza" post="virus mutants dissimilarly in model systems (5,30,33). While viral"/>
   <result pre="T cells) in driving such changes. The objective of universal" exact="influenza" post="HA vaccines is to generate a specific immunity in"/>
   <result pre="found in the review from Bloom and colleagues (31). First," exact="influenza" post="is an acute and limited infection in immunocompetent individuals."/>
   <result pre="with various viruses such as the human immunodeficiency virus (HIV)," exact="lymphocytic choriomeningitis," post="hepatitis, or herpes viruses (3,4,14,18–20,25,28). In these infections, the"/>
   <result pre="typically observed for acute infections. In contrast, in immunocompromised individuals," exact="influenza" post="infection becomes more protracted, lasts for weeks, and is"/>
   <result pre="of novel specificity selections. Furthermore, the segmented nature of the" exact="influenza" post="virus genome complicates the selection of multiple mutation variants."/>
   <result pre="While the generation of quasi-species virus is well known during" exact="influenza" post="virus replication, the selection of multi-epitopic variants on different"/>
   <result pre="may be gathered from chronic infections such as HIV or" exact="hepatitis" post="C virus. In these infections, the virus can escape"/>
   <result pre="pool of virus variants for selection, a concept shared by" exact="influenza" post="viruses. For HIV, preventing viral replication using combinations of"/>
   <result pre="highly active antiretroviral therapies, is now the basis of viral" exact="suppression" post="and has changed the lives of HIV-infected patients worldwide"/>
   <result pre="a fate that is also true for the treatment of" exact="influenza" post="with adamantanes. In a similar manner, a host response"/>
   <result pre="NIAID, Bethesda, MD. References References 1.AltmanMO, AngelM, KosikI, et al.Human" exact="influenza" post="A virus hemagglutinin glycan evolution follows a temporal pattern"/>
   <result pre="5.DavisAKF, McCormickK, GuminaME, et al.Sera from individuals with narrowly focused" exact="influenza" post="virus antibodies rapidly select viral escape mutations in ovo."/>
   <result pre="al.Deep sequencing reveals potential antigenic variants at low frequencies in" exact="influenza" post="A virus-infected humans. J Virol2016;90:3355–336526739054 7.EffrosRB, DohertyPC, GerhardW, et"/>
   <result pre="cross-reactive and virus-specific T-cell populations after immunization with serologically distinct" exact="influenza" post="A viruses. J Exp Med1977;145:557–568233901 8.EhrlichPNobel Lecture, December 11,"/>
   <result pre="Elsevier Publishing Company, 1967. 9.EkiertDC, and WilsonIABroadly neutralizing antibodies against" exact="influenza" post="virus and prospects for universal therapies. Curr Opin Virol2012;2:134–14122482710"/>
   <result pre="universal therapies. Curr Opin Virol2012;2:134–14122482710 10.EpsteinSL, and PriceGECross-protective immunity to" exact="influenza" post="A viruses. Expert Rev Vaccines2010;9:1325–134121087110 11.EpsteinSLPrior H1N1 influenza infection"/>
   <result pre="immunity to influenza A viruses. Expert Rev Vaccines2010;9:1325–134121087110 11.EpsteinSLPrior H1N1" exact="influenza" post="infection and susceptibility of Cleveland Family Study participants during"/>
   <result pre="Dis2006;193:49–5316323131 12.HensleySE, DasSR, BaileyAL, et al.Hemagglutinin receptor binding avidity drives" exact="influenza" post="A virus antigenic drift. Science2009;326:734–73619900932 13.HoelzerK, MurciaPR, BaillieGJ, et"/>
   <result pre="Science2009;326:734–73619900932 13.HoelzerK, MurciaPR, BaillieGJ, et al.Intrahost evolutionary dynamics of canine" exact="influenza" post="virus in naïve and partially immune dogs. J Virol2010;84:5329–533520219907"/>
   <result pre="progression. Nat Med1995;1:330–3367585062 15.KrammerF, and PalesePAdvances in the development of" exact="influenza" post="virus vaccines. Nat Rev Drug Discov2015;14:167–18225722244 16.KrammerFNovel universal influenza"/>
   <result pre="of influenza virus vaccines. Nat Rev Drug Discov2015;14:167–18225722244 16.KrammerFNovel universal" exact="influenza" post="virus vaccine approaches. Curr Opin Virol2016;17:95–10326927813 17.LaskeySB, and SilicianoRFA"/>
   <result pre="and ZinkernagelRMImmunobiology of cytotoxic T-cell resistant virus variants studies on" exact="lymphocytic choriomeningitis" post="virus (LCMV). Semin Virol1996;7:3–11 21.MurciaPR, BaillieGJ, DalyJ, et al.Intra-"/>
   <result pre="BaillieGJ, DalyJ, et al.Intra- and interhost evolutionary dynamics of equine" exact="influenza" post="virus. J Virol2010;84:6943–695420444896 22.MurciaPR, BaillieGJ, StackJC, et al.Evolution of"/>
   <result pre="virus. J Virol2010;84:6943–695420444896 22.MurciaPR, BaillieGJ, StackJC, et al.Evolution of equine" exact="influenza" post="virus in vaccinated horses. J Virol2013;87:4768–477123388708 23.NgonoAE, and ShrestaSImmune"/>
   <result pre="al.Effects of egg-adaptation on receptor-binding and antigenic properties of recent" exact="influenza" post="A (H3N2) vaccine viruses. J Gen Virol2016;97:1333–134426974849 25.PeweL, WuGL,"/>
   <result pre="a virus-induced demyelinating disease. Immunity1996;5:253–2628808680 26.PicaN, and PalesePToward a universal" exact="influenza" post="virus vaccine: prospects and challenges. Annu Rev Med2013;64:189–20223327522 27."/>
   <result pre="the number of nonoverlapping antigenic areas on Hong Kong (H3N2)" exact="influenza" post="virus hemagglutinin with monoclonal antibodies and the selection of"/>
   <result pre="significance. Virology1980;104:139–1486156537 31.XueKS, MonclaLH, BedfordT, et al.Within-host evolution of human" exact="influenza" post="virus. Trends Microbiol2018;26:781–79329534854 32.XueKS, Stevens-AyersT, CampbellAP, et al.Parallel evolution"/>
   <result pre="virus. Trends Microbiol2018;26:781–79329534854 32.XueKS, Stevens-AyersT, CampbellAP, et al.Parallel evolution of" exact="influenza" post="across multiple spatiotemporal scales. Elife2017;6:e2687528653624 33.YewdellJ, WebsterR, and GerhardWAntigenic"/>
   <result pre="WebsterR, and GerhardWAntigenic variation in three distinct determinants of an" exact="influenza" post="type A haemagglutinin molecule. Nature1979;279:246–24886955 34.YewdellJW, CatonAJ, and GerhardWSelection"/>
   <result pre="type A haemagglutinin molecule. Nature1979;279:246–24886955 34.YewdellJW, CatonAJ, and GerhardWSelection of" exact="influenza" post="A virus adsorptive mutants by growth in the presence"/>
   <result pre="35.ZinkernagelRM, and DohertyPCRestriction of in vitro T cell-mediated cytotoxicity in" exact="lymphocytic choriomeningitis" post="within a syngeneic or semiallogeneic system. Nature1974;248:701–7024133807 36.ZostSJ, ParkhouseK,"/>
   <result pre="or semiallogeneic system. Nature1974;248:701–7024133807 36.ZostSJ, ParkhouseK, GuminaME, et al.Contemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7185698\results\search\disease\results.xml">
   <result pre="very intuitive, it is explained by the exponential nature of" exact="infectious disease" post="outbreaks, during which cases multiply rapidly. Each infected individual"/>
   <result pre="maternal deaths [33]. As many as 3.5 million cases of" exact="malaria" post="were estimated to have been left untreated and 10,623"/>
   <result pre="left untreated and 10,623 additional deaths from HIV/AIDS, tuberculosis, and" exact="malaria" post="were estimated to have occurred during and immediately after"/>
   <result pre="to have received important childhood vaccines against diphtheria, tetanus, pertussis," exact="hepatitis" post="B, Haemophilus influenza type B, tuberculosis, and polio [45],"/>
   <result pre="important childhood vaccines against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus" exact="influenza" post="type B, tuberculosis, and polio [45], increasing the likelihood"/>
   <result pre="Lancet (London, England). 2011;377:849–62. Epub 2010/11/19. 10.1016/s0140-6736(10)60667-821084112 2DixonMG, SchaferIJ. Ebola" exact="viral disease" post="outbreak—West Africa, 2014. MMWR Morbidity and mortality weekly report."/>
   <result pre="MossWJ, TrueloveSA, TatemAJ, et al.Reduced vaccination and the risk of" exact="measles" post="and other childhood infections post-Ebola. Science. 2015;347(6227):1240–2. Epub 2015/03/15."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7186774\results\search\disease\results.xml">
   <result pre="phylogenetically related to West Nile virus, Yellow fever virus, Japanese" exact="encephalitis" post="virus, tick-borne encephalitis virus and dengue viruses (DENV) [1]."/>
   <result pre="to West Nile virus, Yellow fever virus, Japanese encephalitis virus," exact="tick-borne encephalitis" post="virus and dengue viruses (DENV) [1]. It has a"/>
   <result pre="West Nile virus, Yellow fever virus, Japanese encephalitis virus, tick-borne" exact="encephalitis" post="virus and dengue viruses (DENV) [1]. It has a"/>
   <result pre="been historically associated with mild and self-limiting fever, akin to" exact="dengue fever" post="[3,4]. ZIKV may also be transmitted between humans sexually"/>
   <result pre="linked to neurodevelopmental malfunction resulting in congenital birth defects including" exact="microcephaly" post="[7,[10], [11], [12]]. On the other hand, ZIKV infection"/>
   <result pre="hand, ZIKV infection in adults appears to lead to an" exact="autoimmune disease" post="known as Guillain Barré syndrome [13]. These neurological abnormalities"/>
   <result pre="[17,26,27]. Several of these, including an mRNA-based vaccine, a recombinant" exact="measles" post="virus-vectored vaccine and several plasmid DNA-based and inactivated ZIKV"/>
   <result pre="Puerto Rican or African ZIKV strains, in terms of either" exact="suppression" post="of viremia or survival [65,66]. One study which used"/>
   <result pre="sequencing of Zika virus from amniotic fluid of fetuses with" exact="microcephaly" post="in Brazil: a case studyLancet Infect Dis16201665366026897108 13Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barre syndrome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7187655\results\search\disease\results.xml">
   <result pre="interfering particles (DIPs) were first described in the 1950's in" exact="influenza" post="virus (Gard et al., 1952). DIPs are viral particles"/>
   <result pre="genome. The first DIPs in mononegavirales were found in vesicular" exact="stomatitis" post="virus Indiana strain (Huang and Baltimore, 1970). There are"/>
   <result pre="the NP gene (antisense strand from 5′ to 3′), a" exact="hepatitis" post="delta virus ribozyme sequence and the T7 terminator sequence."/>
   <result pre="have to occur prior to the establishment of EBOV VP35" exact="suppression" post="of Dicer co-factors (Fabozzi et al., 2011). It was"/>
   <result pre="DesmyterJ.MelnickJ. L.RawlsW. E. (1968). Defectiveness of interferon production and of" exact="rubella" post="virus interference in a line of African green monkey"/>
   <result pre="5120–5135. 10.1021/pr500556d25158218 GardS.Von MagnusP.SvedmyrA.Birch-AndersenA. (1952). Studies on the sedimentation of" exact="influenza" post="virus. Arch. Gesamte Virusforsch.4, 591–611.14953289 HuangA. S.BaltimoreD. (1970). Defective"/>
   <result pre="Gesamte Virusforsch.4, 591–611.14953289 HuangA. S.BaltimoreD. (1970). Defective viral particles and" exact="viral disease" post="processes. Nature226, 325–327.5439728 JensenS.ThomsenA. R. (2012). Sensing of RNA"/>
   <result pre="origin of a snapback defective interfering particle RNA of vesicular" exact="stomatitis" post="virus. J. Virol.37, 661–672.6261012 SinghR. K.DhamaK.MalikY. S.RamakrishnanM. A.KarthikK.KhandiaR.et al.."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7188197\results\search\disease\results.xml">
   <result pre="illustrates the power of genomic epidemiology to identify pathways of" exact="infectious disease" post="emergence. Disease epidemics can be man-made: Molecular clocks and"/>
   <result pre="release is thought to have been responsible for the 1977" exact="influenza" post="A H1N1 outbreak, caused by a virus that closely"/>
   <result pre="circulating in the 1950s [58,59]; likewise, the 1995 Venezuelan equine" exact="encephalitis" post="subtype IC epidemic was caused by a virus closely"/>
   <result pre="new areas requiring thorough surveillance programmes for the control of" exact="infectious disease" post="of livestock. In addition, our approach illustrates how unrecognised"/>
   <result pre="emergence of arthropod-borne viral diseases: A global prospective on dengue," exact="chikungunya" post="and zika fevers. Acta Trop. 2017;166:155–63. 10.1016/j.actatropica.2016.11.02027876643 4WeaverS, ReisenW."/>
   <result pre="2017;36(2):467–78. 10.20506/rst.36.2.266730152470 19MaclachlanN, ZientaraS, WilsonW, RichtJ, SaviniG. Bluetongue and epizootic" exact="hemorrhagic disease" post="viruses: recent developments with these globally re-emerging arboviral infections"/>
   <result pre="Phylogenetic evidence against evolutionary stasis and natural abiotic reservoirs of" exact="influenza" post="A virus. J Virol. 2008;82(7):3769–74. 10.1128/JVI.02207-0718234791 42OsborneC, MayoC, MullensB,"/>
   <result pre="2008;6(8):e21010.1371/journal.pbio.006021018752350 46NowakM, BonhoefferS, HillA, BoehmeR, ThomasH, McDadeH. Viral dynamics in" exact="hepatitis" post="B virus infection. Proc Natl Acad Sci U S"/>
   <result pre="ParkerJ, LemeyP, SalemiM, KatzourakisA, PybusO. The mode and tempo of" exact="hepatitis" post="C virus evolution within and among hosts. BMC Evol"/>
   <result pre="hosts. BMC Evol Biol. 2011;11:13110.1186/1471-2148-11-13121595904 58NakajimaK, DesselbergerU, PaleseP. Recent human" exact="influenza" post="A (H1N1) viruses are closely related genetically to strains"/>
   <result pre="IC Epidemic. Journal of Virology. 2001;75:5823–32. 10.1128/JVI.75.13.5823-5832.200111390583 61AndersonI. Foot and" exact="mouth disease" post="2007: a review and lessons learned. The Stationery Office;"/>
   <result pre="Research. 2012;40:11189–201. 10.1093/nar/gks91823066108 79NagarajanN, KingsfordC. GiRaF: Robust, computational identification of" exact="influenza" post="reassortments via graph mining. Nucleic Acids Research. 2011;39:e3410.1093/nar/gkq123221177643 80HuelsenbeckJP,"/>
   <result pre="Biology and Evolution. 2008;25:1459–71. 10.1093/molbev/msn09018408232 88WertheimJ. The re-emergence of H1N1" exact="influenza" post="virus in 1977: a cautionary tale for estimating divergence"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7189213\results\search\disease\results.xml">
   <result pre="the original work is properly cited.S0950268820000345a.pdf During the 2017 European" exact="hepatitis" post="A (HA) outbreak we assessed HA incidence in our"/>
   <result pre="diagnosed with HIV and another STD. None were vaccinated against" exact="hepatitis" post="A virus (HAV). Hospitalisation was required for 52%. We"/>
   <result pre="knowledge about the risks of STD acquisition: HIV infection; syphilis;" exact="hepatitis" post="A, B, C; gonorrhoeae and chlamydiosis. For each of"/>
   <result pre="20 patients had been recently documented with another STD, including" exact="syphilis" post="(65%), chlamydiosis (20%), human papillomavirus infection (15%), hepatitis B"/>
   <result pre="STD, including syphilis (65%), chlamydiosis (20%), human papillomavirus infection (15%)," exact="hepatitis" post="B or C (10%) or gonorrhoeae (10%). Liver cytolysis"/>
   <result pre="to the survey had a history of another STD, including" exact="syphilis" post="(n = 28; 38%), chlamydiosis (n = 19; 26%),"/>
   <result pre="(39%) regarding chlamydiosis, 23 (31%) regarding HBV/HCV, 15 (20%) regarding" exact="syphilis" post="and finally 15 (20%) regarding HAV. Our infectious disease"/>
   <result pre="(20%) regarding syphilis and finally 15 (20%) regarding HAV. Our" exact="infectious disease" post="unit in Marseille, Southern France, did not escape the"/>
   <result pre="HAV diagnosed in our centre were hospitalised, in gastroenterology or" exact="infectious disease" post="units. This proportion is similar to the mean proportion"/>
   <result pre="Lee et al. described a prolonged duration of symptoms of" exact="hepatitis" post="for HIV positive patients than for those HIV negative"/>
   <result pre="Homosexual Men. AIDS Reviews19, 113–114. 2.MartinAet al. (2018) A foretold" exact="hepatitis" post="A outbreak in France. Liver International38, 955–956.29282863 3.PenotPet al."/>
   <result pre="5.LeeY-Let al. (2018) Less severe but prolonged course of acute" exact="hepatitis" post="A in HIV-positive patients than HIV-negative patients during an"/>
   <result pre="Infectious Diseases67, 1595–1602.29672699 6.NeilsenGA, BodsworthNJ and WattsN (1997) Response to" exact="hepatitis" post="A vaccination in human immunodeficiency virus-infected and -uninfected homosexual"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7190742\results\search\disease\results.xml">
   <result pre="common. Subject terms Virology Medical research Epidemiology Introduction The global" exact="hepatitis" post="C virus (HCV) and human immunodeficiency virus (HIV) pandemics"/>
   <result pre="of decades, putting HCV patients at higher risk for developing" exact="cirrhosis" post="and hepatocellular carcinoma3. The clinical consequences of HCV infection"/>
   <result pre="is a critical first step towards HCV elimination. Likewise, the" exact="suppression" post="of HIV achieved by antiretroviral therapy (ART) reduces the"/>
   <result pre="S.M., and S.S.S. declare no competing interests. References References 1.Global" exact="hepatitis" post="report, 2017. (World Health Organization). 2.World Health Organization, HIV"/>
   <result pre="Hepatol20171412213210.1038/nrgastro.2016.17627924080 4.Organization, W. H. Close to 3 million people access" exact="hepatitis" post="C cure. (2017). 5.Fauci, A. S., Redfield, R. R.,"/>
   <result pre="global survey, and trend analysisThe Lancet. Infectious diseases20191914315510.1016/S1473-3099(18)30647-930509777 7.Gonzalez-CandelasFLopez-LabradorFXBrachoMARecombination in" exact="hepatitis" post="C virusViruses201132006202410.3390/v310200622069526 8.RaghwaniJet al.Origin and evolution of the unique"/>
   <result pre="hepatitis C virusViruses201132006202410.3390/v310200622069526 8.RaghwaniJet al.Origin and evolution of the unique" exact="hepatitis" post="C virus circulating recombinant form 2k/1bJournal of virology2012862212222010.1128/JVI.06184-1122114341 9.KalininaONorderHMukomolovSMagniusLOA"/>
   <result pre="recombinant form 2k/1bJournal of virology2012862212222010.1128/JVI.06184-1122114341 9.KalininaONorderHMukomolovSMagniusLOA natural intergenotypic recombinant of" exact="hepatitis" post="C virus identified in St. PetersburgJournal of virology2002764034404310.1128/jvi.76.8.4034-4043.200211907242 10.Torres-CornejoALauerGMHurdles"/>
   <result pre="Expanding HCV ClassificationOpen Forum Infect Dis20196ofz07610.1093/ofid/ofz07630949527 14.SmithDBet al.Expanded classification of" exact="hepatitis" post="C virus into 7 genotypes and 67 subtypes: updated"/>
   <result pre="J Virol20122334935310.1007/s13337-012-0103-224293823 16.BarmanBBoraKLynrahKGLyngdohWVJamilMHepatitis C virus and its genotypes in chronic" exact="liver disease" post="patients from Meghalaya, Northeast IndiaIndian J Med Microbiol20183637638010.4103/ijmm.IJMM_17_37130429390 17.PrakashSShuklaSRamakrishnaVJainADistribution"/>
   <result pre="patients from Meghalaya, Northeast IndiaIndian J Med Microbiol20183637638010.4103/ijmm.IJMM_17_37130429390 17.PrakashSShuklaSRamakrishnaVJainADistribution of" exact="hepatitis" post="C genotypes in Uttar Pradesh, India; rare genotype 4"/>
   <result pre="load in a large cohort of Indian patients with chronic" exact="hepatitis" post="C virus infection: A retrospective analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet"/>
   <result pre="infection: A retrospective analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet al.The burden of" exact="hepatitis" post="C virus infection in Punjab, India: A population-based serosurveyPloS"/>
   <result pre="in Punjab, India: A population-based serosurveyPloS one201813e020046110.1371/journal.pone.020046130048454 20.GuptaDet al.Recombination in" exact="hepatitis" post="C virus is not uncommon among people who inject"/>
   <result pre="of unique recombinant formsJournal of medical virology20178998999910.1002/jmv.2473827869320 30.SolomonSSet al.Burden of" exact="hepatitis" post="C virus disease and access to hepatitis C virus"/>
   <result pre="30.SolomonSSet al.Burden of hepatitis C virus disease and access to" exact="hepatitis" post="C virus services in people who inject drugs in"/>
   <result pre="quantification in the diagnosis and management of patients with chronic" exact="hepatitis" post="C receiving an all-oral, interferon-free regimen. Antiviral therapy, 10.3851/IMP3042"/>
   <result pre="genotype 1 infected patientsJournal of virological methods2017245141810.1016/j.jviromet.2017.03.00228359920 38.ChevaliezSSoulierAPoiteauLBouvier-AliasMPawlotskyJMClinical utility of" exact="hepatitis" post="C virus core antigen quantification in patients with chronic"/>
   <result pre="hepatitis C virus core antigen quantification in patients with chronic" exact="hepatitis" post="CJournal of clinical virology: the official publication of the"/>
   <result pre="2017 report. Annual Report NACO 2016-2017, 339-407 (2017). 46.GoelASeguyNAggarwalRBurden of" exact="hepatitis" post="C virus infection in India: A systematic review and"/>
   <result pre="and meta-analysisJournal of gastroenterology and hepatology20193432132910.1111/jgh.1446630176181 47.Organization, W. H. Combating" exact="hepatitis" post="B and C to reach elimination by 2030. Advocacy"/>
   <result pre="Virology20135852252710.1016/j.jcv.2013.09.00524095028 49.LaRueHRigaliLBalada-LlasatJMPancholiPPerformance of the Abbott RealTime and Roche Cobas TaqMan" exact="hepatitis" post="C virus (HCV) assays for quantification of HCV genotypesJournal"/>
   <result pre="of HCV genotypesJournal of clinical microbiology2012501769177210.1128/JCM.06723-1122378914 50.HezodeCPan-genotypic treatment regimens for" exact="hepatitis" post="C virus: Advantages and disadvantages in high- and low-income"/>
   <result pre="51.ZorattiMJet al.Pangenotypic direct acting antivirals for the treatment of chronic" exact="hepatitis" post="C virus infection: A systematic literature review and meta-analysisEClinicalMedicine20201810023710.1016/j.eclinm.2019.12.00731922124"/>
   <result pre="A. et al. Comparison of three therapeutic regimens for genotype-3" exact="hepatitis" post="C virus infection in a large real-life multicenter cohort."/>
   <result pre="D. a. World Drug Report. (2019). 55.SahaKet al.Transmission dynamics of" exact="hepatitis" post="C virus among intra venous drug users in the"/>
   <result pre="individuals from PakistanArchives of virology2018163334010.1007/s00705-017-3564-128942522 57.SievertWet al.A systematic review of" exact="hepatitis" post="C virus epidemiology in Asia, Australia and EgyptLiver Int201131Suppl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7190837\results\search\disease\results.xml">
   <result pre="studies are based on single outbreaks, during emergency scenarios (e.g." exact="avian influenza" post="outbreaks), and on the evaluation of factors associated to"/>
   <result pre="are based on single outbreaks, during emergency scenarios (e.g. avian" exact="influenza" post="outbreaks), and on the evaluation of factors associated to"/>
   <result pre="Moreover, most of the available studies are focused on Avian" exact="influenza" post="and, to a lesser extent, Newcastle disease and Infectious"/>
   <result pre="two sectors, as demonstrated in the Italian low pathogenicity Avian" exact="influenza" post="(AI) outbreaks occurred in 2007–200934. After these episodes, a"/>
   <result pre="Italian poultry production. Samples were obtained mainly from outbreaks of" exact="respiratory disease," post="following a standard protocol that enforced the collection of"/>
   <result pre="Pathogenic Avian Influenza Virus between Farms. Plos One7, (2012). 12.HommePJEasterdayBCAndersonDPAvian" exact="influenza" post="virus infections. II. Experimental epizootiology of influenza A-turkey-Wisconsin-1966 virus"/>
   <result pre="One7, (2012). 12.HommePJEasterdayBCAndersonDPAvian influenza virus infections. II. Experimental epizootiology of" exact="influenza" post="A-turkey-Wisconsin-1966 virus in turkeysAvian Dis197014240710.2307/15884685427232 13.AlexanderDJSpackmanDCharacterisation of influenza A"/>
   <result pre="epizootiology of influenza A-turkey-Wisconsin-1966 virus in turkeysAvian Dis197014240710.2307/15884685427232 13.AlexanderDJSpackmanDCharacterisation of" exact="influenza" post="A viruses isolated from turkeys in England during March-May"/>
   <result pre="E., Naqi, S. A. &amp;amp; Grumbles, L. C. Isolation of" exact="avian influenza" post="virus in Texas. Avian Dis. 25, 545–9. 16.SinghMet al.Assessing"/>
   <result pre="Naqi, S. A. &amp;amp; Grumbles, L. C. Isolation of avian" exact="influenza" post="virus in Texas. Avian Dis. 25, 545–9. 16.SinghMet al.Assessing"/>
   <result pre="545–9. 16.SinghMet al.Assessing the probability of introduction and spread of" exact="avian influenza" post="(AI) virus in commercial Australian poultry operations using an"/>
   <result pre="16.SinghMet al.Assessing the probability of introduction and spread of avian" exact="influenza" post="(AI) virus in commercial Australian poultry operations using an"/>
   <result pre="an expert opinion elicitationPlos One201813e019373010.1371/journal.pone.019373029494696 17.MannelliABusaniLTosonMBertoliniSMarangonSTransmission parameters of highly pathogenic" exact="avian influenza" post="(H7N1) among industrial poultry farms in northern Italy in"/>
   <result pre="expert opinion elicitationPlos One201813e019373010.1371/journal.pone.019373029494696 17.MannelliABusaniLTosonMBertoliniSMarangonSTransmission parameters of highly pathogenic avian" exact="influenza" post="(H7N1) among industrial poultry farms in northern Italy in"/>
   <result pre="22.Busani, L. et al. Risk factors for highly pathogenic H7N1" exact="avian influenza" post="virus infection in poultry during the 1999–2000 epidemic in"/>
   <result pre="L. et al. Risk factors for highly pathogenic H7N1 avian" exact="influenza" post="virus infection in poultry during the 1999–2000 epidemic in"/>
   <result pre="to Newcastle-disease virusPrev. Vet. Med.20067719921410.1016/j.prevetmed.2006.07.00416950528 24.JohnsonYJet al.Wind-borne transmission of infectious" exact="laryngotracheitis" post="between commercial poultry operationsInt. J. Poult. Sci.2005426326710.3923/ijps.2005.263.267 25.KühnertDWuCHDrummondAJPhylogenetic and"/>
   <result pre="within vaccinated and unvaccinated groups of chickensAvian Pathol.19982746447110.1080/0307945980841937018484273 29.CapuaIMarangonSControl of" exact="avian influenza" post="in poultryEmerg. Infect. Dis.20061213192410.3201/eid1209.06043017073078 30.CummingRBStudies on Australian infectious bronchitis"/>
   <result pre="vaccinated and unvaccinated groups of chickensAvian Pathol.19982746447110.1080/0307945980841937018484273 29.CapuaIMarangonSControl of avian" exact="influenza" post="in poultryEmerg. Infect. Dis.20061213192410.3201/eid1209.06043017073078 30.CummingRBStudies on Australian infectious bronchitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7190985\results\search\disease\results.xml">
   <result pre="growing population of OPXV-naive individuals after the discontinuation of routine" exact="smallpox" post="vaccination. Antiviral drugs that are effective as postexposure treatments"/>
   <result pre="that host Golgi-associated retrograde proteins play an important role in" exact="monkeypox" post="virus (MPXV) and vaccinia virus (VACV) EV formation. Inhibition"/>
   <result pre="proteins play an important role in monkeypox virus (MPXV) and" exact="vaccinia virus" post="(VACV) EV formation. Inhibition of the retrograde pathway by"/>
   <result pre="antivirals against OPXV. viral inhibitor poxvirus antiviral agent retrograde transport" exact="vaccinia virus" post="Retro-1 retrograde inhibitor ST-246 fig-count: table-count: equation-count: ref-count: page-count:"/>
   <result pre="health concern, including variola virus (the causative agent of smallpox)," exact="monkeypox" post="virus (MPXV), cowpox virus, and vaccinia virus (VACV, the"/>
   <result pre="variola virus (the causative agent of smallpox), monkeypox virus (MPXV)," exact="cowpox" post="virus, and vaccinia virus (VACV, the virus that formulates"/>
   <result pre="causative agent of smallpox), monkeypox virus (MPXV), cowpox virus, and" exact="vaccinia virus" post="(VACV, the virus that formulates the smallpox vaccine) (Fenner"/>
   <result pre="virus, and vaccinia virus (VACV, the virus that formulates the" exact="smallpox" post="vaccine) (Fenner and Nakano, 1988). While smallpox has been"/>
   <result pre="that formulates the smallpox vaccine) (Fenner and Nakano, 1988). While" exact="smallpox" post="has been eradicated, other OPXVs continue to pose a"/>
   <result pre="the lack of protective immunity post the cessation of routine" exact="smallpox" post="vaccination (Durski et al., 2018). In particular, the incidence"/>
   <result pre="among international travellers-serious monkey business?.J. Travel Med.26:taz002. BlascoR.MossB. (1991). Extracellular" exact="vaccinia virus" post="formation and cell-to-cell virus transmission are prevented by deletion"/>
   <result pre="envelope protein.J. Virol.655910–5920. 1920620 BlascoR.MossB. (1992). Role of cell-associated enveloped" exact="vaccinia virus" post="in cell-to-cell spread.J. Virol.664170–4179. 1602540 CarneyD. W.NelsonC. D.FerrisB. D.StevensJ."/>
   <result pre="identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and" exact="vaccinia virus" post="antiviral activity.Pharm. Biol.551586–1591. 10.1080/13880209.2017.131090728395583 DaiW.WuY.BiJ.WangJ.WangS.KongW.et al. (2018). Antiviral effect"/>
   <result pre="1970-2017.MMWR Morb. Mortal. Wkly. Rep.67306–310. 10.15585/mmwr.mm6710a529543790 EngelstadM.SmithG. L. (1993). The" exact="vaccinia virus" post="42-kDa envelope protein is required for the envelopment and"/>
   <result pre="for virus virulence.Virology194627–637. 8503178 ErezN.AchdoutH.MilrotE.SchwartzY.Wiener-WellY.ParanN.et al. (2019). Diagnosis of imported" exact="monkeypox" post="Israel, 2018.Emerg. Infect. Dis.25980–983. 10.3201/eid2505.19007630848724 FennerF.NakanoJ. H. (1988). &quot;Poxviridae:"/>
   <result pre="E. (2011). Development of the small-molecule antiviral ST-246 as a" exact="smallpox" post="therapeutic.Future Virol.6653–671. 21837250 HarrisonK.HagaI. R.Pechenick JowersT.JasimS.CintratJ. C.GilletD.et al. (2016)."/>
   <result pre="of the reservoir: phenotypic and genotypic characterization of a novel" exact="cowpox" post="virus isolated from a common vole.J. Virol.8910959–10969. 10.1128/JVI.01195-1526311891 JohnsonM."/>
   <result pre="Virol.8910959–10969. 10.1128/JVI.01195-1526311891 JohnsonM. C.DamonI. K.KaremK. L. (2008). A rapid, high-throughput" exact="vaccinia virus" post="neutralization assay for testing smallpox vaccine efficacy based on"/>
   <result pre="(2008). A rapid, high-throughput vaccinia virus neutralization assay for testing" exact="smallpox" post="vaccine efficacy based on detection of green fluorescent protein.J."/>
   <result pre="W.GrahamM. B.RegneryR. L.SotirM. J.WegnerM. V.et al. (2004). The detection of" exact="monkeypox" post="in humans in the Western Hemisphere.N. Engl. J. Med.350342–350."/>
   <result pre="to the trans-Golgi network enables membrane wrapping and egress of" exact="vaccinia virus" post="virions.J. Virol.908891–8905. 10.1128/JVI.01114-1627466413 SmithG. L.VanderplasschenA.LawM. (2002). The formation and"/>
   <result pre="systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with" exact="monkeypox" post="virus.J. Virol.859176–9187. 10.1128/JVI.02173-1021697474 SpoonerR. A.SmithD. C.EastonA. J.RobertsL. M.LordJ. M."/>
   <result pre="Infect. Dis.641737–1741. 10.1093/cid/cix21928329402 VaughanA.AaronsE.AstburyJ.BalasegaramS.BeadsworthM.BeckC. R.et al. (2018). Two cases of" exact="monkeypox" post="imported to the United Kingdom, September 2018.Euro. Surveill.2310.2807/1560-7917.ES.2018.23.38.180050930255836 VoraN."/>
   <result pre="J. Med.3721223–1230. 10.1056/NEJMoa140764725806914 WolffeE. J.IsaacsS. N.MossB. (1993). Deletion of the" exact="vaccinia virus" post="B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7192419\results\search\disease\results.xml">
   <result pre="base Hexon Fiber Hunan2012- E109 Hunan Male 6m 2012/5/13 Severe" exact="pneumonia" post="/ MT019924 MT019906 MT019942 Hunan2012- E009 Hunan Male 16m"/>
   <result pre="MT019924 MT019906 MT019942 Hunan2012- E009 Hunan Male 16m 2012/1/17 Severe" exact="pneumonia" post="11/2012-2014 MT019925 MT019907 MT019943 Hunan2012- E100 Hunan Female 8m"/>
   <result pre="MT019925 MT019907 MT019943 Hunan2012- E100 Hunan Female 8m 2012/4/30 Severe" exact="pneumonia" post="9/2012-2014 MT019926 MT019908 MT019944 Hunan2012-E103 Hunan Male 12m 2012/5/15"/>
   <result pre="9/2012-2014 MT019926 MT019908 MT019944 Hunan2012-E103 Hunan Male 12m 2012/5/15 Severe" exact="pneumonia" post="2/2012 MT019927 MT019909 MT019945 Hunan2012- E114 Hunan Male 6m"/>
   <result pre="MT019927 MT019909 MT019945 Hunan2012- E114 Hunan Male 6m 2012/6/5 Severe" exact="pneumonia" post="/ MT019928 MT019910 MT019946 Hunan2012- E134 Hunan Male 3y"/>
   <result pre="5/2012-2013 MT019931 MT019913 MT019949 Hunan2013-026 Hunan Male 18m 2013/2/18 Severe" exact="pneumonia" post="/ MT019932 MT019914 MT019950 Shaanxi2012-12011 Shaanxi Male 18y 2012/3/20"/>
   <result pre="2 years). Moreover, 27 (22.1%) cases were related to severe" exact="pneumonia" post="(median age: 1.2 years). No deaths were reported. HAdV-7"/>
   <result pre="of Samples Number of cases/Proportion Age (median) URI URI, pharyngitis," exact="tonsillitis" post="nasopharyngeal swab 1/1, 2/2, 3/14, 4/3, 5/1, 7/4, 9/3,"/>
   <result pre="2/2, 3/14, 4/3, 5/1, 7/4, 9/3, 12/1 29 18 LRI" exact="pneumonia" post="asthmatic pneumonia, bronchopneumonia, bronchoalveolar lavage fluid, sputum, Nasopharyngeal swab"/>
   <result pre="5/8, 6/10, 7/5, 8/1, 10/1, 11/4, 12/2 66 2 severe" exact="pneumonia" post="bronchoalveolar lavage fluid 1/2, 2/4, 3/3, 4/4, 5/5, 6/2,"/>
   <result pre="the 1950s to 1970s, a serious epidemic of HAdV-associated infantile" exact="pneumonia" post="occurred in northern China, and the fatality rate associated"/>
   <result pre="of a national surveillance system, few reports of HAdV-7-related acute" exact="respiratory disease" post="(ARD) have been published until recently. However, HAdV-7 epidemics"/>
   <result pre="in recent years. In China, a long-term survey of adenoviral-related" exact="pneumonia" post="since 1958 indicated that HAdV-7b was the predominant type"/>
   <result pre="WangHY, et al.Epidemical features of HAdV-3 and HAdV-7 in pediatric" exact="pneumonia" post="in Chongqing, China. Arch Virol. 2015;160(3):633–8. 10.1007/s00705-014-2308-825504360 7WangH, ZhengY,"/>
   <result pre="11YuP, MaC, NawazM, HanL, ZhangJ, DuQ, et al.Outbreak of acute" exact="respiratory disease" post="caused by human adenovirus type 7 in a military"/>
   <result pre="and transmission characteristics of human adenovirus type 7 caused acute" exact="respiratory disease" post="outbreak in military trainees in East China. American journal"/>
   <result pre="of adenovirus types 3 and 7 isolated from children with" exact="pneumonia" post="in Beijing. Journal of medical virology. 1996;49(3):170–7. 10.1002/(SICI)1096-9071(199607)49:3&amp;lt;170::AID-JMV3&amp;gt;3.0.CO;2-18818961 20LuQB,"/>
   <result pre="et al.Re-emergent human adenovirus genome type 7d caused an acute" exact="respiratory disease" post="outbreak in Southern China after a twenty-one year absence."/>
   <result pre="epidemiology of adenovirus of types 3 and 7 on infant" exact="pneumonia" post="in northern China. Chinese medical journal. 1989;102(11):857–61. 2561554 29YuZ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7192973\results\search\disease\results.xml">
   <result pre=": Original Article Erucic acid from Isatis indigotica Fort. suppresses" exact="influenza" post="A virus replication and inflammation in vitro and in"/>
   <result pre="Isatis indigotica Fort. (Ban-Lan-Gen) is an herbal medicine prescribed for" exact="influenza" post="treatment. However, its active components and mode of action"/>
   <result pre="from Isatis indigotica Fort., and subsequently its underlying mechanism against" exact="influenza" post="A virus (IAV) infection was investigated in vitro and"/>
   <result pre="antiviral drugs such as oseltamivir are efficient approaches for controlling" exact="influenza" post="symptoms, but numerous studies reported that they are insufficiency"/>
   <result pre="required to identify novel agents that may effectively fight future" exact="influenza" post="pandemics. To date, the expanding understanding of the pathogenesis"/>
   <result pre="pandemics. To date, the expanding understanding of the pathogenesis of" exact="influenza" post="virus infections provided direction for the development of effective"/>
   <result pre="has elucidated their function and virulence in the pathogenicity of" exact="influenza" post="diseases. For instance, recombinant viruses carrying PB2 segments from"/>
   <result pre="therapeutic benefits but is ineffective in critically ill patients with" exact="influenza" post="virus infection [7]. Excessive inflammation triggered by viruses is"/>
   <result pre="of cytokines was found in humans and ferrets with seasonal" exact="influenza" post="virus infections [8,9]. Intense pro-inflammatory responses were observed in"/>
   <result pre="factors and the host immune response are important contributors of" exact="influenza" post="diseases. Indeed, combination of antiviral agents with immunomodulators has"/>
   <result pre="agents with immunomodulators has been shown to effectively reduce lethal" exact="influenza" post="virus-induced morbidity and mortality as a proof of principle"/>
   <result pre="mortality as a proof of principle [12,13]. The replication of" exact="influenza" post="virus in host cells is dependent on a variety"/>
   <result pre="NF-κB signaling plays a critical role in productive replication of" exact="influenza" post="viruses. Cell lines with decreased NF-κB activities result in"/>
   <result pre="lines with decreased NF-κB activities result in decreased susceptibility to" exact="influenza" post="virus propagation [14]. Several studies revealed that influenza virus"/>
   <result pre="susceptibility to influenza virus propagation [14]. Several studies revealed that" exact="influenza" post="virus affects NF-κB signaling to reduce viral (v) RNA"/>
   <result pre="responses, inhibition of NF-κB activation or its genetic deficiency suppresses" exact="influenza" post="virus-mediated robust production of inflammatory mediators, such as interleukin"/>
   <result pre="[17]. Strikingly, administration of NF-κB inhibitors protects mice against lethal" exact="influenza" post="virus infection [18]. Additionally, activation of p38 kinase, a"/>
   <result pre="and levels of dysregulated cytokines [23]. The severity of seasonal" exact="influenza" post="virus infection in patients is associated with p38 kinase-mediated"/>
   <result pre="excessive pro-inflammatory responses, and may be promising therapeutic interventions in" exact="influenza" post="diseases. Isatis indigotica Fort. belongs to the plant family"/>
   <result pre="may be of interest in the development of drugs for" exact="influenza" post="disease intervention. Among these active components, the monounsaturated fatty"/>
   <result pre="pathway [31]. However, potential beneficial properties of erucic acid against" exact="influenza" post="have not yet been reported. In the present study,"/>
   <result pre="we hypothesized that erucic acid exerts a protective effect against" exact="influenza" post="diseases and the underlying mechanism of anti-viral properties and"/>
   <result pre="influenza diseases and the underlying mechanism of anti-viral properties and" exact="suppression" post="of virus-mediated pro-inflammatory responses was investigated. 2 Materials and"/>
   <result pre="Antiviral activity assays The antiviral activity of erucic acid against" exact="influenza" post="viruses was evaluated in MDCK cells. Monolayers of MDCK"/>
   <result pre="of the 50% tissue culture infectious dose (100 × TCID50) of the" exact="influenza" post="virus strains including A/PR/8/34 (H1N1), A/GZ/GIRD07/09 (H1N1), A/HK/8/68 (H3N2),"/>
   <result pre="Microsystems GmbH, Wetzlar, Germany). The 50% inhibitory concentration (IC50) for" exact="influenza" post="virus inhibition by the compounds was determined using the"/>
   <result pre="to IC50. MDCK cells in 6-well plates were infected with" exact="influenza" post="viruses (100 PFU/well) and incubated with the indicated concentration of"/>
   <result pre="(6 × 105 cells/well) grown in 6-well plates were inoculated with 100 PFU/well indicated" exact="influenza" post="virus diluted in serum-free DMEM and incubated at 37 °C"/>
   <result pre="Mice were randomly divided into five groups: Control group (non-infected);" exact="influenza" post="virus-infected group; erucic acid high dose treatment groups, erucic"/>
   <result pre="isoflurane and inoculated intranasally with 5 LD50 of mouse-adapted A/FM/1/47(H1N1)" exact="influenza" post="virus. 2.7 Lung histopathology and immunohistochemical staining At day"/>
   <result pre="2000 (Invitrogen) for 6 h. Subsequently, transfected cells were stimulated with" exact="influenza" post="virus (MOI = 0.1) or IFN-β (500 ng/mL) in the presence or"/>
   <result pre="assays, 293 cells stably expressing pNF-κB-TATA-F-Luc and pQCXIP-eGFP were infected with" exact="influenza" post="virus (MOI = 0.1) in the presence or absence of erucic"/>
   <result pre="was performed to study the efficacy of erucic acid against" exact="influenza" post="A viruses. Our results showed that erucic acid treatment"/>
   <result pre="significantly reduced the CPE in MDCK cells induced by five" exact="influenza" post="virus strains, including A/PR/8/34 (H1N1), A/GZ/GIRD07/09 (H1N1), A/HK/8/68 (H3N2),"/>
   <result pre="transcription activity. Table 1 Antiviral activity of erucic acid against" exact="influenza" post="viruses. [alt-text] Table 1 Virus strain Erucic acid Oseltamivir"/>
   <result pre="formation in MDCK cells. Monolayers of MDCK were inoculated with" exact="influenza" post="virus (A/PR/8/34 [H1N1], A/GZ/GIRD07/09 [H1N1], A/HK/8/68 [H3N2], A/HK/Y280/97 [H9N2]"/>
   <result pre="the production of progeny viruses. MDCK cells were infected with" exact="influenza" post="virus (A/PR/8/34 [H1N1], A/GZ/GIRD07/09 [H1N1], A/HK/8/68 [H3N2], A/HK/Y280/97 [H9N2]"/>
   <result pre="and JNK), NF-κB and AKT signaling pathways were activated by" exact="influenza" post="A virus infection. Moreover, we observed that the activation"/>
   <result pre="by aberrant signaling contributes to the severity and mortality of" exact="influenza" post="diseases [35]. Since erucic acid suppressed activation of p38"/>
   <result pre="using Luminex assays. The cytokine profile revealed that infection with" exact="influenza" post="A virus resulted in a significant elevation of an"/>
   <result pre="and NF-κB signaling [36,37], were associated with the pathogenesis of" exact="influenza" post="infection. Therefore, we suggested that erucic acid may decrease"/>
   <result pre="pro-inflammatory mediators, lung damage is worsened by apoptosis induction during" exact="influenza" post="virus infection [38]. In this regard, the effect of"/>
   <result pre="[38]. In this regard, the effect of erucic acid on" exact="influenza" post="virus-induced apoptosis in A549 cells was determined. Annexin V staining"/>
   <result pre="blot analysis of expression of cleaved caspase-3 and PARP in" exact="influenza" post="virus-infected cells (Fig. 5B). It is well established that"/>
   <result pre="and p38 MAPK inhibitor SB203580 (column 6) treatment resulted in" exact="suppression" post="of type I INF (IFN-β) and III INF (IFN-λ1)"/>
   <result pre="(Fig. 6A, column 7 and 9). This indicated that IFN" exact="suppression" post="effects by erucic acid were potentially associated with NF-κB"/>
   <result pre="analysis of pro-inflammatory cytokines secreted in IFN-pre-treated cells prior to" exact="influenza" post="A/PR8/34(H1N1) (MOI = 0.1) infection. A549 cells were pre-treated"/>
   <result pre="pre-treated with IFN-β (500 ng/mL) for 4 h, infected with" exact="influenza" post="A/PR8/34(H1N1) and treated with or without erucic acid. Data"/>
   <result pre="days prior to challenge with 5 LD50 of mouse-adapted H1N1" exact="influenza" post="strain (A/FM/1/47). On day 7 p.i., IAV-infected mice exhibited"/>
   <result pre="pro-inflammatory responses through inhibition of aberrant signaling cascades linked to" exact="influenza" post="severity. Fig. 8 Erucic acid attenuates excessive pulmonary inflammation"/>
   <result pre="vs. IAV-infected. 4 Discussion Seasonal epidemics and occasional pandemics of" exact="influenza" post="viruses constitute a serious public health risk and inflict"/>
   <result pre="immense morbidity and mortality. Antiviral drugs are used clinically in" exact="influenza" post="therapy; however, even early oseltamivir treatment does not improve"/>
   <result pre="uncontrollable cytokine storm [10,45]. Clinical evidence demonstrated an association of" exact="influenza" post="pathogenesis with the intensity of the inflammatory response, highlighting"/>
   <result pre="inflammatory response, highlighting the potential benefits of immunomodulatory agents for" exact="influenza" post="treatments. Nevertheless, given that viral PAMPs are detected by"/>
   <result pre="properties shows potential in the treatment of hypercytokinemia in severe" exact="influenza" post="cases. Antiviral activity further acts to reduce inflammation by"/>
   <result pre="Viral load is a critical contributor in the pathogenesis of" exact="influenza" post="diseases. Erucic acid presented efficiency against several strains of"/>
   <result pre="diseases. Erucic acid presented efficiency against several strains of human" exact="influenza" post="viruses, including A/PR/8/34 (H1N1), A/GZ/GIRD07/09 (H1N1), A/HK/8/68 (H3N2), A/HK/Y280/97"/>
   <result pre="this study, data revealed that erucic acid treatment suppressed the" exact="influenza" post="virus-mediated activation of NF-κB and p38 MAPK signaling in"/>
   <result pre="inhibitors (Fig. 3C). Therefore, it was proposed that inhibition of" exact="influenza" post="virus-mediated activation of the NF-κB and p38 MAPK signaling"/>
   <result pre="acute lung injury (ALI) or continues progress to form severe" exact="acute respiratory distress syndrome" post="(ARDS), which has been ascribed to the disordered inflammatory"/>
   <result pre="IL-6 are closely correlated with symptoms and fever in human" exact="influenza" post="infection [9,46]. Elevation of IL-17 and IP-10 was reported"/>
   <result pre="IP-10 was reported to mediate ALI during the 2009 pandemic" exact="influenza" post="A (H1N1) virus infection [47,48]. Development of ALI or"/>
   <result pre="activation of NF-κB and p38 kinase signaling is involved in" exact="influenza" post="virus-induced dysregulation of pro-inflammatory mediator production. NF-κB deficiency markedly"/>
   <result pre="[36,37]. Overexpression of COX-2 is implicated in the pathogenesis of" exact="avian influenza" post="H5N1 infections [54]. Expression of COX-2 is induced upon"/>
   <result pre="Overexpression of COX-2 is implicated in the pathogenesis of avian" exact="influenza" post="H5N1 infections [54]. Expression of COX-2 is induced upon"/>
   <result pre="effects via inhibition of NF-κB and p38 kinase signaling during" exact="influenza" post="virus infection. Erucic acid treatment was also found to"/>
   <result pre="exhibit increased susceptibility to various types of viral infection, including" exact="vaccinia virus" post="[61], coxsackievirus B3 [62], Friend retrovirus [63] and influenza"/>
   <result pre="vaccinia virus [61], coxsackievirus B3 [62], Friend retrovirus [63] and" exact="influenza" post="virus [64]. However, given immunomodulatory properties of IFNs, the"/>
   <result pre="to the IFN-mediated amplification of a detrimental pro-inflammatory response to" exact="influenza" post="virus infection. In vitro data suggested that an increasing"/>
   <result pre="data suggested that an increasing percentage of apoptotic cells following" exact="influenza" post="virus infection and vRNA stimulation was decreased upon erucic"/>
   <result pre="to eliminate invading pathogens. However, an increasing evidence suggests that" exact="influenza" post="progression has a direct link to the apoptosis of"/>
   <result pre="CD8+ T lymphocytes are more abundant in patients with severe" exact="pneumonia" post="than moderate pneumonia [72]. Histological findings of the lungs"/>
   <result pre="are more abundant in patients with severe pneumonia than moderate" exact="pneumonia" post="[72]. Histological findings of the lungs of novel swine"/>
   <result pre="In conclusion, it was revealed that erucic acid treatment of" exact="influenza" post="virus-infected cells resulted in the significant suppression of viral"/>
   <result pre="acid treatment of influenza virus-infected cells resulted in the significant" exact="suppression" post="of viral propagation and pro-inflammatory mediator production via NF-κB"/>
   <result pre="in IFN-β pre-treated cells. Moreover, erucic acid protected mice from" exact="influenza" post="virus-induced lung injury and improved mortality by attenuating viral"/>
   <result pre="pro-inflammatory responses that may have potential in the treatment of" exact="influenza" post="illness. Conflicts of interest The authors declare that there"/>
   <result pre="References 1JohnsonN.P.MuellerJ.Updating the accounts: global mortality of the 1918-1920 &quot;Spanish&quot;" exact="influenza" post="pandemicBull. Hist. Med.76200210511511875246 2GaoH.N.LuH.Z.CaoB.Clinical findings in 111 cases of"/>
   <result pre="influenza pandemicBull. Hist. Med.76200210511511875246 2GaoH.N.LuH.Z.CaoB.Clinical findings in 111 cases of" exact="influenza" post="A (H7N9) virus infectionN. Engl. J. Med.36820132277228523697469 3ToK.K.W.NgK.H.L.QueT.-L.Avian influenza"/>
   <result pre="of influenza A (H7N9) virus infectionN. Engl. J. Med.36820132277228523697469 3ToK.K.W.NgK.H.L.QueT.-L.Avian" exact="influenza" post="A H5N1 virus: a continuous threat to humansEmerg. Microb."/>
   <result pre="Infect.12012e25 4BianJ.-R.Clinical aspects and cytokine response in adults with seasonal" exact="influenza" post="infectionInt. J. Clin. Exp. Med.720145593560225664078 5ZamarinD.Garcia-SastreA.XiaoX.Influenza virus PB1-F2 protein"/>
   <result pre="cell death through mitochondrial ANT3 and VDAC1PLoS Pathog.12005e416201016 6ForeroA.Tisoncik-GoJ.WatanabeT.The 1918" exact="influenza" post="virus PB2 protein enhances virulence through the disruption of"/>
   <result pre="late oseltamivir treatment in severely ill patients with 2009 pandemic" exact="influenza" post="A (H1N1): speed is lifeJ. Antimicrob. Chemother.66201195996321406435 8SvitekN.RuddP.A.ObojesK.Severe seasonal"/>
   <result pre="influenza A (H1N1): speed is lifeJ. Antimicrob. Chemother.66201195996321406435 8SvitekN.RuddP.A.ObojesK.Severe seasonal" exact="influenza" post="in ferrets correlates with reduced interferon and increased IL-6"/>
   <result pre="inductionVirology3762008535918420248 9GentileD.DoyleW.WhitesideT.Increased interleukin-6 levels in nasal lavage samples following experimental" exact="influenza" post="A virus infectionClin. Diagn. Lab. Immunol.519986046089729523 10De JongM.D.SimmonsC.P.ThanhT.T.Fatal outcome"/>
   <result pre="virus infectionClin. Diagn. Lab. Immunol.519986046089729523 10De JongM.D.SimmonsC.P.ThanhT.T.Fatal outcome of human" exact="influenza" post="A (H5N1) is associated with high viral load and"/>
   <result pre="of the cytokine response does not protect against lethal H5N1" exact="influenza" post="infectionProc. Natl. Acad. Sci. U.S.A.1042007124791248117640882 12ZhengB.J.ChanK.W.LinY.P.Delayed antiviral plus immunomodulator"/>
   <result pre="still reduces mortality in mice infected by high inoculum of" exact="influenza" post="A/H5N1 virusProc. Natl. Acad. Sci. U.S.A.10520088091809618523003 13SharmaG.Champalal SharmaD.Hwei FenL.Reduction"/>
   <result pre="A/H5N1 virusProc. Natl. Acad. Sci. U.S.A.10520088091809618523003 13SharmaG.Champalal SharmaD.Hwei FenL.Reduction of" exact="influenza" post="virus-induced lung inflammation and mortality in animals treated with"/>
   <result pre="inhibitorEmerg. Microbes Infect.22013e5426038487 14NimmerjahnF.DudziakD.DirmeierU.Active NF-kappaB signalling is a prerequisite for" exact="influenza" post="virus infectionJ. Gen. Virol.8520042347235615269376 15KumarN.XinZ.T.LiangY.NF-kappaB signaling differentially regulates influenza"/>
   <result pre="for influenza virus infectionJ. Gen. Virol.8520042347235615269376 15KumarN.XinZ.T.LiangY.NF-kappaB signaling differentially regulates" exact="influenza" post="virus RNA synthesisJ. Virol.8220089880988918701591 16PintoR.HeroldS.CakarovaL.Inhibition of influenza virus-induced NF-kappaB"/>
   <result pre="signaling differentially regulates influenza virus RNA synthesisJ. Virol.8220089880988918701591 16PintoR.HeroldS.CakarovaL.Inhibition of" exact="influenza" post="virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus"/>
   <result pre="Res.922011455621641936 17DroebnerK.ReilingS.J.PlanzO.Role of hypercytokinemia in NF-kappaB p50-deficient mice after H5N1" exact="influenza" post="A virus infectionJ. Virol.822008114611146618768968 18MazurI.WurzerW.J.EhrhardtC.Acetylsalicylic acid (ASA) blocks influenza"/>
   <result pre="H5N1 influenza A virus infectionJ. Virol.822008114611146618768968 18MazurI.WurzerW.J.EhrhardtC.Acetylsalicylic acid (ASA) blocks" exact="influenza" post="virus propagation via its NF-kappaB-inhibiting activityCell Microbiol.920071683169417324159 19MarchantD.SingheraG.K.UtokaparchS.Toll-like receptor"/>
   <result pre="20NencioniL.De ChiaraG.SgarbantiR.Bcl-2 expression and p38MAPK activity in cells infected with" exact="influenza" post="A virus: impact on virally induced apoptosis and viral"/>
   <result pre="Chem.2842009160041601519336399 21HuiK.P.Y.LeeS.M.Y.CheungC.y.Induction of proinflammatory cytokines in primary human macrophages by" exact="influenza" post="A virus (H5N1) is selectively regulated by IFN regulatory"/>
   <result pre="mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by" exact="influenza" post="virus-infected human bronchial epithelial cellsJ. Immunol.16420003222322810706714 23BorgelingY.SchmolkeM.ViemannD.Inhibition of p38"/>
   <result pre="epithelial cellsJ. Immunol.16420003222322810706714 23BorgelingY.SchmolkeM.ViemannD.Inhibition of p38 mitogen-activated protein kinase impairs" exact="influenza" post="virus-induced primary and secondary host gene responses and protects"/>
   <result pre="and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human" exact="influenza" post="A virus infectionClin. Infect. Dis.45200772373117712756 25LiZ.ZhaoJ.ZhouH.Cappariloside A shows antiviral"/>
   <result pre="Dis.45200772373117712756 25LiZ.ZhaoJ.ZhouH.Cappariloside A shows antiviral and better anti-inflammatory effects against" exact="influenza" post="virus via regulating host IFN signaling, in vitro and"/>
   <result pre="in vivo and in vitroFront. Pharmacol.1020197830792656 27LiZ.LiL.ZhouH.Radix isatidis polysaccharides inhibit" exact="influenza" post="a virus and influenza A virus-induced inflammation via suppression"/>
   <result pre="vitroFront. Pharmacol.1020197830792656 27LiZ.LiL.ZhouH.Radix isatidis polysaccharides inhibit influenza a virus and" exact="influenza" post="A virus-induced inflammation via suppression of host TLR3 signaling"/>
   <result pre="inhibit influenza a virus and influenza A virus-induced inflammation via" exact="suppression" post="of host TLR3 signaling in vitroMolecules222017 28YangZ.WangY.ZhengZ.Antiviral activity of"/>
   <result pre="activity of Isatis indigotica root-derived clemastanin B against human and" exact="avian influenza" post="A and B viruses in vitroInt. J. Mol. Med.31201386787323403777"/>
   <result pre="of Isatis indigotica root-derived clemastanin B against human and avian" exact="influenza" post="A and B viruses in vitroInt. J. Mol. Med.31201386787323403777"/>
   <result pre="Mol. Med.31201386787323403777 29LiJ.ZhouB.LiC.Lariciresinol-4-O-beta-D-glucopyranoside from the root of Isatis indigotica inhibits" exact="influenza" post="A virus-induced pro-inflammatory responseJ. Ethnopharmacol.174201537938626320688 30ZhouB.LiJ.LiangX.Transcriptome profiling of influenza"/>
   <result pre="inhibits influenza A virus-induced pro-inflammatory responseJ. Ethnopharmacol.174201537938626320688 30ZhouB.LiJ.LiangX.Transcriptome profiling of" exact="influenza" post="A virus-infected lung epithelial (A549) cells with lariciresinol-4-beta-D-glucopyranoside treatmentPLoS"/>
   <result pre="anti-viral effects via inhibition of the NF-kappaB signaling pathway in" exact="influenza" post="A virus-infected cellsJ. Ethnopharmacol.2017 34LudwigS.Targeting cell signalling pathways to"/>
   <result pre="anti-influenza therapyJ. Antimicrob. Chemother.6420091419420020 35RamosI.Fernandez-SesmaA.Modulating the innate immune response to" exact="influenza" post="A virus: potential therapeutic use of anti-inflammatory drugsFront. Immunol.62015"/>
   <result pre="IFN-β contributes to apoptotic alveolar epithelial cell injury in severe" exact="influenza" post="virus pneumoniaPLoS Pathog.92013e1003188 39BeschR.PoeckH.HohenauerT.Proapoptotic signaling induced by RIG-I and"/>
   <result pre="in human melanoma cellsJ. Clin. Investig.11920092399241119620789 40RossmanJ.S.LambR.A.Autophagy, apoptosis, and the" exact="influenza" post="virus M2 proteinCell Host Microbe6200929930019837369 41ZhangC.YangY.ZhouX.The NS1 protein of"/>
   <result pre="influenza virus M2 proteinCell Host Microbe6200929930019837369 41ZhangC.YangY.ZhouX.The NS1 protein of" exact="influenza" post="A virus interacts with heat shock protein Hsp90 in"/>
   <result pre="mechanismJ. Biol. Chem.28220077576758117204473 44DavidsonS.CrottaS.McCabeT.M.Pathogenic potential of interferon αβ in acute" exact="influenza" post="infectionNat. Commun.52014386424844667 45ChiY.ZhuY.WenT.Cytokine and chemokine levels in patients infected"/>
   <result pre="45ChiY.ZhuY.WenT.Cytokine and chemokine levels in patients infected with the novel" exact="avian influenza" post="A (H7N9) virus in ChinaJ. Infect. Dis.20820131962196723990573 46KaiserL.FritzR.S.StrausS.E.Symptom pathogenesis"/>
   <result pre="and chemokine levels in patients infected with the novel avian" exact="influenza" post="A (H7N9) virus in ChinaJ. Infect. Dis.20820131962196723990573 46KaiserL.FritzR.S.StrausS.E.Symptom pathogenesis"/>
   <result pre="other cytokine responsesJ. Med. Virol.64200126226811424113 47WangW.YangP.ZhongY.Monoclonal antibody against CXCL-10/IP-10 ameliorates" exact="influenza" post="A (H1N1) virus induced acute lung injuryCell Res.23201357758023419516 48LiC.YangP.SunY.IL-17"/>
   <result pre="response mediates acute lung injury induced by the 2009 pandemic" exact="influenza" post="A (H1N1) virusCell Res.22201252853822025253 49MullinJ.M.SnockK.V.Effect of tumor necrosis factor"/>
   <result pre="hyperinduction of tumor necrosis factor alpha expression in response to" exact="avian influenza" post="virus H5N1J. Virol.792005101471015416051807 54LeeS.M.CheungC.Y.NichollsJ.M.Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a"/>
   <result pre="of tumor necrosis factor alpha expression in response to avian" exact="influenza" post="virus H5N1J. Virol.792005101471015416051807 54LeeS.M.CheungC.Y.NichollsJ.M.Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a"/>
   <result pre="of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of" exact="avian influenza" post="H5N1 infectionJ. Infect. Dis.198200852553518613795 55KirkbyN.S.ZaissA.K.WrightW.R.Differential COX-2 induction by viral"/>
   <result pre="cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian" exact="influenza" post="H5N1 infectionJ. Infect. Dis.198200852553518613795 55KirkbyN.S.ZaissA.K.WrightW.R.Differential COX-2 induction by viral"/>
   <result pre="cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to" exact="influenza" post="A viral infectionJ. Immunol.17520056878688416272346 58CareyM.A.BradburyJ.A.RebollosoY.D.Pharmacologic inhibition of COX-1 and"/>
   <result pre="viral infectionJ. Immunol.17520056878688416272346 58CareyM.A.BradburyJ.A.RebollosoY.D.Pharmacologic inhibition of COX-1 and COX-2 in" exact="influenza" post="A viral infection in micePLoS One52010e11610 59CoulombeF.JaworskaJ.VerwayM.Targeted prostaglandin E2"/>
   <result pre="Virol.8020063438344416537611 64KoernerI.KochsG.KalinkeU.Protective role of beta interferon in host defense against" exact="influenza" post="A virusJ. Virol.8120072025203017151098 65GoritzkaM.DurantL.R.PereiraC.Alpha/beta interferon receptor signaling amplifies early"/>
   <result pre="ultrastructural analysis of surgical lung biopsies in patients with swine-origin" exact="influenza" post="type A/H1N1 and acute respiratory failureClinics (Sao Paulo)6520101229123721340209 69UiprasertkulM.KitphatiR.PuthavathanaP.Apoptosis"/>
   <result pre="and acute respiratory failureClinics (Sao Paulo)6520101229123721340209 69UiprasertkulM.KitphatiR.PuthavathanaP.Apoptosis and pathogenesis of" exact="avian influenza" post="A (H5N1) virus in humansEmerg. Infect. Dis.13200770871217553248 70IshikawaE.NakazawaM.YoshinariM.Role of"/>
   <result pre="acute respiratory failureClinics (Sao Paulo)6520101229123721340209 69UiprasertkulM.KitphatiR.PuthavathanaP.Apoptosis and pathogenesis of avian" exact="influenza" post="A (H5N1) virus in humansEmerg. Infect. Dis.13200770871217553248 70IshikawaE.NakazawaM.YoshinariM.Role of"/>
   <result pre="of tumor necrosis factor-related apoptosis-inducing ligand in immune response to" exact="influenza" post="virus infection in miceJ. Virol.7920057658766315919918 71KohlmeierJ.E.CookenhamT.RobertsA.D.Type I interferons regulate"/>
   <result pre="72KimJ.E.BauerS.LaK.S.CD4+/CD8+ T lymphocytes imbalance in children with severe 2009 pandemic" exact="influenza" post="A (H1N1) pneumoniaKorean J. Pediatr.54201120721121829412 73MauadT.HajjarL.A.CallegariG.D.Lung pathology in fatal"/>
   <result pre="(H1N1) pneumoniaKorean J. Pediatr.54201120721121829412 73MauadT.HajjarL.A.CallegariG.D.Lung pathology in fatal novel human" exact="influenza" post="A (H1N1) infectionAm. J. Respir. Crit. Care Med.1812010727919875682 74EnelowR.I.MohammedA.Z.StolerM.H.Structural"/>
   <result pre="de SandtC.E.BarcenaM.KosterA.J.Human CD8(+) T cells damage noninfected epithelial cells during" exact="influenza" post="virus infection in vitroAm. J. Respir. Cell Mol. Biol.57201753654628613916"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7198842\results\search\disease\results.xml">
   <result pre="disease (CHIKD) is a viral infection caused by an alphavirus," exact="chikungunya" post="virus (CHIKV), and triggers large outbreaks leading to epidemics."/>
   <result pre="and the factors that dictate disease progression and its resolution." exact="chikungunya" post="virus incubation phase acute phase immunopathology disease resolution chronic"/>
   <result pre="virus incubation phase acute phase immunopathology disease resolution chronic phase" exact="chikungunya" post="induced arthritis viral clearance Funding International Center for Genetic"/>
   <result pre="phase acute phase immunopathology disease resolution chronic phase chikungunya induced" exact="arthritis" post="viral clearance Funding International Center for Genetic Engineering and"/>
   <result pre="word-count: Introduction Chikungunya disease (CHIKD), caused by an arthritogenic alphavirus," exact="chikungunya" post="virus (CHIKV), is becoming a major public health hazard"/>
   <result pre="mother and unborn child and results in complications such as" exact="encephalopathy" post="(22, 23). CHIKD establishes itself and progresses to a"/>
   <result pre="clinical symptoms such as joint pain, fever, maculopapular and petechial" exact="rash" post="appear. As the viral load increases the host innate"/>
   <result pre="been reported in mice models as a therapeutic treatment against" exact="chikungunya" post="persistence (104, 112–118). In accordance with that, mice mutant"/>
   <result pre="leading to high viral titres in various tissues, concluded that" exact="chikungunya" post="infection persists in tissues that are controlled by adaptive"/>
   <result pre="blood (25). Similarly, administration of human monoclonal CHIKV-specific antibodies in" exact="chikungunya" post="infected rhesus monkeys led to inhibition of viral spread"/>
   <result pre="CHIKV infection which indicates that these act as biomarkers in" exact="chikungunya" post="infection (146). Target analysis suggests that targets of these"/>
   <result pre="to the IRF transcription factors and (149, 150) leads to" exact="suppression" post="of inflammatory responses by promoting M2 switching. Similarly, miR-210"/>
   <result pre="switching. Similarly, miR-210 targets the NF-κB factors and elicits the" exact="suppression" post="of M1 switching, resulting in suppression of inflammation (151–153)."/>
   <result pre="factors and elicits the suppression of M1 switching, resulting in" exact="suppression" post="of inflammation (151–153). Other key players of CHIKD resolution"/>
   <result pre="differentiating into Th17 cells (160), is a key player in" exact="arthritis" post="and rheumatism (161). Several studies have shown a significant"/>
   <result pre="(172, 173). Bregs have been studied for their role in" exact="rheumatoid arthritis" post="(RA) and its regulation seems to be one of"/>
   <result pre="173). Bregs have been studied for their role in rheumatoid" exact="arthritis" post="(RA) and its regulation seems to be one of"/>
   <result pre="players that enhance RA disease (174, 175). Considering that chikungunya-induced" exact="arthritis" post="is an inflammatory response triggered by the virus that"/>
   <result pre="for several months or years, resulting in symptoms similar to" exact="rheumatoid arthritis," post="and is termed as the chronic phase of CHIKD"/>
   <result pre="joint links the abnormal T-cell response to bone damage in" exact="arthritis" post="(184, 185). One study found increased expression of CD95/CD95L"/>
   <result pre="association by looking into other similar autoimmune disorders such as" exact="rheumatoid arthritis?" post="Will employing animal models specific to autoimmune disorders help"/>
   <result pre="Nat Rev Rheumatol. (2012) 8:420. 10.1038/nrrheum.2012.6422565316 2.WahidBAliARafiqueSIdreesM. Global expansion of" exact="chikungunya" post="virus: mapping the 64-year history. Int J Infect Dis."/>
   <result pre="J Infect Dis. (2017) 58:69–76. 10.1016/j.ijid.2017.03.00628288924 3.PowersAMLogueCH. Changing patterns of" exact="chikungunya" post="virus: re-emergence of a zoonotic arbovirus. J Genrl Virol."/>
   <result pre="Lancet. (2014) 383:514. 10.1016/S0140-6736(14)60185-924506907 5.RaoTRCareyDEPavriKM. Preliminary isolation and identification of" exact="chikungunya" post="virus from cases of dengue-like illness in Madras city."/>
   <result pre="J Med Res. (1965) 53:689–93.5830402 6.SchuffeneckerIItemanIMichaultAMurriSFrangeulLVaneyCet al.. Genome microevolution of" exact="chikungunya" post="viruses causing the Indian Ocean outbreak. PLoS Med. (2006)"/>
   <result pre="Ocean outbreak. PLoS Med. (2006) 3:e263. 10.1371/journal.pmed.003026316700631 7.VazeilleMMoutaillerSCoudrierDRousseauxCKhunHHuerreMet al.. Two" exact="chikungunya" post="isolates from the outbreak of La Reunion (Indian Ocean)"/>
   <result pre="countries?Acta Tropica. (2008) 105:200–2. 10.1016/j.actatropica.2007.09.00918005927 9.TsetsarkinKAVanlandinghamDLMcGeeCEHiggsS. A single mutation in" exact="chikungunya" post="virus affects vector specificity and epidemic potential. PLoS Pathog."/>
   <result pre="Med J. (1983) 68:313–5. 14.BorgheriniGPoubeauPJossaumeAGouixACotteLMichaultAet al.. Persistent arthralgia associated with" exact="chikungunya" post="virus: a study of 88 adult patients on reunion"/>
   <result pre="Island. Rev Neurol. (2009) 165:48–51. 10.1016/j.neurol.2008.06.00918835614 17.RampalMSMeenaH. Neurological complications in" exact="chikungunya" post="fever. J Assoc Physicians India. (2007) 55:765–9. Available online"/>
   <result pre="Med Hyg. (2017) 97:356–60. 10.4269/ajtmh.15-075328722564 19.MehtaRGerardinPde BritoCAASoaresCNFerreiraLBSolomonTThe neurological complications of" exact="chikungunya" post="virus: a systematic review. Rev Med Virol. (2018) 28:e197810.1002/rmv.197829671914"/>
   <result pre="Med Virol. (2018) 28:e197810.1002/rmv.197829671914 20.RenaultPSoletJLSissokoDBalleydierELarrieuSFilleulLet al.. A major epidemic of" exact="chikungunya" post="virus infection on Reunion Island, France, 2005-2006. Am J"/>
   <result pre="10.4269/ajtmh.2007.77.72717978079 21.HsuCHCruz-LopezFTorresDVPerez-PadillaJLorenziODRiveraAet al.. Risk factors for hospitalization of patients with" exact="chikungunya" post="virus infection at sentinel hospitals in Puerto Rico. PLoS"/>
   <result pre="Trop D. (2019) 13:e0007084. 10.1371/journal.pntd.000708430640900 22.RamfulDCarbonnierMPasquetMBouhmaniBGhazouaniJNoormahomedTet al.. Mother-to-child transmission of" exact="chikungunya" post="virus infection. Pediatr Infect Dis J. (2007) 26:811–5. 10.1097/INF.0b013e3180616d4f17721376"/>
   <result pre="(2007) 26:811–5. 10.1097/INF.0b013e3180616d4f17721376 23.GérardinPBarauGMichaultABintnerMRandrianaivoHChokerGet al.. Multidisciplinary prospective study of mother-to-child" exact="chikungunya" post="virus infections on the island of La Reunion. PLoS"/>
   <result pre="Multiple immune factors are involved in controlling acute and chronic" exact="chikungunya" post="virus infection. PLoS Neglect Trop Dis. (2014) 8:e3354. 10.1371/journal.pntd.000335425474568"/>
   <result pre="8:e3354. 10.1371/journal.pntd.000335425474568 26.HoarauJJBandjeeMCJTrototPKDasTLi-Pat-YuenGDassaBet al.. Persistent chronic inflammation and infection by" exact="chikungunya" post="arthritogenic alphavirus in spite of a robust host immune"/>
   <result pre="85:606–20. 10.1128/JVI.00767-1020962078 28.AkahataWYangYAndersenHSunSHoldawayHAKongPet al.. A virus-like particle vaccine for epidemic" exact="chikungunya" post="virus protects nonhuman primates against infection. Nat Med. (2010)"/>
   <result pre="Virol. (2018) 28:53–60. 10.1016/j.coviro.2017.11.00629175515 30.LongKMHeiseMT. Protective and pathogenic responses to" exact="chikungunya" post="virus infection. Curr Trop Med Rep. (2015) 2:13–21. 10.1007/s40475-015-0037-z26366337"/>
   <result pre="Trop Med Rep. (2015) 2:13–21. 10.1007/s40475-015-0037-z26366337 31.GérardinPFianuAMichaultAMussardCBoussaïdKRollotOet al.. Predictors of" exact="chikungunya" post="rheumatism: a prognostic survey ancillary to the TELECHIK cohort"/>
   <result pre="ONE. (2013) 8:e84695. 10.1371/journal.pone.008469524376836 33.RemenyiRGaoYHughesRECurdAZothnerCPeckhamMet al.. Persistent replication of a" exact="chikungunya" post="virus replicon in human cells is associated with presence"/>
   <result pre="10.1128/JVI.00477-1829875241 34.StaplesJEBreimanRFPowersAM. Chikungunya fever: an epidemiological review of a re-emerging" exact="infectious disease." post="Clin Infect Dis. (2009) 49:942–8. 10.1086/60549619663604 35.MohanAKiranDManoharICKumarDP. Epidemiology, clinical"/>
   <result pre="(2009) 49:942–8. 10.1086/60549619663604 35.MohanAKiranDManoharICKumarDP. Epidemiology, clinical manifestations, and diagnosis of" exact="chikungunya" post="fever: lessons learned from the re-emerging epidemic. Indian J"/>
   <result pre="55:54. 10.4103/0019-5154.6035520418981 36.TanabeISTanabeELSantosECMartinsWVAraújoIMCavalcanteMCet al.. Cellular and molecular immune response to" exact="chikungunya" post="virus infection. Front Cell Infect Microbiol. (2018) 8:345. 10.3389/fcimb.2018.0034530364124"/>
   <result pre="Infect Microbiol. (2018) 8:345. 10.3389/fcimb.2018.0034530364124 37.�?lvarez-ArgüellesMEAlbaSRPérezMRRiveiroJABGarcíaSMDiagnosis and molecular characterization of" exact="chikungunya" post="virus infections. In: Rodriguez-Morales AJ, editor. Current Topics in"/>
   <result pre="44.LongKMFerrisMTWhitmoreACMontgomerySAThurlowLRMcGeeCEet al.. γδ T cells play a protective role in" exact="chikungunya" post="virus-induced disease. J Virol. (2016) 90:433–43. 10.1128/JVI.02159-1526491151 45.FuYXRoarkCEKellyKDrevetsDCampbellPO'BrienRet al.."/>
   <result pre="Immunol. (2004) 17:565–73. 10.1089/vim.2004.17.56515671753 53.ThangamaniSHiggsSZieglerSVanlandinghamDTeshRWikelS. Host immune response to mosquito-transmitted" exact="chikungunya" post="virus differs from that elicited by needle inoculated virus."/>
   <result pre="Med. (2020) 12:eaax2421. 10.1126/scitranslmed.aax242131969486 57.SchilteCCoudercTChretienFSourisseauMGangneuxNGuivel-BenhassineFet al.. Type I IFN controls" exact="chikungunya" post="virus via its action on nonhematopoietic cells. J Exp"/>
   <result pre="J Exp Med. (2010) 207:429–42. 10.1084/jem.2009085120123960 58.HarrisonVBinnLRandallR. Comparative immunogenicities of" exact="chikungunya" post="vaccines prepared in avian and mammalian tissues. Am J"/>
   <result pre="Med Hyg. (1967) 16:786–91. 10.4269/ajtmh.1967.16.7864965219 59.SchwartzOAlbertML. Biology and pathogenesis of" exact="chikungunya" post="virus. Nat Rev Microbiol. (2010) 8:491. 10.1038/nrmicro236820551973 60.JinJGalaz-MontoyaJGShermanMBSunSYGoldsmithCSO'TooleETet al.."/>
   <result pre="Rev Microbiol. (2010) 8:491. 10.1038/nrmicro236820551973 60.JinJGalaz-MontoyaJGShermanMBSunSYGoldsmithCSO'TooleETet al.. Neutralizing antibodies inhibit" exact="chikungunya" post="virus budding at the plasma membrane. Cell Host Microbe."/>
   <result pre="the Brazilian Society of Rheumatology for diagnosis and treatment of" exact="chikungunya" post="fever. Part 1-Diagnosis and special situations. Rev Bras Reumatol"/>
   <result pre="(2012) 86:2900–10. 10.1128/JVI.05738-1122258243 65.ChenWFooSSZaidATengTSHerreroLJWolfSet al.. Specific inhibition of NLRP3 in" exact="chikungunya" post="disease reveals a role for inflammasomes in alphavirus-induced inflammation."/>
   <result pre="10.1038/s41564-017-0015-428848230 66.EkchariyawatPHamelRBernardEWichitSSurasombatpattanaPTalignaniLet al.. Inflammasome signaling pathways exert antiviral effect against" exact="chikungunya" post="virus in human dermal fibroblasts. Infect Genet Evol. (2015)"/>
   <result pre="Evol. (2015) 32:401–8. 10.1016/j.meegid.2015.03.02525847693 67.OlagnierDScholteFEChiangCAlbulescuICNicholsCHeZet al.. Inhibition of dengue and" exact="chikungunya" post="virus infections by RIG-I-mediated type I interferon-independent stimulation of"/>
   <result pre="mediated innate immune response in mice brain following infection with" exact="chikungunya" post="virus. Virus Res. (2014) 189:194–205. 10.1016/j.virusres.2014.05.01024905288 69.PrykeKMAbrahamJSaliTMGallBJArcherILiuAet al.. A"/>
   <result pre="70.RuddPAWilsonJGardnerJLarcherTBabaritCLeTTet al.. Interferon response factors 3 and 7 protect against" exact="chikungunya" post="virus hemorrhagic fever and shock. J Virol. (2012) 86:9888–98."/>
   <result pre="shock. J Virol. (2012) 86:9888–98. 10.1128/JVI.00956-1222761364 71.TengTSFooSSimamartaDLumFMTeoTHLullaAet al.. Viperin restricts" exact="chikungunya" post="virus replication and pathology. J Clin Invest. (2012) 122:4447–60."/>
   <result pre="Clin Invest. (2012) 122:4447–60. 10.1172/JCI6312023160199 72.SourisseauMSchilteCCasartelliNTrouilletCGuivel-BenhassineFRudnickaDet al.. Characterization of reemerging" exact="chikungunya" post="virus. PLoS Pathog. (2007) 3:e89. 10.1371/journal.ppat.003008917604450 73.WikanNSakoonwatanyooPUbolSYoksanSSmithDR. Chikungunya virus"/>
   <result pre="10.1186/1743-422X-8-43221902836 75.HerZMalleretBChanMOngEKWongS-CKwekDJet al.. Active infection of human blood monocytes by" exact="chikungunya" post="virus triggers an innate immune response. J Immunol. (2010)"/>
   <result pre="TNF receptor. J Neuroimmunol. (1994) 50:101–7. 10.1016/0165-5728(94)90220-88300851 82.RulliNERolphMSSrikiatkhachornAAnantapreechaSGuglielmottiAMahalingamS. Protection from" exact="arthritis" post="and myositis in a mouse model of acute chikungunya"/>
   <result pre="J Neuroimmunol. (1994) 50:101–7. 10.1016/0165-5728(94)90220-88300851 82.RulliNERolphMSSrikiatkhachornAAnantapreechaSGuglielmottiAMahalingamS. Protection from arthritis and" exact="myositis" post="in a mouse model of acute chikungunya virus disease"/>
   <result pre="from arthritis and myositis in a mouse model of acute" exact="chikungunya" post="virus disease by bindarit, an inhibitor of monocyte chemotactic"/>
   <result pre="10.1093/infdis/jir47021881117 83.PooYSNakayaHGardnerJLarcherTSchroderWALeTTet al.. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated" exact="chikungunya" post="virus arthritis. J Virol. (2014) 88:6862–72. 10.1128/JVI.03364-1324696480 84.SchönrichGRafteryMJ. Neutrophil"/>
   <result pre="188:844–53. 10.4049/jimmunol.110173622156344 86.HirokiCHToller-KawahisaJEFumagalliMJColónDFFigueiredoLTFonsecaBAet al.. Neutrophil extracellular traps effectively control acute" exact="chikungunya" post="virus infection. Front Immunol. (2019) 10:3108. 10.3389/fimmu.2019.0310832082301 87.LandeRGangulyDFacchinettiVFrascaLConradCGregorioJet al.."/>
   <result pre="Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in" exact="systemic lupus erythematosus." post="Sci Transl Med. (2011) 3:73ra19. 10.1126/scitranslmed.300118021389263 88.SwieckiMColonnaM. The multifaceted"/>
   <result pre="activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic" exact="lupus erythematosus." post="Sci Transl Med. (2011) 3:73ra19. 10.1126/scitranslmed.300118021389263 88.SwieckiMColonnaM. The multifaceted"/>
   <result pre="15:471. 10.1038/nri386526160613 89.WebsterBWernekeSWZafirovaBThisSColéonSDecembreEet al.. Plasmacytoid dendritic cells control dengue and" exact="chikungunya" post="virus infections via IRF7-regulated interferon responses. Elife. (2018) 7:e34273."/>
   <result pre="10.7554/eLife.3427329914621 90.PetitdemangeCBecquartPWauquierNBeziatVDebrePLeroyEMet al.. Unconventional repertoire profile is imprinted during acute" exact="chikungunya" post="infection for natural killer cells polarization toward cytotoxicity. PLoS"/>
   <result pre="Front Immunol. (2013) 4:422. 10.3389/fimmu.2013.0042224367364 92.WauquierNBecquartPNkogheDPadillaCNdjoyi-MbiguinoALeroyEM. The acute phase of" exact="chikungunya" post="virus infection in humans is associated with strong innate"/>
   <result pre="J Infect Dis. (2011) 204:115–23. 10.1093/infdis/jiq00621628665 93.GardnerJAnrakuILeTTLarcherTMajorLRoquesPet al.. Chikungunya virus" exact="arthritis" post="in adult wild-type mice. J Virol. (2010) 84:8021–32. 10.1128/JVI.02603-0920519386"/>
   <result pre="Virol. (2010) 84:8021–32. 10.1128/JVI.02603-0920519386 94.MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMet al.. A mouse model of" exact="chikungunya" post="virus–induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
   <result pre="95.TeoTHLumMClaserCLullaVLullaAMeritsAet al.. A pathogenic role for CD4+ T cells during" exact="chikungunya" post="virus infection in mice. J Immunol. (2013) 190:259–69. 10.4049/jimmunol.120217723209328"/>
   <result pre="10.3201/eid1403.07090618325256 97.JainJNayakKTanwarNGaindRGuptaBShastriJet al.. Clinical, serological, and virological analysis of 572" exact="chikungunya" post="patients from 2010 to 2013 in India. Clin Infect"/>
   <result pre="(2017) 65:133–40. 10.1093/cid/cix28328379375 98.KamYWLumFMTeoTHLeeWWSimarmataDHarjantoSet al.. Early neutralizing IgG response to" exact="chikungunya" post="virus in infected patients targets a dominant linear epitope"/>
   <result pre="Early appearance of neutralizing immunoglobulin G3 antibodies is associated with" exact="chikungunya" post="virus clearance and long-term clinical protection. J Infect Dis."/>
   <result pre="100.LumMTeoHLeeWWKamWRéniaLNgLF. An essential role of antibodies in the control of" exact="chikungunya" post="virus infection. J Immunol. (2013) 190:6295–302. 10.4049/jimmunol.130030423670192 101.FoxJMDiamondMS. Immune-mediated"/>
   <result pre="Immunol. (2013) 190:6295–302. 10.4049/jimmunol.130030423670192 101.FoxJMDiamondMS. Immune-mediated protection and pathogenesis of" exact="chikungunya" post="virus. J Immunol. (2016) 197:4210–8. 10.4049/jimmunol.160142627864552 102.WolintPBettsMRKoupRAOxeniusAImmediate cytotoxicity but"/>
   <result pre="103.DiasNSGoisBMLimaVSGuerra-GomesICAraujoMGGomesASet al.. Human CD8 T-cell activation in acute and chronic" exact="chikungunya" post="infection. Immunology. (2018) 155:499–504. 10.1111/imm.1299230099739 104.CoudercTKhandoudiNGrandadamMVisseCGangneuxNBagotSet al.. Prophylaxis and"/>
   <result pre="Immunology. (2018) 155:499–504. 10.1111/imm.1299230099739 104.CoudercTKhandoudiNGrandadamMVisseCGangneuxNBagotSet al.. Prophylaxis and therapy for" exact="chikungunya" post="virus infection. J Infect Dis. (2009) 200:516–23. 10.1086/60038119572805 105.TandaleBVSathePSArankalleVAWadiaRSKulkarniRShahSVet"/>
   <result pre="(2009) 200:516–23. 10.1086/60038119572805 105.TandaleBVSathePSArankalleVAWadiaRSKulkarniRShahSVet al.. Systemic involvements and fatalities during" exact="chikungunya" post="epidemic in India, (2006). J Clin Virol. (2009) 46:145–9."/>
   <result pre="J Clin Virol. (2009) 46:145–9. 10.1016/j.jcv.2009.06.02719640780 106.JohnsonBWRussellBJGoodmanCH. Laboratory diagnosis of" exact="chikungunya" post="virus infections and commercial sources for diagnostic assays. J"/>
   <result pre="of immune competent mice, C57BL/6J using an Indian isolate of" exact="chikungunya" post="virus (CHIKV). Viruses. (2019) 11:578. 10.3390/v1106057831242674 108.PierroARossiniGGaibaniPFinarelliACMoroMLLandiniMPet al.. Persistence"/>
   <result pre="N Microbes N Infect. (2015) 7:23–5. 10.1016/j.nmni.2015.04.00226106482 109.MalvyDEzzedineKMamani-MatsudaMAutranBTolouHReceveurMCet al.. Destructive" exact="arthritis" post="in a patient with chikungunya virus infection with persistent"/>
   <result pre="7:23–5. 10.1016/j.nmni.2015.04.00226106482 109.MalvyDEzzedineKMamani-MatsudaMAutranBTolouHReceveurMCet al.. Destructive arthritis in a patient with" exact="chikungunya" post="virus infection with persistent specific IgM antibodies. BMC Infect"/>
   <result pre="9:200. 10.1186/1471-2334-9-20020003320 110.MizunoYKatoYTakeshitaNUjiieMKobayashiTKanagawaSet al.. Clinical and radiological features of imported" exact="chikungunya" post="fever in Japan: a study of six cases at"/>
   <result pre="broad and ultrapotent human monoclonal antibodies with therapeutic activity against" exact="chikungunya" post="virus. Cell Host Microbe. (2015) 18:86–95. 10.1016/j.chom.2015.06.00926159721 115.HawmanDWFoxJMAshbrookAWMayNASchroederKMTorresRMet al.."/>
   <result pre="virus. Cell Host Microbe. (2015) 18:86–95. 10.1016/j.chom.2015.06.00926159721 115.HawmanDWFoxJMAshbrookAWMayNASchroederKMTorresRMet al.. Pathogenic" exact="chikungunya" post="virus evades B cell responses to establish persistence. Cell"/>
   <result pre="of a recombinant human monoclonal antibody reduces the severity of" exact="chikungunya" post="virus disease in rhesus macaques. PLoS Neglect Trop Dis."/>
   <result pre="Development of a highly protective combination monoclonal antibody therapy against" exact="chikungunya" post="virus. PLoS Pathog. (2013) 9:e1003312. 10.1371/journal.ppat.100331223637602 118.FricJBertin-MaghitSWangCINardinAWarterL. Use of"/>
   <result pre="9:e1003312. 10.1371/journal.ppat.100331223637602 118.FricJBertin-MaghitSWangCINardinAWarterL. Use of human monoclonal antibodies to treat" exact="chikungunya" post="virus infection. J Infect Dis. (2013) 207:319–22. 10.1093/infdis/jis67423125446 119.HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSet"/>
   <result pre="207:319–22. 10.1093/infdis/jis67423125446 119.HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSet al.. Chronic joint disease caused by persistent" exact="chikungunya" post="virus infection is controlled by the adaptive immune response."/>
   <result pre="onset?Front Immunol. (2016) 7:160. 10.3389/fimmu.2016.0016027199985 135.WilsonJAProwNASchroderWAEllisJJCummingHEGearingLJet al.. RNA-Seq analysis of" exact="chikungunya" post="virus infection and identification of granzyme A as a"/>
   <result pre="Microbe. (2008) 3:375–87. 10.1016/j.chom.2008.05.00218541214 143.ChatzikyriakidouAVoulgariPVGeorgiouIDrososAA. miRNAs and related polymorphisms in" exact="rheumatoid arthritis" post="susceptibility. Autoimmun Rev. (2012) 11:636–41. 10.1016/j.autrev.2011.11.00422100329 144.Kurowska-StolarskaMAliverniniSBallantineLEAsquithDLMillarNLGilchristDSet al.. MicroRNA-155"/>
   <result pre="(2008) 3:375–87. 10.1016/j.chom.2008.05.00218541214 143.ChatzikyriakidouAVoulgariPVGeorgiouIDrososAA. miRNAs and related polymorphisms in rheumatoid" exact="arthritis" post="susceptibility. Autoimmun Rev. (2012) 11:636–41. 10.1016/j.autrev.2011.11.00422100329 144.Kurowska-StolarskaMAliverniniSBallantineLEAsquithDLMillarNLGilchristDSet al.. MicroRNA-155"/>
   <result pre="mRNA signature identifies key molecular players and pathways involved in" exact="chikungunya" post="virus infection in human cells. PLoS ONE. (2013) 8:e79886."/>
   <result pre="(2018) 19:730. 10.3390/ijms1903073029510522 159.LeeWWTeoTHHerZLumFMKamYWHaaseDet al.. Expanding regulatory T cells alleviates" exact="chikungunya" post="virus-induced pathology in mice. J Virol. (2015) 89:7893–904. 10.1128/JVI.00998-1525995249"/>
   <result pre="162.ChaaitanyaIKMuruganandamNSundaramSGKawalekarOSugunanAPManimundaSPet al.. Role of proinflammatory cytokines and chemokines in chronic" exact="arthropathy" post="in CHIKV infection. Viral Immunol. (2011) 24:265–71. 10.1089/vim.2010.012321830898 163.NgLFChowASunYJKwekDJLimPLDimatatacFet"/>
   <result pre="10.1089/vim.2010.012321830898 163.NgLFChowASunYJKwekDJLimPLDimatatacFet al.. IL-1beta, IL-6, and RANTES as biomarkers of" exact="chikungunya" post="severity. PLoS ONE. (2009) 4:e4261. 10.1371/journal.pone.000426119156204 164.LohachanakulJPhukliaWThannagithMThonsakulprasertTUbolS. High concentrations"/>
   <result pre="protein-1 with low concentrations of interleukin-8 were associated with severe" exact="chikungunya" post="fever during the 2009-2010 outbreak in Thailand. Microbiol Immunol."/>
   <result pre="al.. Changes in regulatory B cells and their relationship with" exact="rheumatoid arthritis" post="disease activity. Clin Exp Med. (2015) 15:285–92. 10.1007/s10238-014-0310-925245953 175.LorenzettiRJanowskaISmulskiCRFredeNHennebergerNWalterLet"/>
   <result pre="Changes in regulatory B cells and their relationship with rheumatoid" exact="arthritis" post="disease activity. Clin Exp Med. (2015) 15:285–92. 10.1007/s10238-014-0310-925245953 175.LorenzettiRJanowskaISmulskiCRFredeNHennebergerNWalterLet"/>
   <result pre="human B-cells. J Autoimmun. (2019) 101:145–52. 10.1016/j.jaut.2019.04.01631054942 176.SissokoDMalvyDEzzedineKRenaultPMoscettiFLedransMet al.. Post-epidemic" exact="chikungunya" post="disease on Reunion Island: course of rheumatic manifestations and"/>
   <result pre="period. PLoS Negl Trop Dis. (2009) 3:e389. 10.1371/journal.pntd.000038919274071 177.ChopraAAnuradhaVGhorpadeRSalujaM. Acute" exact="chikungunya" post="and persistent musculoskeletal pain following the 2006 Indian epidemic:"/>
   <result pre="86:31–8. 10.1016/j.jcv.2016.11.00327912127 180.KelvinAABannerDSilviGMoroMLSpataroNGaibaniPet al.. Inflammatory cytokine expression is associated with" exact="chikungunya" post="virus resolution and symptom severity. PLoS Negl Trop Dis."/>
   <result pre="Dis. (2011) 5:e1279. 10.1371/journal.pntd.000127921858242 181.ChowAHerZOngEKChenJMDimatatacFKwekDJet al.. Persistent arthralgia induced by" exact="chikungunya" post="virus infection is associated with interleukin-6 and granulocyte macrophage"/>
   <result pre="Jesus BarretoMCristiny PereiraMda Rocha PittaIet al.. IL-27 in patients with" exact="chikungunya" post="fever: a possible chronicity biomarker?Acta Trop. (2019) 196:48–51. 10.1016/j.actatropica.2019.05.00531075222"/>
   <result pre="183.YoungARLockeMCCookLEHillerBEZhangRHedbergMLet al.. Dermal and muscle fibroblasts and skeletal myofibers survive" exact="chikungunya" post="virus infection and harbor persistent RNA. PLoS Pathog. (2019)."/>
   <result pre="285:809–27. 10.1111/febs.1429229032605 187.NoretMHerreroLRulliNRolphMSmithPNLiRWet al.Interleukin 6, RANKL, and osteoprotegerin expression by" exact="chikungunya" post="virus-infected human osteoblasts. J Infect Dis. (2012) 206:455–7:7–9. 10.1093/infdis/jis368"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7199921\results\search\disease\results.xml">
   <result pre="of use:http://www.nature.com/authors/editorial_policies/license.html#terms Abstract SUMMARY The recent Zika virus (ZIKV) and" exact="chikungunya" post="virus (CHIKV) epidemics highlight the explosive nature of arthropod-borne"/>
   <result pre="the emergence and global spread of dengue virus (DENV; Flaviviridae)," exact="chikungunya" post="virus (CHIKV; Togaviridae), and Zika virus (ZIKV; Flaviviridae)5,6. These"/>
   <result pre="al. which showed higher midgut titers in mosquitoes with disseminated" exact="western equine encephalitis" post="virus infection32. The midgut is encased in a proteoglycan"/>
   <result pre="showed higher midgut titers in mosquitoes with disseminated western equine" exact="encephalitis" post="virus infection32. The midgut is encased in a proteoglycan"/>
   <result pre="emergence of arthropod-borne viral diseases: A global prospective on dengue," exact="chikungunya" post="and zika fevers. Acta Trop166, 155–163, doi:10.1016/j.actatropica.2016.11.020 (2017).27876643 2FariaNRet"/>
   <result pre="Senegal and Cape Verde archipelago for West African lineages of" exact="chikungunya" post="virus. Am J Trop Med Hyg91, 635–641, doi:10.4269/ajtmh.13-0627 [pii]"/>
   <result pre="(1998).9886207 32KramerLD, HardyJL, PresserSB &amp;amp; HoukEJDissemination barriers for western equine" exact="encephalomyelitis" post="virus in Culex tarsalis infected after ingestion of low"/>
   <result pre="imperial, and San Joaquin Valleys of California for St. Louis" exact="encephalitis" post="virus. Am J Trop Med Hyg32, 305–311, doi:10.4269/ajtmh.1983.32.305 (1983).6301301"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7200043\results\search\disease\results.xml">
   <result pre="are associated with high viraemia, liver damage, renal failure, bleeding," exact="encephalopathy" post="and a shock-like syndrome.4 7–10 Health systems in areas"/>
   <result pre="ribavirin are only available for different dosing regimens used for" exact="hepatitis" post="C.25 The multiple dose half-life of ribavirin is estimated"/>
   <result pre="al.Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic" exact="hepatitis" post="C genotype 1 infection. Aaps J2012;14:571–80. 10.1208/s12248-012-9368-z22639111 30collab: CMRCMaximum"/>
   <result pre="exploratory approach to optimize the dosing of Peg-IFN/RBV in cirrhotic" exact="hepatitis" post="C patients treated with triple therapy. CPT Pharmacometrics Syst"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7201406\results\search\disease\results.xml">
   <result pre="or malaria. respiratory syncytial virus Nicaragua cohort study incidence rate" exact="pneumonia" post="Funding Centers for Disease Control and Prevention10.13039/100000030 1U01GH000028-04 National"/>
   <result pre="important cause of acute lower respiratory tract infections (ALRI) like" exact="pneumonia" post="and bronchiolitis, particularly among children [1]. In 2015, there"/>
   <result pre="illnesses and is considered the most common viral cause of" exact="pneumonia" post="among children aged &amp;lt;5 years [18]. In Nicaragua, the"/>
   <result pre="can last from June through February. While the seasonality of" exact="influenza" post="in Nicaragua has been documented [19], the seasonality of"/>
   <result pre="symptomatic RSV illness, 11 (3.2%) of which were coinfected with" exact="influenza" post="A. We did not observe differential illness severities among"/>
   <result pre="medical causes during the study, 3 (37.5%) died of severe" exact="pneumonia" post="(all in-hospital) and were reverse transcriptase-polymerase chain reaction–positive for"/>
   <result pre="months. An additional infant (aged 11 months) died of severe" exact="pneumonia" post="46 days after symptom onset. The RSV-associated mortality rate"/>
   <result pre="the prevalence of human immunodeficiency virus is low [28], and" exact="malaria" post="is absent, suggesting RSV is a significant contributor to"/>
   <result pre="(Guatemala) [31]. The Guatemalan study reported an incidence of RSV" exact="pneumonia" post="among children aged ≤18 months of 143.6 per 1000"/>
   <result pre="[37–39]. Studies using data from cohorts initially designed to study" exact="influenza" post="(like this study) are susceptible to such underestimates, as"/>
   <result pre="J2009; 28:472–6.19504730 16.HomairaN, LubySP, PetriWA, et al.Incidence of respiratory virus-associated" exact="pneumonia" post="in urban poor young children of Dhaka, Bangladesh, 2009–2011."/>
   <result pre="140:543–6.3706232 18.RudanI, O’BrienKL, NairH, et al.Epidemiology and etiology of childhood" exact="pneumonia" post="in 2010: estimates of incidence, severe morbidity, mortality, underlying"/>
   <result pre="Accessed 29 July 2019. 22.GreshL, KuanG, SanchezN, et al.Burden of" exact="influenza" post="and influenza-associated pneumonia in the first year of life"/>
   <result pre="2019. 22.GreshL, KuanG, SanchezN, et al.Burden of influenza and influenza-associated" exact="pneumonia" post="in the first year of life in a prospective"/>
   <result pre="for Disease Control and Prevention (CDC). PAHO-CDC generic proposal for" exact="influenza" post="surveillance2006 Available at: http://www.paho.org/english/ad/dpc/cd/flu-snl-gpis.pdf. Accessed 29 July 2019. 24.collab:"/>
   <result pre="Health Organization. WHO Regional Office for Europe guidance for sentinel" exact="influenza" post="surveillance in humans: May 2011 Edition. Copenhagen, Denmark :"/>
   <result pre="et al.In- and out-of-hospital mortality associated with seasonal and pandemic" exact="influenza" post="and respiratory syncytial virus in South Africa, 2009–2013. Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7202302\results\search\disease\results.xml">
   <result pre="is properly cited.file:MEE3-10-1357.pdf Abstract Abstract Viruses, such as dengue, Zika," exact="yellow fever" post="and chikungunya, depend on mosquitoes for transmission. Their epidemics"/>
   <result pre="Abstract Introdução: Os vírus da dengue, Zika, febre amarela e" exact="chikungunya" post="mantém�?se em ciclos de transmissão entre humanos e mosquitos."/>
   <result pre="version.] 1 INTRODUCTION Common mosquito�?borne viruses include the dengue (DENV)," exact="chikungunya" post="(CHIKV), Zika (ZIKV), yellow fever (YFV), Rift Valley fever"/>
   <result pre="mosquito�?borne viruses include the dengue (DENV), chikungunya (CHIKV), Zika (ZIKV)," exact="yellow fever" post="(YFV), Rift Valley fever (RVFV), West Nile (WNV) and"/>
   <result pre="(YFV), Rift Valley fever (RVFV), West Nile (WNV) and Japanese" exact="encephalitis" post="(JEV) viruses. Due to ongoing human and climatic trends"/>
   <result pre="the classic mosquito�?borne example is the Ross�?Macdonald formulation applied to" exact="malaria" post="(MacDonald, 1957). Generally, the R0 of a mosquito�?borne pathogen"/>
   <result pre="1 day. VC has contributed immensely to the theory of" exact="malaria" post="elimination programmes (Brady et al., 2016; Gething et al.,"/>
   <result pre="2015). (c3) Same P and AaS as in (b), and" exact="chikungunya" post="virus (CHIKV) incidence per month (magenta, for 2015). (c1–c3)"/>
   <result pre="are made available on Figshare https://doi.org/10.6084/m9.figshare.c.4485503 (Louren¸co, 2019). Dengue and" exact="chikungunya" post="incidence from Tegucigalpa (city) for the year 2015 were"/>
   <result pre="C. M. T. (2016). Association between Zika virus infection and" exact="microcephaly" post="in Brazil, January to May, 2016: Preliminary report of"/>
   <result pre="Vectorial capacity and vector control: Reconsidering sensitivity to parameters for" exact="malaria" post="elimination. Transactions of the Royal Society of Tropical Medicine"/>
   <result pre="… Mallet, H. P. (2016). Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013�?15: A retrospective study. The Lancet,"/>
   <result pre="… Pybus, O. G., (2018). Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potential. Science (New York, N.Y.) 361, 894–899.30139911"/>
   <result pre="Alcantara, L., … Carlos Junior Alcantara, L., (2016b). Epidemiology of" exact="chikungunya" post="virus in Bahia, Brazil, 2014–2015. PLoS Currents8. Faria, N."/>
   <result pre="Effectiveness and economic assessment of routine larviciding for prevention of" exact="chikungunya" post="and dengue in temperate urban settings in Europe. PLoS"/>
   <result pre="T. (2018a). The seasonal influence of climate and environment on" exact="yellow fever" post="transmission across Africa. PLoS Neglected Tropical Diseases, 12, 1–17."/>
   <result pre="T. (2018b). The seasonal influence of climate and environment on" exact="yellow fever" post="transmission across Africa. PLOS Neglected Tropical Diseases, 12, e0006284http://dx.plos.org/10.1371/journal.pntd.0006284.29543798"/>
   <result pre="Nikolay, B., Stasse, S., … Cauchemez, S. (2016). Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
   <result pre="… Marques, E. T. (2017). Zika virus displacement by a" exact="chikungunya" post="outbreak in Recife, Brazil. PLoS Neglected Tropical Diseases, 11,"/>
   <result pre="the impact of temperature on transmission of Zika, dengue, and" exact="chikungunya" post="using mechanistic models. PLoS Neglected Tropical Diseases, 11, 1–18."/>
   <result pre="de Souza Kuchenbecker, R., &amp;amp; Schmidt, M. I. (2017). Infection�?related" exact="microcephaly" post="after the 2015 and 2016 Zika virus outbreaks in"/>
   <result pre="Outbreaks. 10.1371/currents.outbreaks.7a6c64436a3085ebba37e5329ba169e6 Rosen, L. (1986). The natural history of Japanese" exact="encephalitis" post="virus. Annual Review of Microbiology, 40, 395–414. 10.1146/annurev.mi.40.100186.002143 Rowley,"/>
   <result pre="Leung, G. M., &amp;amp; Lipsitch, M. (2016). Fractional dosing of" exact="yellow fever" post="vaccine to extend supply: A modelling study. The Lancet,"/>
   <result pre="J., (2017). Estimating and mapping the incidence of dengue and" exact="chikungunya" post="in Honduras during 2015 using Geographic Information Systems (GIS)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7202625\results\search\disease\results.xml">
   <result pre="Respiratory Infections A typology of beliefs and misperceptions about the" exact="influenza" post="disease and vaccine among older adults in Singapore A"/>
   <result pre="and vaccine among older adults in Singapore A typology of" exact="influenza" post="vaccine misperceptions http://orcid.org/0000-0002-3840-556XCummingsChristopher L.ConceptualizationData curationFormal analysisFunding acquisitionInvestigationMethodologyProject administrationResourcesSupervisionValidationWriting –"/>
   <result pre="original author and source are credited.pone.0232472.pdf Abstract Access to the" exact="influenza" post="vaccine pose little barriers in developed countries such as"/>
   <result pre="barriers in developed countries such as Singapore and vaccination against" exact="influenza" post="is highly recommended for at-risk populations including older adults."/>
   <result pre="acceptance and uptake, we explored Singaporean older adults’ misperceptions about" exact="influenza" post="disease and vaccine. Qualitative semi-structured interviews were conducted among"/>
   <result pre="Focusing specifically on older adults’ misperceptions, seven main themes about" exact="influenza" post="disease or vaccine emerged from our data analysis: familiarity"/>
   <result pre="misperceptions about influenza, personal susceptibility to influenza, familiarity with the" exact="influenza" post="vaccine, misperceptions about the influenza vaccine, misperceptions about influenza"/>
   <result pre="to influenza, familiarity with the influenza vaccine, misperceptions about the" exact="influenza" post="vaccine, misperceptions about influenza vaccine usage, and opinions about"/>
   <result pre="the influenza vaccine, misperceptions about the influenza vaccine, misperceptions about" exact="influenza" post="vaccine usage, and opinions about and barriers to influenza"/>
   <result pre="about influenza vaccine usage, and opinions about and barriers to" exact="influenza" post="vaccine uptake. Notably, there is a lack of adequate"/>
   <result pre="a lack of adequate knowledge and motivation in vaccinating against" exact="influenza" post="among older adults in Singapore. Health communication needs to"/>
   <result pre="processing systems and engage health professionals’ involvement in addressing the" exact="influenza" post="disease and vaccine misperceptions identified in this study. Funding"/>
   <result pre="01Singapore 637335. Introduction Preventing the spread of infectious diseases like" exact="influenza" post="is a high-priority public health challenge. Influenza contributes to"/>
   <result pre="to approximately 290,000 to 650,000 global deaths annually [1]. Seasonal" exact="influenza" post="in Singapore presents significant health burdens with 15 influenza-related"/>
   <result pre="the older adult segment than the general population [2]. Furthermore," exact="influenza" post="continues to pose threats of a future global pandemic"/>
   <result pre="concern [3]. Vaccination remains the most effective practice to prevent" exact="influenza" post="infection [4]. In general, vaccines have contributed a three"/>
   <result pre="uptake around the world [9]. In Singapore, the threat of" exact="infectious disease" post="spread is a high-priority public health concern. The high"/>
   <result pre="population density of the country exacerbates human-transmission of diseases like" exact="influenza" post="and has been considered a potential &quot;hot-spot�? for disease"/>
   <result pre="Singapore population were estimated to be infected with the H1N1" exact="influenza" post="virus in the first 10 weeks after the epidemic"/>
   <result pre="authorities to protect residents from foreign disease vectors. However, adequate" exact="influenza" post="prevention requires substantial herd immunity fostered through individuals’ uptake"/>
   <result pre="viral spread, increasing the probability of disease outbreaks. Outbreaks of" exact="influenza" post="in tropical regions such as Singapore are less defined"/>
   <result pre="from the 2013 National Health Surveillance Survey also revealed that" exact="influenza" post="vaccination coverage among Singaporeans aged 50 and above ranged"/>
   <result pre="at higher risks of hospitalization, mortality, and influenza-related complications including" exact="pneumonia" post="[23, 24, 25], yearly vaccinations against influenza are nevertheless"/>
   <result pre="influenza-related complications including pneumonia [23, 24, 25], yearly vaccinations against" exact="influenza" post="are nevertheless recommended [26]. Adults aged 65 and above"/>
   <result pre="Adults aged 65 and above are recommended to get the" exact="influenza" post="vaccine and eligible to use their medical savings to"/>
   <result pre="eligible to use their medical savings to pay for annual" exact="influenza" post="vaccination that costs between 30 and 40 Singapore Dollars"/>
   <result pre="investigations by Sundaram and colleagues [27] that noted challenges for" exact="influenza" post="vaccine uptake among healthcare workers in Singapore. Our study"/>
   <result pre="Singapore. Our study furthers this foundational work by exploring the" exact="influenza" post="disease and vaccination misperceptions of the most vulnerable population"/>
   <result pre="vaccine uptake among older adults, a more robust understanding of" exact="influenza" post="vaccine perceptions is vital to improve health responses to"/>
   <result pre="burden within this high-risk group. By uncovering misperceptions about the" exact="influenza" post="vaccine held by the elderly population through this qualitative"/>
   <result pre="to better understand older adults’ attitudes, knowledge, and perceptions about" exact="influenza" post="disease and vaccination. A mixed team of five male"/>
   <result pre="selection Given the study objective to identify salient misperceptions about" exact="influenza" post="and vaccination among older adults in Singapore, our inclusion"/>
   <result pre="populated questions for our semi-structured interview protocol from reviews of" exact="influenza" post="vaccine perception studies [e.g., 29, 30]. Interview topics included"/>
   <result pre="[e.g., 29, 30]. Interview topics included health information seeking behavior," exact="influenza" post="knowledge, vaccination history, vaccine perceptions and intentions, and responsibility"/>
   <result pre="health misperceptions, personal background, health information seeking, vaccine information access," exact="influenza" post="perceptions, vaccination intentions, vaccine perceptions, social norms, nonverbal behaviors,"/>
   <result pre="vivo codes provided an understanding of how our participants perceived" exact="influenza" post="and vaccination (e.g., &quot;influenza comes from wearing wet clothes�?"/>
   <result pre="13.2% Indian 11.8% Eurasian 1.3% Vaccination History Have taken the" exact="influenza" post="vaccine before at some point 59.2% Have not taken"/>
   <result pre="vaccine before at some point 59.2% Have not taken the" exact="influenza" post="vaccine before 31.6% Unsure 9.2% Our approach of constant"/>
   <result pre="classified into two topic areas of perceptions about 1) the" exact="influenza" post="disease, and 2) the influenza vaccine (Table 2). 10.1371/journal.pone.0232472.t002Table"/>
   <result pre="of perceptions about 1) the influenza disease, and 2) the" exact="influenza" post="vaccine (Table 2). 10.1371/journal.pone.0232472.t002Table 2 Typology of influenza disease"/>
   <result pre="2) the influenza vaccine (Table 2). 10.1371/journal.pone.0232472.t002Table 2 Typology of" exact="influenza" post="disease and influenza vaccine perceptions. Topic Theme (number of"/>
   <result pre="vaccine (Table 2). 10.1371/journal.pone.0232472.t002Table 2 Typology of influenza disease and" exact="influenza" post="vaccine perceptions. Topic Theme (number of codes) Definition Perceptions"/>
   <result pre="perceptions. Topic Theme (number of codes) Definition Perceptions about the" exact="influenza" post="disease Familiarity with influenza (5) This theme covers how"/>
   <result pre="of codes) Definition Perceptions about the influenza disease Familiarity with" exact="influenza" post="(5) This theme covers how well participants know about"/>
   <result pre="(5) This theme covers how well participants know about the" exact="influenza" post="disease and its symptoms. Participants also describe their information"/>
   <result pre="its symptoms. Participants also describe their information source. Misperceptions about" exact="influenza" post="(30) This theme includes participants’ misperceptions about the influenza"/>
   <result pre="about influenza (30) This theme includes participants’ misperceptions about the" exact="influenza" post="in terms of the disease’s characteristics, its transmission, its"/>
   <result pre="its transmission, its severity, and its prevention. Personal susceptibility to" exact="influenza" post="(2) Within this theme, participants describe how susceptible they"/>
   <result pre="participants describe how susceptible they perceive to be toward the" exact="influenza" post="disease Perceptions about the influenza vaccine Familiarity with the"/>
   <result pre="perceive to be toward the influenza disease Perceptions about the" exact="influenza" post="vaccine Familiarity with the influenza vaccine (19) This theme"/>
   <result pre="influenza disease Perceptions about the influenza vaccine Familiarity with the" exact="influenza" post="vaccine (19) This theme covers how well participants know"/>
   <result pre="(19) This theme covers how well participants know about the" exact="influenza" post="vaccine and its symptoms. Participants also describe their information"/>
   <result pre="symptoms. Participants also describe their information source. Misperceptions about the" exact="influenza" post="vaccine (14) This theme includes participants’ misperceptions about the"/>
   <result pre="influenza vaccine (14) This theme includes participants’ misperceptions about the" exact="influenza" post="in terms of the vaccine’s characteristics, its risks, and"/>
   <result pre="the vaccine’s characteristics, its risks, and its costs. Misperceptions about" exact="influenza" post="vaccine usage (13) This theme includes participants’ misperceptions about"/>
   <result pre="vaccine usage (13) This theme includes participants’ misperceptions about the" exact="influenza" post="vaccine in terms of its usage. Here, participants share"/>
   <result pre="times when to get vaccinated. Opinions about and barriers to" exact="influenza" post="vaccine uptake (12) Under this theme participants shared their"/>
   <result pre="(12) Under this theme participants shared their opinions on the" exact="influenza" post="vaccine and what barriers hinder them from taking the"/>
   <result pre="influenza vaccine and what barriers hinder them from taking the" exact="influenza" post="vaccine up. Participants were generally found to hold significant"/>
   <result pre="Participants were generally found to hold significant misperceptions about the" exact="influenza" post="disease as well as the influenza vaccine. Most participants"/>
   <result pre="significant misperceptions about the influenza disease as well as the" exact="influenza" post="vaccine. Most participants regarded influenza as a non-serious illness."/>
   <result pre="disease as well as the influenza vaccine. Most participants regarded" exact="influenza" post="as a non-serious illness. Most participants also reported that"/>
   <result pre="reported that they have received little or no information about" exact="influenza" post="from healthcare providers, nor did they report having been"/>
   <result pre="76 participants, 27 participants (35.5%) indicated that they receive the" exact="influenza" post="vaccine annually. Modeling on the interview structure, we analyzed"/>
   <result pre="reported our major themes and findings below. Perceptions about the" exact="influenza" post="disease Familiarity with influenza Influenza was largely unfamiliar among"/>
   <result pre="and findings below. Perceptions about the influenza disease Familiarity with" exact="influenza" post="Influenza was largely unfamiliar among many participants with most"/>
   <result pre="sickness…influences the lungs. Probably some kind of flu… I think" exact="influenza" post="and flu are about the same family, quite the"/>
   <result pre="be passing flu, sometimes flu may come and go but" exact="influenza" post="may be more serious, I don’t know. I think"/>
   <result pre="think so, so I think.�? (Male, interview 5). Knowledge about" exact="influenza" post="among participants was therefore rudimentary and not comprehensive. Another"/>
   <result pre="point of confusion among participants was in their identification of" exact="influenza" post="as being different from the common cold. This was"/>
   <result pre="in their identification of influenza as being different from the" exact="common cold." post="This was illustrated by one participant who described influenza"/>
   <result pre="common cold. This was illustrated by one participant who described" exact="influenza" post="as manifesting in two forms—one that is less serious"/>
   <result pre="requires medical attention. Although less frequently reported among this sample," exact="influenza" post="was also confused with dengue fever. Among participants who"/>
   <result pre="frequently reported among this sample, influenza was also confused with" exact="dengue fever." post="Among participants who did report that they were familiar"/>
   <result pre="Singapore got SARS, nobody knows.�? (Female, interview 14). Misperceptions about" exact="influenza" post="While familiarity was low in general, the sample did"/>
   <result pre="provide many misperceptions about the disease which we divided into" exact="influenza" post="characteristics, transmission, severity, and prevention. Each of these aspects"/>
   <result pre="illustrates our participants’ level of knowledge about influenza. Misperceptions about" exact="influenza" post="characteristics. Influenza was not universally understood by participants and"/>
   <result pre="wholly inaccurate. Beyond the misunderstanding of disease terms, participants described" exact="influenza" post="as (a) a global epidemic, (b) a type of"/>
   <result pre="but end of the year…�? (Female, interview 26). Misperceptions about" exact="influenza" post="transmission. Most participants reported incorrect knowledge about transmission modes"/>
   <result pre="Most participants reported incorrect knowledge about transmission modes of the" exact="influenza" post="virus. Misperceptions about the source of influenza spread included"/>
   <result pre="modes of the influenza virus. Misperceptions about the source of" exact="influenza" post="spread included (a) foreign countries, (b) animals, (c) the"/>
   <result pre="(h) overexertion, and (i) toxins in the body. Misperceptions about" exact="influenza" post="severity. Understandings about the severity of influenza varied widely."/>
   <result pre="body. Misperceptions about influenza severity. Understandings about the severity of" exact="influenza" post="varied widely. 29 participants (38.2% of the sample) perceived"/>
   <result pre="influenza varied widely. 29 participants (38.2% of the sample) perceived" exact="influenza" post="to be serious and fatal providing insights including, &quot;If"/>
   <result pre="our former P[rime] M[inister] Mr. Lee Kuan Yew died of" exact="pneumonia" post="too�? (Male, interview 41). On the other end of"/>
   <result pre="of the spectrum, 26 participants (34.2% of the sample) regarded" exact="influenza" post="as a minor illness of little concern: &quot;The flu"/>
   <result pre="because I have allergies�? (Female, interview 28)). One participant saw" exact="influenza" post="as an epidemic-level occurrence rather than as a frequently"/>
   <result pre="and how widespread it is�? (Male, interview 23). Misperceptions about" exact="influenza" post="prevention. While some participants identified vaccination and avoiding symptomatic"/>
   <result pre="they engage in behaviors that are not likely to prevent" exact="influenza" post="transmission. In general, participants frequently reported a strong immune"/>
   <result pre="get it (influenza)�? (Male, interview 5). Many participants noted that" exact="influenza" post="could be prevented through general positive health activities like"/>
   <result pre="sleep, exercising, and having good hygiene practices. Personal susceptibility to" exact="influenza" post="Many participants considered themselves to be impervious to influenza"/>
   <result pre="to influenza Many participants considered themselves to be impervious to" exact="influenza" post="infection. Personal susceptibility was mainly thought to depend on"/>
   <result pre="avoiding (sick) people, or e) being happy. Perceptions about the" exact="influenza" post="vaccine Familiarity with the influenza vaccine Participants who had"/>
   <result pre="being happy. Perceptions about the influenza vaccine Familiarity with the" exact="influenza" post="vaccine Participants who had heard about the influenza vaccine"/>
   <result pre="with the influenza vaccine Participants who had heard about the" exact="influenza" post="vaccine (n = 35), cited sources of information included"/>
   <result pre="(51.4%). Some participants mentioned that they had heard about the" exact="influenza" post="vaccine from healthcare professionals but did not receive personal"/>
   <result pre="said that they received little or no information about the" exact="influenza" post="vaccine, and a minority reported having received recommendation to"/>
   <result pre="and a minority reported having received recommendation to avoid the" exact="influenza" post="vaccine from general practitioners and specialists (&quot;My doctor for"/>
   <result pre="influenza vaccine from general practitioners and specialists (&quot;My doctor for" exact="arthritis" post="say it’s not necessary. He says it’s better to"/>
   <result pre="and friends led to an exchange of information about the" exact="influenza" post="vaccine, barriers to vaccination, and personal recommendations to take"/>
   <result pre="last ones I told all my siblings [to get the" exact="influenza" post="vaccine]�? (Female, interview 11) and &quot;They do say they"/>
   <result pre="you know, go traveling�? (Female, interview 69). Misperceptions about the" exact="influenza" post="vaccine Participants’ vaccine perceptions were found to be broadly"/>
   <result pre="Participants’ vaccine perceptions were found to be broadly focused on" exact="influenza" post="vaccine characteristics, risks, and cost. Misperceptions about influenza vaccine"/>
   <result pre="focused on influenza vaccine characteristics, risks, and cost. Misperceptions about" exact="influenza" post="vaccine characteristics. The function of the influenza vaccine was"/>
   <result pre="cost. Misperceptions about influenza vaccine characteristics. The function of the" exact="influenza" post="vaccine was largely unfamiliar among participants. The influenza vaccine"/>
   <result pre="of the influenza vaccine was largely unfamiliar among participants. The" exact="influenza" post="vaccine was commonly misperceived as a travel vaccine only"/>
   <result pre="so much�? (Male, interview 65). Another participant reported that the" exact="influenza" post="vaccine &quot;protects against everything�? (Male, interview 23). This implies"/>
   <result pre="interview 23). This implies confusion about the function of the" exact="influenza" post="vaccine and perhaps vaccines in general—that vaccines are a"/>
   <result pre="also arose among some participants. Two participants reported that the" exact="influenza" post="vaccine contains germs or viruses from animals that would"/>
   <result pre="because [of the] good vitamins�? (Female, interview 33). Misperceptions about" exact="influenza" post="vaccine risks. Apart from safety concerns over vaccine content,"/>
   <result pre="safety concerns over vaccine content, participants reported misperceptions that the" exact="influenza" post="vaccine (a) weakens the body’s immune system, and (b)"/>
   <result pre="users. One participant was also apprehensive about taking the seasonal" exact="influenza" post="vaccine as it is newly formulated each year. As"/>
   <result pre="enough long-time research… too new�? (Male, interview 74). Misperceptions about" exact="influenza" post="vaccine cost. Perceived financial cost played a significant role"/>
   <result pre="played a significant role in participants’ intentions to get the" exact="influenza" post="vaccine. Few participants were aware of government support programs"/>
   <result pre="comes with the decision to vaccinate. The misperception that the" exact="influenza" post="vaccine is expensive was widely prevalent among participants: &quot;[Vaccination"/>
   <result pre="One injection [is] S$40… expensive�? (Male, interview 70). Misperceptions about" exact="influenza" post="vaccine usage Beyond misperceptions about the influenza vaccine, the"/>
   <result pre="70). Misperceptions about influenza vaccine usage Beyond misperceptions about the" exact="influenza" post="vaccine, the study explored participants’ opinion of who should"/>
   <result pre="the study explored participants’ opinion of who should take the" exact="influenza" post="vaccine and when it should be taken. Perceptions about"/>
   <result pre="when it should be taken. Perceptions about non-recommended users of" exact="influenza" post="vaccine. A healthy and active lifestyle was thought to"/>
   <result pre="active lifestyle was thought to be a preventive measure against" exact="influenza" post="to the extent that young, active individuals with strong"/>
   <result pre="vaccination: &quot;Strong people are strong so they don’t need [the" exact="influenza" post="vaccine]�? (Female, interview 20). Accordingly, a participant concluded: &quot;Only"/>
   <result pre="doesn’t need�? (Female, interview 4). Perceptions about recommended users of" exact="influenza" post="vaccine. Many groups were reported to be in-need of"/>
   <result pre="Many groups were reported to be in-need of vaccination against" exact="influenza" post="including (a) those who travel, (b) those who work"/>
   <result pre="States, and less-developed nations were listed as countries that require" exact="influenza" post="vaccination for travelers. Misperceptions about when to get influenza"/>
   <result pre="require influenza vaccination for travelers. Misperceptions about when to get" exact="influenza" post="vaccine. Many participants reported that the vaccine was not"/>
   <result pre="unless there is an urgent need. Maybe it’s a major" exact="influenza" post="crisis�? (Female, interview 34). Others noted that the vaccine"/>
   <result pre="intended for use as a treatment once an individual has" exact="influenza" post="symptoms: &quot;The vaccine prevents the influenza from getting worse,"/>
   <result pre="once an individual has influenza symptoms: &quot;The vaccine prevents the" exact="influenza" post="from getting worse, and for the flu to relapse�?"/>
   <result pre="of vaccines with antiviral drugs that are used for treating" exact="influenza" post="infections rather than as a preventive measure: &quot;Vaccines kill"/>
   <result pre="Disease Control and Prevention [42]. Opinions about and barriers to" exact="influenza" post="vaccine uptake Despite proven vaccine effectiveness against influenza infection,"/>
   <result pre="barriers to influenza vaccine uptake Despite proven vaccine effectiveness against" exact="influenza" post="infection, health officials face tangible and intangible challenges in"/>
   <result pre="tangible and intangible challenges in encouraging vaccine uptake. While the" exact="influenza" post="vaccine is one of the most affordable vaccines ranging"/>
   <result pre="effects and pain, (b) a lack of knowledge about the" exact="influenza" post="vaccine, (c) religious objections, and (d) a dislike for"/>
   <result pre="recommendations for older adults to regularly vaccinate against the seasonal" exact="influenza" post="epidemics. This study thus explored older adults’ influenza disease"/>
   <result pre="the seasonal influenza epidemics. This study thus explored older adults’" exact="influenza" post="disease and vaccine misperceptions with the aim of understanding"/>
   <result pre="contributing effects of misperceptions on Singaporean older adults’ hesitancy toward" exact="influenza" post="vaccination. We discuss possible reasons for these misperceptions and"/>
   <result pre="older adults’ health knowledge and ultimately their uptake of the" exact="influenza" post="vaccine. Perceptions about the influenza disease Participants’ misunderstanding of"/>
   <result pre="ultimately their uptake of the influenza vaccine. Perceptions about the" exact="influenza" post="disease Participants’ misunderstanding of disease terms (&quot;influenza�? versus &quot;flu�?)"/>
   <result pre="of disease terms (&quot;influenza�? versus &quot;flu�?) and the characteristics of" exact="influenza" post="demonstrate partial knowledge. Two participants noted the similarities of"/>
   <result pre="influenza demonstrate partial knowledge. Two participants noted the similarities of" exact="influenza" post="and cold symptoms but claimed that they have not"/>
   <result pre="However, previous studies noted that non-health professionals cannot clearly differentiate" exact="influenza" post="from the common cold [43]. Furthermore, in its precise"/>
   <result pre="noted that non-health professionals cannot clearly differentiate influenza from the" exact="common cold" post="[43]. Furthermore, in its precise definition, influenza is not"/>
   <result pre="from the common cold [43]. Furthermore, in its precise definition," exact="influenza" post="is not a &quot;sickness of the lungs�? but rather"/>
   <result pre="is not a &quot;sickness of the lungs�? but rather a" exact="respiratory disease" post="that leads to fever and can infect the lungs"/>
   <result pre="the lungs which may also lead to the development of" exact="pneumonia" post="for at-risk individuals. Participants generally have some rudimentary knowledge"/>
   <result pre="conflate symptoms with other diseases. The inability to correctly recognize" exact="influenza" post="may encourage incorrect prevention and treatment practices among older"/>
   <result pre="and treatment practices among older adults. Further misperceptions about how" exact="influenza" post="spreads and how it can be prevented pose significant"/>
   <result pre="practices to stop the spread of influenza. Therefore, misperceptions about" exact="influenza" post="may inadvertently be putting this group at further risk"/>
   <result pre="to ancillary diseases and accidents and warrant future engagement regarding" exact="influenza" post="transmission and prevention. Perceptions of good health status and"/>
   <result pre="health status and personal immunity as reasons for an individual’s" exact="influenza" post="infection were prevalent among participants. These misperceptions are consonant"/>
   <result pre="with Sundaram et al.’s [27] findings that healthcare workers perceived" exact="influenza" post="&quot;as a routine illness causing temporary inconvenience but no"/>
   <result pre="indicates that more communication about the non-relationship between immunity and" exact="influenza" post="infection is needed to redress the misperceptions among older"/>
   <result pre="older adults’ susceptibility and likelihood of developing health complications from" exact="influenza" post="to counter this barrier to vaccination. Further aspects should"/>
   <result pre="improve health knowledge. While their recommendation was oriented toward older" exact="cancer" post="patients, this advice is not any less useful for"/>
   <result pre="older adults now that this group’s primary misperceptions about the" exact="influenza" post="disease have been systematically identified in this study. Perceptions"/>
   <result pre="have been systematically identified in this study. Perceptions about the" exact="influenza" post="vaccine Our participants also held various misperceptions about the"/>
   <result pre="influenza vaccine Our participants also held various misperceptions about the" exact="influenza" post="vaccine. Of which, the most common misperception is that"/>
   <result pre="vaccine. Of which, the most common misperception is that the" exact="influenza" post="vaccine functions as a travel vaccine. Singapore has an"/>
   <result pre="contribute to a perpetuated misperception that vaccines including those against" exact="influenza" post="should be taken only before traveling and not as"/>
   <result pre="role in shaping perceptions. Therefore, beyond the recommendation that the" exact="influenza" post="vaccine should be taken before traveling, vaccination as a"/>
   <result pre="and prevent future epidemics. We noted participants’ confusion of the" exact="influenza" post="vaccine with antiviral drugs that are taken to treat"/>
   <result pre="influenza vaccine with antiviral drugs that are taken to treat" exact="influenza" post="infections. This further signifies poor vaccine knowledge among older"/>
   <result pre="knowledge has been recognized as one of the barriers to" exact="influenza" post="vaccination [51]. Our study adds that confusion between the"/>
   <result pre="measure. Participants raised further concerns over the safety of the" exact="influenza" post="vaccine with regards to its content and periodic manufacturing."/>
   <result pre="explanations are necessary to instill knowledge about the mutability of" exact="influenza" post="viruses and the need for vaccine manufacturers to produce"/>
   <result pre="new vaccines every year to protect users from circulating mutated" exact="influenza" post="strains. Misperceptions about the influenza vaccine are suggested to"/>
   <result pre="protect users from circulating mutated influenza strains. Misperceptions about the" exact="influenza" post="vaccine are suggested to be exacerbated by inadequate communication"/>
   <result pre="about the vaccine. Participants who reported having heard about the" exact="influenza" post="vaccine cited doctors as their primary source for vaccine"/>
   <result pre="these individuals have been informed by healthcare professionals about the" exact="influenza" post="vaccine, the message simply is not getting through satisfactorily."/>
   <result pre="and ensure that older adults have access and attend to" exact="influenza" post="vaccine communication from their healthcare providers. Older patients tend"/>
   <result pre="instructions and materials that outline the known risk-benefit relationships between" exact="influenza" post="vaccination and disease prevention. Many misperceptions may be corrected"/>
   <result pre="identify a typology of its older adults’ misperceptions about the" exact="influenza" post="disease and its vaccine. Our findings provide public health"/>
   <result pre="professionals may be better informed of older adults’ concerns about" exact="influenza" post="vaccination and in turn be able to refine their"/>
   <result pre="like Singapore, issues of access to preventive healthcare like the" exact="influenza" post="vaccine are minor—older adults can easily obtain and afford"/>
   <result pre="vaccine are minor—older adults can easily obtain and afford the" exact="influenza" post="vaccine. What remains is a deficiency of public awareness,"/>
   <result pre="and execution in proactive health behaviors including taking the seasonal" exact="influenza" post="vaccine. Reinvigorated efforts of targeted health communication can bridge"/>
   <result pre="http://eresources.nlb.gov.sg/history/events/187adc0f-841a-49cb-86e8-86734b65691a#8 11CutterJL, AngLW, LaiFY, SubramonyH, MaS, JamesL. Outbreak of pandemic" exact="influenza" post="A (H1N1-2009) in Singapore, May to September 2009. Annals"/>
   <result pre="https://www.straitstimes.com/singapore/getting-adults-to-go-for-vaccinations 15CanningHS, PhillipsJ, Stephen AllsupMD. Health care worker beliefs about" exact="influenza" post="vaccine and reasons for non�?vaccination–a cross�?sectional survey. Journal of"/>
   <result pre="Centers for Disease Control and Prevention. Prevention and control of" exact="influenza" post="with vaccines: Recommendations of the Advisory Committee on Immunization"/>
   <result pre="from: https://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf 22LangPO, MendesA, SocquetJ, AssirN, GovindS, AspinallR. Effectiveness of" exact="influenza" post="vaccine in aging and older adults: comprehensive analysis of"/>
   <result pre="ThoonKC, SidhartaS, VenkatachalamI, et al.&quot;I wouldn’t really believe statistics�?–Challenges with" exact="influenza" post="vaccine acceptance among healthcare workers in Singapore. Vaccine. 201845;36(15):1996–2004."/>
   <result pre="factors involved in older people's decision making with regard to" exact="influenza" post="vaccination: a literature review. Journal of Clinical Nursing. 20081;17(1):5–16."/>
   <result pre="al.Attitudes, believes, determinants and organisational barriers behind the low seasonal" exact="influenza" post="vaccination uptake in healthcare workers–a cross-sectional survey. Vaccine. 2018531;36(23):3351–8."/>
   <result pre="SuhKN, et al.Qualitative motivators and barriers to pandemic vs. seasonal" exact="influenza" post="vaccination among healthcare workers: a content analysis. Vaccine. 20141212;32(52):7128–34."/>
   <result pre="Journal of Communication. 200681;56(suppl_1):S184–201. 10.1111/j.1420-2466.2006.00289.x 49SparksL, NussbaumJF. Health literacy and" exact="cancer" post="communication with older adults. Patient Education and Counseling. 200861;71(3):345–50."/>
   <result pre="Counseling. 200861;71(3):345–50. 10.1016/j.pec.2008.02.00718374536 50SchmidP, RauberD, BetschC, LidoltG, DenkerML. Barriers of" exact="influenza" post="vaccination intention and behavior–a systematic review of influenza vaccine"/>
   <result pre="Barriers of influenza vaccination intention and behavior–a systematic review of" exact="influenza" post="vaccine hesitancy, 2005–2016. PloS one. 2017126;12(1):e017055010.1371/journal.pone.017055028125629 51MacDonaldNE. Vaccine hesitancy:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7203554\results\search\disease\results.xml">
   <result pre="functional ASMase. IAV infection in A549 cells was associated with" exact="suppression" post="of ASMase activity starting at 6 h post-infection. Our"/>
   <result pre="metabolism can be a potential target for therapeutic intervention against" exact="influenza" post="virus infection. influenza virus lipid rafts sphingomyelin acid sphingomyelinase"/>
   <result pre="a potential target for therapeutic intervention against influenza virus infection." exact="influenza" post="virus lipid rafts sphingomyelin acid sphingomyelinase viral envelope plasma"/>
   <result pre="al., 2018). Recent studies showed that respiratory infections-associated with seasonal" exact="influenza" post="viruses are responsible for 290,000 to 650,000 deaths per"/>
   <result pre="al., 2009; Zheng and Tao, 2013). During its infectious cycle," exact="influenza" post="A virus (IAV) has to cross the plasma membrane"/>
   <result pre="cycle. Sphingosine-1-phosphate- (S1P) metabolizing enzymes have been shown to modulate" exact="influenza" post="infection in vitro and in vivo (Seo et al.,"/>
   <result pre="is critical during infection by controlling the successful trafficking of" exact="influenza" post="virus to the late endosome and its subsequent fusion"/>
   <result pre="a promising host target for developing novel therapeutic approaches against" exact="influenza" post="infection. Sphingomyelin (SM) is the most abundant membrane sphingolipid."/>
   <result pre="during entry into host cells (Pastenkos et al., 2018). Japanese" exact="encephalitis" post="virus attachment and entry into target cells was shown"/>
   <result pre="the SM biosynthetic pathway is important for the transport of" exact="influenza" post="virus glycoproteins to lipid rafts located at the apical"/>
   <result pre="and Emerging Infections Research Resources Repository (BEI Resources), human alveolar" exact="lung carcinoma" post="(A549) were obtained from ATCC (Manassas, VA, United States),"/>
   <result pre="the cells were left unpermeabilized. However, to visualize the internalized" exact="influenza" post="virus particles, the cells were permeabilized using 0.2% Triton"/>
   <result pre="6 and 24 hpi (Figure 1D). To verify whether the" exact="suppression" post="in virus infection by SM depletion is specific for"/>
   <result pre="that require SM during infection such as Ebola virus, Japanese" exact="encephalitis" post="virus, Rubella virus, and porcine alphaherpesvirus (Miller et al.,"/>
   <result pre="al., 2018). It was previously demonstrated that HA-mediated fusion of" exact="influenza" post="virus depends on the lipid composition of the host"/>
   <result pre="viruses. For example, depletion of SM from the envelope of" exact="hepatitis" post="C virus and bovine herpesvirus-1 impaired their infectivity (Aizaki"/>
   <result pre="Supporting the latter hypothesis, bSMase treatment was shown to abolish" exact="rubella" post="virus E1/E2-mediated membrane fusion (Otsuki et al., 2018). In"/>
   <result pre="al. (2008). Critical role of virion-associated cholesterol and sphingolipid in" exact="hepatitis" post="C virus infection.J. Virol.825715–5724. 10.1128/JVI.02530-0718367533 ChernomordikL. V.LeikinaE.FrolovV.BronkP.ZimmerbergJ. (1997). An"/>
   <result pre="of membrane fusion mediated by the low ph conformation of" exact="influenza" post="hemagglutinin depends upon membrane lipids.J. Cell Biol.13681–93. 10.1083/jcb.136.1.819008705 ColomaR.ValpuestaJ."/>
   <result pre="ColomaR.ValpuestaJ. M.ArranzR.CarrascosaJ. L.OrtínJ.Martín-BenitoJ. (2009). The structure of a biologically active" exact="influenza" post="virus ribonucleoprotein complex.PLoS Pathog.5:e1000491. 10.1371/journal.ppat.100049119557158 Di TraniL.SavarinoA.CampitelliL.NorelliS.PuzelliS.D’OstilioD.et al. (2007)."/>
   <result pre="associated with divergent inhibitory effects of chloroquine on human and" exact="avian influenza" post="A viruses.Virol. J.4:39. 10.1186/1743-422X-4-3917477867 DrakeM. J.BrennanB.BrileyK.BartS. M.ShermanE.SzemielA. M.et al."/>
   <result pre="with divergent inhibitory effects of chloroquine on human and avian" exact="influenza" post="A viruses.Virol. J.4:39. 10.1186/1743-422X-4-3917477867 DrakeM. J.BrennanB.BrileyK.BartS. M.ShermanE.SzemielA. M.et al."/>
   <result pre="(2017). A role for glycolipid biosynthesis in severe fever with" exact="thrombocytopenia" post="syndrome virus entry.PLoS Pathog.13:e1006316. 10.1371/journal.ppat.100631628388693 DrewsK.CalgiM. P.HarrisonW. C.DrewsC. M.Costa-PinheiroP.ShawJ."/>
   <result pre="DrewsK.CalgiM. P.HarrisonW. C.DrewsC. M.Costa-PinheiroP.ShawJ. J. P.et al. (2019). Glucosylceramidase maintains" exact="influenza" post="virus infection by regulating endocytosis.J. Virol.93:e00017-19. 10.1128/JVI.00017-1930918081 EdingerT. O.PohlM."/>
   <result pre="regulating endocytosis.J. Virol.93:e00017-19. 10.1128/JVI.00017-1930918081 EdingerT. O.PohlM. O.StertzS. (2014). Entry of" exact="influenza" post="A virus: host factors and antiviral targets.J. Gen. Virol.95263–277."/>
   <result pre="(2010). The epidermal growth factor receptor (EGFR) promotes uptake of" exact="influenza" post="A viruses (IAV) into host cells.PLoS Pathog.6:e1001099. 10.1371/journal.ppat.100109920844577 GoñiF."/>
   <result pre="HeM.GuoS.RenJ.LiZ. (2016). In situ characterizing membrane lipid phenotype of human" exact="lung cancer" post="cell lines using mass spectrometry profiling.J. Cancer7810–816. 10.7150/jca.1431027162539 HidariK."/>
   <result pre="(2016). In situ characterizing membrane lipid phenotype of human lung" exact="cancer" post="cell lines using mass spectrometry profiling.J. Cancer7810–816. 10.7150/jca.1431027162539 HidariK."/>
   <result pre="cellular sphingolipids results in the inhibition of the maturation of" exact="influenza" post="virus particles in MDCK cells.Biol. Pharm. Bull.291575–1579. 10.1248/bpb.29.157516880607 HsiehC.-F.ChenY.-L.LinC.-F.HoJ.-Y.HuangC.-H.ChiuC.-H.et"/>
   <result pre="extract from Taxodium distichum targets hemagglutinin- and neuraminidase-related activities of" exact="influenza" post="virus in vitro.Sci. Rep.6:36015. 10.1038/srep3601527796330 HuangH.TongT.-T.YauL.-F.ChenC.-Y.MiJ.-N.WangJ.-R.et al. (2018). LC-MS"/>
   <result pre="strain.BMC Cancer18:799. 10.1186/s12885-018-4714-x30089463 HuprikarJ.RabinowitzS. (1980). A simplified plaque assay for" exact="influenza" post="viruses in Madin-Darby kidney (MDCK) cells.J. Virol. Methods1117–120. 10.1016/0166-0934(80)90020-87228969"/>
   <result pre="Chem. Hoppe Seyler375447–450. 10.1515/bchm3.1994.375.7.4477945993 KillianM. L. (2014). &quot;Hemagglutination assay for" exact="influenza" post="virus,�? in Animal Influenza Virus Methods in Molecular Biology,"/>
   <result pre="NY: Springer), 3–9. 10.1007/978-1-4939-0758-8_1 KlumppK.RuigrokR. W.BaudinF. (1997). Roles of the" exact="influenza" post="virus polymerase and nucleoprotein in forming a functional RNP"/>
   <result pre="LeeV. J.HoZ. J. M.GohE. H.CampbellH.CohenC.CozzaV.et al. (2018). Advances in measuring" exact="influenza" post="burden of disease.Influenza Other Respir. Viruses123–9. 10.1111/irv.1253329460425 LeserG. P.LambR."/>
   <result pre="membrane.J. Biol. Chem.2742038–2044. 10.1074/jbc.274.4.20389890962 SeoY.-J.BlakeC.AlexanderS.HahmB. (2010). Sphingosine 1-phosphate-metabolizing enzymes control" exact="influenza" post="virus propagation and viral cytopathogenicity.J. Virol.848124–8131. 10.1128/JVI.00510-1020519401 SeoY.-J.PritzlC. J.VijayanM.BombK.McClainM."/>
   <result pre="RNA synthesis and nuclear export of viral ribonucleoprotein complex upon" exact="influenza" post="virus infection.PLoS One8:e0075005. 10.1371/journal.pone.007500524137500 ShivannaV.KimY.ChangK.-O. (2015). Ceramide formation mediated"/>
   <result pre="exposure to sphingomyelinase.Biochim. Biophys. Acta1030251–257. 10.1016/0005-2736(90)90301-42261487 SoudaniN.Hage-SleimanR.KaramW.DbaiboG.ZaraketH. (2019). Ceramide suppresses" exact="influenza" post="a virus replication in vitro.J. Virol.93:e00053-19. 10.1128/JVI.00053-1930700605 SteinhartW. L.BuschJ."/>
   <result pre="L. (1984). Sphingolipid metabolism during infection of human fibroblasts by" exact="herpes simplex" post="virus type 1.Intervirology2170–76. 10.1159/0001495046321394 SteinhauerD. A.WhartonS. A.SkehelJ. J.WileyD. C.HayA."/>
   <result pre="A.SkehelJ. J.WileyD. C.HayA. J. (1991). Amantadine selection of a mutant" exact="influenza" post="virus containing an acid-stable hemagglutinin glycoprotein: evidence for virus-specific"/>
   <result pre="Intact sphingomyelin biosynthetic pathway is essential for intracellular transport of" exact="influenza" post="virus glycoproteins.Proc. Natl. Acad. Sci. U.S.A.1106406–6411. 10.1073/pnas.121990911023576732 TakedaM.LeserG. P.RussellC."/>
   <result pre="synthase 1 is involved in attachment and infection with Japanese" exact="encephalitis" post="virus.Sci. Rep.6:37829. 10.1038/srep3782927892528 TannerL. B.ChngC.GuanX. L.LeiZ.RozenS. G.WenkM. R. (2014)."/>
   <result pre="R. (2014). Lipidomics identifies a requirement for peroxisomal function during" exact="influenza" post="virus replication.J. Lipid Res.551357–1365. 10.1194/jlr.M04914824868094 VermaD. K.GuptaD.LalS. K. (2018)."/>
   <result pre="rafts play a major role in binding and endocytosis of" exact="influenza" post="a virus.Viruses10:650. 10.3390/v1011065030453689 VijayanM.HahmB. (2014). Influenza viral manipulation of"/>
   <result pre="system.Scientifica2014:793815. 10.1155/2014/79381524672735 WangC.TakeuchiK.PintoL. H.LambR. A. (1993). Ion channel activity of" exact="influenza" post="A virus M2 protein: characterization of the amantadine block.J."/>
   <result pre="the amantadine block.J. Virol.675585–5594. 10.1128/jvi.67.9.5585-5594.19937688826 WengL.HirataY.AraiM.KoharaM.WakitaT.WatashiK.et al. (2010). Sphingomyelin activates" exact="hepatitis" post="C virus RNA polymerase in a genotype-specific manner.J. Virol.8411761–11770."/>
   <result pre="J.HahmB. (2018). Transient inhibition of sphingosine kinases confers protection to" exact="influenza" post="A virus infected mice.Antiviral Res.158171–177. 10.1016/j.antiviral.2018.08.01030125617 YagerE. J.KonanK. V."/>
   <result pre="Biomembr.1788178–183. 10.1016/j.bbamem.2008.07.03018786504 ZhengW.TaoY. J. (2013). Structure and assembly of the" exact="influenza" post="A virus ribonucleoprotein complex.FEBS Lett.5871206–1214. 10.1016/j.febslet.2013.02.04823499938"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7206557\results\search\disease\results.xml">
   <result pre="framings of disease, such as those of war or a" exact="plague" post="in the case of Ebola (Vellek, 2016). Vellek’s (2016)"/>
   <result pre="have shown, UK newspapers avoided war metaphors in reports on" exact="severe acute respiratory syndrome" post="(SARS), an emerging infectious disease (EID), just like Ebola."/>
   <result pre="in reports on severe acute respiratory syndrome (SARS), an emerging" exact="infectious disease" post="(EID), just like Ebola. Even though war images add"/>
   <result pre="is capable of dealing with and containing Ebola if the" exact="viral disease" post="reaches our shores. This was the assurance from government"/>
   <result pre="study even subsumes notions of a ‘killer’ alongside war and" exact="plague" post="metaphors, rather than considering the killer from within a"/>
   <result pre="G.ValenciaJ. (2017). Understanding an Ebola outbreak: Social representations of emerging" exact="infectious disease." post="Journal of Health Psychology, 27, 951–960. collab: Nature’s assailants."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7207162\results\search\disease\results.xml">
   <result pre="Inc.Hoboken pmcid: 7207162 doi: 10.15252/emmm.201910938EMMM201910938 : Article: Articles Adeno�?associated virus�?vectored" exact="influenza" post="vaccine elicits neutralizing and Fcγ receptor�?activating antibodies Daniel E"/>
   <result pre="work is properly cited.file:EMMM-12-e10938.pdf Abstract Abstract The current seasonal inactivated" exact="influenza" post="vaccine protects only against a narrow range of virus"/>
   <result pre="discovery of rare broadly protective antibodies against conserved regions in" exact="influenza" post="virus proteins has propelled research on distinct antigens and"/>
   <result pre="strains. Here, we report that adeno�?associated virus (AAV) vectors expressing" exact="influenza" post="virus HA or chimeric HA protected mice against homologous"/>
   <result pre="a rationale for further clinical development of AAV vectors as" exact="influenza" post="vaccine platform, which could benefit from their approved use"/>
   <result pre="that immunization with adeno�?associated virus vectors protects against divergent lethal" exact="influenza" post="A virus infections. Protection correlated with induction of antibodies"/>
   <result pre="adeno�?associated virus vector broadly reactive antibody FcγR HA stalk universal" exact="influenza" post="vaccine Subject Categories Immunology Microbiology, Virology &amp;amp; Host Pathogen"/>
   <result pre="also: https://doi.org/10.15252/emmm.202012059 (May 2020) The paper explained Problem Current seasonal" exact="influenza" post="vaccines show low effectiveness and protection is limited to"/>
   <result pre="within the vaccine. High morbidity and mortality caused by seasonal" exact="influenza" post="and the risk of emergence of pandemic and/or zoonotic"/>
   <result pre="broadly reactive vaccine. Results AAV vectors were used to deliver" exact="influenza" post="antigens to the lung of mice and ferrets to"/>
   <result pre="the AAV vectors are promising carriers for a broadly reactive" exact="influenza" post="vaccine. The vectored expression of the antigen was shown"/>
   <result pre="immune response toward more conserved broadly reactive epitopes within the" exact="influenza" post="virus antigens and to induce high levels of FcγR�?activating"/>
   <result pre="individuals, and has thus considerable socio�?economic impact (WHO, 2018b). Currently," exact="influenza" post="A viruses of the subtypes H1N1 and H3N2 as"/>
   <result pre="of the subtypes H1N1 and H3N2 as well as the" exact="influenza" post="B virus lineages Victoria and Yamagata circulate in humans."/>
   <result pre="surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Moreover, reassortment between" exact="influenza" post="A virus subtypes can generate even larger antigenic alterations,"/>
   <result pre="of deaths worldwide (Johnson &amp;amp; Mueller, 2002). The most recent" exact="influenza" post="pandemic was triggered by a related H1N1 virus in"/>
   <result pre="public health (Fineberg, 2014). Currently, the most effective prophylaxis against" exact="influenza" post="is immunization with trivalent or quadrivalent influenza vaccines, most"/>
   <result pre="effective prophylaxis against influenza is immunization with trivalent or quadrivalent" exact="influenza" post="vaccines, most of which contain inactivated antigenic components of"/>
   <result pre="most of which contain inactivated antigenic components of current seasonal" exact="influenza" post="A and B viruses. However, protection is mainly virus"/>
   <result pre="strains is generally poor. Although a more broadly reactive live�?attenuated" exact="influenza" post="vaccine (LAIV) is available for children, its usefulness is"/>
   <result pre="limited in adults due to pre�?existing immunity against previously encountered" exact="influenza" post="viruses (Belshe et al, 2000). The majority of vaccine"/>
   <result pre="vaccine mismatch and loss of effectiveness if the actually circulating" exact="influenza" post="viruses represent drift variants of the vaccine strains (Rondy"/>
   <result pre="variants of the vaccine strains (Rondy et al, 2017). Seasonal" exact="influenza" post="vaccination also does not provide protection against shifted or"/>
   <result pre="also does not provide protection against shifted or emerging zoonotic" exact="influenza" post="A virus strains, e.g., H5N1 or H7N9, which can"/>
   <result pre="cellular cytotoxicity (ADCC) (DiLillo et al, 2014). Vaccination with inactivated" exact="influenza" post="antigen alone is not able to efficiently induce ADCC�?activating"/>
   <result pre="However, adeno�?associated virus (AAV) vectors might be particularly suited as" exact="influenza" post="vaccine carrier, since AAV is naturally replication�?incompetent and apathogenic"/>
   <result pre="expressing internal (nucleoprotein (NP), matrix protein 1) and surface (HA)" exact="influenza" post="virus antigens protected mice from challenge infection (Xin et"/>
   <result pre="neutralizing antibodies against heterologous HA, the protection against a non�?matched" exact="influenza" post="virus observed in that study was attributed to the"/>
   <result pre="to the ferret model, thought to most accurately represent human" exact="influenza" post="disease (Enkirch &amp;amp; von Messling, 2015). A detailed knowledge"/>
   <result pre="in vitro We evaluated the potency of AAV vectors expressing" exact="influenza" post="virus wild�?type HA and NP, or cHA and headless"/>
   <result pre="cHA and headless HA antigens to confer broad protection from" exact="influenza" post="virus challenge in comparison with an inactivated vaccine (Fig"/>
   <result pre="constructs were based on proteins encoded by the prototypic pandemic" exact="influenza" post="virus A/California/7/2009 (H1N1)pdm (Cal/7/9) (Fig 1B). The cHA contained"/>
   <result pre="the stalk region of Cal/7/9 and head regions derived from" exact="influenza" post="A virus subtypes H2 (cHA1), H10 (cHA2), or H13"/>
   <result pre="were detected by immune sera raised against the respective parental" exact="influenza" post="virus HA subtype, i.e., H2, H10, or H13, indicating"/>
   <result pre="nostrils three times in 3�?week intervals before being challenged with" exact="influenza" post="viruses. Control groups received either three times AAV�?GFP or"/>
   <result pre="samples were taken at indicated time points (red drops). After" exact="influenza" post="challenge, mice were monitored for survival and weight loss"/>
   <result pre="of serum antibodies was tested against a panel of ten" exact="influenza" post="viruses from both antigenic group 1 (H1N1, H2N3, H5N1,"/>
   <result pre="AAV�?NP and WIV immunization led to antibody responses reacting with" exact="influenza" post="A viruses from both antigenic groups. Broadly reactive HA�?specific"/>
   <result pre="four different H1N1 viruses spanning more than 90 years of" exact="influenza" post="virus evolution (Fig EV2A). HA1 contains the head region,"/>
   <result pre="against all viral proteins. MDCKII cells were either infected with" exact="influenza" post="virus before pre�?challenge sera and FcγR�?reporter cells were added."/>
   <result pre="cell, which is quantified by anti�?IL�?2 ELISA. BCorrelation between total" exact="influenza" post="IgG ELISA titers and FcγR�?activating antibody titers against PR8"/>
   <result pre="WIV and then challenged with a lethal dose of homologous" exact="influenza" post="virus (Cal/7/9) (A, B; n = 5) or two"/>
   <result pre="of WIV in reducing mortality and disease severity against heterologous" exact="influenza" post="challenge in mice. AAV�?vectored vaccines reduce disease severity in"/>
   <result pre="ferrets, as they most closely reproduce the course of human" exact="influenza" post="(Enkirch &amp;amp; von Messling, 2015). While focusing on HA�?based"/>
   <result pre="one group was given two doses of the commercial quadrivalent" exact="influenza" post="vaccine (QIV) of season 2017/18 by the intramuscular route."/>
   <result pre="(WHO, 2018c). All animals except for the AAV�?GFP group developed" exact="influenza" post="virus�?specific antibodies (Fig 6B). However, a statistically significant continuous"/>
   <result pre="(H) with an anti�?H1N1 polyclonal antibody (bar: 100 μm; red:" exact="influenza" post="antigen (Neufuchsin); blue: nuclei (hematoxylin)). I, JH&amp;amp;E�?stained histological sections"/>
   <result pre="the linear regression curve. F, GScoring of IHC staining of" exact="influenza" post="A virus antigen expression in submucosal glands (SMG) or"/>
   <result pre="al, 2012). During the 3�?day challenge period, clinical signs of" exact="influenza" post="were monitored, and weight and temperature were measured. At"/>
   <result pre="histopathological examination (Fig 6A). All animals developed classical signs of" exact="influenza" post="disease starting on day 1, including serous nasal exudate,"/>
   <result pre="titers in the nasal turbinates (Fig EV5E). Immunohistochemical staining detected" exact="influenza" post="virus antigen in the lungs of all animals yet"/>
   <result pre="6G and H). Also, all ferrets developed signs of an" exact="influenza" post="virus�?induced bronchio�?interstitial pneumonia, although at varying degrees. Damage of"/>
   <result pre="AAV�?HA and AAV�?cHA immunization reduced the disease severity after homologous" exact="influenza" post="virus infection in ferrets. However, only with AAV�?HA this"/>
   <result pre="important element on the quest for a universal and long�?lasting" exact="influenza" post="vaccine (Erbelding et al, 2018; Ortiz et al, 2018)."/>
   <result pre="2018). Commonly used viral vectors have proven their efficacy as" exact="influenza" post="vaccine carriers in multiple studies (de Vries &amp;amp; Rimmelzwaan,"/>
   <result pre="immune response to HA within the same antigenic group of" exact="influenza" post="A viruses (Krammer et al, 2013; Margine et al,"/>
   <result pre="immunization induced a remarkably broad antibody response covering all tested" exact="influenza" post="viruses and capable to activate FcγR, despite the fact"/>
   <result pre="to a study where vaccination with different cHA expressed by" exact="influenza" post="B�?, VSV�?, or AdV vectors reduced viral titers (Krammer"/>
   <result pre="memory, or to boost and maintain such a response in" exact="influenza" post="experienced individuals (Andrews et al, 2015). In conclusion, the"/>
   <result pre="of AAV vectors into a carrier for a broadly protective" exact="influenza" post="vaccine. Materials and Methods AAV vector design and production"/>
   <result pre="of the head regions, i.e., regions cysteine52–cysteine277, derived from of" exact="avian influenza" post="A viruses of the subtypes H2, H10, or H13"/>
   <result pre="the head regions, i.e., regions cysteine52–cysteine277, derived from of avian" exact="influenza" post="A viruses of the subtypes H2, H10, or H13"/>
   <result pre="amounts of AAV vector genomes per microliter. Cell lines and" exact="influenza" post="viruses 293T were maintained in DMEM, and MDCKII cells"/>
   <result pre="unit 17 and tested negative for mycoplasma contamination. Infections with" exact="influenza" post="viruses were performed in cell culture medium with 0.2%"/>
   <result pre="M145; TaKaRa, Kusatsu, Japan) antibody, rabbit hyperimmune serum against the" exact="influenza" post="subtypes H2, H10, and H13 (1:500; 11688�?RP01�?100, 11693�?RP01�?100, 11721�?RP01�?100"/>
   <result pre="GAPDH antibody (1:1,000) staining. 4–8 μg per lane of sucrose�?purified" exact="influenza" post="viruses was separated on SDS–PAGE under denaturing conditions and"/>
   <result pre="plates (Thermo Fischer Scientific) were coated with 4–8 μg/ml purified" exact="influenza" post="virus or approximately 1 × 1010 vg/ml AAV9 empty"/>
   <result pre="plates (Thermo Fischer Scientific) were coated with 4–8 μg/ml purified" exact="influenza" post="virus in 50 μl carbonate/bicarbonate buffer (pH = 9.6)"/>
   <result pre="2015) with the exception that 3.5 × 104 PFU of" exact="influenza" post="virus was used per 96 well to examine mouse"/>
   <result pre="102 PFU per 96 well for ferret sera. Detection of" exact="influenza" post="antigen was done with anti�?influenza A polyclonal antibody (1:1,000;"/>
   <result pre="were dilutions of 1:100 (for AAV MN), 1:40 (for mouse" exact="influenza" post="MN), and 1:10 (for ferret influenza MN), respectively. Hemagglutinin"/>
   <result pre="MN), 1:40 (for mouse influenza MN), and 1:10 (for ferret" exact="influenza" post="MN), respectively. Hemagglutinin inhibition (HAI) Animal sera were inactivated"/>
   <result pre="μl per 96�?well. Four HAU per 25 μl PBS of" exact="influenza" post="virus were added to each well, and samples were"/>
   <result pre="normalized to negative control serum (AAV�?GFP). FcγR assay To display" exact="influenza" post="virus surface antigens on MDCKII cells, cells were seeded"/>
   <result pre="cells were seeded into 96�?well plates and either infected with" exact="influenza" post="virus (3.5 × 103 PFU per well) or transfected"/>
   <result pre="a single AAV�?GFP�?immunized animal, which survived without weight loss, remained" exact="influenza" post="virus seronegative, indicating that the inoculum was not taken"/>
   <result pre="of the Paul�?Ehrlich�?Institute (Langen, Germany) and tested seronegative for circulating" exact="influenza" post="viruses prior to the experiment. Ferrets were anesthetized by"/>
   <result pre="4�?week intervals. One human dose per ferret of quadrivalent inactivated" exact="influenza" post="vaccine of season 2017/18 containing 15 μg HA per"/>
   <result pre="of pathologic lesions using lung�?specific inflammation score parameters for quantifying" exact="influenza" post="virus�?induced pneumonia as described (Dietert et al, 2017). These"/>
   <result pre="lesions using lung�?specific inflammation score parameters for quantifying influenza virus�?induced" exact="pneumonia" post="as described (Dietert et al, 2017). These parameters included"/>
   <result pre="et al, 2017). These parameters included severity of (i) interstitial" exact="pneumonia" post="with infiltration by macrophages, lymphocytes, neutrophils (ii) bronchitis, (iii)"/>
   <result pre="(v) hyperplasia of type II pneumocytes. For immunohistochemical detection of" exact="influenza" post="A virus, heat�?mediated antigen retrieval was performed in 10"/>
   <result pre="for 12 min. Lung sections were incubated with a polyclonal" exact="influenza" post="A H1N1 antibody (1:250; 5315�?0064, AbD Serotec, Puchheim, Germany)"/>
   <result pre="for histopathological and immunohistochemical analysis. Neither one of the above�?mentioned" exact="influenza" post="infection�?specific parameter nor influenza virus antigen could be detected"/>
   <result pre="analysis. Neither one of the above�?mentioned influenza infection�?specific parameter nor" exact="influenza" post="virus antigen could be detected in these control samples."/>
   <result pre="airway expression of antibody protects old and immunodeficient mice against" exact="influenza" post="virus. Clin Vaccine Immunol21: 1528–153325209558 AlamS, KnowldenZAG, SangsterMY, SantAJ"/>
   <result pre="limiting and selective during the primary B cell response to" exact="influenza" post="virus infection. J Virol88: 314–32424155379 AltmanMO, BenninkJR, YewdellJW, HerrinBR"/>
   <result pre="314–32424155379 AltmanMO, BenninkJR, YewdellJW, HerrinBR (2015) Lamprey VLRB response to" exact="influenza" post="virus supports universal rules of immunogenicity and antigenicity. Elife4:"/>
   <result pre="HasegawaH, SatoY, ShimadaS, NannoM, MatsuokaY, OhwakiMet al (2002) Protection against" exact="influenza" post="virus infection in polymeric Ig receptor knockout mice immunized"/>
   <result pre="2930–293811884464 BalazsAB, BloomJD, HongCM, RaoDS, BaltimoreD (2013) Broad protection against" exact="influenza" post="infection by vectored immunoprophylaxis in mice. Nat Biotechnol31: 647–65223728362"/>
   <result pre="KentSJ, GilchukPet al (2019) A site of vulnerability on the" exact="influenza" post="virus hemagglutinin head domain trimer interface. Cell177: 1136–1152 e1831100268"/>
   <result pre="(2000) Efficacy of vaccination with live attenuated, cold�?adapted, trivalent, intranasal" exact="influenza" post="virus vaccine against a variant (A/Sydney) not contained in"/>
   <result pre="(2019) Cross�?protective potential and protection�?relevant immune mechanisms of whole inactivated" exact="influenza" post="virus vaccines are determined by adjuvants and route of"/>
   <result pre="immunological significance of a human monoclonal antibody directed to the" exact="influenza" post="a virus nucleoprotein. Clin Vaccine Immunol20: 1333–133723761662 BournazosS, RavetchJV"/>
   <result pre="KorseHJWM, KwaksT, OtterstromJJ, JuraszekJet al (2013) Mechanisms of hemagglutinin targeted" exact="influenza" post="virus neutralization. PLoS One8: e8003424348996 BuningH, SchmidtM (2015) Adeno�?associated"/>
   <result pre="role for non�?neutralizing antibodies against nucleoprotein in facilitating resistance to" exact="influenza" post="virus. J Immunol181: 4168–417618768874 CatonAJ, BrownleeGG, YewdellJW, GerhardW (1982)"/>
   <result pre="CatonAJ, BrownleeGG, YewdellJW, GerhardW (1982) The antigenic structure of the" exact="influenza" post="virus A/PR/8/34 hemagglutinin (H1 subtype). Cell31: 417–4276186384 Corrales�?AguilarE, TrillingM,"/>
   <result pre="neutralizing hemagglutinin stalk�?specific antibodies require FcgammaR interactions for protection against" exact="influenza" post="virus in vivo. Nat Med20: 143–15124412922 DiLilloDJ, PaleseP, WilsonPC,"/>
   <result pre="CarnellG, TempertonNet al (2018) Cross�?protective immune responses induced by sequential" exact="influenza" post="virus infection and by sequential vaccination with inactivated influenza"/>
   <result pre="sequential influenza virus infection and by sequential vaccination with inactivated" exact="influenza" post="vaccines. Front Immunol9: 231230356772 EkiertDC, FriesenRHE, BhabhaG, KwaksT, JongeneelenM,"/>
   <result pre="al (2011) A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science (New York, NY)333: 843–850 EllebedyAH, KrammerF,"/>
   <result pre="al (2014) Induction of broadly cross�?reactive antibody responses to the" exact="influenza" post="HA stem region following H5N1 vaccination in humans. Proc"/>
   <result pre="StemmyEJ, RobertsPC, AugustineAD, FergusonS, PaulesCI, GrahamBS, FauciAS (2018) A universal" exact="influenza" post="vaccine: the strategic plan for the national institute of"/>
   <result pre="influenza vaccine: the strategic plan for the national institute of" exact="allergy" post="and infectious diseases. J Infect Dis218: 347–35429506129 collab: FDA"/>
   <result pre="(2014) Pandemic preparedness and response – lessons from the H1N1" exact="influenza" post="of 2009. N Engl J Med370: 1335–134224693893 FriesenRH, LeePS,"/>
   <result pre="KoudstaalW, JongeneelenMet al (2014) A common solution to group 2" exact="influenza" post="virus neutralization. Proc Natl Acad Sci USA111: 445–45024335589 GaoG,"/>
   <result pre="J Virol78: 6381–638815163731 GerdilC (2003) The annual production cycle for" exact="influenza" post="vaccine. Vaccine21: 1776–177912686093 GrimmD, BuningH (2017) Small but increasingly"/>
   <result pre="5774–578122398287 HeW, MullarkeyCE, MillerMS (2015) Measuring the neutralization potency of" exact="influenza" post="A virus hemagglutinin stalk/stem�?binding antibodies in polyclonal preparations by"/>
   <result pre="(2017) Alveolar macrophages are critical for broadly�?reactive antibody�?mediated protection against" exact="influenza" post="A virus in mice. Nat Commun8: 84629018261 Henry DunandCJ,"/>
   <result pre="HirshA, ZhengNYet al (2016) Both neutralizing and non�?neutralizing human H7N9" exact="influenza" post="vaccine�?induced monoclonal antibodies confer protection. Cell Host Microbe19: 800–81327281570"/>
   <result pre="EhrlichHJet al (2011) Vectors based on modified vaccinia ankara expressing" exact="influenza" post="H5N1 hemagglutinin induce substantial cross�?clade protective immunity. PLoS One6:"/>
   <result pre="SchwendingerMG, PilzA, BarrettPN, FalknerFGet al (2014) MVA vectors expressing conserved" exact="influenza" post="proteins protect mice against lethal challenge with H5N1, H9N2"/>
   <result pre="van MeersbergenR, HuizinghJ, WanningenP, VerspuijJet al (2015) A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogen. Science (New"/>
   <result pre="ButlerJ, ParsonsMS, AlcantaraS, PetravicJ, DavenportMP, HurtACet al (2013) Standard trivalent" exact="influenza" post="virus protein vaccination does not prime antibody�?dependent cellular cytotoxicity"/>
   <result pre="WrightPF, TreanorJ, RosenbergerCMet al (2016) Generation and protective ability of" exact="influenza" post="virus�?specific antibody�?dependent cellular cytotoxicity in humans elicited by vaccination,"/>
   <result pre="(2002) Updating the accounts: global mortality of the 1918�?1920 &quot;Spanish�?" exact="influenza" post="pandemic. Bull Hist Med76: 105–11511875246 KrammerF, PicaN, HaiR, MargineI,"/>
   <result pre="Med76: 105–11511875246 KrammerF, PicaN, HaiR, MargineI, PaleseP (2013) Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk�?specific antibodies. J"/>
   <result pre="Leyva�?GradoVH, RyderAB, MillerMS, RoseJK, PaleseP, García�?SastreAet al (2014) Assessment of" exact="influenza" post="virus hemagglutinin stalk�?based immunity in ferrets. J Virol88: 3432–344224403585"/>
   <result pre="MontoAS (2018) NAction! How can neuraminidase�?based immunity contribute to better" exact="influenza" post="virus vaccines?mBio9: e02332�?17 LaursenNS, FriesenRHE, ZhuX, JongeneelenM, BloklandS, VermondJ,"/>
   <result pre="EijgenA, TangC, van DiepenH, ObmolovaGet al (2018) Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutinin. Science"/>
   <result pre="Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutinin. Science (New York, NY)362: 598–602 LeonPE, HeW, MullarkeyCE,"/>
   <result pre="PaleseP, TanGS (2016) Optimal activation of Fc�?mediated effector functions by" exact="influenza" post="virus hemagglutinin antibodies requires two points of contact. Proc"/>
   <result pre="AndrewsSF, ZhengNY, LeeJH, HuangM, QuX, EdupugantiSet al (2012) Pandemic H1N1" exact="influenza" post="vaccine induces a recall response in humans that favors"/>
   <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9. Clin Vaccine Immunol20: 1836–183724132603 LinJ, CalcedoR,"/>
   <result pre="in mouse airway provides partial protection against a new avian" exact="influenza" post="A virus, H7N9. Clin Vaccine Immunol20: 1836–183724132603 LinJ, CalcedoR,"/>
   <result pre="immunization with live�?attenuated chimeric hemagglutinin�?based vaccines confers heterosubtypic immunity against" exact="influenza" post="a viruses in a preclinical ferret model. Front Immunol10:"/>
   <result pre="(2013) Hemagglutinin stalk�?based universal vaccine constructs protect against group 2" exact="influenza" post="A viruses. J Virol87: 10435–1044623903831 MedinaRA, ManicassamyB, StertzS, SeibertCW,"/>
   <result pre="Garcia�?SastreA (2010) Pandemic 2009 H1N1 vaccine protects against 1918 Spanish" exact="influenza" post="virus. Nat Commun1: 2820975689 MelianiA, LeborgneC, TriffaultS, Jeanson�?LehL, VeronP,"/>
   <result pre="RoseJK, PaleseP, Garcia�?SastreA, KrammerF, AlbrechtRA (2015) Hemagglutinin stalk immunity reduces" exact="influenza" post="virus replication and transmission in ferrets. J Virol90: 3268–327326719251"/>
   <result pre="AtlasT, RajendranM, SolorzanoA, Berlanda�?ScorzaF, Garcia�?SastreA, PalesePet al (2017) A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
   <result pre="(1993) A common neutralizing epitope conserved between the hemagglutinins of" exact="influenza" post="A virus H1 and H2 strains. J Virol67: 2552–25587682624"/>
   <result pre="al (2018) Report on eighth WHO meeting on development of" exact="influenza" post="vaccines that induce broadly protective and long�?lasting immune responses:"/>
   <result pre="RondyM, El OmeiriN, ThompsonMG, LevequeA, MorenA, SullivanSG (2017) Effectiveness of" exact="influenza" post="vaccines in preventing severe influenza illness among adults: a"/>
   <result pre="MorenA, SullivanSG (2017) Effectiveness of influenza vaccines in preventing severe" exact="influenza" post="illness among adults: a systematic review and meta�?analysis of"/>
   <result pre="RyderAB, NachbagauerR, BuonocoreL, PaleseP, KrammerF, RoseJK (2015) Vaccination with vesicular" exact="stomatitis" post="virus�?vectored chimeric hemagglutinins protects mice against divergent influenza virus"/>
   <result pre="with vesicular stomatitis virus�?vectored chimeric hemagglutinins protects mice against divergent" exact="influenza" post="virus challenge strains. J Virol90: 2544–255026676789 SipoI, KnaufM, FechnerH,"/>
   <result pre="recombinant AAV vectors expressing codon�?optimized genes from pandemic swine origin" exact="influenza" post="virus (SOIV). Vaccine29: 1690–169921195079 SonntagF, KotherK, SchmidtK, WeghoferM, RauppC,"/>
   <result pre="(2016) Broadly�?reactive neutralizing and non�?neutralizing antibodies directed against the H7" exact="influenza" post="virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog12:"/>
   <result pre="(2018) Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting" exact="influenza" post="HA�?stem. J Clin Invest29: 850–862 TrippRA, TompkinsSM (2014) Virus�?vectored"/>
   <result pre="influenza HA�?stem. J Clin Invest29: 850–862 TrippRA, TompkinsSM (2014) Virus�?vectored" exact="influenza" post="virus vaccines. Viruses6: 3055–307925105278 Van den HoeckeS, EhrhardtK, KolpeA,"/>
   <result pre="Hierarchical and redundant roles of activating FcgammaRs in protection against" exact="influenza" post="disease by M2e�?specific IgG1 and IgG2a antibodies. J Virol129:"/>
   <result pre="antibody dependent natural killer cell activation by antibodies to internal" exact="influenza" post="virus proteins. EBioMedicine8: 277–29027428437 de VriesRD, RimmelzwaanGF (2016) Viral"/>
   <result pre="virus proteins. EBioMedicine8: 277–29027428437 de VriesRD, RimmelzwaanGF (2016) Viral vector�?based" exact="influenza" post="vaccines. Hum Vaccin Immunother12: 2881–290127455345 WalzL, KaysSK, ZimmerG, von"/>
   <result pre="MesslingV (2018) Sialidase�?inhibiting antibody titers correlate with protection from heterologous" exact="influenza" post="virus strains of the same neuraminidase subtype. J Virol92:"/>
   <result pre="(2015) Anti�?HA glycoforms drive B cell affinity selection and determine" exact="influenza" post="vaccine efficacy. Cell162: 160–16926140596 WatanabeA, McCarthyKR, KuraokaM, SchmidtAG, AdachiY,"/>
   <result pre="TonouchiK, CaradonnaTM, BajicG, SongSet al (2019) Antibodies to a conserved" exact="influenza" post="head interface epitope protect by an IgG subtype�?dependent mechanism."/>
   <result pre="mechanism. Cell177: 1124–1135 e1631100267 collab: WHO (2002) Manual on animal" exact="influenza" post="diagnosis and surveillance In WHO global influenza programme, WebsterR,"/>
   <result pre="Manual on animal influenza diagnosis and surveillance In WHO global" exact="influenza" post="programme, WebsterR, CoxN, StöhrK (eds), pp 77�?79. Geneva, Switzerland:"/>
   <result pre="collab: WHO (2018a) Cumulative number of confirmed human cases for" exact="avian influenza" post="A(H5N1) reported to WHO, 2003–2018 In Cumulative number of"/>
   <result pre="WHO (2018a) Cumulative number of confirmed human cases for avian" exact="influenza" post="A(H5N1) reported to WHO, 2003–2018 In Cumulative number of"/>
   <result pre="WHO, 2003–2018 In Cumulative number of confirmed human cases for" exact="avian influenza." post="Geneva, Switzerland: World Health Organizationhttps://www.who.int/influenza/human_animal_interface/2018_03_02_tableH5N1.pdf collab: WHO (2018b) Influenza"/>
   <result pre="Health Organizationhttps://www.who.int/influenza/human_animal_interface/2018_03_02_tableH5N1.pdf collab: WHO (2018b) Influenza (Seasonal) fact sheet on" exact="influenza" post="no. 211 In Fact sheet on influenza no 211."/>
   <result pre="fact sheet on influenza no. 211 In Fact sheet on" exact="influenza" post="no 211. Geneva, Switzerland: World Health Organizationhttps://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) collab: WHO"/>
   <result pre="Organizationhttps://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) collab: WHO (2018c) WHO recommendations on the composition of" exact="influenza" post="virus vaccines In Recommendations on the composition of influenza"/>
   <result pre="of influenza virus vaccines In Recommendations on the composition of" exact="influenza" post="virus vaccines. Geneva, Switzerland: World Health Organizationhttps://www.who.int/influenza/vaccines/virus/recommendations/en/ WohlboldTJ, NachbagauerR,"/>
   <result pre="with soluble headless hemagglutinin protects mice from challenge with divergent" exact="influenza" post="viruses. Vaccine33: 3314–332126026378 WuNC, WilsonIA (2017) A perspective on"/>
   <result pre="the structural and functional constraints for immune evasion: insights from" exact="influenza" post="virus. J Mol Biol429: 2694–270928648617 XinKQ, UrabeM, YangJ, NomiyamaK,"/>
   <result pre="GallagherJR, WangL, ZhangY, JoyceMGet al (2015) Hemagglutinin�?stem nanoparticles generate heterosubtypic" exact="influenza" post="protection. Nat Med21: 1065–107026301691 YuX, TsibaneT, McGrawPA, HouseFS, KeeferCJ,"/>
   <result pre="(2008) Neutralizing antibodies derived from the B cells of 1918" exact="influenza" post="pandemic survivors. Nature455: 532–53618716625"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7210265\results\search\disease\results.xml">
   <result pre="global public health importance, such as dengue virus (DENV) and" exact="yellow fever" post="virus (YFV), originated in sylvatic transmission cycles involving wild"/>
   <result pre="emerging arthropod-borne viruses (arboviruses) of humans such as dengue, Zika," exact="yellow fever" post="and chikungunya viruses originated in sylvatic transmission cycles where"/>
   <result pre="(arboviruses) of humans such as dengue, Zika, yellow fever and" exact="chikungunya" post="viruses originated in sylvatic transmission cycles where they circulate"/>
   <result pre="have potentially serious consequences for wildlife. This was exemplified by" exact="yellow fever" post="virus (YFV), which was introduced into the Americas from"/>
   <result pre="of Singapore as a putative vector of YFV, DENV and" exact="chikungunya" post="virus11,12. Recently, our mosquito surveys in the Nakai National"/>
   <result pre="be competent for diverse arboviruses such as DENV, YFV and" exact="chikungunya" post="virus11,12. A human-baited trap survey demonstrated that this peridomestic"/>
   <result pre="with the olfactometer experiments, and Anna-Bella Failloux for providing the" exact="yellow fever" post="virus isolate. We are grateful to the blood donor"/>
   <result pre="&quot;the development of innovative research technique in genetic epidemiology of" exact="malaria" post="and other parasitic diseases in the Lao PDR for"/>
   <result pre="future distributions of the sylvatic cycles of dengue virus and" exact="yellow fever" post="virusInfect. Genet. Evol.20131929231110.1016/j.meegid.2013.03.00823523817 4.BryantJEHolmesECBarrettADTOut of Africa: a molecular perspective"/>
   <result pre="4.BryantJEHolmesECBarrettADTOut of Africa: a molecular perspective on the introduction of" exact="yellow fever" post="virus into the AmericasPLoS Pathog.20073e7510.1371/journal.ppat.003007517511518 5.DégallierNet al.A comparative study"/>
   <result pre="virus into the AmericasPLoS Pathog.20073e7510.1371/journal.ppat.003007517511518 5.DégallierNet al.A comparative study of" exact="yellow fever" post="in Africa and South AmericaJ. Braz. Assoc. Advanc. Sci.199244143151"/>
   <result pre="12.MiotEFet al.A peridomestic Aedes malayensis population in Singapore can transmit" exact="yellow fever" post="virusPLoS Negl. Trop. Dis.201913e000778310.1371/journal.pntd.000778331589616 13.Motoki, M. T. et al."/>
   <result pre="al.Three-way interactions between mosquito population, viral strain and temperature underlying" exact="chikungunya" post="virus transmission potentialProc. Biol. Sci.20142812014107810.1098/rspb.2014.107825122228 20.McBrideCSet al.Evolution of mosquito"/>
   <result pre="Microbiol.20181614315510.1038/nrmicro.2017.15729332945 25.SmithCEGThe distribution of antibodies to Japanese Encephalitis, dengue, and" exact="yellow fever" post="viruses in five rural communities in MalayaTrans. R. Soc."/>
   <result pre="of viral dissemination in individual mosquitoesSci. Rep.201662488510.1038/srep2488527117953 36.RodhainFHannounCJoussetFXRavisseP[Isolation of the" exact="yellow fever" post="virus in Paris from 2 imported human cases]Bull. Soc."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7210410\results\search\disease\results.xml">
   <result pre="persistent parvovirus B19 bone marrow infection resulting in transfusion- dependent" exact="pure red cell aplasia" post="in multiple myeloma after allogeneic haematopoietic stem cell transplantation"/>
   <result pre="infection resulting in transfusion- dependent pure red cell aplasia in" exact="multiple myeloma" post="after allogeneic haematopoietic stem cell transplantation and severe graft"/>
   <result pre="versus host diseaseHematology222017939827311084 10NagaharuK.SugimotoY.HoshiY.YamaguchiT.ItoR.MatsubayashiK.KawakamiK.OhishiK.Persistent symptomatic parvovirus B19 infection with severe" exact="thrombocytopenia" post="transmitted by red blood cell transfusion containing low parvovirus"/>
   <result pre="productsTransfus. Complicat.512011129136 14KishoreJ.SrivastavaM.ChoudhuryN.Serological study on parvovirus B19 infection in multitransfused" exact="thalassemia" post="major patients and its transmission through donor units Full"/>
   <result pre="through donor units Full Text IntroductionAsian J. Transfus. Sci.5201114014321897592 15StramerS.L.HollingerF.B.KatzL.M.KleinmanS.MetzelP.S.GregoryK.R.DoddR.Y.Emerging" exact="infectious disease" post="agents and their potential threat to transfusion safetyTransfusion4920091S29S19686562 16LeeT.KleinmanS.H.WenL.MontalvoL.ToddD.S.WrightD.J.ToblerL.H.MichaelP.Distribution"/>
   <result pre="immunologyScand. J. Infect. Dis.2919971291359181647 43DorseyK.A.MoritzE.D.SteeleW.R.EderA.F.StramerS.L.A comparison of human immunodeficiency virus," exact="hepatitis" post="C virus, hepatitis B virus, and human T-lymphotropic virus"/>
   <result pre="Dis.2919971291359181647 43DorseyK.A.MoritzE.D.SteeleW.R.EderA.F.StramerS.L.A comparison of human immunodeficiency virus, hepatitis C virus," exact="hepatitis" post="B virus, and human T-lymphotropic virus marker rates for"/>
   <result pre="to the fetusBirth Defect. Res.1092017311323 51KelleherE.McMahonC.McMahonC.J.A case of parvovirus B19-induced" exact="pure red cell aplasia" post="in a child following heart transplantCardiol. Young25201537337524555951 52WürdingerM.ModrowS.PlentzA.Impact of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7211204\results\search\disease\results.xml">
   <result pre="have made significant progress and are demonstrating promising efficacy in" exact="infectious disease" post="and cancer studies in small and large animal models."/>
   <result pre="progress and are demonstrating promising efficacy in infectious disease and" exact="cancer" post="studies in small and large animal models. These platforms"/>
   <result pre="and the possibility for self-administration in several indications, such as" exact="rheumatoid arthritis," post="primary immunodeficiencies, and multiple sclerosis [10, 11]. Drug autoinjectors"/>
   <result pre="in several indications, such as rheumatoid arthritis, primary immunodeficiencies, and" exact="multiple sclerosis" post="[10, 11]. Drug autoinjectors have greatly improved the uptake"/>
   <result pre="an Ad vector-encoded antibody followed by an AAV-encoded mAb targeting" exact="anthrax" post="and demonstrated successful rapid and long-lasting expression [20]. Around"/>
   <result pre="useful. Gene therapy studies with viral vectors have previously considered" exact="herpes simplex" post="virus thymidine kinase (HSV-tk) as a potential &quot;suicide�? gene"/>
   <result pre="successful mAb therapy approved for the treatment of hematological B-cell" exact="lymphoma" post="[113]. Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) are two of"/>
   <result pre="an anti-prostate-specific membrane antigen (anti-PSMA) encoded DNA in a mouse" exact="prostate cancer" post="model [116]. In vivo, their study showed expression for"/>
   <result pre="anti-prostate-specific membrane antigen (anti-PSMA) encoded DNA in a mouse prostate" exact="cancer" post="model [116]. In vivo, their study showed expression for"/>
   <result pre="only target and shrink specific tumors and those in hematological" exact="cancer" post="models in vivo, but they can have a survival"/>
   <result pre="blood mononuclear cells (PBMCs) co-incubated with two different luciferase-expressing lymphoblast" exact="cancer" post="models and showed a dose-dependent blockage of CTLA4, leading"/>
   <result pre="early mouse studies are supportive for continued development of high" exact="cancer" post="value targets. Such developments provide opportunities to broaden the"/>
   <result pre="that receive such high-cost therapies. Cancer: Outlook As the pDNA-mAb" exact="cancer" post="approach continues through preclinical studies, new complementary applications are"/>
   <result pre="first BiTE antibody approved by the FDA. It targets hematological" exact="acute lymphoblastic leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
   <result pre="BiTE antibody approved by the FDA. It targets hematological acute" exact="lymphoblastic leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
   <result pre="antibody approved by the FDA. It targets hematological acute lymphoblastic" exact="leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
   <result pre="These are interesting and promising and likely complementary strategies for" exact="cancer" post="immunotherapy that deserve significant attention. Infectious Disease Control There"/>
   <result pre="successful mAb approved as a standalone intervention to prevent an" exact="infectious disease." post="Synagis costs can be &amp;gt; US$12,000 for a five-dose (15 mg/kg/dose)"/>
   <result pre="raxibacumab and obiltoxaximab, have been approved for treatment of inhalational" exact="anthrax" post="via the FDA Animal Efficacy Rule. The Animal Rule"/>
   <result pre="limitations impede widespread delivery for seasonal outbreaks and epidemics for" exact="influenza" post="viruses. Repeat doses are required to lower HIV viral"/>
   <result pre="The development and manufacturing timeline for rapid response to emerging" exact="infectious disease" post="outbreaks, for example, Ebolavirus, is long and requires cold-chain"/>
   <result pre="DNA- and mRNA-mAbs represent potential rapid delivery platforms for emerging" exact="infectious disease" post="control. Both platforms start with initial antigen-specific mAb sequence"/>
   <result pre="in mice for pDNA-mAbs and mRNA-mAbs targeting dengue virus [101]," exact="influenza" post="A and B viruses [36, 37, 97], Ebolavirus [36,"/>
   <result pre="37, 97], Ebolavirus [36, 42], Zika virus [38], CHIKV [121]," exact="rabies" post="[15], and HIV [49]. Anti-Dengue Virus pDNA-mAbs Close to"/>
   <result pre="estimated 45 million people in the USA were infected by" exact="influenza" post="viruses during the 2017–2018 influenza season, resulting in 810,000"/>
   <result pre="the USA were infected by influenza viruses during the 2017–2018" exact="influenza" post="season, resulting in 810,000 hospitalizations and 61,100 deaths [123]."/>
   <result pre="mAb delivery could have an important impact on lowering overall" exact="influenza" post="disease burden during seasonal influenza epidemics and against potential"/>
   <result pre="important impact on lowering overall influenza disease burden during seasonal" exact="influenza" post="epidemics and against potential pandemic viruses. Yamazaki et al."/>
   <result pre="mouse model to demonstrate preclinical protection against seasonal and pandemic" exact="influenza" post="A and B viruses. Anti-ebolavirus pDNA-mAbs The 2013–2016 Ebolavirus"/>
   <result pre="first demonstration that a nucleic acid-encoded antibody can control an" exact="infectious disease" post="challenge in a larger animal model, further supporting translation"/>
   <result pre="To date, mRNA-mAbs, formulated in LNP, have been evaluated targeting" exact="rabies" post="[15], HIV [49], and CHIKV [127]. Human anti-rabies immunoglobulin"/>
   <result pre="HIV [49], and CHIKV [127]. Human anti-rabies immunoglobulin and the" exact="rabies" post="vaccine must be delivered immediately following potential rabies exposure."/>
   <result pre="and the rabies vaccine must be delivered immediately following potential" exact="rabies" post="exposure. Thran et al. evaluated an mRNA-mAb platform for"/>
   <result pre="pre-exposure (day − 1) and post-exposure (2 h post-infection) protection against lethal" exact="rabies" post="virus challenge in mice. In this study, an anti-influenza"/>
   <result pre="against the virus, with no viral load and protection against" exact="arthritis" post="and muscoskeletal disease in competent C57BL6 mice [127]. They"/>
   <result pre="type III secretion system and Psl exopolysaccharide), protecting against lethal" exact="pneumonia" post="in a mouse challenge model. Lower levels of pro-inflammatory"/>
   <result pre="airway expression of antibody protects old and immunodeficient mice against" exact="influenza" post="virusClin Vaccine Immunol201421111528153310.1128/CVI.00572-1425209558 26.LimberisMPAdamVSWongGGrenJKobasaDRossTMet al.Intranasal antibody gene transfer in"/>
   <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against"/>
   <result pre="in mouse airway provides partial protection against a new avian" exact="influenza" post="A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against"/>
   <result pre="influenza A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutininScience2018362641459860210.1126/science.aaq062030385580 29.LimberisMPTretiakovaANambiarKWongGRacineTCrosariolMet"/>
   <result pre="al.Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutininScience2018362641459860210.1126/science.aaq062030385580 29.LimberisMPTretiakovaANambiarKWongGRacineTCrosariolMet al.Adeno-associated virus serotype 9-expressed ZMapp in mice"/>
   <result pre="following four different methods of administrationBMC Biotechnol20171714310.1186/s12896-017-0365-228506256 32.McNamaraMANairSKHollEKRNA-based vaccines in" exact="cancer" post="immunotherapyJ Immunol Res2015201579452810.1155/2015/79452826665011 33.JulianoRAlamMRDixitVKangHMechanisms and strategies for effective delivery"/>
   <result pre="monoclonal antibodies by gene transfer via electroporation protects against lethal" exact="influenza" post="and Ebola infectionsMol Ther Methods Clin Dev20177748210.1016/j.omtm.2017.09.00329034261 37.ElliottSTCKallewaardNLBenjaminEWachter-RosatiLMcAuliffeJMPatelAet al.DMAb"/>
   <result pre="al.DMAb inoculation of synthetic cross reactive antibodies protects against lethal" exact="influenza" post="A and B infectionsNPJ Vaccines201721810.1038/s41541-017-0020-x29263874 38.EsquivelRNPatelAKudchodkarSBParkDHStettlerKBeltramelloMet al.In vivo delivery"/>
   <result pre="bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a" exact="pneumonia" post="challenge modelNat Commun20178163710.1038/s41467-017-00576-728935938 40.HollevoetKDe VleeschauwerSDe SmidtEVermeireGGeukensNDeclerckPBridging the clinical gap"/>
   <result pre="demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9" exact="influenza" post="virusesMol Ther20172561316132710.1016/j.ymthe.2017.03.03528457665 55.AlbererMGnad-VogtUHongHSMehrKTBackertLFinakGet al.Safety and immunogenicity of a mRNA"/>
   <result pre="influenza virusesMol Ther20172561316132710.1016/j.ymthe.2017.03.03528457665 55.AlbererMGnad-VogtUHongHSMehrKTBackertLFinakGet al.Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
   <result pre="but functions in TLR9-deficient miceJ Immunol2003171115908591210.4049/jimmunol.171.11.590814634101 60.ReidTWarrenRKirnDIntravascular adenoviral agents in" exact="cancer" post="patients: lessons from clinical trialsCancer Gene Ther200291297998610.1038/sj.cgt.770053912522437 61.ZhongLMalaniNLiMBradyTXieJBellPet al.Recombinant"/>
   <result pre="eyePharm Res20183622910.1007/s11095-018-2554-730591984 71.FeldmanRAFuhrRSmolenovIMick RibeiroAPantherLWatsonMet al.mRNA vaccines against H10N8 and H7N9" exact="influenza" post="viruses of pandemic potential are immunogenic and well tolerated"/>
   <result pre="kinase/ganciclovir-mediated apoptotic death of bystander cellsCancer Res19965612269727028665496 83.MesnilMPiccoliCTirabyGWilleckeKYamasakiHBystander killing of" exact="cancer" post="cells by herpes simplex virus thymidine kinase gene is"/>
   <result pre="of bystander cellsCancer Res19965612269727028665496 83.MesnilMPiccoliCTirabyGWilleckeKYamasakiHBystander killing of cancer cells by" exact="herpes simplex" post="virus thymidine kinase gene is mediated by connexinsProc Natl"/>
   <result pre="expression with reduced muscle damageGene Ther20018161264127010.1038/sj.gt.330152211509960 97.YamazakiTNagashimaMNinomiyaDAraiYTeshimaYFujimotoAet al.Passive immune-prophylaxis against" exact="influenza" post="virus infection by the expression of neutralizing anti-hemagglutinin monoclonal"/>
   <result pre="OKT3 (muromonab-CD3): a reviewJ Transpl Coord.19966310911910.7182/prtr.1.6.3.8145l3u1854931829188368 113.BoyiadzisMFoonKAApproved monoclonal antibodies for" exact="cancer" post="therapyExpert Opin Biol Ther2008881151115810.1517/14712598.8.8.115118613766 114.Services CgCfMM. 2019 ASP drug"/>
   <result pre="Accessed 23 Nov 2019. 115.SaltzLBPerspectives on cost and value in" exact="cancer" post="careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel prostate cancer immunotherapy with a"/>
   <result pre="on cost and value in cancer careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel" exact="prostate cancer" post="immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibodyCancer"/>
   <result pre="cost and value in cancer careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel prostate" exact="cancer" post="immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibodyCancer"/>
   <result pre="immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against" exact="chikungunya" post="virusJ Infect Dis2016214336937810.1093/infdis/jiw11127001960 122.BradyJMBaltimoreDBalazsABAntibody gene transfer with adeno-associated viral"/>
   <result pre="as a method for HIV preventionImmunol Rev2017275132433310.1111/imr.1247828133808 123.Prevention CfDCa. Estimated" exact="influenza" post="illnesses, medical visits, hospitalizations, and deaths in the United"/>
   <result pre="illnesses, medical visits, hospitalizations, and deaths in the United States—2017–2018" exact="influenza" post="season. In: Influenza (Flu). Centers for Disease Control and"/>
   <result pre="mRNA encoding a potently neutralizing human monoclonal antibody protects against" exact="chikungunya" post="infectionSci Immunol.201910.1126/sciimmunol.aaw66476629435 128.WuXHIV broadly neutralizing antibodies: VRC01 and beyondAdv"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7211399\results\search\disease\results.xml">
   <result pre="surveillance in pathogen diagnosis, source(s), and transmission tracing during an" exact="infectious disease" post="outbreak. The result highlights the hidden E11 circulation and"/>
   <result pre="and mouth diseases (HFMD)) to severe, potentially fatal conditions (e.g." exact="aseptic meningitis," post="encephalitis, acute flaccid paralysis (AFP), myocarditis, and neonatal enteroviral"/>
   <result pre="Due to the respiratory disease-related symptoms like progressive dyspnea and" exact="pneumonia" post="presenting in multiple cases, a multiplex RT-PCR Respiratory Pathogen"/>
   <result pre="Kristian et al. refers to a more targeted approach to" exact="infectious disease" post="control at both the individual and population-level via genomic"/>
   <result pre="material (DNA and RNA) in clinical samples, is rapidly changing" exact="infectious disease" post="diagnosis and treatment (Grubaugh et al. 2019). It allows"/>
   <result pre="Khetsuriani et al. 2006). In this study, we found that" exact="pneumonia" post="or acute respiratory diseases were observed in fatal cases"/>
   <result pre="for immunocompromised patients, associated with bacteremia (Peces et al. 1997)," exact="pneumonia" post="(Dürst et al. 1991), septic arthritis (Albertson 1978), endocarditis,"/>
   <result pre="bacteremia (Peces et al. 1997), pneumonia (Dürst et al. 1991)," exact="septic arthritis" post="(Albertson 1978), endocarditis, and meningitis (Fosse et al. 1985)."/>
   <result pre="(Peces et al. 1997), pneumonia (Dürst et al. 1991), septic" exact="arthritis" post="(Albertson 1978), endocarditis, and meningitis (Fosse et al. 1985)."/>
   <result pre="(Dürst et al. 1991), septic arthritis (Albertson 1978), endocarditis, and" exact="meningitis" post="(Fosse et al. 1985). The co-occurrence of M. luteus"/>
   <result pre="applied on fifteen throat swab samples from H1 with similar" exact="respiratory disease" post="symptoms. For enterovirus positive samples metatranscriptomic analysis was performed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7212620\results\search\disease\results.xml">
   <result pre="divergent and sylvatic strain of DENV2, QML22, recovered from a" exact="dengue fever" post="patient returning to Australia from Borneo. The objective of"/>
   <result pre="epidemic strain of DENV serotype 2 (QML16) isolated from a" exact="dengue fever" post="patient in Australia in 2015. Mosquitoes were maintained at"/>
   <result pre="USA). The QML16 strain of DENV2 was isolated from a" exact="dengue fever" post="patient in Australia and strain QML22 was isolated from"/>
   <result pre="patient in Australia and strain QML22 was isolated from a" exact="dengue fever" post="patient returning to Australia from Borneo [8]. The virus"/>
   <result pre="virus type 2 strainsVirology200837729630710.1016/j.virol.2008.04.04418570968 4.MotaJRico-HesseRHumanized mice show clinical signs of" exact="dengue fever" post="according to infecting virus genotypeJ Virol2009838638864510.1128/JVI.00581-0919535452 5.VasilakisNShellEJFokamEBMasonPWHanleyKAEstesDMet al.Potential of"/>
   <result pre="26.RoehrigJTMathewsJHTrentDWIdentification of epitopes on the E glycoprotein of Saint Louis" exact="encephalitis" post="virus using monoclonal antibodiesVirology198312811812610.1016/0042-6822(83)90323-96192585 27.HenchalEAGentryMKMcCownJMBrandtWEDengue virus-specific and flavivirus group"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7213748\results\search\disease\results.xml">
   <result pre="relatively mild human infection that generally results in only fever," exact="rash" post="and possibly conjunctivitis [3, 10]. By 2007, the virus"/>
   <result pre="infection that generally results in only fever, rash and possibly" exact="conjunctivitis" post="[3, 10]. By 2007, the virus had escaped Africa"/>
   <result pre="to fetus during pregnancy with the potential to result in" exact="microcephaly" post="which causes fetal abnormalities including possible skull collapse [5]."/>
   <result pre="(2016) [21] also found that the risk of ZIKV induced" exact="microcephaly" post="was 95 cases (34-191) per 10,000 women infected in"/>
   <result pre="weekly cases were documented [26]. In addition, local GBS and" exact="microcephaly" post="cases were also recorded. Over the two years, two"/>
   <result pre="which indicated a possible epidemiological association. A striking wave of" exact="microcephaly" post="cases with a 23-week delay to the first ZIKV"/>
   <result pre="the first trimester of pregnancy are most likely to induce" exact="microcephaly" post="[21, 27, 28, 29]). Fig 2 The reported ZIKV"/>
   <result pre="cohort study was conducted on 345 pregnant women with ZIKV" exact="rash" post="observed (presenting at the Oswaldo Cruz Foundation) in Rio"/>
   <result pre="women were infected with CHIKV. Thus, among pregnant women with" exact="rash" post="observed in this period, the ratio of ZIKV and"/>
   <result pre="in what was felt to be a high number of" exact="microcephaly" post="cases (after a 26-week delay [26]). This is because"/>
   <result pre="microcephaly cases (after a 26-week delay [26]). This is because" exact="microcephaly" post="cases are easier to identify and are thus better"/>
   <result pre="are thus better reported [20]. Nevertheless, the reporting criteria of" exact="microcephaly" post="cases also changed significantly over the two years [34]"/>
   <result pre="IAR of ZIKV directly based on the reported number of" exact="microcephaly" post="cases. Also, we would need to consider the effect"/>
   <result pre="to consider the effect of time-varying birth rates if using" exact="microcephaly" post="cases to infer ZIKV cases. However, it seems a"/>
   <result pre="GBS cases time series. Because of the co-circulation of both" exact="dengue fever" post="and ZIKV during the two waves, misdiagnoses of ZIKV"/>
   <result pre="which provides the basic reproduction number of the classical Ross-Macdonald" exact="malaria" post="model [6, 56, 57]. Model fitting and parameter estimation"/>
   <result pre="used with care. Previous studies in large populations, such as" exact="measles" post="in England and Wales (population size 50 million [72,"/>
   <result pre="studying Zika virus and its impact on human populations including" exact="microcephaly" post="numbers and its relation to GBS. Their analysis heavily"/>
   <result pre="that there is coherence in the dynamics of infectives and" exact="microcephaly" post="populations when aggregated over all NE Brazil. That is"/>
   <result pre="two diseases, the ratio between them is 6.1 (maximum of" exact="microcephaly" post="divided by maximum of GBS wave), which corresponds to"/>
   <result pre="wave), which corresponds to 1 GBS case for every 6.1" exact="microcephaly" post="cases. If we make the reasonable assumption that the"/>
   <result pre="chose to predict ZIKV cases based on GBS rather than" exact="microcephaly" post="cases, because of problems in the correct reporting of"/>
   <result pre="microcephaly cases, because of problems in the correct reporting of" exact="microcephaly" post="over the study period. For example, the criteria for"/>
   <result pre="over the study period. For example, the criteria for identifying" exact="microcephaly" post="changed dramatically at different times over the two year"/>
   <result pre="Eyrolle-GuignotD, et al. and others. &quot;Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013–15: a retrospective study�?. The Lancet."/>
   <result pre="RockKS, YasudaY, KinoshitaR, MiyamatsuYA. theoretical estimate of the risk of" exact="microcephaly" post="during pregnancy with Zika virus infection. Epidemics. 2016;15:66–70. 10.1016/j.epidem.2016.03.00127288540"/>
   <result pre="pregnant women infected with Zika virus and expected infants with" exact="microcephaly" post="following the Zika virus outbreak in Puerto Rico, 2016."/>
   <result pre="2016;375(24):2321–34. 10.1056/NEJMoa160241226943629 30LebrunG, ChaddaK, RebouxAH, MartinetO, GauzereB. Guillain-Barre syndrome after" exact="chikungunya" post="infection. Emerging infectious diseases. 2009;15:310.3201/eid1503.071482 31WielanekAC, De MonredonJ, El"/>
   <result pre="school cycles and environmental forcing on the timing of pandemic" exact="influenza" post="activity in Mexican States, May-December 2009. PLoS computational biology."/>
   <result pre="Inferring the causes of the three waves of the 1918" exact="influenza" post="pandemic in England and Wales. Proceedings of the Royal"/>
   <result pre="Sciences. 2013;280(1766):2013134510.1098/rspb.2013.134523843396 39HeD, DushoffJ, EftimieR, EarnD. Patterns of spread of" exact="influenza" post="A in Canada. Proceedings of the Royal Society B:"/>
   <result pre="Rep. 2017;7(1):27310.1038/s41598-017-00253-128325935 41HeD, IonidesEL, KingA. Plug-and-play inference for disease dynamics:" exact="measles" post="in large and small populations as a case study."/>
   <result pre="Dis. 2015;21(2):359–61. 10.3201/eid2102.14136325625872 44ZhaoS, StoneL, GaoD, HeD. Modelling the large-scale" exact="yellow fever" post="outbreak in Luanda, Angola, and the impact of vaccination."/>
   <result pre="https://www.cdc.gov/dengue/resources/factsheets/mosquitolifecyclefinal.pdf;. 63KraemerMU, FariaNR, ReinerRCJr, GoldingN, NikolayB, StasseS, et al.Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
   <result pre="2016;69:1–43. 66ZhaoS, LouY, ChiuAP, HeD. Modelling the skip-and-resurgence of Japanese" exact="encephalitis" post="epidemics in Hong Kong. Journal of theoretical biology. 2018;454:1–10."/>
   <result pre="28887877 70XiaoY, TangS, WuJ. Media impact switching surface during an" exact="infectious disease" post="outbreak. Scientific reports. 2015;5:783810.1038/srep0783825592757 71MusaSS, ZhaoS, ChanHS, JinZ, HeD."/>
   <result pre="engineering. 2019;16(5):3841–63. 10.3934/mbe.201919031499639 72BolkerBM, GrenfellB. Chaos and biological complexity in" exact="measles" post="dynamics. Proceedings of the Royal Society of London Series"/>
   <result pre="Royal Society Interface. 2018;15(146):2018051510.1098/rsif.2018.0515 79MitchellL, RossJ. A data-driven model for" exact="influenza" post="transmission incorporating media effects. Royal Society open science. 2016;3(10):16048110.1098/rsos.16048127853563"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7215950\results\search\disease\results.xml">
   <result pre="many of the hospitals of the Kingdom, KAMC-R developed an" exact="infectious disease" post="epidemic plan (IDEP) to manage the potential influx of"/>
   <result pre="hospital outbreak of MERS-CoV. In Riyadh the hospital followed the" exact="infectious disease" post="epidemic plan (IDEP), established by the hospital outbreak committee"/>
   <result pre="in the event of infection [9]. Five cases of acute" exact="respiratory failure" post="were admitted to the ICU and subsequently diagnosed with"/>
   <result pre="Description A SEIR-ward model has been used by researchers for" exact="infectious disease" post="modeling spread of coronavirus [10,11,12]. The model uses the"/>
   <result pre="the model is important to consider as many large hospital" exact="infectious disease" post="outbreaks, like the Saudi Arabia’s MERS-CoV outbreak, often show"/>
   <result pre="below the threshold of one upon the escalation of the" exact="infectious disease" post="plan in the hospital (Figure 2a). The IDEP phase"/>
   <result pre="spatial-specific characteristics to replicate transmission and super spreading events of" exact="infectious disease" post="transmission occurring in different hospital wards. That would assist"/>
   <result pre="close the ED department as a required escalation in the" exact="infectious disease" post="plan IDEP. In addition, patients’ isolation and reducing contact"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7216417\results\search\disease\results.xml">
   <result pre="predominantly in southern Vietnam. In 2016, a case of ZIKV-associated" exact="microcephaly" post="was confirmed in the Central Highlands, and several members"/>
   <result pre="lived in the same village as the infant with ZIKV-associated" exact="microcephaly" post="and the other 4 lived in 2 neighboring communes."/>
   <result pre="body fluids [4]. Common symptoms are rash, fever, arthralgia, and" exact="conjunctivitis" post="[5]. While ZIKV infection is sometimes associated with only"/>
   <result pre="also lead to severe complications including Guillain-Barré syndrome [6] and" exact="microcephaly" post="in infants [7]. The first reported ZIKV epidemic occurred"/>
   <result pre="increase in the number of cases of infants born with" exact="microcephaly" post="suspected to be associated with ZIKV [7, 10]. According"/>
   <result pre="Minh City [21–24]. Additionally, in 2016, a case of Zika-associated" exact="microcephaly" post="was reported in the Central Highlands of Vietnam and"/>
   <result pre="Buk District, Dak Lak Province where a case of ZIKV-associated" exact="microcephaly" post="had been reported [25]. The population density in this"/>
   <result pre="of 357.82 km2. In January 2017, 3 months after the case of" exact="microcephaly" post="was reported, blood samples were collected from healthy adults"/>
   <result pre="minority ethnic groups. This may reflect as increased risk of" exact="infectious disease" post="exposure due to ethnic and socio-economical associated activity and"/>
   <result pre="Cu Pong village, the same commune with the case of" exact="microcephaly" post="cases that we reported in the previous study. In"/>
   <result pre="City, VietnamInt J Gynecol Obstet201814139039110.1002/ijgo.12456 25.MoiMLNguyenTTTNguyenCTVuTBHTunMMNPhamTDet al.Zika virus infection and" exact="microcephaly" post="in VietnamLancet Infect Dis20171780580610.1016/S1473-3099(17)30412-728741545 26.HayesEBZika virus outside AfricaEmerg Infect"/>
   <result pre="of arboviral infectionsJ Clin Microbiol2000381823182610.1128/JCM.38.5.1823-1826.200010790107 37.PhamHVDoanHTPhanTTTran MinhNNEcological factors associated with" exact="dengue fever" post="in a central highlands provinceVietnam BMC Infect Dis20111117210.1186/1471-2334-11-17221679398 38.R&amp;amp;D"/>
   <result pre="central highlandsVietnam Rev Biol Trop201765819826 41.Van TuanLVanNTTThiPNgaTDuongLQuanMet al.Seasonal distribution of" exact="dengue fever" post="in the central highlands region, Vietnam (2010- 2015)Am J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7216668\results\search\disease\results.xml">
   <result pre="learning sparse group lasso: a method for quantifying antigenicity of" exact="influenza" post="A(H1N1) virus using mutations and variations in glycosylation of"/>
   <result pre="the data. Abstract Background In addition to causing the pandemic" exact="influenza" post="outbreaks of 1918 and 2009, subtype H1N1 influenza A"/>
   <result pre="the pandemic influenza outbreaks of 1918 and 2009, subtype H1N1" exact="influenza" post="A viruses (IAVs) have caused seasonal epidemics since 1977."/>
   <result pre="(IAVs) have caused seasonal epidemics since 1977. Antigenic property of" exact="influenza" post="viruses are determined by both protein sequence and N-linked"/>
   <result pre="are determined by both protein sequence and N-linked glycosylation of" exact="influenza" post="glycoproteins, especially hemagglutinin (HA). The currently available computational methods"/>
   <result pre="National Institutes of Health (US)U01CA221234ZaiaJoseph Background The subtype of an" exact="influenza" post="A virus (IAV) is determined based on the subtypes"/>
   <result pre="causing significant burdens to public health. Two of four documented" exact="influenza" post="pandemics (in 1918 and 2009) were caused by subtype"/>
   <result pre="addition, H1N1 IAVs have been a predominant cause of seasonal" exact="influenza" post="outbreaks between 1918 to 1957 and since 1977. Strains"/>
   <result pre="1918 to 1957 and since 1977. Strains of the 1977" exact="influenza" post="A(H1N1) virus were responsible for outbreaks during the 1977–78"/>
   <result pre="outbreaks during the 1977–78 to 2008–09 seasons, but in 2009," exact="influenza" post="A(H1N1)pdm09 virus took over as the new seasonal influenza"/>
   <result pre="2009, influenza A(H1N1)pdm09 virus took over as the new seasonal" exact="influenza" post="virus. Genetic characterization suggested that the 1918 A(H1N1) pandemic"/>
   <result pre="and A(H1N1)pdm09 do not cross-react with each other [8–11]. Among" exact="influenza" post="viruses, antigenic drift is caused by gradual changes in"/>
   <result pre="allow IAVs to evade the accumulating herd immunity from prior" exact="influenza" post="infections and/or vaccination, and thus present great challenges in"/>
   <result pre="influenza infections and/or vaccination, and thus present great challenges in" exact="influenza" post="vaccine strain selection. During 1977–2017, such changes resulted in"/>
   <result pre="1977–2017, such changes resulted in 12 updates for the human" exact="influenza" post="vaccine [15]. Recent advances in sequencing technology have allowed"/>
   <result pre="technology have allowed us to identify genetic changes rapidly in" exact="influenza" post="genomes, and genome sequencing has become one of the"/>
   <result pre="sequencing has become one of the routine procedures in the" exact="influenza" post="surveillance program [16–19]. Thus, a genome-based vaccine strain selection"/>
   <result pre="is essential that we understand the key structural features determining" exact="influenza" post="virus antigenicity. Previous studies have suggested that antigenicity is"/>
   <result pre="multi-task formulation can overcome the challenges in data integration for" exact="influenza" post="serological data [38]. To make our model be flexible"/>
   <result pre="the model can learning simultaneously two types of features affecting" exact="influenza" post="virus antigenicity (i.e. sequence and N-glycosylation). The advantages of"/>
   <result pre="also takes advantage of the sparsity of predominant features in" exact="influenza" post="proteins. This is important because high dimensional features can"/>
   <result pre="(i.e., mutation and N-glycosylation) were identified and used to quantify" exact="influenza" post="antigenicity. Of note, O-glycosylation has not been detected in"/>
   <result pre="structure similar to that for the data for H3N2 seasonal" exact="influenza" post="viruses [48]. If we arrange antigens and antibodies in"/>
   <result pre="develop a genomic sequence–based method to quantify antigenic distances between" exact="influenza" post="viruses and to understand the key residues driving antigenic"/>
   <result pre="and to understand the key residues driving antigenic evolution of" exact="influenza" post="viruses. In this study, an MTL-SGL model was developed"/>
   <result pre="from two types of features (i.e. sequence and N-glycosylation) affecting" exact="influenza" post="virus antigenicity by learning the weights for each feature."/>
   <result pre="larger weight indicates a higher impact of this feature on" exact="influenza" post="virus antigenicity. The unique N-glycosylation sites for HA of"/>
   <result pre="HI data for A(H1N1)season1977 viruses, A(H1N1)pdm09 viruses, and A(H1N1) swine" exact="influenza" post="viruses (SIVs), we determined that among a total of"/>
   <result pre="sequence-based maps of 13,591 non-identical human, swine, and avian H1" exact="influenza" post="A viruses (IAVs). Pairwise antigenic distances were inferred from"/>
   <result pre="(Fig. 4). Fig. 4 Large-scale antigenic evolution profile of H1" exact="influenza" post="A viruses in avian species, swine and humans. Different"/>
   <result pre="mutations in protein sequences and glycosylation patterns affect antigenicity of" exact="influenza" post="viruses [29]. However, to our knowledge, the major computational"/>
   <result pre="sequences. A few models and algorithms of sequence-based predictions of" exact="influenza" post="antigenicity were proposed in the past few years. A"/>
   <result pre="and mutations in HA protein sequences. Under the hypothesis that" exact="influenza" post="antigenicity would be determined by a small number of"/>
   <result pre="determined by a small number of features embedded in the" exact="influenza" post="genomic sequence, especially the HA protein sequence and tertiary"/>
   <result pre="labs) have been proved by a prior study on H3N2" exact="influenza" post="data [38]. Similar to the sparse learning model proposed"/>
   <result pre="(2016) adapted sparse learning model to identify residues associated with" exact="influenza" post="viruses by correlating serological data and protein sequence data."/>
   <result pre="mutations in HA sequences affecting antigenic changes of H1N1 seasonal" exact="influenza" post="(1997 through 2009) [28]. Nevertheless, none of these methods"/>
   <result pre="multiple type of features (e.g. glycosylation) in predicting antigenicity of" exact="influenza" post="viruses. In this study, we developed and validated an"/>
   <result pre="associated with acquisition or loss of a N-glycosylation site in" exact="influenza" post="viruses. By using the MTL-SGL model, we constructed a"/>
   <result pre="summary, in this study, we developed and validated a sequence-based" exact="influenza" post="antigenic variant detection method for H1 IAVs. This method"/>
   <result pre="be high throughput and applied in large-scale antigenic characterization in" exact="influenza" post="vaccine strain selection. Supplementary information LINK Additional file 1."/>
   <result pre="have no competing interests. References References 1.TongSLiYRivaillerPConrardyCCastilloDAAChenL-MRecuencoSEllisonJADavisCTYorkIAA distinct lineage of" exact="influenza" post="a virus from batsProc Natl Acad Sci2012109114269427410.1073/pnas.111620010922371588 2.BelsheRBThe origins"/>
   <result pre="Med2005353212209221110.1056/NEJMp05828116306515 3.ThompsonWWShayDKWeintraubEBrammerLBridgesCBCoxNJFukudaKInfluenza-associated hospitalizations in the United StatesJama2004292111333134010.1001/jama.292.11.133315367555 4.ZimmerSMBurkeDSHistorical perspective—emergence of" exact="influenza" post="a (H1N1) virusesN Engl J Med2009361327928510.1056/NEJMra090432219564632 5.MorensDMTaubenbergerJKFauciASThe persistent legacy"/>
   <result pre="virusesN Engl J Med2009361327928510.1056/NEJMra090432219564632 5.MorensDMTaubenbergerJKFauciASThe persistent legacy of the 1918" exact="influenza" post="virusN Engl J Med2009361322522910.1056/NEJMp090481919564629 6.GartenRJDavisCTRussellCAShuBLindstromSBalishASessionsWMXuXSkepnerEDeydeVet al.Antigenic and genetic characteristics"/>
   <result pre="Med2009361322522910.1056/NEJMp090481919564629 6.GartenRJDavisCTRussellCAShuBLindstromSBalishASessionsWMXuXSkepnerEDeydeVet al.Antigenic and genetic characteristics of swine-origin 2009 a(H1N1)" exact="influenza" post="viruses circulating in humansScience2009325593719720110.1126/science.117622519465683 7.SunSWangQZhaoFChenWLiZGlycosylation site alteration in the"/>
   <result pre="circulating in humansScience2009325593719720110.1126/science.117622519465683 7.SunSWangQZhaoFChenWLiZGlycosylation site alteration in the evolution of" exact="influenza" post="a (H1N1) virusesPLoS One201167e2284410.1371/journal.pone.002284421829533 8.ManicassamyBMedinaRAHaiRTsibaneTStertzSNistal-VillánEPalesePBaslerCFGarcía-SastreAProtection of mice against lethal"/>
   <result pre="One201167e2284410.1371/journal.pone.002284421829533 8.ManicassamyBMedinaRAHaiRTsibaneTStertzSNistal-VillánEPalesePBaslerCFGarcía-SastreAProtection of mice against lethal challenge with 2009 H1N1" exact="influenza" post="a virus by 1918-like and classical swine H1N1 based"/>
   <result pre="vaccinesPLoS Pathog201061e100074510.1371/journal.ppat.100074520126449 9.MedinaRAManicassamyBStertzSSeibertCWHaiRBelsheRBFreySEBaslerCFPalesePGarcía-SastreAPandemic 2009 H1N1 vaccine protects against 1918 Spanish" exact="influenza" post="virusNat Commun201012810.1038/ncomms102620975689 10.GrasSKedzierskiLValkenburgSALaurieKLiuYCDenholmJTRichardsMJRimmelzwaanGFKelsoADohertyPCCross-reactive CD8+ T-cell immunity between the pandemic"/>
   <result pre="10.GrasSKedzierskiLValkenburgSALaurieKLiuYCDenholmJTRichardsMJRimmelzwaanGFKelsoADohertyPCCross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918" exact="influenza" post="a virusesProc Natl Acad Sci201010728125991260410.1073/pnas.100727010720616031 11.ShuBGartenREmerySBalishACooperLSessionsWDeydeVSmithCBermanLKlimovAGenetic analysis and antigenic"/>
   <result pre="Acad Sci201010728125991260410.1073/pnas.100727010720616031 11.ShuBGartenREmerySBalishACooperLSessionsWDeydeVSmithCBermanLKlimovAGenetic analysis and antigenic characterization of swine origin" exact="influenza" post="viruses isolated from humans in the United States, 1990–2010Virology2012422115116010.1016/j.virol.2011.10.01622078166"/>
   <result pre="and driftN Engl J Med2004350321822010.1056/NEJMp03823814724300 15.Historical annual reformulations of the" exact="influenza" post="vaccine. https://en.wikipedia.org/wiki/Historical_annual_reformulations_of_the_influenza_vaccine#Northern_Hemisphere_recommended_strains. Accessed 2 Jan 2020. 16.Van DijkELAugerHJaszczyszynYThermesCTen years"/>
   <result pre="Biomed Res Int. 2012;2012. https://scholar.google.com/scholar?hl=en&amp;amp;as_sdt=0%2C14&amp;amp;q=Comparison+of+next-generation+sequencing+systems&amp;amp;btnG=. 20.CatonAJBrownleeGGYewdellJWGerhardWThe antigenic structure of the" exact="influenza" post="virus a/PR/8/34 hemagglutinin (H1 subtype)Cell198231241742710.1016/0092-8674(82)90135-06186384 21.WilsonIACoxNJStructural basis of immune"/>
   <result pre="a/PR/8/34 hemagglutinin (H1 subtype)Cell198231241742710.1016/0092-8674(82)90135-06186384 21.WilsonIACoxNJStructural basis of immune recognition of" exact="influenza" post="virus hemagglutininAnnu Rev Immunol19908173778710.1146/annurev.iy.08.040190.0035132188678 22.XuREkiertDCKrauseJCHaiRCroweJEWilsonIAStructural basis of preexisting immunity"/>
   <result pre="22.XuREkiertDCKrauseJCHaiRCroweJEWilsonIAStructural basis of preexisting immunity to the 2009 H1N1 pandemic" exact="influenza" post="virusScience2010328597635736010.1126/science.118643020339031 23.SmithDJLapedesASde JongJCBestebroerTMRimmelzwaanGFOsterhausADMEFouchierRAMMapping the antigenic and genetic evolution of"/>
   <result pre="influenza virusScience2010328597635736010.1126/science.118643020339031 23.SmithDJLapedesASde JongJCBestebroerTMRimmelzwaanGFOsterhausADMEFouchierRAMMapping the antigenic and genetic evolution of" exact="influenza" post="virusScience2004305568237137610.1126/science.109721115218094 24.ShihAC-CHsiaoT-CHoM-SLiW-HSimultaneous amino acid substitutions at antigenic sites drive"/>
   <result pre="influenza virusScience2004305568237137610.1126/science.109721115218094 24.ShihAC-CHsiaoT-CHoM-SLiW-HSimultaneous amino acid substitutions at antigenic sites drive" exact="influenza" post="a hemagglutinin evolutionProc Natl Acad Sci2007104156283628810.1073/pnas.070139610417395716 25.JinHZhouHLiuHChanWAdhikaryLMahmoodKLeeM-SKembleGTwo residues in"/>
   <result pre="Natl Acad Sci2007104156283628810.1073/pnas.070139610417395716 25.JinHZhouHLiuHChanWAdhikaryLMahmoodKLeeM-SKembleGTwo residues in the hemagglutinin of a/Fujian/411/02-like" exact="influenza" post="viruses are responsible for antigenic drift from a/Panama/2007/99Virology2005336111311910.1016/j.virol.2005.03.01015866076 26.ZhouRDasPRoyyuruAKSingle"/>
   <result pre="high-impact hemagglutinin amino acid substitutions that drive antigenic drift of" exact="influenza" post="a (H1N1) virusesPLoS Pathog2016124e100552610.1371/journal.ppat.100552627057693 29.MedinaRAStertzSManicassamyBZimmermannPSunXAlbrechtRAUusi-KerttulaHZagordiOBelsheRBFreySEGlycosylations in the globular head"/>
   <result pre="protein modulate the virulence and antigenic properties of the H1N1" exact="influenza" post="virusesSci Transl Med20135187187ra17010.1126/scitranslmed.3005996 30.BedfordTSuchardMALemeyPDudasGGregoryVHayAJMcCauleyJWRussellCASmithDJRambautAIntegrating influenza antigenic dynamics with molecular"/>
   <result pre="antigenic properties of the H1N1 influenza virusesSci Transl Med20135187187ra17010.1126/scitranslmed.3005996 30.BedfordTSuchardMALemeyPDudasGGregoryVHayAJMcCauleyJWRussellCASmithDJRambautAIntegrating" exact="influenza" post="antigenic dynamics with molecular evolutionElife20143e0191410.7554/eLife.0191424497547 31.LorussoAVincentALHarlandMLAltDBaylesDOSwensonSLGramerMRRussellCASmithDJLagerKMGenetic and antigenic characterization"/>
   <result pre="dynamics with molecular evolutionElife20143e0191410.7554/eLife.0191424497547 31.LorussoAVincentALHarlandMLAltDBaylesDOSwensonSLGramerMRRussellCASmithDJLagerKMGenetic and antigenic characterization of H1" exact="influenza" post="viruses from United States swine from 2008J Gen Virol201192491993010.1099/vir.0.027557-021177926"/>
   <result pre="viruses from United States swine from 2008J Gen Virol201192491993010.1099/vir.0.027557-021177926 32.BaoYBolotovPDernovoyDKiryutinBZaslavskyLTatusovaTOstellJLipmanDThe" exact="influenza" post="virus resource at the National Center for biotechnology informationJ"/>
   <result pre="informationJ Virol200882259660110.1128/JVI.02005-0717942553 33.SquiresRBNoronhaJHuntVGarcía-SastreAMackenCBaumgarthNSuarezDPickettBEZhangYLarsenCNInfluenza research database: an integrated bioinformatics resource for" exact="influenza" post="research and surveillanceInfluenza Other Respir Viruses20126640441610.1111/j.1750-2659.2011.00331.x22260278 34.Shu Y, McCauley"/>
   <result pre="34.Shu Y, McCauley J. GISAID: Global initiative on sharing all" exact="influenza" post="data–from vision to reality. Eurosurveillance. 2017;22(13). https://scholar.google.com/scholar?hl=en&amp;amp;as_sdt=0%2C14&amp;amp;q=GISAID%3A+Global+initiative+on+sharing+all+influenza+data%E2%80%93from+vision+to+reality&amp;amp;btnG=. 35.CaiZDucatezMFYangJZhangTLongLPBoonACWebbyRJWanXFIdentifying antigenicity-associated"/>
   <result pre="Eurosurveillance. 2017;22(13). https://scholar.google.com/scholar?hl=en&amp;amp;as_sdt=0%2C14&amp;amp;q=GISAID%3A+Global+initiative+on+sharing+all+influenza+data%E2%80%93from+vision+to+reality&amp;amp;btnG=. 35.CaiZDucatezMFYangJZhangTLongLPBoonACWebbyRJWanXFIdentifying antigenicity-associated sites in highly pathogenic H5N1" exact="influenza" post="virus hemagglutinin by using sparse learningJ Mol Biol2012422114515510.1016/j.jmb.2012.05.01122609437 36.SunHYangJZhangTLongLPJiaKYangGWebbyRWanX-FInferring"/>
   <result pre="influenza virus hemagglutinin by using sparse learningJ Mol Biol2012422114515510.1016/j.jmb.2012.05.01122609437 36.SunHYangJZhangTLongLPJiaKYangGWebbyRWanX-FInferring" exact="influenza" post="virus antigenicity using sequence datamBio20134410.1128/mBio.00230-13 37.YangJZhangTWanXFSequence-based antigenic change prediction"/>
   <result pre="sparse learning model: a method for identifying antigenic variants of" exact="influenza" post="a(H3N2) virusBioinformatics2019351778710.1093/bioinformatics/bty45729878046 39.Han L, Zhang Y, Wan X-F, Zhang"/>
   <result pre="Conference on Brain Informatics2017CamSpringer202212 44.BlakeTAWilliamsTLPirkleJLBarrJRTargeted N-linked glycosylation analysis of H5N1" exact="influenza" post="hemagglutinin by selective sample preparation and liquid chromatography/tandem mass"/>
   <result pre="spectrometryAnal Chem20098183109311810.1021/ac900095h19290601 45.SunHYangJZhangTLongL-PJiaKYangGWebbyRJWanX-FUsing sequence data to infer the antigenicity of" exact="influenza" post="virusMBio201344e00230e0021310.1128/mBio.00230-1323820391 46.SmithRFSmmithTFPattern-induced multi-sequence alignment (PUMA) algorithm employing secondary structure-dependent"/>
   <result pre="glycosylation incorporating structural properties and patternsBioinformatics201228172249225510.1093/bioinformatics/bts42622782545 48.CaiZZhangTWanXFA computational framework for" exact="influenza" post="antigenic cartographyPLoS Comput Biol2010610e100094910.1371/journal.pcbi.100094920949097 49.PriceMNDehalPSArkinAPFastTree 2–approximately maximum-likelihood trees for"/>
   <result pre="Hemagglutinin substitution increases Thermostability and improves yields of 2009 H1N1" exact="influenza" post="a virus in cellsJ Virol2018922e01621e0161729118117 55.KhatriKKleinJAWhiteMRGrantOCLeymarieNWoodsRJHartshornKLZaiaJIntegrated Omics and computational"/>
   <result pre="Virol2018922e01621e0161729118117 55.KhatriKKleinJAWhiteMRGrantOCLeymarieNWoodsRJHartshornKLZaiaJIntegrated Omics and computational Glycobiology reveal structural basis for" exact="influenza" post="a virus glycan microheterogeneity and host interactionsMol Cell Proteomics20161561895191210.1074/mcp.M116.05801626984886"/>
   <result pre="sequence constraintsCell2010141589790710.1016/j.cell.2010.04.01220510933 66.Lee M-S, Chen JS-E: Predicting antigenic variants of" exact="influenza" post="a/H3N2 viruses-volume 10, number 8—august 2004-emerging infectious disease journal-CDC."/>
   <result pre="antigenic variants of influenza a/H3N2 viruses-volume 10, number 8—august 2004-emerging" exact="infectious disease" post="journal-CDC. 2004. 67.LiaoY-CLeeM-SKoC-YHsiungCABioinformatics models for predicting antigenic variants of"/>
   <result pre="disease journal-CDC. 2004. 67.LiaoY-CLeeM-SKoC-YHsiungCABioinformatics models for predicting antigenic variants of" exact="influenza" post="a/H3N2 virusBioinformatics200824450551210.1093/bioinformatics/btm63818187440 68.HuangJ-WKingC-CYangJ-MCo-evolution positions and rules for antigenic variants"/>
   <result pre="virusBioinformatics200824450551210.1093/bioinformatics/btm63818187440 68.HuangJ-WKingC-CYangJ-MCo-evolution positions and rules for antigenic variants of human" exact="influenza" post="a/H3N2 virusesBMC bioinformatics2009101S4110.1186/1471-2105-10-S1-S4119208143 69.RenXLiYLiuXShenXGaoWLiJComputational identification of antigenicity-associated sites in"/>
   <result pre="of antigenicity-associated sites in the hemagglutinin protein of a/H1N1 seasonal" exact="influenza" post="virusPLoS One2015105e012674210.1371/journal.pone.012674225978416 70.Neher RA, Bedford T, Daniels RS, Russell"/>
   <result pre="BI. Prediction, dynamics, and visualization of antigenic phenotypes of seasonal" exact="influenza" post="viruses. Proc Natl Acad Sci. 2016;113(12):E1701–9. 71.Shen J, Ma"/>
   <result pre="J, Ma J, Wang Q. Evolutionary trends of A (H1N1)" exact="influenza" post="virus hemagglutinin since 1918. PLoS one. 2009;4(11). 72.Kirkpatrick E,"/>
   <result pre="E, Qiu X, Wilson PC, Bahl J, Krammer F. The" exact="influenza" post="virus hemagglutinin head evolves faster than the stalk domain."/>
   <result pre="near the receptor binding site determine major antigenic change during" exact="influenza" post="virus evolution. Science. 2013;342(6161):976–49. 74.TateMDBrooksAGReadingPCSpecific sites of N-linked glycosylation"/>
   <result pre="sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype" exact="influenza" post="a virus determine sensitivity to inhibitors of the innate"/>
   <result pre="innate immune system and virulence in miceJ Immunol201118741884189410.4049/jimmunol.110029521768397 75.WangC-CChenJ-RTsengY-CHsuC-HHungY-FChenS-WChenC-MKhooK-HChengT-JChengY-SEGlycans on" exact="influenza" post="hemagglutinin affect receptor binding and immune responseProc Natl Acad"/>
   <result pre="addition of oligosaccharides on the biological activities and antigenicity of" exact="influenza" post="a/H3N2 virus hemagglutininJ Virol200478189605961110.1128/JVI.78.18.9605-9611.200415331693 77.AkmalMARasoolNKhanYDPrediction of N-linked glycosylation sites"/>
   <result pre="to explain the origin and virulence of the 1918 Spanish" exact="influenza" post="virusPhilos Trans R Soc Lond Ser B Biol Sci200135614161829183910.1098/rstb.2001.102011779381"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7218330\results\search\disease\results.xml">
   <result pre="Listeria, Toxoplasma, Brucella, Trichinosis Raw fish and shellfish Vibrios, norovirus," exact="hepatitis" post="A, many other pathogens, toxins and parasites Fresh fruits"/>
   <result pre="norovirus, Giardia, Shigella, E coli O157, other E coli species," exact="hepatitis" post="A Sprouts (alfalfa, mung bean) Salmonella, E coli O157,"/>
   <result pre="hepatitis A Sprouts (alfalfa, mung bean) Salmonella, E coli O157," exact="hepatitis" post="A Honey C. botulinum Cream-filled pastry; potato, egg, or"/>
   <result pre="a study that reported a correlation between the incidence of" exact="hepatitis" post="A and the lack of cockroach control. From 1956"/>
   <result pre="the Carmelitos Housing Project had 20% to 39% of the" exact="hepatitis" post="A cases in Los Angeles. However, through a concentrated"/>
   <result pre="in the incidence of endemic infectious hepatitis: in 1960, the" exact="hepatitis" post="A incidence at the housing project reduced to 6.6%,"/>
   <result pre="of the infection. It was observed that the decline in" exact="hepatitis" post="A incidence occurred simultaneously with a significant reduction (about"/>
   <result pre="in cockroach infestation due to the pest control programme. The" exact="hepatitis" post="A virus occurs in the faeces of infected persons"/>
   <result pre="of cockroaches with faeces and food makes their transmission of" exact="hepatitis" post="A virus highly plausible. Although the study of Tarshis28"/>
   <result pre="dysentery through the production of shiga toxins46,47. S. Typhi causes" exact="typhoid fever," post="which is a serious disease as it could lead"/>
   <result pre="Typhi should be viewed with seriousness in developing countries where" exact="typhoid fever" post="is most prevalent and lack of food hygiene is"/>
   <result pre="is also of serious concern. S. Typhimurium causes a mild" exact="gastroenteritis" post="and is often transmitted from animals through consumption of"/>
   <result pre="cells) and is implicated in severe clinical conditions including, haemorrhagic" exact="colitis" post="leading to bloody diarrhoea, haemolytic uremic syndrome and kidney"/>
   <result pre="C. cayetanensis and E. histolytica.63,64 Among food-borne viruses, rotavirus and" exact="hepatitis" post="A virus have been reported to be associated with"/>
   <result pre="health. Hepatitis A is the most common form of acute" exact="viral hepatitis" post="worldwide and therefore its association with cockroaches is a"/>
   <result pre="Hepatitis A is the most common form of acute viral" exact="hepatitis" post="worldwide and therefore its association with cockroaches is a"/>
   <result pre="such as C. perfringens, C. botulinum, Campylobacter spp., norovirus, and" exact="hepatitis" post="A. In addition, there is the need for a"/>
   <result pre="2008;57:366-370.18401330 12.VirayMAHofmeisterMGJohnstonDI, et al.Public health investigation and response to a" exact="hepatitis" post="a outbreak from imported scallops consumed raw-Hawaii, 2016 [published"/>
   <result pre="(Blatta orientalis) as passive vectors of causal agents of avian" exact="tuberculosis" post="and paratuberculosis. Med Vet Entomol. 2003;17:145-150.12823831 34.FotedarRNayarESamantrayJC, et al.Cockroaches"/>
   <result pre="Rev Infect Dis. 1985;7:244-256.3890097 49.EdelmanRLevineMM.Summary of an international workshop on" exact="typhoid fever." post="Rev Infect Dis. 1986;8:329-349.3726393 50.HelmsMEthelbergSMolbakK.International Salmonella typhimurium DT104 infections,"/>
   <result pre="a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136-141.22030330 66.RevelasA.Acute" exact="gastroenteritis" post="among children in the developing world. South Afr J"/>
   <result pre="the developing world. South Afr J Epidemiol Infect. 2012;27:156-162. 67.ElliottEJ.Acute" exact="gastroenteritis" post="in children. BMJ Open. 2007;334:35-40. 68.collab: World Health Organization."/>
   <result pre="Leag Nations. 2013;88:49-64. 69.DamankaSAdikuTKArmahGE, et al.Rotavirus infection in children with" exact="diarrhea" post="at Korle-Bu teaching hospital, Ghana. Jpn J Infect Dis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7219742\results\search\disease\results.xml">
   <result pre="evaluate the ability of local Ae. polynesiensis to transmit the" exact="chikungunya" post="virus (CHIKV), two field populations were analyzed for vector"/>
   <result pre="by several dengue epidemics, but did not face Zika or" exact="chikungunya" post="outbreaks, unlike other neighboring islands. The near-exclusive presence of"/>
   <result pre="the role played by this mosquito as a vector of" exact="dengue fever." post="A local Ae. polynesiensis population was recently shown to"/>
   <result pre="Zika virus under experimental conditions, but its susceptibility to the" exact="chikungunya" post="virus was still unknown, and recent data on the"/>
   <result pre="the ability of local Ae. polynesiensis populations to transmit the" exact="chikungunya" post="virus. These findings highlight the risk of arbovirus transmission"/>
   <result pre="19th century [5] and PICTs have been regularly affected by" exact="dengue fever" post="epidemics caused by the four dengue virus serotypes [6–8]."/>
   <result pre="[9, 10]. The first cases of autochthonous transmission of the" exact="chikungunya" post="virus (CHIKV) were detected in New Caledonia in 2011"/>
   <result pre="Futuna [24]. Ae. polynesiensis is the main vector of lymphatic" exact="filariasis" post="in the South Pacific, a parasitic disease caused by"/>
   <result pre="main vector of lymphatic filariasis in the South Pacific, a" exact="parasitic disease" post="caused by the Wuchereria bancrofti pathogen, but it is"/>
   <result pre="pathogen, but it is also considered a secondary vector of" exact="dengue fever" post="[6, 8, 25]. These observations on Wallis and Futuna"/>
   <result pre="[26]. Also, it did not experience any autochthonous case of" exact="chikungunya" post="or Zika, despite the numerous exchanges with other territories,"/>
   <result pre="populations for CHIKV to determine the risk of transmission of" exact="chikungunya" post="in the territory. Methods Ethics statement Animals were housed"/>
   <result pre="and Futuna are provided in S1 Table. Vector competence for" exact="chikungunya" post="virus To evaluate the ability of Ae. polynesiensis from"/>
   <result pre="mosquito populations with a CHIKV strain isolated during the 2011" exact="chikungunya" post="outbreak in New Caledonia. This viral strain was chosen"/>
   <result pre="in the territory of Wallis and Futuna, especially for the" exact="dengue fever" post="that has already affected the populations on the inhabited"/>
   <result pre="main arbovirus diseases currently circulating in the Pacific region, namely" exact="dengue fever," post="Zika and chikungunya. Furthermore, the presence of Ae. aegypti"/>
   <result pre="and Futuna territory of contracting the two emerging Pacific diseases," exact="chikungunya" post="and Zika, because they are not immune to these"/>
   <result pre="MercierA, LepersC, HoyD, DuituturagaS, BenyonE, et al.Concurrent outbreaks of dengue," exact="chikungunya" post="and Zika virus infections—an unprecedented epidemic wave of mosquito-borne"/>
   <result pre="Hyg. 1954;3(5):878–82. Epub 1954/09/01. 10.4269/ajtmh.1954.3.878 .13197723 33HitchcockJC. Transmission of sub-periodic" exact="filariasis" post="in Tonga by Aedes oceanicus Belkin. Trans R Soc"/>
   <result pre="p. 39FauranP, LacosteJ, CombesD, MarcilleP, CharpinM. [Wuchereria bancrofti human aperiodic" exact="filariasis" post="in French territory of Wallis and Futuna (author's transl)]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7220504\results\search\disease\results.xml">
   <result pre="12 patients died. Four and 3 patients died from underlying" exact="lung disease" post="and cardiovascular events, respectively. In addition, some patients presented"/>
   <result pre="similar in terms of efficacy in preventing secondary transmission of" exact="respiratory disease." post="In addition, no difference was observed in patient survival"/>
   <result pre="such as earthquakes or hurricane, but also man-made disasters. Recently," exact="infectious disease" post="or the epidemic of infectious origin became another threat"/>
   <result pre="is important in preventing further infection transmission. During the previous" exact="influenza" post="A (H1N1) virus pandemic in 2009, kidney professionals overcame"/>
   <result pre="situation and to address new challenges.[10] Moreover, previous articles on" exact="hepatitis" post="B and C outbreaks have shown that adherence to"/>
   <result pre="next outbreak. Clin J Am Soc Nephrol2018;13:669–70.29567861 [11]FabriziFDixitVMessaPet al.Transmission of" exact="hepatitis" post="B virus in dialysis units: a systematic review of"/>
   <result pre="outbreaks. Int J Artif Organs2015;38:1–7.25633894 [12]NguyenDBGutowskiJGhiselliMet al.A large outbreak of" exact="hepatitis" post="C virus infections in a hemodialysis clinic. Infect Control"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7225641\results\search\disease\results.xml">
   <result pre="a country made up of tropical islands, has suffered cyclic" exact="dengue fever" post="(DF) outbreaks in the past three decades. An outbreak"/>
   <result pre="Results The overall prevalence rates of DENV, Zika virus, and" exact="chikungunya" post="virus were 83.4%, 7.6%, and 0.9%, respectively. The qPCR"/>
   <result pre="2016 were as follows: DENV 39.6%, Zika virus 16.7%, and" exact="chikungunya" post="virus 6.3%, which increased to 74%, 48%, and 20%"/>
   <result pre="global expansion and reported occurrence of Zika virus (ZIKV) and" exact="chikungunya" post="virus (CHKV) infections in the region [14, 15], prompted"/>
   <result pre="(74.8–90.3) 0.60   Had fever 69 54 (78.3) (66.7–87.3) 0.07   Had" exact="malaria" post="56 48 (85.7) (73.8–93.6) 0.36   Had dengue fever 15"/>
   <result pre="(66.7–87.3) 0.07   Had malaria 56 48 (85.7) (73.8–93.6) 0.36   Had" exact="dengue fever" post="15 13 (86.7) (59.5–98.3) 0.64 Force of infection   Age"/>
   <result pre="editorAugust 2012. 2.GuzmanMGHarrisEDengueLancet2015385996645346510.1016/S0140-6736(14)60572-925230594 3.TewariKTewariVVMehtaRClinical and hematological profile of patients with" exact="dengue fever" post="at a tertiary care hospital - an observational studyMediterr"/>
   <result pre="Dis2018101e201802110.4084/mjhid.2018.02129531658 4.WeiHYShuPYHungMNCharacteristics and risk factors for fatality in patients with" exact="dengue hemorrhagic fever," post="Taiwan, 2014Am J Trop Med Hyg201695232232710.4269/ajtmh.15-090527273649 5.HolmesECRNA virus genomics:"/>
   <result pre="Caledonia, South Pacific, 2001-2013Virol J2014116110.1186/1743-422X-11-6124684835 9.AubryMTeissierAHuartMMerceronSVanhomwegenJMapotoekeMet al.Seroprevalence of dengue and" exact="chikungunya" post="virus antibodies, French Polynesia, 2014-2015Emerg Infect Dis201824355856110.3201/eid2403.17114929460745 10.DuncombeJLauCWeinsteinPAaskovJRourkeMGrantRet al.Seroprevalence"/>
   <result pre="Hancock T, Guillaumot L, et al. Preparedness for threat of" exact="chikungunya" post="in the pacific. Emerg Infect Dis. 2014;20(8). 16.CraigATJoshuaCASioARTeobasiBDofaiADalipandaTet al.Enhanced"/>
   <result pre="virusBull World Health Organ2016941288089210.2471/BLT.16.17595027994281 20.PhommanivongVKandaSShimonoTLamaningaoPDarcyAWMishimaNet al.Co-circulation of the dengue with" exact="chikungunya" post="virus during the 2013 outbreak in the southern part"/>
   <result pre="children in Colombo, Sri LankaPLoS Negl Trop Dis201376e225910.1371/journal.pntd.000225923755315 24.WhitakerHJFarringtonCPEstimation of" exact="infectious disease" post="parameters from serological survey data: the impact of regular"/>
   <result pre="survey data: the impact of regular epidemicsStat Med200423152429244310.1002/sim.181915273957 25.SennNLuang-SuarkiaDManongDSibaPMMcBrideWJContribution of" exact="dengue fever" post="to the burden of acute febrile illnesses in Papua"/>
   <result pre="PhilippinesPLoS Negl Trop Dis2016102e000433710.1371/journal.pntd.000433726845762 28.VongpunsawadSIntharasongkrohDThongmeeTPoovorawanYSeroprevalence of antibodies to dengue and" exact="chikungunya" post="viruses in ThailandPLoS One2017126e018056010.1371/journal.pone.018056028662144 29.ReichNGShresthaSKingAARohaniPLesslerJKalayanaroojSet al.Interactions between serotypes of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7226564\results\search\disease\results.xml">
   <result pre="a group of chronic autoinflammatory diseases including Crohn’s disease and" exact="ulcerative colitis." post="Although the molecular mechanisms governing the pathogenesis of gastrointestinal"/>
   <result pre="intestinal microbiome was clearly primarily studied from the view of" exact="gastrointestinal disease." post="Inflammatory bowel diseases (IBDs) are a group of chronic"/>
   <result pre="diseases (IBDs) are a group of chronic autoinflammatory diseases including" exact="ulcerative colitis" post="(UC) and Crohn’s disease (CD). They are characterized by"/>
   <result pre="(IBDs) are a group of chronic autoinflammatory diseases including ulcerative" exact="colitis" post="(UC) and Crohn’s disease (CD). They are characterized by"/>
   <result pre="it is associated with many even seemingly unrelated diseases including" exact="liver disease" post="[11], neurobehavioral dysfunction in non-alcoholic steatosis [12], lung cancer"/>
   <result pre="including liver disease [11], neurobehavioral dysfunction in non-alcoholic steatosis [12]," exact="lung cancer" post="[13], or obstructive sleep apnea [14]. Furthermore, dysbiosis may"/>
   <result pre="liver disease [11], neurobehavioral dysfunction in non-alcoholic steatosis [12], lung" exact="cancer" post="[13], or obstructive sleep apnea [14]. Furthermore, dysbiosis may"/>
   <result pre="neurobehavioral dysfunction in non-alcoholic steatosis [12], lung cancer [13], or" exact="obstructive sleep apnea" post="[14]. Furthermore, dysbiosis may provoke the development or exacerbate"/>
   <result pre="dysfunction in non-alcoholic steatosis [12], lung cancer [13], or obstructive" exact="sleep apnea" post="[14]. Furthermore, dysbiosis may provoke the development or exacerbate"/>
   <result pre="development or exacerbate the course of inflammatory diseases such as" exact="rheumatoid arthritis" post="[15], systemic lupus erythematosus [16], or IBD [17]. The"/>
   <result pre="or exacerbate the course of inflammatory diseases such as rheumatoid" exact="arthritis" post="[15], systemic lupus erythematosus [16], or IBD [17]. The"/>
   <result pre="the course of inflammatory diseases such as rheumatoid arthritis [15]," exact="systemic lupus erythematosus" post="[16], or IBD [17]. The term &quot;dysbiosis�? usually encompasses"/>
   <result pre="course of inflammatory diseases such as rheumatoid arthritis [15], systemic" exact="lupus erythematosus" post="[16], or IBD [17]. The term &quot;dysbiosis�? usually encompasses"/>
   <result pre="these results were supported by a T-cell transfer model of" exact="colitis" post="in mice. In animals treated with T cells, reads"/>
   <result pre="carrying antibacterial resistance genes were detected in the sputum from" exact="cystic fibrosis" post="patients [60]. Conversely, another study analyzed the abundance of"/>
   <result pre="[63]. Therefore, phage SopEPhi indirectly contributes to the development of" exact="colitis" post="in streptomycin-pretreated mice [64]. Some proteins are even able"/>
   <result pre="FMT is effective in multiple gastrointestinal diseases such as CDI," exact="irritable bowel syndrome" post="(IBS), IBD, and CRC [67,68]. For instance, in the"/>
   <result pre="may, in turn, lead to other problems such as antibiotic-associated" exact="diarrhea" post="and C. difficile infection [76]. Conversely, phages do not"/>
   <result pre="even helpful in alleviating the symptoms of dextran sodium sulfate-induced" exact="colitis" post="in mice colonized with E. coli LF82. Strikingly, this"/>
   <result pre="the destruction of harmful bacterial strains and the alleviation of" exact="gastrointestinal disease," post="including IBD, must be determined. In addition to the"/>
   <result pre="in IBDJ. Crohns Colitis20171190592010.1093/ecco-jcc/jjx002.03828039310 11.ZengY.ChenS.FuY.WuW.ChenT.ChenJ.YangB.OuQ.Gut microbiota dysbiosis in patients with" exact="hepatitis" post="B virus-induced chronic liver disease covering chronic hepatitis, liver"/>
   <result pre="11.ZengY.ChenS.FuY.WuW.ChenT.ChenJ.YangB.OuQ.Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic" exact="liver disease" post="covering chronic hepatitis, liver cirrhosis and hepatocellular carcinomaJ. Viral"/>
   <result pre="hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver" exact="cirrhosis" post="and hepatocellular carcinomaJ. Viral Hepat.20202714315510.1111/jvh.1321631600845 12.HigarzaS.G.ArboleyaS.GueimondeM.Gomez-LazaroE.AriasJ.L.AriasN.Neurobehavioral dysfunction in non-alcoholic"/>
   <result pre="Alterations in the Enteric Virome in Inflammatory Bowel DiseaseCell201516044746010.1016/j.cell.2015.01.00225619688 30.DuerkopB.A.KleinerM.Paez-EspinoD.ZhuW.BushnellB.HassellB.WinterS.E.KyrpidesN.C.HooperL.V.Murine" exact="colitis" post="reveals a disease-associated bacteriophage communityNat. Microbiol.201831023103110.1038/s41564-018-0210-y30038310 31.FernandesM.A.VerstraeteS.G.PhanT.G.DengX.StekolE.LaMereB.LynchS.V.HeymanM.B.DelwartE.Enteric Virome and"/>
   <result pre="new therapy: From Clostridioides difficile infection to inflammatory bowel disease," exact="irritable bowel syndrome," post="and colon cancerCurr. Opin. Pharmacol.201949435110.1016/j.coph.2019.04.01731173991 68.NowakA.HedenstiernaM.UrsingJ.LidmanC.NowakP.Efficacy of Routine Fecal"/>
   <result pre="live and dead Salmonella-based vector strain on the course of" exact="colitis" post="in miceLett. Appl. Microbiol.20166334034610.1111/lam.1263227501439 75.LiptakR.GromovaB.MaronekM.GardlikR.Reverse phenotype transfer via fecal"/>
   <result pre="and genetically-modified phagesWorld J. Microbiol. Biotechnol.2016326710.1007/s11274-016-2009-426931607 81.ChassaingB.KorenO.CarvalhoF.A.LeyR.E.GewirtzA.T.AIEC pathobiont instigates chronic" exact="colitis" post="in susceptible hosts by altering microbiota compositionGut2014631069108010.1136/gutjnl-2013-30490923896971 82.BretinA.LucasC.LarabiA.DalmassoG.BillardE.BarnichN.BonnetR.NguyenH.T.T.AIEC infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7226716\results\search\disease\results.xml">
   <result pre="Research Article Epidemiological analysis of the Kaohsiung city strategy for" exact="dengue fever" post="quarantine and epidemic prevention PanChao-Ying1LiuWei-Liang2SuMatthew-P.3ChangTe-Pin2HoHui-Pin1ShuPei-Yun4HuangJoh-Jong5LinLi-Jeneight@kcg.gov.tw1ChenChun-Hongchunhong@gmail.com26[1], [2], grid.59784.370000000406229172National Mosquito-Borne Diseases"/>
   <result pre="the validity of this strategy. Methods Data on cases of" exact="dengue fever" post="that occurred between 2013 and 2018 were obtained from"/>
   <result pre="of imported dengue cases, which resulted in epidemics of indigenous" exact="dengue fever" post="within local communities. Further analysis of confirmed cases during"/>
   <result pre="epidemics in Kaohsiung City found that the risk of indigenous" exact="dengue fever" post="may be related to the likelihood that patients with"/>
   <result pre="may be related to the likelihood that patients with imported" exact="dengue fever" post="will stay within local communities. Conclusion Given the correlations"/>
   <result pre="Given the correlations found between imported and indigenous cases of" exact="dengue fever," post="as well as the relationship between the disease concealment"/>
   <result pre="between the disease concealment period and the risk of indigenous" exact="dengue fever," post="prevention of disease importation and efficient identification of dengue"/>
   <result pre="disease control. Keywords Dengue virus Imported dengue cases Concealment Indigenous" exact="dengue fever" post="Airport fever screening Noncontact infrared thermometers Funding National Health"/>
   <result pre="symptoms vary significantly and range from asymptomatic cases to classic" exact="dengue fever" post="(DF), as well as more serious complications (e.g., dengue"/>
   <result pre="dengue fever (DF), as well as more serious complications (e.g.," exact="dengue hemorrhagic fever" post="or dengue shock syndrome) [10]. The dengue virus (DENV)"/>
   <result pre="disease has therefore become the major objective of quarantine for" exact="dengue fever" post="and the epidemic prevention network in Taiwan. The emergence"/>
   <result pre="airport fever screening systems to test individuals suspected of having" exact="dengue fever" post="have become central to the disease control program of"/>
   <result pre="dissect the complex interactions between indigenous and imported cases of" exact="dengue fever." post="In this study, we investigated the number of indigenous"/>
   <result pre="we investigated the number of indigenous and imported cases of" exact="dengue fever" post="in Kaohsiung City between 2013 and 2018, including the"/>
   <result pre="that importation of the virus is indeed driving outbreaks of" exact="dengue fever" post="in Taiwan, indicating that disease prevention strategies should continue"/>
   <result pre="focus on human migration patterns and the efficient identification of" exact="dengue fever" post="to reduce the incidence of disease. Methods Database and"/>
   <result pre="Methods Database and case definitions We identified all cases of" exact="dengue fever" post="reported between January 2013 and September 2018 in the"/>
   <result pre="Diagnostic Center of the Taiwan CDC, a confirmed case of" exact="dengue fever" post="requires positive detection of RNA using real-time reverse transcriptase"/>
   <result pre="local physicians and epidemiologists to collect individual-level information on each" exact="dengue fever" post="case, including the onset of dengue illness, age, gender,"/>
   <result pre="unknown origin and school-based reporting) detection. An imported case of" exact="dengue fever" post="is defined as a confirmed case in a patient"/>
   <result pre="a patient who had traveled to another country, in which" exact="dengue fever" post="is endemic, within 2 weeks prior to the onset of"/>
   <result pre="significant. Results Statistical analysis of indigenous and imported cases of" exact="dengue fever" post="in Kaohsiung City between 2013 and September 2018 Statistics"/>
   <result pre="2018 Statistics for the total number of imported cases of" exact="dengue fever" post="in Kaohsiung City A total of 239 imported cases"/>
   <result pre="for all years Predominant serotypes of annual indigenous cases of" exact="dengue fever" post="in Kaohsiung City Between 2013 and September 2018, there"/>
   <result pre="2013 and September 2018, there were 35,148 indigenous cases of" exact="dengue fever" post="in Kaohsiung City, with 70, 14,999, 19,723, 342, 3,"/>
   <result pre="(up to the end of September), respectively. Primary cases of" exact="dengue fever" post="were concentrated in the 24 consecutive months between May"/>
   <result pre="2). During this period, there were 35,062 indigenous cases of" exact="dengue fever" post="in Kaohsiung City (99.8%). The major epidemic serotype of"/>
   <result pre="fever in Kaohsiung City (99.8%). The major epidemic serotype of" exact="dengue fever" post="in 2014 was serotype 1, while that from 2015"/>
   <result pre="2016 2017 2018 Total Number of confirmed imported cases of" exact="dengue fever" post="32 44 61 37 34 31 239 Number of"/>
   <result pre="37 34 31 239 Number of confirmed imported cases of" exact="dengue fever" post="which did not staying in the community 5 3"/>
   <result pre="analysis of the number of indigenous and imported cases of" exact="dengue fever" post="in Kaohsiung City between 2013 and September 2018 The"/>
   <result pre="2013 and September 2018 The 35,148 confirmed cases of indigenous" exact="dengue fever" post="reported in Kaohsiung City between 2013 and September of"/>
   <result pre="of standard error Group 1 Number of indigenous cases of" exact="dengue fever" post="509.39 69 1534.868 184.776 Number of import cases of"/>
   <result pre="fever 509.39 69 1534.868 184.776 Number of import cases of" exact="dengue fever" post="3.42 69 2.11 0.254 Paired sample correlation N correlation"/>
   <result pre="N correlation signification Group 1 Number of indigenous cases of" exact="dengue fever" post="69 0.407 0.001 Verification of paired sample Paired difference"/>
   <result pre="T df Significance (two tailed) Number of indigenous cases of" exact="dengue fever" post="505.971 1534.009 184.673 137.462 874.48 2.74 68 0.008 Number"/>
   <result pre="137.462 874.48 2.74 68 0.008 Number of import cases of" exact="dengue fever" post="However, actual clinical surveillance reports were delayed by approximately"/>
   <result pre="reports were delayed by approximately 1–2 months during local epidemics of" exact="dengue fever;" post="furthermore, a concealment period ≥2 days was common. Therefore, instead"/>
   <result pre="imported cases of dengue Correlation Number of indigenous cases of" exact="dengue fever" post="Number of imported cases of dengue fever with a"/>
   <result pre="indigenous cases of dengue fever Number of imported cases of" exact="dengue fever" post="with a concealment period of longer than 3 days"/>
   <result pre="of longer than 3 days Number of imported cases of" exact="dengue fever" post="with a concealment period of longer than 2 days"/>
   <result pre="of longer than 2 days Number of imported cases of" exact="dengue fever" post="with a concealment period of longer than 4 days"/>
   <result pre="of longer than 4 days Number of indigenous cases of" exact="dengue fever" post="Pearson correlation 1 Significance (two tailed) 0.459** 0.387** Significance"/>
   <result pre="sites of mosquito breeding) [23, 24]. The large-scale outbreaks of" exact="dengue fever" post="that occurred in Kaohsiung City between 2014 and 2015,"/>
   <result pre="of disease. Kaohsiung City experienced a severe epidemic outbreak of" exact="dengue fever" post="from 2014 to 2015, in part due to a"/>
   <result pre="to improve the anti-epidemic capacity of Kaohsiung City to prevent" exact="dengue fever." post="These efforts included the establishment of a quarantine referral"/>
   <result pre="2015 outbreaks, there were 14,999 and 19,723 cases of indigenous" exact="dengue fever," post="respectively. Case reports from early 2016 showed signs of"/>
   <result pre="before April. However, there were only two cases of native" exact="dengue fever" post="throughout the remainder of 2016. In 2017 and 2018,"/>
   <result pre="border quarantine network in South Taiwan for the prevention of" exact="dengue fever" post="epidemics. Kaohsiung City possesses large native populations of Aedes"/>
   <result pre="above findings, the lowest record of local confirmed cases of" exact="dengue fever" post="in Kaohsiung City in the past few years was"/>
   <result pre="may be several factors influencing disease transmission (including vector migration)," exact="dengue fever" post="outbreaks in Kaohsiung are the likely the result of"/>
   <result pre="high-efficiency health care, are utilized to reduce the likelihood of" exact="dengue fever" post="becoming endemic in Kaohsiung City. Supplementary information LINK Additional"/>
   <result pre="The analysis chart was created after analyzing all collected imported" exact="dengue fever" post="data from 2013 to 2018 and referring to the"/>
   <result pre="emergence of arthropod-borne viral diseases: a global prospective on dengue," exact="chikungunya" post="and zika feversActa Trop201716615516310.1016/j.actatropica.2016.11.02027876643 4.MassadEAmakuMBezerra CoutinhoFAStruchinerCJBurattiniMNKhanKet al.Estimating the probability"/>
   <result pre="escalating problemBMJ20023241563156610.1136/bmj.324.7353.156312089096 14.ChangKHuangCHLeeIKLuPLLinCYChenTCet al.Differences in mortality and clinical manifestations of" exact="dengue hemorrhagic fever" post="in Taiwan in different years: a comparison for cases"/>
   <result pre="Syst Rev 2017. https://doi.org/10.1002/14651858.CD012759. 25.ChangCJChenCSTienCJLuMREpidemiological, clinical and climatic characteristics of" exact="dengue fever" post="in Kaohsiung City, Taiwan with implication for prevention and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7227788\results\search\disease\results.xml">
   <result pre="used previously in Brazil during outbreaks of Zika virus and" exact="yellow fever" post="virus.9,10,11 Sequencing was performed using a multiplex PCR primer"/>
   <result pre="period when Brazil was hit by explosive epidemics of Zika," exact="chikungunya" post="and yellow fever viruses.27,28 This highlights the need of"/>
   <result pre="Brazil was hit by explosive epidemics of Zika, chikungunya and" exact="yellow fever" post="viruses.27,28 This highlights the need of improved longitudinal genomic"/>
   <result pre="Oswaldo Cruz.2019114e18025130624458 18FariaNRKraemerMUGHillSCGoes de JesusJAguiarRSIaniFCMet al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potential.Science2018361640589489930139911 19FariaNRQuickJClaroIMThezeJde JesusJGGiovanettiMet al.Establishment and cryptic transmission"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7228120\results\search\disease\results.xml">
   <result pre="terms. Abstract Since its first introduction into China in 2009," exact="influenza" post="A/H1N1pdm virus has undergone a rapid expansion and replaced"/>
   <result pre="viruses, as well as two lineages (Victoria and Yamagata) of" exact="influenza" post="B virus during 2018–2019, suggesting the simultaneous changes of"/>
   <result pre="might be associated with the recent large outbreak of seasonal" exact="influenza" post="epidemic in China during 2018–2019. Fifteen amino acid mutations"/>
   <result pre="of the A/H1N1pdm virus, and highlight the importance of strengthening" exact="influenza" post="surveillance in East China and South China. A/H1N1pdm genetic"/>
   <result pre="viral evolution fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Seasonal" exact="influenza" post="epidemics are a major public health burden, causing significant"/>
   <result pre="291,000–645,000 per year (Iuliano et al., 2018). Two subtypes of" exact="influenza" post="A virus (A/H1N1 and A/H3N2), and two lineages of"/>
   <result pre="influenza A virus (A/H1N1 and A/H3N2), and two lineages of" exact="influenza" post="B virus (Victoria and Yamagata) are major causative agents"/>
   <result pre="and Yamagata) are major causative agents responsible for the seasonal" exact="influenza" post="epidemics, and often co-circulating. The classical seasonal A(H1N1) had"/>
   <result pre="2009 (Snacken et al., 1999). However, a novel swine-origin H1N1" exact="influenza" post="virus (A/H1N1pdm) emerged in humans during March-April 2009 in"/>
   <result pre="A(H1N1) virus and exhibited similar seasonal epidemic characteristics thereafter. Although" exact="influenza" post="virus vaccines are effective in preventing the spread of"/>
   <result pre="virus vaccines are effective in preventing the spread of seasonal" exact="influenza" post="virus, error-prone trait of viral RNA polymerase enables the"/>
   <result pre="evolutionary and epidemiological dynamics of A/H3N2 and two lineages of" exact="influenza" post="B virus have been well characterized at the global"/>
   <result pre="virus was promptly included into a national surveillance system for" exact="influenza" post="in China since 2009. However, phylodynamics of the A/H1N1pdm"/>
   <result pre="poorly understood. Furthermore, the majority of previous evolutionary analyses of" exact="influenza" post="viruses were conducted before 2015, which leaves a big"/>
   <result pre="nowadays. Since the winter of 2017, higher level of seasonal" exact="influenza" post="activity occurred in China and other countries (Gao, 2018;"/>
   <result pre="et al., 2019). For example, about 63.3% (405/640) children with" exact="influenza" post="were associated with influenza A viruses in Shanghai (unpublished"/>
   <result pre="example, about 63.3% (405/640) children with influenza were associated with" exact="influenza" post="A viruses in Shanghai (unpublished data). The evolutionary reason"/>
   <result pre="The evolutionary reason for the 2017–2019 large outbreak of seasonal" exact="influenza" post="remains to be answered. To well understand the evolutionary"/>
   <result pre="from children’s parents or guardians before sample collection. Infection with" exact="influenza" post="A was determined by Colloidal gold immunochromatographic assay (Wondfo"/>
   <result pre="Co., Ltd, China) and an in-house RT-qPCR assay specific for" exact="influenza" post="A virus. From the influenza A virus positive samples"/>
   <result pre="in-house RT-qPCR assay specific for influenza A virus. From the" exact="influenza" post="A virus positive samples by both assays, we randomly"/>
   <result pre="primers MBTuni12 and MBTnui13 were used to amplify all 8" exact="influenza" post="A viruses genomic segments as described previously (Zhou et"/>
   <result pre="and unique genomic sequences containing the complete ORFs of each" exact="influenza" post="genomic segment were generated. Only the assembled genomic sequence"/>
   <result pre="coverage were used. A total of 99 genomic sequences of" exact="influenza" post="A were obtained, and deposited in GISAID database1 (Supplementary"/>
   <result pre="using Figtree v1.4.4. To understand the evolutionary dynamics of seasonal" exact="influenza" post="in China from 2009 to 2019, all available 1,192"/>
   <result pre="A/H1N1pdm from China were further analyzed, and compared with A/H3N2," exact="influenza" post="B/Victoria and influenza B/Yamagata. There are 1,021, 545, and"/>
   <result pre="were further analyzed, and compared with A/H3N2, influenza B/Victoria and" exact="influenza" post="B/Yamagata. There are 1,021, 545, and 538 HA sequences"/>
   <result pre="There are 1,021, 545, and 538 HA sequences for A/H3N2," exact="influenza" post="B/Victoria and influenza B/Yamagata from China to be downloaded"/>
   <result pre="545, and 538 HA sequences for A/H3N2, influenza B/Victoria and" exact="influenza" post="B/Yamagata from China to be downloaded from GenBank and"/>
   <result pre="infer the phylogeny and the population dynamics of the seasonal" exact="influenza" post="viruses. Discrete Phylogeography Analyses To clarify the spatial dynamics"/>
   <result pre="strong and substantial support, respectively. Results We obtained 99 seasonal" exact="influenza" post="A virus genome sequences, including 66 A/H1N1 and 33"/>
   <result pre="the A/H1N1pdm in China We constructed MCC trees using eight" exact="influenza" post="genomic segments to understand the evolution of the A/H1N1pdm"/>
   <result pre="virus rapidly adapted to human host and evolved into seasonal" exact="influenza" post="under strong bottlenecks between seasons after introduction into human"/>
   <result pre="population dynamics and positive rate of A/H1N1pdm (A), A/H3N2 (B)," exact="influenza" post="B/Victoria (C), and influenza B/Yamagata (D) viruses. Phylogenies were"/>
   <result pre="rate of A/H1N1pdm (A), A/H3N2 (B), influenza B/Victoria (C), and" exact="influenza" post="B/Yamagata (D) viruses. Phylogenies were inferred using the strict"/>
   <result pre="intervals. The positive rate of A/H1N1pdm virus (2009–2019), A/H3N2 (2009–2019)," exact="influenza" post="B/Victoria (2015–2019), influenza B/Yamagata (2015–2019) by week of specimen"/>
   <result pre="rate of A/H1N1pdm virus (2009–2019), A/H3N2 (2009–2019), influenza B/Victoria (2015–2019)," exact="influenza" post="B/Yamagata (2015–2019) by week of specimen collection in China"/>
   <result pre="further analyzed all available HA sequences of A/H1N1pdm, A/H3N2, and" exact="influenza" post="B Victoria and Yamagata lineages, and compared their relative"/>
   <result pre="by a strong seasonal fluctuation during 2014–2019 (Figure 6B). Two" exact="influenza" post="B lineages, Victoria and Yamagata had similar genetic diversity"/>
   <result pre="seasonal fluctuation (Figures 6C,D). A common feature of the four" exact="influenza" post="virus lineages was that their relative genetic diversities were"/>
   <result pre="2016, which might be associated with a sharp increase in" exact="influenza" post="cases in China since the winter-spring season of 2017–2018."/>
   <result pre="of China. Discussion The main force driving the evolution of" exact="influenza" post="viruses is the adaptation to the new hosts and/or"/>
   <result pre="and reassortment are two major patterns involving the evolution of" exact="influenza" post="viruses and can cause antigenic drift and antigenic shift,"/>
   <result pre="Russell, 2018). Apart from A/H1N1pdm, A/H3N2 and two lineages of" exact="influenza" post="B virus are also the major agents responsible for"/>
   <result pre="virus are also the major agents responsible for the seasonal" exact="influenza" post="pandemics. The four influenza subtypes are often co-circulating and"/>
   <result pre="major agents responsible for the seasonal influenza pandemics. The four" exact="influenza" post="subtypes are often co-circulating and compete with each other,"/>
   <result pre="factors determine the high level of activity of all four" exact="influenza" post="subtypes during 2018–2019. HA and NA are the most"/>
   <result pre="are the most crucial proteins for infection and transmission of" exact="influenza" post="viruses. HA is responsible for cell attachment by binding"/>
   <result pre="is the primary target for human adaptive immune response to" exact="influenza" post="viruses. NA is responsible for the release of new"/>
   <result pre="and replaced previously existing antigenic variants to dominate the forthcoming" exact="influenza" post="pandemic. The frequency of emergence of new A/H1N1pdm antigenic"/>
   <result pre="vaccination is the primary measure to prevent and control seasonal" exact="influenza" post="virus infections (Wang et al., 2018). Recent study showed"/>
   <result pre="selection pressure has weak effects on the evolution of seasonal" exact="influenza" post="viruses (Han et al., 2019). However, the effect of"/>
   <result pre="(Han et al., 2019). However, the effect of vaccination on" exact="influenza" post="evolution is less clear. The vaccine-induced effect might be"/>
   <result pre="The vaccine-induced effect might be underestimated because of the low" exact="influenza" post="vaccine coverage rate (&amp;lt;10% of the world population) (Partridge"/>
   <result pre="the United States and Europe), China has a very low" exact="influenza" post="vaccination coverage rate (about 1.5–2%). Therefore, the accumulation of"/>
   <result pre="to be the main factors affecting the seasonal epidemics of" exact="influenza" post="viruses (Lowen et al., 2007; Shaman and Kohn, 2009;"/>
   <result pre="the A/H1N1pdm in several epidemic seasons. Suitable climatic condition for" exact="influenza" post="virus transmission, high population density, and increasing frequency of"/>
   <result pre="the seeding hierarchy of East China and South China in" exact="influenza" post="epidemics in China. Therefore, to strengthen influenza surveillance in"/>
   <result pre="South China in influenza epidemics in China. Therefore, to strengthen" exact="influenza" post="surveillance in East China and South China will aid"/>
   <result pre="activities of A/H1N1pdm virus with A/H3N2 and two lineages of" exact="influenza" post="B virus during this period were associated with the"/>
   <result pre="virus during this period were associated with the severe seasonal" exact="influenza" post="pandemics. Furthermore, East China and South China were found"/>
   <result pre="spread of A/H1N1pdm virus, which is of major significance for" exact="influenza" post="prevention and control in China. Data Availability Statement The"/>
   <result pre="contributed to the methodology. JY analyzed the data of the" exact="influenza" post="positive rates. CZ, YM, JQ, and SL interpreted the"/>
   <result pre="his help in the analyses of surveillance data of two" exact="influenza" post="B virus lineages. We also thank Mr. Jie Chen"/>
   <result pre="10.1126/scitranslmed.aad052226631631 BarrI. G.DengY. M.GrauM. L.HanA. X.GilmourR.IrwinM.et al. (2019). Intense interseasonal" exact="influenza" post="outbreaks.Australia, 2018/19.Euro. Surveill.2428–38. 10.2807/1560-7917.ES.2019.24.33.1900421 BedfordT.RileyS.BarrI. G.BroorS.ChadhaM.CoxN. J.et al. (2015)."/>
   <result pre="BedfordT.RileyS.BarrI. G.BroorS.ChadhaM.CoxN. J.et al. (2015). Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift.Nature523217–220. 10.1038/nature1446026053121 BolgerA. M.LohseM. A.UsadelB."/>
   <result pre="10.1093/bioinformatics/btu17024695404 BrynildsrudO. B.PepperellC. S.SuffysP.GrandjeanL.MonteserinJ.DebechN.et al. (2018). Global expansion of Mycobacterium" exact="tuberculosis" post="lineage 4 shaped by colonial migration and local adaptation.Sci."/>
   <result pre="subtype).Cell31417–427. 10.1016/0092-8674(82)90135-06186384 ChenR.HolmesE. C. (2008). The evolutionary dynamics of human" exact="influenza" post="B virus.J. Mol. Evol.66655–663. 10.1007/s00239-008-9119-z18504518 CohenM.ZhangX. Q.SenaatiH. P.ChenH. W.VarkiN."/>
   <result pre="Vaccination has minimal impact on the intrahost diversity of H3N2" exact="influenza" post="viruses.PLoS Pathog.13:e1006194. 10.1371/journal.ppat.100619428141862 FuX.ZhouY.WuJ.LiuX.DingC.HuangC.et al. (2019). Clinical characteristics and"/>
   <result pre="FuX.ZhouY.WuJ.LiuX.DingC.HuangC.et al. (2019). Clinical characteristics and outcomes during a severe" exact="influenza" post="season in China during 2017-2018.BMC Infect. Dis.19:668. 10.1186/s12879-019-4181-231357951 GaoG."/>
   <result pre="10.1016/j.cell.2018.02.02529522735 GaoJ.CouzensL.BurkeD. F.WanH.WilsonP.MemoliM. J.et al. (2019). Antigenic drift of the" exact="influenza" post="A(H1N1)pdm09 virus neuraminidase results in reduced effectiveness of A/California/7/2009"/>
   <result pre="10.1128/mBio.00307-1930967460 GeogheganJ. L.SaavedraA. F.DucheneS.SullivanS.BarrI.HolmesE. C. (2018). Continental synchronicity of human" exact="influenza" post="virus epidemics despite climatic variation.PLoS Pathog.14:e1006780. 10.1371/journal.ppat.100678029324895 GerhardW.YewdellJ. W.FrankelM."/>
   <result pre="variation.PLoS Pathog.14:e1006780. 10.1371/journal.ppat.100678029324895 GerhardW.YewdellJ. W.FrankelM. E. (1981). Antigenic structure of" exact="influenza" post="virus haemagglutinin defined by hybirdoma antibodies.Nature290713–717. 10.1038/290713a06163993 HanA. X.MaurerS.RussellC."/>
   <result pre="(2019). Individual immune selection pressure has limited impact on seasonal" exact="influenza" post="virus evolution.Nat. Ecol, Evol.3302–311. 10.1038/s41559-018-0741-x30510176 HoffmannE.StechJ.GuanY.WebsterR. G.PerezD. R. (2001)."/>
   <result pre="(2001). Universal primer set for the full-length amplification of all" exact="influenza" post="A viruses.Arch. Virol.1462275–2289. 10.1007/s00705017000211811679 HolmesE. C.GhedinE.MillerN.TaylorJ.BaoY.St GeorgeK.et al. (2005)."/>
   <result pre="10.1007/s00705017000211811679 HolmesE. C.GhedinE.MillerN.TaylorJ.BaoY.St GeorgeK.et al. (2005). Whole-genome analysis of human" exact="influenza" post="A virus reveals multiple persistent lineages and reassortment among"/>
   <result pre="(2010). Predicting the antigenic structure of the pandemic (H1N1) 2009" exact="influenza" post="virus hemagglutinin.PLoS One5:e8553. 10.1371/journal.pone.000855320049332 IulianoA. D.RoguskiK. M.ChangH. H.MuscatelloD. J.PalekarR.TempiaS.et"/>
   <result pre="Res.303059–3066. 10.1093/nar/gkf43612136088 LangatP.RaghwaniJ.DudasG.BowdenT. A.EdwardsS.GallA.et al. (2017). Genome-wide evolutionary dynamics of" exact="influenza" post="B viruses on a global scale.PLoS Pathog.13:e1006749. 10.1371/journal.ppat.100674929284042 LangmeadB.SalzbergS."/>
   <result pre="Genet.8196–205. 10.1038/nrg205317262054 PartridgeJ.KienyM. P. (2013). Global production capacity of seasonal" exact="influenza" post="vaccine in 2011.Vaccine31728–731. 10.1016/j.vaccine.2012.10.11123149268 PetrovaV. N.RussellC. A. (2018). The"/>
   <result pre="2011.Vaccine31728–731. 10.1016/j.vaccine.2012.10.11123149268 PetrovaV. N.RussellC. A. (2018). The evolution of seasonal" exact="influenza" post="viruses.Nat. Rev. Microbiol.1647–60. 10.1038/nrmicro.2017.11829081496 RambautA.LamT. T.Max CarvalhoL.PybusO. G. (2016)."/>
   <result pre="antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2" exact="influenza" post="viruses.Proc. Natl. Acad. Sci. U.S.A.10820748–20753. 10.1073/pnas.111380110822143798 ShamanJ.KohnM. (2009). Absolute"/>
   <result pre="Natl. Acad. Sci. U.S.A.10820748–20753. 10.1073/pnas.111380110822143798 ShamanJ.KohnM. (2009). Absolute humidity modulates" exact="influenza" post="survival, transmission, and seasonality.Proc. Natl. Acad. Sci. U.S.A.1063243–3248. 10.1073/pnas.080685210619204283"/>
   <result pre="(2009). Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemic.Nature4591122–1125. 10.1038/nature0818219516283 SnackenR.KendalA. P.HaaheimL. R.WoodJ. M. (1999). The"/>
   <result pre="A epidemic.Nature4591122–1125. 10.1038/nature0818219516283 SnackenR.KendalA. P.HaaheimL. R.WoodJ. M. (1999). The next" exact="influenza" post="pandemic: lessons from Hong Kong, 1997.Emerg. Microbes Infect.5195–203. 10.3201/eid0502.99020210221870"/>
   <result pre="F.BahlJ.JosephU.ButtK. M.PeckH. A.KoayE. S. C.et al. (2015). Phylodynamics of H1N1/2009" exact="influenza" post="reveals the transition from host adaptation to immune-driven selection.Nat."/>
   <result pre="TameriusJ. D.ShamanJ.AlonsoW. J.Bloom-FeshbachK.UejioC. K.ComrieA.et al. (2013). Environmental predictors of seasonal" exact="influenza" post="epidemics across temperate and tropical climates.PLoS Pathog.9:e1003194. 10.1371/journal.ppat.100319423505366 TaubenbergerJ."/>
   <result pre="VijaykrishnaD.HolmesE. C.JosephU.FourmentM.SuY. C.HalpinR.et al. (2015). The contrasting phylodynamics of human" exact="influenza" post="B viruses.eLife4:e05055. 10.7554/eLife.0505525594904 VijaykrishnaD.PoonL. L. M.ZhuH. C.MaS. K.LiO. T."/>
   <result pre="Swine.Science3281529–1532. 10.1126/science.118913220558710 VirkR. K.JayakumarJ.MendenhallI. H.MoorthyM.LamP. (2019). Divergent evolutionary trajectories of" exact="influenza" post="B viruses underlie their contemporaneous epidemic activity.Proc. Natl. Acad."/>
   <result pre="(2018). Influenza vaccination coverage of population and the factors influencing" exact="influenza" post="vaccination in mainland China: a meta-analysis.Vaccine367262–7269. 10.1016/j.vaccine.2018.10.04530340886 WestgeestK. B.RussellC."/>
   <result pre="al. (2014). Genomewide analysis of reassortment and evolution of human" exact="influenza" post="A(H3N2) viruses circulating between 1968 and 2011.J. Virol.882844–2857. 10.1128/jvi.02163-1324371052"/>
   <result pre="Virol.882844–2857. 10.1128/jvi.02163-1324371052 WilleM.HolmesE. C. (2019). The ecology and evolution of" exact="influenza" post="viruses.Cold Spring Harb. Perspect. Med.2019:a038489. 10.1101/cshperspect.a03848931871237 YangZ. (2007). PAML"/>
   <result pre="changes to the lateral surface of the neuraminidase head of" exact="influenza" post="A virus.Nat. Microbiol.41024–1034. 10.1038/s41564-019-0401-130886361 YuH.FengZ.UyekiT. M.LiaoQ.ZhouL.FengL.et al. (2011). Risk"/>
   <result pre="al. (2011). Risk factors for severe illness with 2009 pandemic" exact="influenza" post="A (H1N1) virus infection in China.Clin. Infect. Dis.52457–465. 10.1093/cid/ciq14421220768"/>
   <result pre="sequencing and vaccine production for classical and swine origin human" exact="influenza" post="A Viruses.J Virol.8310309–10313. 10.1128/jvi.01109-0919605485"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7230280\results\search\disease\results.xml">
   <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Ongoing outbreak of" exact="pneumonia" post="caused by novel coronavirus (2019-nCoV) began in December 2019"/>
   <result pre="coronavirus SEIR model outside China 1. Introduction An outbreak of" exact="pneumonia" post="caused by novel coronavirus (2019-nCoV) began in December 2019"/>
   <result pre="on 31 January 2020) 19.VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.GalanisE.HenryB.Investigation of a nosocomial outbreak of" exact="severe acute respiratory syndrome" post="(SARS) in Toronto, CanadaCMAJ200316928529212925421 20.ParraJ.M.SalmerónO.J.VelascoM.The First Case of Ebola"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7230963\results\search\disease\results.xml">
   <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Severe" exact="influenza" post="is associated with high morbidity and mortality. The aim"/>
   <result pre="investigate the factors affecting the clinical outcomes of critically ill" exact="influenza" post="patients. In this retrospective study, we enrolled critically ill"/>
   <result pre="this retrospective study, we enrolled critically ill adult patients with" exact="influenza" post="at the Kaohsiung Chang Gung Memorial Hospital in Taiwan."/>
   <result pre="associations with mortality. Between 2015 and 2018, 102 critically ill" exact="influenza" post="patients (median age, 62 years) were assessed; among them,"/>
   <result pre="illness. Of the 102 patients, the major influenza-associated complications were" exact="respiratory failure" post="(97%), pneumonia (94.1%), acute kidney injury (65.7%), adult respiratory"/>
   <result pre="102 patients, the major influenza-associated complications were respiratory failure (97%)," exact="pneumonia" post="(94.1%), acute kidney injury (65.7%), adult respiratory distress syndrome"/>
   <result pre="gastrointestinal bleeding were independent predictors of mortality in critically ill" exact="influenza" post="patients. The optimal lactate level cutoff for predicting mortality"/>
   <result pre="mortality that could aid in the care of critically ill" exact="influenza" post="patients. Identification of these prognostic markers could be improved"/>
   <result pre="examinations that might be useful in determining patient outcomes. severe" exact="influenza" post="pneumonia acute respiratory distress syndrome lactate mortality 1. Introduction"/>
   <result pre="that might be useful in determining patient outcomes. severe influenza" exact="pneumonia" post="acute respiratory distress syndrome lactate mortality 1. Introduction Influenza"/>
   <result pre="might be useful in determining patient outcomes. severe influenza pneumonia" exact="acute respiratory distress syndrome" post="lactate mortality 1. Introduction Influenza is an acute viral"/>
   <result pre="an acute viral respiratory infection caused by different types of" exact="influenza" post="viruses: influenza A, B, and C [1]. Influenza A"/>
   <result pre="viral respiratory infection caused by different types of influenza viruses:" exact="influenza" post="A, B, and C [1]. Influenza A subtypes H1N1,"/>
   <result pre="B, and C [1]. Influenza A subtypes H1N1, H3N2, and" exact="influenza" post="B are the most common causes of human influenza"/>
   <result pre="and influenza B are the most common causes of human" exact="influenza" post="[1]. The illness is usually mild and characterized by"/>
   <result pre="patients [2,3]. Annually, the World Health Organization estimated that global" exact="influenza" post="epidemics result in 3 to 5 million cases of"/>
   <result pre="and 290,000 to 650,000 deaths [4,5]. In 2009, a swine-origin" exact="influenza" post="A (pandemic 2009 A/H1N1; pdm09 A/H1) emerged and rapidly"/>
   <result pre="the United States due to pdm09 A/H1 [7]. Severe complicated" exact="influenza" post="has a significantly high mortality and morbidity [8,9]. Secondary"/>
   <result pre="influenza has a significantly high mortality and morbidity [8,9]. Secondary" exact="bacterial pneumonia" post="and acute respiratory distress syndrome (ARDS) are some of"/>
   <result pre="has a significantly high mortality and morbidity [8,9]. Secondary bacterial" exact="pneumonia" post="and acute respiratory distress syndrome (ARDS) are some of"/>
   <result pre="significantly high mortality and morbidity [8,9]. Secondary bacterial pneumonia and" exact="acute respiratory distress syndrome" post="(ARDS) are some of the common pulmonary complications of"/>
   <result pre="rhabdomyolysis have also been reported to be associated with either" exact="influenza" post="A or B [11,12,13]. While early antiviral therapy may"/>
   <result pre="B [11,12,13]. While early antiviral therapy may reduce complications of" exact="influenza" post="[14,15,16], the majority of patients tend to delay seeking"/>
   <result pre="can help clinicians deliver the necessary management to critically ill" exact="influenza" post="patients in a timely manner. In the present study,"/>
   <result pre="clinical course and laboratory data of critically ill patients with" exact="influenza" post="and then explored the risk factors independently associated with"/>
   <result pre="all critically ill adult patients (aged ≥18 years) with laboratory-confirmed" exact="influenza" post="infection admitted between 2015 and 2018, at the Kaohsiung"/>
   <result pre="surgical intensive care units (ICUs) in Taiwan. Included critically ill" exact="influenza" post="patients were those admitted to an ICU, or those"/>
   <result pre="outpatients; or if they had mild flu-like symptoms. Confirmation of" exact="influenza" post="virus infection required a positive finding in the respiratory"/>
   <result pre="swab) by one or more of the following methods: rapid" exact="influenza" post="diagnostic test (Formosa One Sure Flu A/B Rapid Test"/>
   <result pre="TAIGEN Bioscience Corporation, Taiwan). The choice of diagnostic test (rapid" exact="influenza" post="diagnostic test, virus isolation or RT-PCR) for confirming influenza"/>
   <result pre="(rapid influenza diagnostic test, virus isolation or RT-PCR) for confirming" exact="influenza" post="was based on the individual physicians’ judgment. 2.2. Data"/>
   <result pre="during the entire clinical course, in-hospital complications, and fatality. Acute" exact="respiratory failure" post="was defined as arterial partial pressure of oxygen (PaO2)"/>
   <result pre="ratio &amp;lt;300 mmHg) in the absence of evidence for cardiogenic" exact="pulmonary edema" post="[17]. Fulminant hepatitis meant alanine aminotransferase levels (ALT) greater"/>
   <result pre="the absence of evidence for cardiogenic pulmonary edema [17]. Fulminant" exact="hepatitis" post="meant alanine aminotransferase levels (ALT) greater than 16.6 µkat/L."/>
   <result pre="of encephalitis, and (6) abnormal findings on electroencephalography consistent with" exact="encephalitis" post="[18]. A galactomannan cutoff optical density index of &amp;gt;0.5"/>
   <result pre="Analysis To analyze the predictors of mortality among critically ill" exact="influenza" post="patients, we initially compared demographic, clinical characteristics, and laboratory"/>
   <result pre="model to identify independent predictors of mortality in critically ill" exact="influenza" post="patients. We used receiver operating characteristic curves (ROC) to"/>
   <result pre="women, with a median age of 62 years with laboratory-confirmed" exact="influenza" post="virus infection were assessed. The median time from illness"/>
   <result pre="48 h after the onset of symptoms. Among 102 patients," exact="influenza" post="A virus was detected in 77 (75.5%) patients (33.3%"/>
   <result pre="for pdm09 A/H1, 7.8% for H3N2 and 28.4% for untypable" exact="influenza" post="A), influenza B virus in 24 (23.5%), and concurrent"/>
   <result pre="A/H1, 7.8% for H3N2 and 28.4% for untypable influenza A)," exact="influenza" post="B virus in 24 (23.5%), and concurrent influenza A"/>
   <result pre="influenza A), influenza B virus in 24 (23.5%), and concurrent" exact="influenza" post="A (untypable) and influenza B in 1 (0.9%). The"/>
   <result pre="virus in 24 (23.5%), and concurrent influenza A (untypable) and" exact="influenza" post="B in 1 (0.9%). The clinical characteristics of the"/>
   <result pre="during the entire clinical course. The five common complications were" exact="respiratory failure" post="(97%), pneumonia (94.1%), acute kidney injury (65.7%), ARDS (51%),"/>
   <result pre="clinical course. The five common complications were respiratory failure (97%)," exact="pneumonia" post="(94.1%), acute kidney injury (65.7%), ARDS (51%), and gastrointestinal"/>
   <result pre="(11.7%) noninvasively. The median time from illness onset to acute" exact="respiratory failure" post="was four days (range, 1–27). Inotropes or vasopressors were"/>
   <result pre="were treated with ECMO, of whom 15 (88.2%) patients had" exact="influenza" post="A virus and 2 (11.7%) had influenza B virus"/>
   <result pre="(88.2%) patients had influenza A virus and 2 (11.7%) had" exact="influenza" post="B virus infection. The median duration of ECMO support"/>
   <result pre="10), gastrointestinal bleeding (n = 8), rhabdomyolysis (n = 4)," exact="pneumothorax" post="(n = 2), intracranial hemorrhage (n = 1), and"/>
   <result pre="(n = 2), intracranial hemorrhage (n = 1), and fulminant" exact="hepatitis" post="(n = 1) were the most common conditions contributing"/>
   <result pre="days after symptom onset. Of 41 deceased patients, 80.5% had" exact="influenza" post="A virus and 19.5% had influenza B virus infection."/>
   <result pre="deceased patients, 80.5% had influenza A virus and 19.5% had" exact="influenza" post="B virus infection. Of the 38 deceased patients who"/>
   <result pre="of the illness (Table 4). Among the 41 deceased patients," exact="pneumonia" post="developed in 39 (95.1%) patients, acute kidney injury in"/>
   <result pre="= 0.025) were independent predictors of mortality in critically ill" exact="influenza" post="patients (Table 5). 3.6. Event-Based Algorithm The median highest"/>
   <result pre="4. Discussion In a study involving 444 adult patients with" exact="influenza" post="in hospitals in the United States, the mortality rate"/>
   <result pre="in their study of 2059 patients admitted to ICUs for" exact="influenza" post="infection [22]. In our study, a mortality rate as"/>
   <result pre="influenza. However, which variables can predict poor patient outcomes after" exact="influenza" post="virus infection remain to be elucidated. In the present"/>
   <result pre="help clinicians deliver timely and sufficient treatment to critically ill" exact="influenza" post="patients. Our results underscore that high blood lactate levels"/>
   <result pre="bleeding were independent risk factors of mortality in critically ill" exact="influenza" post="patients. High blood lactate levels indicate tissue hypoxia due"/>
   <result pre="significantly and independently associated with fatal outcomes in critically ill" exact="influenza" post="patients. In addition, nonsurvivors had a significantly higher prevalence"/>
   <result pre="marker assisting clinicians in predicting the outcomes in critically ill" exact="influenza" post="patients. Our series here showed gastrointestinal bleeding occurred in"/>
   <result pre="to possible gastrointestinal bleeding when caring for a critically ill" exact="influenza" post="patient because this complication potentially leads to death if"/>
   <result pre="early and treated accordingly. ARDS is a lethal complication of" exact="influenza" post="infection [25]. Ortiz et al. estimated that the incidence"/>
   <result pre="Ortiz et al. estimated that the incidence of influenza-associated acute" exact="respiratory failure" post="was 2.7 events per 100,000 person–years [26]. In a"/>
   <result pre="of 58 patients with ARDS, 28 (48.2%) were due to" exact="influenza" post="virus infection, and 32.1% of the patients with influenza-associated"/>
   <result pre="an independent risk factor for hospital mortality in critically ill" exact="influenza" post="patients, and the mortality rate can be as high"/>
   <result pre="are consistent with previous findings wherein 97% of critically ill" exact="influenza" post="patients developed acute respiratory failure with a median time"/>
   <result pre="findings wherein 97% of critically ill influenza patients developed acute" exact="respiratory failure" post="with a median time of four days between illness"/>
   <result pre="a median time of four days between illness onset and" exact="respiratory failure," post="and 51% of them subsequently developed ARDS during their"/>
   <result pre="the patients with influenza-associated ARDS required ECMO for profound hypoxemic" exact="respiratory failure." post="Our study highlights that severe oxygenation failure occurred rapidly"/>
   <result pre="ICU resources to meet this treatment requirement, particularly during the" exact="influenza" post="epidemic. In the present study, we established a simple"/>
   <result pre="lactate level and ARDS for timely detection of critically ill" exact="influenza" post="patients who are at greater risk of mortality. Notably,"/>
   <result pre="who are at greater risk of mortality. Notably, critically ill" exact="influenza" post="patients without ARDS but with a blood lactate concentration"/>
   <result pre="that developed ARDS. In contrast, only 7.7% of critically ill" exact="influenza" post="patients without ARDS and with normal blood lactate levels"/>
   <result pre="levels died. Considering the high mortality rate among critically ill" exact="influenza" post="patients, this event-based algorithm could aid in the timely"/>
   <result pre="the importance of early treatment with antivirals in critically ill" exact="influenza" post="patients cannot be overemphasized. In our study, bacteremia was"/>
   <result pre="was caused by Staphylococcus aureus. A report of the 2009–2010" exact="influenza" post="pandemic among critically ill children revealed that nearly 5%"/>
   <result pre="poor outcomes were found among patients who were coinfected with" exact="influenza" post="viruses and Staphylococcus aureus [34]. Although we were unable"/>
   <result pre="or not initiating timely additional antimicrobial treatment in critically ill" exact="influenza" post="patients led to better clinical outcomes, our findings and"/>
   <result pre="most important cause of bacterial coinfection in pediatric and adult" exact="influenza" post="patients. Invasive pulmonary Aspergillus as a coinfection in patients"/>
   <result pre="Invasive pulmonary Aspergillus as a coinfection in patients with severe" exact="influenza" post="has been described [35,36,37]. In a cohort study involving"/>
   <result pre="cohort study involving seven ICUs over a period of seven" exact="influenza" post="seasons showed that influenza and the use of corticosteroids"/>
   <result pre="ICUs over a period of seven influenza seasons showed that" exact="influenza" post="and the use of corticosteroids were independent risk factors"/>
   <result pre="the use of corticosteroids were independent risk factors for invasive" exact="aspergillosis" post="[35]. In the present study, invasive pulmonary aspergillosis was"/>
   <result pre="for invasive aspergillosis [35]. In the present study, invasive pulmonary" exact="aspergillosis" post="was confirmed in two deceased influenza patients with high"/>
   <result pre="present study, invasive pulmonary aspergillosis was confirmed in two deceased" exact="influenza" post="patients with high galactomannan index in bronchoalveolar lavage fluid."/>
   <result pre="that clinicians should be aware of the risk of invasive" exact="aspergillosis" post="in critically ill influenza patients, particularly immunocompromised patients or"/>
   <result pre="aware of the risk of invasive aspergillosis in critically ill" exact="influenza" post="patients, particularly immunocompromised patients or those receiving corticosteroids. Further"/>
   <result pre="the incidence, risk factors, and clinical features of invasive pulmonary" exact="aspergillosis" post="in influenza patients. In 2003, an avian influenza virus"/>
   <result pre="risk factors, and clinical features of invasive pulmonary aspergillosis in" exact="influenza" post="patients. In 2003, an avian influenza virus of H5N1"/>
   <result pre="of invasive pulmonary aspergillosis in influenza patients. In 2003, an" exact="avian influenza" post="virus of H5N1 subtype was isolated from a smuggled"/>
   <result pre="invasive pulmonary aspergillosis in influenza patients. In 2003, an avian" exact="influenza" post="virus of H5N1 subtype was isolated from a smuggled"/>
   <result pre="pneumococcus and influenza, and some missing laboratory data such as" exact="pneumonia" post="severity index and coagulation profile, were not collected. Second,"/>
   <result pre="the key factors associated with poor outcomes for critically ill" exact="influenza" post="patients and established a decision-making algorithm that can take"/>
   <result pre="the prediction of the poor outcomes in hospitalized critically ill" exact="influenza" post="patients, as timely intensive supportive care might be lifesaving."/>
   <result pre="services and ICUs can be overwhelmed during the peak of" exact="influenza" post="epidemics, particularly in point-of-care resource-limited areas. Our findings could"/>
   <result pre="primary care at the initial clinical evaluation of critically ill" exact="influenza" post="patients. Acknowledgments We thank the staff members in the"/>
   <result pre="(H1N1) Virus Investigation Team. Emergence of a novel swine origin" exact="influenza" post="A (H1N1) virus in humansN. Engl. J. Med.20093602605261510.1056/nejmoa090381019423869 7.ShresthaS.S.SwerdlowD.L.BorseR.H.PrabhuV.S.FinelliL.AtkinsC.Y.Owusu-EduseiK.BellB.MeadP.S.BiggerstallM.et"/>
   <result pre="Engl. J. Med.20093602605261510.1056/nejmoa090381019423869 7.ShresthaS.S.SwerdlowD.L.BorseR.H.PrabhuV.S.FinelliL.AtkinsC.Y.Owusu-EduseiK.BellB.MeadP.S.BiggerstallM.et al.Estimating the burden of 2009 pandemic" exact="influenza" post="A (H1N1) in the United States (April 2009–April 2010)Clin."/>
   <result pre="Infect. Dis.201152S75S8210.1093/cid/ciq01221342903 8.ZhouF.LiH.GuL.LiuM.XueC.X.CaoB.WangC.Risk factors for nosocomial infection among hospitalised severe" exact="influenza" post="A(H1N1)pdm09 patientsRespir. Med.2018134869110.1016/j.rmed.2017.11.01729413513 9.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnersM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.Myocardial injury and bacterial pneumonia contribute"/>
   <result pre="among hospitalised severe influenza A(H1N1)pdm09 patientsRespir. Med.2018134869110.1016/j.rmed.2017.11.01729413513 9.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnersM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.Myocardial injury and" exact="bacterial pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
   <result pre="hospitalised severe influenza A(H1N1)pdm09 patientsRespir. Med.2018134869110.1016/j.rmed.2017.11.01729413513 9.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnersM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.Myocardial injury and bacterial" exact="pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
   <result pre="injury and bacterial pneumonia contribute to the pathogenesis of fatal" exact="influenza" post="B virus infectionJ. Infect. Dis.201220589590510.1093/infdis/jir86122291193 10.DaoudA.LaktinehA.MacranderC.MushtaqA.SoubaniA.O.Pulmonary complications of influenza"/>
   <result pre="fatal influenza B virus infectionJ. Infect. Dis.201220589590510.1093/infdis/jir86122291193 10.DaoudA.LaktinehA.MacranderC.MushtaqA.SoubaniA.O.Pulmonary complications of" exact="influenza" post="infection: A targeted narrative reviewPostgrad. Med.201913129930810.1080/00325481.2019.159240030845866 11.KumarA.ZarychanskiR.PintoR.CookD.J.MarshallJ.LacroixJ.StelfoxT.BagshawS.ChoongK.LamontagneF.Canadian Critical Care"/>
   <result pre="Care Trials Group H1N1 Collaborative. Critically ill patients with 2009" exact="influenza" post="A (H1N1) infection in CanadaJAMA20093021872187910.1001/jama.2009.149619822627 12.RelloJ.RodríguezA.IbañezP.SociasL.CebrianJ.MarquesA.GuerreroJ.Ruiz-SantanaS.MarquezE.Nogel-SaezF.D.H1N1 SEMICYUC Working Group."/>
   <result pre="12.RelloJ.RodríguezA.IbañezP.SociasL.CebrianJ.MarquesA.GuerreroJ.Ruiz-SantanaS.MarquezE.Nogel-SaezF.D.H1N1 SEMICYUC Working Group. Intensive care adult patients with severe" exact="respiratory failure" post="caused by Influenza A (H1N1)v in SpainCrit. Care200913R14810.1186/cc804419747383 13.Domínguez-CheritG.LapinskyS.E.MaciasA.E.PintoR.Espinosa-PerezL.de"/>
   <result pre="in SpainCrit. Care200913R14810.1186/cc804419747383 13.Domínguez-CheritG.LapinskyS.E.MaciasA.E.PintoR.Espinosa-PerezL.de la TorreA.Poblano-MoralesM.Baltazar-TorresJ.A.BautistaE.MartinezA.Critically Ill patients with 2009" exact="influenza" post="A(H1N1) in MexicoJAMA20093021880188710.1001/jama.2009.153619822626 14.DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for influenza in adults:"/>
   <result pre="patients with 2009 influenza A(H1N1) in MexicoJAMA20093021880188710.1001/jama.2009.153619822626 14.DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for" exact="influenza" post="in adults: A meta analysis of randomised controlled trialsLancet20153851729173710.1016/S0140-6736(14)62449-125640810"/>
   <result pre="randomised controlled trialsLancet20153851729173710.1016/S0140-6736(14)62449-125640810 15.DollM.K.WintersN.BoikosC.Kraicer-MelamedH.GoreG.QuachC.Safety and effectiveness of neuraminidase inhibitors for" exact="influenza" post="treatment, prophylaxis, and outbreak control: A systematic review of"/>
   <result pre="treatment started within 5 days of symptom onset to reduce" exact="influenza" post="illness duration and virus shedding in an urban setting"/>
   <result pre="J. Neurol.201017e5710.1111/j.1468-1331.2010.02970.x 19.HeerK.D.GerritsenM.G.VisserC.E.LeeflangM.M.Galactomannan detection in broncho-alveolar lavage fluid for invasive" exact="aspergillosis" post="in immunocompromised patientsCochrane Database Syst. Rev.201910.1002/14651858.cd012399.pub2 20.MaertensJ.TheunissenK.VerbekenE.LagrouK.VerhaegenJ.BoogaertsM.EldereJ.V.Prospective clinical evaluation"/>
   <result pre="evaluation of lower cut-offs for galactomannan detection in adult neutropenic" exact="cancer" post="patients and haematological stem cell transplant recipientsBr. J. Haematol.200412685286010.1111/j.1365-2141.2004.05140.x15352990"/>
   <result pre="de MolinaF.J.Martín LoechesI.BarbadilloS.RodríguezA.H1N1 GETGAG/SEMICYUC Study Group. Delay in diagnosis of" exact="influenza" post="A (H1N1)pdm09 virus infection in critically ill patients and"/>
   <result pre="Acute Respiratory Distress SyndromeJAMA20093021888189510.1001/jama.2009.153519822628 29.LiG.YilmazM.KojicicM.Fernández-PérezE.WahabR.HuskinsW.C.AfessaB.TruwitJ.D.GajicO.Outcome of critically ill patients with" exact="influenza" post="virus infectionJ. Clin. Virol.20094627527810.1016/j.jcv.2009.07.01519699141 30.JainS.KamimotoL.BramleyA.M.SchmitzA.M.BenoitS.R.LouieJ.SugermanD.E.DruckenmillerJ.K.RitgerK.A.ChughR.Hospitalized Patients with 2009 H1N1"/>
   <result pre="late oseltamivir treatment in severely ill patients with 2009 pandemic" exact="influenza" post="A (H1N1): Speed is lifeJ. Antimicrob. Chemother.20116695996310.1093/jac/dkr09021406435 33.RandolphA.G.VaughnF.SullivanR.RubinsonL.ThompsonB.T.YoonG.SmootE.RiceT.W.LoftisL.L.HelfaerM.et al.Critically"/>
   <result pre="lifeJ. Antimicrob. Chemother.20116695996310.1093/jac/dkr09021406435 33.RandolphA.G.VaughnF.SullivanR.RubinsonL.ThompsonB.T.YoonG.SmootE.RiceT.W.LoftisL.L.HelfaerM.et al.Critically ill children during the 2009–2010" exact="influenza" post="pandemic in the United StatesPediatrics2011128e1450e145810.1542/peds.2011-077422065262 34.McDanelJ.S.PerencevichE.N.StormJ.DiekemaD.J.HerwaldtL.JohnsonJ.K.WinokurP.L.SchweizerM.L.Increased Mortality Rates Associated"/>
   <result pre="and Iowa, USAEmerg. Infect. Dis.2016221253125610.3201/eid2207.15131927315549 35.SchauwvliegheA.RijndersB.PhilipsN.VerwijsR.VanderbekeL.Van TienenC.LagrouK.VerweijP.E.Van de VeerdonkF.L.GommersD.et al.Invasive" exact="aspergillosis" post="in patients admitted to the intensive care unit with"/>
   <result pre="A retrospective cohort studyLancet Respir. Med.2018678279210.1016/S2213-2600(18)30274-130076119 36.WautersJ.BaarI.MeerssemanP.MeerssemanW.DamsK.De PaepR.LagrouK.WilmerA.JorensP.HermansG.et al.Invasive pulmonary" exact="aspergillosis" post="is a frequent complication of critically ill H1N1 patients:"/>
   <result pre="PatientsAm. J. Respir. Crit. Care Med.201719652452710.1164/rccm.201612-2540LE28387526 38.LeeM.S.DengM.C.LinY.J.ChangC.Y.ShiehH.K.ShiauJ.Z.HuangC.C.Characterization of an H5N1" exact="avian influenza" post="virus from TaiwanVet. Microbiol.200712419320110.1016/j.vetmic.2007.04.02117512143 39.GongY.N.KuoR.L.ChenG.W.ShihS.R.Centennial review of influenza in"/>
   <result pre="J. Respir. Crit. Care Med.201719652452710.1164/rccm.201612-2540LE28387526 38.LeeM.S.DengM.C.LinY.J.ChangC.Y.ShiehH.K.ShiauJ.Z.HuangC.C.Characterization of an H5N1 avian" exact="influenza" post="virus from TaiwanVet. Microbiol.200712419320110.1016/j.vetmic.2007.04.02117512143 39.GongY.N.KuoR.L.ChenG.W.ShihS.R.Centennial review of influenza in"/>
   <result pre="H5N1 avian influenza virus from TaiwanVet. Microbiol.200712419320110.1016/j.vetmic.2007.04.02117512143 39.GongY.N.KuoR.L.ChenG.W.ShihS.R.Centennial review of" exact="influenza" post="in TaiwanBiomed. J.20184123424110.1016/j.bj.2018.08.00230348266 Figure 1 Receiver operating characteristic curve"/>
   <result pre="(17.8–37.8) (n = 31) 0.583 Underlying condition, N (%) Bronchial" exact="asthma" post="7 (6.9) 4 (6.6) 3 (7.3) &amp;gt;0.99 Hypertension 56"/>
   <result pre="Hypertension 56 (54.9) 38 (62.3) 18 (43.9) 0.073 Type 2" exact="diabetes mellitus" post="45 (44.1) 28 (45.9) 17 (41.5) 0.689 Chronic kidney"/>
   <result pre="pulmonary disease 8 (7.8) 7 (11.5) 1 (2.4) 0.139 Liver" exact="cirrhosis" post="6 (5.9) 3 (4.9) 3 (7.3) 0.682 qSOFA, median"/>
   <result pre="&amp;lt;0.001 Diagnostic methods for influenza, N/total N (%) Positive of" exact="influenza" post="rapid test 51/93 (54.8) 34/56 (60.7) 17/37 (45.9) -"/>
   <result pre="(54.8) 34/56 (60.7) 17/37 (45.9) - Positive of RT-PCR for" exact="influenza" post="94/98 (95.9) 59/61 (96.7) 35/37 (94.6) - Positive of"/>
   <result pre="94/98 (95.9) 59/61 (96.7) 35/37 (94.6) - Positive of throat" exact="influenza" post="viral culture 37/95 (38.9) 23/59 (39) 14/36 (38.9) -"/>
   <result pre="Influenza B 24 (23.5) 16 (26.2) 8 (19.5) 0.483 Concurrent" exact="influenza" post="A a and B 1 (0.9) 1 (1.6) 0"/>
   <result pre="chain reaction; qSOFA, quick Sequential Organ Failure Assessment. a Untypable" exact="influenza" post="A. jcm-09-01073-t002_Table 2Table 2 Symptom/signs of patients with severe"/>
   <result pre="Chest pain 8 (7.8) 5 (8.2) 3 (7.3) &amp;gt;0.99 Skin" exact="rash" post="1 (1) 1 (1.6) 0 &amp;gt;0.99 Altered consciousness 16"/>
   <result pre="Survivors (n = 61) Nonsurvivors (n = 41) p Acute" exact="respiratory failure" post="99 (97) 58 (95.1) 41 (100) &amp;gt;0.99 Time from"/>
   <result pre="58 (95.1) 41 (100) &amp;gt;0.99 Time from onset illness to" exact="respiratory failure," post="day, median (range) 4 (1–27) (n = 99) 3.5"/>
   <result pre="= 58) 4 (1–27) 0.451 Time from hospital presentation to" exact="respiratory failure," post="day, median (range) 1 (1–21) (n = 99) 1"/>
   <result pre="Gastrointestinal bleeding 36 (35.3) 15 (24.6) 21 (51.2) 0.011 Fulminant" exact="hepatitis" post="9 (8.8) 6 (9.8) 3 (7.3) 0.737 Rhabdomyolysis 12"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232083\results\search\disease\results.xml">
   <result pre="infection Introduction Meningococcal disease may present as meningococcal meningitis, meningococcal" exact="meningitis" post="with meningococcemia, and isolated meningococcemia. It is a disease"/>
   <result pre="one week, with intermittent or continuous fever, arthralgia and cutaneous" exact="vasculitis" post="[1]. Few cases of this presentation have been reported,"/>
   <result pre="laboratory tests performed detected leukocytosis 19,600/ul (81 % neutrophils), and" exact="thrombocytopenia" post="77,000/ul. He received intravenous hydration and was discharged with"/>
   <result pre="leukocytes 4330/ul (53 % neutrophils, 33 % lymphocytes) and improved" exact="thrombocytopenia" post="124,000/uL. As there is epidemiological conditions for arboviruses in"/>
   <result pre="polymerase chain reaction (PCR) were done for dengue, zika and" exact="chikungunya" post="– all tested negative; serology tested non-reactive for toxoplasmosis"/>
   <result pre="and chikungunya – all tested negative; serology tested non-reactive for" exact="toxoplasmosis" post="and syphilis; for cytomegalovirus serology tested IgG reagent IgM"/>
   <result pre="examination with negative bacterioscopy and culture. The patient evolved with" exact="acute respiratory distress syndrome" post="and acute renal failure, requiring endotracheal intubation and hemodialysis."/>
   <result pre="load (155 copies/μL); he has cutaneous scars derived from meningococcal" exact="vasculitis" post="(see Picture 6) Picture 6 Cutaneous scars on the"/>
   <result pre="of intermittent or continuous fever, arthralgia and skin lesions without" exact="meningitis" post="[1]. Initial erythema develops to petechiae and purpura due"/>
   <result pre="lesions without meningitis [1]. Initial erythema develops to petechiae and" exact="purpura" post="due to dermal microvascular thrombosis and perivascular hemorrhage [8]."/>
   <result pre="may occur, such as myalgia, abdominal pain, weight loss, iritis," exact="retinitis" post="[9]. It may be a self-limiting disease, but meningitis"/>
   <result pre="iritis, retinitis [9]. It may be a self-limiting disease, but" exact="meningitis" post="and death may occur as late complications [10]. These"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232137\results\search\disease\results.xml">
   <result pre="gene that modulate polymerase activity and PA-X function. host adaptation" exact="influenza" post="A virus PA PA-X RNA-dependent RNA polymerase 1. Introduction"/>
   <result pre="the vRdRp and are even exploited when making live attenuated" exact="influenza" post="vaccines [8]. Historically, the majority of host adaptive mutations"/>
   <result pre="of host adaptive mutations that have been found in the" exact="influenza" post="A vRdRp are located in the PB2 subunit. Very"/>
   <result pre="preinitiation�? form [43,44,45]. A model has been suggested for the" exact="influenza" post="C vRdRp in which binding of the RNA pol"/>
   <result pre="form [46]. While the mechanism for conformational regulation of the" exact="influenza" post="A vRdRp still remains unclear, it is very likely"/>
   <result pre="domain to PA plays an important role. Dimerization of the" exact="influenza" post="A vRdRp has also been recently shown and is"/>
   <result pre="cap-snatched primers is 11 or 12 nucleotides depending on the" exact="influenza" post="vRNA template, and the endonuclease activity of PA preferentially"/>
   <result pre="after a 3′ G. Deep sequencing the cap-snatched primers from" exact="influenza" post="mRNAs also provided definitive evidence for a mechanism to"/>
   <result pre="median length of cap-snatched primers that are attached to an" exact="influenza" post="mRNA is 11 or 12 nucleotides, not all primers"/>
   <result pre="in the endonuclease active site and inhibits replication of both" exact="influenza" post="A and B viruses [122]. This targeting to the"/>
   <result pre="demonstrated. Baloxavir is currently licensed for usage to treat uncomplicated" exact="influenza" post="A and B infections in both the United States"/>
   <result pre="baloxavir was shown to reduce viral loads and symptoms of" exact="influenza" post="infection similar to treatment with oseltamivir (TamifluTM), a neuraminidase"/>
   <result pre="declare no conflicts of interest. References References 1.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 2.WebsterR.G.BeanW.J.GormanO.T.ChambersT.M.KawaokaY.Evolution and ecology of influenza A virusesMicrobiol."/>
   <result pre="1.BouvierN.M.PaleseP.The biology of influenza virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 2.WebsterR.G.BeanW.J.GormanO.T.ChambersT.M.KawaokaY.Evolution and ecology of" exact="influenza" post="A virusesMicrobiol. Rev.19925615217910.1128/MMBR.56.1.152-179.19921579108 3.WuY.WuY.TefsenB.ShiY.GaoG.F.Bat-derived influenza-like viruses H17N10 and H18N11Trends"/>
   <result pre="viruses H17N10 and H18N11Trends Microbiol.20142218319110.1016/j.tim.2014.01.01024582528 4.LongJ.S.MistryB.HaslamS.M.BarclayW.S.Host and viral determinants of" exact="influenza" post="A virus species specificityNat. Rev. Microbiol.201817678110.1038/s41579-018-0115-z 5.KobayashiM.ToyodaT.IshihamaA.Influenza virus PB1"/>
   <result pre="essential subunit of RNA polymeraseArch. Virol.199614152553910.1007/BF017183158645093 6.FanH.WalkerA.P.CarriqueL.KeownJ.R.Serna MartinI.KariaD.SharpsJ.HengrungN.PardonE.SteyaertJ.et al.Structures of" exact="influenza" post="A virus RNA polymerase offer insight into viral genome"/>
   <result pre="RNA polymerase offer insight into viral genome replicationNature201957328729010.1038/s41586-019-1530-731485076 7.ManzB.SchwemmleM.BrunotteL.Adaptation of" exact="avian influenza" post="A virus polymerase in mammals to overcome the host"/>
   <result pre="polymerase offer insight into viral genome replicationNature201957328729010.1038/s41586-019-1530-731485076 7.ManzB.SchwemmleM.BrunotteL.Adaptation of avian" exact="influenza" post="A virus polymerase in mammals to overcome the host"/>
   <result pre="mammals to overcome the host species barrierJ. Virol.2013877200720910.1128/JVI.00980-1323616660 8.DaltonR.M.MullinA.E.AmorimM.J.MedcalfE.TileyL.S.DigardP.Temperature sensitive" exact="influenza" post="A virus genome replication results from low thermal stability"/>
   <result pre="polymerase-cRNA complexesVirol. J.200635810.1186/1743-422X-3-5816934156 9.KawaokaY.KraussS.WebsterR.G.Avian-to-human transmission of the PB1 gene of" exact="influenza" post="A viruses in the 1957 and 1968 pandemicsJ. Virol.1989634603460810.1128/JVI.63.11.4603-4608.19892795713"/>
   <result pre="pandemicsJ. Virol.1989634603460810.1128/JVI.63.11.4603-4608.19892795713 10.AlmondJ.W.A single gene determines the host range of" exact="influenza" post="virusNature197727061761810.1038/270617a0593388 11.SubbaraoE.K.LondonW.MurphyB.R.A single amino acid in the PB2 gene"/>
   <result pre="virusNature197727061761810.1038/270617a0593388 11.SubbaraoE.K.LondonW.MurphyB.R.A single amino acid in the PB2 gene of" exact="influenza" post="A virus is a determinant of host rangeJ. Virol.1993671761176410.1128/JVI.67.4.1761-1764.19938445709"/>
   <result pre="and human host cell factors that affect the activity of" exact="influenza" post="virus polymeraseJ. Virol.2010849978998610.1128/JVI.01134-1020631125 13.LongJ.S.GiotisE.S.MoncorgeO.FriseR.MistryB.JamesJ.MorissonM.IqbalM.VignalA.SkinnerM.A.et al.Species difference in ANP32A underlies"/>
   <result pre="influenza virus polymeraseJ. Virol.2010849978998610.1128/JVI.01134-1020631125 13.LongJ.S.GiotisE.S.MoncorgeO.FriseR.MistryB.JamesJ.MorissonM.IqbalM.VignalA.SkinnerM.A.et al.Species difference in ANP32A underlies" exact="influenza" post="A virus polymerase host restrictionNature201652910110410.1038/nature1647426738596 14.DominguesP.HaleB.G.Functional Insights into ANP32A-Dependent"/>
   <result pre="15.LongJ.S.Idoko-AkohA.MistryB.GoldhillD.StallerE.SchreyerJ.RossC.GoodbournS.SheltonH.SkinnerM.A.et al.Species specific differences in use of ANP32 proteins by" exact="influenza" post="A virusElife2019810.7554/eLife.45066 16.Czudai-MatwichV.OtteA.MatrosovichM.GabrielG.KlenkH.D.PB2 mutations D701N and S714R promote adaptation"/>
   <result pre="virusElife2019810.7554/eLife.45066 16.Czudai-MatwichV.OtteA.MatrosovichM.GabrielG.KlenkH.D.PB2 mutations D701N and S714R promote adaptation of an" exact="influenza" post="H5N1 virus to a mammalian hostJ. Virol.2014888735874210.1128/JVI.00422-1424899203 17.GabrielG.HerwigA.KlenkH.D.Interaction of"/>
   <result pre="with importin alpha1 is a determinant of host range of" exact="influenza" post="A virusPLoS Pathog.20084e1110.1371/journal.ppat.004001118248089 18.TarendeauF.BoudetJ.GuilligayD.MasP.J.BougaultC.M.BouloS.BaudinF.RuigrokR.W.DaigleN.EllenbergJ.et al.Structure and nuclear import function"/>
   <result pre="al.Structure and nuclear import function of the C-terminal domain of" exact="influenza" post="virus polymerase PB2 subunitNat. Struct. Mol. Biol.20071422923310.1038/nsmb121217310249 19.GartenR.J.DavisC.T.RussellC.A.ShuB.LindstromS.BalishA.SessionsW.M.XuX.SkepnerE.DeydeV.et al.Antigenic"/>
   <result pre="Biol.20071422923310.1038/nsmb121217310249 19.GartenR.J.DavisC.T.RussellC.A.ShuB.LindstromS.BalishA.SessionsW.M.XuX.SkepnerE.DeydeV.et al.Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses circulating in humansScience200932519720110.1126/science.117622519465683 20.BusseyK.A.DesmetE.A.MattiacioJ.L.HamiltonA.Bradel-TrethewayB.BusseyH.E.KimB.DewhurstS.TakimotoT.PA residues in the 2009"/>
   <result pre="circulating in humansScience200932519720110.1126/science.117622519465683 20.BusseyK.A.DesmetE.A.MattiacioJ.L.HamiltonA.Bradel-TrethewayB.BusseyH.E.KimB.DewhurstS.TakimotoT.PA residues in the 2009 H1N1 pandemic" exact="influenza" post="virus enhance avian influenza virus polymerase activity in mammalian"/>
   <result pre="20.BusseyK.A.DesmetE.A.MattiacioJ.L.HamiltonA.Bradel-TrethewayB.BusseyH.E.KimB.DewhurstS.TakimotoT.PA residues in the 2009 H1N1 pandemic influenza virus enhance" exact="avian influenza" post="virus polymerase activity in mammalian cellsJ. Virol.2011857020702810.1128/JVI.00522-1121561908 21.MehleA.DuganV.G.TaubenbergerJ.K.DoudnaJ.A.Reassortment and"/>
   <result pre="residues in the 2009 H1N1 pandemic influenza virus enhance avian" exact="influenza" post="virus polymerase activity in mammalian cellsJ. Virol.2011857020702810.1128/JVI.00522-1121561908 21.MehleA.DuganV.G.TaubenbergerJ.K.DoudnaJ.A.Reassortment and"/>
   <result pre="activity in mammalian cellsJ. Virol.2011857020702810.1128/JVI.00522-1121561908 21.MehleA.DuganV.G.TaubenbergerJ.K.DoudnaJ.A.Reassortment and mutation of the" exact="avian influenza" post="virus polymerase PA subunit overcome species barriersJ. Virol.2012861750175710.1128/JVI.06203-1122090127 22.ZhuW.ZhuY.QinK.YuZ.GaoR.YuH.ZhouJ.ShuY.Mutations"/>
   <result pre="in mammalian cellsJ. Virol.2011857020702810.1128/JVI.00522-1121561908 21.MehleA.DuganV.G.TaubenbergerJ.K.DoudnaJ.A.Reassortment and mutation of the avian" exact="influenza" post="virus polymerase PA subunit overcome species barriersJ. Virol.2012861750175710.1128/JVI.06203-1122090127 22.ZhuW.ZhuY.QinK.YuZ.GaoR.YuH.ZhouJ.ShuY.Mutations"/>
   <result pre="in polymerase genes enhanced the virulence of 2009 pandemic H1N1" exact="influenza" post="virus in micePLoS ONE20127e3338310.1371/journal.pone.003338322438920 23.NeumannG.H5N1 influenza virulence, pathogenicity and"/>
   <result pre="of 2009 pandemic H1N1 influenza virus in micePLoS ONE20127e3338310.1371/journal.pone.003338322438920 23.NeumannG.H5N1" exact="influenza" post="virulence, pathogenicity and transmissibility: What do we know?Future Virol.20151097198010.2217/fvl.15.6226617665"/>
   <result pre="synthesisNat. Rev. Microbiol.20161447949310.1038/nrmicro.2016.8727396566 26.PflugA.LukarskaM.Resa-InfanteP.ReichS.CusackS.Structural insights into RNA synthesis by the" exact="influenza" post="virus transcription-replication machineVirus Res.201723410311710.1016/j.virusres.2017.01.01328115197 27.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.The cap-snatching endonuclease of influenza"/>
   <result pre="the influenza virus transcription-replication machineVirus Res.201723410311710.1016/j.virusres.2017.01.01328115197 27.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.The cap-snatching endonuclease of" exact="influenza" post="virus polymerase resides in the PA subunitNature200945891491810.1038/nature0774519194459 28.YuanP.BartlamM.LouZ.ChenS.ZhouJ.HeX.LvZ.GeR.LiX.DengT.et al.Crystal"/>
   <result pre="resides in the PA subunitNature200945891491810.1038/nature0774519194459 28.YuanP.BartlamM.LouZ.ChenS.ZhouJ.HeX.LvZ.GeR.LiX.DengT.et al.Crystal structure of an" exact="avian influenza" post="polymerase PA(N) reveals an endonuclease active siteNature200945890991310.1038/nature0772019194458 29.HuangX.KotlarekD.WorchR.New Insight"/>
   <result pre="in the PA subunitNature200945891491810.1038/nature0774519194459 28.YuanP.BartlamM.LouZ.ChenS.ZhouJ.HeX.LvZ.GeR.LiX.DengT.et al.Crystal structure of an avian" exact="influenza" post="polymerase PA(N) reveals an endonuclease active siteNature200945890991310.1038/nature0772019194458 29.HuangX.KotlarekD.WorchR.New Insight"/>
   <result pre="Influenza PA-NterPLoS ONE20161110.1371/journal.pone.0156972 30.LukarskaM.FournierG.PflugA.Resa-InfanteP.ReichS.NaffakhN.CusackS.Structural basis of an essential interaction between" exact="influenza" post="polymerase and Pol II CTDNature201754111712110.1038/nature2059428002402 31.HeX.ZhouJ.BartlamM.ZhangR.MaJ.LouZ.LiX.LiJ.JoachimiakA.ZengZ.et al.Crystal structure of"/>
   <result pre="31.HeX.ZhouJ.BartlamM.ZhangR.MaJ.LouZ.LiX.LiJ.JoachimiakA.ZengZ.et al.Crystal structure of the polymerase PA(C)-PB1(N) complex from an" exact="avian influenza" post="H5N1 virusNature20084541123112610.1038/nature0712018615018 32.ObayashiE.YoshidaH.KawaiF.ShibayamaN.KawaguchiA.NagataK.TameJ.R.ParkS.Y.The structural basis for an essential subunit"/>
   <result pre="al.Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian" exact="influenza" post="H5N1 virusNature20084541123112610.1038/nature0712018615018 32.ObayashiE.YoshidaH.KawaiF.ShibayamaN.KawaguchiA.NagataK.TameJ.R.ParkS.Y.The structural basis for an essential subunit"/>
   <result pre="virusNature20084541123112610.1038/nature0712018615018 32.ObayashiE.YoshidaH.KawaiF.ShibayamaN.KawaguchiA.NagataK.TameJ.R.ParkS.Y.The structural basis for an essential subunit interaction in" exact="influenza" post="virus RNA polymeraseNature20084541127113110.1038/nature0722518660801 33.MaierH.J.KashiwagiT.HaraK.BrownleeG.G.Differential role of the influenza A"/>
   <result pre="interaction in influenza virus RNA polymeraseNature20084541127113110.1038/nature0722518660801 33.MaierH.J.KashiwagiT.HaraK.BrownleeG.G.Differential role of the" exact="influenza" post="A virus polymerase PA subunit for vRNA and cRNA"/>
   <result pre="mechanisms for capping viral mRNANat. Rev. Microbiol.201110516510.1038/nrmicro267522138959 37.PlotchS.J.BouloyM.UlmanenI.KrugR.M.A unique cap(m7GpppXm)-dependent" exact="influenza" post="virion endonuclease cleaves capped RNAs to generate the primers"/>
   <result pre="the primers that initiate viral RNA transcriptionCell19812384785810.1016/0092-8674(81)90449-96261960 38.EngelhardtO.G.SmithM.FodorE.Association of the" exact="influenza" post="A virus RNA-dependent RNA polymerase with cellular RNA polymerase"/>
   <result pre="IIJ. Virol.2005795812581810.1128/JVI.79.9.5812-5818.200515827195 39.GuilligayD.TarendeauF.Resa-InfanteP.ColomaR.CrepinT.SehrP.LewisJ.RuigrokR.W.OrtinJ.HartD.J.et al.The structural basis for cap binding by" exact="influenza" post="virus polymerase subunit PB2Nat. Struct. Mol. Biol.20081550050610.1038/nsmb.142118454157 40.NietoA.de la"/>
   <result pre="40.NietoA.de la LunaS.BarcenaJ.PortelaA.OrtinJ.Complex structure of the nuclear translocation signal of" exact="influenza" post="virus polymerase PA subunitJ. Gen. Virol.199475 Pt 1293610.1099/0022-1317-75-1-298113737 41.FodorE.SmithM.The"/>
   <result pre="for efficient nuclear accumulation of the PB1 subunit of the" exact="influenza" post="A virus RNA polymerase complexJ. Virol.2004789144915310.1128/JVI.78.17.9144-9153.200415308710 42.NietoA.de la LunaS.BàrcenaJ.PortelaA.ValcárcelJ.MeleroJ.OrtínJ.Nuclear"/>
   <result pre="virus RNA polymerase complexJ. Virol.2004789144915310.1128/JVI.78.17.9144-9153.200415308710 42.NietoA.de la LunaS.BàrcenaJ.PortelaA.ValcárcelJ.MeleroJ.OrtínJ.Nuclear transport of" exact="influenza" post="virus polymerase PA proteinVirus Res.199224657510.1016/0168-1702(92)90031-41320800 43.PflugA.GuilligayD.ReichS.CusackS.Structure of influenza A"/>
   <result pre="transport of influenza virus polymerase PA proteinVirus Res.199224657510.1016/0168-1702(92)90031-41320800 43.PflugA.GuilligayD.ReichS.CusackS.Structure of" exact="influenza" post="A polymerase bound to the viral RNA promoterNature201451635536010.1038/nature1400825409142 44.HengrungN.El"/>
   <result pre="OmariK.Serna MartinI.VreedeF.T.CusackS.RamboR.P.VonrheinC.BricogneG.StuartD.I.GrimesJ.M.et al.Crystal structure of the RNA-dependent RNA polymerase from" exact="influenza" post="C virusNature201552711411710.1038/nature1552526503046 45.ThierryE.GuilligayD.KosinskiJ.BockT.GaudonS.RoundA.PflugA.HengrungN.El OmariK.BaudinF.et al.Influenza Polymerase Can Adopt an"/>
   <result pre="of the Influenza Virus TranscriptaseMol. Cell2018701101111010.1016/j.molcel.2018.05.01129910112 47.MehleA.DoudnaJ.A.Adaptive strategies of the" exact="influenza" post="virus polymerase for replication in humansProc. Natl. Acad. Sci."/>
   <result pre="polymerase gene mutations for human adaptation occurring in Asian H5N1" exact="influenza" post="virus clinical isolatesSci. Rep.201881306610.1038/s41598-018-31397-330166556 49.QiangX.KouZ.Scoring amino acid mutation to"/>
   <result pre="Rep.201881306610.1038/s41598-018-31397-330166556 49.QiangX.KouZ.Scoring amino acid mutation to predict pandemic risk of" exact="avian influenza" post="virusBMC Bioinform.20192028810.1186/s12859-019-2770-0 50.MiottoO.HeinyA.T.AlbrechtR.Garcia-SastreA.TanT.W.AugustJ.T.BrusicV.Complete-proteome mapping of human influenza A adaptive"/>
   <result pre="49.QiangX.KouZ.Scoring amino acid mutation to predict pandemic risk of avian" exact="influenza" post="virusBMC Bioinform.20192028810.1186/s12859-019-2770-0 50.MiottoO.HeinyA.T.AlbrechtR.Garcia-SastreA.TanT.W.AugustJ.T.BrusicV.Complete-proteome mapping of human influenza A adaptive"/>
   <result pre="risk of avian influenza virusBMC Bioinform.20192028810.1186/s12859-019-2770-0 50.MiottoO.HeinyA.T.AlbrechtR.Garcia-SastreA.TanT.W.AugustJ.T.BrusicV.Complete-proteome mapping of human" exact="influenza" post="A adaptive mutations: Implications for human transmissibility of zoonotic"/>
   <result pre="of zoonotic strainsPLoS ONE20105e902510.1371/journal.pone.000902520140252 51.ChenG.W.ChangS.C.MokC.K.LoY.L.KungY.N.HuangJ.H.ShihY.H.WangJ.Y.ChiangC.ChenC.J.et al.Genomic signatures of human versus" exact="avian influenza" post="A virusesEmerg. Infect. Dis.2006121353136010.3201/eid1209.06027617073083 52.FinkelsteinD.B.MukatiraS.MehtaP.K.ObenauerJ.C.SuX.WebsterR.G.NaeveC.W.Persistent Host Markers in Pandemic"/>
   <result pre="zoonotic strainsPLoS ONE20105e902510.1371/journal.pone.000902520140252 51.ChenG.W.ChangS.C.MokC.K.LoY.L.KungY.N.HuangJ.H.ShihY.H.WangJ.Y.ChiangC.ChenC.J.et al.Genomic signatures of human versus avian" exact="influenza" post="A virusesEmerg. Infect. Dis.2006121353136010.3201/eid1209.06027617073083 52.FinkelsteinD.B.MukatiraS.MehtaP.K.ObenauerJ.C.SuX.WebsterR.G.NaeveC.W.Persistent Host Markers in Pandemic"/>
   <result pre="VirusesJ. Virol.200781102921029910.1128/JVI.00921-0717652405 53.WangQ.LiQ.LiuR.ZhengM.WenJ.ZhaoG.Host cell interactome of PA protein of H5N1" exact="influenza" post="A virus in chicken cellsJ. Proteom.2016136485410.1016/j.jprot.2016.01.018 54.WatanabeT.KawakamiE.ShoemakerJ.E.LopesT.J.MatsuokaY.TomitaY.Kozuka-HataH.GoraiT.KuwaharaT.TakedaE.et al.Influenza virus-host"/>
   <result pre="Pathogenic H5N1 Avian Influenza Virus in Mammalian CellsFront. Microbiol.2017873910.3389/fmicb.2017.0073928503168 56.WangL.FuB.LiW.PatilG.LiuL.DorfM.E.LiS.Comparative" exact="influenza" post="protein interactomes identify the role of plakophilin 2 in"/>
   <result pre="Virus, HIV, and Dengue Virus InfectionImmunity201644465810.1016/j.immuni.2015.12.01726789921 58.Bradel-TrethewayB.G.MattiacioJ.L.KrasnoselskyA.StevensonC.PurdyD.DewhurstS.KatzeM.G.Comprehensive proteomic analysis of" exact="influenza" post="virus polymerase complex reveals a novel association with mitochondrial"/>
   <result pre="Avian Influenza VirusFront. Microbiol.2018993610.3389/fmicb.2018.0093629867845 60.HsuW.B.ShihJ.L.ShihJ.R.DuJ.L.TengS.C.HuangL.M.WangW.B.Cellular protein HAX1 interacts with the" exact="influenza" post="A virus PA polymerase subunit and impedes its nuclear"/>
   <result pre="its nuclear translocationJ. Virol.20138711012310.1128/JVI.00939-1223055567 61.RodriguezA.Perez-GonzalezA.NietoA.Cellular human CLE/C14orf166 protein interacts with" exact="influenza" post="virus polymerase and is required for viral replicationJ. Virol.201185120621206610.1128/JVI.00684-1121900157"/>
   <result pre="a cellular protein required for viral replication, is incorporated into" exact="influenza" post="virus particlesSci. Rep.201662074410.1038/srep2074426864902 63.KoppsteinD.AshourJ.BartelD.P.Sequencing the cap-snatching repertoire of H1N1"/>
   <result pre="influenza virus particlesSci. Rep.201662074410.1038/srep2074426864902 63.KoppsteinD.AshourJ.BartelD.P.Sequencing the cap-snatching repertoire of H1N1" exact="influenza" post="provides insight into the mechanism of viral transcription initiationNucleic"/>
   <result pre="Acids Res.2015435052506410.1093/nar/gkv33325901029 64.SikoraD.RocheleauL.BrownE.G.PelchatM.Deep sequencing reveals the eight facets of the" exact="influenza" post="A/HongKong/1/1968 (H3N2) virus cap-snatching processSci. Rep.20144618110.1038/srep0618125154590 65.GuW.GallagherG.R.DaiW.LiuP.LiR.TromblyM.I.GammonD.B.MelloC.C.WangJ.P.FinbergR.W.Influenza A virus"/>
   <result pre="al.Virulence-affecting amino acid changes in the PA protein of H7N9" exact="influenza" post="A virusesJ. Virol.2014883127313410.1128/JVI.03155-1324371069 67.HuM.ChuH.ZhangK.SinghK.LiC.YuanS.ChowB.K.SongW.ZhouJ.ZhengB.J.Amino acid substitutions V63I or A37S/I61T/V63I/V100A"/>
   <result pre="in the PA N-terminal domain increase the virulence of H7N7" exact="influenza" post="A virusSci. Rep.201663780010.1038/srep3780027886255 68.SongM.S.PascuaP.N.LeeJ.H.BaekY.H.LeeO.J.KimC.J.KimH.WebbyR.J.WebsterR.G.ChoiY.K.The polymerase acidic protein gene of"/>
   <result pre="influenza A virusSci. Rep.201663780010.1038/srep3780027886255 68.SongM.S.PascuaP.N.LeeJ.H.BaekY.H.LeeO.J.KimC.J.KimH.WebbyR.J.WebsterR.G.ChoiY.K.The polymerase acidic protein gene of" exact="influenza" post="a virus contributes to pathogenicity in a mouse modelJ."/>
   <result pre="A Virus ReplicationJ. Virol.20189210.1128/JVI.01773-1729118119 73.De VlugtC.SikoraD.RocheleauL.PelchatM.Priming and realignment by the" exact="influenza" post="a virus RdRp is dependent on the length of"/>
   <result pre="II CTDGenes Dev.2006202922293610.1101/gad.147700617079683 77.GabrielG.DauberB.WolffT.PlanzO.KlenkH.D.StechJ.The viral polymerase mediates adaptation of an" exact="avian influenza" post="virus to a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="CTDGenes Dev.2006202922293610.1101/gad.147700617079683 77.GabrielG.DauberB.WolffT.PlanzO.KlenkH.D.StechJ.The viral polymerase mediates adaptation of an avian" exact="influenza" post="virus to a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="activity in avian and mammalian cells determines host range of" exact="influenza" post="virusJ. Virol.2007819601960410.1128/JVI.00666-0717567688 79.BazM.M’HamdiZ.CarbonneauJ.LavigneS.CoutureC.AbedY.BoivinG.Synergistic PA and HA mutations confer mouse"/>
   <result pre="and HA mutations confer mouse adaptation of a contemporary A/H3N2" exact="influenza" post="virusSci. Rep.201991661610.1038/s41598-019-51877-431719554 80.ChaimayoC.HayashiT.UnderwoodA.HodgesE.TakimotoT.Selective incorporation of vRNP into influenza A"/>
   <result pre="contemporary A/H3N2 influenza virusSci. Rep.201991661610.1038/s41598-019-51877-431719554 80.ChaimayoC.HayashiT.UnderwoodA.HodgesE.TakimotoT.Selective incorporation of vRNP into" exact="influenza" post="A virions determined by its specific interaction with M1"/>
   <result pre="Sci. USA2010107115251153010.1073/pnas.100198410720534471 82.RobbN.C.SmithM.VreedeF.T.FodorE.NS2/NEP protein regulates transcription and replication of the" exact="influenza" post="virus RNA genomeJ. Gen. Virol.2009901398140710.1099/vir.0.009639-019264657 83.OlsonA.C.RosenblumE.KuchtaR.D.Regulation of influenza RNA"/>
   <result pre="of the influenza virus RNA genomeJ. Gen. Virol.2009901398140710.1099/vir.0.009639-019264657 83.OlsonA.C.RosenblumE.KuchtaR.D.Regulation of" exact="influenza" post="RNA polymerase activity and the switch between replication and"/>
   <result pre="levels of dimerization of the heterotrimerPLoS Pathog.201915e100803410.1371/journal.ppat.100803431581279 85.MuramotoY.NodaT.KawakamiE.AkkinaR.KawaokaY.Identification of novel" exact="influenza" post="A virus proteins translated from PA mRNAJ. Virol.2013872455246210.1128/JVI.02656-1223236060 86.JaggerB.W.WiseH.M.KashJ.C.WaltersK.-A.WillsN.M.XiaoY.-L.DunfeeR.L.SchwartzmanL.M.OzinskyA.BellG.L.et"/>
   <result pre="Segment 3 Modulates the Host ResponseScience201233719920410.1126/science.122221322745253 87.FirthA.E.JaggerB.W.WiseH.M.NelsonC.C.ParsawarK.WillsN.M.NapthineS.TaubenbergerJ.K.DigardP.AtkinsJ.F.Ribosomal frameshifting used in" exact="influenza" post="A virus expression occurs within the sequence UCC_UUU_CGU and"/>
   <result pre="of the PA-X open reading frame in segment 3 of" exact="influenza" post="A virusJ. Virol.201286124111241310.1128/JVI.01677-1222951836 89.BelosoA.MartinezC.ValcarcelJ.SantarenJ.F.OrtinJ.Degradation of cellular mRNA during influenza"/>
   <result pre="of influenza A virusJ. Virol.201286124111241310.1128/JVI.01677-1222951836 89.BelosoA.MartinezC.ValcarcelJ.SantarenJ.F.OrtinJ.Degradation of cellular mRNA during" exact="influenza" post="virus infection: Its possible role in protein synthesis shutoffJ."/>
   <result pre="protein synthesis and degradation of cellular mRNAs during infection by" exact="influenza" post="and herpes simplex virusMol. Cell. Biol.198221644164810.1128/MCB.2.12.164414582206 91.KatzeM.G.KrugR.M.Metabolism and expression"/>
   <result pre="and degradation of cellular mRNAs during infection by influenza and" exact="herpes simplex" post="virusMol. Cell. Biol.198221644164810.1128/MCB.2.12.164414582206 91.KatzeM.G.KrugR.M.Metabolism and expression of RNA polymerase"/>
   <result pre="Biol.198221644164810.1128/MCB.2.12.164414582206 91.KatzeM.G.KrugR.M.Metabolism and expression of RNA polymerase II transcripts in" exact="influenza" post="virus-infected cellsMol. Cell. Biol.198442198220610.1128/MCB.4.10.21986095046 92.Bercovich-KinoriA.TaiJ.GelbartI.A.ShitritA.Ben-MosheS.DroriY.ItzkovitzS.MandelboimM.Stern-GinossarN.A systematic view on influenza"/>
   <result pre="in influenza virus-infected cellsMol. Cell. Biol.198442198220610.1128/MCB.4.10.21986095046 92.Bercovich-KinoriA.TaiJ.GelbartI.A.ShitritA.Ben-MosheS.DroriY.ItzkovitzS.MandelboimM.Stern-GinossarN.A systematic view on" exact="influenza" post="induced host shutoffElife2016510.7554/eLife.1831127525483 93.GlaunsingerB.GanemD.Lytic KSHV infection inhibits host gene"/>
   <result pre="the NS1 gene replicates in interferon-deficient systemsVirology199825232433010.1006/viro.1998.95089878611 96.KrugR.M.Functions of the" exact="influenza" post="A virus NS1 protein in antiviral defenseCurr. Opin. Virol.2015121610.1016/j.coviro.2015.01.00725638592"/>
   <result pre="in antiviral defenseCurr. Opin. Virol.2015121610.1016/j.coviro.2015.01.00725638592 97.HaleB.G.RandallR.E.OrtínJ.JacksonD.The multifunctional NS1 protein of" exact="influenza" post="A virusesJ. Gen. Virol.2008892359237610.1099/vir.0.2008/004606-018796704 98.NemeroffM.E.BarabinoS.M.LiY.KellerW.KrugR.M.Influenza virus NS1 protein interacts"/>
   <result pre="3’end formation of cellular pre-mRNAsMol. Cell19981991100010.1016/S1097-2765(00)80099-49651582 99.ChenH.DengG.LiZ.TianG.LiY.JiaoP.ZhangL.LiuZ.WebsterR.G.YuK.The evolution of H5N1" exact="influenza" post="viruses in ducks in southern ChinaProc. Natl. Acad. Sci."/>
   <result pre="southern ChinaProc. Natl. Acad. Sci. USA2004101104521045710.1073/pnas.040321210115235128 100.DasK.MaL.C.XiaoR.RadvanskyB.AraminiJ.ZhaoL.MarklundJ.KuoR.L.TwuK.Y.ArnoldE.et al.Structural basis for" exact="suppression" post="of a host antiviral response by influenza A virusProc."/>
   <result pre="al.Structural basis for suppression of a host antiviral response by" exact="influenza" post="A virusProc. Natl. Acad. Sci. USA2008105130931309810.1073/pnas.080521310518725644 101.HaleB.G.SteelJ.MedinaR.A.ManicassamyB.YeJ.HickmanD.HaiR.SchmolkeM.LowenA.C.PerezD.R.et al.Inefficient control"/>
   <result pre="control of host gene expression by the 2009 pandemic H1N1" exact="influenza" post="A virus NS1 proteinJ. Virol.2010846909692210.1128/JVI.00081-1020444891 102.ChaimayoC.DunaganM.HayashiT.SantosoN.TakimotoT.Specificity and functional interplay"/>
   <result pre="A virus NS1 proteinJ. Virol.2010846909692210.1128/JVI.00081-1020444891 102.ChaimayoC.DunaganM.HayashiT.SantosoN.TakimotoT.Specificity and functional interplay between" exact="influenza" post="virus PA-X and NS1 shutoff activityPLoS Pathog.201814e100746510.1371/journal.ppat.100746530496325 103.DesmetE.A.BusseyK.A.StoneR.TakimotoT.Identification of"/>
   <result pre="shutoff activityPLoS Pathog.201814e100746510.1371/journal.ppat.100746530496325 103.DesmetE.A.BusseyK.A.StoneR.TakimotoT.Identification of the N-terminal domain of the" exact="influenza" post="virus PA responsible for the suppression of host protein"/>
   <result pre="N-terminal domain of the influenza virus PA responsible for the" exact="suppression" post="of host protein synthesisJ. Virol.2013873108311810.1128/JVI.02826-1223283952 104.HayashiT.ChaimayoC.McGuinnessJ.TakimotoT.Critical Role of the"/>
   <result pre="Virol.2015896442645210.1128/JVI.00319-1525855745 107.KhaperskyyD.A.SchmalingS.Larkins-FordJ.McCormickC.GagliaM.M.Selective degradation of host RNA polymerase II transcripts by" exact="influenza" post="A virus PA-X host shutoff proteinPLoS Pathog.201612e100542710.1371/journal.ppat.100542726849127 108.OishiK.YamayoshiS.KawaokaY.Mapping of"/>
   <result pre="acids at the C-terminus of PA-X are associated with increased" exact="influenza" post="A virus replication and pathogenicityJ. Gen. Virol.2015962036204910.1099/vir.0.00014325877935 110.OishiK.YamayoshiS.KawaokaY.Identification of"/>
   <result pre="pathogenicityJ. Gen. Virol.2015962036204910.1099/vir.0.00014325877935 110.OishiK.YamayoshiS.KawaokaY.Identification of novel amino acid residues of" exact="influenza" post="virus PA-X that are important for PA-X shutoff activity"/>
   <result pre="specific metal chelating inhibitor binding to the endonuclease domain of" exact="influenza" post="pH1N1 (2009) polymerasePLoS Pathog.20128e100283110.1371/journal.ppat.100283122876177 113.OishiK.YamayoshiS.Kozuka-HataH.OyamaM.KawaokaY.N-Terminal Acetylation by NatB Is"/>
   <result pre="of host cytokine responses in the pathogenesis of avian H5N1" exact="influenza" post="viruses in miceJ. Virol.2007812736274410.1128/JVI.02336-0617182684 117.GaoH.SunY.HuJ.QiL.WangJ.XiongX.WangY.HeQ.LinY.KongW.et al.The contribution of PA-X"/>
   <result pre="the virulence of pandemic 2009 H1N1 and highly pathogenic H5N1" exact="avian influenza" post="virusesSci. Rep.20155826210.1038/srep0826225652161 118.HuJ.MoY.WangX.GuM.HuZ.ZhongL.WuQ.HaoX.HuS.LiuW.et al.PA-X decreases the pathogenicity of highly"/>
   <result pre="virulence of pandemic 2009 H1N1 and highly pathogenic H5N1 avian" exact="influenza" post="virusesSci. Rep.20155826210.1038/srep0826225652161 118.HuJ.MoY.WangX.GuM.HuZ.ZhongL.WuQ.HaoX.HuS.LiuW.et al.PA-X decreases the pathogenicity of highly"/>
   <result pre="Rep.20155826210.1038/srep0826225652161 118.HuJ.MoY.WangX.GuM.HuZ.ZhongL.WuQ.HaoX.HuS.LiuW.et al.PA-X decreases the pathogenicity of highly pathogenic H5N1" exact="influenza" post="A virus in avian species by inhibiting virus replication"/>
   <result pre="Virol.2015894126414210.1128/JVI.02132-1425631083 119.GongX.Q.SunY.F.RuanB.Y.LiuX.M.WangQ.YangH.M.WangS.Y.ZhangP.WangX.H.ShanT.L.et al.PA-X protein decreases replication and pathogenicity of swine" exact="influenza" post="virus in cultured cells and mouse modelsVet. Microbiol.2017205667010.1016/j.vetmic.2017.05.00428622865 120.BrydonE.W.MorrisS.J.SweetC.Role"/>
   <result pre="and mouse modelsVet. Microbiol.2017205667010.1016/j.vetmic.2017.05.00428622865 120.BrydonE.W.MorrisS.J.SweetC.Role of apoptosis and cytokines in" exact="influenza" post="virus morbidityFEMS Microbiol. Rev.20052983785010.1016/j.femsre.2004.12.00316102605 121.GaoH.XuG.SunY.QiL.WangJ.KongW.SunH.PuJ.ChangK.C.LiuJ.PA-X is a virulence factor"/>
   <result pre="Microbiol. Rev.20052983785010.1016/j.femsre.2004.12.00316102605 121.GaoH.XuG.SunY.QiL.WangJ.KongW.SunH.PuJ.ChangK.C.LiuJ.PA-X is a virulence factor in avian H9N2" exact="influenza" post="virusJ. Gen. Virol.2015962587259410.1099/jgv.0.00023226296365 122.HaydenF.G.SugayaN.HirotsuN.LeeN.de JongM.D.HurtA.C.IshidaT.SekinoH.YamadaK.PortsmouthS.et al.Baloxavir Marboxil for Uncomplicated"/>
   <result pre="Marker for Next-Generation Influenza Virus Endonuclease InhibitorsmBio2018910.1128/mBio.00430-18 125.OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM.KawaguchiK.UeharaT.ShishidoT.NaitoA.et al.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232149\results\search\disease\results.xml">
   <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Every year," exact="influenza" post="B viruses (IBVs) contribute to annual illness, and infection"/>
   <result pre="contribute to annual illness, and infection can lead to serious" exact="respiratory disease" post="among humans. More attention is needed in several areas,"/>
   <result pre="antigenically-relevant IBV strain, for furtherance of anti-influenza drug testing and" exact="influenza" post="vaccine protective efficacy analysis. A Victoria lineage (clade 1A)"/>
   <result pre="forms were noted. Light microscopy showed that mouse-adapted IBVs caused" exact="influenza" post="pneumonia on day 6 post inoculation. We evaluated the"/>
   <result pre="were noted. Light microscopy showed that mouse-adapted IBVs caused influenza" exact="pneumonia" post="on day 6 post inoculation. We evaluated the illness"/>
   <result pre="Assessment of an investigational anti-influenza drug (oseltamivir ethoxysuccinate) and an" exact="influenza" post="vaccine (Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against"/>
   <result pre="(Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against the mouse-adapted" exact="influenza" post="B virus. influenza B virus mouse-adapted amino acid substitutions"/>
   <result pre="Petersburg, Russia) showed effectiveness against the mouse-adapted influenza B virus." exact="influenza" post="B virus mouse-adapted amino acid substitutions pathogenicity influenza model"/>
   <result pre="B virus. influenza B virus mouse-adapted amino acid substitutions pathogenicity" exact="influenza" post="model virulence antiviral drugs influenza vaccine 1. Introduction Influenza"/>
   <result pre="mouse-adapted amino acid substitutions pathogenicity influenza model virulence antiviral drugs" exact="influenza" post="vaccine 1. Introduction Influenza B viruses (IBVs) belong to"/>
   <result pre="seasons [9]. Human infection by IBV can lead to serious" exact="respiratory disease," post="the complications of which are particularly common among children"/>
   <result pre="found significantly higher mortality rates due to IBV compared to" exact="influenza" post="A virus in children younger than 16 years of"/>
   <result pre="children younger than 16 years of age [11]. In Europe," exact="influenza" post="B accounted for 63% of all influenza cases in"/>
   <result pre="[11]. In Europe, influenza B accounted for 63% of all" exact="influenza" post="cases in the 2017–2018 epidemic season [12]. A number"/>
   <result pre="tract infections which frequently lead to fatal complications [13]. Seasonal" exact="influenza" post="vaccines are divided into types: trivalent, which consists of"/>
   <result pre="influenza vaccines are divided into types: trivalent, which consists of" exact="influenza" post="A/H1N1, A/H3N2, and one influenza B strain (B/Yam or"/>
   <result pre="types: trivalent, which consists of influenza A/H1N1, A/H3N2, and one" exact="influenza" post="B strain (B/Yam or B/Vic); or quadrivalent, which contains"/>
   <result pre="threat of IBV has been recently recognized [14], and seasonal" exact="influenza" post="vaccines are moving towards quadrivalent types [15,16,17], which will"/>
   <result pre="reassortant IBVs. Vaccines designs seek to provide protection against seasonal" exact="influenza" post="viruses by eliciting antibody responses to surface viral HA"/>
   <result pre="of (anti-influenza) vaccine-induced protection. BALB/c mice were infected with mouse-adapted" exact="influenza" post="B virus (B/Vic) and were characterized for illness, inflammation,"/>
   <result pre="according to the manufacturer’s instructions. Whole genome amplification of the" exact="influenza" post="B genome was performed using the SuperScriptTM III One-Step"/>
   <result pre="(SPBNIIVS, Saint Petersburg, Russia) containing purified surface antigens from the" exact="influenza" post="strain B/Colorado/06/2017 (lineage B/Victoria/2/87). On the 14th day after"/>
   <result pre="BALB/c mice were immunized with purified surface antigens from the" exact="influenza" post="strain B/Colorado/06/2017 (lineage B/Victoria/2/87) (Ultrix®, SPBNIIVS, Saint Petersburg, Russia)"/>
   <result pre="loss and hypothermia from the 2nd d.p.i, as well as" exact="conjunctivitis" post="(up to 30%), with onsets between 1 and 3"/>
   <result pre="affects vaccinated mice for up to 10 d.p.i. No other" exact="influenza" post="signs were observed in vaccinated mice, which indicate a"/>
   <result pre="have real epidemiological significance, especially among children. Together, IBV and" exact="influenza" post="A cause significant seasonal burdens. A lack of information"/>
   <result pre="antiquated because it is not genetically and antigenically representative of" exact="influenza" post="viruses currently circulating among humans. In the field of"/>
   <result pre="not provide an opportunity to study the pathological process of" exact="influenza" post="infection and makes it difficult to perform studies of"/>
   <result pre="not provide an opportunity to study the pathological process of" exact="influenza" post="infection. Moreover, many of the presented recombinant strains have"/>
   <result pre="in infected mammals. On the 6th d.p.i in BALB/c mice," exact="influenza" post="pneumonia featuring leukocyte and lymphocyte infiltration of bronchioles was"/>
   <result pre="infected mammals. On the 6th d.p.i in BALB/c mice, influenza" exact="pneumonia" post="featuring leukocyte and lymphocyte infiltration of bronchioles was detected"/>
   <result pre="in addition to spherical ones. This may possibly indicate that" exact="influenza" post="B virions are pleomorphic in structure. Comparative analysis of"/>
   <result pre="roles in elevating seasonal morbidity and mortality among humans worldwide," exact="influenza" post="A and B viruses have epidemiological, social, and economic"/>
   <result pre="Selective inhibition of neuraminidase is used in the treatment of" exact="influenza" post="to control the processes of budding and release of"/>
   <result pre="in the initial stages of infection, ensuring the penetration of" exact="influenza" post="viruses into cells. Due to the specific activity of"/>
   <result pre="to the specific activity of NA, inhibitors work effectively against" exact="influenza" post="A and B viruses. Oseltamivir, zanamivir, peramivir, and laninamivir"/>
   <result pre="long-acting neuraminidase inhibitors for the treatment and prophylaxis of human" exact="influenza" post="virus infection [39,40]. Between the NA inhibitors of oseltamivir"/>
   <result pre="shown that Tamiflu® is a lot less effective in treating" exact="influenza" post="B, compared to influenza A [42]. Due to the"/>
   <result pre="a lot less effective in treating influenza B, compared to" exact="influenza" post="A [42]. Due to the facts that the investigational"/>
   <result pre="oseltamivir ethoxysuccinate is a promising drug for the treatment of" exact="influenza" post="caused by the B virus. More attention should be"/>
   <result pre="and mechanisms can enhance the development of vaccines against current" exact="influenza" post="strains. Due to the fact that no significant lung"/>
   <result pre="IBV 17 times in BALB/c mice. The mouse-adapted IBV caused" exact="influenza" post="pneumonia on day 6 post inoculation. Apparently, selective accumulation"/>
   <result pre="17 times in BALB/c mice. The mouse-adapted IBV caused influenza" exact="pneumonia" post="on day 6 post inoculation. Apparently, selective accumulation of"/>
   <result pre="shown. Assessment of the investigational anti-influenza drug oseltamivir ethoxysuccinate and" exact="influenza" post="vaccine Ultrix® showed effectiveness against our mouse-adapted influenza B"/>
   <result pre="ethoxysuccinate and influenza vaccine Ultrix® showed effectiveness against our mouse-adapted" exact="influenza" post="B virus. In summary, we demonstrated productive infection and"/>
   <result pre="useful for estimation of anti-influenza drugs and protective efficacy of" exact="influenza" post="vaccines in vitro and in vivo. Acknowledgments We thank"/>
   <result pre="http://www.Ictvonline.org/virusTaxonomy.asp(accessed on 26 March 2020) 2.BodewesR.MorickD.de MutsertG.OsingaN.BestebroerT.van der VlietS.SmitsS.L.KuikenT.RimmelzwaanG.F.FouchierR.A.et al.Recurring" exact="influenza" post="B virus infections in sealsEmerg. Infect. Dis.20131951151210.3201/eid1903.12096523750359 3.OsterhausA.D.RimmelzwaanG.F.MartinaB.E.BestebroerT.M.FouchierR.A.M.Influenza B"/>
   <result pre="sealsScience20002881051105310.1126/science.288.5468.105110807575 4.SuS.ChavesS.S.PerezA.D’MelloT.KirleyP.D.Yousey-HindesK.FarleyM.M.HarrisM.SharangpaniR.LynfieldR.et al.Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="A and B virus infectionClin. Infect. Dis.20145925225510.1093/cid/ciu26924748521 5.McCullersJ.A.HoffmannE.HuberV.C.NickersonA.D.A single"/>
   <result pre="in the C-terminal domain of the matrix protein M1 of" exact="influenza" post="B virus confers mouse adaptation and virulenceVirology200533631832610.1016/j.virol.2005.03.02815892972 6.SheuT.G.DeydeV.M.Okomo-AdhiamboM.GartenR.J.XuX.BrightR.A.ButlerE.N.WallisT.R.KlimovA.I.GubarevaL.V.Surveillance for"/>
   <result pre="adaptation and virulenceVirology200533631832610.1016/j.virol.2005.03.02815892972 6.SheuT.G.DeydeV.M.Okomo-AdhiamboM.GartenR.J.XuX.BrightR.A.ButlerE.N.WallisT.R.KlimovA.I.GubarevaL.V.Surveillance for neuraminidase inhibitor resistance among human" exact="influenza" post="A and B viruses circulating worldwide from 2004 to"/>
   <result pre="to 2008Antimicrob. Agents Chemother.2008523284329210.1128/AAC.00555-0818625765 7.XuX.LindstromS.E.ShawM.W.SmithC.B.HallH.E.MungallB.A.SubbaraoK.CoxN.J.KlimovA.Reassortment and evolution of current human" exact="influenza" post="A and B virusesVirus Res.2004103556010.1016/j.virusres.2004.02.01315163489 8.SheuT.G.DeydeV.M.GartenR.J.KlimovA.I.GubarevaL.V.Detection of antiviral resistance"/>
   <result pre="Res.2004103556010.1016/j.virusres.2004.02.01315163489 8.SheuT.G.DeydeV.M.GartenR.J.KlimovA.I.GubarevaL.V.Detection of antiviral resistance and genetic lineage markers in" exact="influenza" post="B virus neuraminidase using pyrosequencingAntiviral Res.20108535436010.1016/j.antiviral.2009.10.02219887086 9.VirkR.K.JayakumarJ.MendenhallI.H.MoorthyM.LamP.LinsterM.LimJ.LinC.OonL.L.LeeH.K.et al.Divergent evolutionary"/>
   <result pre="virus neuraminidase using pyrosequencingAntiviral Res.20108535436010.1016/j.antiviral.2009.10.02219887086 9.VirkR.K.JayakumarJ.MendenhallI.H.MoorthyM.LamP.LinsterM.LimJ.LinC.OonL.L.LeeH.K.et al.Divergent evolutionary trajectories of" exact="influenza" post="B viruses underlie their contemporaneous epidemic activityProc. Natl. Acad."/>
   <result pre="States, September 2010–August 2011MMWR Morb. Mortal. Wkly. Rep.2011601233123821918492 11.TranD.VaudryW.MooreD.BettingerJ.A.HalperinS.A.ScheifeleD.W.JadvjiT.LeeL.MersereauT.Hospitalization for" exact="influenza" post="A versus BPediatrics2016138e2015464310.1542/peds.2015-464327535144 12.AdlhochC.SnackenR.MelidouA.IonescuS.PenttinenP.The European Influenza Surveillance Network. Dominant"/>
   <result pre="influenza A versus BPediatrics2016138e2015464310.1542/peds.2015-464327535144 12.AdlhochC.SnackenR.MelidouA.IonescuS.PenttinenP.The European Influenza Surveillance Network. Dominant" exact="influenza" post="A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and"/>
   <result pre="EU/EEA, 2016/17 and 2017/18 seasons, respectivelyEur. Surveill.2018231310.2807/1560-7917.ES.2018.23.13.18-00146 13.BuiC.H.ChanR.W.NgM.M.CheungM.C.NgK.C.ChanM.P.ChanL.L.FongJ.H.NichollsJ.M.PeirisJ.M.et al.Tropism of" exact="influenza" post="B viruses in human respiratory tract explants and airway"/>
   <result pre="J.20195410.1183/13993003.00008-2019 14.SharmaL.RebazaA.Dela CruzC.S.When &quot;B�? becomes &quot;A�?: The emerging threat of" exact="influenza" post="B virusEur. Respir. J.201954190132510.1183/13993003.01325-201931416813 15.collab: CDCInfluenza Vaccination: A Summary"/>
   <result pre="26 March 2020) 17.ShawM.W.XuX.LiY.NormandS.UekiR.T.KunimotoG.Y.HallH.KlimovA.CoxN.J.SubbaraoK.Reappearance and global spread of variants of" exact="influenza" post="B/Victoria/2/87 lineage viruses in the 2000–2001 and 2001–2002 seasonsVirology20023031810.1006/viro.2002.171912482653"/>
   <result pre="the 2000–2001 and 2001–2002 seasonsVirology20023031810.1006/viro.2002.171912482653 18.McCullersJ.A.Insights into the interaction between" exact="influenza" post="virus and pneumococcusClin. Microbiol. Rev.20061957158210.1128/CMR.00058-0516847087 19.collab: US Department of"/>
   <result pre="with high accuracy and high throughputNucleic Acids Res.2004321792179710.1093/nar/gkh34015034147 24.GubarevaL.V.WebsterR.G.HaydenF.G.Detection of" exact="influenza" post="virus resistance to neuraminidase inhibitors by an enzyme inhibition"/>
   <result pre="March 2020) 37.NodaT.Native Morphology of Influenza VirionsFront. Microbiol.2011226910.3389/fmicb.2011.0026922291683 38.MaenoK.Replication of" exact="influenza" post="B viruses: Biological functions of viran neuraminidaseNagoya J. Med."/>
   <result pre="41.BurcevaE.Review of efficacy data and monitoring of oseltamivir susceptibility to" exact="influenza" post="virus strainsVrach Dr.2010126770 42.SatoM.SaitoR.SatoI.TanabeN.ShobugawaY.SasakiA.LiD.SuzukiY.SatoM.SakaiT.et al.Effectiveness of oseltamivir treatment among"/>
   <result pre="strainsVrach Dr.2010126770 42.SatoM.SaitoR.SatoI.TanabeN.ShobugawaY.SasakiA.LiD.SuzukiY.SatoM.SakaiT.et al.Effectiveness of oseltamivir treatment among children with" exact="influenza" post="A or B virus infections during four successive winters"/>
   <result pre="and B/2017-MA strains, and assessment of anti-influenza drugs against mouse-adapted" exact="influenza" post="B virus in vivo. Note: (A) body weight and"/>
   <result pre="cells. Images were taken at ×1000 magnification. (D) Budding of" exact="influenza" post="B virions from the surface of type 1 alveolar"/>
   <result pre="with B/2017-MA strain. bar = 20 microns. (E) Virions of" exact="influenza" post="B; bar = 200 nm. (F) Body weight and"/>
   <result pre="infected mice. Figure 3 Assessment of vaccine efficiency against mouse-adapted" exact="influenza" post="B virus in vivo and in vitro. Note: (A)"/>
   <result pre="from groups of infected mice. (C) On day 3 day," exact="conjunctivitis" post="in a mouse infected with 10 MID50 of B/2017-MA"/>
   <result pre="10 MID50 of B/2017-MA strain. viruses-12-00470-t001_Table 1Table 1 Assessment of" exact="influenza" post="B viruses in neuraminidase (NA) enzyme inhibition assays. Strains"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232181\results\search\disease\results.xml">
   <result pre="line of immune defense. In this study, we analyzed whether" exact="influenza" post="A virus (IAV) and/or Staphylococcus aureus (S. aureus) infections"/>
   <result pre="lung, we used a human alveolus-on-a-chip model and a murine" exact="pneumonia" post="model. Our results show that S. aureus can reduce"/>
   <result pre="the lung, which might contribute to a severe outcome of" exact="bacterial pneumonia." post="Staphylococcus aureus pneumonia surfactant protein-A influenza A virus human"/>
   <result pre="contribute to a severe outcome of bacterial pneumonia. Staphylococcus aureus" exact="pneumonia" post="surfactant protein-A influenza A virus human alveolus-on-a-chip 1. Introduction"/>
   <result pre="severe outcome of bacterial pneumonia. Staphylococcus aureus pneumonia surfactant protein-A" exact="influenza" post="A virus human alveolus-on-a-chip 1. Introduction Pneumonia is the"/>
   <result pre="of the lower respiratory tract and also the most common" exact="infectious disease" post="worldwide. A wide variety of microorganisms can induce pneumonia,"/>
   <result pre="microorganisms can induce pneumonia, including viruses and bacteria. Among these," exact="influenza" post="A and B viruses (IAV, IBV) are primary causative"/>
   <result pre="causative agents [1]. The high mortality rates during the large" exact="influenza" post="virus (IV) epidemics and pandemic outbreaks are associated with"/>
   <result pre="ranging from superficial skin infections to life-threatening diseases, such as" exact="bacterial pneumonia" post="[2]. The first line of defense during infections, apart"/>
   <result pre="from superficial skin infections to life-threatening diseases, such as bacterial" exact="pneumonia" post="[2]. The first line of defense during infections, apart"/>
   <result pre="stored at −80 °C. For the murine model, the A/H1N1/pdm09" exact="influenza" post="virus variant HA-D222-mpJena/5258, expressing an aspartate in position 222"/>
   <result pre="from the lung of BALB/c mice infected with the A/H1N1/pdm09" exact="influenza" post="virus isolate A/Jena/5258/09 (kindly provided by Andi Krumbholz [28]."/>
   <result pre="the cell control. 2.5. In Vivo Infection For the murine" exact="pneumonia" post="model the mice were purchased from Janvier Labs (Le"/>
   <result pre="an in vivo murine lung infection model, we established a" exact="pneumonia" post="model and infected the mice with IAV, S. aureus"/>
   <result pre="or independent (IAV infection) on SP-A expression. 4. Discussion Secondary" exact="bacterial pneumonia" post="is one of the main reasons for increased morbidity"/>
   <result pre="independent (IAV infection) on SP-A expression. 4. Discussion Secondary bacterial" exact="pneumonia" post="is one of the main reasons for increased morbidity"/>
   <result pre="surfactant [39]. Early administration of surfactant reduces the risk of" exact="pneumothorax" post="and decreases mortality rates in preterm children [40]. Particularly"/>
   <result pre="the outcome of infants with RDS [41]. Furthermore, the adult" exact="acute respiratory distress syndrome" post="(ARDS) is also associated with a decreased amount of"/>
   <result pre="surfactant phospholipids [42]. In agreement with this result patients with" exact="respiratory failure" post="aggravated by sepsis also had a decreased surfactant level"/>
   <result pre="were found in the bronchoalveolar lavage (BAL) of patients with" exact="pneumonia" post="and without ARDS [44,45]. These examples demonstrate the great"/>
   <result pre="murine model which might contribute to the severe outcome of" exact="bacterial pneumonia." post="Acknowledgments We thank Elke Teuscher for supplying umbilical cords"/>
   <result pre="a potential conflict of interest. References References 1.TaubenbergerJ.K.MorensD.M.The pathology of" exact="influenza" post="virus infectionsAnnu. Rev. Pathol.2008349952210.1146/annurev.pathmechdis.3.121806.15431618039138 2.LowyF.D.Staphylococcus aureus infectionsN. Engl. J."/>
   <result pre="Structure, function and receptorsMol. Immunol.2006431293131510.1016/j.molimm.2005.08.00416213021 8.HanS.MallampalliR.K.The role of surfactant in" exact="lung disease" post="and host defense against pulmonary infectionsAnn. Am. Thorac. Soc.20151276577410.1513/AnnalsATS.201411-507FR25742123"/>
   <result pre="Soc.20151276577410.1513/AnnalsATS.201411-507FR25742123 9.BenneC.A.KraaijeveldC.A.van StrijpJ.A.BrouwerE.HarmsenM.VerhoefJ.van GoldeL.M.van IwaardenJ.F.Interactions of surfactant protein A with" exact="influenza" post="A viruses: Binding and neutralizationJ. Infect. Dis.199517133534110.1093/infdis/171.2.3357844369 10.GeertsmaM.F.NibberingP.H.HaagsmanH.P.DahaM.R.van FurthR.Binding"/>
   <result pre="of Staphylococcus aureus by monocytesAm. J. Physiol.1994267L578L58410.1152/ajplung.1994.267.5.L5787977768 11.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826Suppl. S4D49D5310.1016/j.vaccine.2008.07.03919230160 12.HsiehI.N.De LunaX.WhiteM.R.HartshornK.L.The role and molecular mechanism of"/>
   <result pre="action of surfactant protein D in innate host defense against" exact="influenza" post="A virusFront. Immunol.20189136810.3389/fimmu.2018.0136829951070 13.Sever-ChroneosZ.KrupaA.DavisJ.HasanM.YangC.H.SzeligaJ.HerrmannM.HussainM.GeisbrechtB.V.KobzikL.et al.Surfactant protein A (SP-A)-mediated clearance"/>
   <result pre="layers with improved perfusion conditionsBiofabrication2015701501310.1088/1758-5090/7/1/01501325727374 25.Deinhardt-EmmerS.RennertK.SchickeE.CseresnyesZ.WindolphM.NietzscheS.HellerR.SiwczakF.HauptK.F.CarlstedtS.et al.Co-infection withStaphylococcus aureusafter primary" exact="influenza" post="virus infection leads to damage of the endothelium in"/>
   <result pre="222D/G polymorphism facilitates fast intra-host evolution of pandemic (H1N1) 2009" exact="influenza" post="A virusesPLoS ONE20149e10423310.1371/journal.pone.010423325162520 28.ManchandaH.SeidelN.KrumbholzA.SauerbreiA.SchmidtkeM.GuthkeR.Within-host influenza dynamics: A small-scale mathematical"/>
   <result pre="evolution of pandemic (H1N1) 2009 influenza A virusesPLoS ONE20149e10423310.1371/journal.pone.010423325162520 28.ManchandaH.SeidelN.KrumbholzA.SauerbreiA.SchmidtkeM.GuthkeR.Within-host" exact="influenza" post="dynamics: A small-scale mathematical modeling approachBio Syst.2014118515910.1016/j.biosystems.2014.02.004 29.TuchscherrL.MedinaE.HussainM.VolkerW.HeitmannV.NiemannS.HolzingerD.RothJ.ProctorR.A.BeckerK.et al.Staphylococcus"/>
   <result pre="in real-time RT-PCRNucleic Acids Res.200129e4510.1093/nar/29.9.e4511328886 31.BloesD.A.HaasbachE.HartmayerC.HertleinT.KlingelK.KretschmerD.PlanzO.PeschelA.Phenol-soluble modulin peptides contribute to" exact="influenza" post="a virus-associated staphylococcus aureus pneumoniaInfect. Immun.20178510.1128/IAI.00620-1728893917 32.JoshiS.KotechaS.Lung growth and"/>
   <result pre="surfactant protein synthesis in the hypoplastic lung of nitrofen-induced diaphragmatic" exact="hernia" post="in ratsJ. Pediatr. Surg.2000351468147310.1053/jpsu.2000.1641611051153 39.KonishiM.FujiwaraT.NaitoT.TakeuchiY.OgawaY.InukaiK.FujimuraM.NakamuraH.HashimotoT.Surfactant replacement therapy in neonatal"/>
   <result pre="Staphylococcus aureus necrotizing pneumonia: The role of PVL and an" exact="influenza" post="coinfectionExpert Rev. Anti Infect. Ther.2013111041105110.1586/14787210.2013.82789124073746 50.NiemannS.EhrhardtC.MedinaE.WarnkingK.TuchscherrL.HeitmannV.LudwigS.PetersG.LofflerB.Combined action of influenza"/>
   <result pre="an influenza coinfectionExpert Rev. Anti Infect. Ther.2013111041105110.1586/14787210.2013.82789124073746 50.NiemannS.EhrhardtC.MedinaE.WarnkingK.TuchscherrL.HeitmannV.LudwigS.PetersG.LofflerB.Combined action of" exact="influenza" post="virus and Staphylococcus aureus panton-valentine leukocidin provokes severe lung"/>
   <result pre="cellsJ. Virol.2002761071107610.1128/JVI.76.3.1071-1076.200211773383 Figure 1 NCI-H441 cells were productively infected with" exact="influenza" post="A virus (IAV) upon mono- and co-infection with S."/>
   <result pre="human alveolus-on-a-chip model shows SP-A staining (red) of mock infected," exact="influenza" post="virus, S. aureus and co-infected scenarios. Scale bar represents"/>
   <result pre="p &amp;lt; 0.01. Figure 5 Murine model of S. aureus" exact="pneumonia" post="showing viral titers (A) as well as S. aureus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232189\results\search\disease\results.xml">
   <result pre="is a respiratory pathogen that infects humans and causes seasonal" exact="influenza" post="epidemics. However, cellular response to IBV infection in humans"/>
   <result pre="(matrix 1 and nucleocapsid) [1]. Recently, a new type of" exact="influenza" post="virus with bovine as a primary reservoir, officially designated"/>
   <result pre="influenza virus with bovine as a primary reservoir, officially designated" exact="influenza" post="type D, has been described [2,3]. Among these influenza"/>
   <result pre="designated influenza type D, has been described [2,3]. Among these" exact="influenza" post="viruses, only influenza A and B viruses (IAV and"/>
   <result pre="D, has been described [2,3]. Among these influenza viruses, only" exact="influenza" post="A and B viruses (IAV and IBV) are of"/>
   <result pre="treatment [7,10]. IBV-associated mortality has been frequently observed in seasonal" exact="influenza" post="epidemics particularly in children and adolescents [11,12], and the"/>
   <result pre="strain for annual vaccine production. The global burden of annual" exact="influenza" post="epidemics involving IBV, coupled with the increasing strong links"/>
   <result pre="the pathogenicity of IBV and help understand the severity of" exact="influenza" post="syndromes and mechanisms of IBV resistance and disease tolerance."/>
   <result pre="NGS using conventional RT-qPCR (Figure 4). Previous studies demonstrated that" exact="influenza" post="A virus infection is mainly detected by three classes"/>
   <result pre="myxovirus genes (Mx1 and Mx2), which are GTPases that block" exact="influenza" post="A virus replication [37,38], were up regulated ~1200-fold at"/>
   <result pre="may serve as one of the primary antiviral defenses against" exact="influenza" post="infection [42]. In addition, we observed no inducible expression"/>
   <result pre="Williams &amp;amp; WilkinsPhiladelphia, PA, USA2007Volume 216471689 2.HauseB.M.CollinE.A.LiuR.HuangB.ShengZ.LuW.WangD.NelsonE.A.LiF.Characterization of a novel" exact="influenza" post="virus in cattle and Swine: Proposal for a new"/>
   <result pre="in the Orthomyxoviridae familyMBio20145e00031-1410.1128/mBio.00031-1424595369 3.HauseB.M.DucatezM.CollinE.A.RanZ.LiuR.ShengZ.ArmienA.KaplanB.ChakravartyS.HoppeA.D.et al.Isolation of a novel swine" exact="influenza" post="virus from Oklahoma in 2011 which is distantly related"/>
   <result pre="from Oklahoma in 2011 which is distantly related to human" exact="influenza" post="C virusesPLoS Pathog.20139e100317610.1371/journal.ppat.100317623408893 4.CoxN.J.SubbaraoK.Global epidemiology of influenza: Past and"/>
   <result pre="Med.20005140742110.1146/annurev.med.51.1.40710774473 5.McCullersJ.A.FacchiniS.ChesneyP.J.WebsterR.G.Influenza B virus encephalitisClin. Infect. Dis19992889890010.1086/51521410825057 6.McCullersJ.A.SaitoT.IversonA.R.Multiple genotypes of" exact="influenza" post="B virus circulated between 1979 and 2003J. Virol.200478128171282810.1128/JVI.78.23.12817-12828.200415542634 7.MontoA.S.Epidemiology"/>
   <result pre="in sealsScience20002881051105310.1126/science.288.5468.105110807575 9.RanZ.ShenH.LangY.KolbE.A.TuranN.ZhuL.MaJ.BawaB.LiuQ.LiuH.et al.Domestic pigs are susceptible to infection with" exact="influenza" post="B virusesJ. Virol.2015894818482610.1128/JVI.00059-1525673727 10.Paul GlezenW.SchmierJ.K.KuehnC.M.RyanK.J.OxfordJ.The burden of influenza B:"/>
   <result pre="infection with influenza B virusesJ. Virol.2015894818482610.1128/JVI.00059-1525673727 10.Paul GlezenW.SchmierJ.K.KuehnC.M.RyanK.J.OxfordJ.The burden of" exact="influenza" post="B: A structured literature reviewAm. J. Public Health2013103e43e5110.2105/AJPH.2012.30113723327249 11.Gutierrez-PizarrayaA.Perez-RomeroP.AlvarezR.AydilloT.A.Osorio-GomezG.Milara-IbanezC.SanchezM.PachonJ.CorderoE.Unexpected"/>
   <result pre="literature reviewAm. J. Public Health2013103e43e5110.2105/AJPH.2012.30113723327249 11.Gutierrez-PizarrayaA.Perez-RomeroP.AlvarezR.AydilloT.A.Osorio-GomezG.Milara-IbanezC.SanchezM.PachonJ.CorderoE.Unexpected severity of cases of" exact="influenza" post="B infection in patients that required hospitalization during the"/>
   <result pre="during the first postpandemic waveJ. Infect.20126542343010.1016/j.jinf.2012.07.00422820034 12.WuP.GoldsteinE.HoL.M.YangL.NishiuraH.WuJ.T.IpD.K.ChuangS.K.TsangT.CowlingB.J.Excess mortality associated with" exact="influenza" post="A and B virus in Hong Kong, 1998–2009J. Infect."/>
   <result pre="of antigenic variants and the vaccine-type virus during the 2004–2005" exact="influenza" post="B virus epidemics in JapanJ. Clin. Microbiol.20094735235710.1128/JCM.01357-0819091818 15.NeromeR.HiromotoY.SugitaS.TanabeN.IshidaM.MatsumotoM.LindstromS.E.TakahashiT.NeromeK.Evolutionary characteristics"/>
   <result pre="B virus epidemics in JapanJ. Clin. Microbiol.20094735235710.1128/JCM.01357-0819091818 15.NeromeR.HiromotoY.SugitaS.TanabeN.IshidaM.MatsumotoM.LindstromS.E.TakahashiT.NeromeK.Evolutionary characteristics of" exact="influenza" post="B virus since its first isolation in 1940: Dynamic"/>
   <result pre="of deletion and insertion mechanismArch. Virol.19981431569158310.1007/s0070500503999739335 16.ShenJ.KirkB.D.MaJ.WangQ.Diversifying selective pressure on" exact="influenza" post="B virus hemagglutininJ. Med. Virol.20098111412410.1002/jmv.2133519031453 17.LinJ.H.ChiuS.C.ShawM.W.LinY.C.LeeC.H.ChenH.Y.KlimovA.Characterization of the epidemic"/>
   <result pre="influenza B virus hemagglutininJ. Med. Virol.20098111412410.1002/jmv.2133519031453 17.LinJ.H.ChiuS.C.ShawM.W.LinY.C.LeeC.H.ChenH.Y.KlimovA.Characterization of the epidemic" exact="influenza" post="B viruses isolated during 2004–2005 season in TaiwanVirus Res.200712420421110.1016/j.virusres.2006.11.00517196288"/>
   <result pre="Res.200712420421110.1016/j.virusres.2006.11.00517196288 18.McCullersJ.A.WangG.C.HeS.WebsterR.G.Reassortment and insertion-deletion are strategies for the evolution of" exact="influenza" post="B viruses in natureJ. Virol.1999737343734810.1128/JVI.73.9.7343-7348.199910438823 19.GlezenW.P.Editorial commentary: Changing epidemiology"/>
   <result pre="B viruses in natureJ. Virol.1999737343734810.1128/JVI.73.9.7343-7348.199910438823 19.GlezenW.P.Editorial commentary: Changing epidemiology of" exact="influenza" post="B virusClin. Infect. Dis2014591525152610.1093/cid/ciu66825139967 20.VijaykrishnaD.HolmesE.C.JosephU.FourmentM.SuY.C.HalpinR.LeeR.T.DengY.M.GunalanV.LinX.et al.The contrasting phylodynamics of"/>
   <result pre="B virusClin. Infect. Dis2014591525152610.1093/cid/ciu66825139967 20.VijaykrishnaD.HolmesE.C.JosephU.FourmentM.SuY.C.HalpinR.LeeR.T.DengY.M.GunalanV.LinX.et al.The contrasting phylodynamics of human" exact="influenza" post="B viruseseLife20154e0505510.7554/eLife.0505525594904 21.McCullersJ.A.HaydenF.G.Fatal influenza B infections: Time to reexamine"/>
   <result pre="20.VijaykrishnaD.HolmesE.C.JosephU.FourmentM.SuY.C.HalpinR.LeeR.T.DengY.M.GunalanV.LinX.et al.The contrasting phylodynamics of human influenza B viruseseLife20154e0505510.7554/eLife.0505525594904 21.McCullersJ.A.HaydenF.G.Fatal" exact="influenza" post="B infections: Time to reexamine influenza research prioritiesJ. Infect."/>
   <result pre="influenza B viruseseLife20154e0505510.7554/eLife.0505525594904 21.McCullersJ.A.HaydenF.G.Fatal influenza B infections: Time to reexamine" exact="influenza" post="research prioritiesJ. Infect. Dis.201220587087210.1093/infdis/jir86522291194 22.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnesM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.et al.Myocardial injury and bacterial"/>
   <result pre="reexamine influenza research prioritiesJ. Infect. Dis.201220587087210.1093/infdis/jir86522291194 22.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnesM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.et al.Myocardial injury and" exact="bacterial pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
   <result pre="influenza research prioritiesJ. Infect. Dis.201220587087210.1093/infdis/jir86522291194 22.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnesM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.et al.Myocardial injury and bacterial" exact="pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
   <result pre="injury and bacterial pneumonia contribute to the pathogenesis of fatal" exact="influenza" post="B virus infectionJ. Infect. Dis.201220589590510.1093/infdis/jir86122291193 23.ReedL.J.MuenchH.A Simple Method of"/>
   <result pre="methodMethods20012540240810.1006/meth.2001.126211846609 32.ShengZ.LiuR.YuJ.RanZ.NewkirkS.J.AnW.LiF.WangD.Identification and characterization of viral defective RNA genomes in" exact="influenza" post="B virusJ. Gen. Virol.20189947548810.1099/jgv.0.00101829458654 33.TissariJ.SirenJ.MeriS.JulkunenI.MatikainenS.IFN-alpha enhances TLR3-mediated antiviral cytokine"/>
   <result pre="Cell Responses during Influenza Virus InfectionPLoS Pathog.201612e100575410.1371/journal.ppat.100575427438481 36.IwasakiA.PillaiP.S.Innate immunity to" exact="influenza" post="virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 37.VerhelstJ.SpitaelsJ.NurnbergerC.De VliegerD.YsenbaertT.StaeheliP.FiersW.SaelensX.Functional Comparison of Mx1"/>
   <result pre="Activity against Influenza A VirusesJ. Virol.201589108791089010.1128/JVI.01744-1526292322 38.VerhelstJ.ParthoensE.SchepensB.FiersW.SaelensX.Interferon-inducible protein Mx1 inhibits" exact="influenza" post="virus by interfering with functional viral ribonucleoprotein complex assemblyJ."/>
   <result pre="for Influenza B Virus-Induced Rapid Interferon Gene ExpressionJ. Virol.201589120141202510.1128/JVI.01576-1526378160 47.OsterlundP.StrengellM.SarinL.P.PoranenM.M.FagerlundR.MelenK.JulkunenI.Incoming" exact="influenza" post="A virus evades early host recognition, while influenza B"/>
   <result pre="Virol.201589120141202510.1128/JVI.01576-1526378160 47.OsterlundP.StrengellM.SarinL.P.PoranenM.M.FagerlundR.MelenK.JulkunenI.Incoming influenza A virus evades early host recognition, while" exact="influenza" post="B virus induces interferon expression directly upon entryJ. Virol.201286111831119310.1128/JVI.01050-1222855501"/>
   <result pre="10−19 4917 Prolactin signaling pathway 16 0.00386 4940 Type I" exact="diabetes mellitus" post="12 0.0017 5133 Pertussis 30 4.58 × 10−12 5134"/>
   <result pre="Chagas disease (American trypanosomiasis) 30 4.32 × 10−08 5143 African" exact="trypanosomiasis" post="11 0.00117 5144 Malaria 12 0.00552 5145 Toxoplasmosis 29"/>
   <result pre="0.00296 5203 Viral carcinogenesis 45 2.64 × 10−08 5320 Autoimmune" exact="thyroid disease" post="13 0.0032 5323 Rheumatoid arthritis 25 2.28 × 10−06"/>
   <result pre="× 10−08 5320 Autoimmune thyroid disease 13 0.0032 5323 Rheumatoid" exact="arthritis" post="25 2.28 × 10−06 5330 Allograft rejection 10 0.00542"/>
   <result pre="rejection 10 0.00542 5332 Graft-versus-host disease 11 0.00245 5416 Viral" exact="myocarditis" post="13 0.00893 viruses-12-00383-t002_Table 2Table 2 KEGG pathways significantly enriched"/>
   <result pre="Metabolic pathways 134 2.40 × 10−07 24 hpi 3460 Fanconi" exact="anemia" post="pathway 17 2.40 × 10−06 24 hpi 4110 Cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232257\results\search\disease\results.xml">
   <result pre="patient was a 29 year-old woman with a type I" exact="neurofibromatosis" post="and a pilocytic astrocytoma (in 2007), further complicated by"/>
   <result pre="29 year-old woman with a type I neurofibromatosis and a" exact="pilocytic astrocytoma" post="(in 2007), further complicated by an extradural empyema. Despite"/>
   <result pre="year-old woman with a type I neurofibromatosis and a pilocytic" exact="astrocytoma" post="(in 2007), further complicated by an extradural empyema. Despite"/>
   <result pre="Rossier Bacteriophages active against Meticillin Resistant Staphylococci isolated from bovine" exact="mastitis" post="infections Z. E. Aynur, G. Basbülbül, B. Bozdoğan Strategy"/>
   <result pre="Strategy using phages to control Staphylococcus aureus responsible for bovine" exact="mastitis" post="M. H. Chatain The use of interferometric microscopy to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232439\results\search\disease\results.xml">
   <result pre="against IAV infection and how IAVs antagonize host immune responses." exact="influenza" post="A virus innate immunity adaptive immunity 1. Introduction Influenza"/>
   <result pre="birds, pigs, horses, and humans. In humans, the viruses cause" exact="respiratory disease" post="and be transmitted by inhalation of virus-containing dust particles"/>
   <result pre="aerosols [1]. Severe IAV infection can cause lung inflammation and" exact="acute respiratory distress syndrome" post="(ARDS), which may lead to mortality. Thus, causing many"/>
   <result pre="syndrome (ARDS), which may lead to mortality. Thus, causing many" exact="influenza" post="epidemics and pandemics, IAV has been a threat to"/>
   <result pre="application of updating licensed vaccines and drugs, seasonal and pandemic" exact="influenza" post="still cause millions of infection cases each year and"/>
   <result pre="global concern on periodic zoonotic infections. Take the emergence of" exact="influenza" post="A (H1N1) pdm09 (pH1N1) and influenza A (H3N2) A/Canada/1158/2006"/>
   <result pre="Take the emergence of influenza A (H1N1) pdm09 (pH1N1) and" exact="influenza" post="A (H3N2) A/Canada/1158/2006 strains for instance, both strains are"/>
   <result pre="active, infection of HPAIVs is more likely to cause severe" exact="pneumonia" post="[78]. Other research on low pathogenic avian IAVs (LPAIVs),"/>
   <result pre="[122]. In addition, they also regulate adaptive immunity via guiding" exact="influenza" post="specific CD8+ T cells to the infection sites [123]."/>
   <result pre="protein via mechanisms including inhibition of the TRIM25-mediated RIG-I ubiquitination," exact="suppression" post="of protein kinase R (PKR), phosphorylation of IκB kinases"/>
   <result pre="present suitable targets for anti-IAV therapies. A comprehensive review on" exact="influenza" post="A virus-induced apoptosis discussed by Ampomah and Lim is"/>
   <result pre="endonuclease inhibitor (Baloxavir Marboxil) targeting PA is also applied against" exact="influenza" post="A and B virus infection [219]. Our progressing understanding"/>
   <result pre="polymerase, is licensed in Japan to be applied against emerging" exact="influenza" post="viruses resistant to other antivirals [222,223]. Oleanolic acid (OA),"/>
   <result pre="Scoparone, were investigated for their antiviral and anti-inflammatory activities against" exact="influenza" post="virus in vitro [31]. Other candidates, such as Naproxen,"/>
   <result pre="Channel with an Antigenically Distinct EctodomainPLoS Pathog.20128e100299810.1371/journal.ppat.100299823133386 7.SelmanM.DankarS.K.ForbesN.JiaJ.-J.BrownE.G.Adaptive mutation in" exact="influenza" post="A virus non-structural gene is linked to host switching"/>
   <result pre="by alternative splicingEmerg. Microbes Infect.20121e4210.1038/emi.2012.3826038410 8.TongS.LiY.RivaillerP.ConrardyC.CastilloD.A.A.ChenL.-M.Recuenco-CabreraS.EllisonJ.A.DavisC.T.YorkI.et al.A distinct lineage of" exact="influenza" post="A virus from batsProc. Natl. Acad. Sci. USA20121094269427410.1073/pnas.111620010922371588 9.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.Recuenco-CabreraS.GómezJ.et"/>
   <result pre="since 2013 in ChinaTrends Microbiol.20172571372810.1016/j.tim.2017.06.00828734617 11.ImpagliazzoA.MilderF.KuipersH.WagnerM.V.ZhuX.HoffmanR.M.B.Van MeersbergenR.HuizinghJ.WanningenP.VerspuijJ.et al.A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogenScience20153491301130610.1126/science.aac726326303961 12.Boyoglu-BarnumS.HutchinsonG.B.BoyingtonJ.C.MoinS.M.GillespieR.A.TsybovskyY.StephensT.VaileJ.R.LederhoferJ.CorbettK.S.et al.Glycan"/>
   <result pre="stem as a broadly protective immunogenScience20153491301130610.1126/science.aac726326303961 12.Boyoglu-BarnumS.HutchinsonG.B.BoyingtonJ.C.MoinS.M.GillespieR.A.TsybovskyY.StephensT.VaileJ.R.LederhoferJ.CorbettK.S.et al.Glycan repositioning of" exact="influenza" post="hemagglutinin stem facilitates the elicitation of protective cross-group antibody"/>
   <result pre="and neuraminidase membrane glycoproteinsJ. Biol. Chem.2010285284032840910.1074/jbc.R110.12980920538598 15.SheltonH.Ayora-TalaveraG.RenJ.LoureiroS.PicklesR.J.BarclayW.S.JonesI.Receptor binding profiles of" exact="avian influenza" post="virus hemagglutinin subtypes on human cells as a predictor"/>
   <result pre="neuraminidase membrane glycoproteinsJ. Biol. Chem.2010285284032840910.1074/jbc.R110.12980920538598 15.SheltonH.Ayora-TalaveraG.RenJ.LoureiroS.PicklesR.J.BarclayW.S.JonesI.Receptor binding profiles of avian" exact="influenza" post="virus hemagglutinin subtypes on human cells as a predictor"/>
   <result pre="pandemic potentialJ. Virol.2010851875188010.1128/JVI.01822-1021106732 16.de GraafM.FouchierR.A.Role of receptor binding specificity in" exact="influenza" post="A virus transmission and pathogenesisEMBO J.20143382384110.1002/embj.20138744224668228 17.ShiY.ZhangW.WangF.QiJ.WuY.SongH.GaoF.BiY.ZhangY.FanZ.et al.Structures and"/>
   <result pre="J.20131032110.1186/1743-422X-10-32124261589 20.BarnardK.N.Alford-LawrenceB.K.BuchholzD.W.WasikB.R.LaClairJ.R.YuH.HonceR.RuhlS.PajicP.DaugherityE.K.et al.Modified sialic acids on mucus and erythrocytes inhibit" exact="influenza" post="A HA and NA functionsJ. Virol.202010.1128/JVI.01567-19 21.AirG.M.Influenza neuraminidaseInfluenza Other"/>
   <result pre="Other Respir. Viruses2012624525610.1111/j.1750-2659.2011.00304.x22085243 22.EvseenkoV.A.SvyatchenkoS.V.KolosovaN.P.KovrizhkinaV.L.MarchenkoV.Y.DurymanovA.G.GoncharovaN.I.RyzhikovA.B.Comparative thermostability analysis of zoonotic and human" exact="influenza" post="virus A and B neuraminidaseArch. Virol.201916520120610.1007/s00705-019-04465-w31745716 23.EichelbergerM.C.MorensD.M.TaubenbergerJ.K.Neuraminidase as an"/>
   <result pre="influenza virus A and B neuraminidaseArch. Virol.201916520120610.1007/s00705-019-04465-w31745716 23.EichelbergerM.C.MorensD.M.TaubenbergerJ.K.Neuraminidase as an" exact="influenza" post="vaccine antigen: A low hanging fruit, ready for picking"/>
   <result pre="Virus by Human Anti-N9 Neuraminidase AntibodiesCell Host Microbe20192672973810.1016/j.chom.2019.10.00231757767 25.NodaT.KawaokaY.Structure of" exact="influenza" post="virus ribonucleoprotein complexes and their packaging into virionsRev. Med."/>
   <result pre="RNA synthesisNat. Rev. Genet.20161447949310.1038/nrmicro.2016.87 28.KönigR.StertzS.ZhouY.InoueA.HoffmannH.-H.BhattacharyyaS.AlamaresJ.G.TscherneN.M.OrtigozaM.LiangY.et al.Human host factors required for" exact="influenza" post="virus replicationNature201046381381710.1038/nature0869920027183 29.KarlasA.MachuyN.ShinY.PleissnerK.-P.ArtariniA.HeuerD.BeckerD.KhalilH.OgilvieL.HessS.et al.Genome-wide RNAi screen identifies human host"/>
   <result pre="29.KarlasA.MachuyN.ShinY.PleissnerK.-P.ArtariniA.HeuerD.BeckerD.KhalilH.OgilvieL.HessS.et al.Genome-wide RNAi screen identifies human host factors crucial for" exact="influenza" post="virus replicationNature201046381882210.1038/nature0876020081832 30.YangC.LiuX.GaoQ.ChengT.XiaoR.MingF.ZhangS.JinM.ChenH.MaW.et al.The Nucleolar Protein LYAR Facilitates Ribonucleoprotein"/>
   <result pre="Virol.20189210.1128/JVI.01042-18 31.WangY.YanW.ChenQ.HuangW.YangZ.LiX.WangX.-H.Inhibition viral RNP and anti-inflammatory activity of coumarins against" exact="influenza" post="virusBiomed. Pharmacother.20178758358810.1016/j.biopha.2016.12.11728081470 32.LambR.A.LaiC.J.ChoppinP.W.Sequences of mRNAs derived from genome RNA"/>
   <result pre="32.LambR.A.LaiC.J.ChoppinP.W.Sequences of mRNAs derived from genome RNA segment 7 of" exact="influenza" post="virus: Colinear and interrupted mRNAs code for overlapping proteinsProc."/>
   <result pre="Is Essential for Efficient Replication in Tissue CultureJ. Virol.2002761391139910.1128/JVI.76.3.1391-1399.200211773413 36.BhowmickS.ChakravartyC.SellathambyS.LalS.K.The" exact="influenza" post="A virus matrix protein 2 undergoes retrograde transport from"/>
   <result pre="proteasomal degradationArch. Virol.201616291992910.1007/s00705-016-3153-827942972 37.Alonso-CaplenF.V.KrugR.M.Regulation of the extent of splicing of" exact="influenza" post="virus NS1 mRNA: Role of the rates of splicing"/>
   <result pre="antagonism and beyondJ. Gen. Virol.2014952594261110.1099/vir.0.069542-025182164 40.HaleB.RandallR.OrtínJ.JacksonD.The multifunctional NS1 protein of" exact="influenza" post="A virusesJ. Gen. Virol.2008892359237610.1099/vir.0.2008/004606-018796704 41.WilkinsC.GaleM.Recognition of viruses by cytoplasmic"/>
   <result pre="Genomic RNA during Negative-Strand RNA Virus InfectionCell201014039740810.1016/j.cell.2010.01.02020144762 43.ZhangK.XieY.Muñoz-MorenoR.WangJ.ZhangL.EsparzaM.García-SastreA.FontouraB.M.A.RenY.Structural basis for" exact="influenza" post="virus NS1 protein block of mRNA nuclear exportNat. Microbiol.201941671167910.1038/s41564-019-0482-x31263181"/>
   <result pre="RNA secondary structure affect NS1 protein expression during early stage" exact="influenza" post="virus infectionVirol. J.20191616216810.1186/s12985-019-1271-031864377 45.HanC.W.JeongM.S.JangS.B.Structure and Function of the Influenza"/>
   <result pre="the Influenza A Virus Non-Structural Protein 1J. Microbiol. Biotechnol.2019291184119210.4014/jmb.1903.0305331154753 46.O’NeillR.E.TalonJ.PaleseP.The" exact="influenza" post="virus NEP (NS2 protein) mediates the nuclear export of"/>
   <result pre="49.HuY.LiuX.ZhangA.ZhouH.LiuZ.ChenH.JinM.CHD3 facilitates vRNP nuclear export by interacting with NES1 of" exact="influenza" post="A virus NS2Cell. Mol. Life Sci.20147297198210.1007/s00018-014-1726-925213355 50.ZengL.-Y.YangJ.LiuS.Investigational hemagglutinin-targeted influenza"/>
   <result pre="of influenza A virus NS2Cell. Mol. Life Sci.20147297198210.1007/s00018-014-1726-925213355 50.ZengL.-Y.YangJ.LiuS.Investigational hemagglutinin-targeted" exact="influenza" post="virus inhibitorsExpert Opin. Investig. Drugs201626637310.1080/13543784.2017.1269170 51.BuiC.ChughtaiA.A.AdamD.C.MacIntyreC.R.An overview of the"/>
   <result pre="Investig. Drugs201626637310.1080/13543784.2017.1269170 51.BuiC.ChughtaiA.A.AdamD.C.MacIntyreC.R.An overview of the epidemiology and emergence of" exact="influenza" post="A infection in humans over timeArch. Public Health2017751510.1186/s13690-017-0182-z28352464 52.CarratF.FlahaultA.Influenza"/>
   <result pre="antigenic driftVaccine2007256852686210.1016/j.vaccine.2007.07.02717719149 53.SunJ.MadanR.KarpC.BracialeT.J.Effector T cells control lung inflammation during acute" exact="influenza" post="virus infection by producing IL-10Nat. Med.20091527728410.1038/nm.192919234462 54.CiminskiK.ThamamongoodT.ZimmerG.SchwemmleM.Novel insights into"/>
   <result pre="virus infection by producing IL-10Nat. Med.20091527728410.1038/nm.192919234462 54.CiminskiK.ThamamongoodT.ZimmerG.SchwemmleM.Novel insights into bat" exact="influenza" post="A virusesJ. Gen. Virol.2017982393240010.1099/jgv.0.00092728906230 55.ButtK.M.SmithG.J.ChenH.ZhangL.J.LeungY.H.C.XuK.M.LimW.WebsterR.G.YuenK.-Y.PeirisJ.S.M.et al.Human Infection with an"/>
   <result pre="56.ChenH.YuanH.GaoR.ZhangJ.WangD.-Y.XiongY.FanG.YangF.LiX.ZhouJ.et al.Clinical and epidemiological characteristics of a fatal case of" exact="avian influenza" post="A H10N8 virus infection: A descriptive studyLancet201438371472110.1016/S0140-6736(14)60111-224507376 57.YangZ.-F.MokC.K.P.PeirisJ.S.M.ZhongN.Human Infection"/>
   <result pre="al.Clinical and epidemiological characteristics of a fatal case of avian" exact="influenza" post="A H10N8 virus infection: A descriptive studyLancet201438371472110.1016/S0140-6736(14)60111-224507376 57.YangZ.-F.MokC.K.P.PeirisJ.S.M.ZhongN.Human Infection"/>
   <result pre="59.ShiY.WuY.ZhangW.QiJ.GaoG.F.Enabling the ’host jump’: Structural determinants of receptor-binding specificity in" exact="influenza" post="A virusesNat. Rev. Genet.20141282283110.1038/nrmicro3362 60.De VriesR.P.PengW.GrantO.ThompsonA.J.ZhuX.BouwmanK.M.De La PenaA.T.T.Van BreemenM.J.WickramasingheI.N.A.De"/>
   <result pre="60.De VriesR.P.PengW.GrantO.ThompsonA.J.ZhuX.BouwmanK.M.De La PenaA.T.T.Van BreemenM.J.WickramasingheI.N.A.De HaanC.A.M.et al.Three mutations switch H7N9" exact="influenza" post="to human-type receptor specificityPLoS Pathog.201713e100639010.1371/journal.ppat.100639028617868 61.StevensJ.BlixtO.TumpeyT.M.TaubenbergerJ.K.PaulsonJ.C.WilsonI.A.Structure and Receptor Specificity"/>
   <result pre="Balance: Preserving Virus MotilityTrends Microbiol.202028576710.1016/j.tim.2019.08.01031629602 63.LongJ.S.MistryB.HaslamS.BarclayW.S.Host and viral determinants of" exact="influenza" post="A virus species specificityNat. Rev. Genet.201917678110.1038/s41579-018-0115-z30487536 64.BrownI.H.History and Epidemiology"/>
   <result pre="66.SmithG.J.DhanasekaranV.BahlJ.LycettS.J.WorobeyM.PybusO.G.MaS.K.CheungC.L.RaghwaniJ.BhattS.et al.Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemicNature20094591122112510.1038/nature0818219516283 67.RobinsonJ.L.LeeB.E.PatelJ.BastienN.GrimsrudK.SealR.F.KingR.MarshallF.LiY.Swine Influenza (H3N2) Infection in a Child"/>
   <result pre="69.IwasakiY.AbeT.WadaY.WadaK.IkemuraT.Novel bioinformatics strategies for prediction of directional sequence changes in" exact="influenza" post="virus genomes and for surveillance of potentially hazardous strainsBMC"/>
   <result pre="in the Human LungJ. Infect. Dis.20122061685169410.1093/infdis/jis45522829640 76.MüllerK.H.KakkolaL.NagarajA.S.CheltsovA.V.AnastasinaM.KainovD.Emerging cellular targets for" exact="influenza" post="antiviral agentsTrends Pharmacol. Sci.201233899910.1016/j.tips.2011.10.00422196854 77.Van RielD.BakkerM.A.D.LeijtenL.M.ChutinimitkulS.MunsterV.De WitE.RimmelzwaanG.F.FouchierR.A.OsterhausA.D.KuikenT.Seasonal and Pandemic"/>
   <result pre="Respiratory Tract of Humans and Other MammalsAm. J. Pathol.20071711215122310.2353/ajpath.2007.07024817717141 79.OlofssonS.KumlinU.DimockK.ArnbergN.Avian" exact="influenza" post="and sialic acid receptors: More than meets the eye?Lancet"/>
   <result pre="into cells lacking sialylated N-glycansProc. Natl. Acad. Sci. USA20121097457746210.1073/pnas.120098710922529385 81.GillJ.S.WebbyR.GilchristM.J.GrayG.C.Avian" exact="influenza" post="among waterfowl hunters and wildlife professionalsEmerg. Infect. Dis.2006121284128610.3201/eid1708.06049216965717 82.ShenL.W.MaoH.J.WuY.-L.TanakaY.ZhangW.TMPRSS2:"/>
   <result pre="professionalsEmerg. Infect. Dis.2006121284128610.3201/eid1708.06049216965717 82.ShenL.W.MaoH.J.WuY.-L.TanakaY.ZhangW.TMPRSS2: A potential target for treatment of" exact="influenza" post="virus and coronavirus infectionsBiochimie201714211010.1016/j.biochi.2017.07.01628778717 83.HamiltonB.S.GludishD.W.J.WhittakerG.R.Cleavage Activation of the Human-Adapted"/>
   <result pre="HemagglutininJ. Virol.2009833200321110.1128/JVI.02205-0819158246 86.DietzeK.GraafA.Homeier-BachmannT.GrundC.ForthL.PohlmannA.JeskeC.WintermannM.BeerM.ConrathsF.J.et al.From low to high pathogenicity-Characterization of H7N7" exact="avian influenza" post="viruses in two epidemiologically linked outbreaksTransbound. Emerg. Dis.2018651576158710.1111/tbed.1290629790657 87.GultyaevA.P.SpronkenM.I.RichardM.SchrauwenE.J.A.OlsthoornR.FouchierR.Subtype-specific"/>
   <result pre="Virol.2009833200321110.1128/JVI.02205-0819158246 86.DietzeK.GraafA.Homeier-BachmannT.GrundC.ForthL.PohlmannA.JeskeC.WintermannM.BeerM.ConrathsF.J.et al.From low to high pathogenicity-Characterization of H7N7 avian" exact="influenza" post="viruses in two epidemiologically linked outbreaksTransbound. Emerg. Dis.2018651576158710.1111/tbed.1290629790657 87.GultyaevA.P.SpronkenM.I.RichardM.SchrauwenE.J.A.OlsthoornR.FouchierR.Subtype-specific"/>
   <result pre="outbreaksTransbound. Emerg. Dis.2018651576158710.1111/tbed.1290629790657 87.GultyaevA.P.SpronkenM.I.RichardM.SchrauwenE.J.A.OlsthoornR.FouchierR.Subtype-specific structural constraints in the evolution of" exact="influenza" post="A virus hemagglutinin genesSci. Rep.201663889210.1038/srep3889227966593 88.BouloS.AkarsuH.RuigrokR.W.BaudinF.Nuclear traffic of influenza"/>
   <result pre="of influenza A virus hemagglutinin genesSci. Rep.201663889210.1038/srep3889227966593 88.BouloS.AkarsuH.RuigrokR.W.BaudinF.Nuclear traffic of" exact="influenza" post="virus proteins and ribonucleoprotein complexesVirus Res.2007124122110.1016/j.virusres.2006.09.01317081640 89.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.H.The cap-snatching endonuclease"/>
   <result pre="virus proteins and ribonucleoprotein complexesVirus Res.2007124122110.1016/j.virusres.2006.09.01317081640 89.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.H.The cap-snatching endonuclease of" exact="influenza" post="virus polymerase resides in the PA subunitNature200945891491810.1038/nature0774519194459 90.RodriguezP.Marcos-VillarL.ZamarreñoN.YángüezE.NietoA.Mutations of"/>
   <result pre="90.RodriguezP.Marcos-VillarL.ZamarreñoN.YángüezE.NietoA.Mutations of the segment-specific nucleotides at the 3′ end of" exact="influenza" post="virus NS segment control viral replicationVirology202053910411310.1016/j.virol.2019.10.01531706162 91.ChengJ.TaoJ.LiB.ShiY.LiuH.The tyrosine 73"/>
   <result pre="91.ChengJ.TaoJ.LiB.ShiY.LiuH.The tyrosine 73 and serine 83 dephosphorylation of H1N1 swine" exact="influenza" post="virus NS1 protein attenuates virus replication and induces high"/>
   <result pre="J.20191615210.1186/s12985-019-1255-031805964 92.AkarsuH.BurmeisterW.PetosaC.PetitI.MüllerC.W.RuigrokR.W.BaudinF.Crystal structure of the M1 protein-binding domain of the" exact="influenza" post="A virus nuclear export protein (NEP/NS2)EMBO J.2003224646465510.1093/emboj/cdg44912970177 93.SunX.JayaramanA.ManiprasadP.RamanR.HouserK.V.PappasC.ZengH.SasisekharanR.KatzJ.M.TumpeyT.M.N-Linked Glycosylation"/>
   <result pre="and Seasonal H1N1 Influenza A VirusesJ. Virol.2013878756876610.1128/JVI.00593-1323740978 94.BrettK.KordyukovaL.V.SerebryakovaM.V.MintaevR.R.AlexeevskiA.V.VeitM.Site-specific S-acylation of" exact="influenza" post="virus hemagglutinin: the location of the acylation site relative"/>
   <result pre="Virol.2011854143415610.1128/JVI.02606-1021307188 98.RossmanJ.LambR.A.Influenza virus assembly and buddingVirology201141122923610.1016/j.virol.2010.12.00321237476 99.PaleseP.TobitaK.UedaM.CompansR.Characterization of temperature sensitive" exact="influenza" post="virus mutants defective in neuraminidaseVirology19746139741010.1016/0042-6822(74)90276-14472498 100.StertzS.ShawM.Uncovering the global host"/>
   <result pre="defective in neuraminidaseVirology19746139741010.1016/0042-6822(74)90276-14472498 100.StertzS.ShawM.Uncovering the global host cell requirements for" exact="influenza" post="virus replication via RNAi screeningMicrobes Infect.20111351652510.1016/j.micinf.2011.01.01221276872 101.TranA.T.RahimM.N.RanadheeraC.KroekerA.CortensJ.P.OpanubiK.J.A WilkinsJ.CoombsK.M.Knockdown of"/>
   <result pre="screeningMicrobes Infect.20111351652510.1016/j.micinf.2011.01.01221276872 101.TranA.T.RahimM.N.RanadheeraC.KroekerA.CortensJ.P.OpanubiK.J.A WilkinsJ.CoombsK.M.Knockdown of specific host factors protects against" exact="influenza" post="virus-induced cell deathCell Death Dis.20134e76910.1038/cddis.2013.29623949218 102.HanJ.PerezJ.T.ChenC.LiY.BenitezA.KandasamyM.LeeY.AndradeJ.TenoeverB.ManicassamyB.Genome-wide CRISPR/Cas9 Screen Identifies"/>
   <result pre="Rep.20182359660710.1016/j.celrep.2018.03.04529642015 103.LiB.ClohiseyS.M.ChiaB.S.WangB.CuiA.EisenhaureT.SchweitzerL.D.HooverP.ParkinsonN.J.NachshonA.et al.Genome-wide CRISPR screen identifies host dependency factors for" exact="influenza" post="A virus infectionNat. Commun.20201116410.1038/s41467-019-13965-x31919360 104.WangC.ForstC.V.ChouT.-W.GeberA.WangM.HamouW.SmithM.SebraR.ZhangB.ZhouB.et al.Cell-to-Cell Variation in Defective"/>
   <result pre="on Host Responses during Influenza Virus InfectionmBio20201110.1128/mBio.02880-19 105.IwasakiA.PillaiP.S.Innate immunity to" exact="influenza" post="virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 106.HaleB.AlbrechtR.A.García-SastreA.Innate immune evasion strategies of"/>
   <result pre="influenza virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 106.HaleB.AlbrechtR.A.García-SastreA.Innate immune evasion strategies of" exact="influenza" post="virusesFuture Microbiol.20105234110.2217/fmb.09.10820020828 107.WilsonE.B.BrooksD.G.The Role of IL-10 in Regulating Immunity"/>
   <result pre="and host protein ClusterinCell Death Dis.20134e56210.1038/cddis.2013.8923538443 112.FeiziN.MehrbodP.RomaniB.SoleimanjahiH.BamdadT.FeiziA.JazaeriE.O.TarghiH.S.SalehM.JamaliA.et al.Autophagy induction regulates" exact="influenza" post="virus replication in a time-dependent mannerJ. Med. Microbiol.20176653654110.1099/jmm.0.00045528463668 113.DouganS.K.AshourJ.KarssemeijerR.A.PoppM.W.AvalosA.M.BarisaM.AltenburgA.IngramJ.R.CragnoliniJ.J.GuoC.et"/>
   <result pre="113.DouganS.K.AshourJ.KarssemeijerR.A.PoppM.W.AvalosA.M.BarisaM.AltenburgA.IngramJ.R.CragnoliniJ.J.GuoC.et al.Antigen-specific B-cell receptor sensitizes B cells to infection by" exact="influenza" post="virusNature201350340640910.1038/nature1263724141948 114.NogalesA.Martínez-SobridoL.TophamD.J.DeDiegoM.L.Modulation of Innate Immune Responses by the Influenza"/>
   <result pre="of Influenza VirusJ. Virol.2010843789379710.1128/JVI.01815-0920147410 117.GuoH.KumarP.MalarkannanS.Evasion of natural killer cells by" exact="influenza" post="virusJ. Leukoc. Biol.20108918919410.1189/jlb.061031920682623 118.LiT.WangJ.WangY.ChenY.WeiH.SunR.TianZ.Respiratory Influenza Virus Infection Induces Memory-like"/>
   <result pre="in MiceJ. Infect. Dis.201220616717710.1093/infdis/jis34022561366 120.ZhouG.JuangS.W.W.KaneK.P.NK cells exacerbate the pathology of" exact="influenza" post="virus infection in miceEur. J. Immunol.20134392993810.1002/eji.20124262023436540 121.ZhouK.WangJ.LiA.ZhaoW.WangN.ZhangW.YanJ.GaoG.F.LiuW.FangM.Swift and Strong"/>
   <result pre="CD8+ T cells in the airwaysScience2015349435210.1126/science.aaa435226339033 124.GeurtsvanKesselC.H.WillartM.A.Van RijtL.S.MuskensF.KoolM.BaasC.ThielemansK.BennettC.L.ClausenB.E.HoogstedenH.C.et al.Clearance of" exact="influenza" post="virus from the lung depends on migratory langerin+CD11b- but"/>
   <result pre="Antigen Presentation to CD4 T CellsJ. Immunol.20202041621162910.4049/jimmunol.190123431996461 127.WaithmanJ.MinternJ.D.Dendritic cells and" exact="influenza" post="A virus infectionVirulence2012360360810.4161/viru.2186423076333 128.TakeshitaF.TanakaT.MatsudaT.TozukaM.KobiyamaK.SahaS.MatsuiK.IshiiK.J.CobanC.AkiraS.et al.Toll-Like Receptor Adaptor Molecules Enhance"/>
   <result pre="receptor 7Proc. Natl. Acad. Sci. USA20041015598560310.1073/pnas.040093710115034168 133.Abdul-CaderM.S.SenapathiU.D.S.NagyE.SharifS.Abdul-CareemM.F.Antiviral response elicited against" exact="avian influenza" post="virus infection following activation of toll-like receptor (TLR)7 signaling"/>
   <result pre="7Proc. Natl. Acad. Sci. USA20041015598560310.1073/pnas.040093710115034168 133.Abdul-CaderM.S.SenapathiU.D.S.NagyE.SharifS.Abdul-CareemM.F.Antiviral response elicited against avian" exact="influenza" post="virus infection following activation of toll-like receptor (TLR)7 signaling"/>
   <result pre="of the NLRP3 inflammasome in regulation of antiviral responses to" exact="influenza" post="A virus infectionAntivir. Res.2017148324210.1016/j.antiviral.2017.10.02029097227 144.JiaX.LiuB.BaoL.LvQ.LiF.LiH.AnY.ZhangX.CaoB.WangC.Delayed oseltamivir plus sirolimus treatment"/>
   <result pre="Gen. Virol.20088914710.1099/vir.0.83391-018089727 146.MordsteinM.KochsG.DumoutierL.RenauldJ.C.PaludanS.R.KlucherK.StaeheilP.Interferon-lambda contributes to innate immunity of mice against" exact="influenza" post="A virus but not against hepatotropic virusesPLoS Pathog20084e100015110.1371/journal.ppat.100015118787692 147.SchneiderW.M.ChevillotteM.D.RiceC.M.Interferon-stimulated"/>
   <result pre="dendritic cells to facilitate T cell immunity during infection with" exact="influenza" post="A virusNat. Immunol.2019201035104510.1038/s41590-019-0408-z31235953 151.XiaoH.KillipM.J.StaeheliP.RandallR.JacksonD.The human interferon-induced MxA protein inhibits"/>
   <result pre="Immunol.2019201035104510.1038/s41590-019-0408-z31235953 151.XiaoH.KillipM.J.StaeheliP.RandallR.JacksonD.The human interferon-induced MxA protein inhibits early stages of" exact="influenza" post="A virus infection by retaining the incoming viral genome"/>
   <result pre="of Host Type I Interferon ReceptorJ. Virol.20209410.1128/JVI.01572-1931915279 164.ChenW.CalvoP.A.MalideD.GibbsJ.SchubertU.BacikI.BastaS.O’NeillR.SchickliJ.PaleseP.et al.A novel" exact="influenza" post="A virus mitochondrial protein that induces cell deathNat. Med.200171306131210.1038/nm1201-130611726970"/>
   <result pre="Cell2009201981199110.1091/mbc.e08-12-124819211835 169.ChengX.LiuH.JiangC.C.FangL.ChenC.ZhangX.D.JiangZ.W.Connecting endoplasmic reticulum stress to autophagy through IRE1/JNK/beclin-1 in" exact="breast cancer" post="cellsInt. J. Mol. Med.20143477278110.3892/ijmm.2014.182224970676 170.ZhongL.ShuW.DaiW.GaoB.XiongS.Reactive Oxygen Species-Mediated c-Jun NH2-Terminal"/>
   <result pre="169.ChengX.LiuH.JiangC.C.FangL.ChenC.ZhangX.D.JiangZ.W.Connecting endoplasmic reticulum stress to autophagy through IRE1/JNK/beclin-1 in breast" exact="cancer" post="cellsInt. J. Mol. Med.20143477278110.3892/ijmm.2014.182224970676 170.ZhongL.ShuW.DaiW.GaoB.XiongS.Reactive Oxygen Species-Mediated c-Jun NH2-Terminal"/>
   <result pre="NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in" exact="cancer" post="cellsOncogene20092888689810.1038/onc.2008.44119060920 172.ZhangR.ChiX.WangS.QiB.YuX.ChenJ.-L.The Regulation of Autophagy by Influenza A VirusBioMed"/>
   <result pre="Microbiol.20189312010.3389/fmicb.2018.0312030619194 175.ShengT.SunY.SunJ.PrinzR.A.PengD.LiuX.XuX.Role of TGF-β-activated kinase 1 (TAK1) activation in H5N1" exact="influenza" post="A virus-induced c-Jun terminal kinase activation and virus replicationVirology201953726327110.1016/j.virol.2019.09.00431539775"/>
   <result pre="role for autophagy in the maintenance of immunological memory against" exact="influenza" post="infectionNat. Med.20142050351010.1038/nm.352124747745 177.GannagéM.DormannR.AlbrechtR.A.DengjelJ.TorossiT.RämerP.C.LeeM.StrowigT.ArreyF.ConenelloG.et al.Matrix Protein 2 of Influenza A"/>
   <result pre="Autophagosome Fusion with LysosomesCell Host Microbe2009636738010.1016/j.chom.2009.09.00519837376 178.BealeR.WiseH.StuartA.RavenhillB.J.DigardP.RandowF.A LIR motif in" exact="influenza" post="A virus M2 is required for virion stabilityCell Host"/>
   <result pre="182.ChapmanT.CastrucciM.R.PadrickR.C.BradleyL.M.TophamD.J.Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during" exact="influenza" post="infectionVirology200534029630610.1016/j.virol.2005.06.02316054188 183.SwainS.L.McKinstryK.StruttT.M.Expanding roles for CD4+ T cells in immunity"/>
   <result pre="Care20111544810.1186/cc1042622040730 186.GoldbergE.L.MolonyR.D.KudoE.SidorovS.KongY.DixitV.D.IwasakiA.Ketogenic diet activates protective γδ T cell responses against" exact="influenza" post="virus infectionSci. Immunol.20194202610.1126/sciimmunol.aav2026 187.HornickE.E.ZachariasZ.R.LeggeK.L.Kinetics and Phenotype of the CD4"/>
   <result pre="191.JiaR.LiuS.XuJ.LiangX.IL16 deficiency enhances Th1 and cytotoxic T lymphocyte response against" exact="influenza" post="A virus infectionBiosci. Trends20201351652210.5582/bst.2019.0128631852865 192.GrantE.J.Quiñones-ParraS.M.ClemensE.B.KedzierskaK.Human influenza viruses and CD8"/>
   <result pre="T lymphocyte response against influenza A virus infectionBiosci. Trends20201351652210.5582/bst.2019.0128631852865 192.GrantE.J.Quiñones-ParraS.M.ClemensE.B.KedzierskaK.Human" exact="influenza" post="viruses and CD8 + T cell responsesCurr. Opin. Virol.20161613214210.1016/j.coviro.2016.01.01626974887"/>
   <result pre="memory CD8+T cells in the upper respiratory tract prevent pulmonary" exact="influenza" post="virus infectionSci. Immunol.20172697010.1126/sciimmunol.aam697028783656 194.PulestonD.J.ZhangH.PowellT.J.LipinaE.SimsS.PanseI.WatsonA.S.CerundoloV.TownsendA.R.M.KlenermanP.et al.Autophagy is a critical regulator"/>
   <result pre="memory CD8+ T cell formationELife20143e0370610.7554/eLife.03706 195.CullenJ.G.McQuiltenH.A.QuinnK.M.OlshanskyM.RussB.E.MoreyA.WeiS.PrierJ.E.La GrutaN.L.DohertyP.C.et al.CD4+T help promotes" exact="influenza" post="virus-specific CD8+T cell memory by limiting metabolic dysfunctionProc. Natl."/>
   <result pre="Sci. USA20191164481448810.1073/pnas.180884911630787194 196.Rangel-MorenoJ.CarragherD.MisraR.S.KusserK.HartsonL.MoquinA.LundF.E.RandallT.D.B cells promote resistance to heterosubtypic strains of" exact="influenza" post="via multiple mechanisms1J. Immunol.200818045446310.4049/jimmunol.180.1.45418097047 197.SeibertC.W.RahmatS.KrauseJ.C.EgginkD.AlbrechtR.A.GoffP.H.KrammerF.DutyJ.A.BouvierN.García-SastreA.et al.Recombinant IgA Is Sufficient"/>
   <result pre="of the H5 hemagglutinin induces the escape of highly pathogenic" exact="avian influenza" post="A H5N1 viruses from vaccine-induced immunityVirology201548613414510.1016/j.virol.2015.08.03326433051 199.A ElmoreS.Apoptosis: A"/>
   <result pre="the H5 hemagglutinin induces the escape of highly pathogenic avian" exact="influenza" post="A H5N1 viruses from vaccine-induced immunityVirology201548613414510.1016/j.virol.2015.08.03326433051 199.A ElmoreS.Apoptosis: A"/>
   <result pre="206.GalluzziL.BrennerC.MorselliE.TouatZ.KroemerG.Viral Control of Mitochondrial ApoptosisPLoS Pathog.20084e100001810.1371/journal.ppat.100001818516228 207.ZhirnovO.P.KlenkH.-D.Control of apoptosis in" exact="influenza" post="virus-infected cells by up-regulation of Akt and p53 signalingApoptosis2007121419143210.1007/s10495-007-0071-y17468837"/>
   <result pre="by up-regulation of Akt and p53 signalingApoptosis2007121419143210.1007/s10495-007-0071-y17468837 208.NailwalH.SharmaS.MayankA.K.LalS.K.The nucleoprotein of" exact="influenza" post="A virus induces p53 signaling and apoptosis via attenuation"/>
   <result pre="attenuation of host ubiquitin ligase RNF43Cell Death Dis.20156e176810.1038/cddis.2015.13125996295 209.MayankA.K.SharmaS.NailwalH.LalS.K.Nucleoprotein of" exact="influenza" post="A virus negatively impacts antiapoptotic protein API5 to enhance"/>
   <result pre="apoptosis and virus replicationCell Death Dis.20156e201810.1038/cddis.2015.360 210.HalderU.C.BagchiP.ChattopadhyayS.DuttaD.Chawla-SarkarM.Cell death regulation during" exact="influenza" post="A virus infection by matrix (M1) protein: A model"/>
   <result pre="Apoptosis in Cultured CellsJ. Virol.2001757875788110.1128/JVI.75.17.7875-7881.200111483732 212.JacksonD.KillipM.J.GallowayC.S.RussellR.J.RandallR.E.Loss of function of the" exact="influenza" post="A virus NS1 protein promotes apoptosis but this is"/>
   <result pre="phosphatidylinositol 3-kinase (PI3K)Virology20103969410510.1016/j.virol.2009.10.00419880155 213.DavidsonS.CrottaS.McCabeT.M.WackA.Pathogenic potential of interferon αβ in acute" exact="influenza" post="infectionNat. Commun.20145386410.1038/ncomms486424844667 214.DavidsonS.McCabeT.M.CrottaS.GadH.H.HesselE.M.BeinkeS.RuneH.AndreasW.IFNλ is a potent anti-influenza therapeutic without"/>
   <result pre="mechanisms of resistanceInfluenza Other Respir. Viruses20137253610.1111/irv.1204723279894 219.O’HanlonR.ShawM.Baloxavir marboxil: The new" exact="influenza" post="drug on the marketCurr. Opin. Virol.201935141810.1016/j.coviro.2019.01.00630852344 220.VanderlindenE.NaesensL.Emerging Antiviral Strategies"/>
   <result pre="synthesis and biological evaluation of amino acids-oleanolic acid conjugates as" exact="influenza" post="virus inhibitorsBioorg. Med. Chem.20192711514710.1016/j.bmc.2019.11514731635892 227.OmiJ.Watanabe-TakahashiM.IgaiK.ShimizuE.TsengC.-Y.MiyasakaT.WakuT.HamaS.NakanishiR.GotoY.et al.The inducible amphisome isolates"/>
   <result pre="227.OmiJ.Watanabe-TakahashiM.IgaiK.ShimizuE.TsengC.-Y.MiyasakaT.WakuT.HamaS.NakanishiR.GotoY.et al.The inducible amphisome isolates viral hemagglutinin and defends against" exact="influenza" post="A virus infectionNat. Commun.20201116210.1038/s41467-019-13974-w31919357 228.ClarkM.P.LedeboerM.W.DaviesI.ByrnR.A.JonesS.M.PerolaE.TsaiA.JacobsM.Nti-AddaeK.BandarageU.K.et al.Discovery of a Novel,"/>
   <result pre="Virus ActivityIn VitroAntimicrob. Agents Chemother.2016605504551410.1128/AAC.00888-1627381402 230.SongM.-S.KumarG.ShadrickW.R.ZhouW.JeevanT.LiZ.SlavishP.J.FabrizioT.YoonS.-W.WebbT.R.et al.Identification and characterization of" exact="influenza" post="variants resistant to a viral endonuclease inhibitorProc. Natl. Acad."/>
   <result pre="of innate immune responses and interferon (IFN) signaling pathway after" exact="influenza" post="A virus (IAV) infection. Intracellular detection conducted by pathogen"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232486\results\search\disease\results.xml">
   <result pre="afflicting millions of people around the world. Aedes aegypti, the" exact="yellow fever" post="mosquito, is the principal vector of dengue, Zika, and"/>
   <result pre="fever mosquito, is the principal vector of dengue, Zika, and" exact="chikungunya" post="viruses, and has well-established populations across tropical and subtropical"/>
   <result pre="landscapes and facilitate urban transmission cycles of dengue virus (DENV)," exact="chikungunya" post="virus (CHIKV), Zika virus (ZIKV), and others [2]. In"/>
   <result pre="such as retro-orbital or ocular pain, rash, headache, arthralgia, myalgia," exact="leukopenia" post="or hemorrhagic manifestations; CHIK: severe arthralgia, intense asymmetric, debilitating"/>
   <result pre="transmission, as originally observed with cattle when describing zooprophylaxis in" exact="malaria" post="transmission [67,68]. This has principally been considered an important"/>
   <result pre="This has principally been considered an important phenomenon in human" exact="malaria" post="transmission with Anopheles spp. wasting bites on cattle, something"/>
   <result pre="spp. wasting bites on cattle, something that protects humans from" exact="malaria" post="infectious bites [69,70,71]. However, Hess and Hayes [64] determined"/>
   <result pre="conclusion that these were likely to be poor vectors of" exact="yellow fever" post="virus [29]. Non-human feeding by Ae. aegypti may have"/>
   <result pre="Public Health201910938739210.2105/AJPH.2018.30484930676796 4.MacphersonC.NoëlT.FieldsP.JungkindD.YearwoodK.SimmonsM.WidjajaS.MitchellG.NoelD.BidaiseeS.Clinical and serological insights from the Asian lineage" exact="chikungunya" post="outbreak in Grenada, 2014: An observational studyAm. J. Trop."/>
   <result pre="7.BradyO.J.Osgood-ZimmermanA.KassebaumN.J.RayS.E.de AraújoV.E.da NóbregaA.A.FrutuosoL.C.LeccaR.C.StevensA.de OliveiraB.Z.The association between Zika virus infection and" exact="microcephaly" post="in Brazil 2015–2017: An observational analysis of over 4"/>
   <result pre="Report2007Available online: https://www.ncbi.nlm.nih.gov/pubmed/17687243(accessed on 6 July 2019) 13.RamosM.M.MohammedH.Zielinski-GutierrezE.HaydenM.H.LopezJ.L.R.FournierM.TrujilloA.R.BurtonR.BrunkardJ.M.Anaya-LopezL.Epidemic dengue and" exact="dengue hemorrhagic fever" post="at the Texas–Mexico border: Results of a household-based seroepidemiologic"/>
   <result pre="and blood feeding patterns of potential vectors of dengue and" exact="yellow fever" post="in Kacheliba, West Pokot County, KenyaActa Trop.2018186505710.1016/j.actatropica.2018.07.00830006028 32.Feria-ArroyoT.P.AguilarC.OrabyT.A tale"/>
   <result pre="Yucatan State, MexicoJ. Insect. Sci.2010103210.1673/031.010.320120578953 36.Garrett-JonesC.The human blood index of" exact="malaria" post="vectors in relation to epidemiological assessmentBull. World Health Organ.19643024126114153413"/>
   <result pre="women in the AmericasNat. Microbiol.201611612610.1038/nmicrobiol.2016.12627562260 39.Ndeffo-MbahM.L.PandeyA.Global risk and elimination of" exact="yellow fever" post="epidemicsJ. Inf. Dis.201910.1093/infdis/jiz375 40.ZhangQ.SunK.ChinazziM.y PionttiA.P.DeanN.E.RojasD.P.MerlerS.MistryD.PolettiP.RossiL.Spread of Zika virus in"/>
   <result pre="description and epidemiologyTrans. R. Soc. Trop. Med. Hyg.195549335710.1016/0035-9203(55)90081-X14373835 47.HeischR.NelsonG.FurlongM.Studies in" exact="filariasis" post="in East Africa. 1. Filariasis on the Island of"/>
   <result pre="malariologyPractical MalariologyOxford University PressLondon, UK1963 70.MahandeA.MoshaF.MahandeJ.KwekaE.Feeding and resting behaviour of" exact="malaria" post="vector, Anopheles arabiensis with reference to zooprophylaxisMalar. J.2007610010.1186/1475-2875-6-10017663787 71.IwashitaH.DidaG.O.SonyeG.O.SunaharaT.FutamiK.NjengaS.M.ChavesL.F.MinakawaN.Push"/>
   <result pre="zooprophylaxis enhance the impact of insecticide treated bed nets on" exact="malaria" post="control?Parasit. Vectors201475210.1186/1756-3305-7-5224472517 72.SchmidtW.-P.SuzukiM.ThiemV.D.WhiteR.G.TsuzukiA.YoshidaL.-M.YanaiH.HaqueU.ThoL.H.AnhD.D.Population density, water supply, and the risk"/>
   <result pre="control?Parasit. Vectors201475210.1186/1756-3305-7-5224472517 72.SchmidtW.-P.SuzukiM.ThiemV.D.WhiteR.G.TsuzukiA.YoshidaL.-M.YanaiH.HaqueU.ThoL.H.AnhD.D.Population density, water supply, and the risk of" exact="dengue fever" post="in Vietnam: Cohort study and spatial analysisPLoS Med.20118e100108210.1371/journal.pmed.100108221918642 73.FritzM.WalkerE.MillerJ.SeversonD.DworkinI.Divergent"/>
   <result pre="of host preference and resting behavior in the major African" exact="malaria" post="vector, Anopheles arabiensisPLoS Genet.201612e100630310.1371/journal.pgen.100630327631375 75.KotsakioziP.EvansB.R.Gloria-SoriaA.KamgangB.MayanjaM.LutwamaJ.Le GoffG.AyalaD.PaupyC.BadoloA.Population structure of a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232498\results\search\disease\results.xml">
   <result pre="circulating strains of IBV in Uruguay. A subset of positive" exact="influenza" post="B samples from influenza-like illness (ILI) outpatients and severe"/>
   <result pre="patients between 5–14 years constituted the majority (33%) of all" exact="influenza" post="B infection (p &amp;lt; 0.05). Interestingly, we found that"/>
   <result pre="individuals &amp;gt;25 years were particularly vulnerable to Yamagata lineage infections." exact="influenza" post="B phylogenetic epidemiology surveillance victoria yamagata 1. Introduction Influenza"/>
   <result pre="year, an average of 772,000 respiratory hospitalizations is attributed to" exact="influenza" post="virus [2]. Although influenza A viruses (IAV) are responsible"/>
   <result pre="772,000 respiratory hospitalizations is attributed to influenza virus [2]. Although" exact="influenza" post="A viruses (IAV) are responsible for pandemics and they"/>
   <result pre="and they have major rates of hospitalization and mortality attribution," exact="influenza" post="B viruses (IBV) cause epidemics worldwide annually, becoming responsible"/>
   <result pre="in some years for more than 25% of human seasonal" exact="influenza" post="infections, and its prevention represents an important public health"/>
   <result pre="[6]. IBV were first identified in the 1940s and, unlike" exact="influenza" post="A, they primarily cause disease in humans [7]. Recurrent"/>
   <result pre="two lineages results in a different pattern of evolution of" exact="influenza" post="B virus and can explain some of the disparate"/>
   <result pre="antigenic drift than the more conserved Yamagata lineage [12]. Annual" exact="influenza" post="vaccination is the most effective method for preventing influenza"/>
   <result pre="Annual influenza vaccination is the most effective method for preventing" exact="influenza" post="and its associated complications. In general, seasonal vaccines are"/>
   <result pre="associated complications. In general, seasonal vaccines are trivalent, including one" exact="influenza" post="B lineage. Despite being only two lineages, the selection"/>
   <result pre="Despite being only two lineages, the selection of the right" exact="influenza" post="B virus strain in the vaccine has been proven"/>
   <result pre="as determine the age groups that are associated with both" exact="influenza" post="B lineages and surveillance type. In addition, we evaluated"/>
   <result pre="In addition, we evaluated the concordance between the predominant circulating" exact="influenza" post="B lineage and the B lineage included in the"/>
   <result pre="hospitalized patients with severe acute respiratory infection (SARI) associated with" exact="influenza" post="and 455 outpatients with clinical evidence of influenza-like illness"/>
   <result pre="Response System (GISRS) for the purposes of global surveillance of" exact="influenza" post="under the WHO Global Influenza Program, neither written informed"/>
   <result pre="p-value &amp;lt; 0.05 was considered statistically significant. The proportion of" exact="influenza" post="B positives among influenza virus positive specimens was separately"/>
   <result pre="considered statistically significant. The proportion of influenza B positives among" exact="influenza" post="virus positive specimens was separately determined in all years"/>
   <result pre="also determined among specimens that could be typed. Comparisons of" exact="influenza" post="B lineages distribution by age were completed by the"/>
   <result pre="statistically significant. In addition, we examined the proportion of each" exact="influenza" post="B lineage across different age groups in the study."/>
   <result pre="RNA mini kit (Qiagen), according to the manufacturer´s suggested protocol.The" exact="influenza" post="B positive specimens previously typified were distinguished into influenza"/>
   <result pre="protocol.The influenza B positive specimens previously typified were distinguished into" exact="influenza" post="B Victoria and Yamagata lineages by RT-PCR assay. Real"/>
   <result pre="hundred sequences. HA and NA nucleotide sequences of the Uruguayan" exact="influenza" post="B viruses generated in this study have been deposited"/>
   <result pre="sentinel surveillance. Of these specimens, 217 (3.8%) were confirmed for" exact="influenza" post="B virus by real-time RT-PCR. During the entire study"/>
   <result pre="in children and teenagers with more than 60% of total" exact="influenza" post="B infections. Those between 5–14 years had the highest"/>
   <result pre="observed two main circulation peaks being the positive rate of" exact="influenza" post="B viruses of SARI patients highest in children &amp;lt;4"/>
   <result pre="of the eight years of the study, the proportion of" exact="influenza" post="B found was significantly higher than that observed among"/>
   <result pre="Influenza A and B Viruses Fluctuations in the prevalence of" exact="influenza" post="A and B were observed during 2012–2019. Overall, 14.6%"/>
   <result pre="and B were observed during 2012–2019. Overall, 14.6% were confirmed" exact="influenza" post="cases, of which 36.9% (311/843), 37.4 % (315/843), and"/>
   <result pre="which 36.9% (311/843), 37.4 % (315/843), and 25.7% (217/843) were" exact="influenza" post="A/H1N1 pdm09, A/H3N2, and B infections, respectively. Influenza B"/>
   <result pre="and B infections, respectively. Influenza B viruses rarely dominate over" exact="influenza" post="A viruses, however in 2012, 2015, and 2017 there"/>
   <result pre="2012, 2015, and 2017 there was an important circulation of" exact="influenza" post="B viruses, reaching 40%, 58% and 47%, respectively, of"/>
   <result pre="viruses, reaching 40%, 58% and 47%, respectively, of the circulating" exact="influenza" post="virus. The co-circulation of influenza A/H3N2 and B was"/>
   <result pre="47%, respectively, of the circulating influenza virus. The co-circulation of" exact="influenza" post="A/H3N2 and B was observed in almost all of"/>
   <result pre="2018). However, in 2013 and 2016, the lowest incidence of" exact="influenza" post="B virus infection was detected (2.8% and 4.5%, respectively),"/>
   <result pre="(2.8% and 4.5%, respectively), along with the highest incidence of" exact="influenza" post="A/H1N1 pdm09 (78% and 95%, respectively) (Figure 2). 3.4."/>
   <result pre="different to the lineage that was included in the trivalent" exact="influenza" post="vaccine (TIV) for that season. A partial mismatch was"/>
   <result pre="only B/Victoria strains were detected. On average, 28% of circulating" exact="influenza" post="B was mismatched to recommended influenza B vaccine strain"/>
   <result pre="average, 28% of circulating influenza B was mismatched to recommended" exact="influenza" post="B vaccine strain during 2012, 2013, and 2015. During"/>
   <result pre="B/Yamagata lineage, respectively, to identify the lineage of the 217" exact="influenza" post="B viruses circulating in Uruguay during 2012–2019. The remaining"/>
   <result pre="not be subtyped. Forty-one samples were randomly selected from 208" exact="influenza" post="B virus for further HA and NA genetic analyses."/>
   <result pre="from 39/41 of the selected samples. Additional 24 Uruguayan HA" exact="influenza" post="B sequences were obtained from GISAID database. Hence, a"/>
   <result pre="obtained from GISAID database. Hence, a total of 63 HA" exact="influenza" post="B sequences from 208 positive samples from 2012 to"/>
   <result pre="the 2014 and 2018 seasons. Victoria Lineage Our 2012–2017 Uruguayan" exact="influenza" post="B/Victoria HA sequences were grouped in clade 1A, together"/>
   <result pre="of N129G, I180V (Figure 4). Yamagata Lineage Our 2012–2019 Uruguayan" exact="influenza" post="B/Yamagata HA sequences clustered into two distinguishable genetic clades:"/>
   <result pre="27/41 of the selected samples. An additional 24 Uruguayan NA" exact="influenza" post="B sequences were obtained from GISAID database. Hence, a"/>
   <result pre="obtained from GISAID database. Hence, a total of 51 NA" exact="influenza" post="B sequences from 208 positive samples from 2012 to"/>
   <result pre="NA K371Q amino acid substitution (Table S4). Our 2012–2019 Uruguayan" exact="influenza" post="Yamagata-lineage NA sequences clustered into two distinguishable genetic clades:"/>
   <result pre="several important conserved residues in the NA active site of" exact="influenza" post="B virus [22]. The NA protein of influenza B"/>
   <result pre="site of influenza B virus [22]. The NA protein of" exact="influenza" post="B has eight catalytic residues (R116, D149, R150, R223,"/>
   <result pre="lineages according to HA gene due to the possibility that" exact="influenza" post="viruses undergo gene reassortment. Although the classification of the"/>
   <result pre="host cells. Using inhibitors to block the cleavage function of" exact="influenza" post="NA does not avoid disease, but it treats influenza"/>
   <result pre="of influenza NA does not avoid disease, but it treats" exact="influenza" post="disease and might shorten the symptoms. We analyzed the"/>
   <result pre="Uruguayan NA sequences from original clinical samples had substitutions for" exact="influenza" post="B virus resistance to NA inhibitors, which suggested that"/>
   <result pre="use might still be suitable as a first-line treatment of" exact="influenza" post="B infections in Uruguay. 4. Discussion Until the present"/>
   <result pre="information regarding the epidemiology and genetic characteristics of the circulating" exact="influenza" post="B viruses in Uruguay [26,27]. On average, influenza B"/>
   <result pre="the circulating influenza B viruses in Uruguay [26,27]. On average," exact="influenza" post="B viruses accounted for approximately 26% of influenza positive"/>
   <result pre="On average, influenza B viruses accounted for approximately 26% of" exact="influenza" post="positive cases during 2012–2019. These results were similar to"/>
   <result pre="These results were similar to other countries that suggest that" exact="influenza" post="B virus contribute significantly to influenza disease [3,28,29,30,31,32,33]. Our"/>
   <result pre="countries that suggest that influenza B virus contribute significantly to" exact="influenza" post="disease [3,28,29,30,31,32,33]. Our findings revealed that types A and"/>
   <result pre="disease [3,28,29,30,31,32,33]. Our findings revealed that types A and B" exact="influenza" post="viruses almost always co-circulated throughout 2012–2019 and they confirm"/>
   <result pre="co-circulated throughout 2012–2019 and they confirm the important role of" exact="influenza" post="B virus in the spread of infection in the"/>
   <result pre="Glezen P and colleagues [4], it was suggested that when" exact="influenza" post="B activity is intense, it can produce an impact"/>
   <result pre="can produce an impact that is similar to that of" exact="influenza" post="A. Influenza B viruses rarely dominate in a season,"/>
   <result pre="in a season, however in 2015, in Uruguay, predominated over" exact="influenza" post="A. The increase of influenza B incidence also coincided"/>
   <result pre="2015, in Uruguay, predominated over influenza A. The increase of" exact="influenza" post="B incidence also coincided with a shift in the"/>
   <result pre="B incidence also coincided with a shift in the predominant" exact="influenza" post="B lineage (from the Yamagata lineage in 2014 to"/>
   <result pre="in 2014). In 2013 and 2016, the lowest incidence of" exact="influenza" post="B virus infection was detected in Uruguay, along with"/>
   <result pre="was detected in Uruguay, along with the highest incidence of" exact="influenza" post="A/H1N1 pdm09. The absence of influenza B viruses in"/>
   <result pre="the highest incidence of influenza A/H1N1 pdm09. The absence of" exact="influenza" post="B viruses in some season is not unusual, since"/>
   <result pre="unusual, since it is known that the activity of the" exact="influenza" post="B virus is highly variable worldwide, without an established"/>
   <result pre="lineages could be related to the genetic variability of the" exact="influenza" post="B virus [34,35,36]. In some years, influenza B viruses"/>
   <result pre="variability of the influenza B virus [34,35,36]. In some years," exact="influenza" post="B viruses represent strong bottlenecks in the population and"/>
   <result pre="and they are generally associated with a high prevalence of" exact="influenza" post="A virus [37,38]. Interaction with the influenza A virus"/>
   <result pre="high prevalence of influenza A virus [37,38]. Interaction with the" exact="influenza" post="A virus might be central in the configuration of"/>
   <result pre="central in the configuration of the evolutionary dynamics of the" exact="influenza" post="B virus and therefore facilitate the change in the"/>
   <result pre="B lineages in different age groups. Regarding the distribution of" exact="influenza" post="B viruses in relation to the surveillance type, the"/>
   <result pre="well known that SARI cases in children could lead to" exact="respiratory failure." post="Respiratory Sincitial Virus (RSV) and human Metapneumovirus (hMPV) significantly"/>
   <result pre="[47,48]. The finding from ILI sentinel sites revealed that the" exact="influenza" post="positivity rate was high among children aged 5–9 years"/>
   <result pre="of the eight years of the study, the proportion of" exact="influenza" post="B found was significantly higher than the observed among"/>
   <result pre="across different groups of age. Some studies have demonstrated that" exact="influenza" post="played an important role in the viral aetiologies of"/>
   <result pre="Phylogenetic analysis indicated that the HA and NA sequences of" exact="influenza" post="B virus could be divided in two distinct lineages:"/>
   <result pre="[21,55]. Insertions or deletions within the 160-loop region might enable" exact="influenza" post="B virus to survive longer without undergoing an antigenic"/>
   <result pre="years after 2012 would be somehow confirming the slowly evolving" exact="influenza" post="B/Yamagata viruses. In some of the years studied, amino"/>
   <result pre="and severity of the disease [63]. The selection of the" exact="influenza" post="B virus strain for the annual trivalent vaccine is"/>
   <result pre="predominant circulating lineage [26,65,66]. Indeed, we show here, that both" exact="influenza" post="B lineages circulated almost 2012–2019, in different proportions. Mismatches"/>
   <result pre="observed in 2015. Our data showed that 28% of the" exact="influenza" post="B infections that circulated in Uruguay did not correspond"/>
   <result pre="and the findings highlighted the effect on the epidemiology of" exact="influenza" post="viruses. Furthermore, it was reported that the vaccine efficacy"/>
   <result pre="viruses. Furthermore, it was reported that the vaccine efficacy for" exact="influenza" post="B was highly reduced when the circulating lineage was"/>
   <result pre="the magnitude of the impact of seasonal vaccine mismatch on" exact="influenza" post="epidemiology depends on several factors during a given season"/>
   <result pre="factors during a given season and the proportion of each" exact="influenza" post="B virus lineage circulating, as reported by Reed and"/>
   <result pre="so far, only a few countries actually recommend the Quadrivalent" exact="influenza" post="vaccination providing the vaccine free of charge [69]. Although"/>
   <result pre="heterogeneity and genetic information for estimating the variability of circulating" exact="influenza" post="B viruses in Uruguay and the neighboring countries. Further"/>
   <result pre="resistance, are needed. Despite the limitations, the surveillance system for" exact="influenza" post="B viruses has been proven useful to describe the"/>
   <result pre="proven useful to describe the epidemiological and evolutionary behavior of" exact="influenza" post="B viruses that have circulated in Uruguay during the"/>
   <result pre="the first to highlight the prevalence and molecular characteristics of" exact="influenza" post="B virus strains, especially the hemagglutinin and neuraminidase genes,"/>
   <result pre="like those other studies, confirm the genetic variability of the" exact="influenza" post="B viruses and show the importance of systematic epidemiological"/>
   <result pre="systematic epidemiological and molecular surveillance for the effective management of" exact="influenza" post="epidemics. Understanding the different evolutionary behavior of the influenza"/>
   <result pre="of influenza epidemics. Understanding the different evolutionary behavior of the" exact="influenza" post="viruses, and how they might interact, is clearly of"/>
   <result pre="the Americas, 2010-2015PLoS ONE201910.1371/journal.pone.022147931490961 3.CainiS.AlonsW.J.BalmasedaA.BrunoA.BustosP.CastilloL.de LozanoC.de MoraD.FasceR.FerreriraW.et al.Characteristics of seasonal" exact="influenza" post="A and B in Latin America: Influenza surveillance data"/>
   <result pre="Influenza surveillance data from ten countriesPLoS ONE201710.1371/journal.pone.017459228346498 4.PaulG.W.SchmierJ.K.KuehnC.M.RyanK.J.OxfordJ.The burden of" exact="influenza" post="B: A structured literature reviewAm. J. Public Health.201310.2105/AJPH.2012 5.JenningsL.HuangQ.BarrI.LeeP.KimW.J.BuchyP.SanicasM.MungalyB.ChenJ.Literature"/>
   <result pre="reviewAm. J. Public Health.201310.2105/AJPH.2012 5.JenningsL.HuangQ.BarrI.LeeP.KimW.J.BuchyP.SanicasM.MungalyB.ChenJ.Literature review of the epidemiology of" exact="influenza" post="B disease in 15 countries in the Asia-Pacific regiónInfluenza"/>
   <result pre="Viruses20181238341110.1111/irv.1252229127742 6.SuS.ChavesS.S.PerezA.D´MelloT.KirleyP.D.YOusey-HindesK.FarleyM.M.HarrisM.SharangpaniR.LynfieldR.et al.Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="A and B infectionClin. Infect. Dis.20145925225510.1093/cid/ciu26924748521 7.Francis T.Jr.A new"/>
   <result pre="7.Francis T.Jr.A new type of virus from epidemic influenzaScience19409240540810.1126/science.92.2392.40517794275 8.BedfordT.SuchardM.A.LemeyP.DudasG.GregoryV.HayA.J.McCaulleyJ.W.RussellC.A.SmithD.J.RambautA.Integrating" exact="influenza" post="antigenic dynamics with molecular evolutionElife201410.7554/eLife.01914 9.RotaP.A.WallisT.R.HarmonM.W.RotaJ.S.KendalA.P.NeromeK.Cocirculation of two distinct"/>
   <result pre="with molecular evolutionElife201410.7554/eLife.01914 9.RotaP.A.WallisT.R.HarmonM.W.RotaJ.S.KendalA.P.NeromeK.Cocirculation of two distinct evolutionary lineages of" exact="influenza" post="type B virus since 1983Virology1990175596810.1016/0042-6822(90)90186-U2309452 10.LoY.-C.ChuangJ.-H.KuoH.-W.HuangW.T.HsuY.F.LiuM.T.ChenC.H.HuangH.H.ChangC.H.ChouJ.H.et al.Surveillance and vaccine"/>
   <result pre="virus since 1983Virology1990175596810.1016/0042-6822(90)90186-U2309452 10.LoY.-C.ChuangJ.-H.KuoH.-W.HuangW.T.HsuY.F.LiuM.T.ChenC.H.HuangH.H.ChangC.H.ChouJ.H.et al.Surveillance and vaccine effectiveness of an" exact="influenza" post="epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan,"/>
   <result pre="and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched" exact="influenza" post="B/Yamagata-lineage viruses in Taiwan, 2011–2012 seasonPLoS ONE20138e5822210.1371/journal.pone.005822223472161 11.ChenG.W.ShihS.R.HsiaoM.R.ChangS.C.LinS.H.SunC.F.TsaoK.C.Multiple genotypes"/>
   <result pre="B/Yamagata-lineage viruses in Taiwan, 2011–2012 seasonPLoS ONE20138e5822210.1371/journal.pone.005822223472161 11.ChenG.W.ShihS.R.HsiaoM.R.ChangS.C.LinS.H.SunC.F.TsaoK.C.Multiple genotypes of" exact="influenza" post="B viruses co-circulated in Taiwan in 2004 and 2005J."/>
   <result pre="and 2005J. Clin. Microbiol.2007451515152210.1128/JCM.02189-0617329451 12.VijaykrishnaD.HolmesE.C.JosephU.FourmentM.SuY.C.HalpinR.LeeR.T.DengY.M.GunalanV.LinX.et al.The contrasting phylodynamics of human" exact="influenza" post="B virusesElife20154e0505510.7554/eLife.0505525594904 13.BeranJ.WertzovaV.HonegrK.KaliskovaE.HavlickovaM.HavlikJ.JirincovaH.Van BelleP.JainV.InnisB.et al.Challenge of conducting a placebo-controlled"/>
   <result pre="BelleP.JainV.InnisB.et al.Challenge of conducting a placebo-controlled randomized efficacy study for" exact="influenza" post="vaccine in a season with low attack rate and"/>
   <result pre="15.collab: World Health OrganizationWHO information for the molecular detection of" exact="influenza" post="virusesUpdated July, 20172017Available online: https://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular_detection_of_influenza_viruses_20171023_Final.pdf(accessed on 20 January 2020)"/>
   <result pre="2020) 16.collab: World Health OrganizationWHO recommendations on the composition of" exact="influenza" post="virus vaccinesAvailable online: https://www.who.int/influenza/vaccines/virus/recommendations/en/(accessed on 20 January 2020) 17.TamuraK.StecherG.PetersonD.FilipskiA.KumarS.MEGA"/>
   <result pre="phylogenies: An approach using the bootstrapEvolution19853978379110.1111/j.1558-5646.1985.tb00420.x28561359 21.WangQ.ChengF.LuM.TianX.MaJ.Crystal structure of unliganded" exact="influenza" post="B virus hemagglutininJ. Virol.2008823011302010.1128/JVI.02477-0718184701 22.ColmanP.M.VargheseJ.N.LaverW.G.Structure of the catalytic and"/>
   <result pre="hemagglutininJ. Virol.2008823011302010.1128/JVI.02477-0718184701 22.ColmanP.M.VargheseJ.N.LaverW.G.Structure of the catalytic and antigenic sites in" exact="influenza" post="virus neuraminidaseNature1983303414410.1038/303041a06188957 23.TewawongN.SuwannakarnK.PrachayangprechaS.KorkongS.VichiwattanaP.VongpunsawadS.PoovorawanY.Molecular epidemiology and phylogenetic analyses of influenza"/>
   <result pre="in influenza virus neuraminidaseNature1983303414410.1038/303041a06188957 23.TewawongN.SuwannakarnK.PrachayangprechaS.KorkongS.VichiwattanaP.VongpunsawadS.PoovorawanY.Molecular epidemiology and phylogenetic analyses of" exact="influenza" post="B virus in Thailand during 2010 to 2014PLoS ONE201510e011630210.1371/journal.pone.011630225602617"/>
   <result pre="24.GubarevaL.MatrosovichM.N.BrennerM.K.BethellR.C.WebsterR.G.Evidence for zanamivir resistance in an immunocompromised child infected with" exact="influenza" post="B virusJ. Infect. Dis.19981781257126210.1086/3144409780244 25.collab: WHOLaboratory methodologies for testing"/>
   <result pre="Dis.19981781257126210.1086/3144409780244 25.collab: WHOLaboratory methodologies for testing the antiviral susceptibility of" exact="influenza" post="viruses: Neuraminidase inhibitor (NAI)A summary of amino acid substitutions"/>
   <result pre="Neuraminidase inhibitor (NAI)A summary of amino acid substitutions in the" exact="influenza" post="neuraminidase associated with resistance or reduced susceptibility to NAIsAvailable"/>
   <result pre="from UruguayRev. Infect. Dis.199012S995S99710.1093/clinids/12.Supplement_8.S9952270420 28.PalekarR.RodriguezA.AvilaC.BarreraG.BarreraM.BrenesH.BrunoA.El OmeiriN.FasceR.Ferreira de AlmeidaW.et al.Patterns of" exact="influenza" post="B circulation in Latin America and the Caribbean, 2010–2017PLoS"/>
   <result pre="in Latin America and the Caribbean, 2010–2017PLoS ONE201914e021959510.1371/journal.pone.021959531393886 29.TranD.VaudryW.MooreD.BettingerJ.A.HalperinS.A.ScheifeleD.W.JadvjiT.LeeL.MersereauT.Hospitalization for" exact="influenza" post="A. versus BPediatrics201610.1542/peds.2015-4643 30.SelekaM.TreurnichtF.K.TempiaS.HellfersceeO.MtshaliS.CohenA.L.BuysA.McAnerneyJ.M.BesselaarT.G.PretoriusM.et al.Epidemiology of influenza B/Yamagata and"/>
   <result pre="ONE201914e021959510.1371/journal.pone.021959531393886 29.TranD.VaudryW.MooreD.BettingerJ.A.HalperinS.A.ScheifeleD.W.JadvjiT.LeeL.MersereauT.Hospitalization for influenza A. versus BPediatrics201610.1542/peds.2015-4643 30.SelekaM.TreurnichtF.K.TempiaS.HellfersceeO.MtshaliS.CohenA.L.BuysA.McAnerneyJ.M.BesselaarT.G.PretoriusM.et al.Epidemiology of" exact="influenza" post="B/Yamagata and B/Victoria lineages in south africa, 2005-2014PLoS ONE201710.1371/journal.pone.0177655"/>
   <result pre="south africa, 2005-2014PLoS ONE201710.1371/journal.pone.0177655 31.CainiS.HuangQ.S.CiblakM.A.KusznierzG.OwenR.WangchukS.HenriquesC.M.NjouomR.FasceR.A.YuH.et al.Epidemiological and virological characteristics of" exact="influenza" post="B: Results of the Global Influenza B StudyInfluenza Other"/>
   <result pre="Influenza B StudyInfluenza Other Respir. Viruses2015931210.1111/irv.1231926256290 32.BarrI.G.VijaykrishnaD.SullivanS.G.Differential age susceptibility to" exact="influenza" post="B/Victoria lineage viruses in the 2015 Australian influenza seasonEuro"/>
   <result pre="susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian" exact="influenza" post="seasonEuro Surveill.201610.2807/1560-7917.ES.2016.21.4.30118 33.GlezenW.P.Changing Epidemiology of Influenza B VirusClin. Infect."/>
   <result pre="Dis.2014591525152610.1093/cid/ciu66825139967 34.McCullersJ.A.WangG.C.HeS.WebsterR.G.Reassortment and insertion-deletion are strategies for the evolution of" exact="influenza" post="B viruses in natureJ. Virol.1999737343734810.1128/JVI.73.9.7343-7348.199910438823 35.BakerS.F.NogalesA.FinchC.TuffyK.M.DommW.PerezD.R.TophamD.J.Martínez-SobridoL.Influenza A and B"/>
   <result pre="intertypic reassortment through compatible viral packaging signalsJ. Virol.201488107781079110.1128/JVI.01440-1425008914 36.DudasG.BedfordT.LycettS.RambautA.Reassortment between" exact="influenza" post="B lineages and the emergence of a co adapted"/>
   <result pre="PB1-PB2-HA gene complexMol. Biol. Evol.20143216217210.1093/molbev/msu28725323575 37.YangJ.R.HuangY.P.ChangF.Y.HsuL.C.LinY.C.HuangH.Y.WuF.T.WuH.S.LiuM.T.Phylogenetic and evolutionary history of" exact="influenza" post="B viruses, which caused a large epidemic in 2011-2012,"/>
   <result pre="epidemic in 2011-2012, TaiwanPLoS ONE20127e4717910.1371/journal.pone.004717923071751 38.ChenR.HolmesE.C.The evolutionary dynamics of human" exact="influenza" post="B virusJ. Mol. Evol.20086665566310.1007/s00239-008-9119-z18504518 39.LangatP.RaghwaniJ.DudasG.BowdenT.A.EdwardsS.GallA.BedfordT.RambautA.DanielsR.S.RussellC.et al.Genome-wide evolutionary dynamics of"/>
   <result pre="influenza B virusJ. Mol. Evol.20086665566310.1007/s00239-008-9119-z18504518 39.LangatP.RaghwaniJ.DudasG.BowdenT.A.EdwardsS.GallA.BedfordT.RambautA.DanielsR.S.RussellC.et al.Genome-wide evolutionary dynamics of" exact="influenza" post="B viruses on a global scalePLoS Pathog.201710.1371/journal.ppat.1006749 40.TsedenbalN.Tsend-AyushA.BadarchD.JavS.PagbajabN.Influenza B"/>
   <result pre="years in MongoliaPLoS ONE201810.1371/journal.pone.0206987 41.HorthongkhamN.AthipanyasilpN.PattamaA.KaewnapanB.SornprasertS.SrisurapanontS.KantakamalakulW.AmaranondP.SutthentR.Epidemiological, Clinical and Virological characteristics of" exact="influenza" post="B virus from patients at the hospital Tertary care"/>
   <result pre="2011–2014PLoS ONE201610.1371/journal.pone.0158244 42.TrucchiC.AlicinoC.OrsiA.PaganinoC.BarberisI.GrammaticoF.CanepaP.RappazzoE.BruzzoneB.SticchiL.et al.Fifteen years of epidemiologic, virologic and syndromic" exact="influenza" post="surveillance: A focus on type B virus and the"/>
   <result pre="mismatch in Liguria region, ItalyHum.Vaccin. Immunother.20171345646310.1080/21645515.2017.126477927924684 43.TanY.GuanW.LamT.T.PanS.WuS.ZhanY.ViboudC.HolmesE.C.YangZ.Differing epidemiological dynamics of" exact="influenza" post="B virus lineages in Guangzhou, Southern China,2009-2010J. Virol.201387124471245610.1128/JVI.01039-1324027322 44.CainiS.KusznierzG.GarateV.V.WangchukS.ThapaB.de"/>
   <result pre="Virol.201387124471245610.1128/JVI.01039-1324027322 44.CainiS.KusznierzG.GarateV.V.WangchukS.ThapaB.de Paula JúniorF.J.Ferreira de AlmeidaW.A.NjouomR.FasceR.A.BustosP.et al.The epidemiological signature of" exact="influenza" post="B virus and its B/Victoria and B/Yamagata lineages in"/>
   <result pre="in the 21 st centuryPLoS ONE201910.1371/journal.pone.0222381 45.OrsiA.ColombaG.M.E.PojeroF.CalamusaG.AlicinoC.TrucchiC.CanepaP.AnsaldiF.VitaleF.TramutoF.Trends of impact of" exact="influenza" post="B during the 2010-2016 seasons in 2 regions of"/>
   <result pre="and south italy: The impact of the vaccine mismatch on" exact="influenza" post="immunization strategyHum. Vaccin. Immunother.20181452353110.1080/21645515.2017.134290728708953 46.ChengW.YuZ.LiuS.ZhangX.WangX.CaiJ.LingF.ChenE.Comparison of influenza epidemiological and"/>
   <result pre="vaccine mismatch on influenza immunization strategyHum. Vaccin. Immunother.20181452353110.1080/21645515.2017.134290728708953 46.ChengW.YuZ.LiuS.ZhangX.WangX.CaiJ.LingF.ChenE.Comparison of" exact="influenza" post="epidemiological and virological characteristics between outpatients and inpatients in"/>
   <result pre="2015Int. J. Env. Res. Public Health201721710.3390/ijerph1402021728241447 47.BurmaaA.KamigakiT.DarmaaB.NymadawaP.OshitaniH.Epidemiology and impact of" exact="influenza" post="in Mongolia 2007–2012Influenza Other Respir. Viruses2014853053710.1111/irv.1226825043147 48.TalloV.L.KamigakiT.TanA.G.Estimating influenza outpatient´s"/>
   <result pre="impact of influenza in Mongolia 2007–2012Influenza Other Respir. Viruses2014853053710.1111/irv.1226825043147 48.TalloV.L.KamigakiT.TanA.G.Estimating" exact="influenza" post="outpatient´s and impatients incidences from 2009 to 2011 in"/>
   <result pre="Shangai, China, 2011 to 2013PLoS ONE201510.1371/journal.pone.0119513 50.NohJ.SongJ.Y.CheongH.J.ChoiW.S.LeeJ.LeeJ.S.WieS.H.JeongH.W.KimY.K.ChoiS.H.et al.Laboratory surveillance of" exact="influenza" post="–like illness in seven teaching hospitals, South Koreal: 2011–2012"/>
   <result pre="infections in ChinaPLoS ONE20138e7260610.1371/journal.pone.007260623991128 52.collab: World Health OrganizationRecommended composition of" exact="influenza" post="virus vaccines for use in the 2018–2019 northern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2018–2019 northern hemisphere" exact="influenza" post="seasonWkly Epidemiol. Rec.20189313315229569429 53.KuoS.ChenG.W.VeluA.B.DashS.HanY.J.TsaoK.C.ShihS.R.Circulating pattern and genomic characteristics of"/>
   <result pre="influenza seasonWkly Epidemiol. Rec.20189313315229569429 53.KuoS.ChenG.W.VeluA.B.DashS.HanY.J.TsaoK.C.ShihS.R.Circulating pattern and genomic characteristics of" exact="influenza" post="B viruses in Taiwan from 2003 to 2014J. Formos."/>
   <result pre="2003 to 2014J. Formos. Med. Assoc.201611551052210.1016/j.jfma.2016.01.01727038555 54.ShenJ.KirkB.D.MaJ.WangQ.Diversifying selective pressure on" exact="influenza" post="B virus hemagglutininJ. Med. Virol.20098111412410.1002/jmv.2133519031453 55.TramutoF.OrsiA.MaidaC.M.CostantinoC.TrucchiC.AlicinoC.VitaleF.AnsaldiF.The molecular epidemiology and"/>
   <result pre="hemagglutininJ. Med. Virol.20098111412410.1002/jmv.2133519031453 55.TramutoF.OrsiA.MaidaC.M.CostantinoC.TrucchiC.AlicinoC.VitaleF.AnsaldiF.The molecular epidemiology and evolutionary dynamics of" exact="influenza" post="B virus in two italian regions during 2010-2015: The"/>
   <result pre="of Sicily and LiguriaInt. J. Mol. Sci.20161754910.3390/ijms1704054927089319 56.NeromeR.HiromotoY.SugitaS.TanabeN.IshidaM.MatsumotoM.LindstromS.E.TakahashiT.NeromeK.Evolutionary characteristics of" exact="influenza" post="B virus since its first isolation in 1940: Dynamic"/>
   <result pre="and insertion mechanismArch. Virol.19981431569158310.1007/s0070500503999739335 57.SuptawiwatO.NinpanK.BoonarkartC.RuangrungK.AuewarakulP.Evolutionary dynamic of antigenic residues on" exact="influenza" post="B hemagglutininVirology2017502849610.1016/j.virol.2016.12.01528024225 58.McAuleyJ.GilbertsonB.TrifkovicS.BrownL.McKimm-BreschkinJ.L.Influenza virus neuraminidase structure and functionsFront. Microbiol.201910.3389/fmicb.2019.00039"/>
   <result pre="structure and functionsFront. Microbiol.201910.3389/fmicb.2019.00039 59.LinY.P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.LackenbyA.DanielsR.HayA.Neuraminidase receptor binding variants of human" exact="influenza" post="A(H3N2) viruses resulting from substitution of aspartic acid 151"/>
   <result pre="in virus attachment?J. Virol.2010846769678110.1128/JVI.00458-1020410266 60.MohrP.G.DengY.M.McKimm-BreschkinJ.L.The neuraminidases of MDCK grown human" exact="influenza" post="A (H3N2) viruses isolated since 1994 can demonstrate receptor"/>
   <result pre="can demonstrate receptor bindingVirol. J.201510.1186/s12985-015-0295-3 61.TivaneA.DanielsR.NguenhaN.MachaleleL.NacotoA.PaleM.MateonaneE.MavaleS.ChilundoJ.MutetoD.Antigenic and genetic characterization of" exact="influenza" post="viruses isolated in Mozambique during the 2015 seasonPLoS ONE201810.1371/journal.pone.0201248"/>
   <result pre="vaccine lineage selection-an optimized trivalent vaccineVaccine2016341617162210.1016/j.vaccine.2016.01.04226896685 64.DemicheliV.JeffersonT.FerroniE.RivettA.Di PietrantonjC.Vaccines for preventing" exact="influenza" post="in healthy adultsCochrane Database Syst. Rev.201810.1002/14651858.CD001269.pub6 65.QinY.ZhangY.WuP.Influenza vaccine effectiveness"/>
   <result pre="preventing hospitalization among Beijing residents in China, 2013–2015Vaccine2016342329233310.1016/j.vaccine.2016.03.06827026147 66.MoaA.M.MuscatelloD.J.TurnerR.M.MacIntyreC.R.Epidemiology of" exact="influenza" post="B in Australia: 2001-2014Influenza Other Respir. Viruses20171110210910.1111/irv.1243227650482 67.TinocoY.O.Azziz-BaumgartnerE.UyekT.M.Burden of"/>
   <result pre="surveillance of a community cohort, 2009-2015Clin. Infect. Dis.2017651532154110.1093/cid/cix56529020267 68.ReedC.ChavesS.S.KirleyP.D.EmersonR.AragonD.HancockE.B.ButlerL.HollickG.BaumbachJ.HollickG.et al.Estimating" exact="influenza" post="disease burden from population-based surveillance data in the United"/>
   <result pre="online: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx(accessed on 27 February 2019) Figure 1 Distribution of" exact="influenza" post="B viruses (IBV) cases in Uruguay according to age"/>
   <result pre="the different age groups are indicated. Figure 2 Incidence of" exact="influenza" post="A and B viruses identified from clinical samples in"/>
   <result pre="Uruguay during 2012 to 2019. The year distribution of the" exact="influenza" post="viruses, including A (H1N1pdm09) (blue color), A(H3N2) (light blue)"/>
   <result pre="viruses, including A (H1N1pdm09) (blue color), A(H3N2) (light blue) and" exact="influenza" post="B (yellow color) activity. Figure 3 Circulation of influenza"/>
   <result pre="and influenza B (yellow color) activity. Figure 3 Circulation of" exact="influenza" post="B lineages according to season (year) and recommended vaccine"/>
   <result pre="indicated, and &quot;Yes�? or &quot;No�? if they coincide with the" exact="influenza" post="B strains that have circulated. Abbreviations V1A, V1A1, Y2,"/>
   <result pre="Figure 4 Phylogenetic analysis of the HA1 nucleotide sequences from" exact="influenza" post="B Victoria-lineage viruses circulating in Uruguay from 2012 to"/>
   <result pre="arrows. Figure 5 Phylogenetic analysis of HA1 nucleotide sequences from" exact="influenza" post="B Yamagata-lineage viruses circulating in Uruguay from 2012 to"/>
   <result pre="6 Phylogenetic analysis of the partial neuraminidase nucleotide sequences from" exact="influenza" post="B Victoria-lineage viruses circulating in Uruguay from 2012 to"/>
   <result pre="7 Phylogenetic analysis of the partial neuraminidase nucleotide sequences from" exact="influenza" post="B Yamagata-lineage viruses circulating in Uruguay from 2012 to"/>
   <result pre="are indicated with arrows. microorganisms-08-00591-t001_Table 1Table 1 Age distribution of" exact="influenza" post="B infections according to type of surveillance and influenza"/>
   <result pre="of influenza B infections according to type of surveillance and" exact="influenza" post="B lineages. Numbers of patients are indicated according to"/>
   <result pre="according to age group, discriminating by type of surveillance and" exact="influenza" post="B lineages between 2012–2019. Lineage determination in samples n"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7232503\results\search\disease\results.xml">
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract In South Africa, canid" exact="rabies" post="virus (RABV) infection is maintained in domestic and wildlife"/>
   <result pre="is maintained in domestic and wildlife species. The identification of" exact="rabies" post="in African civets raised the question of whether this"/>
   <result pre="African civets have two origins related to dog and mongoose" exact="rabies" post="enzootics. The data support observations of the interaction of"/>
   <result pre="transmission chains with conspecifics that may be related to transient" exact="rabies" post="maintenance in African civets. Hence, it is important to"/>
   <result pre="in which bat-eared foxes and black-backed jackal species maintain independent" exact="rabies" post="cycles of what were once dog-maintained RABVs. rabies virus"/>
   <result pre="maintain independent rabies cycles of what were once dog-maintained RABVs." exact="rabies" post="virus African civet incidental host 1. Introduction Lyssaviruses are"/>
   <result pre="source of infection of the majority (≥ 95%) of human" exact="rabies" post="cases globally [8]. There are currently sixteen classified lyssavirus"/>
   <result pre="lyssavirus accounting for the vast majority of human and animal" exact="rabies" post="cases. The African RABVs have been sub-divided into four"/>
   <result pre="as &quot;viverrid viruses�? and now referred to as the &quot;mongoose" exact="rabies" post="biotype�?, are predominantly confirmed in the yellow mongoose (Cynictis"/>
   <result pre="maintenance host species of this biotype [16,17]. Historically, the mongoose" exact="rabies" post="biotype, genetically distant from all dog RABV variants, was"/>
   <result pre="Cynictis penicillata, clearly the definitive reservoir host for the mongoose" exact="rabies" post="variant in South Africa [16]. More recently, a highly"/>
   <result pre="it is merely a dead-end host. In Zimbabwe, African civet" exact="rabies" post="cases were generally diagnosed during jackal rabies outbreaks [23],"/>
   <result pre="Zimbabwe, African civet rabies cases were generally diagnosed during jackal" exact="rabies" post="outbreaks [23], suggesting a spill-over of infection. Furthermore, wildlife"/>
   <result pre="rabies outbreaks [23], suggesting a spill-over of infection. Furthermore, wildlife" exact="rabies" post="contributes approximately 25% of all laboratory-confirmed rabies cases in"/>
   <result pre="infection. Furthermore, wildlife rabies contributes approximately 25% of all laboratory-confirmed" exact="rabies" post="cases in Zimbabwe [24]. Of the wildlife rabies submitted"/>
   <result pre="all laboratory-confirmed rabies cases in Zimbabwe [24]. Of the wildlife" exact="rabies" post="submitted for rabies testing between 2010 and 2017, jackals"/>
   <result pre="cases in Zimbabwe [24]. Of the wildlife rabies submitted for" exact="rabies" post="testing between 2010 and 2017, jackals comprised 35.5% of"/>
   <result pre="amino acid signatures (exclusively found in African civets) in the" exact="rabies" post="virus isolates originating from African civets (but not in"/>
   <result pre="in striped skunks (Mephitis mephitis) relative to fox and raccoon" exact="rabies" post="in North America 2.3. Phylogenies and Evolutionary Analysis Maximum"/>
   <result pre="were detected. All likely ‘dead-end’ hosts (unable to further transmit" exact="rabies" post="virus infection) were removed and the remaining hosts were"/>
   <result pre="exclusively placed in Africa 1 and 3 lineages. The mongoose" exact="rabies" post="biotype (Africa 3) was delineated into five previously recognized"/>
   <result pre="the Northern Cape Province). The fifth clade (#5) consists of" exact="rabies" post="viruses originating from wildlife host species, including two African"/>
   <result pre="the exception of one of a subclade, which exclusively contains" exact="rabies" post="viruses from African civets and a black-backed jackal collected"/>
   <result pre="and mongoose samples. A third small cluster of three civet" exact="rabies" post="viruses sequences from Zimbabwe 1992–1994 has a later common"/>
   <result pre="that raccoons were four times more likely to transmit the" exact="rabies" post="virus to other species than skunks. In Southern Africa,"/>
   <result pre="than skunks. In Southern Africa, the spill-over of the mongoose" exact="rabies" post="biotype to canid hosts (such as the domestic dog),"/>
   <result pre="our current study demonstrated and revealed CST events between dog" exact="rabies" post="virus maintenance hosts (namely dogs and jackal species) and"/>
   <result pre="the canid RABVs, fewer human cases are attributed to mongoose" exact="rabies" post="and it is, therefore, considered less of a public"/>
   <result pre="South African canid and mongoose RABVs showed that the canid" exact="rabies" post="virus exhibited a phenotype associated with survival in their"/>
   <result pre="the mongoose variant. These observations confirmed that, indeed, the canid" exact="rabies" post="variant is more virulent than the mongoose rabies variant"/>
   <result pre="the canid rabies variant is more virulent than the mongoose" exact="rabies" post="variant under experimental conditions in a murine model. In"/>
   <result pre="species. There are fewer host species infected with the mongoose" exact="rabies" post="biotype in the Africa 3 RABV clade, with the"/>
   <result pre="two RABV sequences from dogs within the Africa 3 (mongoose" exact="rabies" post="biotype) clade, demonstrating that spill-over of the mongoose rabies"/>
   <result pre="(mongoose rabies biotype) clade, demonstrating that spill-over of the mongoose" exact="rabies" post="biotype into other species does occur. The majority of"/>
   <result pre="drawn. Surveillance data from southern Africa have demonstrated that wildlife" exact="rabies" post="is a significant veterinary and public health problem, specifically"/>
   <result pre="due to strain differences. Animals with prolonged incubation periods of" exact="rabies" post="infection are believed to act as effective reservoirs of"/>
   <result pre="but can contribute to the maintenance of the disease between" exact="rabies" post="epidemics in jackals, harbouring the infection whilst the jackal"/>
   <result pre="that they were indistinguishable from jackal viruses (Africa 1, canid" exact="rabies" post="biotype), but more recent data supported the notion that"/>
   <result pre="may be capable of supporting the maintenance of enzootic mongoose" exact="rabies" post="[17]. Although Haydon 2012 discussed and highlighted the challenges"/>
   <result pre="identifying reservoirs. Considering the trends analyses (2000–2015) in South Africa," exact="rabies" post="in the African civet occurred sporadically and represented a"/>
   <result pre="and represented a mere 0.3% of the total confirmed positive" exact="rabies" post="cases. These data are heavily skewed due to sampling"/>
   <result pre="in striped skunks (Mephitis mephitis) and in fox and raccoon" exact="rabies" post="in North America, or can maintain its own enzootic"/>
   <result pre="and other poorly understood wildlife species and improved surveillance of" exact="rabies" post="cases from the same regions will help unravel the"/>
   <result pre="lyssaviruses, such as IKOV. There is, however, no evidence of" exact="rabies" post="causing population declines in African civets. The data may"/>
   <result pre="routine surveillance where such facilities exist, or through collaboration with" exact="rabies" post="reference laboratories to undertake genetic typing. The identification of"/>
   <result pre="to undertake genetic typing. The identification of canid and mongoose" exact="rabies" post="viruses do indeed demonstrate the extent that the African"/>
   <result pre="References 1.WunnerW.H.LarsonJ.K.DietzscholdB.SmithC.L.The Molecular Biology of Rabies VirusesRev. Infect. Dis.198810S771S78410.1093/clinids/10.Supplement_4.S7712462742 2.TordoN.KouknetzorffA.The" exact="rabies" post="virus genome: An overviewOnderstepoort J. Vet. Res.199360263269 3.TaylorL.H.LathamS.M.WoolhouseM.E.J.Risk factors"/>
   <result pre="of endemic canine rabiesPLoS Negl. Trop. Dis.20159e000370925881058 6.FooksA.R.BanyardA.C.HortonD.L.JohnsonN.McElhinneyL.M.JacksonA.C.Current status of" exact="rabies" post="and prospects for eliminationLancet20143841389139910.1016/S0140-6736(13)62707-524828901 7.KnobelD.L.CleavelandS.ColemanP.G.FevreE.M.MeltzerM.I.MirandaM.E.G.ShawA.ZinsstagJ.MeslinF.Re-evaluating the burden of rabies"/>
   <result pre="of rabies and prospects for eliminationLancet20143841389139910.1016/S0140-6736(13)62707-524828901 7.KnobelD.L.CleavelandS.ColemanP.G.FevreE.M.MeltzerM.I.MirandaM.E.G.ShawA.ZinsstagJ.MeslinF.Re-evaluating the burden of" exact="rabies" post="in Africa and AsiaBull. World Health Organ.20058336036815976877 8.collab: WHOExpert"/>
   <result pre="a bat in FinlandTransbound Emerg. Dis.20186559359629446230 15.DavidD.HughesG.J.YakobsonB.A.DavidsonI.UnH.AylanO.KuzminI.V.RupprechtC.E.Identification of novel canine" exact="rabies" post="virus clades in the Middle East and North Africa"/>
   <result pre="Middle East and North Africa FreeJ. Gen. Vir.20078810.1099/vir.0.82352-0 16.NelL.H.SabetaC.T.Von TeichmanB.JafthaJ.B.RuppprechtC.E.BinghamJ.Mongoose" exact="rabies" post="in southern Africa: A re-evaluation based on molecular epidemiologyVirus"/>
   <result pre="southern Africa: A re-evaluation based on molecular epidemiologyVirus Res.200510916517310.1016/j.virusres.2004.12.00315763147 17.SabetaC.T.MohaleD.K.MiyenJ.M.ShumbaW.WandelerA.I.NelL.H.Mongoose" exact="rabies" post="and the African civet in ZimbabweVet. Rec.200816358010.1136/vr.163.19.58018997193 18.FogginC.M.Rabies and"/>
   <result pre="al.Complete genome sequence of Ikoma lyssavirusJ. Virol.201286102421024310.1128/JVI.01628-1222923801 22.BinghamJ.FogginC.M.WandelerA.I.HillF.W.G.The epidemiology of" exact="rabies" post="in Zimbabwe. 2. Rabies in jackals (Canis adustus and"/>
   <result pre="divergent African virus, Ikoma lyssavirusJ Gen Virol.2014951025103210.1099/vir.0.061952-024496827 24.BinghamJ.FogginC.M.WandelerA.I.HillF.W.G.The epidemiology of" exact="rabies" post="in Zimbabwe. 1. Rabies in dogs (Canis familiaris)Onderstepoort J."/>
   <result pre="771ppages0-86979-8022 27.HeatonP.R.JohnstoneP.McElhinneyL.M.CowleyR.O’SullivanE.WhitbyJ.E.Heminested PCR assay for detection of six genotypes of" exact="rabies" post="and rabies-related virusesJ. Clin. Microbiol.1997352762276610.1128/JCM.35.11.2762-2766.19979350729 28.McElhinneyL.M.MarstonD.A.FreulingC.M.CraggW.StankovS.LalosevićD.LalosevićV.MüllerT.FooksA.R.Molecular Diversity and Evolutionary"/>
   <result pre="Biol. Evol.20133023924310.1093/molbev/mss24323090976 33.WallaceR.M.GilbertA.SlateD.ChipmanR.SinghA.WeddC.BlantonJ.D.Right Place, Wrong Species: A 20-year review of" exact="rabies" post="virus cross species transmission among terrestrial Mammals in the"/>
   <result pre="Mammals in the United StatesPLoS ONE20149e10753910.1371/journal.pone.010753925295750 34.NgoepeC.E.SabetaC.NelL.H.The spread of canine" exact="rabies" post="into Free State province of South Africa: A molecular"/>
   <result pre="molecular epidemiological characterizationVirus Res.200914217518010.1016/j.virusres.2009.02.01219428751 35.MollentzeN.BiekR.StreickerD.G.The role of viral evolution in" exact="rabies" post="host shiftsCurr. Opin. Virol.20148687210.1016/j.coviro.2014.07.00425064563 36.MarstonD.A.BanyardA.C.McElhinneyL.M.FreulingC.M.FinkeS.de LamballerieX.MüllerT.FooksA.R.The Lyssavirus Host-Specificity Conundrum-Rabies"/>
   <result pre="ApproachMicrobes Infect.20171947648410.1016/j.micinf.2017.05.00628602914 41.NelL.JacobsJ.JafthaJ.MeredithC.Natural Spillover of a distinctly Canidae-Associated Biotype of" exact="rabies" post="virus in an expanded wildlife host range in southern"/>
   <result pre="wildlife host range in southern AfricaVirus Genes199715798210.1023/A:10079795027549354274 42.Velasco-VillaA.OrciariL.A.SouzaV.Juarez-IslasV.Gomez-SierraM.CastilloA.FlisserA.RupprechtC.E.Molecular epizootiology of" exact="rabies" post="associated with terrestrial carnivores in MexicoVirus Res.2005111132710.1016/j.virusres.2005.03.00715896399 43.BinghamJ.Canine Rabies"/>
   <result pre="in the Jos Zoo, NigeriaBrit. Vet. J.198814451551610.1016/0007-1935(88)90092-93191379 45.KingA.A.MeredithC.D.ThomsonG.R.Canid and viverrid" exact="rabies" post="viruses in South AfricaOnderstepoort J. Vet. Res.1993602952997777314 46.LemboT.HampsonK.HaydonD.T.CraftM.DobsonA.P.DushoffJ.ErnestE.HoareR.KaareM.MlengeyaT.et al.Exploring"/>
   <result pre="Vet. Res.1993602952997777314 46.LemboT.HampsonK.HaydonD.T.CraftM.DobsonA.P.DushoffJ.ErnestE.HoareR.KaareM.MlengeyaT.et al.Exploring reservoir dynamics: A case study of" exact="rabies" post="in the Serengeti ecosystemJ. Appl. Ecol.2008451246125710.1111/j.1365-2664.2008.01468.x22427710 47.KeesingF.HoltR.D.OstfeldR.S.Effects of species"/>
   <result pre="tree of complete N-gene coding sequence of representative African canid" exact="rabies" post="virus (RABV) sequences including the African civet N-gene sequences"/>
   <result pre="3 Maximum clade credibility tree from Bayesian reconstruction of 59" exact="rabies" post="virus full nucleoprotein sequences (1353nt), using an HKY +G+I"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7233267\results\search\disease\results.xml">
   <result pre="narrow variations, greatly favouring mosquito proliferation throughout the year.19 Lymphatic" exact="filariasis" post="and dengue fever are both endemic in Recife,18,20 while"/>
   <result pre="greatly favouring mosquito proliferation throughout the year.19 Lymphatic filariasis and" exact="dengue fever" post="are both endemic in Recife,18,20 while Chikungunya and Zika"/>
   <result pre="OliveiraCMFRiosEMda SilvaSBFurtadoAFIntegrated control measures against Culex quinquefasciatus, the vector of" exact="filariasis" post="in RecifeMem Inst Oswaldo Cruz19959011151198524072 21collab: Instituto Brasileiro de"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7233507\results\search\disease\results.xml">
   <result pre="are credited.https://www.cureus.com/articles/30150-influenza-national-trends-using-the-national-inpatient-sample-database-from-1993-to-2015 Abstract Background There is a significant impact of" exact="influenza" post="on individuals, families, and societies both economically and clinically."/>
   <result pre="Inpatient Sample (NIS) from 1993 through 2015. Discharges due to" exact="influenza" post="from 1993 to 2015 were identified, and the rate"/>
   <result pre="and an F value of 19.5. Conclusion Recent advancements in" exact="influenza" post="detection have made the detection feasible, quick, and cost-effective."/>
   <result pre="inpatient mortality over the years between 1993 - 2015. Advanced" exact="influenza" post="virus detection tests are now recommended in both outpatient"/>
   <result pre="to assess the impact of these tests on the outcome." exact="influenza" post="national trends cost effectiveness mortality discharge flu The content"/>
   <result pre="colloquially as &quot;the flu,�? is a viral infection of the" exact="influenza" post="virus with ramifications that range from relatively benign to"/>
   <result pre="fever, coughs, and myalgias [1]. While usually self-limited and benign," exact="influenza" post="may also manifest with more severe sequelae that warrant"/>
   <result pre="neuropathies, such as Guillain-Barré syndrome [2-6]. On an epidemiological scale," exact="influenza" post="has been notorious to cause outbreaks with significant morbidity"/>
   <result pre="outbreaks with significant morbidity and mortality, such as the 2009" exact="influenza" post="pandemic, estimated to have had a global mortality count"/>
   <result pre="[7]. In the United States (US), annual hospitalizations secondary to" exact="influenza" post="range from around 140,000 to over 700,000 based on"/>
   <result pre="attempts in the literature to gauge the fiscal impact of" exact="influenza" post="in the US estimate the figure to be in"/>
   <result pre="factors weighted [9-10]. Nevertheless, there is a profound effect of" exact="influenza" post="on the social framework in the United States, namely,"/>
   <result pre="it is prudent to assess how hospital discharges related to" exact="influenza" post="have changed with advances in healthcare. In this work,"/>
   <result pre="Doing so will present the opportunity to report shifts in" exact="influenza" post="treatments, as well as to elucidate areas for improvement"/>
   <result pre="of the United States healthcare system [12]. Discharges due to" exact="influenza" post="from 1993 to 2015 were identified by using ICD-9"/>
   <result pre="influenza-related admissions from 1993-2015 Figure 2 Characterization of variables in" exact="influenza" post="discharge analysis NIS: National Inpatient Sample Figure 3 Yearly"/>
   <result pre="Figure 3 Yearly inpatient mortality differential in patients hospitalized with" exact="influenza" post="Figure 4 Yearly inpatient mortality in patients hospitalized with"/>
   <result pre="influenza Figure 4 Yearly inpatient mortality in patients hospitalized with" exact="influenza" post="from 1993 to 2015 Discussion Recent advancements in the"/>
   <result pre="1993 to 2015 Discussion Recent advancements in the detection of" exact="influenza" post="make surveillance of the virus feasible, quick, and cost-effective"/>
   <result pre="in mining online data to effectively predict local changes in" exact="influenza" post="flux to predict epidemics of the virus in an"/>
   <result pre="a significant increase in the rate of discharges due to" exact="influenza" post="but no significant changes in the percentage of inpatient"/>
   <result pre="varying mean age of admissions throughout the years analyzed. Advanced" exact="influenza" post="virus detection tests are now recommended in both outpatient"/>
   <result pre="outpatient (including emergency departments) and inpatient admissions, and vaccination against" exact="influenza" post="is still encouraged and supported by many organizational bodies,"/>
   <result pre="was a recent increase in the inpatient admission counts from" exact="influenza" post="as extrapolated by a marked increase in hospital discharges"/>
   <result pre="The interval 2013 to 2015 was comparable to the 2009" exact="influenza" post="pandemic year in the discharge rate for influenza. This"/>
   <result pre="been due to more efficient detection modalities, resulting in more" exact="influenza" post="diagnoses within a population. However, the lack of change"/>
   <result pre="to a higher turnover of the same capability to manage" exact="influenza" post="by healthcare institutions. A further prospective study is warranted"/>
   <result pre="times, so is the mean age of hospital discharges with" exact="influenza" post="since the 2009 influenza pandemic, which shows not only"/>
   <result pre="mean age of hospital discharges with influenza since the 2009" exact="influenza" post="pandemic, which shows not only a return to baseline"/>
   <result pre="features of patients who undergo hospitalization and subsequent discharge for" exact="influenza" post="with a focus on demographics, socioeconomic status, locale, and"/>
   <result pre="improvement. Figure 5 Yearly mean age in patients hospitalized with" exact="influenza" post="from 1993 to 2015 Conclusions Our analysis revealed a"/>
   <result pre="a significant increase in the rate of discharges due to" exact="influenza" post="but there was no significant change in the parentage"/>
   <result pre="fever and myalgia: evidence-based pharmacy practiceSA Pharmaceut JTruterI1014792012https://hdl.handle.net/10520/EJC121898 2Detection of" exact="influenza" post="myocarditis using national healthcare safety network surveillance definitions accounting"/>
   <result pre="and myalgia: evidence-based pharmacy practiceSA Pharmaceut JTruterI1014792012https://hdl.handle.net/10520/EJC121898 2Detection of influenza" exact="myocarditis" post="using national healthcare safety network surveillance definitions accounting for"/>
   <result pre="A infection is an important cause of febrile seizuresPediatricsChiuSSTseCYLauYLPeirisM01082001 6Mild" exact="influenza" post="encephalopathy with biphasic seizures and late reduced diffusionJ Neurol"/>
   <result pre="infection is an important cause of febrile seizuresPediatricsChiuSSTseCYLauYLPeirisM01082001 6Mild influenza" exact="encephalopathy" post="with biphasic seizures and late reduced diffusionJ Neurol SciTakanashiJTsujiMAmemiyaKTadaHBarkovichAJ8689256200717367813"/>
   <result pre="diffusionJ Neurol SciTakanashiJTsujiMAmemiyaKTadaHBarkovichAJ8689256200717367813 7Pandemic preparedness and response--lessons from the H1N1" exact="influenza" post="of 2009N Engl J MedFinebergHV13351342370N Engl J Med24693893 8Annual"/>
   <result pre="Engl J Med24693893 8Annual estimates of the burden of seasonal" exact="influenza" post="in the United States: a tool for strengthening influenza"/>
   <result pre="seasonal influenza in the United States: a tool for strengthening" exact="influenza" post="surveillance and preparednessInfluenza Other Respir VirusesRolfesMAFoppaIMGargSet al.13213712201829446233 9The hidden"/>
   <result pre="burden of influenza: a review of the extra-pulmonary complications of" exact="influenza" post="infectionInfluenza Other Respir VirusesSellersSAHaganRSHaydenFGFischer WA2nd372393201728745014 10Total economic consequences of"/>
   <result pre="infectionInfluenza Other Respir VirusesSellersSAHaganRSHaydenFGFischer WA2nd372393201728745014 10Total economic consequences of an" exact="influenza" post="outbreak in the United StatesRisk AnalPragerFWeiDRoseA41937201727214756 11Surge in hospitalizations"/>
   <result pre="AnalPragerFWeiDRoseA41937201727214756 11Surge in hospitalizations associated with mechanical ventilator use during" exact="influenza" post="outbreaksDisaster Med Public Health PrepKingJCAjaoALichensteinRMagderLS13614282014 12Adherence to methodological standards"/>
   <result pre="RepNagyAJiřinecTJiřincováHČerníkováLHavlí�?kováM16309201930733500 15Highly uniform gold nanobipyramids for ultrasensitive colorimetric detection of" exact="influenza" post="virusAnal ChemXuSOuyangWXiePet al.1617162389201728208287 16Development of a point-of-care diagnostic for"/>
   <result pre="influenza virusAnal ChemXuSOuyangWXiePet al.1617162389201728208287 16Development of a point-of-care diagnostic for" exact="influenza" post="detection with antiviral treatment effectiveness indicationLab ChipMurdockRCGallegosKMHagenJAKelley-LoughnaneNWeissAAPapautskyI33234017201727966711 17Mining twitter"/>
   <result pre="with antiviral treatment effectiveness indicationLab ChipMurdockRCGallegosKMHagenJAKelley-LoughnaneNWeissAAPapautskyI33234017201727966711 17Mining twitter data for" exact="influenza" post="detection and surveillanceSEHS '16: Proceedings of the International Workshop"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7233653\results\search\disease\results.xml">
   <result pre="Influenza virological surveillance is essential for monitoring the evolution of" exact="influenza" post="viruses (IVs) as well as for annual updating of"/>
   <result pre="Genetic characterization was performed for a spatial-temporal representative number of" exact="influenza" post="laboratory-confirmed specimens. Results: Influenza-positive samples per season ranged between"/>
   <result pre="seasons a complete or nearly complete mismatch between the predominant" exact="influenza" post="B lineage of IVs type B circulating and vaccine"/>
   <result pre="IVs circulation, to improve the most appropriate vaccination strategies. (www.actabiomedica.it)" exact="influenza" post="virus virological surveillance antigenic characterisation B lineage vaccine virus"/>
   <result pre="antigenic characterisation B lineage vaccine virus strain mismatch Introduction Seasonal" exact="influenza" post="is an acute, highly contagious viral respiratory infection of"/>
   <result pre="(1). Influenza epidemiology mainly depends on the particular characteristics of" exact="influenza" post="viruses (IVs), able to spread all over the world"/>
   <result pre="every year with different intensity and trend. The impact of" exact="influenza" post="also varies according to different age groups, in terms"/>
   <result pre="antigenically distinct, occurred starting from 1983 (11). Within this context," exact="influenza" post="epidemiological and virological surveillance plays an essential role and"/>
   <result pre="Centre for Disease Prevention and Control (ECDC) (13). The national" exact="influenza" post="surveillance systems, together with the analysis of epidemiological features,"/>
   <result pre="manner (14). In Italy, these activities are carried out by" exact="influenza" post="surveillance system, named InfluNet, coordinated by the National Influenza"/>
   <result pre="a clinical presentation of influenza-like illness (ILI) (15-17). The regional" exact="influenza" post="Laboratories perform isolations and antigenic characterizations of IVs during"/>
   <result pre="the target population, is the real reduction of effectiveness of" exact="influenza" post="vaccine on field. (19,25-28). The aim of this paper"/>
   <result pre="by analysis of virological surveillance data, performed by the regional" exact="influenza" post="reference Laboratory of Parma (29-31). Methods Respiratory specimens from"/>
   <result pre="in compliance with institutional guidelines (33-34). A representative number of" exact="influenza" post="laboratory-confirmed specimens and viral isolates, were sent to the"/>
   <result pre="analysis. Results During the study period, the reference Laboratory for" exact="influenza" post="virological surveillance of Emilia-Romagna, analysed 7882 nasal or throat"/>
   <result pre="the surveyed area, epidemiological trends observed in the first six" exact="influenza" post="seasons were quite similar and analogous to that of"/>
   <result pre="2017-2018 seasons, a clear shift was observed in epidemiological trend:" exact="influenza" post="activity started about four weeks in advance, with a"/>
   <result pre="from 2010-2011 to 2017-2018 season Table 2. Number (%) of" exact="influenza" post="virus positive by age groups and influenza season Flu"/>
   <result pre="Number (%) of influenza virus positive by age groups and" exact="influenza" post="season Flu season Age group (years) Results Flu negative"/>
   <result pre="398 (67.3%) 193 (32.7%) 591 Figure 2. Distribution (%) of" exact="influenza" post="positive samples by age group and by season (from"/>
   <result pre="match with seasonal vaccine strains (Table 3). Table 3. Circulating" exact="influenza" post="viruses in Emilia-Romagna vs vaccine strains from 2010-2011 to"/>
   <result pre="mismatch is highlighted) Season Trivalent vaccine composition (vaccine strains) Circulating" exact="influenza" post="viruses A/H1N1pdm09 A/H3N2 B (lineage) A/H1N1pdm09 A/H3N2 B (lineage)"/>
   <result pre="seasons a complete or nearly complete mismatch between the predominant" exact="influenza" post="B lineage and vaccine B lineage occurred. In 2015-2016"/>
   <result pre="this study we highlight that in none of the epidemic" exact="influenza" post="season full match was achieved. Probably the Health Technology"/>
   <result pre="fill the information gap in the setting of the new" exact="influenza" post="vaccine (48-55). This study also confirms the importance of"/>
   <result pre="(last accessed on 12 June 2019) 2PetrovaVNRussellCThe evolution of seasonal" exact="influenza" post="virusesNature Reviews Microbiology201816476029081496 3HortonKCDuegerELKandeeAAbdallatMEl-KholyAAl-AwaidySet al.Viral etiology, seasonality and severity"/>
   <result pre="the Eastern Mediterranean Region, 2007-2014PLoS ONE2017127e018095428704440 4PirallaALunghiGRuggieroLGirelloABianchiniSRovidaFet al.Molecular epidemiology of" exact="influenza" post="B virus among hospitalized pediatric patients in Northern Italy"/>
   <result pre="ONE20171210e018589329049310 5MertzDGeraciJWinkupJGessnerBDOrtizJRLoebMPregnancy as a risk factor for severe outcomes from" exact="influenza" post="virus infection: A systematic review and meta-analysis of observational"/>
   <result pre="observational studiesVaccine20173552152828024955 6SegaloffHEPetrieJGMaloshREChengCKMcSpaddenEJFerdinandsJMet al.Severe morbidity among hospitalized adults with acute" exact="influenza" post="and other respiratory infections; 2014–15 and 2015–16Epidemiol Infect2018146111350135829880077 7MaloshREMartinETOrtizJRMontoASThe"/>
   <result pre="2015–16Epidemiol Infect2018146111350135829880077 7MaloshREMartinETOrtizJRMontoASThe risk of lower respiratory tract infection following" exact="influenza" post="virus infection: A systematic and narrative reviewVaccine201836114114729157959 8IulianoADRoguskiKMChangHHMuscatelloDJPalekarRTempiaSet al.Estimates"/>
   <result pre="Stockholm, 2019Euro Surveill201924231900348 10NeumannGNodaTKawaokaYEmergence and pandemic potential of swine-origin H1N1" exact="influenza" post="virusNature20194597249931959 11RotaPAWallisTRHarmonMWRotaJSKendalAPNeromeKCocirculation of two distinct evolutionary lineages of influenza"/>
   <result pre="H1N1 influenza virusNature20194597249931959 11RotaPAWallisTRHarmonMWRotaJSKendalAPNeromeKCocirculation of two distinct evolutionary lineages of" exact="influenza" post="type B virus since 1983Virology1990175159682309452 12World Health Organization Global"/>
   <result pre="European Centre for Disease Prevention and Control (ECDC)National and global" exact="influenza" post="surveillance system and reportAvailable from: https://ecdc.europa.eu/en/seasonal-influenza/surveillance-and-disease-data/national-regional-global-reports (last accessed on"/>
   <result pre="from: http://www.salute.gov.it/portale/influenza/homeInfluenza.jsp (last accessed on 12 June 2019) 18BelongiaEASimpsonMDKingJPSundaramMEKelleyNSOsterholmMTet al.Variable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
   <result pre="design studiesLancet Infect Dis2016894295127061888 19EichnerMSchwehmMEichner, GerlierLDirect and indirect effects of" exact="influenza" post="vaccinationBMC Infectious Diseases201717130828441935 20KisslingEValencianoMLarrauriAOrosziBCohenJMNunesBet al.Low and decreasing vaccine effectiveness"/>
   <result pre="vaccinationBMC Infectious Diseases201717130828441935 20KisslingEValencianoMLarrauriAOrosziBCohenJMNunesBet al.Low and decreasing vaccine effectiveness against" exact="influenza" post="A(H3) in 2011/12 among vaccination target groups in Europe:"/>
   <result pre="the I-MOVE multicentre case–control studyEuro Surveill20131852039023399425 21ValencianoMKisslingETeamIEarly estimates of seasonal" exact="influenza" post="vaccine effectiveness in Europe: results from the I-MOVE multicentre"/>
   <result pre="multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against" exact="influenza" post="A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among"/>
   <result pre="effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched" exact="influenza" post="B among childrenInfluenza Other Respir Viruses201812442343729125681 24KisslingERoseAEmborgHDet al.European IVE"/>
   <result pre="childrenInfluenza Other Respir Viruses201812442343729125681 24KisslingERoseAEmborgHDet al.European IVE Group. Interim 2018/19" exact="influenza" post="vaccine effectiveness: six European studies, October 2018 to January"/>
   <result pre="1994-1997Annali di igiene: medicina preventiva e di comunità2000121713 30TanziMLAffanniPRizzieroSVeronesiLColucciMESurveillance of" exact="influenza" post="in a city of north Italy from 1997 to"/>
   <result pre="Medicine and Hygiene20044535156 31ChiapponiCEbranatiEParianiEFacciniSLuppiABaioniLet al.Genetic analysis of human and swine" exact="influenza" post="A viruses isolated in Northern Italy during 2010–2015Zoonoses Public"/>
   <result pre="34World Health Organization - WHO information for molecular diagnosis of" exact="influenza" post="virus – Publication date: July 2017Available from: http://www.who.int/influenza/gisrs_laboratory/molecular_diagnosis/en/ (last"/>
   <result pre="on 12 June 2019) 35collab: WHORecommendations on the composition of" exact="influenza" post="virus vaccinesAvailable from: https://www.who.int/influenza/vaccines/virus/recommendations/2018_19_north/en/ (last accessed on 12 June"/>
   <result pre="accessed on 12 June 2019) 36ParianiEAmendolaAPiattiAAnselmiGRanghiroABubbaLet al.Ten years (2004-2014) of" exact="influenza" post="surveillance in Northern ItalyHum Vaccin Immunother201511119820525483536 37ParianiEAmendolaAEbranatiERanghieroALaiAAnselmiGet al.Genetic drift"/>
   <result pre="influenza surveillance in Northern ItalyHum Vaccin Immunother201511119820525483536 37ParianiEAmendolaAEbranatiERanghieroALaiAAnselmiGet al.Genetic drift" exact="influenza" post="A(H3N2) virus hemagglutinin (HA) variants originated during the last"/>
   <result pre="season in Northern ItalyInfect Genet Evol20131325226023174527 38OrsiAColomba GMEPojeroFCalamusaGAlicinoCTrucchiCet al.Trends of" exact="influenza" post="B during the 2010–2016 seasons in 2 regions of"/>
   <result pre="and south Italy: The impact of the vaccine mismatch on" exact="influenza" post="immunisation strategyHum Vaccin Immunother201814352353128708953 39TramutoFOrsiAMaidaCMCostantinoCTrucchiCAlicinoCet al.The Molecular Epidemiology and"/>
   <result pre="February and March 2012Euro Surveill20121714 41KelvinDJFarooquiAExtremely low vaccine effectiveness against" exact="influenza" post="H3N2 in the elderly during the 2012/2013 flu seasonJ"/>
   <result pre="2017Euro Surveill201722143050628424146 43RondyMGherasimACasadoILaunayORizzoCPitigoiDet al.Low 2016/17 season vaccine effectiveness against hospitalised" exact="influenza" post="A(H3N2) among elderly: awareness warranted for 2017/18 seasonEuro Surveill2017224100645"/>
   <result pre="seasonEuro Surveill2017224100645 44CainiSSpreeuwenbergPKusznierzGFRudiJMOwenRPenningtonKet al.Global Influenza B Study group. Distribution of" exact="influenza" post="virus types by age using case-based global surveillance data"/>
   <result pre="twenty-nine countries, 1999-2014BMC Infect Dis201818126929884140 45SullivanSGPriceOHReganAKBurden, effectiveness and safety of" exact="influenza" post="vaccines in elderly, paediatric and pregnant populationsTherapeutic Advances in"/>
   <result pre="Advances in Vaccines and Immunotherapy20197116 46AngLWCuiLMakTMNgYLeoYSLeeVJMet al.Differential age-specific distribution of" exact="influenza" post="virus types and subtypes in tropical Singapore, 2011 to"/>
   <result pre="Singapore, 2011 to 2017J Med Virol20199181415142230927452 47LytrasTPantavouKMouratidouETsiodrasSMortality attributable to seasonal" exact="influenza" post="in Greece, 2013 to 2017: variation by type/subtype and"/>
   <result pre="the Health Technology Assessment approachVaccine200826131609161018289744 49SimonCKudahlUJSunJOlsenLRZhangGLReinherzELBrusicVFluKB: a knowledge-based system for" exact="influenza" post="vaccine target discovery and analysis of the immunological properties"/>
   <result pre="vaccine target discovery and analysis of the immunological properties of" exact="influenza" post="virusesJ Immunol Res201538097526504853 50RenXLiYLiuXShenXGaoWLiJComputational identification of antigenicity-associated sites in"/>
   <result pre="of antigenicity-associated sites in the hemagglutinin protein of A/H1N1 seasonal" exact="influenza" post="virusPLoS One20151050126742 51HswenYBrownsteinJSLiuJHawkinsJBUse of a Digital Health Application for"/>
   <result pre="influenza virusPLoS One20151050126742 51HswenYBrownsteinJSLiuJHawkinsJBUse of a Digital Health Application for" exact="influenza" post="surveillance in ChinaAm J Public Health201710771130113628520492 52DePasseJVNowalkMPSmithKJRaviottaJMShimEZimmermanRKet al.Does cost-effectiveness"/>
   <result pre="surveillance in ChinaAm J Public Health201710771130113628520492 52DePasseJVNowalkMPSmithKJRaviottaJMShimEZimmermanRKet al.Does cost-effectiveness of" exact="influenza" post="vaccine choice vary across the U.S.? An agent-based modeling"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7235449\results\search\disease\results.xml">
   <result pre="symptoms with other endemic mosquito-borne pathogens in the region, including" exact="chikungunya" post="virus, dengue virus and malaria, ONNV infections are often"/>
   <result pre="joint pathology. Concordantly, in vivo CD4+ T cell depletion, or" exact="suppression" post="with fingolimod, an FDA-approved immunomodulating drug, abrogated CD4+ T"/>
   <result pre="endemic infectious diseases with more pronounced, overlapping symptoms, such as" exact="chikungunya" post="virus (CHIKV), dengue virus (DENV) or malaria. ONNV has"/>
   <result pre="revealed the presence of marked muscle degeneration and necrosis, mild" exact="synovitis" post="at the synovium, and tenosynovitis around the tendon capsule"/>
   <result pre="muscle degeneration and necrosis, mild synovitis at the synovium, and" exact="tenosynovitis" post="around the tendon capsule (Figures 1D,E). There were also"/>
   <result pre="characterized by marked muscle degeneration and necrosis, mild synovitis, and" exact="tenosynovitis" post="around the tendon capsule of the infected joint. However,"/>
   <result pre="of such FDA-approved drugs, together with their wide usage against" exact="multiple sclerosis" post="and rheumatoid arthritis, respectively, highlights the interesting possibility of"/>
   <result pre="drugs, together with their wide usage against multiple sclerosis and" exact="rheumatoid arthritis," post="respectively, highlights the interesting possibility of repositioning immune-modulating drugs"/>
   <result pre="Dis. (1999) 180:1436–43. 10.1086/31507310515801 7.KamYWPokKYEngKETanLKKaurSLeeWWLet al.. Sero-prevalence and cross-reactivity of" exact="chikungunya" post="virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl"/>
   <result pre="56:166–72. 10.1016/0035-9203(62)90144-X14038061 9.LaBeaudADBandaTBrichardJMuchiriEMMungaiPLMutukuFMet al.. High rates of o'nyong nyong and" exact="chikungunya" post="virus transmission in coastal kenya. PLoS Negl Trop Dis."/>
   <result pre="12.KamY-WLeeWWLSimarmataDHarjantoSTengT-STolouHet al.. Longitudinal analysis of the human antibody response to" exact="chikungunya" post="virus infection: implications for serodiagnosis and vaccine development. J"/>
   <result pre="Inhibitors of alphavirus entry and replication identified with a stable" exact="chikungunya" post="replicon cell line and virus-based assays. PLoS ONE. (2011)"/>
   <result pre="assays. PLoS ONE. (2011) 6:e28923. 10.1371/journal.pone.002892322205980 14.ChanYTeoTUttATanJJAmrunSNAbu BakarFet al.. Mutating" exact="chikungunya" post="virus non-structural protein produces potent live-attenuated vaccine candidate. EMBO"/>
   <result pre="16.TeoTHLumFMClaserCLullaVLullaAMeritsAet al.. A pathogenic role for CD4+ T cells during" exact="chikungunya" post="virus infection in mice. J Immunol. (2013) 190:259–69. 10.4049/jimmunol.120217723209328"/>
   <result pre="arXiv. (2018) 3:180203426. 10.21105/joss.00861 20.HartimathSVDraghiciuOvan de WallSManuelliVDierckxRAJONijmanHWet al.Noninvasive monitoring of" exact="cancer" post="therapy induced activated t cells using [18f]fb-il-2 pet imaging."/>
   <result pre="[18f]fb-il-2 pet imaging. Oncoimmunology. (2017) 6:e124801410.1080/2162402X.2016.124801428197364 21.CarissimoGTorres-RuestaAChanY-HLeeBFongS-WChuaT-Ket al.. Viperin controls" exact="chikungunya" post="virus–specific pathogenic T cell IFNγ Th1 stimulation in mice."/>
   <result pre="Alliance. (2019) 2:e201900298. 10.26508/lsa.20190029830665948 22.TeoT-HHerZTanJJLLumFLeeWWLChanY-Het al.. Caribbean and la réunion" exact="chikungunya" post="virus isolates differ in their capacity to induce proinflammatory"/>
   <result pre="Virol. (2015) 89:7955–69. 10.1128/JVI.00909-1525995257 23.MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMet al.. A mouse model of" exact="chikungunya" post="virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
   <result pre="J Pathol. (2011) 178:32–40. 10.1016/j.ajpath.2010.11.01821224040 24.CarissimoGNgLFP. Understanding molecular pathogenesis with" exact="chikungunya" post="virus research tools. Curr Top Microbiol Immunol. (2019) 10.1007/82_2019_15830888547"/>
   <result pre="al.. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls" exact="chikungunya" post="virus arthritis. Sci Transl Med. (2017) 9:eaah3438. 10.1126/scitranslmed.aah343828148840 27.RowellJFGriffinDE."/>
   <result pre="encephalomyelitis. J Neuroimmunol. (2002) 127:106–14. 10.1016/S0165-5728(02)00108-X12044981 28.TeoTChanYLeeWWLLumFAmrunSNHerZet al.Fingolimod treatment abrogates" exact="chikungunya" post="virus-induced arthralgia. Sci Transl Med. (2017) 1333:1–12. 10.1126/scitranslmed.aal1333 29.SeymourRLRossiSLBergrenNAPlanteKSWeaverSC."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7235622\results\search\disease\results.xml">
   <result pre="are needed to address the dual substance use disorder and" exact="infectious disease" post="epidemics in US prisons OhringerAlison R.aohringer@med.miami.edua�?�EzerTamarbSerotaDavid P.a[a], [b], �?�Corresponding"/>
   <result pre="incarcerated [3]. Additionally, one-third of the 20,00,000+ incarcerated Americans have" exact="hepatitis" post="C virus (HCV) infection—and many are unaware of their"/>
   <result pre="among incarcerated people coalesce to drive the substance use and" exact="infectious disease" post="syndemic; in US prisons, harm reduction is an essential"/>
   <result pre="SEP began in Switzerland and quickly decreased transmission of HIV," exact="hepatitis" post="B, and hepatitis C. Prison-based SEPs have since been"/>
   <result pre="Switzerland and quickly decreased transmission of HIV, hepatitis B, and" exact="hepatitis" post="C. Prison-based SEPs have since been initiated in &amp;gt;60"/>
   <result pre="Justice Programs; 2016. [Accessed 2/13/2020 at https://www.bjs.gov/index.cfm?ty=kfdetail&amp;amp;iid=493]. 2CalifanoJ.JrBehind bars II:" exact="substance abuse" post="and America's prison population2010National Center on Addiction and Substance"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7236111\results\search\disease\results.xml">
   <result pre="women should be closely monitored to prevent the emergence of" exact="cervical cancer." post="Keywords HPV HIV Women Yaoundé Background Human papilloma viruses"/>
   <result pre="HPV genotypes are responsible for 95% of the occurrence of" exact="cervical cancer" post="in women [1]. Notably, HPV causes benign and malignant"/>
   <result pre="genotypes are responsible for 95% of the occurrence of cervical" exact="cancer" post="in women [1]. Notably, HPV causes benign and malignant"/>
   <result pre="isolated HR-HPV genotypes from cervical tumor biopsies [3, 4]. Indeed," exact="cervical cancer" post="is known to be a viro-induced neoplasm and that"/>
   <result pre="HR-HPV genotypes from cervical tumor biopsies [3, 4]. Indeed, cervical" exact="cancer" post="is known to be a viro-induced neoplasm and that"/>
   <result pre="4]. Indeed, cervical cancer is known to be a viro-induced" exact="neoplasm" post="and that HPV is the causal agent in 99%"/>
   <result pre="of cases [4]. According to the World Health Organization (WHO)," exact="cervical cancer" post="will kill more than 443,000 people worldwide each year"/>
   <result pre="cases [4]. According to the World Health Organization (WHO), cervical" exact="cancer" post="will kill more than 443,000 people worldwide each year"/>
   <result pre="and other risk factors further increase the burden of this" exact="cancer" post="[5, 6]. In SSA, HPV and HIV co-infection is"/>
   <result pre="commonly found and contributes to a rapid disease progression toward" exact="cervical cancer" post="[4]. Importantly, HIV-positive women, especially those who are severely"/>
   <result pre="found and contributes to a rapid disease progression toward cervical" exact="cancer" post="[4]. Importantly, HIV-positive women, especially those who are severely"/>
   <result pre="severely immunocompromised, are 5 times more likely to develop the" exact="cervical cancer" post="than their HIV-negative peers. Even though little is known"/>
   <result pre="immunocompromised, are 5 times more likely to develop the cervical" exact="cancer" post="than their HIV-negative peers. Even though little is known"/>
   <result pre="(22.9%) [12]. In Cameroon, out of 14,000 new cases of" exact="cancer" post="reported in 2016, cervical cancer occupied the second leading"/>
   <result pre="out of 14,000 new cases of cancer reported in 2016," exact="cervical cancer" post="occupied the second leading position of cancers among women"/>
   <result pre="of 14,000 new cases of cancer reported in 2016, cervical" exact="cancer" post="occupied the second leading position of cancers among women"/>
   <result pre="in the Cameroonian context and need to be depict among" exact="cervical cancer" post="cases, especially in the frame of HIV-infection [14, 20]."/>
   <result pre="the Cameroonian context and need to be depict among cervical" exact="cancer" post="cases, especially in the frame of HIV-infection [14, 20]."/>
   <result pre="low; the presence of other comorbidities or infections such as" exact="hepatitis" post="B, hepatitis C, and tuberculosis, could also affect the"/>
   <result pre="presence of other comorbidities or infections such as hepatitis B," exact="hepatitis" post="C, and tuberculosis, could also affect the immune status."/>
   <result pre="vaccine trials, would are needed to ensure effective prevention of" exact="cervical cancer" post="among HIV-infected women. Abbreviations AIDS Acquired immunodeficiency syndrome CD4"/>
   <result pre="trials, would are needed to ensure effective prevention of cervical" exact="cancer" post="among HIV-infected women. Abbreviations AIDS Acquired immunodeficiency syndrome CD4"/>
   <result pre="in adult women living in N’Djamena, ChadPLOS ONE2019146e021748610.1371/journal.pone.021748631158254 13.LyngeERygaardCBailletMV-PDuguéP-ASanderBBBondeJet al.Cervical" exact="cancer" post="screening at crossroadsAPMIS2014122866767310.1111/apm.1227925046198 14.Republic of Cameroon, Centre for the"/>
   <result pre="35.PikettyCDarraghTMDa CostaMBrunevalPHeardIKazatchkineMDet al.High prevalence of anal human papillomavirus infection and" exact="anal cancer" post="precursors among HIV-infected persons in the absence of anal"/>
   <result pre="CostaMBrunevalPHeardIKazatchkineMDet al.High prevalence of anal human papillomavirus infection and anal" exact="cancer" post="precursors among HIV-infected persons in the absence of anal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7236501\results\search\disease\results.xml">
   <result pre="does not comply with these terms. Abstract Hand, foot, and" exact="mouth disease" post="(HFMD) is a common viral illness affecting infants and"/>
   <result pre="potential application for clinical detection of CVA-16. hand foot and" exact="mouth disease" post="Coxsackievirus A16 polymerase spiral reaction isothermal nucleic acid testing"/>
   <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Hand, foot, and" exact="mouth disease" post="(HFMD) has long been a focus of global public"/>
   <result pre="CVA-16 was identified as our research focus. Hand, foot, and" exact="mouth disease" post="is sometimes difficult to diagnose based on its clinical"/>
   <result pre="the children had clinical symptoms of hand, foot, and skin" exact="rash" post="and oral herpes (Supplementary Table 1). Most children also"/>
   <result pre="× 103 + 40 0 − Discussion Hand, foot, and" exact="mouth disease" post="is a common childhood disease that is increasingly recognized"/>
   <result pre="induce erythematous, enanthem of the oral cavity, and acute viral" exact="cardiomyopathy" post="(Koh et al., 2016). Emerging HFMD has a huge"/>
   <result pre="epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with" exact="hand, foot and mouth disease" post="in Spain.Clin. Microbiol. Infect.20O150–O156. 10.1111/1469-0691.1236124033818 ChenM.HeS.YanQ.XuX.WuW.GeS.et al. (2017). Severe"/>
   <result pre="71, coxsackievirus A16 and A6 associated with hand, foot and" exact="mouth disease" post="in Spain.Clin. Microbiol. Infect.20O150–O156. 10.1111/1469-0691.1236124033818 ChenM.HeS.YanQ.XuX.WuW.GeS.et al. (2017). Severe"/>
   <result pre="disease in Spain.Clin. Microbiol. Infect.20O150–O156. 10.1111/1469-0691.1236124033818 ChenM.HeS.YanQ.XuX.WuW.GeS.et al. (2017). Severe" exact="hand, foot and mouth disease" post="associated with Coxsackievirus A10 infections in Xiamen. China in"/>
   <result pre="Microbiol. Infect.20O150–O156. 10.1111/1469-0691.1236124033818 ChenM.HeS.YanQ.XuX.WuW.GeS.et al. (2017). Severe hand, foot and" exact="mouth disease" post="associated with Coxsackievirus A10 infections in Xiamen. China in"/>
   <result pre="Chem.41293–101. 10.1007/s00216-019-02209-y31797016 HuangJ.LiaoQ.OoiM. H.CowlingB. J.ChangZ.WuP.et al. (2018). Epidemiology of recurrent" exact="hand, foot and mouth disease," post="China, 2008-2015.Emerg. Infect. Dis.24432–442. 10.3201/eid2403.17130329460747 KohW. M.BogichT.SiegelK.JinJ.ChongE. Y.TanC. Y.et"/>
   <result pre="H.CowlingB. J.ChangZ.WuP.et al. (2018). Epidemiology of recurrent hand, foot and" exact="mouth disease," post="China, 2008-2015.Emerg. Infect. Dis.24432–442. 10.3201/eid2403.17130329460747 KohW. M.BogichT.SiegelK.JinJ.ChongE. Y.TanC. Y.et"/>
   <result pre="10.3201/eid2403.17130329460747 KohW. M.BogichT.SiegelK.JinJ.ChongE. Y.TanC. Y.et al. (2016). The epidemiology of" exact="hand, foot and mouth disease" post="in asia: a systematic review and analysis.Pediatr. Infect. Dis."/>
   <result pre="Y.TanC. Y.et al. (2016). The epidemiology of hand, foot and" exact="mouth disease" post="in asia: a systematic review and analysis.Pediatr. Infect. Dis."/>
   <result pre="LiW.LiC.LiuL.LiuX.ShangS.MaoH.et al. (2019). Molecular epidemiology of enterovirus from children with" exact="herpangina" post="or hand, foot, and mouth disease in Hangzhou, 2016.Arch."/>
   <result pre="(2019). Molecular epidemiology of enterovirus from children with herpangina or" exact="hand, foot, and mouth disease" post="in Hangzhou, 2016.Arch. Virol.1642565–2571. 10.1007/s00705-019-04356-031321585 LiX. W.NiX.QianS. Y.WangQ.JiangR. M.XuW."/>
   <result pre="of enterovirus from children with herpangina or hand, foot, and" exact="mouth disease" post="in Hangzhou, 2016.Arch. Virol.1642565–2571. 10.1007/s00705-019-04356-031321585 LiX. W.NiX.QianS. Y.WangQ.JiangR. M.XuW."/>
   <result pre="al. (2018). Chinese guidelines for the diagnosis and treatment of" exact="hand, foot and mouth disease" post="(2018 edition).World J. Pediatr.14437–447. 10.1007/s12519-018-0189-830280313 LiY.ZhouY.ChengY.WuP.ZhouC.CuiP.et al. (2019). Effectiveness"/>
   <result pre="guidelines for the diagnosis and treatment of hand, foot and" exact="mouth disease" post="(2018 edition).World J. Pediatr.14437–447. 10.1007/s12519-018-0189-830280313 LiY.ZhouY.ChengY.WuP.ZhouC.CuiP.et al. (2019). Effectiveness"/>
   <result pre="al. (2019). Effectiveness of EV-A71 vaccination in prevention of paediatric" exact="hand, foot, and mouth disease" post="associated with EV-A71 virus infection requiring hospitalisation in Henan,"/>
   <result pre="of EV-A71 vaccination in prevention of paediatric hand, foot, and" exact="mouth disease" post="associated with EV-A71 virus infection requiring hospitalisation in Henan,"/>
   <result pre="coxsackievirus A16 and enterovirus 71 during a large outbreak of" exact="hand, foot, and mouth disease" post="in Central China.PLoS One9:e96051. 10.1371/journal.pone.009605124776922 Ljubin-SternakS.Slavic-VrzicV.Vilibic-CavlekT.AlerajB.Gjenero-MarganI. (2011). Outbreak of"/>
   <result pre="enterovirus 71 during a large outbreak of hand, foot, and" exact="mouth disease" post="in Central China.PLoS One9:e96051. 10.1371/journal.pone.009605124776922 Ljubin-SternakS.Slavic-VrzicV.Vilibic-CavlekT.AlerajB.Gjenero-MarganI. (2011). Outbreak of"/>
   <result pre="disease in Central China.PLoS One9:e96051. 10.1371/journal.pone.009605124776922 Ljubin-SternakS.Slavic-VrzicV.Vilibic-CavlekT.AlerajB.Gjenero-MarganI. (2011). Outbreak of" exact="hand, foot and mouth disease" post="caused by Coxsackie A16 virus in a childcare centre"/>
   <result pre="China.PLoS One9:e96051. 10.1371/journal.pone.009605124776922 Ljubin-SternakS.Slavic-VrzicV.Vilibic-CavlekT.AlerajB.Gjenero-MarganI. (2011). Outbreak of hand, foot and" exact="mouth disease" post="caused by Coxsackie A16 virus in a childcare centre"/>
   <result pre="(2018). Impact of meteorological factors on the incidence of childhood" exact="hand, foot, and mouth disease" post="(HFMD) analyzed by DLNMs-based time series approach.Infec. Dis. Poverty7:7."/>
   <result pre="meteorological factors on the incidence of childhood hand, foot, and" exact="mouth disease" post="(HFMD) analyzed by DLNMs-based time series approach.Infec. Dis. Poverty7:7."/>
   <result pre="BabuM.RaghavendraA.DhananjayaD.KumarS.MaiyaP. P. (2013). Non-polio enteroviruses and their association with acute" exact="diarrhea" post="in children in India.Infect. Genet. Evol.17153–161. 10.1016/j.meegid.2013.04.01123602838 RaoD. C.NaiduJ."/>
   <result pre="J.QiY.et al. (2012). Distribution of enteroviruses in hospitalized children with" exact="hand, foot and mouth disease" post="and relationship between pathogens and nervous system complications.Virol. J.9:8."/>
   <result pre="Distribution of enteroviruses in hospitalized children with hand, foot and" exact="mouth disease" post="and relationship between pathogens and nervous system complications.Virol. J.9:8."/>
   <result pre="al. (2017). Economic costs and health-related quality of life for" exact="hand, foot and mouth disease" post="(HFMD) patients in China.PLoS One12:e0184266. 10.1371/journal.pone.018426628934232"/>
   <result pre="costs and health-related quality of life for hand, foot and" exact="mouth disease" post="(HFMD) patients in China.PLoS One12:e0184266. 10.1371/journal.pone.018426628934232"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7236962\results\search\disease\results.xml">
   <result pre="Antimicrobials1476-0711BioMed CentralLondon pmcid: 7236962360 doi: 10.1186/s12941-020-00360-4 : Review Venezuelan equine" exact="encephalitis" post="virus: the problem is not over for tropical America"/>
   <result pre="in a credit line to the data. Abstract The equine" exact="encephalitis" post="viruses, Venezuelan (VEEV), East (EEEV) and West (WEEV), belong"/>
   <result pre="both, these infections are characterized by high viremia, rash, fever," exact="encephalitis" post="and death. VEEV encephalitis is similar, clinically, to other"/>
   <result pre="characterized by high viremia, rash, fever, encephalitis and death. VEEV" exact="encephalitis" post="is similar, clinically, to other arboviral diseases, such as"/>
   <result pre="Alphavirus Zoonoses Americas Funding Universidad de Cordoba Background Venezuelan equine" exact="encephalomyelitis" post="is caused by the Venezuelan equine encephalitis virus (VEEV)."/>
   <result pre="Background Venezuelan equine encephalomyelitis is caused by the Venezuelan equine" exact="encephalitis" post="virus (VEEV). Mosquito vectors transmit the virus, mainly affects"/>
   <result pre="the cytoplasm of the host. VEEV and other similar equine" exact="encephalitis" post="in America In addition to VEEV, Eastern equine encephalitis"/>
   <result pre="equine encephalitis in America In addition to VEEV, Eastern equine" exact="encephalitis" post="(EEEV), Western (WEEV) are frequent viral infections in the"/>
   <result pre="VEEV, cause symptoms ranging from mild febrile illness to severe" exact="encephalitis" post="that can lead to death [2]. As a result"/>
   <result pre="are no longer periodically severe epidemics of EEEV and WEEV" exact="encephalitis" post="(Fig. 1). However, sporadic cases and small outbreaks are"/>
   <result pre="populations [3, 4]. Fig. 1 Geographical distribution of the equine" exact="encephalitis" post="in the Americas. a VEEV. b EEEV. c WEEV"/>
   <result pre="EEEV of North America, the MADV, formerly known as equine" exact="encephalitis" post="of the South American East, was not associated with"/>
   <result pre="of equine deaths in Latin America. Epidemiology of Venezuelan equine" exact="encephalitis" post="The clinical manifestation of the disease was described as"/>
   <result pre="was isolated in 1938 from a horse that died of" exact="encephalitis" post="[1, 14, 15]. Subsequently, the virus was isolated in"/>
   <result pre="and epizootic serotypes. Within the group of alphaviruses that cause" exact="encephalitis" post="in Equidae and humans are the EEEV and WEEV,"/>
   <result pre="viruses [16, 17]. Encephalitis caused by VEEV is an emerging" exact="infectious disease" post="in Latin America [1, 18]. Outbreaks have been documented"/>
   <result pre="or influenza, and in reality, several epidemics of Venezuelan equine" exact="encephalitis" post="have been diagnosed in their initial stages as dengue."/>
   <result pre="that affect the central nervous system, ranging from drowsiness to" exact="encephalitis" post="with disorientation, seizures, coma, and death paralysis. The involvement"/>
   <result pre="outbreak. In Colombia, during 2011, there were four foci of" exact="encephalitis" post="in horses, three foci of Venezuelan equine encephalitis in"/>
   <result pre="foci of encephalitis in horses, three foci of Venezuelan equine" exact="encephalitis" post="in the departments of Córdoba and Magdalena, and a"/>
   <result pre="the departments of Córdoba and Magdalena, and a focus of" exact="eastern equine encephalitis" post="in the department of Casanare (Table 2). Additionally, there"/>
   <result pre="of Córdoba and Magdalena, and a focus of eastern equine" exact="encephalitis" post="in the department of Casanare (Table 2). Additionally, there"/>
   <result pre="minor in the municipality of Barrancabermeja, bordering Venezuela. Venezuelan equine" exact="encephalitis" post="has an epidemiological behavior of persistence with apparent epidemiological"/>
   <result pre="available for human use, such as is the case of" exact="yellow fever," post="Japanese encephalitis, and dengue. But for VEEV only vaccines"/>
   <result pre="be used to spread favorable traits through interbreeding populations of" exact="malaria" post="mosquitoes, still to be proved on Culex. Wolbachia is"/>
   <result pre="contacting the insecticide-treated netting [46]. Conclusions In conclusion, Venezuelan equine" exact="encephalitis" post="is a persistent zoonosis in Latin America through long"/>
   <result pre="they have no competing interests. References References 1.AguilarPVEstrada-FrancoJGNavarro-LopezRFerroCHaddowADWeaverSCEndemic Venezuelan equine" exact="encephalitis" post="in the Americas: hidden under the dengue umbrellaFuture Virol.20116672174021765860"/>
   <result pre="under the dengue umbrellaFuture Virol.20116672174021765860 2.JuarezDGuevaraCWileyMTorreAPalaciosGHalseyEet al.Isolation of complete equine" exact="encephalitis" post="virus genome from human swab specimenPeru Emerg Infect Dis20182481578158030016240"/>
   <result pre="during 2010: a cross-sectional study of household contacts during an" exact="encephalitis" post="outbreakAm J Trop Med Hyg20189861798180429737271 5.HahnCSLustigSStraussEGStraussJHWestern equine encephalitis virus"/>
   <result pre="during an encephalitis outbreakAm J Trop Med Hyg20189861798180429737271 5.HahnCSLustigSStraussEGStraussJHWestern equine" exact="encephalitis" post="virus is a recombinant virusProc Natl Acad Sci USA19888516599760013413072"/>
   <result pre="USA19888516599760013413072 6.NeiraMVMahmoodFReisenWKJamesCBRomoserWSComparative study of the pathological effects of western equine" exact="encephalomyelitis" post="virus in four strains of culex tarsalis coquillett (Diptera:"/>
   <result pre="Press39 9.CameronGDWWestern equine encephalitisCan J Public Health194233383387 10.CDC. Western equine" exact="encephalitis" post="virus neuroinvasive disease cases. Reported by State, 1964–2010. CDC."/>
   <result pre="Zika viruses RevMVZ Córdoba.201823Suppl69376941 14.KubesVRíosFAThe causative agent of infectious equine" exact="encephalomyelitis" post="in VenezuelaScience1939902323202117818578 15.RoncaSEDineleyKTPaesslerSNeurological sequelae resulting from encephalitic alphavirus infectionFront"/>
   <result pre="from encephalitic alphavirus infectionFront Microbiol.2016795927379085 16.VittorAYArmienBGonzalezPCarreraJPDominguezCValderramaAet al.Epidemiology of emergent Madariaga" exact="encephalitis" post="in a region with endemic venezuelan equine encephalitis: initial"/>
   <result pre="infection with neurovirulent and partially neurovirulent strains of Venezuelan equine" exact="encephalitis" post="virusBMC Infect Dis20171730928446152 19.ForresterNLWertheimJODuganVGAugusteAJLinDAdamsAPet al.Evolution and spread of Venezuelan"/>
   <result pre="virusBMC Infect Dis20171730928446152 19.ForresterNLWertheimJODuganVGAugusteAJLinDAdamsAPet al.Evolution and spread of Venezuelan equine" exact="encephalitis" post="complex alphavirus in the AmericasPLoS Negl Trop Dis.2017118e000569328771475 20.YunYGUdeniBRBalasuriyaRChong-kyoLZoonotic"/>
   <result pre="encephalitisVaccine.2009274D80D8519837294 22.MedinaGGarzaroDJBarriosMAugusteAJWeaverSCPujolFHGenetic diversity of venezuelan alphaviruses and circulation of a" exact="venezuelan equine encephalitis" post="virus subtype IAB strain during an interepizootic periodAm J"/>
   <result pre="diversity of venezuelan alphaviruses and circulation of a venezuelan equine" exact="encephalitis" post="virus subtype IAB strain during an interepizootic periodAm J"/>
   <result pre="excellent descriptions of the first documentation of endemic Venezuelan equine" exact="encephalitis" post="(VEE), as well as studies of equine virulence and"/>
   <result pre="(Melanoconion) taeniopus for equine-virulent subtype IE strains of Venezuelan equine" exact="encephalitis" post="virusAm J Trop Med Hyg20108261047105220519599 25.LordRDHistory and geographic distribution"/>
   <result pre="Am Health Organ1974821001104604536 26.Mesa FA, Cárdenas JA, Villamil LC. Las" exact="encephalitis" post="equinas en la salud pública. Universidad Nacional de Colombia"/>
   <result pre="Medicina Veterinaria y de Zootecnia. 2005; 74. http://www.col.ops-oms.org/prevencion/encefalitis/libro_encefalitis.pdf. 27.QuirozEAguilarPVCisnerosJTeshRBWeaverSCVenezuelan equine" exact="encephalitis" post="in Panama: fatal endemic disease and genetic diversity of"/>
   <result pre="virus (‘Bijou Bridge’ strain), a member of the Venezuelan equine" exact="encephalomyelitis" post="virus complex, from cliff swallow nest bugs (Oeciacus vicarius)"/>
   <result pre="al.Enzootic activity of pixuna and Rio Negro viruses (Venezuelan equine" exact="encephalitis" post="complex) in a neotropical region of ArgentinaVector Borne Zoonotic"/>
   <result pre="TrinidadZoonoses Public Health.2015621536024751420 31.Sotomayor-BonillaJAbellaCChavesA�?lvarezPRico-ChávezOIbáñezSPotential sympatric vectors and mammalian hosts of" exact="venezuelan equine encephalitis" post="virus in Southern MexicoJ Wildl Dis201753365766128384059 32.PoddarSHydeJLGormanMJFarzanMDiamondMSThe interferon-stimulated gene"/>
   <result pre="Health.2015621536024751420 31.Sotomayor-BonillaJAbellaCChavesA�?lvarezPRico-ChávezOIbáñezSPotential sympatric vectors and mammalian hosts of venezuelan equine" exact="encephalitis" post="virus in Southern MexicoJ Wildl Dis201753365766128384059 32.PoddarSHydeJLGormanMJFarzanMDiamondMSThe interferon-stimulated gene"/>
   <result pre="33.LondonWTLevittNHKentSGWongVSeverJLCongenital cerebral and ocular malformations induced in rhesus monkeys by" exact="venezuelan equine encephalitis" post="virusTeratology.197716285296413204 34.ZacksMAPaesslerSEncephalitic alphavirusesVet Microbiol201014028128619775836 35.GuerboisMVolkovaEForresterNLRossiSLFrolovIWeaverSCet al.IRES-driven expression of the"/>
   <result pre="and ocular malformations induced in rhesus monkeys by venezuelan equine" exact="encephalitis" post="virusTeratology.197716285296413204 34.ZacksMAPaesslerSEncephalitic alphavirusesVet Microbiol201014028128619775836 35.GuerboisMVolkovaEForresterNLRossiSLFrolovIWeaverSCet al.IRES-driven expression of the"/>
   <result pre="Microbiol201014028128619775836 35.GuerboisMVolkovaEForresterNLRossiSLFrolovIWeaverSCet al.IRES-driven expression of the capsid protein of the" exact="venezuelan equine encephalitis" post="virus TC-83 vaccine strain increases its attenuation and safetyPLoS"/>
   <result pre="al.IRES-driven expression of the capsid protein of the venezuelan equine" exact="encephalitis" post="virus TC-83 vaccine strain increases its attenuation and safetyPLoS"/>
   <result pre="36.GrootHVenezuelan encephalitis. The health and economic impact of Venezuelan equine" exact="encephalitis" post="(VEE)Pan Am Health Organ.1972243716 37.AguilarPVGreeneIPCoffeyLLMedinaGMoncayoACAnishchenkoMet al.Endemic Venezuelan equine encephalitis"/>
   <result pre="equine encephalitis (VEE)Pan Am Health Organ.1972243716 37.AguilarPVGreeneIPCoffeyLLMedinaGMoncayoACAnishchenkoMet al.Endemic Venezuelan equine" exact="encephalitis" post="in Northern PeruEmerg Infect Dis200410588088815200823 38.SudiaWDLordRDNewhouseVFMillerDLKisslingREVector–host studies of an"/>
   <result pre="Infect Dis200410588088815200823 38.SudiaWDLordRDNewhouseVFMillerDLKisslingREVector–host studies of an epizootic of Venezuelan equine" exact="encephalomyelitis" post="in Guatemala, 1969Am J Epidemiol19719321371435101139 39.HinmanARMcGowanJEHendersonBEVenezuelan equine encephalomyelitis: surveys"/>
   <result pre="J Epidemiol19719321301365101138 40.ObersteMSWeaverSCWattsDMSmithJFIdentification and genetic analysis of Panama-genotype Venezuelan equine" exact="encephalitis" post="virus subtype ID in PeruAm J Trop Med Hyg199858141469452290"/>
   <result pre="and the Pan American Health OrganizationThe problem of Venezuelan equine" exact="encephalitis" post="in Mexico19706122 42.ZarateMChangREArbovirus and arbovirosis in MexicoVeterinary Sciences (Spanish"/>
   <result pre="encephalitisVeterinary sciences (Spanish version)1976MexicoVeterinary School UNAM163194 44.RivasFDíazLACárdenasVMDazaEBruzonLAlcalaAet al.Epidemic Venezuelan equine" exact="encephalitis" post="in La GuajiraColombia. J Infect Dis.199717548288329086137 45.Suárez Agudelo �?ngela"/>
   <result pre="Trop Dis.2020141e000783131945061 47.GonzaloSotomayor CA study of the virus of equine" exact="encephalomyelitis" post="in EcuadorJ Am Vet Med Assoc194610983747848020274660 48.GrootHKerrJASanmartinCVidalesHAntibodies to yellow"/>
   <result pre="equine encephalomyelitis in EcuadorJ Am Vet Med Assoc194610983747848020274660 48.GrootHKerrJASanmartinCVidalesHAntibodies to" exact="yellow fever" post="and other arthropod-borne viruses in human residents of San"/>
   <result pre="117518913637316 49.Sanmartin-BarberiCGrootHOsorno-MesaEHuman epidemic in Colombia caused by the Venezuelan equine" exact="encephalomyelitis" post="virusAm J Trop Med Hyg19543228329313138831 50.KinneyRMTsuchiyaKRSneiderJMTrentDWMolecular evidence for the"/>
   <result pre="50.KinneyRMTsuchiyaKRSneiderJMTrentDWMolecular evidence for the origin of the widespread Venezuelan equine" exact="encephalitis" post="epizootic of 1969 to 1972J Gen Virol19927312330133051469368 51.Reta-PetterssonGInternational Round"/>
   <result pre="51.Reta-PetterssonGInternational Round Table on VEE. The problem of Venezuelan equine" exact="encephalitis" post="in Mexico1970MexicoMexican Ministry of Agriculture and Livestock and the"/>
   <result pre="52.GrootHVenezuelan Encephalitis. The health and economic impact of Venezuelan equine" exact="encephalitis" post="(VEE)1972WashingtonPan Am Health Organ716 53.RivasFDiazLACardenasVMDazaEBruzonLAlcalaAet al.Epidemic Venezuelan equine encephalitis"/>
   <result pre="equine encephalitis (VEE)1972WashingtonPan Am Health Organ716 53.RivasFDiazLACardenasVMDazaEBruzonLAlcalaAet al.Epidemic Venezuelan equine" exact="encephalitis" post="in La Guajira, Colombia. Excellent epidemiological study of the"/>
   <result pre="Dis199717548288329086137 54.Gonzalez-SalazarDEstrada-FrancoJGCarraraASAronsonJFWeaverSCEquine amplification and virulence of subtype IE Venezuelan equine" exact="encephalitis" post="viruses isolated during the 1993 and 1996 Mexican epizooticsEmerg"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7237041\results\search\disease\results.xml">
   <result pre="Immunity : Medicine and Health Sciences : Immunology: Immunity Eliminating" exact="yellow fever" post="epidemics in Africa: Vaccine demand forecast and impact modelling"/>
   <result pre="Vaccine demand forecast and impact modelling Modelling the elimination of" exact="yellow fever" post="epidemics in africa http://orcid.org/0000-0001-6462-7185JeanKévinData curationFormal analysisMethodologySoftwareValidationVisualizationWriting – original draftWriting"/>
   <result pre="campaigns are begun or continued with the aim to eliminate" exact="yellow fever" post="(YF) epidemics in several countries, estimating disease burden and"/>
   <result pre="current international strategy to counter the increasing global risk of" exact="yellow fever." post="Funding The Bill &amp;amp; Melinda Gates Foundation (grant numbers"/>
   <result pre="fig-count: table-count: page-count: Data Availability Data on presence of any" exact="yellow fever" post="report between 1984 and 2013 used in the main"/>
   <result pre="Recent outbreaks in Angola, Nigeria and Brazil have shown that" exact="yellow fever" post="(YF) remains a significant public health threat [1,2]. The"/>
   <result pre="significant public health threat [1,2]. The epidemics of Zika and" exact="chikungunya" post="in Latin America have also highlighted the risks of"/>
   <result pre="the model. A: presence (red) or absence (white) of any" exact="yellow fever" post="report between 1984 and 2013. B: Location, sample size"/>
   <result pre="both model variants. Fig 4 Estimated 2017 incidence of severe" exact="yellow fever" post="infection per 100,000 persons across 34 African countries. A:"/>
   <result pre="with no or maximized herd effects, respectively. The reality of" exact="yellow fever" post="transmission probably lies within these bounds. Better understanding the"/>
   <result pre="[18]. Secondly, the symptoms associated with mild or even severe" exact="yellow fever" post="infections are wide and non-specific. This leads to cases"/>
   <result pre="leads to cases being frequently confused with severe malaria, leptospirosis," exact="viral hepatitis" post="or infections with other flaviviruses. Thirdly, our under-reporting estimates"/>
   <result pre="to cases being frequently confused with severe malaria, leptospirosis, viral" exact="hepatitis" post="or infections with other flaviviruses. Thirdly, our under-reporting estimates"/>
   <result pre="Supporting information S1 Table Presence or absence of any reported" exact="yellow fever" post="event between 1984 and 2013 at the first sub-national"/>
   <result pre="data file. S1 Fig Observed versus predicted presence/absence of any" exact="yellow fever" post="reported event between 1984 and 2013. A: Presence (red)"/>
   <result pre="Click here for additional data file. S5 Fig Comparison of" exact="yellow fever" post="burden estimates over time between both model versions across"/>
   <result pre="Click here for additional data file. S6 Fig Comparison of" exact="yellow fever" post="burden estimates over time between both model versions across"/>
   <result pre="28429585 6KraemerMUG, FariaNR, ReinerRC, GoldingN, NikolayB, StasseS, et al.Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
   <result pre="Infect Dis. 201610.1016/S1473-3099(16)30513-828017559 7ZhaoS, StoneL, GaoD, HeD. Modelling the large-scale" exact="yellow fever" post="outbreak in Luanda, Angola, and the impact of vaccination."/>
   <result pre="2018;12: e000615810.1371/journal.pntd.000615829338001 8RogersDJ, WilsonAJ, HaySI, GrahamAJ. The global distribution of" exact="yellow fever" post="and dengue. Adv Parasitol. 2006;62: 181–220. 10.1016/S0065-308X(05)62006-416647971 9GarskeT, Van"/>
   <result pre="BradyOJ, KraemerMUG, et al.Existing and potential infection risk zones of" exact="yellow fever" post="worldwide: a modelling analysis. Lancet Glob Health. 2018;010.1016/S2214-109X(18)30024-X29398634 11World"/>
   <result pre="de JesusJG, AguiarRS, IaniFCM, et al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potential. Science. 2018; eaat7115. 10.1126/science.aat711530139911 13MonathTP, VasconcelosPFC."/>
   <result pre="FergusonN, et al.POLICI: A web application for visualising and extracting" exact="yellow fever" post="vaccination coverage in Africa. Vaccine. 2019;37: 1384–1388. 10.1016/j.vaccine.2019.01.07430770224 16JeanK,"/>
   <result pre="10.4269/ajtmh.16-040127928091 17GotuzzoE, YactayoS, CórdovaE. Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: systematic review on the need for a booster"/>
   <result pre="18JohanssonMA, VasconcelosPFC, StaplesJE. The whole iceberg: estimating the incidence of" exact="yellow fever" post="virus infection from the number of severe cases. Trans"/>
   <result pre="349–359. 22KwagonzaL, MasiiraB, Kyobe-BosaH, KadoberaD, AtuheireEB, LubwamaB, et al.Outbreak of" exact="yellow fever" post="in central and southwestern Uganda, February-may 2016. BMC Infect"/>
   <result pre="2016. BMC Infect Dis. 2018;18: 54810.1186/s12879-018-3440-y30390621 23BagcchiS. Looking back at" exact="yellow fever" post="in Angola. Lancet Infect Dis. 2017;17: 269–270. 10.1016/S1473-3099(17)30064-628244394 24GaythorpeKAM,"/>
   <result pre="269–270. 10.1016/S1473-3099(17)30064-628244394 24GaythorpeKAM, JeanK, CibrelusL, GarskeT. Quantifying model evidence for" exact="yellow fever" post="transmission routes in Africa. PLOS Comput Biol. 2019;15: e100735510.1371/journal.pcbi.100735531545790"/>
   <result pre="911–916. 10.1093/cid/cir00721427399 27ShearerFM, MoyesCL, PigottDM, BradyOJ, MarinhoF, DeshpandeA, et al.Global" exact="yellow fever" post="vaccination coverage from 1970 to 2016: an adjusted retrospective"/>
   <result pre="KerkhoveMV, et al.The seasonal influence of climate and environment on" exact="yellow fever" post="transmission across Africa. PLoS Negl Trop Dis. 2018;12: e000628410.1371/journal.pntd.000628429543798"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7238209\results\search\disease\results.xml">
   <result pre="on humans and animals. Malaria is considered the most important" exact="parasitic disease" post="of human beings and is currently endemic and transmitted"/>
   <result pre="S1), and cause various clinical manifestations (25 million men with" exact="hydrocele" post="and over 15 million people with lymphoedema) and at"/>
   <result pre="disease manifestations [26]. However, it is clear that eliminating lymphatic" exact="filariasis" post="is not possible without controlling their vectors. Dengue virus"/>
   <result pre="by four distinct serotypes. Currently, it is the predominant arthropod-borne" exact="viral disease" post="affecting humans [27], with 3.6 billion people living in"/>
   <result pre="areas at risk of transmission and hundreds of millions of" exact="dengue fever" post="cases reported each year [28,29], causing ongoing epidemics in"/>
   <result pre="health. Chikungunya virus (CHIKV): Togaviridae is the causal agent of" exact="chikungunya" post="fever (CHIKF) (Figure 1), known for producing an antalgic"/>
   <result pre="previous outbreaks continue to be identified [52]. The St. Louis" exact="encephalitis" post="virus was the major cause of epidemic encephalitis by"/>
   <result pre="St. Louis encephalitis virus was the major cause of epidemic" exact="encephalitis" post="by an arbovirus in the USA [53]. It is"/>
   <result pre="The debate regarding dichlorodiphenyltrichloroethane (DDT) use for prevention, especially for" exact="malaria" post="control, is polarised because it saved millions of lives"/>
   <result pre="In 2006, the WHO reaffirmed the importance of IRS for" exact="malaria" post="transmission control, which was supported by the President’s Malaria"/>
   <result pre="Mediterranean region seem to have led to the elimination of" exact="malaria" post="[74]. New formulations could last between five and eight"/>
   <result pre="results were observed with a decrease in the incidence of" exact="dengue fever" post="after a large emergency vector-control campaign included several space"/>
   <result pre="one of the most successful mosquito control tools, especially for" exact="malaria" post="prevention [85]. ITNs with synthetic pyrethroid insecticides either incorporated"/>
   <result pre="around their fibres have resulted in a considerable decline in" exact="malaria" post="morbidity and mortality in several countries, especially in sub-Saharan"/>
   <result pre="their use [86,87]. LLINs have contributed to the reduction in" exact="malaria" post="over the past 15 years, combined with other new"/>
   <result pre="led to a dramatic reduction (97%) in the prevalence of" exact="malaria" post="compared to a group of LLIN non-users [92]. 3.4."/>
   <result pre="such as Cx. quinquefasciatus, Ae. albopictus, and anopheline species, including" exact="malaria" post="vectors such as An. gambiae and An. coluzzii but"/>
   <result pre="that Wolbachia inhibits the transmission of CHIKV [155], YFV [156]," exact="malaria" post="parasites in An. stephensi [157] and An. gambiae [158],"/>
   <result pre="and associated with biological control programmes in countries suffering from" exact="malaria" post="and arbovirus outbreaks. 5.4. Asaia To make malaria vectors"/>
   <result pre="suffering from malaria and arbovirus outbreaks. 5.4. Asaia To make" exact="malaria" post="vectors inefficient, interruption of the cycle within the vector"/>
   <result pre="which would be beneficial if applied toward achieving paratransgenesis against" exact="malaria" post="[165]. Advanced studies recently showed that Asaia may activate"/>
   <result pre="immune system, leading to a reduction in the development of" exact="malaria" post="parasites [171]. In the future, additional assets to which"/>
   <result pre="as toxic encephalopathy, seizures, acute manic psychosis, cardiovascular toxicity, and" exact="dermatitis" post="[181], as well as potential resistance that has become"/>
   <result pre="study [206]. Although it has been tested widely for controlling" exact="malaria" post="vectors [207,208,209,210], no laboratory or field resistance has been"/>
   <result pre="Control Consortium (IVCC) has released new product classes, especially for" exact="malaria" post="eradication, and manages international efforts to establish new methods,"/>
   <result pre="as well as their potential use as biological alternatives in" exact="dengue fever" post="control has been highlighted [218]. Auto-dissemination is a phenomenon"/>
   <result pre="to chemical insecticides [226]. When tested, they were effective against" exact="malaria" post="vectors and several other important mosquito species, such as"/>
   <result pre="be a component of integrated mosquito control programmes in lymphatic" exact="filariasis" post="endemic countries [229]. 7.4. Acoustic Larvicides and Traps These"/>
   <result pre="arachno-entomology are urgently neededParasitol. Res.201211025926510.1007/s00436-011-2480-721732184 6.HubálekZ.HalouzkaJ.West Nile fever—A reemerging mosquito-borne" exact="viral disease" post="in EuropeEmerg. Infect. Dis.1999564365010.3201/eid0505.99050510511520 7.VilaM.HulmeP.E.Impact of Biological Invasions on"/>
   <result pre="Dis.201711e000562510.1371/journal.pntd.000562528727779 10.Toledo MarrelliM.Barretto Bruno WILKEA.Toledo MarrelliM.Genetic Control of Mosquitoes: Population" exact="suppression" post="strategiesRev. Inst. Med. Trop. São Paulo20125428729222983293 11.BenelliG.BeierJ.C.Current vector control"/>
   <result pre="role of mosquitoes in the transmission of Malayan and bancroftian" exact="filariasis" post="in JapanBull. World Health Organ.19622758559413940117 14.BarrettoA.WilkeB.Toledo MarrelliM.Paratransgenesis: A promising"/>
   <result pre="populationsPLoS ONE201813e020367310.1371/journal.pone.020367330208075 18.AmatoR.PearsonR.D.Almagro-GarciaJ.AmaratungaC.LimP.SuonS.SrengS.DruryE.StalkerJ.MiottoO.et al.Origins of the current outbreak of multidrug-resistant" exact="malaria" post="in southeast Asia: A retrospective genetic studyLancet Infect. Dis.20181833734510.1016/S1473-3099(18)30068-929398391"/>
   <result pre="with 5.7 million infected this yearBMJ201936610.1136/bmj.l5104 20.EricksonS.M.ThomsenE.K.KevenJ.B.VincentN.KoimbuG.SibaP.M.ChristensenB.M.ReimerL.J.Mosquito-parasite interactions can shape" exact="filariasis" post="transmission dynamics and impact elimination programsPLoS Negl. Trop. Dis.20137e243310.1371/journal.pntd.000243324069488"/>
   <result pre="uniformis are vectors in the transmission of Wuchereria bancrofti lymphatic" exact="filariasis" post="in GhanaParasit. Vectors201258910.1186/1756-3305-5-8922564488 23.JosephH.MoloneyJ.MaiavaF.McClintockS.LammieP.MelroseW.First evidence of spatial clustering of"/>
   <result pre="in GhanaParasit. Vectors201258910.1186/1756-3305-5-8922564488 23.JosephH.MoloneyJ.MaiavaF.McClintockS.LammieP.MelroseW.First evidence of spatial clustering of lymphatic" exact="filariasis" post="in an Aedes polynesiensis endemic areaActa Trop.2011120S39S4710.1016/j.actatropica.2010.12.00421172296 24.SouthgateB.A.BryanJ.H.Factors affecting"/>
   <result pre="epidemiological significanceTrans. R Soc. Trop. Med. Hyg.19928652353010.1016/0035-9203(92)90096-U1475823 25.WadaY.Vector mosquitoes of" exact="filariasis" post="in JapanTrop. Med. Health201139394522028600 26.Lymphatic FilariasisAvailable online: https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis(accessed on"/>
   <result pre="unmet needs, and research prioritiesLancet Infect. Dis.201717e88e10010.1016/S1473-3099(16)30473-X28185868 30.Villamil-GómezW.E.Rodríguez-MoralesA.J.Uribe-GarcíaA.M.González-ArismendyE.CastellanosJ.E.CalvoE.P.�?lvarez-MonM.MussoD.Zika, dengue, and" exact="chikungunya" post="co-infection in a pregnant woman from ColombiaInt. J. Infect."/>
   <result pre="the Pacific areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 39.EdingtonF.VarjãoD.MeloP.Incidence of articular pain and" exact="arthritis" post="after chikungunya fever in the Americas: A systematic review"/>
   <result pre="areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 39.EdingtonF.VarjãoD.MeloP.Incidence of articular pain and arthritis after" exact="chikungunya" post="fever in the Americas: A systematic review of the"/>
   <result pre="FeverStatPearlsTampa/St. Petersburg, FL, USA2018 46.NwachukwuW.E.YusuffH.NwangwuU.OkonA.OgunniyiA.Imuetinyan-ClementJ.BesongM.Ayo-AjayiP.NikauJ.BabaA.et al.The response to re-emergence of" exact="yellow fever" post="in Nigeria, 2017Int. J. Infect. Dis.20209218919610.1016/j.ijid.2019.12.03431935537 47.collab: WHOYellow Fever—NigeriaWHOGeneva,"/>
   <result pre="Infect. Dis.20209218919610.1016/j.ijid.2019.12.03431935537 47.collab: WHOYellow Fever—NigeriaWHOGeneva, Switzerland2019 48.SilvaN.I.O.SacchettoL.De RezendeI.M.TrindadeG.D.S.LabeaudA.D.De ThoisyB.DrumondB.P.Recent sylvatic" exact="yellow fever" post="virus transmission in Brazil: The news from an old"/>
   <result pre="The news from an old diseaseVirol. J.202017910.1186/s12985-019-1277-731973727 49.AugusteA.J.LemeyP.BergrenN.A.GiambalvoD.MoncadaM.MorónD.HernandezR.NavarroJ.-C.WeaverS.C.Enzootic transmission of" exact="yellow fever" post="virus, VenezuelaEmerg. Infect. Dis.2015219910210.3201/eid2101.14081425531105 50.SelemaneI.Epidemiological monitoring of the last"/>
   <result pre="VenezuelaEmerg. Infect. Dis.2015219910210.3201/eid2101.14081425531105 50.SelemaneI.Epidemiological monitoring of the last outbreak of" exact="yellow fever" post="in Brazil—An outlook from PortugalTravel Med. Infect. Dis.201928465110.1016/j.tmaid.2018.12.00830583006 51.SolomonT.HombachJ.JacobsonJ.HokeC.MarfinA.CampbellG.GinsburgA.FischerM.TsaiT.HillsS.et"/>
   <result pre="A Systematic ReviewBull. World Health Organ.20118976677422084515 52.FangY.ZhangY.ZhouZ.B.XiaS.ShiW.Q.XueJ.B.LiY.Y.WuJ.T.New strains of Japanese" exact="encephalitis" post="virus circulating in Shanghai, China after a ten-year hiatus"/>
   <result pre="Vectors2019122210.1186/s13071-018-3267-930626442 53.GriesemerS.B.KramerL.D.Van SlykeG.A.PataJ.D.GoharaD.W.CameronC.E.CiotaA.T.Mutagen resistance and mutation restriction of St. Louis" exact="encephalitis" post="virusJ. Gen. Virol.20179820121110.1099/jgv.0.00068228284278 54.DiazA.CoffeyL.L.Burkett-CadenaN.DayJ.F.Reemergence of St. Louis encephalitis virus"/>
   <result pre="St. Louis encephalitis virusJ. Gen. Virol.20179820121110.1099/jgv.0.00068228284278 54.DiazA.CoffeyL.L.Burkett-CadenaN.DayJ.F.Reemergence of St. Louis" exact="encephalitis" post="virus in the AmericasEmerg. Infect. Dis.2018242150215710.3201/eid2412.180372 55.Castillo-OlivaresJ.WoodJ.West Nile virus"/>
   <result pre="J. Infect. Dis.20076027127917881866 84.GuilletP.AlnwickD.ChamM.K.NeiraM.ZaimM.HeymannD.MukelabaiK.Long-lasting treated mosquito nets: A breakthrough in" exact="malaria" post="preventionBull. World Health Organ.20017999811693984 85.YangG.G.KimD.PhamA.PaulC.J.A meta-regression analysis of the"/>
   <result pre="85.YangG.G.KimD.PhamA.PaulC.J.A meta-regression analysis of the effectiveness of mosquito nets for" exact="malaria" post="control: The value of long-lasting insecticide netsInt. J. Environ."/>
   <result pre="long-lasting insecticide netsInt. J. Environ. Res. Public Health20181511210.3390/ijerph15030546 86.RowlandM.WebsterJ.SalehP.ChandramohanD.FreemanT.PearcyB.DurraniN.RabA.MohammedN.Prevention of" exact="malaria" post="in Afghanistan through social marketing of insecticide-treated nets: Evaluation"/>
   <result pre="the use and efficacy of long lasting insecticidal net on" exact="malaria" post="infection during the first trimester of pregnancy—A pre-conceptional cohort"/>
   <result pre="al.Field evaluation of permethrin long-lasting insecticide treated nets (Olyset®) for" exact="malaria" post="control in an endemic area, southeast of IranActa Trop.201212314615310.1016/j.actatropica.2012.04.00422579798"/>
   <result pre="of genetically modified mosquitoes (Anopheles species) in the control of" exact="malaria" post="transmissionAsian J. Biotechnol. Genet. Eng.20181116 104.MeghaniZ.BoëteC.Genetically engineered mosquitoes, Zika"/>
   <result pre="comparisons of pyriproxyfen, polystyrene beads and other larvicidal methods against" exact="malaria" post="vectors in Sri LankaActa Trop.20028121122310.1016/S0001-706X(01)00208-X11835898 138.AnsariM.A.RazdanR.K.SreehariU.Laboratory and field evaluation"/>
   <result pre="Trop. Dis.201610e000467710.1371/journal.pntd.000467727124663 156.Van den HurkA.F.Hall-MendelinS.PykeA.T.FrentiuF.D.McElroyK.DayA.HiggsS.O’NeillS.L.Impact of Wolbachia on infection with" exact="chikungunya" post="and yellow fever viruses in the mosquito vector Aedes"/>
   <result pre="156.Van den HurkA.F.Hall-MendelinS.PykeA.T.FrentiuF.D.McElroyK.DayA.HiggsS.O’NeillS.L.Impact of Wolbachia on infection with chikungunya and" exact="yellow fever" post="viruses in the mosquito vector Aedes aegyptiPLoS Negl. Trop."/>
   <result pre="10.1371/journal.pone.0143541(accessed on 20 April 2020)10.1371/journal.pone.014354126636338 164.WangS.Jacobs-LorenaM.Genetic approaches to interfere with" exact="malaria" post="transmission by vector mosquitoesTrends Biotechnol.20133118519310.1016/j.tibtech.2013.01.00123395485 165.RamiA.RazA.ZakeriS.Dinparast DjadidN.Isolation and identification"/>
   <result pre="of Asaia sp. in Anopheles spp. mosquitoes collected from Iranian" exact="malaria" post="settings: Steps toward applying paratransgenic tools against malariaParasit Vectors20181136710.1186/s13071-018-2955-929950179"/>
   <result pre="Natl. Acad. Sci. USA20071049047905110.1073/pnas.061045110417502606 168.DamianiC.RicciI.CrottiE.RossiP.RizziA.ScuppaP.EspositoF.BandiC.DaffonchioD.FaviaG.Paternal transmission of symbiotic bacteria in" exact="malaria" post="vectorsCurr. Biol.200818R1087R108810.1016/j.cub.2008.10.04019081038 169.NugapolaN.W.N.P.De SilvaW.A.P.P.KarunaratneS.H.P.P.Distribution and phylogeny of Wolbachia strains"/>
   <result pre="temephos larvicides for control of Anopheles spp. in an endemic" exact="malaria" post="region of southern MexicoParasit. Vectors201475510.1186/1756-3305-7-5524479683 180.PrabhuK.MuruganK.NareshkumarA.BragadeeswaranS.Larvicidal and pupicidal activity"/>
   <result pre="reveals differences in repellent sensitivity between Southeast Asian vectors of" exact="malaria" post="and arbovirusesPLoS Negl. Trop. Dis.20148e332610.1371/journal.pntd.000332625522134 186.CarrollS.P.Prolonged efficacy of IR3535"/>
   <result pre="trial of attractive toxic sugar bait (ATSB) plant-spraying methods against" exact="malaria" post="vectors in the Anopheles gambiae complex in Mali, West"/>
   <result pre="Parasitol.19733323924710.1016/0014-4894(73)90030-14706114 226.AbagliA.Z.AlavoT.B.PlatzerE.G.Efficacy of the insect parasitic nematode, Romanomermis iyengari, for" exact="malaria" post="vector control in Benin West AfricaMalar. J.201211P510.1186/1475-2875-11-S1-P5 227.PailyK.P.BalaramanK.Susceptibility of"/>
   <result pre="Romanomermis iyengari, for the biocontrol of Anopheles gambiae, the major" exact="malaria" post="vector in sub-Saharan AfricaParasit. Vectors20191225310.1186/s13071-019-3508-631118105 229.AbagliA.Z.AlavoBiocontrol of Culex quinquefasciatus"/>
   <result pre="operationsPLoS ONE201813e020170910.1371/journal.pone.020170930071091 234.WhyardS.ErdelyanC.N.G.PartridgeA.L.SinghA.D.BeebeN.W.CapinaR.Silencing the buzz: A new approach to population" exact="suppression" post="of mosquitoes by feeding larvae double-stranded RNAsParasit. Vectors201589610.1186/s13071-015-0716-625880645 235.JesusT.WannerE.CardosoR.A"/>
   <result pre="all reported outbreaks and imported and autochthon cases of malaria," exact="dengue fever," post="yellow fever, chikungunya fever, and Zika fever between 2017"/>
   <result pre="outbreaks and imported and autochthon cases of malaria, dengue fever," exact="yellow fever," post="chikungunya fever, and Zika fever between 2017 and 2019."/>
   <result pre="imported and autochthon cases of malaria, dengue fever, yellow fever," exact="chikungunya" post="fever, and Zika fever between 2017 and 2019. This"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7238951\results\search\disease\results.xml">
   <result pre="citation as to source, however, is appreciated. Identifying persons with" exact="hepatitis" post="C virus (HCV) infection has become an urgent public"/>
   <result pre="(i.e., patients can implicitly accept or explicitly decline testing), universal" exact="hepatitis" post="C screening for all adult patients. ED staff members"/>
   <result pre="opt-out, universal testing approach is supported by new recommendations for" exact="hepatitis" post="C screening at least once in a lifetime for"/>
   <result pre="institution’s local Institutional Review Board. Each ED implemented opt-out, universal" exact="hepatitis" post="C testing at different times and using differing methodologies"/>
   <result pre="months, starting 1 month after initial implementation of opt-out, universal" exact="hepatitis" post="C screening. Because of programmatic changes during the observation"/>
   <result pre="facilitate referral to HCV infection care. ED sites collected cumulative" exact="hepatitis" post="C testing outcomes for the 4-month study period, including"/>
   <result pre="was used to conduct all statistical analyses. Using opt-out, universal" exact="hepatitis" post="C screening (Table 1), EDs performed a total of"/>
   <result pre="of total cases reactive to anti-HCV identified. TABLE 1 Universal" exact="hepatitis" post="C testing programs at four urban emergency departments (EDs)"/>
   <result pre="= HCV antibody; EHR = electronic health record; HCV =" exact="hepatitis" post="C virus. * Limited to a 3-month testing period"/>
   <result pre="programmatic changes occurring during the observation period. TABLE 2 Universal" exact="hepatitis" post="C testing results at four urban emergency departments (EDs)"/>
   <result pre="ED visitors 18,916 18,272 13,069 26,870 77,127 Patients eligible for" exact="hepatitis" post="C testing 13,999 9,585 7,639 12,284 43,507† Anti-HCV tests"/>
   <result pre="= HCV antibody; EHR = electronic health record; HCV =" exact="hepatitis" post="C virus. * Limited to a 3-month testing period"/>
   <result pre="Highland Hospital (3.2%). TABLE 3 Prevalence of positive results for" exact="hepatitis" post="C virus antibody (anti-HCV) and prevalence differences, by study"/>
   <result pre="the HCV infection epidemic. Although recent studies of ED-based, targeted" exact="hepatitis" post="C testing have highlighted the high prevalence of positive"/>
   <result pre="testing efforts, opt-out, universal HCV screening might improve rates of" exact="hepatitis" post="C testing among populations at high risk by reducing"/>
   <result pre="by reducing patient and provider stigma associated with identification of" exact="hepatitis" post="C behavioral risks as a prerequisite for testing. In"/>
   <result pre="by competing priorities. Although both targeted and opt-out, universal ED-based" exact="hepatitis" post="C testing strategies are effective at identifying previously unrecognized"/>
   <result pre="for Medicare &amp;amp; Medicaid Services precluding EDs from reimbursement for" exact="hepatitis" post="C testing might be limiting adoption of any systematic"/>
   <result pre="hepatitis C testing might be limiting adoption of any systematic" exact="hepatitis" post="C testing in the majority of EDs.† In addition,"/>
   <result pre="to bias. Second, 29,255 persons identified as being eligible for" exact="hepatitis" post="C testing in the study EDs were not tested"/>
   <result pre="This is consistent with previously reported findings from ED-based targeted" exact="hepatitis" post="C testing (5,6), and bias was not introduced toward"/>
   <result pre="as those born during 1945–1965 supports continued assessment of ED-based" exact="hepatitis" post="C testing, as well as an opt-out, universal screening"/>
   <result pre="What is already known about this topic? Targeted testing for" exact="hepatitis" post="C virus (HCV) infection in emergency departments (EDs) has"/>
   <result pre="infections, especially among persons born after 1965. ED-based opt-out, universal" exact="hepatitis" post="C screening can be vital in combating and surveilling"/>
   <result pre="MorganRL, BeckettGA, et al.. Recommendations for the identification of chronic" exact="hepatitis" post="C virus infection among persons born during 1945–1965.MMWR Recomm"/>
   <result pre="Rep2018;67:1419–27. 10.15585/mmwr.mm675152e130605448 3. SuryaprasadAG, WhiteJZ, XuF, et al.Emerging epidemic of" exact="hepatitis" post="C virus infections among young nonurban persons who inject"/>
   <result pre="Defic Syndr2016;73:323–31. 10.1097/QAI.000000000000109827763996 5. GalbraithJW, FrancoRA, DonnellyJP, et al.Unrecognized chronic" exact="hepatitis" post="C virus infection among baby boomers in the emergency"/>
   <result pre="6. WhiteDAE, AndersonES, PfeilSK, TrivediTK, AlterHJ. Results of a rapid" exact="hepatitis" post="C virus screening and diagnostic testing program in an"/>
   <result pre="10.1016/j.annemergmed.2015.06.02326253712 7. SchillieS, WesterC, OsborneM, WesolowskiL, RyersonAB. CDC recommendations for" exact="hepatitis" post="C screening among adults—United States, 2020.MMWR Recomm Rep2020;69(No. RR-2)."/>
   <result pre="Rep2020;69(No. RR-2). 10.15585/mmwr.rr6902a132271723 8. RosenbergES, RosenthalEM, HallEW, et al.Prevalence of" exact="hepatitis" post="C virus infection in US states and the District"/>
   <result pre="of the Centers for Disease Control and Prevention recommendations for" exact="hepatitis" post="C virus testing in an urban emergency department.Clin Infect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7239338\results\search\disease\results.xml">
   <result pre="a very narrow range of only nine human viruses (HIV," exact="hepatitis" post="C virus (HCV), herpes simplex virus, influenza, hepatitis B"/>
   <result pre="of only nine human viruses (HIV, hepatitis C virus (HCV)," exact="herpes simplex" post="virus, influenza, hepatitis B virus, Varicella zoster virus, human"/>
   <result pre="viruses (HIV, hepatitis C virus (HCV), herpes simplex virus, influenza," exact="hepatitis" post="B virus, Varicella zoster virus, human cytomegalovirus, respiratory syncytial"/>
   <result pre="polymerase inhibitor approved in Japan for the treatment of noncomplicated" exact="influenza" post="infections and in clinical development in the United States."/>
   <result pre="per os to &amp;gt; 2,000 healthy volunteers or patients with" exact="influenza" post="worldwide,31 and (iii) immediate availability in large quantities. Mathematical"/>
   <result pre="concentration (EC50) was much larger than against most strains of" exact="influenza" post="virus.8 The dosing regimen of favipiravir approved in Japanese"/>
   <result pre="The dosing regimen of favipiravir approved in Japanese patients for" exact="influenza" post="was 1,600 mg twice daily the first day followed"/>
   <result pre="the innate immune response In an acute infection, such as" exact="influenza" post="or EVD, the role of an antiviral treatment is"/>
   <result pre="storm�? is directly related to clinical symptoms, as shown in" exact="influenza" post="infection.62 Thus, in this dynamic interaction between the host"/>
   <result pre="be complementary to it, for exposed people. The promising vesicular" exact="stomatitis" post="virus�?based vaccine used in Guinea provided high level protection"/>
   <result pre="Beauchemin, C., Macken, C.A., Hayden, F.G. &amp;amp; Perelson, A.S.Kinetics of" exact="influenza" post="A virus infection in humans. J. Virol.80, 7590–7599 (2006).16840338"/>
   <result pre="J. Virol.80, 7590–7599 (2006).16840338 13Smith, A.M.et alKinetics of coinfection with" exact="influenza" post="A virus and Streptococcus pneumoniae. PLoS Pathog.9, e1003238 (2013).23555251"/>
   <result pre="Nat. Rev. Immunol.2, 28–36 (2002).11905835 50Perelson, A.S. &amp;amp; Guedj, J.Modelling" exact="hepatitis" post="C therapy�?predicting effects of treatment. Nat. Rev. Gastroenterol. Hepatol.12,"/>
   <result pre="Nat. Rev. Gastroenterol. Hepatol.12, 437–445 (2015).26122475 51Snoeck, E.et alA comprehensive" exact="hepatitis" post="C viral kinetic model explaining cure. Clin. Pharmacol. Ther.87,"/>
   <result pre="Clin. Pharmacol. Ther.87, 706–713 (2010).20463660 52Whalley, S.A.et alKinetics of acute" exact="hepatitis" post="B virus infection in humans. J. Exp. Med.193, 847–854"/>
   <result pre="infections. J. Theor. Biol.347, 63–73 (2014).24440713 56Saenz, R.A.et alDynamics of" exact="influenza" post="virus infection and pathology. J. Virol.84, 3974–3983 (2010).20130053 57Stetson,"/>
   <result pre="96 (2013).24020860 61Hayden, F.G.Experimental human influenza: observations from studies of" exact="influenza" post="antivirals. Antivir. Ther.17, 133–141 (2012).22311616 62Hayden, F.G.et alLocal and"/>
   <result pre="62Hayden, F.G.et alLocal and systemic cytokine responses during experimental human" exact="influenza" post="A virus infection. Relation to symptom formation and host"/>
   <result pre="infections?PLoS One11, e0158237 (2016).27367230 64Pawelek, K.A.et alModeling within�?host dynamics of" exact="influenza" post="virus infection including immune responses. PLoS Comput. Biol.8, e1002588"/>
   <result pre="&amp;amp; Perelson, A.S.Modelling how ribavirin improves interferon response rates in" exact="hepatitis" post="C virus infection. Nature432, 922–924 (2004).15602565 67Dahari, H.et alHCV"/>
   <result pre="characterizing the relationship between nonlinear PSA kinetics and survival in" exact="prostate cancer" post="patients. Biometrics73, 305–312 (2017).27148956 76Rosenke, K.et alUse of favipiravir"/>
   <result pre="the relationship between nonlinear PSA kinetics and survival in prostate" exact="cancer" post="patients. Biometrics73, 305–312 (2017).27148956 76Rosenke, K.et alUse of favipiravir"/>
   <result pre="K.A., Layden, T.J. &amp;amp; Perelson, A.S.Dynamics of alanine aminotransferase during" exact="hepatitis" post="C virus treatment. Hepatology38, 509–517 (2003).12883496 80Carrillo�?Bustamante, P.et alDetermining"/>
   <result pre="(2017).29153266 93Koizumi, Y.et alQuantifying antiviral activity optimizes drug combinations against" exact="hepatitis" post="C virus infection. Proc. Natl. Acad. Sci. USA114, 1922–1927"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7239382\results\search\disease\results.xml">
   <result pre="rearrangement of primary and anamnestic CD8+ T cell responses to" exact="influenza" post="A viral epitopes upon exposure to bacterial superantigens: Implications"/>
   <result pre="bacteria may precede or follow infection with or vaccination against" exact="influenza" post="A viruses (IAVs). However, how SAgs alter the breadth"/>
   <result pre="CD8+ T cell (TCD8) responses to respiratory viral pathogens, including" exact="influenza" post="A viruses (IAVs), is far from clear. Also importantly,"/>
   <result pre="a significant challenge in myriad life-threatening conditions and illnesses, including" exact="toxic shock syndrome" post="[1,2], sepsis [3,4], and influenza A virus (IAV) epidemics"/>
   <result pre="and illnesses, including toxic shock syndrome [1,2], sepsis [3,4], and" exact="influenza" post="A virus (IAV) epidemics and pandemics [5–9]. Some of"/>
   <result pre="reassortant IAV strains, a live attenuated nasal flu vaccine, and" exact="vaccinia virus" post="(VacV). The implications of our findings for sequential infections,"/>
   <result pre="Reserve strain of VacV was propagated in the thymidine kinase-deficient" exact="osteosarcoma" post="cell line 143B. WT and mutant Bacteria The methicillin-resistant"/>
   <result pre="epitopes (Table 1). NP118 is an immunodominant peptide epitope of" exact="lymphocytic choriomeningitis" post="virus (LCMV) [48] (Table 1) to which our animals"/>
   <result pre="E3L140-148 E3L140 VGPSNSPTF H2-Dd LCMV NP118-126 NP118 RPQASGVYM H2-Ld IAV:" exact="influenza" post="A virus; MHC: major histocompatibility complex; LCMV: lymphocytic choriomeningitis"/>
   <result pre="H2-Ld IAV: influenza A virus; MHC: major histocompatibility complex; LCMV:" exact="lymphocytic choriomeningitis" post="virus; VacV: vaccinia virus In vivo killing assay Carboxyfluorescein"/>
   <result pre="virus; MHC: major histocompatibility complex; LCMV: lymphocytic choriomeningitis virus; VacV:" exact="vaccinia virus" post="In vivo killing assay Carboxyfluorescein diacetate succinimidyl ester (CFSE)-based"/>
   <result pre="which may potentially affect their significance in the context of" exact="influenza" post="following exposure to the toxins or bacterial pathogens that"/>
   <result pre="in vaccine formulations to protect against other infectious diseases, including" exact="influenza" post="[82,83,84]; iv) several VacV-derived epitopes have been identified in"/>
   <result pre="2011;1–3. 2SionM, HatzitoliosA, ToulisE, MikoudiK, ZiakasGet al.Toxic shock syndrome complicating" exact="influenza" post="A infection: a two-case report with one case of"/>
   <result pre="Care Medicine. 2001;27(2):44310.1007/s001340000803 .11396292 3FlorescuD, KalilA. The complex link between" exact="influenza" post="and severe sepsis.Virulence. 2013;5(1):137–142. 10.4161/viru.27103 .24253109 4Martin-LoechesI, LemialeV, GeogheganP,"/>
   <result pre="Biology. 2017;15(6):e200193010.1371/journal.pbio.2001930 .28632753 13GuoX, ThomasP. New fronts emerge in the" exact="influenza" post="cytokine storm. Seminars in Immunopathology. 2017;39(5):541–550. .28555383 14YewdellJ, HaeryfarS."/>
   <result pre="of Immunology. 2005;23:651–682. 10.1146/annurev.immunol.23.021704.115702 .15771583 15BrownL, KelsoA. Prospects for an" exact="influenza" post="vaccine that induces cross-protective cytotoxic T lymphocytes. Immunology and"/>
   <result pre="Antibody Selection. Cell Host &amp;amp;Microbe. 2013;13(3):314–323. 10.1016/j.chom.2013.02.008 .23498956 35KilbourneED. Future" exact="influenza" post="vaccines and the use of genetic recombinants. Bulletin of"/>
   <result pre="36BenninkJ, YewdellJ, GerhardW. A viral polymerase involved in recognition of" exact="influenza" post="virus-infected cells by a cytotoxic T-cell clone. Nature. 1982;296(5852):75–76."/>
   <result pre="staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent" exact="toxic shock syndrome." post="Nature Medicine. 2009;15(6):641–648. 10.1038/nm.1965 .19465927 40KapplerJ, HermanA, ClementsJ, MarrackP."/>
   <result pre="2009;157(1):60–70. 10.1111/j.1365-2249.2009.03963.x .19659771 44HosakaY, SasaoF, OharaR. Cell-mediated lysis of heat-inactivated" exact="influenza" post="virus-coated murine targets. Vaccine. 1985;3:245–251. 10.1016/0264-410x(85)90116-1 .3877382 45HuffordM, RichardsonG,"/>
   <result pre="TanB, KedzierskaKet al.Systematic identification of immunodominant CD8+ T-cell responses to" exact="influenza" post="A virus in HLA-A2 individuals. Proceedings of the National"/>
   <result pre="2011;108(22):9178–9183. 10.1073/pnas.1105624108 .21562214 76GrantE, WuC, ChanK, EckleS, BharadwajMet al.Nucleoprotein of" exact="influenza" post="A virus is a major target of immunodominant CD8+"/>
   <result pre="LohL, ClemensE, SantSet al.Broad CD8+ T cell cross-recognition of distinct" exact="influenza" post="A strains in humans. Nature Communications. 2018;9(1):542710.1038/s41467-018-07815-5 .30575715 78VoetenJ,"/>
   <result pre="Respiratory Diseases.Viruses. 2014;6(7):2735–2761. 10.3390/v6072735 .25036462 83de VriesR, RimmelzwaanG. Viral vector-based" exact="influenza" post="vaccines.Human Vaccines &amp;amp; Immunotherapeutics. 2016;12(11):2881–2901. 10.1080/21645515.2016.1210729 .27455345 84de VriesR,"/>
   <result pre="UsherwoodE. CD4+ T-cell dependence of primary CD8+ T-cell response against" exact="vaccinia virus" post="depends upon route of infection and viral dose. Cellular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7240362\results\search\disease\results.xml">
   <result pre="show remarkable resistance and tolerance to the mite, generally keeping" exact="mite infestation" post="levels below the threshold required to kill colonies [147,148,149,150]."/>
   <result pre="invasion biology: Predicting invadersTrends Ecol. Evol.20011619920410.1016/S0169-5347(01)02101-211245943 2.TatemA.J.RogersD.J.HayS.I.Global transport networks and" exact="infectious disease" post="spreadAdv. Parasitol.20066229334316647974 3.EsslF.DullingerS.RabitschW.HulmeP.E.HülberK.JarošíkV.KleinbauerI.KrausmannF.KühnI.NentwigW.et al.Socioeconomic legacy yields an invasion debtProc."/>
   <result pre="climate and infectious disease: The cholera paradigmScience19962742025203110.1126/science.274.5295.20258953025 10.LindgrenE.AnderssonY.SukJ.E.SudreB.SemenzaJ.C.Monitoring EU emerging" exact="infectious disease" post="risk due to climate changeScience201233641841910.1126/science.121573522539705 11.MiharaT.KoyanoH.HingampP.GrimsleyN.GotoS.OgataH.Taxon Richness of &quot;Megaviridae�?"/>
   <result pre="University PressOxford, UK2009 13.BowenD.G.WalkerC.M.Adaptive immune responses in acute and chronic" exact="hepatitis" post="C virus infectionNature200543694695210.1038/nature0407916107834 14.ChoisyM.WoelkC.H.GuéganJ.-F.RobertsonD.L.Comparative study of adaptive molecular evolution"/>
   <result pre="sequence shiftsEnviron. Microbiol.2018204612462810.1111/1462-2920.1448130452113 66.TehelA.VuQ.BigotD.Gogol-DöringA.KochP.JenkinsC.DoubletV.TheodorouP.PaxtonR.The two prevalent genotypes of an emerging" exact="infectious disease," post="deformed wing virus, cause equally low pupal mortality and"/>
   <result pre="EngelsdorpD.Multiyear survey targeting disease incidence in US honey beesApidologie20164732534710.1007/s13592-016-0431-0 132.GrasslyN.C.FraserC.Seasonal" exact="infectious disease" post="epidemiologyProc. R. Soc. B Biol. Sci.20062732541255010.1098/rspb.2006.3604 133.AlauxC.DuclozF.CrauserD.Le ConteY.Diet effects"/>
   <result pre="among apiaries exposed to varying agricultural land usePLoS ONE201611e015268510.1371/journal.pone.015268527027871 137.ManleyR.BootsM.WilfertL.Emerging" exact="viral disease" post="risk to pollinating insects: Ecological, evolutionary and anthropogenic factorsJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7241786\results\search\disease\results.xml">
   <result pre="of the West Nile virus responsible for an outbreak of" exact="encephalitis" post="in the northeastern United States. Science (80-). 1999;286: 2333–2337."/>
   <result pre="BusemanCM, JoynerSN, HughesSM, FombyTB, LubyJP, et al.The 2012 West Nile" exact="encephalitis" post="epidemic in Dallas, Texas. JAMA. 2013;8874: 297–307. 10.1001/jama.2013.826723860988 20TranA,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7241834\results\search\disease\results.xml">
   <result pre="[28, 29], and reports the highest incidence of the sylvatic" exact="malaria" post="parasite Plasmodium knowlesi [30]. Increased incidence rates of P."/>
   <result pre="parasite Plasmodium knowlesi [30]. Increased incidence rates of P. knowlesi" exact="malaria" post="in Sabah have been linked to deforestation and land"/>
   <result pre=".1342799 8HussinN, JaafarJ, NaingNN, MatHA, MuhamadAH, MamatMN. A review of" exact="dengue fever" post="incidence in Kota Bharu, Kelantan, Malaysia during the years"/>
   <result pre="9KwaB.Environmental change, development and vectorborne disease: Malaysia's experience with filariasis," exact="scrub typhus" post="and dengue. Environ Dev Sustain. 2008;10:209–17. Epub 9 July"/>
   <result pre="change, development and vectorborne disease: Malaysia's experience with filariasis, scrub" exact="typhus" post="and dengue. Environ Dev Sustain. 2008;10:209–17. Epub 9 July"/>
   <result pre="https://newss.statistics.gov.my/newss-portalx/ep/epFreeDownloadContentSearch.seam?cid=181040. 30CooperDJ, RajahramGS, WilliamT, JelipJ, MohammadR, BenedictJ, et al.Plasmodium knowlesi" exact="malaria" post="in Sabah, Malaysia, 2015–2017: ongoing increase in incidence despite"/>
   <result pre="WilliamT, CoxJ, et al.Predictive analysis across spatial scales links zoonotic" exact="malaria" post="to deforestation. Proc Biol Sci. 2019;286(1894):2018235110.1098/rspb.2018.235130963872 33OrganizationWH. Dengue guidelines"/>
   <result pre="DubozR, BaehrC, VongS. Can human movements explain heterogeneous propagation of" exact="dengue fever" post="in Cambodia?PLoS Negl Trop Dis. 2012;6(12):e1957 Epub 2012/12/14. 10.1371/journal.pntd.000195723236536"/>
   <result pre="YoshidaLM, et al.Population density, water supply, and the risk of" exact="dengue fever" post="in Vietnam: cohort study and spatial analysis. PLoS Med."/>
   <result pre="in Sarawak, Malaysian Borneo. Parasit Vectors. 2017;10(1):40610.1186/s13071-017-2341-z28859676 60GublerDJ. Dengue and" exact="dengue hemorrhagic fever." post="Clin Microbiol Rev. 1998;11(3):480–96. Epub 1998/07/17. 9665979 61LeeKS, LaiYL,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7242466\results\search\disease\results.xml">
   <result pre="disturbance and resilience dynamics of the upper respiratory tract during" exact="influenza" post="A virus infection KaulDrishti1RathnasingheRaveen2FerresMarcela2TanGene S.13BarreraAldo24PickettBrett E.56MetheBarbara A.57DasSuman5BudnikIsolda2HalpinRebecca A.5WentworthDavid510http://orcid.org/0000-0002-2491-3029SchmolkeMirco811http://orcid.org/0000-0001-5464-7086MenaIgnacio8http://orcid.org/0000-0003-4008-503XAlbrechtRandy A.8SinghIndresh5NelsonKaren"/>
   <result pre="a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract Infection with" exact="influenza" post="can be aggravated by bacterial co-infections, which often results"/>
   <result pre="co-infections, which often results in disease exacerbation. The effects of" exact="influenza" post="infection on the upper respiratory tract (URT) microbiome are"/>
   <result pre="the temporal dynamics of the URT microbiomes of uninfected and" exact="influenza" post="virus-infected humans and ferrets. Uninfected human patients and ferret"/>
   <result pre="microbiomes of infected individuals. The dynamic and resilient microbiome during" exact="influenza" post="virus infection in multiple hosts provides a compelling rationale"/>
   <result pre="race between vaccine design and viral mutation contributes to annual" exact="influenza" post="epidemics worldwide, which on average results in 3–5 million"/>
   <result pre="only confined to pandemics; bacterial and virus co-infection during seasonal" exact="influenza" post="epidemics are commonly associated with increase hospital admissions, severe"/>
   <result pre="the bacterial co-infections associated with influenza-derived morbidity. Results Effects of" exact="influenza" post="on the human URT microbiome dynamics In order to"/>
   <result pre="Diversity of the URT microbiome of human patients infected with" exact="influenza" post="A virus (IAV). Beta-diversity analysis for longitudinal nasopharyngeal swab"/>
   <result pre="Bray–Curtis distances was done for samples from humans, labeled as" exact="influenza" post="positive in red (P, indicating data points with positive"/>
   <result pre="red (P, indicating data points with positive IAV qRT-PCR detection)," exact="influenza" post="unknown in yellow (U, indicates time points from positive"/>
   <result pre="a few patients moved from the unhealthy ecostates during acute" exact="influenza" post="infection to the healthy ecostate in the later time"/>
   <result pre="mock inoculated (uninfected) or intranasally infected with 1 × 106 pfu of" exact="influenza" post="A/Neth/602/09 virus. Body weights were determined daily for 14"/>
   <result pre="Given the unequivocal association between viral and bacterial co-infection and" exact="influenza" post="disease severity, there is a pressing need to better"/>
   <result pre="study of previously healthy individuals experimentally infected with a H3N2" exact="influenza" post="strain from 2005, where no oropharyngeal microbiome changes were"/>
   <result pre="PUC. The remaining two patients could not be confirmed as" exact="influenza" post="positive by qRT-PCR, RT-PCR and/or the hemagglutination inhibition (HI)"/>
   <result pre="Control samples from 22 healthy individuals, confirmed as negative against" exact="influenza" post="A virus and 13 other common respiratory viruses, were"/>
   <result pre="criteria were established in accordance with the hospitalization due to" exact="influenza" post="and/or derivation to critical care unit (which involves oxygen"/>
   <result pre="for a total of 121 samples. The naming convention of" exact="influenza" post="A viruses detected from patients are as follows: A/Santiago/pxdy/2011"/>
   <result pre="for a total of 127 samples, which were negative for" exact="influenza" post="and other respiratory infections. Ferret infection and sample collection"/>
   <result pre="confirmed to be negative against circulating H1N1, H3N2, and B" exact="influenza" post="viruses before they were shipped from the company. Upon"/>
   <result pre="(2017). 2.JohnsonNPMuellerJUpdating the accounts: global mortality of the 1918-1920 &quot;Spanish�?" exact="influenza" post="pandemicBull. Hist. Med.20027610511511875246 3.BrundageJFInteractions between influenza and bacterial respiratory"/>
   <result pre="of the 1918-1920 &quot;Spanish�? influenza pandemicBull. Hist. Med.20027610511511875246 3.BrundageJFInteractions between" exact="influenza" post="and bacterial respiratory pathogens: implications for pandemic preparednessLancet Infect."/>
   <result pre="respiratory pathogens: implications for pandemic preparednessLancet Infect. Dis.2006630331216631551 4.BrundageJFShanksGDDeaths from" exact="bacterial pneumonia" post="during 1918-19 influenza pandemicEmerg. Infect. Dis.2008141193119918680641 5.MorensDMTaubenbergerJKFauciASPredominant role of"/>
   <result pre="pathogens: implications for pandemic preparednessLancet Infect. Dis.2006630331216631551 4.BrundageJFShanksGDDeaths from bacterial" exact="pneumonia" post="during 1918-19 influenza pandemicEmerg. Infect. Dis.2008141193119918680641 5.MorensDMTaubenbergerJKFauciASPredominant role of"/>
   <result pre="pandemic preparednessLancet Infect. Dis.2006630331216631551 4.BrundageJFShanksGDDeaths from bacterial pneumonia during 1918-19" exact="influenza" post="pandemicEmerg. Infect. Dis.2008141193119918680641 5.MorensDMTaubenbergerJKFauciASPredominant role of bacterial pneumonia as"/>
   <result pre="pneumonia during 1918-19 influenza pandemicEmerg. Infect. Dis.2008141193119918680641 5.MorensDMTaubenbergerJKFauciASPredominant role of" exact="bacterial pneumonia" post="as a cause of death in pandemic influenza: implications"/>
   <result pre="during 1918-19 influenza pandemicEmerg. Infect. Dis.2008141193119918680641 5.MorensDMTaubenbergerJKFauciASPredominant role of bacterial" exact="pneumonia" post="as a cause of death in pandemic influenza: implications"/>
   <result pre="a cause of death in pandemic influenza: implications for pandemic" exact="influenza" post="preparednessJ. Infect. Dis.200819896297018710327 6.BlythCCet al.The impact of bacterial and"/>
   <result pre="Crit. Care Med.201118495796321680950 9.TarabichiYet al.The administration of intranasal live attenuated" exact="influenza" post="vaccine induces changes in the nasal microbiota and nasal"/>
   <result pre="S. et al. Early nasopharyngeal microbial signature associated with severe" exact="influenza" post="in children: a retrospective pilot study. J. Gen. Virol."/>
   <result pre="influenzaPLoS ONE20138e6955923844261 16.IchinoheTet al.Microbiota regulates immune defense against respiratory tract" exact="influenza" post="A virus infectionProc. Natl Acad. Sci. USA20111085354535921402903 17.WangJet al.Bacterial"/>
   <result pre="18.WuSet al.Microbiota regulates the TLR7 signaling pathway against respiratory tract" exact="influenza" post="A virus infectionCurr. Microbiol.20136741442223677145 19.BelserJAEckertAMTumpeyTMMainesTRComplexities in ferret influenza virus"/>
   <result pre="respiratory tract influenza A virus infectionCurr. Microbiol.20136741442223677145 19.BelserJAEckertAMTumpeyTMMainesTRComplexities in ferret" exact="influenza" post="virus pathogenesis and transmission modelsMicrobiol. Mol. Biol. Rev.20168073374427412880 20.BelserJAKatzJMTumpeyTMThe"/>
   <result pre="Biol. Rev.20168073374427412880 20.BelserJAKatzJMTumpeyTMThe ferret as a model organism to study" exact="influenza" post="A virus infectionDis. Models Amp; Mechanisms20114575579 21.ZaneveldJRMcMindsRVega ThurberRStress and"/>
   <result pre="Rep.2008237319061488 25.HuangYJet al.A persistent and diverse airway microbiota present during" exact="chronic obstructive pulmonary disease" post="exacerbationsOMICS20101495920141328 26.DicksonRPErb-DownwardJRHuffnagleGBHomeostasis and its disruption in the lung microbiomeAm."/>
   <result pre="Mol. Physiol.2015309L1047L105526432870 27.HeiraliAAet al.The effects of inhaled aztreonam on the" exact="cystic fibrosis" post="lung microbiomeMicrobiome201755128476135 28.RelmanDAThe human microbiome: ecosystem resilience and healthNutr."/>
   <result pre="social-ecological systemsEcol. Soc.200495 30.LeeKHet al.The respiratory microbiome and susceptibility to" exact="influenza" post="virus infectionPLoS ONE201914e020789830625134 31.Tsang, T. K. et al. Association"/>
   <result pre="et al. Association between the respiratory microbiome and susceptibility to" exact="influenza" post="virus infection. Clin. Infect. Dis. 10.1093/cid/ciz968 (2019). 32.Ding, T."/>
   <result pre="al. Microbial composition of the human nasopharynx varies according to" exact="influenza" post="virus type and vaccination status. mBio10, e01296-19 (2019). 33.KillipMJFodorERandallREInfluenza"/>
   <result pre="activation of the interferon systemVirus Res.2015209112225678267 34.Ramos-SevillanoEet al.The effect of" exact="influenza" post="virus on the human oropharyngeal microbiomeClin. Infect. Dis.2019681993200230445563 35.ProctorDMRelmanDAThe"/>
   <result pre="nose, mouth, and throatCell Host Microbe20172142143228407480 36.KleinEYet al.The frequency of" exact="influenza" post="and bacterial coinfection: a systematic review and meta-analysisInfluenza Other"/>
   <result pre="viral infectionClin. Microbiol. Infect.20131993093523167452 38.ChenHWet al.Nasal commensal Staphylococcus epidermidis counteracts" exact="influenza" post="virusSci. Rep.201662787027306590 39.SpinlerJKet al.From prediction to function using evolutionary"/>
   <result pre="diverse probiotic functionsGenome Biol. Evol.201461772178924951561 40.MorrisDEClearyDWClarkeSCSecondary bacterial infections associated with" exact="influenza" post="pandemicsFront Microbiol.20178104128690590 41.HotterbeekxAet al.The endotracheal tube microbiome associated with"/>
   <result pre="the importance of a de-escalating strategy for antibiotic treatment of" exact="pneumonia" post="in the ICUChest20021222183219612475862 45.Sharma-ChawlaNet al.Influenza A virus infection predisposes"/>
   <result pre="pneumoniae serotypes with similar outcome but serotype-specific manifestationInfect. Immun.2016843445345727647871 46.GuptaRKGeorgeRNguyen-Van-TamJSBacterial" exact="pneumonia" post="and pandemic influenza planningEmerg. Infect. Dis.2008141187119218680640 47.KashJCTaubenbergerJKThe role of"/>
   <result pre="similar outcome but serotype-specific manifestationInfect. Immun.2016843445345727647871 46.GuptaRKGeorgeRNguyen-Van-TamJSBacterial pneumonia and pandemic" exact="influenza" post="planningEmerg. Infect. Dis.2008141187119218680640 47.KashJCTaubenbergerJKThe role of viral, host, and"/>
   <result pre="47.KashJCTaubenbergerJKThe role of viral, host, and secondary bacterial factors in" exact="influenza" post="pathogenesisAm. J. Pathol.20151851528153625747532 48.ManicassamyBet al.Protection of mice against lethal"/>
   <result pre="48.ManicassamyBet al.Protection of mice against lethal challenge with 2009 H1N1" exact="influenza" post="A virus by 1918-like and classical swine H1N1 based"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7243378\results\search\disease\results.xml">
   <result pre="Abstract Abstract Background Understanding local epidemiology and etiologies of community-acquired" exact="pneumonia" post="in hospitalized patients is crucial for determining the appropriateness"/>
   <result pre="the etiologies, severity, and outcomes in adults hospitalized for community-acquired" exact="pneumonia" post="and to study the impact of empirical antibiotic therapy"/>
   <result pre="a prospective observational cohort study involving adults hospitalized for community-acquired" exact="pneumonia" post="in Hong Kong. Sputum, nasopharyngeal aspirate, blood, and urine"/>
   <result pre="had bacterial, and 9% had polymicrobial pneumonia. Streptococcus pneumoniae (12%)," exact="influenza" post="virus (12%), and Mycoplasma pneumoniae (1.2%) were the most"/>
   <result pre="with doxycycline, which was less evaluated in other cohorts. community-acquired" exact="pneumonia" post="length of stay mortality treatment guidelines Funding Health and"/>
   <result pre="cause of death worldwide [1]. The annual incidence of community-acquired" exact="pneumonia" post="(CAP) in the United States was 25 cases per"/>
   <result pre="symptoms with or without fever, and (3) evidence consistent with" exact="pneumonia" post="on chest radiograph. Patients were excluded if they had"/>
   <result pre="excluded if they had one of the following: (1) hospital-acquired" exact="pneumonia" post="(occurring ≥48 hours after admission; (2) recent hospitalization in"/>
   <result pre="conditions predisposing to noncommunity-acquired pathogens (including tracheostomy, percutaneous gastrostomy tube," exact="cancer" post="with neutropenia, solid or hematopoietic stem cell transplant within"/>
   <result pre="criteria were reported to be associated with drug-resistant pathogens for" exact="pneumonia" post="[2, 4]. Informed consent was obtained from each patient"/>
   <result pre="day of admission and use of corticosteroid (for exacerbation of" exact="chronic obstructive pulmonary disease" post="or asthma) were documented. Clinical outcomes, including the 30-day,"/>
   <result pre="included in the analysis. Acid-fast smear with culture of Mycobacterium" exact="tuberculosis" post="was performed if pulmonary tuberculosis was suspected. In-house multiplex"/>
   <result pre="Acid-fast smear with culture of Mycobacterium tuberculosis was performed if" exact="pulmonary tuberculosis" post="was suspected. In-house multiplex real-time polymerase chain reactions (PCRs)"/>
   <result pre="smear with culture of Mycobacterium tuberculosis was performed if pulmonary" exact="tuberculosis" post="was suspected. In-house multiplex real-time polymerase chain reactions (PCRs)"/>
   <result pre="urinary antigen tests (Alere BinaxNOW; Abbott, Chicago, IL). Definitions Bacterial" exact="pneumonia" post="was defined as isolation of clinically significant pathogen from"/>
   <result pre="antigen tests, or positive Mycoplasma or Chlamydophila PCR tests. Viral" exact="pneumonia" post="was defined as positive respiratory viruses detected via PCR."/>
   <result pre="was defined as positive respiratory viruses detected via PCR. Polymicrobial" exact="pneumonia" post="was defined as the presence of 2 or more"/>
   <result pre="of 2 or more bacterial, viral, and/or mycobacterial pathogens. Severe" exact="pneumonia" post="was defined as CURB-65 score ≥3 [6], and/or requirement"/>
   <result pre="recommended. Empirical fluoroquinolone is only recommended for patients with documented" exact="allergy" post="to beta-lactam antibiotics. Statistical Analysis Continuous variables were presented"/>
   <result pre="patients (Table 1, Supplementary Figure 1). Fifty-two patients (20%) had" exact="viral pneumonia" post="(most commonly influenza viruses [12%] and rhinovirus [7%]), 38"/>
   <result pre="(Table 1, Supplementary Figure 1). Fifty-two patients (20%) had viral" exact="pneumonia" post="(most commonly influenza viruses [12%] and rhinovirus [7%]), 38"/>
   <result pre="Figure 1). Fifty-two patients (20%) had viral pneumonia (most commonly" exact="influenza" post="viruses [12%] and rhinovirus [7%]), 38 (15%) had bacterial"/>
   <result pre="commonly influenza viruses [12%] and rhinovirus [7%]), 38 (15%) had" exact="bacterial pneumonia" post="(S pneumoniae [12%], Hemophilus influenzae [7%], and M pneumoniae"/>
   <result pre="influenza viruses [12%] and rhinovirus [7%]), 38 (15%) had bacterial" exact="pneumonia" post="(S pneumoniae [12%], Hemophilus influenzae [7%], and M pneumoniae"/>
   <result pre="and Legionella 1). Bacterial pathogens in 93% of patients with" exact="bacterial pneumonia" post="(excluding atypical pathogens) were susceptible to amoxicillin-clavulanate. Table 1."/>
   <result pre="Legionella 1). Bacterial pathogens in 93% of patients with bacterial" exact="pneumonia" post="(excluding atypical pathogens) were susceptible to amoxicillin-clavulanate. Table 1."/>
   <result pre="3 (1.2%) 1 (3.3%) 0 (0%) 2 (1.8%) .229  Mycobacterium" exact="tuberculosis" post="5 (1.9%) 1 (3.3%) 4 (3.5%) 0 (0%) .137"/>
   <result pre="had rhinovirus and S pneumoniae or Hemophilus influenzae, 7 had" exact="influenza" post="and S pneumoniae or H influenzae or Legionella, 3"/>
   <result pre="2 had respiratory syncytial virus and S pneumoniae, 1 had" exact="influenza" post="and mycobacterial, 1 had S pneumoniae and mycobacterial, and"/>
   <result pre="Figure 1. Screening and enrollment of patients hospitalized with community-acquired" exact="pneumonia" post="(CAP). The aetiologic type of pneumonia varied by age"/>
   <result pre="patients hospitalized with community-acquired pneumonia (CAP). The aetiologic type of" exact="pneumonia" post="varied by age group (Table 1). Younger patients had"/>
   <result pre="group (Table 1). Younger patients had the highest incidence of" exact="bacterial pneumonia," post="predominantly due to higher incidence of M pneumoniae and"/>
   <result pre="likely to have a pathogen identified. The different types of" exact="pneumonia" post="were not associated with disease severity. Empirical Antibiotic Treatment"/>
   <result pre="piperacillin-tazobactam monotherapy without macrolide. Among the 20 patients with nonsevere" exact="pneumonia" post="given nonadherent antibiotics, 7 received piperacillin-tazobactam or meropenem, 8"/>
   <result pre="a macrolide, 2 received fluoroquinolone in the absence of documented" exact="allergy" post="to beta-lactam antibiotics, and 3 were not prescribed any"/>
   <result pre="to local treatment guidelines. DISCUSSION In this prospective cohort study," exact="viral pneumonia" post="was the most common cause of CAP. The most"/>
   <result pre="local treatment guidelines. DISCUSSION In this prospective cohort study, viral" exact="pneumonia" post="was the most common cause of CAP. The most"/>
   <result pre="performed on upper respiratory tract samples [14]. In our cohort," exact="influenza" post="and rhinovirus are the predominant viral pathogens, similar to"/>
   <result pre="In our study and others, up to &amp;gt;20% patients with" exact="viral pneumonia" post="had a bacterial copathogen [4]. This increases the difficulty"/>
   <result pre="our study and others, up to &amp;gt;20% patients with viral" exact="pneumonia" post="had a bacterial copathogen [4]. This increases the difficulty"/>
   <result pre="identifying patients not requiring antibacterial coverage in patients with confirmed" exact="viral pneumonia." post="Adopting more sensitive diagnostic tools for detection of bacterial"/>
   <result pre="[4, 15]. Younger age groups had a higher proportion of" exact="bacterial pneumonia," post="largely due to higher detection rates of M pneumoniae"/>
   <result pre="(inadequate coverage for potential drug-resistant pathogens in patients with severe" exact="pneumonia" post="or underlying bronchiectasis). In patients at low risk of"/>
   <result pre="the other hand, undertreatment was observed in patients with severe" exact="pneumonia" post="or bronchiectasis who were prescribed beta-lactam antibiotics in the"/>
   <result pre="hand, undertreatment was observed in patients with severe pneumonia or" exact="bronchiectasis" post="who were prescribed beta-lactam antibiotics in the absence of"/>
   <result pre="worse outcomes. Multiple studies have shown better outcomes in moderate-to-severe" exact="pneumonia" post="with the combination of beta-lactam and macrolide, compared with"/>
   <result pre="macrolide or fluoroquinolone resistance in S pneumoniae [23, 24] or" exact="tuberculosis" post="are prevalent [25]. Our results and others supported that"/>
   <result pre="in atypical pathogens. However, the role of doxycycline in severe" exact="pneumonia" post="is uncertain and needs further evaluation. There are some"/>
   <result pre="45% of patients hospitalized with CAP in Hong Kong. Viral" exact="pneumonia" post="was most common. Influenza virus, S pneumoniae, and M"/>
   <result pre="Disease Study 2017. Lancet2018; 392:1736–88.30496103 2.JainS, SelfWH, WunderinkRG, et al.Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. adults. N Engl J Med2015;"/>
   <result pre="U.S. adults. N Engl J Med2015; 373:415–27.26172429 3.SongJH, HuhK, ChungDRCommunity-acquired" exact="pneumonia" post="in the Asia-Pacific region. Semin Respir Crit Care Med2016;"/>
   <result pre="4.WunderinkRG, WatererGAdvances in the causes and management of community acquired" exact="pneumonia" post="in adults. BMJ2017; 358:j2471.28694251 5.HoPL, WuTC, ChaoDVK, et al.Reducing"/>
   <result pre="2020. 6.LimWS, van der EerdenMM, LaingR, et al.Defining community acquired" exact="pneumonia" post="severity on presentation to hospital: an international derivation and"/>
   <result pre="Infect Dis2014; 59:62–70.24729498 15.TorresA, LeeN, CillonizC, et al.Laboratory diagnosis of" exact="pneumonia" post="in the molecular age. Eur Respir J2016; 48:1764–78.27811073 16.HoPL,"/>
   <result pre="LaJoieAS, BrockGN, et al.Improving outcomes in elderly patients with community-acquired" exact="pneumonia" post="by adhering to national guidelines: community-acquired pneumonia organization international"/>
   <result pre="patients with community-acquired pneumonia by adhering to national guidelines: community-acquired" exact="pneumonia" post="organization international cohort study results. Arch Intern Med2009; 169:1515–24.19752410"/>
   <result pre="VallèsX, et al.Adherence to guidelines’ empirical antibiotic recommendations and community-acquired" exact="pneumonia" post="outcome. Eur Respir J2008; 32:892–901.18550608 20.MenéndezR, ReyesS, MartínezR, et"/>
   <result pre="Infect2012; 18:E71–3.22284533 23.CharlesPG, WhitbyM, FullerAJ, et al.The etiology of community-acquired" exact="pneumonia" post="in Australia: why penicillin plus doxycycline or a macrolide"/>
   <result pre="WongRY, LiF, et al.High mortality in adults hospitalized for active" exact="tuberculosis" post="in a low HIV prevalence setting. PLoS One2014; 9:e92077.24642794"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7245076\results\search\disease\results.xml">
   <result pre="VasudevanEng Eong Ooi page-count: Dengue is the most common vector-borne" exact="viral disease" post="globally. Dengue virus (DENV), which exists as four antigenically"/>
   <result pre="likelihood of DENV transmission, cyclical dengue epidemics will continue to" exact="plague" post="global health. Dengue epidemics are mostly thought to result"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7245956\results\search\disease\results.xml">
   <result pre="provided the original work is properly cited. Abstract The live" exact="smallpox" post="vaccine was a historical first and highly effective vaccine."/>
   <result pre="and highly effective vaccine. However, along with high immunogenicity, the" exact="vaccinia virus" post="(VACV) caused serious side effects in vaccinees, sometimes with"/>
   <result pre="utilized to generate safe and highly immunogenic live VACV vaccines." exact="smallpox" post="vaccination immunogenicity protectiveness immune modulating proteins INTRODUCTION The emergence"/>
   <result pre="the search for ways to protect against diseases such as" exact="smallpox" post="(Latin variola), a particularly dangerous infection that causes epidemics"/>
   <result pre="the loss of dry crusts; these people became immune to" exact="smallpox" post="whenever a new outbreak of the disease occurred. Apparently,"/>
   <result pre="inoculation of infectious material obtained by collecting skin crusts from" exact="smallpox" post="patients into skin incisions (usually in the forearm), or"/>
   <result pre="Edward Jenner described a new, safer procedure for protecting against" exact="smallpox" post="[1, 2]. Rural residents who got infected by animals"/>
   <result pre="resembling those after variolation. In addition, people who had contracted" exact="cowpox" post="were known to have become immune to smallpox. In"/>
   <result pre="woman. To prove that the child had become resistant to" exact="smallpox" post="after the infection, Jenner variolated the child after 6"/>
   <result pre="for cowpox; from Latin vacca (cow)) instead of the term" exact="cowpox" post="and called the procedure &quot;vaccine inoculation.�? In 1803, Richard"/>
   <result pre="the term vaccination for all protective immunization procedures against any" exact="infectious disease" post="[2]. It should be noted that the kingdom of"/>
   <result pre="of Jennerian vaccination. The first animal virus (the foot and" exact="mouth disease" post="virus) was identified only in 1898. The causative agents"/>
   <result pre="virus) was identified only in 1898. The causative agents of" exact="smallpox" post="and cowpox proved to be the largest mammalian viruses."/>
   <result pre="identified only in 1898. The causative agents of smallpox and" exact="cowpox" post="proved to be the largest mammalian viruses. Unlike other"/>
   <result pre="vaccination by E. Jenner was believed to originate from the" exact="cowpox" post="virus (CPXV) [1, 3]. In 1939, it was found"/>
   <result pre="infectious agent nature and mechanisms for protecting a person from" exact="smallpox" post="after vaccine inoculation, E. Jenner, in his study published"/>
   <result pre="campaign for strict epidemiological surveillance of smallpox, as well as" exact="smallpox" post="vaccination carried out under the auspices of the World"/>
   <result pre="the auspices of the World Health Organization (WHO) since 1958," exact="smallpox" post="was completely eradicated and the last natural case of"/>
   <result pre="led to millions of lives being saved. The eradication of" exact="smallpox" post="occurred before the advent of modern practices in virology,"/>
   <result pre="to VARV, the development of a protective immune response to" exact="smallpox" post="has had to be studied indirectly in surrogate models"/>
   <result pre="has had to be studied indirectly in surrogate models of" exact="smallpox" post="infection. These models include the infection of mice with"/>
   <result pre="with the rabbitpox virus (RPXV) or VACV; monkeys with the" exact="monkeypox" post="virus (MPXV), etc. Common patterns of a specific immune"/>
   <result pre="of a specific immune response have also been studied using" exact="smallpox" post="vaccination of volunteers with VACV [7-9]. Poxviruses are unique"/>
   <result pre="SYNTHESIZED IN RESPONSE TO VACV VACCINATION The antibody response to" exact="smallpox" post="vaccination is known to play a crucial role in"/>
   <result pre="subsequent viral infection [8, 9, 20]. Reliable protection against a" exact="smallpox" post="infection was shown to be provided at a virus-neutralizing"/>
   <result pre="1:32 [21]. In humoral immunity defects, vaccination may not provide" exact="smallpox" post="protection. In a B-cell-deficient mouse model, animals were shown"/>
   <result pre="about the development of a humoral immune response to a" exact="smallpox" post="immunization/orthopoxvirus infection. VACV-INDUCED CYTOTOXIC T-LYMPHOCYTES The complex organization of"/>
   <result pre="is the reason why the mechanism of immune defense against" exact="smallpox" post="(and other orthopoxvirus infections) remains not fully understood. Along"/>
   <result pre="complex infectious agents. PREPARATION OF ATTENUATED SMALLPOX VACCINES Because mass" exact="smallpox" post="vaccination with VACV caused serious side effects, sometimes with"/>
   <result pre="accumulation of immunodeficiency states (HIV infection; patients after organ transplantation;" exact="cancer" post="patients, etc.) in recent decades has led to a"/>
   <result pre="vaccines that can be much safer compared to the classic" exact="smallpox" post="vaccine [36, 37]. The modern approach to virus attenuation"/>
   <result pre="was required to maintain a reliable level of protection against" exact="smallpox" post="for a long period of time [1]. In this"/>
   <result pre="[1]. In this regard, it is noteworthy that the causative" exact="smallpox" post="agent, VARV, lacks at least four genes in its"/>
   <result pre="Foundation (grant No. 19-14-00006). Abbreviations WHO World Health Organization CPXV" exact="cowpox" post="virus CTL cytotoxic T lymphocyte EEV extracellular enveloped virion"/>
   <result pre="horsepox virus IMV intracellular mature virion NK natural killer VACV" exact="vaccinia virus" post="VARV variola virus References References 1Smallpox and Its Eradication."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7245998\results\search\disease\results.xml">
   <result pre="doi: 10.1186/s12879-020-05091-7 : Research Article Live poultry market closure and" exact="avian influenza" post="A (H7N9) infection in cities of China, 2013–2017: an"/>
   <result pre="10.1186/s12879-020-05091-7 : Research Article Live poultry market closure and avian" exact="influenza" post="A (H7N9) infection in cities of China, 2013–2017: an"/>
   <result pre="(LPMs) was an effective intervention to reduce human risk of" exact="avian influenza" post="A (H7N9) infection, but evidence is limited on the"/>
   <result pre="was an effective intervention to reduce human risk of avian" exact="influenza" post="A (H7N9) infection, but evidence is limited on the"/>
   <result pre="greater than that of meteorology on H7N9 transmission. Keywords Avian" exact="influenza" post="A (H7N9) Live poultry market closure Effect evaluation CARTs"/>
   <result pre="live poultry directly. Since the first laboratory-confirmed human infection with" exact="avian influenza" post="A (H7N9) was reported on 31 March 2013, epidemics"/>
   <result pre="poultry directly. Since the first laboratory-confirmed human infection with avian" exact="influenza" post="A (H7N9) was reported on 31 March 2013, epidemics"/>
   <result pre="they raised backyard poultry [9], while for cities the highest" exact="influenza" post="A positive rates were detected at the retail LPMs"/>
   <result pre="help policymakers reassess intervention strategy in future human outbreaks of" exact="influenza" post="A (H7N9). The paper aims to quantify the effect"/>
   <result pre="Method Data source We collected the laboratory-confirmed human cases of" exact="avian influenza" post="A (H7N9) virus infection during 2013–2017 from the Chinese"/>
   <result pre="Data source We collected the laboratory-confirmed human cases of avian" exact="influenza" post="A (H7N9) virus infection during 2013–2017 from the Chinese"/>
   <result pre="first to fifth epidemics waves, for preventing human exposure to" exact="avian influenza" post="H7N9 virus. Our study suggests that long-termed and fully"/>
   <result pre="to fifth epidemics waves, for preventing human exposure to avian" exact="influenza" post="H7N9 virus. Our study suggests that long-termed and fully"/>
   <result pre="should remain closed in all affected areas until the current" exact="influenza" post="A (H7N9) epizootic and epidemic are declared definitively over"/>
   <result pre="daily maximum temperature contributed significantly to human infection with the" exact="influenza" post="A H7N9 virus [27], and the temperature range is"/>
   <result pre="ban in the whole city can prevent any type of" exact="avian influenza" post="not only H7N9. It is an optimal measure with"/>
   <result pre="in the whole city can prevent any type of avian" exact="influenza" post="not only H7N9. It is an optimal measure with"/>
   <result pre="with H7N9 virus [33]. Recently, however, there are thousands of" exact="pneumonia" post="patients in Wuhan, a city in central China. The"/>
   <result pre="genes transmit into human beings or emerge other types of" exact="avian influenza." post="It is necessary to adopt long-term, large-scale LPMs closure"/>
   <result pre="suburb and country remain open) for preventing human exposure to" exact="avian influenza" post="H7N9 virus. To extend the closure duration and consider"/>
   <result pre="and country remain open) for preventing human exposure to avian" exact="influenza" post="H7N9 virus. To extend the closure duration and consider"/>
   <result pre="is an Editorial Board Member. References References 1.WangXJiangHWuPUyekiTMFengLLaiSWangLHuoXXuKChenEet al.Epidemiology of" exact="avian influenza" post="A H7N9 virus in human beings across five epidemics"/>
   <result pre="an Editorial Board Member. References References 1.WangXJiangHWuPUyekiTMFengLLaiSWangLHuoXXuKChenEet al.Epidemiology of avian" exact="influenza" post="A H7N9 virus in human beings across five epidemics"/>
   <result pre="Infectious Diseases201868462363110.1093/cid/ciy541 3.ArtoisJJiangHWangXQinYPearcyMLaiSShiYZhangJPengZZhengJet al.Changing geographic patterns and risk factors for" exact="avian influenza" post="A (H7N9) infections in humans, ChinaEmerg Infect Dis2018241879410.3201/eid2401.17139329260681 4.LauSYWangXWangMLiuSZeeBCHanXYuZSunRChongKCChenEIdentification"/>
   <result pre="Diseases201868462363110.1093/cid/ciy541 3.ArtoisJJiangHWangXQinYPearcyMLaiSShiYZhangJPengZZhengJet al.Changing geographic patterns and risk factors for avian" exact="influenza" post="A (H7N9) infections in humans, ChinaEmerg Infect Dis2018241879410.3201/eid2401.17139329260681 4.LauSYWangXWangMLiuSZeeBCHanXYuZSunRChongKCChenEIdentification"/>
   <result pre="Dis2018241879410.3201/eid2401.17139329260681 4.LauSYWangXWangMLiuSZeeBCHanXYuZSunRChongKCChenEIdentification of meteorological factors associated with human infection with" exact="avian influenza" post="A H7N9 virus in Zhejiang Province, ChinaSci Total Environ201864469670910.1016/j.scitotenv.2018.06.39029990917"/>
   <result pre="4.LauSYWangXWangMLiuSZeeBCHanXYuZSunRChongKCChenEIdentification of meteorological factors associated with human infection with avian" exact="influenza" post="A H7N9 virus in Zhejiang Province, ChinaSci Total Environ201864469670910.1016/j.scitotenv.2018.06.39029990917"/>
   <result pre="Environ201864469670910.1016/j.scitotenv.2018.06.39029990917 5.LiaoQLamWTLeungGMJiangCFieldingRLive poultry exposure, Guangzhou, China, 2006Epidemics20091420721210.1016/j.epidem.2009.09.00221352767 6.WuJLauEHXingQZouLZhangHYenHLSongYZhongHLinJKangMet al.Seasonality of" exact="avian influenza" post="A (H7N9) activity and risk of human A (H7N9)"/>
   <result pre="5.LiaoQLamWTLeungGMJiangCFieldingRLive poultry exposure, Guangzhou, China, 2006Epidemics20091420721210.1016/j.epidem.2009.09.00221352767 6.WuJLauEHXingQZouLZhangHYenHLSongYZhongHLinJKangMet al.Seasonality of avian" exact="influenza" post="A (H7N9) activity and risk of human A (H7N9)"/>
   <result pre="from live poultry marketsJ Inf Secur2015716690693 7.WuJ-YLauEHYuanJLuM-LXieC-JLiK-BMaX-WChenJ-DLiuY-HCaoLet al.Transmission risk of" exact="avian influenza" post="virus along poultry supply chains in Guangdong, ChinaJ Infect2019791434810.1016/j.jinf.2019.05.00631100365"/>
   <result pre="live poultry marketsJ Inf Secur2015716690693 7.WuJ-YLauEHYuanJLuM-LXieC-JLiK-BMaX-WChenJ-DLiuY-HCaoLet al.Transmission risk of avian" exact="influenza" post="virus along poultry supply chains in Guangdong, ChinaJ Infect2019791434810.1016/j.jinf.2019.05.00631100365"/>
   <result pre="of live poultry market closure in reducing bird-to-human transmission of" exact="avian influenza" post="A (H7N9) virus: an ecological studyLancet20153839916541548 9.WangLCowlingBJWuPYuJLiFZengLWuJTLiZLeungGMYuHHuman exposure to"/>
   <result pre="live poultry market closure in reducing bird-to-human transmission of avian" exact="influenza" post="A (H7N9) virus: an ecological studyLancet20153839916541548 9.WangLCowlingBJWuPYuJLiFZengLWuJTLiZLeungGMYuHHuman exposure to"/>
   <result pre="exposure to live poultry and psychological and behavioral responses to" exact="influenza" post="A (H7N9), ChinaEmerg Infect Dis20142081296130510.3201/eid2008.13182125076186 10.YuHWuJTCowlingBJLiaoQFangVJZhouSWuPZhouHLauEHGuoDet al.Effect of closure"/>
   <result pre="of closure of live poultry markets on poultry-to-person transmission of" exact="avian influenza" post="A H7N9 virus: an ecological studyLancet2014383991654154810.1016/S0140-6736(13)61904-224183056 11.WuJLuJFariaNRZengXSongYZouLYiLLiangLNiHKangMet al.Effect of"/>
   <result pre="closure of live poultry markets on poultry-to-person transmission of avian" exact="influenza" post="A H7N9 virus: an ecological studyLancet2014383991654154810.1016/S0140-6736(13)61904-224183056 11.WuJLuJFariaNRZengXSongYZouLYiLLiangLNiHKangMet al.Effect of"/>
   <result pre="ecological studyLancet2014383991654154810.1016/S0140-6736(13)61904-224183056 11.WuJLuJFariaNRZengXSongYZouLYiLLiangLNiHKangMet al.Effect of live poultry market interventions on" exact="influenza" post="A (H7N9) virus, Guangdong, ChinaEmerg Infect Dis201622122104211210.3201/eid2212.16045027869613 12.TengYBiDGuoXHuDFengDTongYContact reductions"/>
   <result pre="H7N9 influenzaJ Inf Secur2018763295304 13.HeFChenEFLiFDWangXYWangXXLinJFHuman infection and environmental contamination with" exact="avian influenza" post="A (H7N9) virus in Zhejiang Province, China: risk trend"/>
   <result pre="influenzaJ Inf Secur2018763295304 13.HeFChenEFLiFDWangXYWangXXLinJFHuman infection and environmental contamination with avian" exact="influenza" post="A (H7N9) virus in Zhejiang Province, China: risk trend"/>
   <result pre="Public Health20151593110.1186/s12889-015-2278-026392274 14.PeirisJSMCowlingBJWuJTFengLGuanYYuHLeungGMInterventions to reduce zoonotic and pandemic risks from" exact="avian influenza" post="in AsiaLancet Infect Dis201616225225810.1016/S1473-3099(15)00502-226654122 15.ZhouXLiYWangYEdwardsJGuoFClementsACHuangBMagalhaesRJThe role of live poultry"/>
   <result pre="Health20151593110.1186/s12889-015-2278-026392274 14.PeirisJSMCowlingBJWuJTFengLGuanYYuHLeungGMInterventions to reduce zoonotic and pandemic risks from avian" exact="influenza" post="in AsiaLancet Infect Dis201616225225810.1016/S1473-3099(15)00502-226654122 15.ZhouXLiYWangYEdwardsJGuoFClementsACHuangBMagalhaesRJThe role of live poultry"/>
   <result pre="movement and live bird market biosecurity in the epidemiology of" exact="influenza" post="A (H7N9): a cross-sectional observational study in four eastern"/>
   <result pre="al.Epidemiological, clinical and viral characteristics of fatal cases of human" exact="avian influenza" post="A (H7N9) virus in Zhejiang Province, ChinaJ Infect201367659560510.1016/j.jinf.2013.08.00723958687 18.HuYLuSSongZWangWHaoPLiJZhangXYenH-LShiBLiTet"/>
   <result pre="clinical and viral characteristics of fatal cases of human avian" exact="influenza" post="A (H7N9) virus in Zhejiang Province, ChinaJ Infect201367659560510.1016/j.jinf.2013.08.00723958687 18.HuYLuSSongZWangWHaoPLiJZhangXYenH-LShiBLiTet"/>
   <result pre="between adverse clinical outcome in human disease caused by novel" exact="influenza" post="A H7N9 virus and sustained viral shedding and emergence"/>
   <result pre="logistic regression methods as statistical tools for studying haemophiliaHaemophilia201521671572210.1111/hae.1277826248714 22.ChenYZhangYXuZWangXLuJHuWAvian" exact="influenza" post="A (H7N9) and related internet search query data in"/>
   <result pre="5. 24.TangQShaoMXuLChina is closely monitoring an increase in infection with" exact="avian influenza" post="A (H7N9) virusBiosci Trends201711112212410.5582/bst.2017.0104128250341 25.LuJLiuWXiaRDaiQBaoCTangFZhuYWangQEffects of closing and reopening"/>
   <result pre="24.TangQShaoMXuLChina is closely monitoring an increase in infection with avian" exact="influenza" post="A (H7N9) virusBiosci Trends201711112212410.5582/bst.2017.0104128250341 25.LuJLiuWXiaRDaiQBaoCTangFZhuYWangQEffects of closing and reopening"/>
   <result pre="live poultry markets on the epidemic of human infection with" exact="avian influenza" post="A virusJ Biomed Res201630211211928276666 26.LauSYChenEWangMChengWZeeBCHanXYuZSunRChongKCWangXAssociation between meteorological factors, spatiotemporal"/>
   <result pre="poultry markets on the epidemic of human infection with avian" exact="influenza" post="A virusJ Biomed Res201630211211928276666 26.LauSYChenEWangMChengWZeeBCHanXYuZSunRChongKCWangXAssociation between meteorological factors, spatiotemporal"/>
   <result pre="Res201630211211928276666 26.LauSYChenEWangMChengWZeeBCHanXYuZSunRChongKCWangXAssociation between meteorological factors, spatiotemporal effects, and prevalence of" exact="influenza" post="A subtype H7 in environmental samples in Zhejiang province,"/>
   <result pre="Total Environ201966379380310.1016/j.scitotenv.2019.01.40330738260 27.ZhangYFengCMaCYangPTangSLauASunWWangQThe impact of temperature and humidity measures on" exact="influenza" post="A (H7N9) outbreaks-evidence from ChinaInt J Infect Dis20153012212410.1016/j.ijid.2014.11.01025462179 28.LiuTKangMZhangBXiaoJLinHZhaoYHuangZWangXZhangYHeJet"/>
   <result pre="of ambient temperature and absolute humidity on the risks of" exact="avian influenza" post="A (H7N9) infection in ChinaSci Total Environ2018619-6201358136510.1016/j.scitotenv.2017.11.22629734613 29.WuSSYangPWangQYZhangHYChuYHLiHJHuaWYTangYQLiCHuman exposure"/>
   <result pre="ambient temperature and absolute humidity on the risks of avian" exact="influenza" post="A (H7N9) infection in ChinaSci Total Environ2018619-6201358136510.1016/j.scitotenv.2017.11.22629734613 29.WuSSYangPWangQYZhangHYChuYHLiHJHuaWYTangYQLiCHuman exposure"/>
   <result pre="to live poultry among residents during the second wave of" exact="avian influenza" post="A (H7N9) epidemic in Beijing, 2013-2014Zhonghua Liu Xing Bing"/>
   <result pre="live poultry among residents during the second wave of avian" exact="influenza" post="A (H7N9) epidemic in Beijing, 2013-2014Zhonghua Liu Xing Bing"/>
   <result pre="Zhi201738111484148829141334 30.SilvaWDasTKIzurietaREstimating disease burden of a potential A (H7N9) pandemic" exact="influenza" post="outbreak in the United StatesBMC Public Health201717189810.1186/s12889-017-4884-529178863 31.YuanJLauEHLiKLeungYHYangZXieCLiuYLiuYMaXLiuJet al.Effect"/>
   <result pre="Public Health201717189810.1186/s12889-017-4884-529178863 31.YuanJLauEHLiKLeungYHYangZXieCLiuYLiuYMaXLiuJet al.Effect of live poultry market closure on" exact="avian influenza" post="A (H7N9) virus activity in Guangzhou, China, 2014Emerg Infect"/>
   <result pre="Health201717189810.1186/s12889-017-4884-529178863 31.YuanJLauEHLiKLeungYHYangZXieCLiuYLiuYMaXLiuJet al.Effect of live poultry market closure on avian" exact="influenza" post="A (H7N9) virus activity in Guangzhou, China, 2014Emerg Infect"/>
   <result pre="Infect Dis201521101784179310.3201/eid2110.15062326402310 32.WuYGaoGFLessons learnt from the human infections of avian-origin" exact="influenza" post="A H7N9 virus: live free markets and human healthSci"/>
   <result pre="Lu R, et al. A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. 2020;382(8):727–33."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7246361\results\search\disease\results.xml">
   <result pre="Research Articles Role of hematological parameters in the diagnosis of" exact="influenza" post="virus infection in patients with respiratory tract infection symptoms"/>
   <result pre="differential diagnoses of patients hospitalized for respiratory infections due to" exact="influenza" post="virus vs other pathogens are challenging. Our study investigated"/>
   <result pre="(L), platelet (PLT), and neutrophil�?to�?lymphocyte ratio (NLR) contributed in diagnosing" exact="influenza" post="virus infections and in discriminating other respiratory infections. Methods"/>
   <result pre="100 healthy people. Results The hematological parameters in patients with" exact="influenza" post="virus infection were dramatically altered compared with those in"/>
   <result pre="among the systemic inflammatory markers, the sensitivity of NLR for" exact="influenza" post="detection was higher than that of N and L."/>
   <result pre="that of N and L. PLT was significantly lower in" exact="influenza" post="virus�?positive infection than in influenza virus�?negative infection. Moreover, when"/>
   <result pre="PLT was significantly lower in influenza virus�?positive infection than in" exact="influenza" post="virus�?negative infection. Moreover, when patients with influenza virus infection"/>
   <result pre="infection than in influenza virus�?negative infection. Moreover, when patients with" exact="influenza" post="virus infection were cured, PLT returned to a normal"/>
   <result pre="The red blood cell (RBC) and hemoglobin (Hb) levels of" exact="influenza" post="virus infection were higher than those of bacterial infection."/>
   <result pre="and L, NLR and platelet�?to�?neutrophil (PNR) showed greater significance between" exact="influenza" post="virus and bacterial infection (P &amp;lt; .01). Conclusion Neutrophil�?to�?lymphocyte"/>
   <result pre="with high sensitivity is a preferable diagnostic tool to screen" exact="influenza" post="virus�?infected patients than N and L. PLT accounts in"/>
   <result pre="accounts in the differential diagnoses of respiratory infections due to" exact="influenza" post="virus and other pathogens among patients. In addition, RBC,"/>
   <result pre="addition, RBC, Hb, NLR, and PNR can significantly differentiate between" exact="influenza" post="virus infections and bacterial infections. hematological parameters influenza virus"/>
   <result pre="differentiate between influenza virus infections and bacterial infections. hematological parameters" exact="influenza" post="virus infection neutrophil�?to�?lymphocyte ratio platelet respiratory tract infection Funding"/>
   <result pre="et al. Role of hematological parameters in the diagnosis of" exact="influenza" post="virus infection in patients with respiratory tract infection symptoms."/>
   <result pre="are contributed equally to this work. 1 INTRODUCTION Annual seasonal" exact="influenza" post="epidemics of variable severity result in significant morbidity and"/>
   <result pre="variable severity result in significant morbidity and mortality worldwide.1 Since" exact="avian influenza" post="was first identified in Shanghai, China, in March 2013,"/>
   <result pre="severity result in significant morbidity and mortality worldwide.1 Since avian" exact="influenza" post="was first identified in Shanghai, China, in March 2013,"/>
   <result pre="there have been a total of five epidemics.2 Patients with" exact="influenza" post="virus mostly present with fever and cough are prone"/>
   <result pre="present with fever and cough are prone to progression to" exact="viral pneumonia." post="Moreover, in the event of acute respiratory distress and"/>
   <result pre="rate is even higher. In addition, late diagnosis of community�?acquired" exact="influenza" post="A virus infection is associated with a delay in"/>
   <result pre="recommended as critical diagnostic tests for clinical decision�?making according to" exact="influenza" post="clinical practice guidelines in different countries.4, 5 However, these"/>
   <result pre="community hospitals. Furthermore, antigen tests have poor sensitivity to some" exact="influenza" post="viruses.6, 7 Recently, it was reported that hematological inflammatory"/>
   <result pre="aimed to validate hematological indexes as potential indicators to discriminate" exact="influenza" post="virus infection from non�?influenza infection, which would facilitate a"/>
   <result pre="2.1 Study population The present study retrospectively enrolled 307 suspected" exact="influenza" post="virus�?infected patients with typical acute onset of respiratory symptoms"/>
   <result pre="from January 2017 to June 2019. The diagnostic criteria for" exact="influenza" post="virus infection included the guidelines for the diagnosis and"/>
   <result pre="infection included the guidelines for the diagnosis and treatment of" exact="influenza" post="combined with positive influenza virus nucleic acid detection. Bacterial"/>
   <result pre="for the diagnosis and treatment of influenza combined with positive" exact="influenza" post="virus nucleic acid detection. Bacterial infection was confirmed by"/>
   <result pre="by bacterial cultures. Finally, 107 patients were diagnosed with definite" exact="influenza" post="virus infection (influenza virus positive), of which 88 had"/>
   <result pre="influenza virus infection (influenza virus positive), of which 88 had" exact="influenza" post="A, 16 had influenza B, and 3 had combined"/>
   <result pre="virus positive), of which 88 had influenza A, 16 had" exact="influenza" post="B, and 3 had combined influenza A and B"/>
   <result pre="influenza A, 16 had influenza B, and 3 had combined" exact="influenza" post="A and B (53 male and 54 female; age"/>
   <result pre="blood count was routinely examined in hospitalized patients with suspected" exact="influenza" post="virus infection in the study. Two milliliters of peripheral"/>
   <result pre="WBC, N, RDW, NLR, and PLR increased significantly in the" exact="influenza" post="virus infection group compared with the healthy control (P"/>
   <result pre="and lymphocytes (Table 2). No significant differences were found between" exact="influenza" post="virus A and B. Table 1 Comparison of hematological"/>
   <result pre="and B. Table 1 Comparison of hematological parameters between the" exact="influenza" post="virus infection group and the healthy control group Influenza"/>
   <result pre="Wiley &amp;amp; Sons, Ltd, 3.2 Comparison of hematological parameters between" exact="influenza" post="virus�?positive infection and influenza virus�?negative infection In the present"/>
   <result pre="3.2 Comparison of hematological parameters between influenza virus�?positive infection and" exact="influenza" post="virus�?negative infection In the present paper, we found that"/>
   <result pre="present paper, we found that PLT was lower in the" exact="influenza" post="virus infection group (169.869 ± 93.379) than in the"/>
   <result pre="addition, L and PLT increased to normal levels concomitantly when" exact="influenza" post="patients were completely cured (P &amp;lt; .05). Furthermore, no"/>
   <result pre="were found to have significance with a complete cure of" exact="influenza" post="(P &amp;gt; .05) (Table 4). Table 3 Comparison of"/>
   <result pre=".05) (Table 4). Table 3 Comparison of hematological parameters between" exact="influenza" post="virus infection and negative control Influenza virus infection (N"/>
   <result pre="Sons, Ltd, 3.3 The differential sensitivity of hematological parameters between" exact="influenza" post="virus infection and bacterial infection Compared with bacterial infection,"/>
   <result pre="with bacterial infection, RBC, Hb, and PNR markedly increased in" exact="influenza" post="virus infection, while WBC, RDW, neutrophils, and NLR decreased"/>
   <result pre="decreased (Table 5). Table 5 Comparison of hematological parameters between" exact="influenza" post="virus infection and bacterial infection Influenza virus infection (N"/>
   <result pre="Wiley &amp;amp; Sons, Ltd, 4 DISCUSSION A late diagnosis of" exact="influenza" post="virus infection is associated with greater possibilities of respiratory"/>
   <result pre="mortality rate.3 Due to shared routes of transmission, coinfection with" exact="influenza" post="virus and bacteria has become common among individuals, making"/>
   <result pre="common among individuals, making it even more complicated to confirm" exact="influenza" post="virus infection and choose accurate treatments. As such, we"/>
   <result pre="As such, we demonstrated the relationships between laboratory parameters and" exact="influenza" post="virus infections, bacterial infections and non�?influenza virus infections. Blood"/>
   <result pre="rapid laboratory diagnostic basis for evaluating infectious inflammatory responses.11 The" exact="influenza" post="virus�?infected patients analyzed in this paper were mainly elderly"/>
   <result pre="controls were as close as possible to those of the" exact="influenza" post="virus�?infected group. The results showed that routine blood indicators"/>
   <result pre="study found that many hematological parameters changed significantly due to" exact="influenza" post="virus infection, such as PLT, WBC, RBC, Hb, and"/>
   <result pre="In addition, NLR was as a more sensitive parameter for" exact="influenza" post="virus infection than the other cell count parameters in"/>
   <result pre="was consistent with reports on many other diseases, such as" exact="lung cancer" post="and swine flu.8, 15, 16, 17, 18 A hemogram"/>
   <result pre="consistent with reports on many other diseases, such as lung" exact="cancer" post="and swine flu.8, 15, 16, 17, 18 A hemogram"/>
   <result pre="Here, we evaluated the early predictive value of NLR in" exact="influenza" post="virus infection. Additionally, no significant difference in hematological parameters"/>
   <result pre="difference in hematological parameters was found between different subtypes of" exact="influenza" post="virus A (20 H1N1, 9H7N9, and 10 H3), but"/>
   <result pre="in more cases. Among patients with typical symptoms of respiratory" exact="influenza" post="infection, only approximately 40% were truly infected by influenza"/>
   <result pre="respiratory influenza infection, only approximately 40% were truly infected by" exact="influenza" post="virus during its seasonal peak based on the results"/>
   <result pre="during the non�?epidemic season of influenza.19 The differential diagnosis of" exact="influenza" post="virus from other microbial infections based only on clinical"/>
   <result pre="In our retrospective analysis of the hematological parameters of suspected" exact="influenza" post="patients, PLT count was significantly lower (169.869 ± 93.379)"/>
   <result pre="patients, PLT count was significantly lower (169.869 ± 93.379) in" exact="influenza" post="virus�?positive patients than in negative controls (226.209 ± 119.245)"/>
   <result pre="(P &amp;lt; .001), suggesting that decreased PLT counts could differentiate" exact="influenza" post="virus infections from others. Furthermore, PLT count returned to"/>
   <result pre="Furthermore, PLT count returned to a normal level concomitantly while" exact="influenza" post="patients were completely cured, indicating that PLT count had"/>
   <result pre="that PLT count had a high correlation and specificity in" exact="influenza" post="laboratory diagnosis. This was the first study to present"/>
   <result pre="other reports on the mechanism of platelet inhibition induced by" exact="influenza" post="virus. It has been reported that influenza virus could"/>
   <result pre="inhibition induced by influenza virus. It has been reported that" exact="influenza" post="virus could induce uncontrolled platelet activation to fuel a"/>
   <result pre="23 We hypothesized that such excessive activation of platelets by" exact="influenza" post="virus may lead to a markedly decreased platelet count"/>
   <result pre="data demonstrated that RBC, Hb, and PNR were higher in" exact="influenza" post="virus infection than in bacterial infection. They were differential"/>
   <result pre="infection. They were differential diagnostic indicators for infection caused by" exact="influenza" post="virus vs bacteria. At present, it is well known"/>
   <result pre="virus vs bacteria. At present, it is well known that" exact="influenza" post="hemagglutinin readily binds to sialic acid receptors on the"/>
   <result pre="NLR was found to have a high sensitivity in detecting" exact="influenza" post="virus infection. PLT count had a high correlation and"/>
   <result pre="count had a high correlation and specificity to preliminarily discriminate" exact="influenza" post="virus infection from suspected influenza virus infection. In addition,"/>
   <result pre="and specificity to preliminarily discriminate influenza virus infection from suspected" exact="influenza" post="virus infection. In addition, RBC, Hb, NLR, and PNR"/>
   <result pre="NLR, and PNR showed some diagnostic value for differentiating between" exact="influenza" post="virus infection and bacterial infection. In summary, some hematological"/>
   <result pre="early laboratory indicators have promising value in the diagnosis of" exact="influenza" post="virus infection. Further investigation of the reference ranges of"/>
   <result pre="investigation of the reference ranges of hematological parameters based on" exact="influenza" post="virus infection and individual physiological levels is warranted. AUTHORS'"/>
   <result pre="JiangL�?N, NingC�?Y, et al. First outbreak of human infection with" exact="avian influenza" post="A(H7N9) virus in Guangxi, China, 2016 to 2017. Chin"/>
   <result pre="NingC�?Y, et al. First outbreak of human infection with avian" exact="influenza" post="A(H7N9) virus in Guangxi, China, 2016 to 2017. Chin"/>
   <result pre="2019;132(16):1995�?1997.31348034 3�?lvarez�?LermaF, Marín�?CorralJ, VilaC, et al. Delay in diagnosis of" exact="influenza" post="A (H1N1)pdm09 virus infection in critically ill patients and"/>
   <result pre="al. Diagnostic accuracy of novel and traditional rapid tests for" exact="influenza" post="infection compared with reverse transcriptase polymerase chain reaction: a"/>
   <result pre="Med. 2017;167(6):394�?409.28869986 7FaixDJ, ShermanSS, WatermanSH. Rapid�?test sensitivity for novel swine�?origin" exact="influenza" post="A (H1N1) virus in humans. N Engl J Med."/>
   <result pre="ratio can predict clinical outcomes in patients with metastatic non�?small�?cell" exact="lung cancer" post="treated with nivolumab. J Clin Lab Anal. 2019:33;e22964.31282096 9NaessA,"/>
   <result pre="can predict clinical outcomes in patients with metastatic non�?small�?cell lung" exact="cancer" post="treated with nivolumab. J Clin Lab Anal. 2019:33;e22964.31282096 9NaessA,"/>
   <result pre="2016;9(1940�?5901):11871�?11876. 12WenF, BedfordT, CobeyS. Explaining the geographical origins of seasonal" exact="influenza" post="A (H3N2). Proc Biol Sci. 1838;2016(283):20161312. 13HusainEH, Mullah�?AliA, Al�?SharidahS,"/>
   <result pre="1838;2016(283):20161312. 13HusainEH, Mullah�?AliA, Al�?SharidahS, AzabAF, AdekileA. Infectious etiologies of transient" exact="neutropenia" post="in previously healthy children. Pediatr Infect Dis J. 2012;31(6):575�?577.22414904"/>
   <result pre="et al. Platelet activation and aggregation promote lung inflammation and" exact="influenza" post="virus pathogenesis. Am J Respir Crit Care Med. 2015;191(7):804�?819.25664391"/>
   <result pre="The role of platelets in mediating a response to human" exact="influenza" post="infection. Nat Commun. 2019;10(1):1780.30992428 24NguyenM, FriesK, KhouryR, et al."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7247048\results\search\disease\results.xml">
   <result pre="day 56 50%100% 104104 MVA vectorRecombinant adenovirus type 5Recombinant vesicular" exact="stomatitis" post="virusRecombinant BoHV-4Recombinant adenovirus type 5Formalin inactivated vaccine GPCGPCNPNPNP (3010"/>
   <result pre="each of Rift Valley fever virus, CCHF, Hantaan virus and" exact="tick-borne encephalitis" post="virus DNA vaccine. iNon-neutralizing antibodies in vitro. jAntibody passive"/>
   <result pre="of Rift Valley fever virus, CCHF, Hantaan virus and tick-borne" exact="encephalitis" post="virus DNA vaccine. iNon-neutralizing antibodies in vitro. jAntibody passive"/>
   <result pre="Hantaan and Rift Valley fever viruses encoding the GPC and" exact="tick-borne encephalitis" post="virus encoding the premembrane and envelope genes (Table 1)."/>
   <result pre="and Rift Valley fever viruses encoding the GPC and tick-borne" exact="encephalitis" post="virus encoding the premembrane and envelope genes (Table 1)."/>
   <result pre="development comprise the modified Vaccinia Ankara virus (MVA),101,102 recombinant vesicular" exact="stomatitis" post="virus (rVSV),116 recombinant adenovirus type 5 (AdV-5),90,103 and recombinant"/>
   <result pre="1990;Suppl 1:323–340 19.Sadeuh-MbaSA, Yonga WansiGM, DemanouM, et al.Serological evidence of" exact="rift valley fever" post="Phlebovirus and Crimean-Congo hemorrhagic fever orthonairovirus infections among pygmies"/>
   <result pre="GriffinDE, GiffelsJJ, et al.Myelin basic protein as an encephalitogen in" exact="encephalomyelitis" post="and polyneuritis following rabies vaccination. N Engl J Med."/>
   <result pre="basic protein as an encephalitogen in encephalomyelitis and polyneuritis following" exact="rabies" post="vaccination. N Engl J Med. 1987;316:369–3742433582 85.BinsAD, van den"/>
   <result pre="MoquinA, et al.Contributions of antinucleoprotein IgG to heterosubtypic immunity against" exact="influenza" post="virus. J Immunol. 2011;186:4331–433921357542 93.AltamuraLA, Bertolotti-CiarletA, TeiglerJ, et al.Identification"/>
   <result pre="et al.Immunogenicity of combination DNA vaccines for Rift valley virus," exact="tick-borne encephalitis" post="virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus."/>
   <result pre="al.Immunogenicity of combination DNA vaccines for Rift valley virus, tick-borne" exact="encephalitis" post="virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus."/>
   <result pre="spectrum. Nat Rev Immunol. 2006;6:231–24316498452 116.RodriguezSE, CrossRW, FentonKA, et al.Vesicular" exact="stomatitis" post="virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. Sci"/>
   <result pre="and RANTES enhance antigen-specific Th1-type CD4+ T-cell-mediated protective immunity against" exact="herpes simplex" post="virus type 2 in vivo. J Virol. 2000;74:11173–1118011070014 125.KimJJ,"/>
   <result pre="T cell type 1 CD4+ T cell-mediated protective immunity against" exact="herpes simplex" post="virus type 2 in vivo. Hum Gene Ther. 2001;12:1091–110211399230"/>
   <result pre="MVA modified Vaccinia Ankara virus NP nucleoprotein rVSV recombinant vesicular" exact="stomatitis" post="virus s.c. subcutaneous SNPs single nucleotide polymorphisms Th T-helper"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7247193\results\search\disease\results.xml">
   <result pre="ZIKV is known to cause several debilitating neurological complications, including" exact="microcephaly" post="in newborns and Guillain Barré Syndrome in adults, described"/>
   <result pre="controlling major arboviruses of medical importance such as Zika, dengue," exact="yellow fever" post="and chikungunya. Maintenance rates were quite low compared to"/>
   <result pre="Ae. simpsoni which is one of the main vectors of" exact="yellow fever" post="in East Africa [49]. Nevertheless, further studies are needed"/>
   <result pre="Aedes albopictus?PLoS Negl Trop Dis.20148e268124516683 6.RothAMercierALepersCHoyDDuituturagaSBenyonEet al.Concurrent outbreaks of dengue," exact="chikungunya" post="and Zika virus infections – an unprecedented epidemic wave"/>
   <result pre="Hemisphere, 2015Emerg Infect Dis.20162293393527088323 10.CauchemezSBesnardMBompardPDubTGuillemette-ArturPEyrolle-GuignotDet al.Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013-15: a retrospective studyLancet.20163872125213226993883 11.CapassoAOmpadDCVieiraDLWilder-SmithATozanYIncidence of"/>
   <result pre="http://www.ansd.sn/index.php, Accessed 6 Mar 2017. 26.DialloDSallAABuenemannMChenRFayeODiagneCTet al.Landscape ecology of sylvatic" exact="chikungunya" post="virus and mosquito vectors in southeastern SenegalPLoS Negl Trop"/>
   <result pre="Dis.20126e164922720097 27.RichmanRDialloDDialloMSallAAFayeODiagneCTet al.Ecological niche modeling of Aedes mosquito vectors of" exact="chikungunya" post="virus in southeastern SenegalParasit Vectors.20181125529673389 28.Edwards FW. Mosquitoes of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7248199\results\search\disease\results.xml">
   <result pre="permitted which does not comply with these terms. Abstract Avian" exact="influenza" post="viruses (AIVs) cause major economic losses to the global"/>
   <result pre="as regulators of the inflammatory response and virus replication in" exact="influenza" post="A virus (IAV) infected cells including nucleotide-binding oligomerization domain"/>
   <result pre="IAV protein(s) that may regulate activation of NLRC5. NLRC5 chicken" exact="avian influenza" post="NFκB macrophage Funding College of Agricultural Sciences, Pennsylvania State"/>
   <result pre="protein(s) that may regulate activation of NLRC5. NLRC5 chicken avian" exact="influenza" post="NFκB macrophage Funding College of Agricultural Sciences, Pennsylvania State"/>
   <result pre="due to their wide host range and mutation frequency. Avian" exact="influenza" post="viruses (AIVs), have caused a significant socio-economic impact on"/>
   <result pre="severe or even fatal in the case of highly pathogenic" exact="avian influenza" post="viruses (HPAIVs). In such cases, death typically occurs within"/>
   <result pre="or even fatal in the case of highly pathogenic avian" exact="influenza" post="viruses (HPAIVs). In such cases, death typically occurs within"/>
   <result pre="(high expression). Viruses used in this study include: Low pathogenic" exact="avian influenza" post="viruses (LPAIVs) A/mallard/duck/England/7277/06 (H2N3), A/chicken/Pennsylvania/7659/1985 (H5N2) and A/chicken/Pennsylvania/3779-2/1997 (H7N2)"/>
   <result pre="expression). Viruses used in this study include: Low pathogenic avian" exact="influenza" post="viruses (LPAIVs) A/mallard/duck/England/7277/06 (H2N3), A/chicken/Pennsylvania/7659/1985 (H5N2) and A/chicken/Pennsylvania/3779-2/1997 (H7N2)"/>
   <result pre="A/mallard/duck/England/7277/06 (H2N3), A/chicken/Pennsylvania/7659/1985 (H5N2) and A/chicken/Pennsylvania/3779-2/1997 (H7N2) and highly pathogenic" exact="avian influenza" post="viruses (HPAIVs) A/turkey/England/50-92/91 (H5N1) of classical lineage, A/turkey/Turkey/1/05 (H5N1)"/>
   <result pre="(H2N3), A/chicken/Pennsylvania/7659/1985 (H5N2) and A/chicken/Pennsylvania/3779-2/1997 (H7N2) and highly pathogenic avian" exact="influenza" post="viruses (HPAIVs) A/turkey/England/50-92/91 (H5N1) of classical lineage, A/turkey/Turkey/1/05 (H5N1)"/>
   <result pre="Calculation of the relative equivalent units (REUs) was based on" exact="influenza" post="viral M gene amplification. For REU calculation, viral RNA"/>
   <result pre="during several viral infections in different cell types including Raus" exact="sarcoma" post="virus-infected A549 cells (Guo et al., 2015), cytomegalovirus-infected HFF"/>
   <result pre="wild-type macrophage suppresses the expression of NFκB pathway modulators, this" exact="suppression" post="was reversed when NLRC5 expression was decreased (Figure S2)."/>
   <result pre="shown activation of the NFκB pathway in the absence or" exact="suppression" post="of NLRC5 expression. Bone marrow-derived dendritic cells from NLRC5−/−"/>
   <result pre="References AlexanderD. J. (2007). An overview of the epidemiology of" exact="avian influenza." post="Vaccine25, 5637–5644. 10.1016/j.vaccine.2006.10.05117126960 AllenI. C.ScullM. A.MooreC. B.HollE. K.Mcelvania-TekippeE.TaxmanD. J.et"/>
   <result pre="(2009). The NLRP3 inflammasome mediates in vivo innate immunity to" exact="influenza" post="A virus through recognition of viral RNA. Immunity30, 556–565."/>
   <result pre="viral RNA. Immunity30, 556–565. 10.1016/j.immuni.2009.02.00519362020 BasunoE.YusdjaY.IlhamN. (2010). Socio-economic impacts of" exact="avian influenza" post="outbreaks on small-scale producers in Indonesia. Transbound. Emerg. Dis.57,"/>
   <result pre="RNA. Immunity30, 556–565. 10.1016/j.immuni.2009.02.00519362020 BasunoE.YusdjaY.IlhamN. (2010). Socio-economic impacts of avian" exact="influenza" post="outbreaks on small-scale producers in Indonesia. Transbound. Emerg. Dis.57,"/>
   <result pre="eggs. J. Vis. Exp.97:5242110.3791/52421 CapuaI.MutinelliF.Dalla PozzaM.DonatelliI.PuzelliS.CancellottiF. M. (2002). The 1999-2000" exact="avian influenza" post="(H7N1) epidemic in Italy: veterinary and human health implications."/>
   <result pre="J. Vis. Exp.97:5242110.3791/52421 CapuaI.MutinelliF.Dalla PozzaM.DonatelliI.PuzelliS.CancellottiF. M. (2002). The 1999-2000 avian" exact="influenza" post="(H7N1) epidemic in Italy: veterinary and human health implications."/>
   <result pre="Cell. Signal.23, 1515–1527. 10.1016/j.cellsig.2011.05.00421620960 IchinoheT.LeeH. K.OguraY.FlavellR.IwasakiA. (2009). Inflammasome recognition of" exact="influenza" post="virus is essential for adaptive immune responses. J. Exp."/>
   <result pre="J.BinghamJ.SchatK. A.ChenL. M.DonisR. O.LowenthalJ. W.et al.. (2011). Highly pathogenic (H5N1)" exact="avian influenza" post="induces an inflammatory T helper type 1 cytokine response"/>
   <result pre="A.ChenL. M.DonisR. O.LowenthalJ. W.et al.. (2011). Highly pathogenic (H5N1) avian" exact="influenza" post="induces an inflammatory T helper type 1 cytokine response"/>
   <result pre="Biol.90, 116–123. 10.1038/icb.2011.1721423263 KuchipudiS. V.TellabatiM.SebastianS.LondtB. Z.JansenC.VerveldeL.et al. (2014). Highly pathogenic" exact="avian influenza" post="virus infection in chickens but not ducks is associated"/>
   <result pre="116–123. 10.1038/icb.2011.1721423263 KuchipudiS. V.TellabatiM.SebastianS.LondtB. Z.JansenC.VerveldeL.et al. (2014). Highly pathogenic avian" exact="influenza" post="virus infection in chickens but not ducks is associated"/>
   <result pre="(2013). Excessive cytokine response to rapid proliferation of highly pathogenic" exact="avian influenza" post="viruses leads to fatal systemic capillary leakage in chickens."/>
   <result pre="Excessive cytokine response to rapid proliferation of highly pathogenic avian" exact="influenza" post="viruses leads to fatal systemic capillary leakage in chickens."/>
   <result pre="wide host gene expression analysis in chicken lungs infected with" exact="avian influenza" post="viruses. PLoS ONE11:e0153671. 10.1371/journal.pone.015367127071061 RanjanP.SinghN.KumarA.NeerincxA.KremmerE.CaoW. P.et al.. (2015). NLRC5"/>
   <result pre="host gene expression analysis in chicken lungs infected with avian" exact="influenza" post="viruses. PLoS ONE11:e0153671. 10.1371/journal.pone.015367127071061 RanjanP.SinghN.KumarA.NeerincxA.KremmerE.CaoW. P.et al.. (2015). NLRC5"/>
   <result pre="interacts with RIG-I to induce a robust antiviral response against" exact="influenza" post="virus infection. Eur. J. Immunol.45, 758–772. 10.1002/eji.20134441225404059 SamiullahS.RobertsJ.WuS. B."/>
   <result pre="J.22, 2552–2560. 10.1093/emboj/cdg26712773372 ShawM. L. (2011). The host interactome of" exact="influenza" post="virus presents new potential targets for antiviral drugs. Rev."/>
   <result pre="of a real-time reverse transcriptase PCR assay for type A" exact="influenza" post="virus and the avian H5 and H7 hemagglutinin subtypes."/>
   <result pre="(2009). Association of increased pathogenicity of Asian H5N1 highly pathogenic" exact="avian influenza" post="viruses in chickens with highly efficient viral replication accompanied"/>
   <result pre="Association of increased pathogenicity of Asian H5N1 highly pathogenic avian" exact="influenza" post="viruses in chickens with highly efficient viral replication accompanied"/>
   <result pre="intracellular sensor NLRP3 mediates key innate and healing responses to" exact="influenza" post="A virus via the regulation of caspase-1. Immunity30, 566–575."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7248559\results\search\disease\results.xml">
   <result pre="the RVFV structural glycoprotein (GP) genes under control of the" exact="vaccinia virus" post="P7.5K early/late promoter inserted into the LSDV viral thymidine"/>
   <result pre="Control animal D2-2's temperature peaked at 42.2°C and it developed" exact="diarrhea" post="6 dpc. One control animal (D2-5) died at 5"/>
   <result pre="as has been the case for other poxviruses such as" exact="vaccinia virus" post="and canarypox virus, but with the added advantage of"/>
   <result pre="of the order Bunyavirales. Arch Virol. (2019) 164:1949–65. 10.1007/s00705-019-04253-631065850 7.DaubneyRHudsonJREnzootic" exact="hepatitis" post="or rift valley fever. J Path and Bact. (1931)"/>
   <result pre="order Bunyavirales. Arch Virol. (2019) 164:1949–65. 10.1007/s00705-019-04253-631065850 7.DaubneyRHudsonJREnzootic hepatitis or" exact="rift valley fever." post="J Path and Bact. (1931) 34:54510.1002/path.1700340418 8.DaviesFG. Risk of"/>
   <result pre="Transient marker stabilisation: a general procedure to construct marker-free recombinant" exact="vaccinia virus." post="Arch Virol. (1998) 143:467–74. 10.1007/s0070500503039572548 19.MollaWde JongCMGariGFrankenaKEconomic impact of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7252251\results\search\disease\results.xml">
   <result pre="192Ir, 60Co, 137Cs) are also utilized to examine and treat" exact="cancer" post="patients by shrinking tumors and killing cancer cells [26]."/>
   <result pre="examine and treat cancer patients by shrinking tumors and killing" exact="cancer" post="cells [26]. Radioactive materials could cause many serious negative"/>
   <result pre="one of the most widely prescribed medicines to treat epilepsy," exact="trigeminal neuralgia," post="and some other psychiatric diseases (e.g., bipolar affective disorders),"/>
   <result pre="treatment becomes much difficult thereafter. The most popular examples are" exact="severe acute respiratory syndrome" post="(SARS) occurred in 2002 [41]; 8422 persons were infected"/>
   <result pre="and caused 33 deaths, there were also 470 persons encountering" exact="kidney failure" post="[42]. 3.4 The transportation of pharmaceuticals and pathogens in"/>
   <result pre="[54]. For example, NDM-1 is a typical representative of super" exact="viral disease." post="NDM-1 is in fact a super virus resistance gene,"/>
   <result pre="which are closely related to pathogens in shellfish, can spread" exact="typhoid fever." post="Besides, marine worms also carry pathogens due to predation,"/>
   <result pre="The presence of cyclophosphamide and ifosfamide in water could induce" exact="cancer" post="risk to humans. In the cancer and tumor treatment,"/>
   <result pre="in water could induce cancer risk to humans. In the" exact="cancer" post="and tumor treatment, large amount of the antitumor agents"/>
   <result pre="of shiga toxin-converting bacteriophages in Escherichia coliJ. Bacteriol.1952220135007501523995636 42ChanH.L.Y.TsuiS.K.W.SungJ.J.Y.Coronavirus in" exact="severe acute respiratory syndrome" post="(SARS)Trends Mol. Med.98200332332512928031 43FerrerM.Méndez-GarcíaC.RojoD.BarbasC.MoyaA.Antibiotic use and microbiome functionBiochem. Pharmacol.134201711412627641814"/>
   <result pre="pharmaceuticals in the environmentTrAC Trends Anal. Chem.307201110651087 64KuemmererK.Al-AhmadA.Estimation of the" exact="cancer" post="risk to humans resulting from the presence of cyclophosphamide"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7252625\results\search\disease\results.xml">
   <result pre="found that in Uganda community experience with control programs on" exact="sleeping sickness" post="remains in the memories of people for decades and"/>
   <result pre="of embarrassment in gynaecological screening: a qualitative study from ASPIRE" exact="cervical cancer" post="screening project in Uganda. BMJ Open2016;4: e00478310.1136/bmjopen-2014-00478324727360 17SzarewskiA, CadmanL,"/>
   <result pre="embarrassment in gynaecological screening: a qualitative study from ASPIRE cervical" exact="cancer" post="screening project in Uganda. BMJ Open2016;4: e00478310.1136/bmjopen-2014-00478324727360 17SzarewskiA, CadmanL,"/>
   <result pre="LehaneMJ, TorrSJ, et al.We remember. Elders’ memories and perceptions of" exact="sleeping sickness" post="control interventions in West Nile, Uganda. PLoS Negl Trop"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7252634\results\search\disease\results.xml">
   <result pre="source are credited.ppat.1008517.pdf Abstract Ross River fever is a mosquito-transmitted" exact="viral disease" post="that is endemic to Australia and the surrounding Pacific"/>
   <result pre="domain II of the E1 glycoprotein of the related alphavirus" exact="chikungunya" post="virus (CHIKV) are important targets of neutralizing antibodies [22–24]."/>
   <result pre="Residues that result in loss of Mxra8 binding to cell-surface-displayed" exact="chikungunya" post="proteins are mapped onto the CHIKV E1/E2 trimer of"/>
   <result pre="different competition-binding groups, in an immunocompetent mouse model of RRV-induced" exact="myositis" post="where infection results in high viral burden in muscles"/>
   <result pre="broad and ultrapotent human monoclonal antibodies with therapeutic activity against" exact="chikungunya" post="virus. Cell Host Microbe. 2015;18: 86–95. 10.1016/j.chom.2015.06.00926159721 23ChuaCL, ChanYF,"/>
   <result pre="LissNM, ChenD-H, LiaoM, FoxJM, ShimakRM, et al.Neutralizing monoclonal antibodies block" exact="chikungunya" post="virus entry and release by targeting an epitope critical"/>
   <result pre="28BasoreK, KimAS, NelsonCA, ZhangR, SmithBK, UrangaC, et al.Cryo-EM structure of" exact="chikungunya" post="virus in complex with the Mxra8 receptor. Cell. 2019;177:"/>
   <result pre="et al.Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to" exact="chikungunya" post="virus envelope protein. Cell. 2019. 30SheehanKCF, LaiKS, DunnGP, BruceAT,"/>
   <result pre="tropism and virus-induced inflammation in a mouse model of viral" exact="arthritis" post="and myositis. J Virol. 2006;80: 737–749. 10.1128/JVI.80.2.737-749.200616378976 32HaistKC, BurrackKS,"/>
   <result pre="al.4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine" exact="encephalitis" post="virus. EMBO J. 2011;30: 3854–3863. 10.1038/emboj.2011.26121829169 35NelsonMA, HerreroLJ, JefferyJAL,"/>
   <result pre="mRNA encoding a potently neutralizing human monoclonal antibody protects against" exact="chikungunya" post="infection. Sci Immunol. 2019;4: eaaw664710.1126/sciimmunol.aaw664731101672 43RousselA, LescarJ, VaneyM-C, WenglerG,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7252670\results\search\disease\results.xml">
   <result pre="DENV serotypes and/or other arboviruses such as Zika virus or" exact="chikungunya" post="virus [9]. Interestingly, in 2012, DENV-1 genotype I &quot;Asia�?"/>
   <result pre="demonstrated the ability of Ae. aegypti from NC to transmit" exact="chikungunya" post="or Zika viruses [14, 15]. Few data, however, are"/>
   <result pre="dengue control.Curr Opin Infect Dis. 2017;30(5):449–54. 10.1097/QCO.000000000000039428719400 4GublerDJ. Dengue and" exact="dengue hemorrhagic fever." post="Clin Microbiol Rev. 1998;11(3):480–96. 9665979 5WeaverSC, VasilakisN. Molecular evolution"/>
   <result pre="Aedes aegypti populations in Madeira Island to transmit dengue and" exact="chikungunya" post="viruses.Parasit Vectors.2018;11(1):50910.1186/s13071-018-3081-430208974 26GayeA, WangE, VasilakisN, GuzmanH, DialloD, TallaC, et"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7253103\results\search\disease\results.xml">
   <result pre="for improved surveillance, especially in resource-poor settings. Dengue virus (DENV)," exact="chikungunya" post="virus (CHIKV), and Zika virus (ZIKV) share the same"/>
   <result pre="to suggest alarming global expansion of two other mosquito-borne viruses," exact="chikungunya" post="(CHIKV) and Zika (ZIKV) viruses.3–5 In Southeast Asia (SEA),"/>
   <result pre="reverse transcription real-time polymerase chain reaction detection of dengue virus," exact="chikungunya" post="virus, and Zika virus RNA Chikungunya: Pastorino et al.14"/>
   <result pre="areas that need them most. In Laos, access to laboratory" exact="infectious disease" post="diagnostics is largely confined to the capital city, Vientiane,"/>
   <result pre="extremely useful for the combined surveillance of dengue, Zika, and" exact="chikungunya" post="viruses in Laos, and locations with similar environments. Although"/>
   <result pre="Am J Trop Med Hyg97: 146–150.28719300 5.WahidBAliARafiqueSIdreesM, 2017Global expansion of" exact="chikungunya" post="virus: mapping the 64-year history. Int J Infect Dis58:"/>
   <result pre="RNA extraction step for the detection and quantification of African" exact="chikungunya" post="viruses. J Virol Methods124: 65–71.15664052 15.Leparc-GoffartIBaragattiMTemmamSTuiskunenAMoureauGCharrelRde LamballerieX, 2009Development and"/>
   <result pre="and clinical presentation in Nicaraguan patients infected with Zika virus," exact="chikungunya" post="virus, and dengue virus. Clin Infect Dis63: 1584–1590.27578819 19.PhommanivongVKandaSShimonoTLamaningaoPDarcyAWMishimaNPhaytanavanhBNishiyamaT,"/>
   <result pre="Clin Infect Dis63: 1584–1590.27578819 19.PhommanivongVKandaSShimonoTLamaningaoPDarcyAWMishimaNPhaytanavanhBNishiyamaT, 2016Co-circulation of the dengue with" exact="chikungunya" post="virus during the 2013 outbreak in the southern part"/>
   <result pre="emergence of arthropod-borne viral diseases: a global prospective on dengue," exact="chikungunya" post="and Zika fevers. Acta Trop166: 155–163.27876643"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7254658\results\search\disease\results.xml">
   <result pre="(TB) and human immunodeficiency virus (HIV) co-infection constitute a deadly" exact="infectious disease" post="synergy disease and major public health problem throughout the"/>
   <result pre="Tuberculosis (TB) and HIV make up a deadly synergy of" exact="infectious disease," post="and the combined effect is apparent in resource-limited countries"/>
   <result pre="rest of the world population [2]. The overlap of latent" exact="tuberculosis" post="infection (LTBI) and HIV infection has resulted in marked"/>
   <result pre="activities for IPT among other interventions such as viral load" exact="suppression" post="and retention. The coaches supported sites quality improvement teams"/>
   <result pre="Isoniazid preventive therapy IP Implementing partner INH Isoniazid/isonicotinylhydrazide LTBI Latent" exact="tuberculosis" post="infection MoH Ministry of Health HIV Human immunodeficiency virus"/>
   <result pre="and controlMediterr J Hematol Infect Dis.20146110.4084/mjhid.2014.070 2.World Health Organization. Global" exact="tuberculosis" post="control. WHO report 2017. https://www.who.int/tb/publications/global_report/gtbr2017. Accessed 2 Aug 2017."/>
   <result pre="Med20131631009102110.1001/archinte.163.9.1009 4.World Health Organization. Guidelines on the management of latent" exact="tuberculosis" post="infection. Geneva: WHO; 2015 (http://www.who.int/tb/publications/ltbidocument_page/en/. Accessed 30 Aug 2016."/>
   <result pre="studyAIDS.201024Suppl 5S49S5610.1097/01.aids.0000391022.95412.a6 12.NanooAIzuAIsmailNAIhekweazuCAbubakarIMametjaDet al.Nationwide and regional incidence of microbiologically confirmed" exact="pulmonary tuberculosis" post="in South Africa, 2004–12: a time series analysisLancet Infect"/>
   <result pre="5S49S5610.1097/01.aids.0000391022.95412.a6 12.NanooAIzuAIsmailNAIhekweazuCAbubakarIMametjaDet al.Nationwide and regional incidence of microbiologically confirmed pulmonary" exact="tuberculosis" post="in South Africa, 2004–12: a time series analysisLancet Infect"/>
   <result pre="era: a systematic reviewInt J Tuberc Lung Dis.201115672272810.5588/ijtld.10.028421477422 15.WynneAshleyRichterSolinaBanuraLilianKippWalterChallenges in" exact="tuberculosis" post="care in Western Uganda: health care worker and patient"/>
   <result pre="perspectives InternationalJ Afr Nurs Sci20141610 16.BamLMcLarenZMCoetzeeEVon LeipzigKHReducing stock-outs of essential" exact="tuberculosis" post="medicines: a system dynamics modelling approach to supply chain"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7255596\results\search\disease\results.xml">
   <result pre="(CZS) [2], Guillain-Barré syndrome (GBS) [3], and rare cases of" exact="encephalopathy" post="[4], meningoencephalitis [5], myelitis [6], uveitis [7], and severe"/>
   <result pre="Guillain-Barré syndrome (GBS) [3], and rare cases of encephalopathy [4]," exact="meningoencephalitis" post="[5], myelitis [6], uveitis [7], and severe thrombocytopenia [8]."/>
   <result pre="(GBS) [3], and rare cases of encephalopathy [4], meningoencephalitis [5]," exact="myelitis" post="[6], uveitis [7], and severe thrombocytopenia [8]. ZIKV is"/>
   <result pre="and rare cases of encephalopathy [4], meningoencephalitis [5], myelitis [6]," exact="uveitis" post="[7], and severe thrombocytopenia [8]. ZIKV is mainly transmitted"/>
   <result pre="encephalopathy [4], meningoencephalitis [5], myelitis [6], uveitis [7], and severe" exact="thrombocytopenia" post="[8]. ZIKV is mainly transmitted through the bite of"/>
   <result pre="responsible also for limiting the severity of illness caused by" exact="influenza" post="[59]. This suggests that the CD4+ T cell response"/>
   <result pre="cytokine-secreting and T cell-activating capacities of pDCs. In addition, during" exact="influenza" post="infection pDCs are capable of priming primary and secondary"/>
   <result pre="between the more recent DENV epidemics in Brazil and the" exact="microcephaly" post="epidemic observed after the introduction of ZIKV was in"/>
   <result pre="10.1056/NEJMc1602964 .26958738 6MecharlesS, HerrmannC, PoullainP, TranTH, DeschampsN, MathonG, et al.Acute" exact="myelitis" post="due to Zika virus infection. Lancet. 2016;387(10026):148110.1016/S0140-6736(16)00644-9 .26946926 7FurtadoJM,"/>
   <result pre="burden of disease caused by co-circulation and co-infection of dengue," exact="chikungunya" post="and Zika in the Americas. Travel medicine and infectious"/>
   <result pre="dengue, chikungunya and Zika in the Americas. Travel medicine and" exact="infectious disease." post="2016;14(3):177–9. Epub 2016/05/26. 10.1016/j.tmaid.2016.05.004 .27224471 16LesslerJ, ChaissonLH, KucirkaLM, BiQ,"/>
   <result pre="that maternal dengue antibodies are important in the development of" exact="dengue hemorrhagic fever" post="in infants. The American journal of tropical medicine and"/>
   <result pre="et al.Original antigenic sin and apoptosis in the pathogenesis of" exact="dengue hemorrhagic fever." post="Nature medicine. 2003;9(7):921–7. Epub 2003/06/17. 10.1038/nm887 .12808447 26PantojaP, Perez-GuzmanEX,"/>
   <result pre="al.Preexisting influenza-specific CD4+ T cells correlate with disease protection against" exact="influenza" post="challenge in humans. Nature medicine. 2012;18(2):274–80. Epub 2012/01/31. 10.1038/nm.2612"/>
   <result pre="al.Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during" exact="influenza" post="virus infection. Journal of virology. 2013;87(21):11884–93. Epub 2013/08/30. 10.1128/JVI.01461-13"/>
   <result pre="10.3390/microorganisms8010056 .31905661 75CarvalhoMS, FreitasLP, CruzOG, BrasilP, BastosLS. Association of past" exact="dengue fever" post="epidemics with the risk of Zika microcephaly at the"/>
   <result pre="of past dengue fever epidemics with the risk of Zika" exact="microcephaly" post="at the population level in Brazil. Sci Rep. 2020;10(1):1752"/>
   <result pre="77RobbianiDF, OlsenPC, CostaF, WangQ, OliveiraTY, NeryNJr., et al.Risk of Zika" exact="microcephaly" post="correlates with features of maternal antibodies. J Exp Med."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7256184\results\search\disease\results.xml">
   <result pre="Abstract In July–December 2018, an outbreak of polio-like acute flaccid" exact="myelitis" post="(AFM) occurred in Zhejiang province, China. Enterovirus (EV)-D68 infection"/>
   <result pre="predominant lineage circulating in Zhejiang province in 2018. acute flaccid" exact="myelitis" post="enterovirus spinal gray matter pleocytosis magnetic resonance imaging cerebrospinal"/>
   <result pre="October 2000 (3). Acute flaccid paralysis (AFP), including acute flaccid" exact="myelitis" post="(AFM), Guillain–Barré syndrome, acute transverse myelitis, acute disseminated encephalomyelitis"/>
   <result pre="including acute flaccid myelitis (AFM), Guillain–Barré syndrome, acute transverse myelitis," exact="acute disseminated encephalomyelitis" post="(ADEM), toxic neuropathy, and other muscle disorders, is defined"/>
   <result pre="flaccid myelitis (AFM), Guillain–Barré syndrome, acute transverse myelitis, acute disseminated" exact="encephalomyelitis" post="(ADEM), toxic neuropathy, and other muscle disorders, is defined"/>
   <result pre="(4). In 2014, an outbreak of EV-D68 infection, an emerging" exact="infectious disease," post="was determined to be associated with a cluster of"/>
   <result pre="of the following viruses: human enterovirus (HEV); human rhinovirus (HRV);" exact="influenza" post="virus A and B (including subtype determination); human adenovirus;"/>
   <result pre="B; human coronavirus (hCoV)-OC43,−229E, -NL63, and -HKU1; human metapneumovirus (hMPV);" exact="measles" post="virus; mumps virus; herpes simplex virus; and West Nile"/>
   <result pre="coronavirus (hCoV)-OC43,−229E, -NL63, and -HKU1; human metapneumovirus (hMPV); measles virus;" exact="mumps" post="virus; herpes simplex virus; and West Nile virus. Additionally,"/>
   <result pre="-NL63, and -HKU1; human metapneumovirus (hMPV); measles virus; mumps virus;" exact="herpes simplex" post="virus; and West Nile virus. Additionally, for EV detection,"/>
   <result pre="suckling mice, and they found that EV-D68 strains cause paralytic" exact="myelitis" post="and the spinal cord is the major site of"/>
   <result pre="Sci Rep. (2016) 6:25147. 10.1038/srep2514727121085 3.LiangXZhangYXuWWenNZuoSLeeLAet al.. An outbreak of" exact="poliomyelitis" post="caused by type 1 vaccine-derived poliovirus in china. J"/>
   <result pre="Ann Neurol. (2016) 80:326–38. 10.1002/ana.2473027422805 7.Van HarenKAyscuePWaubantEClaytonASheriffHYagiSet al.. Acute flaccid" exact="myelitis" post="of unknown etiology in california, 2012-2015. JAMA. (2015) 314:2663–71."/>
   <result pre="colorado, uSA. Lancet. (2015) 385:1662–71. 10.1016/S0140-6736(14)62457-025638662 9.HubnerJKruseBChristenHJWeidenmannJWeinerVSchone-BakeJCet al.. Acute flaccid" exact="myelitis" post="in german children in 2016-the return of polio?Dtsch Arztebl"/>
   <result pre="10.3238/arztebl.2017.055128855045 10.KnoesterMHelfferichJPoelmanRVanLeer-Buter CBrouwerOFNiestersHGMet al.. Twenty-nine cases of enterovirus-D68-associated acute flaccid" exact="myelitis" post="in europe 2016: a Case series and epidemiologic overview."/>
   <result pre="A novel outbreak enterovirus d68 strain associated with acute flaccid" exact="myelitis" post="cases in the uSA (2012-14): a retrospective cohort study."/>
   <result pre="(2016) 22:1387–94. 10.3201/eid2208.15194927434186 13.ChongPFKiraRMoriHOkumuraATorisuHYasumotoSet al.. Clinical features of acute flaccid" exact="myelitis" post="temporally associated with an enterovirus d68 outbreak: results of"/>
   <result pre="2015. Clin Infect Dis. (2018) 66:653–64.29028962 14.CarballoCMErroMGSordelliNVazquezGMistchenkoASCejasCet al.. Acute flaccid" exact="myelitis" post="associated with enterovirus d68 in children, argentina, (2016). Emerg"/>
   <result pre="Dis. (2019) 25:170897. 10.3201/eid2503.17089730602120 15.DydaAStelzer-BraidSAdamDChughtaiAAMacIntyreCR. The association between acute flaccid" exact="myelitis" post="(AFM) and enterovirus d68 (EV-D68) - what is the"/>
   <result pre="Comm Dis Bull. (2018) 23:310. 10.2807/1560-7917.ES.2018.23.3.17-0031029386095 16.SejvarJJLopezASCorteseMMLeshemEPastulaDMMillerLet al.. Acute flaccid" exact="myelitis" post="in the United states, august-December 2014: results of nationwide"/>
   <result pre="Neurol Neurosurg Psychiatry. (2014) 85:907–13. 10.1136/jnnp-2013-30621224357682 19.KruppLBTardieuMAmatoMPBanwellBChitnisTDaleRCet al.. International pediatric" exact="multiple sclerosis" post="study group criteria for pediatric multiple sclerosis and immune-mediated"/>
   <result pre="al.. International pediatric multiple sclerosis study group criteria for pediatric" exact="multiple sclerosis" post="and immune-mediated central nervous system demyelinating disorders: revisions to"/>
   <result pre="(2002) 59:499–505. 10.1212/WNL.59.4.49912236201 21.JinLFengYParryRCuiALuY. Real-time pCR and its application to" exact="mumps" post="rapid diagnosis. J Med Virol. (2007) 79:1761–7. 10.1002/jmv.2088017854025 22.UsukuSNoguchiYTakasakiT."/>
   <result pre="JAMA Pediatr. (2018) 10.1001/jamapediatrics.2018.489030500056 27.GiombiniERuecaMBarberiWIoriAPCastillettiCScognamiglioPet al.. Enterovirus d68-Associated acute flaccid" exact="myelitis" post="in immunocompromised woman, italy. Emerg Infect Dis. (2017) 23:1690–3."/>
   <result pre="10.3201/eid2310.17079228930024 28.OkumuraAMoriHFee ChongPKiraRTorisuHYasumotoSet al.. Serial mRI findings of acute flaccid" exact="myelitis" post="during an outbreak of enterovirus d68 infection in japan."/>
   <result pre="Paediatr Neurol. (2017) 21:884–90. 10.1016/j.ejpn.2017.07.00828747261 30.Stelzer-BraidSRawlinsonW. Outbreaks of acute flaccid" exact="myelitis" post="in the uS. BMJ. (2018) 363:k5246. 10.1136/bmj.k524630567703 31.GimferrerLCampinsMCodinaMGEsperalbaJMartin MdelCFuentesFet"/>
   <result pre="(2018) 10:58. 10.3390/v1002005829385753 35.HixonAMYuGLeserJSYagiSClarkePChiuCYet al.. A mouse model of paralytic" exact="myelitis" post="caused by enterovirus d68. PLoS Pathog. (2017) 13:e1006199. 10.1371/journal.ppat.100619928231269"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7256917\results\search\disease\results.xml">
   <result pre="of SIRS criteria and qSOFA score for in-hospital mortality among" exact="influenza" post="patients in the emergency department ChuSheng-En123SeakChen-June13SuTse-Hsuan13ChaouChung-Hsien134TsengHsiao-Jung5http://orcid.org/0000-0002-2235-8914LiChih-Huangchhli2002@gmail.com136[1], grid.454211.70000 0004 1756"/>
   <result pre="a credit line to the data. Abstract Background The seasonal" exact="influenza" post="epidemic is an important public health issue worldwide. Early"/>
   <result pre="in the emergency department (ED). Similarly as with bacterial infection," exact="influenza" post="can cause sepsis. This study was conducted to investigate"/>
   <result pre="research database. Adult ED patients (age ≥ 18 at admission) with laboratory-proven" exact="influenza" post="from 2010 to 2016 were included for data analysis."/>
   <result pre="The qSOFA score potentially is a useful prognostic predictor for" exact="influenza" post="and could be applied in the ED as a"/>
   <result pre="poor sensitivity. The SIRS criteria showed poor predictive performance in" exact="influenza" post="for mortality as an outcome. Further research is needed"/>
   <result pre="needed to determine the role of these predictive tools in" exact="influenza" post="and in other viral infections. Keywords &quot;Influenza�? &quot;Mortality�? &quot;Predictors�?"/>
   <result pre="&quot;Sirs�? Funding http://dx.doi.org/10.13039/501100005795Chang Gung Memorial Hospital, Linkou CORPG3F0911LiChih-Huang Background Worldwide," exact="influenza" post="has long been a threat to public health [1]."/>
   <result pre="been a threat to public health [1]. Patients’ outcomes in" exact="influenza" post="range from simple upper respiratory infection (URI) to acute"/>
   <result pre="simple upper respiratory infection (URI) to acute lung injury (ALI)," exact="acute respiratory distress syndrome" post="(ARDS), and multiorgan dysfunction syndrome. Influenza progresses rapidly and"/>
   <result pre="and leads to morbidity and mortality within days [2]. Furthermore," exact="influenza" post="increases the mortality of vulnerable patient groups [3]. A"/>
   <result pre="65 and 74 years, and ≥ 75 years, respectively [4]. A global pandemic of" exact="influenza" post="(H1N1) occurred in 2009 and caused more than 18,000"/>
   <result pre="2015 to early 2016, resulting in more than 2000 severe" exact="influenza" post="cases (85.5 per million population) and over 160 deaths"/>
   <result pre="emergency department (ED) [8]. The first clinical prediction rule of" exact="influenza" post="infection, comprising 9 parameters, was published in 2004 [9]."/>
   <result pre="hypoxia, bilateral lung infiltration, and old age [10]. The geriatric" exact="influenza" post="death (GID) score and the Shock Index were recently"/>
   <result pre="were recently reported to be prediction rules for patients with" exact="influenza" post="[11]. However, not all prediction rules that have been"/>
   <result pre="response results in severe sepsis and poor outcomes [12]. An" exact="influenza" post="infection shares many common pathways with the immune response"/>
   <result pre="can trigger a similar physiologic inflammatory cascade [12, 13]. Furthermore," exact="influenza" post="could impair antibacterial immune defense mechanisms [14–18] and lead"/>
   <result pre="Asia found that 4% of all sepsis was caused by" exact="influenza" post="viruses [21]. In 1992, the American College of Chest"/>
   <result pre="score in predicting the in-hospital mortality of patients with an" exact="influenza" post="infection. An accurate prediction tool will aid early risk"/>
   <result pre="aid early risk stratification and rapid treatment of patients with" exact="influenza" post="in the ED. Methods Study design and setting This"/>
   <result pre="our ED committee. Most of these patients received the rapid" exact="influenza" post="diagnostic test (RIDT) or influenza reverse transcription-polymerase chain reaction"/>
   <result pre="these patients received the rapid influenza diagnostic test (RIDT) or" exact="influenza" post="reverse transcription-polymerase chain reaction (RT-PCR) test. However, to avoid"/>
   <result pre="the same diagnosis, they were considered to have the same" exact="influenza" post="episode, and data from their last visit would be"/>
   <result pre="patients who visited the ED, 9693 patients tested positive for" exact="influenza" post="A or B; of these, 3561 were adults and"/>
   <result pre="and have been included in our analysis. Four major seasonal" exact="influenza" post="epidemics were recorded between 2010 and 2016 in Taiwan"/>
   <result pre="2016, with more than 350 visits of adult patients with" exact="influenza" post="per month. Fig. 1 The flow chart of sample"/>
   <result pre="analysis Fig. 2 Number of emergency department visits with positive" exact="influenza" post="diagnostic test by months Baseline patient characteristics are shown"/>
   <result pre="results (Fig. 3b). Table 1 Baseline characteristics of patients with" exact="influenza" post="Mean ± SD / N (%) Age 48.08 ± 19.51 Sex = male 1716 (48.19)"/>
   <result pre="disease-rheumatic disease 157 (4.41)  Peptic ulcer disease 850 (23.87)  Mild" exact="liver disease" post="706 (19.83)  Diabetes mellitus, without complications 767 (21.54)  Diabetes,"/>
   <result pre=" Renal disease 644 (18.08)  Cancer 469 (13.17)  Moderate or severe" exact="liver disease" post="83 (2.33)  Metastatic carcinoma 124 (3.48)  AIDS/HIV 14 (0.39)"/>
   <result pre="Thus, the qSOFA score is a better tool to predict" exact="influenza" post="outcomes. Table 4 Predictive performance of SIRS and qSOFA"/>
   <result pre="LR+ positive likelihood ratio, LR- negative likelihood ratio Discussion Worldwide," exact="influenza" post="epidemics emerge almost every year and patient visits to"/>
   <result pre="to the ED increase dramatically during the flu seasons. Most" exact="influenza" post="infections are self-limiting and manageable with symptomatic treatment, and"/>
   <result pre="some patients. Severely ill patients may progress to acute hypoxic" exact="respiratory failure" post="within 24 h even if the initial chest x-ray shows"/>
   <result pre="finding was related to the septic reaction induced by the" exact="influenza" post="or a secondary bacterial infection. The SIRS criteria have"/>
   <result pre="and we included patients with positive RT-PCR test results for" exact="influenza" post="to reduce bias. We found that the SIRS had"/>
   <result pre="studies have reported the use of different prognostic scales of" exact="pneumonia" post="to evaluate influenza [39–44]. Myles et al. [39] compared"/>
   <result pre="the use of different prognostic scales of pneumonia to evaluate" exact="influenza" post="[39–44]. Myles et al. [39] compared the performance of"/>
   <result pre="Pneumonia Severity Index, severity score for the elderly with community-acquired" exact="pneumonia" post="score, SMART-COP Score, and Simple Triage Scoring System, to"/>
   <result pre="and Simple Triage Scoring System, to predict the outcomes of" exact="influenza" post="in the ED [40, 43]. These researchers found that"/>
   <result pre="admission. In the present study, we did not compare these" exact="pneumonia" post="scales because all of these scoring tools need further"/>
   <result pre="required to define the roles of these scoring tools for" exact="influenza" post="in the ED. Other studies have attempted to use"/>
   <result pre="of lactate dehydrogenase &amp;gt; 600 IU/L was associated with mortality in influenza-induced" exact="pneumonia" post="[46]. However, both of the abovementioned studies were limited"/>
   <result pre="blood tests will not be conducted for every patient with" exact="influenza" post="in a busy ED, especially during an epidemic outbreak."/>
   <result pre="to estimate the mortality rates of the human highly pathogenic" exact="avian influenza" post="(HPAI) A/H5N1 based on significant predictors of influenza mortality,"/>
   <result pre="estimate the mortality rates of the human highly pathogenic avian" exact="influenza" post="(HPAI) A/H5N1 based on significant predictors of influenza mortality,"/>
   <result pre="pathogenic avian influenza (HPAI) A/H5N1 based on significant predictors of" exact="influenza" post="mortality, including age, duration from symptom onset to hospitalization,"/>
   <result pre="study design. In addition, we might not have ordered an" exact="influenza" post="test for everyone presenting to the ED with fever"/>
   <result pre="symptoms, especially in the non-flu season. Moreover, all tests for" exact="influenza" post="generate false negatives. These factors might induce some bias."/>
   <result pre="The qSOFA score is potentially a useful prognostic predictor for" exact="influenza" post="and could be applied in the ED after triage,"/>
   <result pre="high-risk patients. The SIRS criteria had poor predictive performance for" exact="influenza" post="outcomes. Further studies are needed to determine whether there"/>
   <result pre="for the qSOFA score in the assessment of patients with" exact="influenza" post="as well as other viral respiratory infections. Abbreviations ALI"/>
   <result pre="assessment tools CAP Severity Score for the Elderly with community-acquired" exact="pneumonia" post="ED Emergency department GID Geriatric influenza death GCS Glasgow"/>
   <result pre="the Elderly with community-acquired pneumonia ED Emergency department GID Geriatric" exact="influenza" post="death GCS Glasgow Coma Scale HPAI Highly pathogenic avian"/>
   <result pre="Geriatric influenza death GCS Glasgow Coma Scale HPAI Highly pathogenic" exact="avian influenza" post="ICU Intensive care unit LDH Lactate dehydrogenase MEDS Mortality"/>
   <result pre="influenza death GCS Glasgow Coma Scale HPAI Highly pathogenic avian" exact="influenza" post="ICU Intensive care unit LDH Lactate dehydrogenase MEDS Mortality"/>
   <result pre="Index qSOFA quick Sequential (Sepsis-related) Organ Failure Assessment RIDT Rapid" exact="influenza" post="diagnostic test RT-CPR Reverse transcription-polymerase chain reaction ROC Receiver"/>
   <result pre="epidemiology of influenza: past and presentAnnu Rev Med20005140742110774473 2.HarperSABradleyJSEnglundJAFileTMGravensteinSHaydenFGet al.Seasonal" exact="influenza" post="in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak"/>
   <result pre="of the Infectious Diseases Society of AmericaClin Infect Dis2009481003103219281331 3.NguyenJLYangWItoKMatteTDShamanJKinneyPLSeasonal" exact="influenza" post="infections and cardiovascular disease mortalityJAMA Cardiol2016127428127438105 4.IulianoADRoguskiKMChangHHMuscatelloDJPalekarRTempiaSet al.Estimates of"/>
   <result pre="Diseases Society of AmericaClin Infect Dis2009481003103219281331 3.NguyenJLYangWItoKMatteTDShamanJKinneyPLSeasonal influenza infections and" exact="cardiovascular disease" post="mortalityJAMA Cardiol2016127428127438105 4.IulianoADRoguskiKMChangHHMuscatelloDJPalekarRTempiaSet al.Estimates of global seasonal influenza-associated respiratory"/>
   <result pre="al.Epidemiology, seasonality and treatment of hospitalized adults and adolescents with" exact="influenza" post="in Jingzhou, China, 2010-2012PLoS One201611e015071326958855 7.HsiehYCTsaoKCHuangCTChangKYHuangYCGongYNClinical characteristics of patients"/>
   <result pre="Jingzhou, China, 2010-2012PLoS One201611e015071326958855 7.HsiehYCTsaoKCHuangCTChangKYHuangYCGongYNClinical characteristics of patients with laboratory-confirmed" exact="influenza" post="a (H1N1) pdm09 during the 2013/2014 and 2015/2016 clade"/>
   <result pre="validation of a clinical prediction rule for hospitalization due to" exact="pneumonia" post="or influenza or death during influenza epidemics among community-dwelling"/>
   <result pre="a clinical prediction rule for hospitalization due to pneumonia or" exact="influenza" post="or death during influenza epidemics among community-dwelling elderly personsJ"/>
   <result pre="for hospitalization due to pneumonia or influenza or death during" exact="influenza" post="epidemics among community-dwelling elderly personsJ Infect Dis2004189345045814745702 10.OhWSLeeSJLeeCSHurJAHurACParkYSet al.A"/>
   <result pre="to identify severe cases among adult patients hospitalized with pandemic" exact="influenza" post="a (H1N1) 2009J Korean Med Sci20112649950621468256 11.ChungJYHsuCCChenJHChenWLLinHJGuoHRet al.Geriatric influenza"/>
   <result pre="pandemic influenza a (H1N1) 2009J Korean Med Sci20112649950621468256 11.ChungJYHsuCCChenJHChenWLLinHJGuoHRet al.Geriatric" exact="influenza" post="death (GID) score: a new tool for predicting mortality"/>
   <result pre="a new tool for predicting mortality in older people with" exact="influenza" post="in the emergency departmentSci Rep20188931229915256 12.FlorescuDFKalilACThe complex link between"/>
   <result pre="influenza in the emergency departmentSci Rep20188931229915256 12.FlorescuDFKalilACThe complex link between" exact="influenza" post="and severe sepsisVirulence.2014513714224253109 13.LjungstromLRJacobssonGClaessonBEBAnderssonREnrothHRespiratory viral infections are underdiagnosed in"/>
   <result pre="otitis mediaInfect Immun1982362892967076299 16.NickersonCLJakabGJPulmonary antibacterial defenses during mild and severe" exact="influenza" post="virus infectionInfect Immun199058280928142143751 17.HinshawVSOlsenCWDybdahl-SissokoNEvansDApoptosis: a mechanism of cell killing"/>
   <result pre="virus infectionInfect Immun199058280928142143751 17.HinshawVSOlsenCWDybdahl-SissokoNEvansDApoptosis: a mechanism of cell killing by" exact="influenza" post="a and B virusesJ Virol199468366736738189504 18.ColamussiMLWhiteMRCrouchEHartshornKLInfluenza a virus accelerates"/>
   <result pre="bacteriaBlood.1999932395240310090951 19.KalilACThomasPGInfluenza virus-related critical illness: pathophysiology and epidemiologyCrit Care20192325831324202 20.JainSBenoitSRSkarbinskiJBramleyAMFinelliLPandemic" exact="influenza" post="AVHIT: influenza-associated pneumonia among hospitalized patients with 2009 pandemic"/>
   <result pre="critical illness: pathophysiology and epidemiologyCrit Care20192325831324202 20.JainSBenoitSRSkarbinskiJBramleyAMFinelliLPandemic influenza AVHIT: influenza-associated" exact="pneumonia" post="among hospitalized patients with 2009 pandemic influenza a (H1N1)"/>
   <result pre="influenza AVHIT: influenza-associated pneumonia among hospitalized patients with 2009 pandemic" exact="influenza" post="a (H1N1) virus--United States, 2009Clin Infect Dis2012541221122922437239 21.collab: Southeast"/>
   <result pre="with pneumoniaPLoS One201712e018891329267291 29.RanzaniOTPrinaEMenendezRCeccatoACillonizCMendezRet al.New sepsis definition (Sepsis-3) and community-acquired" exact="pneumonia" post="mortality. A validation and clinical decision-making studyAm J Respir"/>
   <result pre="response syndrome criteria in predicting mortality among geriatric patients with" exact="influenza" post="in the emergency departmentBMC Infect Dis20191963931324224 39.MylesPRNguyen-Van-TamJSLimWSNicholsonKGBrettSJEnstoneJEet al.Comparison of"/>
   <result pre="of CATs, CURB-65 and PMEWS as triage tools in pandemic" exact="influenza" post="admissions to UK hospitals: case control analysis using retrospective"/>
   <result pre="control analysis using retrospective dataPLoS One20127e3442822509303 40.EstellaAUsefulness of CURB-65 and" exact="pneumonia" post="severity index for influenza a H1N1v pneumoniaMonaldi Arch Chest"/>
   <result pre="dataPLoS One20127e3442822509303 40.EstellaAUsefulness of CURB-65 and pneumonia severity index for" exact="influenza" post="a H1N1v pneumoniaMonaldi Arch Chest Dis20127711812123461247 41.MulrennanSTemponeSSLingITWilliamsSHGanGCMurrayRJet al.Pandemic influenza"/>
   <result pre="for influenza a H1N1v pneumoniaMonaldi Arch Chest Dis20127711812123461247 41.MulrennanSTemponeSSLingITWilliamsSHGanGCMurrayRJet al.Pandemic" exact="influenza" post="(H1N1) 2009 pneumonia: CURB-65 score for predicting severity and"/>
   <result pre="are unreliablePLoS One20105e1284920877727 42.FujikuraYKawanoSKouzakiYShinodaMHaraYShinkaiMet al.Mortality and severity evaluation by routine" exact="pneumonia" post="prediction models among Japanese patients with 2009 pandemic influenza"/>
   <result pre="routine pneumonia prediction models among Japanese patients with 2009 pandemic" exact="influenza" post="a (H1N1) pneumoniaRespir Investig20145228028725169843 43.MullerMPMcGeerAJHassanKMarshallJChristianMcollab: Toronto Invasive Bacterial Disease"/>
   <result pre="(H1N1) pneumoniaRespir Investig20145228028725169843 43.MullerMPMcGeerAJHassanKMarshallJChristianMcollab: Toronto Invasive Bacterial Disease NetworkEvaluation of" exact="pneumonia" post="severity and acute physiology scores to predict ICU admission"/>
   <result pre="for influenzaPLoS One20105e956320221431 44.ChoiWIYimJJParkJKimSCNaMJLeeWYet al.Clinical characteristics and outcomes of H1N1-associated" exact="pneumonia" post="among adults in South KoreaInt J Tuberc Lung Dis20111527027521219693"/>
   <result pre="an early predictor of outcome in patients with pandemic H1N1" exact="influenza" post="a virus infectionBMC Infect Dis20101028820920320 46.ReyesSMontullBMartinezRCordobaJMolinaJMMartiVet al.Risk factors of"/>
   <result pre="infectionBMC Infect Dis20101028820920320 46.ReyesSMontullBMartinezRCordobaJMolinaJMMartiVet al.Risk factors of a/H1N1 etiology in" exact="pneumonia" post="and its impact on mortalityRespir Med20111051404141121561754 47.PatelRBMathurMBGouldMUyekiTMBhattacharyaJXiaoYet al.Demographic and"/>
   <result pre="47.PatelRBMathurMBGouldMUyekiTMBhattacharyaJXiaoYet al.Demographic and clinical predictors of mortality from highly pathogenic" exact="avian influenza" post="a (H5N1) virus infection: CART analysis of international casesPLoS"/>
   <result pre="al.Demographic and clinical predictors of mortality from highly pathogenic avian" exact="influenza" post="a (H5N1) virus infection: CART analysis of international casesPLoS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7258707\results\search\disease\results.xml">
   <result pre="therapies approved by the Food and Drug Administration for countering" exact="anthrax" post="and under development for treatment of Ebola virus infection"/>
   <result pre="by the US Army. Keywords therapeutics biothreat pathogens antibacterial antiviral" exact="anthrax" post="Ebola 1 Introduction The concept of bioterrorism and the"/>
   <result pre="coronaviruses Severe acute respiratory distress CNipah and Hendra viruses Viral" exact="encephalitis" post="and respiratory disease ARift Valley fever virus Rift Valley"/>
   <result pre="acute respiratory distress CNipah and Hendra viruses Viral encephalitis and" exact="respiratory disease" post="ARift Valley fever virus Rift Valley fever BVenezuelan equine"/>
   <result pre="disease ARift Valley fever virus Rift Valley fever BVenezuelan equine" exact="encephalitis" post="virus Encephalitis and fever ALassa virus Lassa fever ASouth"/>
   <result pre="spore-forming bacterium that causes cutaneous, respiratory, or intestinal forms of" exact="anthrax" post="disease, which is an acute, rapidly progressing infection in"/>
   <result pre="aerosol route, thus making it a dangerous bacterium [7]. The" exact="anthrax" post="attacks in 2001 caused widespread panic, damage, disease, and"/>
   <result pre="the early stage of the infection. Two monoclonal antibody (mAB)–based" exact="anthrax" post="antitoxin therapeutics [Abthrax (raxibacumab) and Anthim (obiltoxaximab)] have been"/>
   <result pre="and included in the Strategic National Stockpile for treating inhalational" exact="anthrax" post="[8]. BioThrax, the only licensed anthrax vaccine, is indicated"/>
   <result pre="Stockpile for treating inhalational anthrax [8]. BioThrax, the only licensed" exact="anthrax" post="vaccine, is indicated for preexposure prophylaxis of disease in"/>
   <result pre="Intravenous, human-derived antibotulism toxin antibodies for the treatment of infant" exact="botulism" post="types A and B, and Botulism Antitoxin Heptavalent (A–G),"/>
   <result pre="The nonmotile bacillus B. mallei is the causative agent of" exact="glanders" post="that usually infects equids but is highly infectious to"/>
   <result pre="to persistent infections. F. tularensis is the causative agent of" exact="tularemia" post="and is highly infectious, resulting in an acute, rapidly"/>
   <result pre="virus (VARV) is the causative agent of smallpox, a human" exact="viral disease" post="for which tecovirimat was recently approved as a therapeutic"/>
   <result pre="are also biothreat concerns. For the alphaviruses specifically, the Venezuelan" exact="encephalitis" post="viruses (VEEV), Eastern encephalitis viruses, and Western equine encephalitis"/>
   <result pre="For the alphaviruses specifically, the Venezuelan encephalitis viruses (VEEV), Eastern" exact="encephalitis" post="viruses, and Western equine encephalitis viruses belonging to the"/>
   <result pre="Venezuelan encephalitis viruses (VEEV), Eastern encephalitis viruses, and Western equine" exact="encephalitis" post="viruses belonging to the family Togaviridae are found in"/>
   <result pre="from GPs of viruses such as Ebola, Nipah, Hendra, and" exact="severe acute respiratory syndrome" post="and Middle East respiratory syndrome coronavirus and containing Cat"/>
   <result pre="positron emission tomography; RSV, respiratory syncytial virus; TP, triphosphate; VEEV," exact="venezuelan equine encephalitis" post="virus. Table 7.4 Antiviral therapeutics (small molecules, antibodies, and"/>
   <result pre="tomography; RSV, respiratory syncytial virus; TP, triphosphate; VEEV, venezuelan equine" exact="encephalitis" post="virus. Table 7.4 Antiviral therapeutics (small molecules, antibodies, and"/>
   <result pre="F. tularensis LVS could be successfully used to treat LVS-induced" exact="pneumonia" post="but not a F. tularensis type A strain. Anti-LVS"/>
   <result pre="extracellular virion NHP: prophylactic antibody treatment can protect against severe" exact="monkeypox" post="disease in marmoset model [148] PoxviridaeVariola MultipleMV, H3, A27,"/>
   <result pre="effective than antibiotics alone in a rabbit model of inhalational" exact="anthrax" post="and improved survival compared to the antibiotic treatment alone"/>
   <result pre="treatment alone [155] Ciprofloxacin Clindamycin Treatment of rabbits with systemic" exact="anthrax" post="with clindamycin and ciprofloxacin had improved efficacy compared to"/>
   <result pre="antiprotective antigen (PA IgG) antibodies and ciprofloxacin in a rodent" exact="anthrax" post="model increased survival significantly compared to ciprofloxacin treatment alone"/>
   <result pre="10-fold lower development of resistance compared to antibiotics used for" exact="anthrax" post="treatment in humans [159] Penicillin, meropenem, or rifampin Linezolid"/>
   <result pre="[159] Penicillin, meropenem, or rifampin Linezolid Treatment of antibiotic-resistant inhalation" exact="anthrax" post="with linezolid and penicillin, meropenem, or rifampin had the"/>
   <result pre="fluoroquinolone-resistant B. anthracis infection [160] Rifampin Clindamycin Combination therapy for" exact="anthrax" post="with rifampin and clindamycin was shown to be synergistic"/>
   <result pre="spp. Doxycycline Rifampin Successful combination therapies used to treat pulmonary" exact="brucellosis" post="in humans is doxycycline and rifampin for 6 weeks"/>
   <result pre="using heat-killed B. mallei can protect BALB/c mice from lethal" exact="glanders" post="infection, potentially by stimulating immune responses, such as gamma"/>
   <result pre="for genetically diverse extremely drug resistant isolates of Burkholderia from" exact="cystic fibrosis" post="patients by binding PenA and the combination treatment significantly"/>
   <result pre="with Q fever endocarditis. And a case of Q fever" exact="endocarditis" post="with biological prosthetic aortic valve and aortic homograft was"/>
   <result pre="survival of rats following infection with Y. pestis [176] AIGIV," exact="anthrax" post="immune globulin intravenous; IFN, interferon; LPS, lipopolysaccharide; PA, protective"/>
   <result pre="(a breathing stimulant) mitigated fatal Y. pestis infection in a" exact="pneumonic plague" post="murine model [207]. At 48 h postinfection, these drugs"/>
   <result pre="breathing stimulant) mitigated fatal Y. pestis infection in a pneumonic" exact="plague" post="murine model [207]. At 48 h postinfection, these drugs"/>
   <result pre="with up to 100% protection against challenge with bubonic or" exact="pneumonic plague" post="agents when administered in combination with levofloxacin [208]. Multiple"/>
   <result pre="up to 100% protection against challenge with bubonic or pneumonic" exact="plague" post="agents when administered in combination with levofloxacin [208]. Multiple"/>
   <result pre="been shown to improve the efficacy of postexposure therapeutics against" exact="smallpox" post="[214]. Sometimes modulation of host pathophysiological responses can be"/>
   <result pre="under the FDA’s Animal Efficacy Rule for treatment of inhalation" exact="anthrax" post="[8]. For treatment of Ebola infection, the single mAb"/>
   <result pre="combination of nucleoside, nonnucleoside, protease, and/or host-targeted inhibitors) or chronic" exact="hepatitis" post="C virus infection (e.g., combination of polymerase and RNA-binding"/>
   <result pre="to reach infected tissue. For example, countermeasures against pathogens causing" exact="encephalitis" post="require drug to reach the central nervous system (CNS)."/>
   <result pre="products, including several therapeutics for anthrax, plague, botulinum toxin, and" exact="smallpox" post="[8], [29]. The Animal Rule does not provide an"/>
   <result pre="capabilities. Three FDA-approved drugs have shown potential in mice against" exact="pneumonic plague" post="[207]. Serious challenges still remain with the prevalence of"/>
   <result pre="Three FDA-approved drugs have shown potential in mice against pneumonic" exact="plague" post="[207]. Serious challenges still remain with the prevalence of"/>
   <result pre="Centers for Disease Control and Prevention EBOV Ebola virus EEEV" exact="eastern equine encephalitis" post="virus EF edema factor ELISA enzyme-linked immunosorbent assay EPEC"/>
   <result pre="Disease Control and Prevention EBOV Ebola virus EEEV eastern equine" exact="encephalitis" post="virus EF edema factor ELISA enzyme-linked immunosorbent assay EPEC"/>
   <result pre="target product profile US United States VARV variola virus VEEV" exact="venezuelan equine encephalitis" post="virus VGCC voltage-gated calcium channel VLP virus-like particle WEEV"/>
   <result pre="profile US United States VARV variola virus VEEV venezuelan equine" exact="encephalitis" post="virus VGCC voltage-gated calcium channel VLP virus-like particle WEEV"/>
   <result pre="VGCC voltage-gated calcium channel VLP virus-like particle WEEV Western equine" exact="encephalitis" post="virus Y2H yeast two-hybrid References References 1GreenM.S.LeDucJ.CohenD.FranzD.R.Confronting the threat"/>
   <result pre="anti-plague monoclonal antibodies protect mice from Yersinia pestis in a" exact="bubonic plague" post="modelPLoS One5102010e1304720976274 23NakkaziE.Randomised controlled trial begins for Ebola therapeuticsLancet392101622018233830527603"/>
   <result pre="monoclonal antibodies protect mice from Yersinia pestis in a bubonic" exact="plague" post="modelPLoS One5102010e1304720976274 23NakkaziE.Randomised controlled trial begins for Ebola therapeuticsLancet392101622018233830527603"/>
   <result pre="of tecovirimat for the treatment of smallpoxLancet Infect Dis1962019e221e22430853252 31KupferschmidtK.Labmade" exact="smallpox" post="is possible, study showsScience3576347201711511628706017 32DupuyL.C.SchmaljohnC.S.DNA vaccines for biodefenseExpert Rev"/>
   <result pre="of a small-molecule entry inhibitor for filovirusesJ Virol85720113106311921270170 53XiaoJ.H.RijalP.SchimanskiL.TharkeshwarA.K.WrightE.AnnaertW.Characterization of" exact="influenza" post="virus pseudotyped with ebolavirus glycoproteinJ Virol9242018 54BaeS.E.KimS.S.MoonS.T.ChoY.D.LeeH.LeeJ.Y.Construction of the"/>
   <result pre="drugsSci Rep912019539730932009 67ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.Identification of a broad-spectrum antiviral small molecule against" exact="severe acute respiratory syndrome" post="coronavirus and Ebola, Hendra, and Nipah viruses by using"/>
   <result pre="host proteins important for entry of Marburg virus and H5N1" exact="influenza" post="virusVirol J12201519426596270 82DeffrasnesC.MarshG.A.FooC.H.RootesC.L.GouldC.M.GrusovinJ.Genome-wide siRNA screening at biosafety level 4"/>
   <result pre="plasma concentrations to improve treatment response in patients with chronic" exact="hepatitis" post="CJ Antimicrob Chemother62620081174118018931138 115UckunF.M.PetkevichA.S.VassilevA.O.TibblesH.E.TitovL.Stampidine prevents mortality in an experimental"/>
   <result pre="related thereto2015 119JonssonC.B.CaoX.LeeJ.GabbardJ.D.ChuY.K.FitzpatrickE.A.Efficacy of a ML336 derivative against Venezuelan and" exact="eastern equine encephalitis" post="virusesAntiviral Res1672019253430970271 120SchroederC.E.YaoT.SotskyJ.SmithR.A.RoyS.ChuY.K.Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as"/>
   <result pre="119JonssonC.B.CaoX.LeeJ.GabbardJ.D.ChuY.K.FitzpatrickE.A.Efficacy of a ML336 derivative against Venezuelan and eastern equine" exact="encephalitis" post="virusesAntiviral Res1672019253430970271 120SchroederC.E.YaoT.SotskyJ.SmithR.A.RoyS.ChuY.K.Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as"/>
   <result pre="120SchroederC.E.YaoT.SotskyJ.SmithR.A.RoyS.ChuY.K.Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of" exact="venezuelan equine encephalitis" post="virusJ Med Chem572020148608862125244572 121FlorescuD.F.KalilA.C.HewlettA.L.SchuhA.J.StroherU.UyekiT.M.Administration of brincidofovir and convalescent plasma"/>
   <result pre="(E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine" exact="encephalitis" post="virusJ Med Chem572020148608862125244572 121FlorescuD.F.KalilA.C.HewlettA.L.SchuhA.J.StroherU.UyekiT.M.Administration of brincidofovir and convalescent plasma"/>
   <result pre="and therapy against Nipah virus infection in hamstersJ Virol80420061972197816439553 148MuckerE.M.Wollen-RobertsS.E.KimmelA.ShamblinJ.SampeyD.HooperJ.W.Intranasal" exact="monkeypox" post="marmoset model: Prophylactic antibody treatment provides benefit against severe"/>
   <result pre="monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe" exact="monkeypox" post="virus diseasePLoS Negl Trop Dis1262018e000658129927927 149BregenholtS.JensenA.LanttoJ.HyldigS.HaurumJ.S.Recombinant human polyclonal antibodies:"/>
   <result pre="not purified in mosquitoesJ Virol881520148213822624829346 155KammanadimintiS.PatnaikuniR.K.ComerJ.MeisterG.SinclairC.KodihalliS.Combination therapy with antibiotics and" exact="anthrax" post="immune globulin intravenous (AIGIV) is potentially more effective than"/>
   <result pre="anthraxPLoS One992014e10639325226075 156WeissS.AltboumZ.GlinertI.SchlomovitzJ.SittnerA.Bar-DavidE.Efficacy of single and combined antibiotic treatments of" exact="anthrax" post="in rabbitsAntimicrob Agents Chemother591220157497750326392505 157KarginovV.A.RobinsonT.M.RiemenschneiderJ.GoldingB.KennedyM.ShiloachJ.Treatment of anthrax infection with"/>
   <result pre="antibiotic treatments of anthrax in rabbitsAntimicrob Agents Chemother591220157497750326392505 157KarginovV.A.RobinsonT.M.RiemenschneiderJ.GoldingB.KennedyM.ShiloachJ.Treatment of" exact="anthrax" post="infection with combination of ciprofloxacin and antibodies to protective"/>
   <result pre="160HeineH.S.ShadomyS.V.BoyerA.E.ChuvalaL.RigginsR.KestersonA.Evaluation of combination drug therapy for treatment of antibiotic-resistant inhalation" exact="anthrax" post="in a murine modelAntimicrob Agents Chemother6192017 161AthamnaA.AthamnaM.NuraA.ShlyakovE.BastD.J.FarrellD.Is in vitro"/>
   <result pre="reviewExpert Rev Anti Infect Ther1512017334227790937 163WaagD.M.Efficacy of postexposure therapy against" exact="glanders" post="in miceAntimicrob Agents Chemother59420152236224125645854 164SaqibM.MuhammadG.NaureenA.HussainM.H.AsiM.N.MansoorM.K.Effectiveness of an antimicrobial treatment"/>
   <result pre="Chemother59420152236224125645854 164SaqibM.MuhammadG.NaureenA.HussainM.H.AsiM.N.MansoorM.K.Effectiveness of an antimicrobial treatment scheme in a confined" exact="glanders" post="outbreakBMC Vet Res8201221423134717 165BrilhanteR.S.ValenteL.G.RochaM.F.BandeiraT.J.CordeiroR.A.LimaR.A.Sesquiterpene farnesol contributes to increased susceptibility"/>
   <result pre="restores susceptibility to ceftazidime for burkholderia cepacia complex isolates from" exact="cystic fibrosis" post="patientsACS Infect Dis37201750251128264560 167MosovskyK.SilvaE.TroyerR.Propst-GrahamK.DowS.Interaction of Interferon gamma-induced reactive oxygen"/>
   <result pre="evolution of Burkholderia pseudomallei during chronic infection of seven Australasian" exact="cystic fibrosis" post="patientsMBio822017 187WebbJ.R.PriceE.P.CurrieB.J.SarovichD.S.Loss of methyltransferase function and increased efflux activity"/>
   <result pre="214IsraelyT.MelamedS.AchdoutH.ErezN.PolitiB.WanerT.TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live" exact="smallpox" post="vaccinesPLoS One9102014e11054525350003 215LeeA.Y.VlasukG.P.Recombinant nematode anticoagulant protein c2 and other"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7259386\results\search\disease\results.xml">
   <result pre="minimization of immunopathology. Keywords cognition glia neuroimmune T cells viral" exact="encephalitis" post="INTRODUCTION The central nervous system (CNS) has evolved multiple"/>
   <result pre="proliferation and activation of regulatory T cells (Treg) during acute" exact="lymphocytic choriomeningitis" post="virus (LCMV) infection, and effector functions of CD8 and"/>
   <result pre="produce CCL2 in multiple neurologic disease, such as experimental autoimmune" exact="encephalomyelitis" post="(EAE) [25], mechanical injury [26], and WNV infection [23▪]."/>
   <result pre="that were acutely infected via intravenous (i.v.) injection of Japanese" exact="encephalitis" post="virus (JEV) [20]. High levels of CCR2 expression were"/>
   <result pre="the source of CCL5 in WNV infection [19]. ZIKV and" exact="tick-borne encephalitis" post="virus (TBEV), another neurotropic flavivirus endemic to Europe and"/>
   <result pre="source of CCL5 in WNV infection [19]. ZIKV and tick-borne" exact="encephalitis" post="virus (TBEV), another neurotropic flavivirus endemic to Europe and"/>
   <result pre="Mosquito-borne and tick-borne neurotropic arboviruses cause annual epidemics of virus-induced" exact="encephalitis" post="throughout the world and are considered some of the"/>
   <result pre="cells control viral reactivation and activation state of microglia Theiler's" exact="encephalomyelitis" post="virus (TMEV) Ratio of CD8:CD4 T cells in the"/>
   <result pre="62:16–27.29521099 5AmarillaAASantos-JuniorNNFigueiredoMLet al.CCR2 plays a protective role in rocio virus-induced" exact="encephalitis" post="by promoting macrophage infiltration into the brain. J Infect"/>
   <result pre="CXCL9 and CXCL10 are required for the development of murine" exact="cerebral malaria." post="Proc Natl Acad Sci USA2008; 105:4814–4819.18347328 12FunkKEKleinRSCSF1R antagonism limits"/>
   <result pre="T cells infiltrate the central nervous system during acute Japanese" exact="encephalitis" post="virus infection. Virol Sin2019; 34:538–548.31215000 21▪▪GarberCSoungAVollmerLLet al.T cells promote"/>
   <result pre="infection in primary human astrocytes. BMC Neurosci2018; 19:5.29463209 23▪ZhengZYangJJiangXet al.Tick-borne" exact="encephalitis" post="virus nonstructural protein NS5 induces RANTES expression dependent on"/>
   <result pre="Oswaldo Cruz2018; 113:e170542.29768624 27PatabendigeAMichaelBDCraigAGSolomonTBrain microvascular endothelial-astrocyte cell responses following Japanese" exact="encephalitis" post="virus infection in an in vitro human blood-brain barrier"/>
   <result pre="disease. Int J Infect Dis2013; 17:e494–7.23317528 58CapuzzoMCadorinDPernaPet al.West Nile Virus" exact="encephalitis" post="in intensive care: a small mosquito, a tremendous danger."/>
   <result pre="T Cells, CD8 T cells, and monocytes coordinate to prevent" exact="rift valley fever" post="virus encephalitis. J Virol2018; 92: e01270–18. 70DePaula-SilvaABSondereggerFLLibbeyJEet al.The immune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7259492\results\search\disease\results.xml">
   <result pre="Emergency of International Concern [9]. Despite this, Zika virus and" exact="microcephaly" post="continued to spread to Brazil’s neighbors and Northward to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7259790\results\search\disease\results.xml">
   <result pre="with two divergent arboviruses: dengue virus-2 (DENV-2; Flaviviridae, Flavivirus) and" exact="chikungunya" post="virus (CHIKV; Togaviridae, Alphavirus). While assessing the role of"/>
   <result pre="infection, we observed a somewhat paradoxical outcome. Both induction and" exact="suppression" post="of autophagy via torin-1 and spautin-1, respectively, resulted in"/>
   <result pre="respectively, resulted in increased viral titers for both viruses, yet" exact="suppression" post="of autophagy-related genes had no effect. Interestingly, chemical modulators"/>
   <result pre="tropics, the emergent epidemics of Zika virus (ZIKV; Flaviviridae, Flavivirus)," exact="chikungunya" post="virus (CHIKV; Togaviridae, Alphavirus) and West Nile virus (WNV;"/>
   <result pre="Flaviviridae, Flavivirus) in the Americas, and the sporadic outbreaks of" exact="yellow fever" post="virus (YFV; Flaviviridae, Flavivirus) in Africa and South America."/>
   <result pre="activity has been linked to a number of pathologies, including" exact="cancer" post="and neurodegenerative diseases [3]. This evolutionarily conserved pathway mediates"/>
   <result pre="inhibition and induction of autophagy both increased viral titers, while" exact="suppression" post="of autophagy related genes had no effect. Interestingly, chemical"/>
   <result pre="DMSO control. All experiments were completed in triplicate. Autophagy gene" exact="suppression" post="Aedes aegypti Atg5, Atg14, Atg8 and luciferase genes were"/>
   <result pre="and paradoxical findings, we examined the effects of autophagy through" exact="suppression" post="of three genes within the autophagy pathway: Atg5 (required"/>
   <result pre="of Aag2 cells with gene specific dsRNA resulted in significant" exact="suppression" post="of Atg5 and Atg14 as determined by RT-qPCR as"/>
   <result pre="or 48 hpi compared to the control (Fig 5A). Likewise" exact="suppression" post="of Atg5 and Atg14 had no effect on CHIKV"/>
   <result pre="and mammalian cells upon spautin-1 treatment. Paradoxically, chemical induction and" exact="suppression" post="of autophagy and inhibition of autophagolysosomal acidification all resulted"/>
   <result pre="an attempt to reconcile these conflicting results, we performed RNAi" exact="suppression" post="of autophagy genes. For both DENV-2 and CHIKV, no"/>
   <result pre="For both DENV-2 and CHIKV, no effects were observed upon" exact="suppression" post="of Atg5, Atg14 or Atg8 despite high levels of"/>
   <result pre="may be indirectly beneficial. Alternatively, it could suggest that &amp;gt;80%" exact="suppression" post="was not sufficient to diminish autophagic activity and therefore,"/>
   <result pre="not sufficient to diminish autophagic activity and therefore, the RNAi" exact="suppression" post="infection assays were not sensitive enough to identify a"/>
   <result pre="viral replication in Aag2 cells but not C6/36 cells. Conversely," exact="suppression" post="of autophagy with spautin-1 would in theory increase available"/>
   <result pre="RNAi genes are not significantly upregulated during arbovirus infection so" exact="suppression" post="of autophagy has little effect on the normal levels"/>
   <result pre="cells [9, 21]. However, increased titers were also observed upon" exact="suppression" post="of autophagy by spautin-1 suggesting an antiviral role. While"/>
   <result pre="with dsRNA targeting Atg5, Atg14, or Atg8 and assayed for" exact="suppression" post="48 hours post transfection. Silencing efficiency of A) Atg5"/>
   <result pre="in the induction of ER stress and downstream events in" exact="chikungunya" post="virus infection. Microbial pathogenesis. 2016;101:104–18. 10.1016/j.micpath.2016.11.009 .27863885 12LiangQ, LuoZ,"/>
   <result pre="JiangHH, GordonG, GoldmanJE, BerryG, et al.Protection against fatal Sindbis virus" exact="encephalitis" post="by beclin, a novel Bcl-2-interacting protein. J Virol. 1998;72(11):8586–96."/>
   <result pre="1998;72(11):8586–96. 9765397 14SharmaM, BhattacharyyaS, NainM, KaurM, SoodV, GuptaV, et al.Japanese" exact="encephalitis" post="virus replication is negatively regulated by autophagy and occurs"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7260208\results\search\disease\results.xml">
   <result pre="capsid sequence fused to mCherry, followed by the food and" exact="mouth disease" post="virus 2 A auto cleavage site. The complete sequence of"/>
   <result pre="fragment containing mCherry coding sequence fused to the food and" exact="mouth disease" post="virus 2A (FMDV2A) protein, in such a way to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7261124\results\search\disease\results.xml">
   <result pre="with potential as a pandemic threat. High sequence variability of" exact="influenza" post="A viruses is a major challenge for effective vaccine"/>
   <result pre="A continuing goal towards this is a greater understanding of" exact="influenza" post="A (H5N1) proteome sequence diversity in the context of"/>
   <result pre="of more than 13,000 protein sequences of avian and human" exact="influenza" post="A (H5N1) viruses, reported over at least 50 years."/>
   <result pre="viruses of both hosts, with half conserved to several other" exact="influenza" post="A subtypes. Discussion The presence of distinct sequences (nonatypes)"/>
   <result pre="aid in the surveillance of existing and future strains of" exact="influenza" post="viruses. H5N1 Influenza virus Sequence diversity Variants Fitness-selection Dynamics"/>
   <result pre="highly infectious subtype strains that lead to global pandemics. Major" exact="influenza" post="pandemics have been recorded in the past, starting with"/>
   <result pre="et al., 2011). Without effective means to prevent or control" exact="influenza" post="infection by new strains, there is the looming threat"/>
   <result pre="new strains, there is the looming threat of the next" exact="influenza" post="pandemic (Chaturvedi, 2009). H5N1 subtype of influenza A virus"/>
   <result pre="of the next influenza pandemic (Chaturvedi, 2009). H5N1 subtype of" exact="influenza" post="A virus (H5N1 IAV) is a global concern with"/>
   <result pre="of December 13, 2018 (World Health Organization, 2018). The annual" exact="influenza" post="vaccine formulation is not designed for prevention of H5N1"/>
   <result pre="performed a large-scale analyses on the evolutionary diversity of several" exact="influenza" post="A virus subtypes in the context of the immune"/>
   <result pre="data. The collected data were classified according to the 12" exact="influenza" post="A proteins (PB2, PB1, PB1-F2, PA, PA-X, HA, NP,"/>
   <result pre="were chosen because they cover the majority of the reported" exact="influenza" post="A virus sequences. The classified data were manually checked"/>
   <result pre="of conserved and variable nonamer positions in avian and human" exact="influenza" post="A (H5N1) and immune relevance The index sequence incidences"/>
   <result pre="and recommended as vaccine target candidates. Results Avian and human" exact="influenza" post="A (H5N1) protein sequences Comprehensive collections of protein sequence"/>
   <result pre="of total variants for (A) avian and (B) human H5N1" exact="influenza" post="A virus proteome nonamer positions. The entropy value for"/>
   <result pre="C, E, G) and human (B. D, F, H) H5N1" exact="influenza" post="A virus proteomes. (A–F) Motif incidence (index, major, minor,"/>
   <result pre="of diversity motifs for avian (A–L) and human (M–X) H5N1" exact="influenza" post="A virus proteins. Motif incidence (index, major, minor, unique,"/>
   <result pre="Frequency distribution violin plots of the diversity motifs for H5N1" exact="influenza" post="A virus proteins. Violin plot depicting the frequency distribution"/>
   <result pre="had been reported by Hu et al. (2013). Mutations of" exact="influenza" post="and other viruses are manifsted in the interrelated dynamics"/>
   <result pre="of this motif is strictly limited. Thus, sequence diversity of" exact="influenza" post="is embodied in minor and unique mutations, which can"/>
   <result pre="in nature, providing fitness benefit to the virus. Vaccines against" exact="influenza" post="have been developed empirically (Siegrist, 2013), comprising of H1N1,"/>
   <result pre="been developed empirically (Siegrist, 2013), comprising of H1N1, H3N2, and" exact="influenza" post="B strains that are predicted to be circulating in"/>
   <result pre="selecting vaccine targets that are representative of the majority of" exact="influenza" post="viruses. Several studies (Assarsson et al., 2008; Cassone &amp;amp;"/>
   <result pre="conserved HA stalk region was broadly protective in a murine" exact="influenza" post="model. Other studies (Cassone &amp;amp; Rappuoli, 2010) identified human"/>
   <result pre="of conserved parts (HA, M2, NP, PB1, and M1) of" exact="influenza" post="A virus, containing B and T-cell epitopes, which showed"/>
   <result pre="even more candidates from HA, which may extend to multiple" exact="influenza" post="subtypes, though at a lower conservation level. Careful selection"/>
   <result pre="the need for knowledge-based approaches towards the design of universal" exact="influenza" post="vaccines (Gillim-Ross &amp;amp; Subbarao, 2007). The study herein also"/>
   <result pre="aid in the surveillance of existing and future strains of" exact="influenza" post="viruses. Highly conserved sequences shortlisted in our analysis could"/>
   <result pre="evaluated for specificity to the subtype. The high propensity for" exact="influenza" post="A virus to develop resistance against drugs has been"/>
   <result pre="The bioinformatics approaches applied herein to study the dynamics of" exact="influenza" post="A virus protein sequence diversity can offer a roadmap"/>
   <result pre="selecting vaccine targets that are representative of the majority of" exact="influenza" post="viruses, and raise hope for the possibility of a"/>
   <result pre="reminds us of the imminent threat that continued diversification of" exact="influenza" post="A viruses poses. Although not every mutation will result"/>
   <result pre="Country of origin of reported sequences of avian and human" exact="influenza" post="A H5N1 viruses reported in Influenza Research Database at"/>
   <result pre="Click here for additional data file. 10.7717/peerj.7954/supp-3Table S2 Diversity of" exact="avian influenza" post="A (H5N1) virus proteome (raw data) All percentages are"/>
   <result pre="here for additional data file. 10.7717/peerj.7954/supp-3Table S2 Diversity of avian" exact="influenza" post="A (H5N1) virus proteome (raw data) All percentages are"/>
   <result pre="here for additional data file. 10.7717/peerj.7954/supp-4Table S3 Diversity of human" exact="influenza" post="A (H5N1) virus proteome (raw data) All percentages are"/>
   <result pre="al. (2008)AssarssonEBuiH-HSidneyJZhangQGlennJOseroffCMbawuikeINAlexanderJNewmanMJGreyHSetteA2008Immunomic analysis of the repertoire of T-cell specificities for" exact="influenza" post="A virus in humansJournal of Virology82122411225110.1128/jvi.01563-0818842709 Cassone &amp;amp; Rappuoli"/>
   <result pre="&amp;amp; Tam (2003)CoxNJTamblynSETamT2003Influenza pandemic planningVaccine211801180310.1016/S0264-410X(03)00076-812686098 Deng et al. (2015)DengLChoKFiersWSaelensXDengLChoKJFiersWSaelensX2015M2e-based universal" exact="influenza" post="A vaccinesVaccine310513610.3390/vaccines3010105 Dhanda et al. (2017)DhandaSKUsmaniSSAgrawalPNagpalGGautamARaghavaGPS2017Novel in silico tools"/>
   <result pre="ligandsImmunology Today1460260910.1016/0167-5699(93)90200-58305133 Fiers et al. (2004)FiersWDe FiletteMBirkettANeirynckSMin JouW2004A universal human" exact="influenza" post="A vaccineVirus Research10317317610.1016/J.VIRUSRES.2004.02.03015163506 Gillim-Ross &amp;amp; Subbarao (2007)Gillim-RossLSubbaraoK2007Can immunity induced"/>
   <result pre="Research10317317610.1016/J.VIRUSRES.2004.02.03015163506 Gillim-Ross &amp;amp; Subbarao (2007)Gillim-RossLSubbaraoK2007Can immunity induced by the human" exact="influenza" post="virus N1 neuraminidase provide some protection from avian influenza"/>
   <result pre="the human influenza virus N1 neuraminidase provide some protection from" exact="avian influenza" post="H5N1 viruses?PLOS Medicine4e9110.1371/journal.pmed.004009117298170 Hasan et al. (2019)HasanMGhoshPPAzimKFMuktaSAbirRANaharJHasan KhanMM2019Reverse vaccinology"/>
   <result pre="human influenza virus N1 neuraminidase provide some protection from avian" exact="influenza" post="H5N1 viruses?PLOS Medicine4e9110.1371/journal.pmed.004009117298170 Hasan et al. (2019)HasanMGhoshPPAzimKFMuktaSAbirRANaharJHasan KhanMM2019Reverse vaccinology"/>
   <result pre="vaccinology approach to design a novel multi-epitope subunit vaccine against" exact="avian influenza" post="A (H7N9) virusMicrobial Pathogenesis130193710.1016/j.micpath.2019.02.02330822457 Heiny et al. (2007)HeinyATMiottoOSrinivasanKNKhanMAZhangGLBrusicVTanTWAugustJT2007Evolutionarily conserved"/>
   <result pre="approach to design a novel multi-epitope subunit vaccine against avian" exact="influenza" post="A (H7N9) virusMicrobial Pathogenesis130193710.1016/j.micpath.2019.02.02330822457 Heiny et al. (2007)HeinyATMiottoOSrinivasanKNKhanMAZhangGLBrusicVTanTWAugustJT2007Evolutionarily conserved"/>
   <result pre="virusMicrobial Pathogenesis130193710.1016/j.micpath.2019.02.02330822457 Heiny et al. (2007)HeinyATMiottoOSrinivasanKNKhanMAZhangGLBrusicVTanTWAugustJT2007Evolutionarily conserved protein sequences of" exact="influenza" post="a viruses, avian and human, as vaccine targetsPLOS ONE211e119010.1371/journal.pone.000119018030326"/>
   <result pre="ONE8e5999410.1371/journal.pone.005999423593157 Huber et al. (2015)HuberSKRCampsMGMJacobiRHJMouthaanJVan DijkenHVan BeekJOssendorpFDe JongeJ2015Synthetic long peptide" exact="influenza" post="vaccine containing conserved T and B cell epitopes reduces"/>
   <result pre="Acids Research45W24W2910.1093/nar/gkx34628472356 Kang, Kim &amp;amp; Compans (2012)KangSMKimMCCompansRW2012Virus-like particles as universal" exact="influenza" post="vaccinesExpert Review of Vaccines118995100710.1586/erv.12.7023002980 Khan et al. (2006)KhanAMMiottoOHeinyATSalmonJSrinivasanKNNascimentoEJMMarquesETABrusicVTanTWAugustJT2006A systematic"/>
   <result pre="the conserved hemagglutinin stalk domain and its prospects for universal" exact="influenza" post="vaccine developmentBioMed Research International201454627410.1155/2014/54627424982895 Kim et al. (2009)KimJHSkountzouICompansRJacobJ2009Original antigenic"/>
   <result pre="Research International201454627410.1155/2014/54627424982895 Kim et al. (2009)KimJHSkountzouICompansRJacobJ2009Original antigenic sin responses to" exact="influenza" post="virusesThe Journal of Immunology1833294330110.4049/jimmunol.090039819648276 Koo et al. (2009)KooQYKhanAMJungK-ORamdasSMiottoOTanTWBrusicVSalmonJAugustJT2009Conservation and"/>
   <result pre="T-lymphocyte epitope predictionBMC Bioinformatics842410.1186/1471-2105-8-42417973982 Lee et al. (2014)LeeY-TKimK-HKoE-JLeeY-NKimM-CKwonY-MTangYChoM-KLeeY-JKangS-M2014New vaccines against" exact="influenza" post="virusClinical and Experimental Vaccine Research3122810.7774/cevr.2014.3.1.1224427759 Meng et al. (2014)MengZHanRHuYYuanZJiangSZhangXXuJ2014Possible"/>
   <result pre="Meng et al. (2014)MengZHanRHuYYuanZJiangSZhangXXuJ2014Possible pandemic threat from new reassortment of" exact="influenza" post="A(H7N9) virus in ChinaEurosurveillance1962069910.2807/1560-7917.ES2014.19.6.2069924556346 Miotto et al. (2010)MiottoOHeinyATAlbrechtRGarcía-SastreATanTWAugustJTBrusicV2010Complete-proteome mapping"/>
   <result pre="virus in ChinaEurosurveillance1962069910.2807/1560-7917.ES2014.19.6.2069924556346 Miotto et al. (2010)MiottoOHeinyATAlbrechtRGarcía-SastreATanTWAugustJTBrusicV2010Complete-proteome mapping of human" exact="influenza" post="a adaptive mutations: implications for human transmissibility of zoonotic"/>
   <result pre="ONE5e902510.1371/journal.pone.000902520140252 Neumann et al. (2005)NeumannGFujiiKKinoYKawaokaY2005An improved reverse genetics system for" exact="influenza" post="A virus generation and its implications for vaccine productionProceedings"/>
   <result pre="the United States of America102168251682910.1073/pnas.050558710216267134 Noda &amp;amp; Kawaoka (2010)NodaTKawaokaY2010Structure of" exact="influenza" post="virus ribonucleoprotein complexes and their packaging into virionsReviews in"/>
   <result pre="(2004)ParkAWWoodJLNDalyJMNewtonJRGlassKHenleyWMumfordJAGrenfellBT2004The effects of strain heterology on the epidemiology of equine" exact="influenza" post="in a vaccinated populationProceedings of the Royal Society B:"/>
   <result pre="and antiviral immunityImmune Network1626127010.4110/in.2016.16.5.26127799871 Pica &amp;amp; Palese (2013)PicaNPaleseP2013Toward a universal" exact="influenza" post="virus vaccine: prospects and challengesAnnual Review of Medicine6418920210.1146/annurev-med-120611-145115 Potter"/>
   <result pre="Matter Physics7304191310.1103/PhysRevE.73.041913 Samuel, Smith &amp;amp; Brown Professor (2016)SamuelWSmithJBrown ProfessorI2016Highly pathogenic" exact="avian influenza" post="H5N8 in EuropeDepartment for Environment, Food and Rural Affairs"/>
   <result pre="Physics7304191310.1103/PhysRevE.73.041913 Samuel, Smith &amp;amp; Brown Professor (2016)SamuelWSmithJBrown ProfessorI2016Highly pathogenic avian" exact="influenza" post="H5N8 in EuropeDepartment for Environment, Food and Rural Affairs"/>
   <result pre="623–656 Shrestha et al. (2011)ShresthaSSSwerdlowDLBorseRHPrabhuVSFinelliLAtkinsCYOwusu-EduseiKBellBMeadPSBiggerstaffM2011Estimating the burden of 2009 pandemic" exact="influenza" post="A (H1N1) in the United States (2009–2010)Clinical Infectious Diseases52S75S8210.1093/cid/ciq01221342903"/>
   <result pre="et al. (2012)SquiresRBNoronhaJHuntVGarcía-SastreAMackenCBaumgarthNSuarezDPickettBEZhangYLarsenCN2012Influenza research database: an integrated bioinformatics resource for" exact="influenza" post="research and surveillanceInfluenza and Other Respiratory Viruses640441610.1111/j.1750-2659.2011.00331.x22260278 Steel et"/>
   <result pre="domainmBio1e00018–1010.1128/mBio.00018-1020689752 Szewczyk, Bieńkowska-szewczyk &amp;amp; Król (2014)SzewczykBBieńkowska-szewczykKKrólE2014Introduction to molecular biology of" exact="influenza" post="A virusesActa Biochimica Polonica6139740125180226 Taubenberger &amp;amp; Kash (2010)TaubenbergerJKKashJC2010Influenza virus"/>
   <result pre="Diseases12152210.3201/eid1201.05097916494711 Uyeki (2008)UyekiTM2008Global epidemiology of human infections with highly pathogenic" exact="avian influenza" post="A (H5N1) virusesRespirology13S2S910.1111/j.1440-1843.2008.01246.x18366524 Vita et al. (2018)VitaRMahajanSOvertonJADhandaSKMartiniSCantrellJRWheelerDKSetteAPetersB2018The immune epitope"/>
   <result pre="Uyeki (2008)UyekiTM2008Global epidemiology of human infections with highly pathogenic avian" exact="influenza" post="A (H5N1) virusesRespirology13S2S910.1111/j.1440-1843.2008.01246.x18366524 Vita et al. (2018)VitaRMahajanSOvertonJADhandaSKMartiniSCantrellJRWheelerDKSetteAPetersB2018The immune epitope"/>
   <result pre="Health Organization2007A description of the process of seasonal and H5N1" exact="influenza" post="vaccine virus selection and developmentDraft 19 November 2007World Health"/>
   <result pre="(2013)collab: World Health Organization2013Current WHO phase of pandemic alert (avian" exact="influenza" post="H5N1)https://www.who.int/influenza/preparedness/pandemic/h5n1phase/en/28 December 2018 World Health Organization (2014)collab: World Health"/>
   <result pre="(2018)collab: World Health Organization2018Cumulative number of confirmed human cases for" exact="avian influenza" post="A(H5N1) reported to WHO, 2003–2018https://www.who.int/influenza/human_animal_interface/2018_12_13_tableH5N1.pdf?ua=128 December 2018 World Health"/>
   <result pre="World Health Organization2018Cumulative number of confirmed human cases for avian" exact="influenza" post="A(H5N1) reported to WHO, 2003–2018https://www.who.int/influenza/human_animal_interface/2018_12_13_tableH5N1.pdf?ua=128 December 2018 World Health"/>
   <result pre="2_02_2019.pdf?ua=1 (accessed in 2019) Yuan, Wen &amp;amp; Zhou (2018)YuanSWenLZhouJ2018Inhibitors of" exact="influenza" post="A virus polymeraseACS Infectious Diseases421822310.1021/acsinfecdis.7b0026529355011 Zhou et al. (2018)ZhouZLiuTZhangJZhanPLiuX2018Influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7261188\results\search\disease\results.xml">
   <result pre="Biology Structural and functional characterization of the severe fever with" exact="thrombocytopenia" post="syndrome virus L protein VogelDominik1ThorkelssonSigurdur Rafn2QueminEmmanuelle R J2MeierKristina1KoubaTomas3GogrefeNadja1BuschCarola1ReindlSophia1http://orcid.org/0000-0002-6562-0230GüntherStephan14http://orcid.org/0000-0002-9324-0796CusackStephen3GrünewaldKay2http://orcid.org/0000-0003-2986-936XRosenthalMaria1[1], Department"/>
   <result pre="emerging viruses with high epidemic potential, including Severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV). The lack of medical countermeasures, such"/>
   <result pre="to the structures of La Crosse peribunyavirus L protein and" exact="influenza" post="orthomyxovirus polymerase. Together with a comprehensive biochemical characterization of"/>
   <result pre="Marie Skłodowska-Curie 664726 iNEXT 653706 page-count: INTRODUCTION Severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV) is prevalent in East Asia and"/>
   <result pre="and functions including the viral RNA-dependent RNA polymerase (RdRp). For" exact="influenza" post="virus, another segmented negative-sense RNA virus (sNSV), small molecules"/>
   <result pre="complex have been clinically approved (5,6). However, in contrast to" exact="influenza" post="viruses, whose polymerase has been extensively investigated, structural and"/>
   <result pre="cap-snatching mechanism. This CBD is structurally similar to that of" exact="influenza" post="virus but with distinct differences in its mode of"/>
   <result pre="sequence and are denoted as the conserved promoter regions. For" exact="influenza" post="virus and LACV, the RNA 5′ end forms a"/>
   <result pre="by a prime-and-realign mechanism (13) similar to the initiation of" exact="influenza" post="virus vRNA synthesis from cRNA and Hantaan virus genome"/>
   <result pre="mM of m7GTP, m7GpppG, GTP or ATP. Thermal stability of" exact="influenza" post="A virus PB2 CBD and RVFV CBD was assessed"/>
   <result pre="and comparison with the LACV L (PDB 5AMQ) and the" exact="influenza" post="virus polymerase complex (PDB 6QCV) are shown in Supplementary"/>
   <result pre="apo-L is structurally related to LACV L and the heterotrimeric" exact="influenza" post="virus polymerase complex, although the similarity to LACV is"/>
   <result pre="the sNSV group, and the previously described structural similarity between" exact="influenza" post="virus polymerase and LACV L protein (12). Although the"/>
   <result pre="1C). The endonuclease domain (residues 1–214) is connected to an" exact="influenza" post="virus PA-C like domain via an extended linker (residues"/>
   <result pre="density in the map. According to LACV L protein and" exact="influenza" post="virus polymerase complex, we expect these unresolved regions to"/>
   <result pre="is structurally different compared to the LACV α-ribbon and the" exact="influenza" post="virus β-ribbon. In SFTSV L, the ribbon insertion is"/>
   <result pre="disordered (Figure 1B, Supplementary Figures S2–S5). The corresponding β-ribbon of" exact="influenza" post="virus, which is involved in binding of the RNA"/>
   <result pre="and involved in 5′ vRNA binding in the LACV and" exact="influenza" post="virus structures. A small part of what is presumably"/>
   <result pre="to the LACV fingernode but different from its counterpart in" exact="influenza" post="virus which has a β-hairpin insertion (Supplementary Figures S2–S4)."/>
   <result pre="and 1084–1194), which is structurally highly similar to LACV and" exact="influenza" post="virus (Figure 1, Supplementary Figures S2–S4). The palm domain"/>
   <result pre="1). Residues 1309–1402, which by analogy to the LACV and" exact="influenza" post="virus structures presumably compose the priming loop and the"/>
   <result pre="L protein has a very similar architecture as LACV and" exact="influenza" post="virus polymerase proteins with some particular differences whose functional"/>
   <result pre="and 5′ termini of the genome segments. For LACV and" exact="influenza" post="virus polymerases, distinct 3′ and 5′ RNA binding sites"/>
   <result pre="a hook-like conformation both in LACV as well as in" exact="influenza" post="virus (12,17,18). By comparing with LACV L protein bound"/>
   <result pre="the S, M and L segment promoters. Moreover, whereas in" exact="influenza" post="virus and LACV the 5′ hook structure forms within"/>
   <result pre="to RNA binding sites reported for LACV L and also" exact="influenza" post="virus polymerase. The SFTSV L protein is an active"/>
   <result pre="activating role of the 5′ end is well known for" exact="influenza" post="polymerase, and has also been described for arenaviruses, although"/>
   <result pre="either terminally and without applying a prime-and-realign mechanism similar to" exact="influenza" post="virus cRNA synthesis (22) or by priming at position"/>
   <result pre="L protein contains an active cap-binding domain In analogy to" exact="influenza" post="virus polymerase, the C-terminal region of the bunyavirus L"/>
   <result pre="for the RVFV domain but still quite high compared to" exact="influenza" post="virus PB2 CBD (KD ∼ 1.5 μM) or cellular"/>
   <result pre="Supplementary Figure S13A. (C) Thermal stability of SFTSV CBD and" exact="influenza" post="A virus PB2 CBD was tested in the presence"/>
   <result pre="SFTSV L protein that is structurally similar to RVFV and" exact="influenza" post="virus CBD, but were unable to demonstrate any cap-dependent"/>
   <result pre="in a more collapsed conformation as observed in LACV and" exact="influenza" post="virus polymerase proteins, depending on the functional state of"/>
   <result pre="the apo conformation closely resembles the LACV L protein and" exact="influenza" post="virus polymerase complex structures and, by analogy, allows prediction"/>
   <result pre="in the cryo-EM map. This has been previously observed for" exact="influenza" post="virus PB2 (61) and LACV L (12). Mechanisms for"/>
   <result pre="in combination with oseltamivir for treatment of acute uncomplicated seasonal" exact="influenza" post="A: TOPAZ trial. J. Infect. Dis.2019; 219:1026–1034.30428049 6.NoshiT., KitanoM.,"/>
   <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunit. Antiviral Res.2018; 160:109–117.30316915 7.OlschewskiS., CusackS.,"/>
   <result pre="Natl. Acad. Sci. U.S.A.2019; 116:10518–10524.31072925 17.PflugA., GuilligayD., ReichS., CusackS.Structure of" exact="influenza" post="A polymerase bound to the viral RNA promoter. Nature."/>
   <result pre="NanaoM., RuigrokR.W.et al..Structural insight into cap-snatching and RNA synthesis by" exact="influenza" post="polymerase. Nature. 2014; 516:361–366.25409151 19.GarcinD., KolakofskyD.Tacaribe arenavirus RNA synthesis"/>
   <result pre="22.DengT., VreedeF.T., BrownleeG.G.Different de novo initiation strategies are used by" exact="influenza" post="virus RNA polymerase on its cRNA and viral RNA"/>
   <result pre="LeeW.J.Molecular genomic characterization of tick- and human-derived severe fever with" exact="thrombocytopenia" post="syndrome virus isolates from South Korea. PLoS Negl. Trop."/>
   <result pre="ZhangS.Y., LiuY., LiJ.D., SunY.L., ZhangL., ZhangQ.F., PopovV.L., LiC.et al..Fever with" exact="thrombocytopenia" post="associated with a novel bunyavirus in China. N. Engl."/>
   <result pre="LiA., LiangM., LiD., ElliottR.M.Reverse genetics system for severe fever with" exact="thrombocytopenia" post="syndrome virus. J. Virol.2015; 89:3026–3037.25552716 52.ZhongW., UssA.S., FerrariE., LauJ.Y.,"/>
   <result pre="UssA.S., FerrariE., LauJ.Y., HongZ.De novo initiation of RNA synthesis by" exact="hepatitis" post="C virus nonstructural protein 5B polymerase. J. Virol.2000; 74:2017–2022.10644375"/>
   <result pre="J. Virol.2018; 92:e01414-17.29046442 56.Te VelthuisA.J.W., OymansJ.Initiation, elongation and realignment during" exact="influenza" post="virus mRNA synthesis. J. Virol.2017; 92:e01775-17. 57.JinH., ElliottR.M.Non-viral sequences"/>
   <result pre="activity of VX-787, a first-in-class, orally bioavailable inhibitor of the" exact="influenza" post="virus polymerase PB2 subunit. Antimicrob. Agents Chemother.2015; 59:1569–1582.25547360 61.ThierryE.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7263184\results\search\disease\results.xml">
   <result pre="these networks into account. Smallpox is currently the only human" exact="infectious disease" post="that was successfully eradicated through immunization. There are two"/>
   <result pre="past, epidemiological modeling was essential for example in handling the" exact="avian influenza" post="outbreak in 2005 (Longini et al., 2005). More recently,"/>
   <result pre="epidemiological modeling was essential for example in handling the avian" exact="influenza" post="outbreak in 2005 (Longini et al., 2005). More recently,"/>
   <result pre="mass spectrometry-based proteomicsNature Reviews Molecular Cell Biology116201042743920461098 ChristakisN.A.FowlerJ.H.The spread of" exact="obesity" post="in a large social network over 32 yearsNew England"/>
   <result pre="networks for drug discoverySpecial Topics in Drug Discovery2016InTech LonginiI.M.NizamA.XuS.UngchusakK.HanshaoworakulW.CummingsD.A.T.HalloranM.E.Containing pandemic" exact="influenza" post="at the sourceScience (New York, N.Y.)3095737200510831087 MaslovS.SneppenK.Specificity and stability"/>
   <result pre="exchangeCell Systems14201530230526594663 RauscherB.HeigwerF.HenkelL.HielscherT.VoloshanenkoO.BoutrosM.Toward an integrated map of genetic interactions in" exact="cancer" post="cellsMolecular Systems Biology1422018e7656 RieckmannJ.C.GeigerR.HornburgD.WolfT.KvelerK.JarrossayD.SallustoF.Shen-OrrS.S.LanzavecchiaA.MannM.MeissnerF.Social network architecture of human immune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7263602\results\search\disease\results.xml">
   <result pre="author and source are credited.pone.0232948.pdf Abstract Background An outbreak of" exact="respiratory disease" post="associated with adenovirus type 7 occurred in a boot"/>
   <result pre="nucleic acid detection kit (JC10117, Bioperfectus Technologies, Jiangsu, China) and" exact="influenza" post="type A and type B kits (JC10103 and JC10104,"/>
   <result pre="reaction assay (qRT-PCR). After adenovirus nucleic acid was detected and" exact="influenza" post="virus infection was ruled out, we then used typing"/>
   <result pre="percentages for fever, pharyngalgia, expectoration, cough, weakness, headache, chills, and" exact="diarrhea" post="were 100%, 67% (95% CI: 62% to 72%), 61%"/>
   <result pre="illness in middle school during a 2009 outbreak of H1N1" exact="influenza" post="[15]; however, the underlying cause for this difference was"/>
   <result pre="is longer than the median generation time for a typical" exact="influenza" post="A (H1N1) outbreak (2.7 days) [15]. The median symptom"/>
   <result pre="1976 [22] and the basic reproductive number (3.3) of the" exact="influenza" post="A (H1N1) outbreak in New York City in 2009"/>
   <result pre="which was close to the family transmission rate (0.14) of" exact="influenza" post="A (H1N1) in 2009 but lower than that (0.32"/>
   <result pre="but lower than that (0.32 [23], 0.42 [24]) of interpandemic" exact="influenza" post="A. These differences indicate that the dormitory transmission rate"/>
   <result pre="et al.Re-emergent human adenovirus genome type 7d caused an acute" exact="respiratory disease" post="outbreak in southern China after a twenty-one year absence."/>
   <result pre="WangQS, LiangBB, WuF, LiH, LiuHB, et al.An outbreak of acute" exact="respiratory disease" post="caused by a virus associated RNA II gene mutation"/>
   <result pre="and transmission characteristics of human adenovirus type 7 caused acute" exact="respiratory disease" post="outbreak in military trainees in East China. Am J"/>
   <result pre="11YuPB, MaCF, NawazM, HanL, ZhangJF, DuQL, et al.Outbreak of acute" exact="respiratory disease" post="caused by human adenovirus type 7 in a military"/>
   <result pre="serotype 7 from South Korean military recruits with mild acute" exact="respiratory disease." post="Eur J Clin Microbiol Infect Dis. 2007; 26: 481–483.17541654"/>
   <result pre="599–604.17476782 20VynnyckyE, TindallA, PunamM. Estimating the reproduction numbers of Spanish" exact="influenza" post="using morbidity data. Int J Epidemiol. 2007; 36: 881–889.17517812"/>
   <result pre="3469–3487.15505892 24NishiuraH, ChowellG. Household and community transmission of the Asian" exact="influenza" post="A (H2N2) and influenza B viruses in 1957 and"/>
   <result pre="and community transmission of the Asian influenza A (H2N2) and" exact="influenza" post="B viruses in 1957 and 1961. Southeast Asian J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7265451\results\search\disease\results.xml">
   <result pre="Article The impact of climate and antigenic evolution on seasonal" exact="influenza" post="virus epidemics in Australia http://orcid.org/0000-0002-2115-9331LamEdward K. S.1http://orcid.org/0000-0002-3655-406XMorrisDylan H.2HurtAeron C.34BarrIan"/>
   <result pre="a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract Although seasonal" exact="influenza" post="viruses circulate globally, prevention and treatment occur at the"/>
   <result pre="of a 15-year city-level dataset of 18,250 laboratory-confirmed and antigenically-characterised" exact="influenza" post="virus infections from Australia, we investigate the effects of"/>
   <result pre="the effects of previously hypothesised environmental and virological drivers of" exact="influenza" post="epidemics. We find that anomalous fluctuations in temperature and"/>
   <result pre="size and composition. Our findings suggest that the relationship between" exact="influenza" post="population immunity and epidemiology is more complex than previously"/>
   <result pre="influence of short-term processes may hinder long-term epidemiological forecasts. Seasonal" exact="influenza" post="epidemics vary in timing and size, but the causes"/>
   <result pre="Subject terms Data integration Population dynamics Influenza virus Introduction Seasonal" exact="influenza" post="virus epidemics are a substantial source of disease burden"/>
   <result pre="result in ~650,000 deaths each year1. Four co-circulating subtypes/lineages of" exact="influenza" post="viruses currently cause disease in humans: A/H3N2 (A/H3), A/H1N1"/>
   <result pre="B/Yamagata/16/88-like (B/Yam) viruses. The timing, duration and size of local" exact="influenza" post="virus epidemics can vary substantially from year to year2,3,"/>
   <result pre="resources5. In temperate regions of the Northern and Southern Hemispheres," exact="influenza" post="virus activity is most common in winter months, but"/>
   <result pre="and humidity9. Climatic fluctuations have been implicated as triggers for" exact="influenza" post="epidemics in temperate regions. A study of state-level epidemiological"/>
   <result pre="of state-level epidemiological data from the United States found that" exact="influenza" post="epidemics sometimes follow 2-week periods of anomalously low absolute"/>
   <result pre="France13. Influenza virus evolutionary dynamics are another theorised driver of" exact="influenza" post="virus epidemiology. Within each type and subtype of seasonal"/>
   <result pre="influenza virus epidemiology. Within each type and subtype of seasonal" exact="influenza" post="virus, new major antigenic variants arise every 3–8 years14,15."/>
   <result pre="Japan22 and Australia23. Studies of environmental and virological drivers of" exact="influenza" post="virus epidemiology, including the studies referenced above, have been"/>
   <result pre="wide variety of respiratory infections24, and limited laboratory characterisation obscures" exact="influenza" post="virus type/subtype- and antigenic variant-specific patterns. These patterns become"/>
   <result pre="(county/city/town), which can individually vary substantially in timing, magnitude and" exact="influenza" post="virus composition. Altogether, these sources of obfuscation make it"/>
   <result pre="data set of 18,250 typed, subtyped and antigenically characterised seasonal" exact="influenza" post="viruses from the five most populous cities in Australia"/>
   <result pre="and virological factors on the timing and magnitude of city-level" exact="influenza" post="virus epidemics. We find that climatic fluctuations and virus"/>
   <result pre="short-term transmission processes likely diminishes the feasibility of meaningful long-term" exact="influenza" post="epidemic forecasting at local scales. Results Australia laboratory-confirmed influenza"/>
   <result pre="long-term influenza epidemic forecasting at local scales. Results Australia laboratory-confirmed" exact="influenza" post="We aggregated 18,250 laboratory-confirmed and antigenically characterised cases of"/>
   <result pre="We aggregated 18,250 laboratory-confirmed and antigenically characterised cases of seasonal" exact="influenza" post="viruses from 2000 to 2015 by 2-week (14-day) periods,"/>
   <result pre="values of each city25. Fig. 1 Number of laboratory-confirmed seasonal" exact="influenza" post="virus infections from 2000 to 2015 for the five"/>
   <result pre="impact on virus transmission7 and overall epidemic size: for example," exact="influenza" post="mortality in New York Metropolitan Area was shown to"/>
   <result pre="study by Geoghegan et al.23 estimated epidemic onset timings for" exact="influenza" post="A virus epidemics in Australian postcodes for the seasons"/>
   <result pre="5). Other climatic factors have been proposed as drivers of" exact="influenza" post="dynamics, notably relative humidity and rainfall6,9. We repeated the"/>
   <result pre="Based on city-level analyses of a subtyped and antigenically characterised" exact="influenza" post="virus data set covering the five largest cities in"/>
   <result pre="variants may not be realised. Conversely, competition for hosts among" exact="influenza" post="virus types and subtypes has strong effects on local"/>
   <result pre="city and season typically dominates. A recent study of fine-scale" exact="influenza" post="epidemiology in Australia23 showed that there was substantial heterogeneity"/>
   <result pre="was substantial heterogeneity among Australian cities in the activity of" exact="influenza" post="A and B viruses. Our subtyped and antigenically characterised"/>
   <result pre="unlikely to account for the differences in the patterns of" exact="influenza" post="seasonality between temperate and tropical regions26. Seasonal epidemic waves"/>
   <result pre="on the role of low humidity as a trigger for" exact="influenza" post="epidemics. Rather than acting as specific triggers, it is"/>
   <result pre="absolute humidity over the epidemic period. Given the interest in" exact="influenza" post="virus as a model system for phylodynamics of a"/>
   <result pre="and population immunity are important for the global-level phylodynamics of" exact="influenza" post="viruses. In contrast, at the local level, we find"/>
   <result pre="evidence for the year-on-year depletion of susceptible hosts is that" exact="influenza" post="virus infection often fails to confer strain-specific and effective"/>
   <result pre="same virus strain. The notion that population-level strain-specific immunity to" exact="influenza" post="viruses is monolithic may be an artefact of the"/>
   <result pre="variation in the antigenicity of amino acid escape mutations for" exact="influenza" post="haemagglutinin40. Such heterogeneity between individuals stems from their varied"/>
   <result pre="between individuals stems from their varied exposure histories to different" exact="influenza" post="viruses. Unfortunately, age records for our data set were"/>
   <result pre="given only virus-type data, that the 2009, 2012 and 2014" exact="influenza" post="A virus epidemics in Australia exhibited greater spatiotemporal synchrony"/>
   <result pre="resolution and antigenic characterisation, we find that the majority of" exact="influenza" post="A activity in Adelaide and Melbourne in 2014 was"/>
   <result pre="passive surveillance data that might not accurately reflect true underlying" exact="influenza" post="virus activity. For example, surveillance intensity could plausibly vary"/>
   <result pre="The mean age of infection for A/H3 is greater than" exact="influenza" post="B46 viruses, and healthcare-seeking behaviour may differ between adults,"/>
   <result pre="more severe clinical presentations and greater risk of mortality47 than" exact="influenza" post="B viruses, potentially resulting in differences in the likelihood"/>
   <result pre="antigenic factors are unlikely to be strong drivers of local" exact="influenza" post="epidemiological dynamics. Indeed, the effects of these specific factors"/>
   <result pre="antigenic variants are thought to be strong drivers of seasonal" exact="influenza" post="epidemiology, but seasonal influenza virus epidemiological dynamics in major"/>
   <result pre="to be strong drivers of seasonal influenza epidemiology, but seasonal" exact="influenza" post="virus epidemiological dynamics in major Australian cities appear to"/>
   <result pre="establishment, and into the accumulation of population immunity to seasonal" exact="influenza" post="viruses. Methods Australian surveillance data Influenza viruses from Australia"/>
   <result pre="circulation during the pandemic were anomalous compared with typical seasonal" exact="influenza" post="virus epidemics, and potentially distortive of the patterns we"/>
   <result pre="from preceding variants to warrant an update of the seasonal" exact="influenza" post="virus vaccine. To this end, our analyses only accounted"/>
   <result pre="antigenic changes (neither of which are well studied for seasonal" exact="influenza" post="viruses). The haemagglutination inhibition (HI) assay data used in"/>
   <result pre="reference point is potentially problematic, given that new Southern Hemisphere’s" exact="influenza" post="vaccine composition recommendations are made every September. This is"/>
   <result pre="every September. This is usually after the end of the" exact="influenza" post="season in Australia, and may lead to misidentification during"/>
   <result pre="year (binary, yes or no) X6: the cumulative amount of" exact="influenza" post="activity (of any subtype) in the city that year"/>
   <result pre="D.H.M. performed the data analyses; A.C.H. and I.G.B. generated the" exact="influenza" post="virus data; E.K.S.L., D.H.M. and C.A.R. wrote the first"/>
   <result pre="Health Organization. Influenza (Seasonal) Fact sheet. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (2018). 2.DenoeudLet al.Predicting" exact="pneumonia" post="and influenza mortality from morbidity dataPLoS ONE2007236 3.FinkelmanBSet al.Global"/>
   <result pre="Influenza (Seasonal) Fact sheet. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (2018). 2.DenoeudLet al.Predicting pneumonia and" exact="influenza" post="mortality from morbidity dataPLoS ONE2007236 3.FinkelmanBSet al.Global patterns in"/>
   <result pre="morbidity dataPLoS ONE2007236 3.FinkelmanBSet al.Global patterns in seasonal activity of" exact="influenza" post="A/H3N2, A/H1N1, and B from 1997 to 2005: Viral"/>
   <result pre="dependent on relative humidity and temperaturePLoS Pathog.200731470147617953482 7.ShamanJKohnMAbsolute humidity modulates" exact="influenza" post="survival, transmission, and seasonalityProc. Natl Acad. Sci. USA20091063243324819204283 8.LowenACSteelJRoles"/>
   <result pre="Acad. Sci. USA20091063243324819204283 8.LowenACSteelJRoles of humidity and temperature in shaping" exact="influenza" post="seasonalityJ. Virol.2014887692769524789791 9.TameriusJDet al.Environmental predictors of seasonal influenza epidemics"/>
   <result pre="in shaping influenza seasonalityJ. Virol.2014887692769524789791 9.TameriusJDet al.Environmental predictors of seasonal" exact="influenza" post="epidemics across temperate and tropical climatesPLoS Pathog.20139e100319423505366 10.ShamanJPitzerVEViboudCGrenfellBTLipsitchMAbsolute humidity"/>
   <result pre="tropical climatesPLoS Pathog.20139e100319423505366 10.ShamanJPitzerVEViboudCGrenfellBTLipsitchMAbsolute humidity and the seasonal onset of" exact="influenza" post="in the continental United StatesPLoS Biol.20108e100031620186267 11.ShojiMKatayamaKSanoKAbsolute humidity as"/>
   <result pre="StatesPLoS Biol.20108e100031620186267 11.ShojiMKatayamaKSanoKAbsolute humidity as a deterministic factor affecting seasonal" exact="influenza" post="epidemics in JapanTohoku J. Exp. Med.201122425125621705850 12.DavisRERossierCEEnfieldKBThe impact of"/>
   <result pre="in JapanTohoku J. Exp. Med.201122425125621705850 12.DavisRERossierCEEnfieldKBThe impact of weather on" exact="influenza" post="and pneumonia mortality in New York City, 1975–2002: a"/>
   <result pre="J. Exp. Med.201122425125621705850 12.DavisRERossierCEEnfieldKBThe impact of weather on influenza and" exact="pneumonia" post="mortality in New York City, 1975–2002: a retrospective studyPLoS"/>
   <result pre="1975–2002: a retrospective studyPLoS ONE20127e3409122470518 13.SeleznevNELeonenkoVNAbsolute humidity anomalies and the" exact="influenza" post="onsets in Russia: a computational studyProcedia Comput. Sci.2017119224233 14.SmithDJMapping"/>
   <result pre="studyProcedia Comput. Sci.2017119224233 14.SmithDJMapping the antigenic and genetic evolution of" exact="influenza" post="virusScience200430537137615218094 15.LangatPet al.Genome-wide evolutionary dynamics of influenza B viruses"/>
   <result pre="genetic evolution of influenza virusScience200430537137615218094 15.LangatPet al.Genome-wide evolutionary dynamics of" exact="influenza" post="B viruses on a global scalePLoS Pathog.201713e100674929284042 16.Koelle, K.,"/>
   <result pre="&amp;amp; Pascual, M. Epochal evolution shapes the phylodynamics of interpandemic" exact="influenza" post="A (H3N2) in humans. Science6829, 1898–1904 (2006). 17.KoelleKKamradtMPascualMUnderstanding the"/>
   <result pre="rapidly evolving pathogens through modeling the tempo of antigenic change:" exact="influenza" post="as a case studyEpidemics2009112913721352760 18.Bock AxelsenJYaariRGrenfellBTStoneLMultiannual forecasting of seasonal"/>
   <result pre="influenza as a case studyEpidemics2009112913721352760 18.Bock AxelsenJYaariRGrenfellBTStoneLMultiannual forecasting of seasonal" exact="influenza" post="dynamics reveals climatic and evolutionary driversProc. Natl Acad. Sci."/>
   <result pre="of influenzaScience200631244745116574822 21.CharuVet al.Human mobility and the spatial transmission of" exact="influenza" post="in the United StatesPLoS Comput. Biol.201713123 22.SakaiTet al.Geographic and"/>
   <result pre="illness, Japan, 1992-1999Emerg. Infect. Dis.2004101822182615504270 23.GeogheganJLet al.Continental synchronicity of human" exact="influenza" post="virus epidemics despite climactic variationPLoS Pathog.201814116 24.SchnepfNet al.High burden"/>
   <result pre="above (ASGS 2001), 1991 to 2016. http://www.abs.gov.au (2017). 26.TameriusJet al.Global" exact="influenza" post="seasonality: reconciling patterns across temperate and tropical regionsEnviron. Health"/>
   <result pre="dynamics of pathogens with many strainsJ. Math. Biol.20167212425800537 30.WuAPengYDuXShuYJiangTCorrelation of" exact="influenza" post="virus excess mortality with antigenic variation: application to rapid"/>
   <result pre="excess mortality with antigenic variation: application to rapid estimation of" exact="influenza" post="mortality burdenPLoS Comput. Biol.20106e100088220711361 31.BedfordTet al.Integrating influenza antigenic dynamics"/>
   <result pre="rapid estimation of influenza mortality burdenPLoS Comput. Biol.20106e100088220711361 31.BedfordTet al.Integrating" exact="influenza" post="antigenic dynamics with molecular evolutioneLife20143126 32.YangWLipsitchMShamanJInference of seasonal and"/>
   <result pre="antigenic dynamics with molecular evolutioneLife20143126 32.YangWLipsitchMShamanJInference of seasonal and pandemic" exact="influenza" post="transmission dynamicsPLoS Natl Acad. Sci. USA201511227232729 33.BarrIGet al.A new"/>
   <result pre="transmission dynamicsPLoS Natl Acad. Sci. USA201511227232729 33.BarrIGet al.A new pandemic" exact="influenza" post="A(H1N1) genetic variant predominated in the winter 2010 influenza"/>
   <result pre="pandemic influenza A(H1N1) genetic variant predominated in the winter 2010" exact="influenza" post="season in Australia, New Zealand and SingaporeEurosurveillance20101516 34.HoschlerKet al.Seroprevalence"/>
   <result pre="season in Australia, New Zealand and SingaporeEurosurveillance20101516 34.HoschlerKet al.Seroprevalence of" exact="influenza" post="A (H1N1) pdm09 VirusEmerg. Infect. Dis.20121820102013 35.LesslerJet al.Evidence for"/>
   <result pre="pdm09 VirusEmerg. Infect. Dis.20121820102013 35.LesslerJet al.Evidence for antigenic seniority in" exact="influenza" post="A (H3N2) antibody responses in southern ChinaPLoS Pathog.2012826 36.KucharskiAJet"/>
   <result pre="in southern ChinaPLoS Pathog.2012826 36.KucharskiAJet al.Estimating the life course of" exact="influenza" post="A(H3N2) antibody responses from cross-sectional dataPLoS Biol.201513116 37.NeuzilKMMMet al.Immunogenicity"/>
   <result pre="and reactogenicity of 1 versus 2 doses of trivalent inactivated" exact="influenza" post="vaccine in vaccine-naive 5–8-year-old childrenJ. Infect. Dis.20061941032103916991077 38.Gouma, S.,"/>
   <result pre="Middle-aged individuals may be in a perpetual state of H3N2" exact="influenza" post="virus susceptibility. Preprint at https://www.medrxiv.org/content/10.1101/2020.01.09.20017038v1.full.pdf (2020). 39.MeadePet al.Influenza virus"/>
   <result pre="person-to-person variation in viral mutations that escape polyclonal serum targeting" exact="influenza" post="hemagglutinineLife20198e4932431452511 41.DalzielBDet al.Contact heterogeneity, rather than transmission efficiency, limits"/>
   <result pre="than transmission efficiency, limits the emergence and spread of canine" exact="influenza" post="virusPLoS Pathog.201410e100445525340642 42.DalzielBDet al.Urbanization and humidity shape the intensity"/>
   <result pre="virusPLoS Pathog.201410e100445525340642 42.DalzielBDet al.Urbanization and humidity shape the intensity of" exact="influenza" post="epidemics in U.S. citiesScience.2018362757930287659 43.SonoguchiTNaitoHHaraMTakeuchiYFukumiHCross-subtype protection in humans during"/>
   <result pre="sequential, overlapping, and/or concurrent epidemics caused by h3n2 and h1n1" exact="influenza" post="virusesJ. Infect. Dis.198515181883965596 44.CowlingBJet al.Protective efficacy of seasonal influenza"/>
   <result pre="h1n1 influenza virusesJ. Infect. Dis.198515181883965596 44.CowlingBJet al.Protective efficacy of seasonal" exact="influenza" post="vaccination against seasonal and pandemic influenza virus infection during"/>
   <result pre="al.Protective efficacy of seasonal influenza vaccination against seasonal and pandemic" exact="influenza" post="virus infection during 2009 in Hong KongClin. Infect. Dis.2010511370137921067351"/>
   <result pre="in Hong KongClin. Infect. Dis.2010511370137921067351 45.GoldsteinECobeySTakahashiSMillerJCLipsitchMPredicting the epidemic sizes of" exact="influenza" post="A/H1N1, A/H3N2, and B: a statistical methodPLoS Med.20118112 46.BedfordTet"/>
   <result pre="a statistical methodPLoS Med.20118112 46.BedfordTet al.Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic driftNature201552321722026053121 47.ThompsonWWet al.Mortality associated with"/>
   <result pre="influenza viruses vary with antigenic driftNature201552321722026053121 47.ThompsonWWet al.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesAm. Med."/>
   <result pre="United StatesAm. Med. Assoc.2003289179186 48.CainiSKronemanMWiegersTEl Guerche-SéblainCPagetJClinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype, and lineage: a systematic"/>
   <result pre="systematic literature reviewInfluenza Other Respir. Viruses20181278079229858537 49.BarrIGVijaykrishnaDSullivanSGDifferential age susceptibility to" exact="influenza" post="B/victoria lineage viruses in the 2015 Australian influenza seasonEurosurveillance20162119"/>
   <result pre="susceptibility to influenza B/victoria lineage viruses in the 2015 Australian" exact="influenza" post="seasonEurosurveillance20162119 50.SullivanSGChilverMBNHigginsGChengACStocksNPInfluenza vaccine effectiveness in Australia: results from the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7266344\results\search\disease\results.xml">
   <result pre="Flaviviruses: Dengue Virus From importation to autochthonous transmission: Drivers of" exact="chikungunya" post="and dengue emergence in a temperate area From importation"/>
   <result pre="in a temperate area From importation to autochthonous transmission of" exact="chikungunya" post="and dengue in Europe http://orcid.org/0000-0001-6485-8952JourdainFrédéricData curationFormal analysisMethodologyWriting – original"/>
   <result pre="exposed new geographical areas to the risk of dengue and" exact="chikungunya" post="virus transmission. Several autochthonous transmission events have occurred in"/>
   <result pre="as the main driver for autochthonous transmission of dengue and" exact="chikungunya" post="in Southern France. The presence of wooded areas around"/>
   <result pre="when developing strategies to the emerging threats of dengue and" exact="chikungunya" post="in Southern Europe and can be extrapolated in this"/>
   <result pre="in this area to other viruses such as Zika and" exact="yellow fever," post="which share the same vector. Furthermore, our results allow"/>
   <result pre="of imported cases and swift interventions. Author summary The dengue," exact="chikungunya" post="and Zika viruses have tremendously expanded their geographic range"/>
   <result pre="statistical analysis of the different imported cases of dengue and" exact="chikungunya" post="in Southern France, where the tiger mosquito is already"/>
   <result pre="Diseases at Santé publique France. Introduction The dengue (DENV) and" exact="chikungunya" post="(CHIKV) viruses have greatly expanded their geographic range globally"/>
   <result pre="viremia were included. 10.1371/journal.pntd.0008320.t001Table 1 Case definitions for dengue and" exact="chikungunya" post="virus infection. Definition Dengue Chikungunya Suspected case Fever of"/>
   <result pre="autochthonous event was observed (Table 2). 10.1371/journal.pntd.0008320.t002Table 2 Dengue and" exact="chikungunya" post="autochthonous transmission events in France between 2010 and 2018."/>
   <result pre="Health and Medical Research (Inserm) https://geo.data.gouv.fr/fr/datasets/9c6009a2bb10c4d69a15d399def4770b038be18a Epidemiological data Dengue and" exact="chikungunya" post="case data were obtained through the national surveillance system"/>
   <result pre="based on the reporting of suspected cases of dengue and/or" exact="chikungunya" post="to public health authorities, followed by timely biological diagnosis."/>
   <result pre="above possible explanatory variables on the occurrence of dengue and" exact="chikungunya" post="autochthonous events. Comparison was made using complementary log-log regression."/>
   <result pre="We focused on the identification of drivers of dengue and" exact="chikungunya" post="emergence. All events of autochthonous transmission were therefore considered,"/>
   <result pre="the increased efficacy of transmission observed after the adaptation of" exact="chikungunya" post="virus to Ae. albopictus [72]. The results of this"/>
   <result pre="diagnosis and reporting. The subclinical infection rates of dengue and" exact="chikungunya" post="infections is also a possible limitation of the study,"/>
   <result pre="the efficiency of the surveillance system dedicated to dengue and" exact="chikungunya" post="infections. Aedes albopictus is still expanding its range throughout"/>
   <result pre="emergence of arthropod-borne viral diseases: A global prospective on dengue," exact="chikungunya" post="and Zika fevers. Acta Trop. 2017;166: 155–163. 10.1016/j.actatropica.2016.11.02027876643 2SigfridL,"/>
   <result pre="8FrankeF, GironS, CochetA, JeanninC, Leparc-GoffartI, de ValkH, et al. [Autochthonous" exact="chikungunya" post="and dengue fever outbreak in Mainland France, 2010–2018]. Bull"/>
   <result pre="CochetA, JeanninC, Leparc-GoffartI, de ValkH, et al. [Autochthonous chikungunya and" exact="dengue fever" post="outbreak in Mainland France, 2010–2018]. Bull Epidémiol Hebd. 2019;"/>
   <result pre="9AngeliniR, FinarelliAC, AngeliniP, PoC, PetropulacosK, MaciniP, et al.An outbreak of" exact="chikungunya" post="fever in the province of Ravenna, Italy. Wkly releases."/>
   <result pre="Centre for Disease Prevention and Control (ECDC). Local transmission of" exact="dengue fever" post="in France and Spain– 2018–22 October 2018 [Internet]. 2018"/>
   <result pre="Di LucaM, FortunaC, RemoliME, RiccardoF, SeveriniF, et al.Detection of a" exact="chikungunya" post="outbreak in Central Italy, August to September 2017. Eurosurveillance."/>
   <result pre="Eurosurveillance. 2017;2210.2807/1560-7917.ES.2017.22.39.17-00646 12Gjenero-MarganI, AlerajB, KrajcarD, LesnikarV, Klobu�?arA, Pem-NovoselI, et al.Autochthonous" exact="dengue fever" post="in Croatia, August-September 2010. Euro Surveill. 2011;16. 13CalbaC, Guerbois-GallaM,"/>
   <result pre="FrankeF, JeanninC, Auzet-CaillaudM, GrardG, et al.Preliminary report of an autochthonous" exact="chikungunya" post="outbreak in France, July to September 2017. Eurosurveillance. 2017;2210.2807/1560-7917.ES.2017.22.39.17-00647"/>
   <result pre="SixC, CharletF, HeuzéG, CochetA, WiegandtA, et al.Large number of imported" exact="chikungunya" post="cases in mainland France, 2014: a challenge for surveillance"/>
   <result pre="al.Three-way interactions between mosquito population, viral strain and temperature underlying" exact="chikungunya" post="virus transmission potential. Proc Biol Sci. 2014;28110.1098/rspb.2014.107825122228 22LambrechtsL, ChevillonC,"/>
   <result pre="al.The role of environmental variables on Aedes albopictus biology and" exact="chikungunya" post="epidemiology. Pathog Glob Health. 2013;107: 224–241. 10.1179/2047773213Y.000000010023916332 35LittleE, BajwaW,"/>
   <result pre="of socio-economic and environmental factors on the spatial heterogeneity of" exact="dengue fever" post="investigated at a fine scale. Geospat Health. 2018;1310.4081/gh.2018.68230451470 48ReyG,"/>
   <result pre="58LiuK-K, WangT, HuangX-D, WangANGG-L, XiaIAY, ZhangY-T, et al.Risk assessment of" exact="dengue fever" post="in Zhongshan, China: a time-series regression tree analysis. Epidemiol"/>
   <result pre="10.1017/S095026881600265X27873572 59SochackiT, JourdainF, PerrinY, NoelH, PatyM, de ValkH, et al.Imported" exact="chikungunya" post="cases in an area newly colonized by Aedes albopictus:"/>
   <result pre="ChenR, YunR, RossiSL, PlanteKS, GuerboisM, et al.Multi-peaked adaptive landscape for" exact="chikungunya" post="virus evolution predicts continued fitness optimization in Aedes albopictus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7266482\results\search\disease\results.xml">
   <result pre="1-4. Infection with either of the DENV serotypes generally causes" exact="dengue fever" post="(DF), a self-limiting febrile illness that often lasts between"/>
   <result pre="DF can progress to develop one of two life-threatening conditions," exact="dengue hemorrhagic fever" post="(DHF) and dengue shock syndrome (DSS). DHF is characterized"/>
   <result pre="dengue shock syndrome (DSS). DHF is characterized by hemorrhage and" exact="thrombocytopenia" post="while DSS occurs due to excessive plasma leakage (Gubler"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7266596\results\search\disease\results.xml">
   <result pre="Research0168-17021872-7492Elsevier B.V. pmcid: 7266596S0168-1702(20)30120-9 doi: 10.1016/j.virusres.2020.198045198045 : Article Porcine epidemic" exact="diarrhea" post="virus (PEDV): An update on etiology, transmission, pathogenesis, and"/>
   <result pre="as the COVID-19 resource centre remains active. Highlights •Porcine epidemic" exact="diarrhea" post="virus (PEDV) causes acute diarrhea, dehydration and high mortality"/>
   <result pre="a critical role in sow lactogenic immunity. Abstract Porcine epidemic" exact="diarrhea" post="virus (PEDV), a member of the genus Alphacoronavirus in"/>
   <result pre="of the genus Alphacoronavirus in the family Coronaviridae, causes acute" exact="diarrhea" post="and/or vomiting, dehydration and high mortality in neonatal piglets."/>
   <result pre="and prevention and control of PEDV infection. Keywords Porcine epidemic" exact="diarrhea" post="virus PEDV Pathogenesis Prevention Coronavirus Pigs 1 Introduction Porcine"/>
   <result pre="virus PEDV Pathogenesis Prevention Coronavirus Pigs 1 Introduction Porcine epidemic" exact="diarrhea" post="virus (PEDV), a member of the genus Alphacoronavirus in"/>
   <result pre="economic losses (Jung and Saif, 2015). The disease, porcine epidemic" exact="diarrhea" post="(PED), in the US was caused by two different"/>
   <result pre="Gammacoronavirus, and Deltacoronavirus (Woo et al., 2012). The alphacoronavirus transmissible" exact="gastroenteritis" post="virus (TGEV), which is clinically similar to PEDV, was"/>
   <result pre="was identified in diarrheic pigs and was designated swine acute" exact="diarrhea" post="syndrome coronavirus (SADS-CoV) (Gong et al., 2017; Pan et"/>
   <result pre="INDEL PEDV (Iowa106 strain) at 3−4 days of age had" exact="diarrhea" post="after challenging with a G2b non-S INDEL PEDV at"/>
   <result pre="and then challenged with the same non-S INDEL PEDV showed" exact="diarrhea" post="(Annamalai et al., 2017; Lin et al., 2015a). 2.5"/>
   <result pre="coronaviruses Antigenic cross-reactivity or cross-neutralization between PEDV and feline infectious" exact="peritonitis" post="virus (FIPV) was detected by enzyme linked immunosorbent assay"/>
   <result pre="4.6 Pathophysiology Diarrhea induced by PEDV is a consequence of" exact="malabsorption" post="and maldigestion due to massive loss and functional disorders"/>
   <result pre="(&amp;lt;5%) to all of the inoculated pigs began to show" exact="diarrhea" post="at PID 1, which mostly coincided with or was"/>
   <result pre="Madson et al., 2016). A one-three-day delay in onset of" exact="diarrhea" post="was observed in nursing pigs inoculated with S INDEL"/>
   <result pre="(&amp;lt;5%) to all of the inoculated pigs began to show" exact="diarrhea" post="at PID 1–4, which coincided with or was detected"/>
   <result pre="Fecal viral RNA titers shed peaked by 1–3 days after" exact="diarrhea" post="was first detected (Gallien et al., 2018a; Jung et"/>
   <result pre="and sows experimentally infected with different genogroups of porcine epidemic" exact="diarrhea" post="virus (PEDV) strains via oral inoculation, or direct or"/>
   <result pre="strain and inoculum dose Infection or exposure route Onset of" exact="diarrhea" post="(PID)* Duration of diarrhea (PID) Onset of fecal viral"/>
   <result pre="Infection or exposure route Onset of diarrhea (PID)* Duration of" exact="diarrhea" post="(PID) Onset of fecal viral RNA shedding (PID) Duration"/>
   <result pre="strain, 6 mL of 3.16 × 105 TCID50/mL Oral No" exact="diarrhea" post="No diarrhea (but with slight depression in 2/2 sows"/>
   <result pre="mL of 3.16 × 105 TCID50/mL Oral No diarrhea No" exact="diarrhea" post="(but with slight depression in 2/2 sows for 4"/>
   <result pre="57–59), or late (day 96–97) gestation periods. 4.8 Duration of" exact="diarrhea" post="and fecal virus shedding Duration of diarrhea in infected"/>
   <result pre="4.8 Duration of diarrhea and fecal virus shedding Duration of" exact="diarrhea" post="in infected nursing pigs varied from 2 to 8"/>
   <result pre="plaque-forming unit (PFU)/pig of the non-S INDEL PC22A strain caused" exact="diarrhea" post="in 100 % of 4-day-old Cesarean-derived, colostrum-deprived (CDCD) piglets"/>
   <result pre="pigs to show fecal virus shedding (1 more day), or" exact="diarrhea" post="and lesions (2 more days) (Jung et al., 2015a)."/>
   <result pre="G2b PEDV CT (120th passage in Vero cells) showed mild" exact="diarrhea" post="and moderate fecal viral RNA shedding titers, with mild"/>
   <result pre="caesarean-derived, colostrum-deprived (CDCD) pigs inoculated orally with attenuated porcine epidemic" exact="diarrhea" post="virus (PEDV) strains. [alt-text] Table 2 Strain (cell passage"/>
   <result pre="(classical S INDEL) 8.2 log10 TCID50* 12-week 4 NR¶ No" exact="diarrhea" post="at PID 1−14 Intermittent detection of viral RNA in"/>
   <result pre="2b (non-S INDEL) 6 log10 TCID50 10-day 4 NR No" exact="diarrhea" post="at PID 1−5 No detection [possibly due to no"/>
   <result pre="6 log10 TCID50 1-day 16 0 at PID 1−14 No" exact="diarrhea" post="at PID 1−14 No or little viral RNA shedding"/>
   <result pre="4-day CDCD 6 0 at PID 1−10 or 15 Mild" exact="diarrhea" post="in 3/4 pigs (75 %) at PID 1−10 or"/>
   <result pre="protocols that should include no movement of pigs until the" exact="diarrhea" post="is terminated and the disease is controlled (Niederwerder and"/>
   <result pre="paper. References References AlonsoC.GoedeD.P.MorrisonR.B.DaviesP.R.RoviraA.MarthalerD.G.TorremorellM.Evidence of infectivity of airborne porcine epidemic" exact="diarrhea" post="virus and detection of airborne viral RNA at long"/>
   <result pre="One1082015e0135675 AnnamalaiT.SaifL.J.LuZ.JungK.Age-dependent variation in innate immune responses to porcine epidemic" exact="diarrhea" post="virus infection in suckling versus weaned pigsVet. Immunol. Immunopathol.1683–4201519320226433606"/>
   <result pre="nursing piglets infected with a US spike-insertion deletion porcine epidemic" exact="diarrhea" post="virus strain and challenged with an original US PEDV"/>
   <result pre="of an accelerated hydrogen peroxide disinfectant to inactivate porcine epidemic" exact="diarrhea" post="virus in swine feces on aluminum surfaces under freezing"/>
   <result pre="BakerK.L.MowrerC.L.ZhangJ.ChenQ.RamirezA.WangC.KarrikerL.A.HoltkampD.J.Evaluation of a peroxygen-based disinfectant for inactivation of porcine epidemic" exact="diarrhea" post="virus at low temperatures on metal surfacesVet. Microbiol.21420189910729408040 BeallA.YountB.LinC.M.HouY.WangQ.SaifL.BaricR.Characterization"/>
   <result pre="pathogenic full-length cDNA clone and transmission model for porcine epidemic" exact="diarrhea" post="virus strain PC22AmBio712016e01451141526733065 BeamA.GoedeD.FoxA.McCoolM.J.WallG.HaleyC.MorrisonR.A porcine epidemic diarrhea virus outbreak"/>
   <result pre="for porcine epidemic diarrhea virus strain PC22AmBio712016e01451141526733065 BeamA.GoedeD.FoxA.McCoolM.J.WallG.HaleyC.MorrisonR.A porcine epidemic" exact="diarrhea" post="virus outbreak in one geographic region of the United"/>
   <result pre="BevinsS.N.LutmanM.PedersenK.BarrettN.GidlewskiT.DelibertoT.J.FranklinA.B.Spillover of swine coronaviruses, United StatesEmerging Infect. Dis.24720181390139229912697 BoniottiM.B.PapettiA.LavazzaA.AlboraliG.SozziE.ChiapponiC.FacciniS.BonilauriP.CordioliP.MarthalerD.Porcine epidemic" exact="diarrhea" post="virus and discovery of a recombinant swine enteric coronavirus,"/>
   <result pre="developing mammary glandMol. Immunol.451220083354336218533264 BowmanA.S.KrogwoldR.A.PriceT.DavisM.MoellerS.J.Investigating the introduction of porcine epidemic" exact="diarrhea" post="virus into an Ohio swine operationBMC Vet. Res.1120153825881144 BowmanA.S.NoltingJ.M.NelsonS.W.BlissN.StullJ.W.WangQ.PremanandanC.Effects"/>
   <result pre="BowmanA.S.NoltingJ.M.NelsonS.W.BlissN.StullJ.W.WangQ.PremanandanC.Effects of disinfection on the molecular detection of porcine epidemic" exact="diarrhea" post="virusVet. Microbiol.1793–4201521321826072369 CanningP.RustonC.MadsonD.BatesJ.SkolandK.DavenportJ.GaulS.WangC.ChenQ.ZhangJ.KarrikerL.Effect of direct-fed microbial Bacillus subtilis C-3102"/>
   <result pre="enteric health in nursery pigs after challenge with porcine epidemic" exact="diarrhea" post="virusJ. Swine Health Prod.2532017129137 ChenQ.LiG.StaskoJ.ThomasJ.T.StenslandW.R.PillatzkiA.E.GaugerP.C.SchwartzK.J.MadsonD.YoonK.J.StevensonG.W.BurroughE.R.HarmonK.M.MainR.G.ZhangJ.Isolation and characterization of porcine"/>
   <result pre="virusJ. Swine Health Prod.2532017129137 ChenQ.LiG.StaskoJ.ThomasJ.T.StenslandW.R.PillatzkiA.E.GaugerP.C.SchwartzK.J.MadsonD.YoonK.J.StevensonG.W.BurroughE.R.HarmonK.M.MainR.G.ZhangJ.Isolation and characterization of porcine epidemic" exact="diarrhea" post="viruses associated with the 2013 disease outbreak among swine"/>
   <result pre="of classical and variant virulent parental/attenuated strains of porcine epidemic" exact="diarrhea" post="virusViruses71020155525553826512689 ChenQ.GaugerP.C.StafneM.R.ThomasJ.T.MadsonD.M.HuangH.ZhengY.LiG.ZhangJ.Pathogenesis comparison between the United States porcine epidemic"/>
   <result pre="serological cross-reactivity and cross-neutralization between the United States porcine epidemic" exact="diarrhea" post="virus prototype and S-INDEL-variant strainsBMC Vet. Res.1220167027044253 ChenJ.ZhangC.LiuY.LiuG.Super-oxidized water"/>
   <result pre="I. Histological and histochemical studyVet. Pathol.191198246566280359 CrawfordK.LagerK.MillerL.OpriessnigT.GerberP.HesseR.Evaluation of porcine epidemic" exact="diarrhea" post="virus transmission and the immune response in growing pigsVet."/>
   <result pre="in growing pigsVet. Res.4620154925943434 CrawfordK.LagerK.M.KulshreshthaV.MillerL.C.FaabergK.S.Status of vaccines for porcine epidemic" exact="diarrhea" post="virus in the United States and CanadaVirus Res.226201610811627545066 CurryS.M.SchwartzK.J.YoonK.J.GablerN.K.BurroughE.R.Effects"/>
   <result pre="the United States and CanadaVirus Res.226201610811627545066 CurryS.M.SchwartzK.J.YoonK.J.GablerN.K.BurroughE.R.Effects of porcine epidemic" exact="diarrhea" post="virus infection on nursery pig intestinal function and barrier"/>
   <result pre="of contaminated complete feed as a vehicle for porcine epidemic" exact="diarrhea" post="virus infection of naive pigs following consumption via natural"/>
   <result pre="binding characteristics of the spike protein of two porcine epidemic" exact="diarrhea" post="virus strainsViruses8320165526907329 DengX.van GeelenA.BuckleyA.C.O’BrienA.PillatzkiA.LagerK.M.FaabergK.S.BakerS.C.Coronavirus endoribonuclease activity in porcine epidemic"/>
   <result pre="diarrhea virus strainsViruses8320165526907329 DengX.van GeelenA.BuckleyA.C.O’BrienA.PillatzkiA.LagerK.M.FaabergK.S.BakerS.C.Coronavirus endoribonuclease activity in porcine epidemic" exact="diarrhea" post="virus suppresses type I and type III interferon responsesJ."/>
   <result pre="porcine epidemic diarrhoea virusTransbound. Emerg. Dis.65620181720173229968338 GallienS.MoroA.LediguerherG.CatinotV.PaboeufF.BigaultL.BerriM.GaugerP.C.PozziN.AuthieE.RoseN.GraslandB.Evidence of porcine epidemic" exact="diarrhea" post="virus (PEDV) shedding in semen from infected specific pathogen-free"/>
   <result pre="Res.4912018729368629 GallienS.MoroA.LediguerherG.CatinotV.PaboeufF.BigaultL.GaugerP.C.PozziN.BerriM.AuthieE.RoseN.GraslandB.Limited shedding of an S-InDel strain of porcine epidemic" exact="diarrhea" post="virus (PEDV) in semen and questions regarding the infectivity"/>
   <result pre="infectivity of the detected virusVet. Microbiol.2282019202530593368 GaoQ.ZhaoS.QinT.YinY.YangQ.Effects of porcine epidemic" exact="diarrhea" post="virus on porcine monocyte-derived dendritic cells and intestinal dendritic"/>
   <result pre="and intestinal dendritic cellsVet. Microbiol.1793–4201513114126065617 GerberP.F.XiaoC.T.LagerK.CrawfordK.KulshreshthaV.CaoD.MengX.J.OpriessnigT.Increased frequency of porcine epidemic" exact="diarrhea" post="virus shedding and lesions in suckling pigs compared to"/>
   <result pre="nursery pigs after homologous re-challengeVet. Res.471201611827871312 GerdtsV.ZakhartchoukA.Vaccines for porcine epidemic" exact="diarrhea" post="virus and other swine coronavirusesVet. Microbiol.2062017455127964998 GillespieT.SongQ.InskeepM.StoneS.MurtaughM.P.Effect of booster"/>
   <result pre="coronavirusesVet. Microbiol.2062017455127964998 GillespieT.SongQ.InskeepM.StoneS.MurtaughM.P.Effect of booster vaccination with inactivated porcine epidemic" exact="diarrhea" post="virus on neutralizing antibody response in mammary secretionsViral Immunol.3112018626828783456"/>
   <result pre="antibody response in mammary secretionsViral Immunol.3112018626828783456 Gimenez-LirolaL.G.ZhangJ.Carrillo-AvilaJ.A.ChenQ.MagtotoR.PoonsukK.BaumD.H.PineyroP.ZimmermanJ.Reactivity of porcine epidemic" exact="diarrhea" post="virus structural proteins to antibodies against porcine enteric coronaviruses:"/>
   <result pre="infection of sows with a &quot;mild�? strain of porcine epidemic" exact="diarrhea" post="virus confers protection against infection with a &quot;severe�? strainVet."/>
   <result pre="literatureFront. Vet. Sci.6201927331508430 GraslandB.BigaultL.BernardC.QuenaultH.ToulouseO.FabletC.RoseN.TouzainF.BlanchardY.Complete genome sequence of a porcine epidemic" exact="diarrhea" post="s gene indel strain isolated in france in december"/>
   <result pre="with virulent and CV777 vaccine strain-like strains of porcine epidemic" exact="diarrhea" post="virusJ. Proteomics1302016657526361011 HofmannM.WylerR.Quantitation, biological and physicochemical properties of cell"/>
   <result pre="HofmannM.WylerR.Quantitation, biological and physicochemical properties of cell culture-adapted porcine epidemic" exact="diarrhea" post="coronavirus (PEDV)Vet. Microbiol.20219891311422549681 HoltkampD.J.MyersJ.ThomasP.R.KarrikerL.A.RamirezA.ZhangJ.WangC.Efficacy of an accelerated hydrogen peroxide"/>
   <result pre="of an accelerated hydrogen peroxide disinfectant to inactivate porcine epidemic" exact="diarrhea" post="virus in swine feces on metal surfacesCan. J. Vet."/>
   <result pre="metal surfacesCan. J. Vet. Res.812201710010728408777 HouY.WangQ.Emerging highly virulent porcine epidemic" exact="diarrhea" post="virus: molecular mechanisms of attenuation and rational design of"/>
   <result pre="in the N-terminal domain of spike protein attenuates porcine epidemic" exact="diarrhea" post="virus in pigletsJ. Virol.91142017 HouY.KeH.KimJ.YooD.SuY.BoleyP.ChepngenoJ.VlasovaA.N.SaifL.J.WangQ.Engineering a live attenuated porcine"/>
   <result pre="virus in pigletsJ. Virol.91142017 HouY.KeH.KimJ.YooD.SuY.BoleyP.ChepngenoJ.VlasovaA.N.SaifL.J.WangQ.Engineering a live attenuated porcine epidemic" exact="diarrhea" post="virus vaccine candidate via inactivation of the viral 2’-O-methyltransferase"/>
   <result pre="in the cytoplasmic tail of spike protein attenuates porcine epidemic" exact="diarrhea" post="virus in pigsJ. Virol.9322019 HuangY.W.DickermanA.W.PineyroP.LiL.FangL.KiehneR.OpriessnigT.MengX.J.Origin, evolution, and genotyping of"/>
   <result pre="pigsJ. Virol.9322019 HuangY.W.DickermanA.W.PineyroP.LiL.FangL.KiehneR.OpriessnigT.MengX.J.Origin, evolution, and genotyping of emergent porcine epidemic" exact="diarrhea" post="virus strains in the United StatesmBio452013e007370071324129257 HuangM.Z.WangS.Y.WangH.CuiD.A.YangY.J.LiuX.W.KongX.J.LiJ.Y.Differences in the"/>
   <result pre="microbiota between uninfected piglets and piglets infected with porcine epidemic" exact="diarrhea" post="virusPLoS One1322018e0192992 JeonJ.H.LeeC.Cellular cholesterol is required for porcine nidovirus"/>
   <result pre="for porcine nidovirus infectionArch. Virol.1621220173753376728884395 JiC.M.WangB.ZhouJ.HuangY.W.Aminopeptidase-N-independent entry of porcine epidemic" exact="diarrhea" post="virus into Vero or porcine small intestine epithelial cellsVirology5172018162329502803"/>
   <result pre="enhancement and generation of mammary gland bioreactorFront. Immunol.7201621427375616 JungK.SaifL.J.Porcine epidemic" exact="diarrhea" post="virus infection: etiology, epidemiology, pathogenesis and immunoprophylaxisVet. J.2042201513414325841898 JungK.SaifL.J.Goblet"/>
   <result pre="of conventional nursing and weaned pigs infected with porcine epidemic" exact="diarrhea" post="virusRes. Vet. Sci.1102017121528159230 JungK.AhnK.ChaeC.Decreased activity of brush border membrane-bound"/>
   <result pre="in small intestines from pigs experimentally infected with porcine epidemic" exact="diarrhea" post="virusRes. Vet. Sci.813200631031516759679 JungK.WangQ.ScheuerK.A.LuZ.ZhangY.SaifL.J.Pathology of US porcine epidemic diarrhea"/>
   <result pre="epidemic diarrhea virusRes. Vet. Sci.813200631031516759679 JungK.WangQ.ScheuerK.A.LuZ.ZhangY.SaifL.J.Pathology of US porcine epidemic" exact="diarrhea" post="virus strain PC21A in gnotobiotic pigsEmerg. Infect. Dis.204201466266524795932 JungK.AnnamalaiT.LuZ.SaifL.J.Comparative"/>
   <result pre="gnotobiotic pigsEmerg. Infect. Dis.204201466266524795932 JungK.AnnamalaiT.LuZ.SaifL.J.Comparative pathogenesis of US porcine epidemic" exact="diarrhea" post="virus (PEDV) strain PC21A in conventional 9-day-old nursing piglets"/>
   <result pre="large intestine of conventional nursing piglets infected with porcine epidemic" exact="diarrhea" post="virusVet. Microbiol.1773–4201537337825843943 JungK.HuH.EyerlyB.LuZ.ChepngenoJ.SaifL.J.Pathogenecity of 2 porcine deltacoronavirus strains in"/>
   <result pre="of conventional or gnotobiotic (Gn) pigs infected with porcine epidemic" exact="diarrhea" post="virus (PEDV) and serum cytokine responses of Gn pigs"/>
   <result pre="Gn pigs to acute PEDV infectionRes. Vet. Sci.11920189910829909130 KimY.LeeC.Porcine epidemic" exact="diarrhea" post="virus induces caspase-independent apoptosis through activation of mitochondrial apoptosis-inducing"/>
   <result pre="induces caspase-independent apoptosis through activation of mitochondrial apoptosis-inducing factorVirology460–4612014180193 KimB.KimO.TaiJ.H.ChaeC.Transmissible" exact="gastroenteritis" post="virus induces apoptosis in swine testicular cell lines but"/>
   <result pre="but not in intestinal enterocytesJ. Comp. Pathol.12312000646610906258 KimY.OhC.ShivannaV.HesseR.A.ChangK.O.Trypsin-independent porcine epidemic" exact="diarrhea" post="virus US strain with altered virus entry mechanismBMC Vet."/>
   <result pre="of biosecurity measures to prevent indirect transmission of porcine epidemic" exact="diarrhea" post="virusBMC Vet. Res.13120178928381304 KocherhansR.BridgenA.AckermannM.ToblerK.Completion of the porcine epidemic diarrhoea"/>
   <result pre="in the swine gut microbiota in response to porcine epidemic" exact="diarrhea" post="infectionMicrobes Environ.303201528428726212519 KoonpaewS.TeeravechyanS.FrantzP.N.ChailangkarnT.JongkaewwattanaA.PEDV and PDCoV pathogenesis: the interplay between"/>
   <result pre="porcine enteric coronavirusesFront. Vet. Sci.620193430854373 KweonC.H.KwonB.J.LeeJ.G.KwonG.O.KangY.B.Derivation of attenuated porcine epidemic" exact="diarrhea" post="virus (PEDV) as vaccine candidateVaccine1720–2119992546255310418901 LangelS.N.PaimF.C.LagerK.M.VlasovaA.N.SaifL.J.Lactogenic immunity and vaccines"/>
   <result pre="as vaccine candidateVaccine1720–2119992546255310418901 LangelS.N.PaimF.C.LagerK.M.VlasovaA.N.SaifL.J.Lactogenic immunity and vaccines for porcine epidemic" exact="diarrhea" post="virus (PEDV): historical and current conceptsVirus Res.22620169310727212686 LangelS.N.PaimF.C.AlhamoM.A.BuckleyA.Van GeelenA.LagerK.M.VlasovaA.N.SaifL.J.Stage"/>
   <result pre="current conceptsVirus Res.22620169310727212686 LangelS.N.PaimF.C.AlhamoM.A.BuckleyA.Van GeelenA.LagerK.M.VlasovaA.N.SaifL.J.Stage of gestation at porcine epidemic" exact="diarrhea" post="virus infection of pregnant swine impacts maternal immunity and"/>
   <result pre="suckling pigletsFront. Immunol.10201972731068924 LangelS.N.PaimF.C.AlhamoM.A.LagerK.M.VlasovaA.N.SaifL.J.Oral vitamin A supplementation of porcine epidemic" exact="diarrhea" post="virus infected gilts enhances IgA and lactogenic immune protection"/>
   <result pre="Res.501201910131783923 LangelS.N.WangQ.VlasovaA.N.SaifL.J.Host factors affecting generation of immunity against porcine epidemic" exact="diarrhea" post="virus in pregnant and lactating swine and passive protection"/>
   <result pre="protection of neonatesPathogens92020130 LanghansW.Anorexia of infection: current prospectsNutrition16102000996100511054606 LeeC.Porcine epidemic" exact="diarrhea" post="virus: an emerging and re-emerging epizootic swine virusVirol. J.12201519326689811"/>
   <result pre="re-emerging epizootic swine virusVirol. J.12201519326689811 LeeD.U.KwonT.JeS.H.YooS.J.SeoS.W.SunwooS.Y.LyooY.S.Wild boars harboring porcine epidemic" exact="diarrhea" post="virus (PEDV) may play an important role as a"/>
   <result pre="receptor for the PEDV coronavirusVirology3651200716617217467767 LiW.LiH.LiuY.PanY.DengF.SongY.TangX.HeQ.New variants of porcine epidemic" exact="diarrhea" post="virus, China, 2011Emerg. Infect. Dis.18820121350135322840964 LiW.van KuppeveldF.J.M.HeQ.RottierP.J.M.BoschB.J.Cellular entry of"/>
   <result pre="2011Emerg. Infect. Dis.18820121350135322840964 LiW.van KuppeveldF.J.M.HeQ.RottierP.J.M.BoschB.J.Cellular entry of the porcine epidemic" exact="diarrhea" post="virusVirus Res.226201611712727317167 LiW.LuoR.HeQ.van KuppeveldF.J.M.RottierP.J.M.BoschB.J.Aminopeptidase N is not required for"/>
   <result pre="Res.226201611712727317167 LiW.LuoR.HeQ.van KuppeveldF.J.M.RottierP.J.M.BoschB.J.Aminopeptidase N is not required for porcine epidemic" exact="diarrhea" post="virus cell entryVirus Res.235201761328363778 LiY.WuQ.HuangL.YuanC.WangJ.YangQ.An alternative pathway of enteric"/>
   <result pre="enteroids: a new model for studying enteric coronavirus porcine epidemic" exact="diarrhea" post="virus infection and the host innate responseJ. Virol.9352019 LinC.M.AnnamalaiT.LiuX.GaoX.LuZ.El-TholothM.HuH.SaifL.J.WangQ.Experimental"/>
   <result pre="Virol.9352019 LinC.M.AnnamalaiT.LiuX.GaoX.LuZ.El-TholothM.HuH.SaifL.J.WangQ.Experimental infection of a US spike-insertion deletion porcine epidemic" exact="diarrhea" post="virus in conventional nursing piglets and cross-protection to the"/>
   <result pre="original US PEDV infectionVet. Res.46201513426589292 LinC.M.GaoX.OkaT.VlasovaA.N.EsseiliM.A.WangQ.SaifL.J.Antigenic relationships among porcine epidemic" exact="diarrhea" post="virus and transmissible gastroenteritis virus strainsJ. Virol.89620153332334225589635 LinC.M.SaifL.J.MarthalerD.WangQ.Evolution, antigenicity"/>
   <result pre="Res.46201513426589292 LinC.M.GaoX.OkaT.VlasovaA.N.EsseiliM.A.WangQ.SaifL.J.Antigenic relationships among porcine epidemic diarrhea virus and transmissible" exact="gastroenteritis" post="virus strainsJ. Virol.89620153332334225589635 LinC.M.SaifL.J.MarthalerD.WangQ.Evolution, antigenicity and pathogenicity of global"/>
   <result pre="strainsJ. Virol.89620153332334225589635 LinC.M.SaifL.J.MarthalerD.WangQ.Evolution, antigenicity and pathogenicity of global porcine epidemic" exact="diarrhea" post="virus strainsVirus Res.2262016203927288724 LinC.M.HouY.MarthalerD.G.GaoX.LiuX.ZhengL.SaifL.J.WangQ.Attenuation of an original US porcine"/>
   <result pre="virus strainsVirus Res.2262016203927288724 LinC.M.HouY.MarthalerD.G.GaoX.LiuX.ZhengL.SaifL.J.WangQ.Attenuation of an original US porcine epidemic" exact="diarrhea" post="virus strain PC22A via serial cell culture passageVet. Microbiol.2012017627128284624"/>
   <result pre="LinH.LiB.ChenL.MaZ.HeK.FanH.Differential protein analysis of IPEC-J2 cells infected with porcine epidemic" exact="diarrhea" post="virus pandemic and classical strains elucidates the pathogenesis of"/>
   <result pre="Proteome Res.16620172113212028506058 LiuC.TangJ.MaY.LiangX.YangY.PengG.QiQ.JiangS.LiJ.DuL.LiF.Receptor usage and cell entry of porcine epidemic" exact="diarrhea" post="coronavirusJ. Virol.891120156121612525787280 LiuS.ZhaoL.ZhaiZ.ZhaoW.DingJ.DaiR.SunT.MengH.Porcine epidemic diarrhea virus infection induced the"/>
   <result pre="cell entry of porcine epidemic diarrhea coronavirusJ. Virol.891120156121612525787280 LiuS.ZhaoL.ZhaiZ.ZhaoW.DingJ.DaiR.SunT.MengH.Porcine epidemic" exact="diarrhea" post="virus infection induced the unbalance of gut microbiota in"/>
   <result pre="infectious titer and virulence of an original US porcine epidemic" exact="diarrhea" post="virus PC22A strainVet. Res.46201510926408019 LohseL.KrogJ.S.StrandbygaardB.RasmussenT.B.KjaerJ.BelshamG.J.BotnerA.Experimental infection of young pigs"/>
   <result pre="Emerg. Dis.64520171380138627161288 LoweJ.GaugerP.HarmonK.ZhangJ.ConnorJ.YeskeP.LoulaT.LevisI.DufresneL.MainR.Role of transportation in spread of porcine epidemic" exact="diarrhea" post="virus infection, United StatesEmerging Infect. Dis.205201487287424750785 LuoX.GuoL.ZhangJ.XuY.GuW.FengL.WangY.Tight junction protein"/>
   <result pre="Infect. Dis.205201487287424750785 LuoX.GuoL.ZhangJ.XuY.GuW.FengL.WangY.Tight junction protein occludin is a porcine epidemic" exact="diarrhea" post="virus entry factorJ. Virol.91102017 MaY.ZhangY.LiangX.OglesbeeM.KrakowkaS.NiehausA.WangG.JiaA.SongH.LiJ.Two-way antigenic cross-reactivity between porcine"/>
   <result pre="virus entry factorJ. Virol.91102017 MaY.ZhangY.LiangX.OglesbeeM.KrakowkaS.NiehausA.WangG.JiaA.SongH.LiJ.Two-way antigenic cross-reactivity between porcine epidemic" exact="diarrhea" post="virus and porcine deltacoronavirusVet. Microbiol.1862016909627016762 MadsonD.M.MagstadtD.R.ArrudaP.H.HoangH.SunD.BowerL.P.BhandariM.BurroughE.R.GaugerP.C.PillatzkiA.E.StevensonG.W.WilbertsB.L.BrodieJ.HarmonK.M.WangC.MainR.G.ZhangJ.YoonK.J.Pathogenesis of porcine epidemic"/>
   <result pre="diarrhea virus and porcine deltacoronavirusVet. Microbiol.1862016909627016762 MadsonD.M.MagstadtD.R.ArrudaP.H.HoangH.SunD.BowerL.P.BhandariM.BurroughE.R.GaugerP.C.PillatzkiA.E.StevensonG.W.WilbertsB.L.BrodieJ.HarmonK.M.WangC.MainR.G.ZhangJ.YoonK.J.Pathogenesis of porcine epidemic" exact="diarrhea" post="virus isolate (US/Iowa/18984/2013) in 3-week-old weaned pigsVet. Microbiol.1741–22014606825278366 MadsonD.M.ArrudaP.H.MagstadtD.R.BurroughE.R.HoangH.SunD.BowerL.P.BhandariM.GaugerP.C.StevensonG.W.WilbertsB.L.WangC.ZhangJ.YoonK.J.Characterization"/>
   <result pre="(US/Iowa/18984/2013) in 3-week-old weaned pigsVet. Microbiol.1741–22014606825278366 MadsonD.M.ArrudaP.H.MagstadtD.R.BurroughE.R.HoangH.SunD.BowerL.P.BhandariM.GaugerP.C.StevensonG.W.WilbertsB.L.WangC.ZhangJ.YoonK.J.Characterization of porcine epidemic" exact="diarrhea" post="virus isolate US/Iowa/18984/2013 infection in 1-Day-Old cesarean-derived colostrum-deprived pigletsVet."/>
   <result pre="Health2016WATTAgNetMay 26 MesquitaJ.R.Hakze-van der HoningR.AlmeidaA.LourencoM.van der PoelW.H.NascimentoM.S.Outbreak of porcine epidemic" exact="diarrhea" post="virus in Portugal, 2015Transbound. Emerg. Dis.626201558658826344708 MoonH.W.NormanJ.O.LambertG.Age dependent resistance"/>
   <result pre="in Portugal, 2015Transbound. Emerg. Dis.626201558658826344708 MoonH.W.NormanJ.O.LambertG.Age dependent resistance to transmissible" exact="gastroenteritis" post="of swine (TGE). I. Clinical signs and some mucosal"/>
   <result pre="the porcine aminopeptidase N (CD13) receptor density to porcine epidemic" exact="diarrhea" post="virus infectionVet. Microbiol.1441–22010415020074871 NiederwerderM.C.HesseR.A.Swine enteric coronavirus disease: a review"/>
   <result pre="virus carriage, antibody response, and aerosol transmission of Porcine epidemic" exact="diarrhea" post="virus following inoculation of 4-week-old feeder pigsJ. Vet. Diagn."/>
   <result pre="inoculation of 4-week-old feeder pigsJ. Vet. Diagn. Invest.286201667167827698163 OpriessnigT.XiaoC.T.GerberP.F.ZhangJ.HalburP.G.Porcine epidemic" exact="diarrhea" post="virus RNA present in commercial spray-dried porcine plasma is"/>
   <result pre="pigsPLoS One982014e104766 OuyangK.ShyuD.L.DhakalS.HiremathJ.BinjawadagiB.LakshmanappaY.S.GuoR.RansburghR.BondraK.M.GaugerP.ZhangJ.SpechtT.GilbertieA.MintonW.FangY.RenukaradhyaG.J.Evaluation of humoral immune status in porcine epidemic" exact="diarrhea" post="virus (PEDV) infected sows under field conditionsVet. Res.46201514026667229 PanY.TianX.QinP.WangB.ZhaoP.YangY.L.WangL.WangD.SongY.ZhangX.HuangY.W.Discovery"/>
   <result pre="as a source of the first-detected outbreaks of porcine epidemic" exact="diarrhea" post="in CanadaTransbound. Emerg. Dis.615201439741025098383 PensaertM.B.de BouckP.A new coronavirus-like particle"/>
   <result pre="CanadaTransbound. Emerg. Dis.615201439741025098383 PensaertM.B.de BouckP.A new coronavirus-like particle associated with" exact="diarrhea" post="in swineArch. Virol.583197824324783132 PensaertM.B.MartelliP.Porcine epidemic diarrhea: a retrospect from"/>
   <result pre="epidemiological investigation of the early phase of the porcine epidemic" exact="diarrhea" post="(PED) outbreak in Canadian swine herds in 2014: a"/>
   <result pre="Med. Biol.480200027928610959435 SatoT.TakeyamaN.KatsumataA.TuchiyaK.KodamaT.KusanagiK.Mutations in the spike gene of porcine epidemic" exact="diarrhea" post="virus associated with growth adaptation in vitro and attenuation"/>
   <result pre="in vivoVirus Genes4312011727821559974 SatoT.OrokuK.OhshimaY.FuruyaY.SasakawaC.Efficacy of genogroup 1 based porcine epidemic" exact="diarrhea" post="live vaccine against genogroup 2 field strain in JapanVirol."/>
   <result pre="in JapanVirol. J.15120182829394943 SchumacherL.L.HussA.R.CochraneR.A.StarkC.R.WoodworthJ.C.BaiJ.PoulsenE.G.ChenQ.MainR.G.ZhangJ.GaugerP.C.RamirezA.DerscheidR.J.MagstadtD.M.DritzS.S.JonesC.K.Characterizing the rapid spread of porcine epidemic" exact="diarrhea" post="virus (PEDV) through an animal food manufacturing facilityPLoS One12112017e0187309"/>
   <result pre="SchumacherL.L.CochraneR.A.HussA.R.GebhardtJ.T.WoodworthJ.C.StarkC.R.JonesC.K.BaiJ.MainR.G.ChenQ.ZhangJ.GaugerP.C.DeRoucheyJ.M.GoodbandR.D.TokachM.D.DritzS.S.Feed batch sequencing to decrease the risk of porcine epidemic" exact="diarrhea" post="virus (PEDV) cross-contamination during feed manufacturingJ. Anim. Sci.961120184562457030099515 ScottA.McCluskeyB.Brown-ReidM.GrearD.PitcherP.RamosG.SpencerD.SingreyA.Porcine"/>
   <result pre="virus (PEDV) cross-contamination during feed manufacturingJ. Anim. Sci.961120184562457030099515 ScottA.McCluskeyB.Brown-ReidM.GrearD.PitcherP.RamosG.SpencerD.SingreyA.Porcine epidemic" exact="diarrhea" post="virus introduction into the United States: root cause investigationPrev."/>
   <result pre="aminopeptidase N is not a cellular receptor of porcine epidemic" exact="diarrhea" post="virus, but promotes its infectivity via aminopeptidase activityJ. Gen."/>
   <result pre="Antimicrobial Proteins2017 SongD.S.YangJ.S.OhJ.S.HanJ.H.ParkB.K.Differentiation of a Vero cell adapted porcine epidemic" exact="diarrhea" post="virus from Korean field strains by restriction fragment length"/>
   <result pre="ORF 3Vaccine2117–1820031833184212706667 SongD.S.OhJ.S.KangB.K.YangJ.S.MoonH.J.YooH.S.JangY.S.ParkB.K.Oral efficacy of Vero cell attenuated porcine epidemic" exact="diarrhea" post="virus DR13 strainRes. Vet. Sci.821200713414016730762 SongQ.StoneS.DrebesD.GreinerL.L.DvorakC.M.T.MurtaughM.P.Characterization of anti-porcine epidemic"/>
   <result pre="diarrhea virus DR13 strainRes. Vet. Sci.821200713414016730762 SongQ.StoneS.DrebesD.GreinerL.L.DvorakC.M.T.MurtaughM.P.Characterization of anti-porcine epidemic" exact="diarrhea" post="virus neutralizing activity in mammary secretionsVirus Res.2262016859227287711 SongD.PengQ.ChenY.ZhouX.ZhangF.LiA.HuangD.WuQ.YeY.HeH.WangL.TangY.Altered gut"/>
   <result pre="profiles in sows and neonatal piglets associated with porcine epidemic" exact="diarrhea" post="virus infectionSci. Rep.7120171743929234140 StadlerJ.ZoelsS.FuxR.HankeD.PohlmannA.BlomeS.WeissenbockH.Weissenbacher-LangC.RitzmannM.LadinigA.Emergence of porcine epidemic diarrhea virus"/>
   <result pre="porcine epidemic diarrhea virus infectionSci. Rep.7120171743929234140 StadlerJ.ZoelsS.FuxR.HankeD.PohlmannA.BlomeS.WeissenbockH.Weissenbacher-LangC.RitzmannM.LadinigA.Emergence of porcine epidemic" exact="diarrhea" post="virus in southern GermanyBMC Vet. Res.11201514226135732 SteinriglA.FernandezS.R.StoiberF.PikaloJ.SattlerT.SchmollF.First detection, clinical"/>
   <result pre="SteinriglA.FernandezS.R.StoiberF.PikaloJ.SattlerT.SchmollF.First detection, clinical presentation and phylogenetic characterization of Porcine epidemic" exact="diarrhea" post="virus in AustriaBMC Vet. Res.11201531026714453 StevensonG.W.HoangH.SchwartzK.J.BurroughE.B.SunD.MadsonD.CooperV.L.PillatzkiA.GaugerP.SchmittB.J.KosterL.G.KillianM.L.YoonK.J.Emergence of Porcine epidemic"/>
   <result pre="diarrhea virus in AustriaBMC Vet. Res.11201531026714453 StevensonG.W.HoangH.SchwartzK.J.BurroughE.B.SunD.MadsonD.CooperV.L.PillatzkiA.GaugerP.SchmittB.J.KosterL.G.KillianM.L.YoonK.J.Emergence of Porcine epidemic" exact="diarrhea" post="virus in the United States: clinical signs, lesions, and"/>
   <result pre="genomic sequencesJ. Vet. Diagn. Investig.255201364965423963154 SuY.HouY.PraratM.ZhangY.WangQ.New variants of porcine epidemic" exact="diarrhea" post="virus with large deletions in the spike protein, identified"/>
   <result pre="cecal microbiota community of suckling piglets infected with porcine epidemic" exact="diarrhea" post="virusPLoS One1472019e0219868 TeeravechyanS.FrantzP.N.WongthidaP.ChailangkarnT.Jaru-AmpornpanP.KoonpaewS.JongkaewwattanaA.Deciphering the biology of porcine epidemic diarrhea"/>
   <result pre="epidemic diarrhea virusPLoS One1472019e0219868 TeeravechyanS.FrantzP.N.WongthidaP.ChailangkarnT.Jaru-AmpornpanP.KoonpaewS.JongkaewwattanaA.Deciphering the biology of porcine epidemic" exact="diarrhea" post="virus in the era of reverse geneticsVirus Res.226201615217127212685 ThomasJ.T.ChenQ.GaugerP.C.Gimenez-LirolaL.G.SinhaA.HarmonK.M.MadsonD.M.BurroughE.R.MagstadtD.R.SalzbrennerH.M.WelchM.W.YoonK.J.ZimmermanJ.J.ZhangJ.Effect"/>
   <result pre="the era of reverse geneticsVirus Res.226201615217127212685 ThomasJ.T.ChenQ.GaugerP.C.Gimenez-LirolaL.G.SinhaA.HarmonK.M.MadsonD.M.BurroughE.R.MagstadtD.R.SalzbrennerH.M.WelchM.W.YoonK.J.ZimmermanJ.J.ZhangJ.Effect of porcine epidemic" exact="diarrhea" post="virus infectious doses on infection outcomes in naive conventional"/>
   <result pre="ThomasP.R.KarrikerL.A.RamirezA.ZhangJ.Q.EllingsonJ.S.CrawfordK.K.BatesJ.L.HammenK.J.HoltkampD.J.Evaluation of time and temperature sufficient to inactivate porcine epidemic" exact="diarrhea" post="virus in swine feces on metal surfacesJ. Swine Health"/>
   <result pre="ion channel protein and regulates virus productionFEBS Lett.5864201238439122245155 WangJ.ZhaoP.GuoL.LiuY.DuY.RenS.LiJ.ZhangY.FanY.HuangB.LiuS.WuJ.Porcine epidemic" exact="diarrhea" post="virus variants with high pathogenicity, ChinaEmerg. Infect. Dis.191220132048204924274832 WangL.ByrumB.ZhangY.Detection"/>
   <result pre="Ohio, USA, 2014Emerg. Infect. Dis.20720141227123024964136 WangL.ByrumB.ZhangY.New variant of porcine epidemic" exact="diarrhea" post="virus, United States, 2014Emerg. Infect. Dis.205201491791924750580 WangX.OhnstadM.NelsenA.NelsonE.Porcine epidemic diarrhea"/>
   <result pre="epidemic diarrhea virus, United States, 2014Emerg. Infect. Dis.205201491791924750580 WangX.OhnstadM.NelsenA.NelsonE.Porcine epidemic" exact="diarrhea" post="virus does not replicate in porcine monocyte-derived dendritic cells,"/>
   <result pre="diarrhoeaVet. Rec.100121977243244888300 WuY.LiW.ZhouQ.LiQ.XuZ.ShenH.ChenF.Characterization and pathogenicity of Vero cell-attenuated porcine epidemic" exact="diarrhea" post="virus CT strainVirol. J.161201912131660993 XieW.AoC.YangY.LiuY.LiangR.ZengZ.YeG.XiaoS.FuZ.F.DongW.PengG.Two critical N-terminal epitopes of"/>
   <result pre="the nucleocapsid protein contribute to the cross-reactivity between porcine epidemic" exact="diarrhea" post="virus and porcine transmissible gastroenteritis virusJ. Gen. Virol.1002201920621630652967 YamamotoR.SomaJ.NakanishiM.YamaguchiR.NiinumaS.Isolation"/>
   <result pre="the cross-reactivity between porcine epidemic diarrhea virus and porcine transmissible" exact="gastroenteritis" post="virusJ. Gen. Virol.1002201920621630652967 YamamotoR.SomaJ.NakanishiM.YamaguchiR.NiinumaS.Isolation and experimental inoculation of an"/>
   <result pre="experimental inoculation of an S INDEL strain of porcine epidemic" exact="diarrhea" post="virus in JapanRes. Vet. Sci.103201510310626679803 ZhangQ.YooD.Immune evasion of porcine"/>
   <result pre="modulation of antiviral innate signalingVirus Res.226201612814127212682 ZhangJ.Yim-ImW.ChenQ.ZhengY.SchumacherL.HuangH.GaugerP.HarmonK.LiG.Identification of porcine epidemic" exact="diarrhea" post="virus variant with a large spike gene deletion from"/>
   <result pre="United StatesVirus Genes542201832332729468451 ZhangQ.KeH.BlikslagerA.FujitaT.YooD.Type III interferon restriction by porcine epidemic" exact="diarrhea" post="virus and the role of viral protein nsp1 in"/>
   <result pre="ZhangJ.WuZ.YangH.Aminopeptidase N knockout pigs are not resistant to porcine epidemic" exact="diarrhea" post="virus infectionVirol. Sin.345201959259531134585 ZhaoW.WangY.LiuS.HuangJ.ZhaiZ.HeC.DingJ.WangJ.WangH.FanW.ZhaoJ.MengH.The dynamic distribution of porcine microbiota"/>
   <result pre="ZhaoS.LiW.SchuurmanN.van KuppeveldF.BoschB.J.EgberinkH.Serological screening for coronavirus infections in catsViruses1182019 ZhouY.L.EderveenJ.EgberinkH.PensaertM.HorzinekM.C.Porcine epidemic" exact="diarrhea" post="virus (CV 777) and feline infectious peritonitis virus (FIPV)"/>
   <result pre="catsViruses1182019 ZhouY.L.EderveenJ.EgberinkH.PensaertM.HorzinekM.C.Porcine epidemic diarrhea virus (CV 777) and feline infectious" exact="peritonitis" post="virus (FIPV) are antigenically relatedArch. Virol.1021–2198863713196169 ZhouP.FanH.LanT.YangX.L.ShiW.F.ZhangW.ZhuY.ZhangY.W.XieQ.M.ManiS.ZhengX.S.LiB.LiJ.M.GuoH.PeiG.Q.AnX.P.ChenJ.W.ZhouL.MaiK.J.WuZ.X.LiD.AndersonD.E.ZhangL.B.LiS.Y.MiZ.Q.HeT.T.CongF.GuoP.J.HuangR.LuoY.LiuX.L.ChenJ.HuangY.SunQ.ZhangX.L.WangY.Y.XingS.Z.ChenY.S.SunY.LiJ.DaszakP.WangL.F.ShiZ.L.TongY.G.MaJ.Y.Fatal swine acute"/>
   <result pre="an HKU2-related coronavirus of bat originNature5567700201825525829618817 ZongQ.F.HuangY.J.WuL.S.WuZ.C.WuS.L.BaoW.B.Effects of porcine epidemic" exact="diarrhea" post="virus infection on tight junction protein gene expression and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7266814\results\search\disease\results.xml">
   <result pre="CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus PeiYujunWenKunXiangZhengHuangChunyuWangXiweiMuXiaofengWenLiyanLiuYinpingTuWenweiwwtu@hku.hk[], 0000000121742757grid.194645.bDepartment of Paediatrics and Adolescent Medicine, Li"/>
   <result pre="vaccines and antiviral drugs have achieved great advances in controlling" exact="influenza" post="virus infection, the efficacy of these strategies is limited"/>
   <result pre="pamidronate could be a therapeutic strategy to treat seasonal and" exact="avian influenza" post="virus infections. However, one notable drawback of γδ-T cell-based"/>
   <result pre="could be a therapeutic strategy to treat seasonal and avian" exact="influenza" post="virus infections. However, one notable drawback of γδ-T cell-based"/>
   <result pre="stimulation. CD137+ Vγ9Vδ2-T cells displayed more potent antiviral activity against" exact="influenza" post="virus than their CD137− counterparts in vitro and in"/>
   <result pre="human CD137L protein boosted the therapeutic effects of pamidronate against" exact="influenza" post="virus. Our study provides a novel strategy of targeting"/>
   <result pre="vaccines and antiviral drugs have achieved great advances in controlling" exact="influenza" post="virus infection, the efficacy of these strategies is still"/>
   <result pre="immunity was recently thought to have obvious advantages in controlling" exact="influenza" post="infection without the risks of viral mutation and antiviral"/>
   <result pre="and zoledronate, which are commonly used for the treatment of" exact="osteoporosis" post="and Paget’s disease, can induce the activation and expansion"/>
   <result pre="that phosphoantigen-activated Vγ9Vδ2-T cells have antiviral activities against human and" exact="avian influenza" post="viruses mediated by killing virus-infected monocyte-derived macrophages (MDMs), inhibiting"/>
   <result pre="phosphoantigen-activated Vγ9Vδ2-T cells have antiviral activities against human and avian" exact="influenza" post="viruses mediated by killing virus-infected monocyte-derived macrophages (MDMs), inhibiting"/>
   <result pre="virus-specific antibodies.16–20 Recently, we further reported that PAM can control" exact="influenza" post="diseases by expanding the Vγ9Vδ2-T cell population in humanized"/>
   <result pre="mice.21,22 However, the application of PAM for the treatment of" exact="influenza" post="is limited by the rapid exhaustion of the proliferation"/>
   <result pre="have been shown to enhance the efficacy of vaccines against" exact="influenza" post="virus and poxvirus by enhancing CD8+ or CD4+ T"/>
   <result pre="survival and effector functions of Vγ9Vδ2-T cells in response to" exact="influenza" post="virus infection in vitro and in vivo. Using a"/>
   <result pre="that SA-hCD137L is an efficient adjuvant for PAM therapy for" exact="influenza" post="virus infection that functions by improving the antiviral activity"/>
   <result pre="CD137 on Vγ9Vδ2-T cells while coculturing PAM-expanded Vγ9Vδ2-T cells with" exact="influenza" post="H1N1/A/PR/8/34 virus-infected autologous MDMs. CD137 was rapidly induced in"/>
   <result pre="Vγ9Vδ2-T cells became CD137+ cells after 24 h of coculture with" exact="influenza" post="virus-infected MDMs (Fig. 1c). Importantly, CD137L expression was also"/>
   <result pre="25.7 ± 4.3% of the MDMs became CD137L+ cells after 24 h of" exact="influenza" post="virus infection (Fig. 1d). These data indicated that the"/>
   <result pre="CD137L were upregulated on Vγ9Vδ2-T cells and MDMs, respectively, during" exact="influenza" post="virus infection, raising the possibility that CD137/CD137L could serve"/>
   <result pre="on Vγ9Vδ2-T cells was detected during coculture with mock- or" exact="influenza" post="virus-infected autologous MDMs for the indicated time. d CD137L"/>
   <result pre="d CD137L expression on MDMs was evaluated during mock or" exact="influenza" post="virus infection. Cells were harvested at the indicated time"/>
   <result pre="**p &amp;lt; 0.01 CD137+ Vγ9Vδ2-T cells had more potent antiviral activity against" exact="influenza" post="virus than their CD137− counterparts in vitro We further"/>
   <result pre="function of CD137+ and CD137- Vγ9Vδ2-T cells during coculture with" exact="influenza" post="virus-infected MDMs. As shown in Fig. 2a, CD137+ Vγ9Vδ2-T"/>
   <result pre="CD137+ Vγ9Vδ2-T cells than CD137- Vγ9Vδ2-T cells after coculture with" exact="influenza" post="virus-infected MDMs (Fig. 2a), which suggested that influenza virus-infected"/>
   <result pre="coculture with influenza virus-infected MDMs (Fig. 2a), which suggested that" exact="influenza" post="virus-infected MDMs triggered more intensive granule release from CD137+"/>
   <result pre="2 CD137+ Vγ9Vδ2-T Cells had more potent antiviral activity against" exact="influenza" post="virus than their CD137− counterparts in vitro. a, b"/>
   <result pre="counterparts in vitro. a, b Human MDMs were infected with" exact="influenza" post="virus at an MOI of 2 for 1h and"/>
   <result pre="6h. Then, these cells (effector cells, E) were cocultured with" exact="influenza" post="virus-infected autologous MDMs (target cells, T) at an E:T"/>
   <result pre="sorted these two subsets and detected their cytotoxic activity against" exact="influenza" post="virus-infected MDMs. As shown in Fig. 2c, both CD137+"/>
   <result pre="antiviral activities of both CD137+ and CD137− Vγ9Vδ2-T cells against" exact="influenza" post="virus in vivo, Rag2−/− γc−/− mice were infected with"/>
   <result pre="influenza virus in vivo, Rag2−/− γc−/− mice were infected with" exact="influenza" post="virus intranasally (i.n.). CD137+ and CD137− Vγ9Vδ2-T cell subsets"/>
   <result pre="CD137− or whole Vγ9Vδ2-T cells were adoptively transferred into the" exact="influenza" post="virus-infected mice on days 2, 4, and 6 post"/>
   <result pre="Treatment with CD137+ Vγ9Vδ2-T cells showed more efficacy in controlling" exact="influenza" post="disease than CD137- and whole Vγ9Vδ2-T cells, with the"/>
   <result pre="that CD137+ Vγ9Vδ2-T cells displayed superior antiviral effects in controlling" exact="influenza" post="disease in vivo. Fig. 3 CD137+ Vγ9Vδ2-T cells had"/>
   <result pre="evaluation of the therapeutic effect of Vγ9Vδ2-T cell subsets on" exact="influenza" post="virus-infected Rag2−/− γc−/− mice. Rag2−/− γc−/− mice were infected"/>
   <result pre="Rag2−/− γc−/− mice were infected with a sublethal dose of" exact="influenza" post="virus (25μl, 104 TCID50) intranasally (i.n.) on day 0."/>
   <result pre="CD137 costimulation enhanced the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus We have shown that CD137+ Vγ9Vδ2-T cells display"/>
   <result pre="SA-hCD137L protein to a coculture of whole Vγ9Vδ2-T cells with" exact="influenza" post="virus-infected MDMs significantly enhanced the expression of CD107a, cytolytic"/>
   <result pre="recombinant protein significantly increased the cytotoxicity of Vγ9Vδ2-T cells against" exact="influenza" post="virus-infected MDMs (Fig. 4b). These data demonstrated that CD137"/>
   <result pre="CD137 costimulation enhanced the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus. Human MDMs (target cells, T) were infected with"/>
   <result pre="of CD137 in the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus, an anti-CD137 neutralizing mAb was used to block"/>
   <result pre="costimulation could enhance the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus. CD137 costimulation promoted the proliferation and prolonged the"/>
   <result pre="difference CD137 costimulation improved the therapeutic effect of PAM against" exact="influenza" post="virus infection in vivo To demonstrate whether costimulation through"/>
   <result pre="can improve the therapeutic effect of PAM-expanded Vγ9Vδ2-T cells against" exact="influenza" post="virus in vivo, humanized mice reconstituted with whole huPBMC"/>
   <result pre="with the recombinant SA-hCD137L protein and PAM 3 days after" exact="influenza" post="virus infection (Fig. 6a). During the 20 days of"/>
   <result pre="whether the effect of SA-hCD137L costimulation on the control of" exact="influenza" post="virus infection in humanized mice was mediated by Vγ9Vδ2-T"/>
   <result pre="SA-hCD137L protein had a synergistic effect with PAM to control" exact="influenza" post="disease in vivo and that their antiviral activity against"/>
   <result pre="influenza disease in vivo and that their antiviral activity against" exact="influenza" post="virus was mainly mediated by Vγ9Vδ2-T cells. Fig. 6"/>
   <result pre="6 CD137 costimulation improved the therapeutic effect of PAM on" exact="influenza" post="virus infection in vivo. a Protocol for evaluation of"/>
   <result pre="of the synergistic therapeutic effect of PAM and SA-hCD137L on" exact="influenza" post="virus-infected humanized mice. Humanized mice reconstituted with whole huPBMC"/>
   <result pre="cell-depleted huPBMC (PBMC-γδT) were infected with a sublethal dose of" exact="influenza" post="virus (25μl, 104 TCID50) intranasally (i.n.), and then treated"/>
   <result pre="c The body weight changes (b) and survival (c) of" exact="influenza" post="virus-infected humanized mice were measured at the indicated time"/>
   <result pre="robust αβ-T cell effector responses has been extensively demonstrated in" exact="infectious disease" post="models. However, the role of CD137 signaling in Vγ9Vδ2-T"/>
   <result pre="in Vγ9Vδ2-T cells remains poorly understood in the context of" exact="influenza" post="virus infection. In this study, we demonstrate for the"/>
   <result pre="ligation enhances Vγ9Vδ2-T cell proliferation, survival and antiviral activity against" exact="influenza" post="virus. The CD137+ Vγ9Vδ2-T cell population exhibited an enhanced"/>
   <result pre="CD137+ Vγ9Vδ2-T cell population exhibited an enhanced capability to treat" exact="influenza" post="when employed as an adoptive γδ-T cell therapy. Furthermore,"/>
   <result pre="protein, SA-hCD137L, could boost the effect of PAM therapy on" exact="influenza" post="by costimulating Vγ9Vδ2-T cells. Our study provides a relatively"/>
   <result pre="cells. Our study provides a relatively effective strategy to treat" exact="influenza" post="virus by targeting CD137 to improve the antiviral activity"/>
   <result pre="critical role in αβ-T cell-mediated antiviral immune responses against influenza,33,34" exact="hepatitis" post="C, cytomegalovirus, HIV, lymphocytic choriomeningitis virus, and poxviruses.35 As"/>
   <result pre="cell-mediated antiviral immune responses against influenza,33,34 hepatitis C, cytomegalovirus, HIV," exact="lymphocytic choriomeningitis" post="virus, and poxviruses.35 As shown in previous reports on"/>
   <result pre="2). Using CD137+ Vγ9Vδ2-T cells for adoptive cell-based therapy for" exact="influenza" post="is superior to using CD137− or whole Vγ9Vδ2-T cells"/>
   <result pre="CD137+ Vγ9Vδ2-T cells an attractive agent for the therapy of" exact="influenza" post="diseases. Although CD137+ Vγ9Vδ2-T cells expressed higher levels of"/>
   <result pre="mAb or SA-hCD137L during coculture of PAM-expanded Vγ9Vδ2-T cells with" exact="influenza" post="virus-infected MDMs (Fig. 4). In contrast, CD137 costimulation enhanced"/>
   <result pre="complex to induce effective antitumor immune responses.40,41 SA-mCD137L induces less" exact="lymphadenopathy" post="and splenomegaly than antibody therapy, suggesting that SA-mCD137L has"/>
   <result pre="offers a compelling alternative to anti-CD137 agonistic antibody-mediated stimulation for" exact="influenza" post="immunotherapy. Since murine T cells do not express a"/>
   <result pre="similar to that seen in humans.20,21,31,32 Moreover, we found that" exact="influenza" post="viruses could efficiently replicate and cause pathology in these"/>
   <result pre="for the study of human Vγ9Vδ2-T cell immune responses to" exact="influenza" post="viruses. Using humanized mice, we further showed the synergistic"/>
   <result pre="showed the synergistic effect of PAM and recombinant SA-hCD137L against" exact="influenza" post="virus is mediated by boosting human Vγ9Vδ2-T cell immunity."/>
   <result pre="is becoming a popular cellular immunotherapy paradigm for patients with" exact="infectious disease" post="or cancer. The potential to expand Vγ9Vδ2-T cells in"/>
   <result pre="also provides proof-of-concept data for a novel strategy for treating" exact="influenza" post="virus infection by targeting CD137 to improve the antiviral"/>
   <result pre="treatment of virus-infected humanized and Rag2−/− γc−/− mice A mouse-adapted" exact="influenza" post="H1N1 (A/PR/8/34) virus was cultured in Madin-Darby canine kidney"/>
   <result pre="For in vitro experiments, day 14-differentiated MDMs were infected with" exact="influenza" post="virus at a multiplicity of infection (MOI) of 2."/>
   <result pre="reaction (qRT-PCR) assay by targeting the conserved matrix gene of" exact="influenza" post="virus.45 A serially diluted recombinant plasmid (pET-28b(+)/M1) containing the"/>
   <result pre="target gene was used as a standard. The lungs from" exact="influenza" post="virus-infected mice were harvested at the indicated time and"/>
   <result pre="no competing interests. References References 1.BaileyESet al.The continual threat of" exact="influenza" post="virus infections at the human–animal interface: what is new"/>
   <result pre="a one health perspective?Evol. Med. Public Health2018201819219830210800 2.ZieglerTMamahitACoxNJ65 years of" exact="influenza" post="surveillance by a World Health Organization-coordinated global networkInfluenza Other"/>
   <result pre="of resistanceInfluenza Other Respir. Viruses20137253623279894 6.LeungKLipsitchMYuenKYWuJTMonitoring the fitness of antiviral-resistant" exact="influenza" post="strains during an epidemic: a mathematical modelling studyLancet Infec."/>
   <result pre="a mathematical modelling studyLancet Infec. Dis.20171733934727914853 7.HussainMet al.Drug resistance in" exact="influenza" post="A virus: the epidemiology and managementInfect. Drug Resist.20171012113428458567 8.WangBXFishENGlobal"/>
   <result pre="display potent cytotoxicity against monocyte-derived macrophages infected with human and" exact="avian influenza" post="virusesJ. Infect. Dis.200920085886519656068 17.QinGet al.Type 1 responses of human"/>
   <result pre="potent cytotoxicity against monocyte-derived macrophages infected with human and avian" exact="influenza" post="virusesJ. Infect. Dis.200920085886519656068 17.QinGet al.Type 1 responses of human"/>
   <result pre="17.QinGet al.Type 1 responses of human Vgamma9Vdelta2 T cells to" exact="influenza" post="A virusesJ. Virol.201185101091011621752902 18.QinGet al.Phenotypic and functional characterization of"/>
   <result pre="functional characterization of human gammadelta T-cell subsets in response to" exact="influenza" post="A virusesJ. Infect. Dis.20122051646165322457284 19.LiHet al.Human Vgamma9Vdelta2-T cells efficiently"/>
   <result pre="A virusesJ. Infect. Dis.20122051646165322457284 19.LiHet al.Human Vgamma9Vdelta2-T cells efficiently kill" exact="influenza" post="virus-infected lung alveolar epithelial cellsCell Mol. Immunol.20131015916423353835 20.ChenQet al.Human"/>
   <result pre="Vgamma9Vdelta2-T cells synergize CD4(+) T follicular helper cells to produce" exact="influenza" post="virus-specific antibodyFront. Immunol.2018959929670614 21.TuWet al.The aminobisphosphonate pamidronate controls influenza"/>
   <result pre="produce influenza virus-specific antibodyFront. Immunol.2018959929670614 21.TuWet al.The aminobisphosphonate pamidronate controls" exact="influenza" post="pathogenesis by expanding a gammadelta T cell population in"/>
   <result pre="Exp. Med.20112081511152221708931 22.ZhengJet al.The therapeutic effect of pamidronate on lethal" exact="avian influenza" post="A H7N9 virus infected humanized micePLoS ONE201510e013599926285203 23.SicardHet al.In"/>
   <result pre="Med.20112081511152221708931 22.ZhengJet al.The therapeutic effect of pamidronate on lethal avian" exact="influenza" post="A H7N9 virus infected humanized micePLoS ONE201510e013599926285203 23.SicardHet al.In"/>
   <result pre="nonhuman primate modelJ. Immunol.20051755471548016210655 24.ChesterCAmbulkarSKohrtHE4-1BB agonism: adding the accelerator to" exact="cancer" post="immunotherapyCancer Immunol. Immunother.2016651243124827034234 25.UnoTet al.Eradication of established tumors in"/>
   <result pre="lymphoproliferative diseaseCancer Cell.20142656557625220446 32.NiKet al.PD-1/PD-L1 Pathway mediates the alleviation of" exact="pulmonary fibrosis" post="by human mesenchymal stem cells in humanized miceAm. J."/>
   <result pre="regulates the size of the T cell memory response following" exact="influenza" post="infectionJ. Immunol.20021683777378511937529 34.LinGHet al.Endogenous 4-1BB ligand plays a critical"/>
   <result pre="therapeutic antibodiesSemin. Oncol.20103750851621074066 40.BarsoumianHBet al.A novel form of 4-1BBL prevents" exact="cancer" post="development via nonspecific activation of CD4(+) T and natural"/>
   <result pre="and monophosphoryl lipid A constitute an efficacious combination adjuvant for" exact="cancer" post="vaccinesCancer Res.2014746441645125252915 42.DieliFet al.Targeting human γδ T cells with"/>
   <result pre="cell activation is essential for virus-specific CTL activity during acute" exact="influenza" post="virus infectionCell Mol. Immunol.20181582783728413216"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7268205\results\search\disease\results.xml">
   <result pre="active. Abstract This article summarizes current knowledge on the related" exact="influenza" post="B and C viruses and considers the few studies"/>
   <result pre="viruses and considers the few studies on the recently identified" exact="influenza" post="D virus. We focus on the particular viral genome"/>
   <result pre="address the evolutionary strategies and the epidemiological significance of these" exact="influenza" post="virus types, as well as the current state of"/>
   <result pre="Influenza D virus Influenza vaccine NS1 protein Orthomyxoviridae Palmitoylation Viral" exact="respiratory disease" post="Viral RNA polymerase Glossary EC50 Half maximal effective concentration."/>
   <result pre="splicing factor 35. vRNP Viral ribonucleoprotein. The genomic RNAs of" exact="influenza" post="viruses are complexed with the viral nucleoprotein and polymerase"/>
   <result pre="for the first time during an outbreak of an acute" exact="respiratory disease" post="in 1940 in Northern America, in which it was"/>
   <result pre="in which it was found to lack antigenic cross-reactivity to" exact="influenza" post="A virus (IAV). IBV is classified as the only"/>
   <result pre="IBV is classified as the only member of the genus" exact="influenza" post="virus B within the order of the Orthomyxoviridae. IBV"/>
   <result pre="surveillance detects IBV in some seasons as the dominating circulating" exact="influenza" post="virus type highlighting its significant socio-economic impact. There are"/>
   <result pre="symptoms. Since the virus showed no cross-reactivity with antisera against" exact="influenza" post="A or B viruses, it was classified as a"/>
   <result pre="to reassort with ICV it is now officially named as" exact="influenza" post="D virus (IDV). Subsequent studies showed that IDV can"/>
   <result pre="part of this article reviews current knowledge on type B" exact="influenza" post="virus, whereas the second part addresses important aspects of"/>
   <result pre="NA, NB and BM2 are integrated. Type A and B" exact="influenza" post="viruses cannot be distinguished based upon their morphology or"/>
   <result pre="P proteins were the lowest. Fig. 1 EM pictures of" exact="influenza" post="B and C viruses. Left: Influenza B virus. Negative"/>
   <result pre="lengths of genome segments and encoded gene products from prototypic" exact="influenza" post="B virus, influenza C virus and influenza D virus"/>
   <result pre="segments and encoded gene products from prototypic influenza B virus," exact="influenza" post="C virus and influenza D virus strains [alt-text] Table"/>
   <result pre="products from prototypic influenza B virus, influenza C virus and" exact="influenza" post="D virus strains [alt-text] Table 1 Segment B/Lee/40a B/Lee/40a"/>
   <result pre="incorporated together with six other IAV segments into infectious chimeric" exact="influenza" post="A/B viruses, when the coding regions were flanked with"/>
   <result pre="activities of IBV P proteins. It is generally believed that" exact="influenza" post="viruses express an error-prone RNA polymerase which contributes to"/>
   <result pre="as glycosylation is believed to be a strategy, by which" exact="influenza" post="viruses mask antigenic sites. Cleavage activation of the HA"/>
   <result pre="sulfated glycans. Receptor specificity is considered an important determinant of" exact="influenza" post="virus pathogenesis, but it remains to be established whether"/>
   <result pre="with Pymol2.2 (https://pymol.org/2/) from pdb file 4M40 showing HA from" exact="influenza" post="virus B/Yamanashi/166/1998 and from pdb file 1FLC containing C/Johannesburg/1/66."/>
   <result pre="M1. Neuraminidase (NA) The neuraminidase, the receptor destroying enzyme of" exact="influenza" post="A and B viruses, is a type II transmembrane"/>
   <result pre="target for current antiviral therapy of human infections by circulating" exact="influenza" post="A and B viruses (see below). NB NB is"/>
   <result pre="depend on palmitoylation of cysteine 49. Most interestingly, a recombinant" exact="influenza" post="B/Florida/04/2006 virus engineered to lack NB expression by introduction"/>
   <result pre="to efficiently complement the multi-cyclic growth of a recombinant M2-deficient" exact="influenza" post="A virus, which was otherwise confined to a single"/>
   <result pre="such as amantadine resulting in natural resistance of type B" exact="influenza" post="viruses to this first generation class of anti-influenza compounds."/>
   <result pre="the type A NS1. ISG15 has been shown to regulate" exact="influenza" post="A and B virus infections. It was therefore not"/>
   <result pre="have been established. Epidemiology IBV is considered to cause seasonal" exact="influenza" post="epidemics every 2–4 years, but less comprehensive systematic analyzes"/>
   <result pre="since 2001 showed that the detection of IBV among circulating" exact="influenza" post="viruses ranged from 1% to 70% through all age"/>
   <result pre="long-term global comparison suggested that IBV is the most prevalent" exact="influenza" post="virus type affecting older children (5–17 years) and is"/>
   <result pre="which was in between the rates for A(H3N2) and A(H1N1)" exact="influenza" post="(99 and 56 per 100.000). Significantly, IBV infections were"/>
   <result pre="IBV infections were the main cause of mortality attributable to" exact="influenza" post="in the US in four epidemic seasons between 1997"/>
   <result pre="IBV was detected in 1222 (73%) of the 1674 fatal" exact="influenza" post="cases reported through the German Public Health notification system"/>
   <result pre="but other studies have not confirmed this observation. From outpatient-attended" exact="influenza" post="infections or experimental analyzes there are no data suggesting"/>
   <result pre="by IAV. Complications of IBV infection affect the lungs (e.g.," exact="bronchiolitis" post="or pneumonia), but have also been observed in other"/>
   <result pre="(myositis) or cardiologic presentations (myocarditis). Pathogenesis Clinical symptoms of seasonal" exact="influenza" post="are in general similar for IBV and IAV and"/>
   <result pre="the human respiratory tract. One autopsy study of 45 fatal" exact="influenza" post="B cases showed that both lineage viruses caused inflammation"/>
   <result pre="caused inflammation of the trachea and bronchi with necrotic cells," exact="pulmonary edema" post="and hemorrhages as common findings. Viral antigen was mainly"/>
   <result pre="These findings were similar to the ones seen in fatal" exact="influenza" post="A virus infection. Yet, it is unclear how representative"/>
   <result pre="from post mortem tissue are to the pathogenesis in uncomplicated" exact="influenza" post="for which there is only little data available. The"/>
   <result pre="golden hamsters). Diagnosis It is not possible to diagnose an" exact="influenza" post="B virus infection based on clinical presentation alone as"/>
   <result pre="two classes of compounds licensed for the treatment of acute" exact="influenza" post="A and B virus infections, which target either the"/>
   <result pre="oral anti-influenza compound, was licensed for the treatment of seasonal" exact="influenza" post="in Japan and the US in 2018. It targets"/>
   <result pre="Strong conservation of the PA I38 position in current human" exact="influenza" post="B viruses suggests only a low background level of"/>
   <result pre="Vaccination is the most effective measure to protect against seasonal" exact="influenza" post="A and B, for which either inactivated or live-attenuated"/>
   <result pre="NA proteins from one A(H1N1), one A(H3N2) and one (trivalent" exact="influenza" post="vaccine, TIV) or two IBV strains (quadrivalent influenza vaccine,"/>
   <result pre="one (trivalent influenza vaccine, TIV) or two IBV strains (quadrivalent" exact="influenza" post="vaccine, QIV) designed to elicit a protective humoral immune"/>
   <result pre="lineages by quadrivalent formulations can substantially reduce the burden of" exact="influenza" post="B infection if vaccine uptake is sufficiently high. Influenza"/>
   <result pre="sequences, which are more variable in length than those of" exact="influenza" post="A and B viruses. The first twelve nucleotides at"/>
   <result pre="and endonuclease as determined by X-ray crystallography are conserved between" exact="influenza" post="viruses suggesting that the mechanism of transcription and replication"/>
   <result pre="mechanism of transcription and replication is very similar in all" exact="influenza" post="virus types. The fourth segment of ICV encodes the"/>
   <result pre="of IDV. Some coronaviruses, such as the prototype member mouse" exact="hepatitis" post="virus and human and bovine coronaviruses, contain a hemagglutinin"/>
   <result pre="IDV is the most stable of the four types of" exact="influenza" post="viruses, a feature that likely affects the tissue tropism"/>
   <result pre="cells, which requires the removal of all putative receptors. In" exact="influenza" post="A and B the receptor-destroying activity is carried out"/>
   <result pre="gene encoding mainly the receptor-binding and esterase domains. Epidemiology Although" exact="influenza" post="C virus infections occur primarily in a pattern of"/>
   <result pre="and became epidemic strains. The primary host and reservoir of" exact="influenza" post="C virus are humans, but antibodies against influenza C"/>
   <result pre="reservoir of influenza C virus are humans, but antibodies against" exact="influenza" post="C virus are present in dogs and especially in"/>
   <result pre="present in dogs and especially in pigs. A number of" exact="influenza" post="C virus strains were isolated from pigs in China"/>
   <result pre="swabs or lung tissue. Treatment and Prevention Drugs developed against" exact="influenza" post="A virus are not effective against ICV or IDV,"/>
   <result pre="are currently under development. References Further Reading BurnhamA.J.BaranovichT.GovorkovaE.A.Neuraminidase inhibitors for" exact="influenza" post="B virus infection: Efficacy and resistanceAntiviral Research100201352053424013000 CarratF.VerguE.FergusonN.M.Time lines"/>
   <result pre="challenge studiesAmerican Journal of Epidemiology167200877578518230677 HauseB.M.DucatezM.CollinE.A.Isolation of a novel swine" exact="influenza" post="virus from Oklahoma in 2011 which is distantly related"/>
   <result pre="from Oklahoma in 2011 which is distantly related to human" exact="influenza" post="C virusesPLoS Pathogens92013e1003176 HerrlerG.KlenkH.D.Structure and function of the HEF"/>
   <result pre="virusesPLoS Pathogens92013e1003176 HerrlerG.KlenkH.D.Structure and function of the HEF glycoprotein of" exact="influenza" post="C virusAdvances in Virus Research4019912132341957719 HerrlerG.RottR.KlenkH.D.The receptor-destroying enzyme of"/>
   <result pre="influenza C virusAdvances in Virus Research4019912132341957719 HerrlerG.RottR.KlenkH.D.The receptor-destroying enzyme of" exact="influenza" post="C virus is neuraminate-O-acetylesteraseThe EMBO Journal41985150315062411539 LangatP.RaghwaniJ.DudasG.Genome-wide evolutionary dynamics"/>
   <result pre="C virus is neuraminate-O-acetylesteraseThe EMBO Journal41985150315062411539 LangatP.RaghwaniJ.DudasG.Genome-wide evolutionary dynamics of" exact="influenza" post="B viruses on a global scalePLoS Pathogens132017e1006749 MurakiY.HongoS.The molecular"/>
   <result pre="global scalePLoS Pathogens132017e1006749 MurakiY.HongoS.The molecular virology and reverse genetics of" exact="influenza" post="C virusJapanese Journal of Infectious Diseases63201015716520495266 NakatsuS.MurakamiS.ShindoK.Influenza C and"/>
   <result pre="eight organized ribonucleoprotein complexesJournal of Virology201892 Paul GlezenW.SchmierJ.K.KuehnC.M.RyanK.J.OxfordJ.The burden of" exact="influenza" post="B: A structured literature reviewAmerican Journal of Public Health1032013e43e51"/>
   <result pre="of Public Health1032013e43e51 PflugA.LukarskaM.Resa-InfanteP.ReichS.CusackS.Structural insights into RNA synthesis by the" exact="influenza" post="virus transcription-replication machineVirus Research234201710311728115197 ReichS.GuilligayD.PflugA.Structural insight into cap-snatching and"/>
   <result pre="machineVirus Research234201710311728115197 ReichS.GuilligayD.PflugA.Structural insight into cap-snatching and RNA synthesis by" exact="influenza" post="polymeraseNature516201436136625409151 RosenthalP.B.ZhangX.FormanowskiF.Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C"/>
   <result pre="synthesis by influenza polymeraseNature516201436136625409151 RosenthalP.B.ZhangX.FormanowskiF.Structure of the haemagglutinin-esterase-fusion glycoprotein of" exact="influenza" post="C virusNature396199892969817207 SuS.FuX.LiG.KerlinF.VeitM.Novel influenza D virus: Epidemiology, pathology, evolution"/>
   <result pre="RosenthalP.B.ZhangX.FormanowskiF.Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virusNature396199892969817207 SuS.FuX.LiG.KerlinF.VeitM.Novel" exact="influenza" post="D virus: Epidemiology, pathology, evolution and biological characteristicsVirulence820171580159128812422 WangJ.PielakR.M.McclintockM.A.ChouJ.J.Solution"/>
   <result pre="and biological characteristicsVirulence820171580159128812422 WangJ.PielakR.M.McclintockM.A.ChouJ.J.Solution structure and functional analysis of the" exact="influenza" post="B proton channelNature Structural &amp;amp; Molecular Biology16200912671271 WangQ.TianX.ChenX.MaJ.Structural basis"/>
   <result pre="Structural &amp;amp; Molecular Biology16200912671271 WangQ.TianX.ChenX.MaJ.Structural basis for receptor specificity of" exact="influenza" post="B virus hemagglutininProceedings of the National Academy of Sciences"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7268706\results\search\disease\results.xml">
   <result pre="infection. The diagnoses of T. pallidum, human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV) and hepatitis C virus (HCV) infections"/>
   <result pre="pallidum, human immunodeficiency virus (HIV), hepatitis B virus (HBV) and" exact="hepatitis" post="C virus (HCV) infections were determined by commercial test"/>
   <result pre="female group, correlates for T. pallidum infection included spouse having" exact="syphilis" post="(aOR = 126.66, 95% CI 7.58 to 2122.94), ever having blood"/>
   <result pre="Organization (WHO) estimated that 17.7 million individuals aged 15–49 years had" exact="syphilis" post="globally in 2012, with 5.6 million new cases every"/>
   <result pre="low and middle-income countries, the risk for heterosexual spread of" exact="syphilis" post="has declined in the general population but remains a"/>
   <result pre="can cause cutaneous lesions, late complications such as neurologic and" exact="cardiovascular disease" post="[3, 4], and congenital syphilis with other immediate complications,"/>
   <result pre="complications such as neurologic and cardiovascular disease [3, 4], and" exact="congenital syphilis" post="with other immediate complications, such as premature labor and"/>
   <result pre="such as neurologic and cardiovascular disease [3, 4], and congenital" exact="syphilis" post="with other immediate complications, such as premature labor and"/>
   <result pre="[6]. In 1949, the country experienced one of the biggest" exact="syphilis" post="epidemics in human history [6]. The prevalence was 84%"/>
   <result pre="1950s [6]. Chinese government lunched an unprecedented campaign to make" exact="syphilis" post="eradicated in 1960s [7]. However, syphilis has revived in"/>
   <result pre="unprecedented campaign to make syphilis eradicated in 1960s [7]. However," exact="syphilis" post="has revived in China since the reform and opening"/>
   <result pre="studies were carried out in general population. Epidemiological data on" exact="syphilis" post="prevalence is critical for developing public health strategies towards"/>
   <result pre="syphilis prevalence is critical for developing public health strategies towards" exact="syphilis" post="prevention, care and treatment. Our study site is one"/>
   <result pre="real-time PCR assays with a high specificity (98.0%) for secondary" exact="syphilis" post="can detect the pathogen directly, and avoid the modification"/>
   <result pre="[11–13]. Also, there was no further need to consider the" exact="syphilis" post="serological window period [13]. We applied the diagnostic kit"/>
   <result pre="infection in males and females combined. They were spouse having" exact="syphilis" post="(aOR = 38.51, 95% CI 7.12 to 208.16), injection drug use"/>
   <result pre="Table 3 Univariate and multivariate analyses of factors associated with" exact="syphilis" post="infection Variables No. Cases (%) cOR (95% CI) aOR"/>
   <result pre="31 (1.4) Ref.  Never married 427 1 (0.2) 6.14(0.84–45.12) Spouse" exact="syphilis" post=" No or unknown 2601 30 (1.2) Ref. Ref.  Yes"/>
   <result pre="were related to T. pallidum infection in males. Spouse having" exact="syphilis" post="(aOR = 126.66, 95%CI 7.58 to 2122.94), blood transfution (aOR = 10.51, 95%"/>
   <result pre="(aOR = 4.19, 95% CI 1.35 to 10.93) were significantly associated with" exact="syphilis" post="in females. Table 4 Sex-specific univariate and multivariate analyses"/>
   <result pre="4 Sex-specific univariate and multivariate analyses of factors associated with" exact="syphilis" post="infection Variables Male (N = 608) Female (N = 1700) Prevalence"/>
   <result pre="1.4 1.4 Ref.  Never married 0 0.4 0.32 (0.01–1.52) Spouse" exact="syphilis" post=" No or unknown 1.0 Ref. 1.2 Ref. Ref.  Yes"/>
   <result pre="likelihood of HIV virus shedding [21, 22]. The course of" exact="syphilis" post="is accelerated in patients infected with HIV, and these"/>
   <result pre="T. pallidum infected individuals [29], and also suggested that preventing" exact="syphilis" post="should be included as a part of HBV control"/>
   <result pre="of HBV control strategies. Targeted trainings for physicians and expanded" exact="syphilis" post="screening services for HBV positive individuals are urgently needed"/>
   <result pre="urgently needed [30, 31]. Consistent with previous studies, spouse having" exact="syphilis" post="was a risk factor for T. pallidum infection in"/>
   <result pre="risk factor for T. pallidum infection in females [32] while" exact="syphilis" post="was associated with drug abuse in males. Sharing syringes"/>
   <result pre="in utero [43]. More than half of pregnant women with" exact="syphilis" post="have a spontaneous abortion or stillbirth [44]. Inadequately treated"/>
   <result pre="to quality antenatal care, including rapid T. pallidum testing and" exact="latent syphilis" post="treatment, is important for achieving the elimination of congenital"/>
   <result pre="quality antenatal care, including rapid T. pallidum testing and latent" exact="syphilis" post="treatment, is important for achieving the elimination of congenital"/>
   <result pre="latent syphilis treatment, is important for achieving the elimination of" exact="congenital syphilis" post="[43, 46]. Policy-makers may expand and fund programs more"/>
   <result pre="syphilis treatment, is important for achieving the elimination of congenital" exact="syphilis" post="[43, 46]. Policy-makers may expand and fund programs more"/>
   <result pre="has also committed to eliminate the mother-to-child transmissions of HIV," exact="syphilis" post="and HBV with an ambitious plan for prenatal screening"/>
   <result pre="of T. pallidum transmission and to achieve adequate access to" exact="syphilis" post="treatment, especially for people who are IDUs and their"/>
   <result pre="issuance of the plan for the prevention and control of" exact="syphilis" post="in China (2010-2020): The national health commission of the"/>
   <result pre="Psiquiatr201746 Suppl 1697610.1016/j.rcp.2017.05.00229037341 4.HutchinsonCMHookERSyphilis in adultsMed Clin North Am19907461389141610.1016/S0025-7125(16)30487-42246946 5.TheLCongenital" exact="syphilis" post="in the USALancet201839210154116810.1016/S0140-6736(18)32360-2 6.ChenZQZhangGCGongXDet al.Syphilis in China: results of"/>
   <result pre="[J]N Engl J Med2010362181658166110.1056/NEJMp091114920445179 8.DaiSShenZZhaZet al.Seroprevalence of HIV, syphilis, and" exact="hepatitis" post="C virus in the general population of the Liangshan"/>
   <result pre="Yi minority in southwestern ChinaBiomed Environ Sci2014271082483110.3967/bes2014.12025341820 10.TuckerJDBuJBrownLBet al.Accelerating worldwide" exact="syphilis" post="screening through rapid testing: a systematic reviewLancet Infect Dis201010638138610.1016/S1473-3099(10)70092-X20510278"/>
   <result pre="systematic reviewLancet Infect Dis201010638138610.1016/S1473-3099(10)70092-X20510278 11.KoekAGBruistenSMDierdorpMet al.Specific and sensitive diagnosis of" exact="syphilis" post="using a real-time PCR for Treponema pallidumClin Microbiol Infect200612121233123610.1111/j.1469-0691.2006.01566.x17121633"/>
   <result pre="Infect200612121233123610.1111/j.1469-0691.2006.01566.x17121633 12.Gayet-AgeronANinetBToutous-TrelluLet al.Assessment of a real-time PCR test to diagnose" exact="syphilis" post="from diverse biological samplesSex Transm Infect200985426410.1136/sti.2008.03431419155240 13.HeymansRvan der HelmJJde"/>
   <result pre="PCR for Diagnosis of SyphilisJ Clin Microbiol201048249710.1128/JCM.00720-0920007388 14.YunZLindhGWeilandOet al.Detection of" exact="hepatitis" post="C virus (HCV) RNA by PCR related to HCV"/>
   <result pre="Sichuan Province, ChinaAIDS Care20071911810.1080/0954012060090049617129851 17.ZhouCRouKDongWMet al.High prevalence of HIV and" exact="syphilis" post="and associated factors among low-fee female sex workers in"/>
   <result pre="studyBMC Infect Dis20141422510.1186/1471-2334-14-22524767104 18.PanXJiangJHeHet al.Survey of prevalence of HIV infection," exact="syphilis" post="and HCV infection and related risk behaviors among club"/>
   <result pre="2011Zhonghua Liu Xing Bing Xue Za Zhi201536993494026814857 19.WangBXZhangLWangYJet al.Epidemiology of" exact="syphilis" post="infection among drug users at methadone maintenance treatment clinics"/>
   <result pre="al.Syphilis and HIV prevalence and associated factors to their co-infection," exact="hepatitis" post="B and hepatitis C viruses prevalence among female sex"/>
   <result pre="prevalence and associated factors to their co-infection, hepatitis B and" exact="hepatitis" post="C viruses prevalence among female sex workers in RwandaBMC"/>
   <result pre="Infect Dis201717152510.1186/s12879-017-2625-028754104 22.HuQHXuJJZouHCet al.Risk factors associated with prevalent and incident" exact="syphilis" post="among an HIV-infected cohort in Northeast ChinaBMC Infect Dis20141465810.1186/s12879-014-0658-125471736"/>
   <result pre="Northeast ChinaBMC Infect Dis20141465810.1186/s12879-014-0658-125471736 23.LiDYangXZhangZet al.Incidence of co-infections of HIV," exact="herpes simplex" post="virus type 2 and syphilis in a large cohort"/>
   <result pre="of co-infections of HIV, herpes simplex virus type 2 and" exact="syphilis" post="in a large cohort of men who have sex"/>
   <result pre="in Beijing, ChinaPLoS One2016111e14742210.1371/journal.pone.0147422 24.GoensJLJannigerCKDe WolfKDermatologic and systemic manifestations of" exact="syphilis" post="[J]Am Fam Physician1994505101310207942400 25.Shrestha ACGPTB. Co-infection rate of HIV,"/>
   <result pre="epidemic: a comprehensive analysis of prevalence and correlates of HIV," exact="hepatitis" post="C, and syphilis, and infection among female sex workers"/>
   <result pre="ChinaInt J STD AIDS201728111115112310.1177/095646241668881828120646 29.ScherbaumNBauneBTMikolajczykRet al.Prevalence and risk factors of" exact="syphilis" post="infection among drug addictsBMC Infect Dis200553310.1186/1471-2334-5-3315904501 30.TangWHuangSChenLet al.Late Neurosyphilis"/>
   <result pre="infection among drug addictsBMC Infect Dis200553310.1186/1471-2334-5-3315904501 30.TangWHuangSChenLet al.Late Neurosyphilis and" exact="tertiary syphilis" post="in Guangdong Province, China: results from a cross-sectional studySci"/>
   <result pre="among drug addictsBMC Infect Dis200553310.1186/1471-2334-5-3315904501 30.TangWHuangSChenLet al.Late Neurosyphilis and tertiary" exact="syphilis" post="in Guangdong Province, China: results from a cross-sectional studySci"/>
   <result pre="a case reportSex Transm Dis200229211912010.1097/00007435-200202000-0001011818899 33.ChenYTangZTangSet al.Decreasing HIV, syphilis, and" exact="hepatitis" post="C infection after a decade of harm reduction implementation"/>
   <result pre="34.SunYGuoWLiGet al.Increased synthetic drug abuse and trends in HIV and" exact="syphilis" post="prevalence among female drug users from 2010-2014 from Beijing,"/>
   <result pre="a quest for the transfusion triggerTransfusion198020217918810.1046/j.1537-2995.1980.20280169958.x7368266 40.XiaoYLiSLLinHLet al.Factors associated with" exact="syphilis" post="infection: a comprehensive analysis based on a case-control studyEpidemiol"/>
   <result pre="case-control studyEpidemiol Infect201614461165117410.1017/S095026881500234426467944 41.AdjeiAAArmahHBGbagboFet al.Correlates of HIV, HBV, HCV and" exact="syphilis" post="infections among prison inmates and officers in Ghana: a"/>
   <result pre="Bing Xue Za Zhi20173891165116810.3760/cma.j.issn.0254-6450.2017.09.00428910924 43.WijesooriyaNSRochatRWKambMLet al.Global burden of maternal and" exact="congenital syphilis" post="in 2008 and 2012: a health systems modelling studyLancet"/>
   <result pre="Xue Za Zhi20173891165116810.3760/cma.j.issn.0254-6450.2017.09.00428910924 43.WijesooriyaNSRochatRWKambMLet al.Global burden of maternal and congenital" exact="syphilis" post="in 2008 and 2012: a health systems modelling studyLancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7269036\results\search\disease\results.xml">
   <result pre=": Article IFITM3 affects the level of antibody response after" exact="influenza" post="vaccination Emerging Microbes &amp;amp; Infections N. Lei et al."/>
   <result pre="an antiviral factor can inhibit replication of several viruses including" exact="influenza" post="virus. A single-nucleotide polymorphism rs12252-C of IFITM3 results in"/>
   <result pre="and associated with severe illness in adults infected with pandemic" exact="influenza" post="H1N1/09 virus. To investigate if IFITM3 or IFITM3 rs12252-C"/>
   <result pre="IFITM3 or IFITM3 rs12252-C could affect the antibody response after" exact="influenza" post="vaccination, we detected the haemagglutination inhibition (HI) of 171"/>
   <result pre="further investigation. KEYWORDS Interferon-induced transmembrane protein 3 IFITM3 SNP rs12252" exact="influenza" post="virus trivalent inactivated vaccine immune response Funding National Outstanding"/>
   <result pre="following RNA interference genomic screening for host factors involved in" exact="influenza" post="virus infection during the pandemic influenza H1N1/09 virus outbreak"/>
   <result pre="host factors involved in influenza virus infection during the pandemic" exact="influenza" post="H1N1/09 virus outbreak [6]. IFITM3 was found to be"/>
   <result pre="be one of the most potent antiviral factors in restricting" exact="influenza" post="virus infection, as IFITM3 knockout mice displayed enhanced morbidity"/>
   <result pre="knockout mice displayed enhanced morbidity and mortality associated with pandemic" exact="influenza" post="H1N1/09 virus infection [7]. Several distinct studies have revealed"/>
   <result pre="in mouse lung-resident memory CD8+ T cells after challenge with" exact="influenza" post="virus, enabling the mice to withstand viral infection during"/>
   <result pre="dendritic cells up-regulate the expression of IFITM3 in response to" exact="influenza" post="virus infection [10]. An important single nucleotide polymorphism (SNP)"/>
   <result pre="TIV [15]. Vaccination is the most effective method to prevent" exact="influenza" post="virus infection. Growing evidence suggests that host factors including"/>
   <result pre="milieu, and gut microbiota play important roles as modifiers of" exact="influenza" post="virus vaccine efficacy [16]. We are curious to know"/>
   <result pre="These findings suggest IFITM may affect the antibody response after" exact="influenza" post="vaccination. Materials and methods Study cohort and ethics A"/>
   <result pre="the study from 2009 to 2015. People who infected with" exact="influenza" post="virus within 3 months and self-reported influenza vaccination previously"/>
   <result pre="who infected with influenza virus within 3 months and self-reported" exact="influenza" post="vaccination previously were excluded. All volunteers were injected once"/>
   <result pre="A/Michigan/45/2015, A/Hong Kong/4801/2014 and B/Victoria/60/2008 viruses) for northern hemisphere 2017–2018" exact="influenza" post="season (lot#201706009) (1.5 μg of each haemagglutinin [HA]) from SINOVAC"/>
   <result pre="Haemagglutination inhibition (HI) test HI assays were performed against the" exact="influenza" post="vaccine strains according to the standardized protocol by the"/>
   <result pre="anti-H1N1, H3N2 and B virus were detected at baseline before" exact="influenza" post="vaccination (c) and at day 28 after influenza immunization"/>
   <result pre="baseline before influenza vaccination (c) and at day 28 after" exact="influenza" post="immunization (d). HI antibody was measured for each of"/>
   <result pre="(d). HI antibody was measured for each of the three" exact="influenza" post="strains. Seroconversion (SC) was defined as the percentage of"/>
   <result pre="are committed to become TFH cells, which upregulate B cell" exact="lymphoma" post="6 (BCL6). BCL6 is a master regulator which progresses"/>
   <result pre="time. Discussion IFITM3 is an important antiviral factor in restricting" exact="influenza" post="virus infection. The SNP rs12252-C allele of IFITM3 had"/>
   <result pre="had been linked with severe illness in adults during pandemic" exact="influenza" post="H1N1/09 virus infections, but the mechanisms remain incompletely understood."/>
   <result pre="The research from Ling Qin et al who investigated the" exact="influenza" post="vaccination response is associated with IFITM3 gene in human"/>
   <result pre="Acknowledgments We thank Sinovac Biotech Co., Ltd. for providing the" exact="influenza" post="vaccine. This work was supported by the National Outstanding"/>
   <result pre="Centers for Disease C, PreventionEstimates of deaths associated with seasonal" exact="influenza" post="— United States, 1976-2007. MMWR Morb Mortal Wkly Rep."/>
   <result pre="2010;59(33):1057–1062.20798667 2BedfordT, RileyS, BarrIG, et al.Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature. 2015;523(7559):217–220.26053121 3FriedmanRL, ManlySP,"/>
   <result pre="ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to" exact="influenza" post="virus. J Biol Chem. 2012;287(23):19631–19641.22511783 5LiK, MarkosyanRM, ZhengYM, et"/>
   <result pre="HuangIC, BenitaY, et al.The IFITM proteins mediate cellular resistance to" exact="influenza" post="A H1N1 virus, West Nile virus, and dengue virus."/>
   <result pre="expression of IFITM3 following T cell activation protects cells from" exact="influenza" post="virus infection. PLoS One. 2019;14(1):e0210132.30650117 9WakimLM, GuptaN, MinternJD, et"/>
   <result pre="of lung tissue-resident memory CD8(+) T cells during infection with" exact="influenza" post="virus due to selective expression of IFITM3. Nat Immunol."/>
   <result pre="15QinL, WangD, LiD, et al.High level antibody response to pandemic" exact="influenza" post="H1N1/09 virus is associated with interferon-induced transmembrane protein-3 rs12252-CC"/>
   <result pre="KleinSL.Host factors impact vaccine efficacy: implications for seasonal and universal" exact="influenza" post="vaccine programs. J Virol. 2019;93(21):1–15. 17SakumaT, YamamotoT.Current overview of"/>
   <result pre="al.Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe" exact="influenza" post="in Chinese individuals. Nat Commun. 2013;4:1418.23361009 19AbolhassaniH, ParvanehN, RezaeiN,"/>
   <result pre="responses in mice after immunization with a trivalent inactivated split-virion" exact="influenza" post="vaccine. Vaccine. 2018;36(23):3340–3344.29706292 21CrispeIN.Isolation of mouse intrahepatic lymphocytes. Curr"/>
   <result pre="al.Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated" exact="influenza" post="vaccines among vaccine-naive children in a randomized clinical trial"/>
   <result pre="23MoaAM, ChughtaiAA, MuscatelloDJ, et al.Immunogenicity and safety of inactivated quadrivalent" exact="influenza" post="vaccine in adults: A systematic review and meta-analysis of"/>
   <result pre="MillerJ, et al.Rapid cloning of high-affinity human monoclonal antibodies against" exact="influenza" post="virus. Nature. 2008;453(7195):667–671.18449194 27CrottyS.T follicular helper cell differentiation, function,"/>
   <result pre="differentiation. Sci Signal. 2011;4(169):ra25.21505187 35BaranovichT, VongphrachanhP, KetmayoonP, et al.Antiviral drug-resistant" exact="influenza" post="B viruses carrying H134N substitution in neuraminidase, Laos, February"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7270858\results\search\disease\results.xml">
   <result pre="and resource mobilization for multidisciplinary and intersectorial advocacy on emerging" exact="viral disease" post="outbreaks, accompanied with R&amp;amp;D roadmap and taskforce is crucial."/>
   <result pre="India alone, whereas Bangladesh has borne the brunt of Nipah" exact="viral disease" post="in recent years, with more than 100 deaths out"/>
   <result pre="Flaviviridae family and is related to dengue, Chikungunya, West Nile," exact="yellow fever," post="and Japanese encephalitis viruses. Hajj is among the global"/>
   <result pre="related to dengue, Chikungunya, West Nile, yellow fever, and Japanese" exact="encephalitis" post="viruses. Hajj is among the global travel gatherings, drawing"/>
   <result pre="with a high frequency of neurologic complications such as congenital" exact="microcephaly" post="and Guillain–Barre syndrome. It has not yet been documented"/>
   <result pre="known as the congenital Zika virus syndrome or complications particularly" exact="microcephaly" post="in newborn babies with ZIKV infected pregnant mothers [18],"/>
   <result pre="pregnancy losses and congenital malformations such as cardiac defects and" exact="craniosynostosis" post="[16], [18], [26]. This may cause bias when estimating"/>
   <result pre="host community preventative and precautionary measures. Increasing advocacy on emerging" exact="viral disease" post="R&amp;amp;D roadmap taskforce development and implementation of outbreaks countermeasures"/>
   <result pre="highly lethal infection in humansInt Rev Immunol362201710812128060559 12PrescottJ.DeBuysscherB.L.FeldmannF.GardnerD.J.HaddockE.MartellaroC.ScottD.FeldmannH.Single-dose live-attenuated vesicular" exact="stomatitis" post="virus-based vaccine protects African green monkeys from Nipah virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7270913\results\search\disease\results.xml">
   <result pre="Press pmcid: 7270913 doi: 10.1093/eurheartj/suaa064suaa064 : Articles Causal relationship between" exact="influenza" post="infection and risk of acute myocardial infarction: pathophysiological hypothesis"/>
   <result pre="journals.permissions@oup.comsuaa064.pdf Abstract Abstract Presently several evidences support an association between" exact="acute myocardial infarction" post="and influenza infection. The pathophysiology rationale rests on the"/>
   <result pre="several evidences support an association between acute myocardial infarction and" exact="influenza" post="infection. The pathophysiology rationale rests on the release of"/>
   <result pre="artery occlusion. Several observational evidences support a potential role of" exact="influenza" post="vaccine in cardiovascular prevention. It is estimated that the"/>
   <result pre="in cardiovascular prevention. It is estimated that the efficacy of" exact="influenza" post="vaccine in preventing myocardial infarction could range between 15%"/>
   <result pre="in the high-risk groups. Influenza vaccine as preventive measure of" exact="cardiovascular disease" post="still awaits support from randomized clinical trials. Nonetheless, considering"/>
   <result pre="trials. Nonetheless, considering the favourable cost-efficacy and safety profile of" exact="influenza" post="vaccination, its use should be encouraged in everyday clinical"/>
   <result pre="has emerged for the flu syndrome. The epidemiological relationship between" exact="acute myocardial infarction" post="(AMI) and flu syndrome was first observed in 1930"/>
   <result pre="mortality due to cardiovascular causes in conjunction with the epidemic" exact="influenza" post="peak.1 To date, during influenza epidemics, there is an"/>
   <result pre="in conjunction with the epidemic influenza peak.1 To date, during" exact="influenza" post="epidemics, there is an increased rate of hospitalization and"/>
   <result pre="review, we will, therefore, examine the possible causal link between" exact="influenza" post="infection and AMI. In general, the search for a"/>
   <result pre="AMI. However, in many of them, the clinical diagnosis of" exact="infectious disease" post="was neither sensitive nor specific for the confirmation of"/>
   <result pre="disease was neither sensitive nor specific for the confirmation of" exact="influenza" post="virus infection. In this regard, Smeeth et al.,3 Who"/>
   <result pre="infarction was 4.95 [95% confidence interval (CI): 4.43–5.53] and the" exact="stroke" post="rate of 3.19 (95% CI: 2.81–3.62). More recently, Warren-Gash"/>
   <result pre="Among other things, it emerged that infections occurring during the" exact="influenza" post="epidemic and those coded as ‘likely to be influenza’"/>
   <result pre="Several studies have, therefore, tried to demonstrate the association between" exact="influenza" post="and SCA through laboratory confirmation of influenza infection; the"/>
   <result pre="the association between influenza and SCA through laboratory confirmation of" exact="influenza" post="infection; the results, however, did not always seem convincing."/>
   <result pre="without AMI. The primary outcome measure was laboratory evidence of" exact="influenza" post="infection. Of 559 participants, 34/275 cases and 19/284 controls"/>
   <result pre="and 19/284 controls were positive for laboratory virus determination for" exact="influenza" post="virus [odds ratio (OR) 1.97; 95% CI: 1.09–3.54]; for"/>
   <result pre="this study demonstrates the existence of a strong association between" exact="influenza" post="infection and AMI, it is limited by the fact"/>
   <result pre="serological tests are less robust than those derived from the" exact="influenza" post="virus laboratory research.7 In this regard, a very recent"/>
   <result pre="of Medicine in January 2018, evaluated the association between laboratory-confirmed" exact="influenza" post="infection with highly specific methods and hospitalization for IMA."/>
   <result pre="higher in the first 7 days after laboratory confirmation of the" exact="influenza" post="infection compared to the control interval, and no increase"/>
   <result pre="ratio was higher for more adult subjects, for Type B" exact="influenza" post="and for patients affected by a first myocardial infarction;"/>
   <result pre="respiratory virus, although minor compared to the secondary forms of" exact="influenza" post="infection. Specifically, an incidence ratio for AMI emerged for"/>
   <result pre="Specifically, an incidence ratio for AMI emerged for Type B" exact="influenza" post="(95% CI: 4.37–23.38), 5.17 for Type A influenza (95%"/>
   <result pre="Type B influenza (95% CI: 4.37–23.38), 5.17 for Type A" exact="influenza" post="(95% CI: 3.02–8.84), 3.51 for respiratory syncytial virus (95%"/>
   <result pre="in this case, it is the septic state, rather than" exact="coronary thrombosis," post="the underlying cause of the flu-related myocardial necrosis. However,"/>
   <result pre="flu-related myocardial necrosis. However, it has been hypothesized that the" exact="influenza" post="through multiple mechanisms can induce or facilitate occlusive phenomena"/>
   <result pre="animal model used for the study of atherosclerosis, infection with" exact="influenza" post="virus induces acute inflammation, proliferation of smooth muscle cells,"/>
   <result pre="It has been hypothesized that the flu infection leads to" exact="acute myocardial infarction" post="through the development of thrombosis on pre-existing atherosclerotic plaques."/>
   <result pre="acute coronary syndrome. Influenza vaccination for secondary prevention of coronary" exact="heart disease" post="‘Indirect’ evidence of a possible association between influenza and"/>
   <result pre="coronary heart disease ‘Indirect’ evidence of a possible association between" exact="influenza" post="and AMI derives from studies showing that influenza vaccination"/>
   <result pre="association between influenza and AMI derives from studies showing that" exact="influenza" post="vaccination is effective in the prevention of ischaemic heart"/>
   <result pre="that influenza vaccination is effective in the prevention of ischaemic" exact="heart disease." post="This, in addition to strengthening the causality between the"/>
   <result pre="of some observational studies show that the protective efficacy of" exact="influenza" post="vaccination from new coronary events in secondary prevention is"/>
   <result pre="published in 2015, Barnes et al.17 estimated the association between" exact="influenza" post="vaccination and occurrence of AMI. A total of eight"/>
   <result pre="or recurrent MI. The results showed a protective efficacy of" exact="influenza" post="vaccination against AMI equal to 29% (95% CI: 9–44%)."/>
   <result pre="randomized clinical trials have evaluated the protection provided by the" exact="influenza" post="vaccine against cardiac events in subjects with pre-existing cardiovascular"/>
   <result pre="the influenza vaccine against cardiac events in subjects with pre-existing" exact="cardiovascular disease," post="the FLU vaccination in ACSs and planned percutaneous coronary"/>
   <result pre="whose goal was to test the potential beneficial effect of" exact="influenza" post="vaccination in secondary prevention. Two hundred patients hospitalized for"/>
   <result pre="subjected to elective coronary angioplasty. Subjects were randomized to receive" exact="influenza" post="or placebo vaccination. In the intention to treat analysis,"/>
   <result pre="which 658 patients were already in optimal medical therapy for" exact="cardiovascular disease" post="were contrasting. In it, 325 subjects received influenza vaccine"/>
   <result pre="for cardiovascular disease were contrasting. In it, 325 subjects received" exact="influenza" post="vaccine and 333 received placebo. The average follow-up was"/>
   <result pre="(major adverse cardiac event, MACE) although not statistically significant. However," exact="influenza" post="vaccination statistically significantly reduced the composite outcome measure of"/>
   <result pre="meta-analysis of these randomized trials, Warren-Gash et al.4,17 showed that" exact="influenza" post="vaccination was protective against IMA, although a statistical analysis"/>
   <result pre="CI: 0.44–1.64). Despite the plausibility of a beneficial effect of" exact="influenza" post="vaccination in the prevention of cardiovascular disease, few studies"/>
   <result pre="a beneficial effect of influenza vaccination in the prevention of" exact="cardiovascular disease," post="few studies have been conducted to explain the possible"/>
   <result pre="interactions, showed a cross-reactivity between the antibody induced by the" exact="influenza" post="vaccination and the human bradykinin receptor (bradykinin B2 receptor,"/>
   <result pre="A principle of coherence is respected: the possibility that the" exact="influenza" post="triggers an ACS agrees with the current scientific data"/>
   <result pre="which acute infections can trigger other vascular events, such as" exact="stroke" post="similar to ACS and, analogously, ACS can be triggered"/>
   <result pre="be greater after lower respiratory tract infections rather than after" exact="urinary tract infection." post="Furthermore, in pneumococcal infections, the more severe the infection"/>
   <result pre="associated with an increased risk of AMI. Why does the" exact="influenza" post="remain a potential focus of particular importance? On the"/>
   <result pre="a potential focus of particular importance? On the one hand," exact="influenza" post="is one of the most frequent respiratory infections, on"/>
   <result pre="we can, therefore, deduce that it is highly probable that" exact="influenza" post="has a causal role in triggering ACS. However, in"/>
   <result pre="event. Although there is evidence to support the role of" exact="influenza" post="vaccination for the prevention of ischaemic heart disease, vaccination"/>
   <result pre="the role of influenza vaccination for the prevention of ischaemic" exact="heart disease," post="vaccination is not considered a priority preventive measure in"/>
   <result pre="encouraged to use vaccination as a preventive measure against ischaemic" exact="heart disease," post="considering its favourable cost-effectiveness and safety profile. In the"/>
   <result pre="there is a change in the paradigm that often sees" exact="influenza" post="vaccination as a simple preventive measure against the infectious"/>
   <result pre="References References 1WuP, GoldsteinE, HoLM, et al.Excess mortality associated with" exact="influenza" post="A and B virus in Hong Kong, 1998-2009. J"/>
   <result pre="Med1965;58:295–300.14283879 3SmeethL, ThomasSL, HallAJ, et al.Risk of myocardial infarction and" exact="stroke" post="after acute infection or vaccination. N Engl J Med2004;351:2611–2618.15602021"/>
   <result pre="Engl J Med2004;351:2611–2618.15602021 4Warren-GashC, SmeethL, HaywardAC.Influenza as a trigger for" exact="acute myocardial infarction" post="or death from cardiovascular disease: a systematic review. Lancet"/>
   <result pre="myocardial infarction. Ann Clin Res1981;13:429–432.6814338 6MacintyreCR, HeywoodAE, KovoorP, et al.Ischaemic" exact="heart disease," post="influenza and influenza vaccination: a prospective case control study."/>
   <result pre="Ann Clin Res1981;13:429–432.6814338 6MacintyreCR, HeywoodAE, KovoorP, et al.Ischaemic heart disease," exact="influenza" post="and influenza vaccination: a prospective case control study. Heart2013;99:1843–1848.23966030"/>
   <result pre="Res1981;13:429–432.6814338 6MacintyreCR, HeywoodAE, KovoorP, et al.Ischaemic heart disease, influenza and" exact="influenza" post="vaccination: a prospective case control study. Heart2013;99:1843–1848.23966030 7GuanX, YangW,"/>
   <result pre="case control study. Heart2013;99:1843–1848.23966030 7GuanX, YangW, SunX, et al.Association of" exact="influenza" post="virus infection and inflammatory cytokines with acute myocardial infarction."/>
   <result pre="et al.Association of influenza virus infection and inflammatory cytokines with" exact="acute myocardial infarction." post="Inflamm Res2012;61:591–598.22373653 8KwongJC, SchwartzKL, CampitelliMA, et al.Acute myocardial infarction"/>
   <result pre="Res2012;61:591–598.22373653 8KwongJC, SchwartzKL, CampitelliMA, et al.Acute myocardial infarction after laboratory-confirmed" exact="influenza" post="infection. N Engl J Med2018;378:345–353.29365305 9Corrales-MedinaVF, MadjidM, MusherDM.Role of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7271460\results\search\disease\results.xml">
   <result pre="Abstract Background There is scare information about HIV co-infections with" exact="hepatitis" post="B virus (HBV) and/or hepatitis C virus (HCV) among"/>
   <result pre="information about HIV co-infections with hepatitis B virus (HBV) and/or" exact="hepatitis" post="C virus (HCV) among People Who Inject Drugs (PWID)"/>
   <result pre="to ensure the treatment necessary to decrease the progression of" exact="liver disease" post="and the transmission of both HIV and hepatitis. We"/>
   <result pre="epidemic in the country [6, 7],. In addition to HIV," exact="viral hepatitis" post="remains an important global health issue, characterized by high"/>
   <result pre="in the country [6, 7],. In addition to HIV, viral" exact="hepatitis" post="remains an important global health issue, characterized by high"/>
   <result pre="and mortality, and suboptimal diagnosis and management approaches [8–10]. Viral" exact="hepatitis" post="are the most common viral infections affecting PWIDs [10,"/>
   <result pre="most common viral infections affecting PWIDs [10, 11]. HIV and" exact="viral hepatitis" post="infections share common transmission routes, risk behaviors and their"/>
   <result pre="common viral infections affecting PWIDs [10, 11]. HIV and viral" exact="hepatitis" post="infections share common transmission routes, risk behaviors and their"/>
   <result pre="rates [11, 12]. HIV infection affects the natural course of" exact="hepatitis" post="B virus (HBV) and hepatitis C virus (HCV), promoting"/>
   <result pre="affects the natural course of hepatitis B virus (HBV) and" exact="hepatitis" post="C virus (HCV), promoting faster progression to chronicity, liver"/>
   <result pre="country [13, 14]. Global health targets to reduce HIV and" exact="viral hepatitis" post="infections have been established [15, 16]. Strengthening the prevention"/>
   <result pre="[13, 14]. Global health targets to reduce HIV and viral" exact="hepatitis" post="infections have been established [15, 16]. Strengthening the prevention"/>
   <result pre="been established [15, 16]. Strengthening the prevention and treatment of" exact="substance abuse," post="including narcotic drug abuse, is listed as one of"/>
   <result pre="that the prevention of HIV in PWID will also prevent" exact="hepatitis" post="given their similar modes of transmission and high-risk populations."/>
   <result pre="continues to be lack of integrated services for HIV and" exact="viral hepatitis." post="Since Mozambique has one of the highest HIV prevalence"/>
   <result pre="HBsAg among PWID was 32.8% (95%CI: 26.3–39.5) and 38.3% for" exact="hepatitis" post="C virus antibody (95%CI: 30.6–45.9). Co-infection of HIV/HBV was"/>
   <result pre="9.2% (95%CI: 3.7–14.7) of PWID. Table 2 Prevalence of HIV," exact="hepatitis" post="and co-infections in PWID in two urban settings in"/>
   <result pre="Maputo [13] and 9.1% of untreated HIV-infected adults [14]. The" exact="hepatitis" post="B vaccine was only introduced into the Mozambican national"/>
   <result pre="with age among HIV-infected individuals [31, 32]. Because HIV and" exact="viral hepatitis" post="are chronic and sometimes asymptomatic infections, it is likely"/>
   <result pre="age among HIV-infected individuals [31, 32]. Because HIV and viral" exact="hepatitis" post="are chronic and sometimes asymptomatic infections, it is likely"/>
   <result pre="and HIV/HCV, respectively. Other studies have found that HIV and" exact="hepatitis" post="transmission are associated with high-risk injection practices such as"/>
   <result pre="healthcare services. Clients receive point-of-care screening for HIV, hepatitis, syphilis," exact="tuberculosis" post="and referrals for clinical care as needed [37]. However,"/>
   <result pre="treatment of STIs; prevention, diagnosis and treatment of TB and" exact="viral hepatitis" post="(B and C), risk reduction information and education for"/>
   <result pre="of STIs; prevention, diagnosis and treatment of TB and viral" exact="hepatitis" post="(B and C), risk reduction information and education for"/>
   <result pre="an integrated harm reduction package to prevent both HIV and" exact="hepatitis" post="infection among PWID, given their similar mode of transmission"/>
   <result pre="[42]. Although this represents the first analysis of HIV a" exact="viral hepatitis" post="among PWID in Mozambique, some limitations should be considered."/>
   <result pre="Although this represents the first analysis of HIV a viral" exact="hepatitis" post="among PWID in Mozambique, some limitations should be considered."/>
   <result pre="in including participants with lower recent risk of HIV and" exact="hepatitis" post="infection. However, since most participants reported having injected during"/>
   <result pre="population requires a enhance public health interventions since HIV and" exact="viral hepatitis" post="co-infection increases morbidity and mortality, as well changes the"/>
   <result pre="requires a enhance public health interventions since HIV and viral" exact="hepatitis" post="co-infection increases morbidity and mortality, as well changes the"/>
   <result pre="two urban areas in MozambiqueBMC Infect Dis2019191102231791273 8.UmutesiJSimmonsBMakuzaJDDushimiyimanaDMbituyumuremyiAUwimanaJMet al.Prevalence of" exact="hepatitis" post="B and C infection in persons living with HIV"/>
   <result pre="- a systematic review and meta-analysisPLoS One20163111(3) 10.Ray SaraswatiLSarnaASebastianMPSharmaVMadanIThiorIet al.HIV," exact="hepatitis" post="B and C among people who inject drugs: high"/>
   <result pre="among people who inject drugs: high prevalence of HIV and" exact="hepatitis" post="C RNA positive infections observed in Delhi, IndiaBMC Public"/>
   <result pre="who inject Drugs in Lahore, PakistanViral Immunol201730536637028346804 12.ThorntonACJoseSBhaganiSChadwickDDunnDGilsonRet al.Hepatitis B," exact="hepatitis" post="C, and mortality among HIV-positive individualsAIDS.201731182525253228926400 13.ViegasEOTembeNMacovelaEGonçalvesEAugustoOIsmaelNet al.Incidence of"/>
   <result pre="individualsAIDS.201731182525253228926400 13.ViegasEOTembeNMacovelaEGonçalvesEAugustoOIsmaelNet al.Incidence of HIV and the prevalence of HIV," exact="hepatitis" post="B and syphilis among youths in Maputo, Mozambique: a"/>
   <result pre="of HIV and the prevalence of HIV, hepatitis B and" exact="syphilis" post="among youths in Maputo, Mozambique: a cohort studyPLoS One2015103e012145225798607"/>
   <result pre="Defic Syndr201568S274S28525768867 28.KlinglerCThoumiAIMrithinjayamVSCost-effectiveness analysis of an additional birth dose of" exact="hepatitis" post="B vaccine to prevent perinatal transmission in a medical"/>
   <result pre="J Trop Med. 2018. 10.1155/2018/4239646. 35.ShapatavaENelsonKETsertsvadzeTdel RioCRisk behaviors and HIV," exact="hepatitis" post="B, and hepatitis C seroprevalence among injection drug users"/>
   <result pre="2018. 10.1155/2018/4239646. 35.ShapatavaENelsonKETsertsvadzeTdel RioCRisk behaviors and HIV, hepatitis B, and" exact="hepatitis" post="C seroprevalence among injection drug users in GeorgiaDrug Alcohol"/>
   <result pre="2011 bio-behavioral study using respondent-driven samplingAIDS Behav201519Suppl 12435 39.ScheibeAYoungKMosesLBassonRLVersfeldASpearmanCWet al.Understanding" exact="hepatitis" post="B, hepatitis C and HIV among people who inject"/>
   <result pre="study using respondent-driven samplingAIDS Behav201519Suppl 12435 39.ScheibeAYoungKMosesLBassonRLVersfeldASpearmanCWet al.Understanding hepatitis B," exact="hepatitis" post="C and HIV among people who inject drugs in"/>
   <result pre="country-level coverage of interventions to prevent and manage HIV and" exact="hepatitis" post="C among people who inject drugs: a systematic reviewLancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7272714\results\search\disease\results.xml">
   <result pre="does not comply with these terms. Abstract The trivalent seasonal" exact="influenza" post="vaccine was the only approved and available vaccine during"/>
   <result pre="was the only approved and available vaccine during the 2016–2018" exact="influenza" post="seasons. It did not include the B/Yamagata strain. In"/>
   <result pre="the B/Yamagata strain. In this study, we report an acute" exact="respiratory disease" post="outbreak associated with influenza B/Yamagata infections in Guangzhou, Southern"/>
   <result pre="study, we report an acute respiratory disease outbreak associated with" exact="influenza" post="B/Yamagata infections in Guangzhou, Southern China (January through March,"/>
   <result pre="Among the 9914 patients, 2241 (22.6%) were positive for the" exact="influenza" post="B virus, with only 312 (3.1%) positive for the"/>
   <result pre="influenza B virus, with only 312 (3.1%) positive for the" exact="influenza" post="A virus. The influenza B/Yamagata lineage dominated during this"/>
   <result pre="only 312 (3.1%) positive for the influenza A virus. The" exact="influenza" post="B/Yamagata lineage dominated during this period in Southern China."/>
   <result pre="during this period in Southern China. The highest incidence of" exact="influenza" post="A virus infection occurred in the children aged 5–14"/>
   <result pre="contrast, populations across all age groups were susceptible to the" exact="influenza" post="B virus. Phylogenetic, mutations, and 3D structure analyses of"/>
   <result pre="circulating isolates (clade 6B.1) in Spring 2018. An outbreak of" exact="influenza" post="B/Yamagata (clade 3) infections in 2018 occurred during the"/>
   <result pre="the absence of the corresponding vaccine during 2016–2018. The recommended" exact="influenza" post="B/Yamagata vaccine strain (B/Phuket/3073/2013) for the following season (2018–2019)"/>
   <result pre="season (2018–2019) was antigen-specific. Although there were only a few" exact="influenza" post="B/Victoria infections in Spring 2018, five amino acid mutations"/>
   <result pre="The number was larger than expected and suggested that the" exact="influenza" post="B HA gene may be more variable than previously"/>
   <result pre="mutations, and 3D structural analyses of the HA genes of" exact="influenza" post="strains reported here contribute to the understanding and evaluation"/>
   <result pre="data for screening and selecting more specific, appropriate, and effective" exact="influenza" post="vaccine candidate strains. influenza B virus Yamagata lineage hemagglutinin"/>
   <result pre="selecting more specific, appropriate, and effective influenza vaccine candidate strains." exact="influenza" post="B virus Yamagata lineage hemagglutinin Victoria lineage phylogenetic analysis"/>
   <result pre="et al., 2000). Although there is no direct evidence that" exact="influenza" post="B is transmitted between humans and animals, it has"/>
   <result pre="transmitted between humans and animals, it has been observed that" exact="influenza" post="B can infect seal, swine, ferret, guinea pig, pheasant,"/>
   <result pre="2014; Ran et al., 2015; Pascua et al., 2016). Pandemic" exact="influenza" post="is usually caused by influenza A virus, due to"/>
   <result pre="Pascua et al., 2016). Pandemic influenza is usually caused by" exact="influenza" post="A virus, due to its rapid antigenic variation, strong"/>
   <result pre="has been circulating and, in some seasons, has predominated over" exact="influenza" post="A, particularly among children (Paul Glezen et al., 2013;"/>
   <result pre="Tewawong et al., 2015; Furuse et al., 2016). Vaccines against" exact="influenza" post="A/H1N1 and A/H3N2 have been used effectively for more"/>
   <result pre="than 20 years for controlling and preventing potential pandemics. However," exact="influenza" post="vaccines against the B/Victoria and B/Yamagata lineages were used"/>
   <result pre="lineages were used interchangeably. In the 2016–2018 seasons, the trivalent" exact="influenza" post="vaccine did not include the B/Yamagata lineage. A high"/>
   <result pre="data provide a view into the molecular epidemiology of the" exact="influenza" post="viruses circulating in the current population, which may, in"/>
   <result pre="population, which may, in turn, confirm the efficacy of the" exact="influenza" post="vaccines administered as well as provide insights for the"/>
   <result pre="the future development and deployment of effective subtype or lineage-specific" exact="influenza" post="vaccines. Materials and Methods Influenza Diagnostic Tests From January"/>
   <result pre="9914 patients with influenza-like symptoms were collected and tested for" exact="influenza" post="viral antigens (Li et al., 2019) using the Clearview®"/>
   <result pre="The interaction between the colloidal gold conjugated antibodies and the" exact="influenza" post="antigens will indicate red in the test line. This"/>
   <result pre="are based on the &quot;WHO protocols for molecular diagnosis of" exact="influenza" post="virus�?3 (Table 1). The cDNA was amplified using the"/>
   <result pre="TABLE 1 Primers used for RT and PCR amplification of" exact="influenza" post="A and B viruses. Purpose Primer name Sequence (5′–3′)"/>
   <result pre="viruses. Purpose Primer name Sequence (5′–3′) Expected size RT for" exact="influenza" post="A uni12W AGCRAAAGCAGG N/A RT for influenza B Buni11W"/>
   <result pre="size RT for influenza A uni12W AGCRAAAGCAGG N/A RT for" exact="influenza" post="B Buni11W AGCAGAAGCGS N/A PCR for the HA gene"/>
   <result pre="B Buni11W AGCAGAAGCGS N/A PCR for the HA gene of" exact="influenza" post="A H1F1 AGCAAAAGCAGGGGAAAATAAAAGC 1.7 kb H3A1F6 AAGCAGGGGATAATTCTATTAACC H5A1F1 AGCAAAAGCAGGGGTATAATC"/>
   <result pre="H5A1F1 AGCAAAAGCAGGGGTATAATC HARUc ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT PCR for the NA gene of" exact="influenza" post="A N1F1 AGCAAAAGCAGGAGTTTAAAATG 1.3 kb NARUc AGTAGAAACAAGGAGTTTTTT PCR for"/>
   <result pre="1.3 kb NARUc AGTAGAAACAAGGAGTTTTTT PCR for the HA gene of" exact="influenza" post="B BHAF1ua AGCAGAAGCAGAGCATTTTCTAATATC 1.4 kb BHAR1341 TTCGTTGTGGAGTTCATCCAT nested-PCR for"/>
   <result pre="1.4 kb BHAR1341 TTCGTTGTGGAGTTCATCCAT nested-PCR for the HA gene of" exact="influenza" post="B Bvf224 ACATACCCTCGGCAAGAGTTTC Victoria lineage: Bvr507 TGCTGTTTTGTTGTTGTCGTTTT 284 bp"/>
   <result pre="were chosen from the &quot;WHO protocols for molecular diagnosis of" exact="influenza" post="virus.�? aModified from primer sequences WHO recommended. Phylogenetic Sequence"/>
   <result pre="Analysis Amino acid mutations in the HA genes of 23" exact="influenza" post="A/H1N1 isolates from residues 7 to 566 were compared"/>
   <result pre="addition, amino acid mutations of the HA genes of 80" exact="influenza" post="B/Yamagata isolates from residues 96–215 were compared to the"/>
   <result pre="Amino acid mutations in the HA genes from the 19" exact="influenza" post="B/Victoria isolates and the 2018–2020 B/Victoria vaccine strain from"/>
   <result pre="sites and mutation sites on the HA crystal structure of" exact="influenza" post="A and B isolates. HA and NA Gene Sequences"/>
   <result pre="and BLAST software. These HA and NA gene sequences from" exact="influenza" post="A and B were archived in GenBank with the"/>
   <result pre="of 9914 patients (25.7%) during this outbreak were positive for" exact="influenza" post="viruses, of which 312 (3.1%) were identified as influenza"/>
   <result pre="for influenza viruses, of which 312 (3.1%) were identified as" exact="influenza" post="A and 2241 (22.6%) as influenza B. The dominant"/>
   <result pre="(3.1%) were identified as influenza A and 2241 (22.6%) as" exact="influenza" post="B. The dominant type circulating was influenza B (87.8%)."/>
   <result pre="2241 (22.6%) as influenza B. The dominant type circulating was" exact="influenza" post="B (87.8%). Outpatients of influenza A and B positive"/>
   <result pre="The dominant type circulating was influenza B (87.8%). Outpatients of" exact="influenza" post="A and B positive accounted for 297 (95.2%) and"/>
   <result pre="genes. The sequence data resulted in the typing of the" exact="influenza" post="A strains as 23 H1N1 with one H3N2, and"/>
   <result pre="as 23 H1N1 with one H3N2, and the typing of" exact="influenza" post="B as identified 80 Yamagata and 19 Victoria strains."/>
   <result pre="During the two peaks, there was a total of 1776" exact="influenza" post="positive cases. Among these, influenza B accounted for 1579"/>
   <result pre="was a total of 1776 influenza positive cases. Among these," exact="influenza" post="B accounted for 1579 cases, with only 203 as"/>
   <result pre="influenza B accounted for 1579 cases, with only 203 as" exact="influenza" post="A positive. These include six cases testing as both"/>
   <result pre="influenza A positive. These include six cases testing as both" exact="influenza" post="A and B positive. FIGURE 1 Timeline and type"/>
   <result pre="and B positive. FIGURE 1 Timeline and type distribution of" exact="influenza" post="A and B cases of onset in Guangzhou, Southern"/>
   <result pre="Southern China, January–March 2018. The number of cases of each" exact="influenza" post="A and B are shown encompassing the two peaks"/>
   <result pre="encompassing the two peaks of the epidemic. During the outbreak," exact="influenza" post="A and B viruses circulated in all age groups."/>
   <result pre="to female ratio of 1.1:1. The highest positive rate of" exact="influenza" post="A and B infections appeared in children between the"/>
   <result pre="31.7%, respectively (Table 2). All age groups were susceptible to" exact="influenza" post="B virus, accounting for 17.9–31.7% of the flu-like cases."/>
   <result pre="of the flu-like cases. TABLE 2 The age distribution of" exact="influenza" post="A and B patients in Guangzhou, Southern China, January–March"/>
   <result pre="analysis of the HA (A) and NA (B) genes from" exact="influenza" post="A/H1N1 viruses. The phylogenetic tree was generated by the"/>
   <result pre="by WHO as reference (•). The majority (80/99) of the" exact="influenza" post="B isolates belonged to the Yamagata lineage, which was"/>
   <result pre="3. FIGURE 3 Phylogenetic analysis of the HA genes of" exact="influenza" post="B/Yamagata isolates (A) and B/Victoria isolates (B). The phylogenetic"/>
   <result pre="the absence of B/Yamagata vaccine might have contributed to an" exact="influenza" post="B outbreak due to the low herd immunity. The"/>
   <result pre="HA Antigenic Sites Indicate the Potential Effect on Vaccines Current" exact="influenza" post="vaccines provide important protection in humans by inducing strain-specific"/>
   <result pre="2018). Amino acid mutations of the HA genes of circulating" exact="influenza" post="isolates and the predicted 3D structure were further analyzed,"/>
   <result pre="isolates needs to be investigated further. However, the incidence of" exact="influenza" post="A was significantly lower than influenza B in Jan-Mar"/>
   <result pre="However, the incidence of influenza A was significantly lower than" exact="influenza" post="B in Jan-Mar 2018. The use of the influenza"/>
   <result pre="than influenza B in Jan-Mar 2018. The use of the" exact="influenza" post="A vaccine appears to have been effective in controlling"/>
   <result pre="vaccine appears to have been effective in controlling the potential" exact="influenza" post="A outbreak. FIGURE 4 Structural modeling of the HA"/>
   <result pre="Structural modeling of the HA mutations. The hemagglutinin structures of" exact="influenza" post="A/H1N1 (A), B/Yamagata (B), and B/Victoria (C) vaccine strains"/>
   <result pre="residues 154, 157, 159, and 238–239. Because there was no" exact="influenza" post="B/Yamagata vaccine used during the 2017–2018 season, the 2018–2019"/>
   <result pre="influenza B/Yamagata vaccine used during the 2017–2018 season, the 2018–2019" exact="influenza" post="B/Yamagata vaccine strain (B/Phuket/3073/2013) was used as reference. The"/>
   <result pre="with influenza, of which 119 died. During the outbreak, both" exact="influenza" post="A and B dominated in Northern China. In contrast,"/>
   <result pre="dominated in Northern China. In contrast, our study found that" exact="influenza" post="B, rather than influenza A, dominated in Southern China."/>
   <result pre="In contrast, our study found that influenza B, rather than" exact="influenza" post="A, dominated in Southern China. Throughout the years, influenza"/>
   <result pre="than influenza A, dominated in Southern China. Throughout the years," exact="influenza" post="A viruses have attracted a great deal of attention"/>
   <result pre="less literature focused on the epidemiology and societal burdens of" exact="influenza" post="B, particularly outside the United States and Europe (Caini"/>
   <result pre="the United States and Europe (Caini et al., 2015). Nevertheless," exact="influenza" post="B remains an critical respiratory pathogen that imparts an"/>
   <result pre="and studies such as this provide important context for both" exact="influenza" post="A and B, as well as insights into the"/>
   <result pre="their epidemiology. It should be noted that a domination of" exact="influenza" post="B/Yamagata in both Northern and Southern China has occurred"/>
   <result pre="2018). In this study, we found that, 3 years later," exact="influenza" post="B/Yamagata dominated once again in Southern China. The highest"/>
   <result pre="dominated once again in Southern China. The highest incidence of" exact="influenza" post="infection occurred among the 5–14-year-old children, which indicates that"/>
   <result pre="which indicates that children and adolescents were more susceptible to" exact="influenza" post="viruses. Outpatients accounted for more than 95% of influenza"/>
   <result pre="to influenza viruses. Outpatients accounted for more than 95% of" exact="influenza" post="cases, which suggested that the illness was not particularly"/>
   <result pre="severe during this outbreak. H1N1 was the major subtype of" exact="influenza" post="A (95.8%) and the Yamagata lineage was the major"/>
   <result pre="(95.8%) and the Yamagata lineage was the major lineage of" exact="influenza" post="B (80.8%). The outbreak of influenza viruses in Southern"/>
   <result pre="the major lineage of influenza B (80.8%). The outbreak of" exact="influenza" post="viruses in Southern China in 2018 was mainly caused"/>
   <result pre="caused by Yamagata lineage, which was phylogenetically close to other" exact="influenza" post="B strains circulating worldwide in the same timeframe. With"/>
   <result pre="appeared to be effective in this season. However, the low" exact="influenza" post="vaccination rate in China might have contributed to the"/>
   <result pre="emergence of H1N1 cases9. Due to the lack of the" exact="influenza" post="B/Yamagata vaccine during 2016–2018, the outbreak of the influenza"/>
   <result pre="the influenza B/Yamagata vaccine during 2016–2018, the outbreak of the" exact="influenza" post="B/Yamagata virus in 2018 might have been expected. According"/>
   <result pre="2018 might have been expected. According to our analysis, the" exact="influenza" post="B/Yamagata vaccine strain used during the subsequent season (2018–2019)"/>
   <result pre="(2018–2019) was antigen-specific for the circulating strains. An outbreak of" exact="influenza" post="B/Yamagata infections did not occur in 2019 perhaps due"/>
   <result pre="been the best candidate vaccine for Southern China in future" exact="influenza" post="seasons. According to the reports of the United States"/>
   <result pre="to the reports of the United States CDC, although the" exact="influenza" post="vaccination rate for adults was as high as 45.3%"/>
   <result pre="45.3% in 2018–2019, an increase of 8.2% from the 2017–2018" exact="influenza" post="season, a severe influenza infection still broke out in"/>
   <result pre="increase of 8.2% from the 2017–2018 influenza season, a severe" exact="influenza" post="infection still broke out in 2019–2020, causing more than"/>
   <result pre="in 2019–2020, causing more than 10,000 deaths, primarily caused by" exact="influenza" post="B/Victoria lineage (Owusu et al., 2020)10. HA gene variations"/>
   <result pre="Previous studies demonstrated that vaccination with the live and attenuated" exact="influenza" post="vaccine elicited lung CD4+ and virus-specific CD8+ T cell"/>
   <result pre="T cell responses, similar in phenotype to those generated by" exact="influenza" post="virus infection, and ultimately established lung Tissue-resident memory T"/>
   <result pre="(TRM) capable of providing long-term, hetero-subtypic protection to multiple, non-vaccine" exact="influenza" post="strains. In contrast, vaccination with inactivated influenza vaccine generated"/>
   <result pre="to multiple, non-vaccine influenza strains. In contrast, vaccination with inactivated" exact="influenza" post="vaccine generated durable, strain-specific humoral immunity but failed to"/>
   <result pre="cell responses (Zens et al., 2016). In China, all the" exact="influenza" post="vaccines approved and used are inactivated vaccines. Therefore, the"/>
   <result pre="in this study, contribute to a better understanding of circulating" exact="influenza" post="strains by revealing critical mutations, allowing for an evaluation"/>
   <result pre="basis for the improved selection of more specific and effective" exact="influenza" post="vaccine candidate strains. A continuing surveillance of the sequence"/>
   <result pre="HA genes is important for managing, controlling, and limiting future" exact="influenza" post="outbreaks and pandemics. These surveys and characterizations of circulating"/>
   <result pre="influenza outbreaks and pandemics. These surveys and characterizations of circulating" exact="influenza" post="strains are especially important should there be emergent or"/>
   <result pre="strains are especially important should there be emergent or re-emergent" exact="influenza" post="viral pathogens crossing the human-animal interface. Data Availability Statement"/>
   <result pre="G.FukudaK.et al. (2010). Epidemiological, antigenic and genetic characteristics of seasonal" exact="influenza" post="A(H1N1), A(H3N2) and B influenza viruses: basis for the"/>
   <result pre="and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B" exact="influenza" post="viruses: basis for the WHO recommendation on the composition"/>
   <result pre="viruses: basis for the WHO recommendation on the composition of" exact="influenza" post="vaccines for use in the 2009-2010 northern hemisphere season.Vaccine281156–1167."/>
   <result pre="recommendations for the viruses used in the 2013-2014 Northern Hemisphere" exact="influenza" post="vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09,"/>
   <result pre="Northern Hemisphere influenza vaccine: epidemiology, antigenic and genetic characteristics of" exact="influenza" post="A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October"/>
   <result pre="antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B" exact="influenza" post="viruses collected from October 2012 to January 2013.Vaccine324713–4725. 10.1016/j.vaccine.2014.02.01424582632"/>
   <result pre="CainiS.HuangQ. S.CiblakM. A.KusznierzG.OwenR.WangchukS.et al. (2015). Epidemiological and virological characteristics of" exact="influenza" post="B: results of the global influenza B study.Influenza Other"/>
   <result pre="and virological characteristics of influenza B: results of the global" exact="influenza" post="B study.Influenza Other Respir. Viruses9(Suppl. 1)3–12. 10.1111/irv.1231926256290 CauldwellA. V.LongJ."/>
   <result pre="1)3–12. 10.1111/irv.1231926256290 CauldwellA. V.LongJ. S.MoncorgeO.BarclayW. S. (2014). Viral determinants of" exact="influenza" post="A virus host range.J. Gen. Virol.95(Pt 6)1193–1210. 10.1099/vir.0.062836-024584475 ChanK.-H.ZhangA."/>
   <result pre="K. M.GuoK.et al. (2010). Wild type and mutant 2009 pandemic" exact="influenza" post="A (H1N1) viruses cause more severe disease and higher"/>
   <result pre="global dissemination play a significant role in the circulation of" exact="influenza" post="B viruses in Leyte Island, Philippines.Virology49221–24. 10.1016/j.virol.2016.02.00126896931 HuangP.YuS. Y.WuC."/>
   <result pre="10.1186/1479-5876-11-4723433453 HuangS. S. H.BannerD.PaquetteS. G.LeonA. J.KelvinA. A.KelvinD. J. (2014). Pathogenic" exact="influenza" post="B virus in the ferret model establishes lower respiratory"/>
   <result pre="10)2127–2139. 10.1099/vir.0.064352-024989173 JenningsL. C.SkopnikH.BurckhardtI.HribarI.Del PieroL.DeichmannK. A. (2009). Effect of rapid" exact="influenza" post="testing on the clinical management of paediatric influenza.Influenza Other"/>
   <result pre="Evaluation of a commercial colloidal gold assay for detection of" exact="influenza" post="A and B virus in children’s respiratory specimens.Fetal Pediatr."/>
   <result pre="mechanisms of the hemagglutinin and three internal protein genes of" exact="influenza" post="B virus: multiple cocirculating lineages and frequent reassortment of"/>
   <result pre="al. (2014). Epitope mapping of the hemagglutinin molecule of A/(H1N1)pdm09" exact="influenza" post="virus by using monoclonal antibody escape mutants.J. Virol.8812364–12373. 10.1128/jvi.01381-1425122788"/>
   <result pre="escape mutants.J. Virol.8812364–12373. 10.1128/jvi.01381-1425122788 MorensD. M.TaubenbergerJ. K.FauciA. S. (2013). H7N9" exact="avian influenza" post="A virus and the perpetual challenge of potential human"/>
   <result pre="mutants.J. Virol.8812364–12373. 10.1128/jvi.01381-1425122788 MorensD. M.TaubenbergerJ. K.FauciA. S. (2013). H7N9 avian" exact="influenza" post="A virus and the perpetual challenge of potential human"/>
   <result pre="human pandemicity.mBio4:e00445-13. 10.1128/mBio.00445-1323839219 MostafaA.AbdelwhabE. M.MettenleiterT. C.PleschkaS. (2018). Zoonotic potential of" exact="influenza" post="A viruses: a comprehensive overview.Viruses10:497. 10.3390/v1009049730217093 NakagawaN.KubotaR.OkunoY. (2005). Variation"/>
   <result pre="10.3390/v1009049730217093 NakagawaN.KubotaR.OkunoY. (2005). Variation of the conserved neutralizing epitope in" exact="influenza" post="B virus victoria group isolates in Japan.J. Clin. Microbiol.434212–4214."/>
   <result pre="Clin. Microbiol.434212–4214. 10.1128/JCM.43.8.4212-4214.200516081981 NelsonM. I.VincentA. L. (2015). Reverse zoonosis of" exact="influenza" post="to swine: new perspectives on the human-animal interface.Trends Microbiol.23142–153."/>
   <result pre="seals.Science2881051–1053. 10807575 OwusuD.HandJ.TenfordeM. W.FeldsteinL. R.DaSilvaJ.BarnesJ.et al. (2020). Early season pediatric" exact="influenza" post="B/victoria virus infections associated with a recently emerged virus"/>
   <result pre="N.MaratheB. M.BurnhamA. J.VogelP.WebbyR. J.WebsterR. G.et al. (2016). Competitive fitness of" exact="influenza" post="B viruses possessing E119A and H274Y neuraminidase inhibitor resistance-associated"/>
   <result pre="10.1371/journal.pone.015984727466813 Paul GlezenW.SchmierJ. K.KuehnC. M.RyanK. J.OxfordJ. (2013). The burden of" exact="influenza" post="B: a structured literature review.Am. J. Public Health103e43–e51. 10.2105/ajph.2012.30113723327249"/>
   <result pre="J. Public Health103e43–e51. 10.2105/ajph.2012.30113723327249 PicaN.ChouY. Y.BouvierN. M.PaleseP. (2012). Transmission of" exact="influenza" post="B viruses in the guinea pig.J. Virol.864279–4287. 10.1128/jvi.06645-1122301149 QiZ."/>
   <result pre="L.HuH. Y.WangZ. H.WangG. H.LiY.ZhaoX. R.et al. (2018). Antibodies against H1N1" exact="influenza" post="virus cross-react with -cells of pancreatic islets.J. Diabet. Invest.9265–269."/>
   <result pre="A.TuranN.ZhuL.et al. (2015). Domestic pigs are susceptible to infection with" exact="influenza" post="B viruses.J. Virol.894818–4826. 10.1128/jvi.00059-1525673727 ShenX. T.ZhangX. X.LiuS. W. (2013)."/>
   <result pre="viruses.J. Virol.894818–4826. 10.1128/jvi.00059-1525673727 ShenX. T.ZhangX. X.LiuS. W. (2013). Novel hemagglutinin-based" exact="influenza" post="virus inhibitors.J. Thor. Dis.5S149–S159. 10.3978/j.issn.2072-1439.2013.06.1423977436 TewawongN.SuwannakarnK.PrachayangprechaS.KorkongS.VichiwattanaP.VongpunsawadS.et al. (2015). Molecular"/>
   <result pre="10.3978/j.issn.2072-1439.2013.06.1423977436 TewawongN.SuwannakarnK.PrachayangprechaS.KorkongS.VichiwattanaP.VongpunsawadS.et al. (2015). Molecular epidemiology and phylogenetic analyses of" exact="influenza" post="B virus in Thailand during 2010 to 2014.PLoS One10:e0116302."/>
   <result pre="10.1371/journal.pone.011630225602617 TongS.LiY.RivaillerP.ConrardyC.CastilloD. A.ChenL. M.et al. (2012). A distinct lineage of" exact="influenza" post="A virus from bats.Proc. Natl. Acad. Sci. U.S.A.1094269–4274. 10.1073/pnas.111620010922371588"/>
   <result pre="U.S.A.1094269–4274. 10.1073/pnas.111620010922371588 TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.et al. (2013). New world bats harbor diverse" exact="influenza" post="A viruses.PLoS Pathog.9:e1003657. 10.1371/journal.ppat.100365724130481 WangQ.ChengF.LuM.TianX.MaJ. (2008). Crystal structure of"/>
   <result pre="A viruses.PLoS Pathog.9:e1003657. 10.1371/journal.ppat.100365724130481 WangQ.ChengF.LuM.TianX.MaJ. (2008). Crystal structure of unliganded" exact="influenza" post="B virus hemagglutinin.J. Virol.823011–3020. 10.1128/jvi.02477-0718184701 WaterhouseA.BertoniM.BienertS.StuderG.TaurielloG.GumiennyR.et al. (2018). SWISS-MODEL:"/>
   <result pre="10.1093/nar/gky42729788355 WhiteM. C.LowenA. C. (2018). Implications of segment mismatch for" exact="influenza" post="A virus evolution.J. Gen. Virol.993–16. 10.1099/jgv.0.00098929244017 YangJ.LauY. C.WuP.FengL.WangX.ChenT.et al."/>
   <result pre="evolution.J. Gen. Virol.993–16. 10.1099/jgv.0.00098929244017 YangJ.LauY. C.WuP.FengL.WangX.ChenT.et al. (2018). Variation in" exact="influenza" post="B virus epidemiology by Lineage, China.Emerg. Infect. Dis.241536–1540. 10.3201/eid2408.18006330015611"/>
   <result pre="(2013). Regional variation in mortality impact of the 2009 A(H1N1)" exact="influenza" post="pandemic in China.Influenza Other Respir. Viruses71350–1360. 10.1111/irv.1212123668477 ZensK. D.ChenJ."/>
   <result pre="Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to" exact="influenza" post="infection.JCI Insight1:e85832. 10.1172/jci.insight.8583227468427 ZhangJ.KangJ.DehghanS.SridharS.LauS.OuJ.et al. (2019). A survey of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7273724\results\search\disease\results.xml">
   <result pre="with these terms. Abstract Cross-subtype neutralizing single domain antibodies against" exact="influenza" post="present new opportunities for immunoprophylaxis and pandemic preparedness. Their"/>
   <result pre="cross-subtype neutralization in vitro of H1N1, H5N1, H2N2, and H9N2" exact="influenza" post="viruses, through binding to a highly conserved epitope in"/>
   <result pre="viruses, through binding to a highly conserved epitope in the" exact="influenza" post="hemagglutinin stem region. To evaluate the potential of R1a-B6"/>
   <result pre="protection against lethal challenge with both pandemic A/California/07/2009 (H1N1)pdm09 and" exact="avian influenza" post="A/Vietnam/1194/2004 (H5N1). This data suggests that R1a-B6 is capable"/>
   <result pre="against lethal challenge with both pandemic A/California/07/2009 (H1N1)pdm09 and avian" exact="influenza" post="A/Vietnam/1194/2004 (H5N1). This data suggests that R1a-B6 is capable"/>
   <result pre="cross-subtype neutralizing nanobodies may be an effective strategy to prevent" exact="influenza" post="infection and provide long-term protection independent of a host"/>
   <result pre="provide long-term protection independent of a host induced immune response." exact="influenza" post="vaccine adeno associated viral vectors immunoprophylaxis immunotherapy nanobody monoclonal"/>
   <result pre="epidemics and occasional pandemics (1). In a pandemic, a new" exact="influenza" post="virus emerges and infects the human population which has"/>
   <result pre="the virus their effectiveness is limited in treating patients with" exact="influenza" post="(5, 6). There is clearly an urgent need for"/>
   <result pre="promising strategy is to use recombinant monoclonal antibodies (mAbs) against" exact="influenza" post="and several are currently in clinical development (9–13). These"/>
   <result pre="already been shown as a viable approach to protect from" exact="influenza" post="(20, 21). The intramuscular injection of AAV8 expressing the"/>
   <result pre="mAb F10 could protect young, old, and immunocompromised mice from" exact="influenza" post="challenge through sustained expression in the systemic circulation for"/>
   <result pre="which was shown to protect mice and ferrets from lethal" exact="influenza" post="challenge. In this study FI6 was delivered intranasally which"/>
   <result pre="may be beneficial as this is the natural site of" exact="influenza" post="infection (22, 23). Despite these findings, significant challenges remain"/>
   <result pre="analysis of several of the earliest human mAbs against the" exact="influenza" post="HA stem revealed the unusual feature that they employ"/>
   <result pre="be products of an immediate and sub-optimal immune response to" exact="influenza" post="(26, 27). This prompted our interest in naturally occurring"/>
   <result pre="of high affinity broadly neutralizing single domain antibodies (nanobodies) against" exact="influenza" post="A and B (28, 29). This antibody format is"/>
   <result pre="due to the alpaca’s limited immune history of exposure to" exact="influenza" post="(31). Nanobodies have several well-described advantages over conventional mAbs"/>
   <result pre="over conventional mAbs which make them ideal for applications in" exact="infectious disease" post="(32–34). One interesting feature is that they have a"/>
   <result pre="capable of cross subtype neutralization of pandemic A(H1N1)2009, highly pathogenic" exact="avian influenza" post="H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes influenza"/>
   <result pre="of cross subtype neutralization of pandemic A(H1N1)2009, highly pathogenic avian" exact="influenza" post="H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes influenza"/>
   <result pre="avian influenza H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes" exact="influenza" post="through binding to a highly conserved epitope in the"/>
   <result pre="is required for efficacy of human mAbs specific for the" exact="influenza" post="HA stem (45, 46). Recent studies by Laursen and"/>
   <result pre="and colleagues have also described cross-neutralizing single domain antibodies to" exact="influenza" post="and furthermore shown in vivo efficacy by intranasal AAV"/>
   <result pre="epitopes on HA to provide almost complete protection against both" exact="influenza" post="A and B virus in mouse challenge models. Our"/>
   <result pre="shown to be effective in mice against HIV (50) and" exact="influenza" post="(20). AAV8 and AAV9 share the same tropism, however,"/>
   <result pre="R1a-B6 to accomplish long term, safe, broad protection from pandemic" exact="influenza" post="in vulnerable patient groups. Materials and Methods Nanobody-Fc Expression"/>
   <result pre="of Nanobody-Fc via ELISA The nanobody-Fc constructs were tested against" exact="influenza" post="antigen standards from the National Institute for Biological Standards"/>
   <result pre="Plates were coated overnight with 50 μL/well of 5 μg/mL" exact="influenza" post="virus antigen standard diluted in PBS at 4°C. Serial"/>
   <result pre="G7513) was prepared. For TCID50 determination, a 10–4 dilution of" exact="influenza" post="virus was made and diluted ten-fold across the plate."/>
   <result pre="group, were added and culled 3-days post-challenge, to quantify residual" exact="influenza" post="in the lungs and for histological analysis. Hemagglutination Inhibition"/>
   <result pre="then shown to bind to a broad panel of whole" exact="influenza" post="virus reference reagents (Figure 1E and Supplementary Figure 1)"/>
   <result pre="the breadth of neutralizing activity to include the more divergent" exact="influenza" post="subtype A(H2N2) rather than increasing maximum levels of potency"/>
   <result pre="triplicate. (E) Binding of R1a-B6 against a broad range of" exact="influenza" post="A subtypes as tested by ELISA. Half maximal effective"/>
   <result pre="expressed as the reciprocal of the highest dilution at which" exact="influenza" post="infection is completely blocked. Mice given R1a-B6 (all doses)"/>
   <result pre="of R1a-B6 present in mouse sera would react with other" exact="influenza" post="strains belonging to key influenza subtypes. We obtained mouse"/>
   <result pre="sera would react with other influenza strains belonging to key" exact="influenza" post="subtypes. We obtained mouse sera 6-weeks post AAV IM"/>
   <result pre="These mice were naïve and had not been exposed to" exact="influenza" post="so immunoreactivity to heterologous strains can be attributed solely"/>
   <result pre="monovalent R1a-B6 showed lower reactivity against the panel of whole" exact="influenza" post="virus antigen standards (Figure 3C), which was consistent with"/>
   <result pre="and those given PBS did not show any reactivity against" exact="influenza" post="virus (data not shown). In addition to cross-subtype specificity,"/>
   <result pre="vg AAV encoding nanobodies. (A–C) Binding of R1a-B6 against different" exact="influenza" post="subtypes was tested via ELISA. Plates were coated with"/>
   <result pre="was tested via ELISA. Plates were coated with 5 μg/mL" exact="influenza" post="reference reagent (Supplementary Table 3) and the Absorbance at"/>
   <result pre="(B/BR/08) served as negative controls. (D)In vitro neutralization against different" exact="influenza" post="pseudotypes was determined via a luciferase-reporter assay and given"/>
   <result pre="whether AAV delivery of R1a-B6 transgenes protects mice from lethal" exact="influenza" post="infection, we injected 1 × 1011 vg AAV encoding"/>
   <result pre="confirmation of transgene expression in mouse sera, we proceeded with" exact="influenza" post="challenge via intranasal delivery of 21 MLD50 (mouse lethal"/>
   <result pre="days after AAV administration. Weight loss and clinical symptoms of" exact="influenza" post="were observed for the 14-day study window or until"/>
   <result pre="specific nanobody cAb1-mIgG2a and those given PBS showed symptoms of" exact="influenza" post="including difficulty in breathing, pinched waists and sunken abdomen"/>
   <result pre="In contrast, there was no weight loss or symptoms of" exact="influenza" post="infection observed in mice given R1a-B6-mIgG1 and R1a-B6-mIgG2a (n"/>
   <result pre="for the duration of the study demonstrating complete protection from" exact="influenza" post="(Figures 4B,C and Supplementary Figure 2). Mice given monovalent"/>
   <result pre="Mice given monovalent R1a-B6 without mouse Fc, showed symptoms of" exact="influenza" post="infection 6 days post-challenge, which was a delay of"/>
   <result pre="R1a-B6-mIgG2a, the latter two groups being mice that survived the" exact="influenza" post="challenge with no observable symptoms of infection. We concluded"/>
   <result pre="with no observable symptoms of infection. We concluded that after" exact="influenza" post="challenge, both infection-induced anti-head HA antibodies and anti-stem R1a-B6"/>
   <result pre="the prophylactic efficacy of R1a-B6 can extend to a different" exact="influenza" post="subtype, we tested in an H5N1 influenza challenge model."/>
   <result pre="to a different influenza subtype, we tested in an H5N1" exact="influenza" post="challenge model. The study design was the same as"/>
   <result pre="of a re-assortant virus derived from A/Vietnam/1194/04 (H5N1). Symptoms of" exact="influenza" post="and rapid weight loss were observed 2-days post-challenge in"/>
   <result pre="R1a-B6-mIgG2a (n = 16) did not show any symptoms of" exact="influenza" post="or any appreciable weight loss for the 13 days"/>
   <result pre="having no viral load (Figure 5E), indicating full protection from" exact="influenza" post="infection. In contrast, mice expressing R1a-B6, cAb1-mIgG2a, and those"/>
   <result pre="alveolar space (Figure 5E). Discussion Vaccination is the mainstay of" exact="influenza" post="infection control, however, high-risk patient groups such as the"/>
   <result pre="patient’s immune system and the prior availability of the matching" exact="influenza" post="strain (63, 64). One approach, which is of considerable"/>
   <result pre="broadly neutralizing monoclonal antibodies which bind to conserved epitopes on" exact="influenza" post="HA (10, 13, 20, 65–67). We have previously described"/>
   <result pre="mice by R1a-B6-Fc fusion in challenge models covering two different" exact="influenza" post="subtypes of pandemic potential. The mice that survived had"/>
   <result pre="stem have been described as utilizing additional mechanisms to neutralize" exact="influenza" post="virus in vivo through recruitment of the effector arm"/>
   <result pre="For instance, HA stem-binding antibodies have been reported to neutralize" exact="influenza" post="virus by binding HA on virally infected cells and"/>
   <result pre="mitigates some of the concerns of antibody dependent enhancement of" exact="influenza" post="(71–73) mediated by interactions with the effector arm of"/>
   <result pre="is not essential for R1a-B6 to provide sufficient protection against" exact="influenza" post="opens up new opportunities for designing an optimized transgene"/>
   <result pre="is an attractive approach to confer broad-based protection against important" exact="influenza" post="subtypes (77) which can enhance preparedness against future potential"/>
   <result pre="influenza subtypes (77) which can enhance preparedness against future potential" exact="influenza" post="pandemics. In addition, our data suggest that the potency"/>
   <result pre="functions to HA binding for neutralization of influenza. Highly pathogenic" exact="avian influenza" post="H5N1, as well as viruses of subtype H2N2 and"/>
   <result pre="to HA binding for neutralization of influenza. Highly pathogenic avian" exact="influenza" post="H5N1, as well as viruses of subtype H2N2 and"/>
   <result pre="AAV mediated gene therapy with highly potent cross-neutralizing nanobodies against" exact="influenza" post="to provide broad protection independent of the prior availability"/>
   <result pre="provide broad protection independent of the prior availability of the" exact="influenza" post="strain and the need for a natural host induced"/>
   <result pre="qualified researcher. Ethics Statement The animal studies using AAV and" exact="influenza" post="challenge were reviewed and approved under Home Office Licenses:"/>
   <result pre="Health Organization (2018). 4.FinebergHV.Pandemic preparedness and response–lessons from the H1N1" exact="influenza" post="of 2009.N Engl J Med. (2014) 370:1335–42.24693893 5.collab: Centers"/>
   <result pre="Centers for Disease Control and Prevention (2017). 6.HaydenFG.Antiviral resistance in" exact="influenza" post="viruses — implications for management and pandemic response.N Engl"/>
   <result pre="J Med. (2006) 354:785–8.16495389 7.LukeTCKilbaneEMJacksonJLHoffmanSL.Meta-analysis: convalescent blood products for Spanish" exact="influenza" post="pneumonia: a future H5N1 treatment?Ann Intern Med. (2006) 145:599–609."/>
   <result pre="Intern Med. (2006) 145:599–609. 16940336 8.ZhouBZhongNGuanY.Treatment with convalescent plasma for" exact="influenza" post="A (H5N1) infection.N Engl J Med. (2007) 357:1450–1.17914053 9.SparrowEFriedeMSheikhMTorvaldsenSNewallAT.Passive"/>
   <result pre="(H5N1) infection.N Engl J Med. (2007) 357:1450–1.17914053 9.SparrowEFriedeMSheikhMTorvaldsenSNewallAT.Passive immunization for" exact="influenza" post="through antibody therapies, a review of the pipeline, challenges"/>
   <result pre="and functional bases for broad-spectrum neutralization of avian and human" exact="influenza" post="a viruses.Nat Struct Mol Biol. (2009) 16:265–73. 10.1038/nsmb.156619234466 11.ThrosbyMvan"/>
   <result pre="cells.PLoS One. (2008) 3:e3942. 10.1371/journal.pone.000394219079604 12.BerryCM.Antibody immunoprophylaxis and immunotherapy for" exact="influenza" post="virus infection: utilization of monoclonal or polyclonal antibodies?Hum Vaccin"/>
   <result pre="Immunother. (2018) 14:796–9.28854120 13.EkiertDBhabhaGElsligerMAFriesenRHJongeneelenMThrosbyMet al.Antibody recognition of a highly conserved" exact="influenza" post="virus epitope.Science. (2009) 324:246–51.19251591 14.WarnockJDaigreCAl-RubeaiM.Viral vectors for gene therapy.Methods"/>
   <result pre="vector for gene therapy.BioDrugs. (2017) 31:317–34. 10.1007/s40259-017-0234-528669112 20.BalazsABBloomJDHongCMRaoDSBaltimoreD.Broad protection against" exact="influenza" post="infection by vectored immunoprophylaxis in mice.Nat Biotechnol. (2013) 31:647–52."/>
   <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9.Clin Vaccine Immunol. (2013) 20:1836–7.24132603 24.KashyapASteelJOnerADillonMSwaleRWallKet al.Combinatorial"/>
   <result pre="in mouse airway provides partial protection against a new avian" exact="influenza" post="A virus, H7N9.Clin Vaccine Immunol. (2013) 20:1836–7.24132603 24.KashyapASteelJOnerADillonMSwaleRWallKet al.Combinatorial"/>
   <result pre="24.KashyapASteelJOnerADillonMSwaleRWallKet al.Combinatorial antibody libraries from survivors of the Turkish H5N1" exact="avian influenza" post="outbreak reveal virus neutralization strategies.Proc Natl Acad Sci USA."/>
   <result pre="al.Combinatorial antibody libraries from survivors of the Turkish H5N1 avian" exact="influenza" post="outbreak reveal virus neutralization strategies.Proc Natl Acad Sci USA."/>
   <result pre="Acad Sci USA. (2008) 105:5986–91. 10.1073/pnas.080136710518413603 25.LangSXieJZhuXWuNLernerRWilsonI.Antibody 27F3 broadly targets" exact="influenza" post="A group 1 and 2 hemagglutinins through a further"/>
   <result pre="cross sub-type neutralisation activity of a single domain antibody to" exact="influenza" post="hemagglutinin can be increased by antibody valency.PLoS One. (2014)"/>
   <result pre="9:e103294. 10.1371/journal.pone.010329425084445 29.RamageWGaiottoTBallCRisleyPCarnellGWTempertonNet al.Cross-reactive and lineage-specific single domain antibodies against" exact="influenza" post="B hemagglutinin.Antibodies. (2019) 8:14. 10.3390/antib801001431544820 30.MuyldermansSAtarhouchTSaldanhaJBarbosaJARGHamersR.Sequence and structure of"/>
   <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against" exact="influenza" post="virus in vivo.Nat Med. (2014) 20:143–51. 10.1038/nm.344324412922 47.LaursenNFriesenRHZhuXJongeneelenMBloklandSVermondJet al.Universal"/>
   <result pre="in vivo.Nat Med. (2014) 20:143–51. 10.1038/nm.344324412922 47.LaursenNFriesenRHZhuXJongeneelenMBloklandSVermondJet al.Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutinin.Science. (2018)"/>
   <result pre="al.Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutinin.Science. (2018) 362:598–602. 10.1126/science.aaq062030385580 48.WangDZhongLNahidMAGaoG.The potential of adeno-associated viral"/>
   <result pre="vectors vaccines against infectious diseases.Front Immunol. (2014) 5:5. 10.3389/fimmu.2014.0000524478774 65.CortiDCameroniEGuarinoBKallewaardNLZhuQLanzavecchiaA.Tackling" exact="influenza" post="with broadly neutralizing antibodies.Curr Opin Virol. (2017) 24:60–9. 10.1016/j.coviro.2017.03.00228527859"/>
   <result pre="airway expression of antibody protects old and immunodeficient mice against" exact="influenza" post="virus.Clin Vaccine Immunol. (2014) 21:1528–33. 10.1128/CVI.00572-1425209558 69.JegaskandaS.The potential role"/>
   <result pre="role of Fc-receptor functions in the development of a universal" exact="influenza" post="vaccine.Vaccines (Basel). (2018) 6:27. 10.3390/vaccines602002729772781 70.JegaskandaSVandervenHAWheatleyAKKentSJ.Fc or not Fc;"/>
   <result pre="is the question: antibody Fc-receptor interactions are key to universal" exact="influenza" post="vaccine design.Hum Vaccin Immunother. (2017) 13:1–9. 10.1080/21645515.2017.129001828332900 71.KhuranaSLovingCManischewitzJKingLGaugerPHenningsonJet al.Vaccine-induced"/>
   <result pre="10.1080/21645515.2017.129001828332900 71.KhuranaSLovingCManischewitzJKingLGaugerPHenningsonJet al.Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance" exact="influenza" post="virus respiratory disease.Sci Transl Med. (2013) 5:200ra114. 10.1126/scitranslmed.300636623986398 72.RamakrishnanBViswanathanKTharakaramanKDancikVRamanRBabcockGJet"/>
   <result pre="(2016) 24:933–43. 10.1016/j.tim.2016.09.00327751627 73.SkowronskiDMDe SerresGCrowcroftNSJanjuaNZBoulianneNHottesTSet al.Association between the 2008-09 seasonal" exact="influenza" post="vaccine and pandemic H1N1 illness during spring-summer 2009: four"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7274457\results\search\disease\results.xml">
   <result pre="Vertebrates : Amniotes : Mammals: Swine An outbreak of Japanese" exact="encephalitis" post="caused by genotype Ib Japanese encephalitis virus in China,"/>
   <result pre="An outbreak of Japanese encephalitis caused by genotype Ib Japanese" exact="encephalitis" post="virus in China, 2018: A laboratory and field investigation"/>
   <result pre="the original author and source are credited.pntd.0008312.pdf Abstract Although Japanese" exact="encephalitis" post="virus genotype Ib (JEV GIb) has replaced JEV GIII"/>
   <result pre="was due to infection of JEV GIb. Author summary Japanese" exact="encephalitis" post="virus (JEV) is recognized as an important encephalitis pathogen"/>
   <result pre="summary Japanese encephalitis virus (JEV) is recognized as an important" exact="encephalitis" post="pathogen all over the world. Its genotype is divided"/>
   <result pre="etiology, pathogenic mechanism and prevention and control of epidemic Japanese" exact="encephalitis" post="in ningxia region, key research project of ningxia science"/>
   <result pre="etiology, pathogenic mechanism and prevention and control of epidemic Japanese" exact="encephalitis" post="in ningxia region, key research project of ningxia science"/>
   <result pre="from the National Notifiable Disease Reporting System (NNDRS). Introduction Japanese" exact="encephalitis" post="(JE) is a mosquito-borne arbovirus disease caused by Japanese"/>
   <result pre="encephalitis (JE) is a mosquito-borne arbovirus disease caused by Japanese" exact="encephalitis" post="virus (JEV). JEV can circulate in several hosts: Aquatic"/>
   <result pre="bites, particularly Culex tritaeniorhynchus, and clinical manifestations of fever and" exact="encephalitis" post="may result [1]. Bioinformatics analyses have shown that JEV"/>
   <result pre="cases is part of continuing public health surveillance of an" exact="infectious disease" post="and thus was exempt from review by an institutional"/>
   <result pre="and JEV are both mosquito-borne virus that can cause viral" exact="encephalitis" post="(West Nile viral encephalitis is more likely to occur"/>
   <result pre="mosquito-borne virus that can cause viral encephalitis (West Nile viral" exact="encephalitis" post="is more likely to occur in adults) [16], and"/>
   <result pre="tests of serum and cerebrospinal specimens of suspected clinical Japanese" exact="encephalitis" post="cases, Ningxia, China, 2018. IgM qRT-PCR Sample JEV WNV"/>
   <result pre="please see: http://www.textcheck.com/certificate/CJO6R8 Supporting information S1 Table Strains of Japanese" exact="encephalitis" post="virus used in this study. (DOCX) LINK Click here"/>
   <result pre="Philadelphia P. M: Lippincott Williams &amp;amp; Wilkins. 2HalsteadSB, JacobsonJ. Japanese" exact="encephalitis" post="vaccinesVaccine, 5th ed In: PlotkinSA, OrensteinWA, OffitPA, editors. Philadelphia:"/>
   <result pre="NiH, BeasleyDW, EkkelenkampM, CardosaMJ, BarrettAD. Origin and evolution of Japanese" exact="encephalitis" post="virus in southeast Asia. J Virol. 2003;77(5):3091–8.12584335 4GaoX, LiuH,"/>
   <result pre="LiX, FuS, CaoL, ShaoN, et al.Changing geographic distribution of Japanese" exact="encephalitis" post="virus genotypes, 1935–2017. Vector Borne Zoonotic Dis. 2019;19(1):35–44.30207876 5HillsSL,"/>
   <result pre="FuS, GuoZ, LiangG. Southernmost Asia is the source of Japanese" exact="encephalitis" post="virus (genotype 1) diversity from which the viruses disperse"/>
   <result pre="FuSH, LiuHZ, ZhangHL, et al.Emergence of genotype I of Japanese" exact="encephalitis" post="virus as the dominant genotype in Asia. J Virol."/>
   <result pre="J Virol. 2011;85(19):9847–53.21697481 10SchuhAJ, WardMJ, BrownAJ, BarrettAD. Phylogeography of Japanese" exact="encephalitis" post="virus: Genotype is associated with climate. PLoS Negl Trop"/>
   <result pre="DengZ, et al.Identification and isolation of genotype-I Japaneseencephalitis virus from" exact="encephalitis" post="patients. Virology Journal. 2010;7(1):1–4.20044930 12ZhengY, LiM, WangH, LiangG. Japanese"/>
   <result pre="encephalitis patients. Virology Journal. 2010;7(1):1–4.20044930 12ZhengY, LiM, WangH, LiangG. Japanese" exact="encephalitis" post="and Japanese encephalitis virus in mainland China. Reviews in"/>
   <result pre="Journal. 2010;7(1):1–4.20044930 12ZhengY, LiM, WangH, LiangG. Japanese encephalitis and Japanese" exact="encephalitis" post="virus in mainland China. Reviews in Medical Virology. 2012;22(5):301–22.22407526"/>
   <result pre="Virology. 2012;22(5):301–22.22407526 13Li-HuaW, Shi-HongF, Huan-YuW, Xiao-FengL, Jing-XiaC, Hong-MeiJ, et al.Japanese" exact="encephalitis" post="outbreak, Yuncheng, China, 2006. Emerging Infectious Diseases.2007;13(7):1123–25.18214202 14FuS, SongS,"/>
   <result pre="LiX, et al.Detection of West Nile Virus infection in viral" exact="encephalitis" post="cases, China. Vector Borne Zoonotic Dis. 2019;19(1):45–50.29985780 17CaoL, FuS,"/>
   <result pre="CuiS, LiX, et al.Low protective efficacy of the current Japanese" exact="encephalitis" post="vaccine against the emerging genotype 5 Japanese encephalitis virus."/>
   <result pre="current Japanese encephalitis vaccine against the emerging genotype 5 Japanese" exact="encephalitis" post="virus. Plos Negl Trop Dis. 2016;10(5):e0004686.27139722 18NanS, FanLI, KaiN,"/>
   <result pre="et al.TaqMan real-time RT-PCR assay for detecting and differentiating Japanese" exact="encephalitis" post="virus. Biomedical and environmental science. 2018;31(3):208–14. 19ShiLJ, Mao-MinLV, SunWH,"/>
   <result pre="as a potential risk factor for the prevalence of Japanese" exact="encephalitis" post="virus in adult in Shanxi, China. Infectious Diseases of"/>
   <result pre="GaoX, WangH, SongM, LiM, et al.The spatio-temporal distribution of Japanese" exact="encephalitis" post="cases in different age groups in mainland China, 2004–2014."/>
   <result pre="GaoX, FuS, WangH, LuZ, HeY, et al.An Outbreak of Japanese" exact="encephalitis" post="in Adults in northern China, 2013: A population-based study."/>
   <result pre="WHO[Internet]. https://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis 24Diagnostic criteria and principles of management of Japanese" exact="encephalitis" post="(WS 214–2008) of People’s Republic of China. 25NaH, JamesA,"/>
   <result pre="WeiF, et al.Comparison of genotypes I and III in Japanese" exact="encephalitis" post="virus reveals distinct differences in their genetic and host"/>
   <result pre="Journal of Virology. 2014;88(19):11469–79.25056890 26Flohic G, Gonzalez J. When Japanese" exact="encephalitis" post="virus invaded Eastern hemisphere-the history of the spread of"/>
   <result pre="RameyAM, LeeJH, KyungSG, et al.Molecular detection and genotyping of Japanese" exact="encephalitis" post="virus in mosquitoes during a 2010 outbreak in the"/>
   <result pre="MukhopadhyaySK, ChakrabartiS, ChatterjeeS. Molecular evidence for the occurrence of Japanese" exact="encephalitis" post="virus genotype I and III infection associated with acute"/>
   <result pre="encephalitis virus genotype I and III infection associated with acute" exact="encephalitis" post="in patients of West Bengal, India, 2010. Virology Journal."/>
   <result pre="ParkSL, HiggsS, BarrettAD, HsuWW, et al.Differential infectivities among different Japanese" exact="encephalitis" post="virus genotypes in Culex quinquefasciatus Mosquitoes. Plos Negl Trop"/>
   <result pre="WahaabA, SafdarA, DiD, et al.The emerged genotype I of Japanese" exact="encephalitis" post="virus shows an infectivity similar to genotype III in"/>
   <result pre="Pest Control,102015, 31(10).Chinese 34SongQ, WangY, LiJ, LiZ,WangX,LiL,Epidemiological investigation of Japanese" exact="encephalitis" post="in some pig farms in Ningxia,Gansu Animal Husbandry and"/>
   <result pre="LiX,PengC, YangT, FuY, et al., Epidemiological analysis of epidemic Japanese" exact="encephalitis" post="in Ningxia 1958–2006, Journal of Ningxia Medical College,2008,30(2): 201–202."/>
   <result pre="et al.Vaccine strategies for the control and prevention of Japanese" exact="encephalitis" post="in Mainland China, 1951–2011. PLoS Negl Trop Dis. 2014;8(8):e3015.25121596"/>
   <result pre="39LiMH, FuSH, ChenWX, WangHY, GuoYH, LiuQY, et al.Genotype V Japanese" exact="encephalitis" post="virus is emerging. PLoS Neglected Tropical Diseases.2011, 5: e1231.21750744"/>
   <result pre="5: e1231.21750744 40TakhampunyaR, KimHC, TippayachaiB, KengluechaA, et al.Emergence of Japanese" exact="encephalitis" post="virus genotype V in the Republic of Korea; Virol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7275077\results\search\disease\results.xml">
   <result pre="but challenging due to cross-reactivity with other alphaviruses such as" exact="chikungunya" post="virus (CHIKV). Here, we develop an analytical framework to"/>
   <result pre="sanitaire en région Antilles-Guyane. Point Epidémiologique de janvier 2015: Le" exact="chikungunya" post="dans les Antilles 1–6, (in French, 2015). 14.Cellule de"/>
   <result pre="sanitaire en région Antilles-Guyane. Point Epidémiologique de juillet 2014: Le" exact="chikungunya" post="dans les Antilles 1–7, (in French, 2014). 15.FritzellCet al.Knowledge,"/>
   <result pre="space, and behaviors shape the spread of infectious diseases using" exact="chikungunya" post="as a case studyProc. Natl Acad. Sci USA2016113134201342510.1073/pnas.161139111327821727 22.EpelboinYet"/>
   <result pre="Inst. Oswaldo Cruz2018113e17039810.1590/0074-0276017039829538490 23.FritzellCet al.Current challenges and implications for dengue," exact="chikungunya" post="and Zika seroprevalence studies worldwide: a scoping reviewPLoS Negl."/>
   <result pre="Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 25.CauchemezSet al.Household transmission of 2009 pandemic" exact="influenza" post="A (H1N1) virus in the United StatesN. Engl. J."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7277729\results\search\disease\results.xml">
   <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Background: Chikungunya fever is caused by the" exact="chikungunya" post="virus. Numerous factors affect the risk of chikungunya transmission."/>
   <result pre="by the chikungunya virus. Numerous factors affect the risk of" exact="chikungunya" post="transmission. This study explored the epidemiological characteristics, differences, and"/>
   <result pre="characteristics, differences, and trends in domestic and imported cases of" exact="chikungunya" post="fever in Taiwan in terms of patient sex, age,"/>
   <result pre="area of residence from 2007 to 2019. Methods: Public annual" exact="chikungunya" post="data from Taiwan’s Centers for Disease Control (CDC) were"/>
   <result pre="In total, 21 confirmed domestic and 198 imported cases of" exact="chikungunya" post="were reported. Of the domestic cases, one was sporadic"/>
   <result pre="is the first report comparing domestic and imported cases of" exact="chikungunya" post="from surveillance data from the Taiwan CDC from 2007"/>
   <result pre="identified to inform future surveillance and research efforts in Taiwan." exact="chikungunya" post="surveillance domestic imported epidemiology 1. Introduction Frequent international interactions"/>
   <result pre="worldwide—particularly vector-borne diseases—and their increased frequency. Chikungunya is an acute" exact="infectious disease" post="transmitted by vector mosquitoes [1]. After infectious patients with"/>
   <result pre="disease transmitted by vector mosquitoes [1]. After infectious patients with" exact="chikungunya" post="virus enter the community, vector mosquitoes in residential areas"/>
   <result pre="the community, vector mosquitoes in residential areas can cause a" exact="chikungunya" post="epidemic [2]. The chikungunya virus is a positive-sense single-stranded"/>
   <result pre="in residential areas can cause a chikungunya epidemic [2]. The" exact="chikungunya" post="virus is a positive-sense single-stranded RNA virus classified into"/>
   <result pre="the Pan American Health Organization [13,14], 693,489 suspected cases of" exact="chikungunya" post="were reported in the Americas in 2015, of which"/>
   <result pre="which occurred in Brazil; this indicated a high risk of" exact="chikungunya" post="spread in the Americas. Since the March 2019 outbreak,"/>
   <result pre="[15]. Individuals are infected by bites from mosquitoes carrying the" exact="chikungunya" post="virus. The clinical symptoms of chikungunya are fever, joint"/>
   <result pre="from mosquitoes carrying the chikungunya virus. The clinical symptoms of" exact="chikungunya" post="are fever, joint pain or arthritis, headache, nausea, fatigue,"/>
   <result pre="and muscle pain, and approximately half of patients develop a" exact="rash" post="that lasts approximately 3–7 days [16]. Most patients recover"/>
   <result pre="65 years, and those with high blood pressure, diabetes, or" exact="cardiovascular disease" post="[17]. Because Taiwan is an island, most infectious diseases"/>
   <result pre="Taiwan via traffic vehicles entering its seaports and airports. Since" exact="chikungunya" post="was declared a category-2 infectious disease in the Communicable"/>
   <result pre="its seaports and airports. Since chikungunya was declared a category-2" exact="infectious disease" post="in the Communicable Disease Control Act in October 2007"/>
   <result pre="Control Act in October 2007 and the beginning of the" exact="chikungunya" post="network surveillance report in December 2007, Taiwan has had"/>
   <result pre="authors’ knowledge, no research has provided longitudinal epidemiological data on" exact="chikungunya" post="in Taiwan. Therefore, the present study employed data from"/>
   <result pre="characteristics, differences, and trends among imported and domestic cases of" exact="chikungunya" post="in Taiwan between 2007 and 2019. 2. Materials and"/>
   <result pre="public, academics, and the press to access current information on" exact="chikungunya" post="in Taiwan at any time. Chikungunya was categorized as"/>
   <result pre="following data from the TNIDSS: date when confirmed cases of" exact="chikungunya" post="were reported to the health department, date of symptom"/>
   <result pre="2.4. Definition of Confirmed Cases (Included Laboratory Examination) In Taiwan," exact="chikungunya" post="is a notifiable communicable disease, which is a disease"/>
   <result pre="the competent health authority within 24 h. Suspected patients with" exact="chikungunya" post="exhibit associated clinical conditions (i.e., acute fever ≥38 °C"/>
   <result pre="associated clinical conditions (i.e., acute fever ≥38 °C and severe" exact="arthritis" post="or arthralgia that cannot be explained by a medical"/>
   <result pre="two epidemiological conditions (i.e., the appearance of confirmed cases of" exact="chikungunya" post="in an area near patients’ residences or areas they"/>
   <result pre="following conditions: (1) the separated clinical specimen (blood) contains the" exact="chikungunya" post="virus, indicated by nucleic acid testing yielding a positive"/>
   <result pre="of two specific antibodies (i.e., IgM or IgG) for the" exact="chikungunya" post="virus; and (3) the paired serum (serum in the"/>
   <result pre="patients. According to the Taiwan CDC, a confirmed case of" exact="chikungunya" post="must meet one of the above criteria. 2.5. Data"/>
   <result pre="retrospective historical study on all imported and domestic cases of" exact="chikungunya" post="since 2007. On the basis of the TNIDSS, the"/>
   <result pre="TNIDSS, the numbers of imported and domestic confirmed cases of" exact="chikungunya" post="from January 2007 to October 2019 were determined, and"/>
   <result pre="3 illustrates the regional distribution of domestic confirmed cases of" exact="chikungunya" post="in Taiwan from 2007 to 2019. A total of"/>
   <result pre="1). In the comparison between domestic and imported cases of" exact="chikungunya" post="between July and October 2019, differences in sex were"/>
   <result pre="change and the increased travel between continents, tropical diseases including" exact="chikungunya" post="are more likely to spread in Taiwan. Humans face"/>
   <result pre="publicly available annual summary data of reported imported and domestic" exact="chikungunya" post="cases from 2007 to 2019 published by the Taiwan"/>
   <result pre="2007 to 2019 published by the Taiwan CDC. All 112" exact="chikungunya" post="cases reported during and before 2018 were imported. The"/>
   <result pre="her activities in Tu-Cheng District. This suggests that undetected imported" exact="chikungunya" post="cases were in the area. A few days after"/>
   <result pre="When the patient reported to the hospital, the doctor suspected" exact="dengue fever" post="or measles; although testing excluded a suspected infection, chikungunya"/>
   <result pre="dengue fever or measles; although testing excluded a suspected infection," exact="chikungunya" post="was confirmed in a routine test. Currently, the patient’s"/>
   <result pre="any symptoms of chikungunya. Since July 2019, domestic cases of" exact="chikungunya" post="have been observed in Taiwan, including one single case"/>
   <result pre="the Maldives on 22 October, 2019 [20]. Hot zones for" exact="chikungunya" post="are mainly distributed in tropical and subtropical areas of"/>
   <result pre="control. This study compared the domestic and imported cases of" exact="chikungunya" post="from July 2019 to October 2019 and revealed a"/>
   <result pre="confirmation and place of residence may be risk factors for" exact="chikungunya" post="in the Taiwanese population. Research outside Taiwan has demonstrated"/>
   <result pre="since 1947. Therefore, the first cluster of confirmed cases of" exact="chikungunya" post="in the fall of 2019 was probably caused by"/>
   <result pre="(Aedes aegypti and Aedes albopictus) that bite natural hosts. The" exact="chikungunya" post="virus is maintained in nature in both urban and"/>
   <result pre="population, including people living in urban areas [28]. Additionally, the" exact="chikungunya" post="virus is an RNA virus with a high mutation"/>
   <result pre="in mountains. It was unknown whether any study has described" exact="chikungunya" post="infection in primates in Taiwan. Such a geographical area"/>
   <result pre="arthropod vectors. In particular, international studies have reported that the" exact="chikungunya" post="[9] and dengue viruses [30], which are spread by"/>
   <result pre="health. According to a Taiwan CDC report [31], the 20" exact="chikungunya" post="cluster cases in Taiwan overlapped considerably with imported cases"/>
   <result pre="that the genotype of the virus strain that infected the" exact="chikungunya" post="cluster cases in 2019 originated in Myanmar. A study"/>
   <result pre="in Myanmar. A study also indicated that two genotypes of" exact="chikungunya" post="virus strains were imported to Taiwan between 2006 and"/>
   <result pre="ECSA genotype was the most commonly imported genotype of the" exact="chikungunya" post="virus before 2010; strains with this genotype originated mainly"/>
   <result pre="breeding of vector mosquitoes to effectively prevent the spread of" exact="chikungunya" post="and protect the public from this health crisis. Because"/>
   <result pre="those areas is difficult. Compared with the dengue virus, the" exact="chikungunya" post="virus requires less time to replicate in the body;"/>
   <result pre="transmission speed than the dengue virus does. Vector mosquitoes of" exact="chikungunya" post="are not selective regarding bite targets, implying that, after"/>
   <result pre="are not selective regarding bite targets, implying that, after the" exact="chikungunya" post="virus enters a community that contains breeding sites for"/>
   <result pre="enters a community that contains breeding sites for vector mosquitoes," exact="chikungunya" post="spread is possible. Therefore, people should ensure that breeding"/>
   <result pre="enacted to prevent mosquito bites among people in areas with" exact="chikungunya" post="spread. These people may reside in buildings with installed"/>
   <result pre="spread. In addition to the aforementioned preventive measures to control" exact="infectious disease," post="vaccine development is an epidemic prevention strategy to induce"/>
   <result pre="immunity to external pathogens and achieve community immunity. Although the" exact="chikungunya" post="virus is not associated with a high mortality rate,"/>
   <result pre="experts to rapidly develop a vaccine. Vaccine development for the" exact="chikungunya" post="virus began in 1960, when large-scale spread occurred in"/>
   <result pre="safety of a live attenuated measles-vectored vaccine that expresses the" exact="chikungunya" post="virus structural protein in a double-blind, randomized, placebo-controlled, and"/>
   <result pre="the US CDC argued that &quot;the report of a successful" exact="chikungunya" post="virus vaccine phase 2 clinical trial that might lead"/>
   <result pre="infection by this highly debilitating arbovirus�? [36]. Therefore, an effective" exact="chikungunya" post="vaccine should be developed to prevent vector-borne diseases and"/>
   <result pre="has spread widely and caused cluster infections in Taiwan is" exact="dengue fever," post="which has particularly affected Southern Taiwan. Both dengue fever"/>
   <result pre="is dengue fever, which has particularly affected Southern Taiwan. Both" exact="dengue fever" post="and chikungunya are transmitted by the same types of"/>
   <result pre="which has particularly affected Southern Taiwan. Both dengue fever and" exact="chikungunya" post="are transmitted by the same types of vector mosquitoes."/>
   <result pre="of cases may appear in the north [38]. Chikungunya and" exact="dengue fever" post="have similar incubation periods (from 1–2 days before symptom"/>
   <result pre="1–2 weeks. For patients who have traveled to areas with" exact="chikungunya" post="spread and have suspected dengue fever but have tested"/>
   <result pre="have traveled to areas with chikungunya spread and have suspected" exact="dengue fever" post="but have tested negative to the dengue NS1 test,"/>
   <result pre="doctor should report them as having a suspected case of" exact="chikungunya" post="to more effectively identify people with chikungunya before symptom"/>
   <result pre="suspected case of chikungunya to more effectively identify people with" exact="chikungunya" post="before symptom onset. Moreover, Southern Taiwan has experienced a"/>
   <result pre="onset. Moreover, Southern Taiwan has experienced a domestic spread of" exact="dengue fever" post="over the last 5 years. According to dengue virus"/>
   <result pre="once every 4 years, and mixed viruses, which result in" exact="dengue hemorrhagic fever," post="can easily occur [40]. This has contributed to a"/>
   <result pre="threatened public health. Because domestic sporadic and cluster cases for" exact="chikungunya" post="have been observed in Northern Taiwan and chikungunya is"/>
   <result pre="cases for chikungunya have been observed in Northern Taiwan and" exact="chikungunya" post="is spread by the same vector mosquitoes as those"/>
   <result pre="spread by the same vector mosquitoes as those that spread" exact="dengue fever," post="epidemic-control specialists of health departments and public-health experts have"/>
   <result pre="concerns. Convenient and frequent north–south travel in Taiwan might influence" exact="chikungunya" post="and dengue infections and pose challenges for epidemic control."/>
   <result pre="new control measures in response to concurrent domestic infections of" exact="dengue fever" post="and chikungunya as early as possible to prevent and"/>
   <result pre="in response to concurrent domestic infections of dengue fever and" exact="chikungunya" post="as early as possible to prevent and control the"/>
   <result pre="disease statistics) includes only basic epidemiological data of patients with" exact="chikungunya" post="and provides no clinical data. Therefore, this study could"/>
   <result pre="contain no information about the genotypes or strains of the" exact="chikungunya" post="virus. Accordingly, this study could not analyze (1) the"/>
   <result pre="Accordingly, this study could not analyze (1) the type of" exact="chikungunya" post="virus strain that spread to Taiwan or (2) the"/>
   <result pre="epidemiological characteristics and trends of imported and domestic cases of" exact="chikungunya" post="from 2007 to 2019. On the basis of data"/>
   <result pre="cases of cluster infection occurred. Moreover, domestic cluster infections of" exact="chikungunya" post="in Taiwan exhibited significant differences in age (patients aged"/>
   <result pre="clinical experts in directing prevention and control measures regarding the" exact="chikungunya" post="virus, which causes illness among the Taiwanese population. This"/>
   <result pre="infection: A re-emerging epidemicRheumatol. Ther.2018531732610.1007/s40744-018-0121-730047016 4.RahmanM.YamagishiJ.RahimR.HasanA.SobhanA.East/central/south african genotype in a" exact="chikungunya" post="outbreak, Dhaka, Bangladesh, 2017Emerg. Infect. Dis.20192537010.3201/eid2502.18018830666947 5.SamI.-C.KümmererB.M.ChanY.-F.RoquesP.DrostenC.AbuBakarS.Updates on chikungunya"/>
   <result pre="a chikungunya outbreak, Dhaka, Bangladesh, 2017Emerg. Infect. Dis.20192537010.3201/eid2502.18018830666947 5.SamI.-C.KümmererB.M.ChanY.-F.RoquesP.DrostenC.AbuBakarS.Updates on" exact="chikungunya" post="epidemiology, clinical disease, and diagnosticsVector-Borne Zoonotic Dis.20151522323010.1089/vbz.2014.168025897809 6.AghaS.B.ChepkorirE.MulwaF.TigoiC.ArumS.GuaridoM.M.AmbalaP.ChelangatB.LutomiahJ.TchouassiD.P.Vector competence"/>
   <result pre="of Aedes aegypti from three distinct cities in Kenya for" exact="chikungunya" post="virusPLoS Negl. Trop. Dis.201711e000586010.1371/journal.pntd.000586028820881 7.RobinsonM.C.An epidemic of virus disease"/>
   <result pre="States: US health authorities brace for wider spreadJAMA201431277677710.1001/jama.2014.991625120064 11.RezzaG.NicolettiL.AngeliniR.RomiR.FinarelliA.PanningM.CordioliP.FortunaC.BorosS.MaguranoF.Infection with" exact="chikungunya" post="virus in Italy: An outbreak in a temperate regionLancet20073701840184610.1016/S0140-6736(07)61779-618061059"/>
   <result pre="and prospective intervention strategiesJ. Clin. Investig.201712773774910.1172/JCI8441728248203 17.Van AalstM.NelenC.M.GoorhuisA.StijnisC.GrobuschM.P.Long-term sequelae of" exact="chikungunya" post="virus disease: A systematic reviewTravel Med. Infect. Dis.20171582210.1016/j.tmaid.2017.01.00428163198 18.Taiwan"/>
   <result pre="in Europe: A brief updatePathog. Glob. Health2019113495710.1080/20477724.2019.159812730916639 27.MatusaliG.ColavitaF.BordiL.LalleE.IppolitoG.CapobianchiM.R.CastillettiC.Tropism of the" exact="chikungunya" post="virusViruses20191117510.3390/v11020175 28.DevauxC.A.MediannikovO.MedkourH.RaoultD.Infectious disease risk across the growing human-non human"/>
   <result pre="for Disease ControlAvailable online: https://www.cdc.gov.tw/EpidemicTheme/List/RUqPpi3fECzMjWFhcl-u_Q(accessed on 23 March 2020) 32.YangC.-F.SuC.-L.HsuT.-C.ChangS.-F.LinC.-C.HuangJ.C.ShuP.-Y.Imported" exact="chikungunya" post="virus strains, taiwan, 2006–2014Emerg. Infect. Dis.201622198110.3201/eid2211.16040427767908 33.Guidelines for Dengue/Chikungunya"/>
   <result pre="23 March 2020) 35.ReisingerE.C.TschismarovR.BeublerE.WiedermannU.FirbasC.LoebermannM.PfeifferA.MuellnerM.TauberE.RamsauerK.Immunogenicity, safety, and tolerability of the measles-vectored" exact="chikungunya" post="virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled"/>
   <result pre="A double-blind, randomised, placebo-controlled and active-controlled phase 2 trialLancet20183922718272710.1016/S0140-6736(18)32488-730409443 36.PowersA.M.Licensed" exact="chikungunya" post="virus vaccine: A possibility?Lancet20193922660266110.1016/S0140-6736(18)32809-530409444 37.LinW.N.HungM.N.WangY.Z.YouC.Y.ChangC.C.Investigation of the First Dengue"/>
   <result pre="New Taipei City, 2017Taiwan Epidemiol. Bull.201834190194 39.Van AartC.BraksM.HautvastJ.de MastQ.TostmannA.Dengue and" exact="chikungunya" post="acquired during travel in the tropicsNed. Tijdschr. Geneeskd.2015159A803225784059 40.PangX.ZhangR.ChengG.Progress"/>
   <result pre="of dengue hemorrhagic feverVirol. Sin.201732162210.1007/s12250-016-3855-927853992 Figure 1 Yearly distribution of" exact="chikungunya" post="associated with domestic and imported patients during 2007 and"/>
   <result pre="patients during 2007 and 2019. Figure 2 Monthly distribution of" exact="chikungunya" post="associated with domestic and imported patients during 2019. Figure"/>
   <result pre="and imported patients during 2019. Figure 3 Regional distribution of" exact="chikungunya" post="associated with domestic confirmed cases, Taiwan, 2007–2019. ijerph-17-03615-t001_Table 1Table"/>
   <result pre="cases, Taiwan, 2007–2019. ijerph-17-03615-t001_Table 1Table 1 Epidemiological features by examining" exact="chikungunya" post="in domestic and imported cases. Parameters Domestic Cases Imported"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7278377\results\search\disease\results.xml">
   <result pre="because of their primary importance. These diseases include foot and" exact="mouth disease" post="(FMD), African swine fever (ASF), classical swine fever (CSF),"/>
   <result pre="African swine fever (ASF), classical swine fever (CSF), highly pathogenic" exact="avian influenza" post="(HPAI), and African horse sickness (AHS). Another 53 diseases"/>
   <result pre="swine fever (ASF), classical swine fever (CSF), highly pathogenic avian" exact="influenza" post="(HPAI), and African horse sickness (AHS). Another 53 diseases"/>
   <result pre="(sheep, goats, deer, etc.) have been listed including foot and" exact="mouth disease," post="sheep and goat pox, and pestes de petits ruminants."/>
   <result pre="serious risks of disease outbreaks such as bovine spongiform encephalopathy," exact="avian influenza," post="and blue tongue (BT) [1]. In response to these"/>
   <result pre="because of primary importance (the great viral epizooties: foot and" exact="mouth disease" post="(FMD), classical swine fever, African swine fever, African horse"/>
   <result pre="fever, African swine fever, African horse sickness, and highly pathogenic" exact="avian influenza" post="(HPAI)). Another 24 were derived from internal evaluations by"/>
   <result pre="African swine fever, African horse sickness, and highly pathogenic avian" exact="influenza" post="(HPAI)). Another 24 were derived from internal evaluations by"/>
   <result pre="and anthrax. Other recognized diseases of community interest such as" exact="epididymitis" post="of the ram, Q fever, and paratuberculosis have a"/>
   <result pre="diseases subject to national plans still under eradication such as" exact="tuberculosis" post="(TB) and brucellosis). Category C: These diseases are only"/>
   <result pre="third states (e.g., diseases of economic impact such as ovine" exact="epididymitis" post="and echinococcosis, which are limited to particular sectors). Category"/>
   <result pre="be classified in categories D–E in future Annex IV. Avian" exact="influenza" post="is a disease subject to surveillance and movement control"/>
   <result pre="range of target species. Disease Category Target Species Foot and" exact="mouth disease" post="A + D + E Artiodactyla, Proboscidea Infection with"/>
   <result pre="ssp., Bubalus ssp., Ovis ssp., Capra ssp. Infection with Mycobacterium" exact="tuberculosis" post="complex (M. bovis, M. caprae, M. tuberculosis) B +"/>
   <result pre="+ E Bison spp., Bos spp., Bubalus spp. Infection with" exact="rabies" post="virus B + D + E Carnivora, Bovidae, Suidae,"/>
   <result pre="Antilocapridae, Bovidae, Camelidae, Cervidae, Giraffidae, Moschidae, Tragulidae Infection with epizootic" exact="hemorrhagic disease" post="virus D + E Antilocapridae, Bovidae, Camelidae, Cervidae, Giraffidae,"/>
   <result pre="D + E Ovis ssp., Capra ssp., Gazella ssp. Ovine" exact="epididymitis" post="(Brucella ovis) D + E Ovis ssp., Capra ssp"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7278535\results\search\disease\results.xml">
   <result pre="long as the COVID-19 resource centre remains active. Abstract Acute" exact="viral hepatitis" post="refers to hepatic infection by the hepatotropic viruses hepatitis"/>
   <result pre="as the COVID-19 resource centre remains active. Abstract Acute viral" exact="hepatitis" post="refers to hepatic infection by the hepatotropic viruses hepatitis"/>
   <result pre="viral hepatitis refers to hepatic infection by the hepatotropic viruses" exact="hepatitis" post="A–E. The acute infections look similar with regard to"/>
   <result pre="similar in causing only acute hepatitis, while some cases of" exact="hepatitis" post="B and many of hepatitis C become chronic. The"/>
   <result pre="hepatitis, while some cases of hepatitis B and many of" exact="hepatitis" post="C become chronic. The prevalence of hepatitis D virus"/>
   <result pre="and many of hepatitis C become chronic. The prevalence of" exact="hepatitis" post="D virus (HDV) infection has seen a reduction worldwide"/>
   <result pre="virus (HDV) infection has seen a reduction worldwide due to" exact="hepatitis" post="B vaccination programs. Nonetheless, major cities with continued intravenous"/>
   <result pre="to eliminate new and chronic HCV infections by 2019. Histologic" exact="cholestasis" post="may be a particular feature of acute hepatitis E."/>
   <result pre="2019. Histologic cholestasis may be a particular feature of acute" exact="hepatitis" post="E. It should be noted that hepatitis E virus"/>
   <result pre="feature of acute hepatitis E. It should be noted that" exact="hepatitis" post="E virus has four major genotypes of which 1"/>
   <result pre="of which 1 and 2 infect humans (resulting in travel/endemic-related" exact="hepatitis" post="with cholestasis and high mortality in pregnant women) and"/>
   <result pre="1 and 2 infect humans (resulting in travel/endemic-related hepatitis with" exact="cholestasis" post="and high mortality in pregnant women) and 3 and"/>
   <result pre="and several other animal and avian species (and may cause" exact="hepatitis" post="associated with poorly or uncooked meat). Keywords Bridging necrosis"/>
   <result pre="Hepatitis D virus Hepatitis E virus Spotty necrosis Introduction Acute" exact="hepatitis" post="is not usually an indication for liver biopsy. There"/>
   <result pre="or even a mistaken working diagnosis. Second, a diagnosis of" exact="hepatitis" post="may be well established but the clinician needs information"/>
   <result pre="symptoms or biochemical abnormalities are due to recurrent (or new)" exact="viral hepatitis" post="or to some other cause such as rejection. For"/>
   <result pre="or biochemical abnormalities are due to recurrent (or new) viral" exact="hepatitis" post="or to some other cause such as rejection. For"/>
   <result pre="all these reasons, a knowledge of the pathology of acute" exact="hepatitis" post="is essential. There is a further reason, no less"/>
   <result pre="of acute hepatitis, the pathologist cannot hope to understand chronic" exact="hepatitis" post="and cirrhosis, together the cause of most liver disease"/>
   <result pre="understand chronic hepatitis and cirrhosis, together the cause of most" exact="liver disease" post="in the world. This chapter describes acute viral hepatitis"/>
   <result pre="most liver disease in the world. This chapter describes acute" exact="viral hepatitis" post="and its immediate sequelae in the immunocompetent patient. The"/>
   <result pre="liver disease in the world. This chapter describes acute viral" exact="hepatitis" post="and its immediate sequelae in the immunocompetent patient. The"/>
   <result pre="sequelae in the immunocompetent patient. The specific problems of diagnosing" exact="hepatitis" post="in an immunosuppressed patient after transplantation are reviewed in"/>
   <result pre="immunosuppressed patient after transplantation are reviewed in Chapter 16. The" exact="hepatitis" post="viruses are listed in Table 6.1 . While several"/>
   <result pre="has so far been established as a definite cause of" exact="viral hepatitis," post="and most episodes of acute and chronic hepatitis can"/>
   <result pre="of viral hepatitis, and most episodes of acute and chronic" exact="hepatitis" post="can be attributed to one of the viruses listed,"/>
   <result pre="can be attributed to one of the viruses listed, to" exact="autoimmune hepatitis" post="(Ch. 9) or to a hepatotoxic agent (Ch. 8)."/>
   <result pre="be attributed to one of the viruses listed, to autoimmune" exact="hepatitis" post="(Ch. 9) or to a hepatotoxic agent (Ch. 8)."/>
   <result pre="These agents are further discussed in Chapter 15. Mild acute" exact="hepatitis" post="has been reported in patients infected with the SARS"/>
   <result pre="SARS virus (severe acute respiratory syndrome-associated coronavirus).10., 11.Table 6.1 The" exact="hepatitis" post="viruses Virus Type Spread and disease Hepatitis A (HAV)"/>
   <result pre="disease Occasionally, mild serum liver test abnormalities and mild histological" exact="hepatitis" post="(bystander hepatitis) with apoptotic bodies, focal necrosis and lymphocytic"/>
   <result pre="are seen in systemic, non-hepatic viral infections such as pulmonary" exact="influenza" post="and result from migration to the liver of, and"/>
   <result pre="Pathological features The essential components of the acute phase of" exact="hepatitis" post="are inflammatory-cell infiltration and hepatocellular damage. Other features include"/>
   <result pre="A periportal pattern of necrosis and inflammation, sometimes seen in" exact="hepatitis" post="A, is less common. Fig. 6.1 Acute viral hepatitis."/>
   <result pre="seen in hepatitis A, is less common. Fig. 6.1 Acute" exact="viral hepatitis." post="Surviving hepatocytes in the perivenular area in the centre"/>
   <result pre="of the section. Another form of hepatocellular damage in acute" exact="hepatitis" post="is focal (spotty) necrosis, in which liver-cell plates are"/>
   <result pre="characteristic irregularity of the liver-cell plates, which usually allows acute" exact="hepatitis" post="to be distinguished from hepatocellular damage secondary to cholestasis."/>
   <result pre="seen in reticulin preparations (Fig. 6.4 ). Fig. 6.2 Acute" exact="viral hepatitis." post="Normal liver-cell plate structure is disrupted. Hepatocytes vary in"/>
   <result pre="(Councilman) bodies present (arrows) are characteristic of liver involvement in" exact="yellow fever." post="Fig. 6.4 Acute viral hepatitis. The reticulin framework is"/>
   <result pre="characteristic of liver involvement in yellow fever. Fig. 6.4 Acute" exact="viral hepatitis." post="The reticulin framework is condensed near the efferent venules"/>
   <result pre="When syncytial giant hepatocytes are very prominent, the term giant-cell" exact="hepatitis" post="is appropriate.17., 18. This is only rarely of proven"/>
   <result pre="proven viral origin and is also more characteristic of acute" exact="hepatitis" post="in neonates. In adults, autoimmune hepatitis and hepatitis C"/>
   <result pre="also more characteristic of acute hepatitis in neonates. In adults," exact="autoimmune hepatitis" post="and hepatitis C virus with or without human immunodeficiency"/>
   <result pre="more characteristic of acute hepatitis in neonates. In adults, autoimmune" exact="hepatitis" post="and hepatitis C virus with or without human immunodeficiency"/>
   <result pre="of acute hepatitis in neonates. In adults, autoimmune hepatitis and" exact="hepatitis" post="C virus with or without human immunodeficiency virus co-infection"/>
   <result pre="form of bile thrombi in canaliculi is common in acute" exact="hepatitis" post="but rare in chronic hepatitis, which is diagnostically helpful."/>
   <result pre="at the level of the portal tracts.24 The term cholestatic" exact="hepatitis" post="is best kept as a clinical description of patients"/>
   <result pre="description of patients with a prolonged cholestatic course. Mild hepatocellular" exact="siderosis" post="or steatosis is occasionally seen. The inflammatory infiltrate Unlike"/>
   <result pre="is occasionally seen. The inflammatory infiltrate Unlike classic acute inflammation," exact="viral hepatitis" post="is characterised by a mainly lymphocytic infiltrate within the"/>
   <result pre="occasionally seen. The inflammatory infiltrate Unlike classic acute inflammation, viral" exact="hepatitis" post="is characterised by a mainly lymphocytic infiltrate within the"/>
   <result pre="extension of the infiltrate. This so-called spillover resembles the interface" exact="hepatitis" post="of chronic hepatitis (Ch. 9) and may be difficult"/>
   <result pre="infiltrate. This so-called spillover resembles the interface hepatitis of chronic" exact="hepatitis" post="(Ch. 9) and may be difficult to distinguish from"/>
   <result pre="diagnosis clear. While most of the infiltrating cells in acute" exact="hepatitis" post="are small T lymphocytes,25 plasma cells may also be"/>
   <result pre="neutrophils and eosinophils. The plasma cells do not necessarily indicate" exact="autoimmune hepatitis," post="nor do a few eosinophils prove a diagnosis of"/>
   <result pre="6.6 ), but this is less common. Fig. 6.5 Acute" exact="viral hepatitis." post="Macrophages contain diastase periodic acid–Schiff (PAS)-positive material. Fig. 6.6"/>
   <result pre="Macrophages contain diastase periodic acid–Schiff (PAS)-positive material. Fig. 6.6 Acute" exact="viral hepatitis." post="Enlarged macrophages are strongly iron positive. Some endothelial cells"/>
   <result pre="lymphoid structures (aggregates and follicles), are most often seen in" exact="hepatitis" post="C. Bile-duct loss (ductopenia) is very rare. Fig. 6.7"/>
   <result pre="C. Bile-duct loss (ductopenia) is very rare. Fig. 6.7 Acute" exact="viral hepatitis." post="A portal tract is infiltrated by inflammatory cells, mainly"/>
   <result pre="a short way into the adjacent parenchyma. Fig. 6.8 Acute" exact="viral hepatitis." post="Bile-duct epithelium is irregular and infiltrated by lymphocytes. The"/>
   <result pre="atrophy and dilatation. Histological variants The histological changes in acute" exact="hepatitis" post="are infinitely variable, but a few patterns deserve special"/>
   <result pre="more likely to be due to causes other than acute" exact="viral hepatitis;" post="possibilities to be considered include opportunistic infections with herpes"/>
   <result pre="viral hepatitis; possibilities to be considered include opportunistic infections with" exact="herpes simplex" post="or zoster viruses and lymphoma. Bridging necrosis (Fig. 6.10,"/>
   <result pre="subsequent collapse may be mistaken for the septa of chronic" exact="liver disease." post="In making the important distinction between them, the pathologist"/>
   <result pre="Inset: This contrasts with an elastic fibre-rich septum in chronic" exact="liver disease." post="In a minority of patients with acute viral hepatitis,"/>
   <result pre="chronic liver disease. In a minority of patients with acute" exact="viral hepatitis," post="confluent necrosis extends throughout entire lobules or acini (panlobular"/>
   <result pre="‘Late-onset hepatic failure’ is a term used for patients developing" exact="encephalopathy" post="between 8 and 24 weeks after onset of symptoms.34"/>
   <result pre="usual perivenular necrosis is a feature in some patients with" exact="hepatitis" post="A (discussed later). Individual causes of viral hepatitis There"/>
   <result pre="some patients with hepatitis A (discussed later). Individual causes of" exact="viral hepatitis" post="There are more similarities than differences between hepatitis types"/>
   <result pre="patients with hepatitis A (discussed later). Individual causes of viral" exact="hepatitis" post="There are more similarities than differences between hepatitis types"/>
   <result pre="of viral hepatitis There are more similarities than differences between" exact="hepatitis" post="types A, B, C, D and E, but certain"/>
   <result pre="not allow the pathologist to identify the cause of the" exact="hepatitis" post="on histological appearance alone. The picture may be confused"/>
   <result pre="more than one virus, or by additional damage resulting from" exact="alcohol abuse." post="Hepatitis A Two main patterns are described, occurring separately"/>
   <result pre="together.35., 36., 37. One is a histological picture of perivenular" exact="cholestasis" post="with little liver-cell damage or inflammation, easily mistaken for"/>
   <result pre="liver-cell damage or inflammation, easily mistaken for other causes of" exact="cholestasis" post="(Fig. 6.13 ). The second is a hepatitis with"/>
   <result pre="causes of cholestasis (Fig. 6.13 ). The second is a" exact="hepatitis" post="with periportal necrosis and a dense portal infiltrate which"/>
   <result pre="(Fig. 6.14 ). These two patterns may be related, the" exact="cholestasis" post="resulting from interruption of bile flow by the periportal"/>
   <result pre="of bile flow by the periportal necrosis.23 Other patterns of" exact="hepatitis" post="as described earlier are also found, but fulminant hepatitis"/>
   <result pre="of hepatitis as described earlier are also found, but fulminant" exact="hepatitis" post="with multilobular necrosis is rare. Extensive microvesicular change of"/>
   <result pre="is rare. Extensive microvesicular change of hepatocytes, previously described in" exact="hepatitis" post="D infection, has been seen also in severe acute"/>
   <result pre="hepatitis D infection, has been seen also in severe acute" exact="hepatitis" post="A (Fig. 6.15 ). Fibrin-ring granulomas have been reported.38.,"/>
   <result pre="Hepatitis A. Perivenular area showing irregularity of liver-cell plates and" exact="cholestasis" post="but only mild inflammatory infiltration. Fig. 6.14 Hepatitis A."/>
   <result pre="limiting plate is irregular. The picture resembles that of chronic" exact="hepatitis" post="with interface hepatitis. Fig. 6.15 Hepatitis A. In this"/>
   <result pre="of fulminant hepatitis, hepatocytes are swollen and microvesicular. There is" exact="cholestasis" post="and a lymphocytic infiltrate. Hepatitis B The histological appearances"/>
   <result pre="appearances are broadly similar to those of other forms of" exact="viral hepatitis." post="Some of the differences reported in the literature may"/>
   <result pre="may well reflect patient selection rather than features specific for" exact="hepatitis" post="B virus (HBV) infection. However, lymphocytes and macrophages sometimes"/>
   <result pre="study, periportal inflammation tended to be more severe in acute" exact="hepatitis" post="B than in hepatitis C.41 Liver cells and their"/>
   <result pre="to be more severe in acute hepatitis B than in" exact="hepatitis" post="C.41 Liver cells and their nuclei may show a"/>
   <result pre="degree of pleomorphism. In most cases of acute hepatitis, the" exact="hepatitis" post="B core and surface antigens (HBcAg and HBsAg) are"/>
   <result pre="result of intravenous drug abuse.42 Following clinical recovery of acute" exact="hepatitis" post="B, occult infection and mild histological abnormalities including portal"/>
   <result pre="a decade.43 Reactivation of a previously occult or quiescent chronic" exact="hepatitis" post="B infection may cause changes closely resembling acute hepatitis."/>
   <result pre="of the process. Hepatitis C Usually the histological features of" exact="hepatitis" post="C are those of any acute hepatitis, but two"/>
   <result pre="severe liver-cell damage,44 giving rise to a picture reminiscent of" exact="infectious mononucleosis" post="(Fig. 6.16 ). Second, lymphoid follicles and bile-duct damage,"/>
   <result pre="There may be cholestasis. The common finding of steatosis in" exact="hepatitis" post="C is discussed in Chapter 9. Fulminant hepatitis C"/>
   <result pre="steatosis in hepatitis C is discussed in Chapter 9. Fulminant" exact="hepatitis" post="C is very rare in the Western world,3 but"/>
   <result pre="may be commoner in parts of Asia.46 Fig. 6.16 Acute" exact="hepatitis" post="C. In this example the main abnormality is infiltration"/>
   <result pre="lymphocytes. Hepatitis D (delta hepatitis) Co-infection or superinfection with the" exact="hepatitis" post="D virus (HDV) alters the course of type B"/>
   <result pre="and membrane-associated staining is also sometimes seen. Fig. 6.17 Delta" exact="hepatitis" post="(HDV). Some hepatocyte nuclei contain the delta antigen and"/>
   <result pre="stained red. There is a substantial lymphocytic infiltrate. Severe acute" exact="hepatitis" post="in a patient with markers of HBV infection may"/>
   <result pre="which genotype 3 is the most common, have caused acute" exact="hepatitis" post="in North America and Europe57., 60. but sometimes is"/>
   <result pre="sometimes is misdiagnosed as drug-induced liver injury.61a., 61b., 61c. Chronic" exact="hepatitis" post="E has been described in organ transplant recipients and"/>
   <result pre="features are similar to those seen in other types of" exact="viral hepatitis" post="or in autoimmune or drug-induced hepatitis.58a., 61a. The morphology"/>
   <result pre="are similar to those seen in other types of viral" exact="hepatitis" post="or in autoimmune or drug-induced hepatitis.58a., 61a. The morphology"/>
   <result pre="the acute infection (Fig. 6.18 ).58aEpidemic (genotype 1 or 2)" exact="hepatitis" post="E is well known for its potential for severe"/>
   <result pre="massive hepatic necrosis, but some cases have shown prolonged clinical" exact="cholestasis" post="with bile canalicular cholestasis and cholestatic rosettes on biopsy."/>
   <result pre="some cases have shown prolonged clinical cholestasis with bile canalicular" exact="cholestasis" post="and cholestatic rosettes on biopsy. The changes may resemble"/>
   <result pre="cholestatic rosettes on biopsy. The changes may resemble those of" exact="hepatitis" post="A, with prominent cholestasis and a predominantly portal and"/>
   <result pre="The changes may resemble those of hepatitis A, with prominent" exact="cholestasis" post="and a predominantly portal and periportal inflammatory infiltrate.68 In"/>
   <result pre="infiltrate.68 In one study, a pregnant woman with fatal epidemic" exact="hepatitis" post="E the liver showed little portal inflammation, much cholestasis"/>
   <result pre="epidemic hepatitis E the liver showed little portal inflammation, much" exact="cholestasis" post="with prominent portal vein and central vein endotheliitis and"/>
   <result pre="were identified in bile ductules by electron microscopy.69Cases of autochthonous" exact="hepatitis" post="E (usually genotype 3) have shown portal lymphoid aggregates"/>
   <result pre="immunocompromised subjects with organ transplants, immundeficiencies or corticosteroid therapy, chronic" exact="hepatitis" post="E manifests with the classical features of chronic hepatitis"/>
   <result pre="chronic hepatitis E manifests with the classical features of chronic" exact="hepatitis" post="(i.e., interface hepatitis with variable lobular necroinflammation), but portal"/>
   <result pre="manifests with the classical features of chronic hepatitis (i.e., interface" exact="hepatitis" post="with variable lobular necroinflammation), but portal tract neutrophilia with"/>
   <result pre="settings of HEV infection •Acute, epidemic (genotype 1 or 2)" exact="hepatitis" post="E •Acute autochthonous (genotype 3 or 4-7) hepatitis E"/>
   <result pre="or 2) hepatitis E •Acute autochthonous (genotype 3 or 4-7)" exact="hepatitis" post="E •Acute hepatitis E superimposed on pre-existing chronic liver"/>
   <result pre="E •Acute autochthonous (genotype 3 or 4-7) hepatitis E •Acute" exact="hepatitis" post="E superimposed on pre-existing chronic liver disease (acute-on-chronic liver"/>
   <result pre="4-7) hepatitis E •Acute hepatitis E superimposed on pre-existing chronic" exact="liver disease" post="(acute-on-chronic liver disease) •Acute or chronic hepatitis E in"/>
   <result pre="pre-existing chronic liver disease (acute-on-chronic liver disease) •Acute or chronic" exact="hepatitis" post="E in immunocompromised host (e.g., organ transplant recipients; chemotherapy"/>
   <result pre="host (e.g., organ transplant recipients; chemotherapy administration; HIV positivity) •Chronic" exact="hepatitis" post="E Fig. 6.18 Hepatitis E. Hepatocytes are vacuolated and"/>
   <result pre="licensed in China.73., 74., 75., 76. Differential diagnosis of acute" exact="viral hepatitis" post="The distinction of acute hepatitis from bile-duct obstruction rests"/>
   <result pre="in China.73., 74., 75., 76. Differential diagnosis of acute viral" exact="hepatitis" post="The distinction of acute hepatitis from bile-duct obstruction rests"/>
   <result pre="Differential diagnosis of acute viral hepatitis The distinction of acute" exact="hepatitis" post="from bile-duct obstruction rests mainly on the finding of"/>
   <result pre="The portal tract oedema of duct obstruction is absent. Drug-related" exact="hepatitis" post="may be indistinguishable from viral hepatitis and should always"/>
   <result pre="duct obstruction is absent. Drug-related hepatitis may be indistinguishable from" exact="viral hepatitis" post="and should always be suspected if the cause of"/>
   <result pre="obstruction is absent. Drug-related hepatitis may be indistinguishable from viral" exact="hepatitis" post="and should always be suspected if the cause of"/>
   <result pre="and should always be suspected if the cause of the" exact="hepatitis" post="is in doubt. Features more common in drug-induced than"/>
   <result pre="is in doubt. Features more common in drug-induced than in" exact="viral hepatitis" post="include sharply defined perivenular necrosis, granulomas, bile-duct damage, abundant"/>
   <result pre="in doubt. Features more common in drug-induced than in viral" exact="hepatitis" post="include sharply defined perivenular necrosis, granulomas, bile-duct damage, abundant"/>
   <result pre="portal inflammatory reaction. Cholestasis may overshadow the hepatitic features. Autoimmune" exact="hepatitis" post="may have a clinically acute onset, histologically indistinguishable from"/>
   <result pre="hepatitis may have a clinically acute onset, histologically indistinguishable from" exact="viral hepatitis" post="or alternatively with histological features of chronic disease. This"/>
   <result pre="may have a clinically acute onset, histologically indistinguishable from viral" exact="hepatitis" post="or alternatively with histological features of chronic disease. This"/>
   <result pre="fibrosis in affected areas. The differentiation of acute from chronic" exact="hepatitis" post="is briefly discussed under bridging necrosis in Chapter 4."/>
   <result pre="extensive lobular changes are found during an exacerbation of chronic" exact="hepatitis" post="or in reactivated chronic hepatitis B, as described earlier."/>
   <result pre="during an exacerbation of chronic hepatitis or in reactivated chronic" exact="hepatitis" post="B, as described earlier. Fate and morphological sequelae of"/>
   <result pre="B, as described earlier. Fate and morphological sequelae of acute" exact="viral hepatitis" post="Resolution As far as can be deduced from the"/>
   <result pre="as described earlier. Fate and morphological sequelae of acute viral" exact="hepatitis" post="Resolution As far as can be deduced from the"/>
   <result pre="can be deduced from the available evidence, most examples of" exact="hepatitis" post="A, B and E are followed by complete or"/>
   <result pre="to normal. A chronic course is probably more common when" exact="hepatitis" post="B is complicated by delta infection than otherwise, and"/>
   <result pre="B is complicated by delta infection than otherwise, and in" exact="hepatitis" post="C the risk of chronicity is high. Even in"/>
   <result pre="the risk of chronicity is high. Even in patients whose" exact="hepatitis" post="resolves, some residual changes may persist for many months"/>
   <result pre="are preserved. Scarring Localised collapse, scarring and regeneration following severe" exact="hepatitis" post="with bridging or panlobular necrosis sometimes produce a histological"/>
   <result pre="of surviving hepatocytes or progenitor cells may be seen. Chronic" exact="hepatitis" post="In regions where HBV vaccine programs have not been"/>
   <result pre="programs have not been instituted, many individuals will develop chronic" exact="hepatitis" post="B. The availability of direct-acting antiviral agents to treat"/>
   <result pre="B. The availability of direct-acting antiviral agents to treat acute" exact="hepatitis" post="C virus infections is likely to dramatically reduce the"/>
   <result pre="infections is likely to dramatically reduce the prevalence of chronic" exact="hepatitis" post="C in the future. Cirrhosis Cirrhosis resulting from infection"/>
   <result pre="in the future. Cirrhosis Cirrhosis resulting from infection with a" exact="hepatitis" post="virus almost always follows a period of chronic hepatitis,"/>
   <result pre="may follow directly after a single episode of severe acute" exact="hepatitis" post="where it is termed ‘postnecrotic cirrhosis’. Hepatocellular carcinoma This"/>
   <result pre="cirrhosis’. Hepatocellular carcinoma This may develop on the basis of" exact="cirrhosis" post="in patients infected with HBV or hepatitis C virus."/>
   <result pre="the basis of cirrhosis in patients infected with HBV or" exact="hepatitis" post="C virus. Occasionally, however, hepatocellular carcinoma is found in"/>
   <result pre="patients infected with HBV or hepatitis C virus. Occasionally, however," exact="hepatocellular carcinoma" post="is found in the absence of cirrhosis, usually after"/>
   <result pre="non-cirrhotic patients with non-alcoholic steatohepatitis).77., 78. References References 1.Ben-AriZ.SamuelD.ZemelR.Fulminant non-A-G" exact="viral hepatitis" post="leading to liver transplantationArch Intern Med160200038839210668842 2.PetrovicL.M.ArkadopoulosN.DemetriouA.A.Activation of hepatic"/>
   <result pre="patients with non-alcoholic steatohepatitis).77., 78. References References 1.Ben-AriZ.SamuelD.ZemelR.Fulminant non-A-G viral" exact="hepatitis" post="leading to liver transplantationArch Intern Med160200038839210668842 2.PetrovicL.M.ArkadopoulosN.DemetriouA.A.Activation of hepatic"/>
   <result pre="hepatic necrosis in infants and childrenHum Pathol40200951652619121848 5.PetersD.J.GreeneW.H.RuggieroF.Herpes simplex-induced fulminant" exact="hepatitis" post="in adults: a call for empiric therapyDig Dis Sci4520002399240411258565"/>
   <result pre="call for empiric therapyDig Dis Sci4520002399240411258565 6.PinnaA.D.RakelaJ.DemetrisA.J.Five cases of fulminant" exact="hepatitis" post="due to herpes simplex virus in adultsDig Dis Sci47200275075411991604"/>
   <result pre="therapyDig Dis Sci4520002399240411258565 6.PinnaA.D.RakelaJ.DemetrisA.J.Five cases of fulminant hepatitis due to" exact="herpes simplex" post="virus in adultsDig Dis Sci47200275075411991604 7.CollinL.MoulinP.JungersM.Epstein–Barr virus (EBV)-induced liver"/>
   <result pre="necrosis: a case for cytokine-induced liver dysfunction?J Hepatol41200417417515246231 8.WangW.H.WangH.L.Fulminant adenovirus" exact="hepatitis" post="following bone marrow transplantation. A case report and brief"/>
   <result pre="liver failure in a renal transplant patient caused by adenoviral" exact="hepatitis" post="superimposed on a fibrosing cholestatic hepatitis BHum Pathol35200489489715257556 10.ChauT.N.LeeK.C.YaoH.SARS-associated"/>
   <result pre="patient caused by adenoviral hepatitis superimposed on a fibrosing cholestatic" exact="hepatitis" post="BHum Pathol35200489489715257556 10.ChauT.N.LeeK.C.YaoH.SARS-associated viral hepatitis caused by a novel"/>
   <result pre="hepatitis superimposed on a fibrosing cholestatic hepatitis BHum Pathol35200489489715257556 10.ChauT.N.LeeK.C.YaoH.SARS-associated" exact="viral hepatitis" post="caused by a novel coronavirus: report of three casesHepatology39200430231014767982"/>
   <result pre="superimposed on a fibrosing cholestatic hepatitis BHum Pathol35200489489715257556 10.ChauT.N.LeeK.C.YaoH.SARS-associated viral" exact="hepatitis" post="caused by a novel coronavirus: report of three casesHepatology39200430231014767982"/>
   <result pre="novel coronavirus: report of three casesHepatology39200430231014767982 11.NgW.-F.ToK.-F.LamW.W.L.The comparative pathology of" exact="severe acute respiratory syndrome" post="and avian influenza A subtype H5N1: a reviewHum Pathol37200638139016564911"/>
   <result pre="casesHepatology39200430231014767982 11.NgW.-F.ToK.-F.LamW.W.L.The comparative pathology of severe acute respiratory syndrome and" exact="avian influenza" post="A subtype H5N1: a reviewHum Pathol37200638139016564911 12.PolakosN.K.CornejoJ.C.MurrayD.A.Kupfer cell-dependent hepatitis"/>
   <result pre="11.NgW.-F.ToK.-F.LamW.W.L.The comparative pathology of severe acute respiratory syndrome and avian" exact="influenza" post="A subtype H5N1: a reviewHum Pathol37200638139016564911 12.PolakosN.K.CornejoJ.C.MurrayD.A.Kupfer cell-dependent hepatitis"/>
   <result pre="avian influenza A subtype H5N1: a reviewHum Pathol37200638139016564911 12.PolakosN.K.CornejoJ.C.MurrayD.A.Kupfer cell-dependent" exact="hepatitis" post="occurs during influenza infectionAm J Pathol16820061169117816565492 13.AdamsD.H.HubscherS.G.Systemic viral infections"/>
   <result pre="subtype H5N1: a reviewHum Pathol37200638139016564911 12.PolakosN.K.CornejoJ.C.MurrayD.A.Kupfer cell-dependent hepatitis occurs during" exact="influenza" post="infectionAm J Pathol16820061169117816565492 13.AdamsD.H.HubscherS.G.Systemic viral infections and collateral damage"/>
   <result pre="in northern Brazil: morphological, immunohistochemical and pathogenic aspects of Lábrea" exact="hepatitis" post="and yellow feverTrans Roy Soc Trop Med Hyg101200783183917568643 17.PhillipsM.J.BlendisL.M.PoucellS.Syncytial"/>
   <result pre="feverTrans Roy Soc Trop Med Hyg101200783183917568643 17.PhillipsM.J.BlendisL.M.PoucellS.Syncytial giant-cell hepatitis. Sporadic" exact="hepatitis" post="with distinctive pathological features, a severe clinical course and"/>
   <result pre="featuresN Engl J Med32419914554601988831 18.FimmelC.J.GuoL.CompansR.W.A case of syncytial giant cell" exact="hepatitis" post="with features of a paramyxoviral infectionAm J Gastroenterol931998193119379772058 19.DevaneyK.GoodmanZ.D.IshakK.G.Postinfantile"/>
   <result pre="infectionAm J Gastroenterol931998193119379772058 19.DevaneyK.GoodmanZ.D.IshakK.G.Postinfantile giant-cell transformation in hepatitisHepatology1619923273331639341 20.LauJ.Y.N.KoukoulisG.Mieli-VerganiG.Syncytial giant-cell" exact="hepatitis" post="– a specific disease entity?J Hepatol1519922162191506641 21.ProtzerU.DienesH.P.BianchiL.Post-infantile giant cell"/>
   <result pre="hepatitis – a specific disease entity?J Hepatol1519922162191506641 21.ProtzerU.DienesH.P.BianchiL.Post-infantile giant cell" exact="hepatitis" post="in patients with primary sclerosing cholangitis and autoimmune hepatitisLiver1619962742828878001"/>
   <result pre="entity?J Hepatol1519922162191506641 21.ProtzerU.DienesH.P.BianchiL.Post-infantile giant cell hepatitis in patients with primary" exact="sclerosing cholangitis" post="and autoimmune hepatitisLiver1619962742828878001 22.Ben-AriZ.BroidaE.MonseliseY.Syncytial giant-cell hepatitis due to autoimmune"/>
   <result pre="Hepatol1519922162191506641 21.ProtzerU.DienesH.P.BianchiL.Post-infantile giant cell hepatitis in patients with primary sclerosing" exact="cholangitis" post="and autoimmune hepatitisLiver1619962742828878001 22.Ben-AriZ.BroidaE.MonseliseY.Syncytial giant-cell hepatitis due to autoimmune"/>
   <result pre="patients with primary sclerosing cholangitis and autoimmune hepatitisLiver1619962742828878001 22.Ben-AriZ.BroidaE.MonseliseY.Syncytial giant-cell" exact="hepatitis" post="due to autoimmune hepatitis type II (LKM1+) presenting as"/>
   <result pre="sclerosing cholangitis and autoimmune hepatitisLiver1619962742828878001 22.Ben-AriZ.BroidaE.MonseliseY.Syncytial giant-cell hepatitis due to" exact="autoimmune hepatitis" post="type II (LKM1+) presenting as subfulminant hepatitisAm J Gastroenterol95200079980110710079"/>
   <result pre="cholangitis and autoimmune hepatitisLiver1619962742828878001 22.Ben-AriZ.BroidaE.MonseliseY.Syncytial giant-cell hepatitis due to autoimmune" exact="hepatitis" post="type II (LKM1+) presenting as subfulminant hepatitisAm J Gastroenterol95200079980110710079"/>
   <result pre="presenting as subfulminant hepatitisAm J Gastroenterol95200079980110710079 23.MicchelliS.T.L.ThomasD.BoitnottJ.K.Hepatic giant cells in" exact="hepatitis" post="C virus (HCV) mono-infection and HCV/HIV co-infectionJ Clin Pathol6120081058106118682418"/>
   <result pre="mono-infection and HCV/HIV co-infectionJ Clin Pathol6120081058106118682418 24.SciotR.Van DammeB.DesmetV.J.Cholestatic features in" exact="hepatitis" post="AJ Hepatol319861721813025288 25.VolpesR.van den OordJ.J.DesmetV.J.Memory T cells represent the"/>
   <result pre="hepatocytesAm J Pathol14919964394488701983 32.RoskamsT.De VosR.van EykenP.Hepatic OV-6 expression in human" exact="liver disease" post="and rat experiments: evidence for hepatic progenitor cells in"/>
   <result pre="features, serology and outcome following transplantationJ Hepatol2319953633728655952 35.TeixeiraM.R.Jr.WellerI.V.D.MurrayA.M.The pathology of" exact="hepatitis" post="A in manLiver2198253607176838 36.AbeH.BeningerP.R.IkejiriN.Light microscopic findings of liver biopsy"/>
   <result pre="36.AbeH.BeningerP.R.IkejiriN.Light microscopic findings of liver biopsy specimens from patients with" exact="hepatitis" post="type A and comparison with type BGastroenterology8219829389476174391 37.OkunoT.SanoA.DeguchiT.Pathology of"/>
   <result pre="type A and comparison with type BGastroenterology8219829389476174391 37.OkunoT.SanoA.DeguchiT.Pathology of acute" exact="hepatitis" post="A in humans. Comparison with acute hepatitis BAm J"/>
   <result pre="37.OkunoT.SanoA.DeguchiT.Pathology of acute hepatitis A in humans. Comparison with acute" exact="hepatitis" post="BAm J Clin Pathol8119841621696695857 38.PonzE.Garcia-PaganJ.C.BrugueraM.Hepatic fibrin-ring granulomas in a"/>
   <result pre="J Clin Pathol8119841621696695857 38.PonzE.Garcia-PaganJ.C.BrugueraM.Hepatic fibrin-ring granulomas in a patient with" exact="hepatitis" post="AGastroenterology10019912682701983832 39.RuelM.SevestreH.Henry-BiabaudE.Fibrin ring granulomas in hepatitis ADig Dis Sci371992191519171473440"/>
   <result pre="in a patient with hepatitis AGastroenterology10019912682701983832 39.RuelM.SevestreH.Henry-BiabaudE.Fibrin ring granulomas in" exact="hepatitis" post="ADig Dis Sci371992191519171473440 40.InoueK.YoshibaM.YotsuyanagiH.Chronic hepatitis A with persistent viral"/>
   <result pre="AGastroenterology10019912682701983832 39.RuelM.SevestreH.Henry-BiabaudE.Fibrin ring granulomas in hepatitis ADig Dis Sci371992191519171473440 40.InoueK.YoshibaM.YotsuyanagiH.Chronic" exact="hepatitis" post="A with persistent viral replicationJ Med Virol5019963223248950689 41.ChuC.W.HwangS.J.LuoJ.C.Comparison of"/>
   <result pre="of clinical, virologic and pathologic features in patients with acute" exact="hepatitis" post="B and CJ Gastroenterol Hepatol16200120921411207903 42.UchidaT.ShimojimaS.GotohK.Pathology of livers infected"/>
   <result pre="and CJ Gastroenterol Hepatol16200120921411207903 42.UchidaT.ShimojimaS.GotohK.Pathology of livers infected with ‘silent’" exact="hepatitis" post="B virus mutantLiver1419942512567997084 43.YukiN.NagaokaT.YamashiroM.Long-term histologic and virologic outcomes of"/>
   <result pre="virus mutantLiver1419942512567997084 43.YukiN.NagaokaT.YamashiroM.Long-term histologic and virologic outcomes of acute self-limited" exact="hepatitis" post="BHepatology3720031172117912717399 44.BamberM.MurrayA.ArborghB.A.Short incubation non-A, non-B hepatitis transmitted by factor"/>
   <result pre="outcomes of acute self-limited hepatitis BHepatology3720031172117912717399 44.BamberM.MurrayA.ArborghB.A.Short incubation non-A, non-B" exact="hepatitis" post="transmitted by factor VIII concentrates in patients with congenital"/>
   <result pre="patients with congenital coagulation disordersGut2219818548596795093 45.KobayashiK.HashimotoE.LudwigJ.Liver biopsy features of acute" exact="hepatitis" post="C compared with hepatitis A, B and non-A, non-B,"/>
   <result pre="disordersGut2219818548596795093 45.KobayashiK.HashimotoE.LudwigJ.Liver biopsy features of acute hepatitis C compared with" exact="hepatitis" post="A, B and non-A, non-B, non-CLiver13199369738510489 46.ChuC.M.SheenI.S.LiawY.F.The role of"/>
   <result pre="hepatitis A, B and non-A, non-B, non-CLiver13199369738510489 46.ChuC.M.SheenI.S.LiawY.F.The role of" exact="hepatitis" post="C virus in fulminant viral hepatitis in an area"/>
   <result pre="non-B, non-CLiver13199369738510489 46.ChuC.M.SheenI.S.LiawY.F.The role of hepatitis C virus in fulminant" exact="viral hepatitis" post="in an area with endemic hepatitis A and BGastroenterology10719941891958020661"/>
   <result pre="non-CLiver13199369738510489 46.ChuC.M.SheenI.S.LiawY.F.The role of hepatitis C virus in fulminant viral" exact="hepatitis" post="in an area with endemic hepatitis A and BGastroenterology10719941891958020661"/>
   <result pre="virus in fulminant viral hepatitis in an area with endemic" exact="hepatitis" post="A and BGastroenterology10719941891958020661 47.GovindarajanS.De-CockK.M.RedekerA.G.Natural course of delta superinfection in"/>
   <result pre="A and BGastroenterology10719941891958020661 47.GovindarajanS.De-CockK.M.RedekerA.G.Natural course of delta superinfection in chronic" exact="hepatitis" post="B virus-infected patients: histopathologic study with multiple liver biopsiesHepatology619866406443525368"/>
   <result pre="histopathologic study with multiple liver biopsiesHepatology619866406443525368 48.VermeG.AmorosoP.LettieriG.A histological study of" exact="hepatitis" post="delta virus liver diseaseHepatology61986130313073793008 49.LinH.-H.LiawY.-F.ChenT.-J.Natural course of patients with"/>
   <result pre="liver diseaseHepatology61986130313073793008 49.LinH.-H.LiawY.-F.ChenT.-J.Natural course of patients with chronic type B" exact="hepatitis" post="following acute hepatitis delta virus superinfectionLiver919891291342747438 50.MorenoA.RamónY.CahalS.Sanded nuclei in"/>
   <result pre="course of patients with chronic type B hepatitis following acute" exact="hepatitis" post="delta virus superinfectionLiver919891291342747438 50.MorenoA.RamónY.CahalS.Sanded nuclei in delta patientsLiver919893673712558268 51.SmedileA.FarciP.VermeG.Influence"/>
   <result pre="in delta patientsLiver919893673712558268 51.SmedileA.FarciP.VermeG.Influence of delta infection on severity of" exact="hepatitis" post="BLancetii1982945947 52.PopperH.ThungS.N.GerberM.A.Histologic studies of severe delta agent infection in"/>
   <result pre="histologic features of Santa Marta hepatitis: a severe form of" exact="hepatitis" post="delta-virus infection in Northern South AmericaHepatology61986128512913793005 54.LefkowitchJ.H.GoldsteinH.YattoR.Cytopathic liver injury"/>
   <result pre="virus hepatitisGastroenterology921987126212663557018 55.RizzettoM.Hepatitis D: thirty years afterJ Hepatol5020091043105019285743 56.DaviesS.E.LauJ.Y.N.O’GradyJ.G.Evidence that" exact="hepatitis" post="D virus needs hepatitis B virus to cause hepatocellular"/>
   <result pre="thirty years afterJ Hepatol5020091043105019285743 56.DaviesS.E.LauJ.Y.N.O’GradyJ.G.Evidence that hepatitis D virus needs" exact="hepatitis" post="B virus to cause hepatocellular damageAm J Clin Pathol9819925545581462952"/>
   <result pre="E: an emerging awareness of an old diseaseJ Hepatol48200849450318192058 WooP.C.Y.LauS.K.P.TengJ.L.L.New" exact="hepatitis" post="E virus genotype in camels, the Middle EastEmerg Inf"/>
   <result pre="EastEmerg Inf Dis20201410441048 Kenney SP. The current host range of" exact="hepatitis" post="E viruses. Viruses. 2019;11(5):452.https://doi:10.3390/v11050452. ReinD.B.StevensG.A.TheakerJ.The global burden of hepatitis"/>
   <result pre="of hepatitis E viruses. Viruses. 2019;11(5):452.https://doi:10.3390/v11050452. ReinD.B.StevensG.A.TheakerJ.The global burden of" exact="hepatitis" post="E virus genotypes 1 and 2 in 2005Hepatology55201298899722121109 HakimM.WangW.BramerW.M.The"/>
   <result pre="genotypes 1 and 2 in 2005Hepatology55201298899722121109 HakimM.WangW.BramerW.M.The global burden of" exact="hepatitis" post="E outbreaks: a systematic reviewLiver Int3720171931 60.MalcolmP.DaltonH.HussainiH.S.The histology of"/>
   <result pre="outbreaks: a systematic reviewLiver Int3720171931 60.MalcolmP.DaltonH.HussainiH.S.The histology of acute autochthonous" exact="hepatitis" post="E virus infectionHistopathology51200719019417650215 ChenE.Y.BaumK.CollinsW.Hepatitis E masquerading as drug-induced liver"/>
   <result pre="virus infectionHistopathology51200719019417650215 ChenE.Y.BaumK.CollinsW.Hepatitis E masquerading as drug-induced liver injuryHepatology5620122420242323175167 DavernT.J.ChalasaniN.FontanaR.J.Acute" exact="hepatitis" post="E infection accounts for some cases of suspected drug-induced"/>
   <result pre="in patients with chronic liver diseaseHepatology36200247447812143058 LeeG.-H.TanB.-H.Chi-YuanE.Chronic infection with camelid" exact="hepatitis" post="E virus in a liver transplant recipient who regularly"/>
   <result pre="Lenggenhager D, Weber A. Clinicopathologic features and pathologic diagnosis of" exact="hepatitis" post="E. Hum Pathol. https://doi:10.1016/j.humpath.2019.10.003. 64.RamachandranJ.EapenC.E.KangG.Hepatitis E superinfection produces severe"/>
   <result pre="chronic liver diseaseJ Gastroenterol Hepatol19200413413814731121 65.KamarN.SelvesJ.MansuyJ.-M.Hepatitis E virus and chronic" exact="hepatitis" post="in organ-transplant recipientsN Engl J Med358200881181718287603 66.KamarN.MansuyJ.-M.CointaultO.Hepatitis E virus-related"/>
   <result pre="hepatitis in organ-transplant recipientsN Engl J Med358200881181718287603 66.KamarN.MansuyJ.-M.CointaultO.Hepatitis E virus-related" exact="cirrhosis" post="in kidney- and kidney–pancreas-transplant recipientsAm J Transplant820081744174818557740 67.AggarwalR.Hepatitis E:"/>
   <result pre="69.AsherL.V.S.InnisB.L.ShresthaM.P.Virus-like particles in the liver of a patient with fulminant" exact="hepatitis" post="and antibody to hepatitis E virusJ Med Virol3119902292332391510 70.BeerA.HolzmannH.PischkeS.Chronic"/>
   <result pre="liver of a patient with fulminant hepatitis and antibody to" exact="hepatitis" post="E virusJ Med Virol3119902292332391510 70.BeerA.HolzmannH.PischkeS.Chronic hepatitis E is associated"/>
   <result pre="hepatitis and antibody to hepatitis E virusJ Med Virol3119902292332391510 70.BeerA.HolzmannH.PischkeS.Chronic" exact="hepatitis" post="E is associated with cholangitisLiver Int3920191876188331102493 71.LenggenhagerD.GouttenoireJ.MalehmirM.Visualization of hepatitis"/>
   <result pre="70.BeerA.HolzmannH.PischkeS.Chronic hepatitis E is associated with cholangitisLiver Int3920191876188331102493 71.LenggenhagerD.GouttenoireJ.MalehmirM.Visualization of" exact="hepatitis" post="E virus RNA and proteins in the human liverJ"/>
   <result pre="RNA and proteins in the human liverJ Hepatol67201747147928412294 72.ProstS.CrossanC.L.DaltonH.R.Detection of" exact="viral hepatitis" post="E in clinical liver biopsiesHistopathology71201758059028543644 73.Innis BL, Lynch JA."/>
   <result pre="and proteins in the human liverJ Hepatol67201747147928412294 72.ProstS.CrossanC.L.DaltonH.R.Detection of viral" exact="hepatitis" post="E in clinical liver biopsiesHistopathology71201758059028543644 73.Innis BL, Lynch JA."/>
   <result pre="in clinical liver biopsiesHistopathology71201758059028543644 73.Innis BL, Lynch JA. Immunization against" exact="hepatitis" post="E. Cold Spring Harb Perspect Med 2018;8(11). https://doi:10.1101/cshperspect.a032573. 74.LiY.HuangX.ZhangZ.Prophylactic"/>
   <result pre="hepatitis E. Cold Spring Harb Perspect Med 2018;8(11). https://doi:10.1101/cshperspect.a032573. 74.LiY.HuangX.ZhangZ.Prophylactic" exact="hepatitis" post="E vaccines: antigenic analysis and serological evaluationViruses12202010910.3390/v12010109 75.MelgaçoJ.G.GardinalliN.R.Motta de"/>
   <result pre="carcinoma in non-cirrhotic liver: a comprehensive reviewWorld J Hepatol11201911830705715 77.BoyleM.AnsteeQ.M.Editorial:" exact="hepatocellular carcinoma" post="in non-cirrhotic NASH—a troubling realityAliment Pharmacol Ther4820181021102330318679 78.StineJ.G.WentworthB.J.ZimmetA.Systemic review"/>
   <result pre="troubling realityAliment Pharmacol Ther4820181021102330318679 78.StineJ.G.WentworthB.J.ZimmetA.Systemic review with meta-analysis: risk of" exact="hepatocellular carcinoma" post="in non-alcoholic steatohepatitis without cirrhosis compared to other liver"/>
   <result pre="with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without" exact="cirrhosis" post="compared to other liver diseasesAliment Pharmacol Ther48201869670330136293 References General"/>
   <result pre="other liver diseasesAliment Pharmacol Ther48201869670330136293 References General reading KimB.Y.KimW.R.Epidemiology of" exact="hepatitis" post="B virus infection in the United StatesClin Liver Dis12201813"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7279256\results\search\disease\results.xml">
   <result pre="Virus (HEV) is emerging as the primary cause of acute" exact="viral hepatitis" post="in humans. The virus is commonly transmitted by the"/>
   <result pre="(HEV) is emerging as the primary cause of acute viral" exact="hepatitis" post="in humans. The virus is commonly transmitted by the"/>
   <result pre="drugs such as tacrolimus are a major cause of chronic" exact="hepatitis" post="and reducing its dosage results in viral clearance in"/>
   <result pre="HEV genotypes in blood donors, hemodialysis patients, and transplant recipients." exact="hepatitis" post="E virus seroprevalence HEV genotype chronic hepatitis transfusion transmission"/>
   <result pre="and transplant recipients. hepatitis E virus seroprevalence HEV genotype chronic" exact="hepatitis" post="transfusion transmission blood donors prevention chronic kidney disease hemodialysis"/>
   <result pre="seroprevalence HEV genotype chronic hepatitis transfusion transmission blood donors prevention" exact="chronic kidney disease" post="hemodialysis and organ transplantation 1. Introduction In the last"/>
   <result pre="In the last decade, a change of the epidemiology of" exact="liver disease" post="has been observed with an increasing trend towards non-viral"/>
   <result pre="observed with an increasing trend towards non-viral etiology. However, virus-related" exact="hepatitis" post="remains the main cause of liver disease worldwide [1,2]."/>
   <result pre="non-viral etiology. However, virus-related hepatitis remains the main cause of" exact="liver disease" post="worldwide [1,2]. The most common causes of viral hepatitis"/>
   <result pre="of liver disease worldwide [1,2]. The most common causes of" exact="viral hepatitis" post="are the five hepatotropic viruses, hepatitis A virus (HAV),"/>
   <result pre="liver disease worldwide [1,2]. The most common causes of viral" exact="hepatitis" post="are the five hepatotropic viruses, hepatitis A virus (HAV),"/>
   <result pre="common causes of viral hepatitis are the five hepatotropic viruses," exact="hepatitis" post="A virus (HAV), hepatitis B virus (HBV), hepatitis C"/>
   <result pre="hepatitis are the five hepatotropic viruses, hepatitis A virus (HAV)," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), hepatitis D"/>
   <result pre="hepatotropic viruses, hepatitis A virus (HAV), hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV), hepatitis D virus (HDV), and hepatitis"/>
   <result pre="virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV)," exact="hepatitis" post="D virus (HDV), and hepatitis E virus (HEV). In"/>
   <result pre="(HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and" exact="hepatitis" post="E virus (HEV). In 1980, the bulk of hepatitis"/>
   <result pre="and hepatitis E virus (HEV). In 1980, the bulk of" exact="hepatitis" post="cases in India were attributed to a hitherto unrecognized"/>
   <result pre="of HEV. After ingestion of pooled stool extracts from presumed" exact="hepatitis" post="patients, he too developed hepatitis. The volunteer’s serum did"/>
   <result pre="these were inoculated in cynomolgus monkeys, where they successfully caused" exact="hepatitis" post="and elicited an antibody response [4]. Identification and sequencing"/>
   <result pre="of the virus followed; the disease was thereafter known as" exact="hepatitis" post="E, with HEV as the causative pathogen [5]. This"/>
   <result pre="[6]. HEV is possibly the most prevalent cause of acute" exact="viral hepatitis" post="around the globe [7]. HEV has a small particle"/>
   <result pre="HEV is possibly the most prevalent cause of acute viral" exact="hepatitis" post="around the globe [7]. HEV has a small particle"/>
   <result pre="HEV is not only responsible for acute sporadic or epidemic" exact="viral hepatitis" post="but has been recently shown to be associated with"/>
   <result pre="is not only responsible for acute sporadic or epidemic viral" exact="hepatitis" post="but has been recently shown to be associated with"/>
   <result pre="but has been recently shown to be associated with chronic" exact="hepatitis" post="as well [17]. 2. General Epidemiology HEV has emerged"/>
   <result pre="emerged as the most common etiological agent of adult acute" exact="viral hepatitis" post="in Central and Southeast Asia and is implicated as"/>
   <result pre="as the most common etiological agent of adult acute viral" exact="hepatitis" post="in Central and Southeast Asia and is implicated as"/>
   <result pre="Japan, China, and Taiwan [22]. HEV1 and HEV2 cause self-limiting" exact="hepatitis" post="in young adults, though there is an increased fatality"/>
   <result pre="females and immunocompromised patients. HEV3 and HEV4 can cause symptomatic" exact="hepatitis" post="in middle-aged and older individuals [23]. The first identified"/>
   <result pre="middle-aged and older individuals [23]. The first identified epidemic of" exact="hepatitis" post="E was reported in Delhi, India, in 1955–1956 [24]."/>
   <result pre="each year [25,26]. HEV1 is implicated in many outbreaks of" exact="viral hepatitis" post="in India [27,28,29], Pakistan [30], Bangladesh [29], Egypt [31,32],"/>
   <result pre="year [25,26]. HEV1 is implicated in many outbreaks of viral" exact="hepatitis" post="in India [27,28,29], Pakistan [30], Bangladesh [29], Egypt [31,32],"/>
   <result pre="subtype 1a is seen to be the cause of acute" exact="hepatitis" post="[6,29,34]. HEV1 is the predominant genotype seen in India,"/>
   <result pre="such as 1c may be implicated as causative of fulminant" exact="hepatitis" post="[27]. Genotype 2 sequences of HEV (HEV2) are grouped"/>
   <result pre="liver two to eight weeks before have an onset of" exact="hepatitis" post="symptoms [40]. In France, pig liver sausage displayed the"/>
   <result pre="significant consequences for public health. Although most cases of autochthonous" exact="hepatitis" post="E are caused by HEV3, a study in France"/>
   <result pre="thought that HEV is responsible for exceedingly few cases of" exact="hepatitis" post="in the developed countries [18]. In fact, researchers calculated"/>
   <result pre="in the USA [48]. However, a large number of symptomatic" exact="hepatitis" post="E infection cases are &quot;overlooked�? as there are no"/>
   <result pre="HEV RNA is frequently used as a marker for acute" exact="hepatitis" post="E infection. Reverse transcription–polymerase chain reaction (RT–PCR) assays are"/>
   <result pre="it is not feasible to detect the incidence of sporadic" exact="hepatitis" post="E accurately and with certainty unless HEV-RNA, IgM, and"/>
   <result pre="IgG levels are all used as markers of HEV-caused acute" exact="hepatitis" post="[54]. 4. HEV in Blood Transfusion Blood can be"/>
   <result pre="et al. (2007) reported a case where the recipient developed" exact="hepatitis" post="six weeks after transfusion of blood products. The virus"/>
   <result pre="a clean supply of water had a higher chance of" exact="hepatitis" post="E infection [78]. Serum samples from 178 blood donors"/>
   <result pre="correlation between HEV infection and either renal disease, history of" exact="hepatitis" post="B/C, or history of elevated transaminases. Data concerning anti-HEV"/>
   <result pre="Organ Transplant Recipients Organ-transplant recipients are susceptible to chronic active" exact="hepatitis" post="due to HEV infection that may lead to a"/>
   <result pre="HEV infection that may lead to a prompt progression to" exact="cirrhosis" post="[97]. Chronic hepatitis is usually confirmed by persistently elevated"/>
   <result pre="may lead to a prompt progression to cirrhosis [97]. Chronic" exact="hepatitis" post="is usually confirmed by persistently elevated aminotransferase levels, presence"/>
   <result pre="of an established definition, Kamar et al. (2012) defined chronic" exact="hepatitis" post="as the carriage of HEV for more than six"/>
   <result pre="may be low. HEV infection is reported to cause chronic" exact="hepatitis" post="in 14.1% of solid organ transplant recipients in France"/>
   <result pre="therefore of paramount importance to treat chronic HEV infections lest" exact="cirrhosis" post="occurs. Therapeutic options for chronic HEV infection in renal"/>
   <result pre="be 42.5% [113]. Another study reported the rate of chronic" exact="hepatitis" post="due to HEV as approximately 60% in solid-organ transplant"/>
   <result pre="HEV clearance in liver transplant recipients suffering from chronic active" exact="hepatitis" post="[118]. 6.3. Lung A recent study comprising 468 lung"/>
   <result pre="by viral genotyping [119]. Pas et al. (2012) reported chronic" exact="hepatitis" post="in 1 out of 53 lung transplant recipients [99]."/>
   <result pre="excessive amounts of alcohol have a higher chance of having" exact="hepatitis" post="E [128]. Proper cooking of meats and avoiding raw"/>
   <result pre="immunogenic [131]. Further studies showed that the vaccine effectively prevented" exact="hepatitis" post="E. The second vaccine, HEV239, which is now available"/>
   <result pre="a strong system of sanitation awareness is key in preventing" exact="hepatitis" post="E. HEV3 and HEV4 spread can be prevented by"/>
   <result pre="develop standardized detection kits. There is no standardized treatment for" exact="hepatitis" post="E. The best therapeutic option for transplant recipients is"/>
   <result pre="and Endemic Hepatitis in India: Evidence for a Non-A, Non-B" exact="hepatitis" post="Virus AetiologyLancet198031687687910.1016/S0140-6736(80)92045-0 4.BalayanM.S.AndjaparidzeA.G.Savin SkayaS.S.KetiladzeE.S.BraginskyD.M.SuvinovA.P.PoleschukV.F.Evidence for a Virus in Non-A,"/>
   <result pre="PregnancyJ. Gastroenterol. Hepatol.20072267668210.1111/j.1440-1746.2007.04913.x17444855 16.Golkocheva-MarkovaE.Peleva-PishmishevaM.BruniR.VillanoU.PisaniG.EquestreM.KevorkyanA.CiccozziM.CiccaglioneA.Following a patient with prolonged response against" exact="hepatitis" post="E virusPanminerva Medica20186023223410.23736/S0031-0808.18.03457-230563305 17.KamarN.SelvesJ.MansuyJ.M.OuezzaniL.PéronJ.M.GuitardJ.CointaultO.EspositoL.AbravanelF.DanjouxM.et al.Hepatitis E Virus and Chronic"/>
   <result pre="Detection of Hepatitis E VirusJ. Clin. Microbiol.2009472304230610.1128/JCM.00498-0919403760 58.LiT.TakedaN.MiyamuraT.Oral administration of" exact="hepatitis" post="E virus-like particles induces a systemic and mucosal immune"/>
   <result pre="and mucosal immune response in miceVaccine2001193476348410.1016/S0264-410X(01)00059-711348714 59.YamamotoH.LiT.C.KoshimotoC.ItoK.KitaM.MiyashitaN.ArikawaJ.YagamiK.AsanoM.TezukaH.et al.Serological evidence for" exact="hepatitis" post="e virus infection in laboratory monkeys and pigs in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7279404\results\search\disease\results.xml">
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract During the progression from" exact="hepatitis" post="to fibrosis, cirrhosis, and liver failure, the accumulation of"/>
   <result pre="liver inflammation is critical. The causes of hepatocyte injuries include" exact="viral hepatitis" post="infections, alcoholic hepatitis, and non-alcoholic fatty liver disease. Hepatocyte-derived"/>
   <result pre="inflammation is critical. The causes of hepatocyte injuries include viral" exact="hepatitis" post="infections, alcoholic hepatitis, and non-alcoholic fatty liver disease. Hepatocyte-derived"/>
   <result pre="critical. The causes of hepatocyte injuries include viral hepatitis infections," exact="alcoholic hepatitis," post="and non-alcoholic fatty liver disease. Hepatocyte-derived extracellular vesicles (Hep-EVs)"/>
   <result pre="hepatocyte injuries include viral hepatitis infections, alcoholic hepatitis, and non-alcoholic" exact="fatty liver disease." post="Hepatocyte-derived extracellular vesicles (Hep-EVs) released from stressed/damaged hepatocytes are"/>
   <result pre="injuries include viral hepatitis infections, alcoholic hepatitis, and non-alcoholic fatty" exact="liver disease." post="Hepatocyte-derived extracellular vesicles (Hep-EVs) released from stressed/damaged hepatocytes are"/>
   <result pre="vesicles (Hep-EVs) released from stressed/damaged hepatocytes are partly responsible for" exact="liver disease" post="progression and liver damage because they activate non-parenchymal cells"/>
   <result pre="potential diagnostic tools and novel therapeutic targets in patients with" exact="viral hepatitis," post="fatty liver steatosis, and alcoholic liver diseases. viral hepatitis"/>
   <result pre="with viral hepatitis, fatty liver steatosis, and alcoholic liver diseases." exact="viral hepatitis" post="non-alcoholic fatty liver disease alcoholic liver disease biomarkers extracellular"/>
   <result pre="viral hepatitis, fatty liver steatosis, and alcoholic liver diseases. viral" exact="hepatitis" post="non-alcoholic fatty liver disease alcoholic liver disease biomarkers extracellular"/>
   <result pre="fatty liver steatosis, and alcoholic liver diseases. viral hepatitis non-alcoholic" exact="fatty liver disease" post="alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes 1."/>
   <result pre="liver steatosis, and alcoholic liver diseases. viral hepatitis non-alcoholic fatty" exact="liver disease" post="alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes 1."/>
   <result pre="alcoholic liver diseases. viral hepatitis non-alcoholic fatty liver disease alcoholic" exact="liver disease" post="biomarkers extracellular vesicles microparticles exosomes 1. Introduction Chronic liver"/>
   <result pre="liver disease biomarkers extracellular vesicles microparticles exosomes 1. Introduction Chronic" exact="liver disease" post="is a major public health issue globally. It includes"/>
   <result pre="is a major public health issue globally. It includes chronic" exact="viral hepatitis," post="fatty liver disease, among other causes, and accounts for"/>
   <result pre="major public health issue globally. It includes chronic viral hepatitis," exact="fatty liver disease," post="among other causes, and accounts for approximately 3.5% of"/>
   <result pre="public health issue globally. It includes chronic viral hepatitis, fatty" exact="liver disease," post="among other causes, and accounts for approximately 3.5% of"/>
   <result pre="causes, and accounts for approximately 3.5% of deaths [1]. Viral" exact="hepatitis" post="is a persistent state of liver inflammation caused by"/>
   <result pre="inflammation caused by various viruses. It increases the risk of" exact="cirrhosis" post="and hepatocellular carcinoma (HCC). Chronic hepatitis B virus (CHB)"/>
   <result pre="by various viruses. It increases the risk of cirrhosis and" exact="hepatocellular carcinoma" post="(HCC). Chronic hepatitis B virus (CHB) and chronic hepatitis"/>
   <result pre="increases the risk of cirrhosis and hepatocellular carcinoma (HCC). Chronic" exact="hepatitis" post="B virus (CHB) and chronic hepatitis C virus (CHC)"/>
   <result pre="hepatocellular carcinoma (HCC). Chronic hepatitis B virus (CHB) and chronic" exact="hepatitis" post="C virus (CHC) infections are major risk factors for"/>
   <result pre="to 80% in various regional epidemics. In recent decades, non-alcoholic" exact="fatty liver disease" post="(NAFLD) and alcohol-associated liver disease have emerged as urgent"/>
   <result pre="80% in various regional epidemics. In recent decades, non-alcoholic fatty" exact="liver disease" post="(NAFLD) and alcohol-associated liver disease have emerged as urgent"/>
   <result pre="In recent decades, non-alcoholic fatty liver disease (NAFLD) and alcohol-associated" exact="liver disease" post="have emerged as urgent etiologies associated with an increasingly"/>
   <result pre="noting that the increase in non-alcoholic steatohepatitis (NASH) associated with" exact="obesity" post="and metabolic syndrome may have led, directly or indirectly,"/>
   <result pre="the increase in non-alcoholic steatohepatitis (NASH) associated with obesity and" exact="metabolic syndrome" post="may have led, directly or indirectly, to an increase"/>
   <result pre="(cccDNA) and pre-genomic RNA (pgRNA) formed during the replication of" exact="hepatitis" post="B virus (HBV). The assembly of proteins and nucleic"/>
   <result pre="Viral Hepatitis 2.1. Liquid Biopsies Associated Viral Hepatitis Infections Viral" exact="hepatitis" post="is an inflammation of the liver associated with infection"/>
   <result pre="an inflammation of the liver associated with infection by a" exact="hepatitis" post="virus. Researchers have debated whether viruses have infection strategies"/>
   <result pre="the surfaces of exosomes in numerous studies. This suggests that" exact="hepatitis" post="viruses may incorporate themselves into EVs during biogenesis to"/>
   <result pre="is a picornavirus—uses the host’s EV machinery to propagate enveloped" exact="hepatitis" post="A (eHAV); it comprises of two components: a nonenveloped"/>
   <result pre="solvent-insoluble membranes. This may hinder viral propagation. As with EVs," exact="hepatitis" post="C virus (HCV) targets are determined by multiple factors."/>
   <result pre="naive cells [25]. GB virus C (GBV-C), formally known as" exact="hepatitis" post="G virus (HGV), is a member of the Flaviviridae"/>
   <result pre="suggest that EVs play various functions in the pathogenesis of" exact="viral hepatitis" post="as shown in Figure 1. 2.2. Liquid Biopsies Associated"/>
   <result pre="that EVs play various functions in the pathogenesis of viral" exact="hepatitis" post="as shown in Figure 1. 2.2. Liquid Biopsies Associated"/>
   <result pre="evade immunity by protecting the HCV RNA from degradation. The" exact="hepatitis" post="A virus evades the human immune response by becoming"/>
   <result pre="HBV infection. Immune cell-derived circulating EVs are associated with advanced" exact="liver disease" post="and may be identified by microparticle markers of cell"/>
   <result pre="by Valpha24/Vbeta11 [32]. CHC patients can be identified among chronic" exact="hepatitis" post="patients by cell-derived EV biomarkers. The authors of another"/>
   <result pre="non-HCC patients [36]. A positive correlation among lncRNA-HULC, lncRNA-HEIH, and" exact="hepatitis" post="B X-interacting protein (HBXIP) indicated that hepatitis B X"/>
   <result pre="lncRNA-HULC, lncRNA-HEIH, and hepatitis B X-interacting protein (HBXIP) indicated that" exact="hepatitis" post="B X protein (HBx) may alter lncRNA expression, which"/>
   <result pre="linked to metabolic disorders including dyslipidemia, type 2 diabetes, and" exact="obesity" post="[50]. Various mechanisms contribute to the intrahepatic accumulation of"/>
   <result pre="higher in NAFLD patients and are not influenced by chronic" exact="hepatitis" post="[56]. Furthermore, there is a positive correlation between plasma"/>
   <result pre="discharged from damaged or stressed hepatic cells—exacerbate the progression of" exact="liver disease" post="through the stimulation of non-parenchymal cells [62]. In mouse"/>
   <result pre="patients and in patients with either or both of alcohol-related" exact="cirrhosis" post="and chronic hepatitis C-related cirrhosis [32,71]. Immature myeloid cells"/>
   <result pre="patients with either or both of alcohol-related cirrhosis and chronic" exact="hepatitis" post="C-related cirrhosis [32,71]. Immature myeloid cells (CD11b+, Ly6Chi, Ly6G-)"/>
   <result pre="either or both of alcohol-related cirrhosis and chronic hepatitis C-related" exact="cirrhosis" post="[32,71]. Immature myeloid cells (CD11b+, Ly6Chi, Ly6G-) have also"/>
   <result pre="increased proinflammatory markers (TNF-α, IL-1β, IL-6, and IL-12) [73]. Mouse" exact="obesity" post="models have been used to demonstrate that levels of"/>
   <result pre="Disease (ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease (ALD) Alcoholic" exact="liver disease" post="(ALD) foreshadows a wide variety of liver pathologies from"/>
   <result pre="accompanied by inflammation; this eventually results in liver failure or" exact="cancer" post="[79]. ALD hepatitis is directly related to the toxic"/>
   <result pre="this eventually results in liver failure or cancer [79]. ALD" exact="hepatitis" post="is directly related to the toxic effects of alcohol."/>
   <result pre="that elevated levels of primary bile acids are associated with" exact="alcoholic hepatitis" post="(AH) [80]. Moratti et al. reported that increased plasma"/>
   <result pre="elevated levels of primary bile acids are associated with alcoholic" exact="hepatitis" post="(AH) [80]. Moratti et al. reported that increased plasma"/>
   <result pre="gamma (PTPRG) isoform sPTPRG in EVs excreted from the human" exact="hepatocellular carcinoma" post="cell line HepG2 are associated with alcohol-related hepatic injury"/>
   <result pre="mice model following chronic and binge alcohol consumption, and in" exact="alcoholic hepatitis" post="(AH) patients [82]. The summary of the liquid factors"/>
   <result pre="model following chronic and binge alcohol consumption, and in alcoholic" exact="hepatitis" post="(AH) patients [82]. The summary of the liquid factors"/>
   <result pre="Alcoholic Liver Disease (ALD) Investigations into EVs as biomarkers for" exact="alcoholic hepatitis" post="in humans have revealed increased levels of EVs in"/>
   <result pre="Liver Disease (ALD) Investigations into EVs as biomarkers for alcoholic" exact="hepatitis" post="in humans have revealed increased levels of EVs in"/>
   <result pre="hepatitis in humans have revealed increased levels of EVs in" exact="alcoholic hepatitis" post="patients and patients who consume excessive amounts of alcohol"/>
   <result pre="in humans have revealed increased levels of EVs in alcoholic" exact="hepatitis" post="patients and patients who consume excessive amounts of alcohol"/>
   <result pre="fragments M30 and M65 in EVs [90]. The severity of" exact="alcoholic hepatitis" post="is linked to EVs containing CD34+ and ASGPR+ [91]."/>
   <result pre="M30 and M65 in EVs [90]. The severity of alcoholic" exact="hepatitis" post="is linked to EVs containing CD34+ and ASGPR+ [91]."/>
   <result pre="that CD40L may stimulate the activation of macrophages in experimental" exact="alcoholic hepatitis" post="models [92]. Chemotaxis is the initiating step in neutrophil"/>
   <result pre="CD40L may stimulate the activation of macrophages in experimental alcoholic" exact="hepatitis" post="models [92]. Chemotaxis is the initiating step in neutrophil"/>
   <result pre="in both circulating and hepatic neutrophils, which are associated with" exact="alcoholic hepatitis" post="and disease aggression [94,95,96]. CXCL1 is an IL-8 homologue"/>
   <result pre="both circulating and hepatic neutrophils, which are associated with alcoholic" exact="hepatitis" post="and disease aggression [94,95,96]. CXCL1 is an IL-8 homologue"/>
   <result pre="they are implicated in complex networks of cell-to-cell communication in" exact="liver disease" post="development and progression. Some studies have presented analyses of"/>
   <result pre="and accurate approach to the diagnosis and monitoring of chronic" exact="liver disease." post="Acknowledgments The authors thank all authors for their publications"/>
   <result pre="decision to publish the results. Abbreviations ALT alanine transaminase AH" exact="alcoholic hepatitis" post="ALD alcoholic liver disease ASH alcoholic steatohepatitis cfDNA cell-free"/>
   <result pre="to publish the results. Abbreviations ALT alanine transaminase AH alcoholic" exact="hepatitis" post="ALD alcoholic liver disease ASH alcoholic steatohepatitis cfDNA cell-free"/>
   <result pre="results. Abbreviations ALT alanine transaminase AH alcoholic hepatitis ALD alcoholic" exact="liver disease" post="ASH alcoholic steatohepatitis cfDNA cell-free DNA CCL2 chemokine (C-C"/>
   <result pre="ligand 2 CXCL1 chemokine (C-X-C motif) ligand 1 CHB chronic" exact="hepatitis" post="B virus CHC chronic hepatitis C virus cccDNA covalently"/>
   <result pre="motif) ligand 1 CHB chronic hepatitis B virus CHC chronic" exact="hepatitis" post="C virus cccDNA covalently closed circular DNA dsDNA double-stranded"/>
   <result pre="vesicle GWAS genome-wide association study HSC hepatic stellate cell HAV" exact="hepatitis" post="A virus HBV hepatitis B virus HCV hepatitis C"/>
   <result pre="study HSC hepatic stellate cell HAV hepatitis A virus HBV" exact="hepatitis" post="B virus HCV hepatitis C virus HGV hepatitis G"/>
   <result pre="cell HAV hepatitis A virus HBV hepatitis B virus HCV" exact="hepatitis" post="C virus HGV hepatitis G virus HCC hepatocellular carcinoma"/>
   <result pre="virus HBV hepatitis B virus HCV hepatitis C virus HGV" exact="hepatitis" post="G virus HCC hepatocellular carcinoma Hcy homocysteine HuH human"/>
   <result pre="virus HCV hepatitis C virus HGV hepatitis G virus HCC" exact="hepatocellular carcinoma" post="Hcy homocysteine HuH human hepatocyte-derived carcinoma cell ILV intraluminal"/>
   <result pre="miRNA microRNA mtDNA mitochondrial DNA MVB multivesicular body NAFLD non-alcoholic" exact="fatty liver disease" post="NASH non-alcoholic steatohepatitis PA palmitic acid PBMC peripheral blood"/>
   <result pre="microRNA mtDNA mitochondrial DNA MVB multivesicular body NAFLD non-alcoholic fatty" exact="liver disease" post="NASH non-alcoholic steatohepatitis PA palmitic acid PBMC peripheral blood"/>
   <result pre="al.Early fibrosis but late tumor stage and worse outcomes in" exact="hepatocellular carcinoma" post="patients without hepatitis B or hepatitis CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058"/>
   <result pre="tumor stage and worse outcomes in hepatocellular carcinoma patients without" exact="hepatitis" post="B or hepatitis CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058 4.JunT.W.YehM.L.YangJ.D.ChenV.L.NguyenP.GiamaN.H.HuangC.F.HsingA.W.DaiC.Y.HuangJ.F.et al.More advanced"/>
   <result pre="worse outcomes in hepatocellular carcinoma patients without hepatitis B or" exact="hepatitis" post="CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058 4.JunT.W.YehM.L.YangJ.D.ChenV.L.NguyenP.GiamaN.H.HuangC.F.HsingA.W.DaiC.Y.HuangJ.F.et al.More advanced disease and worse"/>
   <result pre="an envelope by hijacking cellular membranesNature201349636737110.1038/nature1202923542590 22.McKnightK.L.XieL.Gonzalez-LopezO.Rivera-SerranoE.E.ChenX.LemonS.M.Protein composition of the" exact="hepatitis" post="A virus quasi-envelopeProc. Natl. Acad. Sci. USA20171146587659210.1073/pnas.161951911428490497 23.NagashimaS.JirintaiS.TakahashiM.KobayashiT.TanggisNishizawaT.KoukiT.YashiroT.OkamotoH.Hepatitis E"/>
   <result pre="from multivesicular bodiesJ. Gen. Virol.2014952166217510.1099/vir.0.066910-024970738 24.LindenbachB.D.RiceC.M.The ins and outs of" exact="hepatitis" post="C virus entry and assemblyNat. Rev. Microbiol.20131168870010.1038/nrmicro309824018384 25.BukongT.N.Momen-HeraviF.KodysK.BalaS.SzaboG.Exosomes from"/>
   <result pre="hepatitis C virus entry and assemblyNat. Rev. Microbiol.20131168870010.1038/nrmicro309824018384 25.BukongT.N.Momen-HeraviF.KodysK.BalaS.SzaboG.Exosomes from" exact="hepatitis" post="C infected patients transmit HCV infection and contain replication"/>
   <result pre="in complex with Ago2-miR122-HSP90PLoS Pathog.201410e100442410.1371/journal.ppat.100442425275643 26.MeulemanP.HesselgesserJ.PaulsonM.VanwolleghemT.DesombereI.ReiserH.Leroux-RoelsG.Anti-CD81 antibodies can prevent a" exact="hepatitis" post="C virus infection in vivoHepatology2008481761176810.1002/hep.2254719030166 27.HarmanA.N.NasrN.FeethamA.GaloyanA.AlshehriA.A.RambukwelleD.BottingR.A.HienerB.M.DiefenbachE.DiefenbachR.J.et al.HIV blocks interferon"/>
   <result pre="Burden of Disease Liver Cancer CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of primary" exact="liver cancer" post="and underlying etiologies from 1990 to 2015 at the"/>
   <result pre="of Disease Liver Cancer CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of primary liver" exact="cancer" post="and underlying etiologies from 1990 to 2015 at the"/>
   <result pre="TGF-betaCell Mol. Gastroenterol. Hepatol.2016230231610.1016/j.jcmgh.2015.12.00528090562 31.FusegawaH.ShiraishiK.OgasawaraF.ShimizuM.HarukiY.MiyachiH.MatsuzakiS.AndoY.Platelet activation in patients with chronic" exact="hepatitis" post="CTokai J. Exp. Clin. Med.20022710110612713014 32.KornekM.LynchM.MehtaS.H.LaiM.ExleyM.AfdhalN.H.SchuppanD.Circulating microparticles as disease-specific"/>
   <result pre="as disease-specific biomarkers of severity of inflammation in patients with" exact="hepatitis" post="C or nonalcoholic steatohepatitisGastroenterology201214344845810.1053/j.gastro.2012.04.03122537612 33.LiJ.LiuK.LiuY.XuY.ZhangF.YangH.LiuJ.PanT.ChenJ.WuM.et al.Exosomes mediate the cell-to-cell"/>
   <result pre="IFN-alpha-induced antiviral activityNat. Immunol.20131479380310.1038/ni.264723832071 34.RamakrishnaiahV.ThumannC.FofanaI.HabersetzerF.PanQ.de RuiterP.E.WillemsenR.DemmersJ.A.Stalin RajV.JensterG.et al.Exosome-mediated transmission of" exact="hepatitis" post="C virus between human hepatoma Huh7.5 cellsProc. Natl. Acad."/>
   <result pre="hepatoma Huh7.5 cellsProc. Natl. Acad. Sci. USA2013110131091311310.1073/pnas.122189911023878230 35.SzaboG.Momen-HeraviF.Extracellular vesicles in" exact="liver disease" post="and potential as biomarkers and therapeutic targetsNat. Rev. Gastroenterol."/>
   <result pre="Med.20185647948410.1515/cclm-2017-032729252188 37.RuanL.HuangL.ZhaoL.WangQ.PanX.ZhangA.BaiQ.LvZ.The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in" exact="hepatitis" post="B patientsGastroenterol. Res. Pract.20182018918731610.1155/2018/918731630622563 38.LiuY.FengJ.SunM.YangG.YuanH.WangY.BuY.ZhaoM.ZhangS.ZhangX.Long non-coding RNA HULC activates"/>
   <result pre="the MICA promoter which regulates MICA expression and increases HCV-related" exact="hepatocellular carcinoma" post="riskPLoS ONE20138e6127910.1371/journal.pone.006127923593449 41.HuangC.F.WangS.C.YehM.L.HuangC.I.TsaiP.C.LinZ.Y.ChenS.C.DaiC.Y.HuangJ.F.ChuangW.L.et al.Association of serial serum major histocompatibility"/>
   <result pre="serum major histocompatibility complex class I chain-related A measurements with" exact="hepatocellular carcinoma" post="in chronic hepatitis C patients after viral eradicationJ. Gastroenterol."/>
   <result pre="class I chain-related A measurements with hepatocellular carcinoma in chronic" exact="hepatitis" post="C patients after viral eradicationJ. Gastroenterol. Hepatol.20193424925510.1111/jgh.1435929932235 42.HuangC.F.WangS.C.ChangW.T.YehM.L.HuangC.I.LinZ.Y.ChenS.C.ChuangW.L.HuangJ.F.DaiC.Y.et al.Lower"/>
   <result pre="expression levels of MHC class I chain-related gene A in" exact="hepatocellular carcinoma" post="are at high risk of recurrence after surgical resectionSci."/>
   <result pre="cell-free DNA as a predictive marker for distant metastasis of" exact="hepatitis" post="C virus-related hepatocellular carcinomaBr. J. Cancer2007971399140310.1038/sj.bjc.660403417940509 47.IidaM.IizukaN.SakaidaI.MoribeT.FujitaN.MiuraT.TamatsukuriS.IshitsukaH.UchidaK.TeraiS.et al.Relation between"/>
   <result pre="between serum levels of cell-free DNA and inflammation status in" exact="hepatitis" post="C virus-related hepatocellular carcinomaOncol. Rep.20082076176518813815 48.NgC.K.Y.Di CostanzoG.G.TerraccianoL.M.PiscuoglioS.Circulating cell-free DNA"/>
   <result pre="Rev.201645778610.1016/j.ctrv.2016.02.00826995632 52.YangR.X.HuC.X.SunW.L.PanQ.ShenF.YangZ.SuQ.XuG.W.FanJ.G.Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic" exact="fatty liver disease" post="and chronic hepatitis BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on"/>
   <result pre="52.YangR.X.HuC.X.SunW.L.PanQ.ShenF.YangZ.SuQ.XuG.W.FanJ.G.Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty" exact="liver disease" post="and chronic hepatitis BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on"/>
   <result pre="steatohepatitis in patients with non-alcoholic fatty liver disease and chronic" exact="hepatitis" post="BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on progression of fibrosis"/>
   <result pre="of steatosis on progression of fibrosis in patients with mild" exact="hepatitis" post="CHepatology200541828710.1002/hep.2051915690484 54.MehtaS.R.ThomasE.L.BellJ.D.JohnstonD.G.Taylor-RobinsonS.D.Non-invasive means of measuring hepatic fat contentWorld J."/>
   <result pre="diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in non-alcoholic" exact="fatty liver disease" post="(NAFLD)Nutr. J.2013123710.1186/1475-2891-12-3723547829 57.GulsenM.YesilovaZ.BagciS.UygunA.OzcanA.ErcinC.N.ErdilA.SanisogluS.Y.CakirE.AtesY.et al.Elevated plasma homocysteine concentrations as a"/>
   <result pre="56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in non-alcoholic fatty" exact="liver disease" post="(NAFLD)Nutr. J.2013123710.1186/1475-2891-12-3723547829 57.GulsenM.YesilovaZ.BagciS.UygunA.OzcanA.ErcinC.N.ErdilA.SanisogluS.Y.CakirE.AtesY.et al.Elevated plasma homocysteine concentrations as a"/>
   <result pre="liver and adipose tissue of mice with high fat diet-induced" exact="obesity" post="and nonalcoholic fatty liver diseaseEur. J. Gastroenterol. Hepatol.20082084385410.1097/MEG.0b013e3282f9b20318794597 61.YoshidaM.Novel"/>
   <result pre="nonalcoholic fatty liver diseaseCurr. Gastroenterol. Rep.20057323610.1007/s11894-005-0063-415701296 80.TrinchetJ.C.GerhardtM.F.BalkauB.MunzC.PouponR.E.Serum bile acids and" exact="cholestasis" post="in alcoholic hepatitis. Relationship with usual liver tests and"/>
   <result pre="liver diseaseCurr. Gastroenterol. Rep.20057323610.1007/s11894-005-0063-415701296 80.TrinchetJ.C.GerhardtM.F.BalkauB.MunzC.PouponR.E.Serum bile acids and cholestasis in" exact="alcoholic hepatitis." post="Relationship with usual liver tests and histological featuresJ. Hepatol.19942123524010.1016/S0168-8278(05)80401-57989715"/>
   <result pre="reticulum stressHepatol. Commun.2017167569010.1002/hep4.106629404485 85.BodeC.KuglerV.BodeJ.C.Endotoxemia in patients with alcoholic and non-alcoholic" exact="cirrhosis" post="and in subjects with no evidence of chronic liver"/>
   <result pre="non-alcoholic cirrhosis and in subjects with no evidence of chronic" exact="liver disease" post="following acute alcohol excessJ. Hepatol.1987481410.1016/S0168-8278(87)80003-X3571935 86.CaiY.XuM.J.KoritzinskyE.H.ZhouZ.WangW.CaoH.YuenP.S.RossR.A.StarR.A.LiangpunsakulS.et al.Mitochondrial DNA-enriched microparticles"/>
   <result pre="and hepatotoxicityJCI Insight201729263410.1172/jci.insight.9263428724791 87.SahaB.Momen-HeraviF.FuriI.KodysK.CatalanoD.GangopadhyayA.HarasztiR.SatishchandranA.Iracheta-VellveA.AdejumoA.et al.Extracellular vesicles from mice with alcoholic" exact="liver disease" post="carry a distinct protein cargo and induce macrophage activation"/>
   <result pre="infiltration in alcoholic hepatitisAlcohol200227172110.1016/S0741-8329(02)00206-912062632 95.DominguezM.MiquelR.ColmeneroJ.MorenoM.García-PagánJ.C.BoschJ.ArroyoV.GinèsP.CaballeríaJ.BatallerR.Hepatic expression of CXC chemokines predicts" exact="portal hypertension" post="and survival in patients with alcoholic hepatitisGastroenterology20091361639165010.1053/j.gastro.2009.01.05619208360 96.SheronN.BirdG.KoskinasJ.PortmannB.CeskaM.LindleyI.WilliamsR.Circulating and"/>
   <result pre="of the neutrophil chemotaxin interleukin-8 are elevated in severe acute" exact="alcoholic hepatitis," post="and tissue levels correlate with neutrophil infiltrationHepatology19931841468325620 97.RohY.S.ZhangB.LoombaR.SekiE.TLR2 and"/>
   <result pre="1 Summary of the viral liquid biopsy markers driven by" exact="hepatitis" post="viruses in the pathogenesis of viral hepatitis. Classification of"/>
   <result pre="biopsy markers driven by hepatitis viruses in the pathogenesis of" exact="viral hepatitis." post="Classification of viral related liquid biopsies by viral infection"/>
   <result pre="of the liquid factors associated with liver inflammation in Alcoholic" exact="liver disease" post="(ALD). Figure 4 The potential of the liquid biopsy"/>
   <result pre="and accurate approach to the diagnosis and monitoring of chronic" exact="liver disease" post="by disease associated markers from EVs, cfDNA, and serum"/>
   <result pre="efficiency in the future. ijms-21-03732-t001_Table 1Table 1 Liquid biomarkers of" exact="viral hepatitis" post="liver diseases. References Biomarker Type of Liquid Biopsy Application"/>
   <result pre="in the future. ijms-21-03732-t001_Table 1Table 1 Liquid biomarkers of viral" exact="hepatitis" post="liver diseases. References Biomarker Type of Liquid Biopsy Application"/>
   <result pre="DNA (cfDNA); covalently closed circular DNA (cccDNA); extracellular vesicle (EV);" exact="hepatitis" post="A virus (HAV); hepatitis B virus (HBV); hepatitis C"/>
   <result pre="circular DNA (cccDNA); extracellular vesicle (EV); hepatitis A virus (HAV);" exact="hepatitis" post="B virus (HBV); hepatitis C virus (HCV); hepatitis G"/>
   <result pre="vesicle (EV); hepatitis A virus (HAV); hepatitis B virus (HBV);" exact="hepatitis" post="C virus (HCV); hepatitis G virus (HGV); human hepatocyte-derived"/>
   <result pre="virus (HAV); hepatitis B virus (HBV); hepatitis C virus (HCV);" exact="hepatitis" post="G virus (HGV); human hepatocyte-derived carcinoma cells (HuH); intraluminal"/>
   <result pre="vesicles (EVs); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic" exact="fatty liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
   <result pre="(EVs); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic fatty" exact="liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
   <result pre="homocysteine (Hcy); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic" exact="fatty liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
   <result pre="(Hcy); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic fatty" exact="liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
   <result pre="tyrosine phosphatase receptor gamma extracellular domain (sPTPRG); Alanine transaminase (ALT);" exact="alcoholic hepatitis" post="(AH); alcoholic liver disease (ALD); alcoholic steatohepatitis (ASH); chemokine"/>
   <result pre="phosphatase receptor gamma extracellular domain (sPTPRG); Alanine transaminase (ALT); alcoholic" exact="hepatitis" post="(AH); alcoholic liver disease (ALD); alcoholic steatohepatitis (ASH); chemokine"/>
   <result pre="extracellular domain (sPTPRG); Alanine transaminase (ALT); alcoholic hepatitis (AH); alcoholic" exact="liver disease" post="(ALD); alcoholic steatohepatitis (ASH); chemokine (C-C motif) ligand 2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7282336\results\search\disease\results.xml">
   <result pre="no general disease history, OR 1.19, 95% CI 1.14 to 1.25)," exact="obesity" post="(vs normal weight, OR 0.91, 95% CI 0.86 to 0.97);"/>
   <result pre="(vs normal weight, OR 0.91, 95% CI 0.86 to 0.97); and" exact="hepatitis" post="B antibody seropositivity (OR 2.39, 95% CI 2.31 to 2.49)."/>
   <result pre="IgG seropositivity points to a need for implementation of workplace-based" exact="hepatitis" post="A vaccine programmes. To promote workers’ health and prevent"/>
   <result pre="hepatitis A vaccine programmes. To promote workers’ health and prevent" exact="hepatitis" post="A outbreaks, occupational health managers, healthcare providers and policy-makers"/>
   <result pre="difficult to determine causal interference. Background According to the WHO," exact="hepatitis" post="A caused an estimated 7134 deaths in 2016. Hepatitis"/>
   <result pre="estimated 7134 deaths in 2016. Hepatitis A is a viral" exact="liver disease" post="caused by hepatitis A virus (HAV). Globally, HAV infection"/>
   <result pre="2016. Hepatitis A is a viral liver disease caused by" exact="hepatitis" post="A virus (HAV). Globally, HAV infection occurs sporadically and"/>
   <result pre="is susceptible to HAV infection.2 There were 14 214 cases of" exact="hepatitis" post="A reported to the Korea Centers for Disease Control"/>
   <result pre="Immunity against HAV is acquired after complete recovery from acute" exact="hepatitis" post="A and when properly vaccinated. Notwithstanding its relatively low"/>
   <result pre="(figure 1). Figure 1 Flow chart of participant selection. HAV," exact="hepatitis" post="A virus; IgG, immunoglobulin G. Measurement of variables Data"/>
   <result pre="index (BMI), waist circumference, fasting glucose, total cholesterol, presence of" exact="hepatitis" post="B surface antibody (HBsAb) and anti-HAV IgG measured by"/>
   <result pre="disease history such as stroke, cardiac disease, hypertension, diabetes, cancer," exact="pulmonary tuberculosis," post="dyslipidaemia and any chronic or acute disease history were"/>
   <result pre="three categories: normal, &amp;lt;25 kg/m2; overweight, 25–29.9 kg/m2; and obese, ≥30 kg/m2. Abdominal" exact="obesity" post="was defined by waist circumference:&amp;gt;90 cm for men and &amp;gt;85 cm"/>
   <result pre="by waist circumference:&amp;gt;90 cm for men and &amp;gt;85 cm for women. Normal," exact="glucose intolerance" post="and suspected diabetes were defined as a fasting blood"/>
   <result pre="HBsAb positive. None of the participants reported a history of" exact="hepatitis" post="A. The overall seroprevalence of anti-HAV IgG (hereinafter seroprevalence)"/>
   <result pre="(66.3) 19 772 (43.5) 25 729 (56.5) BMI, body mass index; HAV," exact="hepatitis" post="A virus; HBsAb, hepatitis B surface antibody; IgG, immunoglobulin"/>
   <result pre="(56.5) BMI, body mass index; HAV, hepatitis A virus; HBsAb," exact="hepatitis" post="B surface antibody; IgG, immunoglobulin G; IQR, interquartile range."/>
   <result pre="(64.2) *Occupational classifications with &amp;lt;50 workers are not shown. HAV," exact="hepatitis" post="A virus; IgG, immunoglobulin G. Factors associated with the"/>
   <result pre="fully adjusted logistic regression model, age, sex, BMI, disease history," exact="hepatitis" post="B status, occupational classification and number of workplace health"/>
   <result pre="2.68); female sex (OR 1.54, 95% CI 1.48 to 1.59); and" exact="hepatitis" post="B antibody seropositivity (OR 2.39, 95% CI 2.31 to 2.49)"/>
   <result pre="0.91 (0.86 to 0.97) Waist circumference  Normal 1.00 (reference)  Abdominal" exact="obesity" post="0.94 (0.90 to 0.98) Fasting glucose  Normal 1.00 (reference)"/>
   <result pre="values. †P for trend &amp;lt;0.001. BMI, body mass index; HBsAb," exact="hepatitis" post="B surface antibody. Discussion Principal findings The overall seroprevalence"/>
   <result pre="to WHO in 2009, the estimated prevalence of immunity against" exact="hepatitis" post="A in Korea increased with age, from 25% among"/>
   <result pre="IgG than men. In Korea, a survey of the national" exact="influenza" post="vaccination rate revealed that the rate was higher among"/>
   <result pre="studies have directly proved the relationship between personal behaviour and" exact="hepatitis" post="A vaccination yet. Indeed, anti-HAV seroprevalence differed significantly by"/>
   <result pre="need for further longitudinal studies. Second, it was unknown whether" exact="hepatitis" post="A IgG antibody seropositivity of participants was acquired by"/>
   <result pre="Centers for Disease Control and PreventionIn-Depth epidemiologic survey results for" exact="hepatitis" post="A outbreaks in 2019. Available: https://www.cdc.go.kr/board.es?mid=a20501000000&amp;amp;bid=0015&amp;amp;act=view&amp;amp;list_no=364837# [Accessed 14 Oct"/>
   <result pre="8). JAMA2014;311:507–20. 10.1001/jama.2013.28442724352797 6collab: World Health OrganisationThe global prevalence of" exact="hepatitis" post="A virus infection and susceptibility: a systematic review. Available:"/>
   <result pre="Trop Med Hyg2015;109:9–15. 10.1093/trstmh/tru16725573105 9YunH, LeeH-J, CheonD, et al.Seroprevalence of" exact="hepatitis" post="A and E viruses based on the third Korea"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7283454\results\search\disease\results.xml">
   <result pre="natural reservoirs of various, potentially zoonotic viruses, exemplified by the" exact="influenza" post="A-like viruses H17N10 and H18N11 in asymptomatic Neotropical bats."/>
   <result pre="A-like viruses H17N10 and H18N11 in asymptomatic Neotropical bats. These" exact="influenza" post="viruses are evolutionarily distinct, are poorly adapted to laboratory"/>
   <result pre="cannot reassort in vitro with conventional strains to form new" exact="influenza" post="subtypes. However, they have attracted renewed attention following reports"/>
   <result pre="fully assess the zoonotic threat that these strains pose. bats" exact="influenza" post="virus haemagglutinin neuraminidase Major Histocompatibility Complex (MHC) class II"/>
   <result pre="et al., 2013). Intriguingly, genetic material from viruses that resemble" exact="influenza" post="type A viruses has been recovered from asymptomatic fruit"/>
   <result pre="in humans, lower animals and birds (Simonsen, 1999). The bat" exact="influenza" post="viruses (BatIVs) are phylogenetically distinct from the conventional IAVs"/>
   <result pre="human IAVs, but more importantly they allow reassortment between co-infecting" exact="influenza" post="viruses (Dlugolenski et al., 2013). The N-terminal domain of"/>
   <result pre="The N-terminal domain of the H17N10 PA subunit of the" exact="influenza" post="virus polymerase complex possesses endonuclease activity comparable to that"/>
   <result pre="compared to glutamic acid in avian and lysine in mammalian" exact="influenza" post="strains, suggestive of an alternative evolutionary pathway for avian"/>
   <result pre="Figure 1 Countries of Central and South America where bat" exact="influenza" post="A viruses have been reported. Map showing the global"/>
   <result pre="marine mammals New World bats Clinical manifestation Mild to severe" exact="respiratory disease" post="to humans and birds, cause outbreaks/epidemics, and sporadically pandemics"/>
   <result pre="limitations have included: (i) using HA-17 or HA-18 pseudotyped vesicular" exact="stomatitis" post="virus (VSV) and HIV-1 based lentiviruses (Hoffmann et al.,"/>
   <result pre="express MHC-II receptors on their surface such as several human" exact="leukemia" post="and lymphoma cell lines Raji, Ramos, and BJAB B-lymphocytes"/>
   <result pre="receptors on their surface such as several human leukemia and" exact="lymphoma" post="cell lines Raji, Ramos, and BJAB B-lymphocytes could be"/>
   <result pre="2019). Ciminski et al. demonstrated by utilizing a chimeric bat" exact="influenza" post="virus (PR8-H18N11) that viruses encoding the full-length N11 protein"/>
   <result pre="showed that the N10 protein facilitates heterosubtypic (H5 and H7)" exact="influenza" post="hemagglutinin-bearing pseudotype release in the absence of another source"/>
   <result pre="2020). Vampire bats have long been suspected of passing on" exact="rabies" post="to humans and livestock in Latin America by biting"/>
   <result pre="viruses is a key process mediating the genetic evolution of" exact="influenza" post="viruses and the generation of novel epidemic and pandemic"/>
   <result pre="serological studies could lead to the identification of novel bat" exact="influenza" post="subtypes. Conclusions In summary, BatIVs are unconventional influenza viruses"/>
   <result pre="novel bat influenza subtypes. Conclusions In summary, BatIVs are unconventional" exact="influenza" post="viruses that resemble to some extent more paramyxoviruses rather"/>
   <result pre="can provide broader mechanistic insights into the molecular biology of" exact="influenza" post="viruses and might inform translational studies. Author Contributions The"/>
   <result pre="CamposA. C. A.GoesL. G. B.Moreira-SotoA.De CarvalhoC.AmbarG.SanderA. L.et al.. (2019). Bat" exact="influenza" post="A(HL18NL11) virus in fruit bats, Brazil. Emerg. Infect. Dis.25,"/>
   <result pre="Infect. Dis.25, 333–337. 10.3201/eid2502.18124630666923 CarnellG.GiotisE. S.GrehanK.FerraraF.MatherS.MolestiE.et al. (2018). The bat" exact="influenza" post="H17N10 can be neutralized by broadly- neutralizing monoclonal antibodies"/>
   <result pre="Biorxiv49994710.1101/499947 ChotheS. K.BhushanG.NisslyR. H.YehY. T.BrownJ.TurnerG.et al.. (2017). Avian and human" exact="influenza" post="virus compatible sialic acid receptors in little brown bats."/>
   <result pre="MxA is a potent interspecies barrier for the novel bat-derived" exact="influenza" post="A-like virus H18N11. Emerg. Microbes Infect. 8, 556–563. 10.1080/22221751.2019.159930130945621"/>
   <result pre="Emerg. Microbes Infect. 8, 556–563. 10.1080/22221751.2019.159930130945621 CiminskiK.RanW.GorkaM.LeeJ.MalmlovA.SchinkotheJ.et al.. (2019b). Bat" exact="influenza" post="viruses transmit among bats but are poorly adapted to"/>
   <result pre="Nat. Microbiol.4, 2298–2309. 10.1038/s41564-019-0556-931527796 CiminskiK.ThamamongoodT.ZimmerG.SchwemmleM. (2017). Novel insights into bat" exact="influenza" post="A viruses. J. Gen. Virol.98, 2393–2400. 10.1099/jgv.0.00092728906230 DlugolenskiD.JonesL.TompkinsS. M.CrameriG.WangL."/>
   <result pre="A. (2013). Bat cells from Pteropus alecto are susceptible to" exact="influenza" post="A virus infection and reassortment. Influenza Other Respir.7, 900–903."/>
   <result pre="10.1111/irv.1212823710888 FereidouniS.KwasnitschkaL.Balkema BuschmannA.MullerT.FreulingC.SchatzJ.et al.. (2015). No virological evidence for an" exact="influenza" post="A–like virus in European bats. Zoonoses Public Health62, 187–189."/>
   <result pre="S.BingerT.MullerM. A.De BruinE.Van BeekJ.CormanV. M.et al.. (2015). Serological evidence of" exact="influenza" post="A viruses in frugivorous bats from Africa. PLoS ONE10:e0127035."/>
   <result pre="Africa. PLoS ONE10:e0127035. 10.1371/journal.pone.012703525965069 Garcia-SastreA. (2012). The neuraminidase of bat" exact="influenza" post="viruses is not a neuraminidase. Proc. Natl. Acad. Sci."/>
   <result pre="GiotisE. S.CarnellG.YoungE. F.GhannyS.SoteropoulosP.WangL. F.et al.. (2019). Entry of the bat" exact="influenza" post="H17N10 virus into mammalian cells is enabled by the"/>
   <result pre="Public Health60, 2–21. 10.1111/zph.1200022958281 HoffmannM.KrugerN.ZmoraP.WrenschF.HerrlerG.PohlmannS. (2016). The hemagglutinin of bat-associated" exact="influenza" post="viruses is activated by TMPRSS2 for pH-dependent entry into"/>
   <result pre="I.BelkinaT. S.RovnovaZ. I.KosiakovP. N.Selivanov IaM. (1982). Antigenic determinants of human" exact="influenza" post="viruses among the influenza viruses isolated from animals. Vopr."/>
   <result pre="IaM. (1982). Antigenic determinants of human influenza viruses among the" exact="influenza" post="viruses isolated from animals. Vopr. Virusol.27, 681–686.6186090 JenkinsC. N.PimmS."/>
   <result pre="271–282. 10.1038/nri180516557259 JuozapaitisM.Aguiar MoreiraE.MenaI.GieseS.RieggerD.PohlmannA.et al.. (2014). An infectious bat-derived chimeric" exact="influenza" post="virus harbouring the entry machinery of an influenza A"/>
   <result pre="bat-derived chimeric influenza virus harbouring the entry machinery of an" exact="influenza" post="A virus. Nat. Commun.5:4448. 10.1038/ncomms544825055345 KarakusU.ThamamongoodT.CiminskiK.RanW.GuntherS. C.PohlM. O.et al.."/>
   <result pre="(2019). MHC class II proteins mediate cross-species entry of bat" exact="influenza" post="viruses. Nature567, 109–112. 10.1038/s41586-019-0955-330787439 KelkarS. D.KadamS. S.BanerjeeK. (1981). Haemagglutination"/>
   <result pre="109–112. 10.1038/s41586-019-0955-330787439 KelkarS. D.KadamS. S.BanerjeeK. (1981). Haemagglutination inhibition antibodies against" exact="influenza" post="virus in bats. Indian J. Med. Res.74, 147–152.7309178 LiQ.SunX.LiZ.LiuY.VavrickaC."/>
   <result pre="and functional characterization of neuraminidase-like molecule N10 derived from bat" exact="influenza" post="A virus. Proc. Natl. Acad. Sci. U. S. A109,"/>
   <result pre="(1979). Isolation of strains of the Hong Kong complex (H3N2)" exact="influenza" post="virus from Nyctalus noctula bats in Kazakhstan. Vopr. Virusol."/>
   <result pre="338–341.158260 MaruyamaJ.NaoN.MiyamotoH.MaedaK.OgawaH.YoshidaR.et al.. (2016). Characterization of the glycoproteins of bat-derived" exact="influenza" post="viruses. Virology488, 43–50. 10.1016/j.virol.2015.11.00226605499 MehleA. (2014). Unusual influenza A"/>
   <result pre="of bat-derived influenza viruses. Virology488, 43–50. 10.1016/j.virol.2015.11.00226605499 MehleA. (2014). Unusual" exact="influenza" post="A viruses in bats. Viruses6, 3438–3449. 10.3390/v609343825256392 MoratelliR.CalisherC. H."/>
   <result pre="Cruz110, 1–22. 10.1590/0074-0276015004825742261 MoreiraE. A.LocherS.KolesnikovaL.BolteH.AydilloT.Garcia-SastreA.et al.. (2016). Synthetically derived bat" exact="influenza" post="A-like viruses reveal a cell type- but not species-specific"/>
   <result pre="Infect. Dis.2, 327–343. 10.1016/S1473-3099(02)00287-612144896 SatoM.MaruyamaJ.KondohT.NaoN.MiyamotoH.TakadateY.et al.. (2019). Generation of bat-derived" exact="influenza" post="viruses and their reassortants. Sci. Rep.9:1158. 10.1038/s41598-018-37830-x30718752 SimonsenL. (1999)."/>
   <result pre="reassortants. Sci. Rep.9:1158. 10.1038/s41598-018-37830-x30718752 SimonsenL. (1999). The global impact of" exact="influenza" post="on morbidity and mortality. Vaccine17(Suppl.1), S3–S10. 10.1016/S0264-410X(99)00099-710471173 SunX.ShiY.LuX.HeJ.GaoF.YanJ.et al."/>
   <result pre="morbidity and mortality. Vaccine17(Suppl.1), S3–S10. 10.1016/S0264-410X(99)00099-710471173 SunX.ShiY.LuX.HeJ.GaoF.YanJ.et al. (2013). Bat-derived" exact="influenza" post="hemagglutinin H17 does not bind canonical avian or human"/>
   <result pre="10.1128/JVI.03270-1324284327 TongS.LiY.RivaillerP.ConrardyC.CastilloD. A.ChenL. M.et al.. (2012). A distinct lineage of" exact="influenza" post="A virus from bats. Proc. Natl. Acad. Sci. U."/>
   <result pre="4269–4274. 10.1073/pnas.111620010922371588 TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.et al.. (2013). New world bats harbor diverse" exact="influenza" post="A viruses. PLoS Pathog.9:e1003657. 10.1371/journal.ppat.100365724130481 WacharapluesadeeS.BoongirdK.WanghongsaS.RatanasetyuthN.SupavonwongP.SaengsenD.et al.. (2010). A"/>
   <result pre="S.et al.. (2019). Mutations in the NA-like protein of bat" exact="influenza" post="H18N11 virus enhance virus replication in mammalian cells, mice,"/>
   <result pre="Virol.95:01416-19. 10.1128/JVI.01416-1931801857 ZhouB.MaJ.LiuQ.BawaB.WangW.ShabmanR. S.et al.. (2014). Characterization of uncultivable bat" exact="influenza" post="virus using a replicative synthetic virus. PLoS Pathog.10:e1004420. 10.1371/journal.ppat.100442025275541"/>
   <result pre="Crystal structures of two subtype N10 neuraminidase-like proteins from bat" exact="influenza" post="A viruses reveal a diverged putative active site. Proc."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7283535\results\search\disease\results.xml">
   <result pre="the control of 16 major diseases, namely, smallpox, diphtheria, tetanus," exact="yellow fever," post="pertussis, Haemophilus influenzae type b disease, poliomyelitis, measles, mumps,"/>
   <result pre="type b disease, poliomyelitis, measles, mumps, rubella, typhoid, rabies, rotavirus," exact="hepatitis" post="B, pneumococcal, and meningococcal diseases. Noteworthy is the complete"/>
   <result pre="diseases. Noteworthy is the complete or partial eradication achieved for" exact="smallpox" post="and poliomyelitis, respectively (3). To counteract infectious diseases, the"/>
   <result pre="a number even, higher than the 8.2 million caused by" exact="cancer" post="today (9) (Figure 2). Figure 1 Life expectancy increase"/>
   <result pre="by mutation or post-translational modifications. (D) Resistance mechanism of Mycobacterium" exact="tuberculosis" post="to isoniazid drug mutations in the katG gene causes"/>
   <result pre="that are used as first line methods of treatment against" exact="gonorrhea" post="infection (47). The main lethal target of cephalosporins is"/>
   <result pre="be discovered soon, we may enter an era of incurable" exact="gonorrhea" post="infections (48). Therefore, understanding the mechanisms underlying the AMR"/>
   <result pre="also very effective in reducing AMR. For istance, vaccines against" exact="influenza" post="virus reduce the incidence of fever and sickness which"/>
   <result pre="Vaccines Attempts to &quot;vaccinate�? begin even before the Edward Jenner's" exact="smallpox" post="vaccination was introduced. In the 7th century, some Indian"/>
   <result pre="of variolation, consisting in the introduction of dried pus from" exact="smallpox" post="pustules into the skin of a patient, was practiced"/>
   <result pre="in 1796 he tested the protective effect of a prior" exact="cowpox" post="infection against smallpox by actively immunizing an eight-year-old-boy with"/>
   <result pre="tested the protective effect of a prior cowpox infection against" exact="smallpox" post="by actively immunizing an eight-year-old-boy with cowpox and then"/>
   <result pre="cowpox infection against smallpox by actively immunizing an eight-year-old-boy with" exact="cowpox" post="and then carrying out smallpox challenge (variolation) (72). In"/>
   <result pre="actively immunizing an eight-year-old-boy with cowpox and then carrying out" exact="smallpox" post="challenge (variolation) (72). In the 19th century, Louis Pasteur"/>
   <result pre="the induction of antibodies directed against invariable antigens (e.g., smallpox," exact="yellow fever," post="polio, rabies, mumps, measles, rubella, varicella, herpes zoster, hepatitis"/>
   <result pre="(e.g., smallpox, yellow fever, polio, rabies, mumps, measles, rubella, varicella," exact="herpes zoster," post="hepatitis A, and Japanese encephalitis). Therefore, vaccines that were"/>
   <result pre="yellow fever, polio, rabies, mumps, measles, rubella, varicella, herpes zoster," exact="hepatitis" post="A, and Japanese encephalitis). Therefore, vaccines that were developed"/>
   <result pre="effective immune response. This approach has been successfully applied to" exact="diphtheria" post="and tetanus, two diseases caused by bacterial toxins (75)."/>
   <result pre="new approach enabled the generation of the genetically detoxified Bordetella" exact="pertussis" post="toxin (76) and the recombinant hepatitis B surface antigen"/>
   <result pre="the genetically detoxified Bordetella pertussis toxin (76) and the recombinant" exact="hepatitis" post="B surface antigen (HBsAg) (77). Genetic engineering has also"/>
   <result pre="to develop genetic &quot;reassortants,�? as in the case of the" exact="influenza" post="attenuated vaccine or the rotavirus vaccine, which is based"/>
   <result pre="that have been efficiently used for the chemical conjugation are" exact="tetanus" post="toxoid (TT), diphtheria toxoid (DT), and a non-toxic cross-reacting"/>
   <result pre="efficiently used for the chemical conjugation are tetanus toxoid (TT)," exact="diphtheria" post="toxoid (DT), and a non-toxic cross-reacting mutant of DT"/>
   <result pre="of them, namely AS04, was used in 2005 for the" exact="hepatitis" post="B (HBV) vaccine and in 2007 for the human"/>
   <result pre="A, targeting TLR4), has been licensed for a vaccine against" exact="malaria" post="and herpes zoster vaccine. Also, it is currently used"/>
   <result pre="TLR4), has been licensed for a vaccine against malaria and" exact="herpes zoster" post="vaccine. Also, it is currently used in clinical trials"/>
   <result pre="H. influenzae and Moraxella catarrhalis, aimed to prevent exacerbation in" exact="chronic obstructive pulmonary disease." post="The TB vaccine phase 2b trial conducted in Kenya,"/>
   <result pre="Kenya, South Africa, and Zambia provided 54.0% protection in M." exact="tuberculosis" post="infected adults against active pulmonary tuberculosis disease. This vaccine"/>
   <result pre="provided 54.0% protection in M. tuberculosis infected adults against active" exact="pulmonary tuberculosis" post="disease. This vaccine is composed of the M72 recombinant"/>
   <result pre="54.0% protection in M. tuberculosis infected adults against active pulmonary" exact="tuberculosis" post="disease. This vaccine is composed of the M72 recombinant"/>
   <result pre="of the M72 recombinant fusion protein including two immunogenic M." exact="tuberculosis" post="antigens (Mtb32A and Mtb39A), combined with the AS01E adjuvant"/>
   <result pre="toxins approved for clinical use which include two antibodies against" exact="anthrax" post="(97, 98) and one targeting the toxin B of"/>
   <result pre="vaccine technologies and platforms. MenACWY, meningococcus ACWY; Pneumo, pneumococcus; HBV," exact="hepatitis" post="B virus; Hib, type B Haemophilus influenzae; GBS, group"/>
   <result pre="the top. Front Immunol. (2018) 9:1068. 10.3389/fimmu.2018.0106829910799 58.NicholKLNordinJDNelsonDBMulloolyJPHakE. Effectiveness of" exact="influenza" post="vaccine in the community-dwelling elderly. N Engl J Med."/>
   <result pre="J Med. (2007) 357:1373–81. 10.1056/NEJMoa07084417914038 59.KwongJCMaatenSUpshurREPatrickDMMarraF. The effect of universal" exact="influenza" post="immunization on antibiotic prescriptions: an ecological study. Clin Infect"/>
   <result pre="10.1093/jpids/piw00526907814 63.GoldsteinEFinelliLO'HalloranALiuPKaracaZSteinerCAet al.. Hospitalizations associated with respiratory syncytial virus and" exact="influenza" post="in children, including children diagnosed with asthma. Epidemiology. (2019)"/>
   <result pre="Microbiol. (2011) 9:889–93. 10.1038/nrmicro266821963800 72.RiedelSEdward Jenner and the history of" exact="smallpox" post="and vaccination. Proc (Bayl Univ Med Cent). (2005) 18:21–5."/>
   <result pre="J Hyg. (1923) 22:208–21. 10.1017/S002217240000817220474806 76.PizzaMCovacciABartoloniAPeruginiMNencioniLDe MagistrisMTet al.. Mutants of" exact="pertussis" post="toxin suitable for vaccine development. Science. (1989) 246:497–500. 10.1126/science.26830732683073"/>
   <result pre="77.van den EndeCMaranoCvan AheeABungeEMDe MoerloozeL. The immunogenicity of GSK's recombinant" exact="hepatitis" post="B vaccine in children: a systematic review of 30"/>
   <result pre="16:789–809. 10.1080/14760584.2017.133856928586278 78.NogalesAMartinez-SobridoL. Reverse genetics approaches for the development of" exact="influenza" post="vaccines. Int J Mol Sci. (2016) 18:20. 10.3390/ijms1801002028025504 79.JefferiesJMMacdonaldEFaustSNClarkeSC."/>
   <result pre="10.1126/scitranslmed.300223421753121 97.TsaiCWMorrisS. Approval of raxibacumab for the treatment of inhalation" exact="anthrax" post="under the US food and drug administration animal rule."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7284042\results\search\disease\results.xml">
   <result pre="ancient teeth per individual analyzed by PCR and containing the" exact="plague" post="agent Y. pestis was 3/3 teeth, 1/4 teeth, and"/>
   <result pre="&amp;amp; Baziotopoulou�?Valavani, 2006), Mycobacterium leprae (Matheson et al., 2009), Mycobacterium" exact="tuberculosis" post="(Matheson et al., 2009), Y. pestis (Bianucci et al.,"/>
   <result pre="current emerging infections. Certainly, Y. pestis is the cause of" exact="plague" post="disease, responsible for at least three high�?mortality pandemics in"/>
   <result pre="at least three high�?mortality pandemics in human history and many" exact="plague" post="foci today, and about 40 historical burial places have"/>
   <result pre="genomes from about 1,500 to 3,000 years before the first" exact="plague" post="recording (Andrades Valtueña et al., 2017; Rasmussen et al.,"/>
   <result pre="al., 2018). Borrelia recurrentis is the causative pathogen of louse�?borne" exact="relapsing fever" post="(LBRF), this disease killed millions of people in European"/>
   <result pre="that Y. pestis was the cause of the death of" exact="plague" post="victims from different sites in Europe (Bianucci et al.,"/>
   <result pre="techniques. MALDI�?TOF MS, a new approach by proteomics, identified M." exact="tuberculosis" post="from human ancient bone samples through spectra of proteins"/>
   <result pre="article revealed that the presence of mycolic acids of M." exact="tuberculosis" post="in the previous research was not enough evidence to"/>
   <result pre="in 2016 showed the difficulties of protein identification from M." exact="tuberculosis" post="because of the lack of specific proteins, the peptide"/>
   <result pre="by one (Figure 1). The availability of skeletal samples of" exact="plague" post="has facilitated investigation, as evidenced by many methods created"/>
   <result pre="protein S12 IS6110 1/11 (9%) Matheson et al. (2009) Mycobacterium" exact="tuberculosis" post="3/11 (2.7%) Salmonella typhi Athen �? Greece 430−426 BC"/>
   <result pre="Tran, Forestier, et al., 2011; Tran, Signoli, et al., 2011)," exact="cowpox" post="virus (cowpox), and Bartonella henselae (cat�?scratch disease; Papagrigorakis et"/>
   <result pre="Bagasra, &amp;amp; Pliskin, 1991; Glick, Trope, &amp;amp; Pliskin, 1989) and" exact="hepatitis" post="C virus (HCV), with a higher rate of identification"/>
   <result pre="a female Italian mummy (1503–1568) in Naples, showing signs of" exact="tertiary syphilis" post="(Fornaciari, Castagna, Tognetti, Tornaboni, &amp;amp; Bruno, 1989); Rickettsia rickettsii,"/>
   <result pre="female Italian mummy (1503–1568) in Naples, showing signs of tertiary" exact="syphilis" post="(Fornaciari, Castagna, Tognetti, Tornaboni, &amp;amp; Bruno, 1989); Rickettsia rickettsii,"/>
   <result pre="Tornaboni, &amp;amp; Bruno, 1989); Rickettsia rickettsii, which causes Rocky Mountain" exact="spotted fever" post="(RMSF), was also identified in some ancient tissues from"/>
   <result pre="al., 2006). Among bacteria found in ancient dental pulp, Mycobacterium" exact="tuberculosis" post="can enter a dormant state during its life cycle"/>
   <result pre="to the environment and infected host. PCR testing for M." exact="tuberculosis" post="on samples of 300�?year�?old mummies yielded positive results but"/>
   <result pre="R., Belinskij, A., … Krause, J. (2017). The stone age" exact="plague" post="and its persistence in Eurasia. Current Biology, 27(23), 3683–3691.e8."/>
   <result pre="… Drancourt, M. (2017). Paleoproteomics of the dental pulp: The" exact="plague" post="paradigm. PLoS ONE, 12(7), 10.1371/journal.pone.0180552 Barnett, R., &amp;amp; Larson,"/>
   <result pre="Signoli, M. (2008). Technical note: A rapid diagnostic test detects" exact="plague" post="in ancient human remains: An example of the interaction"/>
   <result pre="Yersinia pestis genomes reveal the long�?term persistence of an historical" exact="plague" post="focus. eLife, 5, e1299410.7554/eLife.12994 Bos, K. I., Schuenemann, V."/>
   <result pre="and testing of a rapid diagnostic test for bubonic and" exact="pneumonic plague." post="Lancet, 361(9353), 211–216. 10.1016/S0140-6736(03)12270-212547544 Cobb, J. C. (2002). Ancient"/>
   <result pre="V., … Raoult, D. (2004). Genotyping, orientalis�?like Yersinia pestis, and" exact="plague" post="pandemics. Emerging Infectious Diseases, 10(9), 1585–1592. 10.3201/eid1009.03093315498160 Drancourt, M.,"/>
   <result pre="Raoult, D. (2007). Yersinia pestis Orientalis in remains of ancient" exact="plague" post="patients. Emerging Infectious Diseases, 13(2), 332–333. 10.3201/eid1302.06019717479906 Drancourt, M.,"/>
   <result pre="191(4), 607–611. 10.1086/42704115655785 Dumler, J. S. (1991). Fatal Rocky Mountain" exact="spotted fever" post="in Maryland—1901. JAMA, 265(6), 71810.1001/jama.1991.034600600480121899275 Eckhardt, A., Jágr, M.,"/>
   <result pre="(2016). A high�?coverage Yersinia pestis genome from a sixth�?century justinianic" exact="plague" post="victim. Molecular Biology and Evolution, 33(11), 2911–2923. 10.1093/molbev/msw17027578768 Fornaciari,"/>
   <result pre="A. Ø., … Bramanti, B. (2018). Genomic blueprint of a" exact="relapsing fever" post="pathogen in 15th century Scandinavia. Proceedings of the National"/>
   <result pre="M., Molnár, A., Maász, G., … Márk, L. (2012). Bone" exact="tuberculosis" post="in Roman Period Pannonia (western Hungary). Memorias do Instituto"/>
   <result pre="H. D., … Buckley, M. (2016). The challenge of identifying" exact="tuberculosis" post="proteins in archaeological tissues. Journal of Archaeological Science, 66,"/>
   <result pre="Vernon, K., &amp;amp; Spigelman, M. (2008). Attempts to revive Mycobacterium" exact="tuberculosis" post="from 300�?year�?old human mummies. FEMS Microbiology Letters, 283(1), 54–61."/>
   <result pre="D. (2012). Immuno�?PCR – A new tool for paleomicrobiology: The" exact="plague" post="paradigm. PLoS ONE, 7(2), e3174410.1371/journal.pone.003174422347507 Mark, L., Patonai, Z.,"/>
   <result pre="spectrometric analysis of 1400�?year�?old mycolic acids as biomarkers for ancient" exact="tuberculosis" post="infection. Journal of Archaeological Science, 37(2), 302–305. 10.1016/j.jas.2009.09.041 Matheson,"/>
   <result pre="(2010). Essentials in the use of mycolic acid biomarkers for" exact="tuberculosis" post="detection : Response to &quot;High�?throughput mass spectrometric analysis of"/>
   <result pre="spectrometric analysis of 1400�?year�?old mycolic acids as biomarkers for ancient" exact="tuberculosis" post="infection�? by Mark et al,Essentials in the use of"/>
   <result pre="et al,Essentials in the use of mycolic acid biomarkers for" exact="tuberculosis" post="detection: Response to &quot;High�?throughput mass spectrometric analysis of 1400�?year�?old"/>
   <result pre="spectrometric analysis of 1400�?year�?old mycolic acids as biomarkers for ancient" exact="tuberculosis" post="infection�? by Mark. Journal of Archaeological Science, 10(37), 2407–2412."/>
   <result pre="&amp;amp; Raoult, D. (2010). Evidence of a louse�?borne outbreak involving" exact="typhus" post="in douai, 1710–1712 during the war of Spanish succession."/>
   <result pre="Baziotopoulou�?Valavani, E. (2006). DNA examination of ancient dental pulp incriminates" exact="typhoid fever" post="as a probable cause of the Plague of Athens."/>
   <result pre="European black death as the source of ancient and modern" exact="plague" post="pandemics. Cell Host &amp;amp; Microbe, 19(6), 874–881. 10.1016/j.chom.2016.05.01227281573 Spyrou,"/>
   <result pre="of 3800�?year�?old Yersinia pestis genomes suggests Bronze Age origin for" exact="bubonic plague." post="Nature Communications, 9(1), 223410.1038/s41467-018-04550-9 Tran, T.�?N.�?N., Aboudharam, G., Gardeisen,"/>
   <result pre="&amp;amp; Drancourt, M. (2011). High throughput, multiplexed pathogen detection authenticates" exact="plague" post="waves in medieval Venice, Italy. PLoS ONE, 6(3), e1673510.1371/journal.pone.001673521423736"/>
   <result pre="J. W., … Poinar, H. (2014). Yersinia pestis and the" exact="plague" post="of Justinian 541–543 AD: A genomic analysis. The Lancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7285376\results\search\disease\results.xml">
   <result pre="the potential to cause pandemics. In 2013, low pathogenic novel" exact="avian influenza" post="A(H7N9) viruses emerged in China, resulting from the reassortment"/>
   <result pre="potential to cause pandemics. In 2013, low pathogenic novel avian" exact="influenza" post="A(H7N9) viruses emerged in China, resulting from the reassortment"/>
   <result pre="of avian-origin viruses. Following evolutionary changes, highly pathogenic strains of" exact="avian influenza" post="A(H7N9) viruses emerged in late 2016. Changes in pathogenicity"/>
   <result pre="avian-origin viruses. Following evolutionary changes, highly pathogenic strains of avian" exact="influenza" post="A(H7N9) viruses emerged in late 2016. Changes in pathogenicity"/>
   <result pre="protein 2 (PB2). Recognizing that effective viral transmission of the" exact="influenza" post="A virus (IAV) between humans requires efficient attachment to"/>
   <result pre="into a highly virulent and infectious, human-to-human transmitted virus. H7N9" exact="avian influenza" post="virus hemagglutinin neuraminidase polymerase basic protein 2 evolution mutation"/>
   <result pre="a highly virulent and infectious, human-to-human transmitted virus. H7N9 avian" exact="influenza" post="virus hemagglutinin neuraminidase polymerase basic protein 2 evolution mutation"/>
   <result pre="evolution mutation reassortment 1. Introduction The pandemic potential of the" exact="influenza" post="A virus (IAV) is well known, with the most"/>
   <result pre="since this initial event, evolutionary adaptations in human and animal" exact="influenza" post="viruses have resulted in another three IAV pandemic events;"/>
   <result pre="[2]. While pandemic events remain limited in number, recurring seasonal" exact="influenza" post="virus epidemics result in approximately three to five million"/>
   <result pre="to virally associated respiratory diseases [3]. The morbidity rate for" exact="influenza" post="epidemics underscores the constant molecular changes taking place within"/>
   <result pre="viral segments are exchanged within a cell co-infected with differing" exact="influenza" post="viruses. Reassortment of an IAV genome can then generate"/>
   <result pre="antiviral drug resistance [10]. The poor proof-reading capacity of the" exact="influenza" post="virus RNA polymerase contributes to molecular changes within the"/>
   <result pre="aquatic bird species are recognized as a major reservoir for" exact="influenza" post="viruses, including IAV, providing viral seeding for domestic birds"/>
   <result pre="are not considered principal reservoirs for IAV, the potential for" exact="influenza" post="viruses normally circulating in three distinct species (humans, swine"/>
   <result pre="and cross-species transmission of novel IAVs [10]. Identification of the" exact="avian influenza" post="A(H7N9) virus was first reported in March 2013, when"/>
   <result pre="cross-species transmission of novel IAVs [10]. Identification of the avian" exact="influenza" post="A(H7N9) virus was first reported in March 2013, when"/>
   <result pre="H7N9 viruses supports a minimum two-step sequential reassortment for generating" exact="avian influenza" post="A(H7N9) viruses (Figure 3). This analysis proposed at least"/>
   <result pre="viruses supports a minimum two-step sequential reassortment for generating avian" exact="influenza" post="A(H7N9) viruses (Figure 3). This analysis proposed at least"/>
   <result pre="that act as a cell surface receptor determinant for all" exact="influenza" post="A virus (IAV) strains [28]. The attachment of all"/>
   <result pre="IAV transmission [34]. Hence, to achieve effective airborne transmission of" exact="avian influenza" post="viruses, there needs to be aerosol transmission via coughing/sneezing"/>
   <result pre="transmission [34]. Hence, to achieve effective airborne transmission of avian" exact="influenza" post="viruses, there needs to be aerosol transmission via coughing/sneezing"/>
   <result pre="is a crucial adaptation in the transmissibility of previous pandemic" exact="influenza" post="strains [36]. Importantly, it has been shown that of"/>
   <result pre="swine are recognized as mixing vessels for human, swine and" exact="avian influenza" post="viruses [40]. Using a recombinant wild-type virus (rAnhui-WT), Liu"/>
   <result pre="are recognized as mixing vessels for human, swine and avian" exact="influenza" post="viruses [40]. Using a recombinant wild-type virus (rAnhui-WT), Liu"/>
   <result pre="[31]. The authors used site-directed mutagenesis of the wild type" exact="influenza" post="A virus (A/Shanghai/2/2013), where HA-Q226L was already present. Two"/>
   <result pre="waves caused by H7N9 strains were classified as low pathogenic" exact="avian influenza" post="(LPAI), although with the emergence of the fifth wave"/>
   <result pre="caused by H7N9 strains were classified as low pathogenic avian" exact="influenza" post="(LPAI), although with the emergence of the fifth wave"/>
   <result pre="2016, the LPAI H7N9 virus mutated into a highly pathogenic" exact="avian influenza" post="virus [45]. The geographic distribution of H7N9 was more"/>
   <result pre="the LPAI H7N9 virus mutated into a highly pathogenic avian" exact="influenza" post="virus [45]. The geographic distribution of H7N9 was more"/>
   <result pre="related to the accumulation of specific PB2 protein mutations. Avian" exact="influenza" post="viruses typically carry glutamic acid (E) at Residue 627"/>
   <result pre="in human isolates of H5N1 and H7N7, both highly pathogenic" exact="avian influenza" post="viruses [47]. Thus, there is some evidence that 627K"/>
   <result pre="human isolates of H5N1 and H7N7, both highly pathogenic avian" exact="influenza" post="viruses [47]. Thus, there is some evidence that 627K"/>
   <result pre="be instrumental in enhancing the replication efficiency and virulence of" exact="avian influenza" post="viruses in mammals, and potentially contribute to mammalian adaptation"/>
   <result pre="instrumental in enhancing the replication efficiency and virulence of avian" exact="influenza" post="viruses in mammals, and potentially contribute to mammalian adaptation"/>
   <result pre="pro-inflammatory cytokines in mice lungs following viral infection with the" exact="influenza" post="A virus (IAV) (PB2-627E), compared to mice infected with"/>
   <result pre="virulence of H7N9. An increase in the replication efficiency of" exact="avian influenza" post="viruses in humans is associated with specific mutations in"/>
   <result pre="of H7N9. An increase in the replication efficiency of avian" exact="influenza" post="viruses in humans is associated with specific mutations in"/>
   <result pre="Enhances Pathogenicity and Virulence of H7N9 Host tropism of the" exact="influenza" post="virus is strongly influenced by virus-receptor specificity and avidity"/>
   <result pre="between HA and NA activity is considered critical for effective" exact="influenza" post="A virus transmission and replication [54,55], hence mutations in"/>
   <result pre="73 in the NA stalk, a feature consistent with other" exact="influenza" post="subtypes. Chen et al. [56] postulated that this was"/>
   <result pre="that a decreased stalk length was statistically significant in other" exact="avian influenza" post="subtypes (H5N1, H6N1, H7N1, H7N3 and H9N2), and therefore"/>
   <result pre="a decreased stalk length was statistically significant in other avian" exact="influenza" post="subtypes (H5N1, H6N1, H7N1, H7N3 and H9N2), and therefore"/>
   <result pre="limited attention within the research literature. Although present in other" exact="influenza" post="subtypes, the natural deletion of five amino acid sequences"/>
   <result pre="acid at Residue 627 (PB2-E627K) occurs across many highly pathogenic" exact="avian influenza" post="viruses, delivering enhanced replication efficiency and virulence in mammals."/>
   <result pre="at Residue 627 (PB2-E627K) occurs across many highly pathogenic avian" exact="influenza" post="viruses, delivering enhanced replication efficiency and virulence in mammals."/>
   <result pre="the H7N9 NA stalk are noted to occur in other" exact="influenza" post="subtypes, and have been shown to have no significant"/>
   <result pre="References 1.JohnsonN.P.MuellerJ.Updating the accounts: Global mortality of the 1918-1920 &quot;Spanish�?" exact="influenza" post="pandemicBull. Hist. Med.20027610511510.1353/bhm.2002.002211875246 2.SchrauwenE.J.FouchierR.A.Host adaptation and transmission of influenza"/>
   <result pre="&quot;Spanish�? influenza pandemicBull. Hist. Med.20027610511510.1353/bhm.2002.002211875246 2.SchrauwenE.J.FouchierR.A.Host adaptation and transmission of" exact="influenza" post="A viruses in mammalsEmerg. Microbes Infect.20143e910.1038/emi.2014.926038511 3.World Health OrganizationAvailable"/>
   <result pre="online: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)(accessed on 16 February 2019) 4.ArranzR.ColomaR.ChichónF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtínJ.Martín-BenitoJ.The structure of native" exact="influenza" post="virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 5.MoellerA.KirchdoerferR.N.PotterC.S.CarragherB.WilsonI.A.Organization of the influenza virus replication machineryScience20123381631163410.1126/science.122727023180774"/>
   <result pre="4.ArranzR.ColomaR.ChichónF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtínJ.Martín-BenitoJ.The structure of native influenza virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 5.MoellerA.KirchdoerferR.N.PotterC.S.CarragherB.WilsonI.A.Organization of the" exact="influenza" post="virus replication machineryScience20123381631163410.1126/science.122727023180774 6.KrammerF.SmithG.J.D.FouchierR.A.M.PeirisM.KedzierskaK.DohertyP.C.PaleseP.ShawM.L.TreanorJ.WebsterR.G.et al.InfluenzaNat. Rev. Dis. Primers201842110.1038/s41572-018-0002-y30190489 7.BouvierN.M.PaleseP.The"/>
   <result pre="replication machineryScience20123381631163410.1126/science.122727023180774 6.KrammerF.SmithG.J.D.FouchierR.A.M.PeirisM.KedzierskaK.DohertyP.C.PaleseP.ShawM.L.TreanorJ.WebsterR.G.et al.InfluenzaNat. Rev. Dis. Primers201842110.1038/s41572-018-0002-y30190489 7.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826D49D5310.1016/j.vaccine.2008.07.03919230160 8.HaleB.G.RandallR.E.OrtínJ.JacksonD.The multifunctional NS1 protein of influenza A virusesJ."/>
   <result pre="7.BouvierN.M.PaleseP.The biology of influenza virusesVaccine200826D49D5310.1016/j.vaccine.2008.07.03919230160 8.HaleB.G.RandallR.E.OrtínJ.JacksonD.The multifunctional NS1 protein of" exact="influenza" post="A virusesJ. Gen. Vir.2008892359237610.1099/vir.0.2008/004606-018796704 9.O’NeillR.E.TalonJ.PaleseP.The influenza virus NEP (NS2"/>
   <result pre="multifunctional NS1 protein of influenza A virusesJ. Gen. Vir.2008892359237610.1099/vir.0.2008/004606-018796704 9.O’NeillR.E.TalonJ.PaleseP.The" exact="influenza" post="virus NEP (NS2 protein) mediates the nuclear export of"/>
   <result pre="Control-Volume ISpringerCham, Switzerland201410.1007/82_2014_395 11.DomingoE.PeralesC.Viral quasispeciesPLoS Genet.20191510.1371/journal.pgen.1008271 12.WebsterR.G.BeanW.J.GormanO.T.ChambersT.M.KawaokaY.Evolution and ecology of" exact="influenza" post="A virusesMicrobiol. Rev.19925615217910.1128/MMBR.56.1.152-179.19921579108 13.YoonS.-W.WebbyR.J.WebsterR.G.Evolution and ecology of influenza A"/>
   <result pre="ecology of influenza A virusesMicrobiol. Rev.19925615217910.1128/MMBR.56.1.152-179.19921579108 13.YoonS.-W.WebbyR.J.WebsterR.G.Evolution and ecology of" exact="influenza" post="A virusesInfluenza Pathogenesis and Control-Volume ICompansR.OldstoneM.SpringerCham, Switzerland2014Volume 385359375 14.NelsonM.I.GramerM.R.VincentA.L.HolmesE.C.Global"/>
   <result pre="virusesInfluenza Pathogenesis and Control-Volume ICompansR.OldstoneM.SpringerCham, Switzerland2014Volume 385359375 14.NelsonM.I.GramerM.R.VincentA.L.HolmesE.C.Global transmission of" exact="influenza" post="viruses from humans to swineJ. Gen. Virol.2012932195220310.1099/vir.0.044974-022791604 15.LewisN.DalyJ.RussellC.HortonD.SkepnerE.BryantN.BurkeD.RashA.WoodJ.ChambersT.et al.Antigenic"/>
   <result pre="swineJ. Gen. Virol.2012932195220310.1099/vir.0.044974-022791604 15.LewisN.DalyJ.RussellC.HortonD.SkepnerE.BryantN.BurkeD.RashA.WoodJ.ChambersT.et al.Antigenic and genetic evolution of equine" exact="influenza" post="A (H3N8) virus from 1968 to 2007J. Virol.201185127421274910.1128/JVI.05319-1121937642 16.PerezD.R.LimW.SeilerJ.P.YiG.PeirisM.ShortridgeK.F.WebsterR.G.Role"/>
   <result pre="Virol.201185127421274910.1128/JVI.05319-1121937642 16.PerezD.R.LimW.SeilerJ.P.YiG.PeirisM.ShortridgeK.F.WebsterR.G.Role of quail in the interspecies transmission of H9" exact="influenza" post="A viruses: Molecular changes on HA that correspond to"/>
   <result pre="adaptation from ducks to chickensJ. Virol.2003773148315610.1128/JVI.77.5.3148-3156.200312584339 17.CrawfordP.DuboviE.J.CastlemanW.L.StephensonI.GibbsE.ChenL.SmithC.HillR.C.FerroP.PompeyJ.et al.Transmission of equine" exact="influenza" post="virus to dogsScience200531048248510.1126/science.111795016186182 18.WebsterR.HinshawV.BeanW.Van WykeK.GeraciJ.AubinD.S.PeturssonG.Characterization of an influenza A"/>
   <result pre="of equine influenza virus to dogsScience200531048248510.1126/science.111795016186182 18.WebsterR.HinshawV.BeanW.Van WykeK.GeraciJ.AubinD.S.PeturssonG.Characterization of an" exact="influenza" post="A virus from sealsVirology198111371272410.1016/0042-6822(81)90200-26267805 19.MunsterV.J.BaasC.LexmondP.WaldenströmJ.WallenstenA.FranssonT.RimmelzwaanG.F.BeyerW.E.SchuttenM.OlsenB.et al.Spatial, temporal, and species"/>
   <result pre="sealsVirology198111371272410.1016/0042-6822(81)90200-26267805 19.MunsterV.J.BaasC.LexmondP.WaldenströmJ.WallenstenA.FranssonT.RimmelzwaanG.F.BeyerW.E.SchuttenM.OlsenB.et al.Spatial, temporal, and species variation in prevalence of" exact="influenza" post="A viruses in wild migratory birdsPLoS Pathog.20073e6110.1371/journal.ppat.003006117500589 20.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.New world"/>
   <result pre="in wild migratory birdsPLoS Pathog.20073e6110.1371/journal.ppat.003006117500589 20.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.New world bats harbor diverse" exact="influenza" post="A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 21.KandeilA.GomaaM.R.ShehataM.M.El TaweelA.N.MahmoudS.H.BagatoO.MoatasimY.KutkatO.KayedA.S.DawsonP.Isolation and characterization of a"/>
   <result pre="A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 21.KandeilA.GomaaM.R.ShehataM.M.El TaweelA.N.MahmoudS.H.BagatoO.MoatasimY.KutkatO.KayedA.S.DawsonP.Isolation and characterization of a distinct" exact="influenza" post="A virus from Egyptian batsJ. Virol.201993e01059-1810.1128/JVI.01059-1830381492 22.FouchierR.A.MunsterV.WallenstenA.BestebroerT.M.HerfstS.SmithD.RimmelzwaanG.F.OlsenB.OsterhausA.D.Characterization of a"/>
   <result pre="A virus from Egyptian batsJ. Virol.201993e01059-1810.1128/JVI.01059-1830381492 22.FouchierR.A.MunsterV.WallenstenA.BestebroerT.M.HerfstS.SmithD.RimmelzwaanG.F.OlsenB.OsterhausA.D.Characterization of a novel" exact="influenza" post="A virus hemagglutinin subtype (H16) obtained from black-headed gullsJ."/>
   <result pre="black-headed gullsJ. Virol.2005792814282210.1128/JVI.79.5.2814-2822.200515709000 23.GaoR.CaoB.HuY.FengZ.WangD.HuW.ChenJ.JieZ.QiuH.XuK.et al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virusN. Engl. J. Med.20133681888189710.1056/NEJMoa130445923577628 24.CuiL.LiuD.ShiW.PanJ.QiX.LiX.GuoX.ZhouM.LiW.LiJ.et al.Dynamic reassortments"/>
   <result pre="Med.20133681888189710.1056/NEJMoa130445923577628 24.CuiL.LiuD.ShiW.PanJ.QiX.LiX.GuoX.ZhouM.LiW.LiJ.et al.Dynamic reassortments and genetic heterogeneity of the human-infecting" exact="influenza" post="A (H7N9) virusNat. Commun.20145314210.1038/ncomms414224457975 25.WuA.SuC.WangD.PengY.LiuM.HuaS.LiT.GaoG.F.TangH.ChenJ.et al.Sequential reassortments underlie diverse"/>
   <result pre="influenza A (H7N9) virusNat. Commun.20145314210.1038/ncomms414224457975 25.WuA.SuC.WangD.PengY.LiuM.HuaS.LiT.GaoG.F.TangH.ChenJ.et al.Sequential reassortments underlie diverse" exact="influenza" post="H7N9 genotypes in ChinaCell Host Microbe20131444645210.1016/j.chom.2013.09.00124055604 26.LamT.T.-Y.WangJ.ShenY.ZhouB.DuanL.CheungC.-L.MaC.LycettS.J.LeungC.Y.-H.ChenX.The genesis and"/>
   <result pre="ChinaCell Host Microbe20131444645210.1016/j.chom.2013.09.00124055604 26.LamT.T.-Y.WangJ.ShenY.ZhouB.DuanL.CheungC.-L.MaC.LycettS.J.LeungC.Y.-H.ChenX.The genesis and source of the H7N9" exact="influenza" post="viruses causing human infections in ChinaNature201350224124410.1038/nature1251523965623 27.LamT.T.-Y.ZhouB.WangJ.ChaiY.ShenY.ChenX.MaC.HongW.ChenY.ZhangY.Dissemination, divergence and"/>
   <result pre="human infections in ChinaNature201350224124410.1038/nature1251523965623 27.LamT.T.-Y.ZhouB.WangJ.ChaiY.ShenY.ChenX.MaC.HongW.ChenY.ZhangY.Dissemination, divergence and establishment of H7N9" exact="influenza" post="viruses in ChinaNature201552210210510.1038/nature1434825762140 28.SuzukiY.ItoT.SuzukiT.HollandR.E.ChambersT.M.KisoM.IshidaH.KawaokaY.Sialic acid species as a determinant"/>
   <result pre="acid species as a determinant of the host range of" exact="influenza" post="A virusesJ. Virol.200074118251183110.1128/JVI.74.24.11825-11831.200011090182 29.MatrosovichM.HerrlerG.KlenkH.D.Sialic acid receptors of virusesSialoGlyco Chemistry"/>
   <result pre="31.De VriesR.P.PengW.GrantO.C.ThompsonA.J.ZhuX.BouwmanK.M.de la PenaA.T.T.van BreemenM.J.WickramasingheI.N.A.de HaanC.A.et al.Three mutations switch H7N9" exact="influenza" post="to human-type receptor specificityPLoS Pathog.201713e100639010.1371/journal.ppat.100639028617868 32.HuangD.T.-N.LuC.-Y.ChiY.-H.LiW.-L.ChangL.-Y.LaiM.-J.ChenJ.-S.HsuW.-M.HuangL.-M.Adaptation of influenza A"/>
   <result pre="switch H7N9 influenza to human-type receptor specificityPLoS Pathog.201713e100639010.1371/journal.ppat.100639028617868 32.HuangD.T.-N.LuC.-Y.ChiY.-H.LiW.-L.ChangL.-Y.LaiM.-J.ChenJ.-S.HsuW.-M.HuangL.-M.Adaptation of" exact="influenza" post="A (H7N9) virus in primary human airway epithelial cellsSci."/>
   <result pre="human airway epithelial cellsSci. Rep.201771130010.1038/s41598-017-10749-528900138 33.TharakaramanK.JayaramanA.RamanR.ViswanathanK.StebbinsN.W.JohnsonD.ShriverZ.SasisekharanV.SasisekharanR.Glycan receptor binding of the" exact="influenza" post="A virus H7N9 hemagglutininCell20131531486149310.1016/j.cell.2013.05.03423746830 34.CowlingB.J.IpD.K.M.FangV.J.SuntarattiwongP.OlsenS.J.LevyJ.UyekiT.M.LeungG.M.PeirisJ.M.ChotpitayasunondhT.et al.Aerosol transmission is an"/>
   <result pre="H7N9 hemagglutininCell20131531486149310.1016/j.cell.2013.05.03423746830 34.CowlingB.J.IpD.K.M.FangV.J.SuntarattiwongP.OlsenS.J.LevyJ.UyekiT.M.LeungG.M.PeirisJ.M.ChotpitayasunondhT.et al.Aerosol transmission is an important mode of" exact="influenza" post="A virus spreadNat. Commun.20134193510.1038/ncomms292223736803 35.LentzT.L.Binding of viral attachment protein"/>
   <result pre="HA and polymerase subunit PB2 proteins confer transmission of an" exact="avian influenza" post="virus through the airProc. Natl. Acad. Sci. USA20091063366337110.1073/pnas.081317210619211790 37.WangX.WuP.PeiY.TsangT.K.GuD.WangW.ZhangJ.HorbyP.W.UyekiT.M.CowlingB.J.Assessment"/>
   <result pre="and polymerase subunit PB2 proteins confer transmission of an avian" exact="influenza" post="virus through the airProc. Natl. Acad. Sci. USA20091063366337110.1073/pnas.081317210619211790 37.WangX.WuP.PeiY.TsangT.K.GuD.WangW.ZhangJ.HorbyP.W.UyekiT.M.CowlingB.J.Assessment"/>
   <result pre="airProc. Natl. Acad. Sci. USA20091063366337110.1073/pnas.081317210619211790 37.WangX.WuP.PeiY.TsangT.K.GuD.WangW.ZhangJ.HorbyP.W.UyekiT.M.CowlingB.J.Assessment of human-to-human transmissibility of" exact="avian influenza" post="A (H7N9) virus across 5 waves by analyzing clusters"/>
   <result pre="Natl. Acad. Sci. USA20091063366337110.1073/pnas.081317210619211790 37.WangX.WuP.PeiY.TsangT.K.GuD.WangW.ZhangJ.HorbyP.W.UyekiT.M.CowlingB.J.Assessment of human-to-human transmissibility of avian" exact="influenza" post="A (H7N9) virus across 5 waves by analyzing clusters"/>
   <result pre="of the hemagglutinin from the fifth epidemic wave A (H7N9)" exact="influenza" post="virusesJ. Virol.201892e00375-1810.1128/JVI.00375-1829848588 40.MaW.LagerK.VincentA.JankeB.GramerM.RichtJ.The role of swine in the generation"/>
   <result pre="Virol.201892e00375-1810.1128/JVI.00375-1829848588 40.MaW.LagerK.VincentA.JankeB.GramerM.RichtJ.The role of swine in the generation of novel" exact="influenza" post="virusesZoonoses Public Health20095632633710.1111/j.1863-2378.2008.01217.x19486316 41.XuR.de VriesR.P.ZhuX.NycholatC.M.McBrideR.YuW.PaulsonJ.C.WilsonI.A.Preferential recognition of avian-like receptors"/>
   <result pre="Public Health20095632633710.1111/j.1863-2378.2008.01217.x19486316 41.XuR.de VriesR.P.ZhuX.NycholatC.M.McBrideR.YuW.PaulsonJ.C.WilsonI.A.Preferential recognition of avian-like receptors in human" exact="influenza" post="A H7N9 virusesScience20133421230123510.1126/science.124376124311689 42.ConnorR.J.KawaokaY.WebsterR.G.PaulsonJ.C.Receptor specificity in human, avian, and"/>
   <result pre="42.ConnorR.J.KawaokaY.WebsterR.G.PaulsonJ.C.Receptor specificity in human, avian, and equine H2 and H3" exact="influenza" post="virus isolatesVirology1994205172310.1006/viro.1994.16157975212 43.MatrosovichM.TuzikovA.BovinN.GambaryanA.KlimovA.CastrucciM.R.DonatelliI.KawaokaY.Early alterations of the receptor-binding properties of"/>
   <result pre="alterations of the receptor-binding properties of H1, H2, and H3" exact="avian influenza" post="virus hemagglutinins after their introduction into mammalsJ. Virol.2000748502851210.1128/JVI.74.18.8502-8512.200010954551 44.DingX.LuoJ.QuanL.WuA.JiangT.Evolutionary"/>
   <result pre="of the receptor-binding properties of H1, H2, and H3 avian" exact="influenza" post="virus hemagglutinins after their introduction into mammalsJ. Virol.2000748502851210.1128/JVI.74.18.8502-8512.200010954551 44.DingX.LuoJ.QuanL.WuA.JiangT.Evolutionary"/>
   <result pre="hemagglutinins after their introduction into mammalsJ. Virol.2000748502851210.1128/JVI.74.18.8502-8512.200010954551 44.DingX.LuoJ.QuanL.WuA.JiangT.Evolutionary genotypes of" exact="influenza" post="A (H7N9) viruses over five epidemic waves in ChinaInfect."/>
   <result pre="in ChinaInfect. Genet. Evol.20175526927610.1016/j.meegid.2017.09.02728943407 45.KeC.MokC.K.P.ZhuW.ZhouH.HeJ.GuanW.WuJ.SongW.WangD.LiuJ.et al.Human infection with highly pathogenic" exact="avian influenza" post="A (H7N9) virus, ChinaEmerg. Infect. Dis.201723133210.3201/eid2308.17060028580899 46.GabrielG.DauberB.WolffT.PlanzO.KlenkH.-D.StechJ.The viral polymerase"/>
   <result pre="ChinaInfect. Genet. Evol.20175526927610.1016/j.meegid.2017.09.02728943407 45.KeC.MokC.K.P.ZhuW.ZhouH.HeJ.GuanW.WuJ.SongW.WangD.LiuJ.et al.Human infection with highly pathogenic avian" exact="influenza" post="A (H7N9) virus, ChinaEmerg. Infect. Dis.201723133210.3201/eid2308.17060028580899 46.GabrielG.DauberB.WolffT.PlanzO.KlenkH.-D.StechJ.The viral polymerase"/>
   <result pre="ChinaEmerg. Infect. Dis.201723133210.3201/eid2308.17060028580899 46.GabrielG.DauberB.WolffT.PlanzO.KlenkH.-D.StechJ.The viral polymerase mediates adaptation of an" exact="avian influenza" post="virus to a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="Infect. Dis.201723133210.3201/eid2308.17060028580899 46.GabrielG.DauberB.WolffT.PlanzO.KlenkH.-D.StechJ.The viral polymerase mediates adaptation of an avian" exact="influenza" post="virus to a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318 47.LeQ.M.Sakai-TagawaY.OzawaM.ItoM.KawaokaY.Selection of H5N1" exact="influenza" post="virus PB2 during replication in humansJ. Virol.2009835278528110.1128/JVI.00063-0919264775 48.HattaM.GaoP.HalfmannP.KawaokaY.Molecular basis"/>
   <result pre="Virol.2009835278528110.1128/JVI.00063-0919264775 48.HattaM.GaoP.HalfmannP.KawaokaY.Molecular basis for high virulence of Hong Kong H5N1" exact="influenza" post="A virusesScience20012931840184210.1126/science.106288211546875 49.MokC.K.P.LeeH.H.Y.LestraM.NichollsJ.M.ChanC.W.M.SiaS.F.ZhuH.PoonL.L.M.GuanY.PeirisJ.M.S.Amino acid substitutions in polymerase basic protein"/>
   <result pre="2 gene contributes to the pathogenicity of the novel A/H7N9" exact="influenza" post="virus in mammalian hostsJ. Virol.2014883568357610.1128/JVI.02740-1324403592 50.LiW.LeeH.H.Y.LiR.F.ZhuH.M.YiG.PeirisJ.S.M.YangZ.F.MokC.K.P.The PB2 mutation with"/>
   <result pre="PB2 mutation with lysine at 627 enhances the pathogenicity of" exact="avian influenza" post="(H7N9) virus which belongs to a non-zoonotic lineageSci. Rep.201771110.1038/s41598-017-02598-z28127060"/>
   <result pre="mutation with lysine at 627 enhances the pathogenicity of avian" exact="influenza" post="(H7N9) virus which belongs to a non-zoonotic lineageSci. Rep.201771110.1038/s41598-017-02598-z28127060"/>
   <result pre="Rep.201771110.1038/s41598-017-02598-z28127060 51.YamayoshiS.FukuyamaS.YamadaS.ZhaoD.MurakamiS.UrakiR.WatanabeT.TomitaY.NeumannG.KawaokaY.Amino acids substitutions in the PB2 protein of H7N9" exact="influenza" post="A viruses are important for virulence in mammalian hostsSci."/>
   <result pre="V promotes the mammalian adaptation of H10N8, H7N9 and H9N2" exact="avian influenza" post="virusesSci. Rep.201661947410.1038/srep1947426782141 53.BentonD.J.WhartonS.A.MartinS.R.McCauleyJ.W.Role of neuraminidase in influenza A (H7N9)"/>
   <result pre="promotes the mammalian adaptation of H10N8, H7N9 and H9N2 avian" exact="influenza" post="virusesSci. Rep.201661947410.1038/srep1947426782141 53.BentonD.J.WhartonS.A.MartinS.R.McCauleyJ.W.Role of neuraminidase in influenza A (H7N9)"/>
   <result pre="and H9N2 avian influenza virusesSci. Rep.201661947410.1038/srep1947426782141 53.BentonD.J.WhartonS.A.MartinS.R.McCauleyJ.W.Role of neuraminidase in" exact="influenza" post="A (H7N9) receptor bindingJ. Virol.201791e02293-1610.1128/JVI.02293-1628356530 54.DaiM.McBrideR.DortmansJ.C.PengW.BakkersM.J.de GrootR.J.van KuppeveldF.J.PaulsonJ.C.de VriesE.de"/>
   <result pre="site resulting in reduced neuraminidase activity preceded emergence of H7N9" exact="influenza" post="a virusJ. Virol.201791e00049-1710.1128/JVI.00049-1728202753 55.GuoH.RabouwH.SlompA.DaiM.van der VegtF.van LentJ.W.McBrideR.PaulsonJ.C.de GrootR.J.van KuppeveldF.J.et"/>
   <result pre="55.GuoH.RabouwH.SlompA.DaiM.van der VegtF.van LentJ.W.McBrideR.PaulsonJ.C.de GrootR.J.van KuppeveldF.J.et al.Kinetic analysis of the" exact="influenza" post="A virus HA/NA balance reveals contribution of NA to"/>
   <result pre="deletion in neuraminidase stalk strengthen human tropism of the novel" exact="avian influenza" post="virus H7N9 in China, 2013?Int. J. Environ. Res. Public"/>
   <result pre="in neuraminidase stalk strengthen human tropism of the novel avian" exact="influenza" post="virus H7N9 in China, 2013?Int. J. Environ. Res. Public"/>
   <result pre="in miceJ. Virol.2016902142214910.1128/JVI.02553-1526656694 58.WagnerR.MatrosovichM.KlenkH.D.Functional balance between haemagglutinin and neuraminidase in" exact="influenza" post="virus infectionsRev. Med. Virol.20021215916610.1002/rmv.35211987141 59.MatsuokaY.SwayneD.E.ThomasC.Rameix-WeltiM.-A.NaffakhN.WarnesC.AltholtzM.DonisR.SubbaraoK.Neuraminidase stalk length and additional"/>
   <result pre="and additional glycosylation of the hemagglutinin influence the virulence of" exact="influenza" post="H5N1 viruses for miceJ. Virol.2009834704470810.1128/JVI.01987-0819225004 60.ZhouH.YuZ.HuY.TuJ.ZouW.PengY.ZhuJ.LiY.ZhangA.YuZ.The special neuraminidase stalk-motif"/>
   <result pre="neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1" exact="influenza" post="A virusPLoS ONE20094e627710.1371/journal.pone.000627719609439 Figure 1 Diagrammatic representation of the"/>
   <result pre="influenza A virusPLoS ONE20094e627710.1371/journal.pone.000627719609439 Figure 1 Diagrammatic representation of the" exact="influenza" post="A virus (IAV) and its viral genome. Eight internal"/>
   <result pre="Figure 2 Aquatic birds remain the principal reservoir of all" exact="influenza" post="viruses. Cross-species transmission adds to viral reassortment and mixing"/>
   <result pre="and mixing possibilities with swine acting as mixing vessels for" exact="influenza" post="viruses uniquely adapted to birds and humans. Adapted by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7286216\results\search\disease\results.xml">
   <result pre="data. Abstract Background Hepatitis E virus (HEV) generally causes self-limiting" exact="viral hepatitis." post="However, in pregnant women, HEV infection can be severe"/>
   <result pre="is a hepatotropic infectious agent that generally causes self-limiting acute" exact="hepatitis" post="in healthy adults and chronic hepatitis in immunocompromised individuals"/>
   <result pre="generally causes self-limiting acute hepatitis in healthy adults and chronic" exact="hepatitis" post="in immunocompromised individuals [1]. Annually, there are an estimated"/>
   <result pre="are an estimated 20 million HEV infections, 3.3 million symptomatic" exact="hepatitis" post="E cases, and 60,000 deaths worldwide [1, 2]. In"/>
   <result pre="manifestations, including pancreatitis, neurological symptoms, hematological disorders, glomerulonephritis, and mixed" exact="cryoglobulinemia" post="have been associated with HEV infection [1, 3]. HEV"/>
   <result pre="countries and are associated with sporadic and clustered cases of" exact="hepatitis" post="E in these regions [1, 4]. In recent years,"/>
   <result pre="therapy can be fairly efficient in most cases of chronic" exact="hepatitis" post="E [1, 2, 13, 14]. In some specific situations,"/>
   <result pre="against HEV, particularly for pregnant women [1, 15]. A recombinant" exact="hepatitis" post="E vaccine, HEV 239, has been demonstrated to be"/>
   <result pre="to be well tolerated and effective in the prevention of" exact="hepatitis" post="E in China; however, it is currently only approved"/>
   <result pre="available elsewhere [2, 16, 17]. HEV infection can cause fulminant" exact="hepatitis" post="failure (FHF), especially in pregnant women, with a mortality"/>
   <result pre="[12, 17] (Fig. 1). Fig. 1 Schematic description of the" exact="hepatitis" post="E virus (HEV) genome and viral proteins. The HEV"/>
   <result pre="field study carried out by Khuroo et al. showed that" exact="hepatitis" post="E developed in 36 (17.3%) of 208 pregnant women,"/>
   <result pre="developed in 8 (22.2%) of the 36 pregnant women with" exact="hepatitis" post="E. In contrast, none of the nonpregnant women showed"/>
   <result pre="the first time, this study revealed that the incidence of" exact="hepatitis" post="E and fulminant rates were higher in pregnant women"/>
   <result pre="subcontinent reported that the prevalence rate of HEV in acute" exact="viral hepatitis" post="during pregnancy ranged from 58 to 86% [44–46]. HEV"/>
   <result pre="reported that the prevalence rate of HEV in acute viral" exact="hepatitis" post="during pregnancy ranged from 58 to 86% [44–46]. HEV"/>
   <result pre="47, 48]. The frequent occurrence of other complications, such as" exact="disseminated intravascular coagulation" post="(DIC), is also associated with HEV infection in pregnant"/>
   <result pre="HEV-4 do not appear to cause fatal infections with fulminant" exact="hepatitis" post="in pregnant women [10, 49]. However, considering that the"/>
   <result pre="for HEV, and HEV-4 is currently the dominant cause of" exact="hepatitis" post="E [52, 53]. HEV infection has considerable potential for"/>
   <result pre="rate. It is estimated that in patients suffering from chronic" exact="liver disease" post="(e.g., hepatitis B virus (HBV) infection), these infections often"/>
   <result pre="estimated that in patients suffering from chronic liver disease (e.g.," exact="hepatitis" post="B virus (HBV) infection), these infections often progress to"/>
   <result pre="and anti-HEV IgG-positive pregnant women. In pregnant women with chronic" exact="hepatitis" post="C virus (HCV) coinfection, a marked increase in anti-HEV"/>
   <result pre="infections combined with HEV infection in pregnancy. Clinical manifestations Acute" exact="hepatitis" post="E According to previous data, the clinical manifestations of"/>
   <result pre="with HAV, patients with HEV are known to have prolonged" exact="cholestasis" post="[68]. Mansuy et al. [69] studied 62 confirmed cases"/>
   <result pre="Mansuy et al. [69] studied 62 confirmed cases of acute" exact="hepatitis" post="E over a 5 year period in south-west France and"/>
   <result pre="encephalopathy, appear to occur at a higher rate [18]. Hepatic" exact="encephalopathy" post="is the most common cause of death among these"/>
   <result pre="newborn have also been observed in these patients [72]. Chronic" exact="hepatitis" post="E Chronic HEV infection is defined as an HEV"/>
   <result pre="for HEV-3 and 4, leading to life-threatening liver fibrosis and" exact="cirrhosis" post="[75, 80, 83–85]. It has been reported that HEV-3"/>
   <result pre="83–85]. It has been reported that HEV-3 can cause acute" exact="hepatitis" post="E in pregnant women, followed by rapid clearance without"/>
   <result pre="any signs of severe courses [50, 51]. Extrahepatic manifestations of" exact="hepatitis" post="E Acute or chronic or previous HEV infection can"/>
   <result pre="range of neurological symptoms and impaired kidney function associated with" exact="cryoglobulinemia" post="[84, 88]. Other extrahepatic manifestations documented in the literature"/>
   <result pre="[84, 88]. Other extrahepatic manifestations documented in the literature include" exact="acute thyroiditis" post="[89], thrombocytopenia [90], and acute pancreatitis [91]. However, it"/>
   <result pre="88]. Other extrahepatic manifestations documented in the literature include acute" exact="thyroiditis" post="[89], thrombocytopenia [90], and acute pancreatitis [91]. However, it"/>
   <result pre="extrahepatic manifestations documented in the literature include acute thyroiditis [89]," exact="thrombocytopenia" post="[90], and acute pancreatitis [91]. However, it remains uncertain"/>
   <result pre="in the literature include acute thyroiditis [89], thrombocytopenia [90], and" exact="acute pancreatitis" post="[91]. However, it remains uncertain whether extrahepatic manifestations of"/>
   <result pre="the literature include acute thyroiditis [89], thrombocytopenia [90], and acute" exact="pancreatitis" post="[91]. However, it remains uncertain whether extrahepatic manifestations of"/>
   <result pre="the disease, especially for infections such as influenza, cytomegalovirus (CMV)," exact="severe acute respiratory syndrome" post="(SARS), varicella- zoster, malaria, and herpes simplex virus (HSV)"/>
   <result pre="(CMV), severe acute respiratory syndrome (SARS), varicella- zoster, malaria, and" exact="herpes simplex" post="virus (HSV) infection, in which cell-mediated immunity is important"/>
   <result pre="higher than those in nonpregnant women and women with acute" exact="viral hepatitis" post="(AVH) without FHF. An analysis of the NF-κB complex"/>
   <result pre="than those in nonpregnant women and women with acute viral" exact="hepatitis" post="(AVH) without FHF. An analysis of the NF-κB complex"/>
   <result pre="In contrast, the association of increased incidence and severity of" exact="hepatitis" post="E in pregnant women infected with HEV-1 or HEV-2"/>
   <result pre="patients [124]. V239A mutation in ORF1-encoded Hel identified in severe" exact="hepatitis" post="cases might be associated with increased virulence of the"/>
   <result pre="adults, three doses of HEV 239 (30 μg of purified recombinant" exact="hepatitis" post="E antigen absorbed to 0.8 mg of aluminium hydroxide suspended"/>
   <result pre="HEV-3 Genotypes 3 HEV-4 Genotypes 4 IFN-α Interferon-α FHF Fulminant" exact="hepatitis" post="failure eHEV Enveloped HEV UTR Untranslated region ORFs Open"/>
   <result pre="Severe acute respiratory syndrome HSV Herpes simplex virus AVH Acute" exact="viral hepatitis" post="HCG Human chorionic gonadotropin PR Progesterone receptor PROGINS Progesterone"/>
   <result pre="acute respiratory syndrome HSV Herpes simplex virus AVH Acute viral" exact="hepatitis" post="HCG Human chorionic gonadotropin PR Progesterone receptor PROGINS Progesterone"/>
   <result pre="E. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-e. Accessed 8 July 2019. 3.BazerbachiFHaffarSGargSKLakeJRExtra-hepatic manifestations associated with" exact="hepatitis" post="E virus infection: a comprehensive review of the literatureGastroenterol"/>
   <result pre="control and cureWorld J Gastroenterol2016227030704527610014 5.MengXJZoonotic and foodborne transmission of" exact="hepatitis" post="E virusSemin Liver Dis201333414923564388 6.RivadullaEVarelaMFMesquitaJRNascimentoMSJRomaldeJLDetection of hepatitis E virus"/>
   <result pre="foodborne transmission of hepatitis E virusSemin Liver Dis201333414923564388 6.RivadullaEVarelaMFMesquitaJRNascimentoMSJRomaldeJLDetection of" exact="hepatitis" post="E virus in shellfish harvesting areas from Galicia (northwestern"/>
   <result pre="shellfish harvesting areas from Galicia (northwestern Spain)Viruses2019117618 7.GengYZhaoCGengKWangCWangXLiuHWangYHigh seroprevalence of" exact="hepatitis" post="E virus in rabbit slaughterhouse workersTransbound Emerg Dis2019661085108930661292 8.SaidBIjazSKafatosGBoothLThomasHLWalshARamsayMMorganDHepatitisEIITHepatitis"/>
   <result pre="E outbreak on cruise shipEmerg Infect Dis2009151738174419891860 9.TeiSKitajimaNTakahashiKMishiroSZoonotic transmission of" exact="hepatitis" post="E virus from deer to human beingsLancet200336237137312907011 10.CapaiLCharrelRFalchiAHepatitis E"/>
   <result pre="shift to screening?Euro Surveill201722163051428449730 12.HimmelsbachKBenderDHildtELife cycle and morphogenesis of the" exact="hepatitis" post="E virusEmerg Microbes Infect2018719630498191 13.Kamar N, Abravanel F, Behrendt"/>
   <result pre="L, Horvatits T, De Man RA, et al. Ribavirin for" exact="hepatitis" post="E virus infection after organ transplantation: a large European"/>
   <result pre="study. Clin Infect Dis. 2019. 10.1093/cid/ciz953. 14.KamarNIzopetJTriponSBismuthMHillaireSDumortierJRadenneSCoillyAGarrigueVD'AlterocheLet al.Ribavirin for chronic" exact="hepatitis" post="E virus infection in transplant recipientsN Engl J Med20143701111112024645943"/>
   <result pre="infection in transplant recipientsN Engl J Med20143701111112024645943 15.ShaoZAl TibiMWakim-FlemingJUpdate on" exact="viral hepatitis" post="in pregnancyCleve Clin J Med20178420220628322675 16.ZhuFCZhangJZhangXFZhouCWangZZHuangSJWangHYangCLJiangHMCaiJPet al.Efficacy and safety"/>
   <result pre="in transplant recipientsN Engl J Med20143701111112024645943 15.ShaoZAl TibiMWakim-FlemingJUpdate on viral" exact="hepatitis" post="in pregnancyCleve Clin J Med20178420220628322675 16.ZhuFCZhangJZhangXFZhouCWangZZHuangSJWangHYangCLJiangHMCaiJPet al.Efficacy and safety"/>
   <result pre="Clin J Med20178420220628322675 16.ZhuFCZhangJZhangXFZhouCWangZZHuangSJWangHYangCLJiangHMCaiJPet al.Efficacy and safety of a recombinant" exact="hepatitis" post="E vaccine in healthy adults: a large-scale, randomised, double-blind"/>
   <result pre="placebo-controlled, phase 3 trialLancet201037689590220728932 17.KenneySPMengXJTherapeutic targets for the treatment of" exact="hepatitis" post="E virus infectionExpert Opin Ther Targets2015191245126026073772 18.KhurooMSKamiliSAetiology, clinical course"/>
   <result pre="Ther Targets2015191245126026073772 18.KhurooMSKamiliSAetiology, clinical course and outcome of sporadic acute" exact="viral hepatitis" post="in pregnancyJ Viral Hepat200310616912558914 19.Perez-GraciaMTSuay-GarciaBMateos-LindemannMLHepatitis E and pregnancy: current"/>
   <result pre="Targets2015191245126026073772 18.KhurooMSKamiliSAetiology, clinical course and outcome of sporadic acute viral" exact="hepatitis" post="in pregnancyJ Viral Hepat200310616912558914 19.Perez-GraciaMTSuay-GarciaBMateos-LindemannMLHepatitis E and pregnancy: current"/>
   <result pre="Virol2017273e192928318080 20.PatraSKumarATrivediSSPuriMSarinSKMaternal and fetal outcomes in pregnant women with acute" exact="hepatitis" post="E virus infectionAnn Intern Med2007147283317606958 21.KhurooMSKhurooMSKhurooNSTransmission of hepatitis E"/>
   <result pre="with acute hepatitis E virus infectionAnn Intern Med2007147283317606958 21.KhurooMSKhurooMSKhurooNSTransmission of" exact="hepatitis" post="E virus in developing countriesViruses201689253 22.KhurooMSKamiliSKhurooMSClinical course and duration"/>
   <result pre="countriesViruses201689253 22.KhurooMSKamiliSKhurooMSClinical course and duration of viremia in vertically transmitted" exact="hepatitis" post="E virus (HEV) infection in babies born to HEV-infected"/>
   <result pre="babies born to HEV-infected mothersJ Viral Hepat20091651952319228284 23.DebingYNeytsJAntiviral strategies for" exact="hepatitis" post="E virusAntivir Res201410210611824374149 24.KinastVBurkardTLTodtDSteinmannEHepatitis E virus drug developmentViruses2019116485 25.SinclairSMJonesJKMillerRKGreeneMFKwoPYMaddreyWCThe"/>
   <result pre="26.EmersonSUPurcellRHHepatitis E Virus2013PhiladelphiaLippincott Williams &amp;amp; Wilkins 27.KarpeYALoleKSDeubiquitination activity associated with" exact="hepatitis" post="E virus putative papain-like cysteine proteaseJ Gen Virol2011922088209221653754 28.LhommeSAbravanelFDuboisMSandres-SauneKMansuyJMRostaingLKamarNIzopetJCharacterization"/>
   <result pre="proteaseJ Gen Virol2011922088209221653754 28.LhommeSAbravanelFDuboisMSandres-SauneKMansuyJMRostaingLKamarNIzopetJCharacterization of the polyproline region of the" exact="hepatitis" post="E virus in immunocompromised patientsJ Virol201488120171202525100839 29.KarpeYALoleKSRNA 5′-triphosphatase activity"/>
   <result pre="virus in immunocompromised patientsJ Virol201488120171202525100839 29.KarpeYALoleKSRNA 5′-triphosphatase activity of the" exact="hepatitis" post="E virus helicase domainJ Virol2010849637964120592074 30.KarpeYALoleKSNTPase and 5′ to"/>
   <result pre="30.KarpeYALoleKSNTPase and 5′ to 3′ RNA duplex-unwinding activities of the" exact="hepatitis" post="E virus helicase domainJ Virol2010843595360220071563 31.AgrawalSGuptaDPandaSKThe 3′ end of"/>
   <result pre="hepatitis E virus helicase domainJ Virol2010843595360220071563 31.AgrawalSGuptaDPandaSKThe 3′ end of" exact="hepatitis" post="E virus (HEV) genome binds specifically to the viral"/>
   <result pre="to the viral RNA-dependent RNA polymerase (RdRp)Virology20012828710111259193 32.RehmanSKapurNDurgapalHPandaSKSubcellular localization of" exact="hepatitis" post="E virus (HEV) replicaseVirology2008370779217904184 33.KooninEVGorbalenyaAEPurdyMARozanovMNReyesGRBradleyDWComputer-assisted assignment of functional domains"/>
   <result pre="33.KooninEVGorbalenyaAEPurdyMARozanovMNReyesGRBradleyDWComputer-assisted assignment of functional domains in the nonstructural polyprotein of" exact="hepatitis" post="E virus: delineation of an additional group of positive-strand"/>
   <result pre="subgenomic mRNA encodes both the ORF2 and ORF3 proteins of" exact="hepatitis" post="E virusJ Virol2006805919592616731930 35.YinXYingDLhommeSTangZWalkerCMXiaNZhengZFengZOrigin, antigenicity, and function of a"/>
   <result pre="antigenicity, and function of a secreted form of ORF2 in" exact="hepatitis" post="E virus infectionProc Natl Acad Sci U S A20181154773477829669922"/>
   <result pre="of the ORF2 capsid proteinGastroenterology2018154211223.e21828958858 37.CaoDMengXJMolecular biology and replication of" exact="hepatitis" post="E virusEmerg Microbes Infect20121e1726038426 38.YinXAmbardekarCLuYFengZDistinct entry mechanisms for nonenveloped"/>
   <result pre="virusEmerg Microbes Infect20121e1726038426 38.YinXAmbardekarCLuYFengZDistinct entry mechanisms for nonenveloped and quasi-enveloped" exact="hepatitis" post="E virusesJ Virol2016904232424226865708 39.PerttilaJSpuulPAholaTEarly secretory pathway localization and lack"/>
   <result pre="Virol2016904232424226865708 39.PerttilaJSpuulPAholaTEarly secretory pathway localization and lack of processing for" exact="hepatitis" post="E virus replication protein pORF1J Gen Virol20139480781623255617 40.GraffJNguyenHKasorndorkbuaCHalburPGSt ClaireMPurcellRHEmersonSUIn"/>
   <result pre="and in vivo mutational analysis of the 3′-terminal regions of" exact="hepatitis" post="e virus genomes and repliconsJ Virol2005791017102615613330 41.SurjitMJameelSLalSKThe ORF2 protein"/>
   <result pre="e virus genomes and repliconsJ Virol2005791017102615613330 41.SurjitMJameelSLalSKThe ORF2 protein of" exact="hepatitis" post="E virus binds the 5′ region of viral RNAJ"/>
   <result pre="of viral RNAJ Virol20047832032814671114 42.KarPSenguptaAA guide to the management of" exact="hepatitis" post="E infection during pregnancyExpert Rev Gastroenterol Hepatol20191320521130791760 43.KhurooMSTeliMRSkidmoreSSofiMAKhurooMIIncidence and"/>
   <result pre="infection during pregnancyExpert Rev Gastroenterol Hepatol20191320521130791760 43.KhurooMSTeliMRSkidmoreSSofiMAKhurooMIIncidence and severity of" exact="viral hepatitis" post="in pregnancyAm J Med1981702522556781338 44.JaiswalSPJainAKNaikGSoniNChitnisDSViral hepatitis during pregnancyInt J"/>
   <result pre="during pregnancyExpert Rev Gastroenterol Hepatol20191320521130791760 43.KhurooMSTeliMRSkidmoreSSofiMAKhurooMIIncidence and severity of viral" exact="hepatitis" post="in pregnancyAm J Med1981702522556781338 44.JaiswalSPJainAKNaikGSoniNChitnisDSViral hepatitis during pregnancyInt J"/>
   <result pre="and severity of viral hepatitis in pregnancyAm J Med1981702522556781338 44.JaiswalSPJainAKNaikGSoniNChitnisDSViral" exact="hepatitis" post="during pregnancyInt J Gynaecol Obstet20017210310811166742 45.AzizABHamidSIqbalSIslamWKarimSAPrevalence and severity of"/>
   <result pre="hepatitis during pregnancyInt J Gynaecol Obstet20017210310811166742 45.AzizABHamidSIqbalSIslamWKarimSAPrevalence and severity of" exact="viral hepatitis" post="in Pakistani pregnant women: a five year hospital based"/>
   <result pre="during pregnancyInt J Gynaecol Obstet20017210310811166742 45.AzizABHamidSIqbalSIslamWKarimSAPrevalence and severity of viral" exact="hepatitis" post="in Pakistani pregnant women: a five year hospital based"/>
   <result pre="a five year hospital based studyJ Pak Med Assoc1997471982019339616 46.DahiyaMKumarAKarPGuptaRKKumarAAcute" exact="viral hepatitis" post="in third trimester of pregnancyIndian J Gastroenterol20052412812916041115 47.ShresthaPBhandariDSharmaDBhandariBPA study"/>
   <result pre="five year hospital based studyJ Pak Med Assoc1997471982019339616 46.DahiyaMKumarAKarPGuptaRKKumarAAcute viral" exact="hepatitis" post="in third trimester of pregnancyIndian J Gastroenterol20052412812916041115 47.ShresthaPBhandariDSharmaDBhandariBPA study"/>
   <result pre="in third trimester of pregnancyIndian J Gastroenterol20052412812916041115 47.ShresthaPBhandariDSharmaDBhandariBPA study of" exact="viral hepatitis" post="during pregnancy in Nepal medical college teaching hospitalNepal Med"/>
   <result pre="third trimester of pregnancyIndian J Gastroenterol20052412812916041115 47.ShresthaPBhandariDSharmaDBhandariBPA study of viral" exact="hepatitis" post="during pregnancy in Nepal medical college teaching hospitalNepal Med"/>
   <result pre="medical college teaching hospitalNepal Med Coll J20091119219420334069 48.KhurooMSKamiliSJameelSVertical transmission of" exact="hepatitis" post="E virusLancet1995345102510267723501 49.LachishTErezODaudiNShouvalDSchwartzEAcute hepatitis E virus in pregnant women"/>
   <result pre="Med Coll J20091119219420334069 48.KhurooMSKamiliSJameelSVertical transmission of hepatitis E virusLancet1995345102510267723501 49.LachishTErezODaudiNShouvalDSchwartzEAcute" exact="hepatitis" post="E virus in pregnant women in Israel and in"/>
   <result pre="Clin Virol201573202426521225 50.AntyROllierLPeronJMNicandECannavoIBongainAGiordanengoVTranAFirst case report of an acute genotype 3" exact="hepatitis" post="E infected pregnant woman living in south-eastern FranceJ Clin"/>
   <result pre="south-eastern FranceJ Clin Virol201254767822336086 51.TabatabaiJWenzelJJSoboletzkiMFluxCNavidMHSchnitzlerPFirst case report of an acute" exact="hepatitis" post="E subgenotype 3c infection during pregnancy in GermanyJ Clin"/>
   <result pre="3c infection during pregnancy in GermanyJ Clin Virol20146117017224996764 52.LiRCGeSXLiYPZhengYJNongYGuoQSZhangJNgMHXiaNSSeroprevalence of" exact="hepatitis" post="E virus infection, rural southern People's Republic of ChinaEmerg"/>
   <result pre="E virus infection in Wuhan, Central ChinaArch Virol2019164273230229302 54.CongWSuiJCZhangXYQianADChenJZhuXQSeroprevalence of" exact="hepatitis" post="E virus among pregnant women and control subjects in"/>
   <result pre="postpartum evolution during six yearsBMC Infect Dis20151556026653888 56.HuangFMaTLiLZengWJingSLow seroprevalence of" exact="hepatitis" post="E virus infection in pregnant women in Yunnan, ChinaBraz"/>
   <result pre="Infect Dis20131771671724055390 57.DrobeniucJMengJReuterGGreene-MontfortTKhudyakovaNDimitrovaZKamiliSTeoCGSerologic assays specific to immunoglobulin M antibodies against" exact="hepatitis" post="E virus: pangenotypic evaluation of performancesClin Infect Dis201051e24e2720578874 58.KhudyakovYKamiliSSerological"/>
   <result pre="virus: pangenotypic evaluation of performancesClin Infect Dis201051e24e2720578874 58.KhudyakovYKamiliSSerological diagnostics of" exact="hepatitis" post="E virus infectionVirus Res2011161849221704091 59.ArendsJEGhisettiVIrvingWDaltonHRIzopetJHoepelmanAISalmonDHepatitis E: an emerging infection"/>
   <result pre="income countriesJ Clin Virol201459818824388207 60.Al-SadeqDWMajdalawiehAFMeslehAGAbdallaOMNasrallahGKLaboratory challenges in the diagnosis of" exact="hepatitis" post="E virusJ Med Microbiol20186746648029485390 61.Li M, Bu Q, Gong"/>
   <result pre="2019:1–5. 10.1080/14767058.2019.1582630. 62.BouquetJChevalJRogeeSPavioNEloitMIdentical consensus sequence and conserved genomic polymorphism of" exact="hepatitis" post="E virus during controlled interspecies transmissionJ Virol2012866238624522457521 63.AyeTTUchidaTMaXZIidaFShikataTZhuangHWinKMComplete nucleotide"/>
   <result pre="during controlled interspecies transmissionJ Virol2012866238624522457521 63.AyeTTUchidaTMaXZIidaFShikataTZhuangHWinKMComplete nucleotide sequence of a" exact="hepatitis" post="E virus isolated from the Xinjiang epidemic (1986-1988) of"/>
   <result pre="from the Xinjiang epidemic (1986-1988) of ChinaNucleic Acids Res19922035121630924 64.AslamASusheelaAIrianaSChanSSLauDAcute" exact="hepatitis" post="E superinfection leading to chronic hepatitis B reactivationBMJ Case"/>
   <result pre="ChinaNucleic Acids Res19922035121630924 64.AslamASusheelaAIrianaSChanSSLauDAcute hepatitis E superinfection leading to chronic" exact="hepatitis" post="B reactivationBMJ Case Rep20182018bcr2017223616 65.Blasco-PerrinHMaddenRGStanleyACrossanCHunterJGVineLLaneKDevooght-JohnsonNMcLaughlinCPetrikJet al.Hepatitis E virus in"/>
   <result pre="pregnant women in Dakahlya Governorate, EgyptAsian J Transfus Sci2011513613921897591 67.SayedIMVercouterASAbdelwahabSFVercauterenKMeulemanPIs" exact="hepatitis" post="E virus an emerging problem in industrialized countries?Hepatology2015621883189226175182 68.ChauTNLaiSTTseCNgTKLeungVKLimWNgMHEpidemiology"/>
   <result pre="problem in industrialized countries?Hepatology2015621883189226175182 68.ChauTNLaiSTTseCNgTKLeungVKLimWNgMHEpidemiology and clinical features of sporadic" exact="hepatitis" post="E as compared with hepatitis AAm J Gastroenterol200610129229616454833 69.MansuyJMAbravanelFMiedougeMMengelleCMervielCDuboisMKamarNRostaingLAlricLMoreauJet"/>
   <result pre="and clinical features of sporadic hepatitis E as compared with" exact="hepatitis" post="AAm J Gastroenterol200610129229616454833 69.MansuyJMAbravanelFMiedougeMMengelleCMervielCDuboisMKamarNRostaingLAlricLMoreauJet al.Acute hepatitis E in south-west"/>
   <result pre="E as compared with hepatitis AAm J Gastroenterol200610129229616454833 69.MansuyJMAbravanelFMiedougeMMengelleCMervielCDuboisMKamarNRostaingLAlricLMoreauJet al.Acute" exact="hepatitis" post="E in south-west France over a 5-year periodJ Clin"/>
   <result pre="over a 5-year periodJ Clin Virol200944747718993112 70.WedemeyerHPischkeSMannsMPPathogenesis and treatment of" exact="hepatitis" post="e virus infectionGastroenterology201214213881397.e138122537448 71.DonnellyMCScobieLCrossanCLDaltonHHayesPCSimpsonKJReview article: hepatitis E-a concise review"/>
   <result pre="70.WedemeyerHPischkeSMannsMPPathogenesis and treatment of hepatitis e virus infectionGastroenterology201214213881397.e138122537448 71.DonnellyMCScobieLCrossanCLDaltonHHayesPCSimpsonKJReview article:" exact="hepatitis" post="E-a concise review of virology, epidemiology, clinical presentation and"/>
   <result pre="epidemiology, clinical presentation and therapyAliment Pharmacol Ther20174612614128449246 72.RayisDAJumaaAMGasimGIKarsanyMSAdamIAn outbreak of" exact="hepatitis" post="E and high maternal mortality at Port Sudan, eastern"/>
   <result pre="maternal mortality at Port Sudan, eastern SudanPathog Glob Health2013107666823683332 73.KhaskheliMNBalochSSheebaABalochSAcute" exact="hepatitis" post="E viral infection in pregnancy and maternal morbidityJ Coll"/>
   <result pre="pregnancy and maternal morbidityJ Coll Physicians Surg Pak20152573473726454389 74.KamarNRostaingLLegrand-AbravanelFIzopetJHow should" exact="hepatitis" post="E virus infection be defined in organ-transplant recipients?Am J"/>
   <result pre="virus infection be defined in organ-transplant recipients?Am J Transplant2013131935193623659713 75.GerolamiRMoalVColsonPChronic" exact="hepatitis" post="E with cirrhosis in a kidney-transplant recipientN Engl J"/>
   <result pre="defined in organ-transplant recipients?Am J Transplant2013131935193623659713 75.GerolamiRMoalVColsonPChronic hepatitis E with" exact="cirrhosis" post="in a kidney-transplant recipientN Engl J Med200835885986018287615 76.de NietAZaaijerHLten"/>
   <result pre="in a kidney-transplant recipientN Engl J Med200835885986018287615 76.de NietAZaaijerHLten BergeIWeeginkCJReesinkHWBeuersUChronic" exact="hepatitis" post="E after solid organ transplantationNeth J Med20127026126622859417 77.HaagsmaEBvan den"/>
   <result pre="E after solid organ transplantationNeth J Med20127026126622859417 77.HaagsmaEBvan den BergAPPorteRJBenneCAVennemaHReimerinkJHKoopmansMPChronic" exact="hepatitis" post="E virus infection in liver transplant recipientsLiver Transpl20081454755318383084 78.RenouCLafeuilladeACadranelJFPavioNParienteAAllegreTPoggiCPenarandaGCordierFNicandEHepatitis"/>
   <result pre="Transpl20081454755318383084 78.RenouCLafeuilladeACadranelJFPavioNParienteAAllegreTPoggiCPenarandaGCordierFNicandEHepatitis E virus in HIV-infected patientsAIDS2010241493149920467291 79.DaltonHRBendallRPKeaneFETedderRSIjazSPersistent carriage of" exact="hepatitis" post="E virus in patients with HIV infectionN Engl J"/>
   <result pre="virus in patients with HIV infectionN Engl J Med20093611025102719726781 80.GengYZhangHHuangWHarrisonTJGengKLiZWangYPersistent" exact="hepatitis" post="e virus genotype 4 infection in a child with"/>
   <result pre="infection in a child with acute lymphoblastic leukemiaHepat Mon201414e1561824596581 81.GaussAWenzelJJFlechtenmacherCNavidMHEisenbachCJilgWStremmelWSchnitzlerPChronic" exact="hepatitis" post="E virus infection in a patient with leukemia and"/>
   <result pre="Mon201414e1561824596581 81.GaussAWenzelJJFlechtenmacherCNavidMHEisenbachCJilgWStremmelWSchnitzlerPChronic hepatitis E virus infection in a patient with" exact="leukemia" post="and elevated transaminases: a case reportJ Med Case Rep2012633423031738"/>
   <result pre="hematological malignanciesJ Clin Virol20104914114420678959 83.KamarNSelvesJMansuyJMOuezzaniLPeronJMGuitardJCointaultOEspositoLAbravanelFDanjouxMet al.Hepatitis E virus and chronic" exact="hepatitis" post="in organ-transplant recipientsN Engl J Med200835881181718287603 84.LhommeSMarionOAbravanelFIzopetJKamarNClinical manifestations, pathogenesis"/>
   <result pre="recipientsN Engl J Med200835881181718287603 84.LhommeSMarionOAbravanelFIzopetJKamarNClinical manifestations, pathogenesis and treatment of" exact="hepatitis" post="E virus infectionsJ Clin Med202092331 85.KamarNMansuyJMCointaultOSelvesJAbravanelFDanjouxMOtalPEspositoLDurandDIzopetJRostaingLHepatitis E virus-related cirrhosis"/>
   <result pre="of hepatitis E virus infectionsJ Clin Med202092331 85.KamarNMansuyJMCointaultOSelvesJAbravanelFDanjouxMOtalPEspositoLDurandDIzopetJRostaingLHepatitis E virus-related" exact="cirrhosis" post="in kidney- and kidney-pancreas-transplant recipientsAm J Transplant200881744174818557740 86.LhommeSMarionOAbravanelFChapuy-RegaudSKamarNIzopetJHepatitis E"/>
   <result pre="liver?J Hepatol2017661082109527913223 88.KamarNIzopetJPavioNAggarwalRLabriqueAWedemeyerHDaltonHRHepatitis E virus infectionNat Rev Dis Primers201731708629154369 89.DumoulinFLLieseHAcute" exact="hepatitis" post="E virus infection and autoimmune thyroiditis: yet another trigger?BMJ"/>
   <result pre="infection and autoimmune thyroiditis: yet another trigger?BMJ Case Rep20122012bcr122011544122604767 90.FourquetEMansuyJMBureauCRecherCVinelJPIzopetJPeronJMSevere" exact="thrombocytopenia" post="associated with acute autochthonous hepatitis EJ Clin Virol201048737420308017 91.DenielCCotonTBrardjanianSGuissetMNicandESimonFAcute"/>
   <result pre="another trigger?BMJ Case Rep20122012bcr122011544122604767 90.FourquetEMansuyJMBureauCRecherCVinelJPIzopetJPeronJMSevere thrombocytopenia associated with acute autochthonous" exact="hepatitis" post="EJ Clin Virol201048737420308017 91.DenielCCotonTBrardjanianSGuissetMNicandESimonFAcute pancreatitis: a rare complication of"/>
   <result pre="EJ Clin Virol201048737420308017 91.DenielCCotonTBrardjanianSGuissetMNicandESimonFAcute pancreatitis: a rare complication of acute" exact="hepatitis" post="EJ Clin Virol20115120220421628104 92.Munoz-SuanoAHamiltonABBetzAGGimme shelter: the immune system during"/>
   <result pre="and non-selfNat Immunol2005634535215785760 101.PalRAggarwalRNaikSRDasVDasSNaikSImmunological alterations in pregnant women with acute" exact="hepatitis" post="EJ Gastroenterol Hepatol2005201094110115955220 102.WedemeyerHRybczynskaJPischkeSKrawczynskiKImmunopathogenesis of hepatitis E virus infectionSemin"/>
   <result pre="pregnant women with acute hepatitis EJ Gastroenterol Hepatol2005201094110115955220 102.WedemeyerHRybczynskaJPischkeSKrawczynskiKImmunopathogenesis of" exact="hepatitis" post="E virus infectionSemin Liver Dis201333717823564391 103.GuidottiLGChisariFVNoncytolytic control of viral"/>
   <result pre="105.SehgalRPatraSDavidPVyasAKhanamAHissarSGuptaEKumarGKottililSMaiwallRet al.Impaired monocyte-macrophage functions and defective toll-like receptor signaling in" exact="hepatitis" post="E virus-infected pregnant women with acute liver failureHepatology2015621683169626331854 106.PrustyBKHedauSSinghAKarPDasBCSelective"/>
   <result pre="hepatitis E virus-infected pregnant women with acute liver failureHepatology2015621683169626331854 106.PrustyBKHedauSSinghAKarPDasBCSelective" exact="suppression" post="of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe"/>
   <result pre="women with acute liver failureHepatology2015621683169626331854 106.PrustyBKHedauSSinghAKarPDasBCSelective suppression of NF-kBp65 in" exact="hepatitis" post="virus-infected pregnant women manifesting severe liver damage and high"/>
   <result pre="liver damage and high mortalityMol Med20071351852617660862 107.KumarADeviSGKarPAgarwalSHusainSAGuptaRKSharmaSAssociation of cytokines in" exact="hepatitis" post="E with pregnancy outcomeCytokine2014659510424416783 108.KmushBLLabriqueALiWKleinSLSchulzeKShaikhSAliHEngleREWuLPurcellRHet al.The association of cytokines"/>
   <result pre="pregnancy outcomeCytokine2014659510424416783 108.KmushBLLabriqueALiWKleinSLSchulzeKShaikhSAliHEngleREWuLPurcellRHet al.The association of cytokines and micronutrients with" exact="hepatitis" post="E virus infection during pregnancy and the postpartum period"/>
   <result pre="Immunologic dysregulation and micronutrient deficiencies associated with risk of intrapartum" exact="hepatitis" post="E infections in pregnant Bangladeshi women, vol. 26: Federation"/>
   <result pre="alter immune responses and disease pathogenesisHorm Behav20126226327122406114 114.YangCYuWBiYLongFLiYWeiDHaoXSituJZhaoYHuangFIncreased oestradiol in" exact="hepatitis" post="E virus-infected pregnant women promotes viral replicationJ Viral Hepat20182574275129345855"/>
   <result pre="pregnant women promotes viral replicationJ Viral Hepat20182574275129345855 115.BiYYangCYuWZhaoXZhaoCHeZJingSWangHHuangFPregnancy serum facilitates" exact="hepatitis" post="E virus replication in vitroJ Gen Virol2015961055106125614592 116.SinghSDagaMKKumarAHusainSAKarPRole of"/>
   <result pre="and deregulation of the progesterone receptor signaling pathway: association with" exact="hepatitis" post="E-related poor pregnancy outcomeJ Hepatol2011541107111321145845 118.AnderssonMIHughesJGordonFHIjazSDonatiMOf pigs and pregnancyLancet2008372119218926280"/>
   <result pre="119.RenouCGobertVLocherCMoumenATimbelyOSavaryJRoque-AfonsoAMcollab: Association Nationale des Hepato-Gastroenterologues des Hopitaux GProspective study of" exact="hepatitis" post="E virus infection among pregnant women in FranceVirol J2014116824716485"/>
   <result pre="pregnant women in FranceVirol J2014116824716485 120.GouillyJChenQSiewieraJCartronGLevyCDuboisMAl-DaccakRIzopetJJabrane-FerratNEl CostaHGenotype specific pathogenicity of" exact="hepatitis" post="E virus at the human maternal-fetal interfaceNat Commun20189474830420629 121.van"/>
   <result pre="functional and clinical relevanceEBioMedicine201611314227528267 122.HorvatitsTSchulze Zur WieschJLutgehetmannMLohseAWPischkeSThe clinical perspective on" exact="hepatitis" post="EViruses2019117617 123.DebingYGisaADallmeierKPischkeSBremerBMannsMWedemeyerHSuneethaPVNeytsJA mutation in the hepatitis E virus RNA"/>
   <result pre="WieschJLutgehetmannMLohseAWPischkeSThe clinical perspective on hepatitis EViruses2019117617 123.DebingYGisaADallmeierKPischkeSBremerBMannsMWedemeyerHSuneethaPVNeytsJA mutation in the" exact="hepatitis" post="E virus RNA polymerase promotes its replication and associates"/>
   <result pre="with acute liver failureJ Clin Virol2017911428359977 125.TakahashiKOkamotoHAbeNKawakamiMMatsudaHMochidaSSakugawaHSuginoshitaYWatanabeSYamamotoKet al.Virulent strain of" exact="hepatitis" post="E virus genotype 3, JapanEmerg Infect Dis20091570470919402955 126.NanYYuYMaZKhattarSKFredericksenBZhangYJHepatitis E"/>
   <result pre="and inhibits its secretionMol Cell Biochem2016417758527170377 128.LinSYangYNanYMaZYangLZhangYJThe capsid protein of" exact="hepatitis" post="E virus inhibits interferon induction via its N-terminal arginine-rich"/>
   <result pre="induction via its N-terminal arginine-rich motifViruses201911111050 129.SurjitMVarshneyBLalSKThe ORF2 glycoprotein of" exact="hepatitis" post="E virus inhibits cellular NF-kappaB activity by blocking ubiquitination"/>
   <result pre="2003-2009Birth Defects Res A Clin Mol Teratol20108855155920564430 133.SperaAMEldinTKTosoneGOrlandoRAntiviral therapy for" exact="hepatitis" post="C: has anything changed for pregnant/lactating women?World J Hepatol2016855756527134703"/>
   <result pre="anything changed for pregnant/lactating women?World J Hepatol2016855756527134703 134.Dao ThiVLDebingYWuXRiceCMNeytsJMoradpourDGouttenoireJSofosbuvir inhibits" exact="hepatitis" post="E virus replication in vitro and results in an"/>
   <result pre="der ValkMZaaijerHLKaterAPSchinkelJSofosbuvir shows antiviral activity in a patient with chronic" exact="hepatitis" post="E virus infectionJ Hepatol20176624224327702641 136.NishiyamaTKobayashiTJirintaiSKiiINagashimaSPrathiwi PrimadharsiniPNishizawaTOkamotoHScreening of novel drugs"/>
   <result pre="virus infectionJ Hepatol20176624224327702641 136.NishiyamaTKobayashiTJirintaiSKiiINagashimaSPrathiwi PrimadharsiniPNishizawaTOkamotoHScreening of novel drugs for inhibiting" exact="hepatitis" post="E virus replicationJ Virol Methods201927011131004661 137.TodtDFrancoisCAnggakusumaBehrendtPEngelmannMKnegendorfLVieyresGWedemeyerHHartmannRPietschmannTet al.Antiviral activities of"/>
   <result pre="subtypes against Hepatitis E virus replicationAntimicrob Agents Chemother2016602132213926787701 138.NanYMaZKannanHSteinDAIversenPIMengXJZhangYJInhibition of" exact="hepatitis" post="E virus replication by peptide-conjugated morpholino oligomersAntivir Res201512013413926086884 139.NetzlerNEEnosi"/>
   <result pre="by peptide-conjugated morpholino oligomersAntivir Res201512013413926086884 139.NetzlerNEEnosi TuipulotuDVasudevanSGMackenzieJMWhitePAAntiviral candidates for treating" exact="hepatitis" post="E virus infectionAntimicrob Agents Chemother2019636e00003e0001930885901 140.NishiyamaTKobayashiTJirintaiSNagashimaSPrimadharsiniPPNishizawaTOkamotoHAntiviral candidates against the"/>
   <result pre="hepatitis E virus infectionAntimicrob Agents Chemother2019636e00003e0001930885901 140.NishiyamaTKobayashiTJirintaiSNagashimaSPrimadharsiniPPNishizawaTOkamotoHAntiviral candidates against the" exact="hepatitis" post="E virus (HEV) and their combinations inhibit HEV growth"/>
   <result pre="HEV growth in in vitroAntivir Res201917010457031362004 141.RacMWSheffieldJSPrevention and management of" exact="viral hepatitis" post="in pregnancyObstet Gynecol Clin N Am201441573592 142.collab: European Association"/>
   <result pre="growth in in vitroAntivir Res201917010457031362004 141.RacMWSheffieldJSPrevention and management of viral" exact="hepatitis" post="in pregnancyObstet Gynecol Clin N Am201441573592 142.collab: European Association"/>
   <result pre="the Study of the L: EASL clinical practice guidelines on" exact="hepatitis" post="E virus infectionJ Hepatol2018681256127129609832 143.WuTZhuFCHuangSJZhangXFWangZZZhangJXiaNSSafety of the hepatitis E"/>
   <result pre="guidelines on hepatitis E virus infectionJ Hepatol2018681256127129609832 143.WuTZhuFCHuangSJZhangXFWangZZZhangJXiaNSSafety of the" exact="hepatitis" post="E vaccine for pregnant women: a preliminary analysisHepatology201255203822161542 144.LiMLiSHeQLiangZWangLWangQWangLHepatitis"/>
   <result pre="analysisHepatology201255203822161542 144.LiMLiSHeQLiangZWangLWangQWangLHepatitis E-related adverse pregnancy outcomes and their prevention by" exact="hepatitis" post="E vaccine in a rabbit modelEmerg Microbes Infect201981066107531339458 145.ZamanKDudmanSStene-JohansenKQadriFYunusMSandbuSGurleyESOverboJJulinCHDembinskiJLet"/>
   <result pre="trial to assess the safety, immunogenicity and effectiveness of the" exact="hepatitis" post="E vaccine HEV 239 (Hecolin) in women of childbearing"/>
   <result pre="women of childbearing age in rural BangladeshBMJ Open202010e03370231959609 146.ChenXGongPWagnerALLiYWangGLuYIdentification of" exact="hepatitis" post="E virus subtype 4f in blood donors in Shanghai,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7286522\results\search\disease\results.xml">
   <result pre="Sciences : Genetics : Gene Expression: Protein Translation Bortezomib inhibits" exact="chikungunya" post="virus replication by interfering with viral protein synthesis Bortezomib"/>
   <result pre="in a dose-dependent manner. Bortezomib, which has been FDA-approved for" exact="multiple myeloma" post="and mantle cell lymphoma, was further investigated in downstream"/>
   <result pre="manner. Bortezomib, which has been FDA-approved for multiple myeloma and" exact="mantle cell lymphoma," post="was further investigated in downstream studies. The inhibitory activities"/>
   <result pre="a febrile illness accompanied by debilitating polyarthralgia, myalgia and maculopapular" exact="rash" post="[3, 4]. Chronic polyarthralgia lasting for several months to"/>
   <result pre="has been well documented for picornaviruses, including encephalomyocarditis virus and" exact="hepatitis" post="A virus, [25–27]. Given the role of the viral"/>
   <result pre="inhibitors. Bortezomib, a proteasome inhibitor approved for the treatment of" exact="multiple myeloma" post="and mantle cell lymphoma [37, 38], was selected for"/>
   <result pre="proteasome inhibitor approved for the treatment of multiple myeloma and" exact="mantle cell lymphoma" post="[37, 38], was selected for downstream experiments to investigate"/>
   <result pre="approved for the treatment of multiple myeloma and mantle cell" exact="lymphoma" post="[37, 38], was selected for downstream experiments to investigate"/>
   <result pre="manner. Bortezomib, which has been FDA-approved for the treatment of" exact="multiple myeloma" post="and mantle cell lymphoma, showed dose-dependent reductions of CHIKV"/>
   <result pre="has been FDA-approved for the treatment of multiple myeloma and" exact="mantle cell lymphoma," post="showed dose-dependent reductions of CHIKV titers in several cell"/>
   <result pre="titers in several cell lines (BHK21, HeLa and HSMM). Bortezomib-mediated" exact="suppression" post="of CHIKV titers was found to occur at an"/>
   <result pre="inhibition of viral replication [48]. As for severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV), a phlebovirus related to RVFV, bortezomib"/>
   <result pre="induced by the viral non-structural protein (NS), thereby removing virus-mediated" exact="suppression" post="of host innate immunity [49]. Bortezomib has also been"/>
   <result pre="limitation of bortezomib is its narrow therapeutic window [61]. In" exact="cancer" post="patients, the most significant adverse effect reported is peripheral"/>
   <result pre="however, that bortezomib-induced toxicity is related to accumulated dose, with" exact="neuropathy" post="usually surfacing within the first five cycles of treatment,"/>
   <result pre="to subcutaneous has been found to significantly reduce instances of" exact="neuropathy" post="in patients, while retaining similar efficacy [37]. In addition,"/>
   <result pre="study include BHK21 baby hamster kidney cells (ATCC CCL-10), HeLa" exact="cervical cancer" post="epithelial cells (ATCC CCL-2), human skeletal muscle myoblasts (HSMM,"/>
   <result pre="include BHK21 baby hamster kidney cells (ATCC CCL-10), HeLa cervical" exact="cancer" post="epithelial cells (ATCC CCL-2), human skeletal muscle myoblasts (HSMM,"/>
   <result pre="Res. 2015;120:32–9. 10.1016/j.antiviral.2015.04.01625979669 2WahidB, AliA, RafiqueS, IdreesM. Global expansion of" exact="chikungunya" post="virus: mapping the 64-year history. Int J Infect Dis."/>
   <result pre="BreimanRF, PowersAM. Chikungunya fever: an epidemiological review of a re-emerging" exact="infectious disease." post="Clin Infect Dis. 2009;49(6):942–8. 10.1086/60549619663604 5FourieED, MorrisonJG. Rheumatoid arthritic"/>
   <result pre="Infect Dis. 2009;49(6):942–8. 10.1086/60549619663604 5FourieED, MorrisonJG. Rheumatoid arthritic syndrome after" exact="chikungunya" post="fever. S Afr Med J. 1979;56(4):130–2. 494034 6JavelleE, RiberaA,"/>
   <result pre="2006–2012.PLoS Negl Trop Dis.2015;9(3):e000360310.1371/journal.pntd.000360325760632 7SchwartzO, AlbertML. Biology and pathogenesis of" exact="chikungunya" post="virus. Nat Rev Microbiol. 2010;8(7):491–500. 10.1038/nrmicro236820551973 8Fernandez-SalasI, Danis-LozanoR, Casas-MartinezM,"/>
   <result pre="Aedes aegypti as a main contributor of fast dispersal of" exact="chikungunya" post="outbreaks in Latin America. Antiviral Res. 2015;124:30–42. 10.1016/j.antiviral.2015.10.01526518229 9ChenR,"/>
   <result pre="10.1128/JVI.01166-1627654297 10JohanssonMA, PowersAM, PesikN, CohenNJ, StaplesJE. Nowcasting the spread of" exact="chikungunya" post="virus in the Americas.PLoS One.2014;9(8):e10491510.1371/journal.pone.010491525111394 11AmraouiF, FaillouxAB. Chikungunya: an"/>
   <result pre="ZhangJ, LewisE, PlanchartA, LawsonTG. Degradation of the encephalomyocarditis virus and" exact="hepatitis" post="A virus 3C proteases by the ubiquitin/26S proteasome system"/>
   <result pre="Alphaviruses.Viruses. 2019;11(4). 34ThioCL, YusofR, Abdul-RahmanPS, KarsaniSA. Differential proteome analysis of" exact="chikungunya" post="virus infection on host cells.PLoS One. 2013;8(4):e6144410.1371/journal.pone.006144423593481 35AbrahamR, MudaliarP,"/>
   <result pre="Replicase. J Virol. 2018;92(14). 58KimDY, AtashevaS, FrolovaEI, FrolovI. Venezuelan equine" exact="encephalitis" post="virus nsP2 protein regulates packaging of the viral genome"/>
   <result pre="JagannathS, WenPY, BarlogieB, BerensonJ, et al.Frequency, characteristics, and reversibility of" exact="peripheral neuropathy" post="during treatment of advanced multiple myeloma with bortezomib.J Clin"/>
   <result pre="WenPY, BarlogieB, BerensonJ, et al.Frequency, characteristics, and reversibility of peripheral" exact="neuropathy" post="during treatment of advanced multiple myeloma with bortezomib.J Clin"/>
   <result pre="characteristics, and reversibility of peripheral neuropathy during treatment of advanced" exact="multiple myeloma" post="with bortezomib.J Clin Oncol. 2006;24(19):3113–20. 10.1200/JCO.2005.04.777916754936 63AleA, BrunaJ, NavarroX,"/>
   <result pre="2019;63(4). 69KaurP, ThiruchelvanM, LeeRC, ChenH, ChenKC, NgML, et al.Inhibition of" exact="chikungunya" post="virus replication by harringtonine, a novel antiviral that suppresses"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7288254\results\search\disease\results.xml">
   <result pre="understanding of virus-induced cell death leads to highly immunogenic oncolytic" exact="influenza" post="viruses KabiljoJulijan1http://orcid.org/0000-0003-4771-1398LaengleJohannes12http://orcid.org/0000-0001-8529-1166BergmannMichaelmichael.bergmann@meduniwien.ac.at12[1], 0000 0000 9259 8492grid.22937.3dDivision of General Surgery,"/>
   <result pre="http://creativecommons.org/licenses/by/4.0/. Abstract Oncolytic viruses constitute an emerging strategy in immunomodulatory" exact="cancer" post="treatment. The first oncolytic virus, Talimogene laherparepvec (T-VEC), based"/>
   <result pre="treatment. The first oncolytic virus, Talimogene laherparepvec (T-VEC), based on" exact="herpes simplex" post="virus 1 (HSV-1), was approved by the Food and"/>
   <result pre="infection but never leads to a chronic disease. While oncolytic" exact="influenza" post="A viruses are in preclinical development, they have not"/>
   <result pre="Recent insights into different types of cell death caused by" exact="influenza" post="A virus infection illuminate novel possibilities of enhancing its"/>
   <result pre="of enhancing its therapeutic effect. Genetic engineering and experience in" exact="influenza" post="A virus vaccine development allow safe application of the"/>
   <result pre="we give a summary of efforts undertaken to develop oncolytic" exact="influenza" post="A viruses. We discuss strategies for targeting viral replication"/>
   <result pre="furthermore describe which modes of cell death are induced by" exact="influenza" post="A virus infection and how these insights may be"/>
   <result pre="infection and how these insights may be utilized to optimize" exact="influenza" post="A virus-based oncolytic virus design. Subject terms Tumour immunology"/>
   <result pre="terms Tumour immunology Tumour virus infections Cancer immunotherapy Facts Oncolytic" exact="influenza" post="A virus displays selective replication in tumor cells. Influenza"/>
   <result pre="be targeted to tumors and armed with cytokines. Growth optimized" exact="influenza" post="A virus for a phase I application can be"/>
   <result pre="virus for a phase I application can be generated. Oncolytic" exact="influenza" post="A virus prototypes have been tested in humans as"/>
   <result pre="of a complete tumor remission in the context of an" exact="influenza" post="A infection dates back to 19043. Preclinical models solidified"/>
   <result pre="19043. Preclinical models solidified the assertion of oncolytic effects of" exact="influenza" post="A viruses4,5. However, the lack of understanding of virus"/>
   <result pre="the clinical development of a variety of oncolytic viruses, including" exact="herpes simplex" post="virus (HSV)6, reovirus7, vaccinia virus (VV)8, vesicular stomatitis virus"/>
   <result pre="variety of oncolytic viruses, including herpes simplex virus (HSV)6, reovirus7," exact="vaccinia virus" post="(VV)8, vesicular stomatitis virus (VSV)9, adenovirus10, newcastle disease virus"/>
   <result pre="including herpes simplex virus (HSV)6, reovirus7, vaccinia virus (VV)8, vesicular" exact="stomatitis" post="virus (VSV)9, adenovirus10, newcastle disease virus (NDV)11, measles virus"/>
   <result pre="(VV)8, vesicular stomatitis virus (VSV)9, adenovirus10, newcastle disease virus (NDV)11," exact="measles" post="virus (MeV)12 and picornaviridae13. This renewed interest in oncolytic"/>
   <result pre="interest in the field of virotherapy. With respect to oncolytic" exact="influenza" post="A viruses, only preclinical studies have been accomplished yet,"/>
   <result pre="review we summarize major milestones in the development of oncolytic" exact="influenza" post="A viruses. We delineate in which manner targeted replication"/>
   <result pre="A viruses. We delineate in which manner targeted replication in" exact="cancer" post="cells was achieved. Furthermore, we discuss strategies to arm"/>
   <result pre="cancer cells was achieved. Furthermore, we discuss strategies to arm" exact="influenza" post="A viruses with immuno-stimulatory transgenes. Finally, we discuss which"/>
   <result pre="immuno-stimulatory transgenes. Finally, we discuss which types of cell death" exact="influenza" post="A virus-infected cancer cells succumb to and their implications"/>
   <result pre="we discuss which types of cell death influenza A virus-infected" exact="cancer" post="cells succumb to and their implications for future design"/>
   <result pre="enhance its immunogenicity or stimulate targeted anti-cancer mechanisms. Utilizing an" exact="influenza" post="A virus as an oncolytic agent has several advantages."/>
   <result pre="A virus as an oncolytic agent has several advantages. The" exact="influenza" post="virus is a small virus of the Orthomyxoviridae family,"/>
   <result pre="commonly known for causing the flu28. It comprises 4 genera," exact="influenza" post="A, B, C, and D viruses, type A being"/>
   <result pre="type A being the most extensively studied one28,29. While the" exact="influenza" post="virus can induce strong immunogenic reactions and intense pathology"/>
   <result pre="ideal vector for oncolytic therapy. Oncolytic virus development focused on" exact="influenza" post="A virus. This virus subtype contains 8 separate RNA"/>
   <result pre="that has previously been established for the production of seasonal" exact="influenza" post="vaccinations reduces the amount of novel biotechnological engineering and"/>
   <result pre="in the field of oncology33. Fig. 1 Components of the" exact="influenza" post="A virus. Schematic representation of all components of the"/>
   <result pre="influenza A virus. Schematic representation of all components of the" exact="influenza" post="A virus virion. The interplay of influenza virus and"/>
   <result pre="components of the influenza A virus virion. The interplay of" exact="influenza" post="virus and cell death The rational development of a"/>
   <result pre="with the pro-apoptotic scribbled planar cell polarity protein (scribble)42. However," exact="influenza" post="A viruses have a two-sided relationship to apoptosis37. There"/>
   <result pre="two-sided relationship to apoptosis37. There is evidence, that growth of" exact="influenza" post="viruses is dependent on apoptosis43. Specifically, caspase 3 appears"/>
   <result pre="3 appears important for viral replication44. In this line, the" exact="influenza" post="A virus can actively induce apoptosis. Apoptotic signaling may"/>
   <result pre="viral protein PB1-F245. A further major inducer of apoptosis during" exact="influenza" post="A virus infections is the viral nucleoprotein (NP), interacting"/>
   <result pre="transforming growth factor beta (TGF-β)49. There are multiple theories, why" exact="influenza" post="A virus may actively induce apoptosis. Overall, there seems"/>
   <result pre="tightly controlled by the virus. Upon overexpression of anti-apoptotic molecules" exact="influenza" post="A virus titers are reduced due to viral RNA-protein"/>
   <result pre="reinforced by the observation, that the anti-mycotic amphotericin B enhances" exact="influenza" post="virus growth52. Amphotericin B stabilizes pores within cellular membranes."/>
   <result pre="from the nucleus. Fig. 2 A proposed model of how" exact="influenza" post="A virus controls apoptosis in 2 phases. a In"/>
   <result pre="in 2 phases. a In the early phase of an" exact="influenza" post="virus infection, the virus benefits from reduced apoptosis, in"/>
   <result pre="NF-κB induced TNFα release. b In the late phase of" exact="influenza" post="virus infection, the pro apoptotic viral protein PB1-F2 and"/>
   <result pre="out of the cell, resulting in immunogenic reactions55,56. In conclusion," exact="influenza" post="A virus induces an apoptotic cell death through a"/>
   <result pre="a virus that initiates potent anti-cancer-immune responses without causing an" exact="infectious disease," post="it is necessary to target them to cancer cells."/>
   <result pre="an infectious disease, it is necessary to target them to" exact="cancer" post="cells. Mammalian cells react to viral infections by secreting"/>
   <result pre="to circumvent these immunogenic effects. It was shown, that the" exact="influenza" post="A virus lacking NS1 (delNS1) generated by Egorov et"/>
   <result pre="appeared to be an attractive strategy for targeting growth of" exact="influenza" post="A viruses to malignant tissue. We were able to"/>
   <result pre="deletions of various lengths within the NS1 gene of an" exact="influenza" post="A/Puerto Rico/8/34 (PR8) based H1N1 virus yielded potent anti-cancer"/>
   <result pre="xenografts61. Another mechanism through which NS1 counteracts cellular responses to" exact="influenza" post="A virus infection is the inhibition of the double-stranded"/>
   <result pre="the double-stranded RNA sensor PKR36,62,63. We demonstrated that NS1 deleted" exact="influenza" post="A virus was lethal to PKR knockout mice but"/>
   <result pre="mice but was not lethal in wild-type mice36. Oncogenic rat" exact="sarcoma" post="(RAS) gene mutation, present in approximately a third of"/>
   <result pre="(RAS) gene mutation, present in approximately a third of all" exact="cancer" post="subtypes, results in PKR inhibition64. We showed that NS1"/>
   <result pre="PKR inhibition64. We showed that NS1 deletion targets a PR8" exact="influenza" post="virus towards RAS mutated tumors in a PKR dependent"/>
   <result pre="transfected with oncogenic RAS65. There are also developments of oncolytic" exact="influenza" post="A viruses, which are based on attenuation markers other"/>
   <result pre="the NS1 deletion. One preclinical study in murine non-small cell" exact="lung cancer" post="(NSCLC) xenografts showed efficacy and safety of wild-type NS1,"/>
   <result pre="NS1 deletion. One preclinical study in murine non-small cell lung" exact="cancer" post="(NSCLC) xenografts showed efficacy and safety of wild-type NS1,"/>
   <result pre="PR8 H1N1 virus66. Another study screened a variety of wild-type" exact="influenza" post="A viruses for their infectivity in pancreatic carcinoma cell"/>
   <result pre="system Apart from the conditionally replicating phenotype in malignant cells" exact="influenza" post="A viruses with NS1 deletions are associated with a"/>
   <result pre="interferon regulatory factor 3 (IRF3) and NF-κB48,68. Since NS1 deleted" exact="influenza" post="A viruses are capable of inducing strong PKR pathway"/>
   <result pre="as a DAMP, causing enhanced immunogenicity of apoptotic bodies after" exact="influenza" post="A virus infection in PKR sensitive cancers70. Fig. 3"/>
   <result pre="infection in PKR sensitive cancers70. Fig. 3 Functions of the" exact="influenza" post="A virus NS1 protein and generation of an armed"/>
   <result pre="A virus NS1 protein and generation of an armed oncolytic" exact="influenza" post="A virus. a Schematic representation of the NS1 protein."/>
   <result pre="to are indicated42,48,62,63,68,72,75. b Example of genetic modifications in an" exact="influenza" post="virus designed to be used as oncolytic agent94. Modifications"/>
   <result pre="peptide, 2A FMDV 2A cleavage site of the foot and" exact="mouth disease" post="virus. A transcriptional profiling confirmed that a delNS1 virus"/>
   <result pre="&quot;panhandle�?, which holds the single stranded RNA segments of the" exact="influenza" post="A virus genome in a circular conformation78–81. The immunogenic"/>
   <result pre="cell and B cell responses, protecting mice and ferrets against" exact="influenza" post="A virus challenge31,82. Importantly, the virus did not cause"/>
   <result pre="B cells, monocytes and natural killer (NK) cells against various" exact="cancer" post="cell lines87. These cytotoxic effects might contribute to the"/>
   <result pre="to the viruses’ therapeutic effect in the tumor microenvironment. Targeting" exact="influenza" post="viruses to tumor cells by viral entry Influenza A"/>
   <result pre="the tissue is substantial for host restriction. It restricts the" exact="influenza" post="A virus infection to the lung, the enteric system"/>
   <result pre="some viral isolates to the brain. We discovered that various" exact="colon cancer" post="cell lines express trypsin and allow oncolytic influenza A"/>
   <result pre="viral isolates to the brain. We discovered that various colon" exact="cancer" post="cell lines express trypsin and allow oncolytic influenza A"/>
   <result pre="various colon cancer cell lines express trypsin and allow oncolytic" exact="influenza" post="A virus growth in the absence of exogenous protease73."/>
   <result pre="in the absence of exogenous protease73. To further target the" exact="influenza" post="A virus to tumor tissue we generated a virus"/>
   <result pre="with an elastase cleavage site has been shown to attenuate" exact="influenza" post="A virus replication in swine and mice88–90. We therefore"/>
   <result pre="trypsin cleavage site within the partially NS1 deleted (116AA) PR8" exact="influenza" post="virus to elastase. Elastase-dependent viruses yielded a potent therapeutic"/>
   <result pre="human population, including the H7 or H9 subtypes. Arming oncolytic" exact="influenza" post="viruses to enhance immunogenicity Many clinical and preclinical studies"/>
   <result pre="preclinical studies have shown effectiveness of &quot;non-armed�? oncolytic viruses in" exact="cancer" post="treatment. Still, their immuno-stimulatory properties do not always result"/>
   <result pre="cytokines like interleukin-2 (IL-2), interleukin-15 (IL-15) or GM-CSF91. Within the" exact="influenza" post="A virus background we were able to establish potent"/>
   <result pre="maximum transgene loading capacity has not yet been tested in" exact="influenza" post="viruses. We demonstrated superior therapeutic efficacy and enhancement of"/>
   <result pre="cell activation and proliferation when the partially NS1 deleted (116)" exact="influenza" post="virus was armed with IL-1594 (Fig. 3b) in murine"/>
   <result pre="al. were able to show anti-cancer activity of an NS1-deleted" exact="influenza" post="A virus armed with GM-CSF in a human Hep-G2"/>
   <result pre="influenza A virus armed with GM-CSF in a human Hep-G2" exact="liver cancer" post="cell line xenograft model95. Hamilton et al. expressed a"/>
   <result pre="A virus armed with GM-CSF in a human Hep-G2 liver" exact="cancer" post="cell line xenograft model95. Hamilton et al. expressed a"/>
   <result pre="checkpoint inhibiting antibody from two different RNA fragments of the" exact="influenza" post="A virus genome in order to enhance its anti-cancer"/>
   <result pre="model96. In order to elicit specific immunological memory against known" exact="cancer" post="epitopes, Efferson et al. established a combined strategy of"/>
   <result pre="epitopes, Efferson et al. established a combined strategy of oncolytic" exact="influenza" post="A viruses armed with a vaccination peptide against the"/>
   <result pre="therapeutic outcomes in preclinical models have been postulated for oncolytic" exact="influenza" post="A viruses. Safety aspects of oncolytic influenza viruses Influenza"/>
   <result pre="postulated for oncolytic influenza A viruses. Safety aspects of oncolytic" exact="influenza" post="viruses Influenza viruses remain a major health concern as"/>
   <result pre="tested for its stable attenuation. The existence of licensed live" exact="influenza" post="A virus vaccines clearly indicates, that the genetic stability"/>
   <result pre="vaccines clearly indicates, that the genetic stability of attenuated live" exact="influenza" post="viruses is feasible. We could demonstrate that delNS1 viruses,"/>
   <result pre="reassortment of the chimeric segment with wild-type segments of other" exact="influenza" post="virus subtypes might lead to an unexpected pathogenic phenotype."/>
   <result pre="the background of various subtypes. Fig. 4 Reassortment of oncolytic" exact="influenza" post="A viruses and wild-type influenza A viruses. Examples of"/>
   <result pre="Fig. 4 Reassortment of oncolytic influenza A viruses and wild-type" exact="influenza" post="A viruses. Examples of reassortment of an armed oncolytic"/>
   <result pre="influenza A viruses. Examples of reassortment of an armed oncolytic" exact="influenza" post="virus attenuated by NS1 truncation during co-infection with wild-type"/>
   <result pre="influenza virus attenuated by NS1 truncation during co-infection with wild-type" exact="influenza" post="virus. a represents transgene expression from the NS1 reading"/>
   <result pre="virus. NS1 nonstructural 1 protein. Enhancing oncolytic activity of the" exact="influenza" post="A virus by optimizing immunogenic cell death – potential"/>
   <result pre="such as interleukin-24 (IL-24). We have shown that IL-24 sensitizes" exact="cancer" post="cells to apoptosis within the background of an influenza"/>
   <result pre="sensitizes cancer cells to apoptosis within the background of an" exact="influenza" post="A virus infection98. Importantly the apoptotic effect of IL-24"/>
   <result pre="achieved by IL-24 to the tumor microenvironment, as the attenuated" exact="influenza" post="virus used in this experiment cannot replicate otherwise. However,"/>
   <result pre="virus used in this experiment cannot replicate otherwise. However, an" exact="influenza" post="virus armed with IL-24 might be difficult to translate"/>
   <result pre="to passive release of a large variety of DAMPs and" exact="cancer" post="neo-antigen101. A recent report implicates necroptosis signaling through RIPK3"/>
   <result pre="protein 2 (cIAP2) protein has been shown to protect against" exact="influenza" post="A virus-induced necroptosis104. Necroptosis but also necrosis might be"/>
   <result pre="necroptosis104. Necroptosis but also necrosis might be induced by specific" exact="influenza" post="subtypes. Examples are the avian H5N1 and a reconstructed"/>
   <result pre="virus strains to cause necroptosis, specifically describing seasonal NC/99 H1N1" exact="influenza" post="A viruses as inducers and pandemic Cal/09 as inhibitors"/>
   <result pre="cell fate in this experiment. These results indicate that choosing" exact="influenza" post="A virus vectors according to their capability to initiate"/>
   <result pre="is a promising strategy for future oncolytic virus design. The" exact="influenza" post="A virus NS1 protein can directly cause necroptosis through"/>
   <result pre="been due to the lack of RIPK3 expression in the" exact="cancer" post="cell lines examined. It is well established, that RIPK3"/>
   <result pre="contribute to positive outcomes at least as much as necroptotic" exact="cancer" post="cells102. Therefore, the potential of candidate oncolytic viruses to"/>
   <result pre="of regulating immunogenicity in viral infections is oxeiptosis113. Viruses like" exact="influenza" post="A virus generate radical oxidative species (ROS). Cells can"/>
   <result pre="like necroptosis. PGAM5 knockout mice were shown to react to" exact="influenza" post="A virus infection with enhanced necrotic histology and rapid"/>
   <result pre="promising strategy to enhance oncolytic virotherapy. Further effects of oncolytic" exact="influenza" post="A viruses on the cancer-immune microenvironment shown in murine"/>
   <result pre="polarization towards immuno-stimulatory M1 phenotypes66,114. Recent evidence suggests NS1 deleted" exact="influenza" post="virus to exhibit enhanced growth when combined with an"/>
   <result pre="mechanisms like antibody-dependent, cell-mediated cytotoxicity (ADCC), which is reduced in" exact="breast cancer" post="patients118,119. The clinically approved oncolytic virus T-VEC is experimentally"/>
   <result pre="like antibody-dependent, cell-mediated cytotoxicity (ADCC), which is reduced in breast" exact="cancer" post="patients118,119. The clinically approved oncolytic virus T-VEC is experimentally"/>
   <result pre="checkpoint blockade26,121. Similar methods may prove to be successful in" exact="influenza" post="virus-based oncolytic virotherapy. Conclusion and outlook Influenza viruses attenuated"/>
   <result pre="a cofounder of Vacthera, a company seeking to develop oncolytic" exact="influenza" post="viruses. M.B. and J.L. received an investigator-sponsored research grant"/>
   <result pre="received consultant fees from Bristol-Myers-Squibb. References References 1.BlumingAZZieglerJLRegression of Burkitt’s" exact="lymphoma" post="in association with measles infectionLancet (Lond., Engl.)19712105106 2.TaqiAMAbdurrahmanMBYakubuAMFlemingAFRegression of"/>
   <result pre="Bristol-Myers-Squibb. References References 1.BlumingAZZieglerJLRegression of Burkitt’s lymphoma in association with" exact="measles" post="infectionLancet (Lond., Engl.)19712105106 2.TaqiAMAbdurrahmanMBYakubuAMFlemingAFRegression of Hodgkin’s disease after measlesLancet"/>
   <result pre="4.LindenmannJKleinPAViral oncolysis: increased immunogenicity of host cell antigen associated with" exact="influenza" post="virusJ. Exp. Med1967126931084290961 5.OnoSHattoriONagaiYNagataIOncolytic effect of influenza virus upon"/>
   <result pre="antigen associated with influenza virusJ. Exp. Med1967126931084290961 5.OnoSHattoriONagaiYNagataIOncolytic effect of" exact="influenza" post="virus upon Ehrlich carcinoma and Yoshida ascites hepatomaGan19554651251413262476 6.HarringtonKJet"/>
   <result pre="hepatomaGan19554651251413262476 6.HarringtonKJet al.Clinical development of talimogene laherparepvec (T-VEC): a modified" exact="herpes simplex" post="virus type-1-derived oncolytic immunotherapyExpert Rev. Anticancer Ther.2015151389140326558498 7.SamsonAet al.Intravenous"/>
   <result pre="immunotherapeutic vaccinia JX-594 in liver cancerNat. Med.20131932933623396206 9.MuikAet al.Semireplication-competent vesicular" exact="stomatitis" post="virus as a novel platform for oncolytic virotherapyJ. Mol."/>
   <result pre="specific immunization with Newcastle disease virus modified tumor cells in" exact="colorectal cancer" post="patients following resection of liver metastases: results of a"/>
   <result pre="immunization with Newcastle disease virus modified tumor cells in colorectal" exact="cancer" post="patients following resection of liver metastases: results of a"/>
   <result pre="prospective randomized trialCancer Immunol. Immunother.200958616918488223 12.MsaouelPet al.Clinical trials with oncolytic" exact="measles" post="virus: current status and future prospectsCurr. Cancer Drug Targets20181817718728228086"/>
   <result pre="18.BarlesiFet al.Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell" exact="lung cancer" post="(JAVELIN Lung 200): an open-label, randomised, phase 3 studyLancet"/>
   <result pre="al.Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung" exact="cancer" post="(JAVELIN Lung 200): an open-label, randomised, phase 3 studyLancet"/>
   <result pre="22.RittmeyerAet al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell" exact="lung cancer" post="(OAK): a phase 3, open-label, multicentre randomised controlled trialLancet"/>
   <result pre="al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung" exact="cancer" post="(OAK): a phase 3, open-label, multicentre randomised controlled trialLancet"/>
   <result pre="Sci.20201171119 LP112831888983 25.EngelandCEet al.CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic" exact="measles" post="virus therapyMol. Ther.2014221949195925156126 26.PuzanovIet al.Talimogene laherparepvec in combination with"/>
   <result pre="for the detection of immunogenic cell deathOncoimmunology20143e95569125941621 28.BouvierNMPalesePThe biology of" exact="influenza" post="virusesVaccine200826Suppl 4D49D5319230160 29.SuSFuXLiGKerlinFVeitMNovel influenza D virus: epidemiology, pathology, evolution"/>
   <result pre="immunogenic cell deathOncoimmunology20143e95569125941621 28.BouvierNMPalesePThe biology of influenza virusesVaccine200826Suppl 4D49D5319230160 29.SuSFuXLiGKerlinFVeitMNovel" exact="influenza" post="D virus: epidemiology, pathology, evolution and biological characteristicsVirulence201781580159128812422 30.BardsleySAAn"/>
   <result pre="vaccine approachProc. Natl Acad. Sci. U. S. A.2000974309431410725408 32.EgorovAet al.Transfectant" exact="influenza" post="A viruses with long deletions in the NS1 protein"/>
   <result pre="Dis.20189100230254192 35.ZhangJMiaoJHouJLuCMitochondrial antiviral signaling adaptor mediated apoptosis in H3N2 swine" exact="influenza" post="virus infection is inhibited by viral protein NS1 in"/>
   <result pre="Virol.2000746203 LP620610846107 37.LudwigSPleschkaSPlanzOWolffTRinging the alarm bells: signalling and apoptosis in" exact="influenza" post="virus infected cellsCell. Microbiol.2006837538616469051 38.TakizawaTet al.Induction of programmed cell"/>
   <result pre="cellsCell. Microbiol.2006837538616469051 38.TakizawaTet al.Induction of programmed cell death (apoptosis) by" exact="influenza" post="virus infection in tissue culture cellsJ. Gen. Virol.199374Pt 11234723557504071"/>
   <result pre="cellsJ. Gen. Virol.199374Pt 11234723557504071 39.GrahamACHilmerKMZickovichJMObarJJInflammatory response of mast cells during" exact="influenza" post="A virus infection is mediated by active infection and"/>
   <result pre="involvement of double-stranded RNA-activated protein kinase in cell death by" exact="influenza" post="virus infectionJ. Virol.199670812881328892939 41.BalachandranSet al.Alpha/beta interferons potentiate virus-induced apoptosis"/>
   <result pre="signaling pathwayJ. Virol.2000741513152310627563 42.LiuHet al.The ESEV PDZ-binding motif of the" exact="avian influenza" post="A virus NS1 protein protects infected cells from apoptosis"/>
   <result pre="pathwayJ. Virol.2000741513152310627563 42.LiuHet al.The ESEV PDZ-binding motif of the avian" exact="influenza" post="A virus NS1 protein protects infected cells from apoptosis"/>
   <result pre="cells from apoptosis by directly targeting ScribbleJ. Virol.201084111641117420702615 43.OlsenCWKehrenJCDybdahl-SissokoNRHinshawVSbcl-2 alters" exact="influenza" post="virus yield, spread, and hemagglutinin glycosylationJ. Virol.1996706636668523590 44.WurzerWJet al.Caspase"/>
   <result pre="glycosylationJ. Virol.1996706636668523590 44.WurzerWJet al.Caspase 3 activation is essential for efficient" exact="influenza" post="virus propagationEMBO J.2003222717272812773387 45.ChenWet al.A novel influenza A virus"/>
   <result pre="essential for efficient influenza virus propagationEMBO J.2003222717272812773387 45.ChenWet al.A novel" exact="influenza" post="A virus mitochondrial protein that induces cell deathNat. Med.200171306131211726970"/>
   <result pre="factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient" exact="influenza" post="virus propagationJ. Biol. Chem.2004279309313093715143063 48.WangXet al.Influenza A virus NS1"/>
   <result pre="factor betaJ. Virol.199670862486298970987 50.HinshawVSOlsenCWDybdahl-SissokoNEvansDApoptosis: a mechanism of cell killing by" exact="influenza" post="A and B virusesJ. Virol.199468366736738189504 51.FaleiroLLazebnikYCaspases disrupt the nuclear-cytoplasmic"/>
   <result pre="the nuclear-cytoplasmic barrierJ. Cell Biol.200015195195911085998 52.RoethlEet al.Antimycotic-antibiotic amphotericin B promotes" exact="influenza" post="virus replication in cell cultureJ. Virol.201185111391114521849438 53.YuHet al.Overcoming endosomal"/>
   <result pre="L. et al. Progesterone receptor attenuates STAT1-mediated IFN signaling in" exact="breast cancer." post="J. Immunol.10.4049/jimmunol.1801152 (2019) 61.MusterTet al.Interferon resistance promotes oncolysis by"/>
   <result pre="cancer. J. Immunol.10.4049/jimmunol.1801152 (2019) 61.MusterTet al.Interferon resistance promotes oncolysis by" exact="influenza" post="virus NS1-deletion mutantsInt. J. Cancer2004110152115054864 62.MinJ-YLiSSenGCKrugRMA site on the"/>
   <result pre="influenza virus NS1-deletion mutantsInt. J. Cancer2004110152115054864 62.MinJ-YLiSSenGCKrugRMA site on the" exact="influenza" post="A virus NS1 protein mediates both inhibition of PKR"/>
   <result pre="PKR activation and temporal regulation of viral RNA synthesisVirology200736323624317320139 63.HatadaESaitoSFukudaRMutant" exact="influenza" post="viruses with a defective NS1 protein cannot block the"/>
   <result pre="factor 2 alpha-kinase activationJ. Biol. Chem.199226723092230981358881 65.BergmannMet al.A genetically engineered" exact="influenza" post="A virus with ras-dependent oncolytic propertiesCancer Res.2001618188819311719449 66.MasemannDet al.Oncolytic"/>
   <result pre="influenza A virus with ras-dependent oncolytic propertiesCancer Res.2001618188819311719449 66.MasemannDet al.Oncolytic" exact="influenza" post="virus infection restores immunocompetence of lung tumor-associated alveolar macrophagesOncoimmunology20187e142317129721377"/>
   <result pre="immunocompetence of lung tumor-associated alveolar macrophagesOncoimmunology20187e142317129721377 67.KasloffSBet al.Oncolytic activity of" exact="avian influenza" post="virus in human pancreatic ductal adenocarcinoma cell linesJ. Virol.2014889321933424899201"/>
   <result pre="of lung tumor-associated alveolar macrophagesOncoimmunology20187e142317129721377 67.KasloffSBet al.Oncolytic activity of avian" exact="influenza" post="virus in human pancreatic ductal adenocarcinoma cell linesJ. Virol.2014889321933424899201"/>
   <result pre="al.Activation of interferon regulatory factor 3 is inhibited by the" exact="influenza" post="A virus NS1 proteinJ. Virol.2000747989799610933707 69.GiglioPet al.PKR and GCN2"/>
   <result pre="in melanoma cellsOncoimmunology20187e146676530221067 70.ObeidMet al.Calreticulin exposure dictates the immunogenicity of" exact="cancer" post="cell deathNat. Med.200713546117187072 71.GeissGKet al.Cellular transcriptional profiling in influenza"/>
   <result pre="of cancer cell deathNat. Med.200713546117187072 71.GeissGKet al.Cellular transcriptional profiling in" exact="influenza" post="A virus-infected lung epithelial cells: the role of the"/>
   <result pre="and 18J. Gen. Virol.20058618519515604446 73.SturlanSet al.Endogenous expression of proteases in" exact="colon cancer" post="cells facilitate influenza A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775"/>
   <result pre="18J. Gen. Virol.20058618519515604446 73.SturlanSet al.Endogenous expression of proteases in colon" exact="cancer" post="cells facilitate influenza A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775"/>
   <result pre="73.SturlanSet al.Endogenous expression of proteases in colon cancer cells facilitate" exact="influenza" post="A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775 74.KuznetsovaIet al.Targeting an"/>
   <result pre="A viruses mediated oncolysisCancer Biol. Ther.20101059259920647775 74.KuznetsovaIet al.Targeting an oncolytic" exact="influenza" post="A virus to tumor tissue by elastaseMol. Ther. Oncolytics20177374429034314"/>
   <result pre="genomic RNA during negative-strand RNA virus infectionCell201014039740820144762 78.HsuMTParvinJDGuptaSKrystalMPalesePGenomic RNAs of" exact="influenza" post="viruses are held in a circular conformation in virions"/>
   <result pre="sequencingProc. Natl Acad. Sci. USA2010107163031630820805493 80.BergmannMMusterTThe relative amount of an" exact="influenza" post="A virus segment present in the viral particle is"/>
   <result pre="5’-phosphatesScience2006314997100117038589 82.RomanovaJet al.Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1" exact="influenza" post="vaccinePLoS One20094e598419543385 83.WacheckVet al.A novel type of influenza vaccine:"/>
   <result pre="DeltaNS1 H5N1 influenza vaccinePLoS One20094e598419543385 83.WacheckVet al.A novel type of" exact="influenza" post="vaccine: safety and immunogenicity of replication-deficient influenza virus created"/>
   <result pre="novel type of influenza vaccine: safety and immunogenicity of replication-deficient" exact="influenza" post="virus created by deletion of the interferon antagonist NS1J."/>
   <result pre="Infect. Dis.201020135436220039806 84.NicolodiCet al.Safety and immunogenicity of a replication-deficient H5N1" exact="influenza" post="virus vaccine lacking NS1Vaccine2019373722372931155415 85.SachetMet al.Improvement of a dendritic"/>
   <result pre="85.SachetMet al.Improvement of a dendritic cell-based tumour vaccine by an" exact="influenza" post="virusEur. J. Clin. Invest2009391000100919807781 86.EffersonCLet al.Prostate tumor cells infected"/>
   <result pre="Clin. Invest2009391000100919807781 86.EffersonCLet al.Prostate tumor cells infected with a recombinant" exact="influenza" post="virus expressing a truncated NS1 protein activate cytolytic CD8+"/>
   <result pre="of peripheral blood mononuclear cellsPLoS One20094e412219125202 88.MasicABabiukLAZhouYReverse genetics-generated elastase-dependent swine" exact="influenza" post="viruses are attenuated in pigsJ. Gen. Virol.20099037538519141446 89.StechJGarnHWegmannMWagnerRKlenkH-DA new"/>
   <result pre="attenuated in pigsJ. Gen. Virol.20099037538519141446 89.StechJGarnHWegmannMWagnerRKlenkH-DA new approach to an" exact="influenza" post="live vaccine: modification of the cleavage site of hemagglutininNat."/>
   <result pre="al.Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine" exact="influenza" post="virus vaccine administered intranasally in pigsVaccine2010287098710820708697 91.de GraafJFde VorLFouchierRAMvan"/>
   <result pre="nuclear export protein allows stable transgene expression in a chimaeric" exact="influenza" post="A virus vectorJ. Gen. Virol.20149533734924222196 93.WolschekMet al.Establishment of a"/>
   <result pre="virus vectorJ. Gen. Virol.20149533734924222196 93.WolschekMet al.Establishment of a chimeric, replication-deficient" exact="influenza" post="A virus vector by modulation of splicing efficiencyJ. Virol.2011852469247321177819"/>
   <result pre="virus vector by modulation of splicing efficiencyJ. Virol.2011852469247321177819 94.HockKet al.Oncolytic" exact="influenza" post="A virus expressing interleukin-15 decreases tumor growth in vivoSurgery201716173574627776794"/>
   <result pre="tumor growth in vivoSurgery201716173574627776794 95.PenghuiYet al.Oncolytic activity of a novel" exact="influenza" post="A virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinomaHum."/>
   <result pre="colony-stimulating factor in hepatocellular carcinomaHum. Gene Ther.20193033033830205709 96.HamiltonJRVijayakumarGPalesePA recombinant antibody-expressing" exact="influenza" post="virus delays tumor growth in a mouse modelCell Rep.2018221729298413"/>
   <result pre="lymphocytes (CTLs) by human dendritic cells infected with an attenuated" exact="influenza" post="A virus expressing a CTL epitope derived from the"/>
   <result pre="tumor cells to TLR3-mediated apoptosisCell Death Differ.20132082383323449395 99.WeissRet al.Interleukin-24 inhibits" exact="influenza" post="A virus replication in vitro through induction of toll-like"/>
   <result pre="Cell Biol.20141513514724452471 101.KabiljoJHarpainFCarottaSBergmannMRadiotherapy as a backbone for novel concepts in" exact="cancer" post="immunotherapyCancers (Basel)20191279 102.SnyderAGet al.Intratumoral activation of the necroptotic pathway"/>
   <result pre="antitumor immunitySci. Immunol.20194eaaw200431227597 103.KuriakoseTet al.ZBP1/DAI is an innate sensor of" exact="influenza" post="virus triggering the NLRP3 inflammasome and programmed cell death"/>
   <result pre="of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during" exact="influenza" post="virus infection to promote host survivalCell Host Microbe201415233524439895 105.TeifkeJPet"/>
   <result pre="Microbe201415233524439895 105.TeifkeJPet al.Pathology of natural infections by H5N1 highly pathogenic" exact="avian influenza" post="virus in mute (Cygnus olor) and whooper (Cygnus cygnus)"/>
   <result pre="105.TeifkeJPet al.Pathology of natural infections by H5N1 highly pathogenic avian" exact="influenza" post="virus in mute (Cygnus olor) and whooper (Cygnus cygnus)"/>
   <result pre="increased host immune and cell death responses induced by 1918" exact="influenza" post="virusNature200644357858117006449 107.HuiKPYet al.Highly pathogenic avian influenza H5N1 virus delays"/>
   <result pre="death responses induced by 1918 influenza virusNature200644357858117006449 107.HuiKPYet al.Highly pathogenic" exact="avian influenza" post="H5N1 virus delays apoptotic responses via activation of STAT3Sci."/>
   <result pre="responses induced by 1918 influenza virusNature200644357858117006449 107.HuiKPYet al.Highly pathogenic avian" exact="influenza" post="H5N1 virus delays apoptotic responses via activation of STAT3Sci."/>
   <result pre="delays apoptotic responses via activation of STAT3Sci. Rep.201662859327344974 108.HuiKPYet al.H5N1" exact="influenza" post="virus-induced mediators upregulate RIG-I in uninfected cells by paracrine"/>
   <result pre="in a specific imbalanced inflammatory responseJ. Immunol.201118616417321106851 110.HartmannBMet al.Pandemic H1N1" exact="influenza" post="A viruses suppress immunogenic RIPK3-driven dendritic cell deathNat. Commun.20178193129203926"/>
   <result pre="RIPK3-driven dendritic cell deathNat. Commun.20178193129203926 111.GabaAet al.The NS1 protein of" exact="influenza" post="A virus participates in necroptosis by interacting with MLKL"/>
   <result pre="and membrane translocationJ. Virol.201993e018351830355688 112.GongYet al.The role of necroptosis in" exact="cancer" post="biology and therapyMol. Cancer20191810031122251 113.HolzeCet al.Oxeiptosis, a ROS-induced caspase-independent"/>
   <result pre="apoptosis-like cell-death pathwayNat. Immunol.20181913014029255269 114.OgbomoHet al.Tumor cells infected with oncolytic" exact="influenza" post="A virus prime natural killer cells for lysis of"/>
   <result pre="In VitroPLoS One20149e11201425390891 116.NakashimaHNguyenTChioccaEACombining HDAC inhibitors with oncolytic virotherapy for" exact="cancer" post="therapyOncolytic Viroth20154183191 117.HamanoSet al.Oncolytic reovirus combined with trastuzumab enhances"/>
   <result pre="enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric" exact="cancer" post="cellsCancer Lett.201535684685425444894 118.LaengleJet al.Histone deacetylase inhibitors valproic acid and"/>
   <result pre="to the same extent in both adjuvant and metastatic HER2/neu" exact="breast cancer" post="patientsJ. Transl. Med.20131130724330813 120.JhawarSRet al.Radiation therapy and talimogene laherparepvec"/>
   <result pre="the same extent in both adjuvant and metastatic HER2/neu breast" exact="cancer" post="patientsJ. Transl. Med.20131130724330813 120.JhawarSRet al.Radiation therapy and talimogene laherparepvec"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7289343\results\search\disease\results.xml">
   <result pre="Surveillance A comparative analysis of the 2007 and 2017 Italian" exact="chikungunya" post="outbreaks and implication for public health response CaputoBeniamino1*http://orcid.org/0000-0002-8764-7389RussoGianluca1http://orcid.org/0000-0003-3709-1199ManicaMattia23VairoFrancesco4PolettiPiero35GuzzettaGiorgio35MerlerStefano35ScagnolariCarolina6SoliminiAngelo1[1], Dipartimento"/>
   <result pre="reported, though a higher frequency of ocular symptoms, myalgia, and" exact="rash" post="was observed in 2017. Very little is known about"/>
   <result pre="of residence of human cases during the 2007 and 2017" exact="chikungunya" post="outbreaks. For 2017, 3 cases epidemiologically linked to Anzio"/>
   <result pre="10.1371/journal.pntd.0008159.t001Table 1 Selected epidemiological parameters of the 2007 and 2017" exact="chikungunya" post="outbreaks in Italy. 2007 2017 Infection Probable cases 337"/>
   <result pre="outbreaks, though a higher frequency of ocular symptoms, myalgia, and" exact="rash" post="was observed in 2017 (Table 2). Finally, concerning hospital"/>
   <result pre="= 200) and probable (n = 202) cases. Abbreviations: CHIKV," exact="chikungunya" post="virus. During 2017, Italy experienced also a large spread"/>
   <result pre="28.8 cases/100,000 inhabitants). It should be noticed that CHIKV-related skin" exact="rash" post="is usually morbilliform (measles-like) [31–33], with or without acral"/>
   <result pre="Romi R, Finarelli A, Panning M, et al. Infection with" exact="chikungunya" post="virus in Italy: an outbreak in a temperate region."/>
   <result pre="E, Castilletti C, Carletti F, et al. Local transmission of" exact="chikungunya" post="in Rome and the Lazio region, Italy. Roques P,"/>
   <result pre="PolettiP, FilipponiF, SoliminiA, CaputoB, et al.Transmission dynamics of the ongoing" exact="chikungunya" post="outbreak in Central Italy: From coastal areas to the"/>
   <result pre="7VairoF, MammoneA, LaniniS, NicastriE, CastillettiC, CarlettiF, et al.Local transmission of" exact="chikungunya" post="in Rome and the Lazio region, Italy. RoquesP, editor."/>
   <result pre="Di LucaM, FortunaC, RemoliME, RiccardoF, SeveriniF, et al.Detection of a" exact="chikungunya" post="outbreak in central Italy, August to September 2017. Eurosurveillance."/>
   <result pre="10.2807/1560-7917.ES.2017.22.39.17-00646 9RezzaG, NicolettiL, AngeliniR, RomiR, FinarelliA, PanningM, et al.Infection with" exact="chikungunya" post="virus in Italy: an outbreak in a temperate region."/>
   <result pre="FrankeF, JeanninC, Auzet-CaillaudM, GrardG, et al.Preliminary report of an autochthonous" exact="chikungunya" post="outbreak in France, July to September 2017. Eurosurveillance. 2017;22:"/>
   <result pre="Le, TarantolaA, DepoortereE. Assessing the risk of importing dengue and" exact="chikungunya" post="viruses to the European Union. Epidemics. 2009;1(3): 175–184. 10.1016/j.epidem.2009.06.00321352765"/>
   <result pre="2018;25(1): tay00410.1093/jtm/tay00429669058 24SeylerT, RizzoC, FinarelliAC, PoC, AlessioP, SambriV, et al.Autochthonous" exact="chikungunya" post="virus transmission may have occurred in Bologna, Italy, during"/>
   <result pre="https://www.ecdc.europa.eu/en/publications-data/mission-report-chikungunya-italy 26PolettiP, MesseriG, AjelliM, ValloraniR, RizzoC, MerlerS. Transmission potential of" exact="chikungunya" post="virus and control measures: The case of Italy. PLoS"/>
   <result pre="Med Entomol. 2012;49(2): 388–399. 10.1603/me1025922493859 28Pugliese A. Expert meeting on" exact="chikungunya" post="modelling -. European Centre for Disease Prevention and Control."/>
   <result pre="competence of Aedes albopictus for the Indian Ocean lineage (IOL)" exact="chikungunya" post="viruses of the 2007 and 2017 outbreaks in Italy:"/>
   <result pre="E1:A226V mutation. Euro Surveill. 2018;23(22): 180024610.2807/1560-7917.ES.2018.23.22.180024629871722 31TiniML, RezzaG. Morbilliform skin" exact="rash" post="with prominent involvement of the palms in Chikungunya fever."/>
   <result pre="139–50. 10.1097/QCO.000000000000014525706914 34MoroML, GrilliE, CorvettaA, SilviG, AngeliniR, MascellaF, et al.Long-term" exact="chikungunya" post="infection clinical manifestations after an outbreak in Italy: A"/>
   <result pre="Infect Dis. 2019;6: ofy32110.1093/OFID/OFY32130697571 39MallhiTH, KhanYH, KhanAH, TanveerN, QadirMI. First" exact="chikungunya" post="outbreak in Pakistan: a trail of viral attacks. New"/>
   <result pre="Antiviral activity of the combination of interferon and ribavirin against" exact="chikungunya" post="virus: are the results conclusive?J Infect Dis. 2017;215(3): 492–493."/>
   <result pre="48AngeliniR, FinarelliAC, AngeliniP, PoC, PetropulacosK, MaciniP, et al.An outbreak of" exact="chikungunya" post="fever in the province of Ravenna, Italy. Euro Surveill."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7289416\results\search\disease\results.xml">
   <result pre="Worldwide, in over 100 countries of the tropics and subtropics," exact="dengue fever" post="is mainly transmitted by Ae. aegypti and Ae. albopictus"/>
   <result pre="of vaccinations and effective drugs, the prevention and control of" exact="dengue fever" post="are still focused on the elimination of the mosquito"/>
   <result pre="containers and houses, is considered the best indices for predicting" exact="dengue fever" post="risk [7]. However, incongruences have been found between those"/>
   <result pre="mosquito [15–17], which have been found to be associated with" exact="dengue fever" post="[18–19]. Among the meteorological features, temperature is considered the"/>
   <result pre="selected as the study sites. Besides, no major epidemics of" exact="dengue fever" post="have occurred in this area during the study period,"/>
   <result pre="[16]. Humidity could also increase the transmission rate of human" exact="dengue fever" post="infection in the context of imported dengue cases and"/>
   <result pre="al. found that wind direction and speed could influence the" exact="malaria" post="vector populations by affecting the effect of CO2 attraction"/>
   <result pre="or larva with or without a time lag. To prevent" exact="dengue fever," post="new monitoring method and thresholds should be developed based"/>
   <result pre="et al.Building Infestation Index for Aedes aegypti and occurrence of" exact="dengue fever" post="in the municipality of Foz do Iguaçu, Paraná, Brazil,"/>
   <result pre="Island. Acta Trop. 2015; 143:89–96. 10.1016/j.actatropica.2014.12.01125592432 38EndoN, EltahirEAB. Prevention of" exact="malaria" post="transmission around reservoirs: an observational and modelling study on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7290434\results\search\disease\results.xml">
   <result pre="more than a quarter of all cases of acute intermittent" exact="hepatitis" post="and impending hepatitis, however, jaundice epidemics caused by HEV"/>
   <result pre="4. Discussion HEV has been considered the cause of acute" exact="hepatitis" post="for a long time and is transmitted mainly through"/>
   <result pre="virus has now been reported in developed countries where autochthonous" exact="hepatitis" post="E is increasingly recognized [40]. It is reported to"/>
   <result pre="16.9% and 18% in blood donors in Jeddah (west) and" exact="sickle cell anemia" post="children in Jazan (south) [33,34]; respectively. This study is"/>
   <result pre="18% in blood donors in Jeddah (west) and sickle cell" exact="anemia" post="children in Jazan (south) [33,34]; respectively. This study is"/>
   <result pre="DcHEV might play a role in the spread of HEV" exact="hepatitis" post="in regions where consumption of camel milk and camel"/>
   <result pre="interest. References References 1.BalayanM.S.AndjaparidzeA.G.SavinskayaS.S.KetiladzeE.S.BraginskyD.M.SavinovA.P.PoleschukV.F.Evidence for a virus in non-A, non-B" exact="hepatitis" post="transmitted via the fecal-oral routeIntervirology19832023316409836 2.CaiY.QinS.-Y.QianA.XuP.XuY.-T.XieL.-H.ZhaoQ.ZhangX.-X.Seroprevalence and risk factors"/>
   <result pre="transmitted via the fecal-oral routeIntervirology19832023316409836 2.CaiY.QinS.-Y.QianA.XuP.XuY.-T.XieL.-H.ZhaoQ.ZhangX.-X.Seroprevalence and risk factors of" exact="hepatitis" post="E virus infection among the Korean, Manchu, Mongol, and"/>
   <result pre="population: First reportInt. J. Infect. Dis.20186612112510.1016/j.ijid.2017.11.01529146513 4.BricksG.SeniseJ.F.Pott JuniorH.GrandiG.PassariniA.CaldeiraD.B.Carnaúba JuniorD.MoraesH.A.B.D.GranatoC.F.H.CasteloA.Seroprevalence of" exact="hepatitis" post="E virus in chronic hepatitis C in BrazilBraz. J."/>
   <result pre="Dis.20186612112510.1016/j.ijid.2017.11.01529146513 4.BricksG.SeniseJ.F.Pott JuniorH.GrandiG.PassariniA.CaldeiraD.B.Carnaúba JuniorD.MoraesH.A.B.D.GranatoC.F.H.CasteloA.Seroprevalence of hepatitis E virus in chronic" exact="hepatitis" post="C in BrazilBraz. J. Infect. Dis.201822859110.1016/j.bjid.2018.02.00129494796 5.GrabarczykP.SulkowskaE.GdowskaJ.KopaczA.LiszewskiG.Kubicka-RusselD.BaylisS.A.CormanV.M.NoceńE.PiotrowskiD.et al.Molecular and"/>
   <result pre="infection marker screening in blood donors indicates high endemicity of" exact="hepatitis" post="E virus in PolandTransfusion2018581245125310.1111/trf.1453129492976 6.FarshadpourF.TaherkhaniR.RavanbodM.R.EghbaliS.S.TaherkhaniS.MahdaviE.Prevalence, risk factors and molecular"/>
   <result pre="virus in PolandTransfusion2018581245125310.1111/trf.1453129492976 6.FarshadpourF.TaherkhaniR.RavanbodM.R.EghbaliS.S.TaherkhaniS.MahdaviE.Prevalence, risk factors and molecular evaluation of" exact="hepatitis" post="E virus infection among pregnant women resident in the"/>
   <result pre="and meta-analysisBMC Infect. Dis.20191951910.1186/s12879-019-4125-x31195988 11.PischkeS.BehrendtP.MannsM.P.WedemeyerH.HEV-associated cryoglobulinaemia and extrahepatic manifestations of" exact="hepatitis" post="ELancet Infect. Dis.20141467867910.1016/S1473-3099(14)70823-025056019 12.DerouxA.BrionJ.P.HyerleL.BelbezierA.VaillantM.MosnierE.LarratS.MorandP.PaveseP.Association between hepatitis E and neurological"/>
   <result pre="and extrahepatic manifestations of hepatitis ELancet Infect. Dis.20141467867910.1016/S1473-3099(14)70823-025056019 12.DerouxA.BrionJ.P.HyerleL.BelbezierA.VaillantM.MosnierE.LarratS.MorandP.PaveseP.Association between" exact="hepatitis" post="E and neurological disorders: Two case studies and literature"/>
   <result pre="13.MengX.J.Hepatitis E virus: Animal reservoirs and zoonotic riskVet. Microbiol.201014025626510.1016/j.vetmic.2009.03.01719361937 14.LinJ.NorderH.UhlhornH.BelákS.WidénF.Novel" exact="hepatitis" post="E like virus found in Swedish mooseJ. General Virol.20149555757010.1099/vir.0.059238-0"/>
   <result pre="like virus found in Swedish mooseJ. General Virol.20149555757010.1099/vir.0.059238-0 15.WooP.C.Y.LauS.K.P.TengJ.L.L.TsangA.K.L.JosephM.WongE.Y.M.TangY.SivakumarS.XieJ.BaiR.et al.New" exact="hepatitis" post="E virus genotype in camels, the Middle EastEmerg. Infect."/>
   <result pre="threat to blood safetyInfection201644112210.1007/s15010-015-0807-526112744 22.CorwinA.L.TienN.T.BounluK.WinarnoJ.PutriM.P.LarasK.LarasatiR.P.SukriN.EndyT.SulaimanH.A.et al.The unique riverine ecology of" exact="hepatitis" post="E virus transmission in South-East AsiaTrans. R. Soc. Trop."/>
   <result pre="E virus in South America: The current scenarioLiver Int.2018381536154610.1111/liv.1388129788538 24.GhabrahT.M.SticklandG.T.TsarevS.YarboughP.FarciP.EngleR.EmersonS.PurcellR.Acute" exact="viral hepatitis" post="in Saudi Arabia: Seroepidemiological analysis, risk factors, clinical manifestations,"/>
   <result pre="virus in South America: The current scenarioLiver Int.2018381536154610.1111/liv.1388129788538 24.GhabrahT.M.SticklandG.T.TsarevS.YarboughP.FarciP.EngleR.EmersonS.PurcellR.Acute viral" exact="hepatitis" post="in Saudi Arabia: Seroepidemiological analysis, risk factors, clinical manifestations,"/>
   <result pre="analysis, risk factors, clinical manifestations, and evidence for a sixth" exact="hepatitis" post="agentClin. Infect. Dis.19952162162710.1093/clinids/21.3.6218527554 25.AmerA.F.ZakiS.A.NagatiA.M.DarwishM.A.Hepatitis E antibodies in Egyptian adolescent"/>
   <result pre="and possible relevanceJ. Egypt. Public Health Assoc.19967127328417217013 26.DarwishM.A.FarisR.ClemensJ.D.RaoM.R.EdelmanR.High seroprevalence of" exact="hepatitis" post="A, B, C, and E viruses in residents in"/>
   <result pre="novel virus in swine is closely related to the human" exact="hepatitis" post="E virusProc. Natl. Acad. Sci. USA1997949860986510.1073/pnas.94.18.98609275216 28.MengX.-J.From barnyard to"/>
   <result pre="Sci. USA1997949860986510.1073/pnas.94.18.98609275216 28.MengX.-J.From barnyard to food table: The omnipresence of" exact="hepatitis" post="E virus and risk for zoonotic infection and food"/>
   <result pre="and risk for zoonotic infection and food safetyVirus Res.2011161233010.1016/j.virusres.2011.01.01621316404 29.PavioN.MengX.-J.RenouC.Zoonotic" exact="hepatitis" post="E: Animal reservoirs and emerging risksVet. Res.2010414610.1051/vetres/201001820359452 30.LiT.C.ZhouX.YoshizakiS.AmiY.SuzakiY.NakamuraT.TakedaN.WakitaT.Production of"/>
   <result pre="reservoirs and emerging risksVet. Res.2010414610.1051/vetres/201001820359452 30.LiT.C.ZhouX.YoshizakiS.AmiY.SuzakiY.NakamuraT.TakedaN.WakitaT.Production of infectious dromedary camel" exact="hepatitis" post="E virus by a reverse genetic system: Potential for"/>
   <result pre="infectionJ. Hepatol.2016651104111110.1016/j.jhep.2016.07.01327449916 31.ZhouX.KataokaM.LiuZ.TakedaN.WakitaT.LiT.C.Characterization of self-assembled virus-like particles of dromedary camel" exact="hepatitis" post="e virus generated by recombinant baculovirusesVirus Res.201521081710.1016/j.virusres.2015.06.02226160190 32.LiT.C.YoshizakiS.ZhouX.SentsuiH.ShiratoK.MatsuyamaS.MelakuS.K.BazartserenB.TakedaN.WakitaT.Serological evidence"/>
   <result pre="e virus generated by recombinant baculovirusesVirus Res.201521081710.1016/j.virusres.2015.06.02226160190 32.LiT.C.YoshizakiS.ZhouX.SentsuiH.ShiratoK.MatsuyamaS.MelakuS.K.BazartserenB.TakedaN.WakitaT.Serological evidence of" exact="hepatitis" post="E virus infection in dromedary camels in EthiopiaJ. Virol."/>
   <result pre="in dromedary camels in EthiopiaJ. Virol. Methods2017246343710.1016/j.jviromet.2017.04.00828438608 33.AbdelaalM.ZawawiT.H.al SobhiE.JejeO.GilpinC.KinsaraA.OsobaA.OniG.A.Epidemiology of" exact="hepatitis" post="E virus in male blood donors in Jeddah, Saudi"/>
   <result pre="in patients from Saudi Arabia with sickle cell anaemia and" exact="beta-thalassemia" post="major: Possible transmission by blood transfusionJ. Viral. Hepat.1996320320510.1111/j.1365-2893.1996.tb00096.x8871882 35.AyoolaE.A.WantM.A.GadourM.O.Al-HazmiM.H.H"/>
   <result pre="genomic studyLancet Planet. Health20193e521e52810.1016/S2542-5196(19)30243-831843456 39.HimmelsbachK.BenderD.HildtE.Life cycle and morphogenesis of the" exact="hepatitis" post="E virusEmerg. Microb. Infect.2018719610.1038/s41426-018-0198-7 40.KhurooM.S.KhurooM.S.KhurooN.S.Hepatitis E: Discovery, global impact,"/>
   <result pre="selected European countries: A shift to screening?Eurosurveillance2017223051410.2807/1560-7917.ES.2017.22.16.3051428449730 43.BassalR.WaxM.ShiraziR.ShohatT.CohenD.DavidD.Abu-MouchS.Abu-GhanemY.MendelsonE.Ben-AriZ.et al.Seroprevalence of" exact="hepatitis" post="E virus in dromedary camels, Bedouins, Muslim Arabs and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7290441\results\search\disease\results.xml">
   <result pre="receptor agonist, nylidrin, was identified as an antiviral compound against" exact="influenza" post="A virus. The molecule was effective against multiple isolates"/>
   <result pre="acidic pH. In a mouse model, preincubation of a mouse-adapted" exact="influenza" post="A virus (H1N1) with nylidrin completely blocked intranasal viral"/>
   <result pre="chemical skeleton for the development of a direct-acting inhibitor of" exact="influenza" post="A virus entry. influenza A virus hemagglutinin 2 fusion"/>
   <result pre="development of a direct-acting inhibitor of influenza A virus entry." exact="influenza" post="A virus hemagglutinin 2 fusion inhibitor nylidrin β2-adrenergic receptor"/>
   <result pre="mRNA synthesis. Despite the high potency of these drugs against" exact="influenza" post="A and/or B viruses, the emergence or global spread"/>
   <result pre="diacetate (FDA); hit compounds were those that allowed 80% of" exact="influenza" post="A or B virus-infected cells to survive at a"/>
   <result pre="[16,17]. One of the hits, nylidrin showed antiviral activity against" exact="influenza" post="A viruses, but not against influenza B viruses (Table"/>
   <result pre="showed antiviral activity against influenza A viruses, but not against" exact="influenza" post="B viruses (Table 1). Also known as buphenine, nylidrin"/>
   <result pre="analogues, ifenprodil and clenbuterol, reliably inhibited H1N1 isolates of the" exact="influenza" post="A virus. In the present study, we suggest that"/>
   <result pre="of HA that occur at low pH. Accordingly, preincubation of" exact="influenza" post="virus with nylidrin completely blocked intranasal infection of mice."/>
   <result pre="could lead to the development of a direct-acting antiviral against" exact="influenza" post="A with a distinct and novel mode of action."/>
   <result pre="grown overnight. The cells were mock-infected or infected with individual" exact="influenza" post="strains at a multiplicity of infection (MOI) of 0.001"/>
   <result pre="secondary antibody (Invitrogen). 2.7. Polykaryon Assay Syncytia formation caused by" exact="influenza" post="infection was evaluated as described previously [16,22]. Vero E6"/>
   <result pre="visualization of cell–cell fusion. Herein, a well-known neutralizing antibody for" exact="influenza" post="A virus HA2, MEDI8852, was chosen as a control"/>
   <result pre="[16,17], we identified nylidrin as a hit compound that inhibits" exact="influenza" post="A viruses (PR8 and HK). At a concentration of"/>
   <result pre="µM, nylidrin maintained 80% viability in MDCK cells infected with" exact="influenza" post="A, but conferred no benefit in CPE-reduction following infection"/>
   <result pre="but conferred no benefit in CPE-reduction following infection with an" exact="influenza" post="B strain (Lee). To verify this finding, we performed"/>
   <result pre="partially including nylidrin, ifenprodil, labetalol, eliprodil, and clenbuterol, against additional" exact="influenza" post="A and B viruses (Table 2). Nylidrin, ifenprodil, and"/>
   <result pre="the H3N2 viral strains, and none had antiviral activity in" exact="influenza" post="B-infected cells. As expected, the remaining two compounds, labetalol"/>
   <result pre="can reliably inhibit the infection of H1N1 strains of the" exact="influenza" post="A virus at subtoxic concentrations. 3.2. Field-Based Pharmacophore Analysis"/>
   <result pre="assay, it was necessary to determine whether nylidrin could inhibit" exact="influenza" post="viral infection by monitoring viral proteins or plaque reduction"/>
   <result pre="of viral entry. This time-of-addition experiment revealed that nylidrin affected" exact="influenza" post="virus replication in an incubation period-dependent manner (Figure 2C)."/>
   <result pre="infection in vivo by directly targeting the HA2 function of" exact="influenza" post="A virus (H1N1). 4. Discussion From screening of a"/>
   <result pre="identified nylidrin, an ADRB2 agonist, as an antiviral compound against" exact="influenza" post="A virus. ADRB2 is a G protein-coupled receptor (GPCR)"/>
   <result pre="an agonist of the �?�2 adrenergic receptor (ARDA2), inhibited various" exact="influenza" post="strains at the viral assembly step [29]. As a"/>
   <result pre="was wondered how ADRB2 agonists have antiviral activity against the" exact="influenza" post="A virus. Here, this question was answered by the"/>
   <result pre="point to be stressed is that nylidrin completely blocked intranasal" exact="influenza" post="infections of mice when it was preincubated with the"/>
   <result pre="suggest that although nylidrin is a potent, direct-acting inhibitor of" exact="influenza" post="virus HA2, the pharmacokinetics of gastrointestinal absorption is not"/>
   <result pre="gastrointestinal absorption is not sufficient for oral administration to treat" exact="influenza" post="virus infection. Future studies could also focus on chemical"/>
   <result pre="No effect of nylidin on the proton channel activity of" exact="influenza" post="viral M2, Figure S4: Increase of mean survival time"/>
   <result pre="to publish the results. References References 1.ArranzR.ColomaR.ChichonF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtinJ.Martin-BenitoJ.The structure of native" exact="influenza" post="virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 2.PflugA.GuilligayD.ReichS.CusackS.Structure of influenza A polymerase bound to"/>
   <result pre="References 1.ArranzR.ColomaR.ChichonF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtinJ.Martin-BenitoJ.The structure of native influenza virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 2.PflugA.GuilligayD.ReichS.CusackS.Structure of" exact="influenza" post="A polymerase bound to the viral RNA promoterNature201451635536010.1038/nature1400825409142 3.NakatsuS.SagaraH.Sakai-TagawaY.SugayaN.NodaT.KawaokaY.Complete"/>
   <result pre="Packaging of Influenza A and B VirusesmBio2016710.1128/mBio.01248-1627601575 4.WeisW.BrownJ.H.CusackS.PaulsonJ.C.SkehelJ.J.WileyD.C.Structure of the" exact="influenza" post="virus haemagglutinin complexed with its receptor, sialic acidNature198833342643110.1038/333426a03374584 5.GamblinS.J.SkehelJ.J.Influenza"/>
   <result pre="5.GamblinS.J.SkehelJ.J.Influenza hemagglutinin and neuraminidase membrane glycoproteinsJ. Biol. Chem.2010285284032840910.1074/jbc.R110.12980920538598 6.BulloughP.A.HughsonF.M.SkehelJ.J.WileyD.C.Structure of" exact="influenza" post="haemagglutinin at the pH of membrane fusionNature1994371374310.1038/371037a08072525 7.PintoL.H.LambR.A.The M2"/>
   <result pre="the pH of membrane fusionNature1994371374310.1038/371037a08072525 7.PintoL.H.LambR.A.The M2 proton channels of" exact="influenza" post="A and B virusesJ. Biol. Chem.20062818997900010.1074/jbc.R50002020016407184 8.NeumannG.CastrucciM.R.KawaokaY.Nuclear import and"/>
   <result pre="and B virusesJ. Biol. Chem.20062818997900010.1074/jbc.R50002020016407184 8.NeumannG.CastrucciM.R.KawaokaY.Nuclear import and export of" exact="influenza" post="virus nucleoproteinJ. Virol.1997719690970010.1128/JVI.71.12.9690-9700.19979371635 9.AbrahamG.M.MortonJ.B.SaravolatzL.D.Baloxavir: A Novel Antiviral Agent in"/>
   <result pre="Treatment of InfluenzaClin. Infect. Dis.202010.1093/cid/ciaa107 10.De ClercqE.Antiviral agents active against" exact="influenza" post="A virusesNat. Rev. Drug Discov.200651015102510.1038/nrd217517139286 11.BragstadK.HungnesO.LitleskareI.NyrerodH.C.DorenbergD.H.HaugeS.H.Community spread and late"/>
   <result pre="Discov.200651015102510.1038/nrd217517139286 11.BragstadK.HungnesO.LitleskareI.NyrerodH.C.DorenbergD.H.HaugeS.H.Community spread and late season increased incidence of oseltamivir-resistant" exact="influenza" post="A(H1N1) viruses in Norway 2016Influenza Other Respir. Viruses20191337238110.1111/irv.1263730834715 12.PielakR.M.SchnellJ.R.ChouJ.J.Mechanism"/>
   <result pre="Respir. Viruses20191337238110.1111/irv.1263730834715 12.PielakR.M.SchnellJ.R.ChouJ.J.Mechanism of drug inhibition and drug resistance of" exact="influenza" post="A M2 channelProc. Natl. Acad. Sci. USA20091067379738410.1073/pnas.090254810619383794 13.HurtA.C.BesselaarT.G.DanielsR.S.ErmetalB.FryA.GubarevaL.HuangW.LackenbyA.LeeR.T.LoJ.et al.Global"/>
   <result pre="Sci. USA20091067379738410.1073/pnas.090254810619383794 13.HurtA.C.BesselaarT.G.DanielsR.S.ErmetalB.FryA.GubarevaL.HuangW.LackenbyA.LeeR.T.LoJ.et al.Global update on the susceptibility of human" exact="influenza" post="viruses to neuraminidase inhibitors, 2014-2015Antiviral Res.201613217818510.1016/j.antiviral.2016.06.00127265623 14.HurtA.C.ChotpitayasunondhT.CoxN.J.DanielsR.FryA.M.GubarevaL.V.HaydenF.G.HuiD.S.HungnesO.LackenbyA.et al.Antiviral resistance"/>
   <result pre="neuraminidase inhibitors, 2014-2015Antiviral Res.201613217818510.1016/j.antiviral.2016.06.00127265623 14.HurtA.C.ChotpitayasunondhT.CoxN.J.DanielsR.FryA.M.GubarevaL.V.HaydenF.G.HuiD.S.HungnesO.LackenbyA.et al.Antiviral resistance during the 2009" exact="influenza" post="A H1N1 pandemic: Public health, laboratory, and clinical perspectivesLancet"/>
   <result pre="Acidification and Viral Matrix Protein 2 FunctionJ. Virol.201892e01441-1810.1128/JVI.01441-1830282713 17.KimM.KimS.Y.LeeH.W.ShinJ.S.KimP.JungY.S.JeongH.S.HyunJ.K.LeeC.K.Inhibition of" exact="influenza" post="virus internalization by (-)-epigallocatechin-3-gallateAntiviral Res.201310046047210.1016/j.antiviral.2013.08.00223954192 18.NiemeyerG.CottierD.ReschH.Effects of buphenine (nylidrin)"/>
   <result pre="phosphateJ. Microbiol.20175597998310.1007/s12275-017-7371-x29214495 20.JangY.LeeH.W.ShinJ.S.GoY.Y.KimC.ShinD.MalpaniY.HanS.B.JungY.S.KimM.Antiviral activity of KR-23502 targeting nuclear export of" exact="influenza" post="B virus ribonucleoproteinsAntiviral Res.2016134778810.1016/j.antiviral.2016.07.02427565992 21.VinterJ.G.Extended electron distributions applied to"/>
   <result pre="some intermolecular interactionsJ. Comput Aided Mol Des.1994865366810.1007/BF001240137738602 22.VanderlindenE.GoktasF.CesurZ.FroeyenM.ReedM.L.RussellC.J.CesurN.NaesensL.Novel inhibitors of" exact="influenza" post="virus fusion: Structure-activity relationship and interaction with the viral"/>
   <result pre="to viral infectionJ. Exp. Med.202021710.1084/jem.20190554 29.MatsuiK.OzawaM.KisoM.YamashitaM.MaekawaT.KubotaM.SuganoS.KawaokaY.Stimulation of alpha2-adrenergic receptors impairs" exact="influenza" post="virus infectionSci. Rep.20188463110.1038/s41598-018-22927-029545586 30.LiT.W.ChengS.F.TsengY.T.YangY.C.LiuW.C.WangS.C.ChouM.J.LinY.J.WangY.HsiaoP.W.et al.Development of single-chain variable fragments"/>
   <result pre="infectionSci. Rep.20188463110.1038/s41598-018-22927-029545586 30.LiT.W.ChengS.F.TsengY.T.YangY.C.LiuW.C.WangS.C.ChouM.J.LinY.J.WangY.HsiaoP.W.et al.Development of single-chain variable fragments (scFv) against" exact="influenza" post="virus targeting hemagglutinin subunit 2 (HA2)Arch. Virol.2016161193110.1007/s00705-015-2625-626446888 31.GocnikM.FislovaT.SladkovaT.MuchaV.KostolanskyF.VareckovaE.Antibodies specific"/>
   <result pre="2 (HA2)Arch. Virol.2016161193110.1007/s00705-015-2625-626446888 31.GocnikM.FislovaT.SladkovaT.MuchaV.KostolanskyF.VareckovaE.Antibodies specific to the HA2 glycopolypeptide of" exact="influenza" post="A virus haemagglutinin with fusion-inhibition activity contribute to the"/>
   <result pre="against the fusion peptide of hemagglutinin protect mice from lethal" exact="influenza" post="A virus H5N1 infectionJ. Virol.2009832553256210.1128/JVI.02165-0819109379 33.BasuA.AntanasijevicA.WangM.LiB.MillsD.M.AmesJ.A.NashP.J.WilliamsJ.D.PeetN.P.MoirD.T.et al.New small molecule"/>
   <result pre="infectionJ. Virol.2009832553256210.1128/JVI.02165-0819109379 33.BasuA.AntanasijevicA.WangM.LiB.MillsD.M.AmesJ.A.NashP.J.WilliamsJ.D.PeetN.P.MoirD.T.et al.New small molecule entry inhibitors targeting hemagglutinin-mediated" exact="influenza" post="a virus fusionJ. Virol.2014881447146010.1128/JVI.01225-1324198411 34.WhiteK.M.De JesusP.ChenZ.AbreuP.Jr.BarileE.MakP.A.AndersonP.NguyenQ.T.InoueA.StertzS.et al.A Potent Anti-influenza"/>
   <result pre="hydrophobic; and yellow, van der Waals. Figure 2 Inhibition of" exact="influenza" post="virus infection by nylidrin. (A) Western blot analysis showing"/>
   <result pre="stained with DAPI. Original magnification, 630×. Figure 4 Inhibition of" exact="influenza" post="HA2-mediated membrane fusion by nylidrin. (A) Polykaryon formation assay."/>
   <result pre="5 In vivo antiviral activity of nylidrin against a mouse-adapted" exact="influenza" post="A virus (H1N1), maPR8. Before viral challenge, maPR8 (5"/>
   <result pre="1Table 1 Antiviral activity of nylidrin and its analogues against" exact="influenza" post="viruses, PR8, HK, and Lee. Compound CC50 (μM) a"/>
   <result pre="2 Antiviral activity of nylidrin and its analogues against various" exact="influenza" post="A and B viruses. Compound CC50 (μM) a to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7290740\results\search\disease\results.xml">
   <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Influenza virus infections can lead to" exact="viral pneumonia" post="and acute respiratory distress syndrome in severe cases, causing"/>
   <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Influenza virus infections can lead to viral" exact="pneumonia" post="and acute respiratory distress syndrome in severe cases, causing"/>
   <result pre="Abstract Influenza virus infections can lead to viral pneumonia and" exact="acute respiratory distress syndrome" post="in severe cases, causing significant morbidity and mortality and"/>
   <result pre="great threat to human health. Because of the diversity of" exact="influenza" post="virus strains and drug resistance to the current direct"/>
   <result pre="effective drugs as yet to cure all patients infected by" exact="influenza" post="viruses. Natural products from plants contain compounds with diverse"/>
   <result pre="as an inhibitor against the replication of a panel of" exact="influenza" post="A and B viruses both on human pulmonary epithelial"/>
   <result pre="and improves the survival rate of mice infected with lethal" exact="influenza" post="virus. Also, EEC treatment attenuated lung injury and reduced"/>
   <result pre="be further developed as a resource of new anti-influenza drugs." exact="influenza" post="virus caesalpinia decapetala antiviral extract 1. Introduction Despite the"/>
   <result pre="Introduction Despite the availability of vaccines and direct-acting antiviral drugs," exact="influenza" post="causes substantial morbidity and mortality every year [1]. Vaccination"/>
   <result pre="widespread drug-resistant strains, they are no longer recommended to treat" exact="influenza" post="[6]. Current therapy for influenza includes virus neuraminidase inhibitors"/>
   <result pre="no longer recommended to treat influenza [6]. Current therapy for" exact="influenza" post="includes virus neuraminidase inhibitors and polymerase inhibitors [7]. The"/>
   <result pre="which cannot shorten the course of the disease [11]. Since" exact="influenza" post="causes a huge burden on society every year in"/>
   <result pre="to develop new anti-influenza drugs against a broad spectrum of" exact="influenza" post="viruses, including the resistant strains [12]. Plants produce a"/>
   <result pre="extracted from Artemisia annua and has been used to treat" exact="malaria" post="[15]. To explore the potential of plant extracts in"/>
   <result pre="of the 600 plants in a U937 cell model against" exact="influenza" post="virus infection [16], we found that the ethanol extract"/>
   <result pre="of Caesalpinia decapetala (Roth) Alston (EEC) has antiviral activity against" exact="influenza" post="virus infection. Caesalpinia decapetala (Roth) Alston (C. decapetala) is"/>
   <result pre="as a folk medicine to prevent colds, treat bronchitis, and" exact="malaria" post="[20]. However, the extract of C. decapetala has never"/>
   <result pre="broad-spectrum inhibitory effect on the replication of all strains of" exact="influenza" post="viruses tested on Madin–Darby Canine Kidney (MDCK), A549, and"/>
   <result pre="could improve the survival rate of mice infected with lethal" exact="influenza" post="virus and decrease the virus titers and pathological damage"/>
   <result pre="amplified from 10-day-old chicken embryos. The virus titers of different" exact="influenza" post="strains were determined using 50% tissue culture infective dose"/>
   <result pre="the antiviral assay, cells were plated and infected with the" exact="influenza" post="virus in the presence or absence of the drug."/>
   <result pre="2′-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA, Sigma, M8639), for the neuraminidase (NA) of" exact="influenza" post="viruses was used to detect the levels of NA."/>
   <result pre="were anesthetized with pentobarbital sodium and then infected with the" exact="influenza" post="virus through the nasal cavity. Infected mice were treated"/>
   <result pre="extract of C. decapetala (EEC) inhibits the replication of the" exact="influenza" post="virus on A549 cells. As shown in Figure 1A,"/>
   <result pre="cells. As shown in Figure 1A, EEC inhibited the H1N1" exact="influenza" post="virus PR8 strain infection on A549 cells, with a"/>
   <result pre="At concentrations higher than 43 μg/mL, the production of infectious" exact="influenza" post="virions was below the detection limit (10 TCID50/mL). The"/>
   <result pre="to A549 cells. In conclusion, we demonstrated that EEC inhibits" exact="influenza" post="virus replication on A549 cells. 3.2. EEC Has a"/>
   <result pre="of Influenza Viruses in A549, U937, and MDCK Cells Human" exact="influenza" post="A and B viruses cause annual influenza epidemics, whereas"/>
   <result pre="MDCK Cells Human influenza A and B viruses cause annual" exact="influenza" post="epidemics, whereas influenza A viruses can also cause sporadic"/>
   <result pre="influenza A and B viruses cause annual influenza epidemics, whereas" exact="influenza" post="A viruses can also cause sporadic infections or spread"/>
   <result pre="antiviral spectrum of EEC against different types and subtypes of" exact="influenza" post="viruses, we infected A549 cells with 0.25 MOI of"/>
   <result pre="influenza viruses, we infected A549 cells with 0.25 MOI of" exact="influenza" post="A/Puerto Rico/8/1934, A/Puerto Rico/8/1934 (H274Y), A/human/Hubei/1/2009 (H1N1), A/human/Hubei/3/2005 (H3N2),"/>
   <result pre="diluted EEC. We found that EEC could inhibit all the" exact="influenza" post="viruses, including the oseltamivir-resistant H1N1 (H274Y) virus, on A549"/>
   <result pre="a similar efficiency (Figure 2). During infection of humans, the" exact="influenza" post="virus can infect multiple cell types, including epithelial cells"/>
   <result pre="cells and monocytes that are important for the pathogenesis of" exact="influenza" post="[24]. We next checked the antiviral effect of EEC"/>
   <result pre="on epithelial MDCK cells and monocytic U937 cells against both" exact="influenza" post="virus A and B viruses. Surprisingly, EEC was found"/>
   <result pre="B viruses. Surprisingly, EEC was found to inhibit all the" exact="influenza" post="virus strains both in MDCK cells and U937 cells."/>
   <result pre="canine MDCK cells, EEC inhibits more efficiently the replication of" exact="influenza" post="viruses in human A549 and U937 cells (Table 1)."/>
   <result pre="Influenza Virus Life Cycle To determine the stage of the" exact="influenza" post="virus life cycle inhibited by EEC, a time-of-addition assay"/>
   <result pre="was conducted. MDCK cells were infected with 0.1 MOI of" exact="influenza" post="virus at 4 °C for 1 h, followed by"/>
   <result pre="that EEC may inhibit the very late stage of the" exact="influenza" post="virus life cycle, which includes mainly the release of"/>
   <result pre="results show that EEC inhibits the late stage of the" exact="influenza" post="virus life cycle. Since the virus neuraminidase activity is"/>
   <result pre="virions, we speculate that EEC may inhibit the release of" exact="influenza" post="viruses. 3.4. EEC Protects Mice from Lethal Influenza Virus"/>
   <result pre="infection. These observations suggest that EEC protects mice from lethal" exact="influenza" post="virus infection. 3.5. EEC Reduces Virus Titer and Pathogenic"/>
   <result pre="the selective indexes of EEC in the inhibitory effects against" exact="influenza" post="virus A and B strains in human A549 and"/>
   <result pre="to 52 (Table 1), EEC does protect mice from lethal" exact="influenza" post="virus infection. To confirm whether EEC inhibits virus replication"/>
   <result pre="of the placebo group. When mice are infected with the" exact="influenza" post="virus, a large number of inflammatory cells are often"/>
   <result pre="pathological changes in the lungs of mice infected by lethal" exact="influenza" post="and treated or untreated with EEC, the total cell"/>
   <result pre="mediated by the antiviral effect of EEC. 4. Discussion/Conclusions Seasonal" exact="influenza" post="is an acute respiratory infection caused by influenza viruses"/>
   <result pre="Discussion/Conclusions Seasonal influenza is an acute respiratory infection caused by" exact="influenza" post="viruses that circulate the world [27]. Influenza A and"/>
   <result pre="disease. Currently circulating in humans are subtype A(H1N1) and A(H3N2)" exact="influenza" post="viruses [28]. Influenza viruses circulating in animals, e.g., birds,"/>
   <result pre="to infect humans and cause illness [29]. In patients with" exact="influenza" post="pneumonia, multiple cell types, including epithelial cells, alveolar cells,"/>
   <result pre="epithelial cells, alveolar cells, and monocytes, are infected by the" exact="influenza" post="virus and contribute to direct cytopathogenic and inflammatory damage"/>
   <result pre="tested the antiviral effect of EEC against a panel of" exact="influenza" post="viruses on the epithelial A549 cells and monocytic U937"/>
   <result pre="to that of ribavirin (Figure S1). In addition to human" exact="influenza" post="A viruses H1N1 and H3N2, human influenza B virus"/>
   <result pre="addition to human influenza A viruses H1N1 and H3N2, human" exact="influenza" post="B virus strains, the 2009 (H1N1) pandemic strain, oseltamivir-resistant"/>
   <result pre="the therapeutic effect of EEC was tested on a mouse" exact="influenza" post="model. Our results demonstrated that EEC protected mice from"/>
   <result pre="model. Our results demonstrated that EEC protected mice from lethal" exact="influenza" post="infection by increasing the survival rate that is associated"/>
   <result pre="total alkaloid extract from Commelina communis showed antiviral activity against" exact="influenza" post="virus H1N1 in vivo [33]. Utsunomiya et al. found"/>
   <result pre="production by T cells. Glycyrrhizin, by itself, does not inhibit" exact="influenza" post="virus replication [34]. Compared with these reported herb medicines,"/>
   <result pre="found at https://www.mdpi.com/1999-4915/12/5/557/s1. Figure S1: Antiviral effects of ribavirin against" exact="influenza" post="virus PR 8 were determined in A 549 U"/>
   <result pre="analysis of the TCID 50 and neuraminidase (NA) activity of" exact="influenza" post="virus solutions produced in cell culture. LINK Click here"/>
   <result pre="respiratory mortality: A modelling studyLancet20183911285130010.1016/S0140-6736(17)33293-229248255 2.KrammerF.The human antibody response to" exact="influenza" post="A virus infection and vaccinationNat. Rev. Immunol.20191938339710.1038/s41577-019-0143-630837674 3.YamayoshiS.KawaokaY.Current and"/>
   <result pre="A virus infection and vaccinationNat. Rev. Immunol.20191938339710.1038/s41577-019-0143-630837674 3.YamayoshiS.KawaokaY.Current and future" exact="influenza" post="vaccinesNat. Med.20192521222010.1038/s41591-018-0340-z30692696 4.DarwishI.MubarekaS.LilesW.C.Immunomodulatory therapy for severe influenzaExpert Rev Anti-Infect."/>
   <result pre="5.DunningJ.BaillieJ.K.CaoB.HaydenF.G.Antiviral combinations for severe influenzaLancet Infect. Dis.2014141259127010.1016/S1473-3099(14)70821-725213733 6.JeffersonT.DemicheliV.RivettiD.JonesM.Di PietrantonjC.RivettiA.Antivirals for" exact="influenza" post="in healthy adults: Systematic reviewLancet200636730331310.1016/S0140-6736(06)67970-116443037 7.Van DongenM.J.P.KadamR.U.JuraszekJ.LawsonE.BrandenburgB.SchmitzF.WilsonI.A.A small-molecule fusion"/>
   <result pre="healthy adults: Systematic reviewLancet200636730331310.1016/S0140-6736(06)67970-116443037 7.Van DongenM.J.P.KadamR.U.JuraszekJ.LawsonE.BrandenburgB.SchmitzF.WilsonI.A.A small-molecule fusion inhibitor of" exact="influenza" post="virus is orally active in miceScience2019363pii:eaar622110.1126/science.aar6221 8.NaesensL.StevaertA.VanderlindenE.Antiviral therapies on"/>
   <result pre="the horizon for influenzaCurr. Opin. Pharmacol.20163010611510.1016/j.coph.2016.08.00327570127 9.PaulesC.SubbaraoK.InfluenzaLancet201739069770810.1016/S0140-6736(17)30129-028302313 10.ShinyaO.ValentinaS.TakashiH.TakeshiN.HirotoY.MakotoK.KeikoK.TakekiU.TakaoS.AkiraN.et al.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
   <result pre="J. Med.201837991392310.1056/NEJMoa171619730184455 12.HurtA.C.The epidemiology and spread of drug resistant human" exact="influenza" post="virusesCurr. Opin. Virol.20148222910.1016/j.coviro.2014.04.00924866471 13.HanX.ZhangD.-K.GuoY.-M.FengW.-W.DongQ.ZhangC.-E.ZhouY.-F.LiuY.WangJ.-B.ZhaoY.-L.et al.Screening and evaluation of commonly-used"/>
   <result pre="Influenza Viruses of Animals and HumansSpringerCham, Switzerland2014 25.IwasakiA.PillaiP.Innate immunity to" exact="influenza" post="virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 26.ShortK.KroezeE.FouchierR.KuikenT.Pathogenesis of influenza-induced acute respiratory"/>
   <result pre="al.Tissue tropisms opt for transmissible reassortants during avian and swine" exact="influenza" post="A virus co-infection in swinePLoS Pathog.201814e100741710.1371/journal.ppat.100741730507946 30.LiuQ.ZhouY.-H.YangZ.-Q.The cytokine storm"/>
   <result pre="virus co-infection in swinePLoS Pathog.201814e100741710.1371/journal.ppat.100741730507946 30.LiuQ.ZhouY.-H.YangZ.-Q.The cytokine storm of severe" exact="influenza" post="and development of immunomodulatory therapyCell. Mol. Immunol.20151331010.1038/cmi.2015.7426189369 31.PeirisJ.S.HuiK.YenH.-L.Host response"/>
   <result pre="and development of immunomodulatory therapyCell. Mol. Immunol.20151331010.1038/cmi.2015.7426189369 31.PeirisJ.S.HuiK.YenH.-L.Host response to" exact="influenza" post="virus: Protection versus immunopathologyCurr. Opin. Immunol.20102247548110.1016/j.coi.2010.06.00320594815 32.ChonH.Chapter 11—Medicinal Herbs"/>
   <result pre="Agents Chemother19974155155610.1128/AAC.41.3.5519055991 Figure 1 Caesalpinia decapetala (Roth) Alston (EEC) inhibits" exact="influenza" post="virus replication in A549 cells. A549 cells were infected"/>
   <result pre="virus replication in A549 cells. A549 cells were infected with" exact="influenza" post="virus A/Puerto Rico/8/1934 (H1N1) at an multiplicity of infection"/>
   <result pre="2 EEC has a broad spectrum of antiviral activities against" exact="influenza" post="viruses in A549 cells. A549 cells were infected with"/>
   <result pre="influenza viruses in A549 cells. A549 cells were infected with" exact="influenza" post="viruses A/Puerto Rico/8/1934 (H1N1), A/Puerto Rico/8/1934 (H1N1, H274Y oseltamivir-resistant),"/>
   <result pre="activity assay, respectively. The dose-response curves of EEC against different" exact="influenza" post="viruses were made using Prism software (GraphPad Software, San"/>
   <result pre="USA). Figure 3 EEC affects the late stage of the" exact="influenza" post="virus life cycle by inhibiting neuraminidase activity. The stages"/>
   <result pre="life cycle by inhibiting neuraminidase activity. The stages of the" exact="influenza" post="virus life cycle affected by EEC were determined by"/>
   <result pre="(PerkinElmer, MA, USA). Figure 4 EEC protects mice from lethal" exact="influenza" post="virus infection. Six-week-old female BALB/c mice weighing 16–18 g"/>
   <result pre="200 μm) (G). viruses-12-00557-t001_Table 1Table 1 Inhibition of 6 different" exact="influenza" post="virus strains in A549, Madin–Darby Canine Kidney (MDCK), and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7291174\results\search\disease\results.xml">
   <result pre="have been converted into oil palm plantations, several outbreaks of" exact="yellow fever" post="and dengue have been documented [16]. Around 60 examples"/>
   <result pre="deforestation and land-use changes and increases in mosquito populations and" exact="malaria" post="risk were noted by Yasuoka and Levins [17]. In"/>
   <result pre="spread of new diseases [25,26]. For example, the transmission of" exact="yellow fever" post="virus (YFV) to human populations from sylvatic cycles was"/>
   <result pre="urbanisation on mosquito vector communities in Cameroon mostly focused on" exact="malaria" post="vector populations [29,30] whilst abundance trends and diversity patterns"/>
   <result pre="due to minor viral genome mutations, including Zika (ZIKV) and" exact="chikungunya" post="(CHIKV) viruses [33,34]. In Cameroon, Braack et al. [35]"/>
   <result pre="of anopheles arabiensis and anopheles coustani in indoor and outdoor" exact="malaria" post="transmission in Taveta district, KenyaParasites Vectors2013611410.1186/1756-3305-6-11423601146 6.OchiengC.LutomiahJ.MakioA.KokaH.ChepkorirE.YalwalaS.MutisyaJ.MusilaL.KhamadiS.RichardsonJ.Mosquito-borne arbovirus surveillance"/>
   <result pre="17.YasuokaJ.LevinsR.Impact of deforestation and agricultural development on anopheline ecology and" exact="malaria" post="epidemiologyAm. J. Trop. Med. Hyg.20077645046010.4269/ajtmh.2007.76.45017360867 18.TchoumbouM.A.MayiM.P.A.MalangeE.N.FonchaF.D.KowoC.Fru-choJ.TchuinkamT.Awah-NdukumJ.DorazioR.AnongD.N.Effect of deforestation on"/>
   <result pre="in a tropical rainforest of CameroonInt. J. Parasitol.202050637310.1016/j.ijpara.2019.10.00631866311 19.BamouR.MbakopL.R.KopyaE.NdoC.Awono-AmbeneP.TchuinkamT.RonoM.K.MwangangiJ.Antonio-NkondjioC.Changes in" exact="malaria" post="vector bionomics and transmission patterns in the equatorial forest"/>
   <result pre="emergence in humans and macaquesPLoS Pathog.2011710.1371/journal.ppat.1002015 27.BarrettA.D.MonathT.P.Epidemiology and ecology of" exact="yellow fever" post="virusAdv. Virus Res.20036129131714714435 28.StrodeG.K.Yellow FeverMcGraw-Hill Book Co. Inc.London, UK1951"/>
   <result pre="28.StrodeG.K.Yellow FeverMcGraw-Hill Book Co. Inc.London, UK1951 29.Antonio-NkondjioC.Defo-TalomB.Tagne-FotsoR.Tene-FossogB.NdoC.LehmanL.High mosquito burden and" exact="malaria" post="transmission in a district of the city of Douala,"/>
   <result pre="circulation of arboviruses in CameroonEast Afr. Med. J.20108726226810.4314/eamj.v87i6.6308523057269 41.NdipL.BouyerD.da RosaT.A.TitanjiV.TeshR.WalkerD.Acute" exact="spotted fever" post="rickettsiosis among febrile patients, CameroonEmerg. Infect. Dis.20041010.3201/eid1003.020713 42.TchuandomS.B.TchouangueuT.F.Antonio-NkondjioC.LissomA.DjangJ.O.N.AtabonkengE.P.KechiaA.NchindaG.KuiateJ.-R.Seroprevalence of"/>
   <result pre="J.2018311078108310.11604/pamj.2018.31.177.1639031086629 43.KeiserJ.UtzingerJ.Caldas de CastroM.SmithT.TannerM.SingerB.Urbanization in sub-saharan Africa and implication for" exact="malaria" post="controlAm. J. Trop. Med. Hyg.20047111812710.4269/ajtmh.2004.71.11815331827 44.HayS.GuerraC.TatemA.AtkinsonP.SnowR.Urbanization, malaria transmission and"/>
   <result pre="and implication for malaria controlAm. J. Trop. Med. Hyg.20047111812710.4269/ajtmh.2004.71.11815331827 44.HayS.GuerraC.TatemA.AtkinsonP.SnowR.Urbanization," exact="malaria" post="transmission and disease burden in AfricaNat. Rev. Microbiol.20053819010.1038/nrmicro106915608702 45.KlinkenbergE.McCallP.WilsonM.AmerasingheF.DonnellyM.Impact"/>
   <result pre="burden in AfricaNat. Rev. Microbiol.20053819010.1038/nrmicro106915608702 45.KlinkenbergE.McCallP.WilsonM.AmerasingheF.DonnellyM.Impact of urban agriculture on" exact="malaria" post="vectors in Accra, GhanaMalar. J.2008715110.1186/1475-2875-7-15118680565 46.TchuandomS.B.TchadjiJ.C.TchouangueuT.F.BiloaM.Z.AtabonkengE.P.FumbaM.I.M.MassomE.S.NchindaG.KuiateJ.-R.A cross-sectional study of"/>
   <result pre="from mosquitoesBull. World Health Organ.1966358118254381758 60.HubálekZ.HalouzkaJ.West Nile fever-a reemerging mosquito-borne" exact="viral disease" post="in EuropeEmerg. Infect. Dis.1999564310.3201/eid0505.99050510511520 61.GouldE.PetterssonJ.HiggsS.CharrelR.De LamballerieX.Emerging arboviruses: Why today?One"/>
   <result pre="70.DialloM.A.DiongueK.NdiayeM.GayeA.DemeA.BadianeA.S.Evaluation of CareStart™ Malaria HRP2/pLDH (Pf/pan) combo test in a" exact="malaria" post="low transmission region of SenegalMalar. J.20171610.1186/s12936-017-1980-z 71.LindahlJ.ChiricoJ.BoqvistS.ThuH.T.V.MagnussonU.Occurrence of Japanese"/>
   <result pre="malaria low transmission region of SenegalMalar. J.20171610.1186/s12936-017-1980-z 71.LindahlJ.ChiricoJ.BoqvistS.ThuH.T.V.MagnussonU.Occurrence of Japanese" exact="encephalitis" post="virus mosquito vectors in relation to urban pig holdingsAm."/>
   <result pre="virus; BOZV: Bozo; BUNV: Bunyamwera virus; BWAV: Bwamba virus; CHIKV:" exact="chikungunya" post="virus; Cx. Culex.; Cq. Coquillettidia; DENV: dengue virus; DUGV:"/>
   <result pre="Coquillettidia; DENV: dengue virus; DUGV: Dugbe virus; EEEV: Eastern equine" exact="encephalitis" post="virus; Er. Eretmapodites; ILEV: Ilesha virus; JEV: Japanese encephalitis"/>
   <result pre="equine encephalitis virus; Er. Eretmapodites; ILEV: Ilesha virus; JEV: Japanese" exact="encephalitis" post="virus; KAMV: Kamese virus; KEDV: Kedougou virus; KUNV: Kunjin"/>
   <result pre="Tataguine virus; USUV: Usutu virus; Ur. Uranotaenia; VEEV: Venezuelan equine" exact="encephalitis" post="virus; WANV: Wanowrie virus; WEEV: Western equine encephalitis virus;"/>
   <result pre="Venezuelan equine encephalitis virus; WANV: Wanowrie virus; WEEV: Western equine" exact="encephalitis" post="virus; WESV: Wesselsbron virus; WNV: West Nile virus; YAOV:"/>
   <result pre="Wesselsbron virus; WNV: West Nile virus; YAOV: Yaounde virus; YFV:" exact="yellow fever" post="virus; ZIKV: Zika virus; Arb11266 unidentified Flavivirus related to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7291249\results\search\disease\results.xml">
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Influenza viruses cause infectious" exact="respiratory disease" post="characterized by fever, myalgia, and congestion, ranging in severity"/>
   <result pre="life-threating. Although enormous efforts have aimed to prevent and treat" exact="influenza" post="infections, seasonal and pandemic influenza outbreaks remain a major"/>
   <result pre="aimed to prevent and treat influenza infections, seasonal and pandemic" exact="influenza" post="outbreaks remain a major public health concern. This is"/>
   <result pre="remain a major public health concern. This is largely because" exact="influenza" post="viruses rapidly undergo genetic mutations that restrict the long-lasting"/>
   <result pre="regimens. In this review, we discuss the virological features of" exact="influenza" post="A viruses and provide an overview of current knowledge"/>
   <result pre="overview of current knowledge of the innate sensing of invading" exact="influenza" post="viruses and the protective immune responses in the host."/>
   <result pre="influenza viruses and the protective immune responses in the host." exact="influenza" post="virus anti-influenza immune responses 1. Introduction The influenza virus,"/>
   <result pre="the host. influenza virus anti-influenza immune responses 1. Introduction The" exact="influenza" post="virus, or ‘flu’, causes an acute respiratory disease that"/>
   <result pre="1. Introduction The influenza virus, or ‘flu’, causes an acute" exact="respiratory disease" post="that results in moderate to severe symptoms including fever,"/>
   <result pre="muscle pain, headaches, and sometimes even death. Each year, seasonal" exact="influenza" post="strains spread across the globe, causing significant economic and"/>
   <result pre="Organization releases a recommendation for the composition of the seasonal" exact="influenza" post="vaccine each year on the basis of strains that"/>
   <result pre="several distinct steps of the viral replication cycle to inhibit" exact="influenza" post="propagation in hosts. Matrix 2 (M2) inhibitors block the"/>
   <result pre="endonuclease inhibitor, which received FDA approval for the treatment of" exact="influenza" post="in 2018 [2,3], targets the influenza polymerase acidic (PA)"/>
   <result pre="for the treatment of influenza in 2018 [2,3], targets the" exact="influenza" post="polymerase acidic (PA) endonuclease to prevent viral replication [4]."/>
   <result pre="symptoms by a few days. Additionally, constant mutations in the" exact="influenza" post="virus can result in resistance, thus reducing therapeutic efficacy."/>
   <result pre="result in resistance, thus reducing therapeutic efficacy. Throughout history, several" exact="influenza" post="pandemics have emerged as a result of cross-species transmission,"/>
   <result pre="was generated in 2009 after a reassortment event among H1N1" exact="influenza" post="subtypes in swine [5], and that virus subsequently spread"/>
   <result pre="young children, the elderly, and patients with comorbidities. Because seasonal" exact="influenza" post="mutations and cross-species events are relatively unpredictable, it is"/>
   <result pre="important to understand the factors that influence successful defense against" exact="influenza" post="infections. In this review, we describe the virological characteristics"/>
   <result pre="infections. In this review, we describe the virological characteristics of" exact="influenza" post="A viruses that facilitate viral propagation in host cells"/>
   <result pre="cells and the mechanisms by which host cells recognize invading" exact="influenza" post="viruses and produce a protective response against infection. 2."/>
   <result pre="against infection. 2. Virological Features of Influenza A Virus The" exact="influenza" post="virus is a respiratory pathogen that causes acute febrile"/>
   <result pre="is a respiratory pathogen that causes acute febrile disease called" exact="influenza" post="or flu. It belongs to the Orthomyxoviridae family and"/>
   <result pre="infect diverse host species including humans, pigs, and birds. The" exact="influenza" post="viruses that cause disease in humans are classified into"/>
   <result pre="differences in their NP and M proteins [7,8]. The novel" exact="influenza" post="D virus, which was first identified in 2011 [9],"/>
   <result pre="as cattle and pigs [10,11]. However, it remains unclear whether" exact="influenza" post="D virus (IDV) can cause disease in humans. While"/>
   <result pre="later in the season, is responsible for 15–30% of total" exact="influenza" post="infections [14]. While the disease severity due to both"/>
   <result pre="[15,16,17], IBV does not cause pandemics. In contrast, strains of" exact="influenza" post="A virus (IAV) are often responsible for seasonal influenza"/>
   <result pre="of influenza A virus (IAV) are often responsible for seasonal" exact="influenza" post="epidemics and pandemic outbreaks due to frequent genetic mutations"/>
   <result pre="shift, the primary mechanisms behind the antigenic variation of the" exact="influenza" post="virus, occur in both HA and NA. The accumulation"/>
   <result pre="and are capable of bypassing pre-existing adaptive immunity, to cause" exact="influenza" post="pandemics [22,23,24,25]. To achieve successful infection, the influenza virus"/>
   <result pre="to cause influenza pandemics [22,23,24,25]. To achieve successful infection, the" exact="influenza" post="virus must first pass through the respiratory mucus layer"/>
   <result pre="cells from infection by inhibiting viral entry [26]. However, the" exact="influenza" post="virus cleaves sialylated mucins using NA, which disables the"/>
   <result pre="and enter the host cell via receptor-mediated endocytosis. However, SIA-independent" exact="influenza" post="infection has also been reported [27,28]. C-type lectin receptors"/>
   <result pre="act as alternative receptors that allow infectious entry of the" exact="influenza" post="virus in a manner independent of SIA. The macrophage’s"/>
   <result pre="macrophage’s galactose-type lectin and mannose receptors play important roles in" exact="influenza" post="infection [29,30,31]. DC-SIGN (DC209) and L-SIGN (CD209L) have been"/>
   <result pre="[29,30,31]. DC-SIGN (DC209) and L-SIGN (CD209L) have been identified as" exact="influenza" post="attachment receptors [32,33,34,35], and the blocking of DC-SIGN decreases"/>
   <result pre="both transcription and replication of the viral RNA genome. The" exact="influenza" post="RdRP protein consists of three subunits: PB1, PB2, and"/>
   <result pre="it has been suggested that NS2 is important for efficient" exact="influenza" post="virion formation and budding due to its interactions with"/>
   <result pre="of the NLRP3-inflammasome [61]. Therapeutics targeting various stages of the" exact="influenza" post="virus’ replication cycle have been developed. There are three"/>
   <result pre="budding from host cells, and the cap-dependent endonuclease inhibitor targets" exact="influenza" post="polymerase to prevent viral replication. While these drugs are"/>
   <result pre="Sensors Recognizing the Influenza Virus After entering the host, the" exact="influenza" post="virus infects bronchiolar-alveolar epithelial cells lining the respiratory tract"/>
   <result pre="patterns (PAMPs) and initiate innate immune responses. Recognition of the" exact="influenza" post="virus is mediated by several types of PRRs, including"/>
   <result pre="produce dsRNA during replication [63,64], TLR3 activation can occur during" exact="influenza" post="infection [65]. However, the specific TLR3 ligand that is"/>
   <result pre="single-stranded RNA (ssRNA), is involved in the recognition of the" exact="influenza" post="virus [69]. Plasmacytoid DCs (pDCs) express TLR7 in their"/>
   <result pre="unclear whether TLR7-MyD88 signaling is necessary for the protection against" exact="influenza" post="infection. However, TLR7 deficiency results in attenuated production of"/>
   <result pre="TLR7 is responsible for efficient innate immune responses against the" exact="influenza" post="virus. Indeed, prior evidence has supported the function of"/>
   <result pre="proinflammatory cytokines and type I IFNs. Although replication of the" exact="influenza" post="virus occurs in the nucleus, the RIG-I signaling pathway"/>
   <result pre="for detection of viral ssRNA by RIG-I. Of note, the" exact="influenza" post="virus actually prevents the formation of these stress granules"/>
   <result pre="manner dependent on functional NS1 protein [78,79]. Taken together, the" exact="influenza" post="virus NS1 protein disrupts RIG-I signaling, thus suppressing IFN-α/β"/>
   <result pre="against viral infection; survival and adaptive immune responses against the" exact="influenza" post="virus were unchanged in MAVS-deficient mice relative to wild-type"/>
   <result pre="mediates production of the proinflammatory cytokines IL-1β and IL-18. Several" exact="influenza" post="virus proteins are associated with the activation of the"/>
   <result pre="inflammasome. For example, M2 protein, the proton channel of the" exact="influenza" post="virus, activates the formation of the NLRP3 inflammasome [71]."/>
   <result pre="in the Golgi apparatus is essential for inflammasome activation. Interestingly," exact="influenza" post="virus NS1 proteins inhibit the secretion of IL-1β through"/>
   <result pre="a crucial role for the inflammasome in cellular defense against" exact="influenza" post="virus infection. Inflammasome-deficient mice have impaired recruitment of monocytes"/>
   <result pre="the activation of T and B cell responses against the" exact="influenza" post="virus during low dose infection; deficiency of the inflammasome"/>
   <result pre="important role in the defense against DNA viruses including the" exact="herpes simplex" post="virus [92]. Interestingly, a recent study has revealed that"/>
   <result pre="an RNA virus, also activates the cGAS-STING pathway [93]. After" exact="influenza" post="virus infection, the M2 protein promotes the release of"/>
   <result pre="the cytosol, where it stimulates the cGAS pathway. Interestingly, the" exact="influenza" post="virus NS1 protein appears to associate with mtDNA and"/>
   <result pre="whether the cGAS-STING pathway is crucial for host survival after" exact="influenza" post="virus infection. 4. Innate Effector Cell Types in the"/>
   <result pre="Effector Cell Types in the Response to Influenza Infection During" exact="influenza" post="virus infections, innate signaling and adaptive immune responses both"/>
   <result pre="immune cells are responsible for both protection and immunopathology following" exact="influenza" post="virus infection. 4.1. Natural Killer Cells, Neutrophils, and Macrophages"/>
   <result pre="[101,102]. Defects in NK cells lead to increased susceptibility to" exact="influenza" post="infection and uncontrolled viral growth in the lungs [103,104]."/>
   <result pre="cell-induced inflammation can also contribute to pathology following high dose" exact="influenza" post="virus infection [105,106]. Neutrophils, monocytes, and macrophages inhibit the"/>
   <result pre="in animal studies showing that neutrophil depletion leads to increased" exact="influenza" post="mortality due to impaired viral clearance [109,110]. Neutropenic mice"/>
   <result pre="These studies indicate that neutrophils play a protective role in" exact="influenza" post="infection, but that excessive recruitment of neutrophils can also"/>
   <result pre="lines of evidence supporting the protective role of AMs during" exact="influenza" post="infection. Clodronate-induced depletion of AMs increases the mortality of"/>
   <result pre="increases the mortality of mice and enhances pulmonary inflammation during" exact="influenza" post="infection [116]. Csf2−/− mice, which are deficient in AM"/>
   <result pre="[116]. Csf2−/− mice, which are deficient in AM development, experience" exact="respiratory failure" post="and reduced resistance to influenza infection despite having normal"/>
   <result pre="in AM development, experience respiratory failure and reduced resistance to" exact="influenza" post="infection despite having normal adaptive immune responses against influenza"/>
   <result pre="to influenza infection despite having normal adaptive immune responses against" exact="influenza" post="virus [117]. Consistently, an AM depletion model in CD169-DTR"/>
   <result pre="led to aggressive inflammatory responses and severe lung pathology after" exact="influenza" post="infection [118]. AMs control lung dysfunction by increasing the"/>
   <result pre="AMs play a crucial role in maintaining pulmonary homeostasis during" exact="influenza" post="infection. 4.2. Dendritic Cells DCs, which belong to the"/>
   <result pre="have been conducted to clarify the role of DCs during" exact="influenza" post="virus infection. CD11c-DTR transgenic mice express a high-affinity diphtheria"/>
   <result pre="during influenza virus infection. CD11c-DTR transgenic mice express a high-affinity" exact="diphtheria" post="toxin receptor (DTR) in CD11c+ cells [120], allowing targeted"/>
   <result pre="[120], allowing targeted depletion of DCs by the administration of" exact="diphtheria" post="toxin (DT). CD11c-DTR mice have been used to study"/>
   <result pre="used to study the function of DCs in vivo. Following" exact="influenza" post="virus infection, DT-treated mice experience significantly more severe weight"/>
   <result pre="of CD8+ T cells and T cell-mediated viral clearance during" exact="influenza" post="virus infection. In the lungs, DCs are classified into"/>
   <result pre="various DC subsets have specialized functions in the response to" exact="influenza" post="virus infection. Remarkably, respiratory DC subsets display different susceptibility"/>
   <result pre="virus infection. Remarkably, respiratory DC subsets display different susceptibility to" exact="influenza" post="virus infection. cDC1 is more susceptible to influenza virus"/>
   <result pre="susceptibility to influenza virus infection. cDC1 is more susceptible to" exact="influenza" post="virus infection than cDC2 and pDCs [126], but influenza"/>
   <result pre="to influenza virus infection than cDC2 and pDCs [126], but" exact="influenza" post="infection of cDC1 does not lead to productive viral"/>
   <result pre="cDC1 does not lead to productive viral replication [127]. Following" exact="influenza" post="infection, lung-migratory cDCs take up viral antigen and migrate"/>
   <result pre="anti-influenza response. Most studies determining the role of DCs in" exact="influenza" post="virus infection have focused on the cDC1 subset. CD103+"/>
   <result pre="and this process reaches its peak within 48–72 h after" exact="influenza" post="virus infection [130]. There have been several reports that"/>
   <result pre="for activation of effective CD8+ T cell responses against the" exact="influenza" post="virus [121,127,131,132]. For example, Batf3−/− mice, which lack cDC1s"/>
   <result pre="lectin receptor-expressing cells such as cDC1, are highly susceptible to" exact="influenza" post="virus infection after treatment with DT [129]. These cDC1-depleted"/>
   <result pre="T cell proliferation and Th1 responses after stimulation with live-attenuated" exact="influenza" post="virus [134], indicating that cDC1 can be responsible for"/>
   <result pre="cDC2s in lymph nodes that drain from the lungs during" exact="influenza" post="virus infection, these cells rarely carried intact viral antigens"/>
   <result pre="the role of cDC1s and cDC2s in the response to" exact="influenza" post="virus infection. pDCs, which are primarily known as producers"/>
   <result pre="seem to play a minor role in the defense against" exact="influenza" post="virus infection. Despite the accumulation of pDCs in the"/>
   <result pre="infection. Despite the accumulation of pDCs in the lung following" exact="influenza" post="virus infection, pDC-depleted mice showed identical survival rate and"/>
   <result pre="loss, effector CD8+ T cell responses, or viral clearance after" exact="influenza" post="virus infection in mice [121]. Consistently, both wild-type and"/>
   <result pre="IkarosL/L mice showed comparable weight loss, viral burden in lung," exact="influenza" post="virus-specific antibody production, and lung pathology following viral infection"/>
   <result pre="[139]. However, there is some evidence that pDCs may cross-present" exact="influenza" post="virus antigens to CD8+ T cells [140,141]. Although the"/>
   <result pre="CD8+ T cells [140,141]. Although the role of MoDCs during" exact="influenza" post="virus infection has not been well established, it has"/>
   <result pre="reported that the number of CCR2-expressing MoDCs are increased in" exact="influenza" post="virus-infected lungs [124]. These cells induce the robust production"/>
   <result pre="pulmonary pathology, and mortality after a lethal dose of the" exact="influenza" post="virus. While the specific mechanisms remain unknown, these results"/>
   <result pre="remain unknown, these results indicate that MoDCs are associated with" exact="influenza" post="virus-induced pulmonary pathology. On the other hand, other work"/>
   <result pre="work has suggested a protective role for MoDCs during secondary" exact="influenza" post="virus infection [142]. Researchers found that MoDC-deficient CCR2−/− mice"/>
   <result pre="an impairment of antigen-specific CD8+ T cell formation following primary" exact="influenza" post="challenge, and lack of MoDCs during primary influenza infection"/>
   <result pre="following primary influenza challenge, and lack of MoDCs during primary" exact="influenza" post="infection reduced host resistance to secondary virus infection, suggesting"/>
   <result pre="suggesting that MoDCs could be considered as putative targets of" exact="influenza" post="vaccine. 5. Protective Adaptive Immune Responses against Influenza Infections"/>
   <result pre="from reinfection. As expected, immunodeficient mice that are infected with" exact="influenza" post="experience a significantly higher rate of mortality than healthy"/>
   <result pre="responses. CD4+ T cell responses peak at 10 days after" exact="influenza" post="infection in the mouse lung [145]. Adaptive transfer of"/>
   <result pre="of effector CD4+ T cells isolated from mice infected with" exact="influenza" post="lead to increased survival of recipient mice after influenza"/>
   <result pre="with influenza lead to increased survival of recipient mice after" exact="influenza" post="challenge [145]. The cytokine milieu generated during influenza virus"/>
   <result pre="mice after influenza challenge [145]. The cytokine milieu generated during" exact="influenza" post="virus infection is polarized to support the generation of"/>
   <result pre="mediate cellular immune responses. Th2 responses are also induced following" exact="influenza" post="virus infection. Th2 cells secrete IL-4, IL-5, and IL-13"/>
   <result pre="However, Th1 cells are more closely associated with survival after" exact="influenza" post="virus infection compared with Th2 cells [148]. Some CD4+"/>
   <result pre="role in host protection during and after infection with the" exact="influenza" post="virus. 5.2. Cytotoxic CD8+ T Cell Response CD8+ T"/>
   <result pre="cells are important for viral clearance and host protection during" exact="influenza" post="virus infection. CD8+ T cells recognize viral antigens loaded"/>
   <result pre="T cells, display delayed viral clearance and severe mortality following" exact="influenza" post="virus infection [155]. Activated cytotoxic CD8+ T cells (CTLs)"/>
   <result pre="for the regulation of pulmonary inflammation during the response to" exact="influenza" post="virus infections. Previous studies have suggested that CD8+ effector"/>
   <result pre="of IL-10 in the lungs of mice infected with the" exact="influenza" post="virus [161]. Further, blockade of IL-10 signaling increases pulmonary"/>
   <result pre="IL-10 signaling increases pulmonary inflammation and lethal injury following sublethal" exact="influenza" post="virus challenge [161]. 5.3. Humoral Immunity The protective role"/>
   <result pre="immune response has been extensively studied in recent years. During" exact="influenza" post="virus infection, naïve B cells in the mLNs encounter"/>
   <result pre="virus infection, naïve B cells in the mLNs encounter the" exact="influenza" post="virus antigen and differentiate into antibody-forming cells (AFCs). B"/>
   <result pre="cells (AFCs). B lymphocyte-deficient μMT mice are more susceptible to" exact="influenza" post="virus infection compared to wild-type mice [162,163]. The B"/>
   <result pre="compared to wild-type mice [162,163]. The B cell response against" exact="influenza" post="virus begins approximately 3 days after infection, and B"/>
   <result pre="days post-infection in mice [121]. In mice, the majority of" exact="influenza" post="virus antigen-specific AFCs in the lung produce IgG and"/>
   <result pre="their target [171]. In addition to the previously described functions," exact="influenza" post="virus-specific antibodies mediate antibody-dependent cell cytotoxicity and Fc receptor-mediated"/>
   <result pre="natural IgM, independent of antigenic priming, contribute to protection against" exact="influenza" post="virus infection. Natural IgM in the airway has neutralizing"/>
   <result pre="health burden. Further, the average annual total economic burden of" exact="influenza" post="has been estimated at $11.2 billion in the United"/>
   <result pre="burden of influenza. Vaccination remains the best way to prevent" exact="influenza" post="infection. Flu vaccines contain virus strains that are expected"/>
   <result pre="vaccination can provide effective protection against viral infection. However, because" exact="influenza" post="viruses constantly change their antigens to escape from vaccine-induced"/>
   <result pre="a new flu vaccine each year. A long-standing goal of" exact="influenza" post="research is the development of universal vaccines that provide"/>
   <result pre="of universal vaccines that provide protection against multiple subtypes of" exact="influenza" post="viruses. Current studies are mainly focused on identifying conserved"/>
   <result pre="influenza viruses. Current studies are mainly focused on identifying conserved" exact="influenza" post="epitopes, and the highly conserved HA stem has been"/>
   <result pre="to improve the effectiveness of universal vaccines. The current licensed" exact="influenza" post="vaccine products have several limitations. Although the live-attenuated and"/>
   <result pre="immune responses [178]. Immunogenicity has been a major concern for" exact="influenza" post="vaccine development. Novel types of vaccines, such as recombinant"/>
   <result pre="agonist, has been shown to increase the effectiveness of recombinant" exact="influenza" post="vaccines [180,181]. Similarly, the inclusion of a RIG-I agonist"/>
   <result pre="of a RIG-I agonist increases humoral immune responses to DNA" exact="influenza" post="vaccines [182], suggesting that innate sensor agonists can improve"/>
   <result pre="sensor agonists can improve the immunogenicity of new types of" exact="influenza" post="vaccines. In order to overcome the limitations of traditional"/>
   <result pre="In order to overcome the limitations of traditional and emerging" exact="influenza" post="vaccines, it is necessary to first understand the complex"/>
   <result pre="interplay between host immune responses and the pathologic mechanisms of" exact="influenza" post="viruses. The lack of proofreading ability in the viral"/>
   <result pre="antiviral resistance. At present, there are three classes of FDA-approved" exact="influenza" post="drugs targeting the influenza virus replication cycle. While these"/>
   <result pre="there are three classes of FDA-approved influenza drugs targeting the" exact="influenza" post="virus replication cycle. While these drugs are currently effective,"/>
   <result pre="drugs are effective at reducing the risk and severity of" exact="influenza" post="infection. However, there is still room for improvement. Advancing"/>
   <result pre="References References 1.BarrI.G.McCauleyJ.CoxN.DanielsR.EngelhardtO.G.FukudaK.GrohmannG.HayA.KelsoA.KlimovA.et al.Epidemiological, antigenic and genetic characteristics of seasonal" exact="influenza" post="A(H1N1), A(H3N2) and B influenza viruses: Basis for the"/>
   <result pre="and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B" exact="influenza" post="viruses: Basis for the WHO recommendation on the composition"/>
   <result pre="viruses: Basis for the WHO recommendation on the composition of" exact="influenza" post="vaccines for use in the 2009–2010 northern hemisphere seasonVaccine2010281156116710.1016/j.vaccine.2009.11.04320004635"/>
   <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunitAntivir. Res.201816010911710.1016/j.antiviral.2018.10.00830316915 5.VijaykrishnaD.PoonL.L.ZhuH.C.MaS.K.LiO.T.CheungC.L.SmithG.J.PeirisJ.S.GuanY.Reassortment of pandemic H1N1/2009"/>
   <result pre="influenza virus polymerase PA subunitAntivir. Res.201816010911710.1016/j.antiviral.2018.10.00830316915 5.VijaykrishnaD.PoonL.L.ZhuH.C.MaS.K.LiO.T.CheungC.L.SmithG.J.PeirisJ.S.GuanY.Reassortment of pandemic H1N1/2009" exact="influenza" post="A virus in swineScience2010328152910.1126/science.118913220558710 6.DawoodF.S.IulianoA.D.ReedC.MeltzerM.I.ShayD.K.ChengP.Y.BandaranayakeD.BreimanR.F.BrooksW.A.BuchyP.et al.Estimated global mortality associated"/>
   <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="A H1N1 virus circulation: A modelling studyLancet Infect. Dis.20121268769510.1016/S1473-3099(12)70121-422738893"/>
   <result pre="H1N1 virus circulation: A modelling studyLancet Infect. Dis.20121268769510.1016/S1473-3099(12)70121-422738893 7.CheungT.K.PoonL.L.Biology of" exact="influenza" post="a virusAnn. N. Y. Acad. Sci.2007110212510.1196/annals.1408.00117470908 8.HayashidaH.TohH.KikunoR.MiyataT.Evolution of influenza"/>
   <result pre="of influenza a virusAnn. N. Y. Acad. Sci.2007110212510.1196/annals.1408.00117470908 8.HayashidaH.TohH.KikunoR.MiyataT.Evolution of" exact="influenza" post="virus genesMol. Biol. Evol.1985228930310.1093/oxfordjournals.molbev.a0403523870863 9.DucatezM.F.PelletierC.MeyerG.Influenza D virus in cattle,"/>
   <result pre="viral infection in swineSci. Rep.201771166010.1038/s41598-017-12012-328916759 12.WhiteS.K.MaW.McDanielC.J.GrayG.C.LednickyJ.A.Serologic evidence of exposure to" exact="influenza" post="D virus among persons with occupational contact with cattleJ."/>
   <result pre="contact with cattleJ. Clin. Virol.201681313310.1016/j.jcv.2016.05.01727294672 13.VirkR.K.JayakumarJ.MendenhallI.H.MoorthyM.LamP.LinsterM.LimJ.LinC.OonL.L.E.LeeH.K.et al.Divergent evolutionary trajectories of" exact="influenza" post="B viruses underlie their contemporaneous epidemic activityProc. Natl. Acad."/>
   <result pre="of Reporter Influenza B VirusesViruses20191173610.3390/v1108073631404985 15.Gutierrez-PizarrayaA.Perez-RomeroP.AlvarezR.AydilloT.A.Osorio-GomezG.Milara-IbanezC.SanchezM.PachonJ.CorderoE.Unexpected severity of cases of" exact="influenza" post="B infection in patients that required hospitalization during the"/>
   <result pre="Infect.20126542343010.1016/j.jinf.2012.07.00422820034 16.SuS.ChavesS.S.PerezA.D’MelloT.KirleyP.D.Yousey-HindesK.FarleyM.M.HarrisM.SharangpaniR.LynfieldR.et al.Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="A and B virus infectionClin. Infect. Dis.20145925225510.1093/cid/ciu26924748521 17.MosnierA.CainiS.DaviaudI.NauleauE.BuiT.T.DebostE.BedouretB.AgiusG.van der"/>
   <result pre="A and B Influenza Virus InfectionsPLoS ONE201510e013618610.1371/journal.pone.013618626325069 18.PingJ.LopesT.J.NeumannG.KawaokaY.Development of high-yield" exact="influenza" post="B virus vaccine virusesProc. Natl. Acad. Sci. USA2016113E8296E830510.1073/pnas.161653011327930325 19.BuiM.WillsE.G.HeleniusA.WhittakerG.R.Role"/>
   <result pre="virus vaccine virusesProc. Natl. Acad. Sci. USA2016113E8296E830510.1073/pnas.161653011327930325 19.BuiM.WillsE.G.HeleniusA.WhittakerG.R.Role of the" exact="influenza" post="virus M1 protein in nuclear export of viral ribonucleoproteinsJ."/>
   <result pre="nuclear export of viral ribonucleoproteinsJ. Virol.2000741781178610.1128/JVI.74.4.1781-1786.200010644350 20.PaleseP.TobitaK.UedaM.CompansR.W.Characterization of temperature sensitive" exact="influenza" post="virus mutants defective in neuraminidaseVirology19746139741010.1016/0042-6822(74)90276-14472498 21.KosikI.YewdellJ.W.Influenza Hemagglutinin and Neuraminidase:"/>
   <result pre="the viral life cycleYale J. Biol. Med.20098215315920027280 23.IwasakiA.PillaiP.S.Innate immunity to" exact="influenza" post="virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 24.SubbaraoK.JosephT.Scientific barriers to developing vaccines"/>
   <result pre="virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 24.SubbaraoK.JosephT.Scientific barriers to developing vaccines against" exact="avian influenza" post="virusesNat. Rev. Immunol.2007726727810.1038/nri205417363960 25.NelsonM.I.HolmesE.C.The evolution of epidemic influenzaNat. Rev."/>
   <result pre="infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 24.SubbaraoK.JosephT.Scientific barriers to developing vaccines against avian" exact="influenza" post="virusesNat. Rev. Immunol.2007726727810.1038/nri205417363960 25.NelsonM.I.HolmesE.C.The evolution of epidemic influenzaNat. Rev."/>
   <result pre="of human airway epithelium by human and avian strains of" exact="influenza" post="a virusJ. Virol.2006808060806810.1128/JVI.00384-0616873262 29.ReadingP.C.MillerJ.L.AndersE.M.Involvement of the mannose receptor in"/>
   <result pre="29.ReadingP.C.MillerJ.L.AndersE.M.Involvement of the mannose receptor in infection of macrophages by" exact="influenza" post="virusJ. Virol.2000745190519710.1128/JVI.74.11.5190-5197.200010799594 30.UphamJ.P.PickettD.IrimuraT.AndersE.M.ReadingP.C.Macrophage receptors for influenza A virus: Role"/>
   <result pre="infection of macrophages by influenza virusJ. Virol.2000745190519710.1128/JVI.74.11.5190-5197.200010799594 30.UphamJ.P.PickettD.IrimuraT.AndersE.M.ReadingP.C.Macrophage receptors for" exact="influenza" post="A virus: Role of the macrophage galactose-type lectin and"/>
   <result pre="lectin can function as an attachment and entry receptor for" exact="influenza" post="virusJ. Virol.2014881659167210.1128/JVI.02014-1324257596 32.HillaireM.L.NieuwkoopN.J.BoonA.C.de MutsertG.Vogelzang-van TrierumS.E.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Binding of DC-SIGN to the"/>
   <result pre="Virol.2014881659167210.1128/JVI.02014-1324257596 32.HillaireM.L.NieuwkoopN.J.BoonA.C.de MutsertG.Vogelzang-van TrierumS.E.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Binding of DC-SIGN to the hemagglutinin of" exact="influenza" post="A viruses supports virus replication in DC-SIGN expressing cellsPLoS"/>
   <result pre="ONE20138e5616410.1371/journal.pone.005616423424649 33.LondriganS.L.TurvilleS.G.TateM.D.DengY.M.BrooksA.G.ReadingP.C.N-linked glycosylation facilitates sialic acid-independent attachment and entry of" exact="influenza" post="A viruses into cells expressing DC-SIGN or L-SIGNJ. Virol.2011852990300010.1128/JVI.01705-1021191006"/>
   <result pre="cells expressing DC-SIGN or L-SIGNJ. Virol.2011852990300010.1128/JVI.01705-1021191006 34.WangS.F.HuangJ.C.LeeY.M.LiuS.J.ChanY.J.ChauY.P.ChongP.ChenY.M.DC-SIGN mediates avian H5N1" exact="influenza" post="virus infection in cis and in transBiochem. Biophys. Res."/>
   <result pre="in transBiochem. Biophys. Res. Commun.200837356156610.1016/j.bbrc.2008.06.07818593570 35.GillespieL.RoosendahlP.NgW.C.BrooksA.G.ReadingP.C.LondriganS.L.Endocytic function is critical for" exact="influenza" post="A virus infection via DC-SIGN and L-SIGNSci. Rep.201661942810.1038/srep1942826763587 36.Stencel-BaerenwaldJ.E.ReissK.ReiterD.M.StehleT.DermodyT.S.The"/>
   <result pre="sweet spot: Defining virus-sialic acid interactionsNat. Rev. Microbiol.20141273974910.1038/nrmicro334625263223 37.DasK.AraminiJ.M.MaL.C.KrugR.M.ArnoldE.Structures of" exact="influenza" post="A proteins and insights into antiviral drug targetsNat. Struct."/>
   <result pre="antiviral drug targetsNat. Struct. Mol. Biol.20101753053810.1038/nsmb.177920383144 38.LiS.SiebenC.LudwigK.HoferC.T.ChiantiaS.HerrmannA.EghiaianF.SchaapI.A.pH-Controlled two-step uncoating of" exact="influenza" post="virusBiophys. J.20141061447145610.1016/j.bpj.2014.02.01824703306 39.GrambasS.BennettM.S.HayA.J.Influence of amantadine resistance mutations on the"/>
   <result pre="on the pH regulatory function of the M2 protein of" exact="influenza" post="A virusesVirology199219154154910.1016/0042-6822(92)90229-I1448912 40.WangC.TakeuchiK.PintoL.H.LambR.A.Ion channel activity of influenza A virus"/>
   <result pre="M2 protein of influenza A virusesVirology199219154154910.1016/0042-6822(92)90229-I1448912 40.WangC.TakeuchiK.PintoL.H.LambR.A.Ion channel activity of" exact="influenza" post="A virus M2 protein: Characterization of the amantadine blockJ."/>
   <result pre="Characterization of the amantadine blockJ. Virol.1993675585559410.1128/JVI.67.9.5585-5594.19937688826 41.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.The cap-snatching endonuclease of" exact="influenza" post="virus polymerase resides in the PA subunitNature200945891491810.1038/nature0774519194459 42.GuilligayD.TarendeauF.Resa-InfanteP.ColomaR.CrepinT.SehrP.LewisJ.RuigrokR.W.OrtinJ.HartD.J.et al.The"/>
   <result pre="PA subunitNature200945891491810.1038/nature0774519194459 42.GuilligayD.TarendeauF.Resa-InfanteP.ColomaR.CrepinT.SehrP.LewisJ.RuigrokR.W.OrtinJ.HartD.J.et al.The structural basis for cap binding by" exact="influenza" post="virus polymerase subunit PB2Nat. Struct. Mol. Biol.20081550050610.1038/nsmb.142118454157 43.BiswasS.K.NayakD.P.Mutational analysis"/>
   <result pre="Struct. Mol. Biol.20081550050610.1038/nsmb.142118454157 43.BiswasS.K.NayakD.P.Mutational analysis of the conserved motifs of" exact="influenza" post="A virus polymerase basic protein 1J. Virol.1994681819182610.1128/JVI.68.3.1819-1826.19948107244 44.UlmanenI.BroniB.A.KrugR.M.Role of"/>
   <result pre="polymerase basic protein 1J. Virol.1994681819182610.1128/JVI.68.3.1819-1826.19948107244 44.UlmanenI.BroniB.A.KrugR.M.Role of two of the" exact="influenza" post="virus core P proteins in recognizing cap 1 structures"/>
   <result pre="Acad. Sci. USA1981787355735910.1073/pnas.78.12.73556950380 45.PflugA.LukarskaM.Resa-InfanteP.ReichS.CusackS.Structural insights into RNA synthesis by the" exact="influenza" post="virus transcription-replication machineVirus Res.201723410311710.1016/j.virusres.2017.01.01328115197 46.FanH.WalkerA.P.CarriqueL.KeownJ.R.Serna MartinI.KariaD.SharpsJ.HengrungN.PardonE.SteyaertJ.et al.Structures of influenza"/>
   <result pre="the influenza virus transcription-replication machineVirus Res.201723410311710.1016/j.virusres.2017.01.01328115197 46.FanH.WalkerA.P.CarriqueL.KeownJ.R.Serna MartinI.KariaD.SharpsJ.HengrungN.PardonE.SteyaertJ.et al.Structures of" exact="influenza" post="A virus RNA polymerase offer insight into viral genome"/>
   <result pre="virus RNA polymerase offer insight into viral genome replicationNature201957328729010.1038/s41586-019-1530-731485076 47.EgorovA.BrandtS.SereinigS.RomanovaJ.FerkoB.KatingerD.GrassauerA.AlexandrovaG.KatingerH.MusterT.Transfectant" exact="influenza" post="A viruses with long deletions in the NS1 protein"/>
   <result pre="gene replicates in interferon-deficient systemsVirology199825232433010.1006/viro.1998.95089878611 49.KochsG.Garcia-SastreA.Martinez-SobridoL.Multiple anti-interferon actions of the" exact="influenza" post="A virus NS1 proteinJ. Virol.2007817011702110.1128/JVI.02581-0617442719 50.FortesP.BelosoA.OrtinJ.Influenza virus NS1 protein"/>
   <result pre="inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transportEMBO J.19941370471210.1002/j.1460-2075.1994.tb06310.x8313914 51.QiuY.KrugR.M.The" exact="influenza" post="virus NS1 protein is a poly(A)-binding protein that inhibits"/>
   <result pre="nuclear export of mRNAs containing poly(A)J. Virol.1994682425243210.1128/JVI.68.4.2425-2432.19947908060 52.ZhangK.XieY.Munoz-MorenoR.WangJ.ZhangL.EsparzaM.Garcia-SastreA.FontouraB.M.A.RenY.Structural basis for" exact="influenza" post="virus NS1 protein block of mRNA nuclear exportNat. Microbiol.201941671167910.1038/s41564-019-0482-x31263181"/>
   <result pre="of NLRP3 Inflammasome-Mediated Interleukin-1beta SecretionJ. Virol.2016904105411410.1128/JVI.00120-1626865721 54.RuckleA.HaasbachE.JulkunenI.PlanzO.EhrhardtC.LudwigS.The NS1 protein of" exact="influenza" post="A virus blocks RIG-I-mediated activation of the noncanonical NF-kappaB"/>
   <result pre="I-mediated induction of beta interferon by the NS1 protein of" exact="influenza" post="A virusJ. Virol.20078151452410.1128/JVI.01265-0617079289 57.GuoZ.ChenL.M.ZengH.GomezJ.A.PlowdenJ.FujitaT.KatzJ.M.DonisR.O.SambharaS.NS1 protein of influenza A virus"/>
   <result pre="NS1 protein of influenza A virusJ. Virol.20078151452410.1128/JVI.01265-0617079289 57.GuoZ.ChenL.M.ZengH.GomezJ.A.PlowdenJ.FujitaT.KatzJ.M.DonisR.O.SambharaS.NS1 protein of" exact="influenza" post="A virus inhibits the function of intracytoplasmic pathogen sensor,"/>
   <result pre="vRNP nuclear export through NES-independent interaction with hCRM1EMBO J.2000196751675810.1093/emboj/19.24.675111118210 59.O’NeillR.E.TalonJ.PaleseP.The" exact="influenza" post="virus NEP (NS2 protein) mediates the nuclear export of"/>
   <result pre="proton-translocating ATPase, at the plasma membrane is critical for efficient" exact="influenza" post="virus buddingProc. Natl. Acad. Sci. USA20121094615462010.1073/pnas.111472810922393008 61.McAuleyJ.L.TateM.D.MacKenzie-KludasC.J.PinarA.ZengW.StutzA.LatzE.BrownL.E.MansellA.Activation of the"/>
   <result pre="UAP56 is required for prevention of double-stranded RNA formation during" exact="influenza" post="A virus infectionJ. Virol.2011858646865510.1128/JVI.02559-1021680511 64.PichlmairA.SchulzO.TanC.P.NaslundT.I.LiljestromP.WeberF.Reis e SousaC.RIG-I-mediated antiviral responses"/>
   <result pre="USA20041013533353810.1073/pnas.030849610114982987 67.Le GofficR.BalloyV.LagranderieM.AlexopoulouL.EscriouN.FlavellR.ChignardM.Si-TaharM.Detrimental contribution of the Toll-like receptor (TLR)3 to" exact="influenza" post="A virus-induced acute pneumoniaPLoS Pathog.20062e5310.1371/journal.ppat.002005316789835 68.HeerA.K.ShamshievA.DondaA.UematsuS.AkiraS.KopfM.MarslandB.J.TLR signaling fine-tunes anti-influenza"/>
   <result pre="responses by means of TLR7-mediated recognition of single-stranded RNAScience20043031529153110.1126/science.109361614976261 70.PangI.K.PillaiP.S.IwasakiA.Efficient" exact="influenza" post="A virus replication in the respiratory tract requires signals"/>
   <result pre="Virus Infection and VaccinationJ. Immunol.20071794711472010.4049/jimmunol.179.7.471117878370 75.Jeisy-ScottV.KimJ.H.DavisW.G.CaoW.KatzJ.M.SambharaS.TLR7 recognition is dispensable for" exact="influenza" post="virus A infection but important for the induction of"/>
   <result pre="vaccine in miceJ. Virol.201286109881099810.1128/JVI.01064-1222837197 76.SeoS.U.KwonH.J.SongJ.H.ByunY.H.SeongB.L.KawaiT.AkiraS.KweonM.N.MyD88 signaling is indispensable for primary" exact="influenza" post="A virus infection but dispensable for secondary infectionJ. Virol.201084127131272210.1128/JVI.01675-1020943980"/>
   <result pre="cytoplasmic stress granule formationFASEB J.2012261629163910.1096/fj.11-19691522202676 79.MokB.W.SongW.WangP.TaiH.ChenY.ZhengM.WenX.LauS.Y.WuW.L.MatsumotoK.et al.The NS1 protein of" exact="influenza" post="A virus interacts with cellular processing bodies and stress"/>
   <result pre="Commun.20145471310.1038/ncomms571325140902 83.AllenI.C.ScullM.A.MooreC.B.HollE.K.McElvania-TeKippeE.TaxmanD.J.GuthrieE.H.PicklesR.J.TingJ.P.The NLRP3 inflammasome mediates in vivo innate immunity to" exact="influenza" post="A virus through recognition of viral RNAImmunity20093055656510.1016/j.immuni.2009.02.00519362020 84.ThomasP.G.DashP.AldridgeJ.R.Jr.EllebedyA.H.ReynoldsC.FunkA.J.MartinW.J.LamkanfiM.WebbyR.J.BoydK.L.et al.The"/>
   <result pre="intracellular sensor NLRP3 mediates key innate and healing responses to" exact="influenza" post="A virus via the regulation of caspase-1Immunity20093056657510.1016/j.immuni.2009.02.00619362023 85.IchinoheT.LeeH.K.OguraY.FlavellR.IwasakiA.Inflammasome recognition"/>
   <result pre="A virus via the regulation of caspase-1Immunity20093056657510.1016/j.immuni.2009.02.00619362023 85.IchinoheT.LeeH.K.OguraY.FlavellR.IwasakiA.Inflammasome recognition of" exact="influenza" post="virus is essential for adaptive immune responsesJ. Exp. Med.2009206798710.1084/jem.2008166719139171"/>
   <result pre="cellsVirology20063459610410.1016/j.virol.2005.09.04316253303 95.WareingM.D.LyonA.InglisC.GiannoniF.CharoI.SarawarS.R.Chemokine regulation of the inflammatory response to a low-dose" exact="influenza" post="infection in CCR2-/- miceJ. Leukoc. Biol.20078179380110.1189/jlb.050629917179466 96.WareingM.D.LyonA.B.LuB.GerardC.SarawarS.R.Chemokine expression during"/>
   <result pre="the development and resolution of a pulmonary leukocyte response to" exact="influenza" post="A virus infection in miceJ. Leukoc. Biol.20047688689510.1189/jlb.120364415240757 97.MandelboimO.LiebermanN.LevM.PaulL.ArnonT.I.BushkinY.DavisD.M.StromingerJ.L.YewdellJ.W.PorgadorA.Recognition of"/>
   <result pre="are involved in the interaction with hemagglutinin type 1 of" exact="influenza" post="virusJ. Virol.2010843789379710.1128/JVI.01815-0920147410 100.JegaskandaS.VandervenH.A.TanH.X.AlcantaraS.WraggK.M.ParsonsM.S.ChungA.W.JunoJ.A.KentS.J.Influenza Virus Infection Enhances Antibody-Mediated NK Cell"/>
   <result pre="PathwaysJ. Virol.20199310.1128/JVI.02090-18 101.HwangI.ScottJ.M.KakarlaT.DuriancikD.M.ChoiS.ChoC.LeeT.ParkH.FrenchA.R.BeliE.et al.Activation mechanisms of natural killer cells during" exact="influenza" post="virus infectionPLoS ONE20127e5185810.1371/journal.pone.005185823300570 102.CooperG.E.OstridgeK.KhakooS.I.WilkinsonT.M.A.StaplesK.J.Human CD49a(+) Lung Natural Killer Cell"/>
   <result pre="103.NogusaS.RitzB.W.KassimS.H.JenningsS.R.GardnerE.M.Characterization of age-related changes in natural killer cells during primary" exact="influenza" post="infection in miceMech. Ageing Dev.200812922323010.1016/j.mad.2008.01.00318304606 104.LiuB.MoriI.HossainM.J.DongL.TakedaK.KimuraY.Interleukin-18 improves the early"/>
   <result pre="miceMech. Ageing Dev.200812922323010.1016/j.mad.2008.01.00318304606 104.LiuB.MoriI.HossainM.J.DongL.TakedaK.KimuraY.Interleukin-18 improves the early defence system against" exact="influenza" post="virus infection by augmenting natural killer cell-mediated cytotoxicityJ. Gen."/>
   <result pre="cell-mediated cytotoxicityJ. Gen. Virol.20048542342810.1099/vir.0.19596-014769900 105.ZhouG.JuangS.W.KaneK.P.NK cells exacerbate the pathology of" exact="influenza" post="virus infection in miceEur. J. Immunol.20134392993810.1002/eji.20124262023436540 106.Abdul-CareemM.F.MianM.F.YueG.GillgrassA.ChenowethM.J.BarraN.G.ChewM.V.ChanT.Al-GarawiA.A.JordanaM.et al.Critical role"/>
   <result pre="al.Critical role of natural killer cells in lung immunopathology during" exact="influenza" post="infection in miceJ. Infect. Dis.201220616717710.1093/infdis/jis34022561366 107.HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY.Evidence for phagocytosis of"/>
   <result pre="influenza infection in miceJ. Infect. Dis.201220616717710.1093/infdis/jis34022561366 107.HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY.Evidence for phagocytosis of" exact="influenza" post="virus-infected, apoptotic cells by neutrophils and macrophages in miceJ."/>
   <result pre="Neutrophils in Viral Respiratory DiseaseFront. Immunol.2017855010.3389/fimmu.2017.0055028553293 109.TumpeyT.M.Garcia-SastreA.TaubenbergerJ.K.PaleseP.SwayneD.E.Pantin-JackwoodM.J.Schultz-CherryS.SolorzanoA.Van RooijenN.KatzJ.M.et al.Pathogenicity of" exact="influenza" post="viruses with genes from the 1918 pandemic virus: Functional"/>
   <result pre="of neutrophils in the upper and lower respiratory tract during" exact="influenza" post="virus infection of miceRespir. Res.200895710.1186/1465-9921-9-5718671884 111.TateM.D.BrooksA.G.ReadingP.C.MinternJ.D.Neutrophils sustain effective CD8(+)"/>
   <result pre="sustain effective CD8(+) T-cell responses in the respiratory tract following" exact="influenza" post="infectionImmunol. Cell Biol.20129019720510.1038/icb.2011.2621483446 112.LimK.HyunY.M.Lambert-EmoK.CapeceT.BaeS.MillerR.TophamD.J.KimM.Neutrophil trails guide influenza-specific CD8(+) T"/>
   <result pre="systems analysis identifies a feedforward inflammatory circuit leading to lethal" exact="influenza" post="infectionCell201315419721210.1016/j.cell.2013.06.01323827683 114.TrapnellB.C.WhitsettJ.A.Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated"/>
   <result pre="RooijenN.BrooksA.G.ReadingP.C.Critical role of airway macrophages in modulating disease severity during" exact="influenza" post="virus infection of miceJ. Virol.2010847569758010.1128/JVI.00291-1020504924 117.SchneiderC.NobsS.P.HeerA.K.KurrerM.KlinkeG.van RooijenN.VogelJ.KopfM.Alveolar macrophages are"/>
   <result pre="miceJ. Virol.2010847569758010.1128/JVI.00291-1020504924 117.SchneiderC.NobsS.P.HeerA.K.KurrerM.KlinkeG.van RooijenN.VogelJ.KopfM.Alveolar macrophages are essential for protection from" exact="respiratory failure" post="and associated morbidity following influenza virus infectionPLoS Pathog.201410e100405310.1371/journal.ppat.100405324699679 118.PurnamaC.NgS.L.TetlakP.SetiaganiY.A.KandasamyM.BaalasubramanianS.KarjalainenK.RuedlC.Transient"/>
   <result pre="essential for protection from respiratory failure and associated morbidity following" exact="influenza" post="virus infectionPLoS Pathog.201410e100405310.1371/journal.ppat.100405324699679 118.PurnamaC.NgS.L.TetlakP.SetiaganiY.A.KandasamyM.BaalasubramanianS.KarjalainenK.RuedlC.Transient ablation of alveolar macrophages leads"/>
   <result pre="118.PurnamaC.NgS.L.TetlakP.SetiaganiY.A.KandasamyM.BaalasubramanianS.KarjalainenK.RuedlC.Transient ablation of alveolar macrophages leads to massive pathology of" exact="influenza" post="infection without affecting cellular adaptive immunityEur. J. Immunol.2014442003201210.1002/eji.20134435924687623 119.CardaniA.BoultonA.KimT.S.BracialeT.J.Alveolar"/>
   <result pre="T cells by exogenous cell-associated antigensImmunity20021721122010.1016/S1074-7613(02)00365-512196292 121.GeurtsvanKesselC.H.WillartM.A.van RijtL.S.MuskensF.KoolM.BaasC.ThielemansK.BennettC.ClausenB.E.HoogstedenH.C.et al.Clearance of" exact="influenza" post="virus from the lung depends on migratory langerin+CD11b- but"/>
   <result pre="VivoFront. Immunol.20178141910.3389/fimmu.2017.0141929163495 126.HaoX.KimT.S.BracialeT.J.Differential response of respiratory dendritic cell subsets to" exact="influenza" post="virus infectionJ. Virol.2008824908491910.1128/JVI.02367-0718353940 127.HelftJ.ManicassamyB.GuermonprezP.HashimotoD.SilvinA.AgudoJ.BrownB.D.SchmolkeM.MillerJ.C.LeboeufM.et al.Cross-presenting CD103+ dendritic cells are"/>
   <result pre="infectionJ. Virol.2008824908491910.1128/JVI.02367-0718353940 127.HelftJ.ManicassamyB.GuermonprezP.HashimotoD.SilvinA.AgudoJ.BrownB.D.SchmolkeM.MillerJ.C.LeboeufM.et al.Cross-presenting CD103+ dendritic cells are protected from" exact="influenza" post="virus infectionJ. Clin. Investig.20121224037404710.1172/JCI6065923041628 128.WaithmanJ.ZankerD.XiaoK.OveissiS.WylieB.NgR.TogelL.ChenW.Resident CD8(+) and migratory CD103(+)"/>
   <result pre="CD103(+) dendritic cells control CD8 T cell immunity during acute" exact="influenza" post="infectionPLoS ONE20138e6613610.1371/journal.pone.006613623750278 129.NgS.L.TeoY.J.SetiaganiY.A.KarjalainenK.RuedlC.Type 1 Conventional CD103(+) Dendritic Cells Control"/>
   <result pre="replaces pattern-recognition receptors in promoting CD8(+) T cell responses to" exact="influenza" post="A virusNat. Immunol.20131424625310.1038/ni.251423314004 131.HoA.W.PrabhuN.BettsR.J.GeM.Q.DaiX.HutchinsonP.E.LewF.C.WongK.L.HansonB.J.MacaryP.A.et al.Lung CD103+ dendritic cells efficiently"/>
   <result pre="A virusNat. Immunol.20131424625310.1038/ni.251423314004 131.HoA.W.PrabhuN.BettsR.J.GeM.Q.DaiX.HutchinsonP.E.LewF.C.WongK.L.HansonB.J.MacaryP.A.et al.Lung CD103+ dendritic cells efficiently transport" exact="influenza" post="virus to the lymph node and load viral antigen"/>
   <result pre="dendritic cells regulate CD8(+) T-cell differentiation and memory responses in" exact="influenza" post="infectionMucosal Immunol.2019121025103710.1038/s41385-019-0173-131089186 138.WonH.Y.LeeJ.Y.RyuD.KimH.T.ChangS.Y.The Role of Plasmacytoid Dendritic Cells in"/>
   <result pre="Gut HealthImmune Netw.201919e610.4110/in.2019.19.e630838161 139.WolfA.I.BuehlerD.HensleyS.E.CavanaghL.L.WherryE.J.KastnerP.ChanS.WeningerW.Plasmacytoid dendritic cells are dispensable during primary" exact="influenza" post="virus infectionJ. Immunol.200918287187910.4049/jimmunol.182.2.87119124730 140.LuiG.ManchesO.AngelJ.MolensJ.P.ChaperotL.PlumasJ.Plasmacytoid dendritic cells capture and cross-present"/>
   <result pre="Cell ResponseJ. Virol.2015902830283710.1128/JVI.02546-1526719269 142.CruzJ.L.Perez-GironJ.V.LudtkeA.Gomez-MedinaS.RuibalP.IdoyagaJ.Munoz-FontelaC.Monocyte-derived dendritic cells enhance protection against secondary" exact="influenza" post="challenge by controlling the switch in CD8(+) T-cell immunodominanceEur."/>
   <result pre="143.WuH.HaistV.BaumgartnerW.SchughartK.Sustained viral load and late death in Rag2-/- mice after" exact="influenza" post="A virus infectionVirol. J.2010717210.1186/1743-422X-7-17220667098 144.PalladinoG.MozdzanowskaK.WashkoG.GerhardW.Virus-neutralizing antibodies of immunoglobulin G"/>
   <result pre="(IgG) but not of IgM or IgA isotypes can cure" exact="influenza" post="virus pneumonia in SCID miceJ. Virol.1995692075208110.1128/JVI.69.4.2075-2081.19957884853 145.BrownD.M.LeeS.Garcia-Hernandez MdeL.SwainS.L.Multifunctional CD4"/>
   <result pre="not of IgM or IgA isotypes can cure influenza virus" exact="pneumonia" post="in SCID miceJ. Virol.1995692075208110.1128/JVI.69.4.2075-2081.19957884853 145.BrownD.M.LeeS.Garcia-Hernandez MdeL.SwainS.L.Multifunctional CD4 cells expressing"/>
   <result pre="cells expressing gamma interferon and perforin mediate protection against lethal" exact="influenza" post="virus infectionJ. Virol.2012866792680310.1128/JVI.07172-1122491469 146.BrownD.M.DilzerA.M.MeentsD.L.SwainS.L.CD4 T Cell-Mediated Protection from Lethal"/>
   <result pre="PunchJ. Immunol.20061772888289810.4049/jimmunol.177.5.288816920924 147.BaumgarthN.KelsoA.In vivo blockade of gamma interferon affects the" exact="influenza" post="virus-induced humoral and the local cellular immune response in"/>
   <result pre="150.HuaL.YaoS.PhamD.JiangL.WrightJ.SawantD.DentA.L.BracialeT.J.KaplanM.H.SunJ.Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during" exact="influenza" post="virus infectionJ. Virol.201387118841189310.1128/JVI.01461-1323986597 151.BettsR.J.PrabhuN.HoA.W.LewF.C.HutchinsonP.E.RotzschkeO.MacaryP.A.KemenyD.M.Influenza A virus infection results in"/>
   <result pre="Commun.20145349510.1038/ncomms449524633065 154.BelzG.T.XieW.AltmanJ.D.DohertyP.C.A previously unrecognized H-2D(b)-restricted peptide prominent in the primary" exact="influenza" post="A virus-specific CD8(+) T-cell response is much less apparent"/>
   <result pre="T cells have delayed viral clearance and increased mortality after" exact="influenza" post="virus challengeJ. Exp. Med.19921751143114510.1084/jem.175.4.11431552285 156.KreijtzJ.H.FouchierR.A.RimmelzwaanG.F.Immune responses to influenza virus"/>
   <result pre="mortality after influenza virus challengeJ. Exp. Med.19921751143114510.1084/jem.175.4.11431552285 156.KreijtzJ.H.FouchierR.A.RimmelzwaanG.F.Immune responses to" exact="influenza" post="virus infectionVirus Res.2011162193010.1016/j.virusres.2011.09.02221963677 157.BrincksE.L.KatewaA.KucabaT.A.GriffithT.S.LeggeK.L.CD8 T cells utilize TRAIL to"/>
   <result pre="virus infectionVirus Res.2011162193010.1016/j.virusres.2011.09.02221963677 157.BrincksE.L.KatewaA.KucabaT.A.GriffithT.S.LeggeK.L.CD8 T cells utilize TRAIL to control" exact="influenza" post="virus infectionJ. Immunol.20081814918492510.4049/jimmunol.181.7.491818802095 158.KimC.W.YooH.J.ParkJ.H.OhJ.E.LeeH.K.Exogenous Interleukin-33 Contributes to Protective Immunity"/>
   <result pre="InfectionsFront. Immunol.2018967810.3389/fimmu.2018.0067829686673 161.SunJ.MadanR.KarpC.L.BracialeT.J.Effector T cells control lung inflammation during acute" exact="influenza" post="virus infection by producing IL-10Nat. Med.20091527728410.1038/nm.192919234462 162.GrahamM.B.BracialeT.J.Resistance to and"/>
   <result pre="by producing IL-10Nat. Med.20091527728410.1038/nm.192919234462 162.GrahamM.B.BracialeT.J.Resistance to and recovery from lethal" exact="influenza" post="virus infection in B lymphocyte-deficient miceJ. Exp. Med.19971862063206810.1084/jem.186.12.20639396777 163.LeeB.O.Rangel-MorenoJ.Moyron-QuirozJ.E.HartsonL.MakrisM.SpragueF.LundF.E.RandallT.D.CD4"/>
   <result pre="Med.19971862063206810.1084/jem.186.12.20639396777 163.LeeB.O.Rangel-MorenoJ.Moyron-QuirozJ.E.HartsonL.MakrisM.SpragueF.LundF.E.RandallT.D.CD4 T cell-independent antibody response promotes resolution of primary" exact="influenza" post="infection and helps to prevent reinfectionJ. Immunol.20051755827583810.4049/jimmunol.175.9.582716237075 164.WaffarnE.E.BaumgarthN.Protective B"/>
   <result pre="B cell responses to flu--no fluke!J. Immunol.20111863823382910.4049/jimmunol.100209021422252 165.TamuraS.KurataT.Defense mechanisms against" exact="influenza" post="virus infection in the respiratory tract mucosaJpn. J. Infect."/>
   <result pre="mucosaJpn. J. Infect. Dis.20045723624715623947 166.HensleyS.E.DasS.R.BaileyA.L.SchmidtL.M.HickmanH.D.JayaramanA.ViswanathanK.RamanR.SasisekharanR.BenninkJ.R.et al.Hemagglutinin receptor binding avidity drives" exact="influenza" post="A virus antigenic driftScience200932673473610.1126/science.117825819900932 167.NeuK.E.Henry DunandC.J.WilsonP.C.Heads, stalks and everything"/>
   <result pre="167.NeuK.E.Henry DunandC.J.WilsonP.C.Heads, stalks and everything else: How can antibodies eradicate" exact="influenza" post="as a human disease?Curr. Opin. Immunol.201642485510.1016/j.coi.2016.05.01227268395 168.AngelettiD.GibbsJ.S.AngelM.KosikI.HickmanH.D.FrankG.M.DasS.R.WheatleyA.K.PrabhakaranM.LeggatD.J.et al.Defining B"/>
   <result pre="B cell immunodominance to virusesNat. Immunol.20171845646310.1038/ni.368028192417 169.van de SandtC.E.KreijtzJ.H.RimmelzwaanG.F.Evasion of" exact="influenza" post="A viruses from innate and adaptive immune responsesViruses201241438147610.3390/v409143823170167 170.TreanorJ.J.TierneyE.L.ZebedeeS.L.LambR.A.MurphyB.R.Passively"/>
   <result pre="responsesViruses201241438147610.3390/v409143823170167 170.TreanorJ.J.TierneyE.L.ZebedeeS.L.LambR.A.MurphyB.R.Passively transferred monoclonal antibody to the M2 protein inhibits" exact="influenza" post="A virus replication in miceJ. Virol.1990641375137710.1128/JVI.64.3.1375-1377.19902304147 171.CarragherD.M.KaminskiD.A.MoquinA.HartsonL.RandallT.D.A novel role"/>
   <result pre="role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to" exact="influenza" post="virusJ. Immunol.20081814168417610.4049/jimmunol.181.6.416818768874 172.JegaskandaS.WeinfurterJ.T.FriedrichT.C.KentS.J.Antibody-dependent cellular cytotoxicity is associated with control"/>
   <result pre="172.JegaskandaS.WeinfurterJ.T.FriedrichT.C.KentS.J.Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1" exact="influenza" post="virus infection of macaquesJ. Virol.2013875512552210.1128/JVI.03030-1223468501 173.ChoiY.S.BaumgarthN.Dual role for B-1a"/>
   <result pre="macaquesJ. Virol.2013875512552210.1128/JVI.03030-1223468501 173.ChoiY.S.BaumgarthN.Dual role for B-1a cells in immunity to" exact="influenza" post="virus infectionJ. Exp. Med.20082053053306410.1084/jem.2008097919075288 174.PutriW.MuscatelloD.J.StockwellM.S.NewallA.T.Economic burden of seasonal influenza"/>
   <result pre="to influenza virus infectionJ. Exp. Med.20082053053306410.1084/jem.2008097919075288 174.PutriW.MuscatelloD.J.StockwellM.S.NewallA.T.Economic burden of seasonal" exact="influenza" post="in the United StatesVaccine2018363960396610.1016/j.vaccine.2018.05.05729801998 175.PagetJ.SpreeuwenbergP.CharuV.TaylorR.J.IulianoA.D.BreseeJ.SimonsenL.ViboudC.collab: Global Seasonal Influenza-associated Mortality"/>
   <result pre="Mortality Collaborator Networkcollab: GLaMOR Collaborating TeamsGlobal mortality associated with seasonal" exact="influenza" post="epidemics: New burden estimates and predictors from the GLaMOR"/>
   <result pre="Stem Domain From Influenza HemagglutininFront. Immunol.20201143110.3389/fimmu.2020.0043132269566 178.HoftD.F.BabusisE.WorkuS.SpencerC.T.LottenbachK.TruscottS.M.AbateG.SakalaI.G.EdwardsK.M.CreechC.B.et al.Live and inactivated" exact="influenza" post="vaccines induce similar humoral responses, but only live vaccines"/>
   <result pre="responses in young childrenJ. Infect. Dis.201120484585310.1093/infdis/jir43621846636 179.SoemaP.C.KompierR.AmorijJ.P.KerstenG.F.Current and next generation" exact="influenza" post="vaccines: Formulation and production strategiesEur. J. Pharm. Biopharm.20159425126310.1016/j.ejpb.2015.05.02326047796 180.HuleattJ.W.NakaarV.DesaiP.HuangY.HewittD.JacobsA.TangJ.McDonaldW.SongL.EvansR.K.et"/>
   <result pre="Pharm. Biopharm.20159425126310.1016/j.ejpb.2015.05.02326047796 180.HuleattJ.W.NakaarV.DesaiP.HuangY.HewittD.JacobsA.TangJ.McDonaldW.SongL.EvansR.K.et al.Potent immunogenicity and efficacy of a universal" exact="influenza" post="vaccine candidate comprising a recombinant fusion protein linking influenza"/>
   <result pre="universal influenza vaccine candidate comprising a recombinant fusion protein linking" exact="influenza" post="M2e to the TLR5 ligand flagellinVaccine20082620121410.1016/j.vaccine.2007.10.06218063235 181.WangB.Z.GillH.S.HeC.OuC.WangL.WangY.C.FengH.ZhangH.PrausnitzM.R.CompansR.W.Microneedle delivery of"/>
   <result pre="an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective" exact="influenza" post="immunityJ. Control. Release20141781710.1016/j.jconrel.2014.01.00224417966 182.LukeJ.M.SimonG.G.SoderholmJ.ErrettJ.S.AugustJ.T.GaleM.Jr.HodgsonC.P.WilliamsJ.A.Coexpressed RIG-I agonist enhances humoral immune"/>
   <result pre="Control. Release20141781710.1016/j.jconrel.2014.01.00224417966 182.LukeJ.M.SimonG.G.SoderholmJ.ErrettJ.S.AugustJ.T.GaleM.Jr.HodgsonC.P.WilliamsJ.A.Coexpressed RIG-I agonist enhances humoral immune response to" exact="influenza" post="virus DNA vaccineJ. Virol.2011851370138310.1128/JVI.01250-1021106745 183.SheuT.G.DeydeV.M.Okomo-AdhiamboM.GartenR.J.XuX.BrightR.A.ButlerE.N.WallisT.R.KlimovA.I.GubarevaL.V.Surveillance for neuraminidase inhibitor resistance"/>
   <result pre="DNA vaccineJ. Virol.2011851370138310.1128/JVI.01250-1021106745 183.SheuT.G.DeydeV.M.Okomo-AdhiamboM.GartenR.J.XuX.BrightR.A.ButlerE.N.WallisT.R.KlimovA.I.GubarevaL.V.Surveillance for neuraminidase inhibitor resistance among human" exact="influenza" post="A and B viruses circulating worldwide from 2004 to"/>
   <result pre="neuraminidase inhibitors conferred by an R292K mutation in a human" exact="influenza" post="virus H7N9 isolate can be masked by a mixed"/>
   <result pre="masked by a mixed R/K viral populationmBio2013410.1128/mBio.00396-13 186.BurnhamA.J.BaranovichT.GovorkovaE.A.Neuraminidase inhibitors for" exact="influenza" post="B virus infection: Efficacy and resistanceAntivir. Res.201310052053410.1016/j.antiviral.2013.08.02324013000 Figure 1"/>
   <result pre="infection: Efficacy and resistanceAntivir. Res.201310052053410.1016/j.antiviral.2013.08.02324013000 Figure 1 The structure of" exact="influenza" post="A virus. IAV is a negative-stranded RNA virus belonging"/>
   <result pre="from host cells. Anti-influenza drugs inhibit various steps of the" exact="influenza" post="virus replication cycle. Figure 3 Overview of dendritic cell"/>
   <result pre="cell subsets in the lung and DC-mediated immune responses. After" exact="influenza" post="virus infection, viral antigen-captured cDCs migrate to lymph nodes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7293210\results\search\disease\results.xml">
   <result pre="of the infant immune system and the legacy of enhanced" exact="respiratory disease" post="(ERD) after RSV infection following immunization with formalin inactivated"/>
   <result pre="addition, RSV remains the leading cause of hospitalization due to" exact="respiratory disease" post="in infants and children under 5 years of age3."/>
   <result pre="obstacle in RSV vaccine development is the legacy of vaccine-enhanced" exact="respiratory disease" post="(ERD). In clinical trials in the 1960s, children vaccinated"/>
   <result pre="and reduced cytotoxic CD8+ T cell priming and evidence of" exact="eosinophilia" post="in the lung after RSV challenge9–16. The neonatal immune"/>
   <result pre="of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated" exact="hypersensitivity" post="to subsequent RSV infectionJ. Virol.200276115611156912388717 12.GrahamBSet al.Priming immunization determines"/>
   <result pre="36.TamerisMet al.A double-blind, randomised, placebo-controlled, dose-finding trial of the novel" exact="tuberculosis" post="vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated"/>
   <result pre="in West African children and infantsMol. Ther.2016241470147727109630 47.KaginaBMet al.The novel" exact="tuberculosis" post="vaccine, AERAS-402, is safe in healthy infants previously vaccinated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7293723\results\search\disease\results.xml">
   <result pre="the original work is properly cited. Abstract The spread of" exact="avian influenza" post="virus among Asian countries is becoming a concern after"/>
   <result pre="original work is properly cited. Abstract The spread of avian" exact="influenza" post="virus among Asian countries is becoming a concern after"/>
   <result pre="influenza virus among Asian countries is becoming a concern after" exact="influenza" post="epidemics in recent years. This study is aimed at"/>
   <result pre="years. This study is aimed at identifying the subtypes of" exact="avian influenza" post="viruses collected from healthy chickens and ducks at two"/>
   <result pre="This study is aimed at identifying the subtypes of avian" exact="influenza" post="viruses collected from healthy chickens and ducks at two"/>
   <result pre="collected in May 2017. All samples were screened to detect" exact="avian influenza" post="virus by real-time reverse transcriptase PCR. Samples that are"/>
   <result pre="in May 2017. All samples were screened to detect avian" exact="influenza" post="virus by real-time reverse transcriptase PCR. Samples that are"/>
   <result pre="influenza virus by real-time reverse transcriptase PCR. Samples that are" exact="avian influenza" post="virus-positive were isolated in embryonated chicken eggs, and the"/>
   <result pre="virus by real-time reverse transcriptase PCR. Samples that are avian" exact="influenza" post="virus-positive were isolated in embryonated chicken eggs, and the"/>
   <result pre="by RT-PCR with the specific primers. The samples positive for" exact="influenza" post="virus H5 were sequenced to identify HA and NA"/>
   <result pre="sequenced to identify HA and NA genes. The prevalence of" exact="avian influenza" post="virus (AIV) among chicken and duck samples was 27.5%"/>
   <result pre="to identify HA and NA genes. The prevalence of avian" exact="influenza" post="virus (AIV) among chicken and duck samples was 27.5%"/>
   <result pre="strain. Results suggested that while the presence of low pathogenic" exact="avian influenza" post="virus is predominant, potential risks of the appearance of"/>
   <result pre="Results suggested that while the presence of low pathogenic avian" exact="influenza" post="virus is predominant, potential risks of the appearance of"/>
   <result pre="is predominant, potential risks of the appearance of high pathogen" exact="avian influenza" post="virus in the east-west boundary in Vietnam should be"/>
   <result pre="predominant, potential risks of the appearance of high pathogen avian" exact="influenza" post="virus in the east-west boundary in Vietnam should be"/>
   <result pre="20th century, millions of people died in four pandemics of" exact="influenza" post="virus in 1918 (H1N1), 1952 (H2N2), 1968 (H3N2), and"/>
   <result pre="2009. To overcome the species barrier and direct human infection," exact="avian influenza" post="viruses were thought to be transmitted through intermediate hosts"/>
   <result pre="To overcome the species barrier and direct human infection, avian" exact="influenza" post="viruses were thought to be transmitted through intermediate hosts"/>
   <result pre="poultry to humans [1]. Between 2003 and 2017, the H5N1" exact="avian influenza" post="virus caused widespread outbreaks of poultry and in various"/>
   <result pre="to humans [1]. Between 2003 and 2017, the H5N1 avian" exact="influenza" post="virus caused widespread outbreaks of poultry and in various"/>
   <result pre="cases and 454 deaths diagnosed by the laboratory [2]. Avian" exact="influenza" post="viruses are generally species-specific and are primarily pathogenic to"/>
   <result pre="the species barrier to infect humans and other mammals. However," exact="influenza" post="viruses have fragmented genomes that allow them to be"/>
   <result pre="various places. LBMs provide a very favorable environment for the" exact="avian influenza" post="virus to exchange and disperse [6, 7]. Previous studies"/>
   <result pre="places. LBMs provide a very favorable environment for the avian" exact="influenza" post="virus to exchange and disperse [6, 7]. Previous studies"/>
   <result pre="the poultry markets in Vietnam have many different subtypes of" exact="influenza" post="viruses such as H3, H4, H5, H6, H7, and"/>
   <result pre="samples at Vietnamese domestic markets. It is concerned that the" exact="influenza" post="virus may cross a national border to spread to"/>
   <result pre="other regions [10, 11]. Understanding the geographical spread of the" exact="influenza" post="virus is important for controlling transmissions among countries and"/>
   <result pre="border with Lao PDR to find out the diversity of" exact="influenza" post="virus strains. This study is aimed at identifying the"/>
   <result pre="strains. This study is aimed at identifying the subtypes of" exact="avian influenza" post="viruses collected from chickens and ducks at two live"/>
   <result pre="This study is aimed at identifying the subtypes of avian" exact="influenza" post="viruses collected from chickens and ducks at two live"/>
   <result pre="Veterinary Diagnostics, the samples were tested for the presence of" exact="influenza" post="type A viruses (M gene detection) using a real-time"/>
   <result pre="Eggs were provided by a commercial hatchery and certified as" exact="influenza" post="virus-free since 2003. Allantoic fluids were clarified by centrifugation"/>
   <result pre="hemagglutination test (HA test). After isolation, the subtypes of the" exact="avian influenza" post="virus were identified by RT-PCR with the specific primers"/>
   <result pre="test (HA test). After isolation, the subtypes of the avian" exact="influenza" post="virus were identified by RT-PCR with the specific primers"/>
   <result pre="N2, N3, N5, N6, N7, N8, and N9. Genes of" exact="influenza" post="virus samples positive with H5 were sequenced to identify"/>
   <result pre="were sequenced to identify H and N clades of the" exact="influenza" post="virus. The prevalence of AIV at the individual poultry"/>
   <result pre="(70.3%). Among 402 samples, 105 samples were found to be" exact="influenza" post="A-positive (26.1%). The prevalence of AIV among chicken and"/>
   <result pre="specificity [13]. 4. Discussion Although the national surveillance program for" exact="avian influenza" post="has been applied widely across the country, it has"/>
   <result pre="[13]. 4. Discussion Although the national surveillance program for avian" exact="influenza" post="has been applied widely across the country, it has"/>
   <result pre="Therefore, LBMs provide a favorable environment for the spreading of" exact="influenza" post="virus within the poultry population. Our study is the"/>
   <result pre="a bordering district to examine the presence of the poultry" exact="influenza" post="strain at LBMs. Findings showed that the presence of"/>
   <result pre="strain at LBMs. Findings showed that the presence of the" exact="avian influenza" post="virus in the Khe Sanh market was significant, while"/>
   <result pre="at LBMs. Findings showed that the presence of the avian" exact="influenza" post="virus in the Khe Sanh market was significant, while"/>
   <result pre="virus in the Khe Sanh market was significant, while the" exact="avian influenza" post="virus in the Lao Bảo market was not detected."/>
   <result pre="in the Khe Sanh market was significant, while the avian" exact="influenza" post="virus in the Lao Bảo market was not detected."/>
   <result pre="in one previous study, which reported a prevalence of 22.1%" exact="influenza" post="virus A positive among 9790 pooled oropharyngeal swabs collected"/>
   <result pre="[14]. Study results suggested that the presence of low pathogenic" exact="avian influenza" post="(LPAI) was more common than the presence of high"/>
   <result pre="Study results suggested that the presence of low pathogenic avian" exact="influenza" post="(LPAI) was more common than the presence of high"/>
   <result pre="(LPAI) was more common than the presence of high pathogenic" exact="avian influenza" post="(HPAI) in the study site. After isolation, we found"/>
   <result pre="was more common than the presence of high pathogenic avian" exact="influenza" post="(HPAI) in the study site. After isolation, we found"/>
   <result pre="trade [8]. In Thailand, besides many studies on high pathogenic" exact="avian influenza," post="some studies have reported genetic characteristics of LPAI in"/>
   <result pre="a poultry body suggested the risks of gene recombination among" exact="influenza" post="viruses. In this study, we found four among 14"/>
   <result pre="of H5N6 in Vietnam were reported in 2014. This new" exact="avian influenza" post="strain was found in the poultry population in Lang"/>
   <result pre="H5N6 in Vietnam were reported in 2014. This new avian" exact="influenza" post="strain was found in the poultry population in Lang"/>
   <result pre="similarity nucleotide), this finding suggested the risk of a new" exact="influenza" post="strain outbreak among the poultry population in another bordering"/>
   <result pre="studies should be focused on the genetic characteristics of circulating" exact="avian influenza" post="strains in these LBMs. 5. Conclusions There was a"/>
   <result pre="should be focused on the genetic characteristics of circulating avian" exact="influenza" post="strains in these LBMs. 5. Conclusions There was a"/>
   <result pre="There was a considerable and diverse presence of low pathogenic" exact="avian influenza" post="virus in the Khe Sanh market, more prevalent in"/>
   <result pre="was a considerable and diverse presence of low pathogenic avian" exact="influenza" post="virus in the Khe Sanh market, more prevalent in"/>
   <result pre="prevalent in ducks than chicken. Potential risks of the recombinant" exact="avian influenza" post="virus and the appearance of new strain HPAI are"/>
   <result pre="in ducks than chicken. Potential risks of the recombinant avian" exact="influenza" post="virus and the appearance of new strain HPAI are"/>
   <result pre="are identified. Intervention actions to reduce the risk of an" exact="avian influenza" post="outbreak in a border area between Vietnam and Lao"/>
   <result pre="identified. Intervention actions to reduce the risk of an avian" exact="influenza" post="outbreak in a border area between Vietnam and Lao"/>
   <result pre="this paper. References 1ShortridgeK. F.ZhouN. N.GuanY.et al.Characterization of avian H5N1" exact="influenza" post="viruses from poultry in Hong KongVirology1998252233134210.1006/viro.1998.94889878612 2collab: World Health"/>
   <result pre="2collab: World Health OrganizationCumulative number of confirmed human cases for" exact="avian influenza" post="A (H5N1) reported to WHO, 2003-2017September 2019, https://www.who.int/influenza/human_animal_interface/2017_12_07_tableH5N1.pdf?ua=1 3WebsterR."/>
   <result pre="World Health OrganizationCumulative number of confirmed human cases for avian" exact="influenza" post="A (H5N1) reported to WHO, 2003-2017September 2019, https://www.who.int/influenza/human_animal_interface/2017_12_07_tableH5N1.pdf?ua=1 3WebsterR."/>
   <result pre="2019, https://www.who.int/influenza/human_animal_interface/2017_12_07_tableH5N1.pdf?ua=1 3WebsterR. G.BeanW. J.GormanO. T.ChambersT. M.KawaokaY.Evolution and ecology of" exact="influenza" post="A virusesMicrobiological Reviews199256115217910.1128/MMBR.56.1.152-179.19921579108 4NomuraN.SakodaY.EndoM.et al.Characterization of avian influenza viruses"/>
   <result pre="and ecology of influenza A virusesMicrobiological Reviews199256115217910.1128/MMBR.56.1.152-179.19921579108 4NomuraN.SakodaY.EndoM.et al.Characterization of" exact="avian influenza" post="viruses isolated from domestic ducks in Vietnam in 2009"/>
   <result pre="ecology of influenza A virusesMicrobiological Reviews199256115217910.1128/MMBR.56.1.152-179.19921579108 4NomuraN.SakodaY.EndoM.et al.Characterization of avian" exact="influenza" post="viruses isolated from domestic ducks in Vietnam in 2009"/>
   <result pre="live poultry markets are a major source of human H5N1" exact="influenza" post="virus infection in ChinaJournal of Virology20118524134321343810.1128/JVI.05266-1121976646 6ChuD.-H.StevensonM. A.NguyenL. V.et"/>
   <result pre="A.NguyenL. V.et al.A cross-sectional study to quantify the prevalence of" exact="avian influenza" post="viruses in poultry at intervention and non-intervention live bird"/>
   <result pre="V.et al.A cross-sectional study to quantify the prevalence of avian" exact="influenza" post="viruses in poultry at intervention and non-intervention live bird"/>
   <result pre="Emerging Diseases20176461991199910.1111/tbed.1260528120423 7NguyenD. T.BryantJ. E.DavisC. T.et al.Prevalence and distribution of" exact="avian influenza" post="A(H5N1) virus clade variants in live bird markets of"/>
   <result pre="Diseases20176461991199910.1111/tbed.1260528120423 7NguyenD. T.BryantJ. E.DavisC. T.et al.Prevalence and distribution of avian" exact="influenza" post="A(H5N1) virus clade variants in live bird markets of"/>
   <result pre="2011–2013Avian Diseases201458459960810.1637/10814-030814-Reg25619005 8KimK.-I.ChoiJ. G.KangH. M.et al.Geographical distribution of low pathogenic" exact="avian influenza" post="viruses of domestic poultry in Vietnam and their genetic"/>
   <result pre="Diseases201458459960810.1637/10814-030814-Reg25619005 8KimK.-I.ChoiJ. G.KangH. M.et al.Geographical distribution of low pathogenic avian" exact="influenza" post="viruses of domestic poultry in Vietnam and their genetic"/>
   <result pre="9ChuD.-H.OkamatsuM.MatsunoK.et al.Genetic and antigenic characterization of H5, H6 and H9" exact="avian influenza" post="viruses circulating in live bird markets with intervention in"/>
   <result pre="al.Genetic and antigenic characterization of H5, H6 and H9 avian" exact="influenza" post="viruses circulating in live bird markets with intervention in"/>
   <result pre="12collab: Ministry of Agriculture and Rural DevelopmentDiagnostic testing procedures for" exact="avian influenza" post="Hanoi, Vietnam2005 13PaulsonJ. C.de VriesR. P.H5N1 receptor specificity as"/>
   <result pre="Ministry of Agriculture and Rural DevelopmentDiagnostic testing procedures for avian" exact="influenza" post="Hanoi, Vietnam2005 13PaulsonJ. C.de VriesR. P.H5N1 receptor specificity as"/>
   <result pre="a factor in pandemic riskVirus Research201317819911310.1016/j.virusres.2013.02.01523619279 14KarlssonE. A.HormS. V.TokS.et al.Avian" exact="influenza" post="virus detection, temporality and co-infection in poultry in Cambodian"/>
   <result pre="Cambodian border provinces, 2017–2018Emerging Microbes &amp;amp; Infections20198163763910.1080/22221751.2019.160408530999819 15WisedchanwetT.WongphatcharachaiM.BoonyapisitsopaS.BunpapongN.KitikoonP.AmonsinA.Genetic characterization of" exact="avian influenza" post="subtype H4N6 and H4N9 from live bird market, ThailandVirology"/>
   <result pre="border provinces, 2017–2018Emerging Microbes &amp;amp; Infections20198163763910.1080/22221751.2019.160408530999819 15WisedchanwetT.WongphatcharachaiM.BoonyapisitsopaS.BunpapongN.KitikoonP.AmonsinA.Genetic characterization of avian" exact="influenza" post="subtype H4N6 and H4N9 from live bird market, ThailandVirology"/>
   <result pre="market, ThailandVirology Journal201181p. 13110.1186/1743-422X-8-13121418614 16WongF. Y. K.PhommachanhP.KalpravidhW.et al.Reassortant highly pathogenic" exact="influenza" post="A(H5N6) virus in LaosEmerging Infectious Diseases201521351151610.3201/eid2103.14148825695754 17JiaoP.CuiJ.SongY.et al.New reassortant"/>
   <result pre="in LaosEmerging Infectious Diseases201521351151610.3201/eid2103.14148825695754 17JiaoP.CuiJ.SongY.et al.New reassortant H5N6 highly pathogenic" exact="avian influenza" post="viruses in southern China, 2014Frontiers in Microbiology20167p. 75410.3389/fmicb.2016.00754 18collab:"/>
   <result pre="LaosEmerging Infectious Diseases201521351151610.3201/eid2103.14148825695754 17JiaoP.CuiJ.SongY.et al.New reassortant H5N6 highly pathogenic avian" exact="influenza" post="viruses in southern China, 2014Frontiers in Microbiology20167p. 75410.3389/fmicb.2016.00754 18collab:"/>
   <result pre="in Microbiology20167p. 75410.3389/fmicb.2016.00754 18collab: World Animal Health Information DatabaseHighly pathogenic" exact="avian influenza," post="VietnamApril 2020, http://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&amp;amp;reportid=15802 Figure 1 The phylogeny of AIV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7293853\results\search\disease\results.xml">
   <result pre="and feather disease virusAvian Pathology2362163010.1080/0307945940841903218671129 Raidal &amp;amp; Cross (1995)RaidalSRCrossGM1995Acute necrotizing" exact="hepatitis" post="caused by experimental infection with psittacine beak and feather"/>
   <result pre="Veterinary Research53151215181416348 Rohani et al. (2009)RohaniPBrebanRStallknechtDEDrakeJM2009Environmental transmission of low pathogenicity" exact="avian influenza" post="viruses and its implications for pathogen invasionProceedings of the"/>
   <result pre="Research53151215181416348 Rohani et al. (2009)RohaniPBrebanRStallknechtDEDrakeJM2009Environmental transmission of low pathogenicity avian" exact="influenza" post="viruses and its implications for pathogen invasionProceedings of the"/>
   <result pre="species: a reviewAvian Pathology2937339410.1080/03079450075004712619184829 Vong et al. (2008)VongSLySMardySHollDBuchyP2008Environmental contamination during" exact="influenza" post="A virus (H5N1) outbreaks, Cambodia, 2006Emerging Infectious Diseases141303130510.3201/eid1408.07091218680663 Wu"/>
   <result pre="Diseases141303130510.3201/eid1408.07091218680663 Wu et al. (2020)WuFZhaoSYuBChenY-MWangWSongZ-GHuYTaoZ-WTianJ-HPeiY-YYuanM-LZhangY-LDaiF-HLiuYWangQ-MZhengJ-JXuLHolmesECZhangY-Z2020A new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature57926526910.1038/s41586-020-2008-332015508"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7294235\results\search\disease\results.xml">
   <result pre="A systematic review of temporal trends in diagnostics for Japanese" exact="encephalitis" post="virus infection, and perspectives for future research BharuchaTehminat.bharucha@doctors.org.ukab�?�ShearerFreya M.cVongsouvathManivanhbMayxayMayfongbdde"/>
   <result pre="access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Highlights •Japanese" exact="encephalitis" post="virus (JEV) remains a leading cause of neurological infection"/>
   <result pre="throughout JE endemic regions of the world. Abstract Objective Japanese" exact="encephalitis" post="virus infection (JE) remains a leading cause of neurological"/>
   <result pre="Keywords Flaviviruses Neurological infection Diagnostics Introduction The mosquito-borne flavivirus Japanese" exact="encephalitis" post="virus (JEV) accounts for an estimated 68,000 cases of"/>
   <result pre="virus (JEV) accounts for an estimated 68,000 cases of Japanese" exact="encephalitis" post="and 709,000 disability-adjusted life years annually (Fischer et al.,"/>
   <result pre="annually (Fischer et al., 2008, Campbell et al., 2011). Japanese" exact="encephalitis" post="virus (JEV) primarily affects children in rural areas when"/>
   <result pre="1. Table 1 Country-specific data on the introduction of Japanese" exact="encephalitis" post="virus vaccine in JEV endemic countries. Data adapted from"/>
   <result pre="A case that meets the clinical case definition for acute" exact="encephalitis" post="syndrome (AES) that occurs in close geographical and temporal"/>
   <result pre="diagram. Table 3 Diagnostic methods used for evidence of Japanese" exact="encephalitis" post="virus infection. [alt-text] Table 3 Diagnostic method Confirmatory level"/>
   <result pre="Hayashi demonstrated that a filterable agent inoculated into monkeys produced" exact="encephalitis" post="(Hayashi, 1933). The experiment was performed using homogenized brain"/>
   <result pre="obtained at post-mortem from a fatally-infected child who presented with" exact="encephalitis" post="in Tokyo during the 1924 epidemic. Early studies relied"/>
   <result pre="Chronological representation of discoveries related to the detection of Japanese" exact="encephalitis" post="virus infection (Miyake, 1964, Sever, 1962, Kuttner and Ts’un,"/>
   <result pre="other flaviviruses such as dengue viruses, West Nile virus, or" exact="yellow fever" post="virus. Table 5 Details of seroneutralization testing. [alt-text] Table"/>
   <result pre="neutralizing antibodies in JE patients who had previously received the" exact="yellow fever" post="vaccine (Saito et al., 1999c). Similarly, in a study"/>
   <result pre="years, with the international focus on emerging flaviviruses following the" exact="chikungunya" post="virus and theZika virus global epidemics, there have been"/>
   <result pre="virus infectionsViruses1122019 AngaG.BarnabasR.KaminielO.TefuaraniN.VinceJ.RipaP.The aetiology, clinical presentations and outcome of febrile" exact="encephalopathy" post="in children in Papua New GuineaAnn Trop Paediatr302201010911820522297 AnukumarB.SapkalG.N.TandaleB.V.BalasubramanianR.GangaleD.West"/>
   <result pre="Encephalitis outbreak in Kerala, India, 2011J Clin Virol611201415215524985196 AnukumarB.SapkalG.N.TandaleB.V.BalasubramanianR.GangaleD.West Nile" exact="encephalitis" post="outbreak in Kerala, India, 2011J Clin Virol611201415215524985196 AriffinE.Y.TanL.L.Abd KarimN.H.Yook"/>
   <result pre="Trop Med Public Health20419895875922561715 BenensonM.W.TopF.H.Jr.GressoW.AmesC.W.AltstattL.B.The virulence to man of Japanese" exact="encephalitis" post="virus in ThailandAm J Trop Med Hyg246 Pt 11975974980173200"/>
   <result pre="BharuchaT.SengvilaipaseuthO.VongsouvathM.VongsouvathM.DavongV.PanyanouvongP.Development of an improved RT-qPCR Assay for detection of Japanese" exact="encephalitis" post="virus (JEV) RNA including a systematic review and comprehensive"/>
   <result pre="pilot studySci Rep82018 BorahJ.DuttaP.KhanS.A.MahantaJ.A comparison of clinical features of Japanese" exact="encephalitis" post="virus infection in the adult and pediatric age group"/>
   <result pre="SyndromeJ Clin Virol5212011454921715224 BorahJ.DuttaP.KhanS.A.MahantaJ.A comparison of clinical features of Japanese" exact="encephalitis" post="virus infection in the adult and pediatric age group"/>
   <result pre="prM protein distinguish between previous infection with dengue and Japanese" exact="encephalitis" post="virusesBMC Microbiol22002912019028 CasalsJ.PalaciosR.Diagnosis of epidemic Encephalitis by complement-fixation testScience942440194133017836028"/>
   <result pre="Systematic Review and Meta-analysisAnais da Academia Brasileira de Ciencias90320183147315429947679 CutfieldN.J.AndersonN.E.BrickellK.HuestonL.PikholzC.RoxburghR.Japanese" exact="encephalitis" post="acquired during travel in ChinaInt Med J3582005497498 de VasconcelosZ.F.M.AzevedoR.C.ThompsonN.GomesL.GuidaL.MoreiraM.E.L.Challenges"/>
   <result pre="and serological ZIKV infection confirmationChilds Nerv Syst3412018798429110196 DesaiA.ShankarS.K.JayakumarP.N.ChandramukiA.Gourie-DeviM.RavikumarB.V.Co-existence of cerebral" exact="cysticercosis" post="with Japanese encephalitis: a prognostic modulatorEpidemiol Infect118219971651719129593 DesaiA.ShankarS.K.JayakumarP.N.ChandramukiA.GourieDeviM.RavikumarB.V.Co-existence of"/>
   <result pre="with Japanese encephalitis: a prognostic modulatorEpidemiol Infect118219971651719129593 DesaiA.ShankarS.K.JayakumarP.N.ChandramukiA.GourieDeviM.RavikumarB.V.Co-existence of cerebral" exact="cysticercosis" post="with Japanese encephalitis: a prognostic modulatorEpidemiol Infect118219971651719129593 DingD.HongZ.ZhaoS.J.ClemensJ.D.ZhouB.WangB.Long-term disability"/>
   <result pre="Organ5761979937942317020 EdelmanR.PariyanondaA.Human immunoglobulin M antibody in the sero-diagnosis of Japanese" exact="encephalitis" post="virus infectionsAm J Epidemiol981197329384360765 FengY.FuS.ZhangH.PetersenL.R.ZhangB.GaoX.High incidence of Japanese encephalitis,"/>
   <result pre="report of a collaborative study on PRNT50 assays for Japanese" exact="encephalitis" post="virus (JE) antibodiesBiologicals362200811111617892945 FischerM.HillsS.StaplesE.JohnsonB.YaichM.SolomonT.Japanese Encephalitis prevention and control: advances,"/>
   <result pre="Microdevices19420177328831630 GaoX.LiX.LiM.FuS.WangH.LuZ.Vaccine strategies for the control and prevention of Japanese" exact="encephalitis" post="in Mainland China, 1951-2011PLoS Negl Trop Dis882014e301525121596 GC-YLeeGraystonJ.T.KennyG.E.Growth of"/>
   <result pre="C201711328785601 GranerodJ.CunninghamR.ZuckermanM.MuttonK.DaviesN.W.WalshA.L.Causality in acute encephalitis: defining aetiologiesEpidemiol Infect1386201078380020388231 GranerodJ.AmbroseH.E.DaviesN.W.ClewleyJ.P.WalshA.L.MorganD.Causes of" exact="encephalitis" post="and differences in their clinical presentations in England: a"/>
   <result pre="adults with Japanese encephalitis, 2010-2012J Travel Med215201431031324861145 HokeC.H.NisalakA.SangawhipaN.JatanasenS.LaorakapongseT.InnisB.L.Protection against Japanese" exact="encephalitis" post="by inactivated vaccinesN Engl J Med3191019886086142842677 HossainM.J.GurleyE.S.MontgomeryS.PetersenL.SejvarJ.FischerM.Hospital-based surveillance for"/>
   <result pre="immunosorbent assay to characterize dengue infections where dengue and Japanese" exact="encephalitis" post="co-circulateAm J Trop Med Hyg4019894184272540664 JohnC.C.CarabinH.MontanoS.M.BangiranaP.ZuntJ.R.PetersonP.K.Global research priorities for"/>
   <result pre="of Japanese B encephalitisJpn Med J341950237242 KumarR.MathurA.KumarA.SethiG.D.SharmaS.ChaturvediU.C.Virological investigations of acute" exact="encephalopathy" post="in IndiaArch Dis Child65111990122712302174227 KumarR.SelvanA.S.SharmaS.MathurA.MisraP.K.SinghG.K.Clinical predictors of Japanese EncephalitisNeuroepidemiology1331994971028015669"/>
   <result pre="of circulating non-structural protein NS1: Implications for early diagnosis of" exact="japanese encephalitis" post="virus infectionJ Med Virol83620111063107021503922 KumarJ.S.SaxenaD.ParidaM.RathinamS.Evaluation of real-time reverse-transcription loop-mediated"/>
   <result pre="circulating non-structural protein NS1: Implications for early diagnosis of japanese" exact="encephalitis" post="virus infectionJ Med Virol83620111063107021503922 KumarJ.S.SaxenaD.ParidaM.RathinamS.Evaluation of real-time reverse-transcription loop-mediated"/>
   <result pre="neutralization testsJ Clin Invest155193652553016694426 KyawA.K.Ngwe TunM.M.NabeshimaT.BueranoC.C.AndoT.InoueS.Japanese Encephalitis- and Dengue-Associated acute" exact="encephalitis" post="syndrome cases in MyanmarAm J Trop Med Hyg1003201964364630628568 LambL.E.BartoloneS.N.TreeM.O.ConwayM.J.RossignolJ.SmithC.P.Rapid"/>
   <result pre="a trip in ThailandJ Travel Med192201212712922414040 LangevinS.LibmanM.DrebotM.A.LaverdiereM.A case of Japanese" exact="encephalitis" post="virus infection acquired during a trip in ThailandJ Travel"/>
   <result pre="application in a multiplexed serotyping assayPLoS One1272017e0180669 LeeD.W.ChoeY.J.KimJ.H.SongK.M.ChoH.BaeG.R.Epidemiology of Japanese" exact="encephalitis" post="in South Korea, 2007-2010Int J Infect Dis1662012e4485222497964 LehtinenV.A.HuhtamoE.SiikamakiH.VapalahtiO.Japanese encephalitis"/>
   <result pre="Japanese encephalitis in South Korea, 2007-2010Int J Infect Dis1662012e4485222497964 LehtinenV.A.HuhtamoE.SiikamakiH.VapalahtiO.Japanese" exact="encephalitis" post="in a Finnish traveler on a two-week holiday in"/>
   <result pre="sensitive antigen capture assay for NS1 protein quantitation in Japanese" exact="encephalitis" post="virus infectionJ Virol Methods1791201281621704081 LiJ.W.GaoX.Y.WuY.FuS.H.TanX.J.CaoY.X.A Centralized Report on Pediatric"/>
   <result pre="Sci Biol285–61975235253180319 OlsenS.J.SupawatK.CampbellA.P.AnantapreechaS.LiamsuwanS.TunlayadechanontS.Japanese Encephalitis virus remains an important cause of" exact="encephalitis" post="in ThailandInt J Infect Dis14102010e8889220674433 OmpusungguS.HillsS.L.MahaM.S.MoniagaV.A.SusilariniN.K.WidjayaA.Confirmation of Japanese encephalitis"/>
   <result pre="of encephalitis in ThailandInt J Infect Dis14102010e8889220674433 OmpusungguS.HillsS.L.MahaM.S.MoniagaV.A.SusilariniN.K.WidjayaA.Confirmation of Japanese" exact="encephalitis" post="as an endemic human disease through sentinel surveillance in"/>
   <result pre="in enzyme-linked immunosorbent assayVector Borne Zoonotic Dis1712201782583529083957 PrasadS.R.KumarV.MarwahaR.K.BatraK.L.RathR.K.PalS.R.An epidemic of" exact="encephalitis" post="in Haryana: serological evidence of Japanese encephalitis in a"/>
   <result pre="PrasadS.R.KumarV.MarwahaR.K.BatraK.L.RathR.K.PalS.R.An epidemic of encephalitis in Haryana: serological evidence of Japanese" exact="encephalitis" post="in a few patientsIndian Pediatr30719939059108132283 PreziusoS.MariS.MariottiF.RossiG.Detection of Japanese Encephalitis"/>
   <result pre="enzyme-linked immunosorbent assay kits for detection of IgM against Japanese" exact="encephalitis" post="virus in cerebrospinal fluid samplesAm J Trop Med Hyg81620091144115019996450"/>
   <result pre="randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese" exact="encephalitis" post="in NepalPLoS One1042015e0122608 RobinsonJ.S.FeatherstoneD.VasanthapuramR.BiggerstaffB.J.DesaiA.RamamurtyN.Evaluation of three commercially available Japanese"/>
   <result pre="J Hyg4631947356-&amp;amp; SabinA.B.SchlesingerR.W.GinderD.R.Clinically apparent and inapparent infection with Japanese B" exact="encephalitis" post="virus in Shanghai and TientsinProc Soc Exp Biol Med"/>
   <result pre="Med Soc Exp Biol Med (New York, NY)6521947183187 SaitoM.SunagawaT.MakinoY.TadanoM.HasegawaH.KanemuraK.Three Japanese" exact="encephalitis" post="cases in Okinawa, Japan, 1991Southeast Asian J Trop Med"/>
   <result pre="Japan, 1991Southeast Asian J Trop Med Public Health302199927727910774694 SaitoM.SunagawaT.MakinoY.TadanoM.HasegawaH.KanemuraK.Three Japanese" exact="encephalitis" post="cases in Okinawa, Japan, 1991Southeast Asian J Trop Med"/>
   <result pre="Japan, 1991Southeast Asian J Trop Med Public Health302199927727910774694 SaitoM.SunagawaT.MakinoY.TadanoM.HasegawaH.KanemuraK.Three Japanese" exact="encephalitis" post="cases in Okinawa, Japan, 1991Southeast Asian J Trop Med"/>
   <result pre="Asian J Trop Med Public Health302199927727910774694 SaitoM.SoukalounD.PhongsavathK.PhommasackB.MakinoY.Epidemiological study of Japanese" exact="encephalitis" post="virus in Vientiane, Lao PDR, in 1990sSci World J20152015235934"/>
   <result pre="Organ86200817818618368204 SolomonT.ThaoT.T.LewthwaiteP.OoiM.H.KneenR.DungN.M.A cohort study to assess the new WHO Japanese" exact="encephalitis" post="surveillance standardsBull World Health Organ863200817818618368204 SolomonT.MichaelB.D.SmithP.E.SandersonF.DaviesN.W.HartI.J.Management of suspected viral"/>
   <result pre="encephalitis surveillance standardsBull World Health Organ863200817818618368204 SolomonT.MichaelB.D.SmithP.E.SandersonF.DaviesN.W.HartI.J.Management of suspected viral" exact="encephalitis" post="in adults–association of British Neurologists and British Infection Association"/>
   <result pre="encephalitisJ Trop Pediat4932003153156 TouchS.HillsS.SokhalB.SamnangC.SovannL.KhieuV.Epidemiology and burden of disease from Japanese" exact="encephalitis" post="in Cambodia: results from two years of sentinel surveillanceTrop"/>
   <result pre="Med Int Health141120091365137319747185 TouchS.HillsS.SokhalB.SamnangC.SovannL.KhieuV.Epidemiology and burden of disease from Japanese" exact="encephalitis" post="in Cambodia: results from two years of sentinel surveillanceTrop"/>
   <result pre="pathology and laboratory medicine services: a crucial gapThe Lancet39110133201819271938 WittesjoB.EitremR.NiklassonB.VeneS.MangiaficoJ.A.Japanese" exact="encephalitis" post="after a 10-day holiday in BaliLancet34589531995856 World Health Organization"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7294518\results\search\disease\results.xml">
   <result pre="response in 144 individuals from 3 different subpopulations: HIV patients," exact="tuberculosis" post="patients and healthy individuals first tested in 2016 and"/>
   <result pre="Yellow fever virus, Bussuquara, Cacipacoré, Ilhéus, Rocio and Saint Louis" exact="encephalitis" post="virus might elicit unique flaviviral antibody responses that impact"/>
   <result pre="HIV-positive patients and healthy individuals from the UHPES and treated" exact="tuberculosis" post="patients from the José Silveira Foundation-Brazilian Institute for Investigation"/>
   <result pre="samples were obtained from 28 patients on treatment for active" exact="pulmonary tuberculosis;" post="93 immunologically stable HIV-positive patients under antiretroviral therapy; and"/>
   <result pre="level of seroreversion did not differ significantly among HIV-positive and" exact="tuberculosis" post="patients [25 serorevertants (26.9%) versus 5 serorevertants (17.8%); Fisher,"/>
   <result pre="in 2017–2018 (shown in gray) in the HIV patients (HIV)," exact="tuberculosis" post="patients (TB), healthy individuals (HI) subpopulations and total patients"/>
   <result pre="with generally lower antibody responses of HIV-positive individuals, e.g., following" exact="hepatitis" post="A virus vaccination [19]. However, the decrease of ELISA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7296089\results\search\disease\results.xml">
   <result pre="the Research Topic Respiratory Virus Infection: Recent Advances respiratory virus" exact="influenza" post="epidemiology pathogenesis therapeutics vaccines fig-count: table-count: equation-count: ref-count: page-count:"/>
   <result pre="human pathogens with epidemic or pandemic potential. Such viruses include" exact="avian influenza" post="viruses and the Middle East Respiratory Syndrome (MERS) and"/>
   <result pre="pathogens with epidemic or pandemic potential. Such viruses include avian" exact="influenza" post="viruses and the Middle East Respiratory Syndrome (MERS) and"/>
   <result pre="RSV and one each on rhinovirus and MERS coronavirus. Seasonal" exact="influenza" post="A and B virus epidemics globally cause up to"/>
   <result pre="permanent threat of pandemics. Vaccines and specific antiviral drugs against" exact="influenza" post="are available but they have limitations including variable vaccine"/>
   <result pre="al. review the current knowledge on the structure of the" exact="influenza" post="virus neuraminidase and link the structural features of this"/>
   <result pre="Guo et al. studied the genetic changes that occur in" exact="avian influenza" post="A H5 viruses when they infect humans. Identification of"/>
   <result pre="et al. studied the genetic changes that occur in avian" exact="influenza" post="A H5 viruses when they infect humans. Identification of"/>
   <result pre="humans is needed for evaluating the pandemic risk related to" exact="avian influenza" post="viruses. National reporting of clinical microbiology results is an"/>
   <result pre="is needed for evaluating the pandemic risk related to avian" exact="influenza" post="viruses. National reporting of clinical microbiology results is an"/>
   <result pre="et al. studied the effects of such laboratory merging on" exact="influenza" post="surveillance in Belgium. They report benefits of the integration"/>
   <result pre="report benefits of the integration of whole genome sequencing of" exact="influenza" post="viruses performed in centralized clinical microbiology laboratories into the"/>
   <result pre="inhibitors are widely used for treatment (and sometimes prevention) of" exact="influenza" post="infection, and they have demonstrated efficacy. However, new drugs"/>
   <result pre="scenario of developing antiviral resistance. Several new antiviral drugs against" exact="influenza" post="have been developed or are under development, including polymerase"/>
   <result pre="are the cornerstone in protection against influenza. However, currently used" exact="influenza" post="vaccines have limitations and the process of production in"/>
   <result pre="not only against H1N1pdm09 virus but also against avian H5N1" exact="influenza" post="virus. RSV occurs in yearly epidemics that cause high"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7296109\results\search\disease\results.xml">
   <result pre="1st of March, 1968) (57) &quot;The outbreak of African swine" exact="plague" post="in Italy�? (article in Italian) PubMed PS (article) (58)"/>
   <result pre="and laboratory information on ASF, lumpy skin disease, and Avian" exact="influenza" post="(93). A coherent and harmonized data collection system would"/>
   <result pre="Med. (1984) 2:63–70. 10.1016/0167-5877(84)90049-73870957 13.Sánchez-CordónPJMontoyaMReisALDixonLK. African swine fever: a reemerging" exact="viral disease" post="threatening the global pig industry. Vet J. (2018) 233:41–8."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7296759\results\search\disease\results.xml">
   <result pre="levels have been used to evaluate the vectorial capacity for" exact="malaria" post="[49]. For the YOUNG group, EIPmax was 23 dpi"/>
   <result pre="7.ChristoffersonRCMoresCNWearingHJBridging the gap between experimental data and model parameterization for" exact="chikungunya" post="virus transmission predictionsJ Infect Dis2016214Suppl. 5S466S47027920175 8.OhmJRBaldiniFBarreauxPLefevreTLynchPASuhEet al.Rethinking the"/>
   <result pre="Infect Dis2016214Suppl. 5S466S47027920175 8.OhmJRBaldiniFBarreauxPLefevreTLynchPASuhEet al.Rethinking the extrinsic incubation period of" exact="malaria" post="parasitesParasit Vectors20181117829530073 9.BellanSEThe importance of age dependent mortality and"/>
   <result pre="al.Vectorial capacity and vector control: reconsidering sensitivity to parameters for" exact="malaria" post="eliminationTrans R Soc Trop Med Hyg201611010711726822603 12.RobertMAChristoffersonRCSilvaNJVasquezCMoresCNWearingHJModeling mosquito-borne disease"/>
   <result pre="of Aedes aegypti and Aedes albopictus and vectorial capacity for" exact="chikungunya" post="virusJ Infect Dis2016214Suppl. 5S453S45827920173 17.MacdonaldGThe epidemiology and control of"/>
   <result pre="and control of malaria1957LondonOxford University Press 18.Garrett-JonesCPrognosis for interruption of" exact="malaria" post="transmission through assessment of the mosquito’s cectorial capacityNature19642041173117514268587 19.BagnyLDelatteHQuiliciSFontenilleDProgressive"/>
   <result pre="Island since the 1900sJ Med Entomol2009461541154519960710 20.TsetsarkinKAVanlandinghamDLMcGeeCEHiggsSA single mutation in" exact="chikungunya" post="virus affects vector specificity and epidemic potentialPLoS Pathog20073e20118069894 21.VazeilleMMoutaillerSCoudrierDRousseauxCKhunHHuerreMet"/>
   <result pre="virus affects vector specificity and epidemic potentialPLoS Pathog20073e20118069894 21.VazeilleMMoutaillerSCoudrierDRousseauxCKhunHHuerreMet al.Two" exact="chikungunya" post="isolates from the outbreak of La Reunion (Indian Ocean)"/>
   <result pre="transmission due to viral phenotypePLoS ONE20116e1629821298018 29.SmithDLMcKenzieFEStatics and dynamics of" exact="malaria" post="infection in Anopheles mosquitoesMalar J200431315180900 30.MassadECoutinhoFAVectorial capacity, basic reproduction"/>
   <result pre="temperature-driven asynchrony between parasite development and mosquito biting rate reduce" exact="malaria" post="transmission intensityPLoS ONE20138e5577723383280 44.ChristoffersonRCMoresCNWearingHJCharacterizing the likelihood of dengue emergence"/>
   <result pre="oral infectionPLoS ONE20094e589519521520 49.PaaijmansKPBlanfordSChanBHThomasMBWarmer temperatures reduce the vectorial capacity of" exact="malaria" post="mosquitoesBiol Lett2012846546822188673 50.KucharskiAJFunkSEggoRMMalletHPEdmundsWJNillesEJTransmission dynamics of Zika virus in island"/>
   <result pre="and clinical presentation in Nicaraguan patients infected with Zika virus," exact="chikungunya" post="virus, and dengue virusClin Infect Dis2016631584159027578819 54.CarringtonLBArmijosMVLambrechtsLScottTWFluctuations at a"/>
   <result pre="by Aedes aegyptiPLoS Negl Trop Dis20137e219023638208 55.AltoBWWigginsKEastmondBOrtizSZirbelKLounibosLPDiurnal temperature range and" exact="chikungunya" post="virus infection in invasive mosquito vectorsJ Med Entomol20185521722429040730 56.MuttisEBalsalobreAChuchuyAMangudoCCiotaATKramerLDet"/>
   <result pre="reproduction number (R0) and eco-environmental variables in Colombian municipalities with" exact="chikungunya" post="outbreaks during 2014–2016PLoS Negl Trop Dis201913e000787831697681 65.GoddardLBRothAEReisenWKScottTWVector competence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7297309\results\search\disease\results.xml">
   <result pre="circadian rhythms of population movement and the immune system in" exact="infectious disease" post="modeling Coupling the circadian rhythms of population movement and"/>
   <result pre="circadian rhythms of population movement and the immune system in" exact="infectious disease" post="modeling DuZhanweiConceptualizationFormal analysisInvestigationSoftwareWriting – original draftWriting – review &amp;amp;"/>
   <result pre="in human mobility can affect the pace and extent of" exact="infectious disease" post="spreading. Shifting commuting times could mitigate the emergence of"/>
   <result pre="manner.�? The best evidence comes from studies of herpes and" exact="influenza" post="virus infection associated with the circadian clock [7]. Typically,"/>
   <result pre="We use a susceptible-exposed-infectious-removed (SEIR) model with realistic parameters for" exact="influenza" post="[15] and a susceptible-infectious-removed (SIR) model with realistic parameters"/>
   <result pre="respect to two well-studied infectious diseases: First, the 2009 H1N1" exact="influenza" post="pandemic (which we model by an SEIR model)—β0 ="/>
   <result pre="the medical literature. There are some results about herpes and" exact="influenza" post="virus infections, respectively, with respect to viral replication volumes"/>
   <result pre="negative. The SEIR simulation (with a lower R0) of the" exact="influenza" post="simulation makes the negative effects of advancing the travel"/>
   <result pre="we parameterized to reflect two recent urban disease outbreaks of" exact="influenza" post="and varicella [12, 22]. We modeled the circadian response"/>
   <result pre="NicollMP, EfstathiouS, O’NeillJS, et al.Cell autonomous regulation of herpes and" exact="influenza" post="virus infection by the circadian clock. Proceedings of the"/>
   <result pre="GanapathiL, GrefenstetteJ, et al.The role of subway travel in an" exact="influenza" post="epidemic: a New York City simulation. J Urban Health."/>
   <result pre="Van KerkhoveMD, HollingsworthTD, et al.Pandemic potential of a strain of" exact="influenza" post="A (H1N1): early findings. Science. 2009;324(5934):1557–1561. 10.1126/science.117606219433588 16YangB, PeiH,"/>
   <result pre="et al.Multinational patterns of seasonal asymmetry in human movement influence" exact="infectious disease" post="dynamics. Nature Communications. 2017;8(1):206910.1038/s41467-017-02064-429234011 23EubankS, GucluH, KumarVA, MaratheMV, SrinivasanA,"/>
   <result pre="2016;12(7). 10.1371/journal.pcbi.100492827415615 25FoxSJ, MillerJC, MeyersLA. Seasonality in risk of pandemic" exact="influenza" post="emergence. PLoS computational biology. 2017;13(10):e100574910.1371/journal.pcbi.100574929049288 26BallF, NealP. Network epidemic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7297909\results\search\disease\results.xml">
   <result pre="closely associated with several infectious diseases, including encephalitis; myocarditis; and" exact="hand, foot, and mouth disease." post="Although many E-30 outbreaks associated with encephalitis have been"/>
   <result pre="several infectious diseases, including encephalitis; myocarditis; and hand, foot, and" exact="mouth disease." post="Although many E-30 outbreaks associated with encephalitis have been"/>
   <result pre="foot, and mouth disease. Although many E-30 outbreaks associated with" exact="encephalitis" post="have been reported around the world, it was not"/>
   <result pre="the future. echovirus 30 (E-30) phylogenetic analysis molecular epidemiology phylodynamics" exact="encephalitis" post="Funding National Science and Technology Infrastructure Program10.13039/5011000121672017ZX101040012017ZX101030062018ZX10711001 fig-count: table-count:"/>
   <result pre="associated with a series of diseases, such as encephalitis; myocarditis;" exact="hand, foot, and mouth disease" post="(HFMD); acute flaccid paralysis (AFP); and other diseases. For"/>
   <result pre="series of diseases, such as encephalitis; myocarditis; hand, foot, and" exact="mouth disease" post="(HFMD); acute flaccid paralysis (AFP); and other diseases. For"/>
   <result pre="and other diseases. For example, CV-B3 has been linked to" exact="myocarditis" post="and encephalitis, whereas it could also cause outbreaks of"/>
   <result pre="CV-B5 is an important pathogen that caused the outbreaks of" exact="encephalitis" post="and HFMD (Han et al., 2012; Chen et al.,"/>
   <result pre="1999b; Palacios et al., 2002). There were several reports of" exact="encephalitis" post="caused by E-30 worldwide (Wang et al., 2002; Cabrerizo"/>
   <result pre="2019; Sousa et al., 2019). In 2001, an outbreak of" exact="encephalitis" post="occurred in Taiwan, China. One thousand one hundred thirty"/>
   <result pre="In Jiangsu Province of China in 2003, 1,681 patients with" exact="encephalitis" post="were reported, and E-30 was confirmed as the etiologic"/>
   <result pre="of China, showing that E-30 was a major pathogen in" exact="encephalitis" post="patients (Tao et al., 2014). The outbreaks of E-30,"/>
   <result pre="we have described a large-scale outbreak of E-30 associated with" exact="viral meningitis," post="fever, headache, nausea, and vomiting symptoms, which led to"/>
   <result pre="of E-30 in China. This is the first report about" exact="encephalitis" post="caused by E-30 in the northwest region of China."/>
   <result pre="of their clinical samples. Patients were classified as having viral" exact="encephalitis" post="infection in Gansu province between June 27 and August"/>
   <result pre="total of 95 patients met the clinical diagnostic criteria of" exact="encephalitis" post="according to their clinical manifestations (Table 1). The representative"/>
   <result pre="(Figure 1). We have excluded the common infections of Japanese" exact="encephalitis" post="virus, adenovirus, mumps virus, and human herpesvirus hominis using"/>
   <result pre="have excluded the common infections of Japanese encephalitis virus, adenovirus," exact="mumps" post="virus, and human herpesvirus hominis using ELISA immunoglobulin M"/>
   <result pre="demographic characteristics of probable cases and laboratory-confirmed cases from the" exact="encephalitis" post="outbreak in Gansu, 2015. Probable cases Laboratory-confirmed cases Age"/>
   <result pre="standard procedures described before and were then inoculated into human" exact="rhabdomyosarcoma" post="(RD) cells and human laryngeal epidermoid carcinoma (HEp-2) cells,"/>
   <result pre="Clinical Characteristics of Large-Scale Outbreak Associated With E-30 A large-scale" exact="encephalitis" post="outbreak caused by E-30 was confirmed through clinical characteristics,"/>
   <result pre="(9/15) towns of this prefecture were attacked by the large-scale" exact="infectious disease" post="outbreak. Among the laboratory-confirmed cases (n 50), the male"/>
   <result pre="TABLE 2 Genome detection and viral isolation results of the" exact="encephalitis" post="outbreak in Gansu Province, 2015. Species Numbers Positive number"/>
   <result pre="E-30 strains isolated from the mainland of China, including the" exact="encephalitis" post="outbreak isolates of this study (Figure 4A, colored in"/>
   <result pre="16.6% detection ratios of E-30 in 1130 enterovirus-infected patients with" exact="encephalitis" post="(Wang et al., 2002). The E-30 strains isolated from"/>
   <result pre="of the prefecture of Gansu Province and caused a severe" exact="infectious disease" post="transmission. The Nancha town of Gansu Province has the"/>
   <result pre="formed in China, which have played an causal role in" exact="encephalitis" post="outbreaks (Wang et al., 2002; Zhao et al., 2005;"/>
   <result pre="in many provinces of China, evolved rapidly and caused several" exact="encephalitis" post="outbreaks. For example, 1,681 encephalitis patients were reported in"/>
   <result pre="evolved rapidly and caused several encephalitis outbreaks. For example, 1,681" exact="encephalitis" post="patients were reported in Jiangsu Province in 2003, and"/>
   <result pre="2005). It was also reported as a major pathogen of" exact="encephalitis" post="cases in Shandong Province of China between 2006 and"/>
   <result pre="which hinders the formulation of countermeasures for E-30 associated with" exact="encephalitis" post="outbreaks. The basic research efforts and current surveillance should"/>
   <result pre="T.ThanhT. T.HangV. T. T.et al. (2018). Emerging coxsackievirus A6 causing" exact="hand, foot and mouth disease," post="vietnam.Emerg. Infect. Dis.24654–662.29553326 BaeleG.LemeyP.BedfordT.RambautA.SuchardM. A.AlekseyenkoA. V. (2012). Improving the"/>
   <result pre="T.et al. (2018). Emerging coxsackievirus A6 causing hand, foot and" exact="mouth disease," post="vietnam.Emerg. Infect. Dis.24654–662.29553326 BaeleG.LemeyP.BedfordT.RambautA.SuchardM. A.AlekseyenkoA. V. (2012). Improving the"/>
   <result pre="epidemiological study of HEV-B enteroviruses involved in the increase in" exact="meningitis" post="cases occurred in Spain during 2006.J. Med. Virol.801018–1024. 10.1002/jmv.2119718428125"/>
   <result pre="(2018). Analysis of enterovirus types in patients with symptoms of" exact="aseptic meningitis" post="in 2014 in Shandong, China.Virology516196–201. 10.1016/j.virol.2018.01.02229407377 ChenP.TaoZ.SongY.LiuG.WangH.LiuY.et al. (2013)."/>
   <result pre="Analysis of enterovirus types in patients with symptoms of aseptic" exact="meningitis" post="in 2014 in Shandong, China.Virology516196–201. 10.1016/j.virol.2018.01.02229407377 ChenP.TaoZ.SongY.LiuG.WangH.LiuY.et al. (2013)."/>
   <result pre="in Shandong, China.Virology516196–201. 10.1016/j.virol.2018.01.02229407377 ChenP.TaoZ.SongY.LiuG.WangH.LiuY.et al. (2013). A coxsackievirus B5-associated" exact="aseptic meningitis" post="outbreak in Shandong province, China in 2009.J. Med. Virol.85483–489."/>
   <result pre="Shandong, China.Virology516196–201. 10.1016/j.virol.2018.01.02229407377 ChenP.TaoZ.SongY.LiuG.WangH.LiuY.et al. (2013). A coxsackievirus B5-associated aseptic" exact="meningitis" post="outbreak in Shandong province, China in 2009.J. Med. Virol.85483–489."/>
   <result pre="SilvaE. E. (2011). Genetic diversity of Echovirus 30 involved in" exact="aseptic meningitis" post="cases in Brazil (1998-2008).J. Med. Virol.832164–2171. 10.1002/jmv.2223522012725 DrummondA. J.SuchardM."/>
   <result pre="E. (2011). Genetic diversity of Echovirus 30 involved in aseptic" exact="meningitis" post="cases in Brazil (1998-2008).J. Med. Virol.832164–2171. 10.1002/jmv.2223522012725 DrummondA. J.SuchardM."/>
   <result pre="GeogheganJ. L.Tan LeV.KuhnertD.HalpinR. A.LinX.SimenauerA.et al. (2015). Phylodynamics of enterovirus A71-associated" exact="hand, foot, and mouth disease" post="in viet nam.J. Virol.898871–8879.26085170 HanJ. F.JiangT.FanX. L.YangL. M.YuM.CaoR. Y.et"/>
   <result pre="A.LinX.SimenauerA.et al. (2015). Phylodynamics of enterovirus A71-associated hand, foot, and" exact="mouth disease" post="in viet nam.J. Virol.898871–8879.26085170 HanJ. F.JiangT.FanX. L.YangL. M.YuM.CaoR. Y.et"/>
   <result pre="M.YuM.CaoR. Y.et al. (2012). Recombination of human coxsackievirus B5 in" exact="hand, foot, and mouth disease" post="patients, China.Emerg. Infect. Dis.18351–353. 10.3201/eid1802.11152422305307 HanZ.ZhangY.HuangK.CuiH.HongM.TangH.et al. (2018). Genetic"/>
   <result pre="(2012). Recombination of human coxsackievirus B5 in hand, foot, and" exact="mouth disease" post="patients, China.Emerg. Infect. Dis.18351–353. 10.3201/eid1802.11152422305307 HanZ.ZhangY.HuangK.CuiH.HongM.TangH.et al. (2018). Genetic"/>
   <result pre="Infect.7:193. HanZ.ZhangY.HuangK.WangJ.TianH.SongY.et al. (2019). Two Coxsackievirus B3 outbreaks associated with" exact="hand, foot, and mouth disease" post="in China and the evolutionary history worldwide.BMC Infect. Dis.19:466."/>
   <result pre="(2019). Two Coxsackievirus B3 outbreaks associated with hand, foot, and" exact="mouth disease" post="in China and the evolutionary history worldwide.BMC Infect. Dis.19:466."/>
   <result pre="Predominance of enterovirus B and echovirus 30 as cause of" exact="viral meningitis" post="in a UK population.J. Clin. Virol.8190–93. 10.1016/j.jcv.2016.06.00727367546 HuangJ.LiaoQ.OoiM. H.CowlingB."/>
   <result pre="of enterovirus B and echovirus 30 as cause of viral" exact="meningitis" post="in a UK population.J. Clin. Virol.8190–93. 10.1016/j.jcv.2016.06.00727367546 HuangJ.LiaoQ.OoiM. H.CowlingB."/>
   <result pre="Virol.8190–93. 10.1016/j.jcv.2016.06.00727367546 HuangJ.LiaoQ.OoiM. H.CowlingB. J.ChangZ.WuP.et al. (2018). Epidemiology of recurrent" exact="hand, foot and mouth disease," post="China, 2008-2015.Emerg. Infect. Dis.24432–442. KimH. J.KangB.HwangS.HongJ.KimK.CheonD. S. (2012). Epidemics"/>
   <result pre="H.CowlingB. J.ChangZ.WuP.et al. (2018). Epidemiology of recurrent hand, foot and" exact="mouth disease," post="China, 2008-2015.Emerg. Infect. Dis.24432–442. KimH. J.KangB.HwangS.HongJ.KimK.CheonD. S. (2012). Epidemics"/>
   <result pre="China, 2008-2015.Emerg. Infect. Dis.24432–442. KimH. J.KangB.HwangS.HongJ.KimK.CheonD. S. (2012). Epidemics of" exact="viral meningitis" post="caused by echovirus 6 and 30 in Korea in"/>
   <result pre="2008-2015.Emerg. Infect. Dis.24432–442. KimH. J.KangB.HwangS.HongJ.KimK.CheonD. S. (2012). Epidemics of viral" exact="meningitis" post="caused by echovirus 6 and 30 in Korea in"/>
   <result pre="Q.YuW. Z.WenN.YanD. M.et al. (2013). Identification and control of a" exact="poliomyelitis" post="outbreak in Xinjiang, China.N. Engl. J. Med.3691981–1990.24256377 MaruoY.NakanishiM.SuzukiY.KaneshiY.TerashitaY.NarugamiM.et al."/>
   <result pre="Xinjiang, China.N. Engl. J. Med.3691981–1990.24256377 MaruoY.NakanishiM.SuzukiY.KaneshiY.TerashitaY.NarugamiM.et al. (2019). Outbreak of" exact="aseptic meningitis" post="caused by echovirus 30 in Kushiro, Japan in 2017.J."/>
   <result pre="China.N. Engl. J. Med.3691981–1990.24256377 MaruoY.NakanishiM.SuzukiY.KaneshiY.TerashitaY.NarugamiM.et al. (2019). Outbreak of aseptic" exact="meningitis" post="caused by echovirus 30 in Kushiro, Japan in 2017.J."/>
   <result pre="71.J. Virol.862676–2685. 10.1128/jvi.06065-1122205739 MiliaM. G.CeruttiF.GregoriG.BurdinoE.AlliceT.RuggieroT.et al. (2013). Recent outbreak of" exact="aseptic meningitis" post="in Italy due to Echovirus 30 and phylogenetic relationship"/>
   <result pre="Virol.862676–2685. 10.1128/jvi.06065-1122205739 MiliaM. G.CeruttiF.GregoriG.BurdinoE.AlliceT.RuggieroT.et al. (2013). Recent outbreak of aseptic" exact="meningitis" post="in Italy due to Echovirus 30 and phylogenetic relationship"/>
   <result pre="1998 and 2003.J. Clin. Microbiol.436171–6175. 10.1128/jcm.43.12.6171-6175.200516333123 MladenovaZ.ButtinelliG.DikovaA.StoyanovaA.TroyanchevaM.KomitovaR.et al. (2014). Aseptic" exact="meningitis" post="outbreak caused by echovirus 30 in two regions in"/>
   <result pre="echovirus 6 and 30 with coxsackievirus A6 among children with" exact="hand, foot, and mouth disease" post="in Ahvaz, Southwest Iran.Arch. Clin. Infect. Dis.14:e83522. RieuxA.KhatchikianC. E."/>
   <result pre="30 with coxsackievirus A6 among children with hand, foot, and" exact="mouth disease" post="in Ahvaz, Southwest Iran.Arch. Clin. Infect. Dis.14:e83522. RieuxA.KhatchikianC. E."/>
   <result pre="TaoZ.WangH.LiY.LiuG.XuA.LinX.et al. (2014). Molecular epidemiology of human enterovirus associated with" exact="aseptic meningitis" post="in shandong province, China, 2006-2012.PLoS One9:e89766. 10.1371/journal.pone.008976624587020 TapparelC.SiegristF.PettyT. J.KaiserL."/>
   <result pre="al. (2014). Molecular epidemiology of human enterovirus associated with aseptic" exact="meningitis" post="in shandong province, China, 2006-2012.PLoS One9:e89766. 10.1371/journal.pone.008976624587020 TapparelC.SiegristF.PettyT. J.KaiserL."/>
   <result pre="diagnosis and genetic analysis of an echovirus 30-associated outbreak of" exact="aseptic meningitis" post="in Taiwan in 2001.J. Clin. Microbiol.404439–4444. 10.1128/jcm.40.12.4439-4444.200212454133 WieczorekM.KrzysztoszekA.FigasA. (2016)."/>
   <result pre="and genetic analysis of an echovirus 30-associated outbreak of aseptic" exact="meningitis" post="in Taiwan in 2001.J. Clin. Microbiol.404439–4444. 10.1128/jcm.40.12.4439-4444.200212454133 WieczorekM.KrzysztoszekA.FigasA. (2016)."/>
   <result pre="10.1007/s11262-016-1310-526957092 WuZ.DuJ.ZhangT.XueY.YangF.JinQ. (2013). Recombinant human coxsackievirus B3 from children with" exact="acute myocarditis" post="in China.J. Clin. Microbiol.513083–3086. 10.1128/jcm.00270-1323804378 XingW.LiaoQ.ViboudC.ZhangJ.SunJ.WuJ. T.et al. (2014)."/>
   <result pre="WuZ.DuJ.ZhangT.XueY.YangF.JinQ. (2013). Recombinant human coxsackievirus B3 from children with acute" exact="myocarditis" post="in China.J. Clin. Microbiol.513083–3086. 10.1128/jcm.00270-1323804378 XingW.LiaoQ.ViboudC.ZhangJ.SunJ.WuJ. T.et al. (2014)."/>
   <result pre="Clin. Microbiol.513083–3086. 10.1128/jcm.00270-1323804378 XingW.LiaoQ.ViboudC.ZhangJ.SunJ.WuJ. T.et al. (2014). Hand, foot, and" exact="mouth disease" post="in China, 2008-12: an epidemiological study.Lancet Infect. Dis.14308–318.24485991 YanD.LiL.ZhuS.ZhangY.AnJ.WangD.et"/>
   <result pre="of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated" exact="hand, foot, and mouth disease" post="in China.J. Clin. Microbiol.48619–622. 10.1128/jcm.02338-0920018819 ZhangY.YanD.ZhuS.WenN.LiL.WangH.et al. (2010b). Type"/>
   <result pre="and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and" exact="mouth disease" post="in China.J. Clin. Microbiol.48619–622. 10.1128/jcm.02338-0920018819 ZhangY.YanD.ZhuS.WenN.LiL.WangH.et al. (2010b). Type"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7302680\results\search\disease\results.xml">
   <result pre="Abstract Abstract To observe the efficacy of telbivudine in chronic" exact="hepatitis" post="B (CHB) women with high viral load during pregnancy"/>
   <result pre="to principle of informed consent. All infants received injection of" exact="hepatitis" post="B immune globulin (HBIG; 200 IU) and were vaccinated"/>
   <result pre="efficacy and safety mother-neonatal transmission pregnancy telbivudine 1 Introduction Chronic" exact="hepatitis" post="B virus (CHB) infection remains to be a global"/>
   <result pre="a major contributor to HBV epidemics.[6,7] The combination of both" exact="hepatitis" post="B immunoglobulin (HBIg) and HBV vaccine in newborn was"/>
   <result pre="patients had HBV DNA levels great than 107 IU/mL. Coinfection with" exact="hepatitis" post="C virus, hepatitis D virus, hepatitis A virus, hepatitis"/>
   <result pre="DNA levels great than 107 IU/mL. Coinfection with hepatitis C virus," exact="hepatitis" post="D virus, hepatitis A virus, hepatitis E virus, human"/>
   <result pre="than 107 IU/mL. Coinfection with hepatitis C virus, hepatitis D virus," exact="hepatitis" post="A virus, hepatitis E virus, human immunodeficiency virus, concurrently"/>
   <result pre="with hepatitis C virus, hepatitis D virus, hepatitis A virus," exact="hepatitis" post="E virus, human immunodeficiency virus, concurrently being confirmed with"/>
   <result pre="being confirmed with other liver diseases (drug-induced hepatitis, nonalcoholic steatohepatitis," exact="autoimmune hepatitis," post="ntrahepatic cholestasis of pregnancy, etc.) or having signs of"/>
   <result pre="other liver diseases (drug-induced hepatitis, nonalcoholic steatohepatitis, autoimmune hepatitis, ntrahepatic" exact="cholestasis" post="of pregnancy, etc.) or having signs of fetal dysplasia"/>
   <result pre="hao, lin zhou. Abbreviations: ADV = adefovir, CHB = chronic" exact="hepatitis" post="B, CI = confidence interval, ETV = entecavir, HBsAg"/>
   <result pre="B, CI = confidence interval, ETV = entecavir, HBsAg =" exact="hepatitis" post="B surface antigen, HBV DNA = hepatitis B virus"/>
   <result pre="entecavir, HBsAg = hepatitis B surface antigen, HBV DNA =" exact="hepatitis" post="B virus deoxyribonucleic acid, LAM = lamivudine, PCR ="/>
   <result pre="al.Effect of nucleos(t)ide analogue on serum HBsAg level in chronic" exact="hepatitis" post="B patients: a 3-years study. Biomed Pharmacother2020;122:109698.31918272 [2]ZhengCYanHZengJet al.Comparison"/>
   <result pre="pegylated interferon plus tenofovir combination therapy in patients with chronic" exact="hepatitis" post="B. Infect Drug Resist2019;12:845–54.31114265 [3]SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines"/>
   <result pre="Resist2019;12:845–54.31114265 [3]SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines on the management of" exact="hepatitis" post="B: a 2015 update. Hepatol Int2016;10:1–98. [4]collab: European Association"/>
   <result pre="Liver. EASL 2017 Clinical Practice Guidelines on the management of" exact="hepatitis" post="B virus infection. J Hepatol2017;67:370–98.28427875 [5]AnaedobeCGFowotadeAOmoruyiCEet al.Prevalence, sociodemographic features"/>
   <result pre="Med J2015;20:406.26301010 [6]GoyalAMurrayJMThe impact of vaccination and antiviral therapy on" exact="hepatitis" post="B and hepatitis D epidemiology. PLos One2014;9:e110143.25313681 [7]YiWLiMHXieYet al.Prospective"/>
   <result pre="impact of vaccination and antiviral therapy on hepatitis B and" exact="hepatitis" post="D epidemiology. PLos One2014;9:e110143.25313681 [7]YiWLiMHXieYet al.Prospective cohort study on"/>
   <result pre="of telbivudine used throughout pregnancy in blocking mother-to-child transmission of" exact="hepatitis" post="B virus. J Viral Hepat2017;24: suppl 1: 49–56.29082650 [8]LiJChangMSTranTTet"/>
   <result pre="infected mothers-Guam, 2014. J Pediatric Infect Dis Soc2018;7:290–5.28992071 [10]LimSSLiaoHTTsaiCYTelbivudine associated" exact="mitochondrial myopathy." post="Liver Int2018;38:1139.29570939 [11]ZhangHPanCQPangQet al.Telbivudine or lamivudine use in late"/>
   <result pre="lamivudine use in late pregnancy safely reduces perinatal transmission of" exact="hepatitis" post="B virus in real-life practice. Hepatology2014;60:468–76.25187919 [12]HuYXuCXuBet al.Safety and"/>
   <result pre="of telbivudine in late pregnancy to prevent mother-to-child transmission of" exact="hepatitis" post="B virus: a multicenter prospective cohort study. J Viral"/>
   <result pre="telbivudine in pregnancy for the prevention of perinatal transmission of" exact="hepatitis" post="B virus infection. J Hepatol2011;55:1215–21.21703206 [16]HanGRJiangHXYueXet al.Efficacy and safety"/>
   <result pre="in pregnant women for the prevention of perinatal transmission of" exact="hepatitis" post="B virus infection. J Viral Hepat2015;22:754–62.25641421 [17]WuQHuangHSunXet al.Telbivudine prevents"/>
   <result pre="infection. J Viral Hepat2015;22:754–62.25641421 [17]WuQHuangHSunXet al.Telbivudine prevents vertical transmission of" exact="hepatitis" post="B virus from women with high viral loads: a"/>
   <result pre="prospective long-term study. Clin Gastroenterol Hepatol2015;13:1170–6.25251571 [18]TanZYinYZhouJet al.Telbivudine treatment of" exact="hepatitis" post="B virus-infected pregnant women at different gestational stages for"/>
   <result pre="treatment during pregnancy. Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in chronic" exact="hepatitis" post="B viral infection during pregnancy: a systematic review and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7302871\results\search\disease\results.xml">
   <result pre="enterica serotype Typhimurium (S. Typhimurium) is a leading cause of" exact="gastroenteritis" post="and bacteraemia worldwide, and a model organism for the"/>
   <result pre="of foodborne disease. Most of the approximately 2500 serovars cause" exact="gastroenteritis" post="in humans and other animals, while some have evolved"/>
   <result pre="an estimated 75 million cases and 27 thousand deaths from" exact="gastroenteritis" post="worldwide [2]. S. Typhi and S. Paratyphi A circulate"/>
   <result pre="serotype, has a broad host range and is associated with" exact="gastroenteritis" post="in the human population. Such broad host range strains"/>
   <result pre="ducks, pigeon, and passerine birds, respectively, and only rarely cause" exact="gastroenteritis" post="in the human population [11–13]. Also, specific clonal groups"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7302872\results\search\disease\results.xml">
   <result pre="Cell Biology : Cellular Structures and Organelles: Lysosomes Virus subtype-specific" exact="suppression" post="of MAVS aggregation and activation by PB1-F2 protein of"/>
   <result pre="suppression of MAVS aggregation and activation by PB1-F2 protein of" exact="influenza" post="A (H7N9) virus H7N9 PB1-F2 suppresses MAVS aggregation http://orcid.org/0000-0003-3682-7571CheungPak-Hin"/>
   <result pre="original author and source are credited.ppat.1008611.pdf Abstract Human infection with" exact="avian influenza" post="A (H5N1) and (H7N9) viruses causes severe respiratory diseases."/>
   <result pre="author and source are credited.ppat.1008611.pdf Abstract Human infection with avian" exact="influenza" post="A (H5N1) and (H7N9) viruses causes severe respiratory diseases."/>
   <result pre="findings reveal a subtype-specific mechanism for destabilization of MAVS and" exact="suppression" post="of interferon response by PB1-F2 of H7N9 virus. Author"/>
   <result pre="response by PB1-F2 of H7N9 virus. Author summary Exactly why" exact="avian influenza" post="A (H5N1) and (H7N9) viruses cause severe diseases in"/>
   <result pre="by PB1-F2 of H7N9 virus. Author summary Exactly why avian" exact="influenza" post="A (H5N1) and (H7N9) viruses cause severe diseases in"/>
   <result pre="severe diseases in humans remains unclear. PB1-F2 protein encoded by" exact="influenza" post="A virus is one virulence factor that might make"/>
   <result pre="PB1-F2 protein of H7N9 virus is particularly strong in the" exact="suppression" post="of host antiviral defense. This was achieved by inhibiting"/>
   <result pre="prevents MAVS aggregation and promotes MAVS degradation, leading to the" exact="suppression" post="of host antiviral defense. Funding http://dx.doi.org/10.13039/501100005847Health and Medical Research"/>
   <result pre="within the manuscript and its Supporting Information files. Introduction Avian" exact="influenza" post="A (H5N1) and (H7N9) viruses occasionally cross species barrier"/>
   <result pre="viruses occasionally cross species barrier to infect humans, causing severe" exact="respiratory disease" post="and posing pandemic threats. In 1997, human infection with"/>
   <result pre="caused 6 deaths out of 18 infected individuals presented with" exact="viral pneumonia," post="acute respiratory distress syndrome and multiple organ failure [1,"/>
   <result pre="deaths out of 18 infected individuals presented with viral pneumonia," exact="acute respiratory distress syndrome" post="and multiple organ failure [1, 2]. Since then, H5N1"/>
   <result pre="protein named PB1-F2 is one of the virulence factors of" exact="influenza" post="A virus [10]. It is expressed from the largest"/>
   <result pre="and compete with HAX-1, an inhibitor of PA subunit of" exact="influenza" post="A virus RNA polymerase [14, 15]. More importantly, PB1-F2"/>
   <result pre="[14, 15]. More importantly, PB1-F2 suppresses innate immunity and this" exact="suppression" post="correlates with viral pathogenicity. PB1-F2 with an S66 residue"/>
   <result pre="of host antiviral response against H7N9 virus. This virus subtype-specific" exact="suppression" post="of MAVS aggregation and type I IFN production by"/>
   <result pre="H5N1 viruses are known to be more virulent than human" exact="influenza" post="viruses including the WSN laboratory strain [28]. When we"/>
   <result pre="of RIG-IN, a dominant active version of RIG-I [46], the" exact="suppression" post="of RIG-IN activity by H5N1 PB1-F2 and H7N9 PB1-F2"/>
   <result pre="bars 4 and 5 vs 2). The specificity of this" exact="suppression" post="on RIG-I signaling was verified since PB1-F2 from any"/>
   <result pre="an N66S mutation was introduced to H7N9 PB1-F2. Surprisingly, the" exact="suppression" post="of Sendai virus- or MAVS-induced activation of IFNβ promoter"/>
   <result pre="S66-independent mechanism. H7N9 PB1-F2 suppresses type I IFN production during" exact="influenza" post="A virus infection To monitor if PB1-F2 has an"/>
   <result pre="PB1-F2 has an impact on type I IFN response during" exact="influenza" post="A virus infection, recombinant viruses H7-2 wild type (WT)"/>
   <result pre="at 24 hpi (Fig 4C). This was compatible with the" exact="suppression" post="of IFNβ expression by H7N9 PB1-F2 in infected A549"/>
   <result pre="IFN response by H7N9 PB1-F2 in cells infected with recombinant" exact="influenza" post="A virus. (A) Schematic representation of the genotypes of"/>
   <result pre="for 6 and 16 hours could not fully rescue the" exact="suppression" post="of MAVS protein expression by H7N9 PB1-F2 (Fig 6A,"/>
   <result pre="to H7N9 PB1-F2, WSN PB1-F2 was much weaker in the" exact="suppression" post="of MAVS-TRAF6, MAVS-TBK1 and MAVS-IKKε interaction (Fig 8A–8D). These"/>
   <result pre="H7N9 virus prevents aggregation and activation of MAVS leading to" exact="suppression" post="of innate immune response. H7N9 PB1-F2 had unique properties"/>
   <result pre="Our findings highlight the importance of PB1-F2 in pathogenicity of" exact="avian influenza" post="A viruses H7N9 and H5N1. We demonstrated the aggregation-prone"/>
   <result pre="findings highlight the importance of PB1-F2 in pathogenicity of avian" exact="influenza" post="A viruses H7N9 and H5N1. We demonstrated the aggregation-prone"/>
   <result pre="and how the aggregation of H7N9 PB1-F2 might control its" exact="suppression" post="of MAVS aggregation and activation merit further investigations. MAVS"/>
   <result pre="phosphotidyethanolamine [79]. Here we showed that viral protein PB1-F2 of" exact="avian influenza" post="virus H7N9 formed protein aggregates on mitochondria, perturbed TRIM31-MAVS"/>
   <result pre="[79]. Here we showed that viral protein PB1-F2 of avian" exact="influenza" post="virus H7N9 formed protein aggregates on mitochondria, perturbed TRIM31-MAVS"/>
   <result pre="destabilize MAVS (Fig 5G and 5I). Thus, the two pathogenic" exact="avian influenza" post="viruses share a similar MAVS-destabilizing property. It will be"/>
   <result pre="MAVS (Fig 5G and 5I). Thus, the two pathogenic avian" exact="influenza" post="viruses share a similar MAVS-destabilizing property. It will be"/>
   <result pre="such as TNFα (Fig 4B and 4C). This suggests that" exact="suppression" post="of MAVS-mediated antiviral signaling by H7N9 PB1-F2 might exert"/>
   <result pre="effect on RNA-induced interleukin 1β maturation and secretion [83]. Recombinant" exact="influenza" post="A viruses deficient of another IFN antagonist NS1 have"/>
   <result pre="cells has recently been reported for making optimal live attenuated" exact="influenza" post="vaccines [86]. Although the elevation of the type I"/>
   <result pre="I.M.A.G.E. clone 3846513 into pCMV-Tag3B vector. Eight-plasmid system for recombinant" exact="influenza" post="A virus based on pHW2000 vector have been described"/>
   <result pre="Viruses Sendai virus (VR-907) was purchased from ATCC. For recombinant" exact="influenza" post="A viruses H7-2 WT and H7-2 ΔF, 8-plasmid reverse"/>
   <result pre="features and rapid viral diagnosis of human disease associated with" exact="avian influenza" post="A H5N1 virus. Lancet. 1998;351: 467–471. 10.1016/s0140-6736(98)01182-99482437 2ToKK, NgKH,"/>
   <result pre="and rapid viral diagnosis of human disease associated with avian" exact="influenza" post="A H5N1 virus. Lancet. 1998;351: 467–471. 10.1016/s0140-6736(98)01182-99482437 2ToKK, NgKH,"/>
   <result pre="467–471. 10.1016/s0140-6736(98)01182-99482437 2ToKK, NgKH, QueTL, ChanJM, TsangKY, TsangAK, et al.Avian" exact="influenza" post="A H5N1 virus: a continuous threat to humans. Emerg"/>
   <result pre="3LaiS, QinY, CowlingBJ, RenX, WardropNA, GilbertM, et al.Global epidemiology of" exact="avian influenza" post="A H5N1 virus infection in humans, 1997–2015: a systematic"/>
   <result pre="QinY, CowlingBJ, RenX, WardropNA, GilbertM, et al.Global epidemiology of avian" exact="influenza" post="A H5N1 virus infection in humans, 1997–2015: a systematic"/>
   <result pre="FengZ, WangD, HuW, et al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virus.N Engl J Med. 2013;368: 1888–1897. 10.1056/NEJMoa130445923577628"/>
   <result pre="DuB, ShangH, GanJH, et al.Clinical findings in 111 cases of" exact="influenza" post="A (H7N9) virus infection.N Engl J Med. 2013;368: 2277–2285."/>
   <result pre="CuiJ, GaoGF, ZhouJ, et al.Epidemiology, evolution, and pathogenesis of H7N9" exact="influenza" post="viruses in five epidemic waves since 2013 in China.Trends"/>
   <result pre="WuS, et al.Clusters of human infection and human-to-human transmission of" exact="avian influenza" post="A(H7N9) virus, 2013–2017.Emerging Infect Dis.2018; 24: 397–400. 8ImaiM, WatanabeT,"/>
   <result pre="et al.Clusters of human infection and human-to-human transmission of avian" exact="influenza" post="A(H7N9) virus, 2013–2017.Emerging Infect Dis.2018; 24: 397–400. 8ImaiM, WatanabeT,"/>
   <result pre="WatanabeT, KisoM, NakajimaN, YamayoshiS, Iwatsuki-HorimotoK, et al.Highly pathogenic avian H7N9" exact="influenza" post="virus isolated from a human is lethal in some"/>
   <result pre="Microbe. 2017;22: 615–626.e618. 10.1016/j.chom.2017.09.00829056430 9KoutsakosM, KedzierskaK, SubbaraoK. Immune responses to" exact="avian influenza" post="viruses. J Immunol. 2019;202: 382–391. 10.4049/jimmunol.180107030617120 10ZamarinD, OrtigozaMB, PaleseP."/>
   <result pre="2017;22: 615–626.e618. 10.1016/j.chom.2017.09.00829056430 9KoutsakosM, KedzierskaK, SubbaraoK. Immune responses to avian" exact="influenza" post="viruses. J Immunol. 2019;202: 382–391. 10.4049/jimmunol.180107030617120 10ZamarinD, OrtigozaMB, PaleseP."/>
   <result pre="and its multifunctional role in enhancing the pathogenicity of the" exact="influenza" post="A viruses. Virology. 2013;440: 97–104. 10.1016/j.virol.2013.02.02523545143 12KamalRP, AlymovaIV, YorkIA."/>
   <result pre="2013;440: 97–104. 10.1016/j.virol.2013.02.02523545143 12KamalRP, AlymovaIV, YorkIA. Evolution and virulence of" exact="influenza" post="A virus protein PB1-F2.Int J Mol Sci.2017; 19: E9610.3390/ijms1901009629286299"/>
   <result pre="E9610.3390/ijms1901009629286299 13ChenW, CalvoPA, MalideD, GibbsJ, SchubertU, BacikI, et al.A novel" exact="influenza" post="A virus mitochondrial protein that induces cell death. Nat"/>
   <result pre="HeG, CardonaC.J, SongY, XingZ. Critical Role of HAX-1 in promoting" exact="avian influenza" post="virus replication in lung epithelial cells. Mediators Inflamm. 2018;2018:"/>
   <result pre="CardonaC.J, SongY, XingZ. Critical Role of HAX-1 in promoting avian" exact="influenza" post="virus replication in lung epithelial cells. Mediators Inflamm. 2018;2018:"/>
   <result pre="Mediators Inflamm. 2018;2018: 12. 15Mazel-SanchezB, Boal-CarvalhoI, SilvaF, DijkmanR, SchmolkeM. H5N1" exact="influenza" post="A virus PB1-F2 relieves HAX-1-mediated restriction of avian virus"/>
   <result pre="single mutation in the PB1-F2 of H5N1 (HK/97) and 1918" exact="influenza" post="A viruses contributes to increased virulence.PLoS Pathog. 2017;3: 1414–1421."/>
   <result pre="KatzeMG. A single N66S mutation in the PB1-F2 protein of" exact="influenza" post="A virus increases virulence by inhibiting the early interferon"/>
   <result pre="2011;85: 652–662. 10.1128/JVI.01987-1021084483 18VargaZT, RamosIHaiR, SchmolkeM, Garcia-SastreA, Fernandez-SesmaA, et al.The" exact="influenza" post="virus protein PB1-F2 inhibits the induction of type I"/>
   <result pre="Comprehensive global amino acid sequence analysis of PB1F2 protein of" exact="influenza" post="A H5N1 viruses and the influenza A virus subtypes"/>
   <result pre="of PB1F2 protein of influenza A H5N1 viruses and the" exact="influenza" post="A virus subtypes responsible for the 20th-century pandemics.Influenza Other"/>
   <result pre="al.Epidemiological and molecular characteristics of the PB1-F2 proteins in H7N9" exact="influenza" post="viruses, Jiangsu.Biomed Res Int. 2015;2015: 80473110.1155/2015/80473125649785 24ChevalierC, Al BazzalA,"/>
   <result pre="80473110.1155/2015/80473125649785 24ChevalierC, Al BazzalA, VidicJ, FevrierV, BourdieuC, BouguyonE, et al.PB1-F2" exact="influenza" post="A virus protein adopts a beta-sheet conformation and forms"/>
   <result pre="GofficR, Korri-YoussoufiH, ChevalierC. Electrochemical detection of the oligomerization of PB1-F2" exact="influenza" post="A virus protein in infected cells. Anal Chem. 2014;86:"/>
   <result pre="PéchouxC, Da CostaB, BerthoN, MazeratS, DelmasB, ChevalierC. Amyloid Assemblies of" exact="influenza" post="A virus PB1-F2 protein damage membrane and induce cytotoxicity."/>
   <result pre="deep UV fluorescent microspectroscopy study of PB1-F2 β-aggregated structures in" exact="influenza" post="A virus-infected cells. J Biol Chem. 2016;291: 9060–9072. 10.1074/jbc.M115.71053326896002"/>
   <result pre="Chem. 2016;291: 9060–9072. 10.1074/jbc.M115.71053326896002 28RadiganKA, MisharinAV, ChiM, BudingerGS. Modeling human" exact="influenza" post="infection in the laboratory.Infect Drug Resist. 2015;8: 311–320. 10.2147/IDR.S5855126357484"/>
   <result pre="36YamadaH, ChounanR, HigashiY, KuriharaN, KidoH. Mitochondrial targeting sequence of the" exact="influenza" post="A virus PB1-F2 protein and its function in mitochondria."/>
   <result pre="Lett. 2004;578: 331–336. 10.1016/j.febslet.2004.11.01715589841 37GibbsJS, MalideD, HornungF, BenninkJR, YewdellJW. The" exact="influenza" post="A virus PB1-F2 protein targets the inner mitochondrial membrane"/>
   <result pre="PráznovskáM, KošíkováM, BobišováZ, HollýJ, Vare�?kováE, et al.The ubiquitination of the" exact="influenza" post="A virus PB1-F2 protein is crucial for its biological"/>
   <result pre="RossC, IqbalM, GoodbournS, DigardP, BarclayWS, SheltonH. The cellular localization of" exact="avian influenza" post="virus PB1-F2 protein alters the magnitude of IFN2 promoter"/>
   <result pre="IqbalM, GoodbournS, DigardP, BarclayWS, SheltonH. The cellular localization of avian" exact="influenza" post="virus PB1-F2 protein alters the magnitude of IFN2 promoter"/>
   <result pre="contribution of PB1-F2 to the virulence of highly pathogenic H5N1" exact="influenza" post="A virus in mammalian and avian species.PLoS Pathog. 2011;7:"/>
   <result pre="localization and function of PB1-F2 derived from different strains of" exact="influenza" post="A virus. J Virol. 2010;84: 10051–10062. 10.1128/JVI.00592-1020660199 81ToKKW, LauCCY,"/>
   <result pre="JossetL, TchitchekN, ChangJ, BelserJA, SwayneDE, et al.H7N9 and other pathogenic" exact="avian influenza" post="viruses elicit a three-pronged transcriptomic signature that is reminiscent"/>
   <result pre="TchitchekN, ChangJ, BelserJA, SwayneDE, et al.H7N9 and other pathogenic avian" exact="influenza" post="viruses elicit a three-pronged transcriptomic signature that is reminiscent"/>
   <result pre="elicit a three-pronged transcriptomic signature that is reminiscent of 1918" exact="influenza" post="virus and is associated with lethal outcome in mice."/>
   <result pre="YeZ, LeeTWT, ChenH, ChanCP, JinDY. PB1-F2 protein of highly pathogenic" exact="influenza" post="A (H7N9) virus selectively suppresses RNA-induced NLRP3 inflammasome activation"/>
   <result pre="86WangP, ZhengM, LauSY, ChenP, MokBW, LiuS, et al.Generation of DelNS1" exact="influenza" post="viruses: a strategy for optimizing live attenuated influenza vaccines.mBio."/>
   <result pre="of DelNS1 influenza viruses: a strategy for optimizing live attenuated" exact="influenza" post="vaccines.mBio. 2019;10: e02180–02119. 10.1128/mBio.02180-1931530680 87HuangX, ZhengM, WangP, MokBWY, LiuS,"/>
   <result pre="MokBWY, LiuS, LauSY, et al.An NS-segment exonic splicing enhancer regulates" exact="influenza" post="A virus replication in mammalian cells.Nat Commun.2017;8: 1475110.1038/ncomms1475128323816 88ChengY,"/>
   <result pre="2393810.1038/srep2393827029215 89NeumannG, WatanabeT, ItoH, WatanabeS, GotoH, GaoP, et al.Generation of" exact="influenza" post="A viruses entirely from cloned cDNAs. Proc Natl Acad"/>
   <result pre="KawaokaY, HobomG, WebsterRG. A DNA transfection system for generation of" exact="influenza" post="A virus from eight plasmids. Proc Natl Acad Sci"/>
   <result pre="ChenH, et al.Antiviral activity of double-stranded RNA–binding protein PACT against" exact="influenza" post="A virus mediated via suppression of viral RNA polymerase."/>
   <result pre="double-stranded RNA–binding protein PACT against influenza A virus mediated via" exact="suppression" post="of viral RNA polymerase. FASEB J. 2018;32: 4380–4393. 10.1096/fj.201701361R29513570"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7303813\results\search\disease\results.xml">
   <result pre="from infectious agents continues to grow. Enterovirus is a major" exact="infectious disease" post="of childhood and has been linked to numerous chronic"/>
   <result pre="outcomes, including attention deficit and hyperactivity disorder (ADHD), epilepsy, asthma," exact="allergic rhinitis," post="and atopic dermatitis, were recorded. Results: The risks of"/>
   <result pre="deficit and hyperactivity disorder (ADHD), epilepsy, asthma, allergic rhinitis, and" exact="atopic dermatitis," post="were recorded. Results: The risks of ADHD, asthma, allergic"/>
   <result pre="atopic dermatitis, were recorded. Results: The risks of ADHD, asthma," exact="allergic rhinitis," post="and epilepsy were significantly increased in the EV group"/>
   <result pre="recorded. Results: The risks of ADHD, asthma, allergic rhinitis, and" exact="epilepsy" post="were significantly increased in the EV group compared with"/>
   <result pre="EV group compared with the control group. The risk of" exact="atopic dermatitis" post="was significantly increased in the crude model. However, there"/>
   <result pre="group compared with the control group. The risk of atopic" exact="dermatitis" post="was significantly increased in the crude model. However, there"/>
   <result pre="differences in the adjusted model. The risks of ADHD, asthma," exact="allergic rhinitis," post="and epilepsy were also significantly increased in patients with"/>
   <result pre="adjusted model. The risks of ADHD, asthma, allergic rhinitis, and" exact="epilepsy" post="were also significantly increased in patients with severe EV"/>
   <result pre="EV infection. Conclusion: Chronic diseases, such as ADHD, epilepsy, asthma," exact="allergic rhinitis," post="and atopic dermatitis were shown to be associated with"/>
   <result pre="Chronic diseases, such as ADHD, epilepsy, asthma, allergic rhinitis, and" exact="atopic dermatitis" post="were shown to be associated with enterovirus infection during"/>
   <result pre="diseases, such as ADHD, epilepsy, asthma, allergic rhinitis, and atopic" exact="dermatitis" post="were shown to be associated with enterovirus infection during"/>
   <result pre="implications and thus prevention strategies should be implemented. enterovirus ADHD" exact="epilepsy" post="allergic disease NHIRD fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
   <result pre="(EV71) is responsible for a number of large epidemics of" exact="hand, foot, and mouth disease" post="in children, and in rare cases can lead to"/>
   <result pre="for a number of large epidemics of hand, foot, and" exact="mouth disease" post="in children, and in rare cases can lead to"/>
   <result pre="other long-term effects resulting in common health problems, such as" exact="allergy" post="diseases, autoimmune diseases, and diseases involving other systems, and"/>
   <result pre="disorder (ADHD), epilepsy, atopic diseases, coronary artery disease (CAD), stroke," exact="rheumatoid arthritis" post="(RA), or systemic lupus erythematosus (SLE) before the diagnosis"/>
   <result pre="(ADHD), epilepsy, atopic diseases, coronary artery disease (CAD), stroke, rheumatoid" exact="arthritis" post="(RA), or systemic lupus erythematosus (SLE) before the diagnosis"/>
   <result pre="diseases, coronary artery disease (CAD), stroke, rheumatoid arthritis (RA), or" exact="systemic lupus erythematosus" post="(SLE) before the diagnosis of enterovirus were excluded. Subjects"/>
   <result pre="coronary artery disease (CAD), stroke, rheumatoid arthritis (RA), or systemic" exact="lupus erythematosus" post="(SLE) before the diagnosis of enterovirus were excluded. Subjects"/>
   <result pre="NHI program, a major outcome such as ADHD, epilepsy, asthma," exact="allergic rhinitis," post="or atopic dermatitis occurred, or until December 31, 2013"/>
   <result pre="major outcome such as ADHD, epilepsy, asthma, allergic rhinitis, or" exact="atopic dermatitis" post="occurred, or until December 31, 2013 was reached, as"/>
   <result pre="outcome such as ADHD, epilepsy, asthma, allergic rhinitis, or atopic" exact="dermatitis" post="occurred, or until December 31, 2013 was reached, as"/>
   <result pre="from EV. Major outcomes were as follows: ADHD (ICD-9-CM 314)," exact="epilepsy" post="(ICD-9-CM 345), asthma (ICD-9-CM 493), allergic rhinitis (ICD-9-CM 477),"/>
   <result pre="outcomes were as follows: ADHD (ICD-9-CM 314), epilepsy (ICD-9-CM 345)," exact="asthma" post="(ICD-9-CM 493), allergic rhinitis (ICD-9-CM 477), and atopic dermatitis"/>
   <result pre="follows: ADHD (ICD-9-CM 314), epilepsy (ICD-9-CM 345), asthma (ICD-9-CM 493)," exact="allergic rhinitis" post="(ICD-9-CM 477), and atopic dermatitis (ICD-9-CM 691). Demographic variables"/>
   <result pre="ADHD (ICD-9-CM 314), epilepsy (ICD-9-CM 345), asthma (ICD-9-CM 493), allergic" exact="rhinitis" post="(ICD-9-CM 477), and atopic dermatitis (ICD-9-CM 691). Demographic variables"/>
   <result pre="(ICD-9-CM 345), asthma (ICD-9-CM 493), allergic rhinitis (ICD-9-CM 477), and" exact="atopic dermatitis" post="(ICD-9-CM 691). Demographic variables including age, sex, parental occupation,"/>
   <result pre="345), asthma (ICD-9-CM 493), allergic rhinitis (ICD-9-CM 477), and atopic" exact="dermatitis" post="(ICD-9-CM 691). Demographic variables including age, sex, parental occupation,"/>
   <result pre="control group (HR = 1.25, 95%CI-1.11–1.41). The incidence rates of" exact="epilepsy" post="were 13.7/10,000 person-years and 10.7/10,000 person-years in the EV"/>
   <result pre="confounding factors, there was a 1.25 times higher risk for" exact="epilepsy" post="in the EV cohort group compared with the control"/>
   <result pre="Three major allergic diseases were analyzed in this study: asthma," exact="allergic rhinitis," post="and atopic dermatitis. The incidence of asthma was 150/10,000"/>
   <result pre="diseases were analyzed in this study: asthma, allergic rhinitis, and" exact="atopic dermatitis." post="The incidence of asthma was 150/10,000 person-years in the"/>
   <result pre="study: asthma, allergic rhinitis, and atopic dermatitis. The incidence of" exact="asthma" post="was 150/10,000 person-years in the EV cohort group and"/>
   <result pre="and 93.0/10,000 person-years in the control group. The risk of" exact="asthma" post="was higher in the EV cohort group after adjusting"/>
   <result pre="confounders (HR = 1.49, 95%CI = 1.41–1.58). The incidence of" exact="allergic rhinitis" post="in the EV cohort group was 1.37 times higher"/>
   <result pre="(HR = 1.49, 95%CI = 1.41–1.58). The incidence of allergic" exact="rhinitis" post="in the EV cohort group was 1.37 times higher"/>
   <result pre="confounding factors, there was a 1.37 times higher risk for" exact="allergic rhinitis" post="in the EV cohort group (HR = 1.37, 95%CI"/>
   <result pre="factors, there was a 1.37 times higher risk for allergic" exact="rhinitis" post="in the EV cohort group (HR = 1.37, 95%CI"/>
   <result pre="(HR = 1.37, 95%CI = 1.33–1.42). The incidence rates of" exact="atopic dermatitis" post="were 45.6 and 39.3/10,000 person-years, respectively. However, after adjusting"/>
   <result pre="= 1.37, 95%CI = 1.33–1.42). The incidence rates of atopic" exact="dermatitis" post="were 45.6 and 39.3/10,000 person-years, respectively. However, after adjusting"/>
   <result pre="confounders, there was no significant difference in the risk of" exact="atopic dermatitis" post="between the two groups (HR = 1.09, 95%CI ="/>
   <result pre="there was no significant difference in the risk of atopic" exact="dermatitis" post="between the two groups (HR = 1.09, 95%CI ="/>
   <result pre="156,650 150 2,663 286,305 93.0 1.56 (1.48–1.65) 1.49 (1.41–1.58) Allergic" exact="rhinitis" post="5,812 125,691 462 7,677 243,124 316 1.42 (1.37–1.47) 1.37"/>
   <result pre="125,691 462 7,677 243,124 316 1.42 (1.37–1.47) 1.37 (1.33–1.42) Atopic" exact="dermatitis" post="791 173,414 45.6 1,188 302,104 39.3 1.14 (1.05–1.25) 1.09"/>
   <result pre="for children with or without EV infection. (A) asthma, (B)" exact="allergic rhinitis," post="(C) atopic dermatitis. Figure 3 Cumulative risk of CNS"/>
   <result pre="or without EV infection. (A) asthma, (B) allergic rhinitis, (C)" exact="atopic dermatitis." post="Figure 3 Cumulative risk of CNS sequelae for children"/>
   <result pre="(HR = 1.12, 95% CI = 0.84–1.47). The incidence of" exact="epilepsy" post="was 29.5/10,000 person-years in patients with severe EV infection"/>
   <result pre="severe EV patients had a 2.36 times greater risk for" exact="epilepsy" post="(HR = 2.36, 95%CI = 1.62–3.24). Comparing the risk"/>
   <result pre="the two groups, there was no difference in risk of" exact="atopic dermatitis" post="(HR = 1.10, 95%CI = 0.88–1.38), but there was"/>
   <result pre="two groups, there was no difference in risk of atopic" exact="dermatitis" post="(HR = 1.10, 95%CI = 0.88–1.38), but there was"/>
   <result pre="95%CI = 0.88–1.38), but there was a higher risk of" exact="asthma" post="(HR = 1.33, 95%CI = 1.18–1.50) and allergic rhinitis"/>
   <result pre="risk of asthma (HR = 1.33, 95%CI = 1.18–1.50) and" exact="allergic rhinitis" post="(HR = 1.17, 95%CI = 1.08–1.28) in patients with"/>
   <result pre="of asthma (HR = 1.33, 95%CI = 1.18–1.50) and allergic" exact="rhinitis" post="(HR = 1.17, 95%CI = 1.08–1.28) in patients with"/>
   <result pre="13,762 222 2,037 142,888 143 1.55 (1.37–1.75) 1.33 (1.18–1.50) Allergic" exact="rhinitis" post="617 10,915 565 5,195 114,776 453 1.24 (1.14–1.35) 1.17"/>
   <result pre="10,915 565 5,195 114,776 453 1.24 (1.14–1.35) 1.17 (1.08–1.28) Atopic" exact="dermatitis" post="87 16,190 53.7 704 157,224 44.8 1.21 (0.97–1.52) 1.10"/>
   <result pre="children with severe and non-severe EV infection. (A) asthma, (B)" exact="allergic rhinitis," post="(C) atopic dermatitis. Figure 5 Cumulative risk of CNS"/>
   <result pre="and non-severe EV infection. (A) asthma, (B) allergic rhinitis, (C)" exact="atopic dermatitis." post="Figure 5 Cumulative risk of CNS sequelae for children"/>
   <result pre="number of outpatients and emergency visits due to enterovirus, i.e.," exact="herpangina" post="or hand-foot-mouth disease, increases during late March, peaks around"/>
   <result pre="There was a higher risk of ADHD, epilepsy, asthma, and" exact="allergic rhinitis" post="in children with severe EV infection compared with children"/>
   <result pre="was a higher risk of ADHD, epilepsy, asthma, and allergic" exact="rhinitis" post="in children with severe EV infection compared with children"/>
   <result pre="non-severe EV infection. The cumulative risks for ADHD, epilepsy, asthma," exact="allergic rhinitis," post="and atopic dermatitis were significantly increased in children with"/>
   <result pre="The cumulative risks for ADHD, epilepsy, asthma, allergic rhinitis, and" exact="atopic dermatitis" post="were significantly increased in children with EV infection, especially"/>
   <result pre="cumulative risks for ADHD, epilepsy, asthma, allergic rhinitis, and atopic" exact="dermatitis" post="were significantly increased in children with EV infection, especially"/>
   <result pre="long-term neurologic sequelae, such as limb weakness, cranial nerve palsy," exact="cerebral palsy," post="non-affective psychotic illness, cognitive impairment, attention deficit hyperactivity disorder"/>
   <result pre="cranial nerve palsy, cerebral palsy, non-affective psychotic illness, cognitive impairment," exact="attention deficit hyperactivity disorder" post="(ADHD), learning disability, and epilepsy (16–20). Enterovirus has been"/>
   <result pre="non-affective psychotic illness, cognitive impairment, attention deficit hyperactivity disorder (ADHD)," exact="learning disability," post="and epilepsy (16–20). Enterovirus has been reported as one"/>
   <result pre="cognitive impairment, attention deficit hyperactivity disorder (ADHD), learning disability, and" exact="epilepsy" post="(16–20). Enterovirus has been reported as one of the"/>
   <result pre="school (23). In our study, the risks of ADHD and" exact="epilepsy" post="were increased, especially in children with severe EV infection."/>
   <result pre="shown to be significantly correlated with an increased occurrence of" exact="asthma" post="(35–38). Human enterovirus has been reported to be correlated"/>
   <result pre="in the United States in 2014. EV-D68 can cause severe" exact="respiratory disease" post="similar to human rhinovirus, and exacerbates the severity of"/>
   <result pre="rhinovirus, and exacerbates the severity of symptoms in children with" exact="asthma" post="and wheezing (5, 42). Furthermore, previous studies reported an"/>
   <result pre="et al. observed an increased risk of subsequently developing allergic" exact="dermatitis" post="and allergic rhinitis in children who had previously been"/>
   <result pre="observed an increased risk of subsequently developing allergic dermatitis and" exact="allergic rhinitis" post="in children who had previously been infected with herpangina"/>
   <result pre="an increased risk of subsequently developing allergic dermatitis and allergic" exact="rhinitis" post="in children who had previously been infected with herpangina"/>
   <result pre="allergic rhinitis in children who had previously been infected with" exact="herpangina" post="and a decreased risk of subsequent occurrence of asthma"/>
   <result pre="with herpangina and a decreased risk of subsequent occurrence of" exact="asthma" post="in children with a prior diagnosis of HFMD compared"/>
   <result pre="population-based database (40). However, in our study, increased risks of" exact="asthma" post="and allergic rhinitis were noted in children who had"/>
   <result pre="(40). However, in our study, increased risks of asthma and" exact="allergic rhinitis" post="were noted in children who had previously had an"/>
   <result pre="However, in our study, increased risks of asthma and allergic" exact="rhinitis" post="were noted in children who had previously had an"/>
   <result pre="the general population. We also found an increased risk of" exact="asthma" post="and allergic rhinitis in children who had been hospitalized"/>
   <result pre="population. We also found an increased risk of asthma and" exact="allergic rhinitis" post="in children who had been hospitalized with severe enterovirus"/>
   <result pre="We also found an increased risk of asthma and allergic" exact="rhinitis" post="in children who had been hospitalized with severe enterovirus"/>
   <result pre="there was only a borderline significant difference in risk of" exact="atopic dermatitis" post="between the EV cohort and control group. A significantly"/>
   <result pre="was only a borderline significant difference in risk of atopic" exact="dermatitis" post="between the EV cohort and control group. A significantly"/>
   <result pre="cohort and control group. A significantly increased cumulative risk of" exact="atopic dermatitis" post="in the follow-up period was observed. The difference between"/>
   <result pre="and control group. A significantly increased cumulative risk of atopic" exact="dermatitis" post="in the follow-up period was observed. The difference between"/>
   <result pre="(15). Several chronic diseases such as type I DM (46)," exact="leukemia" post="(47), tic disorders (48), autoimmune disease (49, 50), and"/>
   <result pre="as type I DM (46), leukemia (47), tic disorders (48)," exact="autoimmune disease" post="(49, 50), and cardiovascular diseases might be associated with"/>
   <result pre="(2009) 28:904–10. 10.1097/INF.0b013e3181a41d6320118685 7.ChenKTChangHLWangSTChengYTYangJY. Epidemiologic features of hand-foot-mouth disease and" exact="herpangina" post="caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics. (2007)"/>
   <result pre="Clinical features and risk factors of pulmonary oedema after enterovirus-71-related" exact="hand, foot, and mouth disease." post="Lancet. (1999) 354:1682–6. 10.1016/S0140-6736(99)04434-710568570 14.LinTYChangLYHsiaSHHuangYCChiuCHHsuehCet al.. The 1998 enterovirus"/>
   <result pre="risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and" exact="mouth disease." post="Lancet. (1999) 354:1682–6. 10.1016/S0140-6736(99)04434-710568570 14.LinTYChangLYHsiaSHHuangYCChiuCHHsuehCet al.. The 1998 enterovirus"/>
   <result pre="viral infections. Epilepsy Curr. (2014) 14:35–42. 10.5698/1535-7511-14.s2.3524955074 21.MichosAGSyriopoulouVPHadjichristodoulouCDaikosGLLagonaEDouridasPet al.. Aseptic" exact="meningitis" post="in children: analysis of 506 cases. PLoS ONE. (2007)"/>
   <result pre="506 cases. PLoS ONE. (2007) 2:e674. 10.1371/journal.pone.000067417668054 22.FowlkesALHonarmandSGlaserCYagiSSchnurrDObersteMSet al.. Enterovirus-associated" exact="encephalitis" post="in the California encephalitis project, 1998-2005. J Infect Dis."/>
   <result pre="(2007) 2:e674. 10.1371/journal.pone.000067417668054 22.FowlkesALHonarmandSGlaserCYagiSSchnurrDObersteMSet al.. Enterovirus-associated encephalitis in the California" exact="encephalitis" post="project, 1998-2005. J Infect Dis. (2008) 198:1685–91. 10.1086/59298818959496 23.ChangLYHuangLMGauSSWuYYHsiaSHFanTYet"/>
   <result pre="the central nervous system. Pediatrics. (2008) 122:e452–8. 10.1542/peds.2007-379918606624 25.ChouICLinCCKaoCH. Enterovirus" exact="encephalitis" post="increases the risk of attention deficit hyperactivity disorder: a"/>
   <result pre="illnesses. Pediatr Allergy Immunol. (1994) 5:7–12. 10.1111/j.1399-3038.1994.tb00341.x7728232 31.MaziakWBehrensTBraskyTMDuhmeHRzehakPWeilandSKet al.. Are" exact="asthma" post="and allergies in children and adolescents increasing? Results from"/>
   <result pre="Germany. Allergy. (2003) 58:572–9. 10.1034/j.1398-9995.2003.00161.x12823113 32.WoonPYChangWCLiangCCHsuCHKlahanSHuangYHet al.. Increased risk of" exact="atopic dermatitis" post="in preschool children with kawasaki disease: a population-based study"/>
   <result pre="Allergy. (2003) 58:572–9. 10.1034/j.1398-9995.2003.00161.x12823113 32.WoonPYChangWCLiangCCHsuCHKlahanSHuangYHet al.. Increased risk of atopic" exact="dermatitis" post="in preschool children with kawasaki disease: a population-based study"/>
   <result pre="33.TagiyevaNSheikhA. Domestic exposure to volatile organic compounds in relation to" exact="asthma" post="and allergy in children and adults. Expert Rev Clin"/>
   <result pre="exposure to volatile organic compounds in relation to asthma and" exact="allergy" post="in children and adults. Expert Rev Clin Immunol. (2014)"/>
   <result pre="Respiratory viral infection, epithelial cytokines, and innate lymphoid cells in" exact="asthma" post="exacerbations. J Leukocyte Biol. (2014) 96:391–6. 10.1189/jlb.3RI0314-129R24904000 37.AjamianFWuYEbelingCIlarrazaROdemuyiwaSOMoqbelRet al.."/>
   <result pre="Medicine. (2017) 96:e5827. 10.1097/MD.000000000000582728121929 41.YehJJLinCLHsuWH. Effect of enterovirus infections on" exact="asthma" post="in young children: A national cohort study. Eur J"/>
   <result pre="Lower anti-echovirus antibody responses in children presenting to hospital with" exact="asthma" post="exacerbations. Clin Exp Allergy. (2015) 45:1523–30. 10.1111/cea.1250125640320 45.WuJCuiDYangXLouJLinJYeXet al.."/>
   <result pre="frequency of circulating follicular helper T cells in children with" exact="hand, foot, and mouth disease" post="caused by enterovirus 71 infection. J Immunol Res. (2014)"/>
   <result pre="follicular helper T cells in children with hand, foot, and" exact="mouth disease" post="caused by enterovirus 71 infection. J Immunol Res. (2014)"/>
   <result pre="49.ChristensenMLPachmanLMSchneidermanRPatelDCFriedmanJM. Prevalence of Coxsackie B virus antibodies in patients with" exact="juvenile dermatomyositis." post="Arthritis Rheum. (1986) 29:1365–70. 10.1002/art.17802911093022759 50.TriantafyllopoulouATapinosNMoutsopoulosHM. Evidence for coxsackievirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7304608\results\search\disease\results.xml">
   <result pre="it. Introduction With the emergence and reemergence of dengue (DENV)," exact="chikungunya" post="(CHIKV), and Zika (ZIKV), arthropod-borne viruses (arboviruses) are increasingly"/>
   <result pre="including 96 million (95% CI: 67–136 million) clinical cases, 500,000" exact="dengue hemorrhagic fever" post="cases, and 22,000 deaths, mostly among children &amp;lt;5 years"/>
   <result pre="meningoencephalitis, nephritis, retinitis, uveitis, myelitis, cranial nerve palsies, and acute" exact="encephalopathy" post="[9]. First identified in Uganda in 1947, ZIKV expanded"/>
   <result pre="also been linked to congenital microcephaly, Guillain-Barré syndrome, craniofacial disproportion," exact="cerebral palsy," post="spasticity, hearing loss, brainstem dysfunctions, joint deformities, and developmental"/>
   <result pre="firewood smoke as an effective mosquito repellent with respect to" exact="malaria" post="infection, which is transmitted by Anopheles [32–34]. The repellent"/>
   <result pre="HAP contributes to 1.6 million deaths annually from stroke, ischemic" exact="heart disease," post="chronic obstructive pulmonary disease, and lung cancer [35, 38]."/>
   <result pre="to 1.6 million deaths annually from stroke, ischemic heart disease," exact="chronic obstructive pulmonary disease," post="and lung cancer [35, 38]. HAP exposure has also"/>
   <result pre="from stroke, ischemic heart disease, chronic obstructive pulmonary disease, and" exact="lung cancer" post="[35, 38]. HAP exposure has also been linked with"/>
   <result pre="stroke, ischemic heart disease, chronic obstructive pulmonary disease, and lung" exact="cancer" post="[35, 38]. HAP exposure has also been linked with"/>
   <result pre="of an obvious source of fever on physical examination (e.g.," exact="otitis media," post="septic arthritis, pyogenic soft tissue infection) determined by the"/>
   <result pre="obvious source of fever on physical examination (e.g., otitis media," exact="septic arthritis," post="pyogenic soft tissue infection) determined by the examining healthcare"/>
   <result pre="included diarrheal controls with confirmed bacterial or viral infections because" exact="diarrhea" post="may be a symptom of an arbovirus infection [54]."/>
   <result pre="outside of the sleeping room were at greater risk for" exact="malaria" post="[69]. However, we are unaware of any studies examining"/>
   <result pre="demonstrated PM10, COH, NO2, and O3 were not associated with" exact="gastroenteritis" post="[84]. An attempt was made to minimize this risk"/>
   <result pre="acute phase reaction; respiratory infections, emergency department visits, and hospitalizations;" exact="asthma" post="development; and premature mortality in people with chronic lung"/>
   <result pre="hospitalizations; asthma development; and premature mortality in people with chronic" exact="lung disease" post="[35, 39]. We found anecdotal evidence that suggests households"/>
   <result pre="[cited 2018 September 16]. Available from: https://www.paho.org/hq/index.php?option=com_topics&amp;amp;view=rdmore&amp;amp;cid=5927&amp;amp;item=chikungunya&amp;amp;type=statistics&amp;amp;Itemid=40931&amp;amp;lang=en. 4GublerDJ. Dengue and" exact="dengue hemorrhagic fever." post="Clinical Microbiology Reviews. 1998;11(3):480–96. 9665979 5collab: World Health Organization."/>
   <result pre="2018 November 10]. Available from: http://www.cdc.gov/zika/pdfs/zika-key-messages.pdf. 12PaixãoES, TeixeiraMG, RodriguesLC. Zika," exact="chikungunya" post="and dengue: the causes and threats of new and"/>
   <result pre="MalvyD, GiryC, EzzedineK, SoletJL, et al.Seroprevalence and risk factors of" exact="chikungunya" post="virus infection in Mayotte, Indian Ocean, 2005–2006: a population-based"/>
   <result pre="Repellent properties of volatiles emitted from ethnomedicinal plant leaves against" exact="malaria" post="and yellow fever vectors in Ethiopia.Malaria Journal. 2011;10(1):375.22182798 26VernedeR,"/>
   <result pre="of volatiles emitted from ethnomedicinal plant leaves against malaria and" exact="yellow fever" post="vectors in Ethiopia.Malaria Journal. 2011;10(1):375.22182798 26VernedeR, AlpersM. Smoke as"/>
   <result pre="FortiniD, EvoraJ, et al.Control of endophagic Anopheles mosquitoes and human" exact="malaria" post="in Guinea Bissau, West Africa by permethrin-treated bed nets."/>
   <result pre="al.Prevalence and genetic diversity of norovirus among patients with acute" exact="diarrhea" post="in Guatemala. Journal of Medical Virology. 2013;85(7):1293–8. 10.1002/jmv.2357823595770 43BenoitSR,"/>
   <result pre="65AliA, ur RehmanH, NisarM, RafiqueS, AliS, HussainA, et al.Seroepidemiology of" exact="dengue fever" post="in Khyber Pakhtunkhawa, Pakistan.International Journal of Infectious Diseases. 2013;17(7):e518–e23."/>
   <result pre="HaileM, WittenKH, GetachewA, YohannesM, LindsaySW, et al.Household risk factors for" exact="malaria" post="among children in the Ethiopian highlands. Transactions of the"/>
   <result pre="insecticide-Treated bed nets use in Kamuli District, Uganda: Implications for" exact="malaria" post="control. International Journal of Mosquito Research. 2016;3(4):30–8. 73Centers for"/>
   <result pre="Epidemiology. 2010;20(5):40610.1038/jes.2009.3019536077 80TakkenW, SnellenW, VerhaveJ, KnolsB, AtmosoedjonoS. Environmental measures for" exact="malaria" post="control in Indonesia. A historical review on species sanitation:"/>
   <result pre="84LipsettM, HurleyS, OstroB. Air pollution and emergency room visits for" exact="asthma" post="in Santa Clara County, California. Environmental Health Perspectives. 1997;105(2):216–22."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7304630\results\search\disease\results.xml">
   <result pre="RNA copies per milliliter of blood.[9,10] Several studies reported variable" exact="chikungunya" post="symptomatology, i.e., La Reunion outbreak in 2004 showed patients"/>
   <result pre="epidemics, such as diarrhea, rhinitis, conjunctival congestion, hepatomegaly, splenomegaly and" exact="lymphadenopathy" post="were rarely observed in the India outbreak.[13,14] Comparison of"/>
   <result pre="technicians who were responsible for gathering information about the CHIKV" exact="infectious disease" post="emergency and carrying out case and contact investigations, in"/>
   <result pre="symptoms included fever &amp;gt;38°C, severe joint pain or initial acute" exact="arthritis" post="symptoms and rash, which could not attributed to other"/>
   <result pre="symptoms included fever &amp;gt;38°C, severe joint pain or initial acute" exact="arthritis" post="symptoms and rash, could not be attributed to other"/>
   <result pre="general discomfort (59%), neck (54%) and back pain (53%), maculopapular" exact="rash" post="(51%), myalgia (38%), arthritis (29%), conjunctivitis (7%), and nausea/vomiting"/>
   <result pre="(54%) and back pain (53%), maculopapular rash (51%), myalgia (38%)," exact="arthritis" post="(29%), conjunctivitis (7%), and nausea/vomiting (24%/21%) (Table 2). Some"/>
   <result pre="back pain (53%), maculopapular rash (51%), myalgia (38%), arthritis (29%)," exact="conjunctivitis" post="(7%), and nausea/vomiting (24%/21%) (Table 2). Some patients manifested"/>
   <result pre="of dizziness (30.2% women vs. 25% men; P = 0.045)," exact="conjunctivitis" post="(9% women vs. 4.6% men; P = 0.011), localized"/>
   <result pre="to the development of autoimmunological disorders in females, such as," exact="systemic lupus erythematosus," post="Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, rheumatoid arthritis and"/>
   <result pre="the development of autoimmunological disorders in females, such as, systemic" exact="lupus erythematosus," post="Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, rheumatoid arthritis and"/>
   <result pre="females, such as, systemic lupus erythematosus, Graves’ disease, Hashimoto’s thyroiditis," exact="multiple sclerosis," post="rheumatoid arthritis and scleroderma.[36] A stronger female immune response"/>
   <result pre="as, systemic lupus erythematosus, Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis," exact="rheumatoid arthritis" post="and scleroderma.[36] A stronger female immune response towards CHIKV"/>
   <result pre="systemic lupus erythematosus, Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, rheumatoid" exact="arthritis" post="and scleroderma.[36] A stronger female immune response towards CHIKV"/>
   <result pre="the infection to the joints results in arthralgia, which mirrors" exact="rheumatoid arthritis," post="a condition characterized by joint pain as the result"/>
   <result pre="applied to diagnosis of Dengue virus infection (S1 Table). The" exact="chikungunya" post="outbreak occurred in the Colombian Caribbean back in 2014/15,"/>
   <result pre="PoubeauP.; StaikowskyF.; LoryM.; Le MoullecN.; BecquartJ.P.; WenglingC.; MichaultA.; PaganinF.Outbreak of" exact="chikungunya" post="on Reunion Island: early clinical and laboratory features in"/>
   <result pre="FernandezS.; ThaisomboonsukB.; KlungthongC.; LevyJ.W.; VelascoJ.M., et al.High rate of subclinical" exact="chikungunya" post="virus infection and association of neutralizing antibody with protection"/>
   <result pre="17RulliN.E.; MeltonJ.; WilmesA.; EwartG.; MahalingamS.The molecular and cellular aspects of" exact="arthritis" post="due to alphavirus infections: lesson learned from Ross River"/>
   <result pre="MaryM.; van BelkumA.Semantic data interoperability, digital medicine, and e-health in" exact="infectious disease" post="management: a review. Eur J Clin Microbiol Infect Dis2019,"/>
   <result pre="DoushaL.F.; ZoskyG.R.; SlyP.D.Sexual dimorphism in lung function responses to acute" exact="influenza" post="A infection. Influenza Other Respir Viruses2011, 5, 334–342, 10.1111/j.1750-2659.2011.00236.x21668688"/>
   <result pre="10.4269/ajtmh.15-037526856917 47DuttaS.K.; TripathiA.Association of toll-like receptor polymorphisms with susceptibility to" exact="chikungunya" post="virus infection. Virology2017, 511, 207–213, 10.1016/j.virol.2017.08.00928888110 48Barragán-Duarte, J.L. Mapa"/>
   <result pre="54StaplesJ.E.; BreimanR.F.; PowersA.M.Chikungunya fever: an epidemiological review of a re-emerging" exact="infectious disease." post="Clin Infect Dis2009, 49, 942–948, 10.1086/60549619663604 55Shahadat HossainM.; SultanaZ.;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7304733\results\search\disease\results.xml">
   <result pre="immunity and seeing the relevance to current issues such as" exact="measles" post="outbreaks and global epidemics. Curtin Science Experience This initiative"/>
   <result pre="bit of fun, it happened to take place when a" exact="measles" post="epidemic was causing the deaths of many children in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7305415\results\search\disease\results.xml">
   <result pre="targets for human immunodeficiency virus (HIV) diagnosis, treatment and viral" exact="suppression" post="[1]; it also marks completion of one�?third of the"/>
   <result pre="settings with generalized HIV epidemics, non�?communicable diseases (NCDs), such as" exact="cardiovascular disease" post="(CVD) and cancer, are exacting an increasing toll of"/>
   <result pre="people who inject drugs (PWID) and thus overlaps strongly with" exact="hepatitis" post="C and risk of drug overdose, integration of HIV"/>
   <result pre="overdose, integration of HIV services with substance use services and" exact="hepatitis" post="C treatment programmes might be the overriding priority [8]."/>
   <result pre="and treatment as a package that also includes services for" exact="substance abuse." post="Although each individual article addresses a narrowly defined topic,"/>
   <result pre="Abbreviations AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; CVD," exact="cardiovascular disease;" post="HIV, human immunodeficiency virus; NCD, non�?communicable disease; PLHIV, people"/>
   <result pre="intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral" exact="suppression" post="in East Africa. JAMA. 2017;317(21):2196–206.28586888 13SandoD, KintuA, OkelloS, KawungeziP,"/>
   <result pre="NewallAT, ChattranukulchaiP, ChaiwarithR, KhusuwanS, AvihignsanonA, et al. Statins for atherosclerotic" exact="cardiovascular disease" post="prevention in people living with HIV in Thailand: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7308418\results\search\disease\results.xml">
   <result pre="are the cause of more than 95% of epidemic non-bacterial" exact="gastroenteritis" post="worldwide, with some lethal cases. These viral agents affect"/>
   <result pre="Introduction Human noroviruses (HuNoV) are the main cause of non-bacterial" exact="gastroenteritis" post="worldwide, producing high morbidity and mortality rates (1, 2)."/>
   <result pre="developing countries (10, 11). HuNoV produces rapid and self-limited acute" exact="gastroenteritis" post="characterized by the development of symptoms such as vomiting,"/>
   <result pre="characterized by the development of symptoms such as vomiting, watery" exact="diarrhea" post="with or without nausea, and abdominal cramps (12). HuNoV"/>
   <result pre="(13). Only GI, GII, and GIV infect and cause acute" exact="gastroenteritis" post="in humans. These genogroups are classified according to the"/>
   <result pre="by expressing different interferon-stimulated genes (ISGs) into the human Huh7" exact="hepatocellular carcinoma" post="cells expressing the NV replicon (HG23), RTP4, and HPSE"/>
   <result pre="strain (GII.2-1976) or in fecal samples from travelers with HuNoV" exact="gastroenteritis" post="(128). Particularly, peripheral blood mononuclear cells (PBMCs) from healthy"/>
   <result pre="and molecular trends of &quot;Norwalk-like viruses�? associated with outbreaks of" exact="gastroenteritis" post="in the United States. J Infect Dis. (2002) 186:1–7."/>
   <result pre="10.1186/1471-2458-3-1312659651 7.FankhauserRLNoelJSMonroeSSAndoTGlassRI. Molecular epidemiology of &quot;Norwalk-like viruses�? in outbreaks of" exact="gastroenteritis" post="in the United States. J Infect Dis. (1998) 178:1571–8."/>
   <result pre="(2010) 51:123–30. 10.1086/65353020540620 11.KooHLAjamiNJJiangZDNeillFHAtmarRLEricssonCDet al.. Noroviruses as a cause of" exact="diarrhea" post="in travelers to Guatemala, India, and Mexico. J Clin"/>
   <result pre="and genetic variability of small round-structured viruses in outbreaks of" exact="gastroenteritis" post="in The Netherlands. J Infect Dis. (1997) 176:1374–8. 10.1086/5173259359742"/>
   <result pre="SNARE regulator VAP-A and prevents cell surface expression of vesicular" exact="stomatitis" post="virus G protein. J Virol. (2003) 77:11790–7. 10.1128/JVI.77.21.11790-11797.200314557663 31.HuangPFarkasTZhongWTanMThorntonSMorrowALet"/>
   <result pre="9:548–53. 10.1038/nm86012692541 85.HemmingMRäsänenSHuhtiLPaloniemiMSalminenMVesikariT. Major reduction of rotavirus, but not norovirus," exact="gastroenteritis" post="in children seen in hospital after the introduction of"/>
   <result pre="155:48–59. 10.1016/j.antiviral.2018.05.00429753657 105.JohnsonPCMathewsonJJDuPontHLGreenbergHB. Multiple-challenge study of host susceptibility to Norwalk" exact="gastroenteritis" post="in US adults. J Infect Dis. (1990) 161:18–21. 10.1093/infdis/161.1.182153184"/>
   <result pre="PLoS Pathogens. (2008) 4:236. 10.1371/journal.ppat.100023619079577 111.ParrinoTASchreiberDSTrierJSKapikianAZBlacklowNR. Clinical immunity in acute" exact="gastroenteritis" post="caused by Norwalk agent. N Engl J Med. (1977)"/>
   <result pre="112.WyattRGDolinRBlacklowNRDuPontHLBuschoRFThornhillTSet al.. Comparison of three agents of acute infectious non-bacterial" exact="gastroenteritis" post="by cross-challenge in volunteers. J Infect Dis. (1974) 129:709–14."/>
   <result pre="genotype dominate as a cause of nosocomial outbreaks of viral" exact="gastroenteritis" post="in Sweden 1997–2005: Arrival of new variants is associated"/>
   <result pre="J Clin Virol. (2008) 42:135–40. 10.1016/j.jcv.2008.02.01418420454 118.TuET-VBullRAGreeningGEHewittJLyonMJMarshallJAet al.. Epidemics of" exact="gastroenteritis" post="during 2006 were associated with the spread of norovirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7310742\results\search\disease\results.xml">
   <result pre="pyogenes M protein or streptolysin O to treat or prevent" exact="influenza" post="A superinfection Immunotherapy to treat or prevent influenza A"/>
   <result pre="or prevent influenza A superinfection Immunotherapy to treat or prevent" exact="influenza" post="A superinfection HerreraAndrea L.Data curationFormal analysisInvestigationSupervisionWriting – original draft1Van"/>
   <result pre="streptococcus (GAS), is not the most common bacteria associated with" exact="influenza" post="A virus (IAV) superinfections but did cause significant mortality"/>
   <result pre="(IAV) superinfections but did cause significant mortality during the 2009" exact="influenza" post="pandemic even though all isolates are susceptible to penicillin."/>
   <result pre="diseases, including IAV-GAS superinfections, which may be particularly important during" exact="influenza" post="pandemics. Funding Funding for the project was provided by"/>
   <result pre="All relevant data are within the paper. Introduction Infection with" exact="influenza" post="A virus (IAV) creates a permissive environment for secondary"/>
   <result pre="[1]. Streptococcus pyogenes (the group A Streptococcus, GAS) typically causes" exact="pharyngitis" post="but also can cause more serious invasive GAS infections"/>
   <result pre="cause more serious invasive GAS infections (iGAS) such as bacteremia," exact="toxic shock syndrome," post="necrotizing fasciitis, and IAV superinfections. An analysis of lung"/>
   <result pre="invasive GAS infections (iGAS) such as bacteremia, toxic shock syndrome," exact="necrotizing fasciitis," post="and IAV superinfections. An analysis of lung biopsies from"/>
   <result pre="IAV superinfections. An analysis of lung biopsies from the 1918" exact="influenza" post="pandemic revealed that Streptococcus pneumoniae and GAS were the"/>
   <result pre="approximately 90% of the estimated 50 million deaths attributed to" exact="influenza" post="[2]. IAV increases host susceptibility to secondary bacterial infections"/>
   <result pre="and particularly influenza, increase the incidence of iGAS diseases including" exact="pneumonia" post="[3, 12]. Many antibiotics, including penicillin, are effective against"/>
   <result pre="[16]. Thus, while GAS remains susceptible to many antibiotics and" exact="influenza" post="vaccines and anti-viral agents are widely used, the mortality"/>
   <result pre="in mortality between the groups. Discussion Despite the availability of" exact="influenza" post="vaccines, anti-viral agents, and antibiotics that are effective against"/>
   <result pre="containing other GAS antigens) induced non-opsonizing SLO-specific antibodies and decreased" exact="pharyngitis" post="[44]. Thus, the antisera to the M protein and"/>
   <result pre="clinical success using IVIG to treat iGAS diseases, especially streptococcal" exact="toxic shock syndrome" post="[51, 53, 54]; however, definitive results from robust clinical"/>
   <result pre="vaccines do not abolish disease including the pneumococcal, Hib, and" exact="influenza" post="vaccines [71–74]. Therefore, the development of therapeutic antibodies designed"/>
   <result pre="including IAV-GAS superinfections, may prove to be beneficial, particularly during" exact="influenza" post="pandemics. References References 1MorensDM, TaubenbergerJK, FauciAS. Predominant role of"/>
   <result pre="influenza pandemics. References References 1MorensDM, TaubenbergerJK, FauciAS. Predominant role of" exact="bacterial pneumonia" post="as a cause of death in pandemic influenza: implications"/>
   <result pre="pandemics. References References 1MorensDM, TaubenbergerJK, FauciAS. Predominant role of bacterial" exact="pneumonia" post="as a cause of death in pandemic influenza: implications"/>
   <result pre="a cause of death in pandemic influenza: implications for pandemic" exact="influenza" post="preparedness. The Journal of infectious diseases. 2008;198(7):962–70. Epub 2008/08/20."/>
   <result pre="infectious diseases. 2008;198(7):962–70. Epub 2008/08/20. 10.1086/59170818710327 2MorensDM, FauciAS. The 1918" exact="influenza" post="pandemic: insights for the 21st century. The Journal of"/>
   <result pre="Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an" exact="influenza" post="superinfection. Scientific reports. 2018;8(1):12126 Epub 2018/08/16. 10.1038/s41598-018-29714-x30108238 6OkamotoS, NagaseS."/>
   <result pre="NagaseS. Pathogenic mechanisms of invasive group A Streptococcus infections by" exact="influenza" post="virus-group A Streptococcus superinfection. Microbiology and immunology. 2018;62(3):141–9. Epub"/>
   <result pre="9Weeks-GorospeJN, HurtigHR, IversonAR, SchunemanMJ, WebbyRJ, McCullersJA, et al.Naturally occurring swine" exact="influenza" post="A virus PB1-F2 phenotypes that contribute to superinfection with"/>
   <result pre="10.1128/JVI.00369-1222674997 10OkamotoS, KawabataS, FujitakaH, UehiraT, OkunoY, HamadaS. Vaccination with formalin-inactivated" exact="influenza" post="vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection."/>
   <result pre="HamadaS. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal" exact="influenza" post="Streptococcus pyogenes superinfection. Vaccine. 2004;22(21–22):2887–93. Epub 2004/07/13. 10.1016/j.vaccine.2003.12.024 .15246625"/>
   <result pre="SandbulteHR, SchunemanMJ, DepaulaFP, AddengastLA, SchlenkerEH, et al.Inactivated and live, attenuated" exact="influenza" post="vaccines protect mice against influenza: Streptococcus pyogenes super-infections. Vaccine."/>
   <result pre="EfstratiouA, McCarthyN, O'MooreE. Group A streptococcal infections during the seasonal" exact="influenza" post="outbreak 2010/11 in South East England. Euro surveillance: bulletin"/>
   <result pre="GregsonD, et al.Clinical and epidemiologic features of group a streptococcal" exact="pneumonia" post="in Ontario, Canada. Archives of internal medicine. 2003;163(4):467–72. Epub"/>
   <result pre="streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and" exact="diphtheria" post="toxoid-specific antibodies to protection. The Journal of infectious diseases."/>
   <result pre="against the M protein of Streptococcus pyogenes prevents death after" exact="influenza" post="virus: S. pyogenes super-infection. Vaccine. 2014;32(40):5241–9. Epub 2014/08/01. 10.1016/j.vaccine.2014.06.09325077423"/>
   <result pre="Epub 2015/10/22. 10.1146/annurev-micro-091014-104233 .26488276 27McCullersJA. Insights into the interaction between" exact="influenza" post="virus and pneumococcus. Clinical microbiology reviews. 2006;19(3):571–82. Epub 2006/07/19."/>
   <result pre="A multi-valent vaccine approach that elicits broad immunity within an" exact="influenza" post="subtype. Vaccine. 2009;27(8):1192–200. Epub 2009/01/13. 10.1016/j.vaccine.2008.12.02319135117 30DaleJB. Multivalent group"/>
   <result pre="G against streptococcal and staphylococcal superantigens: implications for therapy of" exact="toxic shock syndrome." post="Clinical infectious diseases: an official publication of theInfectious Diseases"/>
   <result pre="GuildayRE, BraxtonGR, et al.Intravenous immunoglobulin as adjunctive treatment for streptococcal" exact="toxic shock syndrome" post="associated with necrotizing fasciitis: case report and review. Pharmacotherapy."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7312578\results\search\disease\results.xml">
   <result pre="affecting pregnant women and their infants. Zika virus causes a" exact="viral disease" post="transmitted to humans mainly by the infected Aedes mosquito"/>
   <result pre="associated with fetal genetic abnormalities (including microcephaly). In addition to" exact="microcephaly" post="and other malformations, some specific lesions in the central"/>
   <result pre="this systematic review was to determine the risk of developing" exact="microcephaly" post="in infants whose mothers were infected with Zika virus"/>
   <result pre="In order to understand the relationship between Zika virus and" exact="microcephaly" post="in infants, a cohort study will be able to"/>
   <result pre="outcomes. Zika virus Zika virus and pregnancy Zika virus and" exact="microcephaly" post="Zika virus and congenital malformations 1. Introduction The purpose"/>
   <result pre="available data to promote an informed discussion of trends in" exact="microcephaly" post="cases in infants after mothers’ infection with Zika virus"/>
   <result pre="virus was diagnosed in Southern America linked to cases of" exact="microcephaly" post="in infants with malformations and neurological disorders [2]. The"/>
   <result pre="mosquitoes [3] and infection in early pregnancy is linked with" exact="microcephaly" post="and other malformations such as damage to the central"/>
   <result pre="of the same age and sex. The measure value for" exact="microcephaly" post="is more than 2 standard deviations (SDs) below the"/>
   <result pre="deviations (SDs) below the average. During routine ultrasounds in pregnancy," exact="microcephaly" post="can be diagnosed in the second or early third"/>
   <result pre="According to Ellington et al. in 2016, the probability of" exact="microcephaly" post="in infants was about 1% to 13%, with limited"/>
   <result pre="researchers, e.g., Alvarado 2017, claim that the relationship of the" exact="microcephaly" post="and Zika virus is in doubt and perhaps there"/>
   <result pre="shown a strong relation but only the exposed infants with" exact="microcephaly" post="or other malformations are more likely to have low"/>
   <result pre="of Flavivirus, Pegivirus, and Pestivirus. Flaviviruses include the Zika virus," exact="yellow fever" post="virus, West Nile virus, and dengue virus, while Hepacivirus"/>
   <result pre="West Nile virus, and dengue virus, while Hepacivirus comprises the" exact="hepatitis" post="C virus [11]. Zika virus is transmitted in various"/>
   <result pre="and it is classically characterized by low fever, arthralgia, maculopapular" exact="rash" post="accompanied by pruritis, and conjunctivitis. After a 12 day"/>
   <result pre="misdiagnosed because the symptoms are similar to the ones of" exact="dengue fever" post="and chikungunya. The diagnostic value of Zika virus disease"/>
   <result pre="or without symptoms and women who were diagnosed with fetal" exact="microcephaly" post="must be tested for Zika virus infection. Exposed neonates"/>
   <result pre="by examinations. As an outcome, we analyzed the frequency of" exact="microcephaly" post="in infants (smaller head circumference more than 2 SDs"/>
   <result pre="SDs depending on the sex and age). All infants with" exact="microcephaly" post="underwent neural imaging examinations. Regarding the methodological quality of"/>
   <result pre="studies met the seventh criterion for evaluating the effects of" exact="microcephaly" post="through examinations and also, in all studies there was"/>
   <result pre="support a causal relationship between the Zika virus and related" exact="microcephaly" post="and (CNS) abnormalities in infants. The 8301 cases of"/>
   <result pre="microcephaly and (CNS) abnormalities in infants. The 8301 cases of" exact="microcephaly" post="were analyzed and confirmed by laboratory tests and neuroimaging"/>
   <result pre="abnormalities. The results showed that 15% of the patients with" exact="microcephaly" post="was related to Zika virus infection. According to the"/>
   <result pre="had the aim to describe CNS lesions in fetuses with" exact="microcephaly" post="after congenital Zika infection. The researchers concluded that Zika"/>
   <result pre="The purpose of the research was to identify infants with" exact="microcephaly" post="and make a complete clinical record. From this study,"/>
   <result pre="Zika syndrome. The research also shows that the earlier the" exact="rash" post="is reported in pregnancy, the smaller the circumference of"/>
   <result pre="neonatal microcephaly. The cases studied consisted of 30 infants with" exact="microcephaly" post="and 62 infants without outcome. Infants selected as controls"/>
   <result pre="showed positive IgG–IgM against Zika virus, while serological analysis for" exact="chikungunya" post="virus was negative. Furthermore, at 16 weeks, the presence"/>
   <result pre="Martinez et al., 2016 [27], samples from two neonates with" exact="microcephaly" post="(estimates gestational ages of 36 and 38 weeks), dying"/>
   <result pre="National Public Health Surveillance System, two cases of embryos with" exact="microcephaly" post="were studied. Amniotic fluid samples were examined by RT-PCR,"/>
   <result pre="women, while at the same time tests for dengue virus," exact="chikungunya" post="virus, Toxoplasma, rubella, herpes simplex virus, HIV, Treponema pallidum,"/>
   <result pre="same time tests for dengue virus, chikungunya virus, Toxoplasma, rubella," exact="herpes simplex" post="virus, HIV, Treponema pallidum, and B19 parvovirus were all"/>
   <result pre="the period October 2015–February 2016, several cases of fetuses with" exact="microcephaly" post="were reported to the Paraiba Institute of Embryonic Medicine,"/>
   <result pre="developmental abnormalities. Moreover, despite the fact that most infants had" exact="microcephaly" post="measuring the circumference of the skull, some infants had"/>
   <result pre="Zika virus were included. From this research, the risk of" exact="microcephaly" post="is higher in the first trimester of pregnancy infection"/>
   <result pre="pregnancy infection than in the second while increased rates of" exact="microcephaly" post="are also present when the infection occurs in the"/>
   <result pre="trimester. Therefore, according to the findings the increased rates of" exact="microcephaly" post="(moderate or proportionate) in the third trimester show the"/>
   <result pre="proportionate) in the third trimester show the increased risk of" exact="microcephaly" post="throughout pregnancy. Finally, Miner J et al., 2016 [33],"/>
   <result pre="determine the degree of association of Zika virus with neonatal" exact="microcephaly" post="as well as with other congenital disorders. Scientists, referring"/>
   <result pre="and the CNS of the mouse are presented—resulting in massive" exact="neurodegeneration" post="of infected regions. The Brazilian Zika virus stain is"/>
   <result pre="are due to the short time of the virus and" exact="microcephaly" post="worldwide. The results, according to the articles, show that"/>
   <result pre="results, according to the articles, show that the prevalence of" exact="microcephaly" post="cases in Southern America (confirmed by laboratory tests), has"/>
   <result pre="more prone to risk than the second trimester, cases of" exact="microcephaly" post="are confirmed (or not) by reporting mothers’ infection symptoms"/>
   <result pre="suggests that congenital Zika syndrome may occur in infants with" exact="microcephaly" post="and without the presence of imaging brain abnormalities. According"/>
   <result pre="findings, public health surveillance authorities should not disregard patients with" exact="microcephaly" post="without findings from imaging methods [5]. Concerning the prevention"/>
   <result pre="early, or mid-pregnancy, indicate fetal death or genetic abnormalities with" exact="microcephaly" post="[31]. Regarding preventive measures, international organizations (CDC/MEDICHEM/WHO) have made"/>
   <result pre="international organizations (CDC/MEDICHEM/WHO) have made recommendations on Zika virus and" exact="microcephaly" post="in infants. The CDC recommends measures to prevent disease"/>
   <result pre="goals with emphasis on the prevention and management of neonatal" exact="microcephaly" post="caused by Zika infection. These goals include detection, prevention,"/>
   <result pre="most appropriate to established the relationship between Zika virus and" exact="microcephaly" post="in infants. 5. Conclusions In the present study, an"/>
   <result pre="approximate the frequency and conditions under which Zika may cause" exact="microcephaly" post="as well as factors increasing the risk of vertical"/>
   <result pre="to the appearance of brain damage in newborns. Consequently, congenital" exact="microcephaly" post="is the hallmark of Zika’s intrauterine infection. The period"/>
   <result pre="and increased stress on the healthcare system, affected individuals with" exact="microcephaly" post="may be unable to join the labor force in"/>
   <result pre="the region. As recently observed, epidemics spread by mosquitoes (Zika," exact="yellow fever," post="dengue, chikungunya) can expand rapidly, including to other parts,"/>
   <result pre="- Research Institute Mice USA Microcephaly Notes: The cases of" exact="microcephaly" post="were defined as moderate (the head circumference was between"/>
   <result pre="head circumference was more than 3SDs for gestation age). Moderate" exact="microcephaly" post="defined as proportionate (the infant was small for gestation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7314749\results\search\disease\results.xml">
   <result pre="10.1038/s42003-020-1046-6 : Article Vector competence of Aedes albopictus populations for" exact="chikungunya" post="virus is shaped by their demographic history Vega-RúaAnubis1http://orcid.org/0000-0002-6785-9106MarconciniMichele2MadecYoann3http://orcid.org/0000-0002-4146-6523ManniMosè24CarrarettoDavide2http://orcid.org/0000-0002-1506-7051GomulskiLudvik Marcus2http://orcid.org/0000-0001-6972-8591GasperiGiulianogasperi@unipv.it2http://orcid.org/0000-0001-6890-0820FaillouxAnna-Bellaanna-bella.failloux@pasteur.fr5http://orcid.org/0000-0003-4566-8795MalacridaAnna"/>
   <result pre="major vector of arboviruses of public health significance such as" exact="chikungunya" post="(CHIKV). Dynamics of different genetic backgrounds and admixture events"/>
   <result pre="20 arboviruses and it is considered the main vector for" exact="chikungunya" post="(CHIKV), and to a lesser degree for dengue (DENV)"/>
   <result pre="it has been increasingly involved in local autochthonous transmission of" exact="chikungunya" post="in many places where it has become established, including"/>
   <result pre="the Ae. albopictus ancestral lineages (K6 and K5), inducing major" exact="chikungunya" post="epidemics53. Prior to 2007, Ae. albopictus had never been"/>
   <result pre="to a growing number of imported cases55 led to autochthonous" exact="chikungunya" post="transmission in France56–58 and Italy in 2007 and 201759–62."/>
   <result pre="longevity, fecundity, and gonotrophic cycles of Aedes albopictus, vector of" exact="chikungunya" post="and dengue in the Indian OceanJ. Med. Entomol.200946334119198515 4.MedlockJMet"/>
   <result pre="of Aedes aegypti and Aedes albopictus and vectorial capacity for" exact="chikungunya" post="virusJ. Infect. Dis.2016214S453S45827920173 8.PoelchauMFReynoldsJAElsikCGDenlingerDLArmbrusterPADeep sequencing reveals complex mechanisms of"/>
   <result pre="regions in 2013–2014J. Infect. Dis.2016214S436S44027920169 25.GouldEAGallianPDe LamballerieXCharrelRNFirst cases of autochthonous" exact="dengue fever" post="and chikungunya fever in France: from bad dream to"/>
   <result pre="Infect. Dis.2016214S436S44027920169 25.GouldEAGallianPDe LamballerieXCharrelRNFirst cases of autochthonous dengue fever and" exact="chikungunya" post="fever in France: from bad dream to reality!Clin. Microbiol."/>
   <result pre="France: from bad dream to reality!Clin. Microbiol. Infect.2010161702170421040155 26.Gjenero-MarganIet al.Autochthonous" exact="dengue fever" post="in Croatia, August-September 2010Eur. Surveill.201116pii=19805 27.Martinet, J. P., Ferté,"/>
   <result pre="R. Soc. Trop. Med Hyg.195549283214373834 29.VolkSMet al.Genome-scale phylogenetic analyses of" exact="chikungunya" post="virus reveal independent emergences of recent epidemics and various"/>
   <result pre="the Isthmus of Panama: implications for the control of emergent" exact="viral disease" post="agentsPLoS ONE201813e019487429579112 46.MaiaRTScarpassaVMMaciel-LitaiffLHTadeiWPReduced levels of genetic variation in Aedes"/>
   <result pre="in the mosquito, Aedes albopictusPLoS ONE20072e116818000540 51.TsetsarkinKAVanlandinghamDLMcGeeCEHiggsSA single mutation in" exact="chikungunya" post="virus affects vector specificity and epidemic potentialPLoS Pathog.20073e20118069894 52.CoffeyLLForresterNTsetsarkinKVasilakisNWeaverSCFactors"/>
   <result pre="the emergence of diseaseFuture Microbiol2013815517623374123 53.TheamboonlersARianthavornPPraianantathavornKWuttirattanakowitNPoovorawanYClinical and molecular characterization of" exact="chikungunya" post="virus in South ThailandJpn J. Infect. Dis.20096230330519628911 54.Zouache, K."/>
   <result pre="Three-way interactions between mosquito population, viral strain and temperature underlying" exact="chikungunya" post="virus transmission potential. Proc. Biol. Sci.10.1098/rspb.2014.1078 (2014). 55.EnserinkMInfectious diseases."/>
   <result pre="(2015). 58.Calba, C. et al. Preliminary report of an autochthonous" exact="chikungunya" post="outbreak in France, July to September 2017. Euro Surveill."/>
   <result pre="22, 10.2807/1560-7917.ES.2017.22.39.17-00647 (2017). 59.Angelini, R. et al. An outbreak of" exact="chikungunya" post="fever in the province of Ravenna, Italy. Euro Surveill12,"/>
   <result pre="Ravenna, Italy. Euro Surveill12, E070906.070901, 10.2807/esw.12.36.03260-en (2007). 60.RezzaGet al.Infection with" exact="chikungunya" post="virus in Italy: an outbreak in a temperate regionLancet20073701840184618061059"/>
   <result pre="competence of Aedes albopictus for the Indian Ocean lineage (IOL)" exact="chikungunya" post="viruses of the 2007 and 2017 outbreaks in Italy:"/>
   <result pre="competence dataSci. Rep.201991785231780744 64.MachadoLCet al.Genome sequencing reveals coinfection by multiple" exact="chikungunya" post="virus genotypes in a recent outbreak in BrazilPLoS Negl."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7316228\results\search\disease\results.xml">
   <result pre=": Post-Translational Modification: Glycosylation Implications of localized charge for human" exact="influenza" post="A H1N1 hemagglutinin evolution: Insights from deep mutational scans"/>
   <result pre="from deep mutational scans Implications of localized charge for human" exact="influenza" post="A H1N1 hemagglutinin evolution http://orcid.org/0000-0002-2217-3071Saad-RoyChadi M.ConceptualizationFormal analysisInvestigationMethodologyWriting – original"/>
   <result pre="provided the original author and source are credited.pcbi.1007892.pdf Abstract Seasonal" exact="influenza" post="A viruses of humans evolve rapidly due to strong"/>
   <result pre="evolutionary hypotheses. Author summary The hemagglutinin (HA) surface protein of" exact="influenza" post="A viruses evolves rapidly to evade host immunity, leading"/>
   <result pre="electrostatic charge. Beyond H1N1 and H3N2 viruses, numerous subtypes of" exact="influenza" post="circulate or have circulated among a variety of hosts."/>
   <result pre="BrammerL, SingletonJA, et al.Annual estimates of the burden of seasonal" exact="influenza" post="in the United States: A tool for strengthening influenza"/>
   <result pre="seasonal influenza in the United States: A tool for strengthening" exact="influenza" post="surveillance and preparedness. Influenza and Other Respiratory Viruses. 2018;12(1):132–137."/>
   <result pre="10.1111/irv.1248629446233 4WebsterRG, BeanWJ, GormanOT, ChambersTM, KawaokaY. Evolution and ecology of" exact="influenza" post="A viruses. Microbiological Reviews. 1992;56(1):152–179. 10.1128/MMBR.56.1.152-179.19921579108 5GamblinSJ, SkehelJJ. Influenza"/>
   <result pre="Ecology &amp;amp; Evolution. 2002;17(7):334–340. 10.1016/S0169-5347(02)02502-8 7BouvierNM, PaleseP. The biology of" exact="influenza" post="viruses. Vaccine. 2008;26:D49—D53. 10.1016/j.vaccine.2008.07.03919230160 8CatonAJ, BrownleeGG, YewdellJW, GerhardW. The"/>
   <result pre="10.1016/j.vaccine.2008.07.03919230160 8CatonAJ, BrownleeGG, YewdellJW, GerhardW. The antigenic structure of the" exact="influenza" post="virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982;31(2):417–427. 10.1016/0092-8674(82)90135-06186384 9CobeyS,"/>
   <result pre="(H1 subtype). Cell. 1982;31(2):417–427. 10.1016/0092-8674(82)90135-06186384 9CobeyS, HensleySE. Immune history and" exact="influenza" post="virus susceptibility. Current Opinion in Virology. 2017;22:105—111. 10.1016/j.coviro.2016.12.00428088686 10AngelettiD,"/>
   <result pre="11LiuSTH, BehzadiMA, SunW, FreynA, LiuWC, BroeckerF, et al.Antigenic sites in" exact="influenza" post="H1 hemagglutinin display species-specific immunodominance. Journal of Clinical Investigation."/>
   <result pre="near the receptor binding site determine major antigenic change during" exact="influenza" post="virus evolution. Science. 2013;342:976–979. 10.1126/science.124473024264991 13MeyerAG, WilkeCO. Geometric constrains"/>
   <result pre="10.1126/science.124473024264991 13MeyerAG, WilkeCO. Geometric constrains dominate the antigenic evolution of" exact="influenza" post="H3N2 hemagglutinin. PLoS Pathogens. 2015;11:e100494010.1371/journal.ppat.100494026020774 14GrenfellBT, PybusOG, GogJR, WoodJLN,"/>
   <result pre="phenotype of low-yielding (L) and high-yielding (H) variants of swine" exact="influenza" post="virus A/NJ/11/76 are associated with their different receptor-binding activity."/>
   <result pre="to increase charge in immunodominant epitopes of the H3 hemagglutinin" exact="influenza" post="protein. Journal of Molecular Evolution. 2011;72:90–103. 10.1007/s00239-010-9405-421086120 20LindmanS, XueW-F,Szczepankiewicz,"/>
   <result pre="Accurate measurement of the effect of all amino-acid mutations on" exact="influenza" post="hemagglutinin. Viruses. 2016;155. 23Schrödinger, LLC. The PyMOL Molecular Graphics"/>
   <result pre="Viral Immunology. 2018;31(2):142–149. 10.1089/vim.2017.012929356618 26KirkpatrickE, QiuX, WilsonPC, BahlJ, KrammerF. The" exact="influenza" post="virus hemagglutinin head evolves faster than the stalk domain."/>
   <result pre="GuZ, et al.Influenza Research Database: an integrated bioinformatics resource for" exact="influenza" post="virus research. Nucleic Acids Research. 2017;45:D466–D474. 10.1093/nar/gkw85727679478 29BloomJD. Software"/>
   <result pre="scanning of hemagglutinin helps predict evolutionary fates of human H3N2" exact="influenza" post="variants. Proceedings of the National Academy of Sciences. 201810.1073/pnas.1806133115"/>
   <result pre="BarrIG, BroorS, ChadhaM, CoxNJ, et al.Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature. 2015;217–220. 10.1038/nature1446026053121 36PielouEC."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7316273\results\search\disease\results.xml">
   <result pre="Abstract Rotavirus infection is the most common cause of viral" exact="diarrhea" post="in infants and young children but uncommon and usually"/>
   <result pre="importance of investigating rotavirus diagnosis in adults suffering from acute" exact="gastroenteritis" post="and taking appropriate preventive measures. Funding The Research Chair"/>
   <result pre="Rotavirus (RV) is a common pathogen associated with acute viral" exact="gastroenteritis" post="in humans worldwide, especially in developing countries [1]. Although"/>
   <result pre="playing major roles in individual epidemics [18–20]. In Thailand, RV" exact="gastroenteritis" post="is common in children but not as prevalent in"/>
   <result pre="the winter season of 2017–2018, an outbreak of acute RV-induced" exact="gastroenteritis" post="in adults was reported in Thailand (mainly Bangkok). As"/>
   <result pre="2019, 4,472 stool specimens from routine testing service for acute" exact="gastroenteritis" post="at King Chulalongkorn Memorial Hospital and Bangpakok 9 International"/>
   <result pre="2,598 stool specimens from hospitalized and outpatient adults with acute" exact="gastroenteritis" post="(≥15 years) were used for this study (1,058 males"/>
   <result pre="co-infection, RV RNA was tested along with those of other" exact="gastroenteritis" post="viruses, such as norovirus, astrovirus, sapovirus, bocavirus, enterovirus, adenovirus"/>
   <result pre="astrovirus, sapovirus, bocavirus, enterovirus, adenovirus and parechovirus. Detection of other" exact="gastroenteritis" post="viruses was performed by polymerase chain reation (PCR) or"/>
   <result pre="2019. The monthly number of samples from adults with acute" exact="gastroenteritis" post="is shown in gray (left scale). Bar graphs show"/>
   <result pre="2019. The monthly number of samples from adults with acute" exact="gastroenteritis" post="is shown in gray (left scale). Bar graphs show"/>
   <result pre="study, the molecular characteristics of RV in adult patients with" exact="gastroenteritis" post="in Bangkok, Thailand were investigated over a 3-year period"/>
   <result pre="positive rate of rotavirus infection in adults presenting with acute" exact="gastroenteritis" post="in this study was 8.7%. This rate was similar"/>
   <result pre="children population [18, 31, 32]. Apart from being seasonal-specific, rotavirus" exact="gastroenteritis" post="can be transmitted from children to adults [2–4]. Unfortunately,"/>
   <result pre="of contact with sick children, therefore, the burden of RV" exact="gastroenteritis" post="from children-to-adult transmission cannot be determined. The results of"/>
   <result pre="study showed that rotavirus was an important agent for acute" exact="gastroenteritis" post="in adults, and should not be underestimated. In addition"/>
   <result pre="of adult RV infections, the molecular characteristics of RV-induced acute" exact="gastroenteritis" post="in adults were investigated. The distribution of G and"/>
   <result pre="some advantage to viral propagation and survival, although severity of" exact="diarrhea" post="may not be affected. While no data on effectiveness"/>
   <result pre="essential for preventive measures, vaccine efficacy, and control of viral" exact="gastroenteritis" post="outbreaks. We are grateful to the staff of the"/>
   <result pre="a novel equine-like G3P[8] inter-genogroup reassortant rotavirus strain associated with" exact="gastroenteritis" post="in Australian children. J Gen Virol. 2016;97(2):403–10. 10.1099/jgv.0.000352 .26588920"/>
   <result pre="FeikinDR, et al.Efficacy of pentavalent rotavirus vaccine against severe rotavirus" exact="gastroenteritis" post="in infants in developing countries in sub-Saharan Africa: a"/>
   <result pre="DallasMJ, et al.Efficacy of pentavalent rotavirus vaccine against severe rotavirus" exact="gastroenteritis" post="in infants in developing countries in Asia: a randomised,"/>
   <result pre="DiraphatP, HirunpetcharatC. Rotavirus infection in children and adults with acute" exact="gastroenteritis" post="in Thailand. Southeast Asian J Trop Med Public Health."/>
   <result pre="of equine-like G3P[8] rotavirus in children and adults with acute" exact="gastroenteritis" post="in Thailand. J Med Virol. 2020;92(2):174–86. Epub 2019/09/10. 10.1002/jmv.25591"/>
   <result pre="Duang-InA, KlinfuengS, ThaneskongtongN, et al.Human enteroviruses associated with and without" exact="diarrhea" post="in Thailand between 2010 and 2016. PLoS One. 2017;12(7):e018207810.1371/journal.pone.018207828750058"/>
   <result pre="VimolketL, TheamboonlersA, PoovorawanY. Human bocavirus infection in children with acute" exact="gastroenteritis" post="and healthy controls. Jpn J Infect Dis. 2008;61(6):479–81. .19050360"/>
   <result pre="CukorGG, VibulbandhitkitS, ChangchawalitS, BoonthaiP. Rotavirus as a cause of severe" exact="gastroenteritis" post="in adults. J Clin Microbiol. 1983;18(3):663–7. 6313748 31BahlR, RayP,"/>
   <result pre="RayP, SubodhS, ShambharkarP, SaxenaM, ParasharU, et al.Incidence of severe rotavirus" exact="diarrhea" post="in New Delhi, India, and G and P types"/>
   <result pre="35Chan-ItW, ChantaC. Emergence of G9P[8] rotaviruses in children with acute" exact="gastroenteritis" post="in Thailand, 2015–2016. J Med Virol. 2018;90(3):477–84. 10.1002/jmv.24985 .29077213"/>
   <result pre="al.Detection of a novel equine-like G3 rotavirus associated with acute" exact="gastroenteritis" post="in Brazil. J Gen Virol. 2016;97(12):3131–8. 10.1099/jgv.0.000626 .27902376 38LuchsA,"/>
   <result pre="al.Detection of a novel equine-like G3 rotavirus associated with acute" exact="gastroenteritis" post="in Brazil. J Gen Virol. 2016;97(12):3131–8. 10.1099/jgv.0.000626 .27902376 45DoroR,"/>
   <result pre="al.Evolution of DS-1-like G1P[8] double-gene reassortant rotavirus A strains causing" exact="gastroenteritis" post="in children in Vietnam in 2012/2013. Arch Virol. 2017;162(3):739–48."/>
   <result pre="of rotavirus vaccination in prevention of hospital admissions for rotavirus" exact="gastroenteritis" post="among young children in Belgium: case-control study. BMJ. 2012;345:e475210.1136/bmj.e475222875947"/>
   <result pre="CorreiaNB, et al.Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe" exact="diarrhea" post="caused by serotypically unrelated G2P[4] strains in Brazil. J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7316275\results\search\disease\results.xml">
   <result pre="lack of capacity to prevent, detect, and respond to emerging" exact="infectious disease" post="threats in time to prevent regional and global epidemics"/>
   <result pre="burden of these epidemic-prone diseases, specifically cholera, meningococcal meningitis, measles," exact="yellow fever," post="dengue, and viral hemorrhagic fever, in Guinea was not"/>
   <result pre="reported cases of cholera in 2011, 480 reported cases of" exact="meningitis" post="in 2013 (most commonly identified during the dry season"/>
   <result pre="dry season from December through June), 2 reported cases of" exact="yellow fever" post="in 2014, and 243 reported cases of meningitis in"/>
   <result pre="of yellow fever in 2014, and 243 reported cases of" exact="meningitis" post="in 2015 [8, 10, 11]. In 2015 during the"/>
   <result pre="systems in Guinea for weekly reporting of priority diseases, including" exact="malaria" post="(Fig 2) [17]. Ministry of Health officials routinely engaged"/>
   <result pre="data indicate three and two reported cases of cholera and" exact="yellow fever," post="respectively, across Guinea during a proximate time; therefore, it"/>
   <result pre="11, 16]. However, we expected to document reported cases of" exact="meningitis" post="and measles through this surveillance system assessment, considering the"/>
   <result pre="However, we expected to document reported cases of meningitis and" exact="measles" post="through this surveillance system assessment, considering the country-wide case"/>
   <result pre="inclusion of the dry season (i.e., December through June when" exact="meningitis" post="is most commonly identified) during our evaluation period [8,"/>
   <result pre="four neighboring prefectures (Boké, Dubréka, Fria, and Télimélé) as follows:" exact="yellow fever" post="(75 cases), meningitis (9 cases), measles (50 cases), and"/>
   <result pre="Dubréka, Fria, and Télimélé) as follows: yellow fever (75 cases)," exact="meningitis" post="(9 cases), measles (50 cases), and cholera (0 cases)."/>
   <result pre="Télimélé) as follows: yellow fever (75 cases), meningitis (9 cases)," exact="measles" post="(50 cases), and cholera (0 cases). Considering the similarities"/>
   <result pre="the sensitivity of the system. When evaluating the IDSR for" exact="infectious disease" post="control in northern Ghana, researchers identified through key informant"/>
   <result pre="with our data from this evaluation [20]. An evaluation of" exact="measles" post="surveillance in Nigeria also noted that, as with Guinea,"/>
   <result pre="not determine whether the absence of reported cases, specifically of" exact="meningitis" post="and measles, in Boffa is a true reflection of"/>
   <result pre="June 15 2018]. World Health Organizationhttp://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=GIN&amp;amp;commit=OK. 17World Health Organization. World" exact="malaria" post="report. 2018 [cited October 22 2019]. Geneva, Switzerland: World"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7319105\results\search\disease\results.xml">
   <result pre="evolvability in a novel habitat. Prior work showed that vesicular" exact="stomatitis" post="virus (VSV) populations evolved at constant 37°C improved in"/>
   <result pre="a novel habitat. We tested whether prior evolution of vesicular" exact="stomatitis" post="virus (VSV) populations at either at constant temperature or"/>
   <result pre="populations in a novel environment has rarely been tested. Vesicular" exact="stomatitis" post="virus (VSV) is a zoonotic Vesiculovirus of veterinary importance"/>
   <result pre="&amp;amp; Takimoto, 2015; Massin, Werf, &amp;amp; Naffakh, 2001). Virulent H5N1" exact="influenza" post="variants have a replicative advantage and are more tolerant"/>
   <result pre="E. (2010). Consequences of host adaptation for performance of vesicular" exact="stomatitis" post="virus in novel thermal environments. Evolutionary Ecology, 24(2), 299–315."/>
   <result pre="L. A., &amp;amp; Scott, T. W. (2001). Differential evolution of" exact="eastern equine encephalitis" post="virus populations in response to host cell type. Genetics,"/>
   <result pre="&amp;amp; Scott, T. W. (2001). Differential evolution of eastern equine" exact="encephalitis" post="virus populations in response to host cell type. Genetics,"/>
   <result pre="K., Nguyen, T., … Kawaoka, Y. (2007). Growth of H5N1" exact="influenza" post="A viruses in the upper respiratory tracts of mice."/>
   <result pre="J. (1983). Properties of DI particle resistant mutants of vesicular" exact="stomatitis" post="virus isolated from persistent infections and from undiluted passages."/>
   <result pre="VarScan 2: Somatic mutation and copy number alteration discovery in" exact="cancer" post="by exome sequencing. Genome Research, 22(3), 568–576. 10.1101/gr.129684.11122300766 Kryazhimskiy,"/>
   <result pre="is a determinant of cold sensitivity in RNA replication of" exact="avian influenza" post="viruses. Journal of Virology, 75(11), 5398–5404. 10.1128/jvi.75.11.5398-5404.200111333924 McBride, R."/>
   <result pre="a determinant of cold sensitivity in RNA replication of avian" exact="influenza" post="viruses. Journal of Virology, 75(11), 5398–5404. 10.1128/jvi.75.11.5398-5404.200111333924 McBride, R."/>
   <result pre="P. A. (2008). Evolutionary genomics of host adaptation in vesicular" exact="stomatitis" post="virus. Molecular Biology and Evolution, 25, 1138–1147. 10.1093/molbev/msn05918353798 Rohland,"/>
   <result pre="Rozo�?Lopez, P., Drolet, B. S., &amp;amp; Londoño�?Renteria, B. (2018). Vesicular" exact="stomatitis" post="transmission: A comparison of incriminated vectors. Insects, 9, 190."/>
   <result pre="&amp;amp; Saelens, X. (2015). Analysis of the genetic diversity of" exact="influenza" post="A viruses using next�?generation DNA sequencing. BMC Genomics, 16(1),"/>
   <result pre="&amp;amp; Turner, P. E. (2016). Repeatable population dynamics among vesicular" exact="stomatitis" post="virus lineages evolved under high co�?infection. Frontiers in Microbiology,"/>
   <result pre="105(23), 7899–7906.18524956 Zárate, S., &amp;amp; Novella, I. S. (2004). Vesicular" exact="stomatitis" post="virus evolution during alternation between persistent infection in insect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7319124\results\search\disease\results.xml">
   <result pre="testing and antiretroviral therapy (ART) [1, 2], and poorer viral" exact="suppression" post="in sub�?Saharan Africa (SSA), public health responses to address"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7319941\results\search\disease\results.xml">
   <result pre="gentleman in his 40s-who presented to an outside hospital with" exact="acute myocardial infarction," post="he was transferred to our institution for coronary artery"/>
   <result pre="the 4th post-operative day Case #1 developed fever, chest pain," exact="shortness" post="of breath (SOB), and was diagnosed with pneumonia and"/>
   <result pre="chest pain, shortness of breath (SOB), and was diagnosed with" exact="pneumonia" post="and a MERS-CoV PCR test from a respiratory sample"/>
   <result pre="patient had presented to two hospitals with symptoms of ischemic" exact="heart disease." post="A careful retrospective review of his medical records at"/>
   <result pre="4ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med367192012 Nov 81814182010.1056/NEJMoa121172123075143 5RyuS.KimJ.J.CowlingB.J.Kim"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7323528\results\search\disease\results.xml">
   <result pre="Salvador, BA, Brazil; email: guilherme.ribeiro@bahia.fiocruz.br ppub: 2020-726713641373 Abstract After a" exact="chikungunya" post="outbreak in Salvador, Brazil, we performed a cross-sectional, community-based"/>
   <result pre="performed a cross-sectional, community-based study of 1,776 inhabitants to determine" exact="chikungunya" post="virus (CHIKV) seroprevalence, identify factors associated with exposure, and"/>
   <result pre="fever with arthralgia in 2015–2016. Our findings indicate that the" exact="chikungunya" post="outbreak in Salvador may not have conferred sufficient herd"/>
   <result pre="better investigate these findings. Keywords: Arboviral infections asymptomatic infection Brazil" exact="chikungunya" post="virus cross-sectional study epidemics epidemiology herd immunity outbreaks seroprevalence"/>
   <result pre="outbreaks seroprevalence urban vector-borne infections viruses In the 21st century," exact="chikungunya" post="virus (CHIKV) has emerged as a mosquitoborne disease of"/>
   <result pre="aiming to determine the epidemiology and the transmission dynamics of" exact="leptospirosis" post="(17–19), dengue, and other arboviral diseases (15,16,20,21), as well"/>
   <result pre="plaque counts (PRNT90), as described elsewhere (25). To investigate whether" exact="cryoglobulinemia" post="could have reduced the sensitivity of the IgG ELISA,"/>
   <result pre="a positive IgM test result, and presumptive clinical suspicion of" exact="chikungunya" post="by calculating the proportion of those who reported having"/>
   <result pre="the 100 IgG-negative samples that we retested to evaluate whether" exact="cryoglobulinemia" post="had reduced ELISA sensitivity, 2 (2%) returned positive results,"/>
   <result pre="emerged in Salvador (Table 1). Table 1 Prevalence of previous" exact="chikungunya" post="virus infection, determined by detection of IgG, by demographic"/>
   <result pre="CHIKV infection included recall of a presumptive medical diagnosis of" exact="chikungunya" post="(PR 2.83, 95% CI 1.97–4.05) and report of an"/>
   <result pre="2 Crude and adjusted prevalence ratios for persons with previous" exact="chikungunya" post="virus infection, by demographic and clinical characteristics, Salvador, Brazil,"/>
   <result pre="symptom); and more commonly received a presumptive clinical diagnosis of" exact="chikungunya" post="or Zika (p&amp;lt;0.01 for both) but not of dengue"/>
   <result pre="sociodemographic and clinical characteristic of participants with symptomatic versus asymptomatic" exact="chikungunya" post="virus infection Salvador, Brazil, November 2016 to February 2017*"/>
   <result pre="symptomatic disease, 20 (62.5%) reported a presumptive clinical diagnosis of" exact="chikungunya" post="(Table 3). On the other hand, of the 48"/>
   <result pre="IgM (data not shown). Discussion Despite retrospective evidence of a" exact="chikungunya" post="outbreak in Salvador during June–November 2015 (12,15), we found"/>
   <result pre="living near sites where water accumulates are associated with increased" exact="chikungunya" post="incidence. The widely accepted understanding of CHIKV infection has"/>
   <result pre="did find that report of a presumptive clinical diagnosis of" exact="chikungunya" post="disease was strongly associated with having CHIKV IgG (positive"/>
   <result pre="be clinically tested because of the likelihood of having confirmed" exact="chikungunya" post="disease. Our study findings have limitations. First, we surveyed"/>
   <result pre="ELISA retesting of 100 IgG negative samples, we found that" exact="cryoglobulinemia" post="likely did not influence our seroprevalence; moreover, we found"/>
   <result pre="agreement between the IgG ELISA and the PRNT90. However, because" exact="cryoglobulinemia" post="had been described for CHIKV (45), further surveys should"/>
   <result pre="have been underestimated because of the 2-year gap between the" exact="chikungunya" post="outbreak in Salvador and when the study was conducted"/>
   <result pre="Survey used to collect data for study of transmission of" exact="chikungunya" post="virus in an urban slum, Brazil. LINK Suggested citation"/>
   <result pre="Carvalho CX, Portilho MM, Khouri R, et al. Transmission of" exact="chikungunya" post="virus in an urban slum, Brazil. Emerg Infect Dis."/>
   <result pre="Emerging and Zoonotic Infectious Diseases, CDC. Notes from the field:" exact="chikungunya" post="virus spreads in the Americas - Caribbean and South"/>
   <result pre="4. GallianP, Leparc-GoffartI, RichardP, MaireF, FlusinO, DjoudiR, et al.Epidemiology of" exact="chikungunya" post="virus outbreaks in Guadeloupe and Martinique, 2014: an observational"/>
   <result pre="PanellaAJ, KosoyOI, KirkingHL, et al.Seroprevalence and symptomatic attack rate of" exact="chikungunya" post="virus infection, United States Virgin Islands, 2014–2015.Am J Trop"/>
   <result pre="TeixeiraMG, AndradeAMS, CostaMC, CastroJN, OliveiraFLS, GoesCSB, et al.East/Central/South African genotype" exact="chikungunya" post="virus, Brazil, 2014.Emerg Infect Dis. 2015;21:906–7. 10.3201/eid2105.14172725898939 9. Secretaria"/>
   <result pre="Vigilância em Saúde/Ministério da Saúde. Monitoring of cases of dengue," exact="chikungunya" post="fever and fever by the Zika virus until epidemiological"/>
   <result pre="Vigilância em Saúde/Ministério da Saúde. Monitoring of cases of dengue," exact="chikungunya" post="fever and fever by the Zika virus until epidemiological"/>
   <result pre="Vigilância em Saúde/Ministério da Saúde. Monitoring of cases of dengue," exact="chikungunya" post="fever and fever by the Zika virus until epidemiological"/>
   <result pre="CardosoCW, KikutiM, PratesAPPB, PaploskiIAD, TauroLB, SilvaMMO, et al.Unrecognized emergence of" exact="chikungunya" post="virus during a Zika virus outbreak in Salvador, Brazil.PLoS"/>
   <result pre="TauroLB, KikutiM, AnjosRO, SantosVC, GonçalvesTSF, et al.Concomitant transmission of dengue," exact="chikungunya" post="and Zika viruses in Brazil: clinical and epidemiological findings"/>
   <result pre="FelzemburghRDM, RibeiroGS, CostaF, ReisRB, HaganJE, MelendezAXTO, et al.Prospective study of" exact="leptospirosis" post="transmission in an urban slum community: role of poor"/>
   <result pre="MoragaP, CostaF, CapianN, RibeiroGS, WunderEAJr, et al.Spatiotemporal determinants of urban" exact="leptospirosis" post="transmission: four-year prospective cohort study of slum residents in"/>
   <result pre="29. DiasJP, CostaMDCN, CamposGS, PaixãoES, NatividadeMS, BarretoFR, et al.Seroprevalence of" exact="chikungunya" post="virus after its emergence in Brazil.Emerg Infect Dis. 2018;24:617–24."/>
   <result pre="CunhaRV, TrintaKS, MontalbanoCA, SucupiraMVF, de LimaMM, MarquesE, et al.Seroprevalence of" exact="chikungunya" post="virus in a rural community in Brazil.PLoS Negl Trop"/>
   <result pre="JeanSE, BullardSM, et al.Use of bead-based serologic assay to evaluate" exact="chikungunya" post="virus epidemic, Haiti.Emerg Infect Dis. 2018;24:995–1001. 10.3201/eid2406.17144729774861 32. TauroLB,"/>
   <result pre="in children and adults in Managua, Nicaragua, after the first" exact="chikungunya" post="epidemic, 2014–2015.PLoS Negl Trop Dis. 2016;10:e0004773. 10.1371/journal.pntd.000477327322692 37. KrystosikAR,"/>
   <result pre="et al.Community context and sub-neighborhood scale detail to explain dengue," exact="chikungunya" post="and Zika patterns in Cali, Colombia.PLoS One. 2017;12:e0181208. 10.1371/journal.pone.018120828767730"/>
   <result pre="AleraMT, LagoCB, Tac-AnIA, VillaD, FernandezS, et al.High rate of subclinical" exact="chikungunya" post="virus infection and association of neutralizing antibody with protection"/>
   <result pre="HerZ, TanJJL, LumF-M, LeeWWL, ChanY-H, et al.Caribbean and La Réunion" exact="chikungunya" post="virus isolates differ in their capacity to induce proinflammatory"/>
   <result pre="et al.HLA class II allele polymorphism in an outbreak of" exact="chikungunya" post="fever in Middle Andaman, India.Immunology. 2013;140:202–10. 10.1111/imm.1212823710940 42. GordonA,"/>
   <result pre="LanciottiR, Leparc-GoffartI. Evaluation of commercially available serologic diagnostic tests for" exact="chikungunya" post="virus.Emerg Infect Dis. 2014;20:2129–32. 10.3201/eid2012.14126925418184 44. De SalazarPM, ValadereAM,"/>
   <result pre="44. De SalazarPM, ValadereAM, GoodmanCH, JohnsonBW. Evaluation of three commercially-available" exact="chikungunya" post="virus immunoglobulin G immunoassays.Rev Panam Salud Publica. 2017;41:e62. 10.26633/RPSP.2017.6228902275"/>
   <result pre="45. OliverM, GrandadamM, MarimoutouC, RogierC, Botelho-NeversE, TolouH, et al.Persisting mixed" exact="cryoglobulinemia" post="in Chikungunya infection.PLoS Negl Trop Dis. 2009;3:e374. 10.1371/journal.pntd.000037419190731 46."/>
   <result pre="CalheirosAS, et al.Differential shedding and antibody kinetics of Zika and" exact="chikungunya" post="viruses, Brazil.Emerg Infect Dis. 2019;25:311–5. 10.3201/eid2502.18016630666934 47. CardosoCW, PaploskiIAD,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7324804\results\search\disease\results.xml">
   <result pre="origin, which are transmitted through contact with animals (animal-to-person) (e.g." exact="rabies" post="and leptospirosis) named zoonosis. From environmental sources (e.g. water,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7324857\results\search\disease\results.xml">
   <result pre="Commons Attribution-NonCommercial-NoDerivatives 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/).pjm-69-2-217.pdf Abstract Abstract Clinical diagnosis of" exact="hepatitis" post="E viral (HEV) infection mainly relies on serological assays,"/>
   <result pre="and IgG classes. Our findings demonstrate that the diagnosis of" exact="hepatitis" post="E may be missed if only serological assays are"/>
   <result pre="optimal sensitivity and specificity to the diagnostic process. Key words:" exact="hepatitis" post="E virus serological markers diagnostic performance enzyme-linked immunosorbent assay"/>
   <result pre="of the liver caused by a virus known as the" exact="hepatitis" post="E virus (HEV) and has posed severe public health"/>
   <result pre="measures of HEV are similar to those of other acute" exact="hepatitis" post="(Zhang et al. 2019). There are four major methods"/>
   <result pre="et al. 2019). There are four major methods for diagnosing" exact="hepatitis" post="E, including the detection of anti-HEV IgM and IgG"/>
   <result pre="(Ag), and HEV RNA. Presently, the clinical diagnosis of acute" exact="hepatitis" post="E cases mainly depends on the serological detection of"/>
   <result pre="mainly relies on serological assays with a few reports of" exact="hepatitis" post="E misdiagnoses occurring in China. In the present study,"/>
   <result pre="Hospital. A total of 86 cases were diagnosed with acute" exact="viral hepatitis" post="E (Kamar et al. 2014; European Association for the"/>
   <result pre="A total of 86 cases were diagnosed with acute viral" exact="hepatitis" post="E (Kamar et al. 2014; European Association for the"/>
   <result pre="the Liver 2018), 91 cases with rheumatic diseases (RD) including" exact="systemic lupus erythematosus" post="(SLE) and rheumatoid arthritis (RA), and 91 cases with"/>
   <result pre="Liver 2018), 91 cases with rheumatic diseases (RD) including systemic" exact="lupus erythematosus" post="(SLE) and rheumatoid arthritis (RA), and 91 cases with"/>
   <result pre="with rheumatic diseases (RD) including systemic lupus erythematosus (SLE) and" exact="rheumatoid arthritis" post="(RA), and 91 cases with viral hepatitis by CMV"/>
   <result pre="rheumatic diseases (RD) including systemic lupus erythematosus (SLE) and rheumatoid" exact="arthritis" post="(RA), and 91 cases with viral hepatitis by CMV"/>
   <result pre="erythematosus (SLE) and rheumatoid arthritis (RA), and 91 cases with" exact="viral hepatitis" post="by CMV or EBV according to the diagnostic guidelines"/>
   <result pre="(SLE) and rheumatoid arthritis (RA), and 91 cases with viral" exact="hepatitis" post="by CMV or EBV according to the diagnostic guidelines"/>
   <result pre="86 (100) Fig. 1. Flow diagram for patients with acute" exact="viral hepatitis" post="E. Discussion To date, the identification of serological markers"/>
   <result pre="(100) Fig. 1. Flow diagram for patients with acute viral" exact="hepatitis" post="E. Discussion To date, the identification of serological markers"/>
   <result pre="measurements. Anti-HEV IgM appears in the early phase of acute" exact="hepatitis" post="E. The antibodies can be detected as early as"/>
   <result pre="PCR result. In conclusion, for the successful diagnosis of acute" exact="viral hepatitis" post="E, a combination of nucleic acid and serological tests"/>
   <result pre="result. In conclusion, for the successful diagnosis of acute viral" exact="hepatitis" post="E, a combination of nucleic acid and serological tests"/>
   <result pre="AlricL, RostaingL, KamarN, IzopetJ.Performance of anti-HEV assays for diagnosing acute" exact="hepatitis" post="E in immunocompromised patients. J Clin Virol.2013Dec;58(4):624–628. 10.1016/j.jcv.2013.10.00324183927 AggarwalR,"/>
   <result pre="JameelS.Hepatitis E. Hepatology.2011Dec;54(6): 2218–2226. 10.1002/hep.2467421932388 AhmadI, HollaRP, JameelS.Molecular virology of" exact="hepatitis" post="E virus. Virus Res.2011Oct;161(1):47–58. 10.1016/j.virusres.2011.02.01121345356 Al-AbsiES, Al-SadeqDW, YounisMH, YassineHM,"/>
   <result pre="Med Microbiol.2018Sep 01;67(9):1302–1309. 10.1099/jmm.0.00080730051802 Al-SadeqDW, MajdalawiehAF, NasrallahGK.Seroprevalence and incidence of" exact="hepatitis" post="E virus among blood donors: A review. Rev Med"/>
   <result pre="HjortC, HomburgKM, VachW, GeorgsenJ, PurcellRH.Time trend of the prevalence of" exact="hepatitis" post="E antibodies among farmers and blood donors: a potential"/>
   <result pre="ColsonP, RomanetP, MoalV, BorentainP, PurgusR, BenezechA, MotteA, GérolamiR.Autochthonous infections with" exact="hepatitis" post="E virus genotype 4, France. Emerg Infect Dis.2012Aug;18(8): 1361–1364."/>
   <result pre="genotype 4, France. Emerg Infect Dis.2012Aug;18(8): 1361–1364. 10.3201/eid1808.11182722840196 DreierJ, JuhlD.Autochthonous" exact="hepatitis" post="e virus infections: a new transfusion-associated risk?Transfus Med Hemother.2014;"/>
   <result pre="DimitrovaZ, KamiliS, TeoCG.Serologic assays specific to immunoglobulin M antibodies against" exact="hepatitis" post="E virus: pangenotypic evaluation of performances. Clin Infect Dis.2010Aug;"/>
   <result pre="for the Study of the LiverEASL Clinical Practice Guidelines on" exact="hepatitis" post="E virus infection. J Hepatol.2018Jun;68(6):1256–1271. 10.1016/j.jhep.2018.03.00529609832 FragaM, DoerigC, MoulinH,"/>
   <result pre="Beretta-PiccoliB, et al.Hepatitis E virus as a cause of acute" exact="hepatitis" post="acquired in Switzerland. Liver Int.2018Apr;38(4):619–626. 10.1111/liv.1355728834649 HerremansM, BakkerJ, DuizerE,"/>
   <result pre="BakkerJ, DuizerE, VennemaH, KoopmansMPG.Use of serological assays for diagnosis of" exact="hepatitis" post="E virus genotype 1 and 3 infections in a"/>
   <result pre="SiederdissenC, PischkeS, SchlueJ, DeterdingK, HellmsT, Schuler-LüttmannS, SchwarzA, MannsMP, CornbergM, WedemeyerH.Chronic" exact="hepatitis" post="E virus infection beyond transplantation or human immunodeficiency virus"/>
   <result pre="CMV and EBV causes problems in the diagnosis of acute" exact="hepatitis" post="E virus infection. J Med Virol.2014Mar;86(3):478–483. 10.1002/jmv.2382724402843 InnisBL, SeriwatanaJ,"/>
   <result pre="RobinsonRA, ShresthaMP, YarboughPO, LongerCF, ScottRM, VaughnDW, MyintKS.Quantitation of immunoglobulin to" exact="hepatitis" post="E virus by enzyme immunoassay. Clin Diagn Lab Immunol.2002May;9(3):639–648.11986273"/>
   <result pre="Rev.2014Jan 01;27(1):116–138. 10.1128/CMR.00057-1324396139 KuniholmMH, PurcellRH, McQuillanGM, EngleRE, WasleyA, NelsonKE.Epidemiology of" exact="hepatitis" post="E virus in the united states: results from the"/>
   <result pre="IzopetJ.Good performance of immunoglobulin M assays in diagnosing genotype 3" exact="hepatitis" post="E virus infections. Clin Vaccine Immunol.2009May;16(5):772–774. 10.1128/CVI.00438-0819321696 LuL, LiC,"/>
   <result pre="Clin Vaccine Immunol.2009May;16(5):772–774. 10.1128/CVI.00438-0819321696 LuL, LiC, HagedornCH.Phylogenetic analysis of global" exact="hepatitis" post="E virus sequences: genetic diversity, subtypes and zoonosis. Rev"/>
   <result pre="Eur Arch Otorhinolaryngol.2018Sep; 275(9):2349–2354. 10.1007/s00405-018-5063-830019190 OkamotoH.Genetic variability and evolution of" exact="hepatitis" post="E virus. Virus Res.2007Aug;127(2):216–228. 10.1016/j.virusres.2007.02.00217363102 ParkHK, JeongSH, KimJW, WooBH,"/>
   <result pre="KitagawaK, SonodaY, UsuiT, SakamotoH, YoshinoS, et al.A nationwide survey of" exact="hepatitis" post="E virus (HEV) infection in wild boars in Japan:"/>
   <result pre="SatoY, Jirintai, NagashimaS, OkamotoH.Analysis of the full-length genome of a" exact="hepatitis" post="E virus isolate obtained from a wild boar in"/>
   <result pre="ObriadinaAP, TalekarG, BurkovAN, FieldsHA, KhudyakovYE.A new artificial antigen of the" exact="hepatitis" post="E virus. J Immunoassay Immunochem.2008Dec 31;30(1):18–39. 10.1080/15321810802570269 ZhangF, LiX,"/>
   <result pre="HEV antigen as a novel marker for the diagnosis of" exact="hepatitis" post="E. J Med Virol.2006Nov; 78(11):1441–1448. 10.1002/jmv.2071716998897 ZhangH, RaoH, WangY,"/>
   <result pre="al.Evaluation of an antigen assay for diagnosing acute and chronic" exact="hepatitis" post="E genotype 4 infection. J Gastroenterol Hepatol.2019Feb;34(2):458–465. 10.1111/jgh.1440530069920 ZhaoC,"/>
   <result pre="SongA, WangY.Evaluation of an antigen-capture EIA for the diagnosis of" exact="hepatitis" post="E virus infection. J Viral Hepat.2015Nov;22(11):957–963. 10.1111/jvh.1239725732029"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7324928\results\search\disease\results.xml">
   <result pre="Travel Tourism GeoSentinel Arbovirus Vector-borne disease Abbreviations Ae Aedes CHIKV" exact="chikungunya" post="virus ECDC European Center for Disease Control EIA enzyme"/>
   <result pre="was historically confined to Africa and Asia [1]. Since 2006," exact="chikungunya" post="has emerged on a global scale, with outbreaks occurring"/>
   <result pre="long-term sequelae, such as incapacitating arthralgias [4]. In the Maldives," exact="chikungunya" post="was first reported in 2006 with a total of"/>
   <result pre="circulation was rarely documented in the Maldives. Only five imported" exact="chikungunya" post="cases were reported to EuroTravNet/GeoSentinel networks over the period"/>
   <result pre="fever in all patients (8/8), arthralgia and headache (8/8), diffuse" exact="rash" post="(4/8), lymphadenitis (1/8), edema (1/8) and joint swelling (1/8)."/>
   <result pre="all patients (8/8), arthralgia and headache (8/8), diffuse rash (4/8)," exact="lymphadenitis" post="(1/8), edema (1/8) and joint swelling (1/8). Two patients"/>
   <result pre="(Table 1 ). Interestingly, the French case had a positive" exact="chikungunya" post="RT-PCR [9] and travelled with two other individuals who"/>
   <result pre="lab to have chikungunya. Table 1 Overview of eight confirmed" exact="chikungunya" post="cases among travellers returning from the Maldives, by date"/>
   <result pre="on plasma Negative dengue and Zika RT-PCR and serology, negative" exact="malaria" post="blood smear microscopy 7 Italy Maldives,Thinadhoo island 12/01/20–26/01/20 80"/>
   <result pre="1 ). Fig. 1 Cumulative number of confirmed and suspected" exact="chikungunya" post="virus infection cases by year, built according to data"/>
   <result pre="United States Virgin Islands in 2014, current and possibly recurrent" exact="chikungunya" post="outbreaks in the Maldives could have major human and"/>
   <result pre="illness, and other symptoms included joint pain, arthritis, arthralgia, headache," exact="rash" post="and sore throat, but lymph nodes were not noticed"/>
   <result pre="clinical description from the recent epidemic are available yet, however," exact="lymphadenitis" post="presented by the French case in this series have"/>
   <result pre="series have been mostly reported during infection with the Asian" exact="chikungunya" post="lineage. Basically, we do not know exactly the origin"/>
   <result pre="of the viruses responsible for the 2006 and the 2019" exact="chikungunya" post="Maldivian outbreaks. Whether it is the same strains or"/>
   <result pre="Pre-travel visits have led to a significant decrease in malaria," exact="hepatitis" post="A virus infection and HIV/AIDS infections among travellers [3]."/>
   <result pre="and post-travel multi-disciplinary management of cases. 4 Conclusion These eight" exact="chikungunya" post="cases in returned travellers from the Maldives, over a"/>
   <result pre="of the pre-travel consultationLancet Infect Dis1512015556425477022 4van AalstM.NelenC.M.GoorhuisA.StijnisC.GrobuschM.P.Long-term sequelae of" exact="chikungunya" post="virus disease: a systematic reviewTrav Med Infect Dis152017822 5YoosufA.A.ShihamI.MohamedA.J.First"/>
   <result pre="disease: a systematic reviewTrav Med Infect Dis152017822 5YoosufA.A.ShihamI.MohamedA.J.First report of" exact="chikungunya" post="from the MaldivesTrans R Soc Trop Med Hyg1032200919219618930301 6European"/>
   <result pre="of illness and burden of disease associated with the 2014–2015" exact="chikungunya" post="outbreak in the U.S. Virgin IslandsMaheu-GirouxM.PLoS Negl Trop Disvol."/>
   <result pre="vectors Aedes aegypti and Aedes albopictusNat Microbiol45201985486330833735 18WahidB.AliA.RafiqueS.IdreesM.Global expansion of" exact="chikungunya" post="virus: mapping the 64-year historyInt J Infect Dis582017697628288924 19HapuarachchiH.C.BandaraK.B.SumanadasaS.D.Re-emergence"/>
   <result pre="Dis25820191535153831310218 24HalsteadS.B.Travelling arboviruses: a historical perspectiveTrav Med Infect Dis312019101471 25Díaz-MenéndezM.EstebanE.T.UjiieM.Travel-associated" exact="chikungunya" post="acquired in Myanmar in 2019Euro Surveill2512020pii=1900721 26JavelleE.FlorescuS.-A.AsgeirssonH.Increased risk of"/>
   <result pre="chikungunya acquired in Myanmar in 2019Euro Surveill2512020pii=1900721 26JavelleE.FlorescuS.-A.AsgeirssonH.Increased risk of" exact="chikungunya" post="infection in travellers to Thailand during ongoing outbreak in"/>
   <result pre="individual and community mitigation measures for prevention and control of" exact="chikungunya" post="virusSamyA.M.Plos onevol. 142019(2):e0212054 29SchlagenhaufP.Santos-O’ConnorF.ParolaP.The practice of travel medicine in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7325039\results\search\disease\results.xml">
   <result pre="10.1186/s12879-020-05192-3 : Case Report An adult co-presented with varicella and" exact="herpes zoster" post="caused by varicella zoster virus genotype J, China: a"/>
   <result pre="by endogenous reactivation of latent VZV. Until now, varicella and" exact="herpes zoster" post="have seldom been reported simultaneously in one patient. Here,"/>
   <result pre="Here, we report a rare case co-presenting with varicella and" exact="herpes zoster" post="in a Chinese adult. Case presentation A 44-year-old Chinese"/>
   <result pre="calamine lotion for 5 days was effective therapy for varicella and" exact="herpes zoster." post="Polymerase chain reaction for vesicular fluids from varicella and"/>
   <result pre="zoster. Polymerase chain reaction for vesicular fluids from varicella and" exact="herpes zoster" post="was positive for VZV, and further phylogenetic analysis and"/>
   <result pre="2). Conclusions This rare case highlights awareness of varicella and" exact="herpes zoster" post="caused by VZV infection in adults. Our report provides"/>
   <result pre="life-threatening neurological syndrome complications, such as postherpetic neuralgia (PHN) and" exact="vasculitis" post="[1]. Varicella (chickenpox) and herpes zoster (shingles) are two"/>
   <result pre="as postherpetic neuralgia (PHN) and vasculitis [1]. Varicella (chickenpox) and" exact="herpes zoster" post="(shingles) are two distinct clinical presentations of mucocutaneous lesions"/>
   <result pre="in peripheral ganglia, and reactivation of latently persistent virus causes" exact="herpes zoster" post="decades later [2]. However, varicella in adult populations have"/>
   <result pre="Japan [4, 5]. Several studies have confirmed concurrent varicella and" exact="herpes zoster" post="in middle-aged and old adults [6–9], but the pathogen"/>
   <result pre="case of varicella on the neck, trunk and back and" exact="herpes zoster" post="on the left ear in a Chinese adult caused"/>
   <result pre="5 days, and they were ulcerated. These lesions were diagnosed as" exact="herpes zoster" post="(Fig. 1a). To exclude immunocompromised conditions and other diseases,"/>
   <result pre="Fig. 1 a and b Clinical presentation of varicella and" exact="herpes zoster" post="in the patient’s trunk, back and head before or"/>
   <result pre="To determine the causative pathogen, vesicular fluids from varicella and" exact="herpes zoster" post="were collected. Herpes simplex virus type 1 (HSV-1), HSV-2"/>
   <result pre="middle-aged and old adults with simultaneous occurrence of varicella and" exact="herpes zoster" post="[6–9]; however, these rare cases with varicella and herpes"/>
   <result pre="herpes zoster [6–9]; however, these rare cases with varicella and" exact="herpes zoster" post="have seldom been reported. Here, we also described a"/>
   <result pre="Here, we also described a rare case of varicella and" exact="herpes zoster" post="in late adulthood. For this case, we excluded the"/>
   <result pre="case, we excluded the possibility of contact with varicella or" exact="herpes zoster" post="patients because his family members were healthy and he"/>
   <result pre="reactivation of VZV. This rare simultaneous infection of varicella and" exact="herpes zoster" post="in this patient was confirmed to be caused by"/>
   <result pre="VZV infection and varicella, understanding the pathogenesis of varicella and" exact="herpes zoster" post="occurring at the same time will provide more useful"/>
   <result pre="the central nervous system (CNS) may present without accompanying zoster" exact="rash" post="[12], so our understanding of the molecular triggers for"/>
   <result pre="genotype J causes a rare case of concurrent varicella and" exact="herpes zoster" post="in an adult. Supplementary information LINK Additional file 1:"/>
   <result pre="S1. Clinical characteristics of a rare case with varicella and" exact="herpes zoster" post="in Xiamen, China Abbreviations VZV Varicella zoster virus PHN"/>
   <result pre="zoster virus among university students, IndiaEmerg Infect Dis201824236636910.3201/eid2402.17065929350152 4.EgawaGEgawaKKabashimaKCase of" exact="chickenpox" post="in which varicella zoster virus genotype E was identified"/>
   <result pre="a referral gospital, Central Tokyo, Japan, 2012–2016Emerg Infect Dis202026111411710.3201/eid2601.17056531855138 6.MullerBKGomesWJConcurrent" exact="herpes zoster" post="and varicellaBr Med J1965154421127112810.1136/bmj.1.5442.1127-a 7.FetterFSchnabelTGConcurrent herpes zoster and chickenpox;"/>
   <result pre="Infect Dis202026111411710.3201/eid2601.17056531855138 6.MullerBKGomesWJConcurrent herpes zoster and varicellaBr Med J1965154421127112810.1136/bmj.1.5442.1127-a 7.FetterFSchnabelTGConcurrent" exact="herpes zoster" post="and chickenpox; report of a caseArch Intern Med (Chic)194983550250410.1001/archinte.1949.0022034002700218129805"/>
   <result pre="Intern Med (Chic)194983550250410.1001/archinte.1949.0022034002700218129805 8.GelfandMLHerpes zoster with a varicelliform eruption and" exact="parotitis" post="in chronic leukemiaJAMA1951145856056110.1001/jama.1951.72920260003008a 9.AlmeydaJSimultaneous occurrence of herpes zoster and"/>
   <result pre="varicelliform eruption and parotitis in chronic leukemiaJAMA1951145856056110.1001/jama.1951.72920260003008a 9.AlmeydaJSimultaneous occurrence of" exact="herpes zoster" post="and varicella: with a report of three casesPostgrad Med"/>
   <result pre="clustering and strategies for genotypingJ Virol200478158349835810.1128/JVI.78.15.8349-8358.200415254207 14.SchmutzhardJMerete RiedelHZweygberg WirgartBGrillnerLDetection of" exact="herpes simplex" post="virus type 1, herpes simplex virus type 2 and"/>
   <result pre="Virol200478158349835810.1128/JVI.78.15.8349-8358.200415254207 14.SchmutzhardJMerete RiedelHZweygberg WirgartBGrillnerLDetection of herpes simplex virus type 1," exact="herpes simplex" post="virus type 2 and varicella-zoster virus in skin lesions."/>
   <result pre="and virus isolationJ Clin Virol200429212012610.1016/S1386-6532(03)00113-614747031 15.KanekoHHigakiSFukudaMShimomuraYIshiokaKFukushimaEet al.The quantitative detection of" exact="herpes simplex" post="virus, varicella zoster virus, and cytomegalovirus DNAs in recipient"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7325846\results\search\disease\results.xml">
   <result pre="replacing nonfunctional genes with functional gene-carrying cells. 4.The characterization of" exact="cancer" post="cells, the role of various chemicals, viruses, and radiation"/>
   <result pre="cells, the role of various chemicals, viruses, and radiation in" exact="cancer" post="cells. 5.Production of vaccines, mABs, and pharmaceutical drugs. 6.Production"/>
   <result pre="for use in vaccine production (e.g., chicken pox, polio, rabies," exact="hepatitis" post="B, and measles). Today, mammalian cell culture is a"/>
   <result pre="period of 34 years. 1913 Steinhardt, Israeli, and Lambert Grew" exact="vaccinia virus" post="in fragments of guinea pig corneal tissue. 1916 Rous"/>
   <result pre="that inhibits the growth of blood vessels or angiogenesis (for" exact="cancer" post="therapy). 2005 Sanford, Earle, and Likely Single-cell culture in"/>
   <result pre="This has been used to analyze the growth characteristics of" exact="cancer" post="cells in comparison to their normal counterparts, especially with"/>
   <result pre="adenovirus Human HeLa Epithelial cell Human HL 60 Human promyelocytic" exact="leukemia" post="cells Human MCF-7 Breast cancer Human A549 Lung cancer"/>
   <result pre="Human HL 60 Human promyelocytic leukemia cells Human MCF-7 Breast" exact="cancer" post="Human A549 Lung cancer Human A1 to A5-E Amnion"/>
   <result pre="promyelocytic leukemia cells Human MCF-7 Breast cancer Human A549 Lung" exact="cancer" post="Human A1 to A5-E Amnion Human ND-E Esophagus Human"/>
   <result pre="karyotype; for example, HeLa cells were the first human epithelial" exact="cancer" post="cell line established in long-term culture, and they have"/>
   <result pre="cell production work are human immunodeficiency virus, human papilloma virus," exact="hepatitis" post="virus, human herpes virus, hantavirus, simian virus, sendai virus,"/>
   <result pre="herpes virus, hantavirus, simian virus, sendai virus, and bovine viral" exact="diarrhea" post="virus. For detection of viruses causing immunodeficiency diseases and"/>
   <result pre="has led to the development of a recombinant vaccine against" exact="hepatitis" post="B virus (HBV) and several others potential vaccines that"/>
   <result pre="the final phase of clinical trials. Table 14.4 lists recombinant" exact="hepatitis" post="B vaccines in eukaryotic cells. Table 14.4 Recombinant hepatitis"/>
   <result pre="recombinant hepatitis B vaccines in eukaryotic cells. Table 14.4 Recombinant" exact="hepatitis" post="B vaccines in eukaryotic cells. Trade name Manufacture Recombinant"/>
   <result pre="of virus-like particles Most of the existing classical vaccines for" exact="viral disease" post="are either altered or chemically inactive live viruses. However,"/>
   <result pre="are known to induce lesions and warts and also cause" exact="cervical cancer." post="Fifteen strains of Papillomaviridae are known to cause cervical"/>
   <result pre="cervical cancer. Fifteen strains of Papillomaviridae are known to cause" exact="cervical cancer." post="HPV-16 is considered a high-risk HPV type as the"/>
   <result pre="is considered a high-risk HPV type as the risk of" exact="cancer" post="may be higher than for other high-risk HPV types."/>
   <result pre="C Severe sepsis Xigris 2001 Hybridoma CHO Immunoglobulin G2a Non-Hodgkin’s" exact="lymphoma" post="Bexxar 2003 CHO Immunoglobulin GI Colorectal cancer Avastin 2004"/>
   <result pre="Immunoglobulin G2a Non-Hodgkin’s lymphoma Bexxar 2003 CHO Immunoglobulin GI Colorectal" exact="cancer" post="Avastin 2004 CHO Humanized IgG Cancer Perjeta 2012 CHO"/>
   <result pre="IgG1 Multiple sclerosis Ocrevus 2017 CHO Human recombinant IgG1 Rheumatoid" exact="arthritis" post="Kevzara 2017 Cytokines Cytokines are proteins of the immune"/>
   <result pre="treatment of hepatitis, and more recently has been approved for" exact="leukemia" post="and other types of cancers. IFNβ is used for"/>
   <result pre="other types of cancers. IFNβ is used for treatment of" exact="multiple sclerosis" post="and is marketed under the names Avonex, Belaseron, and"/>
   <result pre="Belaseron, and Rebif. IFNγ is used for the treatment of" exact="chronic granulomatous disease." post="Interleukin is another kind of cytokine that helps regulate"/>
   <result pre="recombinant form of IL-2 is used for the treatment of" exact="renal cell carcinoma." post="Growth factors Growth factors are proteins that bind to"/>
   <result pre="the treatment of acute myocardial infraction. Fabry disease, a genetic" exact="metabolic disorder," post="is characterized by a lack of enzyme α-galactosidase A."/>
   <result pre="Antibodies Therapeutic antibodies are used in the treatment of cancer," exact="cardiovascular disease," post="infections, and autoimmune diseases. In 2004, the antibody Avasin"/>
   <result pre="antibody Avasin (Bevacizeimab) was approved for the treatment of metastatic" exact="colorectal cancer." post="This antibody acts as an inhibitor of vascular endothelial"/>
   <result pre="therapy. Monogenic diseases caused by single gene defects (such as" exact="cystic fibrosis," post="hemophilia, muscular dystrophy, and sickle cell anemia) are the"/>
   <result pre="caused by single gene defects (such as cystic fibrosis, hemophilia," exact="muscular dystrophy," post="and sickle cell anemia) are the primary targets of"/>
   <result pre="have been reported; 70% of these studies are intended for" exact="cancer" post="treatment. The first product designed for gene therapy was"/>
   <result pre="holds great promise for applications in various fields, such as" exact="cancer" post="cell biology, stem cell research, drug discovery, and various"/>
   <result pre="for up to several weeks. Tumor-on-a-chip A significant challenge for" exact="cancer" post="research is the early detection and development of in"/>
   <result pre="design in tumor transport and therapies for targeting rapidly dividing" exact="cancer" post="cells while leaving normal, healthy cells untouched. The microfluidics"/>
   <result pre="in blood flow, which may lead to early diagnosis of" exact="cancer" post="(Millner et al., 2013). A variety of designs for"/>
   <result pre="a novel microfluidic system to study the multidrug resistance of" exact="cancer" post="cells to chemotherapeutic combinations. Jang et al. (2011) fabricated"/>
   <result pre="isolated chambers. To optimize system parameters for varied types of" exact="cancer" post="cells while requiring minute amounts of reagents and cells,"/>
   <result pre="Vitro22200810991106 ClarkeB.E.NewtonS.E.CarrollA.R.FrancisM.J.AppleyardG.SyredA.D.Improved immunogenicity of a peptide epitope after fusion to" exact="hepatitis" post="B core proteinNature33019873813842446137 CruzP.E.MarangaL.CarrondoM.J.T.Integrated process optimisation: lessons from retrovirus"/>
   <result pre="of human diploid cell strainsExp. Cell Res.31961585621 HoY.LinP.H.LiuC.Y.LeeS.P.ChaoY.C.Assembly of human" exact="severe acute respiratory syndrome" post="coronavirus-like particlesBiochemical and biophysical research communications3184200483383815147946 JangY.H.HancockM.J.KimS.B.SelimovićŠ.SimW.Y.BaeH.An integrated microfluidic"/>
   <result pre="microfluidic chipJ. Micromech. Microeng.1862008065020 XuX.Farach-CarsonM.C.JiaX.Three-dimensional in vitro tumor models for" exact="cancer" post="research and drug evaluationBiotechnol. Adv.32720141256126825116894 YamshcikovG.V.RitterG.D.VeyM.CompansR.W.Assembly of SIV virus-like"/>
   <result pre="tissues, and organs on chips: challenges and opportunities for the" exact="cancer" post="tumor microenvironmentIntegr. Biol.59201310961109 ZiółkowskaK.KwapiszewskiR.BrzózkaZ.Microfluidic devices as tools for mimicking"/>
   <result pre="purity of culture? 4.Is IFN-α used for the treatment of" exact="multiple sclerosis?" post="5.Is Bevacizumab approved for the treatment of colorectal cancer?"/>
   <result pre="of multiple sclerosis? 5.Is Bevacizumab approved for the treatment of" exact="colorectal cancer?" post="6.Does passage effect leads to an increase in the"/>
   <result pre="PCR or ELISA. 4.No—IFN-β is used in the treatment of" exact="multiple sclerosis." post="5.Yes—It is an inhibitor of vascular endothelial growth factor."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7329513\results\search\disease\results.xml">
   <result pre="at Makerere University, Kampala Uganda, with a research focus on" exact="infectious disease" post="epidemiology. The corresponding author and the co-authors have long"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7330273\results\search\disease\results.xml">
   <result pre="prospectively collect epidemiological and virological data on patients hospitalized with" exact="influenza" post="virus infection. Here, we describe influenza virus strain circulation"/>
   <result pre="on patients hospitalized with influenza virus infection. Here, we describe" exact="influenza" post="virus strain circulation in the GIHSN participant countries during"/>
   <result pre="factors associated with complicated hospitalization among patients admitted with laboratory-confirmed" exact="influenza" post="illness. Methods The study enrolled patients who were hospitalized"/>
   <result pre="with acute respiratory symptoms and who had symptoms consistent with" exact="influenza" post="within the 7 days before admission. Enrolled patients were tested"/>
   <result pre="patients were tested by reverse transcription-polymerase chain reaction to confirm" exact="influenza" post="virus infection. &quot;Complicated hospitalization�? was defined as a need"/>
   <result pre="patients. Factors associated with complicated hospitalization in influenza-positive patients included" exact="chronic obstructive pulmonary disease" post="(15–&amp;lt; 50 years and ≥ 65 years), diabetes (15–&amp;lt; 50 years), male sex (50–&amp;lt; 65 years), hospitalization during"/>
   <result pre="(≥65 years). Chronic obstructive pulmonary disease (50–&amp;lt; 65 years), other chronic conditions (15–&amp;lt; 50 years)," exact="influenza" post="A (50–&amp;lt; 65 years), and hospitalization during the last 12 months (&amp;lt; 15 years)"/>
   <result pre="a longer hospital stay. The proportion of patients with complicated" exact="influenza" post="did not differ between influenza A and B. Conclusions"/>
   <result pre="proportion of patients with complicated influenza did not differ between" exact="influenza" post="A and B. Conclusions Complicated hospitalizations occurred in over"/>
   <result pre="Complicated hospitalizations occurred in over 10% of patients hospitalized with" exact="influenza" post="virus infection. Factors commonly associated with complicated or longer"/>
   <result pre="or longer hospitalization differed by age group but commonly included" exact="chronic obstructive pulmonary disease," post="diabetes, and hospitalization during the last 12 months. Keywords Influenza"/>
   <result pre="Influenza Hospitalization Mortality Risk factors Epidemiology Background Each year, seasonal" exact="influenza" post="epidemics cause an estimated 3 to 5 million severe"/>
   <result pre="diseases are considered to have the highest risk of severe" exact="influenza" post="illness [3, 4]. Hospitalization and death due to influenza,"/>
   <result pre="Disease Control and Prevention collect data on hospitalizations with laboratory-confirmed" exact="influenza" post="illness through a network covering approximately 9% of the"/>
   <result pre="detailed data are needed from geographically diverse settings over several" exact="influenza" post="seasons to assess how the different influenza viruses affect"/>
   <result pre="settings over several influenza seasons to assess how the different" exact="influenza" post="viruses affect clinically meaningful outcomes. Recognizing this need, the"/>
   <result pre="sites linked with local health authorities, each of which coordinates" exact="influenza" post="surveillance at participating hospitals according to a common core"/>
   <result pre="to investigate the associations between severe illness, patient characteristics, and" exact="influenza" post="virology. In the 2017–2018 season, the GIHSN included 20"/>
   <result pre="findings from 2012–2013 [5], 2013–2014 [8], 2014–2015 [9], and 2016–2017" exact="influenza" post="seasons [10]. The studies have shown that all strains"/>
   <result pre="seasons [10]. The studies have shown that all strains of" exact="influenza" post="can result in hospitalization, intensive care unit (ICU) admission,"/>
   <result pre="regions or countries. In addition, these studies have confirmed that" exact="influenza" post="can cause serious outcomes not only in older adults,"/>
   <result pre="we report the results from the GIHSN for the 2017–2018" exact="influenza" post="season. In addition to describing the epidemiology of hospitalized"/>
   <result pre="data from patients hospitalized with acute respiratory symptoms during the" exact="influenza" post="season [11]. All sites share the same core protocol"/>
   <result pre="share the same core protocol and use RT-PCR to confirm" exact="influenza" post="virus infection. The core protocol was approved by the"/>
   <result pre="and at least one respiratory symptom (cough, sore throat, or" exact="shortness" post="of breath) consistent with influenza and had to have"/>
   <result pre="symptom (cough, sore throat, or shortness of breath) consistent with" exact="influenza" post="and had to have been hospitalized ≤7 days after the"/>
   <result pre="be hospitalized ≤7 days after the appearance of symptoms associated with" exact="influenza" post="(see Additional file 2 for diagnosis codes). Patients were"/>
   <result pre="local language, are used to collect patient demographics, comorbidities, and" exact="influenza" post="vaccination status through face-to-face interviews of patients or legal"/>
   <result pre="had received at least one dose of a 2017–2018 seasonal" exact="influenza" post="vaccine ≥14 days before the onset of symptoms. Physicians involved"/>
   <result pre="(&amp;lt; 15, 15–&amp;lt; 50, 50–&amp;lt; 65, and ≥65 years). For admissions aged ≥15 years, covariates included" exact="cardiovascular disease," post="chronic obstructive pulmonary disease (COPD), diabetes, obesity, other chronic"/>
   <result pre="50–&amp;lt; 65, and ≥65 years). For admissions aged ≥15 years, covariates included cardiovascular disease," exact="chronic obstructive pulmonary disease" post="(COPD), diabetes, obesity, other chronic conditions, sex, current smoking,"/>
   <result pre="disease (COPD), diabetes, obesity, other chronic conditions, sex, current smoking," exact="influenza" post="type (A vs B), antiviral prescription during the current"/>
   <result pre="episode, hospitalization during the previous 12 months, site (as random effect)," exact="influenza" post="vaccination status, and age. For admissions aged &amp;lt; 15 years, covariates"/>
   <result pre="admissions aged &amp;lt; 15 years, covariates included any chronic condition, sex, age," exact="influenza" post="type (A vs. B), antiviral prescription during the current"/>
   <result pre="episode, hospitalization during the previous 12 months, site (as random effect)," exact="influenza" post="vaccination status, and age. Factors tested in the mixed"/>
   <result pre="of the sites included in the GIHSN during the 2017–2018" exact="influenza" post="season (Paris [France], Ivory Coast, Kazakhstan, Peru, Poland, and"/>
   <result pre="hospitals Included patients Inclusion period (calendar week and year of" exact="influenza" post="season) Influenza transmission zone a St. Petersburg (Russian Federation)"/>
   <result pre="South America All sites 46 12,803 a World Health Organization" exact="influenza" post="transmission zone [14] Fig. 1 Disposition and influenza positivity"/>
   <result pre="Health Organization influenza transmission zone [14] Fig. 1 Disposition and" exact="influenza" post="positivity of included patients. Community-dwelling patients residing in predefined"/>
   <result pre="hospitals and hospitalized &amp;lt; 48 h with presenting complaints potentially associated with" exact="influenza" post="were eligible. Patients aged &amp;gt; 5 years had to have ≥1"/>
   <result pre="headache, or myalgia) and ≥ 1 respiratory symptom (cough, sore throat, or" exact="shortness" post="of breath) and had to have been hospitalized &amp;lt; 7 days"/>
   <result pre="patients with comorbidities or underlying diseases, the most common was" exact="cardiovascular disease" post="(23.8% [3048/12,803]). Twenty percent of adult patients (1300/6516) were"/>
   <result pre="29.2% had been hospitalized in the previous 12 months. The overall" exact="influenza" post="vaccination rate was 14.3%, and antivirals were used by"/>
   <result pre="Of the 12,803 included patients, 4306 (33.6%) tested positive for" exact="influenza" post="virus infection by RT-PCR (Fig. 1). In the influenza"/>
   <result pre="for influenza virus infection by RT-PCR (Fig. 1). In the" exact="influenza" post="transmission zones of North America (Canada), Eastern Europe (Moscow,"/>
   <result pre="Asia (China), and South West Europe (Spain, Serbia, and France)," exact="influenza" post="was first detected during the last few weeks of"/>
   <result pre="South West Europe. In Eastern Asia, all strains co-circulated, but" exact="influenza" post="A/H1N1pdm09 virus was dominant. Even within these transmission zones,"/>
   <result pre="zones, however, strain circulation varied substantially (Fig. 3). For example," exact="influenza" post="B/Yamagata-like virus was common at all sites within the"/>
   <result pre="at all sites within the East Europe transmission zone, but" exact="influenza" post="A/H3N2 virus was common only at the St. Petersburg"/>
   <result pre="file 7). Likewise, within the South West Europe transmission zone," exact="influenza" post="B/Yamagata-like virus was common at all sites, but influenza"/>
   <result pre="zone, influenza B/Yamagata-like virus was common at all sites, but" exact="influenza" post="A/H3N2 virus was common only in Spain (Fig. 3"/>
   <result pre="2 Influenza strain circulation by year-week and World Health Organization" exact="influenza" post="transmission zone. Influenza strains were detected by RT-PCR. An"/>
   <result pre="could have been positive for more than one strain of" exact="influenza" post="Fig. 3 Influenza strain circulation by site and overall"/>
   <result pre="could have been positive for more than one strain of" exact="influenza" post="In the Central American Caribbean transmission zone (Mexico), the"/>
   <result pre="Central American Caribbean transmission zone (Mexico), the timing of seasonal" exact="influenza" post="was similar to that of the Northern Hemisphere transmission"/>
   <result pre="the Northern Hemisphere transmission zones. However, strain circulation differed, with" exact="influenza" post="A/H3N2 (67.2%) virus dominating and little influenza B detected."/>
   <result pre="circulation differed, with influenza A/H3N2 (67.2%) virus dominating and little" exact="influenza" post="B detected. In the Temperate South America transmission zone"/>
   <result pre="B detected. In the Temperate South America transmission zone (Argentina)," exact="influenza" post="circulated earlier (weeks 30 to 39 of 2017), with"/>
   <result pre="influenza circulated earlier (weeks 30 to 39 of 2017), with" exact="influenza" post="B/Yamagata-like (49.0%) and A/H1N1pdm09 (45.1%) viruses dominating. In contrast"/>
   <result pre="(49.0%) and A/H1N1pdm09 (45.1%) viruses dominating. In contrast to the" exact="influenza" post="transmission zones in the Northern Hemisphere, two distinct peaks"/>
   <result pre="transmission zones in the Northern Hemisphere, two distinct peaks of" exact="influenza" post="activity were detected in Southern Africa (South Africa) and"/>
   <result pre="Asia (India). In Southern Africa, a first peak, dominated by" exact="influenza" post="A/H1N1pdm09 virus, occurred between weeks 18 and 28 of"/>
   <result pre="18 and 28 of 2017, and a second, dominated by" exact="influenza" post="A/H3N2 virus, between weeks 30 and 42 of 2017."/>
   <result pre="of 2017. In Southern Asia, a first peak, dominated by" exact="influenza" post="A/H1N1pdm09 virus, occurred between week 41 of 2017 and"/>
   <result pre="and week 1 of 2018 and a second, dominated by" exact="influenza" post="A/H3N2 virus, between weeks 3 and 9 of 2018."/>
   <result pre="weeks 3 and 9 of 2018. No discernable peak of" exact="influenza" post="circulation was detected in Eastern Africa (Kenya), although influenza"/>
   <result pre="of influenza circulation was detected in Eastern Africa (Kenya), although" exact="influenza" post="A/H1N1pdm09 virus dominated. Overall, across all regions of the"/>
   <result pre="A/H1N1pdm09 virus dominated. Overall, across all regions of the GIHSN," exact="influenza" post="B/Yamagata-like virus (26.1% of influenza-positive patients) and influenza A/H3N2"/>
   <result pre="the GIHSN, influenza B/Yamagata-like virus (26.1% of influenza-positive patients) and" exact="influenza" post="A/H3N2 (25.6%) were the most frequently detected strains, closely"/>
   <result pre="B/Victoria-like virus was detected in 2.3% of influenza-positive patients, unsubtyped" exact="influenza" post="A virus in 12.2%, and influenza B of unknown"/>
   <result pre="of influenza-positive patients, unsubtyped influenza A virus in 12.2%, and" exact="influenza" post="B of unknown lineage in 12.7%. Except in Mexico"/>
   <result pre="unknown lineage in 12.7%. Except in Mexico and South Africa," exact="influenza" post="B/Yamagata-like was the dominant B lineage detected in all"/>
   <result pre="CI, 1.10–2.60]) (Fig. 5). Prescription of antivirals during the current" exact="influenza" post="episode was associated with complicated hospitalization in influenza-positive admissions"/>
   <result pre="&amp;lt; 15 years. The frequency of complicated hospitalization did not differ between" exact="influenza" post="A and B for any age group. The frequency"/>
   <result pre="mixed effects logistic regression adjusted for age and vaccination for" exact="influenza" post="during the previous 12 months and with site as a"/>
   <result pre="defined as ICU admission, mechanical ventilation, or death. Abbreviations: COPD," exact="chronic obstructive pulmonary disease;" post="CVD, cardiovascular disease Length of hospital stay The mean"/>
   <result pre="ventilation, or death. Abbreviations: COPD, chronic obstructive pulmonary disease; CVD," exact="cardiovascular disease" post="Length of hospital stay The mean length of hospital"/>
   <result pre="CI, 0.59–4.94]) were associated with a longer hospital stay and" exact="influenza" post="B (vs. A) with a shorter hospital stay (coefficient,"/>
   <result pre="aged ≥65 years. Length of hospital stay did not differ between" exact="influenza" post="A and B for any age group. The length"/>
   <result pre="by one unit (i.e. from yes to no). Abbreviations: COPD," exact="chronic obstructive pulmonary disease;" post="CVD, cardiovascular disease Discussion The current study showed that"/>
   <result pre="yes to no). Abbreviations: COPD, chronic obstructive pulmonary disease; CVD," exact="cardiovascular disease" post="Discussion The current study showed that during the 2017–2018"/>
   <result pre="disease Discussion The current study showed that during the 2017–2018" exact="influenza" post="season, approximately 10% of all hospitalized cases of influenza"/>
   <result pre="2017–2018 influenza season, approximately 10% of all hospitalized cases of" exact="influenza" post="virus infection were complicated, as defined by admission to"/>
   <result pre="or death. Factors associated with complicated hospitalization in patients with" exact="influenza" post="virus infection included COPD, diabetes, and hospitalization during the"/>
   <result pre="diabetes, and hospitalization during the previous 12 months, although male sex," exact="cardiovascular disease," post="and some lifestyle factors (smoking and obesity) were also"/>
   <result pre="complicated hospitalization and a longer hospital stay in patients with" exact="influenza" post="virus infection. Most of these are known risk factors"/>
   <result pre="infection. Most of these are known risk factors for severe" exact="influenza" post="illness [4]. In addition to these factors, prescription of"/>
   <result pre="frequency of complications, probably because antivirals were mostly prescribed for" exact="influenza" post="cases with a high likelihood of developing complications. Influenza"/>
   <result pre="are often thought to result in more severe illness than" exact="influenza" post="B infections [15]. The current study, however, did not"/>
   <result pre="The current study, however, did not find a difference between" exact="influenza" post="A and B or between A/H1N1pdm09 and A/H3N2 in"/>
   <result pre="hospitalization. It also did not find a consistent difference between" exact="influenza" post="A and B in the risk for individual components"/>
   <result pre="of complicated hospitalization or in the length of hospital stay:" exact="influenza" post="B was associated with shorter hospital stay in influenza-positive"/>
   <result pre="systematic literature review concluding that clinical presentation and severity of" exact="influenza" post="illness do not appear to differ between influenza strains"/>
   <result pre="severity of influenza illness do not appear to differ between" exact="influenza" post="strains [16]. During the 2017–2018 influenza season, influenza accounted"/>
   <result pre="appear to differ between influenza strains [16]. During the 2017–2018" exact="influenza" post="season, influenza accounted for approximately one-third of hospital admissions"/>
   <result pre="differ between influenza strains [16]. During the 2017–2018 influenza season," exact="influenza" post="accounted for approximately one-third of hospital admissions with influenza-like"/>
   <result pre="of hospital admissions with influenza-like symptoms, which agrees with previous" exact="influenza" post="seasons in the GISHN, where proportions were between 21"/>
   <result pre="31% [8–10, 17]. As in previous studies, all strains of" exact="influenza" post="were detected, with widely varying strain circulation between sites"/>
   <result pre="even neighboring regions. Influenza B/Yamagata was the most frequently detected" exact="influenza" post="strain, although A/H3N2 and A/H1N1pdm09 were nearly as common."/>
   <result pre="in the 2017–2018 Northern Hemisphere and 2018 Southern Hemisphere trivalent" exact="influenza" post="vaccines, Yamagata was the dominant lineage of influenza B"/>
   <result pre="Hemisphere trivalent influenza vaccines, Yamagata was the dominant lineage of" exact="influenza" post="B [18, 19]. Finally, as in previous studies, more"/>
   <result pre="previous studies, more than half of the patients hospitalized with" exact="influenza" post="virus infection did not have known chronic conditions, highlighting"/>
   <result pre="virus infection did not have known chronic conditions, highlighting that" exact="influenza" post="can cause severe illness even in individuals without high-risk"/>
   <result pre="extensive global virological data and clinical data on severe seasonal" exact="influenza" post="illness. Data from the GIHSN can be used to"/>
   <result pre="from the GIHSN can be used to identify associations between" exact="influenza" post="virology/epidemiology, patient characteristics, and severe cases of influenza illness."/>
   <result pre="associations between influenza virology/epidemiology, patient characteristics, and severe cases of" exact="influenza" post="illness. In the current study, we pooled data from"/>
   <result pre="and a common core protocol for identifying hospitalized cases of" exact="influenza" post="illness. In addition, to reduce bias caused by false-negative"/>
   <result pre="of the effects. We did not examine the effect of" exact="influenza" post="vaccination on complications or length of hospital stay because"/>
   <result pre="of hospital stay because of low vaccination rates; the overall" exact="influenza" post="vaccination rate across all sites and all included patients"/>
   <result pre="for more than half of the sites, the rate of" exact="influenza" post="vaccination was below 10%, although a few sites had"/>
   <result pre="patients. Given the limitations of influenza-like-illness case definitions for predicting" exact="influenza" post="in individuals, particularly in older adults, to identify the"/>
   <result pre="in older adults, to identify the maximum number of hospitalized" exact="influenza" post="cases, potential cases were identified based on the presence"/>
   <result pre="the presence of any acute respiratory symptoms possibly associated with" exact="influenza" post="rather than based on a specific influenza-like illness case"/>
   <result pre="specificity of the inclusion criteria, specificity was ensured by confirming" exact="influenza" post="virus infection by RT-PCR. Care should be taken when"/>
   <result pre="showed that more than one in ten hospitalized cases of" exact="influenza" post="virus infections detected during the 2017–2018 influenza season was"/>
   <result pre="hospitalized cases of influenza virus infections detected during the 2017–2018" exact="influenza" post="season was complicated by need for mechanical ventilation, admission"/>
   <result pre="death. Common factors associated with an increased risk of severe" exact="influenza" post="were also found to be associated with complicated or"/>
   <result pre="these patients, but the study did not find differences between" exact="influenza" post="strains. The study also provides further evidence that influenza"/>
   <result pre="between influenza strains. The study also provides further evidence that" exact="influenza" post="can cause severe illness even in individuals without high-risk"/>
   <result pre="and appropriate use of antivirals influence complicated hospitalization due to" exact="influenza" post="virus infection. Supplementary information LINK Additional file 1: Supplemental"/>
   <result pre="1: Supplemental Table 1. Admission diagnoses possibly associated with an" exact="influenza" post="infection in patients ≥5 years of age. LINK Additional file"/>
   <result pre="2: Supplemental Table 2. Admission diagnoses possibly associated with an" exact="influenza" post="infection in patients &amp;lt; 5 years of age. LINK Additional file"/>
   <result pre="circulation by year-week for individual sites within the East Europe" exact="influenza" post="transmission zone. LINK Additional file 8: Supplemental Figure 2."/>
   <result pre="by year-week for individual sites within the South West Europe" exact="influenza" post="transmission zone. LINK Additional file 9: Supplemental Figure 3."/>
   <result pre="CI Confidence interval COPD Chronic obstructive pulmonary disease GIHSN Global" exact="influenza" post="hospital surveillance network ICU Intensive care unit OR Odds"/>
   <result pre="de France created by Sanofi Pasteur in 2015 to support" exact="influenza" post="epidemiological research. In addition, the Foundation for Influenza Epidemiology"/>
   <result pre="respiratory mortality: a modelling studyLancet20183911285130010.1016/S0140-6736(17)33293-229248255 3.collab: World Health OrganizationVaccines against" exact="influenza" post="WHO position paper - November 2012Wkly Epidemiol Rec20128746147623210147 4.ColemanBLFadelSAFitzpatrickTThomasSMRisk"/>
   <result pre="2012Wkly Epidemiol Rec20128746147623210147 4.ColemanBLFadelSAFitzpatrickTThomasSMRisk factors for serious outcomes associated with" exact="influenza" post="illness in high- versus low- and middle-income countries: systematic"/>
   <result pre="meta-analysisInfluenza Other Respir Viruses201812222910.1111/irv.1250429197154 5.Puig-BarberaJTormosASomininaABurtsevaELaunayOCiblakMAet al.First-year results of the global" exact="influenza" post="hospital surveillance network: 2012-2013 northern hemisphere influenza seasonBMC Public"/>
   <result pre="of the global influenza hospital surveillance network: 2012-2013 northern hemisphere" exact="influenza" post="seasonBMC Public Health20141456410.1186/1471-2458-14-56424903737 6.BlantonLDuganVGAbd ElalAIAlabiNBarnesJBrammerLet al.Update: influenza activity -"/>
   <result pre="2012-2013 northern hemisphere influenza seasonBMC Public Health20141456410.1186/1471-2458-14-56424903737 6.BlantonLDuganVGAbd ElalAIAlabiNBarnesJBrammerLet al.Update:" exact="influenza" post="activity - United States, September 30, 2018-February 2, 2019MMWR"/>
   <result pre="10 Apr 2019. (2019). 8.Puig-BarberaJNatividad-SanchoATrushakovaSSomininaAPisarevaMCiblakMAet al.Epidemiology of hospital admissions with" exact="influenza" post="during the 2013/2014 northern hemisphere influenza season: results from"/>
   <result pre="of hospital admissions with influenza during the 2013/2014 northern hemisphere" exact="influenza" post="season: results from the global influenza hospital surveillance networkPLoS"/>
   <result pre="the 2013/2014 northern hemisphere influenza season: results from the global" exact="influenza" post="hospital surveillance networkPLoS One201611e015497010.1371/journal.pone.015497027196667 9.Puig-BarberaJBurtsevaEYuHCowlingBJBadurSKynclJet al.Influenza epidemiology and influenza"/>
   <result pre="global influenza hospital surveillance networkPLoS One201611e015497010.1371/journal.pone.015497027196667 9.Puig-BarberaJBurtsevaEYuHCowlingBJBadurSKynclJet al.Influenza epidemiology and" exact="influenza" post="vaccine effectiveness during the 2014–2015 season: annual report from"/>
   <result pre="effectiveness during the 2014–2015 season: annual report from the global" exact="influenza" post="hospital surveillance networkBMC Public Health201616Suppl 175710.1186/s12889-016-3378-127556802 10.Baselga-MorenoVTrushakovaSMcNeilSSomininaANunesMCDraganescuAet al.Influenza epidemiology"/>
   <result pre="hospital surveillance networkBMC Public Health201616Suppl 175710.1186/s12889-016-3378-127556802 10.Baselga-MorenoVTrushakovaSMcNeilSSomininaANunesMCDraganescuAet al.Influenza epidemiology and" exact="influenza" post="vaccine effectiveness during the 2016-2017 season in the global"/>
   <result pre="influenza vaccine effectiveness during the 2016-2017 season in the global" exact="influenza" post="hospital surveillance network (GIHSN)BMC Public Health20191948710.1186/s12889-019-6713-531046725 11.GIHSN: Global Influenza"/>
   <result pre="(2011). 15.SuSChavesSSPerezAD'MelloTKirleyPDYousey-HindesKet al.Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="a and B virus infectionClin Infect Dis20145925225510.1093/cid/ciu26924748521 16.CainiSKronemanMWiegersTEl Guerche-SeblainCPagetJClinical"/>
   <result pre="virus infectionClin Infect Dis20145925225510.1093/cid/ciu26924748521 16.CainiSKronemanMWiegersTEl Guerche-SeblainCPagetJClinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype, and lineage: a systematic"/>
   <result pre="a systematic literature reviewInfluenza Other Respir Viruses20181278079210.1111/irv.1257529858537 17.Puig-BarberaJNatividad-SanchoALaunayOBurtsevaECiblakMATormosAet al.2012-2013 seasonal" exact="influenza" post="vaccine effectiveness against influenza hospitalizations: results from the global"/>
   <result pre="Other Respir Viruses20181278079210.1111/irv.1257529858537 17.Puig-BarberaJNatividad-SanchoALaunayOBurtsevaECiblakMATormosAet al.2012-2013 seasonal influenza vaccine effectiveness against" exact="influenza" post="hospitalizations: results from the global influenza hospital surveillance networkPLoS"/>
   <result pre="influenza vaccine effectiveness against influenza hospitalizations: results from the global" exact="influenza" post="hospital surveillance networkPLoS One20149e10049710.1371/journal.pone.010049724945510 18.World Health Organization: Recommended composition"/>
   <result pre="hospital surveillance networkPLoS One20149e10049710.1371/journal.pone.010049724945510 18.World Health Organization: Recommended composition of" exact="influenza" post="virus vaccines for use in the 2017–2018 northern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2017–2018 northern hemisphere" exact="influenza" post="season. https://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/ . Accessed 03 Sep 2019 (2017). 19.World"/>
   <result pre="03 Sep 2019 (2017). 19.World Health Organization: Recommended composition of" exact="influenza" post="virus vaccines for use in the 2018 southern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2018 southern hemisphere" exact="influenza" post="season. https://www.who.int/influenza/vaccines/virus/recommendations/2018_south/en/. Accessed 03 Sep 2019 (2017). 20.JaegerTFCategorical data"/>
   <result pre="associated with severe outcomes in adult hospitalized patients according to" exact="influenza" post="type and subtypePLoS One201914e021035310.1371/journal.pone.021035330633778 23.NicholsMKAndrewMKHatchetteTFAmbroseABoivinGBowieWet al.Influenza vaccine effectiveness to"/>
   <result pre="serious outcomes in Canadian adults over the 2011/12 through 2013/14" exact="influenza" post="seasons: a pooled analysis from the Canadian immunization research"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="openVirus\examples\priya950\4-part\PMC7330967\results\search\disease\results.xml">
   <result pre="doi: 10.1186/s12985-020-01364-4 : Research Promising application of monoclonal antibody against" exact="chikungunya" post="virus E1-antigen across genotypes in immunochromatographic rapid diagnostic tests"/>
   <result pre="line to the data. Abstract Background Three different genotypes of" exact="chikungunya" post="virus (CHIKV) have been classified: East/Central/South African (ECSA), West"/>
   <result pre="cross-reactivity to other alphaviruses, including eastern, western, and Venezuela equine" exact="encephalitis" post="viruses. Here, we report the development and evaluation of"/>
   <result pre="myalgia, arthralgia, and headache; some patients also experienced a maculopapular" exact="rash" post="and/or gastrointestinal symptoms. Out of 1688 febrile cases, 643"/>
   <result pre="febrile cases, 643 (38.1%) and 269 (15.9%) were laboratory-confirmed as" exact="chikungunya" post="fever and dengue fever, respectively, by RT-PCR with the"/>
   <result pre="(38.1%) and 269 (15.9%) were laboratory-confirmed as chikungunya fever and" exact="dengue fever," post="respectively, by RT-PCR with the simultaneous detection and differentiation"/>
   <result pre="IgG (Table 2, Additional file 3). As the kinetics of" exact="chikungunya" post="antigenemia are not well understood, it is possible that"/>
   <result pre="new health global riskJ Clin Virol20156414415210.1016/j.jcv.2014.08.03225453326 6.SchuffeneckerIItemanIMichaultAMurriSFrangeulLVaneyMCLavenirRPardigonNReynesJMPettinelliFet al.Genome microevolution of" exact="chikungunya" post="viruses causing the Indian Ocean outbreakPLoS Med20063e26310.1371/journal.pmed.003026316700631 7.ArankalleVAShrivastavaSCherianSGunjikarRSWalimbeAMJadhavSMSudeepABMishraACGenetic divergence"/>
   <result pre="India: a major public-health disasterLancet Infect Dis2007730630710.1016/S1473-3099(07)70091-917448932 9.RianthavornPPrianantathavornKWuttirattanakowitNTheamboonlersAPoovorawanYAn outbreak of" exact="chikungunya" post="in southern Thailand from 2008 to 2009 caused by"/>
   <result pre="virus of different genotypes from MalaysiaPLoS One20127e5047610.1371/journal.pone.005047623209750 12.RezzaGNicolettiLAngeliniRRomiRFinarelliACPanningMCordioliPFortunaCBorosSMaguranoFet al.Infection with" exact="chikungunya" post="virus in Italy: an outbreak in a temperate regionLancet.20073701840184610.1016/S0140-6736(07)61779-618061059"/>
   <result pre="in the AmericasLancet.201438351410.1016/S0140-6736(14)60185-924506907 17.SahadeoNSDAllicockOMDe SalazarPMAugusteAJWidenSOlowokureBGutierrezCValadereAMPolson-EdwardsKWeaverSCCarringtonCVFUnderstanding the evolution and spread of" exact="chikungunya" post="virus in the Americas using complete genome sequencesVirus Evol20173vex01010.1093/ve/vex01028480053"/>
   <result pre="using complete genome sequencesVirus Evol20173vex01010.1093/ve/vex01028480053 18.LanciottiRSValadereAMTranscontinental movement of Asian genotype" exact="chikungunya" post="virusEmerg Infect Dis2014201400140210.3201/eid2008.14026825076384 19.Khan K, Bogoch I, Brownstein JS,"/>
   <result pre="Assessing the origin of and potential for international spread of" exact="chikungunya" post="virus from the Caribbean. PLoS Curr. 2014;6. 20.Nsoesie EO,"/>
   <result pre="Khan K, et al. Global distribution and environmental suitability for" exact="chikungunya" post="virus, 1952 to 2015. Euro Surveill. 2016;21. 21.ThibervilleSDMoyenNDupuis-MaguiragaLNougairedeAGouldEARoquesPde LamballerieXChikungunya"/>
   <result pre="clinical syndrome, pathogenesis and therapyAntivir Res20139934537010.1016/j.antiviral.2013.06.00923811281 22.SchwartzOAlbertMLBiology and pathogenesis of" exact="chikungunya" post="virusNat Rev Microbiol2010849150010.1038/nrmicro236820551973 23.MorrisonTEReemergence of chikungunya virusJ Virol201488116441164710.1128/JVI.01432-1425078691 24.WaggonerJJBallesterosGGreshLMohamed-HadleyATellezYSahooMKAbeynayakeJBalmasedaAHarrisEPinskyBAClinical"/>
   <result pre="22.SchwartzOAlbertMLBiology and pathogenesis of chikungunya virusNat Rev Microbiol2010849150010.1038/nrmicro236820551973 23.MorrisonTEReemergence of" exact="chikungunya" post="virusJ Virol201488116441164710.1128/JVI.01432-1425078691 24.WaggonerJJBallesterosGGreshLMohamed-HadleyATellezYSahooMKAbeynayakeJBalmasedaAHarrisEPinskyBAClinical evaluation of a single-reaction real-time RT-PCR"/>
   <result pre="24.WaggonerJJBallesterosGGreshLMohamed-HadleyATellezYSahooMKAbeynayakeJBalmasedaAHarrisEPinskyBAClinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and" exact="chikungunya" post="virus detectionJ Clin Virol201678576110.1016/j.jcv.2016.01.00726991052 25.OkabayashiTSasakiTMasrinoulPChantawatNYoksanSNitatpattanaNChusriSMorales VargasREGrandadamMBreyPTet al.Detection of chikungunya"/>
   <result pre="and chikungunya virus detectionJ Clin Virol201678576110.1016/j.jcv.2016.01.00726991052 25.OkabayashiTSasakiTMasrinoulPChantawatNYoksanSNitatpattanaNChusriSMorales VargasREGrandadamMBreyPTet al.Detection of" exact="chikungunya" post="virus antigen by a novel rapid immunochromatographic testJ Clin"/>
   <result pre="26.JainJOkabayashiTKaurNNakayamaEShiodaTGaindRKurosuTSunilSEvaluation of an immunochromatography rapid diagnosis kit for detection of" exact="chikungunya" post="virus antigen in India, a dengue-endemic countryVirol J2018158410.1186/s12985-018-1000-029751761 27.HuitsROkabayashiTCnopsLBarbeBVan"/>
   <result pre="Den BergRBartholomeeusenKArienKKJacobsJBottieauENakayamaEEet al.Diagnostic accuracy of a rapid E1-antigen test for" exact="chikungunya" post="virus infection in a reference settingClin Microbiol Infect201824788110.1016/j.cmi.2017.06.00428606643 28.TuekprakhonANakayamaEEBartholomeeusenKPuipromOSasakiTHuitsRLuplertlopNKosoltanapiwatNManeekanPArienKKet"/>
   <result pre="a rapid E1-antigen testSci Rep20188109410.1038/s41598-018-19174-829348674 29.TuekprakhonAPuipromOSasakiTMichielsJBartholomeeusenKNakayamaEEMenoMKPhadungsombatJHuitsRArienKKet al.Broad-spectrum monoclonal antibodies against" exact="chikungunya" post="virus structural proteins: promising candidates for antibody-based rapid diagnostic"/>
   <result pre="virus was isolated in Thailand, 2010Virus Genes20144948548910.1007/s11262-014-1105-525113745 31.PuipromOMorales VargasREPotiwatRChaichanaPIkutaKRamasootaPOkabayashiTCharacterization of" exact="chikungunya" post="virus infection of a human keratinocyte cell line: role"/>
   <result pre="Shioda T, Arien KK, Huits R. Two distinct lineages of" exact="chikungunya" post="virus cocirculated in Aruba during the 2014-2015 epidemic. Infect"/>
   <result pre="and serological diagnosis of Chikungunya virus infectionPathol Biol (Paris)20075549049410.1016/j.patbio.2007.07.00217920211 39.MalvyDEzzedineKMamani-MatsudaMAutranBTolouHReceveurMCPistoneTRambertJMoynetDMossalayiDDestructive" exact="arthritis" post="in a patient with chikungunya virus infection with persistent"/>
   <result pre="virus infectionPathol Biol (Paris)20075549049410.1016/j.patbio.2007.07.00217920211 39.MalvyDEzzedineKMamani-MatsudaMAutranBTolouHReceveurMCPistoneTRambertJMoynetDMossalayiDDestructive arthritis in a patient with" exact="chikungunya" post="virus infection with persistent specific IgM antibodiesBMC Infect Dis2009920010.1186/1471-2334-9-20020003320"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
